ID ACK1_HUMAN Reviewed; 1038 AA. AC Q07912; Q6ZMQ0; Q8N6U7; Q96H59; DT 24-OCT-2003, integrated into UniProtKB/Swiss-Prot. DT 05-MAY-2009, sequence version 3. DT 28-JAN-2026, entry version 240. DE RecName: Full=Activated CDC42 kinase 1; DE Short=ACK-1; DE EC=2.7.10.2 {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:20333297}; DE EC=2.7.11.1 {ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; DE AltName: Full=Tyrosine kinase non-receptor protein 2; GN Name=TNK2; Synonyms=ACK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CDC42. RC TISSUE=Hippocampus; RX PubMed=8497321; DOI=10.1038/363364a0; RA Manser E., Leung T., Salihuddin H., Tan L., Lim L.; RT "A non-receptor tyrosine kinase that inhibits the GTPase activity of RT p21cdc42."; RL Nature 363:364-367(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT LEU-725. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP INTERACTION WITH CSPG4. RX PubMed=10587647; DOI=10.1038/70302; RA Eisenmann K.M., McCarthy J.B., Simpson M.A., Keely P.J., Guan J.-L., RA Tachibana K., Lim L., Manser E., Furcht L.T., Iida J.; RT "Melanoma chondroitin sulphate proteoglycan regulates cell spreading RT through Cdc42, Ack-1 and p130cas."; RL Nat. Cell Biol. 1:507-513(1999). RN [6] RP FUNCTION AS MCF2 KINASE, CATALYTIC ACTIVITY, AND COFACTOR. RX PubMed=10652228; DOI=10.1006/bbrc.2000.2106; RA Kato J., Kaziro Y., Satoh T.; RT "Activation of the guanine nucleotide exchange factor Dbl following ACK1- RT dependent tyrosine phosphorylation."; RL Biochem. Biophys. Res. Commun. 268:141-147(2000). RN [7] RP FUNCTION. RX PubMed=11278436; DOI=10.1074/jbc.m008795200; RA Teo M., Tan L., Lim L., Manser E.; RT "The tyrosine kinase ACK1 associates with clathrin-coated vesicles through RT a binding motif shared by arrestin and other adaptors."; RL J. Biol. Chem. 276:18392-18398(2001). RN [8] RP SUBCELLULAR LOCATION. RX PubMed=14733946; DOI=10.1016/j.bbrc.2003.12.137; RA Ahmed I., Calle Y., Sayed M.A., Kamal J.M., Rengaswamy P., Manser E., RA Meiners S., Nur-E-Kamal A.; RT "Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase, RT ACK."; RL Biochem. Biophys. Res. Commun. 314:571-579(2004). RN [9] RP AUTOPHOSPHORYLATION, INTERACTION WITH HSP90AB1; MTERK AND WWOX, AND RP MUTAGENESIS OF LYS-158 AND LEU-487. RX PubMed=16288044; DOI=10.1158/0008-5472.can-05-1127; RA Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.; RT "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of RT Ack1 in polyubiquitination of tumor suppressor Wwox."; RL Cancer Res. 65:10514-10523(2005). RN [10] RP INTERACTION WITH SNX9, AND SUBCELLULAR LOCATION. RX PubMed=16137687; DOI=10.1016/j.febslet.2005.07.093; RA Yeow-Fong L., Lim L., Manser E.; RT "SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector RT ACK1."; RL FEBS Lett. 579:5040-5048(2005). RN [11] RP FUNCTION AS WAS KINASE, INTERACTION WITH WASL, CATALYTIC ACTIVITY, AND RP COFACTOR. RX PubMed=16257963; DOI=10.1074/jbc.m506996200; RA Yokoyama N., Lougheed J., Miller W.T.; RT "Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual RT hydroxyamino acid specificity in a tyrosine kinase."; RL J. Biol. Chem. 280:42219-42226(2005). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [13] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=16247015; DOI=10.1073/pnas.0508014102; RA van der Horst E.H., Degenhardt Y.Y., Strelow A., Slavin A., Chinn L., RA Orf J., Rong M., Li S., See L.-H., Nguyen K.Q.C., Hoey T., Wesche H., RA Powers S.; RT "Metastatic properties and genomic amplification of the tyrosine kinase RT gene ACK1."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15901-15906(2005). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP FUNCTION IN CELL MIGRATION, AND INTERACTION WITH BCAR1; CDC42 AND CRK. RX PubMed=17038317; DOI=10.1074/jbc.m604342200; RA Modzelewska K., Newman L.P., Desai R., Keely P.J.; RT "Ack1 mediates Cdc42-dependent cell migration and signaling to p130Cas."; RL J. Biol. Chem. 281:37527-37535(2006). RN [16] RP FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT TYR-284. RX PubMed=16472662; DOI=10.1016/s0076-6879(06)06018-6; RA Yokoyama N., Miller W.T.; RT "Purification and enzyme activity of ACK1."; RL Methods Enzymol. 406:250-260(2006). RN [17] RP INTERACTION WITH AR. RX PubMed=17494760; DOI=10.1073/pnas.0700420104; RA Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L., RA Earp H.S., Whang Y.E.; RT "Activated Cdc42-associated kinase Ack1 promotes prostate cancer RT progression via androgen receptor tyrosine phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:8438-8443(2007). RN [18] RP INTERACTION WITH NPHP1. RX PubMed=18477472; DOI=10.1016/j.bbrc.2008.05.016; RA Eley L., Moochhala S.H., Simms R., Hildebrandt F., Sayer J.A.; RT "Nephrocystin-1 interacts directly with Ack1 and is expressed in human RT collecting duct."; RL Biochem. Biophys. Res. Commun. 371:877-882(2008). RN [19] RP FUNCTION. RX PubMed=18435854; DOI=10.1186/bcr2087; RA Howlin J., Rosenkvist J., Andersson T.; RT "TNK2 preserves epidermal growth factor receptor expression on the cell RT surface and enhances migration and invasion of human breast cancer cells."; RL Breast Cancer Res. 10:R36-R36(2008). RN [20] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18262180; DOI=10.1016/j.yexcr.2007.12.017; RA Groevdal L.M., Johannessen L.E., Roedland M.S., Madshus I.H., Stang E.; RT "Dysregulation of Ack1 inhibits down-regulation of the EGF receptor."; RL Exp. Cell Res. 314:1292-1300(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-881, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP INTERACTION WITH NEDD4, AND UBIQUITINATION. RX PubMed=19144635; DOI=10.1074/jbc.m806877200; RA Chan W., Tian R., Lee Y.-F., Sit S.T., Lim L., Manser E.; RT "Down-regulation of active ACK1 is mediated by association with the E3 RT ubiquitin ligase Nedd4-2."; RL J. Biol. Chem. 284:8185-8194(2009). RN [24] RP FUNCTION, AND INTERACTION WITH AXL; LTK; PDGFRL AND GRB2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-284 AND SER-724, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [26] RP SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-284, AND DOMAIN RP SAM-LIKE. RX PubMed=20979614; DOI=10.1186/1471-2091-11-42; RA Prieto-Echaguee V., Gucwa A., Brown D.A., Miller W.T.; RT "Regulation of Ack1 localization and activity by the amino-terminal SAM RT domain."; RL BMC Biochem. 11:42-42(2010). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, VARIANTS LEU-34; GLN-99; LYS-346 AND RP ILE-409, CHARACTERIZATION OF VARIANTS LEU-34; GLN-99; LYS-346 AND ILE-409, RP AND MUTAGENESIS OF LEU-120; LEU-197 AND VAL-365. RX PubMed=20110370; DOI=10.1074/jbc.m109.060459; RA Prieto-Echaguee V., Gucwa A., Craddock B.P., Brown D.A., Miller W.T.; RT "Cancer-associated mutations activate the nonreceptor tyrosine kinase RT Ack1."; RL J. Biol. Chem. 285:10605-10615(2010). RN [28] RP FUNCTION AS AR KINASE, AND ACTIVITY REGULATION. RX PubMed=20383201; DOI=10.1038/onc.2010.103; RA Liu Y., Karaca M., Zhang Z., Gioeli D., Earp H.S., Whang Y.E.; RT "Dasatinib inhibits site-specific tyrosine phosphorylation of androgen RT receptor by Ack1 and Src kinases."; RL Oncogene 29:3208-3216(2010). RN [29] RP FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH AKT1, SUBCELLULAR RP LOCATION, CHARACTERIZATION OF VARIANT LYS-346, PHOSPHORYLATION AT TYR-284, RP AND TISSUE SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [30] RP PHOSPHORYLATION AT TYR-284, TISSUE SPECIFICITY, AND ACTIVITY REGULATION. RX PubMed=20623637; DOI=10.1002/pros.21163; RA Mahajan K., Challa S., Coppola D., Lawrence H., Luo Y., Gevariya H., RA Zhu W., Chen Y.A., Lawrence N.J., Mahajan N.P.; RT "Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen RT receptor activity."; RL Prostate 70:1274-1285(2010). RN [31] RP PHOSPHORYLATION AT TYR-284, AND INTERACTION WITH SRC. RX PubMed=21309750; DOI=10.1042/bj20102156; RA Chan W., Sit S.T., Manser E.; RT "The Cdc42-associated kinase ACK1 is not auto-inhibited but requires Src RT for activation."; RL Biochem. J. 435:355-364(2011). RN [32] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-284; TYR-518; TYR-827; RP TYR-859 AND TYR-872. RX PubMed=21169560; DOI=10.1091/mbc.e10-07-0637; RA Shen H., Ferguson S.M., Dephoure N., Park R., Yang Y., Volpicelli-Daley L., RA Gygi S., Schlessinger J., De Camilli P.; RT "Constitutive activated Cdc42-associated kinase (Ack) phosphorylation at RT arrested endocytic clathrin-coated pits of cells that lack dynamin."; RL Mol. Biol. Cell 22:493-502(2011). RN [33] RP REVIEW ON TUMOR GROWTH. RX PubMed=20432460; DOI=10.1002/jcp.22162; RA Mahajan K., Mahajan N.P.; RT "Shepherding AKT and androgen receptor by Ack1 tyrosine kinase."; RL J. Cell. Physiol. 224:327-333(2010). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP STRUCTURE BY NMR OF 448-489. RX PubMed=10360579; DOI=10.1038/20732; RA Mott H.R., Owen D., Nietlispach D., Lowe P.N., Manser E., Lim L., RA Laue E.D.; RT "Structure of the small G protein Cdc42 bound to the GTPase-binding domain RT of ACK."; RL Nature 399:384-388(1999). RN [36] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 107-395, AND PHOSPHORYLATION AT RP TYR-284. RX PubMed=15308621; DOI=10.1074/jbc.m406703200; RA Lougheed J.C., Chen R.-H., Mak P., Stout T.J.; RT "Crystal structures of the phosphorylated and unphosphorylated kinase RT domains of the Cdc42-associated tyrosine kinase ACK1."; RL J. Biol. Chem. 279:44039-44045(2004). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 117-392 IN COMPLEX WITH INHIBITOR, RP AND CATALYTIC ACTIVITY. RX PubMed=18993068; DOI=10.1016/j.bmcl.2008.10.092; RA Kopecky D.J., Hao X., Chen Y., Fu J., Jiao X., Jaen J.C., Cardozo M.G., RA Liu J., Wang Z., Walker N.P., Wesche H., Li S., Farrelly E., Xiao S.H., RA Kayser F.; RT "Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4- RT d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors."; RL Bioorg. Med. Chem. Lett. 18:6352-6356(2008). RN [38] RP VARIANTS LEU-34; ARG-71; GLN-99; TRP-99; MET-152; LYS-346; ILE-409; RP SER-507; LEU-725; GLN-748 AND HIS-1038. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [39] RP VARIANT MET-638, INTERACTION WITH NEDD4 AND NEDD4L, AND CHARACTERIZATION OF RP VARIANT MET-638. RX PubMed=23686771; DOI=10.1002/ana.23934; RA Hitomi Y., Heinzen E.L., Donatello S., Dahl H.H., Damiano J.A., RA McMahon J.M., Berkovic S.F., Scheffer I.E., Legros B., Rai M., RA Weckhuysen S., Suls A., De Jonghe P., Pandolfo M., Goldstein D.B., RA Van Bogaert P., Depondt C.; RT "Mutations in TNK2 in severe autosomal recessive infantile onset RT epilepsy."; RL Ann. Neurol. 74:496-501(2013). CC -!- FUNCTION: Non-receptor tyrosine-protein and serine/threonine-protein CC kinase that is implicated in cell spreading and migration, cell CC survival, cell growth and proliferation. Transduces extracellular CC signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, CC MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated CC endocytosis through binding to epidermal growth factor receptor (EGFR) CC and clathrin. Binds to both poly- and mono-ubiquitin and regulates CC ligand-induced degradation of EGFR, thereby contributing to the CC accumulation of EGFR at the limiting membrane of early endosomes. CC Downstream effector of CDC42 which mediates CDC42-dependent cell CC migration via phosphorylation of BCAR1. May be involved both in adult CC synaptic function and plasticity and in brain development. Activates CC AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' CC and 'Tyr-363' thereby promoting its recruitment to androgen-responsive CC enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates CC MCF2, thereby enhancing its activity as a guanine nucleotide exchange CC factor (GEF) toward Rho family proteins. Contributes to the control of CC AXL receptor levels. Confers metastatic properties on cancer cells and CC promotes tumor growth by negatively regulating tumor suppressor such as CC WWOX and positively regulating pro-survival factors such as AKT1 and CC AR. Phosphorylates WASP (PubMed:20110370). CC {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:11278436, CC ECO:0000269|PubMed:16247015, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:17038317, CC ECO:0000269|PubMed:18262180, ECO:0000269|PubMed:18435854, CC ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20110370, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20383201}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, CC ECO:0000269|PubMed:20333297}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:20333297}; CC -!- ACTIVITY REGULATION: Inhibited by AIM-100 (4-amino-5,6-biaryl-furo[2,3- CC d]pyrimidine), which suppresses activating phosphorylation at Tyr-284. CC Repressed by dasatinib. {ECO:0000269|PubMed:20383201, CC ECO:0000269|PubMed:20623637}. CC -!- SUBUNIT: Interacts with NEDD4 (via WW3 domain). NEDD4L and EGF promote CC association with NEDD4 (By similarity). Homodimer. Interacts with AR, CC CDC42, WWASL and WWOX. Interacts with CSPG4 (activated). Interacts with CC MERTK (activated); stimulates autophosphorylation. May interact CC (phosphorylated) with HSP90AB1; maintains kinase activity. Interacts CC with NPHP1. Interacts with SNX9 (via SH3 domain). Interacts with SRC CC (via SH2 and SH3 domain). Interacts with EGFR, and this interaction is CC dependent on EGF stimulation and kinase activity of EGFR. Interacts CC (via kinase domain) with AKT1. Part of a collagen stimulated complex CC involved in cell migration composed of CDC42, CRK, TNK2 and CC BCAR1/p130cas. Interacts with BCAR1/p130cas via SH3 domains. Forms CC complexes with GRB2 and numerous receptor tyrosine kinases (RTK) CC including LTK, AXL or PDGFRL, in which GRB2 promotes RTK recruitment by CC TNK2. {ECO:0000250, ECO:0000269|PubMed:10587647, CC ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:17038317, CC ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:18477472, CC ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:19144635, CC ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20979614, ECO:0000269|PubMed:21309750, CC ECO:0000269|PubMed:23686771, ECO:0000269|PubMed:8497321}. CC -!- INTERACTION: CC Q07912; P29972: AQP1; NbExp=3; IntAct=EBI-603457, EBI-745213; CC Q07912; P56945: BCAR1; NbExp=5; IntAct=EBI-603457, EBI-702093; CC Q07912; P60953-2: CDC42; NbExp=2; IntAct=EBI-603457, EBI-287394; CC Q07912; Q00610: CLTC; NbExp=3; IntAct=EBI-603457, EBI-354967; CC Q07912; P07902: GALT; NbExp=3; IntAct=EBI-603457, EBI-750827; CC Q07912; P62993: GRB2; NbExp=6; IntAct=EBI-603457, EBI-401755; CC Q07912; P08238: HSP90AB1; NbExp=3; IntAct=EBI-603457, EBI-352572; CC Q07912; P16333: NCK1; NbExp=4; IntAct=EBI-603457, EBI-389883; CC Q07912; Q9HC98: NEK6; NbExp=3; IntAct=EBI-603457, EBI-740364; CC Q07912; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-603457, EBI-945833; CC Q07912; O60880: SH2D1A; NbExp=3; IntAct=EBI-603457, EBI-6983382; CC Q07912; Q9Y5X1: SNX9; NbExp=4; IntAct=EBI-603457, EBI-77848; CC Q07912; Q07912: TNK2; NbExp=2; IntAct=EBI-603457, EBI-603457; CC Q07912-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-11994780, EBI-3867333; CC Q07912-2; Q9BQC3: DPH2; NbExp=3; IntAct=EBI-11994780, EBI-10237931; CC Q07912-2; P07902: GALT; NbExp=3; IntAct=EBI-11994780, EBI-750827; CC Q07912-2; Q92569: PIK3R3; NbExp=3; IntAct=EBI-11994780, EBI-79893; CC Q07912-2; O60880: SH2D1A; NbExp=3; IntAct=EBI-11994780, EBI-6983382; CC Q07912-2; O14796: SH2D1B; NbExp=3; IntAct=EBI-11994780, EBI-3923013; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20979614}. Nucleus {ECO:0000269|PubMed:14733946, CC ECO:0000269|PubMed:20333297}. Endosome {ECO:0000250|UniProtKB:O54967}. CC Cell junction, adherens junction {ECO:0000305}. Cytoplasmic vesicle CC membrane; Peripheral membrane protein; Cytoplasmic side CC {ECO:0000269|PubMed:16137687}. Cytoplasmic vesicle, clathrin-coated CC vesicle {ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:18262180}. CC Membrane, clathrin-coated pit {ECO:0000269|PubMed:21169560}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:20110370}. Cytoplasm, cytosol CC {ECO:0000250|UniProtKB:O54967}. Note=The Tyr-284 phosphorylated form is CC found both in the membrane and nucleus (By similarity). Co-localizes CC with EGFR on endosomes (PubMed:20333297). Nuclear translocation is CC CDC42-dependent (By similarity). Detected in long filamentous cytosolic CC structures where it co-localizes with CTPS1 (By similarity). CC {ECO:0000250|UniProtKB:O54967, ECO:0000269|PubMed:20333297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q07912-1; Sequence=Displayed; CC Name=2; CC IsoId=Q07912-2; Sequence=VSP_008655, VSP_008656; CC Name=3; CC IsoId=Q07912-3; Sequence=VSP_037284, VSP_037285, VSP_037286; CC -!- TISSUE SPECIFICITY: The Tyr-284 phosphorylated form shows a significant CC increase in expression in breast cancers during the progressive stages CC i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), CC invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) CC stages. It also shows a significant increase in expression in prostate CC cancers during the progressive stages. {ECO:0000269|PubMed:16247015, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20623637}. CC -!- DOMAIN: The EBD (EGFR-binding domain) domain is necessary for CC interaction with EGFR. {ECO:0000250}. CC -!- DOMAIN: The SAM-like domain is necessary for NEDD4-mediated CC ubiquitination. Promotes membrane localization and dimerization to CC allow for autophosphorylation. {ECO:0000269|PubMed:20979614}. CC -!- DOMAIN: The UBA domain binds both poly- and mono-ubiquitin. CC {ECO:0000269|PubMed:20979614}. CC -!- PTM: Autophosphorylation regulates kinase activity. Phosphorylation on CC Tyr-518 is required for interaction with SRC and is observed during CC association with clathrin-coated pits. {ECO:0000269|PubMed:15308621, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614, CC ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750}. CC -!- PTM: Polyubiquitinated by NEDD4 and NEDD4L. Degradation can be induced CC by EGF and is lysosome-dependent (By similarity). {ECO:0000250}. CC -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH08884.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform. Aberrant splice sites.; Evidence={ECO:0000305}; CC Sequence=BAD18675.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L13738; AAA53570.2; -; mRNA. DR EMBL; AK131539; BAD18675.1; ALT_INIT; mRNA. DR EMBL; AC124944; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC008884; AAH08884.1; ALT_SEQ; mRNA. DR EMBL; BC028164; AAH28164.1; -; mRNA. DR CCDS; CCDS33927.2; -. [Q07912-3] DR CCDS; CCDS33928.1; -. [Q07912-1] DR PIR; S33596; S33596. DR RefSeq; NP_001010938.2; NM_001010938.2. [Q07912-3] DR RefSeq; NP_001294975.1; NM_001308046.1. DR RefSeq; NP_001374642.1; NM_001387713.1. [Q07912-1] DR RefSeq; NP_001374643.1; NM_001387714.1. [Q07912-1] DR RefSeq; NP_005772.3; NM_005781.4. [Q07912-1] DR RefSeq; XP_047303107.1; XM_047447151.1. [Q07912-1] DR RefSeq; XP_047303116.1; XM_047447160.1. [Q07912-1] DR RefSeq; XP_054200839.1; XM_054344864.1. [Q07912-1] DR RefSeq; XP_054200851.1; XM_054344876.1. [Q07912-1] DR PDB; 1CF4; NMR; -; B=448-489. DR PDB; 1U46; X-ray; 2.00 A; A/B=109-395. DR PDB; 1U4D; X-ray; 2.10 A; A/B=109-395. DR PDB; 1U54; X-ray; 2.80 A; A/B=109-395. DR PDB; 3EQP; X-ray; 2.30 A; A/B=117-392. DR PDB; 3EQR; X-ray; 2.00 A; A/B=117-392. DR PDB; 4EWH; X-ray; 2.50 A; A/B=117-391. DR PDB; 4HZR; X-ray; 1.31 A; A/B=115-389. DR PDB; 4HZS; X-ray; 3.23 A; A/B/C/D=115-453. DR PDB; 4ID7; X-ray; 3.00 A; A=117-389. DR PDB; 5ZXB; X-ray; 2.20 A; A/B=117-391. DR PDB; 6VQM; X-ray; 2.87 A; A/B=109-395. DR PDB; 7KP6; X-ray; 1.79 A; A/B=110-391. DR PDB; 8FE9; X-ray; 3.20 A; A=110-391. DR PDB; 8FZ3; X-ray; 2.78 A; A/B/C/D=958-1038. DR PDB; 8HMT; X-ray; 3.17 A; A/B/C/D=117-389. DR PDB; 8Q5P; X-ray; 1.81 A; B=508-519. DR PDB; 8THA; X-ray; 1.68 A; A=954-1038. DR PDBsum; 1CF4; -. DR PDBsum; 1U46; -. DR PDBsum; 1U4D; -. DR PDBsum; 1U54; -. DR PDBsum; 3EQP; -. DR PDBsum; 3EQR; -. DR PDBsum; 4EWH; -. DR PDBsum; 4HZR; -. DR PDBsum; 4HZS; -. DR PDBsum; 4ID7; -. DR PDBsum; 5ZXB; -. DR PDBsum; 6VQM; -. DR PDBsum; 7KP6; -. DR PDBsum; 8FE9; -. DR PDBsum; 8FZ3; -. DR PDBsum; 8HMT; -. DR PDBsum; 8Q5P; -. DR PDBsum; 8THA; -. DR AlphaFoldDB; Q07912; -. DR SMR; Q07912; -. DR BioGRID; 115485; 135. DR CORUM; Q07912; -. DR DIP; DIP-33858N; -. DR FunCoup; Q07912; 728. DR IntAct; Q07912; 73. DR MINT; Q07912; -. DR STRING; 9606.ENSP00000371341; -. DR BindingDB; Q07912; -. DR ChEMBL; CHEMBL4599; -. DR DrugBank; DB18236; (R)-9b. DR DrugBank; DB00171; ATP. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q07912; -. DR GuidetoPHARMACOLOGY; 2246; -. DR GlyCosmos; Q07912; 2 sites, 1 glycan. DR GlyGen; Q07912; 6 sites, 1 O-linked glycan (5 sites). DR iPTMnet; Q07912; -. DR PhosphoSitePlus; Q07912; -. DR BioMuta; TNK2; -. DR DMDM; 229462980; -. DR CPTAC; CPTAC-1779; -. DR CPTAC; CPTAC-2789; -. DR jPOST; Q07912; -. DR MassIVE; Q07912; -. DR PaxDb; 9606-ENSP00000371341; -. DR PeptideAtlas; Q07912; -. DR ProteomicsDB; 58556; -. [Q07912-1] DR ProteomicsDB; 58557; -. [Q07912-2] DR ProteomicsDB; 58558; -. [Q07912-3] DR Pumba; Q07912; -. DR Antibodypedia; 4095; 764 antibodies from 40 providers. DR CPTC; Q07912; 5 antibodies. DR DNASU; 10188; -. DR Ensembl; ENST00000333602.14; ENSP00000329425.6; ENSG00000061938.22. [Q07912-1] DR Ensembl; ENST00000439230.6; ENSP00000395588.1; ENSG00000061938.22. [Q07912-2] DR Ensembl; ENST00000671753.1; ENSP00000499858.1; ENSG00000061938.22. [Q07912-3] DR GeneID; 10188; -. DR KEGG; hsa:10188; -. DR UCSC; uc003fvt.2; human. [Q07912-1] DR AGR; HGNC:19297; -. DR ClinPGx; PA134909759; -. DR CTD; 10188; -. DR DisGeNET; 10188; -. DR GeneCards; TNK2; -. DR HGNC; HGNC:19297; TNK2. DR HPA; ENSG00000061938; Low tissue specificity. DR MalaCards; TNK2; -. DR MIM; 606994; gene. DR OpenTargets; ENSG00000061938; -. DR Orphanet; 391316; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression. DR VEuPathDB; HostDB:ENSG00000061938; -. DR eggNOG; KOG0199; Eukaryota. DR GeneTree; ENSGT00940000160853; -. DR HOGENOM; CLU_000288_7_39_1; -. DR InParanoid; Q07912; -. DR OrthoDB; 635774at2759; -. DR PAN-GO; Q07912; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q07912; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q07912; -. DR Reactome; R-HSA-9842663; Signaling by LTK. DR SignaLink; Q07912; -. DR SIGNOR; Q07912; -. DR Agora; ENSG00000061938; -. DR BioGRID-ORCS; 10188; 11 hits in 1191 CRISPR screens. DR ChiTaRS; TNK2; human. DR EvolutionaryTrace; Q07912; -. DR GeneWiki; TNK2; -. DR GenomeRNAi; 10188; -. DR Pharos; Q07912; Tclin. DR PRO; PR:Q07912; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q07912; protein. DR Bgee; ENSG00000061938; Expressed in right hemisphere of cerebellum and 192 other cell types or tissues. DR ExpressionAtlas; Q07912; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell. DR GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB. DR GO; GO:0030136; C:clathrin-coated vesicle; IDA:UniProtKB. DR GO; GO:0097268; C:cytoophidium; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; ISS:UniProtKB. DR GO; GO:0070436; C:Grb2-EGFR complex; IDA:BHF-UCL. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IDA:BHF-UCL. DR GO; GO:0005095; F:GTPase inhibitor activity; TAS:ProtInc. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0050699; F:WW domain binding; ISS:BHF-UCL. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:2000369; P:regulation of clathrin-dependent endocytosis; IDA:UniProtKB. DR GO; GO:0007264; P:small GTPase-mediated signal transduction; TAS:ProtInc. DR CDD; cd05040; PTKc_Ack_like; 1. DR CDD; cd09539; SAM_TNK-like; 1. DR CDD; cd14274; UBA_ACK1; 1. DR CDD; cd14328; UBA_TNK1; 1. DR DisProt; DP01772; -. DR FunFam; 4.10.680.10:FF:000001; activated CDC42 kinase 1 isoform X1; 1. DR FunFam; 1.10.510.10:FF:000080; Putative activated CDC42 kinase 1; 1. DR FunFam; 3.30.200.20:FF:000107; Putative activated CDC42 kinase 1; 1. DR Gene3D; 4.10.680.10; Cdc42-like binding domain; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00276; -. DR InterPro; IPR055175; ACK/TNK-like_SAM. DR InterPro; IPR030220; Ack1_UBA_dom. DR InterPro; IPR015116; Cdc42-bd-like. DR InterPro; IPR037085; Cdc42-bd-like_dom_sf. DR InterPro; IPR052112; EGFR_SigReg_Kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR021619; Mig-6. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR049587; TNK-like_SAM. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR14254; GENE 33 POLYPEPTIDE; 1. DR PANTHER; PTHR14254:SF6; NON-SPECIFIC PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF09027; GTPase_binding; 1. DR Pfam; PF11555; Inhibitor_Mig-6; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF22931; SAM_TNK; 1. DR Pfam; PF14604; SH3_9; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell junction; KW Cell membrane; Coated pit; Cytoplasm; Cytoplasmic vesicle; Endocytosis; KW Endosome; Kinase; Magnesium; Membrane; Metal-binding; Methylation; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; SH3 domain; KW Transferase; Tyrosine-protein kinase; Ubl conjugation. FT CHAIN 1..1038 FT /note="Activated CDC42 kinase 1" FT /id="PRO_0000088058" FT DOMAIN 126..385 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 388..448 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 454..466 FT /note="CRIB" FT DOMAIN 958..996 FT /note="UBA" FT REGION 1..110 FT /note="SAM-like domain" FT REGION 90..114 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 497..535 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 623..652 FT /note="Required for interaction with SRC" FT /evidence="ECO:0000269|PubMed:21309750" FT REGION 632..635 FT /note="Required for interaction with NEDD4" FT /evidence="ECO:0000250" FT REGION 659..702 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 718..840 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 733..876 FT /note="EBD domain" FT /evidence="ECO:0000250" FT REGION 917..957 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 738..749 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 772..783 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 794..805 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 252 FT /note="Proton acceptor" FT BINDING 132..140 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 158 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 284 FT /note="Phosphotyrosine; by SRC and autocatalysis" FT /evidence="ECO:0000269|PubMed:15308621, FT ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614, FT ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750, FT ECO:0007744|PubMed:19369195" FT MOD_RES 518 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 724 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 827 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 839 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:O54967" FT MOD_RES 859 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 872 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 881 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT VAR_SEQ 1 FT /note="M -> MGERSAYQRLAGGEEGPQRLGGGRM (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037284" FT VAR_SEQ 485..528 FT /note="LYLGNPMDPPDLLSVELSTSRPPQHLGGVKKPTYDPVSEDQDPL -> CPFS FT AFSPGHPPAETCGQVLWTGRREACASDPRLHPVSSRTKGL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_008655" FT VAR_SEQ 514 FT /note="K -> KREPPPRPPQPAFFTQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037285" FT VAR_SEQ 529..1038 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_008656" FT VAR_SEQ 965..994 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037286" FT VARIANT 34 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation; increased autophosphorylation at Y-284; increased FT function in phosphorylation of peptide substrates; no FT effect on subcellular localization to perinuclear region)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032792" FT VARIANT 71 FT /note="K -> R (in dbSNP:rs56036945)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032793" FT VARIANT 99 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; increased autophosphorylation at Y-284; FT increased function in phosphorylation of peptide substrates FT and WASP; no effect on subcellular localization to FT perinuclear region; dbSNP:rs113498671)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032794" FT VARIANT 99 FT /note="R -> W (in dbSNP:rs3747673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032795" FT VARIANT 152 FT /note="T -> M (in dbSNP:rs56161912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032796" FT VARIANT 346 FT /note="E -> K (in an ovarian endometrioid cancer sample; FT somatic mutation; undergoes autoactivation and causes FT phosphorylation on Y-284 leading to activation of AKT1; FT increased autophosphorylation at Y-284; increased function FT in phosphorylation of peptide substrates and WASP; no FT effect on catalytic activity itself as the purified kinase FT domain has activity in vitro comparable to wild-type FT protein; no effect on subcellular localization to FT perinuclear region; dbSNP:rs970946035)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370, ECO:0000269|PubMed:20333297" FT /id="VAR_032797" FT VARIANT 409 FT /note="M -> I (in a gastric adenocarcinoma sample; somatic FT mutation; increased autophosphorylation at Y-284; increased FT function in phosphorylation of peptide substrates and WASP; FT no effect on subcellular localization to perinuclear FT region)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032798" FT VARIANT 507 FT /note="P -> S (in dbSNP:rs35759128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032799" FT VARIANT 638 FT /note="V -> M (found in patients with childhood-onset FT epilepsy; uncertain significance; loss of interaction with FT NEDD4 and NEDD4L; increased protein abundance; FT dbSNP:rs201407161)" FT /evidence="ECO:0000269|PubMed:23686771" FT /id="VAR_076966" FT VARIANT 725 FT /note="P -> L (in dbSNP:rs56260729)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_032800" FT VARIANT 748 FT /note="R -> Q (in dbSNP:rs57872314)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032801" FT VARIANT 802 FT /note="P -> L (in dbSNP:rs3749333)" FT /id="VAR_057115" FT VARIANT 1038 FT /note="R -> H (in dbSNP:rs13433937)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032802" FT MUTAGEN 120 FT /note="L->Q: No effect on autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 158 FT /note="K->R: Loss of autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:16288044, FT ECO:0000269|PubMed:20110370" FT MUTAGEN 197 FT /note="L->Q: No effect on autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 365 FT /note="V->R: Increased autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 487 FT /note="L->F: Constantly active kinase." FT /evidence="ECO:0000269|PubMed:16288044" FT CONFLICT 138 FT /note="G -> V (in Ref. 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 304..352 FT /note="TRTFSHASDTWMFGVTLWEMFTYGQEPWIGLNGSQILHKIDKEGERLPR -> FT PPWRDISASSSTQFPHAVPCFPTSLLAKLLLRHSVPASSREIKLVSILC (in Ref. FT 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 353..1038 FT /note="Missing (in Ref. 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 586 FT /note="A -> P (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT CONFLICT 722 FT /note="Missing (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT CONFLICT 838..840 FT /note="PRA -> AG (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:4HZS" FT HELIX 123..125 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 126..133 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 140..146 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:3EQP" FT STRAND 152..159 FT /evidence="ECO:0007829|PDB:4HZR" FT TURN 164..166 FT /evidence="ECO:0007829|PDB:3EQR" FT HELIX 171..181 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 192..196 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 198..200 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 202..206 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 209..212 FT /evidence="ECO:0007829|PDB:8FE9" FT HELIX 213..219 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 226..245 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 255..257 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 258..262 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 265..268 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 273..276 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:1U46" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:3EQP" FT HELIX 294..296 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 299..304 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 306..308 FT /evidence="ECO:0007829|PDB:1U46" FT HELIX 309..324 FT /evidence="ECO:0007829|PDB:4HZR" FT TURN 325..327 FT /evidence="ECO:0007829|PDB:4HZS" FT TURN 330..333 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 336..344 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 358..367 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 372..374 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 378..387 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 392..394 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 402..404 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 412..417 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 419..421 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 423..432 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 435..439 FT /evidence="ECO:0007829|PDB:4HZS" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 449..451 FT /evidence="ECO:0007829|PDB:1CF4" FT TURN 484..486 FT /evidence="ECO:0007829|PDB:1CF4" SQ SEQUENCE 1038 AA; 114569 MW; 74A1980665BC3E6B CRC64; MQPEEGTGWL LELLSEVQLQ QYFLRLRDDL NVTRLSHFEY VKNEDLEKIG MGRPGQRRLW EAVKRRKALC KRKSWMSKVF SGKRLEAEFP PHHSQSTFRK TSPAPGGPAG EGPLQSLTCL IGEKDLRLLE KLGDGSFGVV RRGEWDAPSG KTVSVAVKCL KPDVLSQPEA MDDFIREVNA MHSLDHRNLI RLYGVVLTPP MKMVTELAPL GSLLDRLRKH QGHFLLGTLS RYAVQVAEGM GYLESKRFIH RDLAARNLLL ATRDLVKIGD FGLMRALPQN DDHYVMQEHR KVPFAWCAPE SLKTRTFSHA SDTWMFGVTL WEMFTYGQEP WIGLNGSQIL HKIDKEGERL PRPEDCPQDI YNVMVQCWAH KPEDRPTFVA LRDFLLEAQP TDMRALQDFE EPDKLHIQMN DVITVIEGRA ENYWWRGQNT RTLCVGPFPR NVVTSVAGLS AQDISQPLQN SFIHTGHGDS DPRHCWGFPD RIDELYLGNP MDPPDLLSVE LSTSRPPQHL GGVKKPTYDP VSEDQDPLSS DFKRLGLRKP GLPRGLWLAK PSARVPGTKA SRGSGAEVTL IDFGEEPVVP ALRPCAPSLA QLAMDACSLL DETPPQSPTR ALPRPLHPTP VVDWDARPLP PPPAYDDVAQ DEDDFEICSI NSTLVGAGVP AGPSQGQTNY AFVPEQARPP PPLEDNLFLP PQGGGKPPSS AQTAEIFQAL QQECMRQLQA PAGSPAPSPS PGGDDKPQVP PRVPIPPRPT RPHVQLSPAP PGEEETSQWP GPASPPRVPP REPLSPQGSR TPSPLVPPGS SPLPPRLSSS PGKTMPTTQS FASDPKYATP QVIQAPGPRA GPCILPIVRD GKKVSSTHYY LLPERPSYLE RYQRFLREAQ SPEEPTPLPV PLLLPPPSTP APAAPTATVR PMPQAALDPK ANFSTNNSNP GARPPPPRAT ARLPQRGCPG DGPEAGRPAD KIQMAMVHGV TTEECQAALQ CHGWSVQRAA QYLKVEQLFG LGLRPRGECH KVLEMFDWNL EQAGCHLLGS WGPAHHKR // ID AKT1_HUMAN Reviewed; 480 AA. AC P31749; B2RAM5; B7Z5R1; Q9BWB6; DT 01-JUL-1993, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-2005, sequence version 2. DT 28-JAN-2026, entry version 272. DE RecName: Full=RAC-alpha serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; DE AltName: Full=Protein kinase B; DE Short=PKB; DE AltName: Full=Protein kinase B alpha; DE Short=PKB alpha; DE AltName: Full=Proto-oncogene c-Akt; DE AltName: Full=RAC-PK-alpha; GN Name=AKT1 {ECO:0000312|HGNC:HGNC:391}; Synonyms=PKB, RAC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY. RX PubMed=1851997; DOI=10.1073/pnas.88.10.4171; RA Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A.; RT "Molecular cloning and identification of a serine/threonine protein kinase RT of the second-messenger subfamily."; RL Proc. Natl. Acad. Sci. U.S.A. 88:4171-4175(1991). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11508278; DOI=10.1007/s001250100577; RA Matsubara A., Wasson J.C., Donelan S.S., Welling C.M., Glaser B., RA Permutt M.A.; RT "Isolation and characterization of the human AKT1 gene, identification of RT 13 single nucleotide polymorphisms (SNPs), and their lack of association RT with Type II diabetes."; RL Diabetologia 44:910-913(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Adrenal gland; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 63-480 (ISOFORM 1), FUNCTION, CATALYTIC RP ACTIVITY, AND TISSUE SPECIFICITY. RC TISSUE=Foreskin; RX PubMed=1718748; DOI=10.1111/j.1432-1033.1991.tb16305.x; RA Coffer P.J., Woodgett J.R.; RT "Molecular cloning and characterisation of a novel putative protein-serine RT kinase related to the cAMP-dependent and protein kinase C families."; RL Eur. J. Biochem. 201:475-481(1991). RN [8] RP ERRATUM OF PUBMED:1718748, AND SEQUENCE REVISION. RX PubMed=1533586; RA Coffer P.J., Woodgett J.R.; RL Eur. J. Biochem. 205:1217-1218(1992). RN [9] RP FUNCTION IN PHOSPHORYLATION OF CREB1. RX PubMed=9829964; DOI=10.1074/jbc.273.49.32377; RA Du K., Montminy M.; RT "CREB is a regulatory target for the protein kinase Akt/PKB."; RL J. Biol. Chem. 273:32377-32379(1998). RN [10] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-473. RX PubMed=9736715; DOI=10.1073/pnas.95.19.11211; RA Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.; RT "Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase RT kinase 3 and protein kinase B/AKT by the integrin-linked kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998). RN [11] RP MUTAGENESIS OF THR-308 AND SER-473, AND PHOSPHORYLATION AT THR-308 AND RP SER-473. RX PubMed=8978681; DOI=10.1002/j.1460-2075.1996.tb01045.x; RA Alessi D.R., Andjelkovic M., Caudwell F.B., Cron P., Morrice N., Cohen P., RA Hemmings B.A.; RT "Mechanism of activation of protein kinase B by insulin and IGF-1."; RL EMBO J. 15:6541-6551(1996). RN [12] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-308 BY PDPK1. RX PubMed=9512493; DOI=10.1042/bj3310299; RA Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.; RT "Activation of protein kinase B beta and gamma isoforms by insulin in vivo RT and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison RT with protein kinase B alpha."; RL Biochem. J. 331:299-308(1998). RN [13] RP FUNCTION IN PHOSPHORYLATION OF FOXO1. RX PubMed=10358075; DOI=10.1074/jbc.274.24.17179; RA Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.; RT "Phosphorylation of the transcription factor forkhead family member FKHR by RT protein kinase B."; RL J. Biol. Chem. 274:17179-17183(1999). RN [14] RP FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP FUNCTION IN PHOSPHORYLATION OF BAD, AND INTERACTION WITH BAD AND PKN2. RX PubMed=10926925; DOI=10.1074/jbc.m001753200; RA Koh H., Lee K.H., Kim D., Kim S., Kim J.W., Chung J.; RT "Inhibition of Akt and its anti-apoptotic activities by tumor necrosis RT factor-induced protein kinase C-related kinase 2 (PRK2) cleavage."; RL J. Biol. Chem. 275:34451-34458(2000). RN [16] RP INTERACTION WITH MTCP1; TCL1A AND TCL1B. RX PubMed=10983986; DOI=10.1016/s1097-2765(00)00039-3; RA Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.; RT "The protooncogene TCL1 is an Akt kinase coactivator."; RL Mol. Cell 6:395-407(2000). RN [17] RP INTERACTION WITH TCL1A. RX PubMed=10716693; DOI=10.1073/pnas.97.7.3028; RA Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S., RA Russo G., Tsichlis P., Croce C.M.; RT "Tcl1 enhances Akt kinase activity and mediates its nuclear RT translocation."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3028-3033(2000). RN [18] RP FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5. RX PubMed=11154276; DOI=10.1128/mcb.21.3.893-901.2001; RA Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V.; RT "Akt phosphorylates and negatively regulates apoptosis signal-regulating RT kinase 1."; RL Mol. Cell. Biol. 21:893-901(2001). RN [19] RP INTERACTION WITH THEM4, AND SUBCELLULAR LOCATION. RX PubMed=11598301; DOI=10.1126/science.1062030; RA Maira S.-M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., RA Hemmings B.A.; RT "Carboxyl-terminal modulator protein (CTMP), a negative regulator of RT PKB/Akt and v-Akt at the plasma membrane."; RL Science 294:374-380(2001). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TBC1D4. RX PubMed=11994271; DOI=10.1074/jbc.c200198200; RA Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C., RA Lienhard G.E.; RT "A method to identify serine kinase substrates. Akt phosphorylates a novel RT adipocyte protein with a Rab GTPase-activating protein (GAP) domain."; RL J. Biol. Chem. 277:22115-22118(2002). RN [21] RP INTERACTION WITH CDKN1B, AND FUNCTION. RX PubMed=12042314; DOI=10.1074/jbc.m203668200; RA Fujita N., Sato S., Katayama K., Tsuruo T.; RT "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and RT cytoplasmic localization."; RL J. Biol. Chem. 277:28706-28713(2002). RN [22] RP PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474. RX PubMed=12149249; DOI=10.1074/jbc.m203387200; RA Conus N.M., Hannan K.M., Cristiano B.E., Hemmings B.A., Pearson R.B.; RT "Direct identification of tyrosine 474 as a regulatory phosphorylation site RT for the Akt protein kinase."; RL J. Biol. Chem. 277:38021-38028(2002). RN [23] RP FUNCTION IN PHOSPHORYLATION OF TSC2. RX PubMed=12150915; DOI=10.1016/s1097-2765(02)00568-3; RA Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C.; RT "Identification of the tuberous sclerosis complex-2 tumor suppressor gene RT product tuberin as a target of the phosphoinositide 3-kinase/akt pathway."; RL Mol. Cell 10:151-162(2002). RN [24] RP INTERACTION WITH TCL1A. RX PubMed=11839817; DOI=10.1128/mcb.22.5.1513-1525.2002; RA Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F., RA Roumestand C., Stern M.H., Noguchi M.; RT "Identification of Akt association and oligomerization domains of the Akt RT kinase coactivator TCL1."; RL Mol. Cell. Biol. 22:1513-1525(2002). RN [25] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=12172553; DOI=10.1038/ncb839; RA Inoki K., Li Y., Zhu T., Wu J., Guan K.L.; RT "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR RT signalling."; RL Nat. Cell Biol. 4:648-657(2002). RN [26] RP INTERACTION WITH CDKN1B, FUNCTION, AND MUTAGENESIS OF THR-308 AND SER-473. RX PubMed=12244301; DOI=10.1038/nm759; RA Shin I., Yakes F.M., Rojo F., Shin N.-Y., Bakin A.V., Baselga J., RA Arteaga C.L.; RT "PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at RT threonine 157 and modulation of its cellular localization."; RL Nat. Med. 8:1145-1152(2002). RN [27] RP FUNCTION IN PARTICIPATION IN KIT SIGNALING. RX PubMed=12878163; DOI=10.1016/s0014-4827(03)00206-4; RA Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.; RT "Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent RT phosphorylation site mediating interaction with c-Crk."; RL Exp. Cell Res. 288:110-118(2003). RN [28] RP INTERACTION WITH AGAP2, AND PHOSPHORYLATION AT SER-473. RX PubMed=14761976; DOI=10.1074/jbc.m312175200; RA Ahn J.-Y., Rong R., Kroll T.G., Van Meir E.G., Snyder S.H., Ye K.; RT "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt RT activity and mediates cellular invasion."; RL J. Biol. Chem. 279:16441-16451(2004). RN [29] RP PHOSPHORYLATION AT SER-473. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [30] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [31] RP PHOSPHORYLATION AT SER-473. RX PubMed=15262962; DOI=10.1074/jbc.m406731200; RA Feng J., Park J., Cron P., Hess D., Hemmings B.A.; RT "Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA- RT dependent protein kinase."; RL J. Biol. Chem. 279:41189-41196(2004). RN [32] RP INTERACTION WITH AKTIP. RX PubMed=14749367; DOI=10.1128/mcb.24.4.1493-1504.2004; RA Remy I., Michnick S.W.; RT "Regulation of apoptosis by the Ft1 protein, a new modulator of protein RT kinase B/Akt."; RL Mol. Cell. Biol. 24:1493-1504(2004). RN [33] RP INTERACTION WITH AGAP2. RX PubMed=15118108; DOI=10.1073/pnas.0400921101; RA Ahn J.-Y., Hu Y., Kroll T.G., Allard P., Ye K.; RT "PIKE-A is amplified in human cancers and prevents apoptosis by up- RT regulating Akt."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6993-6998(2004). RN [34] RP PHOSPHORYLATION AT SER-473 IN RESPONSE TO FLT3 SIGNALING. RX PubMed=16266983; DOI=10.1158/0008-5472.can-05-0422; RA Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., RA Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E., RA Serve H.; RT "Constitutive activation of Akt by Flt3 internal tandem duplications is RT necessary for increased survival, proliferation, and myeloid RT transformation."; RL Cancer Res. 65:9643-9650(2005). RN [35] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A. RX PubMed=16139227; DOI=10.1016/j.devcel.2005.08.001; RA Enomoto A., Murakami H., Asai N., Morone N., Watanabe T., Kawai K., RA Murakumo Y., Usukura J., Kaibuchi K., Takahashi M.; RT "Akt/PKB regulates actin organization and cell motility via Girdin/APE."; RL Dev. Cell 9:389-402(2005). RN [36] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15861136; DOI=10.1038/sj.emboj.7600648; RA Cartlidge R.A., Knebel A., Peggie M., Alexandrov A., Phizicky E.M., RA Cohen P.; RT "The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK RT in vitro and in cells."; RL EMBO J. 24:1696-1705(2005). RN [37] RP PHOSPHORYLATION AT THR-308, AND PHOSPHORYLATION AT SER-473 BY MTOR. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [38] RP PHOSPHORYLATION AT SER-473. RX PubMed=17013611; DOI=10.1007/s00401-006-0128-y; RA Schick V., Majores M., Engels G., Spitoni S., Koch A., Elger C.E., RA Simon M., Knobbe C., Bluemcke I., Becker A.J.; RT "Activation of Akt independent of PTEN and CTMP tumor-suppressor gene RT mutations in epilepsy-associated Taylor-type focal cortical dysplasias."; RL Acta Neuropathol. 112:715-725(2006). RN [39] RP INTERACTION WITH WDFY2, AND SUBCELLULAR LOCATION. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [40] RP FUNCTION, AND INTERACTION WITH RARA. RX PubMed=16417524; DOI=10.1042/bj20051794; RA Srinivas H., Xia D., Moore N.L., Uray I.P., Kim H., Ma L., Weigel N.L., RA Brown P.H., Kurie J.M.; RT "Akt phosphorylates and suppresses the transactivation of retinoic acid RT receptor alpha."; RL Biochem. J. 395:653-662(2006). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [42] RP BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=16540465; DOI=10.1074/jbc.m601384200; RA Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A., Kendall R.L.; RT "Kinetic mechanism of AKT/PKB enzyme family."; RL J. Biol. Chem. 281:13949-13956(2006). RN [43] RP FUNCTION IN PHOSPHORYLATION OF CDKN1A. RX PubMed=16982699; DOI=10.1128/mcb.00201-06; RA Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D., RA Hemmings B.A., Fernandez A., Lamb N.J.; RT "Only Akt1 is required for proliferation, while Akt2 promotes cell cycle RT exit through p21 binding."; RL Mol. Cell. Biol. 26:8267-8280(2006). RN [44] RP INTERACTION WITH STK4/MST1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17932490; DOI=10.1038/sj.emboj.7601872; RA Cinar B., Fang P.K., Lutchman M., Di Vizio D., Adam R.M., Pavlova N., RA Rubin M.A., Yelick P.C., Freeman M.R.; RT "The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct RT inhibitors of Akt1."; RL EMBO J. 26:4523-4534(2007). RN [45] RP FUNCTION, AND INTERACTION WITH STK4/MST1. RX PubMed=17726016; DOI=10.1074/jbc.m704542200; RA Jang S.W., Yang S.J., Srinivasan S., Ye K.; RT "Akt phosphorylates MstI and prevents its proteolytic activation, blocking RT FOXO3 phosphorylation and nuclear translocation."; RL J. Biol. Chem. 282:30836-30844(2007). RN [46] RP FUNCTION IN PHOSPHORYLATION OF PROHIBITIN. RX PubMed=18507042; RA Han E.K., Mcgonigal T., Butler C., Giranda V.L., Luo Y.; RT "Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is RT an Akt substrate both in vitro and in cells."; RL Anticancer Res. 28:957-963(2008). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND SER-129, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [48] RP UBIQUITINATION BY TTC3. RX PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007; RA Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J., Hirata N., RA Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C., Hatakeyama S., RA Obata T., Noguchi M.; RT "The E3 ligase TTC3 facilitates ubiquitination and degradation of RT phosphorylated Akt."; RL Dev. Cell 17:800-810(2009). RN [49] RP FUNCTION IN PHOSPHORYLATION OF SRPK2, AND INTERACTION WITH SRPK2. RX PubMed=19592491; DOI=10.1074/jbc.m109.026237; RA Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.; RT "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle RT and cell death in neurons."; RL J. Biol. Chem. 284:24512-24525(2009). RN [50] RP FUNCTION. RX PubMed=19934221; DOI=10.1242/jcs.053728; RA Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L., Webb D.J.; RT "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin RT dynamics and thereby regulate cell migration."; RL J. Cell Sci. 122:4535-4546(2009). RN [51] RP UBIQUITINATION, INTERACTION WITH TRAF6, MUTAGENESIS OF LYS-8 AND LYS-14, RP AND CHARACTERIZATION OF VARIANT BREAST CANCER LYS-17. RX PubMed=19713527; DOI=10.1126/science.1175065; RA Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B., RA Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.; RT "The E3 ligase TRAF6 regulates Akt ubiquitination and activation."; RL Science 325:1134-1138(2009). RN [52] RP FUNCTION, AND INTERACTION WITH STK3/MST2. RX PubMed=20086174; DOI=10.1158/0008-5472.can-09-3147; RA Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W.; RT "Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, RT Raf-1, and Akt."; RL Cancer Res. 70:1195-1203(2010). RN [53] RP RETRACTED PAPER. RX PubMed=19940129; DOI=10.1074/jbc.m109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RT "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic RT signaling through phosphorylation of threonine 120."; RL J. Biol. Chem. 285:3815-3824(2010). RN [54] RP RETRACTION NOTICE OF PUBMED:19940129. RX PubMed=27825096; DOI=10.1074/jbc.a109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RL J. Biol. Chem. 291:22858-22858(2016). RN [55] RP FUNCTION, AND INTERACTION WITH CLK2. RX PubMed=20682768; DOI=10.1074/jbc.m110.122044; RA Nam S.Y., Seo H.H., Park H.S., An S., Kim J.Y., Yang K.H., Kim C.S., RA Jeong M., Jin Y.W.; RT "Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls RT cell survival after ionizing radiation."; RL J. Biol. Chem. 285:31157-31163(2010). RN [56] RP FUNCTION IN PHOSPHORYLATION OF PALLD. RX PubMed=20471940; DOI=10.1016/j.molcel.2010.02.031; RA Chin Y.R., Toker A.; RT "The actin-bundling protein palladin is an Akt1-specific substrate that RT regulates breast cancer cell migration."; RL Mol. Cell 38:333-344(2010). RN [57] RP RETRACTED PAPER. RX PubMed=20231902; DOI=10.1371/journal.pone.0009616; RA Kim D., Shu S., Coppola M.D., Kaneko S., Yuan Z.Q., Cheng J.Q.; RT "Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1- RT Akt pathway."; RL PLoS ONE 5:E9616-E9616(2010). RN [58] RP CAUTION, AND RETRACTION NOTICE OF PUBMED:20231902. RX PubMed=37490513; DOI=10.1371/journal.pone.0289329; RG PLOS ONE Editors; RT "Retraction: Regulation of Proapoptotic Mammalian ste20-Like Kinase MST2 by RT the IGF1-Akt Pathway."; RL PLoS ONE 18:e0289329-e0289329(2023). RN [59] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-176; THR-308 AND RP SER-473, MUTAGENESIS OF TYR-176, INTERACTION WITH TNK2, AND TISSUE RP SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [60] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [61] RP INTERACTION WITH TRIM13, AND UBIQUITINATION. RX PubMed=21333377; DOI=10.1016/j.ejcb.2010.12.001; RA Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H., Kim C.S., RA Kim H.S., Jeong M., An S., Jin Y.W.; RT "Ret finger protein 2 enhances ionizing radiation-induced apoptosis via RT degradation of AKT and MDM2."; RL Eur. J. Cell Biol. 90:420-431(2011). RN [62] RP INTERACTION WITH PPP2R5B, AND DEPHOSPHORYLATION. RX PubMed=21329884; DOI=10.1016/j.molcel.2011.02.007; RA Rodgers J.T., Vogel R.O., Puigserver P.; RT "Clk2 and B56-beta mediate insulin-regulated assembly of the PP2A RT phosphatase holoenzyme complex on Akt."; RL Mol. Cell 41:471-479(2011). RN [63] RP INTERACTION WITH FAM168A. RX PubMed=23251525; DOI=10.1371/journal.pone.0051413; RA Peng B., Gu Y., Xiong Y., Zheng G., He Z.; RT "Microarray-assisted pathway analysis identifies MT1X & NFkappaB as RT mediators of TCRP1-associated resistance to cisplatin in oral squamous cell RT carcinoma."; RL PLoS ONE 7:E51413-E51413(2012). RN [64] RP PROTEOLYTIC CLEAVAGE. RX PubMed=23152800; DOI=10.1371/journal.pone.0048770; RA Sen T., Sen N., Noordhuis M.G., Ravi R., Wu T.C., Ha P.K., Sidransky D., RA Hoque M.O.; RT "OGDHL is a modifier of AKT-dependent signaling and NF-kappaB function."; RL PLoS ONE 7:e48770-e48770(2012). RN [65] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [66] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [67] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [68] RP REVIEW ON FUNCTION. RX PubMed=11882383; DOI=10.1016/s0898-6568(01)00271-6; RA Nicholson K.M., Anderson N.G.; RT "The protein kinase B/Akt signalling pathway in human malignancy."; RL Cell. Signal. 14:381-395(2002). RN [69] RP PHOSPHORYLATION AT SER-473. RX PubMed=20978158; DOI=10.1158/1535-7163.mct-10-0730; RA Kunoh T., Noda T., Koseki K., Sekigawa M., Takagi M., Shin-ya K., RA Goshima N., Iemura S., Natsume T., Wada S., Mukai Y., Ohta S., Sasaki R., RA Mizukami T.; RT "A novel human dynactin-associated protein, dynAP, promotes activation of RT Akt, and ergosterol-related compounds induce dynAP-dependent apoptosis of RT human cancer cells."; RL Mol. Cancer Ther. 9:2934-2942(2010). RN [70] RP REVIEW ON FUNCTION. RX PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004; RA Hers I., Vincent E.E., Tavare J.M.; RT "Akt signalling in health and disease."; RL Cell. Signal. 23:1515-1527(2011). RN [71] RP REVIEW ON FUNCTION. RX PubMed=21432781; DOI=10.14670/hh-26.651; RA Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.; RT "Akt1 and Akt2: differentiating the aktion."; RL Histol. Histopathol. 26:651-662(2011). RN [72] RP PHOSPHORYLATION AT THR-308 AND SER-473. RX PubMed=21464307; DOI=10.1073/pnas.1016132108; RA Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., RA Guan K.L.; RT "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011). RN [73] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-14 AND LYS-20, DEACETYLATION AT RP LYS-14 AND LYS-20, AND MUTAGENESIS OF LYS-14; GLU-17 AND LYS-20. RX PubMed=21775285; DOI=10.1126/scisignal.2001465; RA Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P., RA Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P.; RT "The deacetylase SIRT1 promotes membrane localization and activation of Akt RT and PDK1 during tumorigenesis and cardiac hypertrophy."; RL Sci. Signal. 4:RA46-RA46(2011). RN [74] RP UBIQUITINATION AT LYS-284. RX PubMed=22410793; DOI=10.1038/cr.2012.38; RA Bae S., Kim S.Y., Jung J.H., Yoon Y., Cha H.J., Lee H., Kim K., Kim J., RA An I.S., Kim J., Um H.D., Park I.C., Lee S.J., Nam S.Y., Jin Y.W., RA Lee J.H., An S.; RT "Akt is negatively regulated by the MULAN E3 ligase."; RL Cell Res. 22:873-885(2012). RN [75] RP GLYCOSYLATION AT SER-126; SER-129; THR-305 AND THR-312, SUBCELLULAR RP LOCATION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF THR-305 AND THR-312. RX PubMed=22629392; DOI=10.1371/journal.pone.0037427; RA Wang S., Huang X., Sun D., Xin X., Pan Q., Peng S., Liang Z., Luo C., RA Yang Y., Jiang H., Huang M., Chai W., Ding J., Geng M.; RT "Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates RT Akt signaling."; RL PLoS ONE 7:E37427-E37427(2012). RN [76] RP PHOSPHORYLATION AT SER-473, AND DEPHOSPHORYLATION BY CPPED1. RX PubMed=23799035; DOI=10.1371/journal.pone.0065679; RA Zhuo D.X., Zhang X.W., Jin B., Zhang Z., Xie B.S., Wu C.L., Gong K., RA Mao Z.B.; RT "CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell RT apoptosis, and suppresses tumor growth of bladder cancer by directly RT dephosphorylating Akt at Ser473 site."; RL PLoS ONE 8:E65679-E65679(2013). RN [77] RP FUNCTION. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [78] RP INTERACTION WITH SYAP1. RX PubMed=23300339; DOI=10.1126/scisignal.2003295; RA Yao Y., Suraokar M., Darnay B.G., Hollier B.G., Shaiken T.E., Asano T., RA Chen C.H., Chang B.H., Lu Y., Mills G.B., Sarbassov D., Mani S.A., RA Abbruzzese J.L., Reddy S.A.; RT "BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress RT expression of FoxC2 and stimulate adipocyte differentiation."; RL Sci. Signal. 6:RA2-RA2(2013). RN [79] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-448 AND THR-450, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [80] RP PHOSPHORYLATION AT SER-477 AND THR-479, AND MUTAGENESIS OF 76-ARG--LEU-78 RP AND 273-ARG--LEU-275. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26440888; DOI=10.1016/j.celrep.2015.09.007; RA Seo G.J., Yang A., Tan B., Kim S., Liang Q., Choi Y., Yuan W., Feng P., RA Park H.S., Jung J.U.; RT "Akt kinase-mediated checkpoint of cGAS DNA sensing pathway."; RL Cell Rep. 13:440-449(2015). RN [82] RP INTERACTION WITH KIF14. RX PubMed=24784001; DOI=10.1016/j.neo.2014.03.008; RA Singel S.M., Cornelius C., Zaganjor E., Batten K., Sarode V.R., RA Buckley D.L., Peng Y., John G.B., Li H.C., Sadeghi N., Wright W.E., Lum L., RA Corson T.W., Shay J.W.; RT "KIF14 promotes AKT phosphorylation and contributes to chemoresistance in RT triple-negative breast cancer."; RL Neoplasia 16:247-256(2014). RN [83] RP PHOSPHORYLATION AT SER-473, DEPHOSPHORYLATION, AND INTERACTION WITH PHLPP1 RP AND FKBP5. RX PubMed=28147277; DOI=10.1016/j.celrep.2017.01.009; RA Yu J., Qin B., Wu F., Qin S., Nowsheen S., Shan S., Zayas J., Pei H., RA Lou Z., Wang L.; RT "Regulation of serine-threonine kinase Akt activation by NAD+-dependent RT deacetylase SIRT7."; RL Cell Rep. 18:1229-1240(2017). RN [84] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=29343641; DOI=10.1073/pnas.1705954115; RA Choppara S., Malonia S.K., Sankaran G., Green M.R., Santra M.K.; RT "Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 115:998-1003(2018). RN [85] RP FUNCTION. RX PubMed=30504268; DOI=10.15252/embj.201899435; RA Marchi S., Corricelli M., Branchini A., Vitto V.A.M., Missiroli S., RA Morciano G., Perrone M., Ferrarese M., Giorgi C., Pinotti M., Galluzzi L., RA Kroemer G., Pinton P.; RT "Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels RT and tumor growth."; RL EMBO J. 38:0-0(2019). RN [86] RP FUNCTION. RX PubMed=31204173; DOI=10.1016/j.devcel.2019.05.022; RA Walia V., Cuenca A., Vetter M., Insinna C., Perera S., Lu Q., Ritt D.A., RA Semler E., Specht S., Stauffer J., Morrison D.K., Lorentzen E., RA Westlake C.J.; RT "Akt Regulates a Rab11-Effector Switch Required for Ciliogenesis."; RL Dev. Cell 50:229-246(2019). RN [87] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=31548394; DOI=10.1073/pnas.1904774116; RA Padi S.K.R., Singh N., Bearss J.J., Olive V., Song J.H., Cardo-Vila M., RA Kraft A.S., Okumura K.; RT "Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases RT inhibition of mTORC1 and promotes tumor growth."; RL Proc. Natl. Acad. Sci. U.S.A. 116:20505-20510(2019). RN [88] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32322062; DOI=10.1038/s41586-020-2183-2; RA Xu D., Wang Z., Xia Y., Shao F., Xia W., Wei Y., Li X., Qian X., Lee J.H., RA Du L., Zheng Y., Lv G., Leu J.S., Wang H., Xing D., Liang T., Hung M.C., RA Lu Z.; RT "The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis."; RL Nature 580:530-535(2020). RN [89] RP INTERACTION WITH TMEM175, AND FUNCTION. RX PubMed=32228865; DOI=10.7554/elife.53430; RA Oh S., Paknejad N., Hite R.K.; RT "Gating and selectivity mechanisms for the lysosomal K+ channel TMEM175."; RL Elife 9:0-0(2020). RN [90] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=33594058; DOI=10.1038/s41467-021-21206-3; RA Li T., Wang X., Ju E., da Silva S.R., Chen L., Zhang X., Wei S., Gao S.J.; RT "RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 RT for ubiquitination and degradation."; RL Nat. Commun. 12:1055-1055(2021). RN [91] RP INTERACTION WITH SLC9D1, PHOSPHORYLATION AT THR-308 AND SER-473, AND RP SUBCELLULAR LOCATION. RX PubMed=40285646; DOI=10.1002/advs.202504187; RA Li X., Han M., Zhu H., Pan Y., Su C., Liu Y., Liao Z., Zhang B., Chen X.; RT "m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by RT Facilitating the Membrane Translocation and Activation of AKT."; RL Adv. Sci. 12:e2504187-e2504187(2025). RN [92] RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-123, FUNCTION, INTERACTION WITH RP PTDINS(3,4,5)P3 AND PTDINS(3,4)P2, MUTAGENESIS OF LYS-14; ARG-25 AND RP ARG-86, AND CHARACTERIZATION OF VARIANT CWS6 CYS-25. RX PubMed=12176338; DOI=10.1016/s0960-9822(02)00972-7; RA Thomas C.C., Deak M., Alessi D.R., van Aalten D.M.; RT "High-resolution structure of the pleckstrin homology domain of protein RT kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate."; RL Curr. Biol. 12:1256-1262(2002). RN [93] RP X-RAY CRYSTALLOGRAPHY (0.98 ANGSTROMS) OF 1-121, FUNCTION, AND INTERACTION RP WITH PTDINS(1,3,4,5)P4. RX PubMed=12964941; DOI=10.1042/bj20031229; RA Milburn C.C., Deak M., Kelly S.M., Price N.C., Alessi D.R., RA Van Aalten D.M.; RT "Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin RT homology domain of protein kinase B induces a conformational change."; RL Biochem. J. 375:531-538(2003). RN [94] {ECO:0007744|PDB:3CQU, ECO:0007744|PDB:3CQW} RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=18456494; DOI=10.1016/j.bmcl.2008.04.034; RA Lippa B., Pan G., Corbett M., Li C., Kauffman G.S., Pandit J., Robinson S., RA Wei L., Kozina E., Marr E.S., Borzillo G., Knauth E., Barbacci-Tobin E.G., RA Vincent P., Troutman M., Baker D., Rajamohan F., Kakar S., Clark T., RA Morris J.; RT "Synthesis and structure based optimization of novel Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 18:3359-3363(2008). RN [95] {ECO:0007744|PDB:3OCB} RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=20810279; DOI=10.1016/j.bmcl.2010.08.053; RA Blake J.F., Kallan N.C., Xiao D., Xu R., Bencsik J.R., Skelton N.J., RA Spencer K.L., Mitchell I.S., Woessner R.D., Gloor S.L., Risom T., RA Gross S.D., Martinson M., Morales T.H., Vigers G.P., Brandhuber B.J.; RT "Discovery of pyrrolopyrimidine inhibitors of Akt."; RL Bioorg. Med. Chem. Lett. 20:5607-5612(2010). RN [96] {ECO:0007744|PDB:3MV5, ECO:0007744|PDB:3MVH} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=20481595; DOI=10.1021/jm1003842; RA Freeman-Cook K.D., Autry C., Borzillo G., Gordon D., Barbacci-Tobin E., RA Bernardo V., Briere D., Clark T., Corbett M., Jakubczak J., Kakar S., RA Knauth E., Lippa B., Luzzio M.J., Mansour M., Martinelli G., Marx M., RA Nelson K., Pandit J., Rajamohan F., Robinson S., Subramanyam C., Wei L., RA Wythes M., Morris J.; RT "Design of selective, ATP-competitive inhibitors of Akt."; RL J. Med. Chem. 53:4615-4622(2010). RN [97] {ECO:0007744|PDB:3O96} RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2-443, AND DISULFIDE BOND. RX PubMed=20886116; DOI=10.1371/journal.pone.0012913; RA Wu W.I., Voegtli W.C., Sturgis H.L., Dizon F.P., Vigers G.P., RA Brandhuber B.J.; RT "Crystal structure of human AKT1 with an allosteric inhibitor reveals a new RT mode of kinase inhibition."; RL PLoS ONE 5:E12913-E12913(2010). RN [98] {ECO:0007744|PDB:3QKK, ECO:0007744|PDB:3QKL} RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=21392984; DOI=10.1016/j.bmcl.2011.02.073; RA Kallan N.C., Spencer K.L., Blake J.F., Xu R., Heizer J., Bencsik J.R., RA Mitchell I.S., Gloor S.L., Martinson M., Risom T., Gross S.D., RA Morales T.H., Wu W.I., Vigers G.P., Brandhuber B.J., Skelton N.J.; RT "Discovery and SAR of spirochromane Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 21:2410-2414(2011). RN [99] RP VARIANT BREAST CANCER LYS-17, AND CHARACTERIZATION OF VARIANT BREAST CANCER RP LYS-17. RX PubMed=17611497; DOI=10.1038/nature05933; RA Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., RA Hostetter G., Boguslawski S., Moses T.Y., Savage S., Uhlik M., Lin A., RA Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., RA Mousses S., Bittner M., Schevitz R., Lai M.-H.T., Blanchard K.L., RA Thomas J.E.; RT "A transforming mutation in the pleckstrin homology domain of AKT1 in RT cancer."; RL Nature 448:439-444(2007). RN [100] RP CHARACTERIZATION OF VARIANT PROTEUSS LYS-17. RX PubMed=18954143; DOI=10.1021/bi801683k; RA Landgraf K.E., Pilling C., Falke J.J.; RT "Molecular mechanism of an oncogenic mutation that alters membrane RT targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH RT domain."; RL Biochemistry 47:12260-12269(2008). RN [101] RP VARIANT PROTEUSS LYS-17. RX PubMed=21793738; DOI=10.1056/nejmoa1104017; RA Lindhurst M.J., Sapp J.C., Teer J.K., Johnston J.J., Finn E.M., Peters K., RA Turner J., Cannons J.L., Bick D., Blakemore L., Blumhorst C., Brockmann K., RA Calder P., Cherman N., Deardorff M.A., Everman D.B., Golas G., RA Greenstein R.M., Kato B.M., Keppler-Noreuil K.M., Kuznetsov S.A., RA Miyamoto R.T., Newman K., Ng D., O'Brien K., Rothenberg S., RA Schwartzentruber D.J., Singhal V., Tirabosco R., Upton J., Wientroub S., RA Zackai E.H., Hoag K., Whitewood-Neal T., Robey P.G., Schwartzberg P.L., RA Darling T.N., Tosi L.L., Mullikin J.C., Biesecker L.G.; RT "A mosaic activating mutation in AKT1 associated with the Proteus RT syndrome."; RL N. Engl. J. Med. 365:611-619(2011). RN [102] RP VARIANTS CWS6 CYS-25 AND PRO-435. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). CC -!- FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein CC kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate CC many processes including metabolism, proliferation, cell survival, CC growth and angiogenesis (PubMed:11882383, PubMed:15526160, CC PubMed:15861136, PubMed:21432781, PubMed:21620960, PubMed:31204173). CC This is mediated through serine and/or threonine phosphorylation of a CC range of downstream substrates (PubMed:11882383, PubMed:15526160, CC PubMed:21432781, PubMed:21620960, PubMed:29343641, PubMed:31204173). CC Over 100 substrate candidates have been reported so far, but for most CC of them, no isoform specificity has been reported (PubMed:11882383, CC PubMed:15526160, PubMed:21432781, PubMed:21620960). AKT is responsible CC of the regulation of glucose uptake by mediating insulin-induced CC translocation of the SLC2A4/GLUT4 glucose transporter to the cell CC surface (By similarity). Phosphorylation of PTPN1 at 'Ser-50' CC negatively modulates its phosphatase activity preventing CC dephosphorylation of the insulin receptor and the attenuation of CC insulin signaling (By similarity). Phosphorylation of TBC1D4 triggers CC the binding of this effector to inhibitory 14-3-3 proteins, which is CC required for insulin-stimulated glucose transport (PubMed:11994271). CC AKT also regulates the storage of glucose in the form of glycogen by CC phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in CC inhibition of its kinase activity (By similarity). Phosphorylation of CC GSK3 isoforms by AKT is also thought to be one mechanism by which cell CC proliferation is driven (By similarity). AKT also regulates cell CC survival via the phosphorylation of MAP3K5 (apoptosis signal-related CC kinase) (PubMed:11154276). Phosphorylation of 'Ser-83' decreases MAP3K5 CC kinase activity stimulated by oxidative stress and thereby prevents CC apoptosis (PubMed:11154276). AKT mediates insulin-stimulated protein CC synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby CC activating the mTORC1 signaling pathway, and leading to both CC phosphorylation of 4E-BP1 and in activation of RPS6KB1 CC (PubMed:12150915, PubMed:12172553). Also regulates the mTORC1 signaling CC pathway by catalyzing phosphorylation of CASTOR1 and DEPDC5 CC (PubMed:31548394, PubMed:33594058). AKT plays a role as key modulator CC of the AKT-mTOR signaling pathway controlling the tempo of the process CC of newborn neurons integration during adult neurogenesis, including CC correct neuron positioning, dendritic development and synapse formation CC (By similarity). Part of a positive feedback loop of mTORC2 signaling CC by mediating phosphorylation of MAPKAP1/SIN1, promoting mTORC2 CC activation (By similarity). AKT is involved in the phosphorylation of CC members of the FOXO factors (Forkhead family of transcription factors), CC leading to binding of 14-3-3 proteins and cytoplasmic localization CC (PubMed:10358075). In particular, FOXO1 is phosphorylated at 'Thr-24', CC 'Ser-256' and 'Ser-319' (PubMed:10358075). FOXO3 and FOXO4 are CC phosphorylated on equivalent sites (PubMed:10358075). AKT has an CC important role in the regulation of NF-kappa-B-dependent gene CC transcription and positively regulates the activity of CREB1 (cyclic CC AMP (cAMP)-response element binding protein) (PubMed:9829964). The CC phosphorylation of CREB1 induces the binding of accessory proteins that CC are necessary for the transcription of pro-survival genes such as BCL2 CC and MCL1 (PubMed:9829964). AKT phosphorylates 'Ser-454' on ATP citrate CC lyase (ACLY), thereby potentially regulating ACLY activity and fatty CC acid synthesis (By similarity). Activates the 3B isoform of cyclic CC nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', CC resulting in reduced cyclic AMP levels and inhibition of lipolysis (By CC similarity). Phosphorylates PIKFYVE on 'Ser-318', which results in CC increased PI(3)P-5 activity (By similarity). The Rho GTPase-activating CC protein DLC1 is another substrate and its phosphorylation is implicated CC in the regulation cell proliferation and cell growth (By similarity). CC Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate CC the effects of various growth factors such as platelet-derived growth CC factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like CC growth factor 1 (IGF1) (PubMed:12176338, PubMed:12964941). AKT mediates CC the antiapoptotic effects of IGF1 (By similarity). Essential for the CC SPATA13-mediated regulation of cell migration and adhesion assembly and CC disassembly (PubMed:19934221). May be involved in the regulation of the CC placental development (By similarity). Phosphorylates STK4/MST1 at CC 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, CC nuclear translocation, autophosphorylation and ability to phosphorylate CC FOXO3 (PubMed:17726016). Phosphorylates STK3/MST2 at 'Thr-117' and CC 'Thr-384' leading to inhibition of its: cleavage, kinase activity, CC autophosphorylation at Thr-180, binding to RASSF1 and nuclear CC translocation (PubMed:20086174). Phosphorylates SRPK2 and enhances its CC kinase activity towards SRSF2 and ACIN1 and promotes its nuclear CC translocation (PubMed:19592491). Phosphorylates RAF1 at 'Ser-259' and CC negatively regulates its activity (PubMed:10576742). Phosphorylation of CC BAD stimulates its pro-apoptotic activity (PubMed:10926925). CC Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the CC interaction of KAT6A with PML and negatively regulates its acetylation CC activity towards p53/TP53 (PubMed:23431171). Phosphorylates palladin CC (PALLD), modulating cytoskeletal organization and cell motility CC (PubMed:20471940). Phosphorylates prohibitin (PHB), playing an CC important role in cell metabolism and proliferation (PubMed:18507042). CC Phosphorylates CDKN1A, for which phosphorylation at 'Thr-145' induces CC its release from CDK2 and cytoplasmic relocalization (PubMed:16982699). CC These recent findings indicate that the AKT1 isoform has a more CC specific role in cell motility and proliferation (PubMed:16139227). CC Phosphorylates CLK2 thereby controlling cell survival to ionizing CC radiation (PubMed:20682768). Phosphorylates PCK1 at 'Ser-90', reducing CC the binding affinity of PCK1 to oxaloacetate and changing PCK1 into an CC atypical protein kinase activity using GTP as donor (PubMed:32322062). CC Also acts as an activator of TMEM175 potassium channel activity in CC response to growth factors: forms the lysoK(GF) complex together with CC TMEM175 and acts by promoting TMEM175 channel activation, independently CC of its protein kinase activity (PubMed:32228865). Acts as a regulator CC of mitochondrial calcium uptake by mediating phosphorylation of MICU1 CC in the mitochondrial intermembrane space, impairing MICU1 maturation CC (PubMed:30504268). Acts as an inhibitor of tRNA methylation by CC mediating phosphorylation of the N-terminus of METTL1, thereby CC inhibiting METTL1 methyltransferase activity (PubMed:15861136). In CC response to LPAR1 receptor pathway activation, phosphorylates CC Rabin8/RAB3IP which alters its activity and phosphorylates WDR44 which CC induces WDR44 binding to Rab11, thereby switching Rab11 vesicular CC function from preciliary trafficking to endocytic recycling CC (PubMed:31204173). {ECO:0000250|UniProtKB:P31750, CC ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10358075, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10926925, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11994271, CC ECO:0000269|PubMed:12150915, ECO:0000269|PubMed:12172553, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12964941, CC ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:16982699, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:18507042, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19934221, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20471940, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:30504268, CC ECO:0000269|PubMed:31204173, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:32322062, CC ECO:0000269|PubMed:33594058, ECO:0000269|PubMed:9829964, CC ECO:0000303|PubMed:11882383, ECO:0000303|PubMed:15526160, CC ECO:0000303|PubMed:21432781, ECO:0000303|PubMed:21620960}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:1851997, ECO:0000269|PubMed:26440888, CC ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:1851997}; CC -!- ACTIVITY REGULATION: Three specific sites, one in the kinase domain CC (Thr-308) and the two other ones in the C-terminal regulatory region CC (Ser-473 and Tyr-474), need to be phosphorylated for its full CC activation (PubMed:15262962, PubMed:20481595, PubMed:21392984, CC PubMed:9512493, PubMed:9736715). Inhibited by pyrrolopyrimidine CC inhibitors like aniline triazole and spiroindoline (PubMed:18456494, CC PubMed:20810279). {ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20810279, ECO:0000269|PubMed:21392984, CC ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715, CC ECO:0000305|PubMed:20810279}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.8 uM for ATP (for purified and in vitro activated AKT1) CC {ECO:0000269|PubMed:16540465}; CC KM=0.5 uM for peptide substrate (for purified and in vitro activated CC AKT1) {ECO:0000269|PubMed:16540465}; CC KM=143.3 uM for ATP (for recombinant myristoylated AKT1 expressed and CC immunoprecipitated from Rat-1 cells) {ECO:0000269|PubMed:16540465}; CC KM=2.9 uM for peptide substrate (for recombinant myristoylated AKT1 CC expressed and immunoprecipitated from Rat-1 cells) CC {ECO:0000269|PubMed:16540465}; CC -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with KCTD20 CC (By similarity). Interacts (via the C-terminus) with CCDC88A (via its CC C-terminus). Interacts with GRB10; the interaction leads to GRB10 CC phosphorylation thus promoting YWHAE-binding (By similarity). Interacts CC with AGAP2 (isoform 2/PIKE-A); the interaction occurs in the presence CC of guanine nucleotides. Interacts with AKTIP. Interacts (via PH domain) CC with MTCP1, TCL1A and TCL1B. Interacts with CDKN1B; the interaction CC phosphorylates CDKN1B promoting 14-3-3 binding and cell-cycle CC progression. Interacts with MAP3K5 and TRAF6. Interacts with BAD, CC PPP2R5B, STK3 and STK4. Interacts (via PH domain) with SIRT1. Interacts CC with SRPK2 in a phosphorylation-dependent manner. Interacts with RAF1. CC Interacts with TRIM13; the interaction ubiquitinates AKT1 leading to CC its proteasomal degradation. Interacts with TNK2 and CLK2. Interacts CC (via the C-terminus) with THEM4 (via its C-terminus). Interacts with CC and phosphorylated by PDPK1. Interacts with PA2G4 (By similarity). CC Interacts with KIF14; the interaction is detected in the plasma CC membrane upon INS stimulation and promotes AKT1 phosphorylation CC (PubMed:24784001). Interacts with FAM83B; activates the PI3K/AKT CC signaling cascade (PubMed:23676467). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Forms a complex with WDFY2 and FOXO1 CC (By similarity). Interacts with FAM168A (PubMed:23251525). Interacts CC with SYAP1 (via phosphorylated form and BSD domain); this interaction CC is enhanced in a mTORC2-mediated manner in response to epidermal growth CC factor (EGF) stimulation and activates AKT1 (PubMed:23300339). CC Interacts with PKHM3 (By similarity). Interacts with FKBP5/FKBP51; CC promoting interaction between Akt/AKT1 and PHLPP1, thereby enhancing CC dephosphorylation and subsequent activation of Akt/AKT1 CC (PubMed:28147277). Interacts with TMEM175; leading to formation of the CC lysoK(GF) complex (PubMed:32228865). Acts as a negative regulator of CC the cGAS-STING pathway by mediating phosphorylation of CGAS during CC mitosis, leading to its inhibition (PubMed:26440888). Interacts with CC SLC9D1 (when phosphorylated); the interaction facilitates the membrane CC translocation and activation of AKT1 (PubMed:40285646). CC {ECO:0000250|UniProtKB:P31750, ECO:0000250|UniProtKB:P47196, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10716693, CC ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:10983986, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11598301, CC ECO:0000269|PubMed:11839817, ECO:0000269|PubMed:12042314, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12244301, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:14749367, CC ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15118108, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:16417524, CC ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392, CC ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23300339, CC ECO:0000269|PubMed:23676467, ECO:0000269|PubMed:24784001, CC ECO:0000269|PubMed:26440888, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:40285646}. CC -!- INTERACTION: CC P31749; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-296087, EBI-10173507; CC P31749; P31749: AKT1; NbExp=4; IntAct=EBI-296087, EBI-296087; CC P31749; P31751: AKT2; NbExp=3; IntAct=EBI-296087, EBI-296058; CC P31749; Q86V81: ALYREF; NbExp=5; IntAct=EBI-296087, EBI-347640; CC P31749; P32121: ARRB2; NbExp=5; IntAct=EBI-296087, EBI-714559; CC P31749; Q8IXJ9: ASXL1; NbExp=3; IntAct=EBI-296087, EBI-1646500; CC P31749; Q13315: ATM; NbExp=5; IntAct=EBI-296087, EBI-495465; CC P31749; P54253: ATXN1; NbExp=6; IntAct=EBI-296087, EBI-930964; CC P31749; Q99728: BARD1; NbExp=3; IntAct=EBI-296087, EBI-473181; CC P31749; O95999: BCL10; NbExp=5; IntAct=EBI-296087, EBI-958922; CC P31749; Q6W2J9: BCOR; NbExp=3; IntAct=EBI-296087, EBI-950027; CC P31749; P15056: BRAF; NbExp=4; IntAct=EBI-296087, EBI-365980; CC P31749; Q9H0C5: BTBD1; NbExp=3; IntAct=EBI-296087, EBI-935503; CC P31749; P62324: BTG1; NbExp=4; IntAct=EBI-296087, EBI-742279; CC P31749; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-296087, EBI-1383687; CC P31749; P20248: CCNA2; NbExp=2; IntAct=EBI-296087, EBI-457097; CC P31749; P30281: CCND3; NbExp=3; IntAct=EBI-296087, EBI-375013; CC P31749; Q16543: CDC37; NbExp=5; IntAct=EBI-296087, EBI-295634; CC P31749; P46527: CDKN1B; NbExp=4; IntAct=EBI-296087, EBI-519280; CC P31749; Q8TAP6: CEP76; NbExp=4; IntAct=EBI-296087, EBI-742887; CC P31749; Q92793: CREBBP; NbExp=3; IntAct=EBI-296087, EBI-81215; CC P31749; Q15438: CYTH1; NbExp=3; IntAct=EBI-296087, EBI-997830; CC P31749; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-296087, EBI-742054; CC P31749; P26358: DNMT1; NbExp=6; IntAct=EBI-296087, EBI-719459; CC P31749; P00533: EGFR; NbExp=4; IntAct=EBI-296087, EBI-297353; CC P31749; Q9UJM3: ERRFI1; NbExp=3; IntAct=EBI-296087, EBI-2941912; CC P31749; Q15910: EZH2; NbExp=3; IntAct=EBI-296087, EBI-530054; CC P31749; Q1W6H9: FAM110C; NbExp=2; IntAct=EBI-296087, EBI-3942563; CC P31749; Q00597: FANCC; NbExp=4; IntAct=EBI-296087, EBI-81625; CC P31749; Q9HB96: FANCE; NbExp=4; IntAct=EBI-296087, EBI-396803; CC P31749; Q969H0: FBXW7; NbExp=5; IntAct=EBI-296087, EBI-359574; CC P31749; Q12778: FOXO1; NbExp=2; IntAct=EBI-296087, EBI-1108782; CC P31749; O43524: FOXO3; NbExp=4; IntAct=EBI-296087, EBI-1644164; CC P31749; P06241: FYN; NbExp=3; IntAct=EBI-296087, EBI-515315; CC P31749; P22466: GAL; NbExp=3; IntAct=EBI-296087, EBI-6624768; CC P31749; P49841: GSK3B; NbExp=5; IntAct=EBI-296087, EBI-373586; CC P31749; P68431: H3C12; NbExp=4; IntAct=EBI-296087, EBI-79722; CC P31749; Q96LI6-3: HSFY2; NbExp=3; IntAct=EBI-296087, EBI-25830912; CC P31749; P08238: HSP90AB1; NbExp=3; IntAct=EBI-296087, EBI-352572; CC P31749; P42858: HTT; NbExp=3; IntAct=EBI-296087, EBI-466029; CC P31749; P08476: INHBA; NbExp=3; IntAct=EBI-296087, EBI-8077140; CC P31749; Q8WZ60: KLHL6; NbExp=3; IntAct=EBI-296087, EBI-6426464; CC P31749; Q5S007: LRRK2; NbExp=6; IntAct=EBI-296087, EBI-5323863; CC P31749; Q99683: MAP3K5; NbExp=2; IntAct=EBI-296087, EBI-476263; CC P31749; O15264: MAPK13; NbExp=4; IntAct=EBI-296087, EBI-2116951; CC P31749; Q8TD08: MAPK15; NbExp=3; IntAct=EBI-296087, EBI-1383794; CC P31749; Q9BPZ7: MAPKAP1; NbExp=3; IntAct=EBI-296087, EBI-749938; CC P31749; P10636: MAPT; NbExp=2; IntAct=EBI-296087, EBI-366182; CC P31749; Q07820: MCL1; NbExp=3; IntAct=EBI-296087, EBI-1003422; CC P31749; Q00987: MDM2; NbExp=6; IntAct=EBI-296087, EBI-389668; CC P31749; Q14696: MESD; NbExp=3; IntAct=EBI-296087, EBI-6165891; CC P31749; P42345: MTOR; NbExp=6; IntAct=EBI-296087, EBI-359260; CC P31749; P04198: MYCN; NbExp=3; IntAct=EBI-296087, EBI-878369; CC P31749; P25963: NFKBIA; NbExp=3; IntAct=EBI-296087, EBI-307386; CC P31749; Q9BZQ8: NIBAN1; NbExp=2; IntAct=EBI-296087, EBI-6916466; CC P31749; P04150: NR3C1; NbExp=5; IntAct=EBI-296087, EBI-493507; CC P31749; O15530: PDPK1; NbExp=5; IntAct=EBI-296087, EBI-717097; CC P31749; Q96S96: PEBP4; NbExp=2; IntAct=EBI-296087, EBI-8563667; CC P31749; P19174: PLCG1; NbExp=9; IntAct=EBI-296087, EBI-79387; CC P31749; Q03181: PPARD; NbExp=3; IntAct=EBI-296087, EBI-6426768; CC P31749; O60437: PPL; NbExp=2; IntAct=EBI-296087, EBI-368321; CC P31749; P62136: PPP1CA; NbExp=4; IntAct=EBI-296087, EBI-357253; CC P31749; P67775: PPP2CA; NbExp=4; IntAct=EBI-296087, EBI-712311; CC P31749; P30153: PPP2R1A; NbExp=3; IntAct=EBI-296087, EBI-302388; CC P31749; P54646: PRKAA2; NbExp=3; IntAct=EBI-296087, EBI-1383852; CC P31749; P17612: PRKACA; NbExp=3; IntAct=EBI-296087, EBI-476586; CC P31749; Q05513: PRKCZ; NbExp=2; IntAct=EBI-296087, EBI-295351; CC P31749; Q8WUY3: PRUNE2; NbExp=3; IntAct=EBI-296087, EBI-743880; CC P31749; Q06124: PTPN11; NbExp=3; IntAct=EBI-296087, EBI-297779; CC P31749; P04049: RAF1; NbExp=3; IntAct=EBI-296087, EBI-365996; CC P31749; P10276: RARA; NbExp=3; IntAct=EBI-296087, EBI-413374; CC P31749; Q9NS23: RASSF1; NbExp=3; IntAct=EBI-296087, EBI-367363; CC P31749; Q6R327: RICTOR; NbExp=3; IntAct=EBI-296087, EBI-1387196; CC P31749; P15880: RPS2; NbExp=3; IntAct=EBI-296087, EBI-443446; CC P31749; P23443: RPS6KB1; NbExp=3; IntAct=EBI-296087, EBI-1775921; CC P31749; Q15047: SETDB1; NbExp=10; IntAct=EBI-296087, EBI-79691; CC P31749; Q96EB6: SIRT1; NbExp=5; IntAct=EBI-296087, EBI-1802965; CC P31749; Q13309: SKP2; NbExp=4; IntAct=EBI-296087, EBI-456291; CC P31749; Q13485: SMAD4; NbExp=6; IntAct=EBI-296087, EBI-347263; CC P31749; Q8N3U4: STAG2; NbExp=3; IntAct=EBI-296087, EBI-1057252; CC P31749; Q14849: STARD3; NbExp=3; IntAct=EBI-296087, EBI-9819324; CC P31749; Q13043: STK4; NbExp=13; IntAct=EBI-296087, EBI-367376; CC P31749; Q9UNE7-1: STUB1; NbExp=5; IntAct=EBI-296087, EBI-15687717; CC P31749; P56279: TCL1A; NbExp=8; IntAct=EBI-296087, EBI-749995; CC P31749; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-296087, EBI-750109; CC P31749; Q5T1C6: THEM4; NbExp=4; IntAct=EBI-296087, EBI-7684443; CC P31749; Q92547: TOPBP1; NbExp=2; IntAct=EBI-296087, EBI-308302; CC P31749; P53804: TTC3; NbExp=4; IntAct=EBI-296087, EBI-2681313; CC P31749; P10599: TXN; NbExp=3; IntAct=EBI-296087, EBI-594644; CC P31749; P08670: VIM; NbExp=29; IntAct=EBI-296087, EBI-353844; CC P31749; Q6GPH4: XAF1; NbExp=4; IntAct=EBI-296087, EBI-2815120; CC P31749; P17028: ZNF24; NbExp=3; IntAct=EBI-296087, EBI-707773; CC P31749; P29067: Arrb2; Xeno; NbExp=2; IntAct=EBI-296087, EBI-1636616; CC P31749; P06762: Hmox1; Xeno; NbExp=2; IntAct=EBI-296087, EBI-7410266; CC P31749; Q83730: m005R; Xeno; NbExp=3; IntAct=EBI-296087, EBI-6859930; CC P31749; P03165: X; Xeno; NbExp=3; IntAct=EBI-296087, EBI-7683985; CC P31749-1; Q15118-1: PDK1; NbExp=2; IntAct=EBI-12562306, EBI-12562315; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P31750}. Nucleus CC {ECO:0000269|PubMed:20333297}. Cell membrane CC {ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:40285646}. CC Mitochondrion intermembrane space {ECO:0000250|UniProtKB:P31750}. CC Note=Nucleus after activation by integrin-linked protein kinase 1 CC (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. CC Phosphorylation on Tyr-176 by TNK2 results in its localization to the CC cell membrane where it is targeted for further phosphorylations on Thr- CC 308 and Ser-473 leading to its activation and the activated form CC translocates to the nucleus. Colocalizes with WDFY2 in intracellular CC vesicles (PubMed:16792529). Also localizes to mitochondrial CC intermembrane space in response to rapamycin treatment (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:16792529}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P31749-1; Sequence=Displayed; CC Name=2; CC IsoId=P31749-2; Sequence=VSP_056180; CC -!- TISSUE SPECIFICITY: Expressed in prostate cancer and levels increase CC from the normal to the malignant state (at protein level). Expressed in CC all human cell types so far analyzed. The Tyr-176 phosphorylated form CC shows a significant increase in expression in breast cancers during the CC progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma CC in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node CC metastatic (LNMM) stages. {ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5- CC trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase CC alpha (PIK3CA) activity results in its targeting to the plasma membrane CC (PubMed:12176338, PubMed:12964941). PI(3,4,5)P3 is also required for CC phosphorylation at Thr-308 and subsequent activation (By similarity). CC The PH domain mediates interaction with TNK2 and Tyr-176 is also CC essential for this interaction (PubMed:20333297). CC {ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:12176338, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4. CC {ECO:0000269|PubMed:11598301}. CC -!- PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating CC phosphorylation at Thr-308 via disrupting the interaction between AKT1 CC and PDPK1. O-GlcNAcylation at Ser-473 also probably interferes with CC phosphorylation at this site. {ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:17013611, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20978158, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for CC full activity (PubMed:12149249, PubMed:15047712, PubMed:15262962, CC PubMed:16266983, PubMed:18456494, PubMed:20481595, PubMed:20978158, CC PubMed:8978681, PubMed:9512493, PubMed:9736715). Phosphorylation of the CC activation loop at Thr-308 by PDPK1/PDK1 is a prerequisite for full CC activation (PubMed:9512493). Phosphorylation by mTORC2 in response to CC growth factors plays a key role in AKT1 activation: mTORC2 CC phosphorylates different sites depending on the context, such as Thr- CC 450, Ser-473, Ser-477 or Thr-479, thereby facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:15718470, CC PubMed:24670654). Phosphorylation at Ser-473 by mTORC2 promotes CC ubiquitination and degradation by the proteasome (By similarity). Also CC phosphorylated at Ser-477 and Thr-479 by CDK2, facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:24670654). CC Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to CC the anionic plasma membrane phospholipid PA (PubMed:20333297). This CC phosphorylated form localizes to the cell membrane, where it is CC targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and CC Ser-473 leading to its activation (PubMed:20333297). Phosphorylated at CC Thr-308 and Ser-473 by IKBKE and TBK1 (PubMed:21464307). Ser-473 CC phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE- CC A) (PubMed:14761976). Ser-473 phosphorylation is enhanced in focal CC cortical dysplasias with Taylor-type balloon cells (PubMed:17013611). CC Ser-473 phosphorylation is enhanced by signaling through activated FLT3 CC (PubMed:16266983). Ser-473 is dephosphorylated by PHLPP CC (PubMed:28147277). Dephosphorylated at Thr-308 and Ser-473 by PP2A CC phosphatase (PubMed:21329884). The phosphorylated form of PPP2R5B is CC required for bridging AKT1 with PP2A phosphatase (PubMed:21329884). CC Ser-473 is dephosphorylated by CPPED1, leading to termination of CC signaling (PubMed:23799035). AIM2 acts as an inhibitor of AKT1 by CC inhibiting phosphorylation Ser-473: AIM2 acts both by inhibiting the CC activity of PRKDC/DNA-PK kinase and promoting dephosphorylation by PP2A CC phosphatase (By similarity). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:12149249, ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, CC ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21329884, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:24670654, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked CC polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination CC is critical for phosphorylation and activation (PubMed:19713527). When CC ubiquitinated, it translocates to the plasma membrane, where it becomes CC phosphorylated (PubMed:20059950). When fully phosphorylated and CC translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination CC catalyzed by TTC3, leading to its degradation by the proteasome CC (PubMed:20059950). Also ubiquitinated by TRIM13 leading to its CC proteasomal degradation (PubMed:21333377). Phosphorylated, undergoes CC 'Lys-48'-linked polyubiquitination preferentially at Lys-284 catalyzed CC by MUL1, leading to its proteasomal degradation (PubMed:22410793). CC Ubiquitinated via 'Lys-48'-linked polyubiquitination by ZNRF1, leading CC to its degradation by the proteasome (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:19713527, CC ECO:0000269|PubMed:20059950, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:22410793}. CC -!- PTM: Acetylated on Lys-14 and Lys-20 by the histone acetyltransferases CC EP300 and KAT2B. Acetylation results in reduced phosphorylation and CC inhibition of activity. Deacetylated at Lys-14 and Lys-20 by SIRT1. CC SIRT1-mediated deacetylation relieves the inhibition. CC {ECO:0000269|PubMed:21775285}. CC -!- PTM: Cleavage by caspase-3/CASP3 (By similarity). Cleaved at the CC caspase-3 consensus site Asp-462 during apoptosis, resulting in down- CC regulation of the AKT signaling pathway and decreased cell survival CC (PubMed:23152800). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:23152800}. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:17611497}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The gene represented in this entry may be CC involved in disease pathogenesis. CC -!- DISEASE: Note=Genetic variations in AKT1 may play a role in CC susceptibility to ovarian cancer. CC -!- DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highly variable, CC severe disorder of asymmetric and disproportionate overgrowth of body CC parts, connective tissue nevi, epidermal nevi, dysregulated adipose CC tissue, and vascular malformations. Many features of Proteus syndrome CC overlap with other overgrowth syndromes. {ECO:0000269|PubMed:18954143, CC ECO:0000269|PubMed:21793738}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:23246288}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. RAC subfamily. {ECO:0000305}. CC -!- CAUTION: PUBMED:20231902 has been retracted because there was evidence CC of data fabrication and/or falsification in multiple figure panels. CC {ECO:0000305|PubMed:20231902, ECO:0000305|PubMed:37490513}. CC -!- CAUTION: PUBMED:19940129 has been retracted because the same data were CC used to represent different experimental conditions. CC {ECO:0000305|PubMed:19940129, ECO:0000305|PubMed:27825096}. CC -!- CAUTION: In light of strong homologies in the primary amino acid CC sequence, the 3 AKT kinases were long surmised to play redundant and CC overlapping roles. More recent studies has brought into question the CC redundancy within AKT kinase isoforms and instead pointed to isoform CC specific functions in different cellular events and diseases. AKT1 is CC more specifically involved in cellular survival pathways, by inhibiting CC apoptotic processes; whereas AKT2 is more specific for the insulin CC receptor signaling pathway. Moreover, while AKT1 and AKT2 are often CC implicated in many aspects of cellular transformation, the 2 isoforms CC act in a complementary opposing manner. The role of AKT3 is less clear, CC though it appears to be predominantly expressed in brain. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/355/AKT1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M63167; AAA36539.1; -; mRNA. DR EMBL; AF283830; AAL55732.1; -; Genomic_DNA. DR EMBL; AF283819; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283820; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283821; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283822; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283823; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283824; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283825; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283826; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283827; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283828; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283829; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AK299310; BAH12997.1; -; mRNA. DR EMBL; AK314256; BAG36922.1; -; mRNA. DR EMBL; AB451242; BAG70056.1; -; mRNA. DR EMBL; AB451367; BAG70181.1; -; mRNA. DR EMBL; AL583722; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590327; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000479; AAH00479.1; -; mRNA. DR EMBL; BC084538; AAH84538.1; -; mRNA. DR EMBL; X61037; CAA43372.1; -; mRNA. DR CCDS; CCDS9994.1; -. [P31749-1] DR PIR; A39360; A39360. DR RefSeq; NP_001014431.1; NM_001014431.2. [P31749-1] DR RefSeq; NP_001014432.1; NM_001014432.2. [P31749-1] DR RefSeq; NP_001369359.1; NM_001382430.1. [P31749-1] DR RefSeq; NP_001369360.1; NM_001382431.1. [P31749-1] DR RefSeq; NP_001369361.1; NM_001382432.1. [P31749-1] DR RefSeq; NP_001369362.1; NM_001382433.1. [P31749-1] DR RefSeq; NP_005154.2; NM_005163.2. [P31749-1] DR RefSeq; XP_047287025.1; XM_047431069.1. [P31749-1] DR RefSeq; XP_047287026.1; XM_047431070.1. [P31749-1] DR RefSeq; XP_047287027.1; XM_047431071.1. [P31749-1] DR RefSeq; XP_047287028.1; XM_047431072.1. [P31749-1] DR RefSeq; XP_047287029.1; XM_047431073.1. [P31749-1] DR RefSeq; XP_047287030.1; XM_047431074.1. [P31749-1] DR RefSeq; XP_047287031.1; XM_047431075.1. [P31749-1] DR RefSeq; XP_054231528.1; XM_054375553.1. [P31749-1] DR RefSeq; XP_054231529.1; XM_054375554.1. [P31749-1] DR RefSeq; XP_054231530.1; XM_054375555.1. [P31749-1] DR RefSeq; XP_054231531.1; XM_054375556.1. [P31749-1] DR RefSeq; XP_054231532.1; XM_054375557.1. [P31749-1] DR RefSeq; XP_054231533.1; XM_054375558.1. [P31749-1] DR PDB; 1H10; X-ray; 1.40 A; A=1-123. DR PDB; 1UNP; X-ray; 1.65 A; A=1-121. DR PDB; 1UNQ; X-ray; 0.98 A; A=1-123. DR PDB; 1UNR; X-ray; 1.25 A; A=1-123. DR PDB; 2UVM; X-ray; 1.94 A; A=1-123. DR PDB; 2UZR; X-ray; 1.94 A; A=1-123. DR PDB; 2UZS; X-ray; 2.46 A; A=1-123. DR PDB; 3CQU; X-ray; 2.20 A; A=144-480. DR PDB; 3CQW; X-ray; 2.00 A; A=144-480. DR PDB; 3MV5; X-ray; 2.47 A; A=144-480. DR PDB; 3MVH; X-ray; 2.01 A; A=144-480. DR PDB; 3O96; X-ray; 2.70 A; A=2-443. DR PDB; 3OCB; X-ray; 2.70 A; A/B=144-480. DR PDB; 3OW4; X-ray; 2.60 A; A/B=144-480. DR PDB; 3QKK; X-ray; 2.30 A; A=144-480. DR PDB; 3QKL; X-ray; 1.90 A; A=144-480. DR PDB; 3QKM; X-ray; 2.20 A; A=144-480. DR PDB; 4EJN; X-ray; 2.19 A; A=2-446. DR PDB; 4EKK; X-ray; 2.80 A; A/B=144-480. DR PDB; 4EKL; X-ray; 2.00 A; A=144-480. DR PDB; 4GV1; X-ray; 1.49 A; A=144-480. DR PDB; 5KCV; X-ray; 2.70 A; A=2-446. DR PDB; 6BUU; X-ray; 2.40 A; A/B=144-480. DR PDB; 6CCY; X-ray; 2.18 A; A=144-466. DR PDB; 6HHF; X-ray; 2.90 A; A=2-446. DR PDB; 6HHG; X-ray; 2.30 A; A=2-446. DR PDB; 6HHH; X-ray; 2.70 A; A=2-446. DR PDB; 6HHI; X-ray; 2.70 A; A=2-446. DR PDB; 6HHJ; X-ray; 2.30 A; A=2-446. DR PDB; 6NPZ; X-ray; 2.12 A; A/B=123-480, A/B=144-480. DR PDB; 6S9W; X-ray; 2.30 A; A=2-446. DR PDB; 6S9X; X-ray; 2.60 A; A=2-446. DR PDB; 7APJ; X-ray; 2.05 A; A=1-119, A=136-445. DR PDB; 7MYX; X-ray; 1.39 A; A=1-121. DR PDB; 7NH4; X-ray; 2.30 A; A=2-446. DR PDB; 7NH5; X-ray; 1.90 A; A=2-446. DR PDB; 8JOW; X-ray; 1.40 A; B/D=466-477. DR PDB; 8UVY; X-ray; 2.11 A; A=2-446. DR PDB; 8UW2; X-ray; 2.20 A; A=2-446. DR PDB; 8UW7; X-ray; 1.97 A; A=2-446. DR PDB; 8UW9; X-ray; 1.90 A; A=2-446. DR PDB; 8ZPU; X-ray; 2.80 A; C/D=466-477. DR PDBsum; 1H10; -. DR PDBsum; 1UNP; -. DR PDBsum; 1UNQ; -. DR PDBsum; 1UNR; -. DR PDBsum; 2UVM; -. DR PDBsum; 2UZR; -. DR PDBsum; 2UZS; -. DR PDBsum; 3CQU; -. DR PDBsum; 3CQW; -. DR PDBsum; 3MV5; -. DR PDBsum; 3MVH; -. DR PDBsum; 3O96; -. DR PDBsum; 3OCB; -. DR PDBsum; 3OW4; -. DR PDBsum; 3QKK; -. DR PDBsum; 3QKL; -. DR PDBsum; 3QKM; -. DR PDBsum; 4EJN; -. DR PDBsum; 4EKK; -. DR PDBsum; 4EKL; -. DR PDBsum; 4GV1; -. DR PDBsum; 5KCV; -. DR PDBsum; 6BUU; -. DR PDBsum; 6CCY; -. DR PDBsum; 6HHF; -. DR PDBsum; 6HHG; -. DR PDBsum; 6HHH; -. DR PDBsum; 6HHI; -. DR PDBsum; 6HHJ; -. DR PDBsum; 6NPZ; -. DR PDBsum; 6S9W; -. DR PDBsum; 6S9X; -. DR PDBsum; 7APJ; -. DR PDBsum; 7MYX; -. DR PDBsum; 7NH4; -. DR PDBsum; 7NH5; -. DR PDBsum; 8JOW; -. DR PDBsum; 8UVY; -. DR PDBsum; 8UW2; -. DR PDBsum; 8UW7; -. DR PDBsum; 8UW9; -. DR PDBsum; 8ZPU; -. DR AlphaFoldDB; P31749; -. DR SMR; P31749; -. DR BioGRID; 106710; 600. DR CORUM; P31749; -. DR DIP; DIP-24269N; -. DR ELM; P31749; -. DR FunCoup; P31749; 3098. DR IntAct; P31749; 602. DR MINT; P31749; -. DR STRING; 9606.ENSP00000451828; -. DR BindingDB; P31749; -. DR ChEMBL; CHEMBL4282; -. DR DrugBank; DB08073; (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE. DR DrugBank; DB07585; 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. DR DrugBank; DB08568; A-674563. DR DrugBank; DB11648; Afuresertib. DR DrugBank; DB05971; Archexin. DR DrugBank; DB01169; Arsenic trioxide. DR DrugBank; DB00171; ATP. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12218; Capivasertib. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB12795; CMX-2043. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB01645; Genistein. DR DrugBank; DB01863; Inositol 1,3,4,5-Tetrakisphosphate. DR DrugBank; DB11743; Ipatasertib. DR DrugBank; DB15431; M-2698. DR DrugBank; DB14982; Miransertib. DR DrugBank; DB07584; N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB02709; Resveratrol. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugCentral; P31749; -. DR GuidetoPHARMACOLOGY; 1479; -. DR TCDB; 8.A.104.1.10; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; P31749; 6 sites, 1 glycan. DR GlyGen; P31749; 7 sites, 1 O-linked glycan (6 sites). DR iPTMnet; P31749; -. DR MetOSite; P31749; -. DR PhosphoSitePlus; P31749; -. DR BioMuta; AKT1; -. DR DMDM; 60391226; -. DR CPTAC; CPTAC-3162; -. DR CPTAC; CPTAC-3163; -. DR CPTAC; CPTAC-3164; -. DR CPTAC; CPTAC-3165; -. DR CPTAC; CPTAC-3166; -. DR CPTAC; CPTAC-3167; -. DR CPTAC; CPTAC-5758; -. DR CPTAC; CPTAC-5759; -. DR CPTAC; CPTAC-5805; -. DR CPTAC; CPTAC-5806; -. DR CPTAC; CPTAC-5807; -. DR CPTAC; CPTAC-5808; -. DR CPTAC; CPTAC-783; -. DR CPTAC; CPTAC-784; -. DR CPTAC; non-CPTAC-5328; -. DR CPTAC; non-CPTAC-5329; -. DR CPTAC; non-CPTAC-5332; -. DR CPTAC; non-CPTAC-5527; -. DR CPTAC; non-CPTAC-5528; -. DR CPTAC; non-CPTAC-5719; -. DR CPTAC; non-CPTAC-5720; -. DR jPOST; P31749; -. DR MassIVE; P31749; -. DR PaxDb; 9606-ENSP00000451828; -. DR PeptideAtlas; P31749; -. DR ProteomicsDB; 54800; -. [P31749-1] DR ProteomicsDB; 6712; -. DR Pumba; P31749; -. DR ABCD; P31749; 12 sequenced antibodies. DR Antibodypedia; 135; 5291 antibodies from 58 providers. DR CPTC; P31749; 6 antibodies. DR DNASU; 207; -. DR Ensembl; ENST00000349310.7; ENSP00000270202.4; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000402615.6; ENSP00000385326.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000407796.7; ENSP00000384293.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554581.5; ENSP00000451828.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554848.5; ENSP00000451166.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000555528.5; ENSP00000450688.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000649815.2; ENSP00000497822.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000683722.1; ENSP00000507879.1; ENSG00000142208.20. [P31749-1] DR GeneID; 207; -. DR KEGG; hsa:207; -. DR MANE-Select; ENST00000649815.2; ENSP00000497822.1; NM_001382430.1; NP_001369359.1. DR UCSC; uc001ypk.4; human. [P31749-1] DR AGR; HGNC:391; -. DR CIViC; 207; 18 evidence items across 19 molecular profiles. DR ClinPGx; PA24684; -. DR CTD; 207; -. DR DisGeNET; 207; -. DR GeneCards; AKT1; -. DR GeneReviews; AKT1; -. DR HGNC; HGNC:391; AKT1. DR HPA; ENSG00000142208; Low tissue specificity. DR MalaCards; AKT1; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 164730; gene. DR MIM; 176920; phenotype. DR MIM; 615109; phenotype. DR OpenTargets; ENSG00000142208; -. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 744; Proteus syndrome. DR VEuPathDB; HostDB:ENSG00000142208; -. DR eggNOG; KOG0690; Eukaryota. DR GeneTree; ENSGT00940000158752; -. DR HOGENOM; CLU_000288_11_0_1; -. DR InParanoid; P31749; -. DR OMA; MDMEIYL; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P31749; 3 GO annotations based on evolutionary models. DR PhylomeDB; P31749; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P31749; -. DR Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane. DR Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol. DR Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-203615; eNOS activation. DR Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A. DR Reactome; R-HSA-354192; Integrin signaling. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-389513; Co-inhibition by CTLA4. DR Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma. DR Reactome; R-HSA-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA. DR Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition. DR Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs. DR Reactome; R-HSA-8941332; RUNX2 regulates genes involved in cell migration. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9604323; Negative regulation of NOTCH4 signaling. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors. DR Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway. DR Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9841251; Mitochondrial unfolded protein response (UPRmt). DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9856532; Mechanical load activates signaling by PIEZO1 and integrins in osteocytes. DR SABIO-RK; P31749; -. DR SignaLink; P31749; -. DR SIGNOR; P31749; -. DR Agora; ENSG00000142208; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 207; 54 hits in 1212 CRISPR screens. DR ChiTaRS; AKT1; human. DR EvolutionaryTrace; P31749; -. DR GeneWiki; AKT1; -. DR GenomeRNAi; 207; -. DR Pharos; P31749; Tchem. DR PRO; PR:P31749; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P31749; protein. DR Bgee; ENSG00000142208; Expressed in stromal cell of endometrium and 189 other cell types or tissues. DR ExpressionAtlas; P31749; baseline and differential. DR GO; GO:0005938; C:cell cortex; NAS:BHF-UCL. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0030027; C:lamellipodium; NAS:BHF-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProt. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005758; C:mitochondrial intermembrane space; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0033011; C:perinuclear theca; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; IPI:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:MGI. DR GO; GO:0019900; F:kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0030235; F:nitric-oxide synthase regulator activity; IMP:BHF-UCL. DR GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB. DR GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0099104; F:potassium channel activator activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; TAS:Reactome. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; ISS:BHF-UCL. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:1904841; F:TORC2 complex binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0006924; P:activation-induced cell death of T cells; IMP:MGI. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0008637; P:apoptotic mitochondrial changes; IEA:Ensembl. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0160213; P:beta-arrestin-dependent dopamine receptor signaling pathway; NAS:ParkinsonsUK-UCL. DR GO; GO:0030154; P:cell differentiation; TAS:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB. DR GO; GO:0036294; P:cellular response to decreased oxygen levels; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB. DR GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProtKB. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB. DR GO; GO:0140052; P:cellular response to oxidised low-density lipoprotein particle stimulus; IMP:BHF-UCL. DR GO; GO:1901653; P:cellular response to peptide; IEA:Ensembl. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl. DR GO; GO:0072752; P:cellular response to rapamycin; ISS:UniProt. DR GO; GO:0033554; P:cellular response to stress; TAS:Reactome. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IEA:Ensembl. DR GO; GO:0002430; P:complement receptor mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0072655; P:establishment of protein localization to mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0060079; P:excitatory postsynaptic potential; NAS:ParkinsonsUK-UCL. DR GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl. DR GO; GO:0010761; P:fibroblast migration; NAS:BHF-UCL. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW. DR GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0035655; P:interleukin-18-mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IDA:MGI. DR GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0072656; P:maintenance of protein location in mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0022605; P:mammalian oogenesis stage; IEA:Ensembl. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; TAS:UniProtKB. DR GO; GO:0001893; P:maternal placenta development; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:BHF-UCL. DR GO; GO:0160049; P:negative regulation of cGAS/STING signaling pathway; IDA:UniProt. DR GO; GO:1902018; P:negative regulation of cilium assembly; IDA:UniProtKB. DR GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; TAS:BHF-UCL. DR GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IMP:BHF-UCL. DR GO; GO:1903384; P:negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; IMP:BHF-UCL. DR GO; GO:2000402; P:negative regulation of lymphocyte migration; IMP:BHF-UCL. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0045746; P:negative regulation of Notch signaling pathway; TAS:Reactome. DR GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; NAS:BHF-UCL. DR GO; GO:1903898; P:negative regulation of PERK-mediated unfolded protein response; ISS:UniProt. DR GO; GO:0150033; P:negative regulation of protein localization to lysosome; IDA:UniProtKB. DR GO; GO:1903318; P:negative regulation of protein maturation; ISS:UniProt. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IMP:ARUK-UCL. DR GO; GO:0045861; P:negative regulation of proteolysis; IMP:BHF-UCL. DR GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0006809; P:nitric oxide biosynthetic process; TAS:ProtInc. DR GO; GO:0046209; P:nitric oxide metabolic process; TAS:Reactome. DR GO; GO:0001649; P:osteoblast differentiation; IDA:UniProt. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:1905786; P:positive regulation of anaphase-promoting complex-dependent catabolic process; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProt. DR GO; GO:0046326; P:positive regulation of D-glucose import; IMP:BHF-UCL. DR GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IDA:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:BHF-UCL. DR GO; GO:0010763; P:positive regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:BHF-UCL. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IDA:UniProtKB. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:UniProt. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:1905552; P:positive regulation of protein localization to endoplasmic reticulum; IDA:UniProt. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:BHF-UCL. DR GO; GO:0051247; P:positive regulation of protein metabolic process; ISS:BHF-UCL. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL. DR GO; GO:0010765; P:positive regulation of sodium ion transport; IEA:Ensembl. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904515; P:positive regulation of TORC2 signaling; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0005979; P:regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW. DR GO; GO:0110002; P:regulation of tRNA methylation; IDA:UniProt. DR GO; GO:2000074; P:regulation of type B pancreatic cell development; TAS:Reactome. DR GO; GO:0034405; P:response to fluid shear stress; IMP:BHF-UCL. DR GO; GO:0032094; P:response to food; IEA:Ensembl. DR GO; GO:0070848; P:response to growth factor; IDA:UniProtKB. DR GO; GO:0060416; P:response to growth hormone; ISS:AgBase. DR GO; GO:0009408; P:response to heat; TAS:ProtInc. DR GO; GO:1990418; P:response to insulin-like growth factor stimulus; ISS:AgBase. DR GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL. DR GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL. DR GO; GO:0007165; P:signal transduction; TAS:UniProtKB. DR GO; GO:0003376; P:sphingosine-1-phosphate receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0031929; P:TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR CDD; cd01241; PH_PKB; 1. DR CDD; cd05594; STKc_PKB_alpha; 1. DR DisProt; DP03300; -. DR FunFam; 1.10.510.10:FF:000033; Non-specific serine/threonine protein kinase; 1. DR FunFam; 2.30.29.30:FF:000027; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000838; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00412; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034676; Akt1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR039026; PH_PKB. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Carbohydrate metabolism; Cell membrane; Cytoplasm; Developmental protein; KW Disease variant; Disulfide bond; Glucose metabolism; Glycogen biosynthesis; KW Glycogen metabolism; Glycoprotein; Isopeptide bond; Kinase; Membrane; KW Mitochondrion; Neurogenesis; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Sugar transport; Transferase; KW Translation regulation; Transport; Ubl conjugation. FT CHAIN 1..480 FT /note="RAC-alpha serine/threonine-protein kinase" FT /id="PRO_0000085605" FT DOMAIN 5..108 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 150..408 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 409..480 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 113..138 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 450..480 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 274 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 14..19 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 23..25 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 53 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 86 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 156..164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 179 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 462 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000250|UniProtKB:P31750" FT MOD_RES 14 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 20 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 124 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 126 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 129 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 176 FT /note="Phosphotyrosine; by TNK2" FT /evidence="ECO:0000269|PubMed:20333297" FT MOD_RES 308 FT /note="Phosphothreonine; by IKKE, PDPK1 and TBK1" FT /evidence="ECO:0000269|PubMed:15718470, FT ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:40285646, ECO:0000269|PubMed:8978681, FT ECO:0000269|PubMed:9512493" FT MOD_RES 448 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 450 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 473 FT /note="Phosphoserine; by IKKE, MTOR, PRKDC and TBK1; FT alternate" FT /evidence="ECO:0000269|PubMed:14761976, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, FT ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, FT ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:40285646, FT ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9736715" FT MOD_RES 474 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:12149249" FT MOD_RES 477 FT /note="Phosphoserine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT MOD_RES 479 FT /note="Phosphothreonine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT CARBOHYD 126 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 129 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 305 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 312 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 473 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000250|UniProtKB:P31750" FT DISULFID 60..77 FT /evidence="ECO:0000269|PubMed:20886116" FT DISULFID 296..310 FT /evidence="ECO:0000250|UniProtKB:P31751" FT CROSSLNK 284 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:22410793" FT VAR_SEQ 1..62 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056180" FT VARIANT 17 FT /note="E -> K (in PROTEUSS and breast cancer; also detected FT in colorectal and ovarian cancer; somatic mutation; results FT in increased phosphorylation at T-308 and higher basal FT ubiquitination; the mutant protein is more efficiently FT recruited to the plasma membrane; alters FT phosphatidylinositiol phosphates lipid specificity of the FT AKT1 PH domain; dbSNP:rs121434592)" FT /evidence="ECO:0000269|PubMed:17611497, FT ECO:0000269|PubMed:18954143, ECO:0000269|PubMed:19713527, FT ECO:0000269|PubMed:21793738" FT /id="VAR_055422" FT VARIANT 25 FT /note="R -> C (in CWS6; impairs interaction with FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2; dbSNP:rs397514644)" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:23246288" FT /id="VAR_069791" FT VARIANT 167 FT /note="V -> A (in dbSNP:rs11555433)" FT /id="VAR_051617" FT VARIANT 435 FT /note="T -> P (in CWS6; dbSNP:rs397514645)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069792" FT MUTAGEN 8 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation as well FT as IGF1-induced membrane recruitment. Decrease in FT ubiquitination and phosphorylation at T-308 as well as FT impaired association with the membrane; when associated FT with K-17." FT /evidence="ECO:0000269|PubMed:19713527" FT MUTAGEN 14 FT /note="K->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, loss of AKT activation, and loss of binding FT to PIP3 as well as IGF1-induced membrane recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation, loss of FT binding to PIP3 as well as IGF1-induced membrane FT recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 17 FT /note="E->K: Loss of membrane localization; when associated FT with Q-20." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, reduced AKT activation, and reduced binding FT to PIP3 as well as IGF1-induced membrane recruitment. Loss FT of membrane localization; when associated with K-17." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->R: Slight increase of phosphorylation at T-308 FT and S-473." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 25 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 76..78 FT /note="RCL->ACA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 86 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 176 FT /note="Y->F: Significant loss of interaction with TNK2. FT Loss of membrane localization. Significant reduction in FT phosphorylation on Ser-473." FT /evidence="ECO:0000269|PubMed:20333297" FT MUTAGEN 179 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:12172553, FT ECO:0000269|PubMed:33594058" FT MUTAGEN 273..275 FT /note="RDL->ADA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 305 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-312." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 305 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 308 FT /note="T->D: 5-fold activation and 18-fold activation; when FT associated with D-473." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 312 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-305." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 312 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 473 FT /note="S->D: 7-fold activation and 25-fold activation; when FT associated with D-308." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 474 FT /note="Y->F: 55% inhibition of activation." FT /evidence="ECO:0000269|PubMed:12149249" FT CONFLICT 173..174 FT /note="GR -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 202 FT /note="L -> Q (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 212 FT /note="A -> R (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 246 FT /note="S -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 409 FT /note="A -> T (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="A -> P (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> S (in Ref. 1; AAA36539, 2; AAL55732, 3; FT BAG36922 and 4; BAG70056/BAG70181)" FT /evidence="ECO:0000305" FT HELIX 2..4 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 6..15 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 17..19 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 22..30 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 33..40 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 42..44 FT /evidence="ECO:0007829|PDB:7APJ" FT HELIX 45..48 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 67..69 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 72..79 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 82..89 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 147..149 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 150..158 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 160..169 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 170..172 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 175..182 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 183..188 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 192..204 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 213..218 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 220..227 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 235..242 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 247..268 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 280..282 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:4EJN" FT STRAND 288..290 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:3MVH" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 318..322 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 330..344 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 374..383 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 396..398 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 399..403 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 406..408 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 413..417 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 430..433 FT /evidence="ECO:0007829|PDB:3MVH" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:7NH5" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 464..466 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 473..475 FT /evidence="ECO:0007829|PDB:4GV1" SQ SEQUENCE 480 AA; 55686 MW; 6EAFF4F8AD436714 CRC64; MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQREA PLNNFSVAQC QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT TAIQTVADGL KKQEEEEMDF RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF EYLKLLGKGT FGKVILVKEK ATGRYYAMKI LKKEVIVAKD EVAHTLTENR VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS RERVFSEDRA RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLCKEGI KDGATMKTFC GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMCGRLPFY NQDHEKLFEL ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK EIMQHRFFAG IVWQHVYEKK LSPPFKPQVT SETDTRYFDE EFTAQMITIT PPDQDDSMEC VDSERRPHFP QFSYSASGTA // ID AURKA_HUMAN Reviewed; 403 AA. AC O14965; E1P5F9; O60445; O75873; Q9BQD6; Q9UPG5; DT 27-JAN-2003, integrated into UniProtKB/Swiss-Prot. DT 23-FEB-2022, sequence version 3. DT 28-JAN-2026, entry version 254. DE RecName: Full=Aurora kinase A {ECO:0000312|HGNC:HGNC:11393}; DE EC=2.7.11.1 {ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; DE AltName: Full=Aurora 2 {ECO:0000303|PubMed:10851084}; DE AltName: Full=Aurora/IPL1-related kinase 1 {ECO:0000303|PubMed:9153231}; DE Short=ARK-1 {ECO:0000303|PubMed:9153231}; DE Short=Aurora-related kinase 1 {ECO:0000303|PubMed:9514916}; DE AltName: Full=Breast tumor-amplified kinase {ECO:0000303|PubMed:11790771}; DE AltName: Full=Ipl1- and aurora-related kinase 1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase 15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}; DE AltName: Full=Serine/threonine-protein kinase 6 {ECO:0000303|PubMed:9771714}; DE AltName: Full=Serine/threonine-protein kinase Ayk1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase aurora-A {ECO:0000250|UniProtKB:P59241}; GN Name=AURKA {ECO:0000312|HGNC:HGNC:11393}; GN Synonyms=AIK {ECO:0000303|PubMed:9153231}, GN AIRK1 {ECO:0000312|HGNC:HGNC:11393}, ARK1 {ECO:0000312|HGNC:HGNC:11393}, GN AURA {ECO:0000312|HGNC:HGNC:11393}, AYK1 {ECO:0000250|UniProtKB:P97477}, GN BTAK {ECO:0000303|PubMed:9771714}, IAK1 {ECO:0000250|UniProtKB:P97477}, GN STK15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}, GN STK6 {ECO:0000303|PubMed:9771714}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, SUBCELLULAR LOCATION, AND VARIANT RP VAL-57. RC TISSUE=Blood; RX PubMed=9153231; DOI=10.1074/jbc.272.21.13766; RA Kimura M., Kotani S., Hattori T., Sumi N., Yoshioka T., Todokoro K., RA Okano Y.; RT "Cell cycle-dependent expression and spindle pole localization of a novel RT human protein kinase, Aik, related to Aurora of Drosophila and yeast RT Ipl1."; RL J. Biol. Chem. 272:13766-13771(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-57. RX PubMed=9514916; DOI=10.1006/bbrc.1998.8250; RA Shindo M., Nakano H., Kuroyanagi H., Shirasawa T., Mihara M., Gilbert D.J., RA Jenkins N.A., Copeland N.G., Yagita H., Okumura K.; RT "cDNA cloning, expression, subcellular localization, and chromosomal RT assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 RT and 2."; RL Biochem. Biophys. Res. Commun. 244:285-292(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-31 AND VAL-57. RC TISSUE=Mammary gland; RX PubMed=9771714; DOI=10.1038/2496; RA Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray J.W., Sahin A., Brinkley B.R., RA Sen S.; RT "Tumour amplified kinase STK15/BTAK induces centrosome amplification, RT aneuploidy and transformation."; RL Nat. Genet. 20:189-193(1998). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang L., Thibodeau S.N.; RT "Mutational analysis of the STK15 gene in human tumors."; RL Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-57. RC TISSUE=Cervix, Colon, Kidney, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INDUCTION, AND SUBCELLULAR LOCATION. RX PubMed=9606188; DOI=10.1093/emboj/17.11.3052; RA Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., RA Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., RA Novotny M., Slamon D.J., Plowman G.D.; RT "A homologue of Drosophila aurora kinase is oncogenic and amplified in RT human colorectal cancers."; RL EMBO J. 17:3052-3065(1998). RN [9] RP UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF ARG-205. RX PubMed=10851084; DOI=10.1038/sj.onc.1203609; RA Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H., RA Furukawa K., Urano T.; RT "Degradation of human Aurora2 protein kinase by the anaphase-promoting RT complex-ubiquitin-proteasome pathway."; RL Oncogene 19:2812-2819(2000). RN [10] RP FUNCTION, PHOSPHORYLATION AT THR-288, MUTAGENESIS OF THR-288, RP UBIQUITINATION, AND ACTIVITY REGULATION. RX PubMed=11039908; DOI=10.1038/sj.onc.1203847; RA Walter A.O., Seghezzi W., Korver W., Sheung J., Lees E.; RT "The mitotic serine/threonine kinase Aurora2/AIK is regulated by RT phosphorylation and degradation."; RL Oncogene 19:4906-4916(2000). RN [11] RP FUNCTION, INTERACTION WITH PPP1CA; PPP1CB AND PPP1CC, MUTAGENESIS OF RP PHE-165 AND PHE-346, AND PHOSPHORYLATION. RX PubMed=11551964; DOI=10.1074/jbc.m107540200; RA Katayama H., Zhou H., Li Q., Tatsuka M., Sen S.; RT "Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and RT protein phosphatase 1 through mitotic cell division cycle."; RL J. Biol. Chem. 276:46219-46224(2001). RN [12] RP SUBCELLULAR LOCATION. RX PubMed=12576638; DOI=10.1247/csf.27.457; RA Sugimoto K., Urano T., Zushi H., Inoue K., Tasaka H., Tachibana M., RA Dotsu M.; RT "Molecular dynamics of Aurora-A kinase in living mitotic cells RT simultaneously visualized with histone H3 and nuclear membrane protein RT importinalpha."; RL Cell Struct. Funct. 27:457-467(2002). RN [13] RP FUNCTION, INDUCTION, PHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=12390251; DOI=10.1046/j.1365-2443.2002.00592.x; RA Marumoto T., Hirota T., Morisaki T., Kunitoku N., Zhang D., Ichikawa Y., RA Sasayama T., Kuninaka S., Mimori T., Tamaki N., Kimura M., Okano Y., RA Saya H.; RT "Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian RT cells."; RL Genes Cells 7:1173-1182(2002). RN [14] RP INDUCTION. RX PubMed=11790771; DOI=10.1074/jbc.m108252200; RA Tanaka M., Ueda A., Kanamori H., Ideguchi H., Yang J., Kitajima S., RA Ishigatsubo Y.; RT "Cell-cycle-dependent regulation of human aurora A transcription is RT mediated by periodic repression of E4TF1."; RL J. Biol. Chem. 277:10719-10726(2002). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-288. RX PubMed=13678582; DOI=10.1016/s0092-8674(03)00642-1; RA Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., RA Hatakeyama K., Saya H.; RT "Aurora-A and an interacting activator, the LIM protein Ajuba, are required RT for mitotic commitment in human cells."; RL Cell 114:585-598(2003). RN [16] RP FUNCTION. RX PubMed=14523000; DOI=10.1074/jbc.m306275200; RA Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., Saya H.; RT "Aurora-A kinase maintains the fidelity of early and late mitotic events in RT HeLa cells."; RL J. Biol. Chem. 278:51786-51795(2003). RN [17] RP INTERACTION WITH TACC1. RX PubMed=14603251; DOI=10.1038/sj.onc.1206972; RA Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D., Larroque C., RA Prigent C., Seraphin B., Jacquemier J., Birnbaum D.; RT "TACC1-chTOG-Aurora A protein complex in breast cancer."; RL Oncogene 22:8102-8116(2003). RN [18] RP FUNCTION. RX PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x; RA Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S., RA Tamai K., Nojima H.; RT "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A RT kinase."; RL Genes Cells 9:383-397(2004). RN [19] RP RETRACTED PAPER. RX PubMed=14990569; DOI=10.1074/jbc.m311780200; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RT "BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M RT transition."; RL J. Biol. Chem. 279:19643-19648(2004). RN [20] RP RETRACTION NOTICE OF PUBMED:14990569. RX PubMed=26341884; DOI=10.1074/jbc.a115.311780; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RL J. Biol. Chem. 290:22311-22311(2015). RN [21] RP FUNCTION. RX PubMed=15128871; DOI=10.1242/jcs.01108; RA Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C., RA Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E., Monsarrat B., RA Prigent C., Ducommun B.; RT "Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the RT G2-M transition."; RL J. Cell Sci. 117:2523-2531(2004). RN [22] RP FUNCTION, MUTAGENESIS OF LYS-162, AND INTERACTION WITH TP53. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [23] RP INTERACTION WITH CPEB1. RX PubMed=15966895; DOI=10.1111/j.1365-2443.2005.00870.x; RA Sasayama T., Marumoto T., Kunitoku N., Zhang D., Tamaki N., Kohmura E., RA Saya H., Hirota T.; RT "Over-expression of Aurora-A targets cytoplasmic polyadenylation element RT binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1."; RL Genes Cells 10:627-638(2005). RN [24] RP PHOSPHORYLATION AT THR-288 AND SER-342. RX PubMed=16246726; DOI=10.1016/j.molcel.2005.08.035; RA Zhao Z.S., Lim J.P., Ng Y.W., Lim L., Manser E.; RT "The GIT-associated kinase PAK targets to the centrosome and regulates RT Aurora-A."; RL Mol. Cell 20:237-249(2005). RN [25] RP INDUCTION, AND FUNCTION. RX PubMed=15987997; DOI=10.1128/mcb.25.14.5789-5800.2005; RA Yu C.T., Hsu J.M., Lee Y.C., Tsou A.P., Chou C.K., Huang C.Y.; RT "Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP RT as a transforming target of Aurora-A."; RL Mol. Cell. Biol. 25:5789-5800(2005). RN [26] RP INTERACTION WITH BORA. RX PubMed=16890155; DOI=10.1016/j.devcel.2006.06.002; RA Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A., RA Knoblich J.A.; RT "Mitotic activation of the kinase Aurora-A requires its binding partner RT Bora."; RL Dev. Cell 11:147-157(2006). RN [27] RP FUNCTION. RX PubMed=18056443; DOI=10.1158/0008-5472.can-07-2578; RA Sankaran S., Crone D.E., Palazzo R.E., Parvin J.D.; RT "Aurora-A kinase regulates breast cancer associated gene 1 inhibition of RT centrosome-dependent microtubule nucleation."; RL Cancer Res. 67:11186-11194(2007). RN [28] RP FUNCTION, INTERACTION WITH HDAC6, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP ASP-274 AND THR-288. RX PubMed=17604723; DOI=10.1016/j.cell.2007.04.035; RA Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A.; RT "HEF1-dependent Aurora A activation induces disassembly of the primary RT cilium."; RL Cell 129:1351-1363(2007). RN [29] RP INTERACTION WITH ARHGEF2. RX PubMed=17488622; DOI=10.1016/j.devcel.2007.03.014; RA Birkenfeld J., Nalbant P., Bohl B.P., Pertz O., Hahn K.M., Bokoch G.M.; RT "GEF-H1 modulates localized RhoA activation during cytokinesis under the RT control of mitotic kinases."; RL Dev. Cell 12:699-712(2007). RN [30] RP SUBCELLULAR LOCATION, INTERACTION WITH PPP2CA, AND PHOSPHORYLATION AT RP SER-51. RX PubMed=17229885; DOI=10.1091/mbc.e06-12-1152; RA Horn V., Thelu J., Garcia A., Albiges-Rizo C., Block M.R., Viallet J.; RT "Functional interaction of Aurora-A and PP2A during mitosis."; RL Mol. Biol. Cell 18:1233-1241(2007). RN [31] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=17726514; DOI=10.1371/journal.pone.0000784; RA North B.J., Verdin E.; RT "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during RT mitosis."; RL PLoS ONE 2:E784-E784(2007). RN [32] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=17360485; DOI=10.1073/pnas.0608798104; RA Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., RA Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T., RA Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S., RA Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F.; RT "Antitumor activity of MLN8054, an orally active small-molecule inhibitor RT of Aurora A kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 104:4106-4111(2007). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [34] RP FUNCTION. RX PubMed=18615013; DOI=10.1038/nature07185; RA Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R., RA Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.; RT "Polo-like kinase-1 is activated by aurora A to promote checkpoint RT recovery."; RL Nature 455:119-123(2008). RN [35] RP FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PARD3. RX PubMed=19812038; DOI=10.1074/jbc.m109.055897; RA Khazaei M.R., Puschel A.W.; RT "Phosphorylation of the par polarity complex protein Par3 at serine 962 is RT mediated by aurora A and regulates its function in neuronal polarity."; RL J. Biol. Chem. 284:33571-33579(2009). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KIF2A. RX PubMed=19351716; DOI=10.1242/jcs.044321; RA Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.; RT "Plk1 and Aurora A regulate the depolymerase activity and the cellular RT localization of Kif2a."; RL J. Cell Sci. 122:1334-1341(2009). RN [37] RP FUNCTION, INTERACTION WITH TPX2, PHOSPHORYLATION AT THR-287 AND THR-288, RP AND MUTAGENESIS OF THR-287. RX PubMed=19668197; DOI=10.1038/ncb1919; RA Mori D., Yamada M., Mimori-Kiyosue Y., Shirai Y., Suzuki A., Ohno S., RA Saya H., Wynshaw-Boris A., Hirotsune S.; RT "An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite elongation RT by modulation of microtubule dynamics."; RL Nat. Cell Biol. 11:1057-1068(2009). RN [38] RP INTERACTION WITH TPX2, MUTAGENESIS OF GLY-198, AND SUBCELLULAR LOCATION. RX PubMed=19357306; DOI=10.1073/pnas.0900833106; RA Fu J., Bian M., Liu J., Jiang Q., Zhang C.; RT "A single amino acid change converts Aurora-A into Aurora-B-like kinase in RT terms of partner specificity and cellular function."; RL Proc. Natl. Acad. Sci. U.S.A. 106:6939-6944(2009). RN [39] RP FUNCTION, INTERACTION WITH CIMAP3, AND ACTIVATION BY CIMAP3. RX PubMed=20643351; DOI=10.1016/j.devcel.2010.06.005; RA Kinzel D., Boldt K., Davis E.E., Burtscher I., Trumbach D., Diplas B., RA Attie-Bitach T., Wurst W., Katsanis N., Ueffing M., Lickert H.; RT "Pitchfork regulates primary cilia disassembly and left-right asymmetry."; RL Dev. Cell 19:66-77(2010). RN [40] RP IDENTIFICATION IN A COMPLEX WITH AUNIP AND NIN. RX PubMed=20596670; DOI=10.3892/ijo_00000691; RA Lieu A.S., Cheng T.S., Chou C.H., Wu C.H., Hsu C.Y., Huang C.Y., RA Chang L.K., Loh J.K., Chang C.S., Hsu C.M., Howng S.L., Hong Y.R.; RT "Functional characterization of AIBp, a novel Aurora-A binding protein in RT centrosome structure and spindle formation."; RL Int. J. Oncol. 37:429-436(2010). RN [41] RP INTERACTION WITH GADD45A. RX PubMed=20460379; DOI=10.1074/jbc.m109.069344; RA Sanchez R., Pantoja-Uceda D., Prieto J., Diercks T., Marcaida M.J., RA Montoya G., Campos-Olivas R., Blanco F.J.; RT "Solution structure of human growth arrest and DNA damage 45alpha RT (Gadd45alpha) and its interactions with proliferating cell nuclear antigen RT (PCNA) and Aurora A kinase."; RL J. Biol. Chem. 285:22196-22201(2010). RN [42] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [43] RP SUBCELLULAR LOCATION, AND INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [44] RP REVIEW ON FUNCTION. RX PubMed=14625535; DOI=10.1038/nrm1245; RA Carmena M., Earnshaw W.C.; RT "The cellular geography of aurora kinases."; RL Nat. Rev. Mol. Cell Biol. 4:842-854(2003). RN [45] RP REVIEW ON FUNCTION. RX PubMed=19774610; DOI=10.1002/em.20533; RA Lukasiewicz K.B., Lingle W.L.; RT "Aurora A, centrosome structure, and the centrosome cycle."; RL Environ. Mol. Mutagen. 50:602-619(2009). RN [46] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004; RA Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., Li C., RA Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H., Cha Y.I., RA Gius D., Deng C.X.; RT "SIRT2 maintains genome integrity and suppresses tumorigenesis through RT regulating APC/C activity."; RL Cancer Cell 20:487-499(2011). RN [47] RP INTERACTION WITH HNRNPU. RX PubMed=21242313; DOI=10.1242/jcs.063347; RA Ma N., Matsunaga S., Morimoto A., Sakashita G., Urano T., Uchiyama S., RA Fukui K.; RT "The nuclear scaffold protein SAF-A is required for kinetochore-microtubule RT attachment and contributes to the targeting of Aurora-A to mitotic RT spindles."; RL J. Cell Sci. 124:394-404(2011). RN [48] RP INTERACTION WITH KLHL18 AND CUL3, UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=23213400; DOI=10.1242/bio.2011018; RA Moghe S., Jiang F., Miura Y., Cerny R.L., Tsai M.Y., Furukawa M.; RT "The CUL3-KLHL18 ligase regulates mitotic entry and ubiquitylates Aurora- RT A."; RL Biol. Open 1:82-91(2012). RN [49] RP INTERACTION WITH FRY. RX PubMed=22753416; DOI=10.1074/jbc.m112.378968; RA Ikeda M., Chiba S., Ohashi K., Mizuno K.; RT "Furry protein promotes Aurora A-mediated polo-like kinase 1 activation."; RL J. Biol. Chem. 287:27670-27681(2012). RN [50] RP SUBCELLULAR LOCATION. RX PubMed=25657325; DOI=10.1091/mbc.e14-09-1366; RA Ohta S., Wood L., Toramoto I., Yagyu K., Fukagawa T., Earnshaw W.C.; RT "CENP-32 is required to maintain centrosomal dominance in bipolar spindle RT assembly."; RL Mol. Biol. Cell 26:1225-1237(2015). RN [51] RP INTERACTION WITH HNRNPU. RX PubMed=25986610; DOI=10.1128/mcb.01312-14; RA Douglas P., Ye R., Morrice N., Britton S., Trinkle-Mulcahy L., RA Lees-Miller S.P.; RT "Phosphorylation of SAF-A/hnRNP-U serine 59 by polo-like kinase 1 is RT required for mitosis."; RL Mol. Cell. Biol. 35:2699-2713(2015). RN [52] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=27192185; DOI=10.1080/15384101.2016.1187342; RA Meunier S., Timon K., Vernos I.; RT "Aurora-A regulates MCRS1 function during mitosis."; RL Cell Cycle 15:1779-1786(2016). RN [53] RP FUNCTION. RX PubMed=27335426; DOI=10.1242/jcs.184416; RA Kotak S., Afshar K., Busso C., Goenczy P.; RT "Aurora A kinase regulates proper spindle positioning in C. elegans and in RT human cells."; RL J. Cell Sci. 129:3015-3025(2016). RN [54] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [55] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP FOXP1. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=30538148; DOI=10.1261/rna.069773.118; RA Jiao A.L., Perales R., Umbreit N.T., Haswell J.R., Piper M.E., Adams B.D., RA Pellman D., Kennedy S., Slack F.J.; RT "Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing RT factor."; RL RNA 25:352-363(2019). RN [57] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 107-403 IN COMPLEX WITH ADENOSINE, RP AND CATALYTIC ACTIVITY. RX PubMed=12237287; DOI=10.1074/jbc.c200426200; RA Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L., Weber P., RA Lippke J.A., Austen D.A.; RT "Crystal structure of aurora-2, an oncogenic serine/threonine kinase."; RL J. Biol. Chem. 277:42419-42422(2002). RN [58] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 125-391 IN COMPLEX WITH ADP. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [59] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 122-403 IN COMPLEX WITH TPX2, RP MUTAGENESIS OF ASP-274, ACTIVE SITE, PHOSPHORYLATION AT THR-287 AND RP THR-288, AND REGION ACTIVATION SEGMENT. RX PubMed=14580337; DOI=10.1016/s1097-2765(03)00392-7; RA Bayliss R., Sardon T., Vernos I., Conti E.; RT "Structural basis of Aurora-A activation by TPX2 at the mitotic spindle."; RL Mol. Cell 12:851-862(2003). RN [60] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 123-401 IN COMPLEXES WITH ADPNP RP AND 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=16337122; DOI=10.1016/j.bmcl.2005.11.053; RA Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., RA Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A., RA Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S.; RT "SAR and inhibitor complex structure determination of a novel class of RT potent and specific Aurora kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 16:1320-1323(2006). RN [61] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 100-403 IN COMPLEXES WITH RP SYNTHETIC INHIBITORS, AND FUNCTION. RX PubMed=17125279; DOI=10.1021/jm060897w; RA Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S., RA Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B., RA Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M., RA Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P., RA Vianello P.; RT "1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent RT aurora kinase inhibitor with a favorable antitumor kinase inhibition RT profile."; RL J. Med. Chem. 49:7247-7251(2006). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 125-391 IN COMPLEX WITH VX-680 AND RP TPX2, PHOSPHORYLATION AT THR-288, IDENTIFICATION BY MASS SPECTROMETRY, AND RP SUBUNIT. RX PubMed=18662907; DOI=10.1110/ps.036590.108; RA Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A., RA Kirkpatrick R.B., Lai Z.; RT "Modulation of kinase-inhibitor interactions by auxiliary protein binding: RT crystallography studies on Aurora A interactions with VX-680 and with RT TPX2."; RL Protein Sci. 17:1791-1797(2008). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 127-388 IN COMPLEX WITH ADP, RP CHARACTERIZATION OF VARIANTS ARG-155 AND MET-174, AND INTERACTION WITH RP TPX2. RX PubMed=19801554; DOI=10.1074/jbc.m109.032722; RA Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., RA Bayliss R., Linardopoulos S.; RT "A cancer-associated aurora A mutant is mislocalized and misregulated due RT to loss of interaction with TPX2."; RL J. Biol. Chem. 284:33177-33184(2009). RN [64] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 123-401 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19140666; DOI=10.1021/jm801270e; RA Coumar M.S., Leou J.S., Shukla P., Wu J.S., Dixit A.K., Lin W.H., RA Chang C.Y., Lien T.W., Tan U.K., Chen C.H., Hsu J.T., Chao Y.S., Wu S.Y., RA Hsieh H.P.; RT "Structure-based drug design of novel Aurora kinase A inhibitors: RT structural basis for potency and specificity."; RL J. Med. Chem. 52:1050-1062(2009). RN [65] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 125-391 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19402633; DOI=10.1021/jm9000314; RA Aliagas-Martin I., Burdick D., Corson L., Dotson J., Drummond J., RA Fields C., Huang O.W., Hunsaker T., Kleinheinz T., Krueger E., Liang J., RA Moffat J., Phillips G., Pulk R., Rawson T.E., Ultsch M., Walker L., RA Wiesmann C., Zhang B., Zhu B.Y., Cochran A.G.; RT "A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually RT high selectivity against Aurora B."; RL J. Med. Chem. 52:3300-3307(2009). RN [66] RP X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 122-403 OF MUTANTS ALA-290 AND RP ALA-393 IN COMPLEX WITH ADP, INTERACTION WITH MYCN AND TPX2, MUTAGENESIS OF RP CYS-290; TYR-334; GLN-335 AND CYS-393, AND CATALYTIC ACTIVITY. RX PubMed=27837025; DOI=10.1073/pnas.1610626113; RA Richards M.W., Burgess S.G., Poon E., Carstensen A., Eilers M., Chesler L., RA Bayliss R.; RT "Structural basis of N-Myc binding by Aurora-A and its destabilization by RT kinase inhibitors."; RL Proc. Natl. Acad. Sci. U.S.A. 113:13726-13731(2016). RN [67] RP VARIANTS ILE-31 AND VAL-57, AND CHARACTERIZATION OF VARIANT VAL-57. RX PubMed=15867347; DOI=10.1158/0008-5472.can-04-2149; RA Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K., RA Nagase H.; RT "Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) RT coordinately increase esophageal cancer risk."; RL Cancer Res. 65:3548-3554(2005). RN [68] RP VARIANTS ILE-31 AND VAL-57. RX PubMed=16011022; RA Chen L., Ao X., Ren Q., Wang Z.N., Lu C., Xu Y., Jiang L., Luo Y., Xu H.M., RA Zhang X.; RT "Linkage disequilibrium and haplotype analysis of two single nucleotide RT polymorphisms in STK15 in Chinese."; RL Yi Chuan Xue Bao 32:331-336(2005). RN [69] RP VARIANT ILE-31. RX PubMed=16762494; DOI=10.1016/j.canlet.2006.05.002; RA Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A., RA Wappenschmidt B., Kiechle M., Bugert P., Schmutzler R.K., Bartram C.R., RA Burwinkel B.; RT "Aurora kinases A and B and familial breast cancer risk."; RL Cancer Lett. 247:266-272(2007). RN [70] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-31; LEU-50; VAL-57; ARG-155; MET-174 RP AND VAL-373. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [71] RP IDENTIFICATION IN A COMPLEX WITH NEDD9 AND CTTN. RX PubMed=24574519; DOI=10.1158/1541-7786.mcr-13-0654; RA Kozyreva V.K., McLaughlin S.L., Livengood R.H., Calkins R.A., Kelley L.C., RA Rajulapati A., Ice R.J., Smolkin M.B., Weed S.A., Pugacheva E.N.; RT "NEDD9 regulates actin dynamics through cortactin deacetylation in an RT AURKA/HDAC6-dependent manner."; RL Mol. Cancer Res. 12:681-693(2014). RN [72] RP FUNCTION, INTERACTION WITH AAAS, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-288. RX PubMed=26246606; DOI=10.1091/mbc.e15-02-0113; RA Carvalhal S., Ribeiro S.A., Arocena M., Kasciukovic T., Temme A., RA Koehler K., Huebner A., Griffis E.R.; RT "The nucleoporin ALADIN regulates Aurora A localization to ensure robust RT mitotic spindle formation."; RL Mol. Biol. Cell 26:3424-3438(2015). CC -!- FUNCTION: Mitotic serine/threonine kinase that contributes to the CC regulation of cell cycle progression (PubMed:11039908, PubMed:12390251, CC PubMed:17125279, PubMed:17360485, PubMed:18615013, PubMed:26246606). CC Associates with the centrosome and the spindle microtubules during CC mitosis and plays a critical role in various mitotic events including CC the establishment of mitotic spindle, centrosome duplication, CC centrosome separation as well as maturation, chromosomal alignment, CC spindle assembly checkpoint, and cytokinesis (PubMed:14523000, CC PubMed:26246606). Required for normal spindle positioning during CC mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex CC during metaphase (PubMed:27335426). Required for initial activation of CC CDK1 at centrosomes (PubMed:13678582, PubMed:15128871). Phosphorylates CC numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, CC DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, CC p53/TP53 and TPX2 (PubMed:11551964, PubMed:14702041, PubMed:15128871, CC PubMed:15147269, PubMed:15987997, PubMed:17604723, PubMed:18056443, CC PubMed:18615013). Phosphorylates MCRS1 which is required for MCRS1- CC mediated kinetochore fiber assembly and mitotic progression CC (PubMed:27192185). Regulates KIF2A tubulin depolymerase activity CC (PubMed:19351716). Important for microtubule formation and/or CC stabilization (PubMed:18056443). Required for normal axon formation CC (PubMed:19812038). Plays a role in microtubule remodeling during CC neurite extension (PubMed:19668197). Also acts as a key regulatory CC component of the p53/TP53 pathway, and particularly the checkpoint- CC response pathways critical for oncogenic transformation of cells, by CC phosphorylating and destabilizing p53/TP53 (PubMed:14702041). CC Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) CC isoforms, to inhibit their activity (PubMed:11551964). Inhibits cilia CC outgrowth (By similarity). Required for cilia disassembly via CC phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin CC (PubMed:17604723, PubMed:20643351). Regulates protein levels of the CC anti-apoptosis protein BIRC5 by suppressing the expression of the CC SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through CC the phosphorylation of the transcription factor FOXP1 CC (PubMed:28218735). {ECO:0000250|UniProtKB:A0A8I3S724, CC ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14523000, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15128871, ECO:0000269|PubMed:15147269, CC ECO:0000269|PubMed:15987997, ECO:0000269|PubMed:17125279, CC ECO:0000269|PubMed:17360485, ECO:0000269|PubMed:17604723, CC ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:18615013, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19812038, ECO:0000269|PubMed:20643351, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27192185, CC ECO:0000269|PubMed:27335426, ECO:0000269|PubMed:28218735}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; CC -!- ACTIVITY REGULATION: Activation of CDK1, appears to be an upstream CC event of AURKA activation. Phosphatase inhibitor-2 (PPP1R2) and TPX2 CC act also as activators. Inactivated by the G2 checkpoint. Inhibited by CC GADD45A and p53/TP53, and through dephosphorylation by protein CC phosphatase type 1 (PP1). MLN8054 is also a potent and selective CC inhibitor. Activated during the early phase of cilia disassembly in the CC presence of CIMAP3. Inhibited by the small molecule inhibitor VX-680 CC (PubMed:28218735). {ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:17360485, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: Part of a complex composed of NEDD9, AURKA and CTTN; within CC the complex NEDD9 acts as a scaffold protein and is required for CC complex formation (PubMed:24574519). Identified in a complex with AUNIP CC and NIN (PubMed:20596670). Interacts with FBXL7 (By similarity). CC Interacts with CPEB1, JTB, TACC1, TPX2, PPP2CA, as well as with the CC protein phosphatase type 1 (PP1) isoforms PPP1CA, PPP1CB and PPP1CC CC (PubMed:11551964, PubMed:14580337, PubMed:14603251, PubMed:15966895, CC PubMed:17229885, PubMed:18662907, PubMed:19357306, PubMed:19668197, CC PubMed:19801554, PubMed:21225229, PubMed:27837025). Also interacts with CC its substrates ARHGEF2, BORA, KIF2A, PARD3, and p53/TP53 CC (PubMed:14702041, PubMed:16890155, PubMed:17488622, PubMed:19351716, CC PubMed:19812038). Interaction with BORA promotes phosphorylation of CC PLK1 (By similarity). Interacts with CIMAP3 (PubMed:20643351). CC Interacts with GADD45A, competing with its oligomerization CC (PubMed:20460379). Interacts (via C-terminus) with AUNIP (via C- CC terminus) (PubMed:20596670). Interacts with FRY; this interaction CC facilitates AURKA-mediated PLK1 phosphorylation (PubMed:22753416). CC Interacts with SIRT2 (PubMed:17726514, PubMed:22014574). Interacts with CC MYCN; interaction is phospho-independent and triggers AURKA activation; CC AURKA competes with FBXW7 for binding to unphosphorylated MYCN but not CC for binding to phosphorylated MYCN (PubMed:27837025). Interacts with CC HNRNPU (PubMed:21242313, PubMed:25986610). Interacts with AAAS CC (PubMed:26246606). Interacts with KLHL18 and CUL3 (PubMed:23213400). CC Interacts with FOXP1 (PubMed:28218735). Interacts with HDAC6; AURKA- CC mediated phosphorylation of HDAC6 promotes deacetylation of alpha- CC tubulin (PubMed:17604723). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:11551964, ECO:0000269|PubMed:12237287, CC ECO:0000269|PubMed:12467573, ECO:0000269|PubMed:14580337, CC ECO:0000269|PubMed:14603251, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15966895, ECO:0000269|PubMed:16890155, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:17488622, CC ECO:0000269|PubMed:17604723, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:18662907, ECO:0000269|PubMed:19140666, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19801554, ECO:0000269|PubMed:19812038, CC ECO:0000269|PubMed:20460379, ECO:0000269|PubMed:20596670, CC ECO:0000269|PubMed:20643351, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21242313, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:22753416, ECO:0000269|PubMed:23213400, CC ECO:0000269|PubMed:24574519, ECO:0000269|PubMed:25986610, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}. CC -!- INTERACTION: CC O14965; Q9NWT8: AURKAIP1; NbExp=2; IntAct=EBI-448680, EBI-448665; CC O14965; O15392: BIRC5; NbExp=2; IntAct=EBI-448680, EBI-518823; CC O14965; Q6PGQ7: BORA; NbExp=3; IntAct=EBI-448680, EBI-719836; CC O14965; P15056: BRAF; NbExp=5; IntAct=EBI-448680, EBI-365980; CC O14965; P00533: EGFR; NbExp=5; IntAct=EBI-448680, EBI-297353; CC O14965; P06730: EIF4E; NbExp=2; IntAct=EBI-448680, EBI-73440; CC O14965; P61978: HNRNPK; NbExp=2; IntAct=EBI-448680, EBI-304185; CC O14965; Q13123: IK; NbExp=3; IntAct=EBI-448680, EBI-713456; CC O14965; O14920: IKBKB; NbExp=2; IntAct=EBI-448680, EBI-81266; CC O14965; Q9NQS7: INCENP; NbExp=2; IntAct=EBI-448680, EBI-307907; CC O14965; Q9NQS7-1: INCENP; NbExp=2; IntAct=EBI-448680, EBI-15767972; CC O14965; P04198: MYCN; NbExp=12; IntAct=EBI-448680, EBI-878369; CC O14965; P06748: NPM1; NbExp=3; IntAct=EBI-448680, EBI-78579; CC O14965; P53350: PLK1; NbExp=4; IntAct=EBI-448680, EBI-476768; CC O14965; P23468: PTPRD; NbExp=2; IntAct=EBI-448680, EBI-2682990; CC O14965; Q96R06: SPAG5; NbExp=3; IntAct=EBI-448680, EBI-413317; CC O14965; O15350: TP73; NbExp=11; IntAct=EBI-448680, EBI-389606; CC O14965; Q9ULW0: TPX2; NbExp=10; IntAct=EBI-448680, EBI-1037322; CC O14965; Q8VDQ8: Sirt2; Xeno; NbExp=5; IntAct=EBI-448680, EBI-911012; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:21225229, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:23213400, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:30538148, ECO:0000269|PubMed:9153231}. Cytoplasm, CC cytoskeleton, spindle pole {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:9153231, CC ECO:0000269|PubMed:9606188}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome, centriole CC {ECO:0000250|UniProtKB:P97477}. Cell projection, neuron projection CC {ECO:0000250|UniProtKB:P97477}. Cell projection, cilium CC {ECO:0000269|PubMed:17604723}. Cytoplasm, cytoskeleton, cilium basal CC body {ECO:0000269|PubMed:17604723}. Basolateral cell membrane CC {ECO:0000250|UniProtKB:F1PNY0}. Note=Detected at the neurite hillock in CC developing neurons (By similarity). Localizes at the centrosome in CC mitotic cells from early prophase until telophase, but also localizes CC to the spindle pole MTs from prophase to anaphase (PubMed:17229885, CC PubMed:21225229, PubMed:9606188). Colocalized with SIRT2 at centrosome CC (PubMed:22014574). Moves to the midbody during both telophase and CC cytokinesis (PubMed:17726514). Associates with both the pericentriolar CC material (PCM) and centrioles (PubMed:22014574). The localization to CC the spindle poles is regulated by AAAS (PubMed:26246606). CC {ECO:0000250|UniProtKB:P97477, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:22014574, ECO:0000269|PubMed:26246606, CC ECO:0000269|PubMed:9606188}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis and weakly in skeletal CC muscle, thymus and spleen. Also highly expressed in colon, ovarian, CC prostate, neuroblastoma, breast and cervical cancer cell lines. CC -!- INDUCTION: Expression is cell-cycle regulated, low in G1/S, accumulates CC during G2/M, and decreases rapidly after. {ECO:0000269|PubMed:11790771, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:15987997, CC ECO:0000269|PubMed:9153231, ECO:0000269|PubMed:9606188}. CC -!- PTM: Activated by phosphorylation at Thr-288; this brings about a CC change in the conformation of the activation segment. Phosphorylation CC at Thr-288 varies during the cell cycle and is highest during M phase. CC Autophosphorylated at Thr-288 upon TPX2 binding. Thr-288 can be CC phosphorylated by several kinases, including PAK and PKA. Protein CC phosphatase type 1 (PP1) binds AURKA and inhibits its activity by CC dephosphorylating Thr-288 during mitosis. Phosphorylation at Ser-342 CC decreases the kinase activity. PPP2CA controls degradation by CC dephosphorylating Ser-51 at the end of mitosis. CC {ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14580337, ECO:0000269|PubMed:16246726, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:18662907, CC ECO:0000269|PubMed:19668197}. CC -!- PTM: Ubiquitinated by the E3 ubiquitin-protein ligase complex CC SCF(FBXL7) during mitosis, leading to its degradation by the proteasome CC (By similarity). Ubiquitinated by CHFR, leading to its degradation by CC the proteasome (By similarity). Ubiquitinated by the anaphase-promoting CC complex (APC), leading to its degradation by the proteasome CC (PubMed:10851084, PubMed:11039908). Ubiquitinated by the CUL3-KLHL18 CC ligase leading to its activation at the centrosome which is required CC for initiating mitotic entry (PubMed:23213400). Ubiquitination mediated CC by CUL3-KLHL18 ligase does not lead to its degradation by the CC proteasome (PubMed:23213400). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:10851084, ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:23213400}. CC -!- MISCELLANEOUS: Centrosome amplification can occur when the cycles are CC uncoupled, and this amplification is associated with cancer and with an CC increase in the levels of chromosomal instability. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. Aurora subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Authors initially considered AURKA/STK6 and STK15 as 2 CC different proteins (PubMed:9771714). It is clear that they are the same CC protein. {ECO:0000305|PubMed:9771714}. CC -!- CAUTION: An article that concluded that AURKA-mediated phosphorylation CC of BRCA1 'Ser-308' plays a role in the normal cell cycle G2/M CC transition was withdrawn due to data manipulation of flow cytometry CC data. {ECO:0000305|PubMed:14990569, ECO:0000305|PubMed:26341884}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA23592.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/730/AURKA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D84212; BAA23592.1; ALT_FRAME; mRNA. DR EMBL; AF008551; AAC12708.1; -; mRNA. DR EMBL; AF011467; AAC23448.1; -; Genomic_DNA. DR EMBL; AF011468; AAC63902.1; -; mRNA. DR EMBL; AF195947; AAF29508.1; -; Genomic_DNA. DR EMBL; AF195942; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195943; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195944; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195945; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195946; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AL121914; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471077; EAW75550.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75551.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75552.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75553.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75554.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75555.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75556.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75557.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75558.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75559.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75561.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75562.1; -; Genomic_DNA. DR EMBL; BC001280; AAH01280.1; -; mRNA. DR EMBL; BC002499; AAH02499.1; -; mRNA. DR EMBL; BC006423; AAH06423.1; -; mRNA. DR EMBL; BC027464; AAH27464.1; -; mRNA. DR CCDS; CCDS13451.1; -. DR PIR; JC5974; JC5974. DR RefSeq; NP_001310232.1; NM_001323303.2. DR RefSeq; NP_001310233.1; NM_001323304.2. DR RefSeq; NP_001310234.1; NM_001323305.2. DR RefSeq; NP_001411346.1; NM_001424417.1. DR RefSeq; NP_003591.2; NM_003600.3. DR RefSeq; NP_940835.1; NM_198433.3. DR RefSeq; NP_940836.1; NM_198434.3. DR RefSeq; NP_940837.1; NM_198435.3. DR RefSeq; NP_940838.1; NM_198436.3. DR RefSeq; NP_940839.1; NM_198437.3. DR PDB; 1MQ4; X-ray; 1.90 A; A=125-391. DR PDB; 1MUO; X-ray; 2.90 A; A=107-403. DR PDB; 1OL5; X-ray; 2.50 A; A=122-403. DR PDB; 1OL6; X-ray; 3.00 A; A=122-403. DR PDB; 1OL7; X-ray; 2.75 A; A=122-403. DR PDB; 2BMC; X-ray; 2.60 A; A/B/C/D/E/F=100-403. DR PDB; 2C6D; X-ray; 2.20 A; A=124-398. DR PDB; 2C6E; X-ray; 2.10 A; A/B=123-401. DR PDB; 2DWB; X-ray; 2.50 A; A=122-403. DR PDB; 2J4Z; X-ray; 2.00 A; A/B=100-403. DR PDB; 2J50; X-ray; 3.00 A; A/B=126-403. DR PDB; 2NP8; X-ray; 2.25 A; A=125-391. DR PDB; 2W1C; X-ray; 3.24 A; A=122-389. DR PDB; 2W1D; X-ray; 2.97 A; A=122-389. DR PDB; 2W1E; X-ray; 2.93 A; A=122-389. DR PDB; 2W1F; X-ray; 2.85 A; A=122-389. DR PDB; 2W1G; X-ray; 2.71 A; A=122-389. DR PDB; 2WQE; X-ray; 2.50 A; A=127-388. DR PDB; 2WTV; X-ray; 2.40 A; A/B/C/D=122-403. DR PDB; 2WTW; X-ray; 3.30 A; A=122-403. DR PDB; 2X6D; X-ray; 2.80 A; A=122-403. DR PDB; 2X6E; X-ray; 3.35 A; A=122-403. DR PDB; 2X81; X-ray; 2.91 A; A=126-391. DR PDB; 2XNE; X-ray; 2.80 A; A=122-392. DR PDB; 2XNG; X-ray; 2.60 A; A=122-403. DR PDB; 2XRU; X-ray; 2.90 A; A=126-403. DR PDB; 3COH; X-ray; 2.70 A; A/B=124-391. DR PDB; 3E5A; X-ray; 2.30 A; A=125-391. DR PDB; 3EFW; X-ray; 2.29 A; A/B=125-391. DR PDB; 3FDN; X-ray; 1.90 A; A=123-401. DR PDB; 3H0Y; X-ray; 2.50 A; A=124-391. DR PDB; 3H0Z; X-ray; 2.92 A; A/B/C=124-391. DR PDB; 3H10; X-ray; 2.20 A; A/B/D=124-391. DR PDB; 3HA6; X-ray; 2.36 A; A=125-391. DR PDB; 3K5U; X-ray; 2.35 A; A=123-401. DR PDB; 3LAU; X-ray; 2.10 A; A=125-399. DR PDB; 3M11; X-ray; 2.75 A; A=123-401. DR PDB; 3MYG; X-ray; 2.40 A; A=125-391. DR PDB; 3NRM; X-ray; 3.05 A; A=126-403. DR PDB; 3O50; X-ray; 2.00 A; A/B=125-391. DR PDB; 3O51; X-ray; 3.20 A; A=125-391. DR PDB; 3P9J; X-ray; 2.80 A; A=125-391. DR PDB; 3QBN; X-ray; 3.50 A; A=124-403. DR PDB; 3R21; X-ray; 2.90 A; A=126-391. DR PDB; 3R22; X-ray; 2.90 A; A=126-391. DR PDB; 3UNZ; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UO4; X-ray; 2.45 A; A=123-401. DR PDB; 3UO5; X-ray; 2.70 A; A=123-401. DR PDB; 3UO6; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOD; X-ray; 2.50 A; A=123-401. DR PDB; 3UOH; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOJ; X-ray; 2.90 A; A/B=123-401. DR PDB; 3UOK; X-ray; 2.95 A; A/B=123-401. DR PDB; 3UOL; X-ray; 2.40 A; A/B=123-401. DR PDB; 3UP2; X-ray; 2.30 A; A=123-401. DR PDB; 3UP7; X-ray; 3.05 A; A=123-401. DR PDB; 3VAP; X-ray; 2.66 A; A=125-391. DR PDB; 3W10; X-ray; 2.70 A; A=126-403. DR PDB; 3W16; X-ray; 2.80 A; A=126-403. DR PDB; 3W18; X-ray; 2.50 A; A/B=126-403. DR PDB; 3W2C; X-ray; 2.45 A; A/C/E/G=128-388. DR PDB; 4B0G; X-ray; 2.50 A; A=122-403. DR PDB; 4BN1; X-ray; 2.50 A; A=122-403. DR PDB; 4BYI; X-ray; 2.60 A; A=122-403. DR PDB; 4BYJ; X-ray; 2.75 A; A=122-403. DR PDB; 4C3P; X-ray; 2.69 A; A/D=122-403. DR PDB; 4C3R; X-ray; 2.79 A; A=122-403. DR PDB; 4CEG; X-ray; 2.10 A; A=122-403. DR PDB; 4DEA; X-ray; 2.45 A; A=123-401. DR PDB; 4DEB; X-ray; 3.05 A; A=123-401. DR PDB; 4DED; X-ray; 3.05 A; A=123-401. DR PDB; 4DEE; X-ray; 2.30 A; A=123-401. DR PDB; 4DHF; X-ray; 2.80 A; A/B=126-391. DR PDB; 4J8M; X-ray; 1.85 A; A=123-401. DR PDB; 4J8N; X-ray; 3.14 A; A/B/C/D=123-401. DR PDB; 4JAI; X-ray; 3.20 A; A=122-396. DR PDB; 4JAJ; X-ray; 2.70 A; A=122-396. DR PDB; 4JBO; X-ray; 2.49 A; A=123-401. DR PDB; 4JBP; X-ray; 2.45 A; A=123-401. DR PDB; 4JBQ; X-ray; 2.30 A; A=123-401. DR PDB; 4O0S; X-ray; 2.50 A; A=122-403. DR PDB; 4O0U; X-ray; 2.60 A; A=122-403. DR PDB; 4O0W; X-ray; 2.60 A; A=122-403. DR PDB; 4PRJ; X-ray; 2.80 A; A=124-391. DR PDB; 4UYN; X-ray; 1.90 A; A=125-399. DR PDB; 4UZD; X-ray; 3.20 A; A/B=125-399. DR PDB; 4UZH; X-ray; 2.00 A; A=125-399. DR PDB; 4ZS0; X-ray; 3.00 A; A=122-403. DR PDB; 4ZTQ; X-ray; 2.80 A; A=122-403. DR PDB; 4ZTR; X-ray; 2.85 A; A=122-403. DR PDB; 4ZTS; X-ray; 2.90 A; A=122-403. DR PDB; 5AAD; X-ray; 3.10 A; A=122-403. DR PDB; 5AAE; X-ray; 3.11 A; A=122-403. DR PDB; 5AAF; X-ray; 2.78 A; A=122-403. DR PDB; 5AAG; X-ray; 2.85 A; A=122-403. DR PDB; 5DN3; X-ray; 2.05 A; A=125-391. DR PDB; 5DNR; X-ray; 1.95 A; A=125-391. DR PDB; 5DOS; X-ray; 2.98 A; A=126-390. DR PDB; 5DPV; X-ray; 2.29 A; A=126-390. DR PDB; 5DR2; X-ray; 2.46 A; A=128-390. DR PDB; 5DR6; X-ray; 2.53 A; A=126-390. DR PDB; 5DR9; X-ray; 2.47 A; A=126-390. DR PDB; 5DRD; X-ray; 2.13 A; A=126-390. DR PDB; 5DT0; X-ray; 2.15 A; A=126-390. DR PDB; 5DT3; X-ray; 2.33 A; A=126-390. DR PDB; 5DT4; X-ray; 2.86 A; A=126-390. DR PDB; 5EW9; X-ray; 2.18 A; A=123-390. DR PDB; 5G15; X-ray; 2.06 A; A=122-403. DR PDB; 5G1X; X-ray; 1.72 A; A=122-403. DR PDB; 5L8J; X-ray; 1.68 A; A=122-403. DR PDB; 5L8K; X-ray; 1.79 A; A=122-403. DR PDB; 5L8L; X-ray; 1.67 A; A=122-403. DR PDB; 5LXM; X-ray; 2.08 A; A=122-403. DR PDB; 5OBJ; X-ray; 2.90 A; A=125-391. DR PDB; 5OBR; X-ray; 2.62 A; A=125-391. DR PDB; 5ODT; X-ray; 2.02 A; A=122-403. DR PDB; 5ONE; X-ray; 2.60 A; A=122-403. DR PDB; 5ORL; X-ray; 1.69 A; A=127-391. DR PDB; 5ORN; X-ray; 2.19 A; A=127-391. DR PDB; 5ORO; X-ray; 2.12 A; A=127-391. DR PDB; 5ORP; X-ray; 2.19 A; A=127-391. DR PDB; 5ORR; X-ray; 2.09 A; A=127-391. DR PDB; 5ORS; X-ray; 1.98 A; A=127-391. DR PDB; 5ORT; X-ray; 2.56 A; A=127-391. DR PDB; 5ORV; X-ray; 1.88 A; A=127-391. DR PDB; 5ORW; X-ray; 2.00 A; A=127-391. DR PDB; 5ORX; X-ray; 1.88 A; A=127-391. DR PDB; 5ORY; X-ray; 1.99 A; A=127-391. DR PDB; 5ORZ; X-ray; 1.92 A; A=127-391. DR PDB; 5OS0; X-ray; 1.74 A; A=127-391. DR PDB; 5OS1; X-ray; 1.90 A; A=127-391. DR PDB; 5OS2; X-ray; 1.92 A; A=127-391. DR PDB; 5OS3; X-ray; 1.81 A; A=127-391. DR PDB; 5OS4; X-ray; 1.88 A; A=127-391. DR PDB; 5OS5; X-ray; 1.74 A; A=125-392. DR PDB; 5OS6; X-ray; 2.20 A; A=127-391. DR PDB; 5OSD; X-ray; 1.99 A; A=125-391. DR PDB; 5OSE; X-ray; 1.90 A; A=127-391. DR PDB; 5OSF; X-ray; 1.89 A; A=127-391. DR PDB; 5ZAN; X-ray; 2.85 A; A=123-403. DR PDB; 6C2R; X-ray; 1.96 A; A=125-391. DR PDB; 6C2T; X-ray; 1.73 A; A=125-391. DR PDB; 6C83; X-ray; 2.55 A; A/B=122-403. DR PDB; 6CPE; X-ray; 2.45 A; A=122-403. DR PDB; 6CPF; X-ray; 2.30 A; A=122-403. DR PDB; 6CPG; X-ray; 2.80 A; A/D=122-403. DR PDB; 6GRA; X-ray; 2.60 A; A=122-403. DR PDB; 6HJJ; X-ray; 2.13 A; A=122-403. DR PDB; 6HJK; X-ray; 2.40 A; A=122-403. DR PDB; 6I2U; X-ray; 2.50 A; A=122-403. DR PDB; 6R49; X-ray; 2.21 A; A=122-403. DR PDB; 6R4A; X-ray; 1.94 A; A=122-403. DR PDB; 6R4B; X-ray; 2.15 A; A=122-403. DR PDB; 6R4C; X-ray; 2.04 A; A=122-403. DR PDB; 6R4D; X-ray; 2.01 A; A=122-403. DR PDB; 6VPG; X-ray; 2.64 A; A=117-389. DR PDB; 6VPH; X-ray; 2.14 A; A=117-389. DR PDB; 6VPI; X-ray; 2.00 A; A=117-389. DR PDB; 6VPJ; X-ray; 2.10 A; A=117-389. DR PDB; 6VPL; X-ray; 1.86 A; A/B=117-389. DR PDB; 6VPM; X-ray; 1.58 A; A/B=117-389. DR PDB; 6XKA; X-ray; 2.65 A; A=117-389. DR PDB; 6Z4Y; X-ray; 2.25 A; A=122-403. DR PDB; 7AYH; X-ray; 2.80 A; A=122-403. DR PDB; 7AYI; X-ray; 2.86 A; A=122-403. DR PDB; 7FIC; X-ray; 2.32 A; A=127-391. DR PDB; 7O2V; X-ray; 3.10 A; A=116-403. DR PDB; 7ZTL; X-ray; 1.90 A; A=122-403. DR PDB; 8C14; X-ray; 1.93 A; A=125-391. DR PDB; 8C15; X-ray; 2.41 A; A=126-388. DR PDB; 8C1D; X-ray; 2.12 A; A=126-388. DR PDB; 8C1E; X-ray; 2.80 A; A=125-391. DR PDB; 8C1F; X-ray; 1.92 A; A=126-388. DR PDB; 8C1G; X-ray; 1.96 A; A=126-388. DR PDB; 8C1H; X-ray; 2.23 A; A=126-388. DR PDB; 8C1I; X-ray; 2.81 A; A=126-388. DR PDB; 8C1K; X-ray; 2.43 A; A=126-390. DR PDB; 8C1M; X-ray; 2.84 A; A=125-391. DR PDB; 8GUW; X-ray; 2.70 A; A/B/C=123-403. DR PDB; 8JF4; X-ray; 2.89 A; A=127-389. DR PDB; 8JG8; X-ray; 2.90 A; A=127-389. DR PDB; 8JMX; X-ray; 2.95 A; A=127-389. DR PDB; 8OF5; X-ray; 1.97 A; A=122-403. DR PDB; 8PR7; X-ray; 2.76 A; A/D=122-403. DR PDB; 8SSO; X-ray; 1.97 A; A/D=122-403. DR PDB; 8SSP; X-ray; 2.60 A; A=122-403. DR PDB; 9BZG; X-ray; 1.80 A; A=122-403. DR PDB; 9BZL; X-ray; 1.81 A; B=122-403. DR PDBsum; 1MQ4; -. DR PDBsum; 1MUO; -. DR PDBsum; 1OL5; -. DR PDBsum; 1OL6; -. DR PDBsum; 1OL7; -. DR PDBsum; 2BMC; -. DR PDBsum; 2C6D; -. DR PDBsum; 2C6E; -. DR PDBsum; 2DWB; -. DR PDBsum; 2J4Z; -. DR PDBsum; 2J50; -. DR PDBsum; 2NP8; -. DR PDBsum; 2W1C; -. DR PDBsum; 2W1D; -. DR PDBsum; 2W1E; -. DR PDBsum; 2W1F; -. DR PDBsum; 2W1G; -. DR PDBsum; 2WQE; -. DR PDBsum; 2WTV; -. DR PDBsum; 2WTW; -. DR PDBsum; 2X6D; -. DR PDBsum; 2X6E; -. DR PDBsum; 2X81; -. DR PDBsum; 2XNE; -. DR PDBsum; 2XNG; -. DR PDBsum; 2XRU; -. DR PDBsum; 3COH; -. DR PDBsum; 3E5A; -. DR PDBsum; 3EFW; -. DR PDBsum; 3FDN; -. DR PDBsum; 3H0Y; -. DR PDBsum; 3H0Z; -. DR PDBsum; 3H10; -. DR PDBsum; 3HA6; -. DR PDBsum; 3K5U; -. DR PDBsum; 3LAU; -. DR PDBsum; 3M11; -. DR PDBsum; 3MYG; -. DR PDBsum; 3NRM; -. DR PDBsum; 3O50; -. DR PDBsum; 3O51; -. DR PDBsum; 3P9J; -. DR PDBsum; 3QBN; -. DR PDBsum; 3R21; -. DR PDBsum; 3R22; -. DR PDBsum; 3UNZ; -. DR PDBsum; 3UO4; -. DR PDBsum; 3UO5; -. DR PDBsum; 3UO6; -. DR PDBsum; 3UOD; -. DR PDBsum; 3UOH; -. DR PDBsum; 3UOJ; -. DR PDBsum; 3UOK; -. DR PDBsum; 3UOL; -. DR PDBsum; 3UP2; -. DR PDBsum; 3UP7; -. DR PDBsum; 3VAP; -. DR PDBsum; 3W10; -. DR PDBsum; 3W16; -. DR PDBsum; 3W18; -. DR PDBsum; 3W2C; -. DR PDBsum; 4B0G; -. DR PDBsum; 4BN1; -. DR PDBsum; 4BYI; -. DR PDBsum; 4BYJ; -. DR PDBsum; 4C3P; -. DR PDBsum; 4C3R; -. DR PDBsum; 4CEG; -. DR PDBsum; 4DEA; -. DR PDBsum; 4DEB; -. DR PDBsum; 4DED; -. DR PDBsum; 4DEE; -. DR PDBsum; 4DHF; -. DR PDBsum; 4J8M; -. DR PDBsum; 4J8N; -. DR PDBsum; 4JAI; -. DR PDBsum; 4JAJ; -. DR PDBsum; 4JBO; -. DR PDBsum; 4JBP; -. DR PDBsum; 4JBQ; -. DR PDBsum; 4O0S; -. DR PDBsum; 4O0U; -. DR PDBsum; 4O0W; -. DR PDBsum; 4PRJ; -. DR PDBsum; 4UYN; -. DR PDBsum; 4UZD; -. DR PDBsum; 4UZH; -. DR PDBsum; 4ZS0; -. DR PDBsum; 4ZTQ; -. DR PDBsum; 4ZTR; -. DR PDBsum; 4ZTS; -. DR PDBsum; 5AAD; -. DR PDBsum; 5AAE; -. DR PDBsum; 5AAF; -. DR PDBsum; 5AAG; -. DR PDBsum; 5DN3; -. DR PDBsum; 5DNR; -. DR PDBsum; 5DOS; -. DR PDBsum; 5DPV; -. DR PDBsum; 5DR2; -. DR PDBsum; 5DR6; -. DR PDBsum; 5DR9; -. DR PDBsum; 5DRD; -. DR PDBsum; 5DT0; -. DR PDBsum; 5DT3; -. DR PDBsum; 5DT4; -. DR PDBsum; 5EW9; -. DR PDBsum; 5G15; -. DR PDBsum; 5G1X; -. DR PDBsum; 5L8J; -. DR PDBsum; 5L8K; -. DR PDBsum; 5L8L; -. DR PDBsum; 5LXM; -. DR PDBsum; 5OBJ; -. DR PDBsum; 5OBR; -. DR PDBsum; 5ODT; -. DR PDBsum; 5ONE; -. DR PDBsum; 5ORL; -. DR PDBsum; 5ORN; -. DR PDBsum; 5ORO; -. DR PDBsum; 5ORP; -. DR PDBsum; 5ORR; -. DR PDBsum; 5ORS; -. DR PDBsum; 5ORT; -. DR PDBsum; 5ORV; -. DR PDBsum; 5ORW; -. DR PDBsum; 5ORX; -. DR PDBsum; 5ORY; -. DR PDBsum; 5ORZ; -. DR PDBsum; 5OS0; -. DR PDBsum; 5OS1; -. DR PDBsum; 5OS2; -. DR PDBsum; 5OS3; -. DR PDBsum; 5OS4; -. DR PDBsum; 5OS5; -. DR PDBsum; 5OS6; -. DR PDBsum; 5OSD; -. DR PDBsum; 5OSE; -. DR PDBsum; 5OSF; -. DR PDBsum; 5ZAN; -. DR PDBsum; 6C2R; -. DR PDBsum; 6C2T; -. DR PDBsum; 6C83; -. DR PDBsum; 6CPE; -. DR PDBsum; 6CPF; -. DR PDBsum; 6CPG; -. DR PDBsum; 6GRA; -. DR PDBsum; 6HJJ; -. DR PDBsum; 6HJK; -. DR PDBsum; 6I2U; -. DR PDBsum; 6R49; -. DR PDBsum; 6R4A; -. DR PDBsum; 6R4B; -. DR PDBsum; 6R4C; -. DR PDBsum; 6R4D; -. DR PDBsum; 6VPG; -. DR PDBsum; 6VPH; -. DR PDBsum; 6VPI; -. DR PDBsum; 6VPJ; -. DR PDBsum; 6VPL; -. DR PDBsum; 6VPM; -. DR PDBsum; 6XKA; -. DR PDBsum; 6Z4Y; -. DR PDBsum; 7AYH; -. DR PDBsum; 7AYI; -. DR PDBsum; 7FIC; -. DR PDBsum; 7O2V; -. DR PDBsum; 7ZTL; -. DR PDBsum; 8C14; -. DR PDBsum; 8C15; -. DR PDBsum; 8C1D; -. DR PDBsum; 8C1E; -. DR PDBsum; 8C1F; -. DR PDBsum; 8C1G; -. DR PDBsum; 8C1H; -. DR PDBsum; 8C1I; -. DR PDBsum; 8C1K; -. DR PDBsum; 8C1M; -. DR PDBsum; 8GUW; -. DR PDBsum; 8JF4; -. DR PDBsum; 8JG8; -. DR PDBsum; 8JMX; -. DR PDBsum; 8OF5; -. DR PDBsum; 8PR7; -. DR PDBsum; 8SSO; -. DR PDBsum; 8SSP; -. DR PDBsum; 9BZG; -. DR PDBsum; 9BZL; -. DR AlphaFoldDB; O14965; -. DR SMR; O14965; -. DR BioGRID; 112666; 697. DR CORUM; O14965; -. DR DIP; DIP-33068N; -. DR ELM; O14965; -. DR FunCoup; O14965; 1695. DR IntAct; O14965; 219. DR MINT; O14965; -. DR STRING; 9606.ENSP00000216911; -. DR BindingDB; O14965; -. DR ChEMBL; CHEMBL4722; -. DR DrugBank; DB07362; 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB07360; 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB08065; 2-(1H-pyrazol-3-yl)-1H-benzimidazole. DR DrugBank; DB07186; 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE. DR DrugBank; DB07266; AKI-001. DR DrugBank; DB05220; Alisertib. DR DrugBank; DB17197; AMG-900. DR DrugBank; DB05169; AT9283. DR DrugBank; DB06347; Cenisertib. DR DrugBank; DB05198; CYC116. DR DrugBank; DB11778; Danusertib. DR DrugBank; DB16891; ENMD-981693. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB18019; Erbumine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11694; Ilorasertib. DR DrugBank; DB12556; MK-5108. DR DrugBank; DB13061; MLN8054. DR DrugBank; DB08066; N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE. DR DrugBank; DB07801; N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide. DR DrugBank; DB07545; N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE. DR DrugBank; DB12072; Orantinib. DR DrugBank; DB13059; PF-03814735. DR DrugBank; DB02482; Phosphonothreonine. DR DrugBank; DB06134; SNS-314. DR DrugCentral; O14965; -. DR GuidetoPHARMACOLOGY; 1936; -. DR GlyGen; O14965; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O14965; -. DR PhosphoSitePlus; O14965; -. DR BioMuta; AURKA; -. DR CPTAC; CPTAC-1341; -. DR CPTAC; CPTAC-3083; -. DR CPTAC; CPTAC-3084; -. DR jPOST; O14965; -. DR MassIVE; O14965; -. DR PaxDb; 9606-ENSP00000216911; -. DR PeptideAtlas; O14965; -. DR ProteomicsDB; 48339; -. DR Pumba; O14965; -. DR ABCD; O14965; 7 sequenced antibodies. DR Antibodypedia; 1129; 1084 antibodies from 47 providers. DR DNASU; 6790; -. DR Ensembl; ENST00000312783.10; ENSP00000321591.6; ENSG00000087586.19. DR Ensembl; ENST00000347343.6; ENSP00000216911.2; ENSG00000087586.19. DR Ensembl; ENST00000371356.6; ENSP00000360407.2; ENSG00000087586.19. DR Ensembl; ENST00000395911.5; ENSP00000379247.1; ENSG00000087586.19. DR Ensembl; ENST00000395913.7; ENSP00000379249.3; ENSG00000087586.19. DR Ensembl; ENST00000395914.5; ENSP00000379250.1; ENSG00000087586.19. DR Ensembl; ENST00000395915.8; ENSP00000379251.3; ENSG00000087586.19. DR GeneID; 6790; -. DR KEGG; hsa:6790; -. DR MANE-Select; ENST00000395915.8; ENSP00000379251.3; NM_198437.3; NP_940839.1. DR UCSC; uc002xxe.1; human. DR AGR; HGNC:11393; -. DR CIViC; 6790; 8 evidence items across 3 molecular profiles. DR ClinPGx; PA36201; -. DR CTD; 6790; -. DR DisGeNET; 6790; -. DR GeneCards; AURKA; -. DR HGNC; HGNC:11393; AURKA. DR HPA; ENSG00000087586; Tissue enhanced (lymphoid tissue, testis). DR MalaCards; AURKA; -. DR MIM; 603072; gene. DR OpenTargets; ENSG00000087586; -. DR VEuPathDB; HostDB:ENSG00000087586; -. DR eggNOG; KOG0580; Eukaryota. DR GeneTree; ENSGT00940000154900; -. DR InParanoid; O14965; -. DR OMA; KIMNLMF; -. DR OrthoDB; 377346at2759; -. DR PAN-GO; O14965; 6 GO annotations based on evolutionary models. DR PhylomeDB; O14965; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O14965; -. DR Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1. DR Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-8854050; FBXL7 down-regulates AURKA during mitotic entry and in early mitosis. DR Reactome; R-HSA-8854518; AURKA Activation by TPX2. DR Reactome; R-HSA-8854521; Interaction between PHLDA1 and AURKA. DR SignaLink; O14965; -. DR SIGNOR; O14965; -. DR Agora; ENSG00000087586; -. DR BioGRID-ORCS; 6790; 713 hits in 1214 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; AURKA; human. DR EvolutionaryTrace; O14965; -. DR GeneWiki; Aurora_A_kinase; -. DR GenomeRNAi; 6790; -. DR Pharos; O14965; Tchem. DR PRO; PR:O14965; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; O14965; protein. DR Bgee; ENSG00000087586; Expressed in oocyte and 159 other cell types or tissues. DR ExpressionAtlas; O14965; baseline and differential. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB. DR GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0042585; C:germinal vesicle; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; TAS:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:HPA. DR GO; GO:0097431; C:mitotic spindle pole; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0045120; C:pronucleus; IEA:Ensembl. DR GO; GO:0005819; C:spindle; TAS:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0031616; C:spindle pole centrosome; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0035175; F:histone H3S10 kinase activity; IEA:Ensembl. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:CAFA. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl. DR GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl. DR GO; GO:0006915; P:apoptotic process; IEA:Ensembl. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0051642; P:centrosome localization; IEA:Ensembl. DR GO; GO:0061523; P:cilium disassembly; IMP:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0097421; P:liver regeneration; IDA:MGI. DR GO; GO:0000278; P:mitotic cell cycle; TAS:ProtInc. DR GO; GO:0007100; P:mitotic centrosome separation; IEA:Ensembl. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB. DR GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0090141; P:positive regulation of mitochondrial fission; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:1900195; P:positive regulation of oocyte maturation; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0071539; P:protein localization to centrosome; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0046605; P:regulation of centrosome cycle; TAS:UniProtKB. DR GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central. DR GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0009611; P:response to wounding; IDA:MGI. DR GO; GO:0007057; P:spindle assembly involved in female meiosis I; IEA:Ensembl. DR GO; GO:0007051; P:spindle organization; IMP:UniProtKB. DR CDD; cd14116; STKc_Aurora-A; 1. DR DisProt; DP03125; -. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR FunFam; 1.10.510.10:FF:000235; Serine/threonine-protein kinase ark1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR030616; Aur-like. DR InterPro; IPR030611; AURKA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24350; SERINE/THREONINE-PROTEIN KINASE IAL-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cell division; Cell membrane; KW Cell projection; Cilium; Cilium biogenesis/degradation; Cytoplasm; KW Cytoskeleton; Isopeptide bond; Kinase; Membrane; Microtubule; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Reference proteome; Serine/threonine-protein kinase; KW Transferase; Ubl conjugation. FT CHAIN 1..403 FT /note="Aurora kinase A" FT /id="PRO_0000086692" FT DOMAIN 133..383 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..125 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 280..293 FT /note="Activation segment" FT /evidence="ECO:0000269|PubMed:14580337" FT COMPBIAS 27..83 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 91..101 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 114..125 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 256 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027, FT ECO:0000269|PubMed:14580337" FT BINDING 143 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 162 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 211..213 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 260..261 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 274 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT MOD_RES 41 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 51 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17229885" FT MOD_RES 287 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:19668197" FT MOD_RES 288 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11039908, FT ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:16246726, ECO:0000269|PubMed:18662907, FT ECO:0000269|PubMed:19668197, ECO:0000269|PubMed:26246606" FT MOD_RES 342 FT /note="Phosphoserine; by PKA and PAK" FT /evidence="ECO:0000269|PubMed:16246726" FT CROSSLNK 258 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 11 FT /note="G -> R (in dbSNP:rs6069717)" FT /id="VAR_030840" FT VARIANT 31 FT /note="F -> I (in dbSNP:rs2273535)" FT /evidence="ECO:0000269|PubMed:15867347, FT ECO:0000269|PubMed:16011022, ECO:0000269|PubMed:16762494, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9771714" FT /id="VAR_030841" FT VARIANT 50 FT /note="P -> L (in dbSNP:rs34572020)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041127" FT VARIANT 57 FT /note="I -> V (increased kinase activity; dbSNP:rs1047972)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231, FT ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714" FT /id="VAR_030842" FT VARIANT 104 FT /note="S -> L (in dbSNP:rs2230743)" FT /id="VAR_061745" FT VARIANT 155 FT /note="S -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; reduces interaction with TPX2)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041128" FT VARIANT 174 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; constitutively enhanced kinase activity)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041129" FT VARIANT 373 FT /note="M -> V (in dbSNP:rs33923703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041130" FT MUTAGEN 162 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14702041" FT MUTAGEN 165 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 198 FT /note="G->N: Reduces interaction with TPX2. Reduces kinase FT activity tenfold. Promotes interaction with the AURKB FT binding partners INCENP and BIRC5 that are normally not FT bound by AURKA." FT /evidence="ECO:0000269|PubMed:19357306" FT MUTAGEN 205 FT /note="R->A: Reduces ubiquitination and proteasomal FT degradation." FT /evidence="ECO:0000269|PubMed:10851084" FT MUTAGEN 274 FT /note="D->N: Abolishes cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:17604723" FT MUTAGEN 287 FT /note="T->A: No direct effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 287 FT /note="T->E: Enhances interaction with TPX2." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 288 FT /note="T->A: Reduces cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:17604723" FT MUTAGEN 288 FT /note="T->D: Mimics phosphorylation state and increases FT kinase activity." FT /evidence="ECO:0000269|PubMed:11039908" FT MUTAGEN 290 FT /note="C->A: Enhances stability; when associated with A- FT 393." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 334 FT /note="Y->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 335 FT /note="Q->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 346 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 393 FT /note="C->A: Enhances stability; when associated with A- FT 290." FT /evidence="ECO:0000269|PubMed:27837025" FT HELIX 130..132 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 133..141 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 143..152 FT /evidence="ECO:0007829|PDB:6VPM" FT TURN 153..156 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 157..165 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 166..172 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 175..185 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 191..193 FT /evidence="ECO:0007829|PDB:3UO6" FT STRAND 196..201 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:2J50" FT HELIX 218..225 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 230..249 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:6XKA" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 266..268 FT /evidence="ECO:0007829|PDB:3UOL" FT STRAND 270..272 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 275..277 FT /evidence="ECO:0007829|PDB:5ORL" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:5L8L" FT HELIX 288..291 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:5L8J" FT HELIX 298..302 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 304..306 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 307..309 FT /evidence="ECO:0007829|PDB:6C2T" FT HELIX 310..324 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 334..342 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 350..352 FT /evidence="ECO:0007829|PDB:8JF4" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 368..370 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 374..378 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 381..386 FT /evidence="ECO:0007829|PDB:6VPM" SQ SEQUENCE 403 AA; 45823 MW; 7C2E7B438D969187 CRC64; MDRSKENCIS GPVKATAPVG GPKRVLVTQQ FPCQNPLPVN SGQAQRVLCP SNSSQRIPLQ AQKLVSSHKP VQNQKQKQLQ ATSVPHPVSR PLNNTQKSKQ PLPSAPENNP EEELASKQKN EESKKRQWAL EDFEIGRPLG KGKFGNVYLA REKQSKFILA LKVLFKAQLE KAGVEHQLRR EVEIQSHLRH PNILRLYGYF HDATRVYLIL EYAPLGTVYR ELQKLSKFDE QRTATYITEL ANALSYCHSK RVIHRDIKPE NLLLGSAGEL KIADFGWSVH APSSRRTTLC GTLDYLPPEM IEGRMHDEKV DLWSLGVLCY EFLVGKPPFE ANTYQETYKR ISRVEFTFPD FVTEGARDLI SRLLKHNPSQ RPMLREVLEH PWITANSSKP SNCQNKESAS KQS // ID BARD1_HUMAN Reviewed; 777 AA. AC Q99728; F6MDH7; F6MDH8; F6MDH9; O43574; Q53SS5; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 239. DE RecName: Full=BRCA1-associated RING domain protein 1; DE Short=BARD-1; DE EC=2.3.2.27 {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:20351172}; DE AltName: Full=RING-type E3 ubiquitin transferase BARD1 {ECO:0000305}; GN Name=BARD1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION. RC TISSUE=B-cell; RX PubMed=8944023; DOI=10.1038/ng1296-430; RA Wu L.C., Wang Z.W., Tsan J.T., Spillman M.A., Phung A., Xu X.L., RA Yang M.-C.W., Hwang L.-Y., Bowcock A.M., Baer R.; RT "Identification of a RING protein that can interact in vivo with the BRCA1 RT gene product."; RL Nat. Genet. 14:430-440(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-24; GLU-153; SER-378; RP MET-507; SER-557; HIS-564; CYS-658; LEU-695 AND ASN-761. RX PubMed=9425226; DOI=10.1093/hmg/7.2.195; RA Thai T.H., Du F., Tsan J.T., Jin Y., Phung A., Spillman M.A., Massa H.F., RA Muller C.Y., Ashfaq R., Mathis J.M., Miller D.S., Trask B.J., Baer R., RA Bowcock A.M.; RT "Mutations in the BRCA1-associated RING domain (BARD1) gene in primary RT breast, ovarian and uterine cancers."; RL Hum. Mol. Genet. 7:195-202(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), AND RP ALTERNATIVE SPLICING. RX PubMed=18089818; DOI=10.1158/0008-5472.can-07-2370; RA Li L., Ryser S., Dizin E., Pils D., Krainer M., Jefford C.E., Bertoni F., RA Zeillinger R., Irminger-Finger I.; RT "Oncogenic BARD1 isoforms expressed in gynecological cancers."; RL Cancer Res. 67:11876-11885(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP DOMAINS. RX PubMed=10026184; DOI=10.1074/jbc.274.9.5659; RA Meza J.E., Brzovic P.S., King M.-C., Klevit R.E.; RT "Mapping the functional domains of BRCA1. Interaction of the ring finger RT domains of BRCA1 and BARD1."; RL J. Biol. Chem. 274:5659-5665(1999). RN [7] RP POSSIBLE FUNCTION. RX PubMed=10477523; DOI=10.1126/science.285.5433.1576; RA Kleiman F.E., Manley J.L.; RT "Functional interaction of BRCA1-associated BARD1 with polyadenylation RT factor CstF-50."; RL Science 285:1576-1579(1999). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1. RX PubMed=12890688; DOI=10.1074/jbc.c300249200; RA Wu-Baer F., Lagrazon K., Yuan W., Baer R.; RT "The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an RT unconventional linkage involving lysine residue K6 of ubiquitin."; RL J. Biol. Chem. 278:34743-34746(2003). RN [9] RP FUNCTION, AND INTERACTION WITH BRCA1. RX PubMed=14976165; DOI=10.1093/hmg/ddh095; RA Morris J.R., Solomon E.; RT "BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, RT dependent on K6 of ubiquitin, in cells during DNA replication and repair."; RL Hum. Mol. Genet. 13:807-817(2004). RN [10] RP IDENTIFICATION IN THE BRCA1-A COMPLEX. RX PubMed=17643122; DOI=10.1038/nsmb1277; RA Kim H., Huang J., Chen J.; RT "CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage RT response."; RL Nat. Struct. Mol. Biol. 14:710-715(2007). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391 AND THR-394, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [13] RP IDENTIFICATION IN THE BRCA1-A COMPLEX. RX PubMed=19261749; DOI=10.1101/gad.1770309; RA Wang B., Hurov K., Hofmann K., Elledge S.J.; RT "NBA1, a new player in the Brca1 A complex, is required for DNA damage RT resistance and checkpoint control."; RL Genes Dev. 23:729-739(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1. RX PubMed=20351172; DOI=10.1128/mcb.01056-09; RA Wu-Baer F., Ludwig T., Baer R.; RT "The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 RT tumor suppressor and inhibits its enzymatic function."; RL Mol. Cell. Biol. 30:2787-2798(2010). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-186 AND THR-299, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-170, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [18] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-160; LYS-170; LYS-423 AND RP LYS-548, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [19] RP STRUCTURE BY NMR OF 26-140 IN COMPLEX WITH BRCA1 AND ZINC IONS, AND RP SUBUNIT. RX PubMed=11573085; DOI=10.1038/nsb1001-833; RA Brzovic P.S., Rajagopal P., Hoyt D.W., King M.C., Klevit R.E.; RT "Structure of a BRCA1-BARD1 heterodimeric RING-RING complex."; RL Nat. Struct. Biol. 8:833-837(2001). RN [20] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 568-777. RX PubMed=17550235; DOI=10.1021/bi700323t; RA Birrane G., Varma A.K., Soni A., Ladias J.A.; RT "Crystal structure of the BARD1 BRCT domains."; RL Biochemistry 46:7706-7712(2007). RN [21] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 569-777, INTERACTION WITH CSTF1, RP DOMAIN STRUCTURE, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18842000; DOI=10.1021/bi801115g; RA Edwards R.A., Lee M.S., Tsutakawa S.E., Williams R.S., Nazeer I., RA Kleiman F.E., Tainer J.A., Glover J.N.; RT "The BARD1 C-terminal domain structure and interactions with RT polyadenylation factor CstF-50."; RL Biochemistry 47:11446-11456(2008). RN [22] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 425-555, IDENTIFICATION BY MASS RP SPECTROMETRY, DOMAINS ANK REPEATS, AND DOMAIN STRUCTURE. RX PubMed=18480049; DOI=10.1074/jbc.m802333200; RA Fox D. III, Le Trong I., Rajagopal P., Brzovic P.S., Stenkamp R.E., RA Klevit R.E.; RT "Crystal structure of the BARD1 ankyrin repeat domain and its functional RT consequences."; RL J. Biol. Chem. 283:21179-21186(2008). CC -!- FUNCTION: E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer CC specifically mediates the formation of 'Lys-6'-linked polyubiquitin CC chains and coordinates a diverse range of cellular pathways such as DNA CC damage repair, ubiquitination and transcriptional regulation to CC maintain genomic stability. Plays a central role in the control of the CC cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 CC ligase activity that is required for its tumor suppressor function. CC Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing CC and RNAP II stability by inhibiting pre-mRNA 3' cleavage. CC {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, CC ECO:0000269|PubMed:20351172}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; Evidence={ECO:0000269|PubMed:12890688, CC ECO:0000269|PubMed:20351172}; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC -!- SUBUNIT: Homo- and heterodimer. Heterodimer (RING-type zinc finger) CC with BRCA1. Heterodimer (via ANK repeats and BRCT domains) with CC CSTF1/CSTF-50. Component of the BRCA1-A complex, at least composed of CC the BRCA1, BARD1, UIMC1/RAP80, ABRAXAS1, BRCC3/BRCC36, BABAM2 and CC BABAM1/NBA1. Interacts with UBXN1. {ECO:0000269|PubMed:11573085, CC ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, CC ECO:0000269|PubMed:17643122, ECO:0000269|PubMed:18842000, CC ECO:0000269|PubMed:19261749, ECO:0000269|PubMed:20351172}. CC -!- INTERACTION: CC Q99728; P31749: AKT1; NbExp=3; IntAct=EBI-473181, EBI-296087; CC Q99728; Q9Y2T1: AXIN2; NbExp=3; IntAct=EBI-473181, EBI-4400025; CC Q99728; P38398: BRCA1; NbExp=20; IntAct=EBI-473181, EBI-349905; CC Q99728; P38398-1: BRCA1; NbExp=3; IntAct=EBI-473181, EBI-21498346; CC Q99728; Q9P2H0: CEP126; NbExp=2; IntAct=EBI-473181, EBI-473176; CC Q99728; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-473181, EBI-739624; CC Q99728; Q12873: CHD3; NbExp=2; IntAct=EBI-473181, EBI-523590; CC Q99728; Q05048: CSTF1; NbExp=4; IntAct=EBI-473181, EBI-1789619; CC Q99728; P33240: CSTF2; NbExp=8; IntAct=EBI-473181, EBI-711360; CC Q99728; O00471: EXOC5; NbExp=3; IntAct=EBI-473181, EBI-949824; CC Q99728; Q8IZU0: FAM9B; NbExp=3; IntAct=EBI-473181, EBI-10175124; CC Q99728; Q9Y2X7: GIT1; NbExp=2; IntAct=EBI-473181, EBI-466061; CC Q99728; Q08379: GOLGA2; NbExp=6; IntAct=EBI-473181, EBI-618309; CC Q99728; O75031: HSF2BP; NbExp=3; IntAct=EBI-473181, EBI-7116203; CC Q99728; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-473181, EBI-11522367; CC Q99728; O95251: KAT7; NbExp=2; IntAct=EBI-473181, EBI-473199; CC Q99728; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-473181, EBI-14069005; CC Q99728; Q6A162: KRT40; NbExp=3; IntAct=EBI-473181, EBI-10171697; CC Q99728; O95751: LDOC1; NbExp=7; IntAct=EBI-473181, EBI-740738; CC Q99728; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-473181, EBI-11522433; CC Q99728; O95453: PARN; NbExp=4; IntAct=EBI-473181, EBI-372832; CC Q99728; Q15276: RABEP1; NbExp=3; IntAct=EBI-473181, EBI-447043; CC Q99728; O14776: TCERG1; NbExp=2; IntAct=EBI-473181, EBI-473271; CC Q99728; Q13077: TRAF1; NbExp=3; IntAct=EBI-473181, EBI-359224; CC Q99728; Q8N720: ZNF655; NbExp=3; IntAct=EBI-473181, EBI-625509; CC Q99728-1; Q13526: PIN1; NbExp=4; IntAct=EBI-21498323, EBI-714158; CC -!- SUBCELLULAR LOCATION: Nucleus. Note=During S phase of the cell cycle, CC colocalizes with BRCA1 into discrete subnuclear foci. Can translocate CC to the cytoplasm. Localizes at sites of DNA damage at double-strand CC breaks (DSBs); recruitment to DNA damage sites is mediated by the CC BRCA1-A complex. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=FL; CC IsoId=Q99728-1; Sequence=Displayed; CC Name=alpha; CC IsoId=Q99728-2; Sequence=VSP_055876; CC Name=beta; CC IsoId=Q99728-3; Sequence=VSP_055874, VSP_055875; CC Name=gamma; CC IsoId=Q99728-4; Sequence=VSP_055877, VSP_055878; CC -!- PTM: Processed during apoptosis. The homodimer is more susceptible to CC proteolytic cleavage than the BARD1/BRCA1 heterodimer. CC -!- CAUTION: It is uncertain whether Met-1 or Met-26 is the initiator. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/756/BARD1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U76638; AAB38316.1; -; mRNA. DR EMBL; AF038042; AAB99978.1; -; Genomic_DNA. DR EMBL; AF038034; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038035; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038036; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038037; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038038; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038039; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038040; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038041; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; JF790280; AEF57471.1; -; mRNA. DR EMBL; JF790281; AEF57472.1; -; mRNA. DR EMBL; JF790282; AEF57473.1; -; mRNA. DR EMBL; AC016708; AAX93130.1; -; Genomic_DNA. DR EMBL; BC126426; AAI26427.1; -; mRNA. DR CCDS; CCDS2397.1; -. [Q99728-1] DR CCDS; CCDS74646.1; -. [Q99728-2] DR RefSeq; NP_000456.2; NM_000465.4. [Q99728-1] DR RefSeq; NP_001269472.1; NM_001282543.2. [Q99728-2] DR PDB; 1JM7; NMR; -; B=26-140. DR PDB; 2NTE; X-ray; 1.90 A; A/B=568-777. DR PDB; 2R1Z; X-ray; 2.10 A; A/B=569-777. DR PDB; 3C5R; X-ray; 2.00 A; A/B=425-555. DR PDB; 3FA2; X-ray; 2.20 A; A/B=566-777. DR PDB; 6M14; X-ray; 1.88 A; A/B=568-777. DR PDB; 7E8I; EM; 3.10 A; K=425-777. DR PDB; 7JZV; EM; 3.90 A; B=26-140. DR PDB; 7LYB; EM; 3.28 A; N=26-122. DR PDB; 7LYC; EM; 2.94 A; N=415-777. DR PDB; 8GRQ; EM; 3.87 A; M=26-117. DR PDBsum; 1JM7; -. DR PDBsum; 2NTE; -. DR PDBsum; 2R1Z; -. DR PDBsum; 3C5R; -. DR PDBsum; 3FA2; -. DR PDBsum; 6M14; -. DR PDBsum; 7E8I; -. DR PDBsum; 7JZV; -. DR PDBsum; 7LYB; -. DR PDBsum; 7LYC; -. DR PDBsum; 8GRQ; -. DR AlphaFoldDB; Q99728; -. DR EMDB; EMD-22581; -. DR EMDB; EMD-23591; -. DR EMDB; EMD-23592; -. DR EMDB; EMD-31020; -. DR EMDB; EMD-34212; -. DR EMDB; EMD-6340; -. DR EMDB; EMD-6400; -. DR SMR; Q99728; -. DR BioGRID; 107056; 331. DR ComplexPortal; CPX-715; BRCA1-BARD1 complex. DR ComplexPortal; CPX-955; BRCC E3 ubiquitin ligase complex. DR CORUM; Q99728; -. DR DIP; DIP-5972N; -. DR FunCoup; Q99728; 1110. DR IntAct; Q99728; 68. DR MINT; Q99728; -. DR STRING; 9606.ENSP00000260947; -. DR BindingDB; Q99728; -. DR GlyGen; Q99728; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q99728; -. DR PhosphoSitePlus; Q99728; -. DR BioMuta; BARD1; -. DR DMDM; 116241265; -. DR jPOST; Q99728; -. DR MassIVE; Q99728; -. DR PaxDb; 9606-ENSP00000260947; -. DR PeptideAtlas; Q99728; -. DR ProteomicsDB; 78442; -. [Q99728-1] DR Pumba; Q99728; -. DR Antibodypedia; 20039; 288 antibodies from 35 providers. DR DNASU; 580; -. DR Ensembl; ENST00000260947.9; ENSP00000260947.4; ENSG00000138376.12. [Q99728-1] DR Ensembl; ENST00000617164.5; ENSP00000480470.1; ENSG00000138376.12. [Q99728-2] DR Ensembl; ENST00000620057.4; ENSP00000481988.1; ENSG00000138376.12. [Q99728-4] DR GeneID; 580; -. DR KEGG; hsa:580; -. DR MANE-Select; ENST00000260947.9; ENSP00000260947.4; NM_000465.4; NP_000456.2. DR UCSC; uc002veu.4; human. [Q99728-1] DR AGR; HGNC:952; -. DR CIViC; 580; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA25256; -. DR CTD; 580; -. DR DisGeNET; 580; -. DR GeneCards; BARD1; -. DR HGNC; HGNC:952; BARD1. DR HPA; ENSG00000138376; Low tissue specificity. DR MalaCards; BARD1; -. DR MIM; 601593; gene. DR OpenTargets; ENSG00000138376; -. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR VEuPathDB; HostDB:ENSG00000138376; -. DR eggNOG; KOG0504; Eukaryota. DR eggNOG; KOG4362; Eukaryota. DR GeneTree; ENSGT00940000156532; -. DR HOGENOM; CLU_021642_0_0_1; -. DR InParanoid; Q99728; -. DR OMA; LGQCEHV; -. DR OrthoDB; 2384350at2759; -. DR PAN-GO; Q99728; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q99728; -. DR BRENDA; 2.3.2.27; 2681. DR PathwayCommons; Q99728; -. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-5689901; Metalloprotease DUBs. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9663199; Defective DNA double strand break response due to BRCA1 loss of function. DR Reactome; R-HSA-9699150; Defective DNA double strand break response due to BARD1 loss of function. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q99728; -. DR SIGNOR; Q99728; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000138376; -. DR BioGRID-ORCS; 580; 517 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; BARD1; human. DR EvolutionaryTrace; Q99728; -. DR GeneWiki; BARD1; -. DR GenomeRNAi; 580; -. DR Pharos; Q99728; Tbio. DR PRO; PR:Q99728; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q99728; protein. DR Bgee; ENSG00000138376; Expressed in secondary oocyte and 204 other cell types or tissues. DR ExpressionAtlas; Q99728; baseline and differential. DR GO; GO:0070531; C:BRCA1-A complex; IDA:UniProtKB. DR GO; GO:0070532; C:BRCA1-B complex; IPI:ComplexPortal. DR GO; GO:0031436; C:BRCA1-BARD1 complex; IDA:UniProtKB. DR GO; GO:0070533; C:BRCA1-C complex; IPI:ComplexPortal. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:HPA. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0000152; C:nuclear ubiquitin ligase complex; IDA:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000151; C:ubiquitin ligase complex; NAS:UniProtKB. DR GO; GO:0140863; F:histone H2AK127 ubiquitin ligase activity; TAS:ARUK-UCL. DR GO; GO:0140864; F:histone H2AK129 ubiquitin ligase activity; TAS:ARUK-UCL. DR GO; GO:0019900; F:kinase binding; NAS:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0003723; F:RNA binding; IDA:MGI. DR GO; GO:0061649; F:ubiquitin-modified histone reader activity; TAS:ARUK-UCL. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; NAS:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:ComplexPortal. DR GO; GO:0006338; P:chromatin remodeling; TAS:ARUK-UCL. DR GO; GO:0006974; P:DNA damage response; NAS:UniProtKB. DR GO; GO:0006281; P:DNA repair; NAS:ComplexPortal. DR GO; GO:0110025; P:DNA strand resection involved in replication fork processing; NAS:ComplexPortal. DR GO; GO:0035825; P:homologous recombination; NAS:ComplexPortal. DR GO; GO:0044818; P:mitotic G2/M transition checkpoint; NAS:ComplexPortal. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045786; P:negative regulation of cell cycle; NAS:ComplexPortal. DR GO; GO:0031441; P:negative regulation of mRNA 3'-end processing; NAS:UniProtKB. DR GO; GO:0046826; P:negative regulation of protein export from nucleus; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045732; P:positive regulation of protein catabolic process; NAS:UniProtKB. DR GO; GO:0085020; P:protein K6-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; NAS:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; NAS:UniProtKB. DR GO; GO:2000001; P:regulation of DNA damage checkpoint; NAS:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0042325; P:regulation of phosphorylation; IMP:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ARUK-UCL. DR GO; GO:0001894; P:tissue homeostasis; TAS:UniProtKB. DR CDD; cd17734; BRCT_Bard1_rpt1; 1. DR CDD; cd17720; BRCT_Bard1_rpt2; 1. DR CDD; cd16496; RING-HC_BARD1; 1. DR FunFam; 1.25.40.20:FF:000032; BCL-6 corepressor isoform X1; 1. DR FunFam; 3.30.40.10:FF:000349; BRCA1 associated RING domain 1; 1. DR FunFam; 3.40.50.10190:FF:000013; BRCA1 associated RING domain 1; 1. DR FunFam; 3.40.50.10190:FF:000019; BRCA1 associated RING domain 1; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 3.40.50.10190; BRCT domain; 2. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR039503; BARD1_Znf-RING. DR InterPro; IPR001357; BRCT_dom. DR InterPro; IPR036420; BRCT_dom_sf. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR24171; ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 39-RELATED; 1. DR PANTHER; PTHR24171:SF8; BRCA1-ASSOCIATED RING DOMAIN PROTEIN 1; 1. DR Pfam; PF12796; Ank_2; 1. DR Pfam; PF00533; BRCT; 1. DR Pfam; PF14835; zf-RING_6; 1. DR PRINTS; PR01415; ANKYRIN. DR SMART; SM00248; ANK; 3. DR SMART; SM00292; BRCT; 2. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF52113; BRCT domain; 2. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 3. DR PROSITE; PS50172; BRCT; 2. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ANK repeat; DNA damage; DNA repair; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Transferase; KW Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..777 FT /note="BRCA1-associated RING domain protein 1" FT /id="PRO_0000055819" FT REPEAT 427..459 FT /note="ANK 1" FT REPEAT 460..492 FT /note="ANK 2" FT REPEAT 493..525 FT /note="ANK 3" FT REPEAT 526..546 FT /note="ANK 4; degenerate" FT DOMAIN 560..653 FT /note="BRCT 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 667..777 FT /note="BRCT 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT ZN_FING 50..87 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 1..32 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 26..119 FT /note="Interaction with BRCA1" FT REGION 167..211 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 356..404 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 554..558 FT /note="Flexible linker" FT COMPBIAS 197..209 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 389..404 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 186 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 299 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 391 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 394 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT CROSSLNK 160 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25755297, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 423 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 548 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..24 FT /note="MPDNRQPRNRQPRIRSGNEPRSAP -> MVAVPGPTVAPRSTAWRSCCAARV FT (in isoform beta)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055874" FT VAR_SEQ 25..121 FT /note="Missing (in isoform beta)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055875" FT VAR_SEQ 54..72 FT /note="Missing (in isoform alpha)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055876" FT VAR_SEQ 122..127 FT /note="DLKEDK -> GRHTFC (in isoform gamma)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055877" FT VAR_SEQ 128..777 FT /note="Missing (in isoform gamma)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055878" FT VARIANT 24 FT /note="P -> S (in dbSNP:rs1048108)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010354" FT VARIANT 153 FT /note="K -> E (in dbSNP:rs753377280)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010355" FT VARIANT 186 FT /note="S -> G (in dbSNP:rs16852741)" FT /id="VAR_038371" FT VARIANT 241 FT /note="S -> C (in dbSNP:rs3738885)" FT /id="VAR_020109" FT VARIANT 378 FT /note="R -> S (in dbSNP:rs2229571)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_024611" FT VARIANT 507 FT /note="V -> M (in dbSNP:rs2070094)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010356" FT VARIANT 557 FT /note="C -> S (in dbSNP:rs28997576)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010357" FT VARIANT 564 FT /note="Q -> H (in an ovarian clear cell adenocarcinoma; FT dbSNP:rs1168537193)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010358" FT VARIANT 645 FT /note="C -> R (in dbSNP:rs2228456)" FT /id="VAR_038372" FT VARIANT 658 FT /note="R -> C (in dbSNP:rs3738888)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010359" FT VARIANT 695 FT /note="V -> L (in a breast cancer sample; somatic mutation; FT dbSNP:rs111367604)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010360" FT VARIANT 728 FT /note="S -> F (in dbSNP:rs13389423)" FT /id="VAR_028309" FT VARIANT 761 FT /note="S -> N (in an uterine cancer sample; somatic FT mutation; dbSNP:rs142155101)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010361" FT CONFLICT 85 FT /note="V -> A (in Ref. 3; AEF57473)" FT /evidence="ECO:0000305" FT CONFLICT 406 FT /note="R -> Q (in Ref. 1; AAB38316 and 3; AEF57471/ FT AEF57472)" FT /evidence="ECO:0000305" FT HELIX 35..45 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 51..53 FT /evidence="ECO:0007829|PDB:7LYB" FT STRAND 58..61 FT /evidence="ECO:0007829|PDB:7LYB" FT STRAND 64..67 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 72..75 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 78..81 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 84..86 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 99..115 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 431..438 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 441..449 FT /evidence="ECO:0007829|PDB:3C5R" FT STRAND 459..461 FT /evidence="ECO:0007829|PDB:7LYC" FT HELIX 464..470 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 474..482 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 492..494 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 497..503 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 507..515 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 530..533 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 537..543 FT /evidence="ECO:0007829|PDB:3C5R" FT STRAND 571..576 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 579..591 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:2NTE" FT STRAND 606..613 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 618..625 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 629..632 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 634..642 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 648..651 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 656..665 FT /evidence="ECO:0007829|PDB:6M14" FT TURN 671..674 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 676..679 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 684..686 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 688..697 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 701..705 FT /evidence="ECO:0007829|PDB:2NTE" FT HELIX 709..711 FT /evidence="ECO:0007829|PDB:2NTE" FT HELIX 712..716 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 729..731 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 735..739 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 741..744 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 748..752 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 755..759 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 760..769 FT /evidence="ECO:0007829|PDB:6M14" SQ SEQUENCE 777 AA; 86648 MW; 95E2D904046B5646 CRC64; MPDNRQPRNR QPRIRSGNEP RSAPAMEPDG RGAWAHSRAA LDRLEKLLRC SRCTNILREP VCLGGCEHIF CSNCVSDCIG TGCPVCYTPA WIQDLKINRQ LDSMIQLCSK LRNLLHDNEL SDLKEDKPRK SLFNDAGNKK NSIKMWFSPR SKKVRYVVSK ASVQTQPAIK KDASAQQDSY EFVSPSPPAD VSERAKKASA RSGKKQKKKT LAEINQKWNL EAEKEDGEFD SKEESKQKLV SFCSQPSVIS SPQINGEIDL LASGSLTESE CFGSLTEVSL PLAEQIESPD TKSRNEVVTP EKVCKNYLTS KKSLPLENNG KRGHHNRLSS PISKRCRTSI LSTSGDFVKQ TVPSENIPLP ECSSPPSCKR KVGGTSGRKN SNMSDEFISL SPGTPPSTLS SSSYRRVMSS PSAMKLLPNM AVKRNHRGET LLHIASIKGD IPSVEYLLQN GSDPNVKDHA GWTPLHEACN HGHLKVVELL LQHKALVNTT GYQNDSPLHD AAKNGHVDIV KLLLSYGASR NAVNIFGLRP VDYTDDESMK SLLLLPEKNE SSSASHCSVM NTGQRRDGPL VLIGSGLSSE QQKMLSELAV ILKAKKYTEF DSTVTHVVVP GDAVQSTLKC MLGILNGCWI LKFEWVKACL RRKVCEQEEK YEIPEGPRRS RLNREQLLPK LFDGCYFYLW GTFKHHPKDN LIKLVTAGGG QILSRKPKPD SDVTQTINTV AYHARPDSDQ RFCTQYIIYE DLCNYHPERV RQGKVWKAPS SWFIDCVMSF ELLPLDS // ID BRAF_HUMAN Reviewed; 766 AA. AC P15056; A4D1T4; B6HY61; B6HY62; B6HY63; B6HY64; B6HY65; B6HY66; Q13878; AC Q3MIN6; Q9UDP8; Q9Y6T3; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 4. DT 28-JAN-2026, entry version 267. DE RecName: Full=Serine/threonine-protein kinase B-raf {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; DE AltName: Full=Proto-oncogene B-Raf; DE AltName: Full=p94; DE AltName: Full=v-Raf murine sarcoma viral oncogene homolog B1; GN Name=BRAF {ECO:0000312|HGNC:HGNC:1097}; Synonyms=BRAF1, RAFB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, FUNCTION, AND RP PHOSPHORYLATION AT THR-373. RC TISSUE=Testis; RX PubMed=1508179; DOI=10.1128/mcb.12.9.3733-3742.1992; RA Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R., RA Morrison D.K.; RT "95-kilodalton B-Raf serine/threonine kinase: identification of the protein RT and its major autophosphorylation site."; RL Mol. Cell. Biol. 12:3733-3742(1992). RN [2] RP SEQUENCE REVISION TO 31-33. RA Albert S., Wixler L., Rapp U.R.; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200. RC TISSUE=Placenta; RX PubMed=1630826; RA Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.; RT "Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B- RT raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene."; RL Oncogene 7:1657-1660(1992). RN [8] RP PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354; RP 361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698; 702-719; RP 727-735 AND 753-766, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT RP ALA-2, PHOSPHORYLATION AT SER-365; THR-396; SER-399; THR-401 AND SER-729, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Colon carcinoma, and Hepatoma; RA Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-766. RC TISSUE=Testis; RX PubMed=2284096; RA Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.; RT "Complete coding sequence of a human B-raf cDNA and detection of B-raf RT protein kinase with isozyme specific antibodies."; RL Oncogene 5:1775-1780(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 381-766, DISEASE, AND CHROMOSOMAL RP REARRANGEMENT. RC TISSUE=Brain; RX PubMed=18974108; DOI=10.1158/0008-5472.can-08-2097; RA Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., RA Ichimura K., Collins V.P.; RT "Tandem duplication producing a novel oncogenic BRAF fusion gene defines RT the majority of pilocytic astrocytomas."; RL Cancer Res. 68:8673-8677(2008). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 439-766. RX PubMed=3043188; DOI=10.1128/mcb.8.6.2651-2654.1988; RA Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.; RT "B-raf, a new member of the raf family, is activated by DNA RT rearrangement."; RL Mol. Cell. Biol. 8:2651-2654(1988). RN [12] RP PHOSPHORYLATION AT SER-365 BY SGK1. RX PubMed=11410590; DOI=10.1074/jbc.m102808200; RA Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.; RT "Serum- and glucocorticoid-inducible kinase SGK phosphorylates and RT negatively regulates B-Raf."; RL J. Biol. Chem. 276:31620-31626(2001). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447 AND RP SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP SUBUNIT, INTERACTION WITH DGKH, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-753 BY MAPK1. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [18] RP INTERACTION WITH AKAP13; MAP2K1 AND KSR1. RX PubMed=21102438; DOI=10.1038/ncb2130; RA Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., RA Davis R.J., Scott J.D.; RT "AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade."; RL Nat. Cell Biol. 12:1242-1249(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP INTERACTION WITH KSR2, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION, AND RP MUTAGENESIS OF LYS-483. RX PubMed=21441910; DOI=10.1038/nature09860; RA Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., RA Shokat K.M., Barford D.; RT "A Raf-induced allosteric transition of KSR stimulates phosphorylation of RT MEK."; RL Nature 472:366-369(2011). RN [21] RP INTERACTION WITH PRMT5, METHYLATION AT ARG-671, CHARACTERIZATION OF VARIANT RP CRC GLU-600, AND MUTAGENESIS OF ARG-671. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [23] RP UBIQUITINATION BY RNF149. RX PubMed=22628551; DOI=10.1074/jbc.m111.319822; RA Hong S.W., Jin D.H., Shin J.S., Moon J.H., Na Y.S., Jung K.A., Kim S.M., RA Kim J.C., Kim K.P., Hong Y.S., Lee J.L., Choi E.K., Lee J.S., Kim T.W.; RT "Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v- RT Raf murine sarcoma viral oncogene homolog B1 (BRAF)."; RL J. Biol. Chem. 287:24017-24025(2012). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-365; THR-401; RP SER-446 AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP UBIQUITINATION AT LYS-578, AND MUTAGENESIS OF LYS-578. RX PubMed=23907581; DOI=10.1038/srep02344; RA An L., Jia W., Yu Y., Zou N., Liang L., Zhao Y., Fan Y., Cheng J., Shi Z., RA Xu G., Li G., Yang J., Zhang H.; RT "Lys63-linked polyubiquitination of BRAF at lysine 578 is required for RT BRAF-mediated signaling."; RL Sci. Rep. 3:2344-2344(2013). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP INTERACTION WITH FNIP1 AND FNIP2. RX PubMed=27353360; DOI=10.1038/ncomms12037; RA Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., RA Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., RA Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., RA Bratslavsky G., Mollapour M.; RT "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance RT drug binding."; RL Nat. Commun. 7:12037-12037(2016). RN [28] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=36402789; DOI=10.1038/s41467-022-34907-0; RA McGrail K., Granado-Martinez P., Esteve-Puig R., Garcia-Ortega S., Ding Y., RA Sanchez-Redondo S., Ferrer B., Hernandez-Losa J., Canals F., Manzano A., RA Navarro-Sabate A., Bartrons R., Yanes O., Perez-Alea M., Munoz-Couselo E., RA Garcia-Patos V., Recio J.A.; RT "BRAF activation by metabolic stress promotes glycolysis sensitizing RT NRASQ61-mutated melanomas to targeted therapy."; RL Nat. Commun. 13:7113-7113(2022). RN [30] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [31] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.57 ANGSTROMS) OF 444-719 IN COMPLEX WITH RP INHIBITOR. RX PubMed=18287029; DOI=10.1073/pnas.0711741105; RA Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., RA Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., RA Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., RA Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., RA Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., RA Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G.; RT "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent RT antimelanoma activity."; RL Proc. Natl. Acad. Sci. U.S.A. 105:3041-3046(2008). RN [33] {ECO:0007744|PDB:5VR3, ECO:0007744|PDB:5VYK} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 36-110, FUNCTION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH KSR1; KSR2; MAP2K1 AND RP MAP2K2, AND MUTAGENESIS OF MET-53; LYS-88; ARG-509 AND ILE-666. RX PubMed=29433126; DOI=10.1038/nature25478; RA Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T., RA Kurinov I., Sicheri F., Therrien M.; RT "MEK drives BRAF activation through allosteric control of KSR proteins."; RL Nature 554:549-553(2018). RN [34] RP VARIANTS LNCR VAL-466 AND ARG-597. RX PubMed=12460919; RA Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.; RT "Missense mutations of the BRAF gene in human lung adenocarcinoma."; RL Cancer Res. 62:7001-7003(2002). RN [35] RP VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469; RP GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND ASP-600, RP AND CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469; VAL-597 AND RP GLU-600. RX PubMed=12068308; DOI=10.1038/nature00766; RA Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., RA Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., RA Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., RA Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., RA Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., RA Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., RA Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., RA Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., RA Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.; RT "Mutations of the BRAF gene in human cancer."; RL Nature 417:949-954(2002). RN [36] RP VARIANTS CRC ILE-462; SER-463; GLU-464; GLU-600 AND GLU-601. RX PubMed=12198537; DOI=10.1038/418934a; RA Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., RA Velculescu V.E.; RT "Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status."; RL Nature 418:934-934(2002). RN [37] RP VARIANTS NHL ALA-469; ARG-469 AND GLY-594. RX PubMed=14612909; DOI=10.1038/sj.bjc.6601371; RA Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y., RA Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.; RT "BRAF mutations in non-Hodgkin's lymphoma."; RL Br. J. Cancer 89:1958-1960(2003). RN [38] RP CHARACTERIZATION OF VARIANT MELANOMA GLU-600. RX PubMed=14500344; RA Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A.; RT "Suppression of BRAF(V599E) in human melanoma abrogates transformation."; RL Cancer Res. 63:5198-5202(2003). RN [39] RP VARIANTS CFC1 PRO-246; ARG-257; GLU-469; PHE-485; GLU-499; LYS-501; GLY-501 RP AND ASP-581. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [40] RP VARIANT [LARGE SCALE ANALYSIS] GLU-600. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS CFC1 ARG-257; ALA-467; SER-468; GLU-469; PHE-485; GLU-499; RP LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596. RX PubMed=16439621; DOI=10.1126/science.1124642; RA Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., RA Cruz M.S., McCormick F., Rauen K.A.; RT "Germline mutations in genes within the MAPK pathway cause cardio-facio- RT cutaneous syndrome."; RL Science 311:1287-1290(2006). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581; RP ARG-596; ARG-597; VAL-597 AND GLU-600. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [43] RP VARIANTS CFC1 PRO-241; PRO-244; PRO-246; ARG-257; LYS-262; SER-468; RP GLU-469; GLU-499; ASN-499; ASP-580; ASP-581 AND LEU-595. RX PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x; RA Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A., RA Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C., RA Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B., RA Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H., Spranger S., RA Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.; RT "Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous RT and Costello syndrome."; RL Clin. Genet. 73:62-70(2008). RN [44] RP VARIANT LPRD3 PRO-241, VARIANTS NS7 ARG-241; MET-241; CYS-531 AND VAL-597, RP AND VARIANTS CFC1 PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485; RP ASN-499; LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND ARG-709. RX PubMed=19206169; DOI=10.1002/humu.20955; RA Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C., Pantaleoni F., RA Scioletti A.P., Esposito G., Cordeddu V., Lepri F., Petrangeli V., RA Dentici M.L., Mancini G.M., Selicorni A., Rossi C., Mazzanti L., Marino B., RA Ferrero G.B., Silengo M.C., Memo L., Stanzial F., Faravelli F., Stuppia L., RA Puxeddu E., Gelb B.D., Dallapiccola B., Tartaglia M.; RT "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous RT syndromes: molecular diversity and associated phenotypic spectrum."; RL Hum. Mutat. 30:695-702(2009). RN [45] RP VARIANT CRC GLU-600. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [46] RP VARIANT CRC GLU-600. RX PubMed=24455489; DOI=10.3389/fonc.2013.00333; RA D'mello S.A., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., RA Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H., Furneaux C.E., RA During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.; RT "Evidence that GRIN2A mutations in melanoma correlate with decreased RT survival."; RL Front. Oncol. 3:333-333(2014). CC -!- FUNCTION: Protein kinase involved in the transduction of mitogenic CC signals from the cell membrane to the nucleus (Probable). CC Phosphorylates MAP2K1, and thereby activates the MAP kinase signal CC transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates CC PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses CC of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, CC ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, CC ECO:0000269|PubMed:36402789, ECO:0000305}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250}; CC -!- ACTIVITY REGULATION: In quiescent cells, maintained in an inactive CC state via an intramolecular interaction between the protein kinase and CC N-terminal domains. Following mitogen-mediated cell activation, binds CC via its RGB domain to active HRAS (GTP-bound) which releases the CC inhibitory intramolecular interaction between the two domains. This CC allows the MAP2K1-mediated dimerization of KSR1 or KSR2, and BRAF which CC activates BRAF. {ECO:0000269|PubMed:29433126}. CC -!- SUBUNIT: Monomer (PubMed:19710016). Homodimer (PubMed:19710016, CC PubMed:36402789). Heterodimerizes with RAF1, and the heterodimer CC possesses a highly increased kinase activity compared to the respective CC homodimers or monomers (PubMed:19710016). Heterodimerization is CC mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 CC activation can induce a negative feedback that promotes the CC dissociation of the heterodimer by phosphorylating BRAF at Thr-753. CC Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 CC (via N-terminus) in a MAP2K1-dependent manner (PubMed:29433126). CC Interacts with MAP2K1 and MAP2K2 (PubMed:29433126). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. CC Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with RAF1, a CC ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH CC (PubMed:19710016). Interacts with PRMT5 (PubMed:21917714). Interacts CC with KSR2 (PubMed:21441910). Interacts with AKAP13, MAP2K1 and KSR1. CC Identified in a complex with AKAP13, MAP2K1 and KSR1 (PubMed:21102438). CC Interacts with FNIP1 and FNIP2 (PubMed:27353360). {ECO:0000250, CC ECO:0000269|PubMed:18287029, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:21102438, ECO:0000269|PubMed:21441910, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:27353360, CC ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789}. CC -!- INTERACTION: CC P15056; P21399: ACO1; NbExp=4; IntAct=EBI-365980, EBI-2847111; CC P15056; P31749: AKT1; NbExp=4; IntAct=EBI-365980, EBI-296087; CC P15056; P10398: ARAF; NbExp=9; IntAct=EBI-365980, EBI-365961; CC P15056; P49407: ARRB1; NbExp=4; IntAct=EBI-365980, EBI-743313; CC P15056; O14965: AURKA; NbExp=5; IntAct=EBI-365980, EBI-448680; CC P15056; P25311: AZGP1; NbExp=3; IntAct=EBI-365980, EBI-2513837; CC P15056; Q92560: BAP1; NbExp=4; IntAct=EBI-365980, EBI-1791447; CC P15056; Q07817: BCL2L1; NbExp=7; IntAct=EBI-365980, EBI-78035; CC P15056; Q92843: BCL2L2; NbExp=4; IntAct=EBI-365980, EBI-707714; CC P15056; P15056: BRAF; NbExp=14; IntAct=EBI-365980, EBI-365980; CC P15056; P40259: CD79B; NbExp=3; IntAct=EBI-365980, EBI-2873732; CC P15056; Q6P1J9: CDC73; NbExp=4; IntAct=EBI-365980, EBI-930143; CC P15056; P42772: CDKN2B; NbExp=4; IntAct=EBI-365980, EBI-711280; CC P15056; P61024: CKS1B; NbExp=4; IntAct=EBI-365980, EBI-456371; CC P15056; P35221: CTNNA1; NbExp=4; IntAct=EBI-365980, EBI-701918; CC P15056; Q13618: CUL3; NbExp=2; IntAct=EBI-365980, EBI-456129; CC P15056; Q16254: E2F4; NbExp=4; IntAct=EBI-365980, EBI-448943; CC P15056; Q9GZV4: EIF5A2; NbExp=4; IntAct=EBI-365980, EBI-748028; CC P15056; Q7Z589: EMSY; NbExp=4; IntAct=EBI-365980, EBI-6598631; CC P15056; P18074: ERCC2; NbExp=3; IntAct=EBI-365980, EBI-6380590; CC P15056; P28715: ERCC5; NbExp=3; IntAct=EBI-365980, EBI-765885; CC P15056; O43524: FOXO3; NbExp=5; IntAct=EBI-365980, EBI-1644164; CC P15056; Q8WXI9: GATAD2B; NbExp=3; IntAct=EBI-365980, EBI-923440; CC P15056; P17174: GOT1; NbExp=5; IntAct=EBI-365980, EBI-727329; CC P15056; P49840: GSK3A; NbExp=6; IntAct=EBI-365980, EBI-1044067; CC P15056; O95714: HERC2; NbExp=2; IntAct=EBI-365980, EBI-1058922; CC P15056; P01112: HRAS; NbExp=9; IntAct=EBI-365980, EBI-350145; CC P15056; P08238: HSP90AB1; NbExp=5; IntAct=EBI-365980, EBI-352572; CC P15056; O75874: IDH1; NbExp=4; IntAct=EBI-365980, EBI-715695; CC P15056; O14920: IKBKB; NbExp=5; IntAct=EBI-365980, EBI-81266; CC P15056; P46940: IQGAP1; NbExp=4; IntAct=EBI-365980, EBI-297509; CC P15056; P27987: ITPKB; NbExp=4; IntAct=EBI-365980, EBI-751388; CC P15056; Q14145: KEAP1; NbExp=16; IntAct=EBI-365980, EBI-751001; CC P15056; Q02750: MAP2K1; NbExp=65; IntAct=EBI-365980, EBI-492564; CC P15056; P36507: MAP2K2; NbExp=13; IntAct=EBI-365980, EBI-1056930; CC P15056; Q13233: MAP3K1; NbExp=2; IntAct=EBI-365980, EBI-49776; CC P15056; Q15759: MAPK11; NbExp=4; IntAct=EBI-365980, EBI-298304; CC P15056; Q16659: MAPK6; NbExp=3; IntAct=EBI-365980, EBI-1384105; CC P15056; Q13164: MAPK7; NbExp=5; IntAct=EBI-365980, EBI-1213983; CC P15056; Q9NX70: MED29; NbExp=4; IntAct=EBI-365980, EBI-394656; CC P15056; O00255: MEN1; NbExp=4; IntAct=EBI-365980, EBI-592789; CC P15056; P07196: NEFL; NbExp=4; IntAct=EBI-365980, EBI-475646; CC P15056; P01111: NRAS; NbExp=8; IntAct=EBI-365980, EBI-721993; CC P15056; Q9BRP1: PDCD2L; NbExp=6; IntAct=EBI-365980, EBI-2372173; CC P15056; P48736: PIK3CG; NbExp=4; IntAct=EBI-365980, EBI-1030384; CC P15056; P27986: PIK3R1; NbExp=3; IntAct=EBI-365980, EBI-79464; CC P15056; P16885: PLCG2; NbExp=4; IntAct=EBI-365980, EBI-617403; CC P15056; Q07864: POLE; NbExp=6; IntAct=EBI-365980, EBI-348526; CC P15056; O15297: PPM1D; NbExp=4; IntAct=EBI-365980, EBI-1551512; CC P15056; Q02156: PRKCE; NbExp=3; IntAct=EBI-365980, EBI-706254; CC P15056; P57735: RAB25; NbExp=4; IntAct=EBI-365980, EBI-1050500; CC P15056; P04049: RAF1; NbExp=73; IntAct=EBI-365980, EBI-365996; CC P15056; Q12967: RALGDS; NbExp=4; IntAct=EBI-365980, EBI-365861; CC P15056; P61224: RAP1B; NbExp=4; IntAct=EBI-365980, EBI-358143; CC P15056; Q15349: RPS6KA2; NbExp=2; IntAct=EBI-365980, EBI-1384149; CC P15056; Q8N122: RPTOR; NbExp=4; IntAct=EBI-365980, EBI-1567928; CC P15056; Q8IYM1: SEPTIN12; NbExp=4; IntAct=EBI-365980, EBI-2585067; CC P15056; P31947: SFN; NbExp=6; IntAct=EBI-365980, EBI-476295; CC P15056; Q9UMX1: SUFU; NbExp=4; IntAct=EBI-365980, EBI-740595; CC P15056; P04637: TP53; NbExp=4; IntAct=EBI-365980, EBI-366083; CC P15056; Q13114: TRAF3; NbExp=2; IntAct=EBI-365980, EBI-357631; CC P15056; P40337: VHL; NbExp=7; IntAct=EBI-365980, EBI-301246; CC P15056; P31946: YWHAB; NbExp=14; IntAct=EBI-365980, EBI-359815; CC P15056; P62258: YWHAE; NbExp=11; IntAct=EBI-365980, EBI-356498; CC P15056; P61981: YWHAG; NbExp=12; IntAct=EBI-365980, EBI-359832; CC P15056; P27348: YWHAQ; NbExp=12; IntAct=EBI-365980, EBI-359854; CC P15056; P63104: YWHAZ; NbExp=15; IntAct=EBI-365980, EBI-347088; CC P15056; Q61097: Ksr1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-1536336; CC P15056; P29678: MAP2K1; Xeno; NbExp=2; IntAct=EBI-365980, EBI-1631983; CC P15056; Q99N57: Raf1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-397757; CC P15056; Q8CGE9: Rgs12; Xeno; NbExp=2; IntAct=EBI-365980, EBI-7340552; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:19710016}. Cell membrane CC {ECO:0000269|PubMed:19710016}. Note=Colocalizes with RGS14 and RAF1 in CC both the cytoplasm and membranes. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Brain and testis. CC -!- PTM: Phosphorylation at Ser-365 by SGK1 inhibits its activity (Ref.8, CC PubMed:11410590). Phosphorylation at Thr-753 by MAPK1 CC (PubMed:19710016). Dephosphorylation of Ser-365 by the SHOC2-MRAS-PP1c CC (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the CC catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); CC this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35830882). {ECO:0000269|PubMed:11410590, CC ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|Ref.8}. CC -!- PTM: Methylation at Arg-671 decreases stability and kinase activity. CC {ECO:0000269|PubMed:21917714}. CC -!- PTM: Ubiquitinated by RNF149; which leads to proteasomal degradation. CC Polyubiquitinated at Lys-578 in response to EGF. CC {ECO:0000269|PubMed:22628551, ECO:0000269|PubMed:23907581}. CC -!- DISEASE: Note=Defects in BRAF are found in a wide range of cancers. CC {ECO:0000269|PubMed:18974108}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12198537, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24455489}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A CC multiple congenital anomaly disorder characterized by a distinctive CC facial appearance, heart defects and intellectual disability. Heart CC defects include pulmonic stenosis, atrial septal defects and CC hypertrophic cardiomyopathy. Some affected individuals present with CC ectodermal abnormalities such as sparse, friable hair, hyperkeratotic CC skin lesions and a generalized ichthyosis-like condition. Typical CC facial features are similar to Noonan syndrome. They include high CC forehead with bitemporal constriction, hypoplastic supraorbital ridges, CC downslanting palpebral fissures, a depressed nasal bridge, and CC posteriorly angulated ears with prominent helices. CC {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, CC ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:19206169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving BRAF is found in CC pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to CC the expression of a KIAA1549-BRAF fusion protein with a constitutive CC kinase activity and inducing cell transformation. CC {ECO:0000269|PubMed:18974108}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD43193.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAQ43111.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43112.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43113.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43114.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43115.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43116.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/828/BRAF"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M95712; AAA35609.2; -; mRNA. DR EMBL; AC006344; AAD43193.1; ALT_SEQ; Genomic_DNA. DR EMBL; EU600171; ACD11489.1; -; Genomic_DNA. DR EMBL; AC006347; AAD15551.1; -; Genomic_DNA. DR EMBL; CH236950; EAL24023.1; -; Genomic_DNA. DR EMBL; BC101757; AAI01758.1; -; mRNA. DR EMBL; BC112079; AAI12080.1; -; mRNA. DR EMBL; X65187; CAA46301.1; -; Genomic_DNA. DR EMBL; M21001; AAA96495.1; -; mRNA. DR EMBL; AM989472; CAQ43111.1; ALT_INIT; mRNA. DR EMBL; AM989473; CAQ43112.1; ALT_INIT; mRNA. DR EMBL; AM989474; CAQ43113.1; ALT_INIT; mRNA. DR EMBL; AM989475; CAQ43114.1; ALT_INIT; mRNA. DR EMBL; AM989476; CAQ43115.1; ALT_INIT; mRNA. DR EMBL; AM989477; CAQ43116.1; ALT_INIT; mRNA. DR CCDS; CCDS5863.1; -. DR PIR; A57977; TVHUBF. DR RefSeq; NP_004324.2; NM_004333.4. DR PDB; 1UWH; X-ray; 2.95 A; A/B=448-723. DR PDB; 1UWJ; X-ray; 3.50 A; A/B=448-723. DR PDB; 2FB8; X-ray; 2.90 A; A/B=445-723. DR PDB; 2L05; NMR; -; A=149-232. DR PDB; 3C4C; X-ray; 2.57 A; A/B=444-721. DR PDB; 3D4Q; X-ray; 2.80 A; A/B=433-726. DR PDB; 3IDP; X-ray; 2.70 A; A/B=434-727. DR PDB; 3II5; X-ray; 2.79 A; A/B=432-726. DR PDB; 3NY5; X-ray; 1.99 A; A/B/C/D=153-237. DR PDB; 3OG7; X-ray; 2.45 A; A/B=448-720. DR PDB; 3PPJ; X-ray; 3.70 A; A/B=432-726. DR PDB; 3PPK; X-ray; 3.00 A; A/B=432-726. DR PDB; 3PRF; X-ray; 2.90 A; A/B=432-726. DR PDB; 3PRI; X-ray; 3.50 A; A/B=432-726. DR PDB; 3PSB; X-ray; 3.40 A; A/B=433-726. DR PDB; 3PSD; X-ray; 3.60 A; A/B=433-726. DR PDB; 3Q4C; X-ray; 3.20 A; A/B=432-726. DR PDB; 3Q96; X-ray; 3.10 A; A/B=446-727. DR PDB; 3SKC; X-ray; 3.20 A; A/B=432-726. DR PDB; 3TV4; X-ray; 3.40 A; A/B=432-726. DR PDB; 3TV6; X-ray; 3.30 A; A/B=432-726. DR PDB; 4CQE; X-ray; 2.30 A; A/B=448-723. DR PDB; 4DBN; X-ray; 3.15 A; A/B=445-726. DR PDB; 4E26; X-ray; 2.55 A; A/B=432-726. DR PDB; 4E4X; X-ray; 3.60 A; A/B=432-726. DR PDB; 4EHE; X-ray; 3.30 A; A/B=432-726. DR PDB; 4EHG; X-ray; 3.50 A; A/B=432-726. DR PDB; 4FC0; X-ray; 2.95 A; A/B=445-726. DR PDB; 4FK3; X-ray; 2.65 A; A/B=444-723. DR PDB; 4G9C; X-ray; 3.50 A; A/B=432-726. DR PDB; 4G9R; X-ray; 3.20 A; A/B=432-726. DR PDB; 4H58; X-ray; 3.10 A; A/B/C=448-722. DR PDB; 4JVG; X-ray; 3.09 A; A/B/C/D=444-723. DR PDB; 4KSP; X-ray; 2.93 A; A/B=445-726. DR PDB; 4KSQ; X-ray; 3.30 A; A/B=445-726. DR PDB; 4MBJ; X-ray; 3.60 A; A/B=432-723. DR PDB; 4MNE; X-ray; 2.85 A; B/C/F/G=432-726. DR PDB; 4MNF; X-ray; 2.80 A; A/B=432-736. DR PDB; 4PP7; X-ray; 3.40 A; A/B=432-726. DR PDB; 4R5Y; X-ray; 3.50 A; A/B=444-723. DR PDB; 4RZV; X-ray; 2.99 A; A/B=443-723. DR PDB; 4RZW; X-ray; 3.49 A; A/B=443-723. DR PDB; 4WO5; X-ray; 2.83 A; A/B=444-723. DR PDB; 4XV1; X-ray; 2.47 A; A/B=444-705. DR PDB; 4XV2; X-ray; 2.50 A; A/B=444-705. DR PDB; 4XV3; X-ray; 2.80 A; A/B=444-705. DR PDB; 4XV9; X-ray; 2.00 A; A=442-705. DR PDB; 4YHT; X-ray; 3.05 A; A/B=449-720. DR PDB; 5C9C; X-ray; 2.70 A; A/B=432-726. DR PDB; 5CSW; X-ray; 2.66 A; A/B=442-721. DR PDB; 5CSX; X-ray; 2.51 A; A=442-721. DR PDB; 5CT7; X-ray; 3.17 A; A/B=445-723. DR PDB; 5FD2; X-ray; 2.89 A; A/B=433-726. DR PDB; 5HI2; X-ray; 2.51 A; A=444-737. DR PDB; 5HID; X-ray; 2.50 A; A/B=444-737. DR PDB; 5HIE; X-ray; 3.00 A; A/B/C/D=432-726. DR PDB; 5ITA; X-ray; 1.95 A; A/B=448-723. DR PDB; 5J17; NMR; -; A=151-232. DR PDB; 5J18; NMR; -; A=151-232. DR PDB; 5J2R; NMR; -; A=151-232. DR PDB; 5JRQ; X-ray; 2.29 A; A/B=448-723. DR PDB; 5JSM; X-ray; 2.19 A; A/B/C/D=448-723. DR PDB; 5JT2; X-ray; 2.70 A; A/B/C/D=448-723. DR PDB; 5VAL; X-ray; 2.26 A; A/B=445-723. DR PDB; 5VAM; X-ray; 2.10 A; A/B=445-723. DR PDB; 5VR3; X-ray; 2.10 A; A=36-114. DR PDB; 5VYK; X-ray; 1.75 A; A/C=36-110. DR PDB; 6B8U; X-ray; 2.68 A; A/B=445-723. DR PDB; 6CAD; X-ray; 2.55 A; A/B=444-723. DR PDB; 6N0P; X-ray; 2.37 A; A/B=449-721. DR PDB; 6N0Q; X-ray; 2.04 A; A/B=445-723. DR PDB; 6NSQ; X-ray; 3.05 A; A/B=444-723. DR PDB; 6NYB; EM; 4.10 A; A=1-766. DR PDB; 6P3D; X-ray; 2.11 A; A=448-721. DR PDB; 6P7G; X-ray; 2.65 A; A/B/C/D=448-723. DR PDB; 6PP9; X-ray; 2.59 A; A=445-723. DR PDB; 6Q0J; EM; 4.90 A; A/B=1-766. DR PDB; 6Q0K; EM; 6.80 A; A/B=1-766. DR PDB; 6Q0T; EM; 5.70 A; A/B=1-766. DR PDB; 6U2G; X-ray; 2.89 A; B=432-726. DR PDB; 6U2H; X-ray; 2.50 A; C/D=447-735. DR PDB; 6UAN; EM; 3.90 A; B/C=1-766. DR PDB; 6UUO; X-ray; 3.29 A; A/B=444-723. DR PDB; 6V2U; X-ray; 3.78 A; A/B=445-723. DR PDB; 6V2W; X-ray; 3.12 A; A=445-723. DR PDB; 6V34; X-ray; 3.15 A; A/B=448-721. DR PDB; 6XAG; X-ray; 3.30 A; C/D=447-735. DR PDB; 6XFP; X-ray; 2.00 A; A=442-721. DR PDB; 6XLO; X-ray; 2.49 A; A/B=442-721. DR PDB; 7K0V; X-ray; 1.93 A; A/B/C/D=444-723. DR PDB; 7M0T; X-ray; 3.19 A; A=445-723. DR PDB; 7M0U; X-ray; 3.09 A; A=445-723. DR PDB; 7M0V; X-ray; 3.16 A; A=445-723. DR PDB; 7M0W; X-ray; 3.09 A; A=445-723. DR PDB; 7M0X; X-ray; 2.47 A; A=445-723. DR PDB; 7M0Y; X-ray; 3.45 A; A=445-723. DR PDB; 7M0Z; X-ray; 3.12 A; A=445-723. DR PDB; 7MFD; EM; 3.66 A; A=1-766. DR PDB; 7MFE; EM; 4.07 A; A=1-766. DR PDB; 7MFF; EM; 3.89 A; A/B=1-766. DR PDB; 7P3V; X-ray; 2.37 A; A/B=448-719. DR PDB; 7SHV; X-ray; 2.88 A; A/B=432-726. DR PDB; 7ZR0; EM; 3.40 A; K=1-766. DR PDB; 7ZR5; EM; 3.90 A; K=1-766. DR PDB; 7ZR6; EM; 4.20 A; K=1-766. DR PDB; 8C7X; X-ray; 1.65 A; A/B=444-721. DR PDB; 8C7Y; X-ray; 1.65 A; A/B=444-721. DR PDB; 8DGS; EM; 4.30 A; A=1-766. DR PDB; 8DGT; EM; 3.90 A; A=1-766. DR PDB; 8F7O; X-ray; 3.54 A; A/B=441-723. DR PDB; 8F7P; X-ray; 2.74 A; A/B=441-723. DR PDB; 8QQG; X-ray; 2.98 A; A/B/C=448-722. DR PDB; 8VSO; X-ray; 1.50 A; P=361-369. DR PDB; 8VYO; EM; 3.74 A; A=1-766. DR PDB; 8VYP; EM; 3.29 A; C=1-766. DR PDB; 8VYQ; EM; 4.43 A; C=360-734. DR PDB; 8VYR; EM; 4.32 A; A=1-766. DR PDB; 8VYS; EM; 3.06 A; A=1-766. DR PDB; 8VYU; EM; 4.07 A; A=1-766. DR PDB; 8VYV; EM; 5.86 A; C=1-766. DR PDB; 8VYW; EM; 4.76 A; C=360-734. DR PDB; 9AXX; X-ray; 2.07 A; B/D=445-723. DR PDB; 9AXY; X-ray; 3.60 A; A=445-723. DR PDB; 9BFB; X-ray; 1.92 A; A=445-723. DR PDB; 9BP8; X-ray; 1.73 A; A=445-723. DR PDB; 9EW6; X-ray; 1.65 A; P=361-369. DR PDB; 9F35; X-ray; 2.30 A; B=360-370. DR PDBsum; 1UWH; -. DR PDBsum; 1UWJ; -. DR PDBsum; 2FB8; -. DR PDBsum; 2L05; -. DR PDBsum; 3C4C; -. DR PDBsum; 3D4Q; -. DR PDBsum; 3IDP; -. DR PDBsum; 3II5; -. DR PDBsum; 3NY5; -. DR PDBsum; 3OG7; -. DR PDBsum; 3PPJ; -. DR PDBsum; 3PPK; -. DR PDBsum; 3PRF; -. DR PDBsum; 3PRI; -. DR PDBsum; 3PSB; -. DR PDBsum; 3PSD; -. DR PDBsum; 3Q4C; -. DR PDBsum; 3Q96; -. DR PDBsum; 3SKC; -. DR PDBsum; 3TV4; -. DR PDBsum; 3TV6; -. DR PDBsum; 4CQE; -. DR PDBsum; 4DBN; -. DR PDBsum; 4E26; -. DR PDBsum; 4E4X; -. DR PDBsum; 4EHE; -. DR PDBsum; 4EHG; -. DR PDBsum; 4FC0; -. DR PDBsum; 4FK3; -. DR PDBsum; 4G9C; -. DR PDBsum; 4G9R; -. DR PDBsum; 4H58; -. DR PDBsum; 4JVG; -. DR PDBsum; 4KSP; -. DR PDBsum; 4KSQ; -. DR PDBsum; 4MBJ; -. DR PDBsum; 4MNE; -. DR PDBsum; 4MNF; -. DR PDBsum; 4PP7; -. DR PDBsum; 4R5Y; -. DR PDBsum; 4RZV; -. DR PDBsum; 4RZW; -. DR PDBsum; 4WO5; -. DR PDBsum; 4XV1; -. DR PDBsum; 4XV2; -. DR PDBsum; 4XV3; -. DR PDBsum; 4XV9; -. DR PDBsum; 4YHT; -. DR PDBsum; 5C9C; -. DR PDBsum; 5CSW; -. DR PDBsum; 5CSX; -. DR PDBsum; 5CT7; -. DR PDBsum; 5FD2; -. DR PDBsum; 5HI2; -. DR PDBsum; 5HID; -. DR PDBsum; 5HIE; -. DR PDBsum; 5ITA; -. DR PDBsum; 5J17; -. DR PDBsum; 5J18; -. DR PDBsum; 5J2R; -. DR PDBsum; 5JRQ; -. DR PDBsum; 5JSM; -. DR PDBsum; 5JT2; -. DR PDBsum; 5VAL; -. DR PDBsum; 5VAM; -. DR PDBsum; 5VR3; -. DR PDBsum; 5VYK; -. DR PDBsum; 6B8U; -. DR PDBsum; 6CAD; -. DR PDBsum; 6N0P; -. DR PDBsum; 6N0Q; -. DR PDBsum; 6NSQ; -. DR PDBsum; 6NYB; -. DR PDBsum; 6P3D; -. DR PDBsum; 6P7G; -. DR PDBsum; 6PP9; -. DR PDBsum; 6Q0J; -. DR PDBsum; 6Q0K; -. DR PDBsum; 6Q0T; -. DR PDBsum; 6U2G; -. DR PDBsum; 6U2H; -. DR PDBsum; 6UAN; -. DR PDBsum; 6UUO; -. DR PDBsum; 6V2U; -. DR PDBsum; 6V2W; -. DR PDBsum; 6V34; -. DR PDBsum; 6XAG; -. DR PDBsum; 6XFP; -. DR PDBsum; 6XLO; -. DR PDBsum; 7K0V; -. DR PDBsum; 7M0T; -. DR PDBsum; 7M0U; -. DR PDBsum; 7M0V; -. DR PDBsum; 7M0W; -. DR PDBsum; 7M0X; -. DR PDBsum; 7M0Y; -. DR PDBsum; 7M0Z; -. DR PDBsum; 7MFD; -. DR PDBsum; 7MFE; -. DR PDBsum; 7MFF; -. DR PDBsum; 7P3V; -. DR PDBsum; 7SHV; -. DR PDBsum; 7ZR0; -. DR PDBsum; 7ZR5; -. DR PDBsum; 7ZR6; -. DR PDBsum; 8C7X; -. DR PDBsum; 8C7Y; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8F7O; -. DR PDBsum; 8F7P; -. DR PDBsum; 8QQG; -. DR PDBsum; 8VSO; -. DR PDBsum; 8VYO; -. DR PDBsum; 8VYP; -. DR PDBsum; 8VYQ; -. DR PDBsum; 8VYR; -. DR PDBsum; 8VYS; -. DR PDBsum; 8VYU; -. DR PDBsum; 8VYV; -. DR PDBsum; 8VYW; -. DR PDBsum; 9AXX; -. DR PDBsum; 9AXY; -. DR PDBsum; 9BFB; -. DR PDBsum; 9BP8; -. DR PDBsum; 9EW6; -. DR PDBsum; 9F35; -. DR AlphaFoldDB; P15056; -. DR BMRB; P15056; -. DR EMDB; EMD-0541; -. DR EMDB; EMD-14875; -. DR EMDB; EMD-14883; -. DR EMDB; EMD-14884; -. DR EMDB; EMD-20550; -. DR EMDB; EMD-20551; -. DR EMDB; EMD-20552; -. DR EMDB; EMD-20708; -. DR EMDB; EMD-23813; -. DR EMDB; EMD-23814; -. DR EMDB; EMD-23815; -. DR EMDB; EMD-27428; -. DR EMDB; EMD-27429; -. DR EMDB; EMD-43673; -. DR EMDB; EMD-43674; -. DR EMDB; EMD-43675; -. DR EMDB; EMD-43676; -. DR EMDB; EMD-43677; -. DR EMDB; EMD-43678; -. DR EMDB; EMD-43679; -. DR EMDB; EMD-43680; -. DR SMR; P15056; -. DR BioGRID; 107141; 185. DR CORUM; P15056; -. DR DIP; DIP-1045N; -. DR FunCoup; P15056; 5390. DR IntAct; P15056; 446. DR MINT; P15056; -. DR STRING; 9606.ENSP00000419060; -. DR BindingDB; P15056; -. DR ChEMBL; CHEMBL5145; -. DR DrugBank; DB08553; (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB12854; BMS-908662. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB14773; Lifirafenib. DR DrugBank; DB07000; N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide. DR DrugBank; DB06999; PLX-4720. DR DrugBank; DB16038; PLX8394. DR DrugBank; DB05984; RAF-265. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB08881; Vemurafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P15056; -. DR GuidetoPHARMACOLOGY; 1943; -. DR TCDB; 8.A.23.1.48; the basigin (basigin) family. DR GlyGen; P15056; 1 site. DR iPTMnet; P15056; -. DR PhosphoSitePlus; P15056; -. DR SwissPalm; P15056; -. DR BioMuta; BRAF; -. DR DMDM; 50403720; -. DR CPTAC; CPTAC-3112; -. DR CPTAC; CPTAC-3113; -. DR CPTAC; CPTAC-5771; -. DR CPTAC; CPTAC-5817; -. DR CPTAC; CPTAC-5818; -. DR CPTAC; CPTAC-5819; -. DR CPTAC; CPTAC-5820; -. DR CPTAC; CPTAC-5821; -. DR CPTAC; CPTAC-5822; -. DR CPTAC; non-CPTAC-5352; -. DR CPTAC; non-CPTAC-5353; -. DR CPTAC; non-CPTAC-5354; -. DR CPTAC; non-CPTAC-5355; -. DR CPTAC; non-CPTAC-5356; -. DR CPTAC; non-CPTAC-5357; -. DR CPTAC; non-CPTAC-5727; -. DR CPTAC; non-CPTAC-5728; -. DR CPTAC; non-CPTAC-5729; -. DR jPOST; P15056; -. DR MassIVE; P15056; -. DR PaxDb; 9606-ENSP00000288602; -. DR PeptideAtlas; P15056; -. DR ProteomicsDB; 53102; -. DR Pumba; P15056; -. DR Antibodypedia; 751; 2321 antibodies from 54 providers. DR CPTC; P15056; 7 antibodies. DR DNASU; 673; -. DR Ensembl; ENST00000646891.2; ENSP00000493543.1; ENSG00000157764.15. DR GeneID; 673; -. DR KEGG; hsa:673; -. DR MANE-Select; ENST00000646891.2; ENSP00000493543.1; NM_004333.6; NP_004324.2. DR UCSC; uc003vwc.5; human. DR AGR; HGNC:1097; -. DR CIViC; 673; 6 clinical assertions and 454 evidence items across 166 molecular profiles. DR ClinPGx; PA25408; -. DR CTD; 673; -. DR DisGeNET; 673; -. DR GeneCards; BRAF; -. DR GeneReviews; BRAF; -. DR HGNC; HGNC:1097; BRAF. DR HPA; ENSG00000157764; Low tissue specificity. DR MalaCards; BRAF; -. DR MIM; 114500; phenotype. DR MIM; 115150; phenotype. DR MIM; 164757; gene. DR MIM; 211980; phenotype. DR MIM; 605027; phenotype. DR MIM; 613706; phenotype. DR MIM; 613707; phenotype. DR OpenTargets; ENSG00000157764; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 58017; Classic hairy cell leukemia. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 389; Langerhans cell histiocytosis. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 840; Syringocystadenoma papilliferum. DR VEuPathDB; HostDB:ENSG00000157764; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156154; -. DR HOGENOM; CLU_023684_1_0_1; -. DR InParanoid; P15056; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P15056; 3 GO annotations based on evolutionary models. DR PhylomeDB; P15056; -. DR BRENDA; 2.7.10.2; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P15056; -. DR Reactome; R-HSA-1295596; Spry regulation of FGF signaling. DR Reactome; R-HSA-170968; Frs2-mediated activation. DR Reactome; R-HSA-170984; ARMS-mediated activation. DR Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR SignaLink; P15056; -. DR SIGNOR; P15056; -. DR Agora; ENSG00000157764; -. DR BioGRID-ORCS; 673; 88 hits in 1213 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; BRAF; human. DR EvolutionaryTrace; P15056; -. DR GeneWiki; BRAF_(gene); -. DR GenomeRNAi; 673; -. DR Pharos; P15056; Tclin. DR PRO; PR:P15056; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P15056; protein. DR Bgee; ENSG00000157764; Expressed in buccal mucosa cell and 183 other cell types or tissues. DR ExpressionAtlas; P15056; baseline and differential. DR GO; GO:0044297; C:cell body; IEA:Ensembl. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0043005; C:neuron projection; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004708; F:MAP kinase kinase activity; IMP:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IEA:Ensembl. DR GO; GO:0043367; P:CD4-positive, alpha-beta T cell differentiation; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:BHF-UCL. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072577; P:endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IBA:GO_Central. DR GO; GO:0090150; P:establishment of protein localization to membrane; IDA:CACAO. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0060323; P:head morphogenesis; IEA:Ensembl. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB. DR GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010764; P:negative regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000301; P:negative regulation of synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0048680; P:positive regulation of axon regeneration; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0010828; P:positive regulation of D-glucose transmembrane transport; IDA:CACAO. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045580; P:regulation of T cell differentiation; IEA:Ensembl. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0016079; P:synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd20871; C1_B-Raf; 1. DR CDD; cd17134; RBD_BRAF; 1. DR CDD; cd14062; STKc_Raf; 1. DR DisProt; DP03825; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR PANTHER; PTHR44329:SF240; SERINE_THREONINE-PROTEIN KINASE B-RAF; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Allosteric enzyme; ATP-binding; Cardiomyopathy; KW Cell membrane; Chromosomal rearrangement; Cytoplasm; Deafness; KW Direct protein sequencing; Disease variant; Ectodermal dysplasia; KW Intellectual disability; Isopeptide bond; Kinase; Membrane; Metal-binding; KW Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation; Zinc; KW Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8" FT CHAIN 2..766 FT /note="Serine/threonine-protein kinase B-raf" FT /id="PRO_0000085665" FT DOMAIN 155..227 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 457..717 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 234..280 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 308..454 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..13 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 314..341 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 348..363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..447 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 576 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 235 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 248 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 251 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 261 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 264 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 269 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 272 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 280 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 463..471 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 483 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 380..381 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT SITE 438..439 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 365 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:11410590, ECO:0000269|Ref.8, FT ECO:0007744|PubMed:23186163" FT MOD_RES 373 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1508179" FT MOD_RES 396 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 446 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 671 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 750 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 753 FT /note="Phosphothreonine; by MAPK1" FT /evidence="ECO:0000269|PubMed:19710016" FT CROSSLNK 578 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23907581" FT VARIANT 241 FT /note="T -> M (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058620" FT VARIANT 241 FT /note="T -> P (in CFC1 and LPRD3; dbSNP:rs387906661)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058621" FT VARIANT 241 FT /note="T -> R (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058622" FT VARIANT 244 FT /note="T -> P (in CFC1; dbSNP:rs397507465)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065171" FT VARIANT 245 FT /note="L -> F (in CFC1; dbSNP:rs397507466)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058623" FT VARIANT 246 FT /note="A -> P (in CFC1; dbSNP:rs180177034)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_026113" FT VARIANT 257 FT /note="Q -> R (in CFC1; dbSNP:rs180177035)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_026114" FT VARIANT 262 FT /note="Q -> K (in CFC1; dbSNP:rs397507470)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065172" FT VARIANT 275 FT /note="E -> K (in CFC1; dbSNP:rs2129044284)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058624" FT VARIANT 301 FT /note="P -> S (in dbSNP:rs34776339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040391" FT VARIANT 462 FT /note="R -> I (in CRC; dbSNP:rs180177032)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018613" FT VARIANT 463 FT /note="I -> S (in CRC; dbSNP:rs180177033)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018614" FT VARIANT 464 FT /note="G -> E (in CRC; dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537" FT /id="VAR_018615" FT VARIANT 464 FT /note="G -> V (in a colorectal cancer cell line; elevated FT kinase activity; efficiently induces cell transformation; FT dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018616" FT VARIANT 466 FT /note="G -> A (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018617" FT VARIANT 466 FT /note="G -> E (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018618" FT VARIANT 466 FT /note="G -> V (in LNCR; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919" FT /id="VAR_018512" FT VARIANT 467 FT /note="S -> A (in CFC1; dbSNP:rs869025606)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035096" FT VARIANT 468 FT /note="F -> S (in CFC1; dbSNP:rs397507473)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:18042262" FT /id="VAR_035097" FT VARIANT 469 FT /note="G -> A (in NHL; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846" FT /id="VAR_018620" FT VARIANT 469 FT /note="G -> E (in CFC1 and colon cancer; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_018621" FT VARIANT 469 FT /note="G -> R (in NHL; dbSNP:rs121913357)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018622" FT VARIANT 469 FT /note="G -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040392" FT VARIANT 485 FT /note="L -> F (in CFC1; dbSNP:rs180177036)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026115" FT VARIANT 499 FT /note="K -> E (in CFC1; dbSNP:rs180177037)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026116" FT VARIANT 499 FT /note="K -> N (in CFC1; dbSNP:rs397507476)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058625" FT VARIANT 501 FT /note="E -> G (in CFC1; dbSNP:rs180177039)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404" FT /id="VAR_026117" FT VARIANT 501 FT /note="E -> K (in CFC1; dbSNP:rs180177038)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026118" FT VARIANT 525 FT /note="L -> P (in CFC1; dbSNP:rs869025340)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058626" FT VARIANT 531 FT /note="W -> C (in NS7; dbSNP:rs606231228)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058627" FT VARIANT 580 FT /note="N -> D (in CFC1; dbSNP:rs2128999571)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065173" FT VARIANT 581 FT /note="N -> D (in CFC1; dbSNP:rs180177040)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026119" FT VARIANT 581 FT /note="N -> S (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913370)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040393" FT VARIANT 586 FT /note="E -> K (in ovarian cancer; dbSNP:rs121913340)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018623" FT VARIANT 594 FT /note="D -> G (in NHL; dbSNP:rs121913338)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018624" FT VARIANT 595 FT /note="F -> L (in CFC1; also found in colon cancer; FT dbSNP:rs121913341)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_018625" FT VARIANT 596 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913361)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018626" FT VARIANT 596 FT /note="G -> V (in CFC1; dbSNP:rs397507483)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035098" FT VARIANT 597 FT /note="L -> R (in LNCR; also found in an ovarian serous FT carcinoma sample; somatic mutation; dbSNP:rs121913366)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919, ECO:0000269|PubMed:17344846" FT /id="VAR_018513" FT VARIANT 597 FT /note="L -> V (in NS7; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913369)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169" FT /id="VAR_018627" FT VARIANT 599 FT /note="T -> R (in CFC1; dbSNP:rs121913375)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058628" FT VARIANT 600 FT /note="V -> D (in a melanoma cell line; requires 2 FT nucleotide substitutions; dbSNP:rs121913377)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018628" FT VARIANT 600 FT /note="V -> E (in CRC; also found in sarcoma, metastatic FT melanoma, ovarian serous carcinoma, pilocytic astrocytoma; FT somatic mutation; most common mutation; constitutive and FT elevated kinase activity; efficiently induces cell FT transformation; suppression of mutation in melanoma causes FT growth arrest and promotes apoptosis; loss of regulation by FT PMRT5; dbSNP:rs113488022)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:14500344, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:24455489" FT /id="VAR_018629" FT VARIANT 601 FT /note="K -> E (in CRC; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018630" FT VARIANT 601 FT /note="K -> Q (in CFC1; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058629" FT VARIANT 638 FT /note="D -> E (in CFC1; dbSNP:rs180177042)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058630" FT VARIANT 709 FT /note="Q -> R (in CFC1; dbSNP:rs397507486)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058631" FT MUTAGEN 53 FT /note="M->D: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 88 FT /note="K->E: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 483 FT /note="K->S: Reduces kinase activity with MAP2K1." FT /evidence="ECO:0000269|PubMed:21441910" FT MUTAGEN 509 FT /note="R->H: Loss of MAP2K1-mediated-BRAF-KSR1 FT dimerization." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 578 FT /note="K->R: Blocks EGF-induced ubiquitination and ERK FT activation." FT /evidence="ECO:0000269|PubMed:23907581" FT MUTAGEN 666 FT /note="I->R: No effect on MAP2K1-mediated-BRAF-KSR1 FT dimerization, however loss of BRAF-mediated phosphorylation FT of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 671 FT /note="R->K: Increased kinase activity and stability in FT response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 766 FT /note="H -> D (in Ref. 11; AAA96495)" FT /evidence="ECO:0000305" FT HELIX 43..68 FT /evidence="ECO:0007829|PDB:5VYK" FT HELIX 76..103 FT /evidence="ECO:0007829|PDB:5VYK" FT STRAND 156..161 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 165..170 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 177..186 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 195..199 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 214..217 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 448..450 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 454..456 FT /evidence="ECO:0007829|PDB:5JRQ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 469..484 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 487..489 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 492..505 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 516..520 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 522..524 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 526..530 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 534..536 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 537..542 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 543..545 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 550..569 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 579..581 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 582..585 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 586..588 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 589..592 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:6XFP" FT TURN 602..605 FT /evidence="ECO:0007829|PDB:4RZV" FT HELIX 609..612 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 614..619 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 622..626 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 635..651 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 655..658 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 662..671 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 678..680 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 683..685 FT /evidence="ECO:0007829|PDB:5JRQ" FT HELIX 687..696 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 701..703 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 707..721 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 723..726 FT /evidence="ECO:0007829|PDB:6U2H" SQ SEQUENCE 766 AA; 84437 MW; 0798C2AAB487E813 CRC64; MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI KQMIKLTQEH IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL ESLGNGTDFS VSSSASMDTV TSSSSSSLSV LPSSLSVFQN PTDVARSNPK SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS LKKALMMRGL IPECCAVYRI QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK TFFTLAFCDF CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD EDHRNQFGQR DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA TPPASLPGSL TNVKALQKSP GPQRERKSSS SSEDRNRMKT LGRRDSSDDW EIPDGQITVG QRIGSGSFGT VYKGKWHGDV AVKMLNVTAP TPQQLQAFKN EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH LHIIETKFEM IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM TGQLPYSNIN NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK RDERPLFPQI LASIELLARS LPKIHRSASE PSLNRAGFQT EDFSLYACAS PKTPIQAGGY GAFPVH // ID CADH1_HUMAN Reviewed; 882 AA. AC P12830; A8K1U7; Q13799; Q14216; Q15855; Q16194; Q4PJ14; Q9UII8; DT 01-OCT-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1993, sequence version 3. DT 28-JAN-2026, entry version 271. DE RecName: Full=Cadherin-1 {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=CAM 120/80; DE AltName: Full=Epithelial cadherin {ECO:0000305}; DE Short=E-cadherin {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=Uvomorulin {ECO:0000303|PubMed:8459805}; DE AltName: CD_antigen=CD324; DE Contains: DE RecName: Full=E-Cad/CTF1; DE Contains: DE RecName: Full=E-Cad/CTF2; DE Contains: DE RecName: Full=E-Cad/CTF3; DE Flags: Precursor; GN Name=CDH1 {ECO:0000312|HGNC:HGNC:1748}; GN Synonyms=CDHE, UVO {ECO:0000312|HGNC:HGNC:1748}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=8459805; DOI=10.1007/bf00996219; RA Bussemakers M.J.G., Mees S.G.M., van Bokhoven A., Debruyne F.M.J., RA Schalken J.A.; RT "Molecular cloning and characterization of the human E-cadherin cDNA."; RL Mol. Biol. Rep. 17:123-128(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT 274-GLY--PRO-277 DEL. RX PubMed=8127895; DOI=10.1073/pnas.91.5.1858; RA Oda T., Kanai Y., Oyama T., Yoshiura K., Shimoyama Y., Birchmeier W., RA Sugimura T., Hirohashi S.; RT "E-cadherin gene mutations in human gastric carcinoma cell lines."; RL Proc. Natl. Acad. Sci. U.S.A. 91:1858-1862(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Liver; RX PubMed=8185635; DOI=10.1006/bbrc.1994.1656; RA Rimm D.L., Morrow J.S.; RT "Molecular cloning of human E-cadherin suggests a novel subdivision of the RT cadherin superfamily."; RL Biochem. Biophys. Res. Commun. 200:1754-1761(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 586-591, RP PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION. RC TISSUE=Epidermal carcinoma; RX PubMed=10597309; DOI=10.1038/sj.onc.1203191; RA Ito K., Okamoto I., Araki N., Kawano Y., Nakao M., Fujiyama S., Tomita K., RA Mimori T., Saya H.; RT "Calcium influx triggers the sequential proteolysis of extracellular and RT cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from RT cell-cell contacts."; RL Oncogene 18:7080-7090(1999). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Shibamoto S., Fukudome Y., Yanagihara K.; RT "Mutant E-cadherin."; RL Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Hippocampus, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-478; THR-617; MET-832 RP AND LYS-880. RG NIEHS SNPs program; RL Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RX PubMed=8093045; DOI=10.1006/bbrc.1994.2321; RA Bussemakers M.J.G., Giroldi L.A., van Bokhoven A., Schalken J.A.; RT "Transcriptional regulation of the human E-cadherin gene in human prostate RT cancer cell lines: characterization of the human E-cadherin gene RT promoter."; RL Biochem. Biophys. Res. Commun. 203:1284-1290(1994). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RC TISSUE=Placenta; RX PubMed=7543680; DOI=10.1073/pnas.92.16.7416; RA Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T., Hirohashi S.; RT "Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in RT human carcinomas."; RL Proc. Natl. Acad. Sci. U.S.A. 92:7416-7419(1995). RN [12] RP INTERACTION WITH CTNNB1 AND PKP2. RX PubMed=11790773; DOI=10.1074/jbc.m108765200; RA Chen X., Bonne S., Hatzfeld M., van Roy F., Green K.J.; RT "Protein binding and functional characterization of plakophilin 2. Evidence RT for its diverse roles in desmosomes and beta -catenin signaling."; RL J. Biol. Chem. 277:10512-10522(2002). RN [13] RP INTERACTION WITH PIP5K1C. RX PubMed=17261850; DOI=10.1083/jcb.200606023; RA Ling K., Bairstow S.F., Carbonara C., Turbin D.A., Huntsman D.G., RA Anderson R.A.; RT "Type I gamma phosphatidylinositol phosphate kinase modulates adherens RT junction and E-cadherin trafficking via a direct interaction with mu 1B RT adaptin."; RL J. Cell Biol. 176:343-353(2007). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-882. RC TISSUE=Placenta; RX PubMed=7601454; DOI=10.1016/0888-7543(95)80212-5; RA Berx G., Staes K., van Hengel J., Molemans F., Bussemakers M.J.G., RA van Bokhoven A., van Roy F.; RT "Cloning and characterization of the human invasion suppressor gene E- RT cadherin (CDH1)."; RL Genomics 26:281-289(1995). RN [15] RP PROTEIN SEQUENCE OF 155-174, AND FUNCTION AS L.MONOCYTOGENES RECEPTOR RP (MICROBIAL INFECTION). RX PubMed=8601315; DOI=10.1016/s0092-8674(00)81070-3; RA Mengaud J., Ohayon H., Gounon P., Mege R.M., Cossart P.; RT "E-cadherin is the receptor for internalin, a surface protein required for RT entry of L. monocytogenes into epithelial cells."; RL Cell 84:923-932(1996). RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] OF 172-311 (ISOFORM 1/2), AND TISSUE RP SPECIFICITY. RC TISSUE=Liver; RX PubMed=3263290; DOI=10.1111/j.1432-0436.1988.tb00593.x; RA Mansouri A., Spurr N., Goodfellow P.N., Kemler R.; RT "Characterization and chromosomal localization of the gene encoding the RT human cell adhesion molecule uvomorulin."; RL Differentiation 38:67-71(1988). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 265-392 (ISOFORM 1). RC TISSUE=Liver; RA Frixen U.H.; RL Submitted (MAR-1990) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 337-476, AND VARIANTS ALA-370 AND RP ASP-473. RX PubMed=8033105; RA Becker K.-F., Atkinson M.J., Reich U., Becker I., Nekarda H., Siewert J.R., RA Hoefler H.; RT "E-cadherin gene mutations provide clues to diffuse type gastric RT carcinomas."; RL Cancer Res. 54:3845-3852(1994). RN [19] RP PROTEIN SEQUENCE OF 701-714 AND 732-742, PROTEOLYTIC PROCESSING BY RP GAMMA-SECRETASE/PS1 AND A MEMBRANE-BOUND METALLOPROTEINASE, AND MUTAGENESIS RP OF 759-GLY--GLY-761. RX PubMed=11953314; DOI=10.1093/emboj/21.8.1948; RA Marambaud P., Shioi J., Serban G., Georgakopoulos A., Sarner S., Nagy V., RA Baki L., Wen P., Efthimiopoulos S., Shao Z., Wisniewski T., Robakis N.K.; RT "A presenilin-1/gamma-secretase cleavage releases the E-cadherin RT intracellular domain and regulates disassembly of adherens junctions."; RL EMBO J. 21:1948-1956(2002). RN [20] RP PARTIAL PROTEIN SEQUENCE, AND PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION). RX PubMed=23532847; DOI=10.1074/jbc.m113.459875; RA Sumitomo T., Nakata M., Higashino M., Terao Y., Kawabata S.; RT "Group A streptococcal cysteine protease cleaves epithelial junctions and RT contributes to bacterial translocation."; RL J. Biol. Chem. 288:13317-13324(2013). RN [21] RP DOMAIN CATENIN-BINDING. RX PubMed=2349235; DOI=10.1073/pnas.87.11.4246; RA Ozawa M., Ringwald M., Kemler R.; RT "Uvomorulin-catenin complex formation is regulated by a specific domain in RT the cytoplasmic region of the cell adhesion molecule."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4246-4250(1990). RN [22] RP IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9; RA Butz S., Kemler R.; RT "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell RT adhesion."; RL FEBS Lett. 355:195-200(1994). RN [23] RP FUNCTION AS L.MONOCYTOGENES RECEPTOR (MICROBIAL INFECTION), AND MUTAGENESIS RP OF PRO-170. RX PubMed=10406800; DOI=10.1093/emboj/18.14.3956; RA Lecuit M., Dramsi S., Gottardi C., Fedor-Chaiken M., Gumbiner B., RA Cossart P.; RT "A single amino acid in E-cadherin responsible for host specificity towards RT the human pathogen Listeria monocytogenes."; RL EMBO J. 18:3956-3963(1999). RN [24] RP PROTEOLYTIC PROCESSING. RX PubMed=11076937; DOI=10.1074/jbc.m006102200; RA Steinhusen U., Weiske J., Badock V., Tauber R., Bommert K., Huber O.; RT "Cleavage and shedding of E-cadherin after induction of apoptosis."; RL J. Biol. Chem. 276:4972-4980(2001). RN [25] RP INTERACTION WITH PSEN1. RX PubMed=11226248; DOI=10.1073/pnas.041603398; RA Baki L., Marambaud P., Efthimiopoulos S., Georgakopoulos A., Wen P., RA Cui W., Shioi J., Koo E., Ozawa M., Friedrich V.L., Robakis N.K.; RT "Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 RT association, and regulates stability and function of the cadherin/catenin RT adhesion complex."; RL Proc. Natl. Acad. Sci. U.S.A. 98:2381-2386(2001). RN [26] RP INTERCHAIN DISULFIDE BOND. RX PubMed=11856755; DOI=10.1074/jbc.m200916200; RA Makagiansar I.T., Nguyen P.D., Ikesue A., Kuczera K., Dentler W., RA Urbauer J.L., Galeva N., Alterman M., Siahaan T.J.; RT "Disulfide bond formation promotes the cis- and trans-dimerization of the RT E-cadherin-derived first repeat."; RL J. Biol. Chem. 277:16002-16010(2002). RN [27] RP FUNCTION. RX PubMed=11976333; DOI=10.1074/jbc.m201984200; RA Meigs T.E., Fedor-Chaiken M., Kaplan D.D., Brackenbury R., Casey P.J.; RT "Galpha12 and Galpha13 negatively regulate the adhesive functions of RT cadherin."; RL J. Biol. Chem. 277:24594-24600(2002). RN [28] RP INTERACTION WITH DLGAP5, AND SUBCELLULAR LOCATION. RX PubMed=14699157; DOI=10.1074/jbc.m309843200; RA Laprise P., Viel A., Rivard N.; RT "Human homolog of disc-large is required for adherens junction assembly and RT differentiation of human intestinal epithelial cells."; RL J. Biol. Chem. 279:10157-10166(2004). RN [29] RP INTERACTION WITH AJAP1. RC TISSUE=Brain; RX PubMed=14595118; DOI=10.1091/mbc.e03-05-0281; RA Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A., RA Baumann R., Starzinski-Powitz A.; RT "Novel membrane protein shrew-1 targets to cadherin-mediated junctions in RT polarized epithelial cells."; RL Mol. Biol. Cell 15:397-406(2004). RN [30] RP INTERACTION WITH CTNND1. RX PubMed=15240885; DOI=10.1073/pnas.0401366101; RA Krakstad B.F., Ardawatia V.V., Aragay A.M.; RT "A role for Galpha12/Galpha13 in p120ctn regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 101:10314-10319(2004). RN [31] RP INTERACTION WITH PSEN1 AND CTNNB1, AND MUTAGENESIS OF 759-GLY--GLY-761. RX PubMed=16126725; DOI=10.1074/jbc.m507503200; RA Serban G., Kouchi Z., Baki L., Georgakopoulos A., Litterst C.M., Shioi J., RA Robakis N.K.; RT "Cadherins mediate both the association between PS1 and beta-catenin and RT the effects of PS1 on beta-catenin stability."; RL J. Biol. Chem. 280:36007-36012(2005). RN [32] RP SUBCELLULAR LOCATION. RX PubMed=15689490; DOI=10.1091/mbc.e04-10-0867; RA Lock J.G., Stow J.L.; RT "Rab11 in recycling endosomes regulates the sorting and basolateral RT transport of E-cadherin."; RL Mol. Biol. Cell 16:1744-1755(2005). RN [33] RP FUNCTION OF E-CAD/CTF2. RX PubMed=16417575; DOI=10.1111/j.1471-4159.2005.03616.x; RA Agiostratidou G., Muros R.M., Shioi J., Marambaud P., Robakis N.K.; RT "The cytoplasmic sequence of E-cadherin promotes non-amyloidogenic RT degradation of A beta precursors."; RL J. Neurochem. 96:1182-1188(2006). RN [34] RP INDUCTION. RX PubMed=17893710; DOI=10.1038/cr.2007.79; RA Meng Y.G., Han W.-D., Zhao Y.-L., Huang K., Si Y.-L., Wu Z.-Q., Mu Y.-M.; RT "Induction of the LRP16 gene by estrogen promotes the invasive growth of RT Ishikawa human endometrial cancer cells through the downregulation of E- RT cadherin."; RL Cell Res. 17:869-880(2007). RN [35] RP INVOLVEMENT IN LBC. RX PubMed=17660459; DOI=10.1136/jmg.2007.051268; RA Masciari S., Larsson N., Senz J., Boyd N., Kaurah P., Kandel M.J., RA Harris L.N., Pinheiro H.C., Troussard A., Miron P., Tung N., Oliveira C., RA Collins L., Schnitt S., Garber J.E., Huntsman D.; RT "Germline E-cadherin mutations in familial lobular breast cancer."; RL J. Med. Genet. 44:726-731(2007). RN [36] RP SUBCELLULAR LOCATION. RX PubMed=18343367; DOI=10.1016/j.yexcr.2008.01.031; RA Kanno M., Isa Y., Aoyama Y., Yamamoto Y., Nagai M., Ozawa M., Kitajima Y.; RT "P120-catenin is a novel desmoglein 3 interacting partner: identification RT of the p120-catenin association site of desmoglein 3."; RL Exp. Cell Res. 314:1683-1692(2008). RN [37] RP GLYCOSYLATION AT ASN-558; ASN-570; ASN-622 AND ASN-637, AND MUTAGENESIS OF RP ASN-637. RX PubMed=18491227; DOI=10.1007/s10719-008-9133-9; RA Zhou F., Su J., Fu L., Yang Y., Zhang L., Wang L., Zhao H., Zhang D., RA Li Z., Zha X.; RT "Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded RT incorrectly and arrested in endoplasmic reticulum, then sequentially RT degraded by ERAD."; RL Glycoconj. J. 25:727-740(2008). RN [38] RP INTERACTION WITH LIMA1. RX PubMed=18093941; DOI=10.1073/pnas.0710504105; RA Abe K., Takeichi M.; RT "EPLIN mediates linkage of the cadherin catenin complex to F-actin and RT stabilizes the circumferential actin belt."; RL Proc. Natl. Acad. Sci. U.S.A. 105:13-19(2008). RN [39] RP REVIEW ON CADHERINS. RX PubMed=20066110; DOI=10.1101/cshperspect.a003053; RA Shapiro L., Weis W.I.; RT "Structure and biochemistry of cadherins and catenins."; RL Cold Spring Harb. Perspect. Biol. 1:A3053-A3053(2009). RN [40] RP SUBCELLULAR LOCATION, AND GLYCOSYLATION. RX PubMed=19403558; DOI=10.1093/hmg/ddp194; RA Pinho S.S., Reis C.A., Paredes J., Magalhaes A.M., Ferreira A.C., RA Figueiredo J., Xiaogang W., Carneiro F., Gaertner F., Seruca R.; RT "The role of N-acetylglucosaminyltransferase III and V in the post- RT transcriptional modifications of E-cadherin."; RL Hum. Mol. Genet. 18:2599-2608(2009). RN [41] RP INTERACTION WITH TBC1D2. RX PubMed=20116244; DOI=10.1016/j.cub.2009.12.053; RA Frasa M.A., Maximiano F.C., Smolarczyk K., Francis R.E., Betson M.E., RA Lozano E., Goldenring J., Seabra M.C., Rak A., Ahmadian M.R., Braga V.M.; RT "Armus is a Rac1 effector that inactivates Rab7 and regulates E-cadherin RT degradation."; RL Curr. Biol. 20:198-208(2010). RN [42] RP SUBCELLULAR LOCATION, AND INTERACTION WITH DDR1. RX PubMed=20432435; DOI=10.1002/jcp.22134; RA Eswaramoorthy R., Wang C.K., Chen W.C., Tang M.J., Ho M.L., Hwang C.C., RA Wang H.M., Wang C.Z.; RT "DDR1 regulates the stabilization of cell surface E-cadherin and E- RT cadherin-mediated cell aggregation."; RL J. Cell. Physiol. 224:387-397(2010). RN [43] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [44] RP SUBCELLULAR LOCATION. RX PubMed=20859650; DOI=10.1007/s00018-010-0531-3; RA Gosavi P., Kundu S.T., Khapare N., Sehgal L., Karkhanis M.S., Dalal S.N.; RT "E-cadherin and plakoglobin recruit plakophilin3 to the cell border to RT initiate desmosome assembly."; RL Cell. Mol. Life Sci. 68:1439-1454(2011). RN [45] RP UBIQUITINATION BY CBLL1. RX PubMed=21283129; DOI=10.1038/cr.2011.17; RA Zhou W.J., Geng Z.H., Chi S., Zhang W., Niu X.F., Lan S.J., Ma L., Yang X., RA Wang L.J., Ding Y.Q., Geng J.G.; RT "Slit-Robo signaling induces malignant transformation through Hakai- RT mediated E-cadherin degradation during colorectal epithelial cell RT carcinogenesis."; RL Cell Res. 21:609-626(2011). RN [46] RP UBIQUITINATION BY A SKP2-CONTAINING SCF COMPLEX, AND PHOSPHORYLATION BY RP CSNK1A1. RX PubMed=22770219; DOI=10.1016/j.cell.2012.05.038; RA Inuzuka H., Gao D., Finley L.W., Yang W., Wan L., Fukushima H., Chin Y.R., RA Zhai B., Shaik S., Lau A.W., Wang Z., Gygi S.P., Nakayama K., RA Teruya-Feldstein J., Toker A., Haigis M.C., Pandolfi P.P., Wei W.; RT "Acetylation-dependent regulation of Skp2 function."; RL Cell 150:179-193(2012). RN [47] RP PHOSPHORYLATION AT TYR-753; TYR-754 AND TYR-755, AND MUTAGENESIS OF RP TYR-754. RX PubMed=22252131; DOI=10.1038/emboj.2011.496; RA Mukherjee M., Chow S.Y., Yusoff P., Seetharaman J., Ng C., Sinniah S., RA Koh X.W., Asgar N.F., Li D., Yim D., Jackson R.A., Yew J., Qian J., Iyu A., RA Lim Y.P., Zhou X., Sze S.K., Guy G.R., Sivaraman J.; RT "Structure of a novel phosphotyrosine-binding domain in Hakai that targets RT E-cadherin."; RL EMBO J. 31:1308-1319(2012). RN [48] RP INTERACTION WITH DSG3, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=22294297; DOI=10.1002/path.3982; RA Tsang S.M., Brown L., Lin K., Liu L., Piper K., O'Toole E.A., Grose R., RA Hart I.R., Garrod D.R., Fortune F., Wan H.; RT "Non-junctional human desmoglein 3 acts as an upstream regulator of Src in RT E-cadherin adhesion, a pathway possibly involved in the pathogenesis of RT pemphigus vulgaris."; RL J. Pathol. 227:81-93(2012). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-770 AND SER-793, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [50] RP IDENTIFICATION IN A COMPLEX WITH PKP3 AND RAP1A, INTERACTION WITH PKP3 AND RP RAP1A, AND SUBCELLULAR LOCATION. RX PubMed=25208567; DOI=10.1091/mbc.e14-05-0968; RA Todorovic V., Koetsier J.L., Godsel L.M., Green K.J.; RT "Plakophilin 3 mediates Rap1-dependent desmosome assembly and adherens RT junction maturation."; RL Mol. Biol. Cell 25:3749-3764(2014). RN [51] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=27760340; DOI=10.1016/j.immuni.2016.09.014; RA Cronan M.R., Beerman R.W., Rosenberg A.F., Saelens J.W., Johnson M.G., RA Oehlers S.H., Sisk D.M., Jurcic Smith K.L., Medvitz N.A., Miller S.E., RA Trinh L.A., Fraser S.E., Madden J.F., Turner J., Stout J.E., Lee S., RA Tobin D.M.; RT "Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma RT Formation and Promotes Infection."; RL Immunity 45:861-876(2016). RN [52] RP SUBCELLULAR LOCATION. RX PubMed=28169360; DOI=10.1038/srep42125; RA Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R., RA Chen H., Zhou C., Zhang J., Yang J., Liu P.; RT "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo RT signaling pathway."; RL Sci. Rep. 7:42125-42125(2017). RN [53] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-175. RX PubMed=29999492; DOI=10.7554/elife.37629; RA Shafraz O., Ruebsam M., Stahley S.N., Caldara A.L., Kowalczyk A.P., RA Niessen C.M., Sivasankar S.; RT "E-cadherin binds to desmoglein to facilitate desmosome assembly."; RL Elife 7:0-0(2018). RN [54] RP INTERACTION WITH SPEF1. RX PubMed=31473225; DOI=10.1053/j.gastro.2019.08.031; RA Tapia R., Perez-Yepez E.A., Carlino M.J., Karandikar U.C., Kralicek S.E., RA Estes M.K., Hecht G.A.; RT "Sperm Flagellar 1 Binds Actin in Intestinal Epithelial Cells and RT Contributes to Formation of Filopodia and Lamellipodia."; RL Gastroenterology 157:1544-1555(2019). RN [55] RP INDUCTION. RX PubMed=31835537; DOI=10.3390/ijms20246221; RA Uttagomol J., Ahmad U.S., Rehman A., Huang Y., Laly A.C., Kang A., RA Soetaert J., Chance R., Teh M.T., Connelly J.T., Wan H.; RT "Evidence for the Desmosomal Cadherin Desmoglein-3 in Regulating YAP and RT Phospho-YAP in Keratinocyte Responses to Mechanical Forces."; RL Int. J. Mol. Sci. 20:0-0(2019). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=33596089; DOI=10.1091/mbc.e20-12-0775; RA Raya-Sandino A., Luissint A.C., Kusters D.H.M., Narayanan V., Flemming S., RA Garcia-Hernandez V., Godsel L.M., Green K.J., Hagen S.J., Conway D.E., RA Parkos C.A., Nusrat A.; RT "Regulation of intestinal epithelial intercellular adhesion and barrier RT function by desmosomal cadherin desmocollin-2."; RL Mol. Biol. Cell 32:753-768(2021). RN [57] RP SUBCELLULAR LOCATION. RX PubMed=36309486; DOI=10.1038/s41419-022-05326-2; RA Myo Min K.K., Rojas-Canales D., Penko D., DeNichilo M., Cockshell M.P., RA Ffrench C.B., Thompson E.J., Asplund O., Drogemuller C.J., Prasad R.B., RA Groop L., Grey S.T., Thomas H.E., Loudovaris T., Kay T.W., Mahoney M.G., RA Jessup C.F., Coates P.T., Bonder C.S.; RT "Desmoglein-2 is important for islet function and beta-cell survival."; RL Cell Death Dis. 13:911-911(2022). RN [58] {ECO:0007744|PDB:1O6S} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), SUBUNIT (MICROBIAL RP INFECTION), AND MUTAGENESIS OF TRP-156 AND PRO-170. RX PubMed=12526809; DOI=10.1016/s0092-8674(02)01136-4; RA Schubert W.-D., Urbanke C., Ziehm T., Beier V., Machner M.P., Domann E., RA Wehland J., Chakraborty T., Heinz D.W.; RT "Structure of internalin, a major invasion protein of Listeria RT monocytogenes, in complex with its human receptor E-cadherin."; RL Cell 111:825-836(2002). RN [59] RP REVIEW ON VARIANTS. RX PubMed=9744472; RX DOI=10.1002/(sici)1098-1004(1998)12:4<226::aid-humu2>3.0.co;2-d; RA Berx G., Becker K.-F., Hoefler H., van Roy F.; RT "Mutations of the human E-cadherin (CDH1) gene."; RL Hum. Mutat. 12:226-237(1998). RN [60] {ECO:0007744|PDB:2OMV, ECO:0007744|PDB:2OMY} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), AND SUBUNIT RP (MICROBIAL INFECTION). RX PubMed=17540170; DOI=10.1016/j.cell.2007.03.049; RA Wollert T., Pasche B., Rochon M., Deppenmeier S., van den Heuvel J., RA Gruber A.D., Heinz D.W., Lengeling A., Schubert W.D.; RT "Extending the host range of Listeria monocytogenes by rational protein RT design."; RL Cell 129:891-902(2007). RN [61] {ECO:0007744|PDB:2OMU, ECO:0007744|PDB:2OMZ} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, AND SUBUNIT (MICROBIAL INFECTION). RX PubMed=17715295; DOI=10.1073/pnas.0702199104; RA Wollert T., Heinz D.W., Schubert W.D.; RT "Thermodynamically reengineering the listerial invasion complex InlA/E- RT cadherin."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13960-13965(2007). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 155-367, AND CALCIUM-BINDING RP SITES. RX PubMed=17850815; DOI=10.1016/j.jmb.2007.08.011; RA Parisini E., Higgins J.M., Liu J.H., Brenner M.B., Wang J.H.; RT "The crystal structure of human E-cadherin domains 1 and 2, and comparison RT with other cadherins in the context of adhesion mechanism."; RL J. Mol. Biol. 373:401-411(2007). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 155-253 IN COMPLEX WITH KLRG1. RX PubMed=19604491; DOI=10.1016/j.immuni.2009.04.019; RA Li Y., Hofmann M., Wang Q., Teng L., Chlewicki L.K., Pircher H., RA Mariuzza R.A.; RT "Structure of natural killer cell receptor KLRG1 bound to E-cadherin RT reveals basis for MHC-independent missing self recognition."; RL Immunity 31:35-46(2009). RN [64] RP VARIANT LOBULAR BREAST CARCINOMA SER-315. RX PubMed=7961105; DOI=10.1111/j.1349-7006.1994.tb02902.x; RA Kanai Y., Oda T., Tsuda H., Ochiai A., Hirohashi S.; RT "Point mutation of the E-cadherin gene in invasive lobular carcinoma of the RT breast."; RL Jpn. J. Cancer Res. 85:1035-1039(1994). RN [65] RP VARIANTS THR-617 AND VAL-711, AND VARIANT OVARIAN CANCER GLY-838. RX PubMed=8075649; DOI=10.1038/ng0594-98; RA Risinger J.I., Berchuck A., Kohler M.F., Boyd J.; RT "Mutations of the E-cadherin gene in human gynecologic cancers."; RL Nat. Genet. 7:98-102(1994). RN [66] RP VARIANT PRO-193. RX PubMed=8797891; DOI=10.1111/j.1349-7006.1996.tb02109.x; RA Muta H., Noguchi M., Kanai Y., Ochiai A., Nawata H., Hirohashi S.; RT "E-cadherin gene mutations in signet ring cell carcinoma of the stomach."; RL Jpn. J. Cancer Res. 87:843-848(1996). RN [67] RP VARIANTS ASP-400 DEL AND 418-ASP--PHE-423 DEL. RX PubMed=9045944; DOI=10.1111/j.1349-7006.1996.tb03125.x; RA Tamura G., Sakata K., Nishizuka S., Maesawa C., Suzuki Y., Iwaya T., RA Terashima M., Saito K., Satodate R.; RT "Inactivation of the E-cadherin gene in primary gastric carcinomas and RT gastric carcinoma cell lines."; RL Jpn. J. Cancer Res. 87:1153-1159(1996). RN [68] RP VARIANT THYROID CANCER THR-592. RX PubMed=8985087; RX DOI=10.1002/(sici)1097-0215(19970106)70:1<32::aid-ijc5>3.0.co;2-7; RA Soares P., Berx G., van Roy F., Sobrinho-Simoes M.; RT "E-cadherin gene alterations are rare events in thyroid tumors."; RL Int. J. Cancer 70:32-38(1997). RN [69] RP VARIANT DGLBC ASP-336, AND VARIANT ILE-470. RX PubMed=9537325; DOI=10.1038/32918; RA Guilford P.J., Hopkins J.B.W., Harraway J., McLeod M., McLeod N., RA Harawira P., Taite H., Scoular R., Miller A., Reeve A.E.; RT "E-cadherin germline mutations in familial gastric cancer."; RL Nature 392:402-405(1998). RN [70] RP VARIANTS DGLBC GLY-244 AND ALA-487. RX PubMed=10319582; DOI=10.1007/s100380050137; RA Yoon K.-A., Ku J.-L., Yang H.-K., Kim W.H., Park S.Y., Park J.-G.; RT "Germline mutations of E-cadherin gene in Korean familial gastric cancer RT patients."; RL J. Hum. Genet. 44:177-180(1999). RN [71] RP VARIANT ALA-340. RX PubMed=10896919; DOI=10.1136/gut.47.2.262; RA Kim H.C., Wheeler J.M.D., Kim J.C., Ilyas M., Beck N.E., Kim B.S., RA Park K.C., Bodmer W.F.; RT "The E-cadherin gene (CDH1) variants T340A and L599V in gastric and RT colorectal cancer patients in Korea."; RL Gut 47:262-267(2000). RN [72] RP VARIANT ALA-270. RX PubMed=11705864; RA Ikonen T., Matikainen M., Mononen N., Hyytinen E.R., Helin H.J., RA Tommola S., Tammela T.L., Pukkala E., Schleutker J., Kallioniemi O.-P., RA Koivisto P.A.; RT "Association of E-cadherin germ-line alterations with prostate cancer."; RL Clin. Cancer Res. 7:3465-3471(2001). RN [73] RP VARIANT THR-592. RX PubMed=11562785; DOI=10.3892/ijmm.8.4.439; RA Salahshor S., Hou H., Diep C.B., Loukola A., Zhang H., Liu T., Chen J., RA Iselius L., Rubio C., Lothe R.A., Aaltonen L., Sun X.F., Lindmark G., RA Lindblom A.; RT "A germline E-cadherin mutation in a family with gastric and colon RT cancer."; RL Int. J. Mol. Med. 8:439-443(2001). RN [74] RP VARIANT ALA-340. RX PubMed=11968083; DOI=10.1002/humu.10068; RA Oliveira C., Bordin M.C., Grehan N., Huntsman D., Suriano G., Machado J.C., RA Kiviluoto T., Aaltonen L., Jackson C.E., Seruca R., Caldas C.; RT "Screening E-cadherin in gastric cancer families reveals germline mutations RT only in hereditary diffuse gastric cancer kindred."; RL Hum. Mutat. 19:510-517(2002). RN [75] RP VARIANT DGLBC MET-832. RX PubMed=12216071; DOI=10.1002/ijc.10633; RA Yabuta T., Shinmura K., Tani M., Yamaguchi S., Yoshimura K., Katai H., RA Nakajima T., Mochiki E., Tsujinaka T., Takami M., Hirose K., Yamaguchi A., RA Takenoshita S., Yokota J.; RT "E-cadherin gene variants in gastric cancer families whose probands are RT diagnosed with diffuse gastric cancer."; RL Int. J. Cancer 101:434-441(2002). RN [76] RP VARIANTS THR-617 AND VAL-634, AND CHARACTERIZATION OF VARIANTS ALA-340; RP THR-617 AND VAL-634. RX PubMed=12588804; DOI=10.1093/hmg/ddg048; RA Suriano G., Oliveira C., Ferreira P., Machado J.C., Bordin M.C., RA De Wever O., Bruyneel E.A., Moguilevsky N., Grehan N., Porter T.R., RA Richards F.M., Hruban R.H., Roviello F., Huntsman D., Mareel M., RA Carneiro F., Caldas C., Seruca R.; RT "Identification of CDH1 germline missense mutations associated with RT functional inactivation of the E-cadherin protein in young gastric cancer RT probands."; RL Hum. Mol. Genet. 12:575-582(2003). RN [77] RP VARIANTS ILE-282 AND ASN-777. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [78] RP INVOLVEMENT IN BCDS1, VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, RP CHARACTERIZATION OF VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, AND RP SUBCELLULAR LOCATION. RX PubMed=28301459; DOI=10.1038/gim.2017.11; RA Ghoumid J., Stichelbout M., Jourdain A.S., Frenois F., Lejeune-Dumoulin S., RA Alex-Cordier M.P., Lebrun M., Guerreschi P., Duquennoy-Martinot V., RA Vinchon M., Ferri J., Jung M., Vicaire S., Vanlerberghe C., Escande F., RA Petit F., Manouvrier-Hanu S.; RT "Blepharocheilodontic syndrome is a CDH1 pathway-related disorder due to RT mutations in CDH1 and CTNND1."; RL Genet. Med. 19:1013-1021(2017). CC -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins CC (PubMed:11976333). They preferentially interact with themselves in a CC homophilic manner in connecting cells; cadherins may thus contribute to CC the sorting of heterogeneous cell types. CDH1 is involved in mechanisms CC regulating cell-cell adhesions, mobility and proliferation of CC epithelial cells (PubMed:11976333). Promotes organization of radial CC actin fiber structure and cellular response to contractile forces, via CC its interaction with AMOTL2 which facilitates anchoring of radial actin CC fibers to CDH1 junction complexes at the cell membrane (By similarity). CC Plays a role in the early stages of desmosome cell-cell junction CC formation via facilitating the recruitment of DSG2 and DSP to desmosome CC plaques (PubMed:29999492). Has a potent invasive suppressor role. It is CC a ligand for integrin alpha-E/beta-7. {ECO:0000250|UniProtKB:F1PAA9, CC ECO:0000269|PubMed:11976333, ECO:0000269|PubMed:16417575, CC ECO:0000269|PubMed:29999492}. CC -!- FUNCTION: E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta CC precursors. Has a strong inhibitory effect on APP C99 and C83 CC production. {ECO:0000269|PubMed:16417575}. CC -!- FUNCTION: (Microbial infection) Serves as a receptor for Listeria CC monocytogenes; internalin A (InlA) binds to this protein and promotes CC uptake of the bacteria. {ECO:0000269|PubMed:10406800, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:8601315}. CC -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:11856755). Component of an CC E-cadherin/ catenin adhesion complex composed of at least E- CC cadherin/CDH1, beta-catenin/CTNNB1 or gamma-catenin/JUP, and CC potentially alpha-catenin/CTNNA1; the complex is located to adherens CC junctions (PubMed:16126725, PubMed:7982500). Found in a complex CC composed of CDH1, RAP1A and PKP3; PKP3 acts as a scaffold protein CC within the complex, the complex is required for CDH1 localization to CC mature desmosome cell junctions (PubMed:25208567). Interacts with the CC TRPV4 and CTNNB1 complex (By similarity). Interacts with CTNND1 CC (PubMed:15240885). The stable association of CTNNA1 is controversial as CC CTNNA1 was shown not to bind to F-actin when assembled in the complex CC (By similarity). Alternatively, the CTNNA1-containing complex may be CC linked to F-actin by other proteins such as LIMA1 (By similarity). CC Interaction with PSEN1, cleaves CDH1 resulting in the disassociation of CC cadherin-based adherens junctions (CAJs) (PubMed:11226248, CC PubMed:16126725). Interacts with AJAP1 and DLGAP5 (PubMed:14595118, CC PubMed:14699157). Interacts with TBC1D2 (PubMed:20116244). Interacts CC with LIMA1 (PubMed:18093941). Interacts with CAV1. Interacts with CC PIP5K1C (PubMed:17261850). Interacts with RAB8B (By similarity). CC Interacts with RAPGEF2 (By similarity). Interacts with DDR1; this CC stabilizes CDH1 at the cell surface and inhibits its internalization CC (PubMed:20432435). Interacts with KLRG1 (PubMed:19604491). Forms a CC ternary complex composed of ADAM10, CADH1 and EPHA4; within the CC complex, CADH1 is cleaved by ADAM10 which disrupts adherens junctions CC (By similarity). Interacts with SPEF1 (PubMed:31473225). Interacts with CC CTNNB1 and PKP2 (PubMed:11790773). Interacts with AMOTL2; the CC interaction may facilitate binding of radial actin fibers to cell CC junction complexes (By similarity). Interacts with DSG3; the CC interaction is required for CDH1 localization to developing adherens CC junctions (PubMed:22294297). {ECO:0000250, CC ECO:0000250|UniProtKB:F1PAA9, ECO:0000250|UniProtKB:P09803, CC ECO:0000250|UniProtKB:Q9R0T4, ECO:0000269|PubMed:11226248, CC ECO:0000269|PubMed:11790773, ECO:0000269|PubMed:11856755, CC ECO:0000269|PubMed:12526809, ECO:0000269|PubMed:14595118, CC ECO:0000269|PubMed:14699157, ECO:0000269|PubMed:15240885, CC ECO:0000269|PubMed:16126725, ECO:0000269|PubMed:17261850, CC ECO:0000269|PubMed:18093941, ECO:0000269|PubMed:19604491, CC ECO:0000269|PubMed:20116244, ECO:0000269|PubMed:20432435, CC ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:25208567, CC ECO:0000269|PubMed:31473225, ECO:0000269|PubMed:7982500}. CC -!- SUBUNIT: (Microbial infection) Interacts with L.monocytogenes InlA CC (PubMed:12526809, PubMed:17540170, PubMed:17715295). The formation of CC the complex between InlA and cadherin-1 is calcium-dependent CC (PubMed:12526809). {ECO:0000269|PubMed:12526809, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:17715295}. CC -!- INTERACTION: CC P12830; O94983-5: CAMTA2; NbExp=3; IntAct=EBI-727477, EBI-10176008; CC P12830; P30260: CDC27; NbExp=2; IntAct=EBI-727477, EBI-994813; CC P12830; P12830: CDH1; NbExp=8; IntAct=EBI-727477, EBI-727477; CC P12830; Q6UXH1-2: CRELD2; NbExp=3; IntAct=EBI-727477, EBI-21670927; CC P12830; P35221: CTNNA1; NbExp=8; IntAct=EBI-727477, EBI-701918; CC P12830; P35222: CTNNB1; NbExp=23; IntAct=EBI-727477, EBI-491549; CC P12830; O60716: CTNND1; NbExp=9; IntAct=EBI-727477, EBI-701927; CC P12830; P49184: DNASE1L1; NbExp=3; IntAct=EBI-727477, EBI-20894690; CC P12830; Q9H8V3: ECT2; NbExp=3; IntAct=EBI-727477, EBI-1054039; CC P12830; P00533: EGFR; NbExp=4; IntAct=EBI-727477, EBI-297353; CC P12830; P16422: EPCAM; NbExp=3; IntAct=EBI-727477, EBI-1171184; CC P12830; P11362: FGFR1; NbExp=3; IntAct=EBI-727477, EBI-1028277; CC P12830; Q7Z6Z7-2: HUWE1; NbExp=3; IntAct=EBI-727477, EBI-10975491; CC P12830; Q9UHB6: LIMA1; NbExp=2; IntAct=EBI-727477, EBI-351479; CC P12830; P43356: MAGEA2B; NbExp=3; IntAct=EBI-727477, EBI-5650739; CC P12830; Q7Z434: MAVS; NbExp=3; IntAct=EBI-727477, EBI-995373; CC P12830; P08581: MET; NbExp=2; IntAct=EBI-727477, EBI-1039152; CC P12830; Q8NCR3: MFI; NbExp=3; IntAct=EBI-727477, EBI-744790; CC P12830; Q8TB02: MGC39372; NbExp=3; IntAct=EBI-727477, EBI-25834188; CC P12830; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-727477, EBI-3446748; CC P12830; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-727477, EBI-11750983; CC P12830; Q8N323: NXPE1; NbExp=3; IntAct=EBI-727477, EBI-25834085; CC P12830; Q8N2W9: PIAS4; NbExp=3; IntAct=EBI-727477, EBI-473160; CC P12830; Q8NBT0: POC1A; NbExp=3; IntAct=EBI-727477, EBI-2557132; CC P12830; P62136: PPP1CA; NbExp=2; IntAct=EBI-727477, EBI-357253; CC P12830; Q96QH2: PRAM1; NbExp=3; IntAct=EBI-727477, EBI-2860740; CC P12830; P17612: PRKACA; NbExp=3; IntAct=EBI-727477, EBI-476586; CC P12830; Q15139: PRKD1; NbExp=7; IntAct=EBI-727477, EBI-1181072; CC P12830; Q9Y617: PSAT1; NbExp=3; IntAct=EBI-727477, EBI-709652; CC P12830; P49768: PSEN1; NbExp=2; IntAct=EBI-727477, EBI-297277; CC P12830; P50454: SERPINH1; NbExp=3; IntAct=EBI-727477, EBI-350723; CC P12830; Q02978: SLC25A11; NbExp=3; IntAct=EBI-727477, EBI-359174; CC P12830; P12931: SRC; NbExp=2; IntAct=EBI-727477, EBI-621482; CC P12830; P48775: TDO2; NbExp=3; IntAct=EBI-727477, EBI-743494; CC P12830; P37173: TGFBR2; NbExp=3; IntAct=EBI-727477, EBI-296151; CC P12830; Q9BT49: THAP7; NbExp=3; IntAct=EBI-727477, EBI-741350; CC P12830; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-727477, EBI-1220488; CC P12830; Q9ULW0: TPX2; NbExp=3; IntAct=EBI-727477, EBI-1037322; CC P12830; Q96EF9: ZHX1-C8orf76; NbExp=3; IntAct=EBI-727477, EBI-25830993; CC P12830; Q9BQ29; NbExp=3; IntAct=EBI-727477, EBI-22013570; CC P12830; A0A0S2C3P2: cagA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-55025805; CC P12830; Q9JIY2: Cbll1; Xeno; NbExp=21; IntAct=EBI-727477, EBI-7644904; CC P12830; P0DJM0: inlA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-1035388; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:18343367, ECO:0000269|PubMed:22294297, CC ECO:0000269|PubMed:27760340, ECO:0000269|PubMed:28169360}. Cell CC membrane {ECO:0000269|PubMed:19403558, ECO:0000269|PubMed:20859650, CC ECO:0000269|PubMed:28301459, ECO:0000269|PubMed:36309486}; Single-pass CC type I membrane protein. Endosome {ECO:0000269|PubMed:15689490}. Golgi CC apparatus, trans-Golgi network {ECO:0000269|PubMed:15689490}. Cytoplasm CC {ECO:0000269|PubMed:22294297}. Cell junction, desmosome CC {ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492, CC ECO:0000269|PubMed:33596089}. Note=Colocalizes with DLGAP5 at sites of CC cell-cell contact in intestinal epithelial cells. Anchored to actin CC microfilaments through association with alpha-, beta- and gamma- CC catenin. Sequential proteolysis induced by apoptosis or calcium influx, CC results in translocation from sites of cell-cell contact to the CC cytoplasm. Colocalizes with RAB11A endosomes during its transport from CC the Golgi apparatus to the plasma membrane. Recruited to desmosomes at CC the initial assembly phase and also accumulates progressively at mature CC desmosome cell-cell junctions (PubMed:25208567, PubMed:29999492). CC Localizes to cell-cell contacts as keratinocyte differentiation CC progresses (By similarity). {ECO:0000250|UniProtKB:P09803, CC ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P12830-1; Sequence=Displayed; CC Name=2; CC IsoId=P12830-2; Sequence=VSP_055586; CC -!- TISSUE SPECIFICITY: Expressed in granuloma macrophages (at protein CC level) (PubMed:27760340). Expressed in the skin (at protein level) CC (PubMed:22294297). Expressed in the liver (PubMed:3263290). CC {ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:27760340, CC ECO:0000269|PubMed:3263290}. CC -!- INDUCTION: Induced in the hours following cyclic mechanical strain in CC keratinocytes (PubMed:31835537). Expression is repressed by MACROD1 CC (PubMed:17893710). {ECO:0000269|PubMed:17893710, CC ECO:0000269|PubMed:31835537}. CC -!- DOMAIN: Three calcium ions are usually bound at the interface of each CC cadherin domain and strengthen the connections, imparting a strong CC curvature to the full-length ectodomain. {ECO:0000269|PubMed:2349235}. CC -!- PTM: During apoptosis or with calcium influx, cleaved by a membrane- CC bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 CC (PubMed:10597309, PubMed:11076937, PubMed:11953314). Processing by the CC metalloproteinase, induced by calcium influx, causes disruption of CC cell-cell adhesion and the subsequent release of beta-catenin into the CC cytoplasm (PubMed:10597309). The residual membrane-tethered cleavage CC product is rapidly degraded via an intracellular proteolytic pathway CC (PubMed:10597309). Cleavage by caspase-3 releases the cytoplasmic tail CC resulting in disintegration of the actin microfilament system CC (PubMed:11076937). The gamma-secretase-mediated cleavage promotes CC disassembly of adherens junctions (PubMed:11953314). During development CC of the cochlear organ of Corti, cleavage by ADAM10 at adherens CC junctions promotes pillar cell separation (By similarity). CC {ECO:0000250|UniProtKB:P09803, ECO:0000269|PubMed:10597309, CC ECO:0000269|PubMed:11076937, ECO:0000269|PubMed:11953314}. CC -!- PTM: N-glycosylation at Asn-637 is essential for expression, folding CC and trafficking. Addition of bisecting N-acetylglucosamine by MGAT3 CC modulates its cell membrane location (PubMed:19403558). CC {ECO:0000269|PubMed:18491227, ECO:0000269|PubMed:19403558}. CC -!- PTM: Ubiquitinated by a SCF complex containing SKP2, which requires CC prior phosphorylation by CK1/CSNK1A1. Ubiquitinated by CBLL1/HAKAI, CC requires prior phosphorylation at Tyr-754. CC {ECO:0000269|PubMed:21283129, ECO:0000269|PubMed:22252131, CC ECO:0000269|PubMed:22770219}. CC -!- PTM: O-glycosylated. O-manosylated by TMTC1, TMTC2, TMTC3 or TMTC4. CC Thr-285 and Thr-509 are O-mannosylated by TMTC2 or TMTC4 but not TMTC1 CC or TMTC3. {ECO:0000250|UniProtKB:P09803}. CC -!- PTM: (Microbial infection) Cleaved by S.pyogenes SpeB protease; leading CC to its degradation (PubMed:23532847). Degradation by SpeB promotes CC bacterial translocation across the host epithelial barrier CC (PubMed:23532847). {ECO:0000269|PubMed:23532847}. CC -!- DISEASE: Diffuse gastric and lobular breast cancer syndrome (DGLBC) CC [MIM:137215]: A cancer predisposition syndrome with increased CC susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a CC malignant disease characterized by poorly differentiated infiltrating CC lesions resulting in thickening of the stomach. Malignant tumors start CC in the stomach, can spread to the esophagus or the small intestine, and CC can extend through the stomach wall to nearby lymph nodes and organs. CC It also can metastasize to other parts of the body. In addition to CC gastric cancer, most female mutation carriers develop lobular carcinoma CC of the breast. {ECO:0000269|PubMed:10319582, CC ECO:0000269|PubMed:12216071, ECO:0000269|PubMed:9537325}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. Heterozygous CDH1 germline mutations are CC responsible for familial cases of diffuse gastric cancer. Somatic CC mutations has also been found in patients with sporadic diffuse gastric CC cancer and lobular breast cancer. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast CC cancer that begins in the milk-producing glands (lobules) of the CC breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in CC this entry may be involved in disease pathogenesis. CC -!- DISEASE: Blepharocheilodontic syndrome 1 (BCDS1) [MIM:119580]: A form CC of blepharocheilodontic syndrome, a rare autosomal dominant disorder. CC It is characterized by lower eyelid ectropion, upper eyelid CC distichiasis, euryblepharon, bilateral cleft lip and palate, and CC features of ectodermal dysplasia, including hair anomalies, conical CC teeth and tooth agenesis. An additional rare manifestation is CC imperforate anus. There is considerable phenotypic variability among CC affected individuals. {ECO:0000269|PubMed:28301459}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: May play a role in blister formation in Pemphigus CC vulgaris patients, expression is lost at sites of cell-cell contact CC between the basal and suprabasal layers in blisters and immediately CC adjacent to blisters. {ECO:0000269|PubMed:22294297}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA61259.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/166/CDH1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=E-cadherin entry; CC URL="https://en.wikipedia.org/wiki/E-cadherin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z13009; CAA78353.1; -; mRNA. DR EMBL; Z18923; CAA79356.1; -; mRNA. DR EMBL; L08599; AAA61259.1; ALT_FRAME; mRNA. DR EMBL; AB025105; BAA88956.1; -; mRNA. DR EMBL; AK290012; BAF82701.1; -; mRNA. DR EMBL; AK312551; BAG35448.1; -; mRNA. DR EMBL; DQ090940; AAY68225.1; -; Genomic_DNA. DR EMBL; AC099314; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471092; EAW83243.1; -; Genomic_DNA. DR EMBL; CH471092; EAW83244.1; -; Genomic_DNA. DR EMBL; L34545; AAA21764.1; -; Genomic_DNA. DR EMBL; D49685; BAA08537.1; -; Genomic_DNA. DR EMBL; Z35402; CAA84586.1; -; Genomic_DNA. DR EMBL; Z35403; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35404; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35405; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35406; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35407; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35408; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35409; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35410; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35411; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35412; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35413; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35414; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35415; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; X12790; CAA31279.1; -; mRNA. DR EMBL; X52279; CAA36522.1; -; mRNA. DR EMBL; S72492; AAD14108.1; -; Genomic_DNA. DR EMBL; S72397; AAD14108.1; JOINED; Genomic_DNA. DR EMBL; S72491; AAD14108.1; JOINED; Genomic_DNA. DR CCDS; CCDS10869.1; -. [P12830-1] DR CCDS; CCDS82005.1; -. [P12830-2] DR PIR; S37654; IJHUCE. DR RefSeq; NP_001304113.1; NM_001317184.2. [P12830-2] DR RefSeq; NP_001304114.1; NM_001317185.1. DR RefSeq; NP_001304115.1; NM_001317186.1. DR RefSeq; NP_004351.1; NM_004360.5. [P12830-1] DR PDB; 1O6S; X-ray; 1.80 A; B=156-255. DR PDB; 2O72; X-ray; 2.00 A; A=155-367. DR PDB; 2OMT; X-ray; 2.00 A; B=156-255. DR PDB; 2OMU; X-ray; 1.80 A; B=156-255. DR PDB; 2OMV; X-ray; 1.90 A; B=156-255. DR PDB; 2OMX; X-ray; 1.70 A; B=156-258. DR PDB; 2OMY; X-ray; 1.70 A; B=156-254. DR PDB; 2OMZ; X-ray; 1.60 A; B=156-254. DR PDB; 3FF7; X-ray; 1.80 A; A/B=155-253. DR PDB; 3FF8; X-ray; 2.00 A; A/B=155-254. DR PDB; 3L6X; X-ray; 2.40 A; B=756-773. DR PDB; 3L6Y; X-ray; 3.00 A; B/D/F=756-773. DR PDB; 4ZT1; X-ray; 1.92 A; A/B=157-367. DR PDB; 4ZTE; X-ray; 2.13 A; A/B=157-367. DR PDB; 6CXY; X-ray; 2.20 A; C=155-371. DR PDB; 6OLE; EM; 3.10 A; y=693-730. DR PDB; 6OLF; EM; 3.90 A; y=693-730. DR PDB; 6OLG; EM; 3.40 A; A=693-730. DR PDB; 6VEL; X-ray; 2.65 A; C=155-371. DR PDB; 7STZ; X-ray; 2.95 A; C/D=155-698. DR PDB; 8H62; X-ray; 1.91 A; B=155-367. DR PDBsum; 1O6S; -. DR PDBsum; 2O72; -. DR PDBsum; 2OMT; -. DR PDBsum; 2OMU; -. DR PDBsum; 2OMV; -. DR PDBsum; 2OMX; -. DR PDBsum; 2OMY; -. DR PDBsum; 2OMZ; -. DR PDBsum; 3FF7; -. DR PDBsum; 3FF8; -. DR PDBsum; 3L6X; -. DR PDBsum; 3L6Y; -. DR PDBsum; 4ZT1; -. DR PDBsum; 4ZTE; -. DR PDBsum; 6CXY; -. DR PDBsum; 6OLE; -. DR PDBsum; 6OLF; -. DR PDBsum; 6OLG; -. DR PDBsum; 6VEL; -. DR PDBsum; 7STZ; -. DR PDBsum; 8H62; -. DR AlphaFoldDB; P12830; -. DR EMDB; EMD-25883; -. DR EMDB; EMD-25884; -. DR EMDB; EMD-25886; -. DR EMDB; EMD-25892; -. DR SMR; P12830; -. DR BioGRID; 107434; 777. DR CORUM; P12830; -. DR DIP; DIP-477N; -. DR ELM; P12830; -. DR FunCoup; P12830; 811. DR IntAct; P12830; 146. DR MINT; P12830; -. DR STRING; 9606.ENSP00000261769; -. DR BindingDB; P12830; -. DR ChEMBL; CHEMBL2321609; -. DR TCDB; 8.A.204.1.1; the cadhesin (cdh) family. DR UniLectin; P12830; -. DR GlyCosmos; P12830; 13 sites, No reported glycans. DR GlyGen; P12830; 16 sites, 2 O-linked glycans (3 sites). DR iPTMnet; P12830; -. DR PhosphoSitePlus; P12830; -. DR SwissPalm; P12830; -. DR BioMuta; CDH1; -. DR DMDM; 399166; -. DR CPTAC; CPTAC-1599; -. DR CPTAC; CPTAC-5772; -. DR CPTAC; CPTAC-5773; -. DR CPTAC; non-CPTAC-5366; -. DR CPTAC; non-CPTAC-5367; -. DR CPTAC; non-CPTAC-5370; -. DR CPTAC; non-CPTAC-5541; -. DR CPTAC; non-CPTAC-5542; -. DR jPOST; P12830; -. DR MassIVE; P12830; -. DR PaxDb; 9606-ENSP00000261769; -. DR PeptideAtlas; P12830; -. DR ProteomicsDB; 52879; -. [P12830-1] DR ProteomicsDB; 84533; -. DR Pumba; P12830; -. DR TopDownProteomics; P12830-2; -. [P12830-2] DR ABCD; P12830; 29 sequenced antibodies. DR Antibodypedia; 1347; 3254 antibodies from 63 providers. DR CPTC; P12830; 4 antibodies. DR DNASU; 999; -. DR Ensembl; ENST00000261769.10; ENSP00000261769.4; ENSG00000039068.21. [P12830-1] DR Ensembl; ENST00000422392.6; ENSP00000414946.2; ENSG00000039068.21. [P12830-2] DR GeneID; 999; -. DR KEGG; hsa:999; -. DR MANE-Select; ENST00000261769.10; ENSP00000261769.4; NM_004360.5; NP_004351.1. DR UCSC; uc002ewg.2; human. [P12830-1] DR AGR; HGNC:1748; -. DR CIViC; 999; 4 evidence items across 4 molecular profiles. DR ClinPGx; PA26282; -. DR CTD; 999; -. DR DisGeNET; 999; -. DR GeneCards; CDH1; -. DR GeneReviews; CDH1; -. DR HGNC; HGNC:1748; CDH1. DR HPA; ENSG00000039068; Tissue enhanced (parathyroid). DR MalaCards; CDH1; -. DR MIM; 119580; phenotype. DR MIM; 137215; phenotype. DR MIM; 167000; phenotype. DR MIM; 192090; gene. DR MIM; 608089; phenotype. DR OpenTargets; ENSG00000039068; -. DR Orphanet; 1997; Blepharo-cheilo-odontic syndrome. DR Orphanet; 199306; Cleft lip/palate. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 26106; Hereditary diffuse gastric cancer. DR VEuPathDB; HostDB:ENSG00000039068; -. DR eggNOG; KOG3594; Eukaryota. DR GeneTree; ENSGT00940000157175; -. DR HOGENOM; CLU_005284_2_1_1; -. DR InParanoid; P12830; -. DR OrthoDB; 6079678at2759; -. DR PAN-GO; P12830; 8 GO annotations based on evolutionary models. DR PhylomeDB; P12830; -. DR PathwayCommons; P12830; -. DR Reactome; R-HSA-1474228; Degradation of the extracellular matrix. DR Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. DR Reactome; R-HSA-216083; Integrin cell surface interactions. DR Reactome; R-HSA-351906; Apoptotic cleavage of cell adhesion proteins. DR Reactome; R-HSA-418990; Adherens junctions interactions. DR Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs. DR Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells. DR Reactome; R-HSA-9764561; Regulation of CDH1 Function. DR Reactome; R-HSA-9764562; Regulation of CDH1 mRNA translation by microRNAs. DR Reactome; R-HSA-9766229; Degradation of CDH1. DR Reactome; R-HSA-9768727; Regulation of CDH1 posttranslational processing and trafficking to plasma membrane. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. DR Reactome; R-HSA-9926550; Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P12830; -. DR SIGNOR; P12830; -. DR Agora; ENSG00000039068; -. DR BioGRID-ORCS; 999; 47 hits in 1173 CRISPR screens. DR ChiTaRS; CDH1; human. DR EvolutionaryTrace; P12830; -. DR GeneWiki; CDH1_(gene); -. DR GenomeRNAi; 999; -. DR Pharos; P12830; Tbio. DR PRO; PR:P12830; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; P12830; protein. DR Bgee; ENSG00000039068; Expressed in jejunal mucosa and 158 other cell types or tissues. DR ExpressionAtlas; P12830; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:BHF-UCL. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0043296; C:apical junction complex; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0030057; C:desmosome; IDA:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; TAS:Reactome. DR GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0016600; C:flotillin complex; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005796; C:Golgi lumen; TAS:Reactome. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005765; C:lysosomal membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0005802; C:trans-Golgi network; IMP:BHF-UCL. DR GO; GO:0030506; F:ankyrin binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0098631; F:cell adhesion mediator activity; IDA:UniProt. DR GO; GO:0050839; F:cell adhesion molecule binding; IPI:UniProtKB. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0032794; F:GTPase activating protein binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:1990782; F:protein tyrosine kinase binding; IEA:Ensembl. DR GO; GO:0034332; P:adherens junction organization; IMP:UniProtKB. DR GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0000902; P:cell morphogenesis; IBA:GO_Central. DR GO; GO:0098609; P:cell-cell adhesion; IDA:BHF-UCL. DR GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IDA:BHF-UCL. DR GO; GO:0007043; P:cell-cell junction assembly; IBA:GO_Central. DR GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB. DR GO; GO:0071285; P:cellular response to lithium ion; IDA:UniProtKB. DR GO; GO:0002159; P:desmosome assembly; IMP:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; NAS:UniProtKB. DR GO; GO:0030517; P:negative regulation of axon extension; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:ARUK-UCL. DR GO; GO:0022408; P:negative regulation of cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0031175; P:neuron projection development; IEA:Ensembl. DR GO; GO:0021983; P:pituitary gland development; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:BHF-UCL. DR GO; GO:1903829; P:positive regulation of protein localization; IMP:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IDA:BHF-UCL. DR GO; GO:0010468; P:regulation of gene expression; IMP:UniProtKB. DR GO; GO:0099576; P:regulation of protein catabolic process at postsynapse, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0140459; P:response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0071503; P:response to heparin; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0007416; P:synapse assembly; IBA:GO_Central. DR CDD; cd00031; CA_like; 1. DR CDD; cd11304; Cadherin_repeat; 3. DR FunFam; 2.60.40.60:FF:000011; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000191; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000019; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000022; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000027; Cadherin 2; 1. DR FunFam; 4.10.900.10:FF:000001; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000031; Cadherin 3; 1. DR Gene3D; 2.60.40.60; Cadherins; 6. DR Gene3D; 4.10.900.10; TCF3-CBD (Catenin binding domain); 1. DR InterPro; IPR039808; Cadherin. DR InterPro; IPR002126; Cadherin-like_dom. DR InterPro; IPR015919; Cadherin-like_sf. DR InterPro; IPR020894; Cadherin_CS. DR InterPro; IPR014868; Cadherin_pro_dom. DR InterPro; IPR000233; Cadherin_Y-type_LIR. DR InterPro; IPR027397; Catenin-bd_sf. DR PANTHER; PTHR24027:SF319; CADHERIN-1; 1. DR PANTHER; PTHR24027; CADHERIN-23; 1. DR Pfam; PF01049; CADH_Y-type_LIR; 1. DR Pfam; PF00028; Cadherin; 5. DR Pfam; PF08758; Cadherin_pro; 1. DR PRINTS; PR00205; CADHERIN. DR SMART; SM00112; CA; 4. DR SMART; SM01055; Cadherin_pro; 1. DR SUPFAM; SSF49313; Cadherin-like; 6. DR PROSITE; PS00232; CADHERIN_1; 3. DR PROSITE; PS50268; CADHERIN_2; 5. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell junction; KW Cell membrane; Cleavage on pair of basic residues; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Ectodermal dysplasia; Endosome; Glycoprotein; Golgi apparatus; Membrane; KW Metal-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix; KW Ubl conjugation. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT PROPEP 23..154 FT /evidence="ECO:0000255" FT /id="PRO_0000003715" FT CHAIN 155..882 FT /note="Cadherin-1" FT /id="PRO_0000003716" FT CHAIN 701..882 FT /note="E-Cad/CTF1" FT /id="PRO_0000236067" FT CHAIN 732..882 FT /note="E-Cad/CTF2" FT /id="PRO_0000236068" FT CHAIN 751..882 FT /note="E-Cad/CTF3" FT /id="PRO_0000236069" FT TOPO_DOM 155..709 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 710..730 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 731..882 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 155..262 FT /note="Cadherin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 263..375 FT /note="Cadherin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 376..486 FT /note="Cadherin 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 487..593 FT /note="Cadherin 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 594..697 FT /note="Cadherin 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT REGION 747..767 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 758..769 FT /note="Required for binding CTNND1 and PSEN1" FT REGION 811..882 FT /note="Required for binding alpha, beta and gamma catenins" FT COMPBIAS 755..767 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT BINDING 288 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT SITE 364..365 FT /note="Cleavage; by S.pyogenes SpeB" FT /evidence="ECO:0000269|PubMed:23532847" FT SITE 700..701 FT /note="Cleavage; by a metalloproteinase" FT SITE 731..732 FT /note="Cleavage; by gamma-secretase/PS1" FT SITE 750..751 FT /note="Cleavage; by caspase-3" FT MOD_RES 753 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 754 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 755 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 770 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 793 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 838 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 840 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 846 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 280 FT /note="O-linked (Man...) serine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 285 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 358 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 470 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 472 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 509 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 558 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 570 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 576 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 578 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 580 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 622 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 637 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT DISULFID 163 FT /note="Interchain" FT VAR_SEQ 380..440 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.5" FT /id="VSP_055586" FT VARIANT 72 FT /note="D -> N (in dbSNP:rs35606263)" FT /id="VAR_048500" FT VARIANT 123 FT /note="H -> Y (in a gastric cancer sample; FT dbSNP:rs1555514482)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001306" FT VARIANT 193 FT /note="T -> P (in a diffuse gastric cancer sample; FT dbSNP:rs1597891014)" FT /evidence="ECO:0000269|PubMed:8797891" FT /id="VAR_001307" FT VARIANT 244 FT /note="D -> G (in DGLBC; likely benign; FT dbSNP:rs1064794231)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008712" FT VARIANT 254 FT /note="D -> Y (in BCDS1; abolishes protein abundance; loss FT of cell membrane localization; dbSNP:rs1555515445)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079392" FT VARIANT 257 FT /note="D -> V (in BCDS1; slightly decreases protein FT abundance; loss of cell membrane localization; FT dbSNP:rs1555515446)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079393" FT VARIANT 270 FT /note="S -> A (in dbSNP:rs587776399)" FT /evidence="ECO:0000269|PubMed:11705864" FT /id="VAR_013970" FT VARIANT 274..277 FT /note="Missing (found in gastric carcinoma cell lines)" FT /evidence="ECO:0000269|PubMed:8127895" FT /id="VAR_001308" FT VARIANT 282 FT /note="M -> I (in a breast cancer sample; somatic mutation; FT dbSNP:rs200932258)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033026" FT VARIANT 315 FT /note="N -> S (in lobular breast carcinoma)" FT /evidence="ECO:0000269|PubMed:7961105" FT /id="VAR_001309" FT VARIANT 336 FT /note="E -> D (in DGLBC; likely pathogenic; FT dbSNP:rs267606712)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001310" FT VARIANT 340 FT /note="T -> A (found in gastric and colorectal cancer FT samples; cells exhibited decreased aggregation increased FT invasiveness and non-uniform migration in vitro compared to FT cells transfected with wild-type sequence; FT dbSNP:rs116093741)" FT /evidence="ECO:0000269|PubMed:10896919, FT ECO:0000269|PubMed:11968083, ECO:0000269|PubMed:12588804" FT /id="VAR_013971" FT VARIANT 370 FT /note="D -> A (in a diffuse gastric cancer sample; FT dbSNP:rs2152132676)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001311" FT VARIANT 393 FT /note="I -> N (in dbSNP:rs34466743)" FT /id="VAR_048501" FT VARIANT 400 FT /note="Missing (in a gastric carcinoma sample; loss of FT heterozygosity)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001312" FT VARIANT 418..423 FT /note="Missing (in a gastric carcinoma sample)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001313" FT VARIANT 454 FT /note="Missing (in BCDS1; decreases protein abundance; loss FT of cell membrane localization)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079394" FT VARIANT 463 FT /note="E -> Q (in a gastric carcinoma sample; FT dbSNP:rs1960961009)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001314" FT VARIANT 470 FT /note="T -> I (in dbSNP:rs370864592)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001315" FT VARIANT 473 FT /note="V -> D (in a diffuse gastric cancer sample; FT dbSNP:rs2152134881)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001317" FT VARIANT 473 FT /note="V -> I (in dbSNP:rs36087757)" FT /id="VAR_048502" FT VARIANT 478 FT /note="L -> P (in dbSNP:rs35520415)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023357" FT VARIANT 487 FT /note="V -> A (in DGLBC; dbSNP:rs1960965342)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008713" FT VARIANT 592 FT /note="A -> T (in dbSNP:rs35187787)" FT /evidence="ECO:0000269|PubMed:11562785, FT ECO:0000269|PubMed:8985087" FT /id="VAR_001318" FT VARIANT 598 FT /note="R -> Q (in a gastric cancer sample; FT dbSNP:rs780759537)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001319" FT VARIANT 617 FT /note="A -> T (detected in an endometrial cancer sample; FT loss of heterozygosity; cells exhibited an intermediate FT phenotype concerning aggregation invasiveness and migration FT in vitro compared to cells transfected with wild-type FT sequence; dbSNP:rs33935154)" FT /evidence="ECO:0000269|PubMed:12588804, FT ECO:0000269|PubMed:8075649, ECO:0000269|Ref.7" FT /id="VAR_001320" FT VARIANT 630 FT /note="L -> V (in dbSNP:rs2276331)" FT /id="VAR_021868" FT VARIANT 634 FT /note="A -> V (found in a gastric cancer sample; cells FT exhibited decreased aggregation increased invasiveness and FT non-uniform migration in vitro compared to cells FT transfected with wild-type sequence; dbSNP:rs121964878)" FT /evidence="ECO:0000269|PubMed:12588804" FT /id="VAR_055431" FT VARIANT 695 FT /note="C -> R (in dbSNP:rs9282655)" FT /id="VAR_021869" FT VARIANT 711 FT /note="L -> V (detected in an endometrial cancer sample; FT dbSNP:rs121964871)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001321" FT VARIANT 777 FT /note="D -> N (in dbSNP:rs372989292)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033027" FT VARIANT 832 FT /note="V -> M (in DGLBC; benign; dbSNP:rs35572355)" FT /evidence="ECO:0000269|PubMed:12216071, ECO:0000269|Ref.7" FT /id="VAR_023358" FT VARIANT 838 FT /note="S -> G (in an ovarian carcinoma sample; somatic FT mutation; loss of heterozygosity; dbSNP:rs121964872)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001322" FT VARIANT 880 FT /note="E -> K (in dbSNP:rs34507583)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023359" FT MUTAGEN 156 FT /note="W->A,S: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 156 FT /note="W->D: Protein is partially unfolded, no longer binds FT L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->A,E,V: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->E: No longer adheres to L.monocytogenes InlA FT coated beads, nor do cells take up InlA coated beads." FT /evidence="ECO:0000269|PubMed:10406800" FT MUTAGEN 175 FT /note="L->D: Reduces localization to desmosome cell-cell FT junctions. Also reduces the localization of DSG2 and DSP to FT desmosome cell-cell junctions." FT /evidence="ECO:0000269|PubMed:29999492" FT MUTAGEN 637 FT /note="N->Q: CDH1 becomes a substrate for ERAD and is FT retro-translocated from ER to cytoplasm." FT /evidence="ECO:0000269|PubMed:18491227" FT MUTAGEN 754 FT /note="Y->F: Abolishes binding to CBLL1." FT /evidence="ECO:0000269|PubMed:22252131" FT MUTAGEN 759..761 FT /note="GGG->AAA: Binds to CTNNB1 but abolishes interaction FT of CTNNB1 with PSEN1. Abolishes gamma-secretase cleavage." FT /evidence="ECO:0000269|PubMed:11953314, FT ECO:0000269|PubMed:16126725" FT CONFLICT 10 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 29 FT /note="H -> L (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 47 FT /note="E -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 70..71 FT /note="SL -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 483 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 530 FT /note="A -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 543 FT /note="S -> F (in Ref. 2; CAA79356)" FT /evidence="ECO:0000305" FT CONFLICT 615 FT /note="I -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 634..636 FT /note="ASA -> RVP (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="R -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 882 FT /note="D -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT STRAND 163..166 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 169..177 FT /evidence="ECO:0007829|PDB:2OMZ" FT HELIX 181..184 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 189..195 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 213..216 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 222..224 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 227..235 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 241..243 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 246..253 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 261..263 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 265..272 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 292..294 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 301..309 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 316..319 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 321..323 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 325..328 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 335..337 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 340..348 FT /evidence="ECO:0007829|PDB:8H62" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 356..366 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 374..384 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 394..396 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 410..417 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 423..428 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 429..432 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 433..440 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 444..446 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 448..460 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 470..477 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 485..498 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 522..527 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 533..535 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 537..539 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 541..544 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 553..555 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 557..568 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 576..586 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 594..596 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 599..607 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 610..615 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 622..625 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 627..633 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 638..644 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 648..656 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 660..673 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 675..691 FT /evidence="ECO:0007829|PDB:7STZ" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:3L6X" SQ SEQUENCE 882 AA; 97456 MW; E427118043A13C67 CRC64; MGPWSRSLSA LLLLLQVSSW LCQEPEPCHP GFDAESYTFT VPRRHLERGR VLGRVNFEDC TGRQRTAYFS LDTRFKVGTD GVITVKRPLR FHNPQIHFLV YAWDSTYRKF STKVTLNTVG HHHRPPPHQA SVSGIQAELL TFPNSSPGLR RQKRDWVIPP ISCPENEKGP FPKNLVQIKS NKDKEGKVFY SITGQGADTP PVGVFIIERE TGWLKVTEPL DRERIATYTL FSHAVSSNGN AVEDPMEILI TVTDQNDNKP EFTQEVFKGS VMEGALPGTS VMEVTATDAD DDVNTYNAAI AYTILSQDPE LPDKNMFTIN RNTGVISVVT TGLDRESFPT YTLVVQAADL QGEGLSTTAT AVITVTDTND NPPIFNPTTY KGQVPENEAN VVITTLKVTD ADAPNTPAWE AVYTILNDDG GQFVVTTNPV NNDGILKTAK GLDFEAKQQY ILHVAVTNVV PFEVSLTTST ATVTVDVLDV NEAPIFVPPE KRVEVSEDFG VGQEITSYTA QEPDTFMEQK ITYRIWRDTA NWLEINPDTG AISTRAELDR EDFEHVKNST YTALIIATDN GSPVATGTGT LLLILSDVND NAPIPEPRTI FFCERNPKPQ VINIIDADLP PNTSPFTAEL THGASANWTI QYNDPTQESI ILKPKMALEV GDYKINLKLM DNQNKDQVTT LEVSVCDCEG AAGVCRKAQP VEAGLQIPAI LGILGGILAL LILILLLLLF LRRRAVVKEP LLPPEDDTRD NVYYYDEEGG GEEDQDFDLS QLHRGLDARP EVTRNDVAPT LMSVPRYLPR PANPDEIGNF IDENLKAADT DPTAPPYDSL LVFDYEGSGS EAASLSSLNS SESDKDQDYD YLNEWGNRFK KLADMYGGGE DD // ID CAMKV_HUMAN Reviewed; 501 AA. AC Q8NCB2; A6NFD4; Q6FIB8; Q8NBS8; Q8NC85; Q8NDU4; Q8WTT8; Q9BQC9; Q9H0Q5; DT 19-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 19-SEP-2006, sequence version 2. DT 28-JAN-2026, entry version 178. DE RecName: Full=CaM kinase-like vesicle-associated protein; GN Name=CAMKV; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Retinoblastoma, and Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=11230166; DOI=10.1101/gr.gr1547r; RA Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S., RA Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J., RA Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W., RA Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B., RA Klein M., Poustka A.; RT "Towards a catalog of human genes and proteins: sequencing and analysis of RT 500 novel complete protein coding human cDNAs."; RL Genome Res. 11:422-435(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT CYS-491. RC TISSUE=Brain, and Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP VARIANTS [LARGE SCALE ANALYSIS] TRP-40; SER-60; TRP-274; ASP-279 AND RP LEU-472. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Does not appear to have detectable kinase activity. CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with calmodulin, in the presence of calcium. CC {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Peripheral membrane CC protein {ECO:0000250}. Cytoplasmic vesicle membrane {ECO:0000250}; CC Peripheral membrane protein {ECO:0000250}. Note=Predominantly observed CC in association with the plasma membrane of soma and in neurites, both CC axons and dendrites. May be associated with vesicular structures (By CC similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q8NCB2-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8NCB2-2; Sequence=VSP_020600; CC Name=3; CC IsoId=Q8NCB2-3; Sequence=VSP_020601; CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK074856; BAC11248.1; -; mRNA. DR EMBL; AK074899; BAC11278.1; -; mRNA. DR EMBL; AK075294; BAC11528.1; -; mRNA. DR EMBL; AL136697; CAB66632.1; -; mRNA. DR EMBL; CR533508; CAG38539.1; -; mRNA. DR EMBL; AL833943; CAD38798.2; -; Transcribed_RNA. DR EMBL; AC105935; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW65027.1; -; Genomic_DNA. DR EMBL; BC000497; AAH00497.1; -; mRNA. DR EMBL; BC001921; AAH01921.1; -; mRNA. DR EMBL; BC005828; AAH05828.1; -; mRNA. DR EMBL; BC017363; AAH17363.1; -; mRNA. DR EMBL; BC019256; AAH19256.1; -; mRNA. DR CCDS; CCDS33762.1; -. [Q8NCB2-1] DR CCDS; CCDS82776.1; -. [Q8NCB2-3] DR RefSeq; NP_001307076.1; NM_001320147.2. [Q8NCB2-3] DR RefSeq; NP_076951.2; NM_024046.5. [Q8NCB2-1] DR AlphaFoldDB; Q8NCB2; -. DR SMR; Q8NCB2; -. DR BioGRID; 122482; 114. DR FunCoup; Q8NCB2; 552. DR IntAct; Q8NCB2; 138. DR MINT; Q8NCB2; -. DR STRING; 9606.ENSP00000419195; -. DR GlyCosmos; Q8NCB2; 4 sites, 1 glycan. DR GlyGen; Q8NCB2; 6 sites, 1 O-linked glycan (5 sites). DR iPTMnet; Q8NCB2; -. DR PhosphoSitePlus; Q8NCB2; -. DR SwissPalm; Q8NCB2; -. DR BioMuta; CAMKV; -. DR DMDM; 115311319; -. DR jPOST; Q8NCB2; -. DR MassIVE; Q8NCB2; -. DR PaxDb; 9606-ENSP00000419195; -. DR PeptideAtlas; Q8NCB2; -. DR ProteomicsDB; 72868; -. [Q8NCB2-1] DR ProteomicsDB; 72869; -. [Q8NCB2-2] DR ProteomicsDB; 72870; -. [Q8NCB2-3] DR Pumba; Q8NCB2; -. DR Antibodypedia; 2091; 210 antibodies from 29 providers. DR DNASU; 79012; -. DR Ensembl; ENST00000296471.11; ENSP00000296471.6; ENSG00000164076.18. [Q8NCB2-2] DR Ensembl; ENST00000477224.6; ENSP00000419195.1; ENSG00000164076.18. [Q8NCB2-1] DR Ensembl; ENST00000488336.5; ENSP00000418809.1; ENSG00000164076.18. [Q8NCB2-3] DR Ensembl; ENST00000620470.4; ENSP00000484045.1; ENSG00000164076.18. [Q8NCB2-2] DR GeneID; 79012; -. DR KEGG; hsa:79012; -. DR MANE-Select; ENST00000477224.6; ENSP00000419195.1; NM_024046.5; NP_076951.2. DR UCSC; uc003cxt.2; human. [Q8NCB2-1] DR AGR; HGNC:28788; -. DR ClinPGx; PA142672205; -. DR CTD; 79012; -. DR DisGeNET; 79012; -. DR GeneCards; CAMKV; -. DR HGNC; HGNC:28788; CAMKV. DR HPA; ENSG00000164076; Tissue enriched (brain). DR MIM; 614993; gene. DR OpenTargets; ENSG00000164076; -. DR VEuPathDB; HostDB:ENSG00000164076; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000156468; -. DR InParanoid; Q8NCB2; -. DR OMA; GPATCNG; -. DR OrthoDB; 40902at2759; -. DR PAN-GO; Q8NCB2; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q8NCB2; -. DR PathwayCommons; Q8NCB2; -. DR SignaLink; Q8NCB2; -. DR Agora; ENSG00000164076; -. DR BioGRID-ORCS; 79012; 19 hits in 1183 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CAMKV; human. DR GenomeRNAi; 79012; -. DR Pharos; Q8NCB2; Tbio. DR PRO; PR:Q8NCB2; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q8NCB2; protein. DR Bgee; ENSG00000164076; Expressed in cortical plate and 100 other cell types or tissues. DR ExpressionAtlas; Q8NCB2; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0045202; C:synapse; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IBA:GO_Central. DR GO; GO:0005516; F:calmodulin binding; IBA:GO_Central. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0099159; P:regulation of modification of postsynaptic structure; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd14088; STKc_CaMK_like; 1. DR FunFam; 1.10.510.10:FF:000188; CaM kinase-like vesicle-associated, like; 1. DR FunFam; 3.30.200.20:FF:000155; CaM kinase-like vesicle-associated, like; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW Alternative splicing; Calmodulin-binding; Cell membrane; KW Cytoplasmic vesicle; Membrane; Phosphoprotein; Proteomics identification; KW Reference proteome. FT CHAIN 1..501 FT /note="CaM kinase-like vesicle-associated protein" FT /id="PRO_0000250094" FT DOMAIN 24..286 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 327..501 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 331..365 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 387..428 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 438..451 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 435 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q63092" FT MOD_RES 459 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q3UHL1" FT VAR_SEQ 188..215 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11230166, ECO:0000303|Ref.3" FT /id="VSP_020600" FT VAR_SEQ 352..382 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020601" FT VARIANT 40 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1407808379)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041337" FT VARIANT 60 FT /note="G -> S (in an ovarian serous carcinoma sample; FT somatic mutation; dbSNP:rs2082026503)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041338" FT VARIANT 274 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041339" FT VARIANT 279 FT /note="E -> D (in dbSNP:rs56071455)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041340" FT VARIANT 472 FT /note="P -> L (in dbSNP:rs56307047)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041341" FT VARIANT 491 FT /note="Y -> C (in dbSNP:rs17849325)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_027539" FT CONFLICT 22 FT /note="D -> G (in Ref. 3; CAG38539)" FT /evidence="ECO:0000305" FT CONFLICT 64 FT /note="R -> Q (in Ref. 1; BAC11528)" FT /evidence="ECO:0000305" FT CONFLICT 285 FT /note="W -> S (in Ref. 1; BAC11248)" FT /evidence="ECO:0000305" SQ SEQUENCE 501 AA; 54354 MW; 1D6DBF8ABA0D1D70 CRC64; MPFGCVTLGD KKNYNQPSEV TDRYDLGQVI KTEEFCEIFR AKDKTTGKLH TCKKFQKRDG RKVRKAAKNE IGILKMVKHP NILQLVDVFV TRKEYFIFLE LATGREVFDW ILDQGYYSER DTSNVVRQVL EAVAYLHSLK IVHRNLKLEN LVYYNRLKNS KIVISDFHLA KLENGLIKEP CGTPEYLAPE VVGRQRYGRP VDCWAIGVIM YILLSGNPPF YEEVEEDDYE NHDKNLFRKI LAGDYEFDSP YWDDISQAAK DLVTRLMEVE QDQRITAEEA ISHEWISGNA ASDKNIKDGV CAQIEKNFAR AKWKKAVRVT TLMKRLRAPE QSSTAAAQSA SATDTATPGA AGGATAAAAS GATSAPEGDA ARAAKSDNVA PADRSATPAT DGSATPATDG SVTPATDGSI TPATDGSVTP ATDRSATPAT DGRATPATEE STVPTTQSSA MLATKAAATP EPAMAQPDST APEGATGQAP PSSKGEEAAG YAQESQREEA S // ID CDKL2_HUMAN Reviewed; 493 AA. AC Q92772; B2R695; DT 22-NOV-2005, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1997, sequence version 1. DT 28-JAN-2026, entry version 183. DE RecName: Full=Cyclin-dependent kinase-like 2 {ECO:0000305}; DE EC=2.7.11.22; DE AltName: Full=Protein kinase p56 KKIAMRE {ECO:0000303|PubMed:9000130}; DE AltName: Full=Serine/threonine-protein kinase KKIAMRE; GN Name=CDKL2 {ECO:0000312|HGNC:HGNC:1782}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RC TISSUE=Fetal brain; RX PubMed=9000130; RA Taglienti C.A., Wysk M., Davis R.J.; RT "Molecular cloning of the epidermal growth factor-stimulated protein kinase RT p56 KKIAMRE."; RL Oncogene 13:2563-2574(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Hippocampus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] {ECO:0007744|PDB:4AAA, ECO:0007744|PDB:4BBM} RP X-RAY CRYSTALLOGRAPHY (1.53 ANGSTROMS) OF 1-308 IN COMPLEX WITH SYNTHETIC RP INHIBITOR. RX PubMed=29420175; DOI=10.1016/j.celrep.2017.12.083; RA Canning P., Park K., Goncalves J., Li C., Howard C.J., Sharpe T.D., RA Holt L.J., Pelletier L., Bullock A.N., Leroux M.R.; RT "CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary RT Function."; RL Cell Rep. 22:885-894(2018). RN [6] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-98; GLN-149; THR-197 AND VAL-411. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.22; CC -!- INTERACTION: CC Q92772; Q58FG0: HSP90AA5P; NbExp=3; IntAct=EBI-6381227, EBI-11323222; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9000130}. Nucleus CC {ECO:0000269|PubMed:9000130}. CC -!- TISSUE SPECIFICITY: Expressed in testis and kidney, and at lower level CC in brain and lung. {ECO:0000269|PubMed:9000130}. CC -!- DOMAIN: The [NKR]KIAxRE motif seems to be a cyclin-binding region. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U35146; AAC50918.1; -; mRNA. DR EMBL; AK312490; BAG35392.1; -; mRNA. DR EMBL; CH471057; EAX05740.1; -; Genomic_DNA. DR EMBL; BC093646; AAH93646.1; -; mRNA. DR EMBL; BC093981; AAH93981.1; -; mRNA. DR CCDS; CCDS3570.1; -. DR RefSeq; NP_001317653.1; NM_001330724.1. DR RefSeq; NP_003939.1; NM_003948.5. DR RefSeq; XP_016864299.1; XM_017008810.2. DR RefSeq; XP_047272340.1; XM_047416384.1. DR RefSeq; XP_054207164.1; XM_054351189.1. DR PDB; 4AAA; X-ray; 1.53 A; A=1-308. DR PDB; 4BBM; X-ray; 2.00 A; A/B=1-308. DR PDB; 8S6I; X-ray; 1.72 A; A=1-308. DR PDBsum; 4AAA; -. DR PDBsum; 4BBM; -. DR PDBsum; 8S6I; -. DR AlphaFoldDB; Q92772; -. DR SMR; Q92772; -. DR BioGRID; 114479; 71. DR FunCoup; Q92772; 1449. DR IntAct; Q92772; 67. DR STRING; 9606.ENSP00000306340; -. DR BindingDB; Q92772; -. DR ChEMBL; CHEMBL5728; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q92772; -. DR iPTMnet; Q92772; -. DR PhosphoSitePlus; Q92772; -. DR BioMuta; CDKL2; -. DR DMDM; 74762639; -. DR CPTAC; non-CPTAC-3026; -. DR CPTAC; non-CPTAC-3027; -. DR jPOST; Q92772; -. DR MassIVE; Q92772; -. DR PaxDb; 9606-ENSP00000412365; -. DR PeptideAtlas; Q92772; -. DR Antibodypedia; 24675; 254 antibodies from 28 providers. DR DNASU; 8999; -. DR Ensembl; ENST00000429927.6; ENSP00000412365.2; ENSG00000138769.12. DR GeneID; 8999; -. DR KEGG; hsa:8999; -. DR UCSC; uc003hiq.4; human. DR AGR; HGNC:1782; -. DR ClinPGx; PA26318; -. DR CTD; 8999; -. DR DisGeNET; 8999; -. DR GeneCards; CDKL2; -. DR HGNC; HGNC:1782; CDKL2. DR HPA; ENSG00000138769; Tissue enhanced (retina, testis). DR MIM; 603442; gene. DR OpenTargets; ENSG00000138769; -. DR VEuPathDB; HostDB:ENSG00000138769; -. DR eggNOG; KOG0593; Eukaryota. DR GeneTree; ENSGT00940000160368; -. DR HOGENOM; CLU_000288_136_0_1; -. DR InParanoid; Q92772; -. DR OrthoDB; 548217at2759; -. DR PAN-GO; Q92772; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q92772; -. DR PathwayCommons; Q92772; -. DR SignaLink; Q92772; -. DR Agora; ENSG00000138769; -. DR BioGRID-ORCS; 8999; 18 hits in 1177 CRISPR screens. DR ChiTaRS; CDKL2; human. DR EvolutionaryTrace; Q92772; -. DR GeneWiki; CDKL2; -. DR GenomeRNAi; 8999; -. DR Pharos; Q92772; Tchem. DR PRO; PR:Q92772; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q92772; protein. DR Bgee; ENSG00000138769; Expressed in endothelial cell and 147 other cell types or tissues. DR ExpressionAtlas; Q92772; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0007548; P:sex differentiation; TAS:ProtInc. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd07846; STKc_CDKL2_3; 1. DR FunFam; 3.30.200.20:FF:000049; cyclin-dependent kinase-like 1 isoform X1; 1. DR FunFam; 1.10.510.10:FF:000261; cyclin-dependent kinase-like 2 isoform X2; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050108; CDK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24056; CELL DIVISION PROTEIN KINASE; 1. DR PANTHER; PTHR24056:SF241; CYCLIN-DEPENDENT KINASE-LIKE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cytoplasm; Kinase; Nucleotide-binding; Nucleus; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..493 FT /note="Cyclin-dependent kinase-like 2" FT /id="PRO_0000085814" FT DOMAIN 4..287 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 363..384 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 45..51 FT /note="[NKR]KIAxRE" FT ACT_SITE 126 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VARIANT 77 FT /note="Y -> S (in dbSNP:rs35921414)" FT /id="VAR_053928" FT VARIANT 98 FT /note="L -> I (in an ovarian papillary serous FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041987" FT VARIANT 132 FT /note="I -> T (in dbSNP:rs17000707)" FT /id="VAR_053929" FT VARIANT 149 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs755711267)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041988" FT VARIANT 197 FT /note="M -> T (in dbSNP:rs56343717)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041989" FT VARIANT 411 FT /note="A -> V (in dbSNP:rs56231363)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041990" FT HELIX 1..3 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 4..9 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 10..13 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 16..23 FT /evidence="ECO:0007829|PDB:4AAA" FT TURN 24..26 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 29..37 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 42..57 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 66..72 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 84..86 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 87..93 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 100..119 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 129..131 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 147..150 FT /evidence="ECO:0007829|PDB:4BBM" FT HELIX 154..163 FT /evidence="ECO:0007829|PDB:4BBM" FT HELIX 165..167 FT /evidence="ECO:0007829|PDB:4BBM" FT HELIX 170..173 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 182..197 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 207..218 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 223..231 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 233..235 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 249..252 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 258..267 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 272..274 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 278..283 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 285..288 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 289..291 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 292..301 FT /evidence="ECO:0007829|PDB:4AAA" SQ SEQUENCE 493 AA; 56019 MW; 5CC20A91CBF89EFE CRC64; MEKYENLGLV GEGSYGMVMK CRNKDTGRIV AIKKFLESDD DKMVKKIAMR EIKLLKQLRH ENLVNLLEVC KKKKRWYLVF EFVDHTILDD LELFPNGLDY QVVQKYLFQI INGIGFCHSH NIIHRDIKPE NILVSQSGVV KLCDFGFART LAAPGEVYTD YVATRWYRAP ELLVGDVKYG KAVDVWAIGC LVTEMFMGEP LFPGDSDIDQ LYHIMMCLGN LIPRHQELFN KNPVFAGVRL PEIKEREPLE RRYPKLSEVV IDLAKKCLHI DPDKRPFCAE LLHHDFFQMD GFAERFSQEL QLKVQKDARN VSLSKKSQNR KKEKEKDDSL VEERKTLVVQ DTNADPKIKD YKLFKIKGSK IDGEKAEKGN RASNASCLHD SRTSHNKIVP STSLKDCSNV SVDHTRNPSV AIPPLTHNLS AVAPSINSGM GTETIPIQGY RVDEKTKKCS IPFVKPNRHS PSGIYNINVT TLVSGPPLSD DSGADLPQME HQH // ID CPNE3_HUMAN Reviewed; 537 AA. AC O75131; A8KA47; Q8IYA1; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1998, sequence version 1. DT 28-JAN-2026, entry version 200. DE RecName: Full=Copine-3 {ECO:0000305}; DE AltName: Full=Copine III {ECO:0000303|PubMed:11041869, ECO:0000312|HGNC:HGNC:2316}; GN Name=CPNE3 {ECO:0000312|HGNC:HGNC:2316}; GN Synonyms=CPN3, KIAA0636 {ECO:0000303|PubMed:9734811}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, TISSUE SPECIFICITY, RP AND PHOSPHORYLATION. RX PubMed=11041869; DOI=10.1021/bi001250v; RA Caudell E.G., Caudell J.J., Tang C.-H., Yu T.-K., Frederick M.J., RA Grimm E.A.; RT "Characterization of human copine III as a phosphoprotein with associated RT kinase activity."; RL Biochemistry 39:13034-13043(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=9734811; DOI=10.1093/dnares/5.3.169; RA Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H., RA Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. X. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 5:169-176(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-412. RC TISSUE=Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS SPECTROMETRY. RX PubMed=12949241; DOI=10.1189/jlb.0203083; RA Cowland J.B., Carter D., Bjerregaard M.D., Johnsen A.H., Borregaard N., RA Lollike K.; RT "Tissue expression of copines and isolation of copines I and III from the RT cytosol of human neutrophils."; RL J. Leukoc. Biol. 74:379-388(2003). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=21087455; DOI=10.1111/j.1742-4658.2010.07935.x; RA Perestenko P.V., Pooler A.M., Noorbakhshnia M., Gray A., Bauccio C., RA Jeffrey McIlhinney R.A.; RT "Copines-1, -2, -3, -6 and -7 show different calcium-dependent RT intracellular membrane translocation and targeting."; RL FEBS J. 277:5174-5189(2010). RN [8] RP FUNCTION, INTERACTION WITH ERBB2; RACK1 AND SHC1, SUBCELLULAR LOCATION, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20010870; DOI=10.1038/onc.2009.456; RA Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R., RA Lienhard S., Duss S., Hofsteenge J., Hynes N.E.; RT "Copine-III interacts with ErbB2 and promotes tumor cell migration."; RL Oncogene 29:1598-1610(2010). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND SER-243, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND SER-197, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Calcium-dependent phospholipid-binding protein that plays a CC role in ERBB2-mediated tumor cell migration in response to growth CC factor heregulin stimulation (PubMed:20010870). CC {ECO:0000269|PubMed:20010870}. CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00041}; CC -!- SUBUNIT: Monomer (PubMed:12949241). Interacts with ERBB2 CC (preferentially with the tyrosine phosphorylated form); this CC interaction occurs at the cell membrane and is increased in a growth CC factor heregulin-dependent manner (PubMed:20010870). Interacts with CC SHC1; this interaction may mediate the binding of CPNE3 with ERBB2 CC (PubMed:20010870). Interacts with RACK1 (PubMed:20010870). CC {ECO:0000269|PubMed:12949241, ECO:0000269|PubMed:20010870}. CC -!- INTERACTION: CC O75131; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-718988, EBI-717399; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20010870, CC ECO:0000269|PubMed:21087455}. Cytoplasm {ECO:0000269|PubMed:12949241, CC ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21087455}. Cell CC membrane {ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21087455}. CC Cell junction {ECO:0000269|PubMed:20010870}. Cell junction, focal CC adhesion {ECO:0000269|PubMed:20010870}. Note=Associates to the membrane CC in a calcium-dependent manner (PubMed:20010870). Translocates to the CC cell membrane and the nucleus in a calcium- or growth factor heregulin- CC dependent manner (PubMed:20010870, PubMed:21087455). Colocalizes with CC the tyrosine phosphorylated ERBB2 form at cell membrane and focal CC adhesions in a calcium- or growth factor heregulin-dependent manner CC (PubMed:20010870). {ECO:0000269|PubMed:20010870, CC ECO:0000269|PubMed:21087455}. CC -!- TISSUE SPECIFICITY: Expressed in breast and weakly in prostate and CC ovarian tissues (PubMed:20010870). Expressed in neutrophils (at protein CC level) (PubMed:12949241). Widely expressed (PubMed:11041869). Expressed CC in the brain. Expressed in neutrophil precursors from the bone marrow CC and peripheral blood (PubMed:12949241). Expressed in primary breast CC tumors and ovarian endometrioid adenocarcinoma (PubMed:20010870). CC {ECO:0000269|PubMed:11041869, ECO:0000269|PubMed:12949241, CC ECO:0000269|PubMed:20010870}. CC -!- PTM: Phosphorylated on serine and threonine residues (PubMed:11041869). CC {ECO:0000269|PubMed:11041869}. CC -!- SIMILARITY: Belongs to the copine family. {ECO:0000305}. CC -!- CAUTION: Was reported to have a protein kinase activity. CC {ECO:0000305|PubMed:11041869}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA31611.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF077226; AAD46074.2; -; mRNA. DR EMBL; AB014536; BAA31611.2; ALT_INIT; mRNA. DR EMBL; AK292912; BAF85601.1; -; mRNA. DR EMBL; BC036242; AAH36242.1; -; mRNA. DR EMBL; BC066597; AAH66597.1; -; mRNA. DR CCDS; CCDS6243.1; -. DR RefSeq; NP_003900.1; NM_003909.5. DR RefSeq; XP_005251150.1; XM_005251093.5. DR RefSeq; XP_016869434.1; XM_017013945.3. DR RefSeq; XP_024303090.1; XM_024447322.2. DR RefSeq; XP_047278349.1; XM_047422393.1. DR RefSeq; XP_047278350.1; XM_047422394.1. DR RefSeq; XP_047278351.1; XM_047422395.1. DR RefSeq; XP_054217423.1; XM_054361448.1. DR RefSeq; XP_054217424.1; XM_054361449.1. DR RefSeq; XP_054217425.1; XM_054361450.1. DR RefSeq; XP_054217426.1; XM_054361451.1. DR RefSeq; XP_054217427.1; XM_054361452.1. DR RefSeq; XP_054217428.1; XM_054361453.1. DR AlphaFoldDB; O75131; -. DR SMR; O75131; -. DR BioGRID; 114412; 124. DR FunCoup; O75131; 1341. DR IntAct; O75131; 51. DR MINT; O75131; -. DR STRING; 9606.ENSP00000477590; -. DR TCDB; 8.A.210.1.2; the plasma membrane repair (pmr) family. DR GlyCosmos; O75131; 1 site, 1 glycan. DR GlyGen; O75131; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; O75131; -. DR MetOSite; O75131; -. DR PhosphoSitePlus; O75131; -. DR SwissPalm; O75131; -. DR BioMuta; CPNE3; -. DR jPOST; O75131; -. DR MassIVE; O75131; -. DR PaxDb; 9606-ENSP00000477590; -. DR PeptideAtlas; O75131; -. DR ProteomicsDB; 49793; -. DR Pumba; O75131; -. DR Antibodypedia; 25495; 163 antibodies from 29 providers. DR DNASU; 8895; -. DR Ensembl; ENST00000517490.6; ENSP00000477590.1; ENSG00000085719.14. DR GeneID; 8895; -. DR KEGG; hsa:8895; -. DR MANE-Select; ENST00000517490.6; ENSP00000477590.1; NM_003909.5; NP_003900.1. DR UCSC; uc033bsf.1; human. DR AGR; HGNC:2316; -. DR ClinPGx; PA26833; -. DR CTD; 8895; -. DR DisGeNET; 8895; -. DR GeneCards; CPNE3; -. DR HGNC; HGNC:2316; CPNE3. DR HPA; ENSG00000085719; Low tissue specificity. DR MIM; 604207; gene. DR OpenTargets; ENSG00000085719; -. DR VEuPathDB; HostDB:ENSG00000085719; -. DR eggNOG; KOG1327; Eukaryota. DR GeneTree; ENSGT00940000154968; -. DR HOGENOM; CLU_020452_3_2_1; -. DR InParanoid; O75131; -. DR OMA; EMAAQCV; -. DR OrthoDB; 5855668at2759; -. DR PAN-GO; O75131; 5 GO annotations based on evolutionary models. DR PhylomeDB; O75131; -. DR PathwayCommons; O75131; -. DR Reactome; R-HSA-1483206; Glycerophospholipid biosynthesis. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR SignaLink; O75131; -. DR Agora; ENSG00000085719; -. DR BioGRID-ORCS; 8895; 9 hits in 1158 CRISPR screens. DR ChiTaRS; CPNE3; human. DR GenomeRNAi; 8895; -. DR Pharos; O75131; Tbio. DR PRO; PR:O75131; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; O75131; protein. DR Bgee; ENSG00000085719; Expressed in tongue squamous epithelium and 211 other cell types or tissues. DR ExpressionAtlas; O75131; baseline and differential. DR GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome. DR GO; GO:0030054; C:cell junction; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IDA:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005544; F:calcium-dependent phospholipid binding; IDA:UniProtKB. DR GO; GO:0048306; F:calcium-dependent protein binding; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0005543; F:phospholipid binding; TAS:Reactome. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB. DR GO; GO:0038128; P:ERBB2 signaling pathway; IDA:UniProtKB. DR GO; GO:0046474; P:glycerophospholipid biosynthetic process; TAS:Reactome. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR CDD; cd04048; C2A_Copine; 1. DR CDD; cd04047; C2B_Copine; 1. DR CDD; cd01459; vWA_copine_like; 1. DR FunFam; 2.60.40.150:FF:000042; Copine 3; 1. DR FunFam; 2.60.40.150:FF:000099; Copine 3; 1. DR Gene3D; 2.60.40.150; C2 domain; 2. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR037768; C2B_Copine. DR InterPro; IPR045052; Copine. DR InterPro; IPR010734; Copine_C. DR InterPro; IPR002035; VWF_A. DR InterPro; IPR036465; vWFA_dom_sf. DR PANTHER; PTHR10857; COPINE; 1. DR PANTHER; PTHR10857:SF22; COPINE-3; 1. DR Pfam; PF00168; C2; 2. DR Pfam; PF07002; Copine; 1. DR SMART; SM00239; C2; 2. DR SMART; SM00327; VWA; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 2. DR SUPFAM; SSF53300; vWA-like; 1. DR PROSITE; PS50004; C2; 2. PE 1: Evidence at protein level; KW Calcium; Cell junction; Cell membrane; Cytoplasm; KW Direct protein sequencing; Membrane; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat. FT CHAIN 1..537 FT /note="Copine-3" FT /id="PRO_0000144838" FT DOMAIN 1..115 FT /note="C2 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 124..247 FT /note="C2 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 291..513 FT /note="VWFA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00219" FT BINDING 22 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 22 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 28 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 81 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 81 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 83 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 83 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 93 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 154 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 154 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 160 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 216 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 216 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 218 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 218 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT BINDING 224 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 197 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 243 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 252 FT /note="E -> D (in dbSNP:rs41333046)" FT /id="VAR_048848" FT VARIANT 412 FT /note="T -> M (in dbSNP:rs2304789)" FT /evidence="ECO:0000269|PubMed:14702039" FT /id="VAR_024424" FT CONFLICT 394 FT /note="P -> Q (in Ref. 4; AAH36242)" FT /evidence="ECO:0000305" FT CONFLICT 419 FT /note="Q -> R (in Ref. 4; AAH36242)" FT /evidence="ECO:0000305" FT CONFLICT 475 FT /note="R -> H (in Ref. 4; AAH36242)" FT /evidence="ECO:0000305" SQ SEQUENCE 537 AA; 60131 MW; 91F2C5EAD611B842 CRC64; MAAQCVTKVA LNVSCANLLD KDIGSKSDPL CVLFLNTSGQ QWYEVERTER IKNCLNPQFS KTFIIDYYFE VVQKLKFGVY DIDNKTIELS DDDFLGECEC TLGQIVSSKK LTRPLVMKTG RPAGKGSITI SAEEIKDNRV VLFEMEARKL DNKDLFGKSD PYLEFHKQTS DGNWLMVHRT EVVKNNLNPV WRPFKISLNS LCYGDMDKTI KVECYDYDND GSHDLIGTFQ TTMTKLKEAS RSSPVEFECI NEKKRQKKKS YKNSGVISVK QCEITVECTF LDYIMGGCQL NFTVGVDFTG SNGDPRSPDS LHYISPNGVN EYLTALWSVG LVIQDYDADK MFPAFGFGAQ IPPQWQVSHE FPMNFNPSNP YCNGIQGIVE AYRSCLPQIK LYGPTNFSPI INHVARFAAA ATQQQTASQY FVLLIITDGV ITDLDETRQA IVNASRLPMS IIIVGVGGAD FSAMEFLDGD GGSLRSPLGE VAIRDIVQFV PFRQFQNAPK EALAQCVLAE IPQQVVGYFN TYKLLPPKNP ATKQQKQ // ID CTNB1_HUMAN Reviewed; 781 AA. AC P35222; A8K1L7; Q8NEW9; Q8NI94; Q9H391; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1994, sequence version 1. DT 28-JAN-2026, entry version 272. DE RecName: Full=Catenin beta-1 {ECO:0000312|HGNC:HGNC:2514}; DE AltName: Full=Beta-catenin {ECO:0000303|PubMed:7806582}; GN Name=CTNNB1 {ECO:0000312|HGNC:HGNC:2514}; Synonyms=CTNNB; GN ORFNames=OK/SW-cl.35, PRO2286; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta; RX PubMed=7806582; DOI=10.1083/jcb.127.6.2061; RA Huelsken J., Birchmeier W., Behrens J.; RT "E-cadherin and APC compete for the interaction with beta-catenin and the RT cytoskeleton."; RL J. Cell Biol. 127:2061-2069(1994). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Fetal liver; RA Zhang C., Yu Y., Zhang S., Wei H., Bi J., Zhou G., Dong C., Zai Y., Xu W., RA Gao F., Liu M., He F.; RT "Functional prediction of the coding sequences of 75 new genes deduced by RT analysis of cDNA clones from human fetal liver."; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-688. RG NIEHS SNPs program; RL Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Hippocampus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-312. RX PubMed=12019147; RA Kim J.-S., Crooks H., Dracheva T., Nishanian T.G., Singh B., Jen J., RA Waldman T.; RT "Oncogenic beta-catenin is required for bone morphogenetic protein 4 RT expression in human cancer cells."; RL Cancer Res. 62:2744-2748(2002). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 258-781. RC TISSUE=Colon adenocarcinoma; RA Shichijo S., Itoh K.; RT "Identification of immuno-peptidmics that are recognized by tumor-reactive RT CTL generated from TIL of colon cancer patients."; RL Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases. RN [10] RP IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9; RA Butz S., Kemler R.; RT "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell RT adhesion."; RL FEBS Lett. 355:195-200(1994). RN [11] RP CHROMOSOMAL TRANSLOCATION WITH PLAG1. RX PubMed=9020842; DOI=10.1038/ng0297-170; RA Kas K., Voz M.L., Roeijer E., Astroem A.-K., Meyen E., Stenman G., RA Van de Ven W.J.M.; RT "Promoter swapping between the genes for a novel zinc finger protein and RT beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) RT translocations."; RL Nat. Genet. 15:170-174(1997). RN [12] RP CHROMOSOMAL TRANSLOCATION WITH PLAG1. RX PubMed=10029085; RA Astroem A.-K., Voz M.L., Kas K., Roeijer E., Wedell B., Mandahl N., RA Van de Ven W., Mark J., Stenman G.; RT "Conserved mechanism of PLAG1 activation in salivary gland tumors with and RT without chromosome 8q12 abnormalities: identification of SII as a new RT fusion partner gene."; RL Cancer Res. 59:918-923(1999). RN [13] RP STIMULATION OF TYROSINE PHOSPHORYLATION BY EGF, AND DEPHOSPHORYLATION BY RP PTPRF. RX PubMed=10187801; DOI=10.1074/jbc.274.15.10173; RA Mueller T., Choidas A., Reichmann E., Ullrich A.; RT "Phosphorylation and free pool of beta-catenin are regulated by tyrosine RT kinases and tyrosine phosphatases during epithelial cell migration."; RL J. Biol. Chem. 274:10173-10183(1999). RN [14] RP SUBCELLULAR LOCATION. RX PubMed=10725230; DOI=10.1242/jcs.113.8.1481; RA Mariner D.J., Wang J., Reynolds A.B.; RT "ARVCF localizes to the nucleus and adherens junction and is mutually RT exclusive with p120(ctn) in E-cadherin complexes."; RL J. Cell Sci. 113:1481-1490(2000). RN [15] RP INTERACTION WITH LEF1; APC; AXIN1; AXIN2 AND TCF7L2, PHOSPHORYLATION BY RP GSK3B, AND MUTAGENESIS OF PHE-253; HIS-260; LYS-292; LYS-345; TRP-383; RP ARG-386; ASN-426; LYS-435; ARG-469; HIS-470 AND LYS-508. RX PubMed=10966653; DOI=10.1038/79039; RA von Kries J.P., Winbeck G., Asbrand C., Schwarz-Romond T., Sochnikova N., RA Dell'Oro A., Behrens J., Birchmeier W.; RT "Hot spots in beta-catenin for interactions with LEF-1, conductin and RT APC."; RL Nat. Struct. Biol. 7:800-807(2000). RN [16] RP TISSUE SPECIFICITY, AND VARIANT PTR TYR-32. RX PubMed=11703283; DOI=10.1046/j.1365-2133.2001.04455.x; RA Moreno-Bueno G., Gamallo C., Perez-Gallego L., Contreras F., Palacios J.; RT "Beta-catenin expression in pilomatrixomas. Relationship with beta-catenin RT gene mutations and comparison with beta-catenin expression in normal hair RT follicles."; RL Br. J. Dermatol. 145:576-581(2001). RN [17] RP INTERACTION WITH LEF1, AND INHIBITION BY CTNNBIP1 BINDING. RX PubMed=11751639; DOI=10.1101/gad.946501; RA Tutter A.V., Fryer C.J., Jones K.A.; RT "Chromatin-specific regulation of LEF-1-beta-catenin transcription RT activation and inhibition in vitro."; RL Genes Dev. 15:3342-3354(2001). RN [18] RP RETRACTED PAPER. RX PubMed=11279024; DOI=10.1074/jbc.m100194200; RA Piedra J., Martinez D., Castano J., Miravet S., Dunach M., RA de Herreros A.G.; RT "Regulation of beta-catenin structure and activity by tyrosine RT phosphorylation."; RL J. Biol. Chem. 276:20436-20443(2001). RN [19] RP INTERACTION WITH SPN/CD43 CYTOPLASMIC TAIL. RX PubMed=15003504; DOI=10.1016/j.bbrc.2004.02.011; RA Andersson C.X., Fernandez-Rodriguez J., Laos S., Sikut R., Sikut A., RA Baeckstroem D., Hansson G.C.; RT "CD43 has a functional NLS, interacts with beta-catenin, and affects gene RT expression."; RL Biochem. Biophys. Res. Commun. 316:12-17(2004). RN [20] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=21118991; DOI=10.1091/mbc.e10-05-0440; RA Hay-Koren A., Caspi M., Zilberberg A., Rosin-Arbesfeld R.; RT "The EDD E3 ubiquitin ligase ubiquitinates and up-regulates beta-catenin."; RL Mol. Biol. Cell 22:399-411(2011). RN [21] RP RETRACTION NOTICE OF PUBMED:11279024. RX PubMed=27226643; DOI=10.1074/jbc.a116.100194; RA Piedra J., Martinez D., Castano J., Miravet S., Dunach M., RA de Herreros A.G.; RL J. Biol. Chem. 291:11463-11463(2016). RN [22] RP INTERACTION WITH CTNNA3. RX PubMed=11590244; DOI=10.1242/jcs.114.17.3177; RA Janssens B., Goossens S., Staes K., Gilbert B., van Hengel J., Colpaert C., RA Bruyneel E., Mareel M., van Roy F.; RT "AlphaT-catenin: a novel tissue-specific beta-catenin-binding protein RT mediating strong cell-cell adhesion."; RL J. Cell Sci. 114:3177-3188(2001). RN [23] RP INTERACTION WITH SIAH1, AND UBIQUITINATION. RX PubMed=11389839; DOI=10.1016/s1097-2765(01)00242-8; RA Matsuzawa S., Reed J.C.; RT "Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin RT degradation linked to p53 responses."; RL Mol. Cell 7:915-926(2001). RN [24] RP INTERACTION WITH SIAH1, AND UBIQUITINATION. RX PubMed=11389840; DOI=10.1016/s1097-2765(01)00241-6; RA Liu J., Stevens J., Rote C.A., Yost H.J., Hu Y., Neufeld K.L., White R.L., RA Matsunami N.; RT "Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to RT the adenomatous polyposis coli protein."; RL Mol. Cell 7:927-936(2001). RN [25] RP INVOLVEMENT IN MESOM. RX PubMed=11464291; DOI=10.1038/sj.onc.1204557; RA Shigemitsu K., Sekido Y., Usami N., Mori S., Sato M., Horio Y., RA Hasegawa Y., Bader S.A., Gazdar A.F., Minna J.D., Hida T., Yoshioka H., RA Imaizumi M., Ueda Y., Takahashi M., Shimokata K.; RT "Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer RT and malignant mesothelioma and identification of a new 3p21.3 homozygous RT deletion."; RL Oncogene 20:4249-4257(2001). RN [26] RP INTERACTION WITH PTPRU. RX PubMed=12501215; DOI=10.1021/bi026095u; RA Yan H.-X., He Y.-Q., Dong H., Zhang P., Zeng J.-Z., Cao H.-F., Wu M.-C., RA Wang H.-Y.; RT "Physical and functional interaction between receptor-like protein tyrosine RT phosphatase PCP-2 and beta-catenin."; RL Biochemistry 41:15854-15860(2002). RN [27] RP PHOSPHORYLATION AT SER-45, CHARACTERIZATION OF VARIANT HEPATOCELLULAR RP CARCINOMA ALA-41, CHARACTERIZATION OF VARIANT DESMOID TUMOR ALA-41, AND RP CHARACTERIZATION OF VARIANT HEPATOBLASTOMA ALA-41. RX PubMed=12051714; DOI=10.1016/s0006-291x(02)00485-0; RA Hagen T., Vidal-Puig A.; RT "Characterisation of the phosphorylation of beta-catenin at the GSK-3 RT priming site Ser45."; RL Biochem. Biophys. Res. Commun. 294:324-328(2002). RN [28] RP INTERACTION WITH CXADR. RX PubMed=12297051; DOI=10.1016/s0092-8674(02)00912-1; RA Walters R.W., Freimuth P., Moninger T.O., Ganske I., Zabner J., Welsh M.J.; RT "Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing RT virus escape."; RL Cell 110:789-799(2002). RN [29] RP PHOSPHORYLATION AT SER-23 AND SER-29 BY GSK3B, PHOSPHORYLATION AT THR-41, RP MUTAGENESIS OF SER-29, CHARACTERIZATION OF VARIANTS HEPATOCELLULAR RP CARCINOMA ARG-23; ALA-37 AND ALA-41, CHARACTERIZATION OF VARIANT PTR RP TYR-33, CHARACTERIZATION OF VARIANT MDB ALA-37, CHARACTERIZATION OF VARIANT RP DESMOID TUMOR ALA-41, AND CHARACTERIZATION OF VARIANT HEPATOBLASTOMA RP ALA-41. RX PubMed=12027456; DOI=10.1006/excr.2002.5520; RA van Noort M., van de Wetering M., Clevers H.; RT "Identification of two novel regulated serines in the N-terminus of beta- RT catenin."; RL Exp. Cell Res. 276:264-272(2002). RN [30] RP INTERACTION WITH CDH1 AND PKP2, AND SUBCELLULAR LOCATION. RX PubMed=11790773; DOI=10.1074/jbc.m108765200; RA Chen X., Bonne S., Hatzfeld M., van Roy F., Green K.J.; RT "Protein binding and functional characterization of plakophilin 2. Evidence RT for its diverse roles in desmosomes and beta -catenin signaling."; RL J. Biol. Chem. 277:10512-10522(2002). RN [31] RP WNT SIGNALING MODULATES PHOSPHORYLATION. RX PubMed=11834740; DOI=10.1074/jbc.m111635200; RA van Noort M., Meeldijk J., van der Zee R., Destree O., Clevers H.; RT "Wnt signaling controls the phosphorylation status of beta-catenin."; RL J. Biol. Chem. 277:17901-17905(2002). RN [32] RP PHOSPHORYLATION, AND INTERACTION OF PHOSPHORYLATED CTNNB1 WITH BTRC. RX PubMed=12077367; DOI=10.1242/jcs.115.13.2771; RA Sadot E., Conacci-Sorrell M., Zhurinsky J., Shnizer D., Lando Z., RA Zharhary D., Kam Z., Ben-Ze'ev A., Geiger B.; RT "Regulation of S33/S37 phosphorylated beta-catenin in normal and RT transformed cells."; RL J. Cell Sci. 115:2771-2780(2002). RN [33] RP INTERACTION WITH PTPRJ. RX PubMed=12370829; DOI=10.1038/sj.onc.1205858; RA Holsinger L.J., Ward K., Duffield B., Zachwieja J., Jallal B.; RT "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts RT with p120(ctn)."; RL Oncogene 21:7067-7076(2002). RN [34] RP INTERACTION WITH PCDH11Y. RX PubMed=12420223; DOI=10.1038/sj.onc.1205991; RA Chen M.-W., Vacherot F., De La Taille A., Gil-Diez-De-Medina S., Shen R., RA Friedman R.A., Burchardt M., Chopin D.K., Buttyan R.; RT "The emergence of protocadherin-PC expression during the acquisition of RT apoptosis-resistance by prostate cancer cells."; RL Oncogene 21:7861-7871(2002). RN [35] RP INTERACTION WITH NHERF1. RX PubMed=12830000; DOI=10.1053/jhep.2003.50270; RA Shibata T., Chuma M., Kokubu A., Sakamoto M., Hirohashi S.; RT "EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is RT over-expressed in hepatocellular carcinoma."; RL Hepatology 38:178-186(2003). RN [36] RP REVIEW. RX PubMed=10679188; DOI=10.1006/bbrc.1999.1860; RA Kikuchi A.; RT "Regulation of beta-catenin signaling in the Wnt pathway."; RL Biochem. Biophys. Res. Commun. 268:243-248(2000). RN [37] RP PHOSPHORYLATION AT TYR-142 BY FYN. RX PubMed=12640114; DOI=10.1128/mcb.23.7.2287-2297.2003; RA Piedra J., Miravet S., Castano J., Palmer H.G., Heisterkamp N., RA Garcia de Herreros A., Dunach M.; RT "p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin RT Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction."; RL Mol. Cell. Biol. 23:2287-2297(2003). RN [38] RP INTERACTION WITH CBY1. RX PubMed=12712206; DOI=10.1038/nature01570; RA Takemaru K., Yamaguchi S., Lee Y.S., Zhang Y., Carthew R.W., Moon R.T.; RT "Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless RT pathway."; RL Nature 422:905-909(2003). RN [39] RP INTERACTION WITH AJAP1. RC TISSUE=Brain; RX PubMed=14595118; DOI=10.1091/mbc.e03-05-0281; RA Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A., RA Baumann R., Starzinski-Powitz A.; RT "Novel membrane protein shrew-1 targets to cadherin-mediated junctions in RT polarized epithelial cells."; RL Mol. Biol. Cell 15:397-406(2004). RN [40] RP INTERACTION WITH CBY1, AND SUBCELLULAR LOCATION. RX PubMed=16424001; DOI=10.1158/0008-5472.can-05-3124; RA Jung Y., Bang S., Choi K., Kim E., Kim Y., Kim J., Park J., Koo H., RA Moon R.T., Song K., Lee I.; RT "TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving RT antagonistic activity of Chibby."; RL Cancer Res. 66:723-728(2006). RN [41] RP SUBCELLULAR LOCATION, AND INTERACTION WITH NANOS1. RX PubMed=17047063; DOI=10.1158/0008-5472.can-05-3096; RA Strumane K., Bonnomet A., Stove C., Vandenbroucke R., Nawrocki-Raby B., RA Bruyneel E., Mareel M., Birembaut P., Berx G., van Roy F.; RT "E-cadherin regulates human Nanos1, which interacts with p120ctn and RT induces tumor cell migration and invasion."; RL Cancer Res. 66:10007-10015(2006). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-675, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [43] RP SUBCELLULAR LOCATION, AND INTERACTION WITH EMD. RX PubMed=16858403; DOI=10.1038/sj.emboj.7601230; RA Markiewicz E., Tilgner K., Barker N., van de Wetering M., Clevers H., RA Dorobek M., Hausmanowa-Petrusewicz I., Ramaekers F.C.S., Broers J.L.V., RA Blankesteijn W.M., Salpingidou G., Wilson R.G., Ellis J.A., Hutchison C.J.; RT "The inner nuclear membrane protein emerin regulates beta-catenin activity RT by restricting its accumulation in the nucleus."; RL EMBO J. 25:3275-3285(2006). RN [44] RP INTERACTION WITH MUC1, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17524503; DOI=10.1016/j.bbamcr.2007.04.009; RA Lillehoj E.P., Lu W., Kiser T., Goldblum S.E., Kim K.C.; RT "MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism."; RL Biochim. Biophys. Acta 1773:1028-1038(2007). RN [45] RP INTERACTION WITH GLIS2, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=17289029; DOI=10.1016/j.febslet.2007.01.058; RA Kim Y.-S., Kang H.S., Jetten A.M.; RT "The Kruppel-like zinc finger protein Glis2 functions as a negative RT modulator of the Wnt/beta-catenin signaling pathway."; RL FEBS Lett. 581:858-864(2007). RN [46] RP PHOSPHORYLATION AT SER-191 AND SER-246, INTERACTION WITH CDK5, SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17009320; DOI=10.1002/jcb.21041; RA Munoz J.P., Huichalaf C.H., Orellana D., Maccioni R.B.; RT "cdk5 modulates beta- and delta-catenin/Pin1 interactions in neuronal RT cells."; RL J. Cell. Biochem. 100:738-749(2007). RN [47] RP INTERACTION WITH FHIT, IDENTIFICATION IN A COMPLEX WITH LEF1, AND FUNCTION. RX PubMed=18077326; DOI=10.1073/pnas.0703664105; RA Weiske J., Albring K.F., Huber O.; RT "The tumor suppressor Fhit acts as a repressor of beta-catenin RT transcriptional activity."; RL Proc. Natl. Acad. Sci. U.S.A. 104:20344-20349(2007). RN [48] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH NEK2. RX PubMed=18086858; DOI=10.1101/gad.1596308; RA Bahmanyar S., Kaplan D.D., Deluca J.G., Giddings T.H. Jr., O'Toole E.T., RA Winey M., Salmon E.D., Casey P.J., Nelson W.J., Barth A.I.; RT "beta-Catenin is a Nek2 substrate involved in centrosome separation."; RL Genes Dev. 22:91-105(2008). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-556 AND SER-675, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [50] RP INTERACTION WITH SOX7. RX PubMed=18819930; DOI=10.1158/1541-7786.mcr-07-2175; RA Guo L., Zhong D., Lau S., Liu X., Dong X.Y., Sun X., Yang V.W., RA Vertino P.M., Moreno C.S., Varma V., Dong J.T., Zhou W.; RT "Sox7 Is an independent checkpoint for beta-catenin function in prostate RT and colon epithelial cells."; RL Mol. Cancer Res. 6:1421-1430(2008). RN [51] RP INTERACTION WITH CHD8. RX PubMed=18378692; DOI=10.1128/mcb.00322-08; RA Thompson B.A., Tremblay V., Lin G., Bochar D.A.; RT "CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta- RT catenin target genes."; RL Mol. Cell. Biol. 28:3894-3904(2008). RN [52] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [53] RP INTERACTION WITH CBY1. RX PubMed=19435523; DOI=10.1186/1471-2199-10-41; RA Mofunanya A., Li F.Q., Hsieh J.C., Takemaru K.; RT "Chibby forms a homodimer through a heptad repeat of leucine residues in RT its C-terminal coiled-coil motif."; RL BMC Mol. Biol. 10:41-41(2009). RN [54] RP INTERACTION WITH TCF7L2 AND TNIK. RX PubMed=19816403; DOI=10.1038/emboj.2009.285; RA Mahmoudi T., Li V.S.W., Ng S.S., Taouatas N., Vries R.G.J., Mohammed S., RA Heck A.J., Clevers H.; RT "The kinase TNIK is an essential activator of Wnt target genes."; RL EMBO J. 28:3329-3340(2009). RN [55] RP FUNCTION. RX PubMed=18957423; DOI=10.1074/jbc.m805612200; RA Li H., Ray G., Yoo B.H., Erdogan M., Rosen K.V.; RT "Down-regulation of death-associated protein kinase-2 is required for beta- RT catenin-induced anoikis resistance of malignant epithelial cells."; RL J. Biol. Chem. 284:2012-2022(2009). RN [56] RP INTERACTION WITH RUVBL2; APPL2; APPL1; HDAC1 AND HDAC2. RX PubMed=19433865; DOI=10.1074/jbc.m109.007237; RA Rashid S., Pilecka I., Torun A., Olchowik M., Bielinska B., Miaczynska M.; RT "Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta- RT catenin/TCF-mediated transcription."; RL J. Biol. Chem. 284:18115-18128(2009). RN [57] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [58] RP PHOSPHORYLATION AT SER-33 AND SER-37 BY HIPK2, AND UBIQUITINATION. RX PubMed=20307497; DOI=10.1016/j.bbrc.2010.03.099; RA Kim E.-A., Kim J.E., Sung K.S., Choi D.W., Lee B.J., Choi C.Y.; RT "Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for RT phosphorylation and proteasomal degradation."; RL Biochem. Biophys. Res. Commun. 394:966-971(2010). RN [59] RP INTERACTION WITH SESTD1. RX PubMed=20164195; DOI=10.1074/jbc.m109.068304; RA Miehe S., Bieberstein A., Arnould I., Ihdene O., Rutten H., Strubing C.; RT "The phospholipid-binding protein SESTD1 is a novel regulator of the RT transient receptor potential channels TRPC4 and TRPC5."; RL J. Biol. Chem. 285:12426-12434(2010). RN [60] RP INTERACTION WITH TRPC4. RX PubMed=19996314; DOI=10.1074/jbc.m109.060301; RA Graziani A., Poteser M., Heupel W.M., Schleifer H., Krenn M., RA Drenckhahn D., Romanin C., Baumgartner W., Groschner K.; RT "Cell-cell contact formation governs Ca2+ signaling by TRPC4 in the RT vascular endothelium: evidence for a regulatory TRPC4-beta-catenin RT interaction."; RL J. Biol. Chem. 285:4213-4223(2010). RN [61] RP INTERACTION WITH CDK5. RX PubMed=19693690; DOI=10.1007/s11033-009-9752-7; RA Li Q., Liu X., Zhang M., Ye G., Qiao Q., Ling Y., Wu Y., Zhang Y., Yu L.; RT "Characterization of a novel human CDK5 splicing variant that inhibits RT Wnt/beta-catenin signaling."; RL Mol. Biol. Rep. 37:2415-2421(2010). RN [62] RP PHOSPHORYLATION AT TYR-64; TYR-142; TYR-331 AND TYR-333, INTERACTION WITH RP PTK6, AND MUTAGENESIS OF TYR-64. RX PubMed=20026641; DOI=10.1242/jcs.053264; RA Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., RA Tyner A.L.; RT "Identification of beta-catenin as a target of the intracellular tyrosine RT kinase PTK6."; RL J. Cell Sci. 123:236-245(2010). RN [63] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-675, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [64] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [65] RP FUNCTION IN INSULIN INTERNALIZATION, SUBCELLULAR LOCATION, INTERACTION WITH RP CDK2, AND PHOSPHORYLATION BY CDK2. RX PubMed=21262353; DOI=10.1016/j.cellsig.2011.01.019; RA Fiset A., Xu E., Bergeron S., Marette A., Pelletier G., Siminovitch K.A., RA Olivier M., Beauchemin N., Faure R.L.; RT "Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and RT regulates insulin internalization."; RL Cell. Signal. 23:911-919(2011). RN [66] RP INTERACTION WITH PKT7. RX PubMed=21132015; DOI=10.1038/embor.2010.185; RA Puppo F., Thome V., Lhoumeau A.-C., Cibois M., Gangar A., Lembo F., RA Belotti E., Marchetto S., Lecine P., Prebet T., Sebbagh M., Shin W.-S., RA Lee S.-T., Kodjabachian L., Borg J.-P.; RT "Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin RT canonical signalling."; RL EMBO Rep. 12:43-49(2011). RN [67] RP INTERACTION WITH NDRG2. RX PubMed=21247902; DOI=10.1074/jbc.m110.170803; RA Hwang J., Kim Y., Kang H.B., Jaroszewski L., Deacon A.M., Lee H., RA Choi W.C., Kim K.J., Kim C.H., Kang B.S., Lee J.O., Oh T.K., Kim J.W., RA Wilson I.A., Kim M.H.; RT "Crystal structure of the human N-Myc downstream-regulated gene 2 protein RT provides insight into its role as a tumor suppressor."; RL J. Biol. Chem. 286:12450-12460(2011). RN [68] RP INTERACTION WITH PKM ISOFORM M2, PHOSPHORYLATION AT TYR-333, AND RP MUTAGENESIS OF TYR-333. RX PubMed=22056988; DOI=10.1038/nature10598; RA Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., Gao X., Aldape K., RA Lu Z.; RT "Nuclear PKM2 regulates beta-catenin transactivation upon EGFR RT activation."; RL Nature 480:118-122(2011). RN [69] RP INTERACTION WITH AHI1. RX PubMed=21623382; DOI=10.1038/nm.2380; RA Lancaster M.A., Gopal D.J., Kim J., Saleem S.N., Silhavy J.L., Louie C.M., RA Thacker B.E., Williams Y., Zaki M.S., Gleeson J.G.; RT "Defective Wnt-dependent cerebellar midline fusion in a mouse model of RT Joubert syndrome."; RL Nat. Med. 17:726-731(2011). RN [70] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191 AND SER-552, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [71] RP IDENTIFICATION IN A COMPLEX WITH HINT1 AND MITF, AND FUNCTION. RX PubMed=22647378; DOI=10.4161/cc.20765; RA Genovese G., Ghosh P., Li H., Rettino A., Sioletic S., Cittadini A., RA Sgambato A.; RT "The tumor suppressor HINT1 regulates MITF and beta-catenin transcriptional RT activity in melanoma cells."; RL Cell Cycle 11:2206-2215(2012). RN [72] RP FUNCTION, INTERACTION WITH FERMT2, IDENTIFICATION IN A COMPLEX WITH FERMT2 RP AND TCF7L2, AND SUBCELLULAR LOCATION. RX PubMed=22699938; DOI=10.1038/embor.2012.88; RA Yu Y., Wu J., Wang Y., Zhao T., Ma B., Liu Y., Fang W., Zhu W.G., Zhang H.; RT "Kindlin 2 forms a transcriptional complex with beta-catenin and TCF4 to RT enhance Wnt signalling."; RL EMBO Rep. 13:750-758(2012). RN [73] RP FUNCTION, AND INTERACTION WITH PML. RX PubMed=22155184; DOI=10.1053/j.gastro.2011.11.041; RA Satow R., Shitashige M., Jigami T., Fukami K., Honda K., Kitabayashi I., RA Yamada T.; RT "Beta-catenin inhibits promyelocytic leukemia protein tumor suppressor RT function in colorectal cancer cells."; RL Gastroenterology 142:572-581(2012). RN [74] RP SUBCELLULAR LOCATION. RX PubMed=22294297; DOI=10.1002/path.3982; RA Tsang S.M., Brown L., Lin K., Liu L., Piper K., O'Toole E.A., Grose R., RA Hart I.R., Garrod D.R., Fortune F., Wan H.; RT "Non-junctional human desmoglein 3 acts as an upstream regulator of Src in RT E-cadherin adhesion, a pathway possibly involved in the pathogenesis of RT pemphigus vulgaris."; RL J. Pathol. 227:81-93(2012). RN [75] RP INVOLVEMENT IN NEDSDV. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [76] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [77] RP SUBCELLULAR LOCATION, AND INTERACTION WITH FAM53B. RX PubMed=25183871; DOI=10.1242/dev.108415; RA Kizil C., Kuechler B., Yan J.J., Oezhan G., Moro E., Argenton F., Brand M., RA Weidinger G., Antos C.L.; RT "Simplet/Fam53b is required for Wnt signal transduction by regulating beta- RT catenin nuclear localization."; RL Development 141:3529-3539(2014). RN [78] RP GLYCOSYLATION AT SER-23, AND SUBCELLULAR LOCATION. RX PubMed=24342833; DOI=10.1016/j.yexcr.2013.11.021; RA Ha J.R., Hao L., Venkateswaran G., Huang Y.H., Garcia E., Persad S.; RT "beta-catenin is O-GlcNAc glycosylated at Serine 23: implications for beta- RT catenin's subcellular localization and transactivator function."; RL Exp. Cell Res. 321:153-166(2014). RN [79] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191 AND SER-552, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [80] RP INTERACTION WITH RNF220. RX PubMed=25266658; DOI=10.1128/mcb.00731-14; RA Ma P., Yang X., Kong Q., Li C., Yang S., Li Y., Mao B.; RT "The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7- RT mediated deubiquitination of beta-catenin."; RL Mol. Cell. Biol. 34:4355-4366(2014). RN [81] RP ACETYLATION AT LYS-49, AND DEACETYLATION. RX PubMed=24824780; DOI=10.1002/ijc.28967; RA Pangon L., Mladenova D., Watkins L., Van Kralingen C., Currey N., RA Al-Sohaily S., Lecine P., Borg J.P., Kohonen-Corish M.R.; RT "MCC inhibits beta-catenin transcriptional activity by sequestering DBC1 in RT the cytoplasm."; RL Int. J. Cancer 136:55-64(2015). RN [82] RP INTERACTION WITH JPT1, AND PHOSPHORYLATION AT SER-33. RX PubMed=25169422; DOI=10.1002/jcb.24956; RA Varisli L., Ozturk B.E., Akyuz G.K., Korkmaz K.S.; RT "HN1 negatively influences the beta-catenin/E-cadherin interaction, and RT contributes to migration in prostate cells."; RL J. Cell. Biochem. 116:170-178(2015). RN [83] RP INTERACTION WITH CTNND2. RX PubMed=25807484; DOI=10.1038/nature14186; RA Turner T.N., Sharma K., Oh E.C., Liu Y.P., Collins R.L., Sosa M.X., RA Auer D.R., Brand H., Sanders S.J., Moreno-De-Luca D., Pihur V., Plona T., RA Pike K., Soppet D.R., Smith M.W., Cheung S.W., Martin C.L., State M.W., RA Talkowski M.E., Cook E., Huganir R., Katsanis N., Chakravarti A.; RT "Loss of delta-catenin function in severe autism."; RL Nature 520:51-56(2015). RN [84] RP INTERACTION WITH GID8; AXIN1 AND TCF7L2, AND SUBCELLULAR LOCATION. RX PubMed=28829046; DOI=10.1038/cr.2017.107; RA Lu Y., Xie S., Zhang W., Zhang C., Gao C., Sun Q., Cai Y., Xu Z., Xiao M., RA Xu Y., Huang X., Wu X., Liu W., Wang F., Kang Y., Zhou T.; RT "Twa1/Gid8 is a beta-catenin nuclear retention factor in Wnt signaling and RT colorectal tumorigenesis."; RL Cell Res. 27:1422-1440(2017). RN [85] RP IDENTIFICATION IN A CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=28051089; DOI=10.1038/mi.2016.120; RA Caldwell J.M., Collins M.H., Kemme K.A., Sherrill J.D., Wen T., Rochman M., RA Stucke E.M., Amin L., Tai H., Putnam P.E., Jimenez-Dalmaroni M.J., RA Wormald M.R., Porollo A., Abonia J.P., Rothenberg M.E.; RT "Cadherin 26 is an alpha integrin-binding epithelial receptor regulated RT during allergic inflammation."; RL Mucosal Immunol. 10:1190-1201(2017). RN [86] RP INTERACTION WITH TCF7L2/TCF4 AND HERPES VIRUS 8 PROTEIN VPK (MICROBIAL RP INFECTION). RX PubMed=29432739; DOI=10.1016/j.bbrc.2018.02.089; RA Cha S., Kang M.S., Seo T.; RT "KSHV vPK inhibits Wnt signaling via preventing interactions between beta- RT catenin and TCF4."; RL Biochem. Biophys. Res. Commun. 497:381-387(2018). RN [87] RP SUBCELLULAR LOCATION, INTERACTION WITH TMEM170B, AND TISSUE SPECIFICITY. RX PubMed=29367600; DOI=10.1038/s41419-017-0128-y; RA Li M., Han Y., Zhou H., Li X., Lin C., Zhang E., Chi X., Hu J., Xu H.; RT "Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene RT that inhibits the Wnt/beta-catenin pathway."; RL Cell Death Dis. 9:91-91(2018). RN [88] RP INVOLVEMENT IN EVR7, AND VARIANT EVR7 CYS-710. RX PubMed=28575650; DOI=10.1016/j.ajhg.2017.05.001; RA Panagiotou E.S., Sanjurjo Soriano C., Poulter J.A., Lord E.C., Dzulova D., RA Kondo H., Hiyoshi A., Chung B.H., Chu Y.W., Lai C.H.Y., Tafoya M.E., RA Karjosukarso D., Collin R.W.J., Topping J., Downey L.M., Ali M., RA Inglehearn C.F., Toomes C.; RT "Defects in the cell signaling mediator beta-catenin cause the retinal RT vascular condition FEVR."; RL Am. J. Hum. Genet. 100:960-968(2017). RN [89] RP INTERACTION WITH IRF2BPL, AND VARIANT TYR-33. RX PubMed=29374064; DOI=10.1158/0008-5472.can-17-2403; RA Higashimori A., Dong Y., Zhang Y., Kang W., Nakatsu G., Ng S.S.M., RA Arakawa T., Sung J.J.Y., Chan F.K.L., Yu J.; RT "Forkhead Box F2 Suppresses Gastric Cancer through a Novel FOXF2-IRF2BPL- RT beta-Catenin Signaling Axis."; RL Cancer Res. 78:1643-1656(2018). RN [90] RP INTERACTION WITH SOX30 AND TCF7L2, AND SUBCELLULAR LOCATION. RX PubMed=29739711; DOI=10.1016/j.ebiom.2018.04.026; RA Han F., Liu W.B., Shi X.Y., Yang J.T., Zhang X., Li Z.M., Jiang X., Yin L., RA Li J.J., Huang C.S., Cao J., Liu J.Y.; RT "SOX30 Inhibits Tumor Metastasis through Attenuating Wnt-Signaling via RT Transcriptional and Posttranslational Regulation of beta-Catenin in Lung RT Cancer."; RL EBioMedicine 31:253-266(2018). RN [91] RP INTERACTION WITH FLYWCH1. RX PubMed=30097457; DOI=10.1158/1541-7786.mcr-18-0262; RA Muhammad B.A., Almozyan S., Babaei-Jadidi R., Onyido E.K., Saadeddin A., RA Kashfi S.H., Spencer-Dene B., Ilyas M., Lourdusamy A., Behrens A., RA Nateri A.S.; RT "FLYWCH1, a Novel Suppressor of Nuclear beta-Catenin, Regulates Migration RT and Morphology in Colorectal Cancer."; RL Mol. Cancer Res. 16:1977-1990(2018). RN [92] RP FUNCTION, INTERACTION WITH DSG2, AND SUBCELLULAR LOCATION. RX PubMed=29910125; DOI=10.1016/j.stemcr.2018.05.009; RA Park J., Son Y., Lee N.G., Lee K., Lee D.G., Song J., Lee J., Kim S., RA Cho M.J., Jang J.H., Lee J., Park J.G., Kim Y.G., Kim J.S., Lee J., RA Cho Y.S., Park Y.J., Han B.S., Bae K.H., Han S., Kang B., Haam S., RA Lee S.H., Lee S.C., Min J.K.; RT "DSG2 Is a Functional Cell Surface Marker for Identification and Isolation RT of Human Pluripotent Stem Cells."; RL Stem Cell Reports 11:115-127(2018). RN [93] RP INTERACTION WITH FBXO16, SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=30714168; DOI=10.1002/path.5252; RA Paul D., Islam S., Manne R.K., Dinesh U.S., Malonia S.K., Maity B., RA Boppana R., Rapole S., Shetty P.K., Santra M.K.; RT "F-box protein FBXO16 functions as a tumor suppressor by attenuating RT nuclear beta-catenin function."; RL J. Pathol. 248:266-279(2019). RN [94] RP INTERACTION WITH LMBR1L. RX PubMed=31073040; DOI=10.1126/science.aau0812; RA Choi J.H., Zhong X., McAlpine W., Liao T.C., Zhang D., Fang B., Russell J., RA Ludwig S., Nair-Gill E., Zhang Z., Wang K.W., Misawa T., Zhan X., Choi M., RA Wang T., Li X., Tang M., Sun Q., Yu L., Murray A.R., Moresco E.M.Y., RA Beutler B.; RT "LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling."; RL Science 364:0-0(2019). RN [95] RP PHOSPHORYLATION AT THR-556 (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION. RX PubMed=31801859; DOI=10.1128/jvi.01847-19; RA You H., Lin Y., Lin F., Yang M., Li J., Zhang R., Huang Z., Shen Q., RA Tang R., Zheng C.; RT "beta-Catenin Is Required for the cGAS/STING Signaling Pathway but RT Antagonized by the Herpes Simplex Virus 1 US3 Protein."; RL J. Virol. 94:0-0(2020). RN [96] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 133-664. RX PubMed=11136974; DOI=10.1016/s0092-8674(00)00192-6; RA Graham T.A., Weaver C., Mao F., Kimelman D., Xu W.; RT "Crystal structure of a beta-catenin/Tcf complex."; RL Cell 103:885-896(2000). RN [97] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 134-664 IN COMPLEX WITH TCF7L2, RP AND MUTAGENESIS OF LYS-312 AND LYS-435. RX PubMed=11713475; DOI=10.1038/nsb718; RA Graham T.A., Ferkey D.M., Mao F., Kimelman D., Xu W.; RT "Tcf4 can specifically recognize beta-catenin using alternative RT conformations."; RL Nat. Struct. Biol. 8:1048-1052(2001). RN [98] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 134-668 IN COMPLEX WITH TCF7L2. RX PubMed=11713476; DOI=10.1038/nsb720; RA Poy F., Lepourcelet M., Shivdasani R.A., Eck M.J.; RT "Structure of a human Tcf4-beta-catenin complex."; RL Nat. Struct. Biol. 8:1053-1057(2001). RN [99] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 134-664 IN COMPLEX WITH CTNNBIP1, RP AND MUTAGENESIS OF PHE-660 AND ARG-661. RX PubMed=12408824; DOI=10.1016/s1097-2765(02)00637-8; RA Graham T.A., Clements W.K., Kimelman D., Xu W.; RT "The crystal structure of the beta-catenin/ICAT complex reveals the RT inhibitory mechanism of ICAT."; RL Mol. Cell 10:563-571(2002). RN [100] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1-136 IN COMPLEX WITH BCL9 AND RP TCF7L2, INTERACTION WITH BCL9; BCL9L CDH3 AND TCF7L2, AND MUTAGENESIS OF RP TYR-142; LEU-156; LEU-159 AND LEU-178. RX PubMed=17052462; DOI=10.1016/j.molcel.2006.09.001; RA Sampietro J., Dahlberg C.L., Cho U.S., Hinds T.R., Kimelman D., Xu W.; RT "Crystal structure of a beta-catenin/BCL9/Tcf4 complex."; RL Mol. Cell 24:293-300(2006). RN [101] {ECO:0007744|PDB:3TX7} RP X-RAY CRYSTALLOGRAPHY (2.76 ANGSTROMS) OF 183-663 COMPLEX WITH NR5A2, RP FUNCTION, AND INTERACTION WITH NR5A2. RX PubMed=22187462; DOI=10.1073/pnas.1117036108; RA Yumoto F., Nguyen P., Sablin E.P., Baxter J.D., Webb P., Fletterick R.J.; RT "Structural basis of coactivation of liver receptor homolog-1 by beta- RT catenin."; RL Proc. Natl. Acad. Sci. U.S.A. 109:143-148(2012). RN [102] RP VARIANTS COLORECTAL CANCER TYR-33 AND SER-45 DEL. RX PubMed=9065402; DOI=10.1126/science.275.5307.1787; RA Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., RA Kinzler K.W.; RT "Activation of beta-catenin-Tcf signaling in colon cancer by mutations in RT beta-catenin or APC."; RL Science 275:1787-1790(1997). RN [103] RP VARIANTS HEPATOBLASTOMA TYR-32; VAL-34; CYS-37 AND ALA-41. RX PubMed=9927029; RA Koch A., Denkhaus D., Albrecht S., Leuschner I., von Schweinitz D., RA Pietsch T.; RT "Childhood hepatoblastomas frequently carry a mutated degradation targeting RT box of the beta-catenin gene."; RL Cancer Res. 59:269-273(1999). RN [104] RP VARIANT HEPATOBLASTOMA ALA-41. RX PubMed=10398436; RX DOI=10.1002/(sici)1098-2264(199908)25:4<399::aid-gcc14>3.3.co;2-o; RA Blaeker H., Hofmann W.J., Rieker R.J., Penzel R., Graf M., Otto H.F.; RT "Beta-catenin accumulation and mutation of the CTNNB1 gene in RT hepatoblastoma."; RL Genes Chromosomes Cancer 25:399-402(1999). RN [105] RP VARIANTS OVARIAN CANCER CYS-37; ILE-41 AND ALA-41. RX PubMed=10391090; DOI=10.1111/j.1349-7006.1999.tb00777.x; RA Sagae S., Kobayashi K., Nishioka Y., Sugimura M., Ishioka S., Nagata M., RA Terasawa K., Tokino T., Kudo R.; RT "Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: RT frequent mutations in endometrioid carcinomas."; RL Jpn. J. Cancer Res. 90:510-515(1999). RN [106] RP VARIANT DESMOID TUMOR ALA-41. RX PubMed=10655994; DOI=10.1136/jcp.52.9.695; RA Shitoh K., Konishi F., Iijima T., Ohdaira T., Sakai K., Kanazawa K., RA Miyaki M.; RT "A novel case of a sporadic desmoid tumour with mutation of the beta RT catenin gene."; RL J. Clin. Pathol. 52:695-696(1999). RN [107] RP VARIANTS PTR GLY-32; TYR-32; PHE-33; TYR-33; GLU-34; CYS-37; PHE-37 AND RP ILE-41. RX PubMed=10192393; DOI=10.1038/7747; RA Chan E.F., Gat U., McNiff J.M., Fuchs E.; RT "A common human skin tumour is caused by activating mutations in beta- RT catenin."; RL Nat. Genet. 21:410-413(1999). RN [108] RP VARIANTS HEPATOCELLULAR CARCINOMA ARG-23; 25-TRP--SER-33 DEL; ALA-32; RP GLY-32; TYR-32; LEU-33; PHE-33; ARG-34; SER-35; ALA-37; 37-SER-GLY-38 RP DELINS TRP; TYR-37; ALA-41; ILE-41; PHE-45 AND PRO-45. RX PubMed=10435629; DOI=10.1038/sj.onc.1202800; RA Legoix P., Bluteau O., Bayer J., Perret C., Balabaud C., Belghiti J., RA Franco D., Thomas G., Laurent-Puig P., Zucman-Rossi J.; RT "Beta-catenin mutations in hepatocellular carcinoma correlate with a low RT rate of loss of heterozygosity."; RL Oncogene 18:4044-4046(1999). RN [109] RP VARIANTS MDB PHE-33 AND ALA-37. RX PubMed=10666372; DOI=10.1016/s0002-9440(10)64747-5; RA Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., RA Kleihues P., Ohgaki H.; RT "APC mutations in sporadic medulloblastomas."; RL Am. J. Pathol. 156:433-437(2000). RN [110] RP VARIANT NEDSDV PRO-388. RX PubMed=25326669; DOI=10.1007/s00439-014-1498-1; RA Kuechler A., Willemsen M.H., Albrecht B., Bacino C.A., Bartholomew D.W., RA van Bokhoven H., van den Boogaard M.J., Bramswig N., Buettner C., RA Cremer K., Czeschik J.C., Engels H., van Gassen K., Graf E., van Haelst M., RA He W., Hogue J.S., Kempers M., Koolen D., Monroe G., de Munnik S., RA Pastore M., Reis A., Reuter M.S., Tegay D.H., Veltman J., Visser G., RA van Hasselt P., Smeets E.E., Vissers L., Wieland T., Wissink W., Yntema H., RA Zink A.M., Strom T.M., Luedecke H.J., Kleefstra T., Wieczorek D.; RT "De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause RT of intellectual disability: expanding the mutational and clinical RT spectrum."; RL Hum. Genet. 134:97-109(2015). RN [111] RP VARIANT NEDSDV 558-GLN--LEU-781 DEL. RX PubMed=28514307; DOI=10.1097/md.0000000000006914; RA Li N., Xu Y., Li G., Yu T., Yao R.E., Wang X., Wang J.; RT "Exome sequencing identifies a de novo mutation of CTNNB1 gene in a patient RT mainly presented with retinal detachment, lens and vitreous opacities, RT microcephaly, and developmental delay: Case report and literature review."; RL Medicine (Baltimore) 96:E6914-E6914(2017). RN [112] RP VARIANT ASN-292, AND CHARACTERIZATION OF VARIANT ASN-292. RX PubMed=38173341; DOI=10.1210/clinem/dgad757; RA Huybrechts Y., Appelman-Dijkstra N.M., Steenackers E., Van Beylen W., RA Mortier G., Hendrickx G., Van Hul W.; RT "A mosaic variant in CTNNB1/beta-catenin as a novel cause for osteopathia RT striata with cranial sclerosis."; RL J. Clin. Endocrinol. Metab. 0:0-0(2024). CC -!- FUNCTION: Key downstream component of the canonical Wnt signaling CC pathway (PubMed:17524503, PubMed:18077326, PubMed:18086858, CC PubMed:18957423, PubMed:21262353, PubMed:22155184, PubMed:22647378, CC PubMed:22699938). In the absence of Wnt, forms a complex with AXIN1, CC AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N- CC terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and CC its subsequent degradation by the proteasome (PubMed:17524503, CC PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, CC PubMed:22155184, PubMed:22647378, PubMed:22699938). In the presence of CC Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, CC where it acts as a coactivator for transcription factors of the TCF/LEF CC family, leading to activate Wnt responsive genes (PubMed:17524503, CC PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, CC PubMed:22155184, PubMed:22647378, PubMed:22699938). Also acts as a CC coactivator for other transcription factors, such as NR5A2 CC (PubMed:22187462). Promotes epithelial to mesenchymal CC transition/mesenchymal to epithelial transition (EMT/MET) via driving CC transcription of CTNNB1/TCF-target genes (PubMed:29910125). Involved in CC the regulation of cell adhesion, as component of an E-cadherin:catenin CC adhesion complex (By similarity). Acts as a negative regulator of CC centrosome cohesion (PubMed:18086858). Involved in the CC CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization CC (PubMed:21262353). Blocks anoikis of malignant kidney and intestinal CC epithelial cells and promotes their anchorage-independent growth by CC down-regulating DAPK2 (PubMed:18957423). Disrupts PML function and PML- CC NB formation by inhibiting RANBP2-mediated sumoylation of PML CC (PubMed:22155184). Promotes neurogenesis by maintaining sympathetic CC neuroblasts within the cell cycle (By similarity). Involved in CC chondrocyte differentiation via interaction with SOX9: SOX9-binding CC competes with the binding sites of TCF/LEF within CTNNB1, thereby CC inhibiting the Wnt signaling (By similarity). Acts as a positive CC regulator of odontoblast differentiation during mesenchymal tooth germ CC formation, via promoting the transcription of differentiation factors CC such as LEF1, BMP2 and BMP4 (By similarity). Activity is repressed in a CC MSX1-mediated manner at the bell stage of mesenchymal tooth germ CC formation which prevents premature differentiation of odontoblasts (By CC similarity). {ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:18077326, CC ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18957423, CC ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:22155184, CC ECO:0000269|PubMed:22187462, ECO:0000269|PubMed:22647378, CC ECO:0000269|PubMed:22699938, ECO:0000269|PubMed:29910125}. CC -!- SUBUNIT: Two separate complex-associated pools are found in the CC cytoplasm. The majority is present as component of an E- CC cadherin:catenin adhesion complex composed of at least E-cadherin/CDH1 CC and beta-catenin/CTNNB1, and possibly alpha-catenin/CTNNA1; the complex CC is located to adherens junctions. The stable association of CTNNA1 is CC controversial as CTNNA1 was shown not to bind to F-actin when assembled CC in the complex. Alternatively, the CTNNA1-containing complex may be CC linked to F-actin by other proteins such as LIMA1. Another cytoplasmic CC pool is part of a large complex containing AXIN1, AXIN2, APC, CSNK1A1 CC and GSK3B that promotes phosphorylation on N-terminal Ser and Thr CC residues and ubiquitination of CTNNB1 via BTRC and its subsequent CC degradation by the proteasome. Wnt-dependent activation of DVL CC antagonizes the action of GSK3B. When GSK3B activity is inhibited the CC complex dissociates, CTNNB1 is dephosphorylated and is no longer CC targeted for destruction. The stabilized protein translocates to the CC nucleus, where it binds TCF/LEF-1 family members, BCL9, BCL9L and CC possibly also RUVBL1 and CHD8. Binds CTNNBIP and EP300. CTNNB1 forms a CC ternary complex with LEF1 and EP300 that is disrupted by CTNNBIP1 CC binding. Interacts with TAX1BP3 (via the PDZ domain); this interaction CC inhibits the transcriptional activity of CTNNB1. Interacts with AJAP1, CC BAIAP1, CARM1, CTNNA3, CXADR and PCDH11Y. Binds NHERF1. Interacts with CC GLIS2 and MUC1. Interacts with SLC30A9. Interacts with XIRP1. Interacts CC directly with AXIN1; the interaction is regulated by CDK2 CC phosphorylation of AXIN1. Interacts with SCRIB. Interacts with RAPGEF2. CC Interacts with PTPRU (via the cytoplasmic juxtamembrane domain). CC Interacts with EMD. Interacts with TNIK and TCF7L2. Interacts with CC SESTD1 and TRPC4. Interacts with CAV1. Interacts with TRPV4. The TRPV4 CC and CTNNB1 complex can interact with CDH1. Interacts with VCL. CC Interacts with PTPRJ. Interacts with PKT7 and CDK2. Interacts with FAT1 CC (via the cytoplasmic domain). Interacts with NANOS1 and NDRG2. CC Interacts with isoform 1 of NEK2. Interacts with both isoform 1 and CC isoform 2 of CDK5. Interacts with PTK6. Interacts with SOX7; this CC interaction may lead to proteasomal degradation of active CTNNB1 and CC thus inhibition of Wnt/beta-catenin-stimulated transcription. CC Identified in a complex with HINT1 and MITF. Interacts with FHIT. The CC CTNNB1 and TCF7L2/TCF4 complex interacts with PML (isoform PML-4). CC Interacts with FERMT2. Identified in a complex with TCF7L2/TCF4 and CC FERMT2 (PubMed:22699938, PubMed:29739711). Interacts with RORA. May CC interact with P-cadherin/CDH3. Interacts with RNF220 (PubMed:25266658). CC Interacts with CTNND2 (PubMed:25807484). Interacts (via the C-terminal CC region) with CBY1 (PubMed:12712206, PubMed:16424001, PubMed:19435523). CC The complex composed, at least, of APC, CTNNB1 and GSK3B interacts with CC JPT1; the interaction requires the inactive form of GSK3B CC (phosphorylated at 'Ser-9') (PubMed:25169422). Interacts with DLG5 (By CC similarity). Interacts with FAM53B; promoting translocation to the CC nucleus (PubMed:25183871). Interacts with TMEM170B (PubMed:29367600). CC Interacts with AHI1 (PubMed:21623382). Interacts with GID8 CC (PubMed:28829046). Component of an cadherin:catenin adhesion complex CC composed of at least of CDH26, beta-catenin/CTNNB1, alpha- CC catenin/CTNNA1 and p120 catenin/CTNND1 (PubMed:28051089). Forms a CC complex comprising APPL1, RUVBL2, APPL2, HDAC1 and HDAC2 CC (PubMed:19433865). Interacts with IRF2BPL; mediates the ubiquitination CC and degradation of CTNNB1 (PubMed:29374064). Interacts with AMFR (By CC similarity). Interacts with LMBR1L (PubMed:31073040). Interacts with CC SOX30; prevents interaction of CTNNB1 with TCF7L2/TCF4 and leads to CC inhibition of Wnt signaling (PubMed:29739711). Interacts with SOX9; CC inhibiting CTNNB1 activity by competing with the binding sites of CC TCF/LEF within CTNNB1, thereby inhibiting the Wnt signaling (By CC similarity). Interacts with SPN/CD43 cytoplasmic tail CC (PubMed:15003504). Interacts (when phosphorylated at Tyr-333) with CC isoform M2 of PKM (PKM2); promoting transcription activation CC (PubMed:22056988). Interacts with PKP2 (via HEAD domain) CC (PubMed:11790773). Interacts with CDH1 (PubMed:11790773). Interacts CC (when unphosphorylated) with FLYWCH1, perhaps preventing interaction of CC CTNNB1 with TCF4, and thereby regulating transcription activation; CC phosphorylation of CTNNB1 may inhibit the interaction CC (PubMed:30097457). Interacts (via the central armadillo domains) with CC probable transcriptional regulator ADNP (via N-terminal region); CC interaction is direct and stabilizes CTNNB1 by modulating its CC phosphorylation by glycogen synthase kinase-3 beta GSK3B (By CC similarity). Interacts with NR5A2 (PubMed:22187462). Interacts with CC DSG2; the interaction promotes localization of CTNNB1 at cell junctions CC thus reducing its nuclear localization and subsequent transcription of CC CTNNB1/TCF-target genes (PubMed:29910125). Interacts with FBXO16 CC (PubMed:30714168). {ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:10966653, ECO:0000269|PubMed:11389839, CC ECO:0000269|PubMed:11389840, ECO:0000269|PubMed:11590244, CC ECO:0000269|PubMed:11713475, ECO:0000269|PubMed:11713476, CC ECO:0000269|PubMed:11751639, ECO:0000269|PubMed:11790773, CC ECO:0000269|PubMed:12077367, ECO:0000269|PubMed:12297051, CC ECO:0000269|PubMed:12370829, ECO:0000269|PubMed:12408824, CC ECO:0000269|PubMed:12420223, ECO:0000269|PubMed:12501215, CC ECO:0000269|PubMed:12712206, ECO:0000269|PubMed:12830000, CC ECO:0000269|PubMed:14595118, ECO:0000269|PubMed:15003504, CC ECO:0000269|PubMed:16424001, ECO:0000269|PubMed:16858403, CC ECO:0000269|PubMed:17009320, ECO:0000269|PubMed:17047063, CC ECO:0000269|PubMed:17052462, ECO:0000269|PubMed:17289029, CC ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:18077326, CC ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18378692, CC ECO:0000269|PubMed:18819930, ECO:0000269|PubMed:19433865, CC ECO:0000269|PubMed:19435523, ECO:0000269|PubMed:19693690, CC ECO:0000269|PubMed:19816403, ECO:0000269|PubMed:19996314, CC ECO:0000269|PubMed:20026641, ECO:0000269|PubMed:20164195, CC ECO:0000269|PubMed:21132015, ECO:0000269|PubMed:21247902, CC ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:21623382, CC ECO:0000269|PubMed:22056988, ECO:0000269|PubMed:22155184, CC ECO:0000269|PubMed:22187462, ECO:0000269|PubMed:22647378, CC ECO:0000269|PubMed:22699938, ECO:0000269|PubMed:25169422, CC ECO:0000269|PubMed:25183871, ECO:0000269|PubMed:25266658, CC ECO:0000269|PubMed:25807484, ECO:0000269|PubMed:28051089, CC ECO:0000269|PubMed:28829046, ECO:0000269|PubMed:29367600, CC ECO:0000269|PubMed:29374064, ECO:0000269|PubMed:29432739, CC ECO:0000269|PubMed:29739711, ECO:0000269|PubMed:29910125, CC ECO:0000269|PubMed:30714168, ECO:0000269|PubMed:31073040, CC ECO:0000269|PubMed:7982500, ECO:0000305|PubMed:31073040}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein CC vPK; this interaction inhibits the Wnt signaling pathway. CC {ECO:0000269|PubMed:29432739}. CC -!- INTERACTION: CC P35222; P01023: A2M; NbExp=3; IntAct=EBI-491549, EBI-640741; CC P35222; P00519: ABL1; NbExp=2; IntAct=EBI-491549, EBI-375543; CC P35222; O43707: ACTN4; NbExp=7; IntAct=EBI-491549, EBI-351526; CC P35222; Q02952: AKAP12; NbExp=2; IntAct=EBI-491549, EBI-2562430; CC P35222; Q5JTC6: AMER1; NbExp=9; IntAct=EBI-491549, EBI-6169747; CC P35222; P25054: APC; NbExp=22; IntAct=EBI-491549, EBI-727707; CC P35222; P10275: AR; NbExp=15; IntAct=EBI-491549, EBI-608057; CC P35222; Q5T5U3: ARHGAP21; NbExp=2; IntAct=EBI-491549, EBI-1642518; CC P35222; O15169: AXIN1; NbExp=44; IntAct=EBI-491549, EBI-710484; CC P35222; Q9Y2T1: AXIN2; NbExp=2; IntAct=EBI-491549, EBI-4400025; CC P35222; O00512: BCL9; NbExp=5; IntAct=EBI-491549, EBI-533127; CC P35222; A1Z199: BCR/ABL fusion; NbExp=2; IntAct=EBI-491549, EBI-7286259; CC P35222; P23560-2: BDNF; NbExp=3; IntAct=EBI-491549, EBI-12275524; CC P35222; Q2LD37: BLTP1; NbExp=2; IntAct=EBI-491549, EBI-2683809; CC P35222; Q9Y297: BTRC; NbExp=8; IntAct=EBI-491549, EBI-307461; CC P35222; P55212: CASP6; NbExp=3; IntAct=EBI-491549, EBI-718729; CC P35222; P35520: CBS; NbExp=3; IntAct=EBI-491549, EBI-740135; CC P35222; Q6P1J9: CDC73; NbExp=10; IntAct=EBI-491549, EBI-930143; CC P35222; P12830: CDH1; NbExp=23; IntAct=EBI-491549, EBI-727477; CC P35222; P19022: CDH2; NbExp=12; IntAct=EBI-491549, EBI-2256711; CC P35222; P33151: CDH5; NbExp=11; IntAct=EBI-491549, EBI-2903122; CC P35222; Q92793: CREBBP; NbExp=2; IntAct=EBI-491549, EBI-81215; CC P35222; P02511: CRYAB; NbExp=6; IntAct=EBI-491549, EBI-739060; CC P35222; P35221: CTNNA1; NbExp=8; IntAct=EBI-491549, EBI-701918; CC P35222; P26232: CTNNA2; NbExp=5; IntAct=EBI-491549, EBI-3953920; CC P35222; Q9UI47-1: CTNNA3; NbExp=4; IntAct=EBI-491549, EBI-21980640; CC P35222; Q9NSA3: CTNNBIP1; NbExp=19; IntAct=EBI-491549, EBI-747082; CC P35222; Q9NYF0: DACT1; NbExp=3; IntAct=EBI-491549, EBI-3951744; CC P35222; G5E9A7: DMWD; NbExp=3; IntAct=EBI-491549, EBI-10976677; CC P35222; P26358: DNMT1; NbExp=8; IntAct=EBI-491549, EBI-719459; CC P35222; Q8TEK3: DOT1L; NbExp=3; IntAct=EBI-491549, EBI-2619253; CC P35222; P18146: EGR1; NbExp=7; IntAct=EBI-491549, EBI-2834611; CC P35222; P50402: EMD; NbExp=3; IntAct=EBI-491549, EBI-489887; CC P35222; P29317: EPHA2; NbExp=2; IntAct=EBI-491549, EBI-702104; CC P35222; Q9UKB1: FBXW11; NbExp=4; IntAct=EBI-491549, EBI-355189; CC P35222; Q96AC1: FERMT2; NbExp=13; IntAct=EBI-491549, EBI-4399465; CC P35222; Q92915-2: FGF14; NbExp=3; IntAct=EBI-491549, EBI-12836320; CC P35222; P11362: FGFR1; NbExp=3; IntAct=EBI-491549, EBI-1028277; CC P35222; P49789: FHIT; NbExp=4; IntAct=EBI-491549, EBI-741760; CC P35222; Q08050: FOXM1; NbExp=16; IntAct=EBI-491549, EBI-866480; CC P35222; P04406: GAPDH; NbExp=3; IntAct=EBI-491549, EBI-354056; CC P35222; P14136: GFAP; NbExp=3; IntAct=EBI-491549, EBI-744302; CC P35222; Q9BZE0: GLIS2; NbExp=6; IntAct=EBI-491549, EBI-7251368; CC P35222; P49841: GSK3B; NbExp=20; IntAct=EBI-491549, EBI-373586; CC P35222; Q9UBN7: HDAC6; NbExp=4; IntAct=EBI-491549, EBI-301697; CC P35222; Q16665: HIF1A; NbExp=4; IntAct=EBI-491549, EBI-447269; CC P35222; O00291: HIP1; NbExp=3; IntAct=EBI-491549, EBI-473886; CC P35222; P07900: HSP90AA1; NbExp=3; IntAct=EBI-491549, EBI-296047; CC P35222; P42858: HTT; NbExp=14; IntAct=EBI-491549, EBI-466029; CC P35222; P08069: IGF1R; NbExp=3; IntAct=EBI-491549, EBI-475981; CC P35222; P46940: IQGAP1; NbExp=3; IntAct=EBI-491549, EBI-297509; CC P35222; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-491549, EBI-1055254; CC P35222; O75564: JRK; NbExp=3; IntAct=EBI-491549, EBI-8607681; CC P35222; Q14678: KANK1; NbExp=2; IntAct=EBI-491549, EBI-2556221; CC P35222; P13473-2: LAMP2; NbExp=3; IntAct=EBI-491549, EBI-21591415; CC P35222; Q9UJU2: LEF1; NbExp=10; IntAct=EBI-491549, EBI-926131; CC P35222; Q8WVC0: LEO1; NbExp=2; IntAct=EBI-491549, EBI-932432; CC P35222; Q14114-3: LRP8; NbExp=3; IntAct=EBI-491549, EBI-25832196; CC P35222; Q9GZQ8: MAP1LC3B; NbExp=5; IntAct=EBI-491549, EBI-373144; CC P35222; Q9Y2H9: MAST1; NbExp=2; IntAct=EBI-491549, EBI-3385920; CC P35222; P51608: MECP2; NbExp=3; IntAct=EBI-491549, EBI-1189067; CC P35222; P55197: MLLT10; NbExp=5; IntAct=EBI-491549, EBI-1104952; CC P35222; Q92597: NDRG1; NbExp=3; IntAct=EBI-491549, EBI-716486; CC P35222; P19404: NDUFV2; NbExp=3; IntAct=EBI-491549, EBI-713665; CC P35222; P19838: NFKB1; NbExp=3; IntAct=EBI-491549, EBI-300010; CC P35222; Q15599: NHERF2; NbExp=3; IntAct=EBI-491549, EBI-1149760; CC P35222; P29474: NOS3; NbExp=4; IntAct=EBI-491549, EBI-1391623; CC P35222; O00482-1: NR5A2; NbExp=5; IntAct=EBI-491549, EBI-15960777; CC P35222; P49757: NUMB; NbExp=2; IntAct=EBI-491549, EBI-915016; CC P35222; P49757-3: NUMB; NbExp=3; IntAct=EBI-491549, EBI-10692196; CC P35222; P14618: PKM; NbExp=4; IntAct=EBI-491549, EBI-353408; CC P35222; P14618-1: PKM; NbExp=3; IntAct=EBI-491549, EBI-4304679; CC P35222; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-491549, EBI-5280197; CC P35222; Q03431: PTH1R; NbExp=4; IntAct=EBI-491549, EBI-2860297; CC P35222; Q13308: PTK7; NbExp=5; IntAct=EBI-491549, EBI-2803245; CC P35222; P08575: PTPRC; NbExp=2; IntAct=EBI-491549, EBI-1341; CC P35222; P23470: PTPRG; NbExp=2; IntAct=EBI-491549, EBI-2258115; CC P35222; Q12913: PTPRJ; NbExp=2; IntAct=EBI-491549, EBI-2264500; CC P35222; P49023: PXN; NbExp=4; IntAct=EBI-491549, EBI-702209; CC P35222; P62826: RAN; NbExp=3; IntAct=EBI-491549, EBI-286642; CC P35222; Q04206: RELA; NbExp=3; IntAct=EBI-491549, EBI-73886; CC P35222; Q13761: RUNX3; NbExp=12; IntAct=EBI-491549, EBI-925990; CC P35222; Q9Y265: RUVBL1; NbExp=3; IntAct=EBI-491549, EBI-353675; CC P35222; Q01826: SATB1; NbExp=9; IntAct=EBI-491549, EBI-743747; CC P35222; Q14160: SCRIB; NbExp=4; IntAct=EBI-491549, EBI-357345; CC P35222; Q9H6I2: SOX17; NbExp=2; IntAct=EBI-491549, EBI-9106753; CC P35222; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-491549, EBI-5235340; CC P35222; P12931: SRC; NbExp=2; IntAct=EBI-491549, EBI-621482; CC P35222; O14907: TAX1BP3; NbExp=6; IntAct=EBI-491549, EBI-723259; CC P35222; P15884: TCF4; NbExp=22; IntAct=EBI-491549, EBI-533224; CC P35222; P36402: TCF7; NbExp=4; IntAct=EBI-491549, EBI-2119465; CC P35222; Q9NQB0: TCF7L2; NbExp=27; IntAct=EBI-491549, EBI-924724; CC P35222; O14746: TERT; NbExp=2; IntAct=EBI-491549, EBI-1772203; CC P35222; Q9UKE5: TNIK; NbExp=3; IntAct=EBI-491549, EBI-1051794; CC P35222; P11388: TOP2A; NbExp=5; IntAct=EBI-491549, EBI-539628; CC P35222; O14656-2: TOR1A; NbExp=3; IntAct=EBI-491549, EBI-25847109; CC P35222; Q13625: TP53BP2; NbExp=5; IntAct=EBI-491549, EBI-77642; CC P35222; O95071: UBR5; NbExp=6; IntAct=EBI-491549, EBI-358329; CC P35222; P11473: VDR; NbExp=2; IntAct=EBI-491549, EBI-286357; CC P35222; Q9GZV5: WWTR1; NbExp=4; IntAct=EBI-491549, EBI-747743; CC P35222; P46937: YAP1; NbExp=16; IntAct=EBI-491549, EBI-1044059; CC P35222; P46937-3: YAP1; NbExp=2; IntAct=EBI-491549, EBI-6558686; CC P35222; O35625: Axin1; Xeno; NbExp=4; IntAct=EBI-491549, EBI-2365912; CC P35222; Q9YGY0: axin1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-1037449; CC P35222; Q67FY2: Bcl9l; Xeno; NbExp=2; IntAct=EBI-491549, EBI-5234367; CC P35222; P33724: CAV1; Xeno; NbExp=5; IntAct=EBI-491549, EBI-79998; CC P35222; P26231: Ctnna1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-647895; CC P35222; P27782: Lef1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-984464; CC P35222; Q01887: Ryk; Xeno; NbExp=2; IntAct=EBI-491549, EBI-16110594; CC P35222; P18012: sctB; Xeno; NbExp=4; IntAct=EBI-491549, EBI-491541; CC P35222; P40645: Sox6; Xeno; NbExp=2; IntAct=EBI-491549, EBI-3505685; CC P35222; Q9DBG9: Tax1bp3; Xeno; NbExp=3; IntAct=EBI-491549, EBI-1161647; CC P35222; Q9EPK5: Wwtr1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-1211920; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:22294297, CC ECO:0000269|PubMed:25183871, ECO:0000269|PubMed:29739711, CC ECO:0000269|PubMed:29910125, ECO:0000269|PubMed:31801859}. Nucleus CC {ECO:0000269|PubMed:21118991, ECO:0000269|PubMed:24342833, CC ECO:0000269|PubMed:25183871, ECO:0000269|PubMed:28829046, CC ECO:0000269|PubMed:29367600, ECO:0000269|PubMed:29739711, CC ECO:0000269|PubMed:29910125, ECO:0000269|PubMed:30714168, CC ECO:0000269|PubMed:31801859}. Cytoplasm, cytoskeleton CC {ECO:0000250|UniProtKB:B6V8E6}. Cell junction, adherens junction CC {ECO:0000269|PubMed:10725230, ECO:0000269|PubMed:22294297}. Cell CC junction {ECO:0000250|UniProtKB:B6V8E6}. Cell membrane CC {ECO:0000269|PubMed:11790773, ECO:0000269|PubMed:24342833}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, CC cytoskeleton, spindle pole. Synapse {ECO:0000250|UniProtKB:Q02248}. CC Cytoplasm, cytoskeleton, cilium basal body CC {ECO:0000250|UniProtKB:Q02248}. Note=Colocalized with RAPGEF2 and TJP1 CC at cell-cell contacts (By similarity). Cytoplasmic when it is un-stable CC (highly phosphorylated) or bound to CDH1. Translocates to the nucleus CC when it is stabilized (low level of phosphorylation). Interaction with CC GLIS2 and MUC1 promotes nuclear translocation. Interaction with EMD CC inhibits nuclear localization. The majority of CTNNB1 is localized to CC the cell membrane. In interphase, colocalizes with CROCC between CEP250 CC puncta at the proximal end of centrioles, and this localization is CC dependent on CROCC and CEP250. In mitosis, when NEK2 activity CC increases, it localizes to centrosomes at spindle poles independent of CC CROCC. Colocalizes with CDK5 in the cell-cell contacts and plasma CC membrane of undifferentiated and differentiated neuroblastoma cells. CC Interaction with FAM53B promotes translocation to the nucleus CC (PubMed:25183871). Translocates to the nucleus in the presence of CC SNAIL1 (By similarity). Ca(2+)-mediated localization to the cell CC membrane in dental epithelial cells is inhibited via WNT3A (By CC similarity). Localizes to cell-cell contacts as keratinocyte CC differentiation progresses (By similarity). CC {ECO:0000250|UniProtKB:B6V8E6, ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:25183871}. CC -!- TISSUE SPECIFICITY: Expressed in several hair follicle cell types: CC basal and peripheral matrix cells, and cells of the outer and inner CC root sheaths. Expressed in colon. Present in cortical neurons (at CC protein level). Expressed in breast cancer tissues (at protein level) CC (PubMed:29367600). {ECO:0000269|PubMed:11703283, CC ECO:0000269|PubMed:17009320, ECO:0000269|PubMed:17289029, CC ECO:0000269|PubMed:29367600}. CC -!- PTM: Phosphorylation at Ser-552 by AMPK promotes stabilization of the CC protein, enhancing TCF/LEF-mediated transcription (By similarity). CC Phosphorylation by GSK3B requires prior phosphorylation of Ser-45 by CC another kinase (PubMed:10966653, PubMed:12027456, PubMed:12051714). CC Phosphorylation proceeds then from Thr-41 to Ser-37 and Ser-33 CC (PubMed:12077367, PubMed:25169422). Phosphorylated by NEK2 CC (PubMed:18086858). EGF stimulates tyrosine phosphorylation CC (PubMed:10187801). Phosphorylated on Ser-33 and Ser-37 by HIPK2 and CC GSK3B, this phosphorylation triggers proteasomal degradation CC (PubMed:20307497). Phosphorylation on Ser-191 and Ser-246 by CDK5 CC (PubMed:17009320). Phosphorylation by CDK2 regulates insulin CC internalization (PubMed:21262353). Phosphorylation by PTK6 at Tyr-64, CC Tyr-142, Tyr-331 and/or Tyr-333 with the predominant site at Tyr-64 is CC not essential for inhibition of transcriptional activity CC (PubMed:20026641). Phosphorylation by SRC at Tyr-333 promotes CC interaction with isoform M2 of PKM (PKM2); promoting transcription CC activation (PubMed:22056988). {ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:10187801, ECO:0000269|PubMed:10966653, CC ECO:0000269|PubMed:12027456, ECO:0000269|PubMed:12051714, CC ECO:0000269|PubMed:12077367, ECO:0000269|PubMed:17009320, CC ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:20026641, CC ECO:0000269|PubMed:20307497, ECO:0000269|PubMed:21262353, CC ECO:0000269|PubMed:22056988, ECO:0000269|PubMed:25169422}. CC -!- PTM: Ubiquitinated by the SCF(BTRC) E3 ligase complex when CC phosphorylated by GSK3B, leading to its degradation (PubMed:12077367). CC Ubiquitinated by a E3 ubiquitin ligase complex containing UBE2D1, CC SIAH1, CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent CC proteasomal degradation (PubMed:11389839, PubMed:11389840, CC PubMed:20307497). Ubiquitinated and degraded following interaction with CC SOX9 (By similarity). Ubiquitinated via 'Lys-11'- and 'Lys-29'-linked CC ubiquitin chains by UBR5, leading to its stabilization CC (PubMed:21118991). Ubiquitinated by the SCF-FBXO16 E3 ubiquitin ligase, CC leading to proteasomal degradation (PubMed:30714168). CC {ECO:0000250|UniProtKB:Q02248, ECO:0000269|PubMed:11389839, CC ECO:0000269|PubMed:11389840, ECO:0000269|PubMed:12077367, CC ECO:0000269|PubMed:20307497, ECO:0000269|PubMed:21118991, CC ECO:0000269|PubMed:30714168}. CC -!- PTM: S-nitrosylation at Cys-619 within adherens junctions promotes CC VEGF-induced, NO-dependent endothelial cell permeability by disrupting CC interaction with E-cadherin, thus mediating disassembly adherens CC junctions. {ECO:0000250|UniProtKB:Q02248}. CC -!- PTM: O-glycosylation at Ser-23 decreases nuclear localization and CC transcriptional activity, and increases localization to the plasma CC membrane and interaction with E-cadherin CDH1. CC {ECO:0000269|PubMed:24342833}. CC -!- PTM: Deacetylated at Lys-49 by SIRT1. {ECO:0000269|PubMed:24824780}. CC -!- PTM: Phosphorylated at Thr-556 by herpes virus 1/HHV-1 leading to CC CTNNB1 inhibition. {ECO:0000269|PubMed:24824780}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:9065402}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Note=Activating mutations in CTNNB1 have oncogenic activity CC resulting in tumor development. Somatic mutations are found in various CC tumor types, including colon cancers, ovarian and prostate carcinomas, CC hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant CC embryonal tumors mainly affecting young children in the first three CC years of life. CC -!- DISEASE: Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. CC {ECO:0000269|PubMed:10192393, ECO:0000269|PubMed:11703283, CC ECO:0000269|PubMed:12027456}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive CC embryonal tumor of the cerebellum with a preferential manifestation in CC children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:12027456}. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:10391090}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving CTNNB1 is found in CC salivary gland pleiomorphic adenomas, the most common benign epithelial CC tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1. CC {ECO:0000269|PubMed:10029085, ECO:0000269|PubMed:9020842}. CC -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive CC neoplasm of the serosal lining of the chest. It appears as broad sheets CC of cells, with some regions containing spindle-shaped, sarcoma-like CC cells and other regions showing adenomatous patterns. Pleural CC mesotheliomas have been linked to exposure to asbestos. CC {ECO:0000269|PubMed:11464291}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Neurodevelopmental disorder with spastic diplegia and visual CC defects (NEDSDV) [MIM:615075]: An autosomal dominant disorder CC characterized by global developmental delay, severe intellectual CC disability with absent or very limited speech, microcephaly, CC spasticity, and visual abnormalities. {ECO:0000269|PubMed:23033978, CC ECO:0000269|PubMed:25326669, ECO:0000269|PubMed:28514307}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Vitreoretinopathy, exudative 7 (EVR7) [MIM:617572]: An CC autosomal dominant form of exudative vitreoretinopathy, a disorder of CC the retinal vasculature characterized by an abrupt cessation of growth CC of peripheral capillaries, leading to an avascular peripheral retina. CC This may lead to compensatory retinal neovascularization, which is CC thought to be induced by hypoxia from the initial avascular insult. New CC vessels are prone to leakage and rupture causing exudates and bleeding, CC followed by scarring, retinal detachment and blindness. Clinical CC features can be highly variable, even within the same family. Patients CC with mild forms of the disease are asymptomatic, and their only disease CC related abnormality is an arc of avascular retina in the extreme CC temporal periphery. {ECO:0000269|PubMed:28575650}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the beta-catenin family. {ECO:0000305}. CC -!- CAUTION: A paper showing an interaction with TBP and phosphorylation at CC Tyr-86 and Tyr-654 has been retracted due to panel duplication in CC several figures. {ECO:0000269|PubMed:11279024, CC ECO:0000305|PubMed:27226643}. CC -!- SEQUENCE CAUTION: CC Sequence=AAG35511.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=BAB93475.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/71/CTNNB1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Beta-catenin entry; CC URL="https://en.wikipedia.org/wiki/Beta-catenin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X87838; CAA61107.1; -; mRNA. DR EMBL; Z19054; CAA79497.1; -; mRNA. DR EMBL; AF130085; AAG35511.1; ALT_SEQ; mRNA. DR EMBL; AY463360; AAR18817.1; -; Genomic_DNA. DR EMBL; AK289932; BAF82621.1; -; mRNA. DR EMBL; AC104307; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64625.1; -; Genomic_DNA. DR EMBL; BC058926; AAH58926.1; -; mRNA. DR EMBL; AY081165; AAL89457.1; -; Genomic_DNA. DR EMBL; AB062292; BAB93475.1; ALT_INIT; mRNA. DR CCDS; CCDS2694.1; -. DR PIR; A38973; A38973. DR RefSeq; NP_001091679.1; NM_001098209.2. DR RefSeq; NP_001091680.1; NM_001098210.2. DR RefSeq; NP_001425800.1; NM_001438871.1. DR RefSeq; NP_001425801.1; NM_001438872.1. DR RefSeq; NP_001425802.1; NM_001438873.1. DR RefSeq; NP_001895.1; NM_001904.4. DR RefSeq; XP_024309124.1; XM_024453356.2. DR RefSeq; XP_047303434.1; XM_047447478.1. DR RefSeq; XP_047303435.1; XM_047447479.1. DR RefSeq; XP_047303436.1; XM_047447480.1. DR RefSeq; XP_054201285.1; XM_054345310.1. DR RefSeq; XP_054201286.1; XM_054345311.1. DR RefSeq; XP_054201287.1; XM_054345312.1. DR RefSeq; XP_054201288.1; XM_054345313.1. DR PDB; 1G3J; X-ray; 2.10 A; A/C=133-664. DR PDB; 1JDH; X-ray; 1.90 A; A=135-663. DR PDB; 1JPW; X-ray; 2.50 A; A/B/C=131-670. DR PDB; 1LUJ; X-ray; 2.50 A; A=150-663. DR PDB; 1P22; X-ray; 2.95 A; C=19-44. DR PDB; 1QZ7; X-ray; 2.20 A; A=133-665. DR PDB; 1T08; X-ray; 2.10 A; A=146-664. DR PDB; 1TH1; X-ray; 2.50 A; A/B=133-664. DR PDB; 2G57; NMR; -; A=19-44. DR PDB; 2GL7; X-ray; 2.60 A; A/D=138-686. DR PDB; 2Z6H; X-ray; 2.20 A; A=138-781. DR PDB; 3DIW; X-ray; 2.10 A; C/D=772-781. DR PDB; 3FQN; X-ray; 1.65 A; C=30-39. DR PDB; 3FQR; X-ray; 1.70 A; C=30-39. DR PDB; 3SL9; X-ray; 2.20 A; A/B/E/G=141-305. DR PDB; 3SLA; X-ray; 2.50 A; A/B/C/D/E=141-306. DR PDB; 3TX7; X-ray; 2.76 A; A=138-663. DR PDB; 4DJS; X-ray; 3.03 A; A=148-665. DR PDB; 6M90; X-ray; 2.05 A; C=17-48. DR PDB; 6M91; X-ray; 2.40 A; C=17-48. DR PDB; 6M92; X-ray; 2.35 A; C=17-48. DR PDB; 6M93; X-ray; 2.50 A; C=17-48. DR PDB; 6M94; X-ray; 2.70 A; C=17-48. DR PDB; 6O9B; X-ray; 2.20 A; C=41-49. DR PDB; 6O9C; X-ray; 2.45 A; C=41-49. DR PDB; 6WLX; X-ray; 2.20 A; B=671-677. DR PDB; 6WNX; X-ray; 2.50 A; C/F/I=31-39. DR PDB; 7AFW; X-ray; 1.81 A; A=141-305. DR PDB; 7AR4; X-ray; 2.60 A; AAA=134-665. DR PDB; 7UWI; X-ray; 2.32 A; A=143-663. DR PDB; 7UWO; X-ray; 2.75 A; A=134-665. DR PDB; 7ZRB; X-ray; 3.43 A; A/B=133-664. DR PDB; 8EI9; X-ray; 3.90 A; A=134-665. DR PDB; 8EIA; X-ray; 3.60 A; A=134-665. DR PDB; 8EIB; X-ray; 3.76 A; A=134-665. DR PDB; 8EIC; X-ray; 2.62 A; A=134-665. DR PDB; 8RU3; X-ray; 2.00 A; A=134-665. DR PDB; 8RU4; X-ray; 2.13 A; A/B=145-665. DR PDB; 8VME; X-ray; 2.30 A; C=35-61. DR PDB; 8VMF; X-ray; 2.50 A; C=35-61. DR PDB; 8Y0G; X-ray; 2.50 A; A=138-686. DR PDB; 8Y0P; X-ray; 2.62 A; A/B=138-686. DR PDB; 8Y14; X-ray; 2.80 A; A=138-686. DR PDB; 8Z0U; X-ray; 2.21 A; A=138-686. DR PDB; 8Z10; X-ray; 2.35 A; A=138-686. DR PDB; 8Z5J; X-ray; 2.80 A; A=138-686. DR PDB; 8Z61; X-ray; 2.50 A; A=138-686. DR PDBsum; 1G3J; -. DR PDBsum; 1JDH; -. DR PDBsum; 1JPW; -. DR PDBsum; 1LUJ; -. DR PDBsum; 1P22; -. DR PDBsum; 1QZ7; -. DR PDBsum; 1T08; -. DR PDBsum; 1TH1; -. DR PDBsum; 2G57; -. DR PDBsum; 2GL7; -. DR PDBsum; 2Z6H; -. DR PDBsum; 3DIW; -. DR PDBsum; 3FQN; -. DR PDBsum; 3FQR; -. DR PDBsum; 3SL9; -. DR PDBsum; 3SLA; -. DR PDBsum; 3TX7; -. DR PDBsum; 4DJS; -. DR PDBsum; 6M90; -. DR PDBsum; 6M91; -. DR PDBsum; 6M92; -. DR PDBsum; 6M93; -. DR PDBsum; 6M94; -. DR PDBsum; 6O9B; -. DR PDBsum; 6O9C; -. DR PDBsum; 6WLX; -. DR PDBsum; 6WNX; -. DR PDBsum; 7AFW; -. DR PDBsum; 7AR4; -. DR PDBsum; 7UWI; -. DR PDBsum; 7UWO; -. DR PDBsum; 7ZRB; -. DR PDBsum; 8EI9; -. DR PDBsum; 8EIA; -. DR PDBsum; 8EIB; -. DR PDBsum; 8EIC; -. DR PDBsum; 8RU3; -. DR PDBsum; 8RU4; -. DR PDBsum; 8VME; -. DR PDBsum; 8VMF; -. DR PDBsum; 8Y0G; -. DR PDBsum; 8Y0P; -. DR PDBsum; 8Y14; -. DR PDBsum; 8Z0U; -. DR PDBsum; 8Z10; -. DR PDBsum; 8Z5J; -. DR PDBsum; 8Z61; -. DR AlphaFoldDB; P35222; -. DR SMR; P35222; -. DR BioGRID; 107880; 1008. DR ComplexPortal; CPX-316; beta1-catenin - LEF1 complex. DR CORUM; P35222; -. DR DIP; DIP-122N; -. DR FunCoup; P35222; 2315. DR IntAct; P35222; 361. DR MINT; P35222; -. DR STRING; 9606.ENSP00000495360; -. DR BindingDB; P35222; -. DR ChEMBL; CHEMBL5866; -. DR DrugBank; DB03904; Urea. DR GlyCosmos; P35222; 4 sites, 1 glycan. DR GlyGen; P35222; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (4 sites). DR iPTMnet; P35222; -. DR MetOSite; P35222; -. DR PhosphoSitePlus; P35222; -. DR SwissPalm; P35222; -. DR BioMuta; CTNNB1; -. DR DMDM; 461854; -. DR CPTAC; CPTAC-1745; -. DR CPTAC; non-CPTAC-3265; -. DR CPTAC; non-CPTAC-3266; -. DR CPTAC; non-CPTAC-5365; -. DR CPTAC; non-CPTAC-5715; -. DR CPTAC; non-CPTAC-5716; -. DR jPOST; P35222; -. DR MassIVE; P35222; -. DR PaxDb; 9606-ENSP00000344456; -. DR PeptideAtlas; P35222; -. DR PRIDE; P35222; -. DR Pumba; P35222; -. DR ABCD; P35222; 7 sequenced antibodies. DR Antibodypedia; 3432; 5164 antibodies from 59 providers. DR DNASU; 1499; -. DR Ensembl; ENST00000349496.11; ENSP00000344456.5; ENSG00000168036.20. DR Ensembl; ENST00000396183.7; ENSP00000379486.3; ENSG00000168036.20. DR Ensembl; ENST00000396185.8; ENSP00000379488.3; ENSG00000168036.20. DR Ensembl; ENST00000405570.6; ENSP00000385604.1; ENSG00000168036.20. DR Ensembl; ENST00000431914.6; ENSP00000412219.2; ENSG00000168036.20. DR Ensembl; ENST00000433400.6; ENSP00000387455.2; ENSG00000168036.20. DR Ensembl; ENST00000441708.2; ENSP00000401599.2; ENSG00000168036.20. DR Ensembl; ENST00000450969.6; ENSP00000409302.2; ENSG00000168036.20. DR Ensembl; ENST00000642248.1; ENSP00000495244.1; ENSG00000168036.20. DR Ensembl; ENST00000642315.1; ENSP00000495076.1; ENSG00000168036.20. DR Ensembl; ENST00000642426.1; ENSP00000495719.1; ENSG00000168036.20. DR Ensembl; ENST00000642992.1; ENSP00000496385.1; ENSG00000168036.20. DR Ensembl; ENST00000643031.1; ENSP00000495450.1; ENSG00000168036.20. DR Ensembl; ENST00000643297.1; ENSP00000494677.1; ENSG00000168036.20. DR Ensembl; ENST00000643541.1; ENSP00000494411.1; ENSG00000168036.20. DR Ensembl; ENST00000643977.1; ENSP00000494053.1; ENSG00000168036.20. DR Ensembl; ENST00000643992.1; ENSP00000493610.1; ENSG00000168036.20. DR Ensembl; ENST00000644867.1; ENSP00000495992.1; ENSG00000168036.20. DR Ensembl; ENST00000645210.1; ENSP00000496180.1; ENSG00000168036.20. DR Ensembl; ENST00000645320.1; ENSP00000495360.1; ENSG00000168036.20. DR Ensembl; ENST00000645982.1; ENSP00000494845.1; ENSG00000168036.20. DR Ensembl; ENST00000646369.1; ENSP00000494914.1; ENSG00000168036.20. DR Ensembl; ENST00000646725.1; ENSP00000496021.1; ENSG00000168036.20. DR Ensembl; ENST00000647390.1; ENSP00000493533.1; ENSG00000168036.20. DR Ensembl; ENST00000647413.2; ENSP00000493583.2; ENSG00000168036.20. DR GeneID; 1499; -. DR KEGG; hsa:1499; -. DR MANE-Select; ENST00000349496.11; ENSP00000344456.5; NM_001904.4; NP_001895.1. DR UCSC; uc003ckp.3; human. DR AGR; HGNC:2514; -. DR CIViC; 1499; 1 clinical assertion and 42 evidence items across 16 molecular profiles. DR ClinPGx; PA27013; -. DR CTD; 1499; -. DR DisGeNET; 1499; -. DR GeneCards; CTNNB1; -. DR GeneReviews; CTNNB1; -. DR HGNC; HGNC:2514; CTNNB1. DR HPA; ENSG00000168036; Low tissue specificity. DR MalaCards; CTNNB1; -. DR MIM; 114500; phenotype. DR MIM; 116806; gene. DR MIM; 132600; phenotype. DR MIM; 155255; phenotype. DR MIM; 156240; phenotype. DR MIM; 167000; phenotype. DR MIM; 181030; phenotype. DR MIM; 615075; phenotype. DR MIM; 617572; phenotype. DR OpenTargets; ENSG00000168036; -. DR Orphanet; 952; Acrofacial dysostosis, Weyers type. DR Orphanet; 689430; Adenoid ameloblastoma. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 873; Desmoid tumor. DR Orphanet; 891; Familial exudative vitreoretinopathy. DR Orphanet; 404473; Intellectual disability-peripheral spasticity-exudative vitreoretinopathy syndrome. DR Orphanet; 569248; Microcystic stromal tumor. DR Orphanet; 2780; Osteopathia striata-cranial sclerosis syndrome. DR Orphanet; 33402; Pediatric hepatocellular carcinoma. DR Orphanet; 91414; Pilomatrixoma. DR VEuPathDB; HostDB:ENSG00000168036; -. DR eggNOG; KOG4203; Eukaryota. DR GeneTree; ENSGT00940000155471; -. DR InParanoid; P35222; -. DR OMA; YPKLVYT; -. DR OrthoDB; 195736at2759; -. DR PAN-GO; P35222; 12 GO annotations based on evolutionary models. DR PhylomeDB; P35222; -. DR PathwayCommons; P35222; -. DR Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex. DR Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade. DR Reactome; R-HSA-201681; TCF dependent signaling in response to WNT. DR Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex. DR Reactome; R-HSA-3134973; LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production. DR Reactome; R-HSA-351906; Apoptotic cleavage of cell adhesion proteins. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-381771; Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1). DR Reactome; R-HSA-4086398; Ca2+ pathway. DR Reactome; R-HSA-418990; Adherens junctions interactions. DR Reactome; R-HSA-4411364; Binding of TCF/LEF:CTNNB1 to target gene promoters. DR Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-525793; Myogenesis. DR Reactome; R-HSA-5339716; Signaling by GSK3beta mutants. DR Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated. DR Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated. DR Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated. DR Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated. DR Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells. DR Reactome; R-HSA-8951430; RUNX3 regulates WNT signaling. DR Reactome; R-HSA-9733709; Cardiogenesis. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR Reactome; R-HSA-9762292; Regulation of CDH11 function. DR Reactome; R-HSA-9764302; Regulation of CDH19 Expression and Function. DR Reactome; R-HSA-9764561; Regulation of CDH1 Function. DR Reactome; R-HSA-9766229; Degradation of CDH1. DR Reactome; R-HSA-9768727; Regulation of CDH1 posttranslational processing and trafficking to plasma membrane. DR Reactome; R-HSA-9793380; Formation of paraxial mesoderm. DR Reactome; R-HSA-9796292; Formation of axial mesoderm. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9824272; Somitogenesis. DR Reactome; R-HSA-9824585; Regulation of MITF-M-dependent genes involved in pigmentation. DR Reactome; R-HSA-9825892; Regulation of MITF-M-dependent genes involved in cell cycle and proliferation. DR Reactome; R-HSA-9830364; Formation of the nephric duct. DR Reactome; R-HSA-9833576; CDH11 homotypic and heterotypic interactions. DR Reactome; R-HSA-9834899; Specification of the neural plate border. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. DR SignaLink; P35222; -. DR SIGNOR; P35222; -. DR Agora; ENSG00000168036; -. DR BioGRID-ORCS; 1499; 103 hits in 1178 CRISPR screens. DR CD-CODE; 38EC0B30; Transcriptional condensate. DR CD-CODE; 53379B70; LEF1/Beta-catenin condensate. DR CD-CODE; 7FF4107C; Beta-Catenin Destruction Complex. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CTNNB1; human. DR EvolutionaryTrace; P35222; -. DR GeneWiki; Beta-catenin; -. DR GenomeRNAi; 1499; -. DR Pharos; P35222; Tchem. DR PRO; PR:P35222; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P35222; protein. DR Bgee; ENSG00000168036; Expressed in adrenal tissue and 204 other cell types or tissues. DR ExpressionAtlas; P35222; baseline and differential. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0045177; C:apical part of cell; IEA:Ensembl. DR GO; GO:0016327; C:apicolateral plasma membrane; IEA:Ensembl. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB. DR GO; GO:0030877; C:beta-catenin destruction complex; IDA:BHF-UCL. DR GO; GO:1990711; C:beta-catenin-ICAT complex; IEA:Ensembl. DR GO; GO:1990907; C:beta-catenin-TCF complex; IDA:FlyBase. DR GO; GO:0070369; C:beta-catenin-TCF7L2 complex; IDA:UniProtKB. DR GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl. DR GO; GO:0016342; C:catenin complex; IDA:UniProtKB. DR GO; GO:0005938; C:cell cortex; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:BHF-UCL. DR GO; GO:0071944; C:cell periphery; IDA:BHF-UCL. DR GO; GO:0005911; C:cell-cell junction; IDA:MGI. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0000791; C:euchromatin; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005916; C:fascia adherens; IEA:Ensembl. DR GO; GO:0016600; C:flotillin complex; IEA:Ensembl. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0030027; C:lamellipodium; IEA:Ensembl. DR GO; GO:0016328; C:lateral plasma membrane; IDA:MGI. DR GO; GO:0016020; C:membrane; ISS:UniProtKB. DR GO; GO:0031528; C:microvillus membrane; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0099092; C:postsynaptic density, intracellular component; IEA:Ensembl. DR GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl. DR GO; GO:0098831; C:presynaptic active zone cytoplasmic component; IEA:Ensembl. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0032993; C:protein-DNA complex; IDA:BHF-UCL. DR GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl. DR GO; GO:0034750; C:Scrib-APC-beta-catenin complex; IEA:Ensembl. DR GO; GO:0000922; C:spindle pole; IEA:UniProtKB-SubCell. DR GO; GO:0045202; C:synapse; ISS:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:BHF-UCL. DR GO; GO:1990909; C:Wnt signalosome; NAS:ParkinsonsUK-UCL. DR GO; GO:0030018; C:Z disc; IEA:Ensembl. DR GO; GO:0045294; F:alpha-catenin binding; IPI:BHF-UCL. DR GO; GO:0045296; F:cadherin binding; IPI:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; ISS:ParkinsonsUK-UCL. DR GO; GO:0097718; F:disordered domain specific binding; IEA:Ensembl. DR GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:ParkinsonsUK-UCL. DR GO; GO:1990226; F:histone methyltransferase binding; ISS:ARUK-UCL. DR GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL. DR GO; GO:0019900; F:kinase binding; IPI:BHF-UCL. DR GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:BHF-UCL. DR GO; GO:0016922; F:nuclear receptor binding; IPI:BHF-UCL. DR GO; GO:0019902; F:phosphatase binding; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0019903; F:protein phosphatase binding; IBA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:ARUK-UCL. DR GO; GO:0046332; F:SMAD binding; IPI:BHF-UCL. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0001221; F:transcription coregulator binding; ISS:ARUK-UCL. DR GO; GO:0001222; F:transcription corepressor binding; IPI:UniProtKB. DR GO; GO:0044325; F:transmembrane transporter binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; EXP:DisProt. DR GO; GO:0090425; P:acinar cell differentiation; IEA:Ensembl. DR GO; GO:0034333; P:adherens junction assembly; IMP:BHF-UCL. DR GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0036520; P:astrocyte-dopaminergic neuron signaling; IEA:Ensembl. DR GO; GO:0045453; P:bone resorption; IEA:Ensembl. DR GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IEA:Ensembl. DR GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IEA:Ensembl. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB. DR GO; GO:0044338; P:canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation; IEA:Ensembl. DR GO; GO:0007155; P:cell adhesion; IMP:BHF-UCL. DR GO; GO:0001708; P:cell fate specification; IEA:Ensembl. DR GO; GO:0048469; P:cell maturation; IEA:Ensembl. DR GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central. DR GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IMP:BHF-UCL. DR GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IMP:BHF-UCL. DR GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB. DR GO; GO:0022009; P:central nervous system vasculogenesis; IEA:Ensembl. DR GO; GO:0007268; P:chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0061550; P:cranial ganglion development; IEA:Ensembl. DR GO; GO:1904888; P:cranial skeletal system development; IEA:Ensembl. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0035995; P:detection of muscle stretch; TAS:BHF-UCL. DR GO; GO:1990791; P:dorsal root ganglion development; IEA:Ensembl. DR GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl. DR GO; GO:0007398; P:ectoderm development; IEA:Ensembl. DR GO; GO:0000578; P:embryonic axis specification; IEA:Ensembl. DR GO; GO:1990403; P:embryonic brain development; IEA:Ensembl. DR GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0048617; P:embryonic foregut morphogenesis; IEA:Ensembl. DR GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl. DR GO; GO:0035050; P:embryonic heart tube development; IEA:Ensembl. DR GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl. DR GO; GO:0036023; P:embryonic skeletal limb joint morphogenesis; ISS:BHF-UCL. DR GO; GO:0001711; P:endodermal cell fate commitment; IEA:Ensembl. DR GO; GO:0061154; P:endothelial tube morphogenesis; IMP:BHF-UCL. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:ARUK-UCL. DR GO; GO:0002064; P:epithelial cell development; IEA:Ensembl. DR GO; GO:0060742; P:epithelial cell differentiation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0060767; P:epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0001837; P:epithelial to mesenchymal transition; TAS:HGNC-UCL. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0060856; P:establishment of blood-brain barrier; IEA:Ensembl. DR GO; GO:1990963; P:establishment of blood-retinal barrier; IEA:Ensembl. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0061198; P:fungiform papilla formation; IEA:Ensembl. DR GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl. DR GO; GO:0035112; P:genitalia morphogenesis; IEA:Ensembl. DR GO; GO:0007403; P:glial cell fate determination; IEA:Ensembl. DR GO; GO:0035315; P:hair cell differentiation; TAS:BHF-UCL. DR GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl. DR GO; GO:0060789; P:hair follicle placode formation; IEA:Ensembl. DR GO; GO:0030902; P:hindbrain development; IEA:Ensembl. DR GO; GO:0021854; P:hypothalamus development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0021819; P:layer formation in cerebral cortex; IEA:Ensembl. DR GO; GO:0002089; P:lens morphogenesis in camera-type eye; IEA:Ensembl. DR GO; GO:0060487; P:lung epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0060492; P:lung induction; IEA:Ensembl. DR GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl. DR GO; GO:0030539; P:male genitalia development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; IEA:Ensembl. DR GO; GO:0072497; P:mesenchymal stem cell differentiation; IMP:ARUK-UCL. DR GO; GO:0060231; P:mesenchymal to epithelial transition; IMP:UniProtKB. DR GO; GO:0003338; P:metanephros morphogenesis; IEA:Ensembl. DR GO; GO:1904948; P:midbrain dopaminergic neuron differentiation; ISS:ParkinsonsUK-UCL. DR GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl. DR GO; GO:0016525; P:negative regulation of angiogenesis; ISS:BHF-UCL. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:BHF-UCL. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0032331; P:negative regulation of chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:0003340; P:negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis; IEA:Ensembl. DR GO; GO:0045976; P:negative regulation of mitotic cell cycle, embryonic; ISS:UniProtKB. DR GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl. DR GO; GO:1903377; P:negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0033234; P:negative regulation of protein sumoylation; IDA:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0072079; P:nephron tubule formation; IEA:Ensembl. DR GO; GO:0001840; P:neural plate development; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0048664; P:neuron fate determination; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:1990138; P:neuron projection extension; IMP:UniProtKB. DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; IMP:ARUK-UCL. DR GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl. DR GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL. DR GO; GO:0060066; P:oviduct development; IEA:Ensembl. DR GO; GO:0031016; P:pancreas development; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:1905555; P:positive regulation of blood vessel branching; IMP:BHF-UCL. DR GO; GO:0061047; P:positive regulation of branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IEA:Ensembl. DR GO; GO:0045597; P:positive regulation of cell differentiation; NAS:ComplexPortal. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000017; P:positive regulation of determination of dorsal identity; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl. DR GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0010909; P:positive regulation of heparan sulfate proteoglycan biosynthetic process; IMP:BHF-UCL. DR GO; GO:0034112; P:positive regulation of homotypic cell-cell adhesion; IGI:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl. DR GO; GO:2000288; P:positive regulation of myoblast proliferation; IEA:Ensembl. DR GO; GO:0002052; P:positive regulation of neuroblast proliferation; ISS:UniProtKB. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:ParkinsonsUK-UCL. DR GO; GO:1901331; P:positive regulation of odontoblast differentiation; IEA:Ensembl. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl. DR GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; IEA:Ensembl. DR GO; GO:2000648; P:positive regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:ARUK-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:0034394; P:protein localization to cell surface; IMP:BHF-UCL. DR GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB. DR GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl. DR GO; GO:0045765; P:regulation of angiogenesis; TAS:BHF-UCL. DR GO; GO:0090279; P:regulation of calcium ion import; IDA:BHF-UCL. DR GO; GO:0030997; P:regulation of centriole-centriole cohesion; IDA:UniProtKB. DR GO; GO:0070602; P:regulation of centromeric sister chromatid cohesion; IMP:BHF-UCL. DR GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; IMP:UniProtKB. DR GO; GO:0048145; P:regulation of fibroblast proliferation; TAS:BHF-UCL. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0072182; P:regulation of nephron tubule epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0050767; P:regulation of neurogenesis; TAS:ParkinsonsUK-UCL. DR GO; GO:2000008; P:regulation of protein localization to cell surface; IDA:BHF-UCL. DR GO; GO:0031396; P:regulation of protein ubiquitination; IMP:DisProt. DR GO; GO:0003266; P:regulation of secondary heart field cardioblast proliferation; IEA:Ensembl. DR GO; GO:0048660; P:regulation of smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:0051963; P:regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0042129; P:regulation of T cell proliferation; IEA:Ensembl. DR GO; GO:0051884; P:regulation of timing of anagen; IEA:Ensembl. DR GO; GO:0072053; P:renal inner medulla development; IEA:Ensembl. DR GO; GO:0072054; P:renal outer medulla development; IEA:Ensembl. DR GO; GO:0072033; P:renal vesicle formation; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0051145; P:smooth muscle cell differentiation; IEA:Ensembl. DR GO; GO:0019827; P:stem cell population maintenance; TAS:BHF-UCL. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0061549; P:sympathetic ganglion development; ISS:UniProtKB. DR GO; GO:0050808; P:synapse organization; IEA:Ensembl. DR GO; GO:0097091; P:synaptic vesicle clustering; IEA:Ensembl. DR GO; GO:0048489; P:synaptic vesicle transport; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0060440; P:trachea formation; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR CDD; cd21724; CTNNAbd_CTNNB1; 1. DR DisProt; DP01119; -. DR FunFam; 1.25.10.10:FF:000015; Catenin beta-1; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR IDEAL; IID00039; -. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR013284; Beta-catenin. DR PANTHER; PTHR45976; ARMADILLO SEGMENT POLARITY PROTEIN; 1. DR Pfam; PF00514; Arm; 4. DR PRINTS; PR01869; BCATNINFAMLY. DR SMART; SM00185; ARM; 12. DR SUPFAM; SSF48371; ARM repeat; 1. DR PROSITE; PS50176; ARM_REPEAT; 9. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Cell adhesion; Cell junction; KW Cell membrane; Cell projection; Chromosomal rearrangement; Cytoplasm; KW Cytoskeleton; Disease variant; Glycoprotein; Host-virus interaction; KW Intellectual disability; Membrane; Neurogenesis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; S-nitrosylation; KW Synapse; Transcription; Transcription regulation; Ubl conjugation; KW Wnt signaling pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..781 FT /note="Catenin beta-1" FT /id="PRO_0000064271" FT REPEAT 151..191 FT /note="ARM 1" FT REPEAT 193..234 FT /note="ARM 2" FT REPEAT 235..276 FT /note="ARM 3" FT REPEAT 277..318 FT /note="ARM 4" FT REPEAT 319..360 FT /note="ARM 5" FT REPEAT 361..389 FT /note="ARM 6" FT REPEAT 400..441 FT /note="ARM 7" FT REPEAT 442..484 FT /note="ARM 8" FT REPEAT 489..530 FT /note="ARM 9" FT REPEAT 531..571 FT /note="ARM 10" FT REPEAT 594..636 FT /note="ARM 11" FT REPEAT 637..666 FT /note="ARM 12" FT REGION 2..23 FT /note="Interaction with VCL" FT /evidence="ECO:0000250" FT REGION 34..57 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 156..178 FT /note="Interaction with BCL9" FT /evidence="ECO:0000269|PubMed:17052462" FT REGION 705..781 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 772..781 FT /note="Interaction with SCRIB" FT /evidence="ECO:0000250" FT COMPBIAS 734..745 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 23 FT /note="Phosphoserine; by GSK3-beta; alternate" FT /evidence="ECO:0000269|PubMed:12027456" FT MOD_RES 29 FT /note="Phosphoserine; by GSK3-beta" FT /evidence="ECO:0000269|PubMed:12027456" FT MOD_RES 33 FT /note="Phosphoserine; by GSK3-beta and HIPK2" FT /evidence="ECO:0000269|PubMed:20307497, FT ECO:0000269|PubMed:25169422" FT MOD_RES 37 FT /note="Phosphoserine; by GSK3-beta and HIPK2" FT /evidence="ECO:0000269|PubMed:20307497" FT MOD_RES 41 FT /note="Phosphothreonine; by GSK3-beta" FT /evidence="ECO:0000269|PubMed:12027456, FT ECO:0000269|PubMed:30714168" FT MOD_RES 45 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:12051714" FT MOD_RES 49 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24824780" FT MOD_RES 64 FT /note="Phosphotyrosine; by PTK6" FT /evidence="ECO:0000269|PubMed:20026641" FT MOD_RES 142 FT /note="Phosphotyrosine; by FYN and PTK6" FT /evidence="ECO:0000269|PubMed:12640114, FT ECO:0000269|PubMed:20026641" FT MOD_RES 191 FT /note="Phosphoserine; by CDK5" FT /evidence="ECO:0000269|PubMed:17009320, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 246 FT /note="Phosphoserine; by CDK5" FT /evidence="ECO:0000269|PubMed:17009320" FT MOD_RES 331 FT /note="Phosphotyrosine; by PTK6" FT /evidence="ECO:0000269|PubMed:20026641" FT MOD_RES 333 FT /note="Phosphotyrosine; by SRC and PTK6" FT /evidence="ECO:0000269|PubMed:22056988, FT ECO:0000305|PubMed:20026641" FT MOD_RES 552 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:24275569" FT MOD_RES 556 FT /note="(Microbial infection) Phosphothreonine" FT /evidence="ECO:0000269|PubMed:31801859" FT MOD_RES 556 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 619 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000250|UniProtKB:Q02248" FT MOD_RES 675 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:20068231" FT CARBOHYD 23 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:24342833" FT VARIANT 23 FT /note="S -> R (in hepatocellular carcinoma; no effect; FT dbSNP:rs1413975856)" FT /evidence="ECO:0000269|PubMed:10435629, FT ECO:0000269|PubMed:12027456" FT /id="VAR_017612" FT VARIANT 25..33 FT /note="Missing (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017613" FT VARIANT 32 FT /note="D -> A (in hepatocellular carcinoma; FT dbSNP:rs121913396)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017614" FT VARIANT 32 FT /note="D -> G (in PTR and hepatocellular carcinoma; FT dbSNP:rs121913396)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10435629" FT /id="VAR_017615" FT VARIANT 32 FT /note="D -> Y (in PTR, hepatoblastoma and hepatocellular FT carcinoma; dbSNP:rs28931588)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10435629, ECO:0000269|PubMed:11703283, FT ECO:0000269|PubMed:9927029" FT /id="VAR_017616" FT VARIANT 33 FT /note="S -> F (in PTR, MDB and hepatocellular carcinoma; FT dbSNP:rs121913400)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10435629, ECO:0000269|PubMed:10666372" FT /id="VAR_017617" FT VARIANT 33 FT /note="S -> L (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017618" FT VARIANT 33 FT /note="S -> Y (in colorectal cancer and PTR; constitutively FT active Wnt signaling pathway; enhances transactivation of FT target genes; dbSNP:rs121913400)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:12027456, ECO:0000269|PubMed:29374064, FT ECO:0000269|PubMed:9065402" FT /id="VAR_017619" FT VARIANT 34 FT /note="G -> E (in PTR; dbSNP:rs28931589)" FT /evidence="ECO:0000269|PubMed:10192393" FT /id="VAR_017620" FT VARIANT 34 FT /note="G -> R (in hepatocellular carcinoma; FT dbSNP:rs121913399)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017621" FT VARIANT 34 FT /note="G -> V (in hepatoblastoma; dbSNP:rs28931589)" FT /evidence="ECO:0000269|PubMed:9927029" FT /id="VAR_017622" FT VARIANT 35 FT /note="I -> S (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017623" FT VARIANT 37..38 FT /note="SG -> W (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017628" FT VARIANT 37 FT /note="S -> A (in MDB and hepatocellular carcinoma; FT enhances transactivation of target genes; FT dbSNP:rs121913228)" FT /evidence="ECO:0000269|PubMed:10435629, FT ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:12027456" FT /id="VAR_017624" FT VARIANT 37 FT /note="S -> C (in PTR, hepatoblastoma and ovarian cancer; FT dbSNP:rs121913403)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10391090, ECO:0000269|PubMed:9927029" FT /id="VAR_017625" FT VARIANT 37 FT /note="S -> F (in PTR; dbSNP:rs121913403)" FT /evidence="ECO:0000269|PubMed:10192393" FT /id="VAR_017626" FT VARIANT 37 FT /note="S -> Y (in hepatocellular carcinoma; FT dbSNP:rs121913403)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017627" FT VARIANT 41 FT /note="T -> A (in hepatoblastoma and hepatocellular FT carcinoma; also in a desmoid tumor; strongly reduces FT phosphorylation and degradation; abolishes phosphorylation FT on Ser-33 and Ser-37 and enhances transactivation of target FT genes; dbSNP:rs121913412)" FT /evidence="ECO:0000269|PubMed:10391090, FT ECO:0000269|PubMed:10398436, ECO:0000269|PubMed:10435629, FT ECO:0000269|PubMed:10655994, ECO:0000269|PubMed:12027456, FT ECO:0000269|PubMed:12051714, ECO:0000269|PubMed:9927029" FT /id="VAR_017629" FT VARIANT 41 FT /note="T -> I (in PTR, hepatocellular carcinoma and ovarian FT cancer; dbSNP:rs121913413)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10391090, ECO:0000269|PubMed:10435629" FT /id="VAR_017630" FT VARIANT 45 FT /note="S -> F (in hepatocellular carcinoma; FT dbSNP:rs121913409)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017631" FT VARIANT 45 FT /note="S -> P (in hepatocellular carcinoma; FT dbSNP:rs121913407)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017632" FT VARIANT 45 FT /note="Missing (in colorectal cancer)" FT /evidence="ECO:0000269|PubMed:9065402" FT /id="VAR_055430" FT VARIANT 292 FT /note="K -> N (found in a patient with features of FT osteopathia striata cranial sclerosis; uncertain FT significance; results in increased Wnt signaling)" FT /evidence="ECO:0000269|PubMed:38173341" FT /id="VAR_089205" FT VARIANT 388 FT /note="L -> P (in NEDSDV)" FT /evidence="ECO:0000269|PubMed:25326669" FT /id="VAR_072282" FT VARIANT 558..781 FT /note="Missing (in NEDSDV; the patient also manifest FT features of exudative vitreoretinopathy)" FT /evidence="ECO:0000269|PubMed:28514307" FT /id="VAR_079199" FT VARIANT 688 FT /note="M -> V (in dbSNP:rs4135384)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_018954" FT VARIANT 710 FT /note="R -> C (in EVR7; uncertain significance; FT dbSNP:rs748653573)" FT /evidence="ECO:0000269|PubMed:28575650" FT /id="VAR_079200" FT MUTAGEN 29 FT /note="S->F: No effect." FT /evidence="ECO:0000269|PubMed:12027456" FT MUTAGEN 64 FT /note="Y->F: Abolishes phosphorylation by PTK6." FT /evidence="ECO:0000269|PubMed:20026641" FT MUTAGEN 142 FT /note="Y->E: No effect on interaction with BCL9 and BCL9L." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 156 FT /note="L->A: Abolishes interaction with BCL9 but no effect FT on interaction with CDH3; when associated with A-159." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 159 FT /note="L->A: No effect on interaction with BCL9 and CDH3. FT Abolishes interaction with BCL9 but no effect on FT interaction with CDH3; when associated with A-156." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 178 FT /note="L->A: No effect on interaction with BCL9 and CDH3." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 253 FT /note="F->A: Abolishes or strongly reduces AXIN2 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 260 FT /note="H->A: Abolishes or strongly reduces AXIN1 and AXIN2 FT binding. Strongly reduces phosphorylation and degradation; FT when associated with A-386 and A-383." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 292 FT /note="K->A: Abolishes or strongly reduces AXIN1 and AXIN2 FT binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 312 FT /note="K->E: Abolishes TCF7L2 binding." FT /evidence="ECO:0000269|PubMed:11713475" FT MUTAGEN 333 FT /note="Y->F: Abolished phosphorylation by SRC and FT interaction with isoform M2 of PKM (PKM2)." FT /evidence="ECO:0000269|PubMed:22056988" FT MUTAGEN 345 FT /note="K->A: Abolishes APC binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 383 FT /note="W->A: Abolishes APC binding. Strongly reduces FT phosphorylation and degradation; when associated with A-260 FT and A-386." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 386 FT /note="R->A: Strongly reduces APC binding. Strongly reduces FT phosphorylation and degradation; when associated with A-260 FT and A-383." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 426 FT /note="N->A: Abolishes TCF7L2 and LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 435 FT /note="K->A: Strongly reduces or abolishes LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653, FT ECO:0000269|PubMed:11713475" FT MUTAGEN 435 FT /note="K->E: Abolishes TCF7L2 binding." FT /evidence="ECO:0000269|PubMed:10966653, FT ECO:0000269|PubMed:11713475" FT MUTAGEN 469 FT /note="R->A: Abolishes TCF7L2 binding, and strongly reduces FT or abolishes LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 470 FT /note="H->A: Abolishes TCF7L2 binding, and strongly reduces FT or abolishes LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 508 FT /note="K->A: Abolishes TCF7L2 and LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 660 FT /note="F->A: Abolishes CTNNBIP1 binding; when associated FT with A-661." FT /evidence="ECO:0000269|PubMed:12408824" FT MUTAGEN 661 FT /note="R->A: Abolishes CTNNBIP1 binding; when associated FT with A-660." FT /evidence="ECO:0000269|PubMed:12408824" FT TURN 20..22 FT /evidence="ECO:0007829|PDB:2G57" FT STRAND 23..26 FT /evidence="ECO:0007829|PDB:2G57" FT TURN 27..29 FT /evidence="ECO:0007829|PDB:2G57" FT TURN 39..41 FT /evidence="ECO:0007829|PDB:2G57" FT HELIX 145..160 FT /evidence="ECO:0007829|PDB:7AFW" FT STRAND 161..164 FT /evidence="ECO:0007829|PDB:7UWO" FT HELIX 165..179 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 182..189 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 192..204 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 208..221 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 225..233 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 236..243 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 249..265 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 269..275 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 278..284 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 285..287 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 291..303 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 309..317 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 320..330 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 334..347 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 353..359 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 362..367 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 368..371 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 375..389 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 392..394 FT /evidence="ECO:0007829|PDB:7ZRB" FT HELIX 399..408 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 414..427 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 428..430 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 432..440 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 443..454 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 458..471 FT /evidence="ECO:0007829|PDB:1JDH" FT STRAND 473..475 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 478..487 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 491..496 FT /evidence="ECO:0007829|PDB:1JDH" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:4DJS" FT HELIX 504..517 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 521..523 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 524..529 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 532..547 FT /evidence="ECO:0007829|PDB:1JDH" FT STRAND 550..552 FT /evidence="ECO:0007829|PDB:1QZ7" FT STRAND 554..557 FT /evidence="ECO:0007829|PDB:1QZ7" FT STRAND 561..563 FT /evidence="ECO:0007829|PDB:1T08" FT HELIX 566..580 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 584..592 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 596..601 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 602..604 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 608..621 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 625..633 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:8Y0G" FT HELIX 637..642 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 643..645 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 649..662 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 663..665 FT /evidence="ECO:0007829|PDB:2Z6H" FT HELIX 668..682 FT /evidence="ECO:0007829|PDB:2Z6H" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:2Z6H" FT STRAND 778..780 FT /evidence="ECO:0007829|PDB:3DIW" SQ SEQUENCE 781 AA; 85497 MW; CB78F165A3EEF86E CRC64; MATQADLMEL DMAMEPDRKA AVSHWQQQSY LDSGIHSGAT TTAPSLSGKG NPEEEDVDTS QVLYEWEQGF SQSFTQEQVA DIDGQYAMTR AQRVRAAMFP ETLDEGMQIP STQFDAAHPT NVQRLAEPSQ MLKHAVVNLI NYQDDAELAT RAIPELTKLL NDEDQVVVNK AAVMVHQLSK KEASRHAIMR SPQMVSAIVR TMQNTNDVET ARCTAGTLHN LSHHREGLLA IFKSGGIPAL VKMLGSPVDS VLFYAITTLH NLLLHQEGAK MAVRLAGGLQ KMVALLNKTN VKFLAITTDC LQILAYGNQE SKLIILASGG PQALVNIMRT YTYEKLLWTT SRVLKVLSVC SSNKPAIVEA GGMQALGLHL TDPSQRLVQN CLWTLRNLSD AATKQEGMEG LLGTLVQLLG SDDINVVTCA AGILSNLTCN NYKNKMMVCQ VGGIEALVRT VLRAGDREDI TEPAICALRH LTSRHQEAEM AQNAVRLHYG LPVVVKLLHP PSHWPLIKAT VGLIRNLALC PANHAPLREQ GAIPRLVQLL VRAHQDTQRR TSMGGTQQQF VEGVRMEEIV EGCTGALHIL ARDVHNRIVI RGLNTIPLFV QLLYSPIENI QRVAAGVLCE LAQDKEAAEA IEAEGATAPL TELLHSRNEG VATYAAAVLF RMSEDKPQDY KKRLSVELTS SLFRTEPMAW NETADLGLDI GAQGEPLGYR QDDPSYRSFH SGGYGQDALG MDPMMEHEMG GHHPGADYPV DGLPDLGHAQ DLMDGLPPGD SNQLAWFDTD L // ID DAPK3_HUMAN Reviewed; 454 AA. AC O43293; A0AVN4; B3KQE2; Q05JY4; DT 28-NOV-2003, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1998, sequence version 1. DT 28-JAN-2026, entry version 218. DE RecName: Full=Death-associated protein kinase 3; DE Short=DAP kinase 3; DE EC=2.7.11.1 {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; DE AltName: Full=DAP-like kinase; DE Short=Dlk; DE AltName: Full=MYPT1 kinase; DE AltName: Full=Zipper-interacting protein kinase; DE Short=ZIP-kinase; GN Name=DAPK3; Synonyms=ZIPK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9488481; DOI=10.1128/mcb.18.3.1642; RA Kawai T., Matsumoto M., Takeda K., Sanjo H., Akira S.; RT "ZIP kinase, a novel serine/threonine kinase which mediates apoptosis."; RL Mol. Cell. Biol. 18:1642-1651(1998). RN [2] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND COFACTOR. RC TISSUE=Cervix carcinoma; RX PubMed=10356987; DOI=10.1016/s0014-5793(99)00550-5; RA Murata-Hori M., Suizu F., Iwasaki T., Kikuchi A., Hosoya H.; RT "ZIP kinase identified as a novel myosin regulatory light chain kinase in RT HeLa cells."; RL FEBS Lett. 451:81-84(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 165-454 (ISOFORM 2), ALTERNATIVE SPLICING, RP FUNCTION IN PHOSPHORYLATION OF MYOSIN; PPP1R12A AND MYL12B, CATALYTIC RP ACTIVITY, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION RP WITH PPP1R12A AND MYOSIN, AUTOPHOSPHORYLATION, AND TISSUE SPECIFICITY. RC TISSUE=Urinary bladder; RX PubMed=17126281; DOI=10.1016/j.abb.2006.09.026; RA Takamoto N., Komatsu S., Komaba S., Niiro N., Ikebe M.; RT "Novel ZIP kinase isoform lacks leucine zipper."; RL Arch. Biochem. Biophys. 456:194-203(2006). RN [6] RP FUNCTION IN PHOSPHORYLATION OF MUSCLE MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=11384979; DOI=10.1074/jbc.m102753200; RA Niiro N., Ikebe M.; RT "Zipper-interacting protein kinase induces Ca(2+)-free smooth muscle RT contraction via myosin light chain phosphorylation."; RL J. Biol. Chem. 276:29567-29574(2001). RN [7] RP FUNCTION IN PHOSPHORYLATION OF NON-MUSCLE MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=11781833; DOI=10.1038/sj.onc.1205055; RA Murata-Hori M., Fukuta Y., Ueda K., Iwasaki T., Hosoya H.; RT "HeLa ZIP kinase induces diphosphorylation of myosin II regulatory light RT chain and reorganization of actin filaments in nonmuscle cells."; RL Oncogene 20:8175-8183(2001). RN [8] {ECO:0000305} RP FUNCTION IN APOPTOSIS, AND INTERACTION WITH DAXX AND PAWR. RX PubMed=12917339; DOI=10.1128/mcb.23.17.6174-6186.2003; RA Kawai T., Akira S., Reed J.C.; RT "ZIP kinase triggers apoptosis from nuclear PML oncogenic domains."; RL Mol. Cell. Biol. 23:6174-6186(2003). RN [9] RP INTERACTION WITH PPP1R12A, AND TISSUE SPECIFICITY. RX PubMed=15292222; DOI=10.1074/jbc.m403676200; RA Endo A., Surks H.K., Mochizuki S., Mochizuki N., Mendelsohn M.E.; RT "Identification and characterization of zipper-interacting protein kinase RT as the unique vascular smooth muscle myosin phosphatase-associated RT kinase."; RL J. Biol. Chem. 279:42055-42061(2004). RN [10] RP FUNCTION IN PHOSPHORYLATION OF MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=15096528; DOI=10.1083/jcb.200309056; RA Komatsu S., Ikebe M.; RT "ZIP kinase is responsible for the phosphorylation of myosin II and RT necessary for cell motility in mammalian fibroblasts."; RL J. Cell Biol. 165:243-254(2004). RN [11] RP FUNCTION, PHOSPHORYLATION AT THR-299; SER-309; SER-311; SER-312; SER-318 RP AND SER-326, PHOSPHORYLATION BY DAPK1, AND SUBCELLULAR LOCATION. RX PubMed=15367680; DOI=10.1128/mcb.24.19.8611-8626.2004; RA Shani G., Marash L., Gozuacik D., Bialik S., Teitelbaum L., Shohat G., RA Kimchi A.; RT "Death-associated protein kinase phosphorylates ZIP kinase, forming a RT unique kinase hierarchy to activate its cell death functions."; RL Mol. Cell. Biol. 24:8611-8626(2004). RN [12] RP INTERACTION WITH STAT3. RX PubMed=16219639; DOI=10.1093/intimm/dxh331; RA Sato N., Kawai T., Sugiyama K., Muromoto R., Imoto S., Sekine Y., RA Ishida M., Akira S., Matsuda T.; RT "Physical and functional interactions between STAT3 and ZIP kinase."; RL Int. Immunol. 17:1543-1552(2005). RN [13] RP INTERACTION WITH TCP10L, AND SUBCELLULAR LOCATION. RX PubMed=15910542; DOI=10.1111/j.1365-2605.2005.00522.x; RA Yu H., Jiang D., Guo Z., Saiyin H., Guo J., Wang X., Yu L.; RT "TCP10L is expressed specifically in spermatogenic cells and binds to death RT associated protein kinase-3."; RL Int. J. Androl. 28:163-170(2005). RN [14] RP PHOSPHORYLATION AT THR-180; THR-225; THR-265; THR-299; THR-306 AND SER-311, RP ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-299; RP 299-THR-THR-300; VAL-427; VAL-434 AND LEU-441. RX PubMed=15611134; DOI=10.1074/jbc.m412538200; RA Graves P.R., Winkfield K.M., Haystead T.A.; RT "Regulation of zipper-interacting protein kinase activity in vitro and in RT vivo by multisite phosphorylation."; RL J. Biol. Chem. 280:9363-9374(2005). RN [15] RP REVIEW ON FUNCTION. RX PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615; RA Bialik S., Kimchi A.; RT "The death-associated protein kinases: structure, function, and beyond."; RL Annu. Rev. Biochem. 75:189-210(2006). RN [16] RP FUNCTION, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP THR-180; THR-265 AND THR-299, AND MUTAGENESIS OF LYS-42; ASP-161; THR-225; RP THR-265 AND THR-299. RX PubMed=17158456; DOI=10.1074/jbc.m609990200; RA Hagerty L., Weitzel D.H., Chambers J., Fortner C.N., Brush M.H., RA Loiselle D., Hosoya H., Haystead T.A.; RT "ROCK1 phosphorylates and activates zipper-interacting protein kinase."; RL J. Biol. Chem. 282:4884-4893(2007). RN [17] RP SUBCELLULAR LOCATION, AND ABSENCE OF INTERACTION WITH PARW. RX PubMed=17953487; DOI=10.1371/journal.pgen.0030180; RA Shoval Y., Pietrokovski S., Kimchi A.; RT "ZIPK: a unique case of murine-specific divergence of a conserved RT vertebrate gene."; RL PLoS Genet. 3:1884-1893(2007). RN [18] RP REVIEW ON FUNCTION. RX DOI=10.1002/sita.200600112; RA Scheidtmann K.H.; RT "Dlk/ZIP kinase, a novel Ser/Thr-specific protein kinase with multiple RT functions."; RL Signal Transduct. 7:248-259(2007). RN [19] RP FUNCTION IN PHOSPHORYLATION OF RPL13A, AND CATALYTIC ACTIVITY. RX PubMed=18995835; DOI=10.1016/j.molcel.2008.09.019; RA Mukhopadhyay R., Ray P.S., Arif A., Brady A.K., Kinter M., Fox P.L.; RT "DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating RT inflammatory gene expression."; RL Mol. Cell 32:371-382(2008). RN [20] RP FUNCTION IN ANDROGEN RECEPTOR-MEDIATED TRANSCRIPTION. RX PubMed=18084323; DOI=10.1038/sj.onc.1210995; RA Leister P., Felten A., Chasan A.I., Scheidtmann K.H.; RT "ZIP kinase plays a crucial role in androgen receptor-mediated RT transcription."; RL Oncogene 27:3292-3300(2008). RN [21] RP FUNCTION AS TUMOR SUPPRESSOR, CHARACTERIZATION OF VARIANTS MET-112; ASN-161 RP AND SER-216, MUTAGENESIS OF THR-180, AND SELF-ASSOCIATION. RX PubMed=21487036; DOI=10.1158/0008-5472.can-10-3543; RA Brognard J., Zhang Y.W., Puto L.A., Hunter T.; RT "Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor- RT suppressing kinase."; RL Cancer Res. 71:3152-3161(2011). RN [22] RP PHOSPHORYLATION AT THR-299, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 294-ARG-ARG-295. RX PubMed=20854903; DOI=10.1016/j.cellsig.2010.09.016; RA Weitzel D.H., Chambers J., Haystead T.A.; RT "Phosphorylation-dependent control of ZIPK nuclear import is species RT specific."; RL Cell. Signal. 23:297-303(2011). RN [23] RP FUNCTION IN REGULATION OF AUTOPHAGY, AND INTERACTION WITH ULK1. RX PubMed=21169990; DOI=10.1038/emboj.2010.338; RA Tang H.W., Wang Y.B., Wang S.L., Wu M.H., Lin S.Y., Chen G.C.; RT "Atg1-mediated myosin II activation regulates autophagosome formation RT during starvation-induced autophagy."; RL EMBO J. 30:636-651(2011). RN [24] RP FUNCTION, AND INTERACTION WITH NLK. RX PubMed=21454679; DOI=10.1074/jbc.m110.189829; RA Togi S., Ikeda O., Kamitani S., Nakasuji M., Sekine Y., Muromoto R., RA Nanbo A., Oritani K., Kawai T., Akira S., Matsuda T.; RT "Zipper-interacting protein kinase (ZIPK) modulates canonical Wnt/beta- RT catenin signaling through interaction with Nemo-like kinase and T-cell RT factor 4 (NLK/TCF4)."; RL J. Biol. Chem. 286:19170-19177(2011). RN [25] RP FUNCTION, AND INTERACTION WITH ATF4. RX PubMed=21408167; DOI=10.1371/journal.pone.0017344; RA Shoval Y., Berissi H., Kimchi A., Pietrokovski S.; RT "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene RT produces a ZIPk-like isoform."; RL PLoS ONE 6:E17344-E17344(2011). RN [26] RP FUNCTION IN REORGANIZATION OF ACTIN CYTOSKELETON, AND INTERACTION WITH RP RHOD. RX PubMed=23454120; DOI=10.1016/j.bbrc.2013.02.046; RA Nehru V., Almeida F.N., Aspenstrom P.; RT "Interaction of RhoD and ZIP kinase modulates actin filament assembly and RT focal adhesion dynamics."; RL Biochem. Biophys. Res. Commun. 433:163-169(2013). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP FUNCTION, INTERACTION WITH LUZP1, AND SUBCELLULAR LOCATION. RX PubMed=38009294; DOI=10.1111/febs.17017; RA Hyodo T., Asano-Inami E., Ito S., Sugiyama M., Nawa A., Rahman M.L., RA Hasan M.N., Mihara Y., Lam V.Q., Karnan S., Ota A., Tsuzuki S., RA Hamaguchi M., Hosokawa Y., Konishi H.; RT "Leucine zipper protein 1 (LUZP1) regulates the constriction velocity of RT the contractile ring during cytokinesis."; RL FEBS J. 291:927-944(2024). RN [29] RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-277. RA Kursula P., Vahokoski J., Wilmanns M.; RT "Crystal structure of human ZIP kinase."; RL Submitted (JUN-2006) to the PDB data bank. RN [30] {ECO:0007744|PDB:2J90} RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 9-289 IN COMPLEX WITH PYRIDONE-6, RP ACTIVITY REGULATION, SUBUNIT, AND PHOSPHORYLATION AT SER-50 AND THR-265. RX PubMed=18239682; DOI=10.1038/emboj.2008.8; RA Pike A.C., Rellos P., Niesen F.H., Turnbull A., Oliver A.W., Parker S.A., RA Turk B.E., Pearl L.H., Knapp S.; RT "Activation segment dimerization: a mechanism for kinase RT autophosphorylation of non-consensus sites."; RL EMBO J. 27:704-714(2008). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] MET-112; ASN-161 AND SER-216. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which is involved in the regulation CC of apoptosis, autophagy, transcription, translation and actin CC cytoskeleton reorganization. Involved in the regulation of smooth CC muscle contraction. Regulates both type I (caspase-dependent) apoptotic CC and type II (caspase-independent) autophagic cell deaths signal, CC depending on the cellular setting. Involved in regulation of CC starvation-induced autophagy. Regulates myosin phosphorylation in both CC smooth muscle and non-muscle cells. In smooth muscle, regulates myosin CC either directly by phosphorylating MYL12B and MYL9 or through CC inhibition of smooth muscle myosin phosphatase (SMPP1M) via CC phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to CC enhance muscle responsiveness to Ca(2+) and promote a contractile CC state. Phosphorylates MYL12B in non-muscle cells leading to CC reorganization of actin cytoskeleton. Isoform 2 can phosphorylate CC myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of CC actin stress fibers into thick bundles. Involved in actin filament CC focal adhesion dynamics. The function in both reorganization of actin CC cytoskeleton and focal adhesion dissolution is modulated by RhoD. CC Positively regulates canonical Wnt/beta-catenin signaling through CC interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon CC interferon-gamma activation which is causing RPL13A release from the CC ribosome, RPL13A association with the GAIT complex and its subsequent CC involvement in transcript-selective translation inhibition. Enhances CC transcription from AR-responsive promoters in a hormone- and kinase- CC dependent manner. Involved in regulation of cell cycle progression and CC cell proliferation. May be a tumor suppressor. CC {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:12917339, CC ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281, CC ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18084323, CC ECO:0000269|PubMed:18995835, ECO:0000269|PubMed:21169990, CC ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679, CC ECO:0000269|PubMed:21487036, ECO:0000269|PubMed:23454120, CC ECO:0000269|PubMed:38009294}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, CC ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, CC ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10356987}; CC -!- ACTIVITY REGULATION: A sequential activation is proposed: CC autophosphorylation at consensus sites is leading to dimerization of CC the catalytic domain stabilized by phosphorylation at Ser-50 and CC activation segment exchange (producing an active confirmation of both CC kinase modules in trans) followed by phosphorylation at Thr-180 in the CC activation segment and at other regulatory sites (Probable). CC Phosphorylation at Thr-180, Thr-225 and Thr-265 is essential for CC activity. Oligomerization is required for full enzymatic activity. CC Inhibited by pyridone-6 (K00225), a potent, ATP-competitive inhibitor. CC {ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456, CC ECO:0000269|PubMed:18239682, ECO:0000303|PubMed:18239682}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=12 uM for myosin (isoform 2) {ECO:0000269|PubMed:17126281}; CC KM=6.2 uM for myosin (isoform 1) {ECO:0000269|PubMed:17126281}; CC KM=73 uM for MYL12B (isoform 2) {ECO:0000269|PubMed:17126281}; CC KM=10.4 uM for MYL12B (isoform 1) {ECO:0000269|PubMed:17126281}; CC Vmax=248 nmol/min/mg enzyme toward myosin (isoform 2) CC {ECO:0000269|PubMed:17126281}; CC Vmax=120 nmol/min/mg enzyme toward myosin (isoform 1) CC {ECO:0000269|PubMed:17126281}; CC Vmax=1.3 umol/min/mg enzyme toward MYL12B (isoform 2) CC {ECO:0000269|PubMed:17126281}; CC Vmax=271 nmol/min/mg enzyme toward MYL12B (isoform 1) CC {ECO:0000269|PubMed:17126281}; CC -!- SUBUNIT: Homooligomer in its kinase-active form (homotrimers and CC homodimers are reported); monomeric in its kinase-inactive form. CC Homodimerization is required for activation segment autophosphorylation CC (Probable). Isoform 1 and isoform 2 interact with myosin and PPP1R12A; CC interaction of isoform 1 with PPP1R12A is inhibited by RhoA dominant CC negative form. Interacts with NLK, DAXX, STAT3, RHOD (GTP-bound form) CC and TCP10L. Interacts with PAWR; the interaction is reported CC conflictingly: according to PubMed:17953487 does not interact with CC PAWR. Interacts with ULK1; may be a substrate of ULK1. Interacts with CC LUZP1; the interaction is likely to occur throughout the cell cycle and CC reduces the LUZP1-mediated suppression of MYL9 phosphorylation CC (PubMed:38009294). {ECO:0000269|PubMed:12917339, CC ECO:0000269|PubMed:15292222, ECO:0000269|PubMed:15910542, CC ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281, CC ECO:0000269|PubMed:18239682, ECO:0000269|PubMed:21169990, CC ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679, CC ECO:0000269|PubMed:23454120, ECO:0000269|PubMed:38009294, CC ECO:0000303|PubMed:18239682}. CC -!- INTERACTION: CC O43293; O43293: DAPK3; NbExp=3; IntAct=EBI-77293, EBI-77293; CC O43293; Q86V48: LUZP1; NbExp=3; IntAct=EBI-77293, EBI-350467; CC O43293; Q9UBE8: NLK; NbExp=3; IntAct=EBI-77293, EBI-366978; CC O43293; O14974: PPP1R12A; NbExp=5; IntAct=EBI-77293, EBI-351726; CC O43293; Q8TDR4: TCP10L; NbExp=5; IntAct=EBI-77293, EBI-3923210; CC O43293-2; Q10728: Ppp1r12a; Xeno; NbExp=2; IntAct=EBI-9691390, EBI-918263; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:15910542, ECO:0000269|PubMed:20854903}. Nucleus, PML CC body {ECO:0000250|UniProtKB:O54784}. Cytoplasm, cytoskeleton, CC microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:O54784}. Chromosome, centromere CC {ECO:0000269|PubMed:38009294}. Cytoplasm {ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17953487, CC ECO:0000269|PubMed:20854903}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:38009294}. Midbody {ECO:0000269|PubMed:38009294}. CC Note=Predominantly localizes to the cytoplasm but can shuttle between CC the nucleus and cytoplasm; cytoplasmic localization is promoted by CC phosphorylation at Thr-299 and involves Rho/Rock signaling. CC {ECO:0000269|PubMed:17953487, ECO:0000269|PubMed:20854903}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus CC {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=ZIPK-L; CC IsoId=O43293-1; Sequence=Displayed; CC Name=2; Synonyms=ZIPK-S; CC IsoId=O43293-2; Sequence=VSP_042059, VSP_042060; CC -!- TISSUE SPECIFICITY: Widely expressed. Isoform 1 and isoform 2 are CC expressed in the bladder smooth muscle. {ECO:0000269|PubMed:15292222, CC ECO:0000269|PubMed:17126281}. CC -!- PTM: The phosphorylation status is critical for kinase activity, CC oligomerization and intracellular localization. Phosphorylation at Thr- CC 180, Thr-225 and Thr-265 is essential for activity. The phosphorylated CC form is localized in the cytoplasm promoted by phosphorylation at Thr- CC 299; nuclear translocation or retention is maximal when it is not CC phosphorylated. Phosphorylation increases the trimeric form, and its CC dephosphorylation favors a kinase-inactive monomeric form. Both isoform CC 1 and isoform 2 can undergo autophosphorylation. CC {ECO:0000269|PubMed:15367680, ECO:0000269|PubMed:15611134, CC ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:20854903}. CC -!- MISCELLANEOUS: [Isoform 2]: The internal splice site between exon 8 and CC the 3' UTR, which yields this truncated isoform, is non-canonical. CC {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. DAP kinase subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB007144; BAA24955.1; -; mRNA. DR EMBL; AB022341; BAA81746.1; -; mRNA. DR EMBL; AK074799; BAG52004.1; -; mRNA. DR EMBL; BC126430; AAI26431.1; -; mRNA. DR EMBL; BC126432; AAI26433.1; -; mRNA. DR EMBL; AB265224; BAF34614.1; -; mRNA. DR CCDS; CCDS12116.1; -. [O43293-1] DR RefSeq; NP_001339.1; NM_001348.3. [O43293-1] DR RefSeq; NP_001362587.1; NM_001375658.1. [O43293-1] DR PDB; 1YRP; X-ray; 3.10 A; A/B=1-277. DR PDB; 2J90; X-ray; 2.00 A; A/B=9-289. DR PDB; 3BHY; X-ray; 1.24 A; A=9-289. DR PDB; 3BQR; X-ray; 1.75 A; A=9-289. DR PDB; 5A6N; X-ray; 1.70 A; A/B=9-289. DR PDB; 5A6O; X-ray; 1.60 A; A/B=9-289. DR PDB; 5VJA; X-ray; 2.46 A; A/B/C/D=9-289. DR PDBsum; 1YRP; -. DR PDBsum; 2J90; -. DR PDBsum; 3BHY; -. DR PDBsum; 3BQR; -. DR PDBsum; 5A6N; -. DR PDBsum; 5A6O; -. DR PDBsum; 5VJA; -. DR AlphaFoldDB; O43293; -. DR SMR; O43293; -. DR BioGRID; 107983; 101. DR FunCoup; O43293; 2772. DR IntAct; O43293; 75. DR MINT; O43293; -. DR STRING; 9606.ENSP00000442973; -. DR BindingDB; O43293; -. DR ChEMBL; CHEMBL2468; -. DR DrugBank; DB07242; (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile. DR DrugBank; DB04716; 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one. DR DrugBank; DB07125; 4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O43293; -. DR GuidetoPHARMACOLOGY; 2004; -. DR GlyGen; O43293; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O43293; -. DR PhosphoSitePlus; O43293; -. DR BioMuta; DAPK3; -. DR CPTAC; CPTAC-3091; -. DR CPTAC; CPTAC-3092; -. DR jPOST; O43293; -. DR MassIVE; O43293; -. DR PaxDb; 9606-ENSP00000442973; -. DR PeptideAtlas; O43293; -. DR ProteomicsDB; 48863; -. [O43293-1] DR ProteomicsDB; 48864; -. [O43293-2] DR Pumba; O43293; -. DR Antibodypedia; 11137; 420 antibodies from 44 providers. DR DNASU; 1613; -. DR Ensembl; ENST00000301264.7; ENSP00000301264.3; ENSG00000167657.15. [O43293-1] DR Ensembl; ENST00000545797.7; ENSP00000442973.1; ENSG00000167657.15. [O43293-1] DR GeneID; 1613; -. DR KEGG; hsa:1613; -. DR MANE-Select; ENST00000545797.7; ENSP00000442973.1; NM_001348.3; NP_001339.1. DR UCSC; uc002lzc.2; human. [O43293-1] DR AGR; HGNC:2676; -. DR ClinPGx; PA27144; -. DR CTD; 1613; -. DR DisGeNET; 1613; -. DR GeneCards; DAPK3; -. DR HGNC; HGNC:2676; DAPK3. DR HPA; ENSG00000167657; Low tissue specificity. DR MIM; 603289; gene. DR OpenTargets; ENSG00000167657; -. DR VEuPathDB; HostDB:ENSG00000167657; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000161753; -. DR HOGENOM; CLU_000288_63_55_1; -. DR InParanoid; O43293; -. DR OMA; LWYKEEN; -. DR OrthoDB; 74764at2759; -. DR PAN-GO; O43293; 5 GO annotations based on evolutionary models. DR PhylomeDB; O43293; -. DR PathwayCommons; O43293; -. DR Reactome; R-HSA-418889; Caspase activation via Dependence Receptors in the absence of ligand. DR SABIO-RK; O43293; -. DR SignaLink; O43293; -. DR SIGNOR; O43293; -. DR Agora; ENSG00000167657; -. DR BioGRID-ORCS; 1613; 21 hits in 1190 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; DAPK3; human. DR EvolutionaryTrace; O43293; -. DR GeneWiki; DAPK3; -. DR GenomeRNAi; 1613; -. DR Pharos; O43293; Tchem. DR PRO; PR:O43293; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; O43293; protein. DR Bgee; ENSG00000167657; Expressed in apex of heart and 188 other cell types or tissues. DR ExpressionAtlas; O43293; baseline and differential. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0005819; C:spindle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0008140; F:cAMP response element binding protein binding; TAS:ParkinsonsUK-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0043522; F:leucine zipper domain binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0071346; P:cellular response to type II interferon; IDA:UniProtKB. DR GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB. DR GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB. DR GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB. DR GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB. DR GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:0043519; P:regulation of myosin II filament organization; IEA:Ensembl. DR GO; GO:0006940; P:regulation of smooth muscle contraction; TAS:UniProtKB. DR CDD; cd14105; STKc_DAPK; 1. DR FunFam; 3.30.200.20:FF:000110; Death-associated kinase 3, isoform CRA_a; 1. DR FunFam; 1.10.510.10:FF:000250; Death-associated protein kinase 3; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042870; DAPK3_STKc. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24342:SF18; DEATH-ASSOCIATED PROTEIN KINASE 3; 1. DR PANTHER; PTHR24342; SERINE/THREONINE-PROTEIN KINASE 17; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Apoptosis; ATP-binding; KW Centromere; Chromatin regulator; Chromosome; Cytoplasm; Cytoskeleton; KW Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Translation regulation; Tumor suppressor. FT CHAIN 1..454 FT /note="Death-associated protein kinase 3" FT /id="PRO_0000085914" FT DOMAIN 13..275 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 161..204 FT /note="Activation segment" FT /evidence="ECO:0000250|UniProtKB:O96017" FT REGION 427..441 FT /note="Leucine-zipper" FT /evidence="ECO:0000303|PubMed:9488481" FT ACT_SITE 139 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 19..27 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 42 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT BINDING 94 FT /ligand="pyridone 6" FT /ligand_id="ChEBI:CHEBI:87103" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:18239682, FT ECO:0007744|PDB:2J90" FT BINDING 96 FT /ligand="pyridone 6" FT /ligand_id="ChEBI:CHEBI:87103" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:18239682, FT ECO:0007744|PDB:2J90" FT MOD_RES 50 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18239682" FT MOD_RES 180 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15611134, FT ECO:0000269|PubMed:17158456" FT MOD_RES 225 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15611134" FT MOD_RES 265 FT /note="Phosphothreonine; by autocatalysis and ROCK1" FT /evidence="ECO:0000269|PubMed:15611134, FT ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18239682" FT MOD_RES 299 FT /note="Phosphothreonine; by autocatalysis, DAPK1 and ROCK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456, FT ECO:0000269|PubMed:20854903" FT MOD_RES 306 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15611134" FT MOD_RES 309 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT MOD_RES 311 FT /note="Phosphoserine; by autocatalysis and DAPK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0000269|PubMed:15611134" FT MOD_RES 312 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0007744|PubMed:23186163" FT MOD_RES 318 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT MOD_RES 326 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT VAR_SEQ 313..322 FT /note="LPPNNSYADF -> ASPIVAPVDA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17126281" FT /id="VSP_042059" FT VAR_SEQ 323..454 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17126281" FT /id="VSP_042060" FT VARIANT 112 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation and cell survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040438" FT VARIANT 161 FT /note="D -> N (in an ovarian mucinous carcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation and cell survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040439" FT VARIANT 216 FT /note="P -> S (in a lung neuroendocrine carcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation, cell adhesion and cell FT survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040440" FT MUTAGEN 42 FT /note="K->A: Loss of kinase activity at low concentrations FT of ATP." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 161 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 180 FT /note="T->A: Greatly reduced kinase activity." FT /evidence="ECO:0000269|PubMed:21487036" FT MUTAGEN 225 FT /note="T->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 265 FT /note="T->A: Loss of phosphorylation by ROCK1, FT catalytically inactive." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 294..295 FT /note="RR->AA: Cytoplasmic localization." FT /evidence="ECO:0000269|PubMed:20854903" FT MUTAGEN 299..300 FT /note="TT->AA: Predominantly nuclear localization." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 299 FT /note="T->A: Loss of phosphorylation by ROCK1." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 299 FT /note="T->D: Predominantly cytoplasmic localization; FT phosphomimetic." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 427 FT /note="V->A: Predominantly nuclear localization; when FT associated with A-434 and A-441." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 434 FT /note="V->A: Predominantly nuclear localization; when FT associated with A-427 and A-441." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 441 FT /note="L->A: Predominantly nuclear localization; when FT associated with A-427 and A-434." FT /evidence="ECO:0000269|PubMed:15611134" FT HELIX 9..12 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 13..21 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 23..32 FT /evidence="ECO:0007829|PDB:3BHY" FT TURN 33..35 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 49..51 FT /evidence="ECO:0007829|PDB:2J90" FT STRAND 53..56 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 58..70 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 79..84 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 86..94 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 101..108 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 113..132 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 142..144 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 145..148 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 150..154 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 171..175 FT /evidence="ECO:0007829|PDB:5A6N" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:5A6O" FT HELIX 181..183 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 186..189 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 197..212 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 222..230 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 238..241 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 246..253 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 260..262 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 266..271 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 273..280 FT /evidence="ECO:0007829|PDB:3BHY" SQ SEQUENCE 454 AA; 52536 MW; 56773008A6A61CF0 CRC64; MSTFRQEDVE DHYEMGEELG SGQFAIVRKC RQKGTGKEYA AKFIKKRRLS SSRRGVSREE IEREVNILRE IRHPNIITLH DIFENKTDVV LILELVSGGE LFDFLAEKES LTEDEATQFL KQILDGVHYL HSKRIAHFDL KPENIMLLDK NVPNPRIKLI DFGIAHKIEA GNEFKNIFGT PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGE TKQETLTNIS AVNYDFDEEY FSNTSELAKD FIRRLLVKDP KRRMTIAQSL EHSWIKAIRR RNVRGEDSGR KPERRRLKTT RLKEYTIKSH SSLPPNNSYA DFERFSKVLE EAAAAEEGLR ELQRSRRLCH EDVEALAAIY EEKEAWYREE SDSLGQDLRR LRQELLKTEA LKRQAQEEAK GALLGTSGLK RRFSRLENRY EALAKQVASE MRFVQDLVRA LEQEKLQGVE CGLR // ID DJC15_HUMAN Reviewed; 150 AA. AC Q9Y5T4; B2R4L0; Q5T219; Q6X963; DT 25-JUL-2006, integrated into UniProtKB/Swiss-Prot. DT 25-JUL-2006, sequence version 2. DT 28-JAN-2026, entry version 169. DE RecName: Full=DnaJ homolog subfamily C member 15; DE AltName: Full=Cell growth-inhibiting gene 22 protein; DE AltName: Full=Methylation-controlled J protein; DE Short=MCJ; GN Name=DNAJC15; Synonyms=DNAJD1; ORFNames=GIG22, HSD18; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, INVOLVEMENT IN OVARIAN RP ADENOCARCINOMA, AND VARIANT GLY-35. RX PubMed=11358853; RA Shridhar V., Bible K.C., Staub J., Avula R., Lee Y.K., Kalli K., Huang H., RA Hartmann L.C., Kaufmann S.H., Smith D.I.; RT "Loss of expression of a new member of the DNAJ protein family confers RT resistance to chemotherapeutic agents used in the treatment of ovarian RT cancer."; RL Cancer Res. 61:4258-4265(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Testis; RA Yang C.B., Miao S.Y., Zhang X.D., Qiao Y., Liang G., Wang L.F.; RT "A new spermatogenesis-related gene."; RL Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kim J.W.; RT "Identification of a cell growth inhibiting gene."; RL Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLY-35. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-104, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [10] RP FUNCTION, INTERACTION WITH PAM16, ASSOCIATION WITH THE TIM23 COMPLEX, RP SUBCELLULAR LOCATION, AND TOPOLOGY. RX PubMed=23263864; DOI=10.1093/hmg/dds541; RA Schusdziarra C., Blamowska M., Azem A., Hell K.; RT "Methylation-controlled J-protein MCJ acts in the import of proteins into RT human mitochondria."; RL Hum. Mol. Genet. 22:1348-1357(2013). RN [11] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=23530063; DOI=10.1128/mcb.00189-13; RA Hatle K.M., Gummadidala P., Navasa N., Bernardo E., Dodge J., RA Silverstrim B., Fortner K., Burg E., Suratt B.T., Hammer J., RA Radermacher M., Taatjes D.J., Thornton T., Anguita J., Rincon M.; RT "MCJ/DnaJC15, an endogenous mitochondrial repressor of the respiratory RT chain that controls metabolic alterations."; RL Mol. Cell. Biol. 33:2302-2314(2013). CC -!- FUNCTION: Negative regulator of the mitochondrial respiratory chain. CC Prevents mitochondrial hyperpolarization state and restricts CC mitochondrial generation of ATP (By similarity). Acts as an import CC component of the TIM23 translocase complex. Stimulates the ATPase CC activity of HSPA9. {ECO:0000250, ECO:0000269|PubMed:23263864}. CC -!- SUBUNIT: Interacts with the TIM23 complex. Directly interacts with CC PAM16/MAGMAS; this interaction counteracts DNAJC15-dependent CC stimulation of HSPA9 ATPase activity. Associates with complex I of the CC mitochondrial electron transfer chain; this interaction may interfere CC with the formation of supercomplexes that facilitate the transfer of CC electrons between complexes (By similarity). {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane CC {ECO:0000269|PubMed:23263864, ECO:0000269|PubMed:23530063}; Single-pass CC membrane protein {ECO:0000269|PubMed:23263864, CC ECO:0000269|PubMed:23530063}. CC -!- TISSUE SPECIFICITY: Expressed at highest levels in heart, followed by CC liver and kidney. {ECO:0000269|PubMed:11358853, CC ECO:0000269|PubMed:23530063}. CC -!- DISEASE: Note=Absent or down-regulated in many advanced cases of CC ovarian adenocarcinoma, due to hypermethylation and allelic loss. Loss CC of expression correlates with increased resistance to antineoplastic CC drugs, such as cisplatin. {ECO:0000269|PubMed:11358853}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF126743; AAD38506.1; -; mRNA. DR EMBL; AY248898; AAP20049.1; -; mRNA. DR EMBL; AY512565; AAS80157.1; -; mRNA. DR EMBL; AK311866; BAG34807.1; -; mRNA. DR EMBL; AL445217; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471075; EAX08688.1; -; Genomic_DNA. DR EMBL; BC010910; AAH10910.1; -; mRNA. DR EMBL; BC095400; AAH95400.1; -; mRNA. DR CCDS; CCDS9388.1; -. DR RefSeq; NP_037370.2; NM_013238.3. DR AlphaFoldDB; Q9Y5T4; -. DR SMR; Q9Y5T4; -. DR BioGRID; 118871; 166. DR ComplexPortal; CPX-6129; TIM23 mitochondrial inner membrane pre-sequence translocase complex, TIM17A variant. DR ComplexPortal; CPX-6130; TIM23 mitochondrial inner membrane pre-sequence translocase complex, TIM17B variant. DR FunCoup; Q9Y5T4; 105. DR STRING; 9606.ENSP00000368523; -. DR GlyGen; Q9Y5T4; 3 sites, 1 O-linked glycan (3 sites). DR iPTMnet; Q9Y5T4; -. DR PhosphoSitePlus; Q9Y5T4; -. DR BioMuta; DNAJC15; -. DR DMDM; 110808202; -. DR jPOST; Q9Y5T4; -. DR MassIVE; Q9Y5T4; -. DR PaxDb; 9606-ENSP00000368523; -. DR PeptideAtlas; Q9Y5T4; -. DR ProteomicsDB; 86496; -. DR Pumba; Q9Y5T4; -. DR Antibodypedia; 2384; 60 antibodies from 25 providers. DR DNASU; 29103; -. DR Ensembl; ENST00000379221.4; ENSP00000368523.2; ENSG00000120675.7. DR GeneID; 29103; -. DR KEGG; hsa:29103; -. DR MANE-Select; ENST00000379221.4; ENSP00000368523.2; NM_013238.3; NP_037370.2. DR UCSC; uc001uyy.4; human. DR AGR; HGNC:20325; -. DR ClinPGx; PA134932264; -. DR CTD; 29103; -. DR DisGeNET; 29103; -. DR GeneCards; DNAJC15; -. DR HGNC; HGNC:20325; DNAJC15. DR HPA; ENSG00000120675; Low tissue specificity. DR MIM; 615339; gene. DR OpenTargets; ENSG00000120675; -. DR VEuPathDB; HostDB:ENSG00000120675; -. DR eggNOG; KOG0723; Eukaryota. DR GeneTree; ENSGT00940000159907; -. DR HOGENOM; CLU_017633_13_3_1; -. DR InParanoid; Q9Y5T4; -. DR OMA; MRYAEYT; -. DR OrthoDB; 240298at2759; -. DR PAN-GO; Q9Y5T4; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y5T4; -. DR PathwayCommons; Q9Y5T4; -. DR SignaLink; Q9Y5T4; -. DR SIGNOR; Q9Y5T4; -. DR Agora; ENSG00000120675; -. DR BioGRID-ORCS; 29103; 14 hits in 1146 CRISPR screens. DR ChiTaRS; DNAJC15; human. DR GenomeRNAi; 29103; -. DR Pharos; Q9Y5T4; Tbio. DR PRO; PR:Q9Y5T4; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; Q9Y5T4; protein. DR Bgee; ENSG00000120675; Expressed in jejunal mucosa and 208 other cell types or tissues. DR GO; GO:0005743; C:mitochondrial inner membrane; NAS:ComplexPortal. DR GO; GO:0005739; C:mitochondrion; HTP:FlyBase. DR GO; GO:0001405; C:PAM complex, Tim23 associated import motor; IBA:GO_Central. DR GO; GO:0005744; C:TIM23 mitochondrial import inner membrane translocase complex; NAS:ComplexPortal. DR GO; GO:0001671; F:ATPase activator activity; IBA:GO_Central. DR GO; GO:0009267; P:cellular response to starvation; IEA:Ensembl. DR GO; GO:0006886; P:intracellular protein transport; NAS:ComplexPortal. DR GO; GO:0006120; P:mitochondrial electron transport, NADH to ubiquinone; IEA:Ensembl. DR GO; GO:1902957; P:negative regulation of mitochondrial electron transport, NADH to ubiquinone; IEA:Ensembl. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IEA:Ensembl. DR GO; GO:0030150; P:protein import into mitochondrial matrix; IBA:GO_Central. DR GO; GO:0065003; P:protein-containing complex assembly; IEA:Ensembl. DR GO; GO:0019216; P:regulation of lipid metabolic process; IEA:Ensembl. DR CDD; cd06257; DnaJ; 1. DR FunFam; 1.10.287.110:FF:000001; Import inner membrane translocase subunit tim14; 1. DR Gene3D; 1.10.287.110; DnaJ domain; 1. DR InterPro; IPR001623; DnaJ_domain. DR InterPro; IPR036869; J_dom_sf. DR PANTHER; PTHR12763; -; 1. DR PANTHER; PTHR12763:SF7; DNAJ HOMOLOG SUBFAMILY C MEMBER 15; 1. DR SMART; SM00271; DnaJ; 1. DR SUPFAM; SSF46565; Chaperone J-domain; 1. DR PROSITE; PS50076; DNAJ_2; 1. PE 1: Evidence at protein level; KW Chaperone; Membrane; Mitochondrion; Mitochondrion inner membrane; KW Phosphoprotein; Protein transport; Proteomics identification; KW Reference proteome; Translocation; Transmembrane; Transmembrane helix; KW Transport. FT CHAIN 1..150 FT /note="DnaJ homolog subfamily C member 15" FT /id="PRO_0000247139" FT TOPO_DOM 1..35 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000255" FT TRANSMEM 36..58 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 59..150 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000255" FT DOMAIN 96..150 FT /note="J" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00286" FT MOD_RES 104 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT VARIANT 35 FT /note="R -> G (in dbSNP:rs12015)" FT /evidence="ECO:0000269|PubMed:11358853, FT ECO:0000269|PubMed:15489334" FT /id="VAR_027077" FT CONFLICT 34 FT /note="Q -> R (in Ref. 2; AAP20049)" FT /evidence="ECO:0000305" FT CONFLICT 131 FT /note="P -> S (in Ref. 2; AAP20049)" FT /evidence="ECO:0000305" SQ SEQUENCE 150 AA; 16383 MW; 988059B686D39967 CRC64; MAARGVIAPV GESLRYAEYL QPSAKRPDAD VDQQRLVRSL IAVGLGVAAL AFAGRYAFRI WKPLEQVITE TAKKISTPSF SSYYKGGFEQ KMSRREAGLI LGVSPSAGKA KIRTAHRRVM ILNHPDKGGS PYVAAKINEA KDLLETTTKH // ID EGFR_HUMAN Reviewed; 1210 AA. AC P00533; O00688; O00732; P06268; Q14225; Q68GS5; Q92795; Q9BZS2; Q9GZX1; AC Q9H2C9; Q9H3C9; Q9UMD7; Q9UMD8; Q9UMG5; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1997, sequence version 2. DT 28-JAN-2026, entry version 299. DE RecName: Full=Epidermal growth factor receptor {ECO:0000305}; DE EC=2.7.10.1; DE AltName: Full=Proto-oncogene c-ErbB-1; DE AltName: Full=Receptor tyrosine-protein kinase erbB-1; DE Flags: Precursor; GN Name=EGFR {ECO:0000312|HGNC:HGNC:3236}; Synonyms=ERBB, ERBB1, HER1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 25-32. RX PubMed=6328312; DOI=10.1038/309418a0; RA Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., RA Lee J., Yarden Y., Libermann T.A., Schlessinger J., Downward J., RA Mayes E.L.V., Whittle N., Waterfield M.D., Seeburg P.H.; RT "Human epidermal growth factor receptor cDNA sequence and aberrant RT expression of the amplified gene in A431 epidermoid carcinoma cells."; RL Nature 309:418-425(1984). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=7654368; DOI=10.1002/mrd.1080410205; RA Ilekis J.V., Stark B.C., Scoccia B.; RT "Possible role of variant RNA transcripts in the regulation of epidermal RT growth factor receptor expression in human placenta."; RL Mol. Reprod. Dev. 41:149-156(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=8918811; DOI=10.1093/nar/24.20.4050; RA Reiter J.L., Maihle N.J.; RT "A 1.8 kb alternative transcript from the human epidermal growth factor RT receptor gene encodes a truncated form of the receptor."; RL Nucleic Acids Res. 24:4050-4056(1996). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=9103388; DOI=10.1006/gyno.1996.4526; RA Ilekis J.V., Gariti J., Niederberger C., Scoccia B.; RT "Expression of a truncated epidermal growth factor receptor-like protein RT (TEGFR) in ovarian cancer."; RL Gynecol. Oncol. 65:36-41(1997). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Placenta; RX PubMed=11161793; DOI=10.1006/geno.2000.6341; RA Reiter J.L., Threadgill D.W., Eley G.D., Strunk K.E., Danielsen A.J., RA Schehl Sinclair C., Pearsall R.S., Green P.J., Yee D., Lampland A.L., RA Balasubramaniam S., Crossley T.D., Magnuson T.R., James C.D., Maihle N.J.; RT "Comparative genomic sequence analysis and isolation of human and mouse RT alternative EGFR transcripts encoding truncated receptor isoforms."; RL Genomics 71:1-20(2001). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Xu L., Hong A., He X.; RT "Cloning of the cDNA for a short EGF receptor from human placenta."; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-98; ARG-266; LYS-521; RP ILE-674; GLY-962 AND PRO-988. RG NIEHS SNPs program; RL Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 575-687. RA Reiter J.L., Threadgill D.W., Danielsen A.J., Schehl C.M., Lampland A.L., RA Balasubramaniam S., Crossley T.O., Magnuson T.R., Maihle N.J.; RT "Human and mouse alternative EGFR transcripts encoding only the RT extracellular domain of the receptor."; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-924. RX PubMed=6326261; DOI=10.1126/science.6326261; RA Lin C.R., Chen W.S., Kruiger W., Stolarsky L.S., Weber W., Evans R.M., RA Verma I.M., Gill G.N., Rosenfeld M.G.; RT "Expression cloning of human EGF receptor complementary DNA: gene RT amplification and three related messenger RNA products in A431 cells."; RL Science 224:843-848(1984). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 150-962. RX PubMed=6330563; DOI=10.1038/309806a0; RA Xu Y.H., Ishii S., Clark A.J.L., Sullivan M., Wilson R.K., Ma D.P., RA Roe B.A., Merlino G.T., Pastan I.; RT "Human epidermal growth factor receptor cDNA is homologous to a variety of RT RNAs overproduced in A431 carcinoma cells."; RL Nature 309:806-810(1984). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1028-1210. RX PubMed=6093780; DOI=10.1016/0006-291x(84)90926-4; RA Simmen F.A., Gope M.L., Schulz T.Z., Wright D.A., Carpenter G., RA O'Malley B.W.; RT "Isolation of an evolutionarily conserved epidermal growth factor receptor RT cDNA from human A431 carcinoma cells."; RL Biochem. Biophys. Res. Commun. 124:125-132(1984). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29. RX PubMed=3329716; RA Haley J.D., Whittle N., Bennett P., Kinchington D., Ullrich A., RA Waterfield M.D.; RT "The human EGF receptor gene: structure of the 110 kb locus and RT identification of sequences regulating its transcription."; RL Oncogene Res. 1:375-396(1987). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29. RX PubMed=1988448; DOI=10.1016/s0021-9258(18)52359-0; RA Haley J.D., Waterfield M.D.; RT "Contributory effects of de novo transcription and premature transcript RT termination in the regulation of human epidermal growth factor receptor RT proto-oncogene RNA synthesis."; RL J. Biol. Chem. 266:1746-1753(1991). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29. RX PubMed=2991899; DOI=10.1073/pnas.82.15.4920; RA Ishii S., Xu Y.H., Stratton R.H., Roe B.A., Merlino G.T., Pastan I.; RT "Characterization and sequence of the promoter region of the human RT epidermal growth factor receptor gene."; RL Proc. Natl. Acad. Sci. U.S.A. 82:4920-4924(1985). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 25-49. RX PubMed=6324343; DOI=10.1126/science.6324343; RA Weber W., Gill G.N., Spiess J.; RT "Production of an epidermal growth factor receptor-related protein."; RL Science 224:294-297(1984). RN [16] RP PROTEIN SEQUENCE OF 540. RA Kohda D.; RL Submitted (SEP-1997) to UniProtKB. RN [17] RP PROTEIN SEQUENCE OF 687-705; 986-998; 1000-1023; 1026-1030 AND 1068-1077, RP AND PHOSPHORYLATION AT THR-693; SER-695; SER-1070 AND SER-1071. RX PubMed=3138233; DOI=10.1016/s0021-9258(18)37684-1; RA Heisermann G.J., Gill G.N.; RT "Epidermal growth factor receptor threonine and serine residues RT phosphorylated in vivo."; RL J. Biol. Chem. 263:13152-13158(1988). RN [18] RP PROTEIN SEQUENCE OF 25-39. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [19] RP PROTEIN SEQUENCE OF 740-744 AND 746-747. RX PubMed=2985580; DOI=10.1016/s0021-9258(18)89002-0; RA Russo M.W., Lukas T.J., Cohen S., Staros J.V.; RT "Identification of residues in the nucleotide binding site of the epidermal RT growth factor receptor/kinase."; RL J. Biol. Chem. 260:5205-5208(1985). RN [20] RP PROTEIN SEQUENCE OF 861-875 AND 914-932, UBIQUITINATION AT LYS-716; RP LYS-737; LYS-754; LYS-867; LYS-929 AND LYS-970, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=16543144; DOI=10.1016/j.molcel.2006.02.018; RA Huang F., Kirkpatrick D., Jiang X., Gygi S.P., Sorkin A.; RT "Differential regulation of EGF receptor internalization and degradation by RT multiubiquitination within the kinase domain."; RL Mol. Cell 21:737-748(2006). RN [21] RP PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS. RX PubMed=9556602; DOI=10.1074/jbc.273.18.11150; RA Abe Y., Odaka M., Inagaki F., Lax I., Schlessinger J., Kohda D.; RT "Disulfide bond structure of human epidermal growth factor receptor."; RL J. Biol. Chem. 273:11150-11157(1998). RN [22] RP RECEPTOR ACTIVITY. RX PubMed=6325948; DOI=10.1038/309270a0; RA Mroczkowski B., Mosig G., Cohen S.; RT "ATP-stimulated interaction between epidermal growth factor receptor and RT supercoiled DNA."; RL Nature 309:270-273(1984). RN [23] RP REVIEW. RX PubMed=3039909; DOI=10.1146/annurev.bi.56.070187.004313; RA Carpenter G.; RT "Receptors for epidermal growth factor and other polypeptide mitogens."; RL Annu. Rev. Biochem. 56:881-914(1987). RN [24] RP FUNCTION, SUBCELLULAR LOCATION, AND LIGAND-BINDING. RX PubMed=2790960; DOI=10.1016/0092-8674(89)90867-2; RA Chen W.S., Lazar C.S., Lund K.A., Welsh J.B., Chang C.P., Walton G.M., RA Der C.J., Wiley H.S., Gill G.N., Rosenfeld M.G.; RT "Functional independence of the epidermal growth factor receptor from a RT domain required for ligand-induced internalization and calcium RT regulation."; RL Cell 59:33-43(1989). RN [25] RP PHOSPHORYLATION AT TYR-1110. RX PubMed=2543678; DOI=10.1016/s0021-9258(18)81674-x; RA Margolis B.L., Lax I., Kris R., Dombalagian M., Honegger A.M., Howk R., RA Givol D., Ullrich A., Schlessinger J.; RT "All autophosphorylation sites of epidermal growth factor (EGF) receptor RT and HER2/neu are located in their carboxyl-terminal tails. Identification RT of a novel site in EGF receptor."; RL J. Biol. Chem. 264:10667-10671(1989). RN [26] RP IDENTIFICATION OF AREG AS LIGAND, AND FUNCTION. RX PubMed=7679104; DOI=10.1016/s0021-9258(18)53862-x; RA Johnson G.R., Kannan B., Shoyab M., Stromberg K.; RT "Amphiregulin induces tyrosine phosphorylation of the epidermal growth RT factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively RT through the epidermal growth factor receptor at the surface of human RT epithelial cells."; RL J. Biol. Chem. 268:2924-2931(1993). RN [27] RP INTERACTION WITH ZPR1. RX PubMed=8650580; DOI=10.1126/science.272.5269.1797; RA Galcheva-Gargova Z., Konstantinov K.N., Wu I.-H., Klier F.G., Barrett T., RA Davis R.J.; RT "Binding of zinc finger protein ZPR1 to the epidermal growth factor RT receptor."; RL Science 272:1797-1802(1996). RN [28] RP INTERACTION WITH ZPR1. RX PubMed=9852145; DOI=10.1083/jcb.143.6.1471; RA Gangwani L., Mikrut M., Galcheva-Gargova Z., Davis R.J.; RT "Interaction of ZPR1 with translation elongation factor-1alpha in RT proliferating cells."; RL J. Cell Biol. 143:1471-1484(1998). RN [29] RP PHOSPHORYLATION AT THR-678 AND THR-693. RX PubMed=10523301; DOI=10.1093/emboj/18.20.5567; RA Bagowski C.P., Stein-Gerlach M., Choidas A., Ullrich A.; RT "Cell-type specific phosphorylation of threonines T654 and T669 by PKD RT defines the signal capacity of the EGF receptor."; RL EMBO J. 18:5567-5576(1999). RN [30] RP IDENTIFICATION OF BETACELLULIN/BTC AS LIGAND. RX PubMed=8144591; DOI=10.1016/s0021-9258(17)36977-6; RA Watanabe T., Shintani A., Nakata M., Shing Y., Folkman J., Igarashi K., RA Sasada R.; RT "Recombinant human betacellulin. Molecular structure, biological RT activities, and receptor interaction."; RL J. Biol. Chem. 269:9966-9973(1994). RN [31] RP FUNCTION IN PHOSPHORYLATION OF CBL, AND INTERACTION WITH CBL. RX PubMed=7657591; DOI=10.1074/jbc.270.35.20242; RA Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.; RT "Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and RT association with epidermal growth factor (EGF) receptor upon EGF RT stimulation."; RL J. Biol. Chem. 270:20242-20245(1995). RN [32] RP GLYCOSYLATION AT ASN-128; ASN-175; ASN-413; ASN-444 AND ASN-528. RX PubMed=8962717; DOI=10.3109/08977199609034572; RA Smith K.D., Davies M.J., Bailey D., Renouf D.V., Hounsell E.F.; RT "Analysis of the glycosylation patterns of the extracellular domain of the RT epidermal growth factor receptor expressed in Chinese hamster ovary RT fibroblasts."; RL Growth Factors 13:121-132(1996). RN [33] RP IDENTIFICATION OF EPIREGULIN/EREG AS LIGAND, AND FUNCTION. RX PubMed=9419975; DOI=10.1038/sj.onc.1201458; RA Komurasaki T., Toyoda H., Uchida D., Morimoto S.; RT "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and RT induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB- RT 2, ErbB-3 and ErbB-4."; RL Oncogene 15:2841-2848(1997). RN [34] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2. RX PubMed=9488479; DOI=10.1128/mcb.18.3.1622; RA Tiganis T., Bennett A.M., Ravichandran K.S., Tonks N.K.; RT "Epidermal growth factor receptor and the adaptor protein p52Shc are RT specific substrates of T-cell protein tyrosine phosphatase."; RL Mol. Cell. Biol. 18:1622-1634(1998). RN [35] RP INTERACTION WITH AP2M1. RX PubMed=10228163; DOI=10.1093/emboj/18.9.2489; RA Nesterov A., Carter R.E., Sorkina T., Gill G.N., Sorkin A.; RT "Inhibition of the receptor-binding function of clathrin adaptor protein RT AP-2 by dominant-negative mutant mu2 subunit and its effects on RT endocytosis."; RL EMBO J. 18:2489-2499(1999). RN [36] RP INTERACTION WITH GRB2; NCK1 AND NCK2. RX PubMed=10026169; DOI=10.1074/jbc.274.9.5542; RA Braverman L.E., Quilliam L.A.; RT "Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-containing RT adapter protein having similar binding and biological properties to Nck."; RL J. Biol. Chem. 274:5542-5549(1999). RN [37] RP GLYCOSYLATION AT ASN-56; ASN-352; ASN-361; ASN-568 AND ASN-603. RX PubMed=10731668; DOI=10.1093/oxfordjournals.jbchem.a022585; RA Sato C., Kim J.-H., Abe Y., Saito K., Yokoyama S., Kohda D.; RT "Characterization of the N-oligosaccharides attached to the atypical Asn-X- RT Cys sequence of recombinant human epidermal growth factor receptor."; RL J. Biochem. 127:65-72(2000). RN [38] RP FUNCTION IN PHOSPHORYLATION OF RGS16. RX PubMed=11602604; DOI=10.1074/jbc.m108862200; RA Derrien A., Druey K.M.; RT "RGS16 function is regulated by epidermal growth factor receptor-mediated RT tyrosine phosphorylation."; RL J. Biol. Chem. 276:48532-48538(2001). RN [39] RP GLYCOSYLATION AT ASN-56; ASN-128; ASN-175; ASN-196; ASN-352; ASN-361; RP ASN-413; ASN-444; ASN-528; ASN-568; ASN-603 AND ASN-623. RX PubMed=12731890; DOI=10.1021/bi027101p; RA Zhen Y., Caprioli R.M., Staros J.V.; RT "Characterization of glycosylation sites of the epidermal growth factor RT receptor."; RL Biochemistry 42:5478-5492(2003). RN [40] RP FUNCTION IN CELL PROLIFERATION, INTERACTION WITH STAT3, AND PHOSPHORYLATION RP AT TYR-1092 AND TYR-1110. RX PubMed=12873986; RA Shao H., Cheng H.Y., Cook R.G., Tweardy D.J.; RT "Identification and characterization of signal transducer and activator of RT transcription 3 recruitment sites within the epidermal growth factor RT receptor."; RL Cancer Res. 63:3923-3930(2003). RN [41] RP ACTIVITY REGULATION, AND INTERACTION WITH LRIG1. RX PubMed=15282549; DOI=10.1038/sj.emboj.7600342; RA Gur G., Rubin C., Katz M., Amit I., Citri A., Nilsson J., Amariglio N., RA Henriksson R., Rechavi G., Hedman H., Wides R., Yarden Y.; RT "LRIG1 restricts growth factor signaling by enhancing receptor RT ubiquitylation and degradation."; RL EMBO J. 23:3270-3281(2004). RN [42] RP FUNCTION IN EGFR SIGNALING, IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND RP ERBB2, IDENTIFICATION IN A COMPLEX WITH PIK3C2B AND ERBB2, INTERACTION WITH RP PIK3C2B, AND MUTAGENESIS OF TYR-1016; TYR-1092; TYR-1110; TYR-1172 AND RP TYR-1197. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [43] RP FUNCTION IN NF-KAPPA-B ACTIVATION, AND INTERACTION WITH RIPK1. RX PubMed=11116146; DOI=10.1074/jbc.m008458200; RA Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S., RA Vartanian T.; RT "The epidermal growth factor receptor engages receptor interacting protein RT and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF- RT kappa B. Identification of a novel receptor-tyrosine kinase signalosome."; RL J. Biol. Chem. 276:8865-8874(2001). RN [44] RP FUNCTION IN PHOSPHORYLATION OF MUC1, AND INTERACTION WITH MUC1. RX PubMed=11483589; DOI=10.1074/jbc.c100359200; RA Li Y., Ren J., Yu W., Li Q., Kuwahara H., Yin L., Carraway K.L. III, RA Kufe D.; RT "The epidermal growth factor receptor regulates interaction of the human RT DF3/MUC1 carcinoma antigen with c-Src and beta-catenin."; RL J. Biol. Chem. 276:35239-35242(2001). RN [45] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH SOCS5. RX PubMed=15590694; DOI=10.1074/jbc.m408575200; RA Kario E., Marmor M.D., Adamsky K., Citri A., Amit I., Amariglio N., RA Rechavi G., Yarden Y.; RT "Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor RT receptor signaling."; RL J. Biol. Chem. 280:7038-7048(2005). RN [46] RP IDENTIFICATION OF EPIGEN/EPGN AS A LIGAND, AND FUNCTION. RX PubMed=15611079; DOI=10.1074/jbc.m413919200; RA Kochupurakkal B.S., Harari D., Di-Segni A., Maik-Rachline G., Lyass L., RA Gur G., Kerber G., Citri A., Lavi S., Eilam R., Chalifa-Caspi V., RA Eshhar Z., Pikarsky E., Pinkas-Kramarski R., Bacus S.S., Yarden Y.; RT "Epigen, the last ligand of ErbB receptors, reveals intricate relationships RT between affinity and mitogenicity."; RL J. Biol. Chem. 280:8503-8512(2005). RN [47] RP GLYCOSYLATION AT ASN-56; ASN-128; ASN-175; ASN-196; ASN-352; ASN-361; RP ASN-413; ASN-444; ASN-528; ASN-568 AND ASN-603, PHOSPHORYLATION AT THR-693; RP SER-991 AND SER-1026, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16083266; DOI=10.1021/pr050113n; RA Wu S.L., Kim J., Hancock W.S., Karger B.; RT "Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS RT platform for high sequence coverage of complex proteins with extensive RT post-translational modifications-comprehensive analysis of beta-casein and RT epidermal growth factor receptor (EGFR)."; RL J. Proteome Res. 4:1155-1170(2005). RN [48] RP INTERACTION WITH PELP1. RX PubMed=16140940; DOI=10.1158/0008-5472.can-05-0614; RA Vadlamudi R.K., Manavathi B., Balasenthil S., Nair S.S., Yang Z., RA Sahin A.A., Kumar R.; RT "Functional implications of altered subcellular localization of PELP1 in RT breast cancer cells."; RL Cancer Res. 65:7724-7732(2005). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1172 AND TYR-1197, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [50] RP FUNCTION IN CELL PROLIFERATION, FUNCTION IN PCNA PHOSPHORYLATION, RP INTERACTION WITH PCNA, AND SUBCELLULAR LOCATION. RX PubMed=17115032; DOI=10.1038/ncb1501; RA Wang S.C., Nakajima Y., Yu Y.L., Xia W., Chen C.T., Yang C.C., RA McIntush E.W., Li L.Y., Hawke D.H., Kobayashi R., Hung M.C.; RT "Tyrosine phosphorylation controls PCNA function through protein RT stability."; RL Nat. Cell Biol. 8:1359-1368(2006). RN [51] RP INTERACTION WITH STX19. RX PubMed=16420529; DOI=10.1111/j.1600-0854.2005.00378.x; RA Wang Y., Foo L.Y., Guo K., Gan B.Q., Zeng Q., Hong W., Tang B.L.; RT "Syntaxin 9 is enriched in skin hair follicle epithelium and interacts with RT the epidermal growth factor receptor."; RL Traffic 7:216-226(2006). RN [52] RP INTERACTION WITH PIKFYVE, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17909029; DOI=10.1158/0008-5472.can-07-1333; RA Kim J., Jahng W.J., Di Vizio D., Lee J.S., Jhaveri R., Rubin M.A., RA Shisheva A., Freeman M.R.; RT "The phosphoinositide kinase PIKfyve mediates epidermal growth factor RT receptor trafficking to the nucleus."; RL Cancer Res. 67:9229-9237(2007). RN [53] RP TISSUE SPECIFICITY. RX PubMed=17671655; DOI=10.1172/jci31680; RA Groenestege W.M.T., Thebault S., van der Wijst J., van den Berg D., RA Janssen R., Tejpar S., van den Heuvel L.P., van Cutsem E., Hoenderop J.G., RA Knoers N.V., Bindels R.J.; RT "Impaired basolateral sorting of pro-EGF causes isolated recessive renal RT hypomagnesemia."; RL J. Clin. Invest. 117:2260-2267(2007). RN [54] RP INTERACTION WITH TNF2, AND SUBCELLULAR LOCATION. RX PubMed=17182860; DOI=10.1091/mbc.e06-02-0142; RA Shen F., Lin Q., Gu Y., Childress C., Yang W.; RT "Activated Cdc42-associated kinase 1 is a component of EGF receptor RT signaling complex and regulates EGF receptor degradation."; RL Mol. Biol. Cell 18:732-742(2007). RN [55] RP INTERACTION WITH NEU3, AND ACTIVITY REGULATION. RX PubMed=17334392; DOI=10.1038/sj.onc.1210341; RA Wada T., Hata K., Yamaguchi K., Shiozaki K., Koseki K., Moriya S., RA Miyagi T.; RT "A crucial role of plasma membrane-associated sialidase in the survival of RT human cancer cells."; RL Oncogene 26:2483-2490(2007). RN [56] RP INTERACTION WITH ATXN2. RX PubMed=18602463; DOI=10.1016/j.cellsig.2008.05.018; RA Nonis D., Schmidt M.H., van de Loo S., Eich F., Dikic I., Nowock J., RA Auburger G.; RT "Ataxin-2 associates with the endocytosis complex and affects EGF receptor RT trafficking."; RL Cell. Signal. 20:1725-1739(2008). RN [57] RP INTERACTION WITH GAB2. RX PubMed=19172738; DOI=10.1038/emboj.2008.159; RA Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P., RA Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D., Guilhaus M., RA James D.E., Daly R.J.; RT "Phosphorylation-dependent binding of 14-3-3 terminates signalling by the RT Gab2 docking protein."; RL EMBO J. 27:2305-2316(2008). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [59] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-695; SER-1064; RP SER-1081; SER-1166 AND TYR-1197, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [60] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-991; SER-995; TYR-998; RP SER-1039; THR-1041; SER-1042; SER-1064 AND SER-1166, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [61] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [62] RP ACTIVITY REGULATION BY PTPRJ AND PTPRK, PHOSPHORYLATION AT TYR-1197, RP DEPHOSPHORYLATION BY PTPRJ, SUBCELLULAR LOCATION, AND INTERACTION WITH CBL RP AND GRB2. RX PubMed=19836242; DOI=10.1016/j.cub.2009.09.048; RA Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F., RA Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y.; RT "An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase RT controlling EGFR endocytosis."; RL Curr. Biol. 19:1788-1798(2009). RN [63] RP INTERACTION WITH GAREM1. RX PubMed=19509291; DOI=10.1074/jbc.m109.021139; RA Tashiro K., Tsunematsu T., Okubo H., Ohta T., Sano E., Yamauchi E., RA Taniguchi H., Konishi H.; RT "GAREM, a novel adaptor protein for growth factor receptor-bound protein 2, RT contributes to cellular transformation through the activation of RT extracellular signal-regulated kinase signaling."; RL J. Biol. Chem. 284:20206-20214(2009). RN [64] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-352; ASN-413 AND ASN-568. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [65] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [66] RP INTERACTION WITH GPER1. RX PubMed=19749156; DOI=10.1210/me.2009-0120; RA Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F., RA Fuqua S.A., Ando S., Maggiolini M.; RT "G protein-coupled receptor 30 expression is up-regulated by EGF and TGF RT alpha in estrogen receptor alpha-positive cancer cells."; RL Mol. Endocrinol. 23:1815-1826(2009). RN [67] RP MUTAGENESIS OF 525-SER--ALA-1210; ASP-587; HIS-590 AND LYS-609. RX PubMed=19718021; DOI=10.1038/nature08297; RA Alvarado D., Klein D.E., Lemmon M.A.; RT "ErbB2 resembles an autoinhibited invertebrate epidermal growth factor RT receptor."; RL Nature 461:287-291(2009). RN [68] RP INTERACTION WITH COPG1, SUBCELLULAR LOCATION, AND TOPOLOGY. RX PubMed=20674546; DOI=10.1016/j.bbrc.2010.07.096; RA Wang Y.N., Wang H., Yamaguchi H., Lee H.J., Lee H.H., Hung M.C.; RT "COPI-mediated retrograde trafficking from the Golgi to the ER regulates RT EGFR nuclear transport."; RL Biochem. Biophys. Res. Commun. 399:498-504(2010). RN [69] RP INTERACTION WITH GPER1, AND SUBCELLULAR LOCATION. RX PubMed=20551055; DOI=10.1158/0008-5472.can-10-0408; RA Madeo A., Maggiolini M.; RT "Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol- RT induced gene expression and migration in breast cancer-associated RT fibroblasts."; RL Cancer Res. 70:6036-6046(2010). RN [70] RP FUNCTION, IDENTIFICATION IN COMPLEX WITH CCDC88A AND GNAI3, SUBCELLULAR RP LOCATION, AND PHOSPHORYLATION. RX PubMed=20462955; DOI=10.1091/mbc.e10-01-0028; RA Ghosh P., Beas A.O., Bornheimer S.J., Garcia-Marcos M., Forry E.P., RA Johannson C., Ear J., Jung B.H., Cabrera B., Carethers J.M., Farquhar M.G.; RT "A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor RT and determines whether cells migrate or proliferate."; RL Mol. Biol. Cell 21:2338-2354(2010). RN [71] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-991; SER-1064 AND RP TYR-1197, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [72] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [73] RP PHOSPHORYLATION AT SER-229. RX PubMed=21487020; DOI=10.1074/jbc.m111.240796; RA Huang W.C., Chen Y.J., Li L.Y., Wei Y.L., Hsu S.C., Tsai S.L., Chiu P.C., RA Huang W.P., Wang Y.N., Chen C.H., Chang W.C., Chang W.C., Chen A.J., RA Tsai C.H., Hung M.C.; RT "Nuclear translocation of epidermal growth factor receptor by Akt-dependent RT phosphorylation enhances breast cancer-resistant protein expression in RT gefitinib-resistant cells."; RL J. Biol. Chem. 286:20558-20568(2011). RN [74] RP FUNCTION IN CELL PROLIFERATION AND CELL MIGRATION, METHYLATION AT ARG-1199 RP BY PRMT5, AND INTERACTION WITH PRMT5 AND PTPN6. RX PubMed=21258366; DOI=10.1038/ncb2158; RA Hsu J.M., Chen C.T., Chou C.K., Kuo H.P., Li L.Y., Lin C.Y., Lee H.J., RA Wang Y.N., Liu M., Liao H.W., Shi B., Lai C.C., Bedford M.T., Tsai C.H., RA Hung M.C.; RT "Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation RT negatively modulates EGFR-mediated ERK activation."; RL Nat. Cell Biol. 13:174-181(2011). RN [75] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21516087; DOI=10.1038/nm.2341; RA Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., RA Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., RA Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T., RA Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., RA McKeating J.A., Brino L., Baumert T.F.; RT "EGFR and EphA2 are host factors for hepatitis C virus entry and possible RT targets for antiviral therapy."; RL Nat. Med. 17:589-595(2011). RN [76] RP INTERACTION WITH FER, AND PHOSPHORYLATION. RX PubMed=21518868; DOI=10.1073/pnas.1105369108; RA Guo C., Stark G.R.; RT "FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine RT through EGF-dependent activation of NF-kappaB."; RL Proc. Natl. Acad. Sci. U.S.A. 108:7968-7973(2011). RN [77] RP INTERACTION WITH ANKRD13A; ANKRD13B AND ANKRD13D, UBIQUITINATION, AND RP SUBCELLULAR LOCATION. RX PubMed=22298428; DOI=10.1091/mbc.e11-09-0817; RA Tanno H., Yamaguchi T., Goto E., Ishido S., Komada M.; RT "The Ankrd 13 family of UIM-bearing proteins regulates EGF receptor RT endocytosis from the plasma membrane."; RL Mol. Biol. Cell 23:1343-1353(2012). RN [78] RP UBIQUITINATION, AND DEUBIQUITINATION BY OTUD7B. RX PubMed=22179831; DOI=10.1038/onc.2011.587; RA Pareja F., Ferraro D.A., Rubin C., Cohen-Dvashi H., Zhang F., Aulmann S., RA Ben-Chetrit N., Pines G., Navon R., Crosetto N., Kostler W., Carvalho S., RA Lavi S., Schmitt F., Dikic I., Yakhini Z., Sinn P., Mills G.B., Yarden Y.; RT "Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression."; RL Oncogene 31:4599-4608(2012). RN [79] RP INTERACTION WITH CBL, AND PHOSPHORYLATION AT TYR-869; TYR-1016; TYR-1069; RP TYR-1092 AND TYR-1197. RX PubMed=23774213; DOI=10.1158/0008-5472.can-12-4441; RA Hong S.Y., Shih Y.P., Li T., Carraway K.L. III, Lo S.H.; RT "CTEN prolongs signaling by EGFR through reducing its ligand-induced RT degradation."; RL Cancer Res. 73:5266-5276(2013). RN [80] RP INTERACTION WITH RNF115 AND RNF126. RX PubMed=23418353; DOI=10.1242/jcs.116129; RA Smith C.J., Berry D.M., McGlade C.J.; RT "The E3 ubiquitin ligases RNF126 and Rabring7 regulate endosomal sorting of RT the epidermal growth factor receptor."; RL J. Cell Sci. 126:1366-1380(2013). RN [81] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693 AND SER-1064, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [82] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-991; SER-1026 AND RP SER-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [83] RP INTERACTION WITH CCDC88A AND GNAI3. RX PubMed=25187647; DOI=10.1091/mbc.e14-05-0978; RA Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M., RA Kufareva I., Abagyan R., Ghosh P.; RT "Structural basis for activation of trimeric Gi proteins by multiple growth RT factor receptors via GIV/Girdin."; RL Mol. Biol. Cell 25:3654-3671(2014). RN [84] RP SUBCELLULAR LOCATION, AND INTERACTION WITH CD44. RX PubMed=23589287; DOI=10.1074/jbc.m113.451336; RA Midgley A.C., Rogers M., Hallett M.B., Clayton A., Bowen T., Phillips A.O., RA Steadman R.; RT "Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to RT myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated RT epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid RT rafts."; RL J. Biol. Chem. 288:14824-14838(2013). RN [85] RP INTERACTION WITH GPRC5A. RX PubMed=25311788; DOI=10.1186/1476-4598-13-233; RA Lin X., Zhong S., Ye X., Liao Y., Yao F., Yang X., Sun B., Zhang J., Li Q., RA Gao Y., Wang Y., Liu J., Han B., Chin Y.E., Zhou B.P., Deng J.; RT "EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung RT cancer."; RL Mol. Cancer 13:233-233(2014). RN [86] RP INTERACTION WITH FAM83B. RX PubMed=23912460; DOI=10.1038/onc.2013.293; RA Cipriano R., Bryson B.L., Miskimen K.L., Bartel C.A., Hernandez-Sanchez W., RA Bruntz R.C., Scott S.A., Lindsley C.W., Brown H.A., Jackson M.W.; RT "Hyperactivation of EGFR and downstream effector phospholipase D1 by RT oncogenic FAM83B."; RL Oncogene 33:3298-3306(2014). RN [87] RP GLYCOSYLATION AT ASN-528, AND ACTIVITY REGULATION. RX PubMed=25922362; DOI=10.1093/glycob/cwv026; RA Mozzi A., Forcella M., Riva A., Difrancesco C., Molinari F., Martin V., RA Papini N., Bernasconi B., Nonnis S., Tedeschi G., Mazzucchelli L., RA Monti E., Fusi P., Frattini M.; RT "NEU3 activity enhances EGFR activation without affecting EGFR expression RT and acts on its sialylation levels."; RL Glycobiology 25:855-868(2015). RN [88] RP FUNCTION, PALMITOYLATION AT CYS-1049 AND CYS-1146, IDENTIFICATION BY MASS RP SPECTROMETRY, UBIQUITINATION, PHOSPHORYLATION AT TYR-1092; TYR-1172 AND RP TYR-1197, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 1048-ALA--ALA-1210; RP CYS-1049 AND CYS-1146. RX PubMed=27153536; DOI=10.1016/j.molcel.2016.04.003; RA Runkle K.B., Kharbanda A., Stypulkowski E., Cao X.J., Wang W., Garcia B.A., RA Witze E.S.; RT "Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on RT EGFR Signaling."; RL Mol. Cell 62:385-396(2016). RN [89] RP INTERACTION WITH PGRMC1. RX PubMed=26988023; DOI=10.1038/ncomms11030; RA Kabe Y., Nakane T., Koike I., Yamamoto T., Sugiura Y., Harada E., RA Sugase K., Shimamura T., Ohmura M., Muraoka K., Yamamoto A., Uchida T., RA Iwata S., Yamaguchi Y., Krayukhina E., Noda M., Handa H., Ishimori K., RA Uchiyama S., Kobayashi T., Suematsu M.; RT "Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer RT proliferation and chemoresistance."; RL Nat. Commun. 7:11030-11030(2016). RN [90] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-1172. RX PubMed=26918609; DOI=10.18632/oncotarget.7675; RA Overmiller A.M., McGuinn K.P., Roberts B.J., Cooper F., RA Brennan-Crispi D.M., Deguchi T., Peltonen S., Wahl J.K. III, Mahoney M.G.; RT "c-Src/Cav1-dependent activation of the EGFR by Dsg2."; RL Oncotarget 7:37536-37555(2016). RN [91] RP INTERACTION WITH LAPTM4B. RX PubMed=28479384; DOI=10.1016/j.gene.2017.05.006; RA Tian M., Chen Y., Tian D., Qiao X., Ma Z., Li J.; RT "Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer RT cells."; RL Gene 626:48-53(2017). RN [92] RP HYDROXYBUTYRYLATION AT LYS-745. RX PubMed=29192674; DOI=10.1038/cr.2017.149; RA Huang H., Luo Z., Qi S., Huang J., Xu P., Wang X., Gao L., Li F., Wang J., RA Zhao W., Gu W., Chen Z., Dai L., Dai J., Zhao Y.; RT "Landscape of the regulatory elements for lysine 2-hydroxyisobutyrylation RT pathway."; RL Cell Res. 28:111-125(2018). RN [93] RP INTERACTION WITH TRAF4. RX PubMed=30352854; DOI=10.1073/pnas.1809599115; RA Cai G., Zhu L., Chen X., Sun K., Liu C., Sen G.C., Stark G.R., Qin J., RA Li X.; RT "TRAF4 binds to the juxtamembrane region of EGFR directly and promotes RT kinase activation."; RL Proc. Natl. Acad. Sci. U.S.A. 115:11531-11536(2018). RN [94] RP UBIQUITINATION BY ZNRF1 AND CBL. RX PubMed=33996800; DOI=10.3389/fcell.2021.642625; RA Shen C.H., Chou C.C., Lai T.Y., Hsu J.E., Lin Y.S., Liu H.Y., Chen Y.K., RA Ho I.L., Hsu P.H., Chuang T.H., Lee C.Y., Hsu L.C.; RT "ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control RT Receptor Lysosomal Trafficking and Degradation."; RL Front. Cell Dev. Biol. 9:642625-642625(2021). RN [95] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CD82. RX PubMed=35538033; DOI=10.3724/abbs.2022011; RA Bu J., Zhong W., Li M., He S., Zhang M., Zhang Y., Li Y.; RT "CD82 palmitoylation site mutations at Cys5+Cys74 affect EGFR RT internalization and metabolism through recycling pathway."; RL Acta Biochim. Biophys. Sin. 54:400-408(2022). RN [96] RP INTERACTION WITH SNX32. RX PubMed=39073202; DOI=10.1111/tra.12952; RA Wang D., Zhao X., Wang P., Liu J.J.; RT "SNX32 regulates sorting and trafficking of activated EGFR to the lysosomal RT degradation pathway."; RL Traffic 25:e12952-e12952(2024). RN [97] {ECO:0007744|PDB:1MOX} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 25-525 IN COMPLEX WITH TGFA, RP FUNCTION, GLYCOSYLATION AT ASN-56; ASN-196 AND ASN-352, AND DISULFIDE RP BONDS. RX PubMed=12297049; DOI=10.1016/s0092-8674(02)00940-6; RA Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., RA Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., RA Burgess A.W., Ward C.W.; RT "Crystal structure of a truncated epidermal growth factor receptor RT extracellular domain bound to transforming growth factor alpha."; RL Cell 110:763-773(2002). RN [98] {ECO:0007744|PDB:1IVO} RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 25-646 IN COMPLEX WITH EGF, RP FUNCTION IN MAPK1 AND/OR MAPK3 ACTIVATION, SUBUNIT, SUBCELLULAR LOCATION, RP MUTAGENESIS OF TYR-275; PHE-287; ARG-309 AND ARG-429, DISULFIDE BONDS, AND RP GLYCOSYLATION AT ASN-56; ASN-175; ASN-196; ASN-352; ASN-361 AND ASN-444. RX PubMed=12297050; DOI=10.1016/s0092-8674(02)00963-7; RA Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., RA Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S.; RT "Crystal structure of the complex of human epidermal growth factor and RT receptor extracellular domains."; RL Cell 110:775-787(2002). RN [99] {ECO:0007744|PDB:1NQL} RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 25-642 IN COMPLEX WITH EGF, RP FUNCTION, SUBUNIT, MUTAGENESIS OF 587-ASP--HIS-590 AND LYS-609, DISULFIDE RP BONDS, AND GLYCOSYLATION AT ASN-352; ASN-361; ASN-444; ASN-528; ASN-568 AND RP ASN-603. RX PubMed=12620237; DOI=10.1016/s1097-2765(03)00047-9; RA Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., RA Lemmon M.A.; RT "EGF activates its receptor by removing interactions that autoinhibit RT ectodomain dimerization."; RL Mol. Cell 11:507-517(2003). RN [100] {ECO:0007744|PDB:1XKK} RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 695-1022 IN COMPLEX WITH RP GW572016, CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=15374980; DOI=10.1158/0008-5472.can-04-1168; RA Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., RA Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., RA Rusnak D.W., Gilmer T.M., Shewchuk L.; RT "A unique structure for epidermal growth factor receptor bound to GW572016 RT (Lapatinib): relationships among protein conformation, inhibitor off-rate, RT and receptor activity in tumor cells."; RL Cancer Res. 64:6652-6659(2004). RN [101] {ECO:0007744|PDB:1YY9} RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 25-642 IN COMPLEX WITH CETUXIMAB. RX PubMed=15837620; DOI=10.1016/j.ccr.2005.03.003; RA Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M.; RT "Structural basis for inhibition of the epidermal growth factor receptor by RT cetuximab."; RL Cancer Cell 7:301-311(2005). RN [102] RP STRUCTURE BY NMR OF 669-721. RX PubMed=15840573; DOI=10.1074/jbc.m502698200; RA Choowongkomon K., Carlin C.R., Sonnichsen F.D.; RT "A structural model for the membrane-bound form of the juxtamembrane domain RT of the epidermal growth factor receptor."; RL J. Biol. Chem. 280:24043-24052(2005). RN [103] {ECO:0007744|PDB:2ITN, ECO:0007744|PDB:2ITO, ECO:0007744|PDB:2ITP, ECO:0007744|PDB:2ITQ, ECO:0007744|PDB:2ITT, ECO:0007744|PDB:2ITU, ECO:0007744|PDB:2ITV, ECO:0007744|PDB:2J6M} RP X-RAY CRYSTALLOGRAPHY (2.47 ANGSTROMS) OF 696-1022 OF WILD-TYPE AND RP VARIANTS SER-719 AND ARG-858 IN COMPLEXES WITH ATP ANALOGS AND SYNTHETIC RP INHIBITORS, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND CHARACTERIZATION RP OF VARIANTS SER-719 AND ARG-858. RX PubMed=17349580; DOI=10.1016/j.ccr.2006.12.017; RA Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., Eck M.J.; RT "Structures of lung cancer-derived EGFR mutants and inhibitor complexes: RT mechanism of activation and insights into differential inhibitor RT sensitivity."; RL Cancer Cell 11:217-227(2007). RN [104] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 702-1022 IN COMPLEX WITH ERRFI1, RP ACTIVITY REGULATION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBUNIT, AND RP INTERACTION WITH ERRFI1. RX PubMed=18046415; DOI=10.1038/nature05998; RA Zhang X., Pickin K.A., Bose R., Jura N., Cole P.A., Kuriyan J.; RT "Inhibition of the EGF receptor by binding of MIG6 to an activating kinase RT domain interface."; RL Nature 450:741-744(2007). RN [105] {ECO:0007744|PDB:2JIT, ECO:0007744|PDB:2JIU, ECO:0007744|PDB:2JIV} RP X-RAY CRYSTALLOGRAPHY (3.05 ANGSTROMS) OF 695-1022 OF VARIANT MET-790, RP CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT MET-790. RX PubMed=18227510; DOI=10.1073/pnas.0709662105; RA Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., RA Meyerson M., Eck M.J.; RT "The T790M mutation in EGFR kinase causes drug resistance by increasing the RT affinity for ATP."; RL Proc. Natl. Acad. Sci. U.S.A. 105:2070-2075(2008). RN [106] {ECO:0007744|PDB:3GT8} RP X-RAY CRYSTALLOGRAPHY (2.96 ANGSTROMS) OF 696-1022, CATALYTIC ACTIVITY, RP PHOSPHORYLATION AT TYR-998; TYR-1016 AND TYR-1197, MUTAGENESIS OF LEU-688; RP GLU-690; LEU-692; ARG-977 AND 1005-GLU-ASP-1006, AND SUBUNIT. RX PubMed=19563760; DOI=10.1016/j.cell.2009.04.025; RA Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., RA Wemmer D.E., Zhang X., Kuriyan J.; RT "Mechanism for activation of the EGF receptor catalytic domain by the RT juxtamembrane segment."; RL Cell 137:1293-1307(2009). RN [107] RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 669-1022 OF MUTANT MET-745, RP CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, RP AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-688; VAL-689; GLU-690; LEU-692; RP THR-693; PRO-694; PRO-699; ASN-700; LEU-704; ARG-705; ILE-706 AND LYS-745. RX PubMed=19560417; DOI=10.1016/j.molcel.2009.04.034; RA Red Brewer M., Choi S.H., Alvarado D., Moravcevic K., Pozzi A., RA Lemmon M.A., Carpenter G.; RT "The juxtamembrane region of the EGF receptor functions as an activation RT domain."; RL Mol. Cell 34:641-651(2009). RN [108] RP STRUCTURE BY NMR OF 634-677 IN COMPLEX WITH ERBB2, AND SUBUNIT. RX PubMed=20471394; DOI=10.1016/j.jmb.2010.05.016; RA Mineev K.S., Bocharov E.V., Pustovalova Y.E., Bocharova O.V., Chupin V.V., RA Arseniev A.S.; RT "Spatial structure of the transmembrane domain heterodimer of ErbB1 and RT ErbB2 receptor tyrosine kinases."; RL J. Mol. Biol. 400:231-243(2010). RN [109] {ECO:0007744|PDB:3NJP} RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 25-638 IN COMPLEX WITH EGF, RP FUNCTION, SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-56; ASN-73; RP ASN-175; ASN-196; ASN-352; ASN-361; ASN-444 AND ASN-528. RX PubMed=20837704; DOI=10.1128/mcb.00742-10; RA Lu C., Mi L.Z., Grey M.J., Zhu J., Graef E., Yokoyama S., Springer T.A.; RT "Structural evidence for loose linkage between ligand binding and kinase RT activation in the epidermal growth factor receptor."; RL Mol. Cell. Biol. 30:5432-5443(2010). RN [110] RP X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 1066-1076 IN COMPLEX WITH CBLB, RP AND INTERACTION WITH CBLB. RG Structural genomics consortium; RT "Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069 RT peptide."; RL Submitted (OCT-2010) to the PDB data bank. RN [111] RP X-RAY CRYSTALLOGRAPHY (1.52 ANGSTROMS) OF 1062-1074 IN COMPLEX WITH CBLC, RP PHOSPHORYLATION AT TYR-1069, INTERACTION WITH CBLC, AND MUTAGENESIS OF RP GLN-1067; ARG-1068 AND TYR-1069. RX PubMed=22888118; DOI=10.1093/jb/mvs085; RA Takeshita K., Tezuka T., Isozaki Y., Yamashita E., Suzuki M., Kim M., RA Yamanashi Y., Yamamoto T., Nakagawa A.; RT "Structural flexibility regulates phosphopeptide-binding activity of the RT tyrosine kinase binding domain of Cbl-c."; RL J. Biochem. 152:487-495(2012). RN [112] RP VARIANTS ALA-709; GLY-709; CYS-719; SER-719; 746-GLU--ALA-750 DEL; RP 746-GLU--THR-751 DELINS ALA; 746-GLU--SER-752 DELINS ASP; 747-LEU--THR-751 RP DEL; ILE-768; MET-769; VAL-833; LEU-835; VAL-838; ARG-858 AND GLN-861. RX PubMed=15623594; DOI=10.1158/1078-0432.ccr-04-1245; RA Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., Chen Y.T., RA Lin Y.F., Chang W.C., Kuo H.P., Wu Y.C., Chen Y.R., Tsai S.F.; RT "High frequency of epidermal growth factor receptor mutations with complex RT patterns in non-small cell lung cancers related to gefitinib responsiveness RT in Taiwan."; RL Clin. Cancer Res. 10:8195-8203(2004). RN [113] RP VARIANTS SER-719 AND ARG-858, AND POSSIBLE INVOLVEMENT IN LUNG CANCER. RX PubMed=15118125; DOI=10.1126/science.1099314; RA Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., RA Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., RA Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M.; RT "EGFR mutations in lung cancer: correlation with clinical response to RT gefitinib therapy."; RL Science 304:1497-1500(2004). RN [114] RP VARIANTS ALA-709; LYS-709; ALA-719; ASP-719; CYS-719; SER-719; SER-724; RP LYS-734; GLU-746 DEL; PHE-747; 747-LEU--GLU-749 DEL; PRO-748; RP 752-SER--ILE-759 DEL; ARG-787; MET-790; VAL-833; LEU-834; MET-858; ARG-858; RP GLN-861 AND GLU-873, AND POSSIBLE INVOLVEMENT IN LUNG CANCER. RX PubMed=16533793; DOI=10.1158/1078-0432.ccr-05-1981; RA Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K., Lam W.K., RA Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.; RT "Distinct epidermal growth factor receptor and KRAS mutation patterns in RT non-small cell lung cancer patients with different tobacco exposure and RT clinicopathologic features."; RL Clin. Cancer Res. 12:1647-1653(2006). RN [115] RP CHARACTERIZATION OF VARIANTS ALA-709; GLY-709; SER-719; ILE-768; VAL-833; RP LEU-835; VAL-838; ARG-858 AND GLN-861. RX PubMed=16205628; DOI=10.1038/sj.onc.1209159; RA Chen Y.R., Fu Y.N., Lin C.H., Yang S.T., Hu S.F., Chen Y.T., Tsai S.F., RA Huang S.F.; RT "Distinctive activation patterns in constitutively active and gefitinib- RT sensitive EGFR mutants."; RL Oncogene 25:1205-1215(2006). RN [116] RP VARIANT 30-VAL--ARG-297 DEL, AND POSSIBLE INVOLVEMENT IN LUNG CANCER. RX PubMed=16672372; DOI=10.1073/pnas.0510284103; RA Ji H., Zhao X., Yuza Y., Shimamura T., Li D., Protopopov A., Jung B.L., RA McNamara K., Xia H., Glatt K.A., Thomas R.K., Sasaki H., Horner J.W., RA Eck M., Mitchell A., Sun Y., Al-Hashem R., Bronson R.T., Rabindran S.K., RA Discafani C.M., Maher E., Shapiro G.I., Meyerson M., Wong K.K.; RT "Epidermal growth factor receptor variant III mutations in lung RT tumorigenesis and sensitivity to tyrosine kinase inhibitors."; RL Proc. Natl. Acad. Sci. U.S.A. 103:7817-7822(2006). RN [117] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-521; ARG-1034 AND VAL-1210. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [118] RP VARIANT NNCIS ASP-428, CHARACTERIZATION OF VARIANT NNCIS ASP-428, AND RP INVOLVEMENT IN NNCIS. RX PubMed=24691054; DOI=10.1038/jid.2014.164; RA Campbell P., Morton P.E., Takeichi T., Salam A., Roberts N., RA Proudfoot L.E., Mellerio J.E., Aminu K., Wellington C., Patil S.N., RA Akiyama M., Liu L., McMillan J.R., Aristodemou S., Ishida-Yamamoto A., RA Abdul-Wahab A., Petrof G., Fong K., Harnchoowong S., Stone K.L., RA Harper J.I., McLean W.H., Simpson M.A., Parsons M., McGrath J.A.; RT "Epithelial inflammation resulting from an inherited loss-of-function RT mutation in EGFR."; RL J. Invest. Dermatol. 134:2570-2578(2014). CC -!- FUNCTION: Receptor tyrosine kinase binding ligands of the EGF family CC and activating several signaling cascades to convert extracellular cues CC into appropriate cellular responses (PubMed:10805725, PubMed:27153536, CC PubMed:2790960, PubMed:35538033). Known ligands include EGF, TGFA/TGF- CC alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and CC HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, CC PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, CC PubMed:7679104, PubMed:8144591, PubMed:9419975). Ligand binding CC triggers receptor homo- and/or heterodimerization and CC autophosphorylation on key cytoplasmic residues. The phosphorylated CC receptor recruits adapter proteins like GRB2 which in turn activates CC complex downstream signaling cascades. Activates at least 4 major CC downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 CC kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also CC activate the NF-kappa-B signaling cascade (PubMed:11116146). Also CC directly phosphorylates other proteins like RGS16, activating its CC GTPase activity and probably coupling the EGF receptor signaling to the CC G protein-coupled receptor signaling (PubMed:11602604). Also CC phosphorylates MUC1 and increases its interaction with SRC and CC CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell CC migration via interaction with CCDC88A/GIV which retains EGFR at the CC cell membrane following ligand stimulation, promoting EGFR signaling CC which triggers cell migration (PubMed:20462955). Plays a role in CC enhancing learning and memory performance (By similarity). Plays a role CC in mammalian pain signaling (long-lasting hypersensitivity) (By CC similarity). {ECO:0000250|UniProtKB:Q01279, CC ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, CC ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11602604, CC ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, CC ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, CC ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:15590694, CC ECO:0000269|PubMed:15611079, ECO:0000269|PubMed:17115032, CC ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:19560417, CC ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:20837704, CC ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:35538033, CC ECO:0000269|PubMed:7679104, ECO:0000269|PubMed:8144591, CC ECO:0000269|PubMed:9419975}. CC -!- FUNCTION: Isoform 2 may act as an antagonist of EGF action. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C CC virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV CC entry by promoting the formation of the CD81-CLDN1 receptor complexes CC that are essential for HCV entry and by enhancing membrane fusion of CC cells expressing HCV envelope glycoproteins. CC {ECO:0000269|PubMed:21516087}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:17349580, CC ECO:0000269|PubMed:18046415, ECO:0000269|PubMed:18227510, CC ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760}; CC -!- ACTIVITY REGULATION: Endocytosis and inhibition of the activated EGFR CC by phosphatases like PTPRJ and PTPRK constitute immediate regulatory CC mechanisms. Upon EGF-binding phosphorylates EPS15 that regulates EGFR CC endocytosis and activity. Moreover, inducible feedback inhibitors CC including LRIG1, SOCS4, SOCS5 and ERRFI1 constitute alternative CC regulatory mechanisms for the EGFR signaling. Up-regulated by NEU3- CC mediated desialylation of N-linked glycan at Asn-528. CC {ECO:0000269|PubMed:15282549, ECO:0000269|PubMed:15590694, CC ECO:0000269|PubMed:17334392, ECO:0000269|PubMed:18046415, CC ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:25922362}. CC -!- SUBUNIT: Binding of the ligand triggers homo- and/or heterodimerization CC of the receptor triggering its autophosphorylation. Heterodimer with CC ERBB2 (PubMed:10805725). Forms a complex with CCDC88A/GIV (via SH2-like CC regions) and GNAI3 which leads to enhanced EGFR signaling and CC triggering of cell migration; binding to CCDC88A requires CC autophosphorylation of the EGFR C-terminal region, and ligand CC stimulation is required for recruitment of GNAI3 to the complex CC (PubMed:20462955, PubMed:25187647). Interacts with ERRFI1; inhibits CC dimerization of the kinase domain and autophosphorylation CC (PubMed:18046415). Part of a complex with ERBB2 and either PIK3C2A or CC PIK3C2B (PubMed:10805725). Interacts with GRB2; an adapter protein CC coupling the receptor to downstream signaling pathways. Interacts with CC GAB2; involved in signaling downstream of EGFR. Interacts with STAT3; CC mediates EGFR downstream signaling in cell proliferation. Interacts CC with RIPK1; involved in NF-kappa-B activation. Interacts CC (autophosphorylated) with CBL, CBLB and CBLC; involved in EGFR CC ubiquitination and regulation; interaction with CBL is reduced in the CC presence of tensin TNS4 (PubMed:23774213). Interacts with SOCS5; CC regulates EGFR degradation through ELOC- and ELOB-mediated CC ubiquitination and proteasomal degradation. Interacts with PRMT5; CC methylates EGFR and enhances interaction with PTPN6. Interacts CC (phosphorylated) with PTPN6; inhibits EGFR-dependent activation of CC MAPK/ERK. Interacts with COPG1; essential for regulation of EGF- CC dependent nuclear transport of EGFR by retrograde trafficking from the CC Golgi to the ER. Interacts with TNK2; this interaction is dependent on CC EGF stimulation and kinase activity of EGFR. Interacts with PCNA; CC positively regulates PCNA (PubMed:17115032). Interacts with PELP1. CC Interacts with MUC1. Interacts with AP2M1. Interacts with FER. May CC interact with EPS8; mediates EPS8 phosphorylation. Interacts (via SH2 CC domains) with GRB2, NCK1 and NCK2 (PubMed:10026169). Interacts with CC ATXN2. Interacts with GAREM1. Interacts (ubiquitinated) with CC ANKRD13A/B/D; the interaction is direct and may regulate EGFR CC internalization after EGF stimulation. Interacts with GPER1; the CC interaction occurs in an estrogen-dependent manner. Interacts (via C- CC terminal cytoplasmic kinase domain) with ZPR1 (via zinc fingers). CC Interacts with RNF115 and RNF126 (PubMed:23418353). Interacts with CC GPRC5A (via its transmembrane domain) (PubMed:25311788). Interacts with CC FAM83B; positively regulates EGFR inducing its autophosphorylation in CC absence of stimulation by EGF (PubMed:23912460). Interacts with CC LAPTM4B; positively correlates with EGFR activation (PubMed:28479384). CC Interacts with STX19 (PubMed:16420529). Interacts with CD44 CC (PubMed:23589287). Interacts with PGRMC1; the interaction requires CC PGRMC1 homodimerization (PubMed:26988023). Interacts with PIKFYVE CC (PubMed:17909029). Interacts with NEU3. Interacts with TRAF4 CC (PubMed:30352854). Interacts with the ant venom OMEGA- CC myrmeciitoxin(02)-Mg1a (By similarity). Interacts with CD82; this CC interaction facilitates ligand-induced endocytosis of the receptor and CC its subsequent desensitization (PubMed:35538033). Interacts with SNX32; CC the interaction is required for endolysosomal EGFR trafficking CC (PubMed:39073202). {ECO:0000250|UniProtKB:Q01279, CC ECO:0000269|PubMed:10026169, ECO:0000269|PubMed:10228163, CC ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, CC ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:12297050, CC ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, CC ECO:0000269|PubMed:15282549, ECO:0000269|PubMed:15374980, CC ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:15837620, CC ECO:0000269|PubMed:16140940, ECO:0000269|PubMed:16420529, CC ECO:0000269|PubMed:17115032, ECO:0000269|PubMed:17182860, CC ECO:0000269|PubMed:17334392, ECO:0000269|PubMed:17909029, CC ECO:0000269|PubMed:18046415, ECO:0000269|PubMed:18602463, CC ECO:0000269|PubMed:19172738, ECO:0000269|PubMed:19509291, CC ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760, CC ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19836242, CC ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:20471394, CC ECO:0000269|PubMed:20551055, ECO:0000269|PubMed:20674546, CC ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:21258366, CC ECO:0000269|PubMed:21518868, ECO:0000269|PubMed:22298428, CC ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:23418353, CC ECO:0000269|PubMed:23589287, ECO:0000269|PubMed:23774213, CC ECO:0000269|PubMed:23912460, ECO:0000269|PubMed:25187647, CC ECO:0000269|PubMed:25311788, ECO:0000269|PubMed:26988023, CC ECO:0000269|PubMed:28479384, ECO:0000269|PubMed:35538033, CC ECO:0000269|PubMed:39073202, ECO:0000269|PubMed:7657591, CC ECO:0000269|PubMed:8650580, ECO:0000269|PubMed:9852145, CC ECO:0000269|Ref.110}. CC -!- INTERACTION: CC P00533; P00519: ABL1; NbExp=3; IntAct=EBI-297353, EBI-375543; CC P00533; P42684: ABL2; NbExp=9; IntAct=EBI-297353, EBI-1102694; CC P00533; Q15109: AGER; NbExp=2; IntAct=EBI-297353, EBI-1646426; CC P00533; Q9UKV8: AGO2; NbExp=11; IntAct=EBI-297353, EBI-528269; CC P00533; Q09666: AHNAK; NbExp=4; IntAct=EBI-297353, EBI-2555881; CC P00533; O00170: AIP; NbExp=2; IntAct=EBI-297353, EBI-704197; CC P00533; Q02952: AKAP12; NbExp=3; IntAct=EBI-297353, EBI-2562430; CC P00533; P31749: AKT1; NbExp=4; IntAct=EBI-297353, EBI-296087; CC P00533; P49418: AMPH; NbExp=2; IntAct=EBI-297353, EBI-7121510; CC P00533; Q92625: ANKS1A; NbExp=7; IntAct=EBI-297353, EBI-1048612; CC P00533; P04083: ANXA1; NbExp=5; IntAct=EBI-297353, EBI-354007; CC P00533; P07355: ANXA2; NbExp=4; IntAct=EBI-297353, EBI-352622; CC P00533; Q10567: AP1B1; NbExp=4; IntAct=EBI-297353, EBI-1171303; CC P00533; Q96CW1: AP2M1; NbExp=8; IntAct=EBI-297353, EBI-297683; CC P00533; O00213: APBB1; NbExp=4; IntAct=EBI-297353, EBI-81694; CC P00533; Q92870: APBB2; NbExp=7; IntAct=EBI-297353, EBI-79277; CC P00533; O95704: APBB3; NbExp=2; IntAct=EBI-297353, EBI-286427; CC P00533; Q9UKG1: APPL1; NbExp=3; IntAct=EBI-297353, EBI-741243; CC P00533; P49407: ARRB1; NbExp=3; IntAct=EBI-297353, EBI-743313; CC P00533; P32121: ARRB2; NbExp=3; IntAct=EBI-297353, EBI-714559; CC P00533; O14965: AURKA; NbExp=5; IntAct=EBI-297353, EBI-448680; CC P00533; P30530: AXL; NbExp=5; IntAct=EBI-297353, EBI-2850927; CC P00533; Q9UQB8: BAIAP2; NbExp=4; IntAct=EBI-297353, EBI-525456; CC P00533; Q9BXH1: BBC3; NbExp=10; IntAct=EBI-297353, EBI-519884; CC P00533; Q14457: BECN1; NbExp=8; IntAct=EBI-297353, EBI-949378; CC P00533; P51451: BLK; NbExp=3; IntAct=EBI-297353, EBI-2105445; CC P00533; P62158: CALM3; NbExp=6; IntAct=EBI-297353, EBI-397435; CC P00533; P49069: CAMLG; NbExp=3; IntAct=EBI-297353, EBI-1748958; CC P00533; Q03135: CAV1; NbExp=7; IntAct=EBI-297353, EBI-603614; CC P00533; P51636: CAV2; NbExp=3; IntAct=EBI-297353, EBI-603607; CC P00533; P22681: CBL; NbExp=26; IntAct=EBI-297353, EBI-518228; CC P00533; Q16543: CDC37; NbExp=13; IntAct=EBI-297353, EBI-295634; CC P00533; P12830: CDH1; NbExp=4; IntAct=EBI-297353, EBI-727477; CC P00533; P06493: CDK1; NbExp=3; IntAct=EBI-297353, EBI-444308; CC P00533; P23528: CFL1; NbExp=3; IntAct=EBI-297353, EBI-352733; CC P00533; Q9BZP6: CHIA; NbExp=2; IntAct=EBI-297353, EBI-14357960; CC P00533; Q9NSE2: CISH; NbExp=4; IntAct=EBI-297353, EBI-617866; CC P00533; Q7Z7G1: CLNK; NbExp=2; IntAct=EBI-297353, EBI-7878194; CC P00533; Q8IZV2: CMTM8; NbExp=3; IntAct=EBI-297353, EBI-7868911; CC P00533; Q8WXI2: CNKSR2; NbExp=2; IntAct=EBI-297353, EBI-1045119; CC P00533; P46108: CRK; NbExp=4; IntAct=EBI-297353, EBI-886; CC P00533; P46108-1: CRK; NbExp=3; IntAct=EBI-297353, EBI-287556; CC P00533; P46109: CRKL; NbExp=5; IntAct=EBI-297353, EBI-910; CC P00533; P41240: CSK; NbExp=3; IntAct=EBI-297353, EBI-1380630; CC P00533; O60716: CTNND1; NbExp=5; IntAct=EBI-297353, EBI-701927; CC P00533; Q14247: CTTN; NbExp=4; IntAct=EBI-297353, EBI-351886; CC P00533; Q7L591: DOK3; NbExp=2; IntAct=EBI-297353, EBI-2834978; CC P00533; Q6PKX4: DOK6; NbExp=2; IntAct=EBI-297353, EBI-2880244; CC P00533; P01133: EGF; NbExp=29; IntAct=EBI-297353, EBI-640857; CC P00533; P00533: EGFR; NbExp=31; IntAct=EBI-297353, EBI-297353; CC P00533; Q6UW88: EPGN; NbExp=3; IntAct=EBI-297353, EBI-15482510; CC P00533; Q12929: EPS8; NbExp=4; IntAct=EBI-297353, EBI-375576; CC P00533; P04626: ERBB2; NbExp=25; IntAct=EBI-297353, EBI-641062; CC P00533; P21860: ERBB3; NbExp=15; IntAct=EBI-297353, EBI-720706; CC P00533; Q15303: ERBB4; NbExp=4; IntAct=EBI-297353, EBI-80371; CC P00533; P07992: ERCC1; NbExp=21; IntAct=EBI-297353, EBI-750962; CC P00533; O14944: EREG; NbExp=3; IntAct=EBI-297353, EBI-17272224; CC P00533; Q9UJM3: ERRFI1; NbExp=16; IntAct=EBI-297353, EBI-2941912; CC P00533; P03372: ESR1; NbExp=3; IntAct=EBI-297353, EBI-78473; CC P00533; P03372-4: ESR1; NbExp=4; IntAct=EBI-297353, EBI-4309277; CC P00533; Q92731: ESR2; NbExp=8; IntAct=EBI-297353, EBI-78505; CC P00533; Q96A65: EXOC4; NbExp=2; IntAct=EBI-297353, EBI-355383; CC P00533; P15311: EZR; NbExp=3; IntAct=EBI-297353, EBI-1056902; CC P00533; Q9BXW9: FANCD2; NbExp=3; IntAct=EBI-297353, EBI-359343; CC P00533; P09769: FGR; NbExp=3; IntAct=EBI-297353, EBI-1383732; CC P00533; Q13451: FKBP5; NbExp=2; IntAct=EBI-297353, EBI-306914; CC P00533; Q14318: FKBP8; NbExp=4; IntAct=EBI-297353, EBI-724839; CC P00533; Q13480: GAB1; NbExp=5; IntAct=EBI-297353, EBI-517684; CC P00533; Q9UQC2: GAB2; NbExp=3; IntAct=EBI-297353, EBI-975200; CC P00533; P60520: GABARAPL2; NbExp=3; IntAct=EBI-297353, EBI-720116; CC P00533; P47869: GABRA2; NbExp=2; IntAct=EBI-297353, EBI-2685723; CC P00533; P04406: GAPDH; NbExp=7; IntAct=EBI-297353, EBI-354056; CC P00533; Q8NBJ4: GOLM1; NbExp=13; IntAct=EBI-297353, EBI-712073; CC P00533; P17174: GOT1; NbExp=3; IntAct=EBI-297353, EBI-727329; CC P00533; Q14956: GPNMB; NbExp=3; IntAct=EBI-297353, EBI-7250369; CC P00533; Q14956-1: GPNMB; NbExp=2; IntAct=EBI-297353, EBI-16191078; CC P00533; O75791: GRAP2; NbExp=3; IntAct=EBI-297353, EBI-740418; CC P00533; Q13322: GRB10; NbExp=4; IntAct=EBI-297353, EBI-80275; CC P00533; P62993: GRB2; NbExp=59; IntAct=EBI-297353, EBI-401755; CC P00533; P25098: GRK2; NbExp=3; IntAct=EBI-297353, EBI-3904795; CC P00533; Q99075: HBEGF; NbExp=3; IntAct=EBI-297353, EBI-7211558; CC P00533; P08631: HCK; NbExp=3; IntAct=EBI-297353, EBI-346340; CC P00533; Q9UBN7: HDAC6; NbExp=12; IntAct=EBI-297353, EBI-301697; CC P00533; Q8WUI4: HDAC7; NbExp=3; IntAct=EBI-297353, EBI-1048378; CC P00533; P07900: HSP90AA1; NbExp=8; IntAct=EBI-297353, EBI-296047; CC P00533; P08238: HSP90AB1; NbExp=10; IntAct=EBI-297353, EBI-352572; CC P00533; Q6PK50: HSP90AB1; NbExp=2; IntAct=EBI-297353, EBI-9356629; CC P00533; P08107: HSPA1B; NbExp=6; IntAct=EBI-297353, EBI-629985; CC P00533; P34932: HSPA4; NbExp=3; IntAct=EBI-297353, EBI-356933; CC P00533; P11142: HSPA8; NbExp=7; IntAct=EBI-297353, EBI-351896; CC P00533; P38646: HSPA9; NbExp=5; IntAct=EBI-297353, EBI-354932; CC P00533; P17936: IGFBP3; NbExp=3; IntAct=EBI-297353, EBI-715709; CC P00533; P46940: IQGAP1; NbExp=4; IntAct=EBI-297353, EBI-297509; CC P00533; O14654: IRS4; NbExp=2; IntAct=EBI-297353, EBI-356594; CC P00533; Q9NZM3: ITSN2; NbExp=3; IntAct=EBI-297353, EBI-308689; CC P00533; P14923: JUP; NbExp=3; IntAct=EBI-297353, EBI-702484; CC P00533; Q86VI4: LAPTM4B; NbExp=10; IntAct=EBI-297353, EBI-3267258; CC P00533; O43561: LAT; NbExp=3; IntAct=EBI-297353, EBI-1222766; CC P00533; Q13094: LCP2; NbExp=3; IntAct=EBI-297353, EBI-346946; CC P00533; Q96FE5: LINGO1; NbExp=2; IntAct=EBI-297353, EBI-719955; CC P00533; Q96JA1: LRIG1; NbExp=6; IntAct=EBI-297353, EBI-2865191; CC P00533; O94898: LRIG2; NbExp=4; IntAct=EBI-297353, EBI-2830372; CC P00533; Q38SD2: LRRK1; NbExp=2; IntAct=EBI-297353, EBI-1050422; CC P00533; P07948: LYN; NbExp=7; IntAct=EBI-297353, EBI-79452; CC P00533; P07948-1: LYN; NbExp=2; IntAct=EBI-297353, EBI-6895930; CC P00533; Q9BRK4: LZTS2; NbExp=2; IntAct=EBI-297353, EBI-741037; CC P00533; Q12852: MAP3K12; NbExp=3; IntAct=EBI-297353, EBI-710223; CC P00533; Q9UQF2: MAPK8IP1; NbExp=3; IntAct=EBI-297353, EBI-78404; CC P00533; Q13387: MAPK8IP2; NbExp=5; IntAct=EBI-297353, EBI-722813; CC P00533; Q9Y2H9: MAST1; NbExp=3; IntAct=EBI-297353, EBI-3385920; CC P00533; Q9NS73: MBIP; NbExp=3; IntAct=EBI-297353, EBI-741953; CC P00533; P08581: MET; NbExp=8; IntAct=EBI-297353, EBI-1039152; CC P00533; P14174: MIF; NbExp=3; IntAct=EBI-297353, EBI-372712; CC P00533; P15941: MUC1; NbExp=6; IntAct=EBI-297353, EBI-2804728; CC P00533; P16333: NCK1; NbExp=6; IntAct=EBI-297353, EBI-389883; CC P00533; P46934: NEDD4; NbExp=3; IntAct=EBI-297353, EBI-726944; CC P00533; P04150: NR3C1; NbExp=3; IntAct=EBI-297353, EBI-493507; CC P00533; Q16620: NTRK2; NbExp=3; IntAct=EBI-297353, EBI-3904881; CC P00533; P49757: NUMB; NbExp=2; IntAct=EBI-297353, EBI-915016; CC P00533; Q9Y6R0: NUMBL; NbExp=2; IntAct=EBI-297353, EBI-945925; CC P00533; Q13438: OS9; NbExp=3; IntAct=EBI-297353, EBI-725454; CC P00533; Q8WUM4: PDCD6IP; NbExp=4; IntAct=EBI-297353, EBI-310624; CC P00533; P16234: PDGFRA; NbExp=4; IntAct=EBI-297353, EBI-2861522; CC P00533; O00750: PIK3C2B; NbExp=10; IntAct=EBI-297353, EBI-641107; CC P00533; P27986: PIK3R1; NbExp=7; IntAct=EBI-297353, EBI-79464; CC P00533; O00459: PIK3R2; NbExp=5; IntAct=EBI-297353, EBI-346930; CC P00533; Q92569: PIK3R3; NbExp=7; IntAct=EBI-297353, EBI-79893; CC P00533; P19174: PLCG1; NbExp=6; IntAct=EBI-297353, EBI-79387; CC P00533; P16885: PLCG2; NbExp=7; IntAct=EBI-297353, EBI-617403; CC P00533; P35813: PPM1A; NbExp=2; IntAct=EBI-297353, EBI-989143; CC P00533; P17252: PRKCA; NbExp=3; IntAct=EBI-297353, EBI-1383528; CC P00533; Q05397: PTK2; NbExp=7; IntAct=EBI-297353, EBI-702142; CC P00533; Q13882: PTK6; NbExp=2; IntAct=EBI-297353, EBI-1383632; CC P00533; P18031: PTPN1; NbExp=9; IntAct=EBI-297353, EBI-968788; CC P00533; Q06124: PTPN11; NbExp=10; IntAct=EBI-297353, EBI-297779; CC P00533; Q05209: PTPN12; NbExp=5; IntAct=EBI-297353, EBI-2266035; CC P00533; Q9Y2R2: PTPN22; NbExp=3; IntAct=EBI-297353, EBI-1211241; CC P00533; P18433: PTPRA; NbExp=3; IntAct=EBI-297353, EBI-2609645; CC P00533; P23467: PTPRB; NbExp=3; IntAct=EBI-297353, EBI-1265766; CC P00533; P08575: PTPRC; NbExp=2; IntAct=EBI-297353, EBI-1341; CC P00533; P23470: PTPRG; NbExp=3; IntAct=EBI-297353, EBI-2258115; CC P00533; Q9HD43: PTPRH; NbExp=3; IntAct=EBI-297353, EBI-1267176; CC P00533; Q9UJ41: RABGEF1; NbExp=4; IntAct=EBI-297353, EBI-913954; CC P00533; P04049: RAF1; NbExp=3; IntAct=EBI-297353, EBI-365996; CC P00533; Q70E73: RAPH1; NbExp=2; IntAct=EBI-297353, EBI-3940924; CC P00533; P20936: RASA1; NbExp=7; IntAct=EBI-297353, EBI-1026476; CC P00533; Q13671: RIN1; NbExp=3; IntAct=EBI-297353, EBI-366017; CC P00533; Q01973: ROR1; NbExp=8; IntAct=EBI-297353, EBI-6082337; CC P00533; Q92622: RUBCN; NbExp=4; IntAct=EBI-297353, EBI-2952709; CC P00533; P26447: S100A4; NbExp=6; IntAct=EBI-297353, EBI-717058; CC P00533; P61619: SEC61A1; NbExp=2; IntAct=EBI-297353, EBI-358919; CC P00533; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-297353, EBI-358766; CC P00533; P31947: SFN; NbExp=9; IntAct=EBI-297353, EBI-476295; CC P00533; Q9NRF2: SH2B1; NbExp=4; IntAct=EBI-297353, EBI-310491; CC P00533; Q9UQQ2: SH2B3; NbExp=2; IntAct=EBI-297353, EBI-7879749; CC P00533; Q9BRG2: SH2D3A; NbExp=3; IntAct=EBI-297353, EBI-2339271; CC P00533; O75368: SH3BGRL; NbExp=3; IntAct=EBI-297353, EBI-2854777; CC P00533; Q99962: SH3GL2; NbExp=4; IntAct=EBI-297353, EBI-77938; CC P00533; Q96B97: SH3KBP1; NbExp=4; IntAct=EBI-297353, EBI-346595; CC P00533; P29353: SHC1; NbExp=44; IntAct=EBI-297353, EBI-78835; CC P00533; P29353-7: SHC1; NbExp=4; IntAct=EBI-297353, EBI-9691288; CC P00533; P98077: SHC2; NbExp=3; IntAct=EBI-297353, EBI-7256023; CC P00533; Q6S5L8: SHC4; NbExp=3; IntAct=EBI-297353, EBI-9453524; CC P00533; O75563: SKAP2; NbExp=2; IntAct=EBI-297353, EBI-2483161; CC P00533; Q13239: SLA; NbExp=3; IntAct=EBI-297353, EBI-726214; CC P00533; P13866: SLC5A1; NbExp=3; IntAct=EBI-297353, EBI-1772443; CC P00533; Q07889: SOS1; NbExp=3; IntAct=EBI-297353, EBI-297487; CC P00533; P12931: SRC; NbExp=10; IntAct=EBI-297353, EBI-621482; CC P00533; P42224: STAT1; NbExp=7; IntAct=EBI-297353, EBI-1057697; CC P00533; P40763: STAT3; NbExp=16; IntAct=EBI-297353, EBI-518675; CC P00533; P42229: STAT5A; NbExp=4; IntAct=EBI-297353, EBI-749537; CC P00533; P51692: STAT5B; NbExp=2; IntAct=EBI-297353, EBI-1186119; CC P00533; P31948: STIP1; NbExp=3; IntAct=EBI-297353, EBI-1054052; CC P00533; Q9UNE7: STUB1; NbExp=4; IntAct=EBI-297353, EBI-357085; CC P00533; O43752: STX6; NbExp=3; IntAct=EBI-297353, EBI-2695795; CC P00533; P43405: SYK; NbExp=7; IntAct=EBI-297353, EBI-78302; CC P00533; Q15750: TAB1; NbExp=3; IntAct=EBI-297353, EBI-358643; CC P00533; Q9Y6A5: TACC3; NbExp=3; IntAct=EBI-297353, EBI-2554984; CC P00533; P01135: TGFA; NbExp=4; IntAct=EBI-297353, EBI-1034374; CC P00533; Q9Y490: TLN1; NbExp=2; IntAct=EBI-297353, EBI-2462036; CC P00533; O60603: TLR2; NbExp=3; IntAct=EBI-297353, EBI-973722; CC P00533; Q9Y6Q6-2: TNFRSF11A; NbExp=3; IntAct=EBI-297353, EBI-20899422; CC P00533; Q68CZ2: TNS3; NbExp=5; IntAct=EBI-297353, EBI-1220488; CC P00533; Q8IZW8: TNS4; NbExp=2; IntAct=EBI-297353, EBI-7543499; CC P00533; O75674: TOM1L1; NbExp=6; IntAct=EBI-297353, EBI-712991; CC P00533; Q12933: TRAF2; NbExp=4; IntAct=EBI-297353, EBI-355744; CC P00533; Q71U36: TUBA1A; NbExp=4; IntAct=EBI-297353, EBI-302552; CC P00533; Q13885: TUBB2A; NbExp=2; IntAct=EBI-297353, EBI-711595; CC P00533; P10599: TXN; NbExp=5; IntAct=EBI-297353, EBI-594644; CC P00533; P09936: UCHL1; NbExp=3; IntAct=EBI-297353, EBI-714860; CC P00533; Q8TEY7: USP33; NbExp=2; IntAct=EBI-297353, EBI-719283; CC P00533; Q9P0L0: VAPA; NbExp=4; IntAct=EBI-297353, EBI-1059156; CC P00533; Q9UPY6: WASF3; NbExp=3; IntAct=EBI-297353, EBI-3907133; CC P00533; P07947: YES1; NbExp=3; IntAct=EBI-297353, EBI-515331; CC P00533; P27348: YWHAQ; NbExp=7; IntAct=EBI-297353, EBI-359854; CC P00533; P63104: YWHAZ; NbExp=6; IntAct=EBI-297353, EBI-347088; CC P00533; P43403: ZAP70; NbExp=3; IntAct=EBI-297353, EBI-1211276; CC P00533; Q53FC7; NbExp=3; IntAct=EBI-297353, EBI-9356749; CC P00533; Q96BE0; NbExp=2; IntAct=EBI-297353, EBI-9356686; CC P00533; P62161: Calm3; Xeno; NbExp=6; IntAct=EBI-297353, EBI-397530; CC P00533; P22682: Cbl; Xeno; NbExp=2; IntAct=EBI-297353, EBI-640919; CC P00533; P62994: Grb2; Xeno; NbExp=5; IntAct=EBI-297353, EBI-401775; CC P00533; Q9QZC5: Grb7; Xeno; NbExp=7; IntAct=EBI-297353, EBI-22085551; CC P00533; P97313: Prkdc; Xeno; NbExp=4; IntAct=EBI-297353, EBI-2272005; CC P00533; P20417: Ptpn1; Xeno; NbExp=11; IntAct=EBI-297353, EBI-916819; CC P00533; Q80U62: Rubcn; Xeno; NbExp=2; IntAct=EBI-297353, EBI-3506572; CC P00533; P0DTC2: S; Xeno; NbExp=4; IntAct=EBI-297353, EBI-25474821; CC P00533; Q8K424: Trpv3; Xeno; NbExp=2; IntAct=EBI-297353, EBI-2650739; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17182860, CC ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:23589287, CC ECO:0000269|PubMed:26918609, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:35538033}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:27153536}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:27153536}; Single-pass type I CC membrane protein. Golgi apparatus membrane; Single-pass type I membrane CC protein. Nucleus membrane; Single-pass type I membrane protein. CC Endosome {ECO:0000269|PubMed:17182860, ECO:0000269|PubMed:27153536}. CC Endosome membrane. Nucleus {ECO:0000269|PubMed:17115032, CC ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:20674546}. Note=In response to EGF, translocated CC from the cell membrane to the nucleus via Golgi and ER CC (PubMed:17909029, PubMed:20674546). Endocytosed upon activation by CC ligand (PubMed:17182860, PubMed:17909029, PubMed:27153536, CC PubMed:2790960). Colocalized with GPER1 in the nucleus of estrogen CC agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055). CC {ECO:0000269|PubMed:17182860, ECO:0000269|PubMed:17909029, CC ECO:0000269|PubMed:20674546, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:2790960}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=p170; CC IsoId=P00533-1; Sequence=Displayed; CC Name=2; Synonyms=p60, Truncated, TEGFR; CC IsoId=P00533-2; Sequence=VSP_002887, VSP_002888; CC Name=3; Synonyms=p110; CC IsoId=P00533-3; Sequence=VSP_002889, VSP_002890; CC Name=4; CC IsoId=P00533-4; Sequence=VSP_002891, VSP_002892; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is also expressed CC in ovarian cancers. {ECO:0000269|PubMed:17671655}. CC -!- PTM: Phosphorylated on Tyr residues in response to EGF CC (PubMed:20462955, PubMed:27153536). Phosphorylation at Ser-695 is CC partial and occurs only if Thr-693 is phosphorylated. Phosphorylation CC at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 CC activation. Dephosphorylation by PTPRJ prevents endocytosis and CC stabilizes the receptor at the plasma membrane. Autophosphorylation at CC Tyr-1197 is stimulated by methylation at Arg-1199 and enhances CC interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 CC recruits STAT3. Dephosphorylated by PTPN1 and PTPN2. CC {ECO:0000269|PubMed:10523301, ECO:0000269|PubMed:12873986, CC ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19563760, CC ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:20462955, CC ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:2543678, CC ECO:0000269|PubMed:27153536, ECO:0000269|PubMed:3138233}. CC -!- PTM: Monoubiquitinated and polyubiquitinated upon EGF stimulation; CC which does not affect tyrosine kinase activity or signaling capacity CC but may play a role in lysosomal targeting (PubMed:27153536). CC Polyubiquitin linkage is mainly through 'Lys-63', but linkage through CC 'Lys-48', 'Lys-11' and 'Lys-29' also occurs. Deubiquitination by OTUD7B CC prevents degradation. Ubiquitinated by RNF115 and RNF126 (By CC similarity). Ubiquitinated by ZNRF1 or CBL at different lysines in CC response to EGF stimulation; leading to recruitment of the ESCRT CC machinery and subsequent degradation in the lysosomes CC (PubMed:33996800). Deubiquitinated by UCHL1 leading to the inhibition CC of its degradation (By similarity). {ECO:0000250|UniProtKB:Q01279, CC ECO:0000269|PubMed:16543144, ECO:0000269|PubMed:22179831, CC ECO:0000269|PubMed:22298428, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:33996800}. CC -!- PTM: Palmitoylated on Cys residues by ZDHHC20. Palmitoylation inhibits CC internalization after ligand binding, and increases the persistence of CC tyrosine-phosphorylated EGFR at the cell membrane. Palmitoylation CC increases the amplitude and duration of EGFR signaling. CC {ECO:0000269|PubMed:27153536}. CC -!- PTM: Methylated. Methylation at Arg-1199 by PRMT5 stimulates CC phosphorylation at Tyr-1197. {ECO:0000269|PubMed:19563760, CC ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:21258366}. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:16533793, CC ECO:0000269|PubMed:16672372}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Neonatal nephrocutaneous inflammatory syndrome (NNCIS) CC [MIM:616069]: An autosomal recessive disorder characterized by CC intrauterine growth retardation, premature birth, fragile skin, CC recurrent skin infections and sepsis, failure to thrive, CC nephrocalcinosis, and nephromegaly with tubular dysfunction. Some CC patients have chronic diarrhea, and necrotizing enterocolitis. CC {ECO:0000269|PubMed:24691054}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=EGFR entry; CC URL="https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X00588; CAA25240.1; -; mRNA. DR EMBL; U95089; AAB53063.1; -; mRNA. DR EMBL; U48722; AAC50802.1; -; mRNA. DR EMBL; U48723; AAC50804.1; -; Genomic_DNA. DR EMBL; U48724; AAC50796.1; -; Genomic_DNA. DR EMBL; U48725; AAC50797.1; -; Genomic_DNA. DR EMBL; U48726; AAC50798.1; -; Genomic_DNA. DR EMBL; U48727; AAC50799.1; -; Genomic_DNA. DR EMBL; U48728; AAC50800.1; -; Genomic_DNA. DR EMBL; U48729; AAC50801.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35786.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35787.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35788.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35789.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35790.1; -; Genomic_DNA. DR EMBL; AY698024; AAT97979.1; -; mRNA. DR EMBL; AY588246; AAS83109.1; -; Genomic_DNA. DR EMBL; AF277897; AAK01080.1; -; mRNA. DR EMBL; AF125253; AAG43240.1; -; mRNA. DR EMBL; AF125539; AAG43243.1; -; Genomic_DNA. DR EMBL; AF125538; AAG43243.1; JOINED; Genomic_DNA. DR EMBL; X06370; CAA29668.1; -; Genomic_DNA. DR EMBL; X00663; CAA25282.1; -; mRNA. DR EMBL; M38425; AAA63171.1; -; Genomic_DNA. DR EMBL; M11234; AAA52370.1; -; Genomic_DNA. DR CCDS; CCDS47587.1; -. [P00533-2] DR CCDS; CCDS5514.1; -. [P00533-1] DR CCDS; CCDS5515.1; -. [P00533-3] DR CCDS; CCDS5516.1; -. [P00533-4] DR PIR; A00641; GQHUE. DR RefSeq; NP_005219.2; NM_005228.4. [P00533-1] DR RefSeq; NP_958439.1; NM_201282.2. [P00533-4] DR RefSeq; NP_958440.1; NM_201283.2. [P00533-2] DR RefSeq; NP_958441.1; NM_201284.2. [P00533-3] DR PDB; 1IVO; X-ray; 3.30 A; A/B=25-646. DR PDB; 1M14; X-ray; 2.60 A; A=695-1022. DR PDB; 1M17; X-ray; 2.60 A; A=695-1022. DR PDB; 1MOX; X-ray; 2.50 A; A/B=25-525. DR PDB; 1NQL; X-ray; 2.80 A; A=25-642. DR PDB; 1XKK; X-ray; 2.40 A; A=695-1022. DR PDB; 1YY9; X-ray; 2.60 A; A=25-642. DR PDB; 1Z9I; NMR; -; A=669-721. DR PDB; 2EB2; X-ray; 2.50 A; A=695-1022. DR PDB; 2EB3; X-ray; 2.84 A; A=695-1022. DR PDB; 2GS2; X-ray; 2.80 A; A=696-1022. DR PDB; 2GS6; X-ray; 2.60 A; A=696-1022. DR PDB; 2GS7; X-ray; 2.60 A; A/B=696-1022. DR PDB; 2ITN; X-ray; 2.47 A; A=696-1022. DR PDB; 2ITO; X-ray; 3.25 A; A=696-1022. DR PDB; 2ITP; X-ray; 2.74 A; A=696-1022. DR PDB; 2ITQ; X-ray; 2.68 A; A=696-1022. DR PDB; 2ITT; X-ray; 2.73 A; A=696-1022. DR PDB; 2ITU; X-ray; 2.80 A; A=696-1022. DR PDB; 2ITV; X-ray; 2.47 A; A=696-1022. DR PDB; 2ITW; X-ray; 2.88 A; A=696-1022. DR PDB; 2ITX; X-ray; 2.98 A; A=696-1022. DR PDB; 2ITY; X-ray; 3.42 A; A=696-1022. DR PDB; 2ITZ; X-ray; 2.72 A; A=696-1022. DR PDB; 2J5E; X-ray; 3.10 A; A=696-1022. DR PDB; 2J5F; X-ray; 3.00 A; A=696-1022. DR PDB; 2J6M; X-ray; 3.10 A; A=696-1022. DR PDB; 2JIT; X-ray; 3.10 A; A/B=696-1022. DR PDB; 2JIU; X-ray; 3.05 A; A/B=695-1022. DR PDB; 2JIV; X-ray; 3.50 A; A/B=695-1022. DR PDB; 2KS1; NMR; -; B=634-677. DR PDB; 2M0B; NMR; -; A/B=634-677. DR PDB; 2M20; NMR; -; A/B=642-697. DR PDB; 2N5S; NMR; -; A=642-690. DR PDB; 2RF9; X-ray; 3.50 A; A/B=696-1022. DR PDB; 2RFD; X-ray; 3.60 A; A/B=702-1022. DR PDB; 2RFE; X-ray; 2.90 A; A/B/C/D=702-1022. DR PDB; 2RGP; X-ray; 2.00 A; A=702-1016. DR PDB; 3B2U; X-ray; 2.58 A; A/B/E/I/M/P/S/V=335-538. DR PDB; 3B2V; X-ray; 3.30 A; A=25-642. DR PDB; 3BEL; X-ray; 2.30 A; A=702-1016. DR PDB; 3BUO; X-ray; 2.60 A; A/C=1063-1075. DR PDB; 3C09; X-ray; 3.20 A; A/D=336-538. DR PDB; 3G5V; X-ray; 2.00 A; C=311-326. DR PDB; 3G5Y; X-ray; 1.59 A; E=311-326. DR PDB; 3GOP; X-ray; 2.80 A; A=669-1022. DR PDB; 3GT8; X-ray; 2.96 A; A/B/C/D=696-1022. DR PDB; 3IKA; X-ray; 2.90 A; A/B=694-1022. DR PDB; 3LZB; X-ray; 2.70 A; A/B/C/D/E/F/G/H=696-983. DR PDB; 3NJP; X-ray; 3.30 A; A/B=25-638. DR PDB; 3OB2; X-ray; 2.10 A; A=1063-1074. DR PDB; 3OP0; X-ray; 2.52 A; C/D=1066-1076. DR PDB; 3P0Y; X-ray; 1.80 A; A=334-538. DR PDB; 3PFV; X-ray; 2.27 A; C/D=1066-1076. DR PDB; 3POZ; X-ray; 1.50 A; A=696-1022. DR PDB; 3QWQ; X-ray; 2.75 A; A=1-642. DR PDB; 3UG1; X-ray; 2.75 A; A=695-1022. DR PDB; 3UG2; X-ray; 2.50 A; A=695-1022. DR PDB; 3VJN; X-ray; 2.34 A; A=695-1022. DR PDB; 3VJO; X-ray; 2.64 A; A=695-1022. DR PDB; 3VRP; X-ray; 1.52 A; B=1062-1074. DR PDB; 3VRR; X-ray; 2.00 A; C=1062-1074. DR PDB; 3W2O; X-ray; 2.35 A; A=698-1022. DR PDB; 3W2P; X-ray; 2.05 A; A=698-1022. DR PDB; 3W2Q; X-ray; 2.20 A; A=698-1022. DR PDB; 3W2R; X-ray; 2.05 A; A=698-1022. DR PDB; 3W2S; X-ray; 1.90 A; A=696-1022. DR PDB; 3W32; X-ray; 1.80 A; A=696-1022. DR PDB; 3W33; X-ray; 1.70 A; A=696-1022. DR PDB; 4G5J; X-ray; 2.80 A; A=696-1022. DR PDB; 4G5P; X-ray; 3.17 A; A/B=696-1022. DR PDB; 4HJO; X-ray; 2.75 A; A=696-1022. DR PDB; 4I1Z; X-ray; 3.00 A; A=695-1022. DR PDB; 4I20; X-ray; 3.34 A; A=695-1022. DR PDB; 4I21; X-ray; 3.37 A; A/B=695-1022. DR PDB; 4I22; X-ray; 1.71 A; A=695-1022. DR PDB; 4I23; X-ray; 2.80 A; A=695-1022. DR PDB; 4I24; X-ray; 1.80 A; A/B=695-1022. DR PDB; 4JQ7; X-ray; 2.73 A; A=696-1021. DR PDB; 4JQ8; X-ray; 2.83 A; A=696-1021. DR PDB; 4JR3; X-ray; 2.70 A; A=696-1021. DR PDB; 4JRV; X-ray; 2.80 A; A=696-1021. DR PDB; 4KRL; X-ray; 2.85 A; A=335-538. DR PDB; 4KRM; X-ray; 2.66 A; A/C/E/G/I/K=335-538. DR PDB; 4KRO; X-ray; 3.05 A; A=25-642. DR PDB; 4KRP; X-ray; 2.82 A; A=25-642. DR PDB; 4LI5; X-ray; 2.64 A; A=696-1020. DR PDB; 4LL0; X-ray; 4.00 A; A/B=694-1022. DR PDB; 4LQM; X-ray; 2.50 A; A=694-1022. DR PDB; 4LRM; X-ray; 3.53 A; A/B/C/D/E=694-1022. DR PDB; 4R3P; X-ray; 2.90 A; A=696-1018. DR PDB; 4R3R; X-ray; 3.25 A; A=696-1018. DR PDB; 4R5S; X-ray; 3.00 A; A=696-1022. DR PDB; 4RIW; X-ray; 3.10 A; B/D=682-1022. DR PDB; 4RIX; X-ray; 3.10 A; B/D=682-1022. DR PDB; 4RIY; X-ray; 2.98 A; B/D=682-1022. DR PDB; 4RJ4; X-ray; 2.78 A; A=695-1022. DR PDB; 4RJ5; X-ray; 3.10 A; A=695-1022. DR PDB; 4RJ6; X-ray; 2.70 A; A=695-1022. DR PDB; 4RJ7; X-ray; 2.55 A; A=695-1022. DR PDB; 4RJ8; X-ray; 2.50 A; A=695-1022. DR PDB; 4TKS; X-ray; 3.20 A; A=695-1022. DR PDB; 4UIP; X-ray; 2.95 A; A=26-637. DR PDB; 4UV7; X-ray; 2.10 A; A=25-645. DR PDB; 4WD5; X-ray; 3.30 A; A/B=694-1022. DR PDB; 4WKQ; X-ray; 1.85 A; A=696-1022. DR PDB; 4WRG; X-ray; 1.90 A; A=696-1022. DR PDB; 4ZAU; X-ray; 2.80 A; A=696-1022. DR PDB; 4ZJV; X-ray; 2.70 A; A/B=695-1022. DR PDB; 4ZSE; X-ray; 1.97 A; A/B/C/D=695-1022. DR PDB; 5C8K; X-ray; 3.00 A; A=695-1022. DR PDB; 5C8M; X-ray; 2.90 A; A=695-1022. DR PDB; 5C8N; X-ray; 2.40 A; A=695-1022. DR PDB; 5CAL; X-ray; 2.70 A; A=695-1022. DR PDB; 5CAN; X-ray; 2.80 A; A=695-1022. DR PDB; 5CAO; X-ray; 2.60 A; A=695-1022. DR PDB; 5CAP; X-ray; 2.40 A; A=695-1022. DR PDB; 5CAQ; X-ray; 2.50 A; A=695-1022. DR PDB; 5CAS; X-ray; 2.10 A; A=695-1022. DR PDB; 5CAU; X-ray; 2.25 A; A=695-1022. DR PDB; 5CAV; X-ray; 2.73 A; A=695-1022. DR PDB; 5CNN; X-ray; 1.90 A; A/B=696-1042. DR PDB; 5CNO; X-ray; 1.55 A; A/B/X=696-1022. DR PDB; 5CZH; X-ray; 2.80 A; A=694-1022. DR PDB; 5CZI; X-ray; 2.60 A; A=694-1022. DR PDB; 5D41; X-ray; 2.31 A; A/B=695-1022. DR PDB; 5EDP; X-ray; 2.90 A; A=695-1022. DR PDB; 5EDQ; X-ray; 2.80 A; A=695-1022. DR PDB; 5EDR; X-ray; 2.60 A; A=695-1022. DR PDB; 5EM5; X-ray; 2.65 A; A=695-1022. DR PDB; 5EM6; X-ray; 2.78 A; A=695-1022. DR PDB; 5EM7; X-ray; 2.81 A; A=695-1022. DR PDB; 5EM8; X-ray; 2.80 A; A=695-1022. DR PDB; 5FED; X-ray; 2.65 A; A=696-1022. DR PDB; 5FEE; X-ray; 2.70 A; A=696-1022. DR PDB; 5FEQ; X-ray; 3.40 A; A=696-1022. DR PDB; 5GMP; X-ray; 2.80 A; A=696-1022. DR PDB; 5GNK; X-ray; 1.80 A; A=696-988. DR PDB; 5GTY; X-ray; 3.14 A; A/B/C/D/E/F/G/H=696-1022. DR PDB; 5GTZ; X-ray; 3.00 A; A=696-1022. DR PDB; 5HCX; X-ray; 2.60 A; A=696-1022. DR PDB; 5HCY; X-ray; 2.46 A; A=696-1022. DR PDB; 5HCZ; X-ray; 2.62 A; A=696-1022. DR PDB; 5HG5; X-ray; 1.52 A; A=695-1022. DR PDB; 5HG7; X-ray; 1.85 A; A=695-1022. DR PDB; 5HG8; X-ray; 1.42 A; A=695-1022. DR PDB; 5HG9; X-ray; 2.15 A; A=695-1022. DR PDB; 5HIB; X-ray; 2.85 A; A=695-1022. DR PDB; 5HIC; X-ray; 2.60 A; A=695-1022. DR PDB; 5J9Y; X-ray; 2.80 A; A=697-1019. DR PDB; 5J9Z; X-ray; 2.50 A; A=696-1020. DR PDB; 5JEB; X-ray; 3.30 A; A=696-1022. DR PDB; 5LV6; NMR; -; A/B=634-677. DR PDB; 5SX4; X-ray; 2.80 A; M/N=335-525. DR PDB; 5SX5; X-ray; 2.50 A; M/N=335-525. DR PDB; 5U8L; X-ray; 1.60 A; A=695-1022. DR PDB; 5UG8; X-ray; 1.46 A; A=695-1022. DR PDB; 5UG9; X-ray; 1.33 A; A=695-1022. DR PDB; 5UGA; X-ray; 1.82 A; A=695-1022. DR PDB; 5UGB; X-ray; 2.53 A; A=695-1022. DR PDB; 5UGC; X-ray; 1.58 A; A=695-1022. DR PDB; 5UWD; X-ray; 3.06 A; A=695-1022. DR PDB; 5WB7; X-ray; 2.94 A; A/B/C/D=25-525. DR PDB; 5WB8; X-ray; 3.00 A; A/D=25-525. DR PDB; 5X26; X-ray; 2.95 A; A=696-1022. DR PDB; 5X27; X-ray; 2.95 A; A=696-1022. DR PDB; 5X28; X-ray; 2.95 A; A=696-1022. DR PDB; 5X2A; X-ray; 1.85 A; A/B/C/D=696-1022. DR PDB; 5X2C; X-ray; 2.05 A; A/B=696-1022. DR PDB; 5X2F; X-ray; 2.20 A; A/B/C/D=696-1022. DR PDB; 5X2K; X-ray; 3.20 A; A=696-1022. DR PDB; 5XDK; X-ray; 2.35 A; A=696-1022. DR PDB; 5XDL; X-ray; 2.70 A; A=696-1022. DR PDB; 5XGM; X-ray; 2.95 A; A=696-1022. DR PDB; 5XGN; X-ray; 3.00 A; A/B=696-1022. DR PDB; 5XWD; X-ray; 2.89 A; A=1-643. DR PDB; 5Y25; X-ray; 3.10 A; A=698-1022. DR PDB; 5Y9T; X-ray; 3.25 A; A=695-1022. DR PDB; 5YU9; X-ray; 1.95 A; A/B/C/D=696-1022. DR PDB; 5ZTO; X-ray; 2.65 A; A=696-1022. DR PDB; 5ZWJ; X-ray; 2.90 A; A=675-1022. DR PDB; 6ARU; X-ray; 3.20 A; A=25-640. DR PDB; 6B3S; X-ray; 2.80 A; A/B/E/I=335-538. DR PDB; 6D8E; X-ray; 2.54 A; A=696-1022. DR PDB; 6DUK; X-ray; 2.20 A; A/B/C/D/E/F=695-1022. DR PDB; 6JRJ; X-ray; 2.94 A; A=696-1022. DR PDB; 6JRK; X-ray; 2.80 A; A=696-1022. DR PDB; 6JRX; X-ray; 2.20 A; A=696-1022. DR PDB; 6JWL; X-ray; 2.55 A; A=696-1022. DR PDB; 6JX0; X-ray; 2.53 A; A=696-1022. DR PDB; 6JX4; X-ray; 2.53 A; A=696-1022. DR PDB; 6JXT; X-ray; 2.31 A; A=696-1022. DR PDB; 6JZ0; X-ray; 2.86 A; A=696-1021. DR PDB; 6LUB; X-ray; 2.31 A; A=695-1022. DR PDB; 6LUD; X-ray; 2.05 A; A=695-1022. DR PDB; 6P1D; X-ray; 2.40 A; A/B/C/D=696-1022. DR PDB; 6P1L; X-ray; 2.80 A; A/B/C/D=696-1022. DR PDB; 6P8Q; X-ray; 1.90 A; A/B/C/D=696-1022. DR PDB; 6S89; X-ray; 2.70 A; A=695-1022. DR PDB; 6S8A; X-ray; 2.60 A; A=695-1022. DR PDB; 6S9B; X-ray; 3.25 A; A=697-1022. DR PDB; 6S9C; X-ray; 2.73 A; A=696-1022. DR PDB; 6S9D; X-ray; 2.67 A; A=696-1022. DR PDB; 6TFU; X-ray; 2.00 A; A/B=695-1022. DR PDB; 6TFV; X-ray; 1.50 A; A/B=695-1022. DR PDB; 6TFW; X-ray; 2.00 A; A/B=695-1022. DR PDB; 6TFY; X-ray; 1.70 A; A/B=695-1022. DR PDB; 6TFZ; X-ray; 1.80 A; A/B=695-1022. DR PDB; 6TG0; X-ray; 1.50 A; A/B=695-1022. DR PDB; 6TG1; X-ray; 1.60 A; A/B=695-1022. DR PDB; 6V5N; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 6V5P; X-ray; 2.30 A; A/B/C/D=695-1022. DR PDB; 6V66; X-ray; 1.79 A; A/B/C/D=696-1022. DR PDB; 6V6K; X-ray; 2.20 A; A/B/C/D/E/F/G/H=696-1022. DR PDB; 6V6O; X-ray; 2.10 A; A/B/C/D/E/F/G/H=696-1022. DR PDB; 6VH4; X-ray; 2.80 A; A=696-1022. DR PDB; 6VHN; X-ray; 2.40 A; A=696-1022. DR PDB; 6VHP; X-ray; 3.60 A; A=696-1022. DR PDB; 6WA2; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 6WAK; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 6WXN; X-ray; 1.76 A; A/B/C/D=695-1022. DR PDB; 6XL4; X-ray; 2.06 A; A/B/C/D=695-1022. DR PDB; 6Z4B; X-ray; 2.50 A; A/B=695-1022. DR PDB; 6Z4D; X-ray; 2.00 A; A/B=695-1022. DR PDB; 7A2A; X-ray; 1.90 A; A/B=695-1022. DR PDB; 7A6I; X-ray; 2.40 A; A=695-1022. DR PDB; 7A6J; X-ray; 2.00 A; A/B=695-1022. DR PDB; 7A6K; X-ray; 2.00 A; A/B/C/D=695-1022. DR PDB; 7AEI; X-ray; 2.65 A; A=695-1022. DR PDB; 7AEM; X-ray; 2.65 A; A=695-1022. DR PDB; 7B85; X-ray; 2.50 A; A=695-1022. DR PDB; 7ER2; X-ray; 2.66 A; A=696-1022. DR PDB; 7JXI; X-ray; 3.00 A; A/B/C/D=695-1022. DR PDB; 7JXK; X-ray; 3.10 A; A/B/C/D/E/F=695-1022. DR PDB; 7JXL; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 7JXM; X-ray; 2.19 A; A/B/C/D=695-1022. DR PDB; 7JXP; X-ray; 2.16 A; A/B/C/D/E/F=695-1022. DR PDB; 7JXQ; X-ray; 1.83 A; A/B/C/D=695-1022. DR PDB; 7JXW; X-ray; 2.50 A; A/B/C/D=695-1022. DR PDB; 7K1H; X-ray; 2.60 A; A/B/C/D/E/F=695-1022. DR PDB; 7K1I; X-ray; 3.20 A; A=695-1022. DR PDB; 7KXZ; X-ray; 2.40 A; A=695-1022. DR PDB; 7KY0; X-ray; 3.10 A; A/B/C/D=695-1022. DR PDB; 7LEN; X-ray; 2.90 A; A/B=25-525. DR PDB; 7LFR; X-ray; 3.20 A; A/B=25-525. DR PDB; 7LFS; X-ray; 3.50 A; A/B/C/D=25-525. DR PDB; 7LG8; X-ray; 2.93 A; A/B/C/D=695-1022. DR PDB; 7LGS; X-ray; 3.10 A; A/B/C/D=696-1022. DR PDB; 7LTX; X-ray; 2.30 A; A/B/C/D=695-1022. DR PDB; 7OM4; X-ray; 6.05 A; A=25-645. DR PDB; 7OXB; X-ray; 2.56 A; A=696-1020. DR PDB; 7SI1; X-ray; 1.60 A; A=695-1022. DR PDB; 7SYD; EM; 3.10 A; A/B=1-1210. DR PDB; 7SYE; EM; 3.30 A; A/B=1-1210. DR PDB; 7SZ0; EM; 3.30 A; A/B=1-1210. DR PDB; 7SZ1; EM; 3.40 A; A/B=1-1210. DR PDB; 7SZ5; EM; 3.60 A; A/B=1-1210. DR PDB; 7SZ7; EM; 3.40 A; A/B=1-1210. DR PDB; 7T4I; X-ray; 2.61 A; A=696-1022. DR PDB; 7T4J; X-ray; 2.20 A; A/B=696-1022. DR PDB; 7TVD; X-ray; 2.96 A; A=696-1022. DR PDB; 7U98; X-ray; 3.42 A; A/B/C/D=695-1022. DR PDB; 7U99; X-ray; 2.50 A; A=695-1022. DR PDB; 7U9A; X-ray; 2.60 A; A=695-1022. DR PDB; 7UKV; X-ray; 2.40 A; A=695-1022. DR PDB; 7UKW; X-ray; 2.60 A; A/B/C/D=695-1022. DR PDB; 7VRA; X-ray; 2.41 A; A=696-1022. DR PDB; 7VRE; X-ray; 2.51 A; A=696-1022. DR PDB; 7ZYM; X-ray; 2.50 A; A=695-1022. DR PDB; 7ZYN; X-ray; 2.30 A; A=695-1022. DR PDB; 7ZYP; X-ray; 2.80 A; A=695-1022. DR PDB; 7ZYQ; X-ray; 2.10 A; A/B=695-1022. DR PDB; 8A27; X-ray; 1.07 A; A=700-1022. DR PDB; 8A2A; X-ray; 1.43 A; A=700-1022. DR PDB; 8A2B; X-ray; 1.69 A; A=700-1022. DR PDB; 8A2D; X-ray; 1.11 A; A=700-1022. DR PDB; 8D73; X-ray; 2.17 A; A/B=695-1022. DR PDB; 8D76; X-ray; 2.40 A; A/B=695-1022. DR PDB; 8DSW; X-ray; 2.39 A; A=696-1022. DR PDB; 8EME; X-ray; 3.32 A; A/B=695-1022. DR PDB; 8F1H; X-ray; 2.80 A; A=695-1022. DR PDB; 8F1W; X-ray; 3.20 A; A/B/C/D=695-1022. DR PDB; 8F1X; X-ray; 2.30 A; A=695-1022. DR PDB; 8F1Y; X-ray; 2.75 A; A=695-1022. DR PDB; 8F1Z; X-ray; 2.40 A; A=695-1022. DR PDB; 8FV3; X-ray; 2.10 A; A/B/C/D=695-1022. DR PDB; 8FV4; X-ray; 2.20 A; A/B/C/D=695-1022. DR PDB; 8G63; X-ray; 2.50 A; A=696-1022. DR PDB; 8GB4; X-ray; 2.59 A; A/B/C/D=695-1022. DR PDB; 8GK5; X-ray; 2.30 A; A/B/C/D=695-1022. DR PDB; 8H7X; X-ray; 3.40 A; A/B=696-1022. DR PDB; 8HGO; EM; 3.31 A; A=1-683. DR PDB; 8HGP; EM; 4.53 A; A=1-683. DR PDB; 8HGS; EM; 3.81 A; A/B=1-683. DR PDB; 8HV1; X-ray; 2.40 A; A=695-1022. DR PDB; 8HV2; X-ray; 2.80 A; A=694-1022. DR PDB; 8HV3; X-ray; 2.40 A; A=695-1022. DR PDB; 8HV4; X-ray; 2.20 A; A=695-1022. DR PDB; 8HV5; X-ray; 2.20 A; A=695-1022. DR PDB; 8HV6; X-ray; 2.20 A; A=695-1022. DR PDB; 8HV7; X-ray; 2.69 A; A=695-1022. DR PDB; 8HV8; X-ray; 2.40 A; A=695-1022. DR PDB; 8HV9; X-ray; 2.50 A; A=695-1022. DR PDB; 8HVA; X-ray; 2.77 A; A=695-1022. DR PDB; 8HY7; X-ray; 2.91 A; A=695-1022. DR PDB; 8KFQ; X-ray; 3.22 A; A=697-1018. DR PDB; 8PNZ; X-ray; 2.51 A; A=695-1022. DR PDB; 8PO0; X-ray; 2.52 A; A=695-1022. DR PDB; 8PO1; X-ray; 2.11 A; A=695-1022. DR PDB; 8PO2; X-ray; 2.28 A; A/B/D=695-1022. DR PDB; 8PO3; X-ray; 2.13 A; A=695-1022. DR PDB; 8PO4; X-ray; 1.62 A; A/B=695-1022. DR PDB; 8S1M; X-ray; 2.05 A; A=1076-1099. DR PDB; 8SC7; X-ray; 1.98 A; A=696-1022. DR PDB; 8TJL; X-ray; 2.70 A; A=695-1022. DR PDB; 8TO3; X-ray; 2.49 A; A/B/C/D=695-1022. DR PDB; 8TO4; X-ray; 2.99 A; A/B/C/D=695-1022. DR PDB; 8UKV; X-ray; 2.94 A; A/B=298-642. DR PDB; 8UKW; X-ray; 2.39 A; A/B=298-642. DR PDB; 8UKX; X-ray; 3.30 A; A=298-642. DR PDB; 8WD4; X-ray; 2.55 A; A=696-1022. DR PDB; 9BY4; X-ray; 2.31 A; A=696-1022. DR PDB; 9BY6; X-ray; 2.55 A; A=696-1022. DR PDB; 9D3V; X-ray; 2.32 A; A=696-1022. DR PDB; 9D3W; X-ray; 2.53 A; A=696-1022. DR PDB; 9DF2; X-ray; 2.50 A; A=696-1022. DR PDB; 9DF3; X-ray; 1.68 A; A=696-1022. DR PDB; 9DF4; X-ray; 1.78 A; A=696-1022. DR PDB; 9EWS; X-ray; 2.44 A; A=695-1022. DR PDB; 9EWT; X-ray; 3.02 A; A/B=695-1022. DR PDB; 9FQP; X-ray; 2.50 A; A=695-1022. DR PDB; 9FQS; X-ray; 1.78 A; A=695-1022. DR PDB; 9FRD; X-ray; 2.06 A; A=696-1022. DR PDB; 9GC4; X-ray; 2.42 A; A/B/D=695-1022. DR PDB; 9GC5; X-ray; 1.91 A; A/B=695-1022. DR PDB; 9GC6; X-ray; 1.90 A; A/B=695-1022. DR PDB; 9GDV; X-ray; 2.22 A; A/B=695-1022. DR PDB; 9GI9; X-ray; 3.12 A; A=696-1022. DR PDB; 9GL7; X-ray; 1.88 A; A=695-1022. DR PDB; 9GL8; X-ray; 1.63 A; A=695-1022. DR PDB; 9GL9; X-ray; 2.15 A; A=696-1022. DR PDB; 9H46; X-ray; 3.16 A; A=696-1022. DR PDB; 9HBO; X-ray; 2.45 A; A/B=695-1022. DR PDB; 9IP7; EM; 3.21 A; A=25-645. DR PDB; 9IP8; EM; 3.91 A; A=25-645. DR PDB; 9IP9; EM; 3.64 A; A=25-645. DR PDB; 9IPA; EM; 3.85 A; A=25-645. DR PDB; 9IPB; EM; 2.93 A; A=25-645. DR PDB; 9IPC; EM; 3.40 A; A=25-645. DR PDB; 9IPD; EM; 3.29 A; A=25-645. DR PDB; 9IPE; EM; 3.31 A; A=25-645. DR PDBsum; 1IVO; -. DR PDBsum; 1M14; -. DR PDBsum; 1M17; -. DR PDBsum; 1MOX; -. DR PDBsum; 1NQL; -. DR PDBsum; 1XKK; -. DR PDBsum; 1YY9; -. DR PDBsum; 1Z9I; -. DR PDBsum; 2EB2; -. DR PDBsum; 2EB3; -. DR PDBsum; 2GS2; -. DR PDBsum; 2GS6; -. DR PDBsum; 2GS7; -. DR PDBsum; 2ITN; -. DR PDBsum; 2ITO; -. DR PDBsum; 2ITP; -. DR PDBsum; 2ITQ; -. DR PDBsum; 2ITT; -. DR PDBsum; 2ITU; -. DR PDBsum; 2ITV; -. DR PDBsum; 2ITW; -. DR PDBsum; 2ITX; -. DR PDBsum; 2ITY; -. DR PDBsum; 2ITZ; -. DR PDBsum; 2J5E; -. DR PDBsum; 2J5F; -. DR PDBsum; 2J6M; -. DR PDBsum; 2JIT; -. DR PDBsum; 2JIU; -. DR PDBsum; 2JIV; -. DR PDBsum; 2KS1; -. DR PDBsum; 2M0B; -. DR PDBsum; 2M20; -. DR PDBsum; 2N5S; -. DR PDBsum; 2RF9; -. DR PDBsum; 2RFD; -. DR PDBsum; 2RFE; -. DR PDBsum; 2RGP; -. DR PDBsum; 3B2U; -. DR PDBsum; 3B2V; -. DR PDBsum; 3BEL; -. DR PDBsum; 3BUO; -. DR PDBsum; 3C09; -. DR PDBsum; 3G5V; -. DR PDBsum; 3G5Y; -. DR PDBsum; 3GOP; -. DR PDBsum; 3GT8; -. DR PDBsum; 3IKA; -. DR PDBsum; 3LZB; -. DR PDBsum; 3NJP; -. DR PDBsum; 3OB2; -. DR PDBsum; 3OP0; -. DR PDBsum; 3P0Y; -. DR PDBsum; 3PFV; -. DR PDBsum; 3POZ; -. DR PDBsum; 3QWQ; -. DR PDBsum; 3UG1; -. DR PDBsum; 3UG2; -. DR PDBsum; 3VJN; -. DR PDBsum; 3VJO; -. DR PDBsum; 3VRP; -. DR PDBsum; 3VRR; -. DR PDBsum; 3W2O; -. DR PDBsum; 3W2P; -. DR PDBsum; 3W2Q; -. DR PDBsum; 3W2R; -. DR PDBsum; 3W2S; -. DR PDBsum; 3W32; -. DR PDBsum; 3W33; -. DR PDBsum; 4G5J; -. DR PDBsum; 4G5P; -. DR PDBsum; 4HJO; -. DR PDBsum; 4I1Z; -. DR PDBsum; 4I20; -. DR PDBsum; 4I21; -. DR PDBsum; 4I22; -. DR PDBsum; 4I23; -. DR PDBsum; 4I24; -. DR PDBsum; 4JQ7; -. DR PDBsum; 4JQ8; -. DR PDBsum; 4JR3; -. DR PDBsum; 4JRV; -. DR PDBsum; 4KRL; -. DR PDBsum; 4KRM; -. DR PDBsum; 4KRO; -. DR PDBsum; 4KRP; -. DR PDBsum; 4LI5; -. DR PDBsum; 4LL0; -. DR PDBsum; 4LQM; -. DR PDBsum; 4LRM; -. DR PDBsum; 4R3P; -. DR PDBsum; 4R3R; -. DR PDBsum; 4R5S; -. DR PDBsum; 4RIW; -. DR PDBsum; 4RIX; -. DR PDBsum; 4RIY; -. DR PDBsum; 4RJ4; -. DR PDBsum; 4RJ5; -. DR PDBsum; 4RJ6; -. DR PDBsum; 4RJ7; -. DR PDBsum; 4RJ8; -. DR PDBsum; 4TKS; -. DR PDBsum; 4UIP; -. DR PDBsum; 4UV7; -. DR PDBsum; 4WD5; -. DR PDBsum; 4WKQ; -. DR PDBsum; 4WRG; -. DR PDBsum; 4ZAU; -. DR PDBsum; 4ZJV; -. DR PDBsum; 4ZSE; -. DR PDBsum; 5C8K; -. DR PDBsum; 5C8M; -. DR PDBsum; 5C8N; -. DR PDBsum; 5CAL; -. DR PDBsum; 5CAN; -. DR PDBsum; 5CAO; -. DR PDBsum; 5CAP; -. DR PDBsum; 5CAQ; -. DR PDBsum; 5CAS; -. DR PDBsum; 5CAU; -. DR PDBsum; 5CAV; -. DR PDBsum; 5CNN; -. DR PDBsum; 5CNO; -. DR PDBsum; 5CZH; -. DR PDBsum; 5CZI; -. DR PDBsum; 5D41; -. DR PDBsum; 5EDP; -. DR PDBsum; 5EDQ; -. DR PDBsum; 5EDR; -. DR PDBsum; 5EM5; -. DR PDBsum; 5EM6; -. DR PDBsum; 5EM7; -. DR PDBsum; 5EM8; -. DR PDBsum; 5FED; -. DR PDBsum; 5FEE; -. DR PDBsum; 5FEQ; -. DR PDBsum; 5GMP; -. DR PDBsum; 5GNK; -. DR PDBsum; 5GTY; -. DR PDBsum; 5GTZ; -. DR PDBsum; 5HCX; -. DR PDBsum; 5HCY; -. DR PDBsum; 5HCZ; -. DR PDBsum; 5HG5; -. DR PDBsum; 5HG7; -. DR PDBsum; 5HG8; -. DR PDBsum; 5HG9; -. DR PDBsum; 5HIB; -. DR PDBsum; 5HIC; -. DR PDBsum; 5J9Y; -. DR PDBsum; 5J9Z; -. DR PDBsum; 5JEB; -. DR PDBsum; 5LV6; -. DR PDBsum; 5SX4; -. DR PDBsum; 5SX5; -. DR PDBsum; 5U8L; -. DR PDBsum; 5UG8; -. DR PDBsum; 5UG9; -. DR PDBsum; 5UGA; -. DR PDBsum; 5UGB; -. DR PDBsum; 5UGC; -. DR PDBsum; 5UWD; -. DR PDBsum; 5WB7; -. DR PDBsum; 5WB8; -. DR PDBsum; 5X26; -. DR PDBsum; 5X27; -. DR PDBsum; 5X28; -. DR PDBsum; 5X2A; -. DR PDBsum; 5X2C; -. DR PDBsum; 5X2F; -. DR PDBsum; 5X2K; -. DR PDBsum; 5XDK; -. DR PDBsum; 5XDL; -. DR PDBsum; 5XGM; -. DR PDBsum; 5XGN; -. DR PDBsum; 5XWD; -. DR PDBsum; 5Y25; -. DR PDBsum; 5Y9T; -. DR PDBsum; 5YU9; -. DR PDBsum; 5ZTO; -. DR PDBsum; 5ZWJ; -. DR PDBsum; 6ARU; -. DR PDBsum; 6B3S; -. DR PDBsum; 6D8E; -. DR PDBsum; 6DUK; -. DR PDBsum; 6JRJ; -. DR PDBsum; 6JRK; -. DR PDBsum; 6JRX; -. DR PDBsum; 6JWL; -. DR PDBsum; 6JX0; -. DR PDBsum; 6JX4; -. DR PDBsum; 6JXT; -. DR PDBsum; 6JZ0; -. DR PDBsum; 6LUB; -. DR PDBsum; 6LUD; -. DR PDBsum; 6P1D; -. DR PDBsum; 6P1L; -. DR PDBsum; 6P8Q; -. DR PDBsum; 6S89; -. DR PDBsum; 6S8A; -. DR PDBsum; 6S9B; -. DR PDBsum; 6S9C; -. DR PDBsum; 6S9D; -. DR PDBsum; 6TFU; -. DR PDBsum; 6TFV; -. DR PDBsum; 6TFW; -. DR PDBsum; 6TFY; -. DR PDBsum; 6TFZ; -. DR PDBsum; 6TG0; -. DR PDBsum; 6TG1; -. DR PDBsum; 6V5N; -. DR PDBsum; 6V5P; -. DR PDBsum; 6V66; -. DR PDBsum; 6V6K; -. DR PDBsum; 6V6O; -. DR PDBsum; 6VH4; -. DR PDBsum; 6VHN; -. DR PDBsum; 6VHP; -. DR PDBsum; 6WA2; -. DR PDBsum; 6WAK; -. DR PDBsum; 6WXN; -. DR PDBsum; 6XL4; -. DR PDBsum; 6Z4B; -. DR PDBsum; 6Z4D; -. DR PDBsum; 7A2A; -. DR PDBsum; 7A6I; -. DR PDBsum; 7A6J; -. DR PDBsum; 7A6K; -. DR PDBsum; 7AEI; -. DR PDBsum; 7AEM; -. DR PDBsum; 7B85; -. DR PDBsum; 7ER2; -. DR PDBsum; 7JXI; -. DR PDBsum; 7JXK; -. DR PDBsum; 7JXL; -. DR PDBsum; 7JXM; -. DR PDBsum; 7JXP; -. DR PDBsum; 7JXQ; -. DR PDBsum; 7JXW; -. DR PDBsum; 7K1H; -. DR PDBsum; 7K1I; -. DR PDBsum; 7KXZ; -. DR PDBsum; 7KY0; -. DR PDBsum; 7LEN; -. DR PDBsum; 7LFR; -. DR PDBsum; 7LFS; -. DR PDBsum; 7LG8; -. DR PDBsum; 7LGS; -. DR PDBsum; 7LTX; -. DR PDBsum; 7OM4; -. DR PDBsum; 7OXB; -. DR PDBsum; 7SI1; -. DR PDBsum; 7SYD; -. DR PDBsum; 7SYE; -. DR PDBsum; 7SZ0; -. DR PDBsum; 7SZ1; -. DR PDBsum; 7SZ5; -. DR PDBsum; 7SZ7; -. DR PDBsum; 7T4I; -. DR PDBsum; 7T4J; -. DR PDBsum; 7TVD; -. DR PDBsum; 7U98; -. DR PDBsum; 7U99; -. DR PDBsum; 7U9A; -. DR PDBsum; 7UKV; -. DR PDBsum; 7UKW; -. DR PDBsum; 7VRA; -. DR PDBsum; 7VRE; -. DR PDBsum; 7ZYM; -. DR PDBsum; 7ZYN; -. DR PDBsum; 7ZYP; -. DR PDBsum; 7ZYQ; -. DR PDBsum; 8A27; -. DR PDBsum; 8A2A; -. DR PDBsum; 8A2B; -. DR PDBsum; 8A2D; -. DR PDBsum; 8D73; -. DR PDBsum; 8D76; -. DR PDBsum; 8DSW; -. DR PDBsum; 8EME; -. DR PDBsum; 8F1H; -. DR PDBsum; 8F1W; -. DR PDBsum; 8F1X; -. DR PDBsum; 8F1Y; -. DR PDBsum; 8F1Z; -. DR PDBsum; 8FV3; -. DR PDBsum; 8FV4; -. DR PDBsum; 8G63; -. DR PDBsum; 8GB4; -. DR PDBsum; 8GK5; -. DR PDBsum; 8H7X; -. DR PDBsum; 8HGO; -. DR PDBsum; 8HGP; -. DR PDBsum; 8HGS; -. DR PDBsum; 8HV1; -. DR PDBsum; 8HV2; -. DR PDBsum; 8HV3; -. DR PDBsum; 8HV4; -. DR PDBsum; 8HV5; -. DR PDBsum; 8HV6; -. DR PDBsum; 8HV7; -. DR PDBsum; 8HV8; -. DR PDBsum; 8HV9; -. DR PDBsum; 8HVA; -. DR PDBsum; 8HY7; -. DR PDBsum; 8KFQ; -. DR PDBsum; 8PNZ; -. DR PDBsum; 8PO0; -. DR PDBsum; 8PO1; -. DR PDBsum; 8PO2; -. DR PDBsum; 8PO3; -. DR PDBsum; 8PO4; -. DR PDBsum; 8S1M; -. DR PDBsum; 8SC7; -. DR PDBsum; 8TJL; -. DR PDBsum; 8TO3; -. DR PDBsum; 8TO4; -. DR PDBsum; 8UKV; -. DR PDBsum; 8UKW; -. DR PDBsum; 8UKX; -. DR PDBsum; 8WD4; -. DR PDBsum; 9BY4; -. DR PDBsum; 9BY6; -. DR PDBsum; 9D3V; -. DR PDBsum; 9D3W; -. DR PDBsum; 9DF2; -. DR PDBsum; 9DF3; -. DR PDBsum; 9DF4; -. DR PDBsum; 9EWS; -. DR PDBsum; 9EWT; -. DR PDBsum; 9FQP; -. DR PDBsum; 9FQS; -. DR PDBsum; 9FRD; -. DR PDBsum; 9GC4; -. DR PDBsum; 9GC5; -. DR PDBsum; 9GC6; -. DR PDBsum; 9GDV; -. DR PDBsum; 9GI9; -. DR PDBsum; 9GL7; -. DR PDBsum; 9GL8; -. DR PDBsum; 9GL9; -. DR PDBsum; 9H46; -. DR PDBsum; 9HBO; -. DR PDBsum; 9IP7; -. DR PDBsum; 9IP8; -. DR PDBsum; 9IP9; -. DR PDBsum; 9IPA; -. DR PDBsum; 9IPB; -. DR PDBsum; 9IPC; -. DR PDBsum; 9IPD; -. DR PDBsum; 9IPE; -. DR AlphaFoldDB; P00533; -. DR BMRB; P00533; -. DR EMDB; EMD-25522; -. DR EMDB; EMD-25523; -. DR EMDB; EMD-25558; -. DR EMDB; EMD-25559; -. DR EMDB; EMD-25561; -. DR EMDB; EMD-25563; -. DR EMDB; EMD-34744; -. DR EMDB; EMD-34745; -. DR EMDB; EMD-34746; -. DR EMDB; EMD-60764; -. DR EMDB; EMD-60765; -. DR EMDB; EMD-60766; -. DR EMDB; EMD-60767; -. DR EMDB; EMD-60768; -. DR EMDB; EMD-60769; -. DR EMDB; EMD-60770; -. DR EMDB; EMD-60771; -. DR SMR; P00533; -. DR BioGRID; 108276; 3218. DR CORUM; P00533; -. DR DIP; DIP-405N; -. DR ELM; P00533; -. DR FunCoup; P00533; 3104. DR IntAct; P00533; 1179. DR MINT; P00533; -. DR STRING; 9606.ENSP00000275493; -. DR BindingDB; P00533; -. DR ChEMBL; CHEMBL203; -. DR DrugBank; DB15327; Abivertinib. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB18840; Allitinib. DR DrugBank; DB16640; Almonertinib. DR DrugBank; DB03496; Alvocidib. DR DrugBank; DB16695; Amivantamab. DR DrugBank; DB06021; AV-412. DR DrugBank; DB12318; BMS-599626. DR DrugBank; DB11665; BMS-690514. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB00002; Cetuximab. DR DrugBank; DB12174; CUDC-101. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB11731; Depatuxizumab mafodotin. DR DrugBank; DB00530; Erlotinib. DR DrugBank; DB12966; Falnidamol. DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00317; Gefitinib. DR DrugBank; DB11737; Icotinib. DR DrugBank; DB04988; IGN311. DR DrugBank; DB01259; Lapatinib. DR DrugBank; DB16768; Lavendustin A. DR DrugBank; DB16216; Lazertinib. DR DrugBank; DB00281; Lidocaine. DR DrugBank; DB05101; Matuzumab. DR DrugBank; DB06110; MDX-214. DR DrugBank; DB04862; Merimepodib. DR DrugBank; DB16390; Mobocertinib. DR DrugBank; DB12682; Mubritinib. DR DrugBank; DB08462; N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE. DR DrugBank; DB12036; Naquotinib. DR DrugBank; DB16250; Nazartinib. DR DrugBank; DB09559; Necitumumab. DR DrugBank; DB11828; Neratinib. DR DrugBank; DB00727; Nitroglycerin. DR DrugBank; DB13164; Olmutinib. DR DrugBank; DB09330; Osimertinib. DR DrugBank; DB01269; Panitumumab. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB07662; PD-168393. DR DrugBank; DB05524; Pelitinib. DR DrugBank; DB12114; Poziotinib. DR DrugBank; DB08052; PP-121. DR DrugBank; DB14993; Pyrotinib. DR DrugBank; DB05374; Rindopepimut. DR DrugBank; DB11907; Rociletinib. DR DrugBank; DB07602; S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB14944; Tarloxotinib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB05944; Varlitinib. DR DrugBank; DB04879; Vatalanib. DR DrugBank; DB12202; Zalutumumab. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P00533; -. DR GuidetoPHARMACOLOGY; 1797; -. DR MoonDB; P00533; Predicted. DR TCDB; 8.A.23.1.46; the basigin (basigin) family. DR GlyConnect; 137; 81 N-Linked glycans (10 sites). DR GlyCosmos; P00533; 17 sites, 102 glycans. DR GlyGen; P00533; 27 sites, 148 N-linked glycans (18 sites), 1 O-linked glycan (7 sites). DR iPTMnet; P00533; -. DR MetOSite; P00533; -. DR PhosphoSitePlus; P00533; -. DR SwissPalm; P00533; -. DR BioMuta; EGFR; -. DR DMDM; 2811086; -. DR CPTAC; CPTAC-1043; -. DR CPTAC; CPTAC-1560; -. DR CPTAC; CPTAC-1781; -. DR CPTAC; CPTAC-3043; -. DR CPTAC; CPTAC-3044; -. DR CPTAC; CPTAC-5784; -. DR CPTAC; CPTAC-5785; -. DR CPTAC; CPTAC-5830; -. DR CPTAC; CPTAC-5831; -. DR CPTAC; CPTAC-5832; -. DR CPTAC; CPTAC-5833; -. DR CPTAC; CPTAC-5834; -. DR CPTAC; CPTAC-5835; -. DR CPTAC; CPTAC-802; -. DR CPTAC; non-CPTAC-5380; -. DR CPTAC; non-CPTAC-5381; -. DR CPTAC; non-CPTAC-5382; -. DR CPTAC; non-CPTAC-5545; -. DR CPTAC; non-CPTAC-5546; -. DR CPTAC; non-CPTAC-5735; -. DR CPTAC; non-CPTAC-5736; -. DR CPTAC; non-CPTAC-5737; -. DR CPTAC; non-CPTAC-5738; -. DR jPOST; P00533; -. DR MassIVE; P00533; -. DR PaxDb; 9606-ENSP00000275493; -. DR PeptideAtlas; P00533; -. DR ProteomicsDB; 51261; -. [P00533-1] DR ProteomicsDB; 51262; -. [P00533-2] DR ProteomicsDB; 51263; -. [P00533-3] DR ProteomicsDB; 51264; -. [P00533-4] DR ABCD; P00533; 128 sequenced antibodies. DR Antibodypedia; 718; 10780 antibodies from 66 providers. DR CPTC; P00533; 13 antibodies. DR DNASU; 1956; -. DR Ensembl; ENST00000275493.7; ENSP00000275493.2; ENSG00000146648.22. [P00533-1] DR Ensembl; ENST00000342916.7; ENSP00000342376.3; ENSG00000146648.22. [P00533-4] DR Ensembl; ENST00000344576.7; ENSP00000345973.2; ENSG00000146648.22. [P00533-3] DR Ensembl; ENST00000420316.6; ENSP00000413843.2; ENSG00000146648.22. [P00533-2] DR GeneID; 1956; -. DR KEGG; hsa:1956; -. DR MANE-Select; ENST00000275493.7; ENSP00000275493.2; NM_005228.5; NP_005219.2. DR UCSC; uc003tqh.4; human. [P00533-1] DR AGR; HGNC:3236; -. DR CIViC; 1956; 4 clinical assertions and 612 evidence items across 318 molecular profiles. DR ClinPGx; PA7360; -. DR CTD; 1956; -. DR DisGeNET; 1956; -. DR GeneCards; EGFR; -. DR HGNC; HGNC:3236; EGFR. DR HPA; ENSG00000146648; Tissue enhanced (placenta). DR MalaCards; EGFR; -. DR MIM; 131550; gene. DR MIM; 211980; phenotype. DR MIM; 616069; phenotype. DR OpenTargets; ENSG00000146648; -. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 294023; Neonatal inflammatory skin and bowel disease. DR VEuPathDB; HostDB:ENSG00000146648; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000155450; -. DR HOGENOM; CLU_003384_0_2_1; -. DR InParanoid; P00533; -. DR OMA; GYYYEWV; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; P00533; 11 GO annotations based on evolutionary models. DR PhylomeDB; P00533; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P00533; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1236394; Signaling by ERBB4. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-177929; Signaling by EGFR. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180292; GAB1 signalosome. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-182971; EGFR downregulation. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-212718; EGFR interacts with phospholipase C-gamma. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-445144; Signal transduction by L1. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5638303; Inhibition of Signaling by Overexpressed EGFR. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis. DR Reactome; R-HSA-8856828; Clathrin-mediated endocytosis. DR Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9013507; NOTCH3 Activation and Transmission of Signal to the Nucleus. DR Reactome; R-HSA-9609690; HCMV Early Events. DR Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9820960; Respiratory syncytial virus (RSV) attachment and entry. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR SignaLink; P00533; -. DR SIGNOR; P00533; -. DR Agora; ENSG00000146648; -. DR BioGRID-ORCS; 1956; 155 hits in 1222 CRISPR screens. DR ChiTaRS; EGFR; human. DR EvolutionaryTrace; P00533; -. DR GeneWiki; Epidermal_growth_factor_receptor; -. DR GenomeRNAi; 1956; -. DR Pharos; P00533; Tclin. DR PRO; PR:P00533; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P00533; protein. DR Bgee; ENSG00000146648; Expressed in nipple and 206 other cell types or tissues. DR ExpressionAtlas; P00533; baseline and differential. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; NAS:UniProtKB. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0097708; C:intracellular vesicle; IDA:ARUK-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0097489; C:multivesicular body, internal vesicle lumen; IDA:UniProtKB. DR GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IMP:ARUK-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0032587; C:ruffle membrane; IDA:ARUK-UCL. DR GO; GO:0070435; C:Shc-EGFR complex; ISS:BHF-UCL. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0051015; F:actin filament binding; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0051117; F:ATPase binding; ISS:ARUK-UCL. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003690; F:double-stranded DNA binding; NAS:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0048408; F:epidermal growth factor binding; IBA:GO_Central. DR GO; GO:0005006; F:epidermal growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0019900; F:kinase binding; IPI:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; NAS:UniProtKB. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:MGI. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:MGI. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI. DR GO; GO:0098609; P:cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; ISS:UniProtKB. DR GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:UniProtKB. DR GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl. DR GO; GO:0048546; P:digestive tract morphogenesis; IEA:Ensembl. DR GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0038134; P:ERBB2-EGFR signaling pathway; IDA:MGI. DR GO; GO:0061029; P:eyelid development in camera-type eye; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0001942; P:hair follicle development; IEA:Ensembl. DR GO; GO:0007611; P:learning or memory; ISS:UniProtKB. DR GO; GO:0060571; P:morphogenesis of an epithelial fold; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:1905208; P:negative regulation of cardiocyte differentiation; IMP:BHF-UCL. DR GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0001503; P:ossification; NAS:UniProtKB. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:BHF-UCL. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:MGI. DR GO; GO:0045739; P:positive regulation of DNA repair; IDA:UniProtKB. DR GO; GO:0045740; P:positive regulation of DNA replication; IDA:UniProtKB. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:ARUK-UCL. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:BHF-UCL. DR GO; GO:0042327; P:positive regulation of phosphorylation; IDA:UniProtKB. DR GO; GO:0090037; P:positive regulation of protein kinase C signaling; IDA:ParkinsonsUK-UCL. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:ParkinsonsUK-UCL. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0051205; P:protein insertion into membrane; TAS:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl. DR GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IMP:UniProtKB. DR GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL. DR GO; GO:0007435; P:salivary gland morphogenesis; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0070086; P:ubiquitin-dependent endocytosis; IEA:Ensembl. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0042908; P:xenobiotic transport; IEA:Ensembl. DR CDD; cd00064; FU; 3. DR CDD; cd05108; PTKc_EGFR; 1. DR CDD; cd12093; TM_ErbB1; 1. DR DisProt; DP00309; -. DR FunFam; 1.10.510.10:FF:000027; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000008; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000044; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000005; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000006; Receptor protein-tyrosine kinase; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 1.20.5.420; Immunoglobulin FC, subunit C; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00262; -. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF91; EPIDERMAL GROWTH FACTOR RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Developmental protein; Direct protein sequencing; Disease variant; KW Disulfide bond; Endoplasmic reticulum; Endosome; Glycoprotein; KW Golgi apparatus; Host cell receptor for virus entry; KW Host-virus interaction; Hydroxylation; Isopeptide bond; Kinase; KW Lipoprotein; Membrane; Methylation; Nucleotide-binding; Nucleus; Palmitate; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Secreted; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..24 FT /evidence="ECO:0000269|PubMed:15340161, FT ECO:0000269|PubMed:6328312, ECO:0000269|Ref.16" FT CHAIN 25..1210 FT /note="Epidermal growth factor receptor" FT /id="PRO_0000016665" FT TOPO_DOM 25..645 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 646..668 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 669..1210 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 75..300 FT /note="Approximate" FT REPEAT 390..600 FT /note="Approximate" FT DOMAIN 712..979 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 688..704 FT /note="Important for dimerization, phosphorylation and FT activation" FT REGION 1097..1137 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1104..1115 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1128..1137 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 837 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 718..726 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:3GT8, FT ECO:0007744|PDB:4ZSE, ECO:0007744|PDB:5CNN, FT ECO:0007744|PDB:5CNO, ECO:0007744|PDB:5D41" FT BINDING 745 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:17349580, FT ECO:0000269|PubMed:19563760, ECO:0007744|PDB:2EB3, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:2ITN, FT ECO:0007744|PDB:3GT8, ECO:0007744|PDB:3VJN, FT ECO:0007744|PDB:3VJO, ECO:0007744|PDB:4RIW, FT ECO:0007744|PDB:4RIY, ECO:0007744|PDB:4ZSE, FT ECO:0007744|PDB:5CNN, ECO:0007744|PDB:5CNO, FT ECO:0007744|PDB:5D41" FT BINDING 790..791 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:17349580, FT ECO:0000269|PubMed:19563760, ECO:0007744|PDB:2EB3, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:2ITN, FT ECO:0007744|PDB:2ITV, ECO:0007744|PDB:2ITX, FT ECO:0007744|PDB:3GT8, ECO:0007744|PDB:3VJN, FT ECO:0007744|PDB:3VJO, ECO:0007744|PDB:4RIW, FT ECO:0007744|PDB:4RIX, ECO:0007744|PDB:4RIY, FT ECO:0007744|PDB:4ZSE, ECO:0007744|PDB:5CNN, FT ECO:0007744|PDB:5CNO, ECO:0007744|PDB:5D41" FT BINDING 855 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:17349580, FT ECO:0000269|PubMed:19563760, ECO:0007744|PDB:2EB3, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:2ITN, FT ECO:0007744|PDB:2ITV, ECO:0007744|PDB:2ITX, FT ECO:0007744|PDB:3GT8, ECO:0007744|PDB:3VJN, FT ECO:0007744|PDB:4RIW, ECO:0007744|PDB:4RIX, FT ECO:0007744|PDB:4RIY, ECO:0007744|PDB:4ZSE, FT ECO:0007744|PDB:5CNN, ECO:0007744|PDB:5CNO, FT ECO:0007744|PDB:5D41" FT SITE 1016 FT /note="Important for interaction with PIK3C2B" FT MOD_RES 229 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21487020" FT MOD_RES 678 FT /note="Phosphothreonine; by PKC and PKD/PRKD1" FT /evidence="ECO:0000269|PubMed:10523301" FT MOD_RES 693 FT /note="Phosphothreonine; by PKD/PRKD1" FT /evidence="ECO:0000269|PubMed:10523301, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:3138233, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 695 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:3138233, FT ECO:0007744|PubMed:18691976" FT MOD_RES 745 FT /note="N6-(2-hydroxyisobutyryl)lysine" FT /evidence="ECO:0000269|PubMed:29192674" FT MOD_RES 869 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23774213" FT MOD_RES 991 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16083266, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:24275569" FT MOD_RES 995 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 998 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0007744|PubMed:18669648" FT MOD_RES 1016 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0000269|PubMed:23774213" FT MOD_RES 1026 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16083266, FT ECO:0007744|PubMed:24275569" FT MOD_RES 1039 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1041 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1042 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1064 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1069 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23774213, FT ECO:0000305|PubMed:22888118" FT MOD_RES 1070 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:3138233" FT MOD_RES 1071 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:3138233" FT MOD_RES 1081 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 1092 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12873986, FT ECO:0000269|PubMed:23774213, ECO:0000269|PubMed:27153536" FT MOD_RES 1110 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12873986, FT ECO:0000269|PubMed:2543678" FT MOD_RES 1166 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:24275569" FT MOD_RES 1172 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:26918609, FT ECO:0000269|PubMed:27153536, ECO:0007744|PubMed:17081983" FT MOD_RES 1197 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:23774213, FT ECO:0000269|PubMed:27153536, ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231" FT MOD_RES 1199 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000269|PubMed:21258366" FT LIPID 1049 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:27153536" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:27153536" FT CARBOHYD 56 FT /note="N-linked (GlcNAc...) (complex) asparagine; atypical; FT partial" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1MOX, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ" FT /id="CAR_000227" FT CARBOHYD 73 FT /note="N-linked (GlcNAc...) asparagine; atypical" FT /evidence="ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:3NJP" FT CARBOHYD 128 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:8962717" FT CARBOHYD 175 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:8962717, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:3NJP" FT CARBOHYD 196 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:3NJP" FT CARBOHYD 352 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19159218, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1MOX, ECO:0007744|PDB:1NQL, FT ECO:0007744|PDB:1YY9, ECO:0007744|PDB:3B2U, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7" FT CARBOHYD 361 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UV7" FT CARBOHYD 413 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19159218, FT ECO:0000269|PubMed:8962717, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP" FT CARBOHYD 444 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:20837704, FT ECO:0000269|PubMed:8962717, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3P0Y, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7" FT CARBOHYD 528 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:25922362, FT ECO:0000269|PubMed:8962717, ECO:0007744|PDB:1NQL, FT ECO:0007744|PDB:1YY9, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7" FT CARBOHYD 568 FT /note="N-linked (GlcNAc...) asparagine; partial" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19159218, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9" FT CARBOHYD 603 FT /note="N-linked (GlcNAc...) asparagine; partial" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0007744|PDB:1NQL, FT ECO:0007744|PDB:1YY9" FT CARBOHYD 623 FT /note="N-linked (GlcNAc...) (high mannose) asparagine" FT /evidence="ECO:0000305|PubMed:12731890" FT DISULFID 31..58 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 157..187 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 190..199 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 194..207 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 215..223 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 219..231 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 232..240 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 236..248 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 251..260 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 264..291 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 295..307 FT /evidence="ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 311..326 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3G5V, FT ECO:0007744|PDB:3G5Y, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 329..333 FT /evidence="ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 337..362 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3C09, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5SX4, ECO:0007744|PDB:5SX5, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD, ECO:0007744|PDB:6B3S" FT DISULFID 470..499 FT /evidence="ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3C09, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5SX4, ECO:0007744|PDB:5SX5, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD, ECO:0007744|PDB:6B3S" FT DISULFID 506..515 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3P0Y, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5SX4, FT ECO:0007744|PDB:5SX5, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD, FT ECO:0007744|PDB:6B3S" FT DISULFID 510..523 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3C09, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5SX4, ECO:0007744|PDB:5SX5, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD, ECO:0007744|PDB:6B3S" FT DISULFID 526..535 FT /evidence="ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:15837620, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 539..555 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 558..571 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 562..579 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 582..591 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5XWD" FT DISULFID 595..617 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 620..628 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 624..636 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT CROSSLNK 716 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 737 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 754 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 757 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:33996800" FT CROSSLNK 867 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 929 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144" FT CROSSLNK 960 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:33996800" FT CROSSLNK 970 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144" FT VAR_SEQ 404..405 FT /note="FL -> LS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7654368, FT ECO:0000303|PubMed:8918811, ECO:0000303|PubMed:9103388, FT ECO:0000303|Ref.6" FT /id="VSP_002887" FT VAR_SEQ 406..1210 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7654368, FT ECO:0000303|PubMed:8918811, ECO:0000303|PubMed:9103388, FT ECO:0000303|Ref.6" FT /id="VSP_002888" FT VAR_SEQ 628..705 FT /note="CTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTL FT RRLLQERELVEPLTPSGEAPNQALLR -> PGNESLKAMLFCLFKLSSCNQSNDGSVSH FT QSGSPAAQESCLGWIPSLLPSEFQLGWGGCSHLHAWPSASVIITASSCH (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002889" FT VAR_SEQ 628 FT /note="C -> S (in isoform 4)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002891" FT VAR_SEQ 629..1210 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002892" FT VAR_SEQ 706..1210 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002890" FT VARIANT 30..297 FT /note="Missing (variant EGFR vIII; found in a lung cancer FT sample; somatic mutation; induces lung cancer when FT exogenously expressed)" FT /evidence="ECO:0000269|PubMed:16672372" FT /id="VAR_066493" FT VARIANT 98 FT /note="R -> Q (in dbSNP:rs17289589)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019293" FT VARIANT 266 FT /note="P -> R (in dbSNP:rs17336639)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019294" FT VARIANT 428 FT /note="G -> D (in NNCIS; loss of function; the mutant does FT not localize to the cell membrane; has diffuse cytoplasmic FT localization; dbSNP:rs606231253)" FT /evidence="ECO:0000269|PubMed:24691054" FT /id="VAR_072435" FT VARIANT 521 FT /note="R -> K (in dbSNP:rs2227983)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.7" FT /id="VAR_019295" FT VARIANT 674 FT /note="V -> I (in dbSNP:rs17337079)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019296" FT VARIANT 709 FT /note="E -> A (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs397517085)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793" FT /id="VAR_026084" FT VARIANT 709 FT /note="E -> G (found in a lung cancer sample; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs397517085)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069498" FT VARIANT 709 FT /note="E -> K (found in a lung cancer sample; FT dbSNP:rs727504256)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026085" FT VARIANT 719 FT /note="G -> A (found in a lung cancer sample; FT dbSNP:rs121913428)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026086" FT VARIANT 719 FT /note="G -> C (found in a lung cancer sample; FT dbSNP:rs28929495)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16533793" FT /id="VAR_026087" FT VARIANT 719 FT /note="G -> D (found in a lung cancer sample; FT dbSNP:rs121913428)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026088" FT VARIANT 719 FT /note="G -> S (found in a lung cancer sample; somatic FT mutation; strongly increased kinase activity; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs28929495)" FT /evidence="ECO:0000269|PubMed:15118125, FT ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580" FT /id="VAR_019297" FT VARIANT 724 FT /note="G -> S (found in a lung cancer sample; FT dbSNP:rs1051753269)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026089" FT VARIANT 734 FT /note="E -> K (found in a lung cancer sample; FT dbSNP:rs121913420)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026090" FT VARIANT 746..752 FT /note="ELREATS -> D (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069499" FT VARIANT 746..751 FT /note="ELREAT -> A (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069500" FT VARIANT 746..750 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_026092" FT VARIANT 746 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026091" FT VARIANT 747..751 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069501" FT VARIANT 747..749 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026094" FT VARIANT 747 FT /note="L -> F (found in a lung cancer sample; FT dbSNP:rs2128954811)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026093" FT VARIANT 748 FT /note="R -> P (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026095" FT VARIANT 752..759 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026096" FT VARIANT 768 FT /note="S -> I (found in a lung cancer sample; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs121913465)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069502" FT VARIANT 769 FT /note="V -> M (found in a lung cancer sample; FT dbSNP:rs147149347)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069503" FT VARIANT 787 FT /note="Q -> R (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026097" FT VARIANT 790 FT /note="T -> M (found in a lung cancer sample; increased FT kinase activity; dbSNP:rs121434569)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:18227510" FT /id="VAR_026098" FT VARIANT 833 FT /note="L -> V (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs397517126)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793" FT /id="VAR_026099" FT VARIANT 834 FT /note="V -> L (found in a lung cancer sample; FT dbSNP:rs397517127)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026100" FT VARIANT 835 FT /note="H -> L (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs397517128)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069504" FT VARIANT 838 FT /note="L -> V (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs864621996)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069505" FT VARIANT 858 FT /note="L -> M (found in a lung cancer sample; FT dbSNP:rs121913443)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026101" FT VARIANT 858 FT /note="L -> R (found in a lung cancer sample; somatic FT mutation; constitutively activated enzyme with strongly FT increased kinase activity; more sensitive to gefitinib than FT wild-type; dbSNP:rs121434568)" FT /evidence="ECO:0000269|PubMed:15118125, FT ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580" FT /id="VAR_019298" FT VARIANT 861 FT /note="L -> Q (found in a lung cancer sample; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs121913444)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793" FT /id="VAR_026102" FT VARIANT 873 FT /note="G -> E (found in a lung cancer sample; FT dbSNP:rs2128964711)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026103" FT VARIANT 962 FT /note="R -> G (in dbSNP:rs17337451)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019299" FT VARIANT 988 FT /note="H -> P (in dbSNP:rs17290699)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019300" FT VARIANT 1034 FT /note="L -> R (in dbSNP:rs34352568)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042095" FT VARIANT 1210 FT /note="A -> V (in dbSNP:rs35918369)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042096" FT MUTAGEN 275 FT /note="Y->A: Strongly reduced autophosphorylation and FT activation of downstream kinases; when associated with A- FT 309." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 287 FT /note="F->A: Strongly reduced autophosphorylation and FT activation of downstream kinases; when associated with A- FT 309." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 309 FT /note="R->S: Strongly reduced autophosphorylation and FT activation of downstream kinases; when associated with A- FT 275. Strongly reduced autophosphorylation and activation of FT downstream kinases; when associated with A-287." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 429 FT /note="R->E: Abolishes autophosphorylation and activation FT of downstream kinases." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 525..1210 FT /note="Missing: Increased EGF binding." FT /evidence="ECO:0000269|PubMed:19718021" FT MUTAGEN 587..590 FT /note="DGPH->AGPA: Decreases intramolecular interactions FT and facilitates EGF binding." FT /evidence="ECO:0000269|PubMed:12620237" FT MUTAGEN 587 FT /note="D->A: Increased EGF binding; when associated with A- FT 590 and A-609." FT /evidence="ECO:0000269|PubMed:19718021" FT MUTAGEN 590 FT /note="H->A: Increased EGF binding; when associated with A- FT 587; A-590 and A-609." FT /evidence="ECO:0000269|PubMed:19718021" FT MUTAGEN 609 FT /note="K->A: Decreases intramolecular interactions and FT facilitates EGF binding. Increased EGF binding; when FT associated with A-587; A-590 and A-609." FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:19718021" FT MUTAGEN 688 FT /note="L->A: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417, FT ECO:0000269|PubMed:19563760" FT MUTAGEN 689 FT /note="V->A: Reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 689 FT /note="V->M: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 690 FT /note="E->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417, FT ECO:0000269|PubMed:19563760" FT MUTAGEN 692 FT /note="L->A,P: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417, FT ECO:0000269|PubMed:19563760" FT MUTAGEN 693 FT /note="T->A: Increased phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 693 FT /note="T->D: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 694 FT /note="P->A: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 699 FT /note="P->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 700 FT /note="N->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 704 FT /note="L->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 705 FT /note="R->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 706 FT /note="I->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 745 FT /note="K->A,M: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 974 FT /note="D->A: Strongly reduced phosphorylation." FT MUTAGEN 977 FT /note="R->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19563760" FT MUTAGEN 1005..1006 FT /note="ED->RK: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:19563760" FT MUTAGEN 1016 FT /note="Y->F: 50% decrease in interaction with PIK3C2B. 65% FT decrease in interaction with PIK3C2B; when associated with FT F-1197. Abolishes interaction with PIK3C2B; when associated FT with F-1197 and F-1092." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1048..1210 FT /note="Missing: Abolishes palmitoylation." FT /evidence="ECO:0000269|PubMed:27153536" FT MUTAGEN 1049 FT /note="C->A: Decreased palmitoylation." FT /evidence="ECO:0000269|PubMed:27153536" FT MUTAGEN 1067 FT /note="Q->G: No effect on interaction with CBLC." FT /evidence="ECO:0000269|PubMed:22888118" FT MUTAGEN 1068 FT /note="R->G: Strongly decreases interaction with CBLC." FT /evidence="ECO:0000269|PubMed:22888118" FT MUTAGEN 1069 FT /note="Y->F: Abolishes interaction with CBLC." FT /evidence="ECO:0000269|PubMed:22888118" FT MUTAGEN 1092 FT /note="Y->F: No change in interaction with PIK3C2B. FT Abolishes interaction with PIK3C2B; when associated with F- FT 1197 and F-1016." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1110 FT /note="Y->F: No change in interaction with PIK3C2B." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1146 FT /note="C->A: Decreased palmitoylation." FT /evidence="ECO:0000269|PubMed:27153536" FT MUTAGEN 1172 FT /note="Y->F: No change in interaction with PIK3C2B." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1197 FT /note="Y->F: No change in interaction with PIK3C2B. 65% FT decrease in interaction with PIK3C2B; when associated with FT F-1016. Abolishes interaction with PIK3C2B; when associated FT with F-1092 and F-1016." FT /evidence="ECO:0000269|PubMed:10805725" FT CONFLICT 540 FT /note="N -> K (in Ref. 1; CAA25240)" FT /evidence="ECO:0000305" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:3QWQ" FT HELIX 44..55 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 60..69 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 77..81 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 84..87 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 89..93 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 101..103 FT /evidence="ECO:0007829|PDB:1IVO" FT TURN 114..116 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 117..122 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 125..129 FT /evidence="ECO:0007829|PDB:1MOX" FT STRAND 145..152 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 159..161 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 170..173 FT /evidence="ECO:0007829|PDB:1MOX" FT STRAND 183..185 FT /evidence="ECO:0007829|PDB:5XWD" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 199..204 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:1MOX" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:5XWD" FT STRAND 223..227 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 228..230 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 236..238 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 240..244 FT /evidence="ECO:0007829|PDB:4UV7" FT TURN 245..247 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 248..256 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 259..263 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 267..271 FT /evidence="ECO:0007829|PDB:4UV7" FT TURN 272..275 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 276..279 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 285..287 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 290..294 FT /evidence="ECO:0007829|PDB:4UV7" FT TURN 296..298 FT /evidence="ECO:0007829|PDB:3B2V" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:7LEN" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:4KRP" FT STRAND 306..310 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 313..315 FT /evidence="ECO:0007829|PDB:3B2V" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:3G5Y" FT STRAND 323..325 FT /evidence="ECO:0007829|PDB:3G5Y" FT STRAND 330..332 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 336..338 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 340..342 FT /evidence="ECO:0007829|PDB:3QWQ" FT HELIX 343..345 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 349..351 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 353..355 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 356..359 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 363..367 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 373..377 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 380..383 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 389..397 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 400..403 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 405..407 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 418..420 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 433..435 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 436..442 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 458..464 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 472..474 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 477..480 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 481..483 FT /evidence="ECO:0007829|PDB:1YY9" FT STRAND 488..494 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 496..501 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 508..510 FT /evidence="ECO:0007829|PDB:5SX4" FT STRAND 515..519 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 520..522 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 523..526 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 531..533 FT /evidence="ECO:0007829|PDB:4KRL" FT STRAND 534..537 FT /evidence="ECO:0007829|PDB:8UKW" FT STRAND 540..546 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 548..551 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 554..557 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 560..562 FT /evidence="ECO:0007829|PDB:4KRO" FT STRAND 566..568 FT /evidence="ECO:0007829|PDB:8UKW" FT STRAND 570..575 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 578..587 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 590..594 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 597..602 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 606..611 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 615..619 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 622..624 FT /evidence="ECO:0007829|PDB:7SYE" FT STRAND 629..632 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 633..635 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 643..646 FT /evidence="ECO:0007829|PDB:2KS1" FT HELIX 648..669 FT /evidence="ECO:0007829|PDB:2KS1" FT STRAND 671..673 FT /evidence="ECO:0007829|PDB:1Z9I" FT HELIX 679..684 FT /evidence="ECO:0007829|PDB:3GOP" FT HELIX 685..687 FT /evidence="ECO:0007829|PDB:3GOP" FT STRAND 688..692 FT /evidence="ECO:0007829|PDB:1Z9I" FT STRAND 694..697 FT /evidence="ECO:0007829|PDB:1Z9I" FT STRAND 703..706 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 709..711 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 712..720 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 722..731 FT /evidence="ECO:0007829|PDB:8A27" FT TURN 734..736 FT /evidence="ECO:0007829|PDB:5UG9" FT STRAND 740..749 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 753..767 FT /evidence="ECO:0007829|PDB:8A27" FT TURN 771..773 FT /evidence="ECO:0007829|PDB:8PO2" FT STRAND 777..781 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 783..785 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 787..791 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 794..797 FT /evidence="ECO:0007829|PDB:5ZWJ" FT HELIX 798..804 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 806..808 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 811..830 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 840..842 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 843..847 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 850..853 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 856..858 FT /evidence="ECO:0007829|PDB:7VRA" FT TURN 859..865 FT /evidence="ECO:0007829|PDB:8A2A" FT HELIX 866..868 FT /evidence="ECO:0007829|PDB:8A2D" FT STRAND 871..873 FT /evidence="ECO:0007829|PDB:6V66" FT STRAND 875..877 FT /evidence="ECO:0007829|PDB:5CZH" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 883..888 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 893..908 FT /evidence="ECO:0007829|PDB:8A27" FT TURN 909..911 FT /evidence="ECO:0007829|PDB:7JXW" FT TURN 914..917 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 920..922 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 923..928 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 937..939 FT /evidence="ECO:0007829|PDB:8PO0" FT HELIX 941..950 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 951..953 FT /evidence="ECO:0007829|PDB:5JEB" FT HELIX 955..957 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 961..972 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 975..977 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 984..986 FT /evidence="ECO:0007829|PDB:5HG8" FT TURN 992..998 FT /evidence="ECO:0007829|PDB:5HG8" FT TURN 999..1003 FT /evidence="ECO:0007829|PDB:6S89" FT STRAND 1004..1010 FT /evidence="ECO:0007829|PDB:3W2S" FT HELIX 1013..1016 FT /evidence="ECO:0007829|PDB:8A2A" FT STRAND 1068..1070 FT /evidence="ECO:0007829|PDB:3PFV" FT STRAND 1091..1094 FT /evidence="ECO:0007829|PDB:8S1M" SQ SEQUENCE 1210 AA; 134277 MW; D8A2A50B4EFB6ED2 CRC64; MRPSGTAGAA LLALLAALCP ASRALEEKKV CQGTSNKLTQ LGTFEDHFLS LQRMFNNCEV VLGNLEITYV QRNYDLSFLK TIQEVAGYVL IALNTVERIP LENLQIIRGN MYYENSYALA VLSNYDANKT GLKELPMRNL QEILHGAVRF SNNPALCNVE SIQWRDIVSS DFLSNMSMDF QNHLGSCQKC DPSCPNGSCW GAGEENCQKL TKIICAQQCS GRCRGKSPSD CCHNQCAAGC TGPRESDCLV CRKFRDEATC KDTCPPLMLY NPTTYQMDVN PEGKYSFGAT CVKKCPRNYV VTDHGSCVRA CGADSYEMEE DGVRKCKKCE GPCRKVCNGI GIGEFKDSLS INATNIKHFK NCTSISGDLH ILPVAFRGDS FTHTPPLDPQ ELDILKTVKE ITGFLLIQAW PENRTDLHAF ENLEIIRGRT KQHGQFSLAV VSLNITSLGL RSLKEISDGD VIISGNKNLC YANTINWKKL FGTSGQKTKI ISNRGENSCK ATGQVCHALC SPEGCWGPEP RDCVSCRNVS RGRECVDKCN LLEGEPREFV ENSECIQCHP ECLPQAMNIT CTGRGPDNCI QCAHYIDGPH CVKTCPAGVM GENNTLVWKY ADAGHVCHLC HPNCTYGCTG PGLEGCPTNG PKIPSIATGM VGALLLLLVV ALGIGLFMRR RHIVRKRTLR RLLQERELVE PLTPSGEAPN QALLRILKET EFKKIKVLGS GAFGTVYKGL WIPEGEKVKI PVAIKELREA TSPKANKEIL DEAYVMASVD NPHVCRLLGI CLTSTVQLIT QLMPFGCLLD YVREHKDNIG SQYLLNWCVQ IAKGMNYLED RRLVHRDLAA RNVLVKTPQH VKITDFGLAK LLGAEEKEYH AEGGKVPIKW MALESILHRI YTHQSDVWSY GVTVWELMTF GSKPYDGIPA SEISSILEKG ERLPQPPICT IDVYMIMVKC WMIDADSRPK FRELIIEFSK MARDPQRYLV IQGDERMHLP SPTDSNFYRA LMDEEDMDDV VDADEYLIPQ QGFFSSPSTS RTPLLSSLSA TSNNSTVACI DRNGLQSCPI KEDSFLQRYS SDPTGALTED SIDDTFLPVP EYINQSVPKR PAGSVQNPVY HNQPLNPAPS RDPHYQDPHS TAVGNPEYLN TVQPTCVNST FDSPAHWAQK GSHQISLDNP DYQQDFFPKE AKPNGIFKGS TAENAEYLRV APQSSEFIGA // ID EPHB1_HUMAN Reviewed; 984 AA. AC P54762; A8K593; B3KTB2; B5A969; O43569; O95142; O95143; Q0VG87; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1996, sequence version 1. DT 28-JAN-2026, entry version 236. DE RecName: Full=Ephrin type-B receptor 1; DE EC=2.7.10.1; DE AltName: Full=ELK; DE AltName: Full=EPH tyrosine kinase 2; DE AltName: Full=EPH-like kinase 6; DE Short=EK6; DE Short=hEK6; DE AltName: Full=Neuronally-expressed EPH-related tyrosine kinase; DE Short=NET; DE AltName: Full=Tyrosine-protein kinase receptor EPH-2; DE Flags: Precursor; GN Name=EPHB1; Synonyms=ELK, EPHT2, HEK6, NET; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=8666391; DOI=10.1006/geno.1995.9985; RA Tang X.X., Biegel J.A., Nycum L.M., Yoshioka A., Brodeur G.M., RA Pleasure D.E., Ikegaki N.; RT "cDNA cloning, molecular characterization, and chromosomal localization of RT NET(EPHT2), a human EPH-related receptor protein-tyrosine kinase gene RT preferentially expressed in brain."; RL Genomics 29:426-437(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN CELL ADHESION, FUNCTION RP IN JUN CASCADE ACTIVATION, INTERACTION WITH NCK1, MUTAGENESIS OF TYR-594 RP AND LYS-651, AND VARIANT TRP-973. RC TISSUE=Kidney; RX PubMed=9430661; DOI=10.1074/jbc.273.3.1303; RA Stein E., Huynh-Do U., Lane A.A., Cerretti D.P., Daniel T.O.; RT "Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to RT c-Jun kinase."; RL J. Biol. Chem. 273:1303-1308(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP PROTEIN SEQUENCE OF 18-32. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [8] RP INTERACTION WITH GRB2 AND GRB10, MUTAGENESIS OF TYR-928, AND RP PHOSPHORYLATION AT TYR-928. RX PubMed=8798570; DOI=10.1074/jbc.271.38.23588; RA Stein E., Cerretti D.P., Daniel T.O.; RT "Ligand activation of ELK receptor tyrosine kinase promotes its association RT with Grb10 and Grb2 in vascular endothelial cells."; RL J. Biol. Chem. 271:23588-23593(1996). RN [9] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [10] RP FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, INTERACTION WITH ACP1, RP AND MUTAGENESIS OF TYR-928. RX PubMed=9499402; DOI=10.1101/gad.12.5.667; RA Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D., RA Van Etten R.L., Daniel T.O.; RT "Eph receptors discriminate specific ligand oligomers to determine RT alternative signaling complexes, attachment, and assembly responses."; RL Genes Dev. 12:667-678(1998). RN [11] RP INTERACTION WITH EPHB6. RX PubMed=11713248; DOI=10.1074/jbc.m108011200; RA Freywald A., Sharfe N., Roifman C.M.; RT "The kinase-null EphB6 receptor undergoes transphosphorylation in a complex RT with EphB1."; RL J. Biol. Chem. 277:3823-3828(2002). RN [12] RP INTERACTION WITH GRB7, FUNCTION, PHOSPHORYLATION AT TYR-928, AND RP MUTAGENESIS OF TYR-928. RX PubMed=12223469; DOI=10.1074/jbc.m203165200; RA Han D.C., Shen T.L., Miao H., Wang B., Guan J.L.; RT "EphB1 associates with Grb7 and regulates cell migration."; RL J. Biol. Chem. 277:45655-45661(2002). RN [13] RP FUNCTION IN CELL MIGRATION, FUNCTION IN ERK CASCADE ACTIVATION, INTERACTION RP WITH GRB2; SHC1 AND SRC, AND MUTAGENESIS OF TYR-600 AND TYR-778. RX PubMed=12925710; DOI=10.1083/jcb.200302073; RA Vindis C., Cerretti D.P., Daniel T.O., Huynh-Do U.; RT "EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote RT chemotaxis."; RL J. Cell Biol. 162:661-671(2003). RN [14] RP FUNCTION IN ERK CASCADE ACTIVATION, UBIQUITINATION BY CBL, INTERACTION WITH RP CBL, MUTAGENESIS OF LYS-651, AUTOPHOSPHORYLATION, IDENTIFICATION OF EFNB1 RP AS LIGAND, AND SUBCELLULAR LOCATION. RX PubMed=18034775; DOI=10.1111/j.1600-0854.2007.00679.x; RA Fasen K., Cerretti D.P., Huynh-Do U.; RT "Ligand binding induces Cbl-dependent EphB1 receptor degradation through RT the lysosomal pathway."; RL Traffic 9:251-266(2008). RN [15] RP STRUCTURE BY NMR OF 899-984. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C-terminal SAM-domain of mouse ephrin type-B RT receptor 1 precursor (EC 2.7.1.112)."; RL Submitted (JUL-2007) to the PDB data bank. RN [16] RP STRUCTURE BY NMR OF 434-528. RG RIKEN structural genomics initiative (RSGI); RT "Solution structures of the FN3 domain of human ephrin type-B receptor 1."; RL Submitted (FEB-2009) to the PDB data bank. RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-18; MET-387; THR-707; VAL-719; GLN-743; RP THR-912 AND MET-981. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously CC transmembrane ephrin-B family ligands residing on adjacent cells, CC leading to contact-dependent bidirectional signaling into neighboring CC cells. The signaling pathway downstream of the receptor is referred to CC as forward signaling while the signaling pathway downstream of the CC ephrin ligand is referred to as reverse signaling. Cognate/functional CC ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3. During CC nervous system development, regulates retinal axon guidance redirecting CC ipsilaterally ventrotemporal retinal ganglion cells axons at the optic CC chiasm midline. This probably requires repulsive interaction with CC EFNB2. In the adult nervous system together with EFNB3, regulates CC chemotaxis, proliferation and polarity of the hippocampus neural CC progenitors. In addition to its role in axon guidance also plays an CC important redundant role with other ephrin-B receptors in development CC and maturation of dendritic spines and synapse formation. May also CC regulate angiogenesis. More generally, may play a role in targeted cell CC migration and adhesion. Upon activation by EFNB1 and probably other CC ephrin-B ligands activates the MAPK/ERK and the JNK signaling cascades CC to regulate cell migration and adhesion respectively. Involved in the CC maintenance of the pool of satellite cells (muscle stem cells) by CC promoting their self-renewal and reducing their activation and CC differentiation (By similarity). {ECO:0000250|UniProtKB:Q8CBF3, CC ECO:0000269|PubMed:12223469, ECO:0000269|PubMed:12925710, CC ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:9430661, CC ECO:0000269|PubMed:9499402}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts with EPHB6; transphosphorylates EPHB6 to form an active CC signaling complex. Interacts with PICK1 (By similarity). Interacts CC (through Tyr-594) with NCK1 (via SH2 domain); activates the JUN cascade CC to regulate cell adhesion (By similarity). The ligand-activated form CC interacts (through Tyr-928) with GRB7 and GRB10 (via SH2 domains). The CC ligand-activated form interacts (residues within the catalytic domain) CC with GRB2 (via SH2 domain). Interacts with GRB2, SHC1 and SRC; CC activates the MAPK/ERK cascade to regulate cell migration. Interacts CC with CBL; regulates receptor degradation through ubiquitination. CC Interacts with ACP1. {ECO:0000250|UniProtKB:Q8CBF3, CC ECO:0000269|PubMed:11713248, ECO:0000269|PubMed:12223469, CC ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:18034775, CC ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9430661, CC ECO:0000269|PubMed:9499402}. CC -!- INTERACTION: CC P54762; Q13322: GRB10; NbExp=2; IntAct=EBI-80252, EBI-80275; CC P54762; P62993: GRB2; NbExp=2; IntAct=EBI-80252, EBI-401755; CC P54762; Q14451: GRB7; NbExp=4; IntAct=EBI-80252, EBI-970191; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18034775}; CC Single-pass type I membrane protein {ECO:0000269|PubMed:18034775}. CC Early endosome membrane {ECO:0000269|PubMed:18034775}. Cell projection, CC dendrite {ECO:0000250|UniProtKB:Q8CBF3}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P54762-1; Sequence=Displayed; CC Name=2; CC IsoId=P54762-5; Sequence=VSP_056017; CC Name=3; CC IsoId=P54762-6; Sequence=VSP_056018, VSP_056019; CC -!- TISSUE SPECIFICITY: Preferentially expressed in brain. CC -!- PTM: Phosphorylated. Autophosphorylation is stimulated by the ligand CC EFNB1. Required for interaction with SH2 domain-containing interactors, CC for activation of the MAPK/ERK and JUN signaling cascades and for CC ubiquitination by CBL. {ECO:0000269|PubMed:12223469, CC ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:8798570}. CC -!- PTM: Ubiquitinated; (EFNB1)ligand-induced poly- and/or multi- CC ubiquitination by CBL is regulated by SRC and leads to lysosomal CC degradation. {ECO:0000269|PubMed:18034775}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB94627.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305}; CC Sequence=AAB94628.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305}; CC Sequence=AAD02031.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L40636; AAB08520.1; -; mRNA. DR EMBL; AF037331; AAD02030.1; -; mRNA. DR EMBL; AF037332; AAD02031.1; ALT_SEQ; mRNA. DR EMBL; AF037333; AAB94627.1; ALT_SEQ; mRNA. DR EMBL; AF037334; AAB94628.1; ALT_SEQ; mRNA. DR EMBL; EU826607; ACF47643.1; -; mRNA. DR EMBL; AK095305; BAG53024.1; -; mRNA. DR EMBL; AK291208; BAF83897.1; -; mRNA. DR EMBL; AC016931; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC016951; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC063918; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC073244; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC092969; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC111744; AAI11745.1; -; mRNA. DR CCDS; CCDS46921.1; -. [P54762-1] DR RefSeq; NP_004432.1; NM_004441.5. [P54762-1] DR PDB; 2DJS; NMR; -; A=434-528. DR PDB; 2EAO; NMR; -; A=899-984. DR PDB; 3ZFX; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I=602-896. DR PDB; 5MJA; X-ray; 2.14 A; A/B=602-896. DR PDB; 5MJB; X-ray; 2.23 A; A/B=602-896. DR PDB; 6UMW; X-ray; 1.98 A; A=602-896. DR PDB; 7KPL; X-ray; 2.71 A; A=611-889. DR PDB; 7KPM; X-ray; 1.61 A; A=611-889. DR PDBsum; 2DJS; -. DR PDBsum; 2EAO; -. DR PDBsum; 3ZFX; -. DR PDBsum; 5MJA; -. DR PDBsum; 5MJB; -. DR PDBsum; 6UMW; -. DR PDBsum; 7KPL; -. DR PDBsum; 7KPM; -. DR AlphaFoldDB; P54762; -. DR SMR; P54762; -. DR BioGRID; 108361; 30. DR FunCoup; P54762; 1441. DR IntAct; P54762; 45. DR MINT; P54762; -. DR STRING; 9606.ENSP00000381097; -. DR BindingDB; P54762; -. DR ChEMBL; CHEMBL5072; -. DR DrugBank; DB09093; Chlortetracycline. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P54762; -. DR GuidetoPHARMACOLOGY; 1830; -. DR GlyCosmos; P54762; 3 sites, No reported glycans. DR GlyGen; P54762; 4 sites, 1 N-linked glycan (1 site). DR iPTMnet; P54762; -. DR PhosphoSitePlus; P54762; -. DR SwissPalm; P54762; -. DR BioMuta; EPHB1; -. DR DMDM; 1706663; -. DR CPTAC; CPTAC-2920; -. DR CPTAC; CPTAC-2921; -. DR jPOST; P54762; -. DR MassIVE; P54762; -. DR PaxDb; 9606-ENSP00000381097; -. DR PeptideAtlas; P54762; -. DR ProteomicsDB; 3673; -. DR ProteomicsDB; 56716; -. [P54762-1] DR Antibodypedia; 33398; 561 antibodies from 40 providers. DR DNASU; 2047; -. DR Ensembl; ENST00000398015.8; ENSP00000381097.3; ENSG00000154928.20. [P54762-1] DR Ensembl; ENST00000493838.1; ENSP00000419574.1; ENSG00000154928.20. [P54762-5] DR GeneID; 2047; -. DR KEGG; hsa:2047; -. DR MANE-Select; ENST00000398015.8; ENSP00000381097.3; NM_004441.5; NP_004432.1. DR UCSC; uc003eqt.4; human. [P54762-1] DR AGR; HGNC:3392; -. DR ClinPGx; PA27824; -. DR CTD; 2047; -. DR DisGeNET; 2047; -. DR GeneCards; EPHB1; -. DR HGNC; HGNC:3392; EPHB1. DR HPA; ENSG00000154928; Tissue enhanced (brain). DR MalaCards; EPHB1; -. DR MIM; 600600; gene. DR OpenTargets; ENSG00000154928; -. DR VEuPathDB; HostDB:ENSG00000154928; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000155297; -. DR HOGENOM; CLU_000288_141_0_1; -. DR InParanoid; P54762; -. DR OMA; AVAAMEX; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P54762; 8 GO annotations based on evolutionary models. DR PhylomeDB; P54762; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P54762; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P54762; -. DR SIGNOR; P54762; -. DR Agora; ENSG00000154928; -. DR BioGRID-ORCS; 2047; 6 hits in 1191 CRISPR screens. DR ChiTaRS; EPHB1; human. DR EvolutionaryTrace; P54762; -. DR GeneWiki; EPH_receptor_B1; -. DR GenomeRNAi; 2047; -. DR Pharos; P54762; Tchem. DR PRO; PR:P54762; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P54762; protein. DR Bgee; ENSG00000154928; Expressed in cortical plate and 138 other cell types or tissues. DR ExpressionAtlas; P54762; baseline and differential. DR GO; GO:0030424; C:axon; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0032433; C:filopodium tip; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0045121; C:membrane raft; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IDA:UniProtKB. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0048593; P:camera-type eye morphogenesis; IEA:Ensembl. DR GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB. DR GO; GO:0031589; P:cell-substrate adhesion; IDA:UniProtKB. DR GO; GO:0021952; P:central nervous system projection neuron axonogenesis; ISS:UniProtKB. DR GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB. DR GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0021934; P:hindbrain tangential cell migration; IEA:Ensembl. DR GO; GO:0001771; P:immunological synapse formation; IEA:Ensembl. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:1902725; P:negative regulation of satellite cell differentiation; ISS:UniProtKB. DR GO; GO:1902723; P:negative regulation of skeletal muscle satellite cell proliferation; ISS:UniProtKB. DR GO; GO:0061351; P:neural precursor cell proliferation; ISS:UniProtKB. DR GO; GO:0022008; P:neurogenesis; ISS:UniProtKB. DR GO; GO:0021631; P:optic nerve morphogenesis; IEA:Ensembl. DR GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; ISS:UniProtKB. DR GO; GO:0014719; P:skeletal muscle satellite cell activation; ISS:UniProtKB. DR CDD; cd10476; EphR_LBD_B1; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05065; PTKc_EphR_B; 1. DR CDD; cd09551; SAM_EPH-B1; 1. DR FunFam; 2.60.40.10:FF:000041; ephrin type-A receptor 3; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000015; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.120.260:FF:000004; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.40.10:FF:000110; Ephrin type-B receptor 2; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034231; EphB1_rcpt_lig-bd. DR InterPro; IPR042819; EphB1_SAM. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF17; EPHRIN TYPE-B RECEPTOR 1; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Cell projection; Direct protein sequencing; Endosome; KW Glycoprotein; Kinase; Membrane; Neurogenesis; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..17 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 18..984 FT /note="Ephrin type-B receptor 1" FT /id="PRO_0000016824" FT TOPO_DOM 18..540 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 541..563 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 564..984 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 19..201 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 322..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 433..528 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 619..882 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 911..975 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT MOTIF 982..984 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 744 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 625..633 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 651 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 600 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:P54753" FT MOD_RES 928 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 334 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 426 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 480 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..439 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056017" FT VAR_SEQ 158..242 FT /note="VNTEVRSFGPLTRNGFYLAFQDYGACMSLLSVRVFFKKCPSIVQNFAVFPET FT MTGAESTSLVIARGTCIPNAEEVDVPIKLYCNG -> LALQGHSRPARKLKAAPTAPPT FT AAPLQRRLPSAPVGPVITERTLTLQKWHALASHQVPAMLSPSSMRRPSFWSGTLQGRQV FT GGMM (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056018" FT VAR_SEQ 243..984 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056019" FT VARIANT 18 FT /note="M -> V (in dbSNP:rs55650774)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042165" FT VARIANT 87 FT /note="T -> S (in dbSNP:rs1042794)" FT /id="VAR_011801" FT VARIANT 152 FT /note="G -> R (in dbSNP:rs1042793)" FT /id="VAR_011802" FT VARIANT 367 FT /note="R -> G (in dbSNP:rs1042789)" FT /id="VAR_011803" FT VARIANT 387 FT /note="T -> M (in dbSNP:rs56396912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042166" FT VARIANT 485 FT /note="R -> S (in dbSNP:rs1042788)" FT /id="VAR_011804" FT VARIANT 707 FT /note="S -> T (in an ovarian undifferentiated carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042167" FT VARIANT 719 FT /note="I -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042168" FT VARIANT 743 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1338928289)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042169" FT VARIANT 847 FT /note="M -> T (in dbSNP:rs1042785)" FT /id="VAR_011805" FT VARIANT 912 FT /note="A -> T (in dbSNP:rs56345346)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042170" FT VARIANT 973 FT /note="R -> W (in dbSNP:rs1042784)" FT /evidence="ECO:0000269|PubMed:9430661" FT /id="VAR_058479" FT VARIANT 981 FT /note="T -> M (in dbSNP:rs56186270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042171" FT MUTAGEN 594 FT /note="Y->F: Loss of interaction with NCK1." FT /evidence="ECO:0000269|PubMed:9430661" FT MUTAGEN 600 FT /note="Y->F: Loss of interaction with SHC1 and SRC." FT /evidence="ECO:0000269|PubMed:12925710" FT MUTAGEN 651 FT /note="K->R: Kinase-dead mutant. Unable to FT autophosphorylate, to interact with SH2 domain-containing FT interactors, to activate the MAPK/ERK and JUN signaling FT cascades. Not ubiquitinated by CBL." FT /evidence="ECO:0000269|PubMed:18034775, FT ECO:0000269|PubMed:9430661" FT MUTAGEN 778 FT /note="Y->F: Loss of interaction with SHC1." FT /evidence="ECO:0000269|PubMed:12925710" FT MUTAGEN 928 FT /note="Y->F: Disrupts binding with the GRB10 SH2 domain, FT providing evidence for phosphorylation. Disrupts FT interaction with GRB7 and ACP1." FT /evidence="ECO:0000269|PubMed:12223469, FT ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9499402" FT CONFLICT 12 FT /note="A -> E (in Ref. 2; AAD02030/AAB94627/AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 185 FT /note="S -> I (in Ref. 2; AAD02030/AAD02031/AAB94627/ FT AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 274 FT /note="T -> R (in Ref. 2; AAD02030/AAD02031/AAB94627/ FT AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 336 FT /note="T -> S (in Ref. 2; AAD02030/AAD02031/AAB94627/ FT AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 752 FT /note="V -> L (in Ref. 6; AAI11745)" FT /evidence="ECO:0000305" FT CONFLICT 813 FT /note="V -> H (in Ref. 2; AAD02030/AAB94627)" FT /evidence="ECO:0000305" FT CONFLICT 819 FT /note="S -> Y (in Ref. 2; AAD02030/AAB94627)" FT /evidence="ECO:0000305" FT CONFLICT 881 FT /note="M -> I (in Ref. 4; BAF83897)" FT /evidence="ECO:0000305" FT CONFLICT 903 FT /note="L -> H (in Ref. 4; BAF83897)" FT /evidence="ECO:0000305" FT STRAND 441..445 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 447..453 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 464..473 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 482..495 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 501..512 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 514..517 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 521..524 FT /evidence="ECO:0007829|PDB:2DJS" FT HELIX 616..618 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 619..627 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 632..638 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 646..652 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 659..673 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 683..687 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 689..692 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 694..698 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 705..710 FT /evidence="ECO:0007829|PDB:7KPM" FT TURN 711..714 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 718..737 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 747..749 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 750..752 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 758..760 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 783..786 FT /evidence="ECO:0007829|PDB:5MJB" FT HELIX 788..790 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 793..798 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 803..818 FT /evidence="ECO:0007829|PDB:7KPM" FT TURN 824..827 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 830..838 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 851..860 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 865..867 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 871..883 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 885..887 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 889..891 FT /evidence="ECO:0007829|PDB:3ZFX" FT HELIX 916..921 FT /evidence="ECO:0007829|PDB:2EAO" FT TURN 922..924 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 926..928 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 929..935 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 940..943 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 948..954 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 959..975 FT /evidence="ECO:0007829|PDB:2EAO" SQ SEQUENCE 984 AA; 109885 MW; 8044160E24E93A92 CRC64; MALDYLLLLL LASAVAAMEE TLMDTRTATA ELGWTANPAS GWEEVSGYDE NLNTIRTYQV CNVFEPNQNN WLLTTFINRR GAHRIYTEMR FTVRDCSSLP NVPGSCKETF NLYYYETDSV IATKKSAFWS EAPYLKVDTI AADESFSQVD FGGRLMKVNT EVRSFGPLTR NGFYLAFQDY GACMSLLSVR VFFKKCPSIV QNFAVFPETM TGAESTSLVI ARGTCIPNAE EVDVPIKLYC NGDGEWMVPI GRCTCKPGYE PENSVACKAC PAGTFKASQE AEGCSHCPSN SRSPAEASPI CTCRTGYYRA DFDPPEVACT SVPSGPRNVI SIVNETSIIL EWHPPRETGG RDDVTYNIIC KKCRADRRSC SRCDDNVEFV PRQLGLTECR VSISSLWAHT PYTFDIQAIN GVSSKSPFPP QHVSVNITTN QAAPSTVPIM HQVSATMRSI TLSWPQPEQP NGIILDYEIR YYEKEHNEFN SSMARSQTNT ARIDGLRPGM VYVVQVRART VAGYGKFSGK MCFQTLTDDD YKSELREQLP LIAGSAAAGV VFVVSLVAIS IVCSRKRAYS KEAVYSDKLQ HYSTGRGSPG MKIYIDPFTY EDPNEAVREF AKEIDVSFVK IEEVIGAGEF GEVYKGRLKL PGKREIYVAI KTLKAGYSEK QRRDFLSEAS IMGQFDHPNI IRLEGVVTKS RPVMIITEFM ENGALDSFLR QNDGQFTVIQ LVGMLRGIAA GMKYLAEMNY VHRDLAARNI LVNSNLVCKV SDFGLSRYLQ DDTSDPTYTS SLGGKIPVRW TAPEAIAYRK FTSASDVWSY GIVMWEVMSF GERPYWDMSN QDVINAIEQD YRLPPPMDCP AALHQLMLDC WQKDRNSRPR FAEIVNTLDK MIRNPASLKT VATITAVPSQ PLLDRSIPDF TAFTTVDDWL SAIKMVQYRD SFLTAGFTSL QLVTQMTSED LLRIGITLAG HQKKILNSIH SMRVQISQSP TAMA // ID ERBB2_HUMAN Reviewed; 1255 AA. AC P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4; X5D2V5; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-1987, sequence version 1. DT 28-JAN-2026, entry version 281. DE RecName: Full=Receptor tyrosine-protein kinase erbB-2; DE EC=2.7.10.1; DE AltName: Full=Metastatic lymph node gene 19 protein; DE Short=MLN 19; DE AltName: Full=Proto-oncogene Neu; DE AltName: Full=Proto-oncogene c-ErbB-2; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER2; DE AltName: Full=p185erbB2; DE AltName: CD_antigen=CD340; DE Flags: Precursor; GN Name=ERBB2; Synonyms=HER2, MLN19, NEU, NGL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003577; DOI=10.1038/319230a0; RA Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., RA Saito T., Toyoshima K.; RT "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal RT growth factor receptor."; RL Nature 319:230-234(1986). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT ALA-1170. RX PubMed=2999974; DOI=10.1126/science.2999974; RA Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., RA Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., Levinson A., RA Ullrich A.; RT "Tyrosine kinase receptor with extensive homology to EGF receptor shares RT chromosomal location with neu oncogene."; RL Science 230:1132-1139(1985). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND RP ALA-1170. RG NIEHS SNPs program; RL Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Brain; RA Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A., RA Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y., RA Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T., RA Sugano S., Nomura N., Isogai T.; RT "NEDO human cDNA sequencing project focused on splicing variants."; RL Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191 (ISOFORM 1). RX PubMed=3039351; DOI=10.1128/mcb.7.7.2597-2601.1987; RA Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D.; RT "Human HER2 (neu) promoter: evidence for multiple mechanisms for RT transcriptional initiation."; RL Mol. Cell. Biol. 7:2597-2601(1987). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-867 (ISOFORM 6). RC TISSUE=Fetal brain; RX PubMed=24722188; DOI=10.1038/ncomms4650; RA Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L., Broly M., RA Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S., Tasan M., Lemmens I., RA Kuang X., Zhao N., Malhotra D., Michaelson J.J., Vacic V., Calderwood M.A., RA Roth F.P., Tavernier J., Horvath S., Salehi-Ashtiani K., Korkin D., RA Sebat J., Hill D.E., Hao T., Vidal M., Iakoucheva L.M.; RT "Protein interaction network of alternatively spliced isoforms from brain RT links genetic risk factors for autism."; RL Nat. Commun. 5:3650-3650(2014). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031. RX PubMed=2995967; DOI=10.1073/pnas.82.19.6497; RA Semba K., Kamata N., Toyoshima K., Yamamoto T.; RT "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB- RT 1/epidermal growth factor-receptor gene and is amplified in a human RT salivary gland adenocarcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 82:6497-6501(1985). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 832-909. RC TISSUE=Mammary carcinoma; RX PubMed=2992089; DOI=10.1126/science.2992089; RA King C.R., Kraus M.H., Aaronson S.A.; RT "Amplification of a novel v-erbB-related gene in a human mammary RT carcinoma."; RL Science 229:974-976(1985). RN [11] RP NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170. RX PubMed=8104414; DOI=10.1089/dna.1993.12.611; RA Sarkar F.H., Ball D.E., Li Y.W., Crissman J.D.; RT "Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene."; RL DNA Cell Biol. 12:611-615(1993). RN [12] RP INTERACTION WITH ERBB4, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [13] RP IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A RP COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [14] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15380516; DOI=10.1016/j.ccr.2004.07.012; RA Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z., Ali-Seyed M., RA Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K., Hung M.C.; RT "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine RT kinase receptor ErbB-2."; RL Cancer Cell 6:251-261(2004). RN [16] RP INTERACTION WITH PLXNB1. RX PubMed=15210733; DOI=10.1083/jcb.200312094; RA Swiercz J.M., Kuner R., Offermanns S.; RT "Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine RT kinase ErbB-2."; RL J. Cell Biol. 165:869-880(2004). RN [17] RP INTERACTION WITH MEMO1. RX PubMed=15156151; DOI=10.1038/ncb1134; RA Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.; RT "Memo mediates ErbB2-driven cell motility."; RL Nat. Cell Biol. 6:515-522(2004). RN [18] RP SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND INTERACTION WITH RP KPNB1; RANBP2; CRM1; EEA1 AND CLTC. RX PubMed=16314522; DOI=10.1128/mcb.25.24.11005-11018.2005; RA Giri D.K., Ali-Seyed M., Li L.Y., Lee D.F., Ling P., Bartholomeusz G., RA Wang S.C., Hung M.C.; RT "Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell RT surface receptor."; RL Mol. Cell. Biol. 25:11005-11018(2005). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [20] RP FUNCTION, ALTERNATIVE INITIATION (ISOFORMS 2 AND 3), SUBCELLULAR LOCATION, RP AND MUTAGENESIS OF MET-611; MET-687; MET-706 AND MET-712. RX PubMed=16794579; DOI=10.1038/sj.emboj.7601191; RA Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B., Todo F.R., RA Baselga J., Arribas J.; RT "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative RT initiation of translation."; RL EMBO J. 25:3234-3244(2006). RN [21] RP INTERACTION WITH ERBB4, AND AUTOPHOSPHORYLATION IN TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [22] RP PHOSPHORYLATION AT TYR-1248. RX PubMed=17554007; DOI=10.1523/jneurosci.5381-06.2007; RA Deng S., Hirschberg A., Worzfeld T., Penachioni J.Y., Korostylev A., RA Swiercz J.M., Vodrazka P., Mauti O., Stoeckli E.T., Tamagnone L., RA Offermanns S., Kuner R.; RT "Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and RT patterning of the developing nervous system in vivo."; RL J. Neurosci. 27:6333-6347(2007). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [25] RP INTERACTION WITH PTK6, AND ACTIVITY REGULATION. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [26] RP FUNCTION IN NUCLEUS. RX PubMed=19372587; DOI=10.1158/1541-7786.mcr-08-0316; RA Hawthorne V.S., Huang W.C., Neal C.L., Tseng L.M., Hung M.C., Yu D.; RT "ErbB2-mediated Src and signal transducer and activator of transcription 3 RT activation leads to transcriptional up-regulation of p21Cip1 and RT chemoresistance in breast cancer cells."; RL Mol. Cancer Res. 7:592-600(2009). RN [27] RP INTERACTION WITH CPNE3. RX PubMed=20010870; DOI=10.1038/onc.2009.456; RA Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R., RA Lienhard S., Duss S., Hofsteenge J., Hynes N.E.; RT "Copine-III interacts with ErbB2 and promotes tumor cell migration."; RL Oncogene 29:1598-1610(2010). RN [28] RP FUNCTION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP CHROMOSOMAL REARRANGEMENT WITH CDK12. RX PubMed=21097718; DOI=10.1158/0008-5472.can-10-1749; RA Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., Ler L.D., RA Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A., Grabsch H., RA Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.; RT "Genetic and structural variation in the gastric cancer kinome revealed RT through targeted deep sequencing."; RL Cancer Res. 71:29-39(2011). RN [31] RP FUNCTION IN NUCLEUS, INTERACTION WITH ACTB AND RPA194, AND SUBCELLULAR RP LOCATION. RX PubMed=21555369; DOI=10.1158/0008-5472.can-10-3504; RA Li L.Y., Chen H., Hsieh Y.H., Wang Y.N., Chu H.J., Chen Y.H., Chen H.Y., RA Chien P.J., Ma H.T., Tsai H.C., Lai C.C., Sher Y.P., Lien H.C., Tsai C.H., RA Hung M.C.; RT "Nuclear ErbB2 enhances translation and cell growth by activating RT transcription of ribosomal RNA genes."; RL Cancer Res. 71:4269-4279(2011). RN [32] RP INTERACTION WITH EGFR. RX PubMed=21190959; DOI=10.1210/en.2010-0940; RA Kharmate G., Rajput P.S., Watt H.L., Somvanshi R.K., Chaudhari N., Qiu X., RA Kumar U.; RT "Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in RT the presence of somatostatin receptor 5 modulate signaling pathways."; RL Endocrinology 152:931-945(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182; SER-1054; SER-1083 AND RP THR-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054 AND SER-1151, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH HSP90AA1 AND HSP90AB1. RX PubMed=26517842; DOI=10.1371/journal.pone.0141786; RA Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C., RA Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K., RA Trepel J.B., Neckers L.; RT "Client proteins and small molecule inhibitors display distinct binding RT preferences for constitutive and stress-induced HSP90 isoforms and their RT conformationally restricted mutants."; RL PLoS ONE 10:E0141786-E0141786(2015). RN [37] RP PHOSPHORYLATION AT TYR-1112; TYR-1139; TYR-1196 AND TYR-1248, AND RP DEPHOSPHORYLATION BY PTPN12. RX PubMed=27134172; DOI=10.1016/j.celrep.2016.04.016; RA Li H., Yang F., Liu C., Xiao P., Xu Y., Liang Z., Liu C., Wang H., Wang W., RA Zheng W., Zhang W., Ma X., He D., Song X., Cui F., Xu Z., Yi F., Sun J.P., RA Yu X.; RT "Crystal structure and substrate specificity of PTPN12."; RL Cell Rep. 15:1345-1358(2016). RN [38] RP INTERACTION WITH SORL1, AND SUBCELLULAR LOCATION. RX PubMed=31138794; DOI=10.1038/s41467-019-10275-0; RA Pietilae M., Sahgal P., Peuhu E., Jaentti N.Z., Paatero I., Naervae E., RA Al-Akhrass H., Lilja J., Georgiadou M., Andersen O.M., Padzik A., Sihto H., RA Joensuu H., Blomqvist M., Saarinen I., Bostroem P.J., Taimen P., Ivaska J.; RT "SORLA regulates endosomal trafficking and oncogenic fitness of HER2."; RL Nat. Commun. 10:2340-2340(2019). RN [39] RP INTERACTION WITH SH3BGRL, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT RP TYR-877 AND TYR-1196. RX PubMed=32381043; DOI=10.1186/s13046-020-01577-z; RA Li H., Zhang M., Wei Y., Haider F., Lin Y., Guan W., Liu Y., Zhang S., RA Yuan R., Yang X., Yang S., Wang H.; RT "SH3BGRL confers innate drug resistance in breast cancer by stabilizing RT HER2 activation on cell membrane."; RL J. Exp. Clin. Cancer Res. 39:81-81(2020). RN [40] RP SUBCELLULAR LOCATION. RX PubMed=34380438; DOI=10.1186/s12860-021-00379-1; RA Di Pisa F., Pesenti E., Bono M., Mazzarello A.N., Bernardi C., RA Lisanti M.P., Renzone G., Scaloni A., Ciccone E., Fais F., Bruno S., RA Scartezzini P., Ghiotto F.; RT "SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates RT migration in the MDA-MB-231 cell line."; RL BMC Mol. Cell Biol. 22:41-41(2021). RN [41] RP INTERACTION WITH ROR1. RX PubMed=36949068; DOI=10.1038/s41467-023-37306-1; RA Lin W., Niu R., Park S.M., Zou Y., Kim S.S., Xia X., Xing S., Yang Q., RA Sun X., Yuan Z., Zhou S., Zhang D., Kwon H.J., Park S., Il Kim C., Koo H., RA Liu Y., Wu H., Zheng M., Yoo H., Shi B., Park J.B., Yin J.; RT "IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2- RT CREB signaling axis."; RL Nat. Commun. 14:1578-1578(2023). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA AND RP BETA-2 MICROGLOBULIN. RX PubMed=10593938; DOI=10.1074/jbc.274.51.36422; RA Kuhns J.J., Batalia M.A., Yan S., Collins E.J.; RT "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of RT interactions with the center of the peptide."; RL J. Biol. Chem. 274:36422-36427(1999). RN [43] RP X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1247-1255 IN COMPLEX WITH ERBIN, RP AND INTERACTION WITH ERBIN. RX PubMed=12444095; DOI=10.1074/jbc.c200571200; RA Birrane G., Chung J., Ladias J.A.; RT "Novel mode of ligand recognition by the Erbin PDZ domain."; RL J. Biol. Chem. 278:1399-1402(2003). RN [44] RP STRUCTURE BY NMR OF 1135-1144 IN COMPLEX WITH GRB7, AND INTERACTION WITH RP GRB7. RX PubMed=12975581; DOI=10.1023/a:1025498409113; RA Ivancic M., Daly R.J., Lyons B.A.; RT "Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and RT structural basis for Grb7 binding to ErbB2."; RL J. Biomol. NMR 27:205-219(2003). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN. RX PubMed=12610629; DOI=10.1038/nature01392; RA Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., RA Denney D.W. Jr., Leahy D.J.; RT "Structure of the extracellular region of HER2 alone and in complex with RT the Herceptin Fab."; RL Nature 421:756-760(2003). RN [46] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY PERTUZUMAB, INTERACTION WITH ERBB3, MUTAGENESIS OF RP 317-LEU-HIS-318, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-187; ASN-259 AND RP ASN-530. RX PubMed=15093539; DOI=10.1016/s1535-6108(04)00083-2; RA Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., RA Sliwkowski M.X.; RT "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab RT complex."; RL Cancer Cell 5:317-328(2004). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-259 AND RP ASN-530. RX PubMed=19299620; DOI=10.1126/science.1165480; RA Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., RA Peale F., Ross S., Wiesmann C., Fuh G.; RT "Variants of the antibody herceptin that interact with HER2 and VEGF at the RT antigen binding site."; RL Science 323:1610-1614(2009). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH ENGINEERED RP ANTIBODY ZHER2, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-68; ASN-259 AND RP ASN-571. RX PubMed=20696930; DOI=10.1073/pnas.1005025107; RA Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T.; RT "Structural basis for high-affinity HER2 receptor binding by an engineered RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 107:15039-15044(2010). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 703-1029 IN COMPLEX WITH RP INHIBITOR SYR127063, CATALYTIC ACTIVITY, SUBUNIT, AND ACTIVITY REGULATION. RX PubMed=21454582; DOI=10.1074/jbc.m110.206193; RA Aertgeerts K., Skene R., Yano J., Sang B.C., Zou H., Snell G., Jennings A., RA Iwamoto K., Habuka N., Hirokawa A., Ishikawa T., Tanaka T., Miki H., RA Ohta Y., Sogabe S.; RT "Structural analysis of the mechanism of inhibition and allosteric RT activation of the kinase domain of HER2 protein."; RL J. Biol. Chem. 286:18756-18765(2011). RN [50] RP VARIANTS VAL-654 AND VAL-655. RX PubMed=8095488; DOI=10.1006/geno.1993.1081; RA Ehsani A., Low J., Wallace R.B., Wu A.M.; RT "Characterization of a new allele of the human ERBB2 gene by allele- RT specific competition hybridization."; RL Genomics 15:426-429(1993). RN [51] RP INVOLVEMENT IN CANCER, VARIANT GASC SER-776, VARIANT OC SER-857, VARIANT RP GLM LYS-914, AND VARIANTS LNCR PRO-755; ALA-TYR-VAL-MET-774 INS AND RP VAL-GLY-SER-779 INS. RX PubMed=15457249; DOI=10.1038/431525b; RG Cancer genome project and collaborative group; RA Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., RA Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M., RA Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A., Drozd A., RA Edwards K., Forbes S., Foster R., Gray K., Greenman C., Halliday K., RA Hills K., Kosmidou V., Lugg R., Menzies A., Perry J., Petty R., Raine K., RA Ratford L., Shepherd R., Small A., Stephens Y., Tofts C., Varian J., RA West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., RA Knowles M., Leung S.Y., Louis D.N., Looijenga L.H., Malkowicz B., RA Pierotti M.A., Teh B., Chenevix-Trench G., Weber B.L., Yuen S.T., RA Harris G., Goldstraw P., Nicholson A.G., Futreal P.A., Wooster R., RA Stratton M.R.; RT "Lung cancer: intragenic ERBB2 kinase mutations in tumours."; RL Nature 431:525-526(2004). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; ALA-1170 AND RP ASP-1216, VARIANT GASC SER-776, AND VARIANT OC SER-857. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP INVOLVEMENT IN VSCN2, VARIANT VSCN2 VAL-710, CHARACTERIZATION OF VARIANT RP VSCN2 VAL-710, SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=33497358; DOI=10.1172/jci145837; RA Le T.L., Galmiche L., Levy J., Suwannarat P., Hellebrekers D.M., RA Morarach K., Boismoreau F., Theunissen T.E., Lefebvre M., Pelet A., RA Martinovic J., Gelot A., Guimiot F., Calleroz A., Gitiaux C., Hully M., RA Goulet O., Chardot C., Drunat S., Capri Y., Bole-Feysot C., Nitschke P., RA Whalen S., Mouthon L., Babcock H.E., Hofstra R., de Coo I.F., Tabet A.C., RA Molina T.J., Keren B., Brooks A., Smeets H.J., Marklund U., Gordon C.T., RA Lyonnet S., Amiel J., Bondurand N.; RT "Dysregulation of the NRG1/ERBB pathway causes a developmental disorder RT with gastrointestinal dysmotility in humans."; RL J. Clin. Invest. 131:0-0(2021). CC -!- FUNCTION: Protein tyrosine kinase that is part of several cell surface CC receptor complexes, but that apparently needs a coreceptor for ligand CC binding. Essential component of a neuregulin-receptor complex, although CC neuregulins do not interact with it alone. GP30 is a potential ligand CC for this receptor. Regulates outgrowth and stabilization of peripheral CC microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 CC signaling pathway elicits the phosphorylation and thus the inhibition CC of GSK3B at cell membrane. This prevents the phosphorylation of APC and CC CLASP2, allowing its association with the cell membrane. In turn, CC membrane-bound APC allows the localization of MACF1 to the cell CC membrane, which is required for microtubule capture and stabilization. CC {ECO:0000305}. CC -!- FUNCTION: In the nucleus is involved in transcriptional regulation. CC Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter CC and activates its transcription. Implicated in transcriptional CC activation of CDKN1A; the function involves STAT3 and SRC. Involved in CC the transcription of rRNA genes by RNA Pol I and enhances protein CC synthesis and cell growth. {ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:15380516, ECO:0000269|PubMed:21555369}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:21454582}; CC -!- ACTIVITY REGULATION: Activated by dimerization. Not activated by EGF, CC TGF-alpha and amphiregulin. Interaction with PTK6 increases its CC intrinsic kinase activity. {ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:21454582}. CC -!- SUBUNIT: Homodimer (PubMed:21454582). Heterodimer with EGFR, ERBB3 and CC ERBB4 (PubMed:10358079, PubMed:15093539, PubMed:16978839, CC PubMed:21190959). Part of a complex with EGFR and either PIK3C2A or CC PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196 CC (PubMed:10805725). Interacts with PLXNB1 (PubMed:15210733). Interacts CC (when phosphorylated on Tyr-1248) with MEMO1 (PubMed:15156151). CC Interacts with MUC1; the interaction is enhanced by heregulin (HRG) CC (PubMed:12939402). Interacts (when phosphorylated on Tyr-1139) with CC GRB7 (via SH2 domain) (PubMed:12975581). Interacts (when phosphorylated CC on Tyr-1248) with ERBIN (PubMed:12444095). Interacts with KPNB1, CC RANBP2, EEA1, CRM1 and CLTC (PubMed:16314522). Interacts with PTK6 CC (PubMed:18719096). Interacts with RPA194 and ACTB (PubMed:21555369). CC Interacts with PRKCABP, SRC and MYOC (By similarity). Interacts CC (preferentially with the tyrosine phosphorylated form) with CPNE3; this CC interaction occurs at the cell membrane and is increased in a growth CC factor heregulin-dependent manner (PubMed:20010870). Interacts with CC HSP90AA1 and HSP90AB1 in an ATP-dependent manner; the interaction CC suppresses ERBB2 kinase activity (PubMed:26517842). Interacts with CC SORL1; this interaction regulates ERBB2 subcellular distribution by CC promoting its recycling after internalization from endosomes back to CC the plasma membrane, hence stimulates ERBB2-mediated signaling CC (PubMed:31138794). Interacts with SH3BGRL (PubMed:32381043). Interacts CC with ROR1 (PubMed:36949068). {ECO:0000250|UniProtKB:P70424, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:12975581, CC ECO:0000269|PubMed:15093539, ECO:0000269|PubMed:15156151, CC ECO:0000269|PubMed:15210733, ECO:0000269|PubMed:16314522, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21190959, CC ECO:0000269|PubMed:21454582, ECO:0000269|PubMed:21555369, CC ECO:0000269|PubMed:26517842, ECO:0000269|PubMed:31138794, CC ECO:0000269|PubMed:32381043, ECO:0000269|PubMed:36949068}. CC -!- INTERACTION: CC P04626; P00519: ABL1; NbExp=2; IntAct=EBI-641062, EBI-375543; CC P04626; P42684: ABL2; NbExp=6; IntAct=EBI-641062, EBI-1102694; CC P04626; P15309: ACP3; NbExp=2; IntAct=EBI-641062, EBI-1222012; CC P04626; P60709: ACTB; NbExp=10; IntAct=EBI-641062, EBI-353944; CC P04626; Q92625: ANKS1A; NbExp=2; IntAct=EBI-641062, EBI-1048612; CC P04626; O00213: APBB1; NbExp=2; IntAct=EBI-641062, EBI-81694; CC P04626; O75815: BCAR3; NbExp=2; IntAct=EBI-641062, EBI-702336; CC P04626; Q9HB71: CACYBP; NbExp=2; IntAct=EBI-641062, EBI-1047302; CC P04626; Q16543: CDC37; NbExp=5; IntAct=EBI-641062, EBI-295634; CC P04626; Q9NSE2: CISH; NbExp=4; IntAct=EBI-641062, EBI-617866; CC P04626; Q7Z7G1: CLNK; NbExp=2; IntAct=EBI-641062, EBI-7878194; CC P04626; P46109: CRKL; NbExp=2; IntAct=EBI-641062, EBI-910; CC P04626; Q93034: CUL5; NbExp=2; IntAct=EBI-641062, EBI-1057139; CC P04626; Q99704: DOK1; NbExp=2; IntAct=EBI-641062, EBI-1384360; CC P04626; Q8TEW6: DOK4; NbExp=2; IntAct=EBI-641062, EBI-6918542; CC P04626; Q15075: EEA1; NbExp=5; IntAct=EBI-641062, EBI-298113; CC P04626; P98172: EFNB1; NbExp=12; IntAct=EBI-641062, EBI-538287; CC P04626; P00533: EGFR; NbExp=25; IntAct=EBI-641062, EBI-297353; CC P04626; P04626: ERBB2; NbExp=12; IntAct=EBI-641062, EBI-641062; CC P04626; P21860: ERBB3; NbExp=30; IntAct=EBI-641062, EBI-720706; CC P04626; Q15303: ERBB4; NbExp=5; IntAct=EBI-641062, EBI-80371; CC P04626; Q9UJM3: ERRFI1; NbExp=4; IntAct=EBI-641062, EBI-2941912; CC P04626; P09769: FGR; NbExp=3; IntAct=EBI-641062, EBI-1383732; CC P04626; P06241: FYN; NbExp=2; IntAct=EBI-641062, EBI-515315; CC P04626; O75791: GRAP2; NbExp=2; IntAct=EBI-641062, EBI-740418; CC P04626; P62993: GRB2; NbExp=8; IntAct=EBI-641062, EBI-401755; CC P04626; Q14451: GRB7; NbExp=5; IntAct=EBI-641062, EBI-970191; CC P04626; P07900: HSP90AA1; NbExp=6; IntAct=EBI-641062, EBI-296047; CC P04626; P08238: HSP90AB1; NbExp=5; IntAct=EBI-641062, EBI-352572; CC P04626; P14625: HSP90B1; NbExp=2; IntAct=EBI-641062, EBI-359129; CC P04626; P11021: HSPA5; NbExp=3; IntAct=EBI-641062, EBI-354921; CC P04626; P46940: IQGAP1; NbExp=5; IntAct=EBI-641062, EBI-297509; CC P04626; P35568: IRS1; NbExp=2; IntAct=EBI-641062, EBI-517592; CC P04626; Q08881: ITK; NbExp=2; IntAct=EBI-641062, EBI-968552; CC P04626; P23458: JAK1; NbExp=2; IntAct=EBI-641062, EBI-1383438; CC P04626; Q14974: KPNB1; NbExp=14; IntAct=EBI-641062, EBI-286758; CC P04626; Q96JA1: LRIG1; NbExp=7; IntAct=EBI-641062, EBI-2865191; CC P04626; O75367: MACROH2A1; NbExp=6; IntAct=EBI-641062, EBI-2868511; CC P04626; O75367-3: MACROH2A1; NbExp=3; IntAct=EBI-641062, EBI-6250866; CC P04626; Q9UQF2: MAPK8IP1; NbExp=4; IntAct=EBI-641062, EBI-78404; CC P04626; Q13387: MAPK8IP2; NbExp=3; IntAct=EBI-641062, EBI-722813; CC P04626; P42679: MATK; NbExp=2; IntAct=EBI-641062, EBI-751664; CC P04626; Q9Y316: MEMO1; NbExp=6; IntAct=EBI-641062, EBI-1104564; CC P04626; O43639: NCK2; NbExp=2; IntAct=EBI-641062, EBI-713635; CC P04626; Q02297-7: NRG1; NbExp=2; IntAct=EBI-641062, EBI-2460927; CC P04626; O00750: PIK3C2B; NbExp=2; IntAct=EBI-641062, EBI-641107; CC P04626; P27986: PIK3R1; NbExp=12; IntAct=EBI-641062, EBI-79464; CC P04626; O00459: PIK3R2; NbExp=8; IntAct=EBI-641062, EBI-346930; CC P04626; Q92569: PIK3R3; NbExp=10; IntAct=EBI-641062, EBI-79893; CC P04626; P19174: PLCG1; NbExp=5; IntAct=EBI-641062, EBI-79387; CC P04626; P16885: PLCG2; NbExp=3; IntAct=EBI-641062, EBI-617403; CC P04626; O95602: POLR1A; NbExp=16; IntAct=EBI-641062, EBI-359472; CC P04626; Q13882: PTK6; NbExp=4; IntAct=EBI-641062, EBI-1383632; CC P04626; Q06124: PTPN11; NbExp=4; IntAct=EBI-641062, EBI-297779; CC P04626; Q05209: PTPN12; NbExp=4; IntAct=EBI-641062, EBI-2266035; CC P04626; Q99952: PTPN18; NbExp=6; IntAct=EBI-641062, EBI-1384210; CC P04626; Q99952-1: PTPN18; NbExp=5; IntAct=EBI-641062, EBI-12739708; CC P04626; P23467: PTPRB; NbExp=2; IntAct=EBI-641062, EBI-1265766; CC P04626; P08575: PTPRC; NbExp=2; IntAct=EBI-641062, EBI-1341; CC P04626; Q12913: PTPRJ; NbExp=2; IntAct=EBI-641062, EBI-2264500; CC P04626; Q15262: PTPRK; NbExp=2; IntAct=EBI-641062, EBI-474052; CC P04626; Q16827: PTPRO; NbExp=2; IntAct=EBI-641062, EBI-723739; CC P04626; Q15256: PTPRR; NbExp=2; IntAct=EBI-641062, EBI-2265659; CC P04626; P49792: RANBP2; NbExp=3; IntAct=EBI-641062, EBI-973138; CC P04626; P20936: RASA1; NbExp=8; IntAct=EBI-641062, EBI-1026476; CC P04626; O95980: RECK; NbExp=4; IntAct=EBI-641062, EBI-2823742; CC P04626; Q9NP31: SH2D2A; NbExp=2; IntAct=EBI-641062, EBI-490630; CC P04626; P29353: SHC1; NbExp=16; IntAct=EBI-641062, EBI-78835; CC P04626; P98077: SHC2; NbExp=3; IntAct=EBI-641062, EBI-7256023; CC P04626; Q92529: SHC3; NbExp=2; IntAct=EBI-641062, EBI-79084; CC P04626; Q9H6Q3: SLA2; NbExp=2; IntAct=EBI-641062, EBI-1222854; CC P04626; O15524: SOCS1; NbExp=2; IntAct=EBI-641062, EBI-968198; CC P04626; O43791: SPOP; NbExp=6; IntAct=EBI-641062, EBI-743549; CC P04626; P12931: SRC; NbExp=11; IntAct=EBI-641062, EBI-621482; CC P04626; P42224: STAT1; NbExp=3; IntAct=EBI-641062, EBI-1057697; CC P04626; P40763: STAT3; NbExp=9; IntAct=EBI-641062, EBI-518675; CC P04626; P31948: STIP1; NbExp=2; IntAct=EBI-641062, EBI-1054052; CC P04626; Q7KZ85: SUPT6H; NbExp=2; IntAct=EBI-641062, EBI-2515547; CC P04626; P43405: SYK; NbExp=7; IntAct=EBI-641062, EBI-78302; CC P04626; Q9Y490: TLN1; NbExp=3; IntAct=EBI-641062, EBI-2462036; CC P04626; Q63HR2: TNS2; NbExp=4; IntAct=EBI-641062, EBI-949753; CC P04626; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-641062, EBI-1220488; CC P04626; Q96D37: VAV1; NbExp=2; IntAct=EBI-641062, EBI-7875353; CC P04626; P52735: VAV2; NbExp=3; IntAct=EBI-641062, EBI-297549; CC P04626; O14980: XPO1; NbExp=3; IntAct=EBI-641062, EBI-355867; CC P04626; P62258: YWHAE; NbExp=2; IntAct=EBI-641062, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:32381043}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection, CC ruffle membrane {ECO:0000269|PubMed:34380438}; Single-pass type I CC membrane protein {ECO:0000255}. Note=Internalized from the cell CC membrane in response to EGF stimulation. {ECO:0000269|PubMed:32381043}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane CC {ECO:0000269|PubMed:31138794, ECO:0000269|PubMed:33497358}; Single-pass CC type I membrane protein {ECO:0000255}. Early endosome CC {ECO:0000269|PubMed:31138794}. Cytoplasm, perinuclear region. Nucleus. CC Note=Translocation to the nucleus requires endocytosis, probably CC endosomal sorting and is mediated by importin beta-1/KPNB1. Also CC detected in VPS35-positive endosome-to-TGN retrograde vesicles CC (PubMed:31138794). {ECO:0000269|PubMed:31138794}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm. Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=6; CC Name=1; Synonyms=ERBB2, HER2; CC IsoId=P04626-1; Sequence=Displayed; CC Name=2; Synonyms=CTF-611; CC IsoId=P04626-2; Sequence=VSP_039249; CC Name=3; Synonyms=CTF-687; CC IsoId=P04626-3; Sequence=VSP_039250; CC Name=4; CC IsoId=P04626-4; Sequence=VSP_039248; CC Name=5; CC IsoId=P04626-5; Sequence=VSP_054787; CC Name=6; Synonyms=B; CC IsoId=P04626-6; Sequence=VSP_055902, VSP_055903, VSP_055904; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tumor tissues including CC primary breast tumors and tumors from small bowel, esophagus, kidney CC and mouth. {ECO:0000269|PubMed:15380516}. CC -!- PTM: Autophosphorylated. Autophosphorylation occurs in trans, i.e. one CC subunit of the dimeric receptor phosphorylates tyrosine residues on the CC other subunit (Probable). Ligand-binding increases phosphorylation on CC tyrosine residues (PubMed:27134172, PubMed:33497358). Signaling via CC SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). CC Dephosphorylated by PTPN12 (PubMed:27134172). CC {ECO:0000269|PubMed:17554007, ECO:0000269|PubMed:27134172, CC ECO:0000269|PubMed:33497358, ECO:0000305}. CC -!- POLYMORPHISM: There are four alleles due to the variations in positions CC 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency of 0.782; CC allele B2 (Ile-654/Val-655) has a frequency of 0.206; allele B3 (Val- CC 654/Val-655) has a frequency of 0.012. CC -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:15457249}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:15457249}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The protein represented in this CC entry is involved in disease pathogenesis. CC -!- DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a cause CC gastric cancer. Deletions within 17q12 region producing fusion CC transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to CC truncated CDK12 protein not in-frame with ERBB2. CC {ECO:0000269|PubMed:21097718}. CC -!- DISEASE: Visceral neuropathy, familial, 2, autosomal recessive (VSCN2) CC [MIM:619465]: An autosomal recessive disorder characterized by CC intestinal dysmotility due to aganglionosis (Hirschsprung disease), CC hypoganglionosis, and/or chronic intestinal pseudoobstruction. Patients CC also show peripheral axonal neuropathy, hypotonia, mild developmental CC delay, unilateral ptosis, and sensorineural hearing loss. CC {ECO:0000269|PubMed:33497358}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative initiation at Met- CC 611 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative initiation at Met- CC 687 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform CC 1. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/162/ERBB2"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=ERBB2 entry; CC URL="https://en.wikipedia.org/wiki/ERBB2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AH001455; AAA35808.1; -; Genomic_DNA. DR EMBL; X03363; CAA27060.1; -; mRNA. DR EMBL; M11730; AAA75493.1; -; mRNA. DR EMBL; M12036; AAA35978.1; -; Genomic_DNA. DR EMBL; AY208911; AAO18082.1; -; Genomic_DNA. DR EMBL; AK295195; BAG58195.1; -; mRNA. DR EMBL; CH471152; EAW60597.1; -; Genomic_DNA. DR EMBL; BC167147; AAI67147.1; -; mRNA. DR EMBL; M16792; AAA58637.1; -; Genomic_DNA. DR EMBL; M16789; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16790; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16791; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; KJ534964; AHW56604.1; -; mRNA. DR EMBL; L29395; AAA35809.1; -; Genomic_DNA. DR EMBL; M95667; AAC37531.1; -; Genomic_DNA. DR CCDS; CCDS32642.1; -. [P04626-1] DR CCDS; CCDS45667.1; -. [P04626-5] DR CCDS; CCDS74052.1; -. [P04626-4] DR PIR; A24571; A24571. DR RefSeq; NP_001005862.1; NM_001005862.3. [P04626-5] DR RefSeq; NP_001276865.1; NM_001289936.2. [P04626-4] DR RefSeq; NP_001276867.1; NM_001289938.1. DR RefSeq; NP_001369711.1; NM_001382782.1. [P04626-5] DR RefSeq; NP_001369712.1; NM_001382783.1. [P04626-5] DR RefSeq; NP_004439.2; NM_004448.4. [P04626-1] DR RefSeq; XP_047291546.1; XM_047435590.1. [P04626-4] DR PDB; 1MFG; X-ray; 1.25 A; B=1247-1255. DR PDB; 1MFL; X-ray; 1.88 A; B=1247-1255. DR PDB; 1MW4; NMR; -; B=1135-1144. DR PDB; 1N8Z; X-ray; 2.52 A; C=23-629. DR PDB; 1QR1; X-ray; 2.40 A; C/F=654-662. DR PDB; 1S78; X-ray; 3.25 A; A/B=23-646. DR PDB; 2A91; X-ray; 2.50 A; A=22-530. DR PDB; 2JWA; NMR; -; A/B=641-684. DR PDB; 2KS1; NMR; -; A=641-684. DR PDB; 2L4K; NMR; -; B=1135-1144. DR PDB; 2N2A; NMR; -; A/B=644-700. DR PDB; 3BE1; X-ray; 2.90 A; A=23-646. DR PDB; 3H3B; X-ray; 2.45 A; A/B=23-214. DR PDB; 3MZW; X-ray; 2.90 A; A=23-646. DR PDB; 3N85; X-ray; 3.20 A; A=23-646. DR PDB; 3PP0; X-ray; 2.25 A; A/B=703-1029. DR PDB; 3RCD; X-ray; 3.21 A; A/B/C/D=713-1028. DR PDB; 3WLW; X-ray; 3.09 A; A/B=23-586. DR PDB; 3WSQ; X-ray; 3.50 A; A=23-586. DR PDB; 4GFU; X-ray; 2.00 A; F=1246-1252. DR PDB; 4HRL; X-ray; 2.55 A; C=24-219. DR PDB; 4HRM; X-ray; 3.20 A; A/C=24-219. DR PDB; 4HRN; X-ray; 2.65 A; C/D=529-625. DR PDB; 4NND; X-ray; 2.50 A; C/E/F/H=1109-1114. DR PDB; 5K33; X-ray; 3.30 A; C=23-629. DR PDB; 5KWG; X-ray; 4.30 A; C=23-653. DR PDB; 5MY6; X-ray; 2.25 A; A=24-645. DR PDB; 5O4G; X-ray; 3.00 A; C=23-628. DR PDB; 5OB4; NMR; -; A/B=641-684. DR PDB; 5TQS; X-ray; 1.88 A; E/F/G/H=1218-1228. DR PDB; 6ATT; X-ray; 3.77 A; A=23-652. DR PDB; 6BGT; X-ray; 2.70 A; C=1-652. DR PDB; 6J71; X-ray; 2.92 A; A=22-639. DR PDB; 6LBX; X-ray; 2.03 A; B=531-626. DR PDB; 6OGE; EM; 4.36 A; A=23-644. DR PDB; 7JXH; X-ray; 3.27 A; A/B/C/D/E/F/G/H=703-1024. DR PDB; 7MN5; EM; 2.93 A; B=1-1029. DR PDB; 7MN6; EM; 3.09 A; B=1-1029. DR PDB; 7MN8; EM; 3.45 A; B=1-1029. DR PDB; 7PCD; X-ray; 1.77 A; A=703-1029. DR PDB; 7QVK; X-ray; 3.10 A; AAA=23-646. DR PDB; 8FFJ; EM; 7.50 A; X=23-644. DR PDB; 8HGO; EM; 3.31 A; B=1-693. DR PDB; 8HGP; EM; 4.53 A; B=1-693. DR PDB; 8JYQ; X-ray; 1.75 A; C/F=611-618. DR PDB; 8JYR; X-ray; 1.69 A; A=23-216. DR PDB; 8PWH; EM; 3.17 A; E=23-646. DR PDB; 8Q6J; EM; 3.30 A; E=23-646. DR PDB; 8U4K; EM; 4.27 A; B=24-629. DR PDB; 8U4L; EM; 3.31 A; B=24-629. DR PDB; 8U8X; X-ray; 1.69 A; A=694-1029. DR PDB; 8VB5; X-ray; 1.48 A; A=703-1029. DR PDB; 8VQD; EM; 2.61 A; A=23-652. DR PDB; 8VQE; EM; 2.67 A; A/B=23-652. DR PDB; 9IUT; X-ray; 2.09 A; C/F=611-618. DR PDB; 9L1S; EM; 3.00 A; A=23-652. DR PDBsum; 1MFG; -. DR PDBsum; 1MFL; -. DR PDBsum; 1MW4; -. DR PDBsum; 1N8Z; -. DR PDBsum; 1QR1; -. DR PDBsum; 1S78; -. DR PDBsum; 2A91; -. DR PDBsum; 2JWA; -. DR PDBsum; 2KS1; -. DR PDBsum; 2L4K; -. DR PDBsum; 2N2A; -. DR PDBsum; 3BE1; -. DR PDBsum; 3H3B; -. DR PDBsum; 3MZW; -. DR PDBsum; 3N85; -. DR PDBsum; 3PP0; -. DR PDBsum; 3RCD; -. DR PDBsum; 3WLW; -. DR PDBsum; 3WSQ; -. DR PDBsum; 4GFU; -. DR PDBsum; 4HRL; -. DR PDBsum; 4HRM; -. DR PDBsum; 4HRN; -. DR PDBsum; 4NND; -. DR PDBsum; 5K33; -. DR PDBsum; 5KWG; -. DR PDBsum; 5MY6; -. DR PDBsum; 5O4G; -. DR PDBsum; 5OB4; -. DR PDBsum; 5TQS; -. DR PDBsum; 6ATT; -. DR PDBsum; 6BGT; -. DR PDBsum; 6J71; -. DR PDBsum; 6LBX; -. DR PDBsum; 6OGE; -. DR PDBsum; 7JXH; -. DR PDBsum; 7MN5; -. DR PDBsum; 7MN6; -. DR PDBsum; 7MN8; -. DR PDBsum; 7PCD; -. DR PDBsum; 7QVK; -. DR PDBsum; 8FFJ; -. DR PDBsum; 8HGO; -. DR PDBsum; 8HGP; -. DR PDBsum; 8JYQ; -. DR PDBsum; 8JYR; -. DR PDBsum; 8PWH; -. DR PDBsum; 8Q6J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR PDBsum; 8U8X; -. DR PDBsum; 8VB5; -. DR PDBsum; 8VQD; -. DR PDBsum; 8VQE; -. DR PDBsum; 9IUT; -. DR PDBsum; 9L1S; -. DR AlphaFoldDB; P04626; -. DR BMRB; P04626; -. DR EMDB; EMD-17993; -. DR EMDB; EMD-18188; -. DR EMDB; EMD-18189; -. DR EMDB; EMD-18190; -. DR EMDB; EMD-20055; -. DR EMDB; EMD-29044; -. DR EMDB; EMD-34744; -. DR EMDB; EMD-34745; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR EMDB; EMD-43439; -. DR EMDB; EMD-43440; -. DR EMDB; EMD-62753; -. DR SMR; P04626; -. DR BioGRID; 108376; 731. DR CORUM; P04626; -. DR DIP; DIP-8N; -. DR ELM; P04626; -. DR FunCoup; P04626; 2287. DR IntAct; P04626; 558. DR MINT; P04626; -. DR STRING; 9606.ENSP00000269571; -. DR BindingDB; P04626; -. DR ChEMBL; CHEMBL1824; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB06021; AV-412. DR DrugBank; DB12318; BMS-599626. DR DrugBank; DB11665; BMS-690514. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12302; CP-724714. DR DrugBank; DB12174; CUDC-101. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB04988; IGN311. DR DrugBank; DB01259; Lapatinib. DR DrugBank; DB14967; Margetuximab. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04862; Merimepodib. DR DrugBank; DB12682; Mubritinib. DR DrugBank; DB06226; Nelipepimut-S. DR DrugBank; DB11828; Neratinib. DR DrugBank; DB07662; PD-168393. DR DrugBank; DB06366; Pertuzumab. DR DrugBank; DB12114; Poziotinib. DR DrugBank; DB12183; Sapitinib. DR DrugBank; DB14944; Tarloxotinib. DR DrugBank; DB11973; Tesevatinib. DR DrugBank; DB00072; Trastuzumab. DR DrugBank; DB05773; Trastuzumab emtansine. DR DrugBank; DB11652; Tucatinib. DR DrugBank; DB05944; Varlitinib. DR DrugBank; DB15471; Zanidatamab. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P04626; -. DR GuidetoPHARMACOLOGY; 2019; -. DR MoonDB; P04626; Predicted. DR TCDB; 8.A.23.1.39; the basigin (basigin) family. DR CarbonylDB; P04626; -. DR GlyConnect; 1710; 13 N-Linked glycans (5 sites), 1 O-Linked glycan (1 site). DR GlyCosmos; P04626; 9 sites, 13 glycans. DR GlyGen; P04626; 10 sites, 27 N-linked glycans (7 sites), 2 O-linked glycans (2 sites). DR iPTMnet; P04626; -. DR PhosphoSitePlus; P04626; -. DR SwissPalm; P04626; -. DR BioMuta; ERBB2; -. DR DMDM; 119533; -. DR CPTAC; CPTAC-192; -. DR CPTAC; CPTAC-193; -. DR CPTAC; CPTAC-194; -. DR CPTAC; CPTAC-195; -. DR CPTAC; CPTAC-3045; -. DR CPTAC; CPTAC-3046; -. DR CPTAC; CPTAC-5777; -. DR CPTAC; CPTAC-5827; -. DR CPTAC; CPTAC-5839; -. DR CPTAC; CPTAC-5864; -. DR CPTAC; CPTAC-693; -. DR CPTAC; non-CPTAC-5384; -. DR CPTAC; non-CPTAC-5385; -. DR CPTAC; non-CPTAC-5386; -. DR CPTAC; non-CPTAC-5547; -. DR CPTAC; non-CPTAC-5732; -. DR CPTAC; non-CPTAC-5733; -. DR jPOST; P04626; -. DR MassIVE; P04626; -. DR PaxDb; 9606-ENSP00000269571; -. DR PeptideAtlas; P04626; -. DR ProteomicsDB; 51718; -. [P04626-1] DR ProteomicsDB; 51719; -. [P04626-2] DR ProteomicsDB; 51720; -. [P04626-3] DR ProteomicsDB; 51721; -. [P04626-4] DR Pumba; P04626; -. DR ABCD; P04626; 341 sequenced antibodies. DR Antibodypedia; 740; 6685 antibodies from 63 providers. DR CPTC; P04626; 4 antibodies. DR DNASU; 2064; -. DR Ensembl; ENST00000269571.10; ENSP00000269571.4; ENSG00000141736.15. [P04626-1] DR Ensembl; ENST00000584601.5; ENSP00000462438.1; ENSG00000141736.15. [P04626-5] DR GeneID; 2064; -. DR KEGG; hsa:2064; -. DR MANE-Select; ENST00000269571.10; ENSP00000269571.4; NM_004448.4; NP_004439.2. DR UCSC; uc060esv.1; human. [P04626-1] DR AGR; HGNC:3430; -. DR CIViC; 2064; 2 clinical assertions and 302 evidence items across 174 molecular profiles. DR ClinPGx; PA27844; -. DR CTD; 2064; -. DR DisGeNET; 2064; -. DR GeneCards; ERBB2; -. DR HGNC; HGNC:3430; ERBB2. DR HPA; ENSG00000141736; Low tissue specificity. DR MalaCards; ERBB2; -. DR MIM; 137800; phenotype. DR MIM; 164870; gene. DR MIM; 167000; phenotype. DR MIM; 211980; phenotype. DR MIM; 613659; phenotype. DR MIM; 619465; phenotype. DR OpenTargets; ENSG00000141736; -. DR Orphanet; 99976; Adenocarcinoma of the oesophagus and oesophagogastric junction. DR Orphanet; 2800; Extramammary Paget disease. DR Orphanet; 388; Hirschsprung disease. DR Orphanet; 213726; Serous carcinoma of the corpus uteri. DR VEuPathDB; HostDB:ENSG00000141736; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000158232; -. DR InParanoid; P04626; -. DR OMA; DRHCLPC; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; P04626; 10 GO annotations based on evolutionary models. DR PhylomeDB; P04626; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P04626; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9652282; Drug-mediated inhibition of ERBB2 signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665233; Resistance of ERBB2 KD mutants to trastuzumab. DR Reactome; R-HSA-9665244; Resistance of ERBB2 KD mutants to sapitinib. DR Reactome; R-HSA-9665245; Resistance of ERBB2 KD mutants to tesevatinib. DR Reactome; R-HSA-9665246; Resistance of ERBB2 KD mutants to neratinib. DR Reactome; R-HSA-9665247; Resistance of ERBB2 KD mutants to osimertinib. DR Reactome; R-HSA-9665249; Resistance of ERBB2 KD mutants to afatinib. DR Reactome; R-HSA-9665250; Resistance of ERBB2 KD mutants to AEE788. DR Reactome; R-HSA-9665251; Resistance of ERBB2 KD mutants to lapatinib. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9665737; Drug resistance in ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P04626; -. DR SIGNOR; P04626; -. DR Agora; ENSG00000141736; -. DR BioGRID-ORCS; 2064; 92 hits in 1209 CRISPR screens. DR ChiTaRS; ERBB2; human. DR EvolutionaryTrace; P04626; -. DR GeneWiki; HER2/neu; -. DR GenomeRNAi; 2064; -. DR Pharos; P04626; Tclin. DR PRO; PR:P04626; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04626; protein. DR Bgee; ENSG00000141736; Expressed in lower esophagus mucosa and 186 other cell types or tissues. DR ExpressionAtlas; P04626; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0038143; C:ERBB3:ERBB2 complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0043209; C:myelin sheath; IEA:Ensembl. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0002116; C:semaphorin receptor complex; ISS:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015026; F:coreceptor activity; ISS:BHF-UCL. DR GO; GO:0043125; F:ErbB-3 class receptor binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0001042; F:RNA polymerase I core binding; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; IDA:UniProt. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:UniProtKB. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB. DR GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; TAS:ProtInc. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038134; P:ERBB2-EGFR signaling pathway; IDA:MGI. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0033080; P:immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL. DR GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0035025; P:positive regulation of Rho protein signal transduction; ISS:BHF-UCL. DR GO; GO:0045943; P:positive regulation of transcription by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0045765; P:regulation of angiogenesis; NAS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IDA:UniProtKB. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0071526; P:semaphorin-plexin signaling pathway; ISS:BHF-UCL. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0042060; P:wound healing; IDA:BHF-UCL. DR CDD; cd00064; FU; 3. DR CDD; cd05109; PTKc_HER2; 1. DR CDD; cd12094; TM_ErbB2; 1. DR DisProt; DP01484; -. DR FunFam; 1.20.5.100:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000009; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000010; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000184; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000008; Receptor protein-tyrosine kinase; 1. DR FunFam; 4.10.1140.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 1.20.5.100; Cytochrome c1, transmembrane anchor, C-terminal; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 4.10.1140.10; membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor like domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00293; -. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF137; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative initiation; Alternative splicing; KW ATP-binding; Cell membrane; Cell projection; Chromosomal rearrangement; KW Cytoplasm; Disease variant; Disulfide bond; Endosome; Glycoprotein; Kinase; KW Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Signal; KW Transcription; Transcription regulation; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..1255 FT /note="Receptor tyrosine-protein kinase erbB-2" FT /id="PRO_0000016669" FT TOPO_DOM 23..652 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 653..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1255 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 720..987 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 676..689 FT /note="Required for interaction with KPNB1 and EEA1" FT /evidence="ECO:0000269|PubMed:16314522" FT REGION 1035..1179 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1195..1197 FT /note="Interaction with PIK3C2B" FT /evidence="ECO:0000305" FT REGION 1196..1255 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..689 FT /note="Nuclear localization signal" FT COMPBIAS 1146..1155 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 845 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 726..734 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 753 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 182 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 877 FT /note="Phosphotyrosine" FT /evidence="ECO:0000305|PubMed:32381043" FT MOD_RES 1054 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 1078 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P06494" FT MOD_RES 1083 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1107 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1112 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1139 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1166 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1196 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172, FT ECO:0000305|PubMed:32381043" FT MOD_RES 1248 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17554007, FT ECO:0000269|PubMed:27134172, ECO:0007744|PubMed:17081983" FT CARBOHYD 68 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW" FT CARBOHYD 124 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 187 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255, ECO:0007744|PDB:1N8Z, FT ECO:0007744|PDB:1S78, ECO:0007744|PDB:2A91, FT ECO:0007744|PDB:3N85" FT CARBOHYD 259 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85" FT CARBOHYD 530 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0007744|PDB:1S78" FT CARBOHYD 571 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:3MZW" FT CARBOHYD 629 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 26..53 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 162..192 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 195..204 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 199..212 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 220..227 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 224..235 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 236..244 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 240..252 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 255..264 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 268..295 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 299..311 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 315..331 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 334..338 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 342..367 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 475..504 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 511..520 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 515..528 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 531..540 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 544..560 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 563..576 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 567..584 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 587..596 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:4HRN" FT DISULFID 600..623 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3N85" FT DISULFID 626..634 FT /evidence="ECO:0007744|PDB:3N85" FT DISULFID 630..642 FT /evidence="ECO:0007744|PDB:3N85" FT VAR_SEQ 1..686 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_039250" FT VAR_SEQ 1..610 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_039249" FT VAR_SEQ 1..30 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_054787" FT VAR_SEQ 1..23 FT /note="MELAALCRWGLLLALLPPGAAST -> MPRGSWKP (in isoform 4)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_039248" FT VAR_SEQ 633..648 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055902" FT VAR_SEQ 771..883 FT /note="AYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDL FT LNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADG FT GK -> TISNLFSNFAPRGPSACCEPTCWCHSGKGQDSLPREEWGRQRRFCLWGCRGEP FT RVLDTPGRSCPSAPPSSCLQPSLRQPLLLGPGPTRAGGSTQHLQRDTYGREPRVPGSGR FT ASVNQKAKSAEALMCPQGAGKA (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055903" FT VAR_SEQ 884..1255 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055904" FT VARIANT 452 FT /note="W -> C (in dbSNP:rs4252633)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_016317" FT VARIANT 654 FT /note="I -> V (in allele B3; dbSNP:rs1801201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488" FT /id="VAR_004077" FT VARIANT 655 FT /note="I -> V (in allele B2 and allele B3; FT dbSNP:rs1136201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488, ECO:0000269|Ref.3" FT /id="VAR_004078" FT VARIANT 710 FT /note="A -> V (in VSCN2; almost complete loss of ERBB2 and FT ERBB3 phosphorylation in the presence or in the absence of FT NRG1 stimulation, suggesting alteration of downstream FT signaling; does not affect the subcellular localization at FT the cell membrane; dbSNP:rs2145813505)" FT /evidence="ECO:0000269|PubMed:33497358" FT /id="VAR_086107" FT VARIANT 755 FT /note="L -> P (in LNCR; uncertain significance; somatic FT mutation; dbSNP:rs121913469)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055432" FT VARIANT 768 FT /note="L -> S (in dbSNP:rs56366519)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042097" FT VARIANT 774 FT /note="M -> MAYVM (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055433" FT VARIANT 776 FT /note="G -> S (in GASC; uncertain significance; somatic FT mutation; dbSNP:rs28933369)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042098" FT VARIANT 779 FT /note="S -> SVGS (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055434" FT VARIANT 857 FT /note="N -> S (in OC; uncertain significance; somatic FT mutation; dbSNP:rs28933370)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042099" FT VARIANT 914 FT /note="E -> K (in GLM; uncertain significance; somatic FT mutation; dbSNP:rs28933368)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055435" FT VARIANT 1170 FT /note="P -> A (in dbSNP:rs1058808)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2999974, ECO:0000269|PubMed:8104414, FT ECO:0000269|Ref.3" FT /id="VAR_016318" FT VARIANT 1216 FT /note="A -> D (in dbSNP:rs55943169)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042100" FT MUTAGEN 317..318 FT /note="LH->AA: Reduces dimerization with ERBB3." FT /evidence="ECO:0000269|PubMed:15093539" FT MUTAGEN 611 FT /note="M->A: Prevents synthesis of isoform 2." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 687 FT /note="M->A: Prevents synthesis of isoform 3." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 706 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 712 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT STRAND 25..27 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 39..50 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 55..64 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 84..88 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 92..95 FT /evidence="ECO:0007829|PDB:3H3B" FT TURN 109..111 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 112..117 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 123..125 FT /evidence="ECO:0007829|PDB:8PWH" FT TURN 130..132 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 139..141 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 147..150 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 152..156 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 169..171 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 175..177 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 209..211 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 217..219 FT /evidence="ECO:0007829|PDB:1N8Z" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 227..231 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 240..248 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 271..274 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 281..283 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 284..286 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 294..298 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 309..314 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 319..323 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 325..327 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 329..333 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:2A91" FT HELIX 348..350 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 358..360 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 361..364 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 368..376 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 378..382 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 385..387 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 394..400 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 405..408 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 410..413 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 417..421 FT /evidence="ECO:0007829|PDB:8PWH" FT HELIX 423..425 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 430..435 FT /evidence="ECO:0007829|PDB:3WLW" FT TURN 438..440 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 441..447 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 463..469 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 476..479 FT /evidence="ECO:0007829|PDB:8VQE" FT HELIX 482..485 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 493..499 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 501..506 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 507..509 FT /evidence="ECO:0007829|PDB:3N85" FT HELIX 516..518 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 520..524 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 532..536 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 539..542 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 545..551 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 553..556 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 559..562 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 565..567 FT /evidence="ECO:0007829|PDB:3WSQ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 575..580 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 583..592 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 602..604 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 605..608 FT /evidence="ECO:0007829|PDB:8PWH" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:8JYQ" FT STRAND 621..625 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 630..632 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 635..637 FT /evidence="ECO:0007829|PDB:6J71" FT HELIX 651..678 FT /evidence="ECO:0007829|PDB:2JWA" FT HELIX 684..690 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 691..697 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 720..729 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 732..739 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 748..755 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 762..765 FT /evidence="ECO:0007829|PDB:3RCD" FT HELIX 770..775 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 787..799 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 806..813 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 814..816 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 819..838 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 848..850 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 851..855 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 866..870 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 874..876 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 886..888 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 891..896 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 901..916 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 922..925 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 928..930 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 931..936 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 949..958 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 963..965 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 969..980 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 983..985 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 989..992 FT /evidence="ECO:0007829|PDB:3PP0" FT HELIX 1003..1007 FT /evidence="ECO:0007829|PDB:3PP0" FT TURN 1008..1011 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 1140..1142 FT /evidence="ECO:0007829|PDB:1MW4" SQ SEQUENCE 1255 AA; 137910 MW; 39E9DFDA04DCF962 CRC64; MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV // ID ERN1_HUMAN Reviewed; 977 AA. AC O75460; A1L457; A8K8N8; A8MXS7; Q59EE2; DT 16-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-2008, sequence version 2. DT 28-JAN-2026, entry version 226. DE RecName: Full=Serine/threonine-protein kinase/endoribonuclease IRE1 {ECO:0000305}; DE AltName: Full=Endoplasmic reticulum-to-nucleus signaling 1 {ECO:0000303|PubMed:9637683}; DE AltName: Full=Inositol-requiring protein 1 {ECO:0000303|PubMed:9637683}; DE Short=hIRE1p {ECO:0000303|PubMed:9637683}; DE AltName: Full=Ire1-alpha {ECO:0000303|PubMed:11779464}; DE Short=IRE1a {ECO:0000303|PubMed:11779464}; DE Includes: DE RecName: Full=Serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; DE Includes: DE RecName: Full=Endoribonuclease; DE EC=3.1.26.- {ECO:0000269|PubMed:21317875, ECO:0000305|PubMed:30118681}; DE Flags: Precursor; GN Name=ERN1 {ECO:0000312|HGNC:HGNC:3449}; GN Synonyms=IRE1 {ECO:0000312|EMBL:AAC25991.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAC25991.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION, RP COFACTOR, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AUTOPHOSPHORYLATION, RP GLYCOSYLATION, AND MUTAGENESIS OF LYS-599. RC TISSUE=Liver {ECO:0000312|EMBL:AAC25991.1}; RX PubMed=9637683; DOI=10.1101/gad.12.12.1812; RA Tirasophon W., Welihinda A.A., Kaufman R.J.; RT "A stress response pathway from the endoplasmic reticulum to the nucleus RT requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in RT mammalian cells."; RL Genes Dev. 12:1812-1824(1998). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Endothelial cell; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 2-977 (ISOFORM 2). RC TISSUE=Brain, and Leukocyte; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION. RX PubMed=11779464; DOI=10.1016/s0092-8674(01)00611-0; RA Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K.; RT "XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress RT to produce a highly active transcription factor."; RL Cell 107:881-891(2001). RN [8] RP INTERACTION WITH TAOK3 AND TRAF2. RX PubMed=11278723; DOI=10.1074/jbc.m010677200; RA Yoneda T., Imaizumi K., Oono K., Yui D., Gomi F., Katayama T., Tohyama M.; RT "Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, RT through tumor necrosis factor receptor-associated factor 2-dependent RT mechanism in response to the ER stress."; RL J. Biol. Chem. 276:13935-13940(2001). RN [9] {ECO:0000305} RP FUNCTION, AND MUTAGENESIS OF LYS-599. RX PubMed=11175748; DOI=10.1038/35055065; RA Iwawaki T., Hosoda A., Okuda T., Kamigori Y., Nomura-Furuwatari C., RA Kimata Y., Tsuru A., Kohno K.; RT "Translational control by the ER transmembrane kinase/ribonuclease IRE1 RT under ER stress."; RL Nat. Cell Biol. 3:158-164(2001). RN [10] {ECO:0000305} RP FUNCTION, HOMODIMERIZATION, ACTIVITY REGULATION, INTERACTION WITH HSPA5, RP AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332. RX PubMed=12637535; DOI=10.1074/jbc.m300418200; RA Liu C.Y., Xu Z., Kaufman R.J.; RT "Structure and intermolecular interactions of the luminal dimerization RT domain of human IRE1alpha."; RL J. Biol. Chem. 278:17680-17687(2003). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-973, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP FUNCTION, AND INTERACTION WITH TMBIM6. RX PubMed=19328063; DOI=10.1016/j.molcel.2009.02.017; RA Lisbona F., Rojas-Rivera D., Thielen P., Zamorano S., Todd D., Martinon F., RA Glavic A., Kress C., Lin J.H., Walter P., Reed J.C., Glimcher L.H., RA Hetz C.; RT "BAX inhibitor-1 is a negative regulator of the ER stress sensor RT IRE1alpha."; RL Mol. Cell 33:679-691(2009). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP ADP-RIBOSYLATION BY PARP16. RX PubMed=23103912; DOI=10.1038/ncb2593; RA Jwa M., Chang P.; RT "PARP16 is a tail-anchored endoplasmic reticulum protein required for the RT PERK-and IRE1alpha-mediated unfolded protein response."; RL Nat. Cell Biol. 14:1223-1230(2012). RN [15] RP SUBUNIT, AND INTERACTION WITH DNAJB9 AND HSPA5. RX PubMed=29198525; DOI=10.1016/j.cell.2017.10.040; RA Amin-Wetzel N., Saunders R.A., Kamphuis M.J., Rato C., Preissler S., RA Harding H.P., Ron D.; RT "A J-Protein co-chaperone recruits bip to monomerize IRE1 and repress the RT unfolded protein response."; RL Cell 171:1625-1637(2017). RN [16] RP INTERACTION WITH RNF13. RX PubMed=23378536; DOI=10.1074/jbc.m112.368829; RA Arshad M., Ye Z., Gu X., Wong C.K., Liu Y., Li D., Zhou L., Zhang Y., RA Bay W.P., Yu V.C., Li P.; RT "RNF13, a RING finger protein, mediates endoplasmic reticulum stress- RT induced apoptosis through the inositol-requiring enzyme (IRE1alpha)/c-Jun RT NH2-terminal kinase pathway."; RL J. Biol. Chem. 288:8726-8736(2013). RN [17] RP INTERACTION WITH LACC1. RX PubMed=31875558; DOI=10.1016/j.celrep.2019.11.105; RA Huang C., Hedl M., Ranjan K., Abraham C.; RT "LACC1 required for NOD2-induced, ER stress-mediated innate immune outcomes RT in human macrophages and LACC1 risk variants modulate these outcomes."; RL Cell Rep. 29:4525-4539(2019). RN [18] RP FUNCTION. RX PubMed=21884936; DOI=10.1016/j.cell.2011.07.021; RA Gee H.Y., Noh S.H., Tang B.L., Kim K.H., Lee M.G.; RT "Rescue of DeltaF508-CFTR trafficking via a GRASP-dependent unconventional RT secretion pathway."; RL Cell 146:746-760(2011). RN [19] RP FUNCTION, INTERACTION WITH PDIA6, SUBUNIT, AND MUTAGENESIS OF CYS-148. RX PubMed=24508390; DOI=10.1016/j.molcel.2014.01.004; RA Eletto D., Eletto D., Dersh D., Gidalevitz T., Argon Y.; RT "Protein disulfide isomerase A6 controls the decay of IRE1alpha signaling RT via disulfide-dependent association."; RL Mol. Cell 53:562-576(2014). RN [20] RP FUNCTION, INTERACTION WITH DDRGK1, AND PHOSPHORYLATION. RX PubMed=28128204; DOI=10.1038/ncomms14186; RA Liu J., Wang Y., Song L., Zeng L., Yi W., Liu T., Chen H., Wang M., Ju Z., RA Cong Y.S.; RT "A critical role of DDRGK1 in endoplasmic reticulum homoeostasis via RT regulation of IRE1alpha stability."; RL Nat. Commun. 8:14186-14186(2017). RN [21] RP FUNCTION. RX PubMed=28067262; DOI=10.1038/srep39887; RA Piao H., Kim J., Noh S.H., Kweon H.S., Kim J.Y., Lee M.G.; RT "Sec16A is critical for both conventional and unconventional secretion of RT CFTR."; RL Sci. Rep. 7:39887-39887(2017). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND PHOSPHORYLATION AT SER-724 AND RP SER-729. RX PubMed=30118681; DOI=10.1016/j.molcel.2018.06.038; RA Chang T.K., Lawrence D.A., Lu M., Tan J., Harnoss J.M., Marsters S.A., RA Liu P., Sandoval W., Martin S.E., Ashkenazi A.; RT "Coordination between Two Branches of the Unfolded Protein Response RT Determines Apoptotic Cell Fate."; RL Mol. Cell 71:629-636.e5(2018). RN [23] RP INTERACTION WITH P4HB, AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332. RX PubMed=32149426; DOI=10.15252/embj.2019103841; RA Yu J., Li T., Liu Y., Wang X., Zhang J., Wang X., Shi G., Lou J., Wang L., RA Wang C.C., Wang L.; RT "Phosphorylation switches protein disulfide isomerase activity to maintain RT proteostasis and attenuate ER stress."; RL EMBO J. 39:e103841-e103841(2020). RN [24] RP FUNCTION, INTERACTION WITH MANF AND HSPA5, INDUCTION, AND PHOSPHORYLATION RP AT SER-724. RX PubMed=36739529; DOI=10.1016/j.celrep.2023.112066; RA Kovaleva V., Yu L.Y., Ivanova L., Shpironok O., Nam J., Eesmaa A., RA Kumpula E.P., Sakson S., Toots U., Ustav M., Huiskonen J.T., RA Voutilainen M.H., Lindholm P., Karelson M., Saarma M.; RT "MANF regulates neuronal survival and UPR through its ER-located receptor RT IRE1alpha."; RL Cell Rep. 42:112066-112066(2023). RN [25] {ECO:0007744|PDB:2HZ6} RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 24-390, SUBUNIT, AND MUTAGENESIS RP OF GLN-105; ASP-123 AND TRP-125. RX PubMed=16973740; DOI=10.1073/pnas.0606480103; RA Zhou J., Liu C.Y., Back S.H., Clark R.L., Peisach D., Xu Z., Kaufman R.J.; RT "The crystal structure of human IRE1 luminal domain reveals a conserved RT dimerization interface required for activation of the unfolded protein RT response."; RL Proc. Natl. Acad. Sci. U.S.A. 103:14343-14348(2006). RN [26] {ECO:0007744|PDB:3P23} RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 547-977 IN COMPLEX WITH ADP, RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, AND RP COFACTOR. RX PubMed=21317875; DOI=10.1038/emboj.2011.18; RA Ali M.M., Bagratuni T., Davenport E.L., Nowak P.R., Silva-Santisteban M.C., RA Hardcastle A., McAndrews C., Rowlands M.G., Morgan G.J., Aherne W., RA Collins I., Davies F.E., Pearl L.H.; RT "Structure of the Ire1 autophosphorylation complex and implications for the RT unfolded protein response."; RL EMBO J. 30:894-905(2011). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] SER-244; MET-418; ARG-474; TRP-635; RP SER-700; PHE-769 AND LEU-830. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase and endoribonuclease that CC acts as a key sensor for the endoplasmic reticulum unfolded protein CC response (UPR) (PubMed:11175748, PubMed:11779464, PubMed:12637535, CC PubMed:19328063, PubMed:21317875, PubMed:28128204, PubMed:30118681, CC PubMed:36739529, PubMed:9637683). In unstressed cells, the endoplasmic CC reticulum luminal domain is maintained in its inactive monomeric state CC by binding to the endoplasmic reticulum chaperone HSPA5/BiP CC (PubMed:21317875). Accumulation of misfolded proteins in the CC endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal CC domain to homodimerize, promoting autophosphorylation of the kinase CC domain and subsequent activation of the endoribonuclease activity CC (PubMed:21317875). The endoribonuclease activity is specific for XBP1 CC mRNA and excises 26 nucleotides from XBP1 mRNA (PubMed:11779464, CC PubMed:21317875, PubMed:24508390). The resulting spliced transcript of CC XBP1 encodes a transcriptional activator protein that up-regulates CC expression of UPR target genes (PubMed:11779464, PubMed:21317875, CC PubMed:24508390). Acts as an upstream signal for ER stress-induced CC GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of CC CFTR to cell membrane by modulating the expression and localization of CC SEC16A (PubMed:21884936, PubMed:28067262). CC {ECO:0000269|PubMed:11175748, ECO:0000269|PubMed:11779464, CC ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:19328063, CC ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:21884936, CC ECO:0000269|PubMed:28067262, ECO:0000269|PubMed:28128204, CC ECO:0000269|PubMed:30118681, ECO:0000269|PubMed:36739529, CC ECO:0000269|PubMed:9637683, ECO:0000305|PubMed:24508390}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- ACTIVITY REGULATION: The kinase domain is activated by trans- CC autophosphorylation following homodimerization (PubMed:12637535, CC PubMed:9637683). Kinase activity is required for activation of the CC endoribonuclease domain (PubMed:12637535, PubMed:9637683). CC Endoribonuclease activity is specifically inhibited by hydroxy-aryl- CC aldehydes (HAA) (By similarity). {ECO:0000250|UniProtKB:Q9EQY0, CC ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:9637683}. CC -!- SUBUNIT: Monomer (PubMed:16973740, PubMed:29198525). Homodimer; CC disulfide-linked; homodimerization takes place in response to CC endoplasmic reticulum stress and promotes activation of the kinase and CC endoribonuclease activities (PubMed:12637535, PubMed:16973740, CC PubMed:21317875, PubMed:24508390, PubMed:30118681). Dimer formation is CC driven by hydrophobic interactions within the N-terminal luminal CC domains and stabilized by disulfide bridges (PubMed:12637535). CC Interacts (via the luminal region) with DNAJB9/ERdj4; interaction takes CC place in unstressed cells and promotes recruitment of HSPA5/BiP CC (PubMed:29198525). Interacts (via the luminal region) with HSPA5/BiP; CC HSPA5/BiP is a negative regulator of the unfolded protein response CC (UPR) that prevents homodimerization of ERN1/IRE1 and subsequent CC activation of the protein (PubMed:12637535, PubMed:29198525, CC PubMed:36739529). Interaction with HSPA5 also competitively inhibits CC ERN1 interaction with MANF (PubMed:36739529). Interacts with PDIA6, a CC negative regulator of the UPR; the interaction is direct and disrupts CC homodimerization (PubMed:24508390). Interacts with DAB2IP (via PH CC domain); the interaction occurs in a endoplasmic reticulum stress- CC induced dependent manner and is required for subsequent recruitment of CC TRAF2 to ERN1/IRE1 (By similarity). Interacts with TAOK3 and TRAF2 CC (PubMed:11278723). Interacts with RNF13 (PubMed:23378536). Interacts CC with LACC1 (PubMed:31875558). Interacts (when unphosphorylated) with CC DDRGK1; interaction is dependent on UFM1 and takes place in response to CC endoplasmic reticulum stress, regulating ERN1/IRE1-alpha stability CC (PubMed:28128204). Interacts (via N-terminus) with P4HB/PDIA1; the CC interaction is enhanced by phosphorylation of P4HB by FAM20C in CC response to endoplasmic reticulum stress and results in attenuation of CC ERN1 activity (PubMed:32149426). Interacts with TMBIM6; this CC interaction inhibits ERN1 activity (PubMed:19328063). Interacts (via CC luminal domain) with MANF (via C-terminus); the interaction is CC decreased in the presence of increasing concentrations of Ca(2+) CC (PubMed:36739529). {ECO:0000250|UniProtKB:Q9EQY0, CC ECO:0000269|PubMed:11278723, ECO:0000269|PubMed:12637535, CC ECO:0000269|PubMed:16973740, ECO:0000269|PubMed:19328063, CC ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:23378536, CC ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:28128204, CC ECO:0000269|PubMed:29198525, ECO:0000269|PubMed:30118681, CC ECO:0000269|PubMed:31875558, ECO:0000269|PubMed:32149426, CC ECO:0000269|PubMed:36739529}. CC -!- INTERACTION: CC O75460; Q07812: BAX; NbExp=2; IntAct=EBI-371750, EBI-516580; CC O75460; O75460: ERN1; NbExp=2; IntAct=EBI-371750, EBI-371750; CC O75460; P11021: HSPA5; NbExp=3; IntAct=EBI-371750, EBI-354921; CC O75460; Q86TM6: SYVN1; NbExp=2; IntAct=EBI-371750, EBI-947849; CC O75460; Q9H2K8: TAOK3; NbExp=3; IntAct=EBI-371750, EBI-1384100; CC O75460; Q12933: TRAF2; NbExp=3; IntAct=EBI-371750, EBI-355744; CC O75460; Q969M3: YIPF5; NbExp=3; IntAct=EBI-371750, EBI-2124787; CC O75460; O08734: Bak1; Xeno; NbExp=2; IntAct=EBI-371750, EBI-822441; CC O75460; Q07813: Bax; Xeno; NbExp=2; IntAct=EBI-371750, EBI-700711; CC O75460; P20029: Hspa5; Xeno; NbExp=2; IntAct=EBI-371750, EBI-772325; CC O75460-1; O75460-1: ERN1; NbExp=5; IntAct=EBI-15600828, EBI-15600828; CC O75460-1; P11021: HSPA5; NbExp=4; IntAct=EBI-15600828, EBI-354921; CC O75460-1; Q13438: OS9; NbExp=2; IntAct=EBI-15600828, EBI-725454; CC O75460-1; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-15600828, EBI-358766; CC O75460-1; Q86TM6: SYVN1; NbExp=3; IntAct=EBI-15600828, EBI-947849; CC O75460-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-25852368, EBI-18899653; CC O75460-2; Q96MA6: AK8; NbExp=3; IntAct=EBI-25852368, EBI-8466265; CC O75460-2; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-25852368, EBI-5280499; CC O75460-2; Q9UBL3: ASH2L; NbExp=3; IntAct=EBI-25852368, EBI-540797; CC O75460-2; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-25852368, EBI-9089489; CC O75460-2; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-25852368, EBI-742750; CC O75460-2; Q9NNX6-10: CD209; NbExp=3; IntAct=EBI-25852368, EBI-12300031; CC O75460-2; P38936: CDKN1A; NbExp=3; IntAct=EBI-25852368, EBI-375077; CC O75460-2; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-25852368, EBI-11526226; CC O75460-2; Q92782-2: DPF1; NbExp=3; IntAct=EBI-25852368, EBI-23669343; CC O75460-2; O77932: DXO; NbExp=3; IntAct=EBI-25852368, EBI-372173; CC O75460-2; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-618189; CC O75460-2; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-9088619; CC O75460-2; P52655: GTF2A1; NbExp=3; IntAct=EBI-25852368, EBI-389518; CC O75460-2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-25852368, EBI-6509505; CC O75460-2; Q92615: LARP4B; NbExp=3; IntAct=EBI-25852368, EBI-1052558; CC O75460-2; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-25852368, EBI-2802743; CC O75460-2; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-25852368, EBI-25830200; CC O75460-2; Q8N2H9-4: PELI3; NbExp=3; IntAct=EBI-25852368, EBI-25852006; CC O75460-2; O15534: PER1; NbExp=3; IntAct=EBI-25852368, EBI-2557276; CC O75460-2; Q58EX7-2: PLEKHG4; NbExp=3; IntAct=EBI-25852368, EBI-21503705; CC O75460-2; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-25852368, EBI-26412802; CC O75460-2; Q14181: POLA2; NbExp=3; IntAct=EBI-25852368, EBI-712752; CC O75460-2; Q9UHI5: SLC7A8; NbExp=3; IntAct=EBI-25852368, EBI-13292283; CC O75460-2; O14544: SOCS6; NbExp=3; IntAct=EBI-25852368, EBI-3929549; CC O75460-2; Q496A3: SPATS1; NbExp=3; IntAct=EBI-25852368, EBI-3923692; CC O75460-2; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-25852368, EBI-9089156; CC O75460-2; P49459: UBE2A; NbExp=3; IntAct=EBI-25852368, EBI-2339348; CC O75460-2; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-25852368, EBI-10316321; CC O75460-2; Q9BYN7-2: ZNF341; NbExp=3; IntAct=EBI-25852368, EBI-16435478; CC O75460-2; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-25852368, EBI-18036029; CC O75460-2; Q9BRT8: ZNG1A; NbExp=3; IntAct=EBI-25852368, EBI-1054417; CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:9637683}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:9637683}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O75460-1; Sequence=Displayed; CC Name=2; CC IsoId=O75460-2; Sequence=VSP_034582, VSP_034583; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. High levels observed in CC pancreatic tissue. {ECO:0000269|PubMed:9637683}. CC -!- INDUCTION: Induced by the ER stressor tunicamycin. CC {ECO:0000269|PubMed:36739529}. CC -!- PTM: Autophosphorylated following homodimerization. Autophosphorylation CC promotes activation of the endoribonuclease domain (PubMed:12637535, CC PubMed:21317875, PubMed:28128204, PubMed:9637683). In response to ER CC stress, phosphorylated at Ser-724, Ser-729 and possibly Ser-726; CC phosphorylation promotes oligomerization and endoribonuclease activity CC (PubMed:30118681). Dephosphorylated at Ser-724, Ser-729 and possibly CC Ser-726 by RPAP2 to abort failed ER-stress adaptation and trigger CC apoptosis (PubMed:30118681). Phosphorylated at Ser-724; in response to CC the ER stressor tunicamycin (PubMed:36739529). CC {ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:21317875, CC ECO:0000269|PubMed:28128204, ECO:0000269|PubMed:30118681, CC ECO:0000269|PubMed:36739529, ECO:0000269|PubMed:9637683}. CC -!- PTM: ADP-ribosylated by PARP16 upon ER stress, which increases both CC kinase and endonuclease activities. {ECO:0000269|PubMed:23103912}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF059198; AAC25991.1; -; mRNA. DR EMBL; AK292403; BAF85092.1; -; mRNA. DR EMBL; DA254477; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AB209869; BAD93106.1; -; mRNA. DR EMBL; AC005803; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC025362; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471109; EAW94214.1; -; Genomic_DNA. DR EMBL; BC130405; AAI30406.1; -; mRNA. DR EMBL; BC130407; AAI30408.1; -; mRNA. DR EMBL; BI912495; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS45762.1; -. [O75460-1] DR RefSeq; NP_001424.3; NM_001433.5. [O75460-1] DR PDB; 2HZ6; X-ray; 3.10 A; A=24-390. DR PDB; 3P23; X-ray; 2.70 A; A/B/C/D=547-977. DR PDB; 4U6R; X-ray; 2.50 A; A=547-977. DR PDB; 4YZ9; X-ray; 2.46 A; A/B/C=562-966. DR PDB; 4YZC; X-ray; 2.49 A; A/B=562-966. DR PDB; 4YZD; X-ray; 3.10 A; A/B/C=562-966. DR PDB; 4Z7G; X-ray; 2.60 A; A/B=562-977. DR PDB; 4Z7H; X-ray; 2.90 A; A/B=562-977. DR PDB; 5HGI; X-ray; 2.58 A; A=547-977. DR PDB; 6HV0; X-ray; 2.73 A; A=562-977. DR PDB; 6HX1; X-ray; 2.14 A; A=562-964. DR PDB; 6SHC; X-ray; 3.55 A; A=24-390. DR PDB; 6URC; X-ray; 2.20 A; A/B=547-977. DR PDB; 6W39; X-ray; 1.74 A; A/B=547-977. DR PDB; 6W3A; X-ray; 2.61 A; A/B=547-977. DR PDB; 6W3B; X-ray; 2.57 A; A=547-977. DR PDB; 6W3C; X-ray; 2.30 A; A/B/C/D=547-977. DR PDB; 6W3E; X-ray; 2.74 A; A/B=547-977. DR PDB; 6W3K; X-ray; 2.08 A; A=547-977. DR PDB; 6XDB; X-ray; 2.45 A; A=547-977. DR PDB; 6XDD; X-ray; 2.40 A; A/B=547-977. DR PDB; 6XDF; X-ray; 2.54 A; A/B=547-977. DR PDB; 7BMK; X-ray; 1.85 A; A/B=547-977. DR PDB; 8UVL; X-ray; 2.43 A; A=547-977. DR PDBsum; 2HZ6; -. DR PDBsum; 3P23; -. DR PDBsum; 4U6R; -. DR PDBsum; 4YZ9; -. DR PDBsum; 4YZC; -. DR PDBsum; 4YZD; -. DR PDBsum; 4Z7G; -. DR PDBsum; 4Z7H; -. DR PDBsum; 5HGI; -. DR PDBsum; 6HV0; -. DR PDBsum; 6HX1; -. DR PDBsum; 6SHC; -. DR PDBsum; 6URC; -. DR PDBsum; 6W39; -. DR PDBsum; 6W3A; -. DR PDBsum; 6W3B; -. DR PDBsum; 6W3C; -. DR PDBsum; 6W3E; -. DR PDBsum; 6W3K; -. DR PDBsum; 6XDB; -. DR PDBsum; 6XDD; -. DR PDBsum; 6XDF; -. DR PDBsum; 7BMK; -. DR PDBsum; 8UVL; -. DR AlphaFoldDB; O75460; -. DR SMR; O75460; -. DR BioGRID; 108391; 71. DR CORUM; O75460; -. DR DIP; DIP-31711N; -. DR FunCoup; O75460; 1464. DR IntAct; O75460; 74. DR MINT; O75460; -. DR STRING; 9606.ENSP00000401445; -. DR BindingDB; O75460; -. DR ChEMBL; CHEMBL1163101; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07382; N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine. DR DrugCentral; O75460; -. DR GuidetoPHARMACOLOGY; 2020; -. DR TCDB; 8.A.104.1.9; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; O75460; 1 site, No reported glycans. DR GlyGen; O75460; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; O75460; -. DR PhosphoSitePlus; O75460; -. DR BioMuta; ERN1; -. DR CPTAC; CPTAC-3100; -. DR CPTAC; CPTAC-3101; -. DR jPOST; O75460; -. DR MassIVE; O75460; -. DR PaxDb; 9606-ENSP00000401445; -. DR PeptideAtlas; O75460; -. DR ProteomicsDB; 50021; -. [O75460-1] DR Pumba; O75460; -. DR Antibodypedia; 4011; 736 antibodies from 44 providers. DR DNASU; 2081; -. DR Ensembl; ENST00000433197.4; ENSP00000401445.2; ENSG00000178607.17. [O75460-1] DR Ensembl; ENST00000606895.2; ENSP00000475519.1; ENSG00000178607.17. [O75460-2] DR GeneID; 2081; -. DR KEGG; hsa:2081; -. DR MANE-Select; ENST00000433197.4; ENSP00000401445.2; NM_001433.5; NP_001424.3. DR UCSC; uc002jdz.3; human. [O75460-1] DR AGR; HGNC:3449; -. DR ClinPGx; PA27861; -. DR CTD; 2081; -. DR DisGeNET; 2081; -. DR GeneCards; ERN1; -. DR HGNC; HGNC:3449; ERN1. DR HPA; ENSG00000178607; Tissue enhanced (adrenal gland, pancreas). DR MIM; 604033; gene. DR OpenTargets; ENSG00000178607; -. DR VEuPathDB; HostDB:ENSG00000178607; -. DR eggNOG; KOG1027; Eukaryota. DR GeneTree; ENSGT00940000159761; -. DR HOGENOM; CLU_004875_1_1_1; -. DR InParanoid; O75460; -. DR OMA; NYWVERF; -. DR OrthoDB; 63989at2759; -. DR PAN-GO; O75460; 6 GO annotations based on evolutionary models. DR PhylomeDB; O75460; -. DR PathwayCommons; O75460; -. DR Reactome; R-HSA-381070; IRE1alpha activates chaperones. DR SignaLink; O75460; -. DR SIGNOR; O75460; -. DR Agora; ENSG00000178607; -. DR BioGRID-ORCS; 2081; 13 hits in 1188 CRISPR screens. DR ChiTaRS; ERN1; human. DR EvolutionaryTrace; O75460; -. DR GeneWiki; ERN1; -. DR GenomeRNAi; 2081; -. DR Pharos; O75460; Tchem. DR PRO; PR:O75460; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; O75460; protein. DR Bgee; ENSG00000178607; Expressed in parotid gland and 159 other cell types or tissues. DR GO; GO:1990597; C:AIP1-IRE1 complex; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB. DR GO; GO:1990332; C:Ire1 complex; NAS:ParkinsonsUK-UCL. DR GO; GO:1990630; C:IRE1-RACK1-PP2A complex; IDA:ParkinsonsUK-UCL. DR GO; GO:1990604; C:IRE1-TRAF2-ASK1 complex; IDA:ParkinsonsUK-UCL. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0005637; C:nuclear inner membrane; IEA:Ensembl. DR GO; GO:0043531; F:ADP binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0030544; F:Hsp70 protein binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0051879; F:Hsp90 protein binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; IDA:UniProtKB. DR GO; GO:0051082; F:unfolded protein binding; IBA:GO_Central. DR GO; GO:0071333; P:cellular response to glucose stimulus; IDA:ParkinsonsUK-UCL. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl. DR GO; GO:0034620; P:cellular response to unfolded protein; IDA:ParkinsonsUK-UCL. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB. DR GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IDA:ParkinsonsUK-UCL. DR GO; GO:0001935; P:endothelial cell proliferation; IDA:UniProtKB. DR GO; GO:1901142; P:insulin metabolic process; IDA:ParkinsonsUK-UCL. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; ISS:UniProtKB. DR GO; GO:0036498; P:IRE1-mediated unfolded protein response; IDA:UniProtKB. DR GO; GO:0006402; P:mRNA catabolic process; TAS:ParkinsonsUK-UCL. DR GO; GO:0070054; P:mRNA splicing, via endonucleolytic cleavage and ligation; IDA:UniProtKB. DR GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; IMP:UniProtKB. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:ParkinsonsUK-UCL. DR GO; GO:0033120; P:positive regulation of RNA splicing; IDA:UniProtKB. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL. DR GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:ParkinsonsUK-UCL. DR CDD; cd09769; Luminal_IRE1; 1. DR CDD; cd10422; RNase_Ire1; 1. DR CDD; cd13982; STKc_IRE1; 1. DR FunFam; 2.130.10.10:FF:000225; Endoplasmic reticulum to nucleus-signaling 1; 1. DR FunFam; 3.30.200.20:FF:000077; Putative Serine/threonine-protein kinase/endoribonuclease IRE1; 1. DR FunFam; 1.20.1440.180:FF:000001; Serine/threonine-protein kinase/endoribonuclease IRE1; 1. DR FunFam; 1.10.510.10:FF:000215; serine/threonine-protein kinase/endoribonuclease IRE1 isoform X1; 1. DR Gene3D; 1.20.1440.180; KEN domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR045133; IRE1/2-like. DR InterPro; IPR010513; KEN_dom. DR InterPro; IPR038357; KEN_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR018391; PQQ_b-propeller_rpt. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR011047; Quinoprotein_ADH-like_sf. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR PANTHER; PTHR13954; IRE1-RELATED; 1. DR PANTHER; PTHR13954:SF17; SERINE_THREONINE-PROTEIN KINASE_ENDORIBONUCLEASE IRE1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF06479; Ribonuc_2-5A; 1. DR SMART; SM00564; PQQ; 5. DR SMART; SM00580; PUG; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50998; Quinoprotein alcohol dehydrogenase-like; 1. DR PROSITE; PS51392; KEN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ADP-ribosylation; Alternative splicing; Apoptosis; KW ATP-binding; Disulfide bond; Endoplasmic reticulum; Glycoprotein; KW Hydrolase; Kinase; Magnesium; Membrane; Metal-binding; KW Multifunctional enzyme; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Unfolded protein response. FT SIGNAL 1..18 FT /evidence="ECO:0000255" FT CHAIN 19..977 FT /note="Serine/threonine-protein kinase/endoribonuclease FT IRE1" FT /id="PRO_0000024327" FT TOPO_DOM 19..443 FT /note="Lumenal" FT /evidence="ECO:0000255" FT TRANSMEM 444..464 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 465..977 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 571..832 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 835..963 FT /note="KEN" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00725" FT REGION 410..434 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 491..559 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 906..907 FT /note="Interacts with hydroxy-aryl-aldehyde inhibitors" FT /evidence="ECO:0000250|UniProtKB:Q9EQY0" FT COMPBIAS 410..419 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 513..552 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 688 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P32361, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 577..585 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P32361, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 599 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683, FT ECO:0007744|PDB:3P23" FT BINDING 643..645 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT BINDING 690..693 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT BINDING 711 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT SITE 892 FT /note="Interacts with hydroxy-aryl-aldehyde inhibitors" FT /evidence="ECO:0000250|UniProtKB:Q9EQY0" FT MOD_RES 724 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:30118681, FT ECO:0000269|PubMed:36739529" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:30118681" FT MOD_RES 973 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19369195" FT CARBOHYD 176 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 19..70 FT /note="IFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEE FT -> VSDRGAWGGGQLATAGSGPGQRRGAGAGVRAGSATAAARCPVSPAVGGSGRA (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_034582" FT VAR_SEQ 71..977 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_034583" FT VARIANT 244 FT /note="N -> S (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs1397145500)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040488" FT VARIANT 418 FT /note="V -> M (in dbSNP:rs55869215)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040489" FT VARIANT 474 FT /note="L -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs186305118)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040490" FT VARIANT 635 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs146710304)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040491" FT VARIANT 700 FT /note="N -> S (in dbSNP:rs918253870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040492" FT VARIANT 769 FT /note="S -> F (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040493" FT VARIANT 830 FT /note="P -> L (in an ovarian serous carcinoma sample; FT somatic mutation; dbSNP:rs1279653488)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040494" FT MUTAGEN 105 FT /note="Q->E: Impaired ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 109 FT /note="C->S: No effect on dimerization. No effect on FT interaction with P4HB; when associated with S-148 and S- FT 332." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:32149426" FT MUTAGEN 123 FT /note="D->P: Abolishes ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 125 FT /note="W->A: Abolishes ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 148 FT /note="C->S: No effect on dimerization. Weakens dimer; when FT associated with S-332. Abolishes interaction with PDIA6. FT Prolonged splicing of XBP1, probably due to prolonged FT activation of PDIA6. Inhibits formation of oxidized FT multimeric forms of ERN1 in response to ER stress. No FT effect on interaction with P4HB; when associated with S-109 FT and S-332." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:32149426" FT MUTAGEN 332 FT /note="C->S: No effect on dimerization. Weakens dimer; when FT associated with S-148. No effect on interaction with P4HB; FT when associated with S-109 and S-148." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:32149426" FT MUTAGEN 599 FT /note="K->A: Loss of autophosphorylation and of FT endoribonuclease activity. Inhibition of growth arrest." FT /evidence="ECO:0000269|PubMed:11175748, FT ECO:0000269|PubMed:9637683" FT CONFLICT 190..191 FT /note="DV -> EG (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 768 FT /note="I -> V (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 816 FT /note="D -> G (in Ref. 2; BAF85092)" FT /evidence="ECO:0000305" FT CONFLICT 824..825 FT /note="KH -> ND (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 880 FT /note="V -> D (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 904 FT /note="M -> T (in Ref. 2; BAF85092)" FT /evidence="ECO:0000305" FT CONFLICT 924 FT /note="S -> T (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT STRAND 32..37 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 40..46 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 52..57 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 77..79 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 82..84 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 93..95 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 100..104 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 120..128 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 154..164 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 168..172 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 176..182 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 205..209 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 211..213 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 216..221 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 226..231 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 238..240 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 243..246 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 247..264 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 273..279 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 286..288 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 297..300 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 359..361 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 564..566 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 569..578 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 581..583 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 585..591 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 594..601 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 603..605 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 606..619 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 628..633 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 638..643 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 645..648 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 649..654 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 655..657 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 658..661 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 665..681 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 691..693 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 694..697 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 701..703 FT /evidence="ECO:0007829|PDB:6W3E" FT STRAND 707..709 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 711..716 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:6HV0" FT STRAND 723..727 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:6HV0" FT TURN 732..736 FT /evidence="ECO:0007829|PDB:6HV0" FT HELIX 740..743 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 744..746 FT /evidence="ECO:0007829|PDB:6XDF" FT HELIX 754..768 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 778..780 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 781..787 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 793..795 FT /evidence="ECO:0007829|PDB:4YZC" FT HELIX 800..812 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 817..819 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 823..827 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 830..832 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 835..848 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 849..851 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 854..856 FT /evidence="ECO:0007829|PDB:4YZ9" FT HELIX 857..863 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 866..869 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 874..876 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 880..884 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 887..890 FT /evidence="ECO:0007829|PDB:6W3K" FT HELIX 897..909 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 911..913 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 916..922 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 927..936 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 940..947 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 948..951 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 952..954 FT /evidence="ECO:0007829|PDB:3P23" FT HELIX 955..957 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 958..960 FT /evidence="ECO:0007829|PDB:6W39" SQ SEQUENCE 977 AA; 109735 MW; A2DF808CCE015536 CRC64; MPARRLLLLL TLLLPGLGIF GSTSTVTLPE TLLFVSTLDG SLHAVSKRTG SIKWTLKEDP VLQVPTHVEE PAFLPDPNDG SLYTLGSKNN EGLTKLPFTI PELVQASPCR SSDGILYMGK KQDIWYVIDL LTGEKQQTLS SAFADSLCPS TSLLYLGRTE YTITMYDTKT RELRWNATYF DYAASLPEDD VDYKMSHFVS NGDGLVVTVD SESGDVLWIQ NYASPVVAFY VWQREGLRKV MHINVAVETL RYLTFMSGEV GRITKWKYPF PKETEAKSKL TPTLYVGKYS TSLYASPSMV HEGVAVVPRG STLPLLEGPQ TDGVTIGDKG ECVITPSTDV KFDPGLKSKN KLNYLRNYWL LIGHHETPLS ASTKMLERFP NNLPKHRENV IPADSEKKSF EEVINLVDQT SENAPTTVSR DVEEKPAHAP ARPEAPVDSM LKDMATIILS TFLLIGWVAF IITYPLSMHQ QQQLQHQQFQ KELEKIQLLQ QQQQQLPFHP PGDTAQDGEL LDTSGPYSES SGTSSPSTSP RASNHSLCSG SSASKAGSSP SLEQDDGDEE TSVVIVGKIS FCPKDVLGHG AEGTIVYRGM FDNRDVAVKR ILPECFSFAD REVQLLRESD EHPNVIRYFC TEKDRQFQYI AIELCAATLQ EYVEQKDFAH LGLEPITLLQ QTTSGLAHLH SLNIVHRDLK PHNILISMPN AHGKIKAMIS DFGLCKKLAV GRHSFSRRSG VPGTEGWIAP EMLSEDCKEN PTYTVDIFSA GCVFYYVISE GSHPFGKSLQ RQANILLGAC SLDCLHPEKH EDVIARELIE KMIAMDPQKR PSAKHVLKHP FFWSLEKQLQ FFQDVSDRIE KESLDGPIVK QLERGGRAVV KMDWRENITV PLQTDLRKFR TYKGGSVRDL LRAMRNKKHH YRELPAEVRE TLGSLPDDFV CYFTSRFPHL LAHTYRAMEL CSHERLFQPY YFHEPPEPQP PVTPDAL // ID FGFR2_HUMAN Reviewed; 821 AA. AC P21802; B4DFC2; E7EVR6; E9PCR0; P18443; Q01742; Q12922; Q14300; Q14301; AC Q14302; Q14303; Q14304; Q14305; Q14672; Q14718; Q14719; Q1KHY5; Q86YI4; AC Q8IXC7; Q96KL9; Q96KM0; Q96KM1; Q96KM2; Q9NZU2; Q9NZU3; Q9UD01; Q9UD02; AC Q9UIH3; Q9UIH4; Q9UIH5; Q9UIH6; Q9UIH7; Q9UIH8; Q9UM87; Q9UMC6; Q9UNS7; AC Q9UQH7; Q9UQH8; Q9UQH9; Q9UQI0; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 1. DT 28-JAN-2026, entry version 281. DE RecName: Full=Fibroblast growth factor receptor 2; DE Short=FGFR-2; DE EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; DE AltName: Full=K-sam; DE Short=KGFR; DE AltName: Full=Keratinocyte growth factor receptor; DE AltName: CD_antigen=CD332; DE Flags: Precursor; GN Name=FGFR2; Synonyms=BEK, KGFR, KSAM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Neonatal brain stem; RX PubMed=1697263; DOI=10.1002/j.1460-2075.1990.tb07454.x; RA Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G., Ruta M., RA Burgess W.H., Jaye M., Schlessinger J.; RT "Cloning and expression of two distinct high-affinity receptors cross- RT reacting with acidic and basic fibroblast growth factors."; RL EMBO J. 9:2685-2692(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10). RX PubMed=2172978; DOI=10.1073/pnas.87.20.8180; RA Houssaint E., Blanquet P.R., Champion-Arnaud P., Gesnel M.-C., RA Torriglia A., Courtois Y., Breathnach R.; RT "Related fibroblast growth factor receptor genes exist in the human RT genome."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8180-8184(1990). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 11). RX PubMed=1647213; DOI=10.1016/0167-4781(91)90015-e; RA Seno M., Sasada R., Watanabe T., Ishimaru K., Igarashi K.; RT "Two cDNAs encoding novel human FGF receptor."; RL Biochim. Biophys. Acta 1089:244-246(1991). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RC TISSUE=Stomach cancer; RX PubMed=2377625; DOI=10.1073/pnas.87.15.5983; RA Hattori Y., Odagiri H., Nakatani H., Miyagawa K., Naito K., Sakamoto H., RA Katoh O., Yoshida T., Sugimura T., Terada M.; RT "K-sam, an amplified gene in stomach cancer, is a member of the heparin- RT binding growth factor receptor genes."; RL Proc. Natl. Acad. Sci. U.S.A. 87:5983-5987(1990). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 8; 9 AND 16). RX PubMed=1313574; DOI=10.1073/pnas.89.7.2960; RA Katoh M., Hattori Y., Sasaki H., Tanaka M., Sugano K., Yazaki Y., RA Sugimura T., Terada M.; RT "K-sam gene encodes secreted as well as transmembrane receptor tyrosine RT kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 89:2960-2964(1992). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 16), DOMAIN, AND SUBUNIT. RC TISSUE=Placenta; RX PubMed=1400433; DOI=10.1016/s0021-9258(19)36821-8; RA Dell K.R., Williams L.T.; RT "A novel form of fibroblast growth factor receptor 2. Alternative splicing RT of the third immunoglobulin-like domain confers ligand binding RT specificity."; RL J. Biol. Chem. 267:21225-21229(1992). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3; 13 AND 16), SUBUNIT, DOMAIN, AND RP VARIANT ARG-613. RC TISSUE=Mammary gland; RX PubMed=1309608; DOI=10.1073/pnas.89.1.246; RA Miki T., Bottaro D.P., Fleming T.P., Smith C.L., Burgess W.H., RA Chan A.M.-L., Aaronson S.A.; RT "Determination of ligand-binding specificity by alternative splicing: two RT distinct growth factor receptors encoded by a single gene."; RL Proc. Natl. Acad. Sci. U.S.A. 89:246-250(1992). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 13). RC TISSUE=Cornea, and Mammary gland; RX PubMed=7866434; RA Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M., Shay J.W.; RT "Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and RT their receptors in human breast cells and tissues: alternative receptors."; RL Cell. Mol. Biol. Res. 40:337-350(1994). RN [9] RP ERRATUM OF PUBMED:7866434. RA Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M., Shay J.W.; RL Cell. Mol. Biol. Res. 40:707-707(1994). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT CS SER-342. RC TISSUE=Blood; RA Steinberger D., Mueller U.; RL Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-613. RX PubMed=10626794; RA Ueda T., Sasaki H., Kuwahara Y., Nezu M., Shibuya T., Sakamoto H., RA Ishii H., Yanagihara K., Mafune K., Makuuchi M., Terada M.; RT "Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology- RT mediated recombination, generating preferential expression of specific RT messenger RNAs."; RL Cancer Res. 59:6080-6086(1999). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 5; 6; 7; 8 AND 12). RX PubMed=11856867; DOI=10.1159/000048802; RA Ingersoll R.G., Paznekas W.A., Tran A.K., Scott A.F., Jiang G., Jabs E.W.; RT "Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and RT variations."; RL Cytogenet. Cell Genet. 94:121-126(2001). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3). RA Lind D.L., Cox D.R.; RT "Sequence and polymorphisms in fibroblast growth factor receptor 2 (FGFR2) RT gene in humans."; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 17). RA Jang J.; RT "Identification of a novel variant of FGFR2."; RL Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-6 AND THR-186. RG NIEHS SNPs program; RL Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases. RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 15). RC TISSUE=Cerebellum; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 14). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 314-427. RX PubMed=10712195; DOI=10.1086/302831; RA Glaser R.L., Jiang W., Boyadjiev S.A., Tran A.K., Zachary A.A., RA Van Maldergem L., Johnson D., Walsh S., Oldridge M., Wall S.A., RA Wilkie A.O.M., Jabs E.W.; RT "Paternal origin of FGFR2 mutations in sporadic cases of Crouzon syndrome RT and Pfeiffer syndrome."; RL Am. J. Hum. Genet. 66:768-777(2000). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-209; 212-767 AND 771-821 (ISOFORMS RP 5; 8 AND 12). RX PubMed=10196476; DOI=10.1016/s0378-1119(99)00047-5; RA Zhang Y., Gorry M.C., Post J.C., Ehrlich G.D.; RT "Genomic organization of the human fibroblast growth factor receptor 2 RT (FGFR2) gene and comparative analysis of the human FGFR gene family."; RL Gene 230:69-79(1999). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 249-313, AND VARIANTS APRS TRP-252 AND RP ARG-253. RX PubMed=7668257; RA Park W.-J., Theda C., Maestri N.E., Meyers G.A., Fryburg J.S., Dufresne C., RA Cohen M.M. Jr., Jabs E.W.; RT "Analysis of phenotypic features and FGFR2 mutations in Apert syndrome."; RL Am. J. Hum. Genet. 57:321-328(1995). RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-259. RX PubMed=8676562; RA Wada C., Ishigaki M., Toyo-oka Y., Yamabe H., Ohnuki Y., Takada F., RA Yamazaki Y., Ohtani H.; RT "Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth RT factor receptor 2 and rapid mutational analysis in Apert syndrome."; RL Rinsho Byori 44:435-438(1996). RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-318. RX PubMed=8673103; DOI=10.1038/ng0596-48; RA Moloney D.M., Slaney S.F., Oldridge M., Wall S.A., Sahlin P., Stenman G., RA Wilkie A.O.M.; RT "Exclusive paternal origin of new mutations in Apert syndrome."; RL Nat. Genet. 13:48-53(1996). RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 263-361, AND VARIANTS CS PRO-289; RP ARG-338; SER-342; TYR-342; GLY-344 AND CYS-354. RX PubMed=7581378; DOI=10.1093/hmg/4.8.1387; RA Gorry M.C., Preston R.A., White G.J., Zhang Y., Singhal V.K., Losken H.W., RA Parker M.G., Nwokoro N.A., Post J.C., Ehrlich G.D.; RT "Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common RT point mutation shared with Jackson-Weiss syndrome."; RL Hum. Mol. Genet. 4:1387-1390(1995). RN [25] RP FUNCTION (ISOFORM 3), SUBUNIT, AND DOMAIN. RX PubMed=8961926; DOI=10.1021/bi961942c; RA Gray T.E., Eisenstein M., Yayon A., Givol D.; RT "Asparagine-344 is a key residue for ligand binding in keratinocyte growth RT factor receptor."; RL Biochemistry 35:15640-15645(1996). RN [26] RP INTERACTION WITH FGF1; FGF2; FGF3; FGF4; FGF6; FGF7 AND FGF9, AND FUNCTION RP IN CELL PROLIFERATION. RX PubMed=8663044; DOI=10.1074/jbc.271.25.15292; RA Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., RA Gao G., Goldfarb M.; RT "Receptor specificity of the fibroblast growth factor family."; RL J. Biol. Chem. 271:15292-15297(1996). RN [27] RP INVOLVEMENT IN SCS, AND VARIANT SCS 269-VAL-VAL-270 DEL. RX PubMed=9585583; DOI=10.1086/301855; RA Paznekas W.A., Cunningham M.L., Howard T.D., Korf B.R., Lipson M.H., RA Grix A.W., Feingold M., Goldberg R., Borochowitz Z., Aleck K., Mulliken J., RA Yin M., Jabs E.W.; RT "Genetic heterogeneity of Saethre-Chotzen syndrome, due to TWIST and FGFR RT mutations."; RL Am. J. Hum. Genet. 62:1370-1380(1998). RN [28] RP FUNCTION IN PHOSPHORYLATION OF PAK4; REGULATION OF CELL PROLIFERATION AND RP APOPTOSIS, AND INTERACTION WITH GRB2 AND PAK4. RX PubMed=12529371; DOI=10.1074/jbc.m205875200; RA Lu Y., Pan Z.-Z., Devaux Y., Ray P.; RT "p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte RT growth factor receptor and participates in keratinocyte growth factor- RT mediated inhibition of oxidant-induced cell death."; RL J. Biol. Chem. 278:10374-10380(2003). RN [29] RP FUNCTION IN OSTEOBLAST DIFFERENTIATION AND IN PHOSPHORYLATION OF CBL, RP INTERACTION WITH CBL, UBIQUITINATION, AND CHARACTERIZATION OF VARIANT APRS RP TRP-252. RX PubMed=15190072; DOI=10.1074/jbc.m402469200; RA Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J.; RT "Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast RT growth factor receptor-2 activation supports osteoblast differentiation."; RL J. Biol. Chem. 279:36259-36267(2004). RN [30] RP FUNCTION IN CELL PROLIFERATION AND ACTIVATION OF SIGNALING PATHWAYS, RP MUTAGENESIS OF TYR-769, PHOSPHORYLATION AT TYR-769, AND INTERACTION WITH RP PLCG1. RX PubMed=15629145; DOI=10.1016/j.bbrc.2004.12.031; RA Ceridono M., Belleudi F., Ceccarelli S., Torrisi M.R.; RT "Tyrosine 769 of the keratinocyte growth factor receptor is required for RT receptor signaling but not endocytosis."; RL Biochem. Biophys. Res. Commun. 327:523-532(2005). RN [31] RP INTERACTION WITH FGF1; FGF7; FGF8; FGF9; FGF10; FGF19; FGF21; FGF22 AND RP FGF23, AND FUNCTION IN STIMULATION OF CELL PROLIFERATION. RX PubMed=16597617; DOI=10.1074/jbc.m601252200; RA Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.; RT "Receptor specificity of the fibroblast growth factor family. The complete RT mammalian FGF family."; RL J. Biol. Chem. 281:15694-15700(2006). RN [32] RP FUNCTION IN PHOSPHORYLATION OF PLCG1 (ISOFORM 1), CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, GLYCOSYLATION, INTERACTION WITH PLCG1, SUBCELLULAR RP LOCATION, MUTAGENESIS OF ASN-265 AND 656-TYR-TYR-657, UBIQUITINATION, AND RP CHARACTERIZATION OF VARIANT PS PHE-278. RX PubMed=16844695; DOI=10.1074/jbc.m600448200; RA Hatch N.E., Hudson M., Seto M.L., Cunningham M.L., Bothwell M.; RT "Intracellular retention, degradation, and signaling of glycosylation- RT deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F."; RL J. Biol. Chem. 281:27292-27305(2006). RN [33] RP INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN PHOSPHORYLATION OF RP FRS2 AND ACTIVATION OF MAP KINASES. RX PubMed=17623664; DOI=10.1074/jbc.m704165200; RA Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., RA Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.; RT "Tissue-specific expression of betaKlotho and fibroblast growth factor RT (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21."; RL J. Biol. Chem. 282:26687-26695(2007). RN [34] RP FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION. RX PubMed=17311277; DOI=10.1002/jcp.21014; RA Citores L., Bai L., Sorensen V., Olsnes S.; RT "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the RT Golgi apparatus without translocation to the nucleus."; RL J. Cell. Physiol. 212:148-156(2007). RN [35] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18374639; DOI=10.1016/j.bone.2008.02.009; RA Dufour C., Guenou H., Kaabeche K., Bouvard D., Sanjay A., Marie P.J.; RT "FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt RT signaling and osteoblast survival."; RL Bone 42:1032-1039(2008). RN [36] RP FUNCTION AS FGF7 RECEPTOR AND IN PHOSPHORYLATION OF PLCG1 AND FRS2, RP CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656 RP AND TYR-657, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=19410646; DOI=10.1016/j.cellsig.2009.04.004; RA Luo Y., Yang C., Jin C., Xie R., Wang F., McKeehan W.L.; RT "Novel phosphotyrosine targets of FGFR2IIIb signaling."; RL Cell. Signal. 21:1370-1378(2009). RN [37] RP FUNCTION IN FIBROBLAST PROLIFERATION; ACTIVATION OF MAP KINASES AND RP PHOSPHORYLATION OF PLCG1 AND FRS2, INTERACTION WITH PLCG1 AND FRS2, RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-769. RX PubMed=19103595; DOI=10.1074/jbc.m803998200; RA Cha J.Y., Maddileti S., Mitin N., Harden T.K., Der C.J.; RT "Aberrant receptor internalization and enhanced FRS2-dependent signaling RT contribute to the transforming activity of the fibroblast growth factor RT receptor 2 IIIb C3 isoform."; RL J. Biol. Chem. 284:6227-6240(2009). RN [38] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [39] RP FUNCTION, AND UBIQUITINATION. RX PubMed=21596750; DOI=10.1074/jbc.m110.197525; RA Severe N., Miraoui H., Marie P.J.; RT "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic RT differentiation in human mesenchymal stromal cells in part by decreased RT Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast RT growth factor receptor 2 ubiquitination."; RL J. Biol. Chem. 286:24443-24450(2011). RN [40] RP REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, AND SIGNALING. RX PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001; RA Eswarakumar V.P., Lax I., Schlessinger J.; RT "Cellular signaling by fibroblast growth factor receptors."; RL Cytokine Growth Factor Rev. 16:139-149(2005). RN [41] RP REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, SIGNALING, AND ROLE IN RP DISEASE. RX PubMed=19387476; DOI=10.1038/jid.2009.97; RA Katoh M.; RT "FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer RT pathologies."; RL J. Invest. Dermatol. 129:1861-1867(2009). RN [42] RP REVIEW ON FUNCTION IN FGF SIGNALING. RX PubMed=20094046; DOI=10.1038/nrc2780; RA Turner N., Grose R.; RT "Fibroblast growth factor signalling: from development to cancer."; RL Nat. Rev. Cancer 10:116-129(2010). RN [43] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [44] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 147-366 IN COMPLEX WITH FGF2. RX PubMed=10830168; DOI=10.1016/s0092-8674(00)80851-x; RA Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.; RT "Crystal structures of two FGF-FGFR complexes reveal the determinants of RT ligand-receptor specificity."; RL Cell 101:413-424(2000). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 148-366 IN COMPLEX WITH FGF1 AND RP HEPARIN, AND INTERACTION WITH FGF1 AND HEPARIN. RX PubMed=11069186; DOI=10.1038/35039551; RA Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L.; RT "Crystal structure of fibroblast growth factor receptor ectodomain bound to RT ligand and heparin."; RL Nature 407:1029-1034(2000). RN [46] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 147-362 IN COMPLEX WITH FGF1. RX PubMed=10618369; DOI=10.1073/pnas.97.1.49; RA Stauber D.J., DiGabriele A.D., Hendrickson W.A.; RT "Structural interactions of fibroblast growth factor receptor with its RT ligands."; RL Proc. Natl. Acad. Sci. U.S.A. 97:49-54(2000). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 147-366 OF VARIANTS APRS TRP-252 RP AND ARG-253 IN COMPLEX WITH FGF2. RX PubMed=11390973; DOI=10.1073/pnas.121183798; RA Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M., RA Mohammadi M.; RT "Structural basis for fibroblast growth factor receptor 2 activation in RT Apert syndrome."; RL Proc. Natl. Acad. Sci. U.S.A. 98:7182-7187(2001). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 140-371 IN COMPLEX WITH FGF10. RX PubMed=12591959; DOI=10.1073/pnas.0436500100; RA Yeh B.K., Igarashi M., Eliseenkova A.V., Plotnikov A.N., Sher I., Ron D., RA Aaronson S.A., Mohammadi M.; RT "Structural basis by which alternative splicing confers specificity in RT fibroblast growth factor receptors."; RL Proc. Natl. Acad. Sci. U.S.A. 100:2266-2271(2003). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 149-368 IN COMPLEX WITH FGF8, RP FUNCTION AS FGF8 RECEPTOR, INTERACTION WITH FGF8, AND DISULFIDE BONDS. RX PubMed=16384934; DOI=10.1101/gad.1365406; RA Olsen S.K., Li J.Y.H., Bromleigh C., Eliseenkova A.V., Ibrahimi O.A., RA Lao Z., Zhang F., Linhardt R.J., Joyner A.L., Mohammadi M.; RT "Structural basis by which alternative splicing modulates the organizer RT activity of FGF8 in the brain."; RL Genes Dev. 20:185-198(2006). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP RP ANALOG; PEPTIDE SUBSTRATE AND MAGNESIUM, ACTIVITY REGULATION, RP PHOSPHORYLATION AT TYR-586; TYR-656 AND TYR-657, MUTAGENESIS OF ASN-549 AND RP GLU-565, CHARACTERIZATION OF VARIANT FSPC GLU-526, CHARACTERIZATION OF RP VARIANT CS HIS-549, CHARACTERIZATION OF VARIANTS PS GLY-565 AND ARG-641, RP AND CHARACTERIZATION OF VARIANT CRANIOSYNOSTOSIS ASN-659. RX PubMed=17803937; DOI=10.1016/j.molcel.2007.06.028; RA Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A., Miller W.T., RA Mohammadi M.; RT "A molecular brake in the kinase hinge region regulates the activity of RT receptor tyrosine kinases."; RL Mol. Cell 27:717-730(2007). RN [51] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-766 OF VARIANT LADD1 THR-628 RP IN COMPLEX WITH ATP ANALOG, CATALYTIC ACTIVITY, SUBUNIT, AND RP AUTOPHOSPHORYLATION. RX PubMed=18056630; DOI=10.1073/pnas.0709905104; RA Lew E.D., Bae J.H., Rohmann E., Wollnik B., Schlessinger J.; RT "Structural basis for reduced FGFR2 activity in LADD syndrome: Implications RT for FGFR autoinhibition and activation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:19802-19807(2007). RN [52] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP, RP ACTIVE SITE, IDENTIFICATION BY MASS SPECTROMETRY, AUTOPHOSPHORYLATION, AND RP PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656; TYR-657 AND TYR-769. RX PubMed=19060208; DOI=10.1073/pnas.0807752105; RA Chen H., Xu C.F., Ma J., Eliseenkova A.V., Li W., Pollock P.M., RA Pitteloud N., Miller W.T., Neubert T.A., Mohammadi M.; RT "A crystallographic snapshot of tyrosine trans-phosphorylation in action."; RL Proc. Natl. Acad. Sci. U.S.A. 105:19660-19665(2008). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 458-768 IN COMPLEX WITH RP INHIBITOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND ACTIVITY RP REGULATION. RX PubMed=21454610; DOI=10.1074/jbc.m110.213736; RA Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J., RA Chen C.R., Chan T.C., France D.S., Ashwell M.A.; RT "A novel mode of protein kinase inhibition exploiting hydrophobic motifs of RT autoinhibited kinases: discovery of ATP-independent inhibitors of RT fibroblast growth factor receptor."; RL J. Biol. Chem. 286:20677-20687(2011). RN [54] RP VARIANTS CS HIS-340; ARG-342; SER-342; TYR-342 AND CYS-354. RX PubMed=7987400; DOI=10.1038/ng0994-98; RA Reardon W., Winter R.M., Rutland P., Pulleyn L.J., Jones B.M., Malcolm S.; RT "Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon RT syndrome."; RL Nat. Genet. 8:98-103(1994). RN [55] RP VARIANTS CS CYS-328 AND CYS-347, AND VARIANT JWS GLY-344. RX PubMed=7874170; DOI=10.1038/ng1194-275; RA Jabs E.W., Li X., Scott A.F., Meyers G.A., Chen W., Eccles M., Mao J., RA Charnas L.R., Jackson C.E., Jaye M.; RT "Jackson-Weiss and Crouzon syndromes are allelic with mutations in RT fibroblast growth factor receptor 2."; RL Nat. Genet. 8:275-279(1994). RN [56] RP VARIANTS CS PRO-267; PHE-278 AND ARG-290. RX PubMed=7655462; DOI=10.1093/hmg/4.6.1077; RA Oldridge M., Wilkie A.O.M., Slaney S.F., Poole M.D., Pulleyn L.J., RA Rutland P., Hockley A.D., Wake M.J.C., Goldin J.H., Winter R.M., RA Reardon W., Malcolm S.; RT "Mutations in the third immunoglobulin domain of the fibroblast growth RT factor receptor-2 gene in Crouzon syndrome."; RL Hum. Mol. Genet. 4:1077-1082(1995). RN [57] RP VARIANTS CS GLY-290; TRP-342 AND CYS-354, AND VARIANT JWS ARG-342. RX PubMed=8528214; DOI=10.1093/hmg/4.7.1229; RA Park W.-J., Meyers G.A., Li X., Theda C., Day D., Orlow S.J., Jones M.C., RA Jabs E.W.; RT "Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic RT heterogeneity and phenotypic variability."; RL Hum. Mol. Genet. 4:1229-1233(1995). RN [58] RP VARIANT PS ALA-321. RX PubMed=7719333; DOI=10.1038/ng0295-108; RA Lajeunie E., Wei M.H., Bonaventure J., Munnich A., le Merrer M., Renier D.; RT "FGFR2 mutations in Pfeiffer syndrome."; RL Nat. Genet. 9:108-108(1995). RN [59] RP VARIANTS APRS TRP-252 AND ARG-253. RX PubMed=7719344; DOI=10.1038/ng0295-165; RA Wilkie A.O.M., Slaney S.F., Oldridge M., Poole M.D., Ashworth G.J., RA Hockley A.D., Hayward R.D., David D.J., Pulleyn L.J., Rutland P., RA Malcolm S., Winter R.M., Reardon W.; RT "Apert syndrome results from localized mutations of FGFR2 and is allelic RT with Crouzon syndrome."; RL Nat. Genet. 9:165-172(1995). RN [60] RP VARIANTS PS PRO-341; ARG-342 AND TYR-342. RX PubMed=7719345; DOI=10.1038/ng0295-173; RA Rutland P., Pulleyn L.J., Reardon W., Baraister M., Hayward R., Jones B.M., RA Malcolm S., Winter R.M., Oldridge M., Slaney S.F., Poole M.D., RA Wilkie A.O.M.; RT "Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon RT syndrome phenotypes."; RL Nat. Genet. 9:173-176(1995). RN [61] RP VARIANTS CS GLY-268 INS; PHE-342 AND TYR-342, VARIANTS PS PHE-278; ARG-342; RP SER-342; PRO-344 AND PHE-359, AND VARIANT JWS PRO-289. RX PubMed=8644708; RA Meyers G.A., Day D., Goldberg R., Daentl D.L., Przylepa K.A., Abrams L.J., RA Graham J.M. Jr., Feingold M., Moeschler J.B., Rawnsley E., Scott A.F., RA Jabs E.W.; RT "FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer RT syndromes: evidence for missense changes, insertions, and a deletion due to RT alternative RNA splicing."; RL Am. J. Hum. Genet. 58:491-498(1996). RN [62] RP VARIANTS CS CYS-105; GLU-338; CYS-351 AND ARG-384. RX PubMed=8946174; DOI=10.1159/000472215; RA Pulleyn L.J., Reardon W., Wilkes D., Rutland P., Jones B.M., Hayward R., RA Hall C.M., Brueton L., Chun N., Lammer E., Malcolm S., Winter R.M.; RT "Spectrum of craniosynostosis phenotypes associated with novel mutations at RT the fibroblast growth factor receptor 2 locus."; RL Eur. J. Hum. Genet. 4:283-291(1996). RN [63] RP VARIANTS CS ILE-331; ASN-ALA-337 INS AND 356-TRP--THR-358 DEL. RX PubMed=8956050; RX DOI=10.1002/(sici)1098-1004(1996)8:4<386::aid-humu18>3.0.co;2-z; RA Steinberger D., Mulliken J.B., Mueller U.; RT "Crouzon syndrome: previously unrecognized deletion, duplication, and point RT mutation within FGFR2 gene."; RL Hum. Mutat. 8:386-390(1996). RN [64] RP VARIANTS BSTVS CYS-372 AND CYS-375. RX PubMed=8696350; DOI=10.1038/ng0896-492; RA Przylepa K.A., Paznekas W.A., Zhang M., Golabi M., Bias W., Bamshad M.J., RA Carey J.C., Hall B.D., Stevenson R., Orlow S.J., Cohen M.M. Jr., Jabs E.W.; RT "Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis RT gyrata syndrome."; RL Nat. Genet. 13:492-494(1996). RN [65] RP VARIANT PS CYS-290. RX PubMed=9150725; DOI=10.1007/s004390050413; RA Tartaglia M., Valeri S., Velardi F., di Rocco C., Battaglia P.A.; RT "Trp290Cys mutation in exon IIIa of the fibroblast growth factor receptor 2 RT (FGFR2) gene is associated with Pfeiffer syndrome."; RL Hum. Genet. 99:602-606(1997). RN [66] RP VARIANT JWS SER-342. RX PubMed=9385368; DOI=10.1007/s004390050584; RA Tartaglia M., Di Rocco C., Lajeunie E., Valeri S., Velardi F., RA Battaglia P.A.; RT "Jackson-Weiss syndrome: identification of two novel FGFR2 missense RT mutations shared with Crouzon and Pfeiffer craniosynostotic disorders."; RL Hum. Genet. 101:47-50(1997). RN [67] RP VARIANT LEU-252, VARIANT APRS PHE-252, AND VARIANT PS 252-SER-PRO-253 RP DELINS PHE-SER. RX PubMed=9002682; DOI=10.1093/hmg/6.1.137; RA Oldridge M., Lunt P.W., Zackai E.H., McDonald-Mcginn D.M., Muenke M., RA Moloney D.M., Twigg S.R.F., Heath J.K., Howard T.D., Hoganson G., RA Gagnon D.M., Jabs E.W., Wilkie A.O.M.; RT "Genotype-phenotype correlation for nucleotide substitutions in the IgII- RT IgIII linker of FGFR2."; RL Hum. Mol. Genet. 6:137-143(1997). RN [68] RP VARIANT CS GLU-292. RX PubMed=9152842; DOI=10.1136/jmg.34.5.420; RA Steinberger D., Collmann H., Schmalenberger B., Mueller U.; RT "A novel mutation (a886g) in exon 5 of FGFR2 in members of a family with RT Crouzon phenotype and plagiocephaly."; RL J. Med. Genet. 34:420-422(1997). RN [69] RP VARIANTS CS PHE-278; PRO-337; ARG-338; ARG-342; PHE-342 AND TYR-342, RP VARIANTS APRS TRP-252 AND ARG-253, AND VARIANT JWS PHE-278. RX PubMed=9677057; RX DOI=10.1002/(sici)1096-8628(19980707)78:3<237::aid-ajmg5>3.3.co;2-5; RA Passos-Bueno M.R., Sertie A.L., Richieri-Costa A., Alonso L.G., Zatz M., RA Alonso N., Brunoni D., Ribeiro S.F.M.; RT "Description of a new mutation and characterization of FGFR1, FGFR2, and RT FGFR3 mutations among Brazilian patients with syndromic craniosynostoses."; RL Am. J. Med. Genet. 78:237-241(1998). RN [70] RP VARIANTS CS VAL-276 AND CYS-301, AND VARIANT CRANIOSYNOSTOSIS SER-314. RX PubMed=9521581; DOI=10.1007/s004390050668; RA Steinberger D., Vriend G., Mulliken J.B., Mueller U.; RT "The mutations in FGFR2-associated craniosynostoses are clustered in five RT structural elements of immunoglobulin-like domain III of the receptor."; RL Hum. Genet. 102:145-150(1998). RN [71] RP VARIANTS APRS TRP-252 AND ARG-253. RX PubMed=9452027; DOI=10.1002/humu.1380110106; RA Tsai F.-J., Hwu W.-L., Lin S.-P., Chang J.-G., Wang T.-R., Tsai C.-H.; RT "Two common mutations 934C to G and 937C to G of fibroblast growth factor RT receptor 2 (FGFR2) gene in Chinese patients with Apert syndrome."; RL Hum. Mutat. Suppl. 1:S18-S19(1998). RN [72] RP VARIANT PS CYS-351. RX PubMed=9693549; DOI=10.1097/00001665-199805000-00004; RA Mathijssen I.M., Vaandrager J.M., Hoogeboom A.J., Hesseling-Janssen A.L.W., RA van den Ouweland A.M.W.; RT "Pfeiffer's syndrome resulting from an S351C mutation in the fibroblast RT growth factor receptor-2 gene."; RL J. Craniofac. Surg. 9:207-209(1998). RN [73] RP VARIANT PS TRP-252. RX PubMed=9719378; DOI=10.1136/jmg.35.8.677; RA Passos-Bueno M.R., Richieri-Costa A., Sertie A.L., Kneppers A.; RT "Presence of the Apert canonical S252W FGFR2 mutation in a patient without RT severe syndactyly."; RL J. Med. Genet. 35:677-679(1998). RN [74] RP VARIANT CS SER-362. RX PubMed=10574673; DOI=10.1597/1545-1569_1999_036_0533_anfgmi_2.3.co_2; RA Everett E.T., Britto D.A., Ward R.E., Hartsfield J.K. Jr.; RT "A novel FGFR2 gene mutation in Crouzon syndrome associated with apparent RT nonpenetrance."; RL Cleft Palate Craniofac. J. 36:533-541(1999). RN [75] RP VARIANTS PS CYS-340 AND GLY-342. RX PubMed=10394936; DOI=10.1007/s004390050979; RA Cornejo-Roldan L.R., Roessler E., Muenke M.; RT "Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer RT syndrome."; RL Hum. Genet. 104:425-431(1999). RN [76] RP VARIANT PS ASP-273 DEL. RX PubMed=10945669; DOI=10.1034/j.1399-0004.2000.580116.x; RA Priolo M., Lerone M., Baffico M., Baldi M., Ravazzolo R., Cama A., RA Capra V., Silengo M.; RT "Pfeiffer syndrome type 2 associated with a single amino acid deletion in RT the FGFR2 gene."; RL Clin. Genet. 58:81-83(2000). RN [77] RP VARIANTS CS/PS ARG-342 AND TYR-342, VARIANTS CS LEU-263; VAL-276; PHE-278; RP TYR-278; SER-288; PRO-289; PRO-341; TRP-342; CYS-354; TYR-354 AND PHE-359, RP AND VARIANT PS SER-342. RX PubMed=11173845; DOI=10.1159/000056833; RA Kress W., Collmann H., Buesse M., Halliger-Keller B., Mueller C.R.; RT "Clustering of FGFR2 gene mutations in patients with Pfeiffer and Crouzon RT syndromes (FGFR2-associated craniosynostoses)."; RL Cytogenet. Cell Genet. 91:134-137(2000). RN [78] RP VARIANT SER-315. RX PubMed=10951518; DOI=10.1038/sj.ejhg.5200499; RA Johnson D., Wall S.A., Mann S., Wilkie A.O.M.; RT "A novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction RT leading to craniosynostosis?"; RL Eur. J. Hum. Genet. 8:571-577(2000). RN [79] RP VARIANTS ABS2 ARG-342; SER-342 AND CYS-351. RX PubMed=10633130; DOI=10.1136/jmg.37.1.26; RA Reardon W., Smith A., Honour J.W., Hindmarsh P., Das D., Rumsby G., RA Nelson I., Malcolm S., Ades L., Sillence D., Kumar D., RA DeLozier-Blanchet C., McKee S., Kelly T., McKeehan W.L., Baraitser M., RA Winter R.M.; RT "Evidence for digenic inheritance in some cases of Antley-Bixler RT syndrome?"; RL J. Med. Genet. 37:26-32(2000). RN [80] RP VARIANTS CS CYS-281; PRO-289; ARG-342 AND TYR-342. RX PubMed=11380921; DOI=10.1046/j.1442-200x.2001.01392.x; RA Tsai F.-J., Yang C.-F., Wu J.-Y., Tsai C.-H., Lee C.-C.; RT "Mutation analysis of Crouzon syndrome and identification of one novel RT mutation in Taiwanese patients."; RL Pediatr. Int. 43:263-266(2001). RN [81] RP VARIANTS CS CYS-105; PRO-267; VAL-276; CYS-281; PRO-289; ARG-338; HIS-340; RP PHE-342; TRP-342; CYS-347; CYS-354; HIS-549 AND GLY-678, VARIANTS PS RP PHE-172; 252-SER-PRO-253 DELINS PHE-SER; CYS-290; CYS-340; PRO-341; RP ARG-342; SER-342; CYS-375; GLY-565; ARG-641 AND GLU-663, VARIANTS APRS RP TRP-252 AND ARG-253, VARIANTS CS/PS PHE-278 AND TYR-342, VARIANT RP CRANIOSYNOSTOSIS ASN-659, AND VARIANTS THR-186 AND SER-315. RX PubMed=11781872; DOI=10.1086/338758; RA Kan S.-H., Elanko N., Johnson D., Cornejo-Roldan L.R., Cook J., Reich E.W., RA Tomkins S., Verloes A., Twigg S.R.F., Rannan-Eliya S., RA McDonald-McGinn D.M., Zackai E.H., Wall S.A., Muenke M., Wilkie A.O.M.; RT "Genomic screening of fibroblast growth-factor receptor 2 reveals a wide RT spectrum of mutations in patients with syndromic craniosynostosis."; RL Am. J. Hum. Genet. 70:472-486(2002). RN [82] RP VARIANT BSTVS CYS-375. RX PubMed=12000365; DOI=10.1034/j.1399-0004.2002.610309.x; RA Wang T.-J., Huang C.-B., Tsai F.-J., Wu J.-Y., Lai R.-B., Hsiao M.; RT "Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson RT cutis gyrata syndrome."; RL Clin. Genet. 61:218-221(2002). RN [83] RP VARIANT FSPC GLU-526. RX PubMed=16061565; DOI=10.1136/jmg.2004.027888; RA McGillivray G., Savarirayan R., Cox T.C., Stojkoski C., McNeil R., RA Bankier A., Bateman J.F., Roscioli T., Gardner R.J.M., Lamande S.R.; RT "Familial scaphocephaly syndrome caused by a novel mutation in the FGFR2 RT tyrosine kinase domain."; RL J. Med. Genet. 42:656-662(2005). RN [84] RP VARIANTS LADD1 THR-628; THR-648 AND 649-ARG-ASP-650 DELINS SER. RX PubMed=16501574; DOI=10.1038/ng1757; RA Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G., Lew E.D., RA Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., RA Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J., Yueksel-Apak M., RA Nuernberg P., Kubisch C., Schlessinger J., van Bokhoven H., Wollnik B.; RT "Mutations in different components of FGF signaling in LADD syndrome."; RL Nat. Genet. 38:414-417(2006). RN [85] RP VARIANT [LARGE SCALE ANALYSIS] CYS-203. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [86] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-57; THR-186; CYS-203; VAL-272; ASN-283; RP CYS-290 AND THR-612. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [87] RP VARIANTS BBDS1 ASP-381 AND ARG-391, AND CHARACTERIZATION OF VARIANT BBDS1 RP ARG-391. RX PubMed=22387015; DOI=10.1016/j.ajhg.2012.02.005; RA Merrill A.E., Sarukhanov A., Krejci P., Idoni B., Camacho N., Estrada K.D., RA Lyons K.M., Deixler H., Robinson H., Chitayat D., Curry C.J., Lachman R.S., RA Wilcox W.R., Krakow D.; RT "Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has RT deficient canonical FGF signaling."; RL Am. J. Hum. Genet. 90:550-557(2012). RN [88] RP VARIANT LEU-57. RX PubMed=26429889; DOI=10.1136/jmedgenet-2015-103336; RA Perles Z., Moon S., Ta-Shma A., Yaacov B., Francescatto L., Edvardson S., RA Rein A.J., Elpeleg O., Katsanis N.; RT "A human laterality disorder caused by a homozygous deleterious mutation in RT MMP21."; RL J. Med. Genet. 52:840-847(2015). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for fibroblast growth factors and plays an essential role in the CC regulation of cell proliferation, differentiation, migration and CC apoptosis, and in the regulation of embryonic development. Required for CC normal embryonic patterning, trophoblast function, limb bud CC development, lung morphogenesis, osteogenesis and skin development. CC Plays an essential role in the regulation of osteoblast CC differentiation, proliferation and apoptosis, and is required for CC normal skeleton development. Promotes cell proliferation in CC keratinocytes and immature osteoblasts, but promotes apoptosis in CC differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand CC binding leads to the activation of several signaling cascades. CC Activation of PLCG1 leads to the production of the cellular signaling CC molecules diacylglycerol and inositol 1,4,5-trisphosphate. CC Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and CC SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the CC MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. CC FGFR2 signaling is down-regulated by ubiquitination, internalization CC and degradation. Mutations that lead to constitutive kinase activation CC or impair normal FGFR2 maturation, internalization and degradation lead CC to aberrant signaling. Over-expressed FGFR2 promotes activation of CC STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, CC ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, CC ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, CC ECO:0000269|PubMed:8663044}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, CC ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Ligand binding leads to dimerization and activation by CC autophosphorylation on tyrosine residues. Inhibited by ARQ 523 and ARQ CC 069; these compounds maintain the kinase in an inactive conformation CC and inhibit autophosphorylation. {ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:21454610}. CC -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts CC predominantly with FGF1 and FGF2, but can also interact with FGF3, CC FGF4, FGF6, FGF7, FGF8, FGF9, FGF10, FGF17, FGF18 and FGF22 (in vitro). CC Ligand specificity is determined by tissue-specific expression of CC isoforms, and differences in the third Ig-like domain are crucial for CC ligand specificity. Isoform 1 has high affinity for FGF1 and FGF2, but CC low affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7, CC and has much higher affinity for FGF7 than isoform 1 (in vitro). CC Affinity for fibroblast growth factors (FGFs) is increased by heparan CC sulfate glycosaminoglycans that function as coreceptors. Likewise, KLB CC increases the affinity for FGF19 and FGF21. Interacts with PLCG1, GRB2 CC and PAK4. Interacts with FLRT2 (By similarity). CC {ECO:0000250|UniProtKB:P21803, ECO:0000269|PubMed:10618369, CC ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11069186, CC ECO:0000269|PubMed:11390973, ECO:0000269|PubMed:12529371, CC ECO:0000269|PubMed:12591959, ECO:0000269|PubMed:1309608, CC ECO:0000269|PubMed:1400433, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:16844695, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19060208, CC ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:21454610, CC ECO:0000269|PubMed:8663044, ECO:0000269|PubMed:8961926}. CC -!- INTERACTION: CC P21802; P06734: FCER2; NbExp=2; IntAct=EBI-1028658, EBI-10199985; CC P21802; P05230: FGF1; NbExp=3; IntAct=EBI-1028658, EBI-698068; CC P21802; PRO_0000008908 [P05230]: FGF1; NbExp=5; IntAct=EBI-1028658, EBI-6880860; CC P21802; O15520: FGF10; NbExp=2; IntAct=EBI-1028658, EBI-1035684; CC P21802; P09038: FGF2; NbExp=5; IntAct=EBI-1028658, EBI-977447; CC P21802; P09038-2: FGF2; NbExp=2; IntAct=EBI-1028658, EBI-11122080; CC P21802; P11362: FGFR1; NbExp=3; IntAct=EBI-1028658, EBI-1028277; CC P21802; P62993: GRB2; NbExp=6; IntAct=EBI-1028658, EBI-401755; CC P21802; P03968: FGF1; Xeno; NbExp=2; IntAct=EBI-1028658, EBI-6358090; CC P21802-1; P05230-1: FGF1; NbExp=2; IntAct=EBI-15489960, EBI-15489950; CC P21802-1; P09038: FGF2; NbExp=2; IntAct=EBI-15489960, EBI-977447; CC P21802-1; P21802-1: FGFR2; NbExp=3; IntAct=EBI-15489960, EBI-15489960; CC P21802-1; P19174: PLCG1; NbExp=9; IntAct=EBI-15489960, EBI-79387; CC P21802-3; P21781: FGF7; NbExp=2; IntAct=EBI-6354683, EBI-3937699; CC P21802-3; P03968: FGF1; Xeno; NbExp=2; IntAct=EBI-6354683, EBI-6358090; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Golgi apparatus. Cytoplasmic vesicle. Note=Detected on CC osteoblast plasma membrane lipid rafts. After ligand binding, the CC activated receptor is rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I CC membrane protein. Note=After ligand binding, the activated receptor is CC rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane; Single-pass type I CC membrane protein. Note=After ligand binding, the activated receptor is CC rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 13]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=17; CC Name=1; Synonyms=BEK, FGFR2IIIc; CC IsoId=P21802-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=P21802-2; Sequence=VSP_002978; CC Name=3; Synonyms=BFR-1, FGFR2IIIb, KGFR; CC IsoId=P21802-3; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972; CC Name=4; Synonyms=K-sam; CC IsoId=P21802-4; Sequence=VSP_002964, VSP_002969, VSP_002970, CC VSP_002971, VSP_002972, VSP_002975, CC VSP_002976; CC Name=5; Synonyms=K-sam-I, BEK, IgIIIc; CC IsoId=P21802-5; Sequence=VSP_002975; CC Name=6; Synonyms=K-sam-IIC2; CC IsoId=P21802-6; Sequence=VSP_002975, VSP_002984; CC Name=7; Synonyms=K-sam-IIC3; CC IsoId=P21802-8; Sequence=VSP_002975, VSP_002978; CC Name=8; Synonyms=K-sam-IV, Soluble KGFR; CC IsoId=P21802-14; Sequence=VSP_002965, VSP_002966; CC Name=9; Synonyms=K-sam-III; CC IsoId=P21802-15; Sequence=VSP_002968; CC Name=10; Synonyms=TK14; CC IsoId=P21802-16; Sequence=VSP_002967, VSP_002975; CC Name=11; CC IsoId=P21802-17; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002978; CC Name=12; Synonyms=K-sam-IIC1, KGFR, IgIIIb; CC IsoId=P21802-18; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002975; CC Name=13; Synonyms=Soluble KGFR; CC IsoId=P21802-19; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002973, VSP_002974; CC Name=14; CC IsoId=P21802-20; Sequence=VSP_019608, VSP_019609; CC Name=15; CC IsoId=P21802-21; Sequence=VSP_002964, VSP_041915; CC Name=16; CC IsoId=P21802-22; Sequence=VSP_002964, VSP_002969, VSP_002970, CC VSP_002971, VSP_002972, VSP_002978; CC Name=17; CC IsoId=P21802-23; Sequence=VSP_041914; CC -!- DOMAIN: The second and third Ig-like domains directly interact with CC fibroblast growth factors (FGF) and heparan sulfate proteoglycans. CC Alternative splicing events affecting the third Ig-like domain are CC crucial for ligand selectivity. {ECO:0000269|PubMed:1309608, CC ECO:0000269|PubMed:1400433, ECO:0000269|PubMed:8961926}. CC -!- PTM: Autophosphorylated. Binding of FGF family members together with CC heparan sulfate proteoglycan or heparin promotes receptor dimerization CC and autophosphorylation on several tyrosine residues. CC Autophosphorylation occurs in trans between the two FGFR molecules CC present in the dimer. Phosphorylation at Tyr-769 is essential for CC interaction with PLCG1. {ECO:0000269|PubMed:15629145, CC ECO:0000269|PubMed:19060208}. CC -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan chains CC undergo further maturation to an Endo H-resistant form in the Golgi CC apparatus. {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17311277}. CC -!- PTM: Ubiquitinated. FGFR2 is rapidly ubiquitinated after CC autophosphorylation, leading to internalization and degradation. CC Subject to degradation both in lysosomes and by the proteasome. CC {ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:16844695, CC ECO:0000269|PubMed:21596750}. CC -!- DISEASE: Crouzon syndrome (CS) [MIM:123500]: An autosomal dominant CC syndrome characterized by craniosynostosis, hypertelorism, exophthalmos CC and external strabismus, parrot-beaked nose, short upper lip, CC hypoplastic maxilla, and a relative mandibular prognathism. CC {ECO:0000269|PubMed:10574673, ECO:0000269|PubMed:11173845, CC ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, CC ECO:0000269|PubMed:17803937, ECO:0000269|PubMed:7581378, CC ECO:0000269|PubMed:7655462, ECO:0000269|PubMed:7874170, CC ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:8946174, CC ECO:0000269|PubMed:8956050, ECO:0000269|PubMed:9152842, CC ECO:0000269|PubMed:9521581, ECO:0000269|PubMed:9677057, CC ECO:0000269|Ref.10}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Jackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal CC dominant craniosynostosis syndrome characterized by craniofacial CC abnormalities and abnormality of the feet: broad great toes with medial CC deviation and tarsal-metatarsal coalescence. CC {ECO:0000269|PubMed:7874170, ECO:0000269|PubMed:8528214, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368, CC ECO:0000269|PubMed:9677057}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Apert syndrome (APRS) [MIM:101200]: A syndrome characterized CC by facio-cranio-synostosis, osseous and membranous syndactyly of the CC four extremities, and midface hypoplasia. The craniosynostosis is CC bicoronal and results in acrocephaly of brachysphenocephalic type. CC Syndactyly of the fingers and toes may be total (mitten hands and sock CC feet) or partial affecting the second, third, and fourth digits. CC Intellectual deficit is frequent and often severe, usually being CC associated with cerebral malformations. {ECO:0000269|PubMed:11390973, CC ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, CC ECO:0000269|PubMed:9002682, ECO:0000269|PubMed:9452027, CC ECO:0000269|PubMed:9677057}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Pfeiffer syndrome (PS) [MIM:101600]: A syndrome characterized CC by the association of craniosynostosis, broad and deviated thumbs and CC big toes, and partial syndactyly of the fingers and toes. Three CC subtypes are known: mild autosomal dominant form (type 1); cloverleaf CC skull, elbow ankylosis, early death, sporadic (type 2); CC craniosynostosis, early demise, sporadic (type 3). CC {ECO:0000269|PubMed:10394936, ECO:0000269|PubMed:10945669, CC ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, CC ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:7719333, ECO:0000269|PubMed:7719345, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9002682, CC ECO:0000269|PubMed:9150725, ECO:0000269|PubMed:9693549, CC ECO:0000269|PubMed:9719378}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Beare-Stevenson cutis gyrata syndrome (BSTVS) [MIM:123790]: An CC autosomal dominant disease characterized by craniofacial anomalies, CC particularly craniosynostosis, and ear defects, cutis gyrata, CC acanthosis nigricans, anogenital anomalies, skin tags, and prominent CC umbilical stump. The skin furrows have a corrugated appearance and are CC widespread. Cutis gyrata variably affects the scalp, forehead, face, CC preauricular area, neck, trunk, hands, and feet. CC {ECO:0000269|PubMed:12000365, ECO:0000269|PubMed:8696350}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Familial scaphocephaly syndrome (FSPC) [MIM:609579]: An CC autosomal dominant craniosynostosis syndrome characterized by CC scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and CC mild intellectual disability. Scaphocephaly is the most common of the CC craniosynostosis conditions and is characterized by a long, narrow CC head. It is due to premature fusion of the sagittal suture or from CC external deformation. {ECO:0000269|PubMed:16061565, CC ECO:0000269|PubMed:17803937}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome 1 (LADD1) CC [MIM:149730]: A form of lacrimo-auriculo-dento-digital syndrome, an CC autosomal dominant disease characterized by aplastic/hypoplastic CC lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, CC hypodontia and enamel hypoplasia, and distal limb segments anomalies. CC In addition to these cardinal features, facial dysmorphism, CC malformations of the kidney and respiratory system and abnormal CC genitalia have been reported. Craniosynostosis and severe syndactyly CC are not observed. {ECO:0000269|PubMed:16501574, CC ECO:0000269|PubMed:18056630}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Antley-Bixler syndrome, without genital anomalies or CC disordered steroidogenesis (ABS2) [MIM:207410]: A rare syndrome CC characterized by craniosynostosis, radiohumeral synostosis present from CC the perinatal period, midface hypoplasia, choanal stenosis or atresia, CC femoral bowing and multiple joint contractures. Arachnodactyly and/or CC camptodactyly have also been reported. {ECO:0000269|PubMed:10633130}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Bent bone dysplasia syndrome 1 (BBDS1) [MIM:614592]: A CC perinatal lethal skeletal dysplasia characterized by poor CC mineralization of the calvarium, craniosynostosis, dysmorphic facial CC features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, CC and bent long bones. Dysmorphic facial features included low-set ears, CC hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and CC micrognathia. {ECO:0000269|PubMed:22387015}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Saethre-Chotzen syndrome (SCS) [MIM:101400]: A CC craniosynostosis syndrome characterized by coronal synostosis, CC brachycephaly, low frontal hairline, facial asymmetry, hypertelorism, CC broad halluces, and clinodactyly. {ECO:0000269|PubMed:9585583}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Fibroblast growth factor receptor subfamily. CC {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA89296.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89297.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89298.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89299.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89300.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89301.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAG57383.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40570/FGFR2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X52832; CAA37014.1; -; mRNA. DR EMBL; M55614; AAA61188.1; -; mRNA. DR EMBL; X56191; CAA39654.1; -; mRNA. DR EMBL; M35718; AAA36152.1; -; mRNA. DR EMBL; M87770; AAA59470.1; -; mRNA. DR EMBL; M87771; AAA59471.1; -; mRNA. DR EMBL; M87772; AAA59472.1; -; mRNA. DR EMBL; M97193; AAA52449.1; -; mRNA. DR EMBL; U11814; AAA68514.1; -; mRNA. DR EMBL; M80634; AAA36147.1; -; mRNA. DR EMBL; Z71929; CAA96492.1; -; mRNA. DR EMBL; AB030073; BAA89296.1; ALT_SEQ; mRNA. DR EMBL; AB030074; BAA89297.1; ALT_SEQ; mRNA. DR EMBL; AB030075; BAA89298.1; ALT_SEQ; mRNA. DR EMBL; AB030076; BAA89299.1; ALT_SEQ; mRNA. DR EMBL; AB030077; BAA89300.1; ALT_SEQ; mRNA. DR EMBL; AB030078; BAA89301.1; ALT_SEQ; mRNA. DR EMBL; AF360695; AAK94205.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94205.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94206.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94206.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94207.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94207.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94208.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94208.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94209.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94209.1; JOINED; Genomic_DNA. DR EMBL; AF487553; AAM74056.1; -; Genomic_DNA. DR EMBL; AB084153; BAC45037.1; -; mRNA. DR EMBL; DQ493927; ABE96832.1; -; Genomic_DNA. DR EMBL; AK294026; BAG57383.1; ALT_INIT; mRNA. DR EMBL; AC009988; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC039243; AAH39243.2; -; mRNA. DR EMBL; AF169399; AAF43273.1; -; Genomic_DNA. DR EMBL; AF169399; AAF43274.1; -; Genomic_DNA. DR EMBL; AF097353; AAD31560.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097342; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097343; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097345; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097346; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097347; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097348; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097349; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097350; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097351; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097352; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097353; AAD31561.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097342; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097344; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097345; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097346; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097347; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097348; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097349; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097350; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097351; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097352; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097340; AAD31562.1; -; Genomic_DNA. DR EMBL; AF097337; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097338; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097339; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097354; AAD31565.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31567.1; -; Genomic_DNA. DR EMBL; S82438; AAD14392.1; -; Genomic_DNA. DR EMBL; Y17131; CAA76643.1; -; Genomic_DNA. DR EMBL; L49237; AAC41933.1; -; Genomic_DNA. DR EMBL; L49242; AAC41934.1; -; Genomic_DNA. DR EMBL; L49238; AAC41935.1; -; Genomic_DNA. DR EMBL; L49239; AAC41936.1; -; Genomic_DNA. DR EMBL; L49240; AAC41937.1; -; Genomic_DNA. DR EMBL; L49241; AAC41938.1; -; Genomic_DNA. DR CCDS; CCDS31298.1; -. [P21802-1] DR CCDS; CCDS44485.1; -. [P21802-20] DR CCDS; CCDS44486.1; -. [P21802-23] DR CCDS; CCDS44487.1; -. [P21802-15] DR CCDS; CCDS44488.1; -. [P21802-22] DR CCDS; CCDS44489.1; -. [P21802-17] DR CCDS; CCDS53584.1; -. [P21802-21] DR CCDS; CCDS7620.2; -. [P21802-3] DR CCDS; CCDS81515.1; -. [P21802-5] DR PIR; A35969; A35969. DR PIR; A42691; TVHUF2. DR PIR; A45081; A45081. DR PIR; C42691; C42691. DR PIR; S16236; S16236. DR RefSeq; NP_000132.3; NM_000141.5. [P21802-1] DR RefSeq; NP_001138385.1; NM_001144913.1. [P21802-17] DR RefSeq; NP_001138386.1; NM_001144914.1. [P21802-23] DR RefSeq; NP_001138387.1; NM_001144915.2. [P21802-21] DR RefSeq; NP_001138388.1; NM_001144916.1. DR RefSeq; NP_001138389.1; NM_001144917.2. [P21802-15] DR RefSeq; NP_001138390.1; NM_001144918.2. [P21802-20] DR RefSeq; NP_001138391.1; NM_001144919.2. [P21802-22] DR RefSeq; NP_001307583.1; NM_001320654.1. DR RefSeq; NP_001307587.1; NM_001320658.2. [P21802-5] DR RefSeq; NP_001428016.1; NM_001441087.1. [P21802-18] DR RefSeq; NP_075259.4; NM_022970.4. [P21802-3] DR RefSeq; NP_075418.1; NM_023029.2. DR PDB; 1DJS; X-ray; 2.40 A; A=153-362. DR PDB; 1E0O; X-ray; 2.80 A; B/D=148-366. DR PDB; 1EV2; X-ray; 2.20 A; E/F/G/H=147-366. DR PDB; 1GJO; X-ray; 2.40 A; A=456-768. DR PDB; 1II4; X-ray; 2.70 A; E/F/G/H=147-366. DR PDB; 1IIL; X-ray; 2.30 A; E/F/G/H=147-366. DR PDB; 1NUN; X-ray; 2.90 A; B=140-368. DR PDB; 1OEC; X-ray; 2.40 A; A=456-768. DR PDB; 1WVZ; NMR; -; A=147-249. DR PDB; 2FDB; X-ray; 2.28 A; P/R=149-368. DR PDB; 2PSQ; X-ray; 2.40 A; A/B=413-768. DR PDB; 2PVF; X-ray; 1.80 A; A=458-778, B=764-778. DR PDB; 2PVY; X-ray; 2.20 A; A/B/C/D=458-768. DR PDB; 2PWL; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PY3; X-ray; 2.30 A; A/B=458-768. DR PDB; 2PZ5; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PZP; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PZR; X-ray; 3.00 A; A/B=458-768. DR PDB; 2Q0B; X-ray; 2.90 A; A/B=458-768. DR PDB; 3B2T; X-ray; 1.80 A; A/B=458-766. DR PDB; 3CAF; X-ray; 1.96 A; A=150-249. DR PDB; 3CLY; X-ray; 2.00 A; A=458-778. DR PDB; 3CU1; X-ray; 2.60 A; A/C=150-249. DR PDB; 3DAR; X-ray; 2.20 A; A/B=146-249. DR PDB; 3EUU; X-ray; 2.34 A; A/B=150-249. DR PDB; 3OJ2; X-ray; 2.20 A; C/D=140-313. DR PDB; 3OJM; X-ray; 2.10 A; B=140-313. DR PDB; 3RI1; X-ray; 2.10 A; A/B=458-768. DR PDB; 4J23; X-ray; 3.88 A; A=147-366. DR PDB; 4J95; X-ray; 2.38 A; A/B/C/D=458-768. DR PDB; 4J96; X-ray; 2.30 A; A/B=458-768. DR PDB; 4J97; X-ray; 2.55 A; A/B/C/D=458-768. DR PDB; 4J98; X-ray; 2.31 A; A/B=458-768. DR PDB; 4J99; X-ray; 1.85 A; A/B/C/D=458-768. DR PDB; 4WV1; X-ray; 2.36 A; C/F=153-251. DR PDB; 5EG3; X-ray; 2.61 A; A=458-778. DR PDB; 5UGL; X-ray; 1.86 A; A/B=458-768. DR PDB; 5UGX; X-ray; 2.35 A; A/B=458-768. DR PDB; 5UHN; X-ray; 2.91 A; A/B=458-768. DR PDB; 5UI0; X-ray; 2.05 A; A/B=458-768. DR PDB; 6AGX; X-ray; 2.95 A; A/B/C/D=467-764. DR PDB; 6LVK; X-ray; 2.29 A; A/B=459-768. DR PDB; 6LVL; X-ray; 2.98 A; A/B=459-768. DR PDB; 6V6Q; X-ray; 2.46 A; A/B/C/D=413-821. DR PDB; 7KIA; X-ray; 2.22 A; A/B=461-768. DR PDB; 7KIE; X-ray; 2.47 A; A/B=461-768. DR PDB; 7OZY; X-ray; 2.28 A; AAA/BBB=465-763. DR PDB; 8E1X; X-ray; 2.68 A; A/B=459-768. DR PDB; 8H75; X-ray; 3.75 A; A/B/C/D=459-768. DR PDB; 8STG; X-ray; 3.79 A; A/B=458-769. DR PDB; 8SWE; X-ray; 2.24 A; A/B=458-768. DR PDB; 8U1F; X-ray; 3.33 A; A/B=458-768. DR PDB; 8W2X; X-ray; 2.98 A; A/B=458-768. DR PDB; 8W38; X-ray; 2.60 A; A/B/C/D=458-768. DR PDB; 8W3B; X-ray; 2.23 A; A/B/C/D=458-768. DR PDB; 8W3D; X-ray; 2.04 A; A/B/C/D=458-768. DR PDB; 9U3N; X-ray; 3.25 A; A/B=458-768. DR PDBsum; 1DJS; -. DR PDBsum; 1E0O; -. DR PDBsum; 1EV2; -. DR PDBsum; 1GJO; -. DR PDBsum; 1II4; -. DR PDBsum; 1IIL; -. DR PDBsum; 1NUN; -. DR PDBsum; 1OEC; -. DR PDBsum; 1WVZ; -. DR PDBsum; 2FDB; -. DR PDBsum; 2PSQ; -. DR PDBsum; 2PVF; -. DR PDBsum; 2PVY; -. DR PDBsum; 2PWL; -. DR PDBsum; 2PY3; -. DR PDBsum; 2PZ5; -. DR PDBsum; 2PZP; -. DR PDBsum; 2PZR; -. DR PDBsum; 2Q0B; -. DR PDBsum; 3B2T; -. DR PDBsum; 3CAF; -. DR PDBsum; 3CLY; -. DR PDBsum; 3CU1; -. DR PDBsum; 3DAR; -. DR PDBsum; 3EUU; -. DR PDBsum; 3OJ2; -. DR PDBsum; 3OJM; -. DR PDBsum; 3RI1; -. DR PDBsum; 4J23; -. DR PDBsum; 4J95; -. DR PDBsum; 4J96; -. DR PDBsum; 4J97; -. DR PDBsum; 4J98; -. DR PDBsum; 4J99; -. DR PDBsum; 4WV1; -. DR PDBsum; 5EG3; -. DR PDBsum; 5UGL; -. DR PDBsum; 5UGX; -. DR PDBsum; 5UHN; -. DR PDBsum; 5UI0; -. DR PDBsum; 6AGX; -. DR PDBsum; 6LVK; -. DR PDBsum; 6LVL; -. DR PDBsum; 6V6Q; -. DR PDBsum; 7KIA; -. DR PDBsum; 7KIE; -. DR PDBsum; 7OZY; -. DR PDBsum; 8E1X; -. DR PDBsum; 8H75; -. DR PDBsum; 8STG; -. DR PDBsum; 8SWE; -. DR PDBsum; 8U1F; -. DR PDBsum; 8W2X; -. DR PDBsum; 8W38; -. DR PDBsum; 8W3B; -. DR PDBsum; 8W3D; -. DR PDBsum; 9U3N; -. DR AlphaFoldDB; P21802; -. DR BMRB; P21802; -. DR SMR; P21802; -. DR BioGRID; 108554; 241. DR CORUM; P21802; -. DR DIP; DIP-3788N; -. DR FunCoup; P21802; 1763. DR IntAct; P21802; 206. DR MINT; P21802; -. DR STRING; 9606.ENSP00000410294; -. DR BindingDB; P21802; -. DR ChEMBL; CHEMBL4142; -. DR DrugBank; DB02058; 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone. DR DrugBank; DB02491; 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine. DR DrugBank; DB12558; AEE-788. DR DrugBank; DB12903; DEBIO-1347. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15149; Futibatinib. DR DrugBank; DB01109; Heparin. DR DrugBank; DB11886; Infigratinib. DR DrugBank; DB17587; KIN-3248. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB13022; LY-2874455. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB00039; Palifermin. DR DrugBank; DB15102; Pemigatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB01901; Sucrosofate. DR DrugCentral; P21802; -. DR GuidetoPHARMACOLOGY; 1809; -. DR GlyConnect; 1997; 1 N-Linked glycan (1 site). DR GlyCosmos; P21802; 9 sites, 2 glycans. DR GlyGen; P21802; 9 sites, 4 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P21802; -. DR PhosphoSitePlus; P21802; -. DR BioMuta; FGFR2; -. DR DMDM; 120049; -. DR CPTAC; CPTAC-3175; -. DR jPOST; P21802; -. DR MassIVE; P21802; -. DR PaxDb; 9606-ENSP00000410294; -. DR PeptideAtlas; P21802; -. DR ProteomicsDB; 53905; -. [P21802-1] DR ProteomicsDB; 53910; -. [P21802-14] DR ProteomicsDB; 53911; -. [P21802-15] DR ProteomicsDB; 53912; -. [P21802-16] DR ProteomicsDB; 53913; -. [P21802-17] DR ProteomicsDB; 53914; -. [P21802-18] DR ProteomicsDB; 53915; -. [P21802-19] DR ProteomicsDB; 53916; -. [P21802-2] DR ProteomicsDB; 53917; -. [P21802-20] DR ProteomicsDB; 53918; -. [P21802-21] DR ProteomicsDB; 53919; -. [P21802-22] DR ProteomicsDB; 53920; -. [P21802-23] DR ProteomicsDB; 53921; -. [P21802-3] DR ProteomicsDB; 53922; -. [P21802-4] DR ProteomicsDB; 53923; -. [P21802-5] DR ProteomicsDB; 53924; -. [P21802-6] DR ProteomicsDB; 53926; -. [P21802-8] DR TopDownProteomics; P21802-8; -. [P21802-8] DR ABCD; P21802; 5 sequenced antibodies. DR Antibodypedia; 4393; 1424 antibodies from 47 providers. DR DNASU; 2263; -. DR Ensembl; ENST00000346997.6; ENSP00000263451.5; ENSG00000066468.25. [P21802-5] DR Ensembl; ENST00000351936.11; ENSP00000309878.10; ENSG00000066468.25. [P21802-5] DR Ensembl; ENST00000356226.8; ENSP00000348559.4; ENSG00000066468.25. [P21802-20] DR Ensembl; ENST00000357555.9; ENSP00000350166.5; ENSG00000066468.25. [P21802-21] DR Ensembl; ENST00000358487.10; ENSP00000351276.6; ENSG00000066468.25. [P21802-1] DR Ensembl; ENST00000359354.6; ENSP00000352309.2; ENSG00000066468.25. [P21802-14] DR Ensembl; ENST00000360144.7; ENSP00000353262.3; ENSG00000066468.25. [P21802-22] DR Ensembl; ENST00000369056.5; ENSP00000358052.1; ENSG00000066468.25. [P21802-17] DR Ensembl; ENST00000369060.8; ENSP00000358056.4; ENSG00000066468.25. [P21802-15] DR Ensembl; ENST00000369061.8; ENSP00000358057.4; ENSG00000066468.25. [P21802-23] DR Ensembl; ENST00000457416.7; ENSP00000410294.2; ENSG00000066468.25. [P21802-3] DR Ensembl; ENST00000682550.1; ENSP00000507633.1; ENSG00000066468.25. [P21802-20] DR Ensembl; ENST00000683211.1; ENSP00000508257.1; ENSG00000066468.25. [P21802-5] DR GeneID; 2263; -. DR KEGG; hsa:2263; -. DR MANE-Select; ENST00000358487.10; ENSP00000351276.6; NM_000141.5; NP_000132.3. DR UCSC; uc010qtl.3; human. [P21802-1] DR AGR; HGNC:3689; -. DR CIViC; 2263; 42 evidence items across 27 molecular profiles. DR ClinPGx; PA28128; -. DR CTD; 2263; -. DR DisGeNET; 2263; -. DR GeneCards; FGFR2; -. DR GeneReviews; FGFR2; -. DR HGNC; HGNC:3689; FGFR2. DR HPA; ENSG00000066468; Tissue enriched (brain). DR MalaCards; FGFR2; -. DR MIM; 101200; phenotype. DR MIM; 101400; phenotype. DR MIM; 101600; phenotype. DR MIM; 123150; phenotype. DR MIM; 123500; phenotype. DR MIM; 123790; phenotype. DR MIM; 149730; phenotype. DR MIM; 176943; gene. DR MIM; 207410; phenotype. DR MIM; 609579; phenotype. DR MIM; 614592; phenotype. DR OpenTargets; ENSG00000066468; -. DR Orphanet; 596008; Antley-Bixler syndrome without genital anomaly or disorder of steroidogenesis. DR Orphanet; 87; Apert syndrome. DR Orphanet; 207; Crouzon syndrome. DR Orphanet; 1555; Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome. DR Orphanet; 168624; Familial scaphocephaly syndrome, McGillivray type. DR Orphanet; 313855; FGFR2-related bent bone dysplasia. DR Orphanet; 1540; Jackson-Weiss syndrome. DR Orphanet; 2363; Lacrimoauriculodentodigital syndrome. DR Orphanet; 93258; Pfeiffer syndrome type 1. DR Orphanet; 93259; Pfeiffer syndrome type 2. DR Orphanet; 93260; Pfeiffer syndrome type 3. DR Orphanet; 794; Saethre-Chotzen syndrome. DR VEuPathDB; HostDB:ENSG00000066468; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000155447; -. DR HOGENOM; CLU_000288_74_2_1; -. DR InParanoid; P21802; -. DR OMA; PANCTSE; -. DR OrthoDB; 5984265at2759; -. DR PAN-GO; P21802; 7 GO annotations based on evolutionary models. DR PhylomeDB; P21802; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P21802; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-190375; FGFR2c ligand binding and activation. DR Reactome; R-HSA-190377; FGFR2b ligand binding and activation. DR Reactome; R-HSA-2023837; Signaling by FGFR2 amplification mutants. DR Reactome; R-HSA-2033519; Activated point mutants of FGFR2. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5654221; Phospholipase C-mediated cascade, FGFR2. DR Reactome; R-HSA-5654695; PI-3K cascade:FGFR2. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8851708; Signaling by FGFR2 IIIa TM. DR Reactome; R-HSA-8853333; Signaling by FGFR2 fusions. DR SignaLink; P21802; -. DR SIGNOR; P21802; -. DR Agora; ENSG00000066468; -. DR BioGRID-ORCS; 2263; 24 hits in 1187 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; FGFR2; human. DR EvolutionaryTrace; P21802; -. DR GeneWiki; Fibroblast_growth_factor_receptor_2; -. DR GenomeRNAi; 2263; -. DR Pharos; P21802; Tclin. DR PRO; PR:P21802; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P21802; protein. DR Bgee; ENSG00000066468; Expressed in C1 segment of cervical spinal cord and 202 other cell types or tissues. DR ExpressionAtlas; P21802; baseline and differential. DR GO; GO:0005938; C:cell cortex; IDA:UniProtKB. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0060076; C:excitatory synapse; ISS:UniProtKB. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB. DR GO; GO:0005007; F:fibroblast growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; NAS:UniProtKB. DR GO; GO:0001525; P:angiogenesis; ISS:UniProtKB. DR GO; GO:0009887; P:animal organ morphogenesis; ISS:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0007409; P:axonogenesis; ISS:UniProtKB. DR GO; GO:0060348; P:bone development; ISS:UniProtKB. DR GO; GO:0030282; P:bone mineralization; ISS:UniProtKB. DR GO; GO:0060349; P:bone morphogenesis; ISS:UniProtKB. DR GO; GO:0060667; P:branch elongation involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; ISS:UniProtKB. DR GO; GO:0060442; P:branching involved in prostate gland morphogenesis; ISS:UniProtKB. DR GO; GO:0060445; P:branching involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:UniProtKB. DR GO; GO:0060449; P:bud elongation involved in lung branching; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; ISS:UniProtKB. DR GO; GO:0007267; P:cell-cell signaling; ISS:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl. DR GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl. DR GO; GO:0048565; P:digestive tract development; ISS:UniProtKB. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:BHF-UCL. DR GO; GO:0048557; P:embryonic digestive tract morphogenesis; ISS:UniProtKB. DR GO; GO:0048568; P:embryonic organ development; ISS:UniProtKB. DR GO; GO:0048562; P:embryonic organ morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0003416; P:endochondral bone growth; IEA:Ensembl. DR GO; GO:0048730; P:epidermis morphogenesis; ISS:UniProtKB. DR GO; GO:0030855; P:epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0035603; P:fibroblast growth factor receptor signaling pathway involved in hemopoiesis; ISS:UniProtKB. DR GO; GO:0035602; P:fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cell; ISS:UniProtKB. DR GO; GO:0035607; P:fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development; ISS:UniProtKB. DR GO; GO:0035604; P:fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow; ISS:UniProtKB. DR GO; GO:0022612; P:gland morphogenesis; ISS:UniProtKB. DR GO; GO:0031069; P:hair follicle morphogenesis; ISS:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; ISS:UniProtKB. DR GO; GO:0042472; P:inner ear morphogenesis; ISS:UniProtKB. DR GO; GO:0032808; P:lacrimal gland development; ISS:UniProtKB. DR GO; GO:0060601; P:lateral sprouting from an epithelium; ISS:UniProtKB. DR GO; GO:0060174; P:limb bud formation; ISS:UniProtKB. DR GO; GO:0048286; P:lung alveolus development; ISS:UniProtKB. DR GO; GO:0030324; P:lung development; ISS:UniProtKB. DR GO; GO:0060463; P:lung lobe morphogenesis; ISS:UniProtKB. DR GO; GO:0060484; P:lung-associated mesenchyme development; ISS:UniProtKB. DR GO; GO:0060615; P:mammary gland bud formation; ISS:UniProtKB. DR GO; GO:0003149; P:membranous septum morphogenesis; ISS:UniProtKB. DR GO; GO:0048762; P:mesenchymal cell differentiation; ISS:UniProtKB. DR GO; GO:0060915; P:mesenchymal cell differentiation involved in lung development; ISS:UniProtKB. DR GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; ISS:UniProtKB. DR GO; GO:0048333; P:mesodermal cell differentiation; IEA:Ensembl. DR GO; GO:0030901; P:midbrain development; ISS:UniProtKB. DR GO; GO:0016331; P:morphogenesis of embryonic epithelium; ISS:UniProtKB. DR GO; GO:0010839; P:negative regulation of keratinocyte proliferation; IMP:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:0042476; P:odontogenesis; ISS:UniProtKB. DR GO; GO:0021769; P:orbitofrontal cortex development; ISS:UniProtKB. DR GO; GO:0035265; P:organ growth; ISS:UniProtKB. DR GO; GO:0030916; P:otic vesicle formation; ISS:UniProtKB. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISS:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; ISS:UniProtKB. DR GO; GO:0051781; P:positive regulation of cell division; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:UniProtKB. DR GO; GO:0060501; P:positive regulation of epithelial cell proliferation involved in lung morphogenesis; ISS:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:UniProtKB. DR GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0030177; P:positive regulation of Wnt signaling pathway; ISS:UniProtKB. DR GO; GO:0009791; P:post-embryonic development; ISS:UniProtKB. DR GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; ISS:UniProtKB. DR GO; GO:0060523; P:prostate epithelial cord elongation; ISS:UniProtKB. DR GO; GO:0060512; P:prostate gland morphogenesis; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0021860; P:pyramidal neuron development; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0060688; P:regulation of morphogenesis of a branching structure; ISS:UniProtKB. DR GO; GO:0045667; P:regulation of osteoblast differentiation; TAS:UniProtKB. DR GO; GO:0033688; P:regulation of osteoblast proliferation; TAS:UniProtKB. DR GO; GO:0051150; P:regulation of smooth muscle cell differentiation; ISS:UniProtKB. DR GO; GO:0008589; P:regulation of smoothened signaling pathway; ISS:UniProtKB. DR GO; GO:0048608; P:reproductive structure development; ISS:UniProtKB. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl. DR GO; GO:0048705; P:skeletal system morphogenesis; TAS:UniProtKB. DR GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; ISS:UniProtKB. DR GO; GO:0001657; P:ureteric bud development; ISS:UniProtKB. DR GO; GO:0055010; P:ventricular cardiac muscle tissue morphogenesis; ISS:UniProtKB. DR GO; GO:0021847; P:ventricular zone neuroblast division; ISS:UniProtKB. DR CDD; cd04973; IgI_1_FGFR; 1. DR CDD; cd05857; IgI_2_FGFR; 1. DR CDD; cd05858; IgI_3_FGFR2; 1. DR CDD; cd05101; PTKc_FGFR2; 1. DR FunFam; 1.10.510.10:FF:000007; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000016; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000020; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000252; Fibroblast growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000011; Fibroblast growth factor receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00546; -. DR InterPro; IPR016248; FGF_rcpt_fam. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416:SF130; FIBROBLAST GROWTH FACTOR RECEPTOR 2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF13927; Ig_3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000628; FGFR; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 3. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Craniosynostosis; Cytoplasmic vesicle; Disease variant; Disulfide bond; KW Ectodermal dysplasia; Glycoprotein; Golgi apparatus; Heparin-binding; KW Immunoglobulin domain; Intellectual disability; Kinase; KW Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Secreted; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..21 FT /evidence="ECO:0000255" FT CHAIN 22..821 FT /note="Fibroblast growth factor receptor 2" FT /id="PRO_0000016783" FT TOPO_DOM 22..377 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 378..398 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 399..821 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 25..125 FT /note="Ig-like C2-type 1" FT DOMAIN 154..247 FT /note="Ig-like C2-type 2" FT DOMAIN 256..358 FT /note="Ig-like C2-type 3" FT DOMAIN 481..770 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 131..151 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 161..178 FT /note="Heparin-binding" FT COMPBIAS 131..144 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 626 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028, FT ECO:0000269|PubMed:19060208" FT BINDING 487..495 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 517 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 565..567 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 571 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT MOD_RES 466 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19060208, FT ECO:0000269|PubMed:19410646" FT MOD_RES 586 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 588 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19060208, FT ECO:0000269|PubMed:19410646" FT MOD_RES 656 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 657 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 769 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15629145, FT ECO:0000269|PubMed:19060208" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT CARBOHYD 83 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 123 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 228 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 265 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 297 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 318 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 331 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 62..107 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 179..231 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:16384934" FT DISULFID 278..342 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:16384934" FT VAR_SEQ 37..152 FT /note="EPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLI FT GEYLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSEN FT SNNKR -> G (in isoform 14)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_019608" FT VAR_SEQ 37..125 FT /note="Missing (in isoform 4, isoform 15 and isoform 16)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:2377625" FT /id="VSP_002964" FT VAR_SEQ 250..361 FT /note="Missing (in isoform 17)" FT /evidence="ECO:0000303|Ref.14" FT /id="VSP_041914" FT VAR_SEQ 250..254 FT /note="ERSPH -> GSQGL (in isoform 8)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002965" FT VAR_SEQ 255..821 FT /note="Missing (in isoform 8)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002966" FT VAR_SEQ 313 FT /note="K -> KVTK (in isoform 10)" FT /evidence="ECO:0000303|PubMed:2172978" FT /id="VSP_002967" FT VAR_SEQ 314..429 FT /note="Missing (in isoform 9)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002968" FT VAR_SEQ 314..330 FT /note="AAGVNTTDKEIEVLYIR -> HSGINSSNAEVLALF (in isoform 3, FT isoform 4, isoform 11, isoform 12, isoform 13 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002969" FT VAR_SEQ 334..335 FT /note="FE -> EA (in isoform 3, isoform 4, isoform 11, FT isoform 12, isoform 13 and isoform 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002970" FT VAR_SEQ 341..353 FT /note="TCLAGNSIGISFH -> ICKVSNYIGQANQ (in isoform 3, FT isoform 4, isoform 11, isoform 12, isoform 13 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002971" FT VAR_SEQ 361 FT /note="P -> PKQQ (in isoform 3, isoform 4, isoform 11, FT isoform 12, isoform 13 and isoform 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002972" FT VAR_SEQ 362..365 FT /note="APGR -> GRRC (in isoform 13)" FT /evidence="ECO:0000303|PubMed:1309608, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002973" FT VAR_SEQ 366..821 FT /note="Missing (in isoform 13)" FT /evidence="ECO:0000303|PubMed:1309608, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002974" FT VAR_SEQ 428..429 FT /note="Missing (in isoform 4, isoform 5, isoform 6, isoform FT 7, isoform 10 and isoform 12)" FT /evidence="ECO:0000303|PubMed:1313574, FT ECO:0000303|PubMed:2172978, ECO:0000303|PubMed:2377625" FT /id="VSP_002975" FT VAR_SEQ 429..430 FT /note="Missing (in isoform 14)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_019609" FT VAR_SEQ 761..821 FT /note="LTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQY FT PHINGSVKT -> PPNPSLMSIFRK (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2377625" FT /id="VSP_002976" FT VAR_SEQ 768..821 FT /note="EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSV FT KT -> I (in isoform 2, isoform 7, isoform 11 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:1647213" FT /id="VSP_002978" FT VAR_SEQ 769..821 FT /note="YLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVK FT T -> EKKVSGAVDCHKPPCNPSHLPCVLAVDQ (in isoform 15)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041915" FT VAR_SEQ 778..821 FT /note="QYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT -> PYSP FT CYPDPR (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_002984" FT VARIANT 6 FT /note="R -> P (in dbSNP:rs3750819)" FT /evidence="ECO:0000269|Ref.15" FT /id="VAR_017258" FT VARIANT 57 FT /note="S -> L (in dbSNP:rs56226109)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:26429889" FT /id="VAR_042204" FT VARIANT 105 FT /note="Y -> C (in CS; dbSNP:rs1434545235)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:8946174" FT /id="VAR_004112" FT VARIANT 172 FT /note="A -> F (in PS; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017259" FT VARIANT 186 FT /note="M -> T (in dbSNP:rs755793)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.15" FT /id="VAR_017260" FT VARIANT 203 FT /note="R -> C (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation; dbSNP:rs2134829270)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_036380" FT VARIANT 252..253 FT /note="SP -> FS (in PS; dbSNP:rs281865420)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:9002682" FT /id="VAR_004116" FT VARIANT 252 FT /note="S -> F (in APRS; requires 2 nucleotide FT substitutions; dbSNP:rs121918498)" FT /evidence="ECO:0000269|PubMed:9002682" FT /id="VAR_004114" FT VARIANT 252 FT /note="S -> L (in dbSNP:rs79184941)" FT /evidence="ECO:0000269|PubMed:9002682" FT /id="VAR_004113" FT VARIANT 252 FT /note="S -> W (in APRS and PS; common mutation; FT dbSNP:rs79184941)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:7668257, FT ECO:0000269|PubMed:7719344, ECO:0000269|PubMed:9452027, FT ECO:0000269|PubMed:9677057, ECO:0000269|PubMed:9719378" FT /id="VAR_004115" FT VARIANT 253 FT /note="P -> R (in APRS; common mutation; dbSNP:rs77543610)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, FT ECO:0000269|PubMed:9452027, ECO:0000269|PubMed:9677057" FT /id="VAR_004117" FT VARIANT 263 FT /note="P -> L (in CS; dbSNP:rs779326224)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017261" FT VARIANT 267 FT /note="S -> P (in CS; dbSNP:rs121918505)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7655462" FT /id="VAR_004118" FT VARIANT 268 FT /note="T -> TG (in CS)" FT /evidence="ECO:0000269|PubMed:8644708" FT /id="VAR_004119" FT VARIANT 269..270 FT /note="Missing (in SCS)" FT /evidence="ECO:0000269|PubMed:9585583" FT /id="VAR_075856" FT VARIANT 272 FT /note="G -> V (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042205" FT VARIANT 273 FT /note="Missing (in PS; type 2; dbSNP:rs121918503)" FT /evidence="ECO:0000269|PubMed:10945669" FT /id="VAR_017262" FT VARIANT 276 FT /note="F -> V (in CS; dbSNP:rs1057519036)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:9521581" FT /id="VAR_004120" FT VARIANT 278 FT /note="C -> F (in CS, JWS and PS; forms disulfide-linked FT dimers with constitutive kinase activity, is retained in an FT intracellular compartment and not detected at the cell FT surface; dbSNP:rs776587763)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:16844695, FT ECO:0000269|PubMed:7655462, ECO:0000269|PubMed:8644708, FT ECO:0000269|PubMed:9677057" FT /id="VAR_004121" FT VARIANT 278 FT /note="C -> Y (in CS; dbSNP:rs776587763)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017263" FT VARIANT 281 FT /note="Y -> C (in CS; dbSNP:rs1057519038)" FT /evidence="ECO:0000269|PubMed:11380921, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017264" FT VARIANT 283 FT /note="D -> N (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs2134313441)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042206" FT VARIANT 287..289 FT /note="Missing (in CS)" FT /id="VAR_004122" FT VARIANT 288 FT /note="I -> S (in CS)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017265" FT VARIANT 289 FT /note="Q -> P (in CS and JWS; dbSNP:rs121918497)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:8644708" FT /id="VAR_004123" FT VARIANT 290 FT /note="W -> C (in PS; severe; also in a lung squamous cell FT carcinoma sample; somatic mutation; dbSNP:rs121918499)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9150725" FT /id="VAR_004124" FT VARIANT 290 FT /note="W -> G (in CS; dbSNP:rs121918501)" FT /evidence="ECO:0000269|PubMed:8528214" FT /id="VAR_017266" FT VARIANT 290 FT /note="W -> R (in CS; dbSNP:rs121918501)" FT /evidence="ECO:0000269|PubMed:7655462" FT /id="VAR_004125" FT VARIANT 292 FT /note="K -> E (in CS; dbSNP:rs121918500)" FT /evidence="ECO:0000269|PubMed:9152842" FT /id="VAR_004126" FT VARIANT 301 FT /note="Y -> C (in CS; dbSNP:rs1554930684)" FT /evidence="ECO:0000269|PubMed:9521581" FT /id="VAR_004127" FT VARIANT 314 FT /note="A -> S (in craniosynostosis; dbSNP:rs1358919643)" FT /evidence="ECO:0000269|PubMed:9521581" FT /id="VAR_004128" FT VARIANT 315 FT /note="A -> S (in a non-syndromic craniosynostosis patient FT with abnormal intrauterine history; confers predisposition FT to craniosynostosis; dbSNP:rs121918504)" FT /evidence="ECO:0000269|PubMed:10951518, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017267" FT VARIANT 321 FT /note="D -> A (in PS; dbSNP:rs121918510)" FT /evidence="ECO:0000269|PubMed:7719333" FT /id="VAR_004129" FT VARIANT 328 FT /note="Y -> C (in CS; dbSNP:rs121918493)" FT /evidence="ECO:0000269|PubMed:7874170" FT /id="VAR_004130" FT VARIANT 331 FT /note="N -> I (in CS; dbSNP:rs2134258264)" FT /evidence="ECO:0000269|PubMed:8956050" FT /id="VAR_004131" FT VARIANT 337 FT /note="A -> ANA (in CS)" FT /id="VAR_004132" FT VARIANT 337 FT /note="A -> P (in CS; dbSNP:rs387906676)" FT /evidence="ECO:0000269|PubMed:9677057" FT /id="VAR_017268" FT VARIANT 338 FT /note="G -> E (in CS; dbSNP:rs1057519044)" FT /evidence="ECO:0000269|PubMed:8946174" FT /id="VAR_004133" FT VARIANT 338 FT /note="G -> R (in CS; dbSNP:rs1057519043)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:9677057" FT /id="VAR_015011" FT VARIANT 340 FT /note="Y -> C (in PS; dbSNP:rs1554928884)" FT /evidence="ECO:0000269|PubMed:10394936, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017269" FT VARIANT 340 FT /note="Y -> H (in CS; dbSNP:rs121918489)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7987400" FT /id="VAR_004134" FT VARIANT 341 FT /note="T -> P (in PS and CS; dbSNP:rs121918495)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345" FT /id="VAR_004135" FT VARIANT 342 FT /note="C -> F (in CS; dbSNP:rs121918487)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057" FT /id="VAR_004136" FT VARIANT 342 FT /note="C -> G (in PS; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10394936" FT /id="VAR_017270" FT VARIANT 342 FT /note="C -> R (in CS, JWS, PS and ABS2; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11380921, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057" FT /id="VAR_004137" FT VARIANT 342 FT /note="C -> S (in CS, JWS, PS and ABS2; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7987400, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368, FT ECO:0000269|Ref.10" FT /id="VAR_004138" FT VARIANT 342 FT /note="C -> W (in CS; dbSNP:rs121918496)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:8528214" FT /id="VAR_017271" FT VARIANT 342 FT /note="C -> Y (in CS and PS; dbSNP:rs121918487)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7719345, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8644708, FT ECO:0000269|PubMed:9677057" FT /id="VAR_004139" FT VARIANT 344 FT /note="A -> G (in CS and JWS; dbSNP:rs121918492)" FT /evidence="ECO:0000269|PubMed:7581378, FT ECO:0000269|PubMed:7874170" FT /id="VAR_004140" FT VARIANT 344 FT /note="A -> P (in CS and PS; dbSNP:rs2134256250)" FT /evidence="ECO:0000269|PubMed:8644708" FT /id="VAR_004141" FT VARIANT 347 FT /note="S -> C (in CS; dbSNP:rs121918494)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7874170" FT /id="VAR_004142" FT VARIANT 351 FT /note="S -> C (in CS, PS and ABS2; dbSNP:rs121918502)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:8946174, ECO:0000269|PubMed:9693549" FT /id="VAR_004143" FT VARIANT 354 FT /note="S -> C (in CS; dbSNP:rs121918490)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214" FT /id="VAR_004144" FT VARIANT 354 FT /note="S -> Y (in CS; dbSNP:rs121918490)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017272" FT VARIANT 356..358 FT /note="Missing (in CS)" FT /evidence="ECO:0000269|PubMed:8956050" FT /id="VAR_004145" FT VARIANT 359 FT /note="V -> F (in CS and PS; dbSNP:rs1274989878)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:8644708" FT /id="VAR_004146" FT VARIANT 362 FT /note="A -> S (in CS)" FT /evidence="ECO:0000269|PubMed:10574673" FT /id="VAR_017273" FT VARIANT 372 FT /note="S -> C (in BSTVS; dbSNP:rs121913477)" FT /evidence="ECO:0000269|PubMed:8696350" FT /id="VAR_017274" FT VARIANT 375 FT /note="Y -> C (in PS and BSTVS; dbSNP:rs121913478)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:12000365, ECO:0000269|PubMed:8696350" FT /id="VAR_017275" FT VARIANT 381 FT /note="Y -> D (in BBDS1; dbSNP:rs387906678)" FT /evidence="ECO:0000269|PubMed:22387015" FT /id="VAR_067977" FT VARIANT 384 FT /note="G -> R (in CS; dbSNP:rs1554927408)" FT /evidence="ECO:0000269|PubMed:8946174" FT /id="VAR_004147" FT VARIANT 391 FT /note="M -> R (in BBDS1; the mutation selectively reduces FT plasma-membrane levels of the protein and markedly FT diminishes the receptor's responsiveness to extracellular FT FGF; dbSNP:rs387906677)" FT /evidence="ECO:0000269|PubMed:22387015" FT /id="VAR_067978" FT VARIANT 526 FT /note="K -> E (in FSPC; constitutive kinase activity; FT dbSNP:rs121918507)" FT /evidence="ECO:0000269|PubMed:16061565, FT ECO:0000269|PubMed:17803937" FT /id="VAR_023788" FT VARIANT 549 FT /note="N -> H (in CS; constitutive kinase activity; FT dbSNP:rs1057519045)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017276" FT VARIANT 565 FT /note="E -> G (in PS; constitutive kinase activity; FT dbSNP:rs121918506)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017277" FT VARIANT 612 FT /note="R -> T (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1846839725)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046071" FT VARIANT 613 FT /note="G -> R (in dbSNP:rs2133933864)" FT /evidence="ECO:0000269|PubMed:10626794, FT ECO:0000269|PubMed:1309608" FT /id="VAR_015012" FT VARIANT 628 FT /note="A -> T (in LADD1; strongly reduced kinase activity; FT dbSNP:rs121918509)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029884" FT VARIANT 641 FT /note="K -> R (in PS; constitutive kinase activity; FT dbSNP:rs1057519047)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017278" FT VARIANT 648 FT /note="A -> T (in LADD1; dbSNP:rs121918508)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029885" FT VARIANT 649..650 FT /note="RD -> S (in LADD1)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029886" FT VARIANT 659 FT /note="K -> N (in craniosynostosis; constitutive kinase FT activity; dbSNP:rs1589722765)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017279" FT VARIANT 663 FT /note="G -> E (in PS; dbSNP:rs2133825396)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017280" FT VARIANT 678 FT /note="R -> G (in CS; dbSNP:rs1845559552)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017281" FT MUTAGEN 265 FT /note="N->Q: Reduced N-glycosylation. Reduced expression at FT the cell surface." FT /evidence="ECO:0000269|PubMed:16844695" FT MUTAGEN 549 FT /note="N->T: Constitutive kinase activity." FT /evidence="ECO:0000269|PubMed:17803937" FT MUTAGEN 565 FT /note="E->A: Constitutive kinase activity." FT /evidence="ECO:0000269|PubMed:17803937" FT MUTAGEN 656..657 FT /note="Missing: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16844695" FT MUTAGEN 769 FT /note="Y->F: Increases fibroblast proliferation. Decreases FT phosphorylation of PLCG1 and FRS2. Decreases activation of FT MAP kinases." FT /evidence="ECO:0000269|PubMed:15629145, FT ECO:0000269|PubMed:19103595" FT CONFLICT 246 FT /note="L -> P (in Ref. 16; BAG57383)" FT /evidence="ECO:0000305" FT CONFLICT 310 FT /note="K -> N (in Ref. 16; BAG57383)" FT /evidence="ECO:0000305" FT STRAND 152..157 FT /evidence="ECO:0007829|PDB:3CAF" FT TURN 159..162 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 166..170 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 175..178 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 181..185 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 188..193 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4WV1" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 211..213 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 215..218 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 227..235 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 238..249 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 266..269 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 287..293 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:3OJ2" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:1IIL" FT STRAND 309..314 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 315..319 FT /evidence="ECO:0007829|PDB:2FDB" FT HELIX 321..323 FT /evidence="ECO:0007829|PDB:1IIL" FT STRAND 324..327 FT /evidence="ECO:0007829|PDB:3OJM" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 338..346 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 349..360 FT /evidence="ECO:0007829|PDB:3OJM" FT TURN 463..465 FT /evidence="ECO:0007829|PDB:5UI0" FT TURN 472..474 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 478..480 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 481..489 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 490..492 FT /evidence="ECO:0007829|PDB:8W3D" FT STRAND 494..500 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 504..506 FT /evidence="ECO:0007829|PDB:3CLY" FT STRAND 513..518 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 525..541 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 550..554 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 556..558 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 561..565 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 568..571 FT /evidence="ECO:0007829|PDB:1OEC" FT HELIX 572..577 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 585..588 FT /evidence="ECO:0007829|PDB:4J99" FT HELIX 590..592 FT /evidence="ECO:0007829|PDB:8W3D" FT HELIX 594..596 FT /evidence="ECO:0007829|PDB:5UI0" FT HELIX 600..619 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 629..631 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 632..634 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 636..638 FT /evidence="ECO:0007829|PDB:2PVY" FT STRAND 640..642 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 645..647 FT /evidence="ECO:0007829|PDB:5UGL" FT TURN 652..654 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 655..658 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 659..662 FT /evidence="ECO:0007829|PDB:2PZR" FT STRAND 664..666 FT /evidence="ECO:0007829|PDB:5UI0" FT HELIX 667..669 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 672..677 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 682..697 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 709..718 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 726..728 FT /evidence="ECO:0007829|PDB:2PZ5" FT HELIX 730..739 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 744..746 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 750..764 FT /evidence="ECO:0007829|PDB:2PVF" FT CONFLICT P21802-16:315 FT /note="T -> L (in Ref. 2; AAA61188)" FT /evidence="ECO:0000305" SQ SEQUENCE 821 AA; 92025 MW; 6CD5001C960ED82F CRC64; MVSWGRFICL VVVTMATLSL ARPSFSLVED TTLEPEEPPT KYQISQPEVY VAAPGESLEV RCLLKDAAVI SWTKDGVHLG PNNRTVLIGE YLQIKGATPR DSGLYACTAS RTVDSETWYF MVNVTDAISS GDDEDDTDGA EDFVSENSNN KRAPYWTNTE KMEKRLHAVP AANTVKFRCP AGGNPMPTMR WLKNGKEFKQ EHRIGGYKVR NQHWSLIMES VVPSDKGNYT CVVENEYGSI NHTYHLDVVE RSPHRPILQA GLPANASTVV GGDVEFVCKV YSDAQPHIQW IKHVEKNGSK YGPDGLPYLK VLKAAGVNTT DKEIEVLYIR NVTFEDAGEY TCLAGNSIGI SFHSAWLTVL PAPGREKEIT ASPDYLEIAI YCIGVFLIAC MVVTVILCRM KNTTKKPDFS SQPAVHKLTK RIPLRRQVTV SAESSSSMNS NTPLVRITTR LSSTADTPML AGVSEYELPE DPKWEFPRDK LTLGKPLGEG CFGQVVMAEA VGIDKDKPKE AVTVAVKMLK DDATEKDLSD LVSEMEMMKM IGKHKNIINL LGACTQDGPL YVIVEYASKG NLREYLRARR PPGMEYSYDI NRVPEEQMTF KDLVSCTYQL ARGMEYLASQ KCIHRDLAAR NVLVTENNVM KIADFGLARD INNIDYYKKT TNGRLPVKWM APEALFDRVY THQSDVWSFG VLMWEIFTLG GSPYPGIPVE ELFKLLKEGH RMDKPANCTN ELYMMMRDCW HAVPSQRPTF KQLVEDLDRI LTLTTNEEYL DLSQPLEQYS PSYPDTRSSC SSGDDSVFSP DPMPYEPCLP QYPHINGSVK T // ID GPER1_HUMAN Reviewed; 375 AA. AC Q99527; A8K6C5; B5BUJ1; O00143; O43494; Q13631; Q6FHL1; Q96F42; Q99981; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1997, sequence version 1. DT 28-JAN-2026, entry version 209. DE RecName: Full=G-protein coupled estrogen receptor 1 {ECO:0000305}; DE AltName: Full=Chemoattractant receptor-like 2; DE AltName: Full=Flow-induced endothelial G-protein coupled receptor 1; DE Short=FEG-1; DE AltName: Full=G protein-coupled estrogen receptor 1; DE AltName: Full=G-protein coupled receptor 30 {ECO:0000303|PubMed:17379646, ECO:0000303|PubMed:18566127}; DE AltName: Full=GPCR-Br; DE AltName: Full=IL8-related receptor DRY12; DE AltName: Full=Lymphocyte-derived G-protein coupled receptor; DE Short=LYGPR; DE AltName: Full=Membrane estrogen receptor; DE Short=mER; GN Name=GPER1 {ECO:0000312|HGNC:HGNC:4485}; GN Synonyms=CEPR, CMKRL2, DRY12, GPER, GPR30 {ECO:0000303|PubMed:17379646, GN ECO:0000303|PubMed:18566127}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8920907; DOI=10.1006/bbrc.1996.1654; RA Owman C.S.O., Blay P., Nilsson C., Lolait S.J.; RT "Cloning of human cDNA encoding a novel heptahelix receptor expressed in RT Burkitt's lymphoma and widely distributed in brain and peripheral RT tissues."; RL Biochem. Biophys. Res. Commun. 228:285-292(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9070864; DOI=10.1006/bbrc.1997.6161; RA Feng Y., Gregor P.; RT "Cloning of a novel member of the G protein-coupled receptor family related RT to peptide receptors."; RL Biochem. Biophys. Res. Commun. 231:651-654(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9398636; DOI=10.1006/bbrc.1997.7734; RA Takada Y., Kato C., Kondo S., Korenaga R., Ando J.; RT "Cloning of cDNAs encoding G protein-coupled receptor expressed in human RT endothelial cells exposed to fluid shear stress."; RL Biochem. Biophys. Res. Commun. 240:737-741(1997). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9141481; DOI=10.1016/s0014-5793(97)00278-0; RA Kvingedal A.M., Smeland E.B.; RT "A novel putative G-protein-coupled receptor expressed in lung, heart and RT lymphoid tissue."; RL FEBS Lett. 407:59-62(1997). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9367686; DOI=10.1006/geno.1997.4972; RA Carmeci C., Thompson D.A., Ring H.Z., Francke U., Weigel R.J.; RT "Identification of a gene (GPR30) with homology to the G-protein-coupled RT receptor superfamily associated with estrogen receptor expression in breast RT cancer."; RL Genomics 45:607-617(1997). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9479505; DOI=10.1006/geno.1998.5095; RA O'Dowd B.F., Nguyen T., Marchese A., Cheng R., Lynch K.R., Heng H.H.Q., RA Kolakowski L.F. Jr., George S.R.; RT "Discovery of three novel G-protein-coupled receptor genes."; RL Genomics 47:310-313(1998). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Liver; RA McCoy R.L., Perlmutter D.H.; RT "Cloning of novel IL8-related receptors from human hepatic tissue."; RL Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-16. RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-16. RC TISSUE=Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [14] RP FUNCTION. RX PubMed=11043579; DOI=10.1210/mend.14.10.0532; RA Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Jr.; RT "Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein- RT coupled receptor homolog, GPR30, and occurs via trans-activation of the RT epidermal growth factor receptor through release of HB-EGF."; RL Mol. Endocrinol. 14:1649-1660(2000). RN [15] RP INDUCTION. RX PubMed=12027886; DOI=10.1046/j.1432-1033.2002.02912.x; RA Ahola T.M., Purmonen S., Pennanen P., Zhuang Y.H., Tuohimaa P., Ylikomi T.; RT "Progestin upregulates G-protein-coupled receptor 30 in breast cancer RT cells."; RL Eur. J. Biochem. 269:2485-2490(2002). RN [16] RP FUNCTION, ESTROGEN-BINDING, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR RP LOCATION. RX PubMed=15539556; DOI=10.1210/en.2004-1064; RA Thomas P., Pang Y., Filardo E.J., Dong J.; RT "Identity of an estrogen membrane receptor coupled to a G protein in human RT breast cancer cells."; RL Endocrinology 146:624-632(2005). RN [17] RP FUNCTION, ESTROGEN-BINDING, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR RP LOCATION. RX PubMed=15705806; DOI=10.1126/science.1106943; RA Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R.; RT "A transmembrane intracellular estrogen receptor mediates rapid cell RT signaling."; RL Science 307:1625-1630(2005). RN [18] RP ABSENCE OF ESTROGEN-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=16645038; DOI=10.1210/me.2005-0525; RA Pedram A., Razandi M., Levin E.R.; RT "Nature of functional estrogen receptors at the plasma membrane."; RL Mol. Endocrinol. 20:1996-2009(2006). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=17379646; DOI=10.1210/en.2006-1605; RA Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., Thomas P.; RT "Activation of the novel estrogen receptor G protein-coupled receptor 30 RT (GPR30) at the plasma membrane."; RL Endocrinology 148:3236-3245(2007). RN [20] RP ABSENCE OF ESTROGEN-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=18566127; DOI=10.1210/en.2008-0269; RA Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., RA Langer G., Bader B., Prelle K., Nubbemeyer R., Fritzemeier K.H.; RT "G protein-coupled receptor 30 localizes to the endoplasmic reticulum and RT is not activated by estradiol."; RL Endocrinology 149:4846-4856(2008). RN [21] RP FUNCTION. RX PubMed=19179659; DOI=10.1161/circresaha.108.190892; RA Haas E., Bhattacharya I., Brailoiu E., Damjanovic M., Brailoiu G.C., RA Gao X., Mueller-Guerre L., Marjon N.A., Gut A., Minotti R., Meyer M.R., RA Amann K., Ammann E., Perez-Dominguez A., Genoni M., Clegg D.J., Dun N.J., RA Resta T.C., Prossnitz E.R., Barton M.; RT "Regulatory role of G protein-coupled estrogen receptor for vascular RT function and obesity."; RL Circ. Res. 104:288-291(2009). RN [22] RP FUNCTION. RX PubMed=19342448; DOI=10.1210/me.2008-0262; RA Quinn J.A., Graeber C.T., Frackelton A.R. Jr., Kim M., Schwarzbauer J.E., RA Filardo E.J.; RT "Coordinate regulation of estrogen-mediated fibronectin matrix assembly and RT epidermal growth factor receptor transactivation by the G protein-coupled RT receptor, GPR30."; RL Mol. Endocrinol. 23:1052-1064(2009). RN [23] RP INTERACTION WITH EGFR AND ESR1, AND INDUCTION. RX PubMed=19749156; DOI=10.1210/me.2009-0120; RA Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F., RA Fuqua S.A., Ando S., Maggiolini M.; RT "G protein-coupled receptor 30 expression is up-regulated by EGF and TGF RT alpha in estrogen receptor alpha-positive cancer cells."; RL Mol. Endocrinol. 23:1815-1826(2009). RN [24] RP FUNCTION, INTERACTION WITH EGFR, ASSOCIATION WITH CHROMATIN, SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RX PubMed=20551055; DOI=10.1158/0008-5472.can-10-0408; RA Madeo A., Maggiolini M.; RT "Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol- RT induced gene expression and migration in breast cancer-associated RT fibroblasts."; RL Cancer Res. 70:6036-6046(2010). RN [25] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=20203690; DOI=10.1038/cdd.2010.20; RA Chan Q.K., Lam H.M., Ng C.F., Lee A.Y., Chan E.S., Ng H.K., Ho S.M., RA Lau K.M.; RT "Activation of GPR30 inhibits the growth of prostate cancer cells through RT sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, RT and induction of G(2) cell-cycle arrest."; RL Cell Death Differ. 17:1511-1523(2010). RN [26] RP ESTROGEN-BINDING, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=19931550; DOI=10.1016/j.steroids.2009.11.005; RA Thomas P., Alyea R., Pang Y., Peyton C., Dong J., Berg A.H.; RT "Conserved estrogen binding and signaling functions of the G protein- RT coupled estrogen receptor 1 (GPER) in mammals and fish."; RL Steroids 75:595-602(2010). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, GLYCOSYLATION, AND TISSUE SPECIFICITY. RX PubMed=21427217; DOI=10.1210/en.2010-0979; RA Maiti K., Paul J.W., Read M., Chan E.C., Riley S.C., Nahar P., Smith R.; RT "G-1-activated membrane estrogen receptors mediate increased contractility RT of the human myometrium."; RL Endocrinology 152:2448-2455(2011). RN [28] RP ALDOSTERONE-BINDING, AND FUNCTION. RX PubMed=21242460; DOI=10.1161/hypertensionaha.110.161653; RA Gros R., Ding Q., Sklar L.A., Prossnitz E.E., Arterburn J.B., RA Chorazyczewski J., Feldman R.D.; RT "GPR30 expression is required for the mineralocorticoid receptor- RT independent rapid vascular effects of aldosterone."; RL Hypertension 57:442-451(2011). RN [29] RP SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=21540189; DOI=10.1074/jbc.m111.224071; RA Cheng S.B., Quinn J.A., Graeber C.T., Filardo E.J.; RT "Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the RT cell surface occurs via a trans-Golgi-proteasome pathway."; RL J. Biol. Chem. 286:22441-22455(2011). RN [30] RP FUNCTION, INTERACTION WITH KRT7 AND KRT8, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=21149639; DOI=10.1124/mol.110.069500; RA Sanden C., Broselid S., Cornmark L., Andersson K., Daszkiewicz-Nilsson J., RA Martensson U.E., Olde B., Leeb-Lundberg L.M.; RT "G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 RT localizes in the plasma membrane and traffics intracellularly on RT cytokeratin intermediate filaments."; RL Mol. Pharmacol. 79:400-410(2011). RN [31] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21354433; DOI=10.1016/j.steroids.2011.02.018; RA Cheng S.B., Graeber C.T., Quinn J.A., Filardo E.J.; RT "Retrograde transport of the transmembrane estrogen receptor, G-protein- RT coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the RT nucleus."; RL Steroids 76:892-896(2011). RN [32] RP FUNCTION. RX PubMed=23135268; DOI=10.1074/jbc.m112.417303; RA Santolla M.F., Lappano R., De Marco P., Pupo M., Vivacqua A., Sisci D., RA Abonante S., Iacopetta D., Cappello A.R., Dolce V., Maggiolini M.; RT "G protein-coupled estrogen receptor mediates the up-regulation of fatty RT acid synthase induced by 17beta-estradiol in cancer cells and cancer- RT associated fibroblasts."; RL J. Biol. Chem. 287:43234-43245(2012). RN [33] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=23285008; DOI=10.1371/journal.pone.0052357; RA Chakrabarti S., Davidge S.T.; RT "G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial RT inflammation."; RL PLoS ONE 7:E52357-E52357(2012). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP ALDOSTERONE-BINDING, AND FUNCTION. RX PubMed=23283935; DOI=10.1152/ajpcell.00203.2012; RA Gros R., Ding Q., Liu B., Chorazyczewski J., Feldman R.D.; RT "Aldosterone mediates its rapid effects in vascular endothelial cells RT through GPER activation."; RL Am. J. Physiol. 304:C532-C540(2013). RN [36] RP FUNCTION, INTERACTION WITH RAMP3, AND SUBCELLULAR LOCATION. RX PubMed=23674134; DOI=10.1530/jme-13-0021; RA Lenhart P.M., Broselid S., Barrick C.J., Leeb-Lundberg L.M., Caron K.M.; RT "G-protein-coupled receptor 30 interacts with receptor activity-modifying RT protein 3 and confers sex-dependent cardioprotection."; RL J. Mol. Endocrinol. 51:191-202(2013). RN [37] RP REVIEW. RX PubMed=22521564; DOI=10.1016/j.steroids.2012.04.001; RA Barton M.; RT "Position paper: The membrane estrogen receptor GPER--Clues and RT questions."; RL Steroids 77:935-942(2012). RN [38] RP REVIEW. RX PubMed=22495674; DOI=10.1210/en.2012-1061; RA Filardo E.J., Thomas P.; RT "Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism RT of action and role in female reproductive cancer, renal and vascular RT physiology."; RL Endocrinology 153:2953-2962(2012). CC -!- FUNCTION: G-protein coupled estrogen receptor that binds to 17-beta- CC estradiol (E2) with high affinity, leading to rapid and transient CC activation of numerous intracellular signaling pathways. Stimulates CC cAMP production, calcium mobilization and tyrosine kinase Src inducing CC the release of heparin-bound epidermal growth factor (HB-EGF) and CC subsequent transactivation of the epidermal growth factor receptor CC (EGFR), activating downstream signaling pathways such as PI3K/Akt and CC ERK/MAPK. Mediates pleiotropic functions among others in the CC cardiovascular, endocrine, reproductive, immune and central nervous CC systems. Has a role in cardioprotection by reducing cardiac hypertrophy CC and perivascular fibrosis in a RAMP3-dependent manner. Regulates CC arterial blood pressure by stimulating vasodilation and reducing CC vascular smooth muscle and microvascular endothelial cell CC proliferation. Plays a role in blood glucose homeostasis contributing CC to the insulin secretion response by pancreatic beta cells. Triggers CC mitochondrial apoptosis during pachytene spermatocyte differentiation. CC Stimulates uterine epithelial cell proliferation. Enhances uterine CC contractility in response to oxytocin. Contributes to thymic atrophy by CC inducing apoptosis. Attenuates TNF-mediated endothelial expression of CC leukocyte adhesion molecules. Promotes neuritogenesis in developing CC hippocampal neurons. Plays a role in acute neuroprotection against CC NMDA-induced excitotoxic neuronal death. Increases firing activity and CC intracellular calcium oscillations in luteinizing hormone-releasing CC hormone (LHRH) neurons. Inhibits early osteoblast proliferation at CC growth plate during skeletal development. Inhibits mature adipocyte CC differentiation and lipid accumulation. Involved in the recruitment of CC beta-arrestin 2 ARRB2 at the plasma membrane in epithelial cells. Also CC functions as a receptor for aldosterone mediating rapid regulation of CC vascular contractibility through the PI3K/ERK signaling pathway. CC Involved in cancer progression regulation. Stimulates cancer-associated CC fibroblast (CAF) proliferation by a rapid genomic response through the CC EGFR/ERK transduction pathway. Associated with EGFR, may act as a CC transcription factor activating growth regulatory genes (c-fos, cyclin CC D1). Promotes integrin alpha-5/beta-1 and fibronectin (FN) matrix CC assembly in breast cancer cells. {ECO:0000269|PubMed:11043579, CC ECO:0000269|PubMed:15539556, ECO:0000269|PubMed:15705806, CC ECO:0000269|PubMed:19179659, ECO:0000269|PubMed:19342448, CC ECO:0000269|PubMed:20203690, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:21149639, ECO:0000269|PubMed:21242460, CC ECO:0000269|PubMed:21427217, ECO:0000269|PubMed:23135268, CC ECO:0000269|PubMed:23283935, ECO:0000269|PubMed:23285008, CC ECO:0000269|PubMed:23674134}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC Note=Binds 17-beta-estradiol (E2) in plasma membranes with high CC affinity (Kd is 3.3 nM) and displays rapid kinetics of association CC and dissociation. {ECO:0000269|PubMed:15539556, CC ECO:0000269|PubMed:15705806, ECO:0000269|PubMed:19931550}; CC -!- SUBUNIT: Homodimer (Probable). Heterodimer; heterodimerizes with other CC G-protein-coupled receptor (GPCRs) like CRHR1, HTR1A and PAQR8. CC Interacts (via C-terminus tail motif) with DLG4 (via N-terminus tandem CC pair of PDZ domains); the interaction is direct and induces the CC increase of GPER1 protein levels residing at the plasma membrane CC surface in a estradiol-independent manner (By similarity). Interacts CC with RAMP3; the interaction confers proper subcellular localization and CC function in cardioprotection. Interacts with KRT7 and KRT8. Interacts CC with EGFR; the interaction increases after agonist-induced stimulation CC in cancer-associated fibroblasts (CAF). Interacts with EGFR and ESR1. CC {ECO:0000250, ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:21149639, ECO:0000269|PubMed:23674134, ECO:0000305}. CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}. Cytoplasm, CC perinuclear region. Cytoplasm, cytoskeleton. Cell membrane; Multi-pass CC membrane protein. Basolateral cell membrane; Multi-pass membrane CC protein. Cytoplasmic vesicle membrane; Multi-pass membrane protein. CC Early endosome. Recycling endosome. Golgi apparatus membrane CC {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}. Golgi CC apparatus, trans-Golgi network. Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:18566127}; Multi-pass membrane protein. Cell CC projection, dendrite {ECO:0000250}. Cell projection, dendritic spine CC membrane {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}. Cell CC projection, axon {ECO:0000250}. Postsynaptic density {ECO:0000250}. CC Mitochondrion membrane {ECO:0000250}; Multi-pass membrane protein CC {ECO:0000250}. Note=Colocalized with BSN to the active zone of CC presynaptic density. Colocalized with DLG4/PSD95 and neurabin-2 PPP1R9B CC in neuronal synaptosomes (By similarity). Endocytosed in a agonist- and CC arrestin-independent manner. Colocalized with RAMP3 and clathrin-coated CC pits at the plasma membrane. Colocalized with transferrin receptor at CC the plasma membrane and perinuclear region. Accumulated and colocalized CC with RAB11 proteins in recycling endosomes and trans-Golgi network CC (TGN), but does neither recycle back to the cell surface nor traffics CC to late endosome or lysosome. Colocalized with calnexin in the CC endoplasmic reticulum. Traffics to intracellular sites via cytokeratin CC intermediate filaments like KRT7 and KRT8 after constitutive CC endocytosis in epithelial cells. Colocalized with EGFR in the nucleus CC of agonist-induced cancer-associated fibroblasts (CAF). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in placenta, endothelial and epithelial CC cells, non laboring and laboring term myometrium, fibroblasts and CC cancer-associated fibroblasts (CAF), prostate cancer cells and invasive CC adenocarcinoma (at protein level). Ubiquitously expressed, but is most CC abundant in placenta. In brain regions, expressed as a 2.8 kb CC transcript in basal forebrain, frontal cortex, thalamus, hippocampus, CC caudate and putamen. {ECO:0000269|PubMed:20203690, CC ECO:0000269|PubMed:20551055, ECO:0000269|PubMed:21149639, CC ECO:0000269|PubMed:21354433, ECO:0000269|PubMed:21427217, CC ECO:0000269|PubMed:23285008}. CC -!- INDUCTION: Up-regulated by EGF and TGF-alpha in endometrial, ovarian CC and breast tumor cells. Up-regulated by progestin and by phorbol 12- CC myristate 13-acetate (PMA) in breast cancer cell lines. CC {ECO:0000269|PubMed:12027886, ECO:0000269|PubMed:19749156}. CC -!- PTM: Ubiquitinated; ubiquitination occurs at the plasma membrane and CC leads to proteasome-mediated degradation. CC {ECO:0000269|PubMed:21540189}. CC -!- PTM: Glycosylated. {ECO:0000269|PubMed:21427217}. CC -!- MISCELLANEOUS: Does not bind estradiol according to PubMed:18566127 and CC PubMed:16645038. CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. CC {ECO:0000255|PROSITE-ProRule:PRU00521}. CC -!- CAUTION: Data is conflicting regarding whether it fulfills the criteria CC of a membrane-bound estrogen receptor (PubMed:15705806, CC PubMed:17379646). Other reports suggest that it is not CC (PubMed:16645038, PubMed:18566127). {ECO:0000305|PubMed:15705806, CC ECO:0000305|PubMed:16645038, ECO:0000305|PubMed:17379646, CC ECO:0000305|PubMed:18566127}. CC -!- CAUTION: Data is conflicting regarding whether it is localized either CC at the cell membrane (PM) (PubMed:15539556, PubMed:21149639, CC PubMed:21354433, PubMed:21427217, PubMed:21540189, PubMed:23674134). CC Other reports suggest that it localizes at the endoplasmic reticulum CC (ER) (PubMed:15705806, PubMed:18566127). {ECO:0000305|PubMed:15539556, CC ECO:0000305|PubMed:15705806, ECO:0000305|PubMed:18566127, CC ECO:0000305|PubMed:21149639, ECO:0000305|PubMed:21354433, CC ECO:0000305|PubMed:21427217, ECO:0000305|PubMed:21540189, CC ECO:0000305|PubMed:23674134}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44344/GPER"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y08162; CAA69354.1; -; mRNA. DR EMBL; U77827; AAC51173.1; -; Genomic_DNA. DR EMBL; AF015257; AAC51904.1; -; mRNA. DR EMBL; X98510; CAA67133.1; -; mRNA. DR EMBL; U63917; AAB88017.1; -; mRNA. DR EMBL; AF027956; AAC52027.1; -; Genomic_DNA. DR EMBL; U58828; AAB02736.1; -; mRNA. DR EMBL; CR541741; CAG46541.1; -; mRNA. DR EMBL; AK291590; BAF84279.1; -; mRNA. DR EMBL; AB451427; BAG70241.1; -; mRNA. DR EMBL; CH236953; EAL23938.1; -; Genomic_DNA. DR EMBL; CH471144; EAW87194.1; -; Genomic_DNA. DR EMBL; BC011634; AAH11634.1; -; mRNA. DR CCDS; CCDS5322.1; -. DR PIR; G02670; G02670. DR PIR; JC5069; JC5069. DR RefSeq; NP_001035055.1; NM_001039966.2. DR RefSeq; NP_001091671.1; NM_001098201.3. DR RefSeq; NP_001496.1; NM_001505.3. DR PDB; 8XOF; EM; 2.60 A; R=1-375. DR PDB; 8XOG; EM; 2.90 A; R=1-375. DR PDB; 8XOH; EM; 3.20 A; R=1-375. DR PDB; 8XOI; EM; 3.20 A; R=1-375. DR PDB; 8XOJ; EM; 3.10 A; R=1-375. DR PDBsum; 8XOF; -. DR PDBsum; 8XOG; -. DR PDBsum; 8XOH; -. DR PDBsum; 8XOI; -. DR PDBsum; 8XOJ; -. DR AlphaFoldDB; Q99527; -. DR EMDB; EMD-38527; -. DR EMDB; EMD-38528; -. DR EMDB; EMD-38529; -. DR EMDB; EMD-38530; -. DR EMDB; EMD-38531; -. DR SMR; Q99527; -. DR BioGRID; 109110; 4. DR CORUM; Q99527; -. DR FunCoup; Q99527; 533. DR IntAct; Q99527; 1. DR STRING; 9606.ENSP00000380281; -. DR BindingDB; Q99527; -. DR ChEMBL; CHEMBL5872; -. DR DrugBank; DB00783; Estradiol. DR DrugBank; DB13952; Estradiol acetate. DR DrugBank; DB13953; Estradiol benzoate. DR DrugBank; DB13954; Estradiol cypionate. DR DrugBank; DB13955; Estradiol dienanthate. DR DrugBank; DB13956; Estradiol valerate. DR DrugBank; DB01645; Genistein. DR DrugBank; DB18091; LNS-8801. DR DrugBank; DB05939; MK-0354. DR DrugCentral; Q99527; -. DR GuidetoPHARMACOLOGY; 221; -. DR TCDB; 9.A.14.13.19; the g-protein-coupled receptor (gpcr) family. DR GlyCosmos; Q99527; 3 sites, No reported glycans. DR GlyGen; Q99527; 3 sites. DR iPTMnet; Q99527; -. DR PhosphoSitePlus; Q99527; -. DR BioMuta; GPER1; -. DR DMDM; 3023539; -. DR MassIVE; Q99527; -. DR PaxDb; 9606-ENSP00000380281; -. DR PeptideAtlas; Q99527; -. DR Antibodypedia; 10887; 427 antibodies from 34 providers. DR DNASU; 2852; -. DR Ensembl; ENST00000297469.3; ENSP00000297469.3; ENSG00000164850.17. DR Ensembl; ENST00000397088.4; ENSP00000380277.3; ENSG00000164850.17. DR Ensembl; ENST00000397092.5; ENSP00000380281.1; ENSG00000164850.17. DR Ensembl; ENST00000401670.1; ENSP00000385151.1; ENSG00000164850.17. DR GeneID; 2852; -. DR KEGG; hsa:2852; -. DR MANE-Select; ENST00000397088.4; ENSP00000380277.3; NM_001098201.3; NP_001091671.1. DR UCSC; uc003sjz.1; human. DR AGR; HGNC:4485; -. DR ClinPGx; PA28873; -. DR CTD; 2852; -. DR DisGeNET; 2852; -. DR GeneCards; GPER1; -. DR HGNC; HGNC:4485; GPER1. DR HPA; ENSG00000164850; Tissue enhanced (stomach). DR MIM; 601805; gene. DR OpenTargets; ENSG00000164850; -. DR VEuPathDB; HostDB:ENSG00000164850; -. DR eggNOG; ENOG502QU56; Eukaryota. DR GeneTree; ENSGT00940000154307; -. DR HOGENOM; CLU_009579_8_3_1; -. DR InParanoid; Q99527; -. DR OMA; FRTKQHA; -. DR OrthoDB; 5957382at2759; -. DR PAN-GO; Q99527; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q99527; -. DR PathwayCommons; Q99527; -. DR Reactome; R-HSA-375276; Peptide ligand-binding receptors. DR Reactome; R-HSA-418594; G alpha (i) signalling events. DR Reactome; R-HSA-9634597; GPER1 signaling. DR SignaLink; Q99527; -. DR SIGNOR; Q99527; -. DR Agora; ENSG00000164850; -. DR BioGRID-ORCS; 2852; 13 hits in 1132 CRISPR screens. DR GeneWiki; GPR30; -. DR GenomeRNAi; 2852; -. DR Pharos; Q99527; Tchem. DR PRO; PR:Q99527; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q99527; protein. DR Bgee; ENSG00000164850; Expressed in body of stomach and 131 other cell types or tissues. DR ExpressionAtlas; Q99527; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0043679; C:axon terminus; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043198; C:dendritic shaft; ISS:UniProtKB. DR GO; GO:0044327; C:dendritic spine head; ISS:UniProtKB. DR GO; GO:0032591; C:dendritic spine membrane; ISS:UniProtKB. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl. DR GO; GO:0045095; C:keratin filament; IDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; ISS:UniProtKB. DR GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB. DR GO; GO:0048786; C:presynaptic active zone; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; ISS:UniProtKB. DR GO; GO:0055037; C:recycling endosome; IDA:UniProtKB. DR GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0038054; F:G protein-coupled estrogen receptor activity; ISS:UniProtKB. DR GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc. DR GO; GO:0030284; F:nuclear estrogen receptor activity; IDA:UniProtKB. DR GO; GO:0005496; F:steroid binding; IDA:UniProtKB. DR GO; GO:1990239; F:steroid hormone binding; IDA:UniProtKB. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0030263; P:apoptotic chromosome condensation; ISS:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:UniProtKB. DR GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB. DR GO; GO:0071389; P:cellular response to mineralocorticoid stimulus; ISS:UniProtKB. DR GO; GO:0071375; P:cellular response to peptide hormone stimulus; IDA:UniProtKB. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:AgBase. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0010948; P:negative regulation of cell cycle process; IMP:AgBase. DR GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:AgBase. DR GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:AgBase. DR GO; GO:0050728; P:negative regulation of inflammatory response; IDA:UniProtKB. DR GO; GO:0002695; P:negative regulation of leukocyte activation; IDA:UniProtKB. DR GO; GO:0051055; P:negative regulation of lipid biosynthetic process; ISS:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:AgBase. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:AgBase. DR GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW. DR GO; GO:0019228; P:neuronal action potential; ISS:UniProtKB. DR GO; GO:0030264; P:nuclear fragmentation involved in apoptotic nuclear change; ISS:UniProtKB. DR GO; GO:0030518; P:nuclear receptor-mediated steroid hormone signaling pathway; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:2000724; P:positive regulation of cardiac vascular smooth muscle cell differentiation; IMP:AgBase. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB. DR GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; ISS:UniProtKB. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; ISS:UniProtKB. DR GO; GO:0045745; P:positive regulation of G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:AgBase. DR GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; IDA:UniProtKB. DR GO; GO:0032024; P:positive regulation of insulin secretion; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0050769; P:positive regulation of neurogenesis; ISS:UniProtKB. DR GO; GO:0001956; P:positive regulation of neurotransmitter secretion; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:UniProtKB. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0070474; P:positive regulation of uterine smooth muscle contraction; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; ISS:UniProtKB. DR GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; ISS:UniProtKB. DR GO; GO:0043401; P:steroid hormone receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0042311; P:vasodilation; ISS:UniProtKB. DR CDD; cd14989; 7tmA_GPER1; 1. DR FunFam; 1.20.1070.10:FF:000093; G-protein coupled estrogen receptor 1; 1. DR Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1. DR InterPro; IPR000276; GPCR_Rhodpsn. DR InterPro; IPR017452; GPCR_Rhodpsn_7TM. DR InterPro; IPR047143; GPER1-like. DR PANTHER; PTHR24226:SF2; G-PROTEIN COUPLED ESTROGEN RECEPTOR 1; 1. DR PANTHER; PTHR24226; G-PROTEIN COUPLED RECEPTOR 182 AND ESTROGEN RECEPTOR 1; 1. DR Pfam; PF00001; 7tm_1; 1. DR PRINTS; PR00237; GPCRRHODOPSN. DR SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1. DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1. DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Apoptosis; Cell cycle; Cell membrane; KW Cell projection; Cytoplasm; Cytoplasmic vesicle; Cytoskeleton; KW Differentiation; Disulfide bond; Endoplasmic reticulum; Endosome; KW G-protein coupled receptor; Glycoprotein; Golgi apparatus; Immunity; KW Inflammatory response; Innate immunity; Membrane; Mitochondrion; KW Neurogenesis; Nucleus; Postsynaptic cell membrane; KW Proteomics identification; Receptor; Reference proteome; Synapse; KW Transducer; Transmembrane; Transmembrane helix; Ubl conjugation. FT CHAIN 1..375 FT /note="G-protein coupled estrogen receptor 1" FT /id="PRO_0000069310" FT TOPO_DOM 1..62 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 63..84 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 85..96 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 97..120 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 121..132 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 133..153 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 154..175 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 176..194 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 195..220 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 221..236 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 237..259 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 260..280 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 281..306 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 307..327 FT /note="Helical; Name=7" FT /evidence="ECO:0000255" FT TOPO_DOM 328..375 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT CARBOHYD 25 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 32 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 44 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 130..207 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00521" FT VARIANT 16 FT /note="P -> L (in dbSNP:rs11544331)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:19054851" FT /id="VAR_033319" FT CONFLICT 20..21 FT /note="QP -> HA (in Ref. 6; AAC52027)" FT /evidence="ECO:0000305" FT CONFLICT 32..49 FT /note="Missing (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 104 FT /note="A -> G (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 140..146 FT /note="NMYSSVF -> QHVQAASS (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 179 FT /note="G -> A (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 184 FT /note="A -> S (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 312 FT /note="A -> T (in Ref. 2; AAC51173)" FT /evidence="ECO:0000305" FT CONFLICT 320 FT /note="N -> T (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 355 FT /note="A -> V (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 358 FT /note="A -> V (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT HELIX 53..86 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 88..90 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 116..118 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 121..124 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 127..160 FT /evidence="ECO:0007829|PDB:8XOG" FT STRAND 161..164 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 171..199 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 212..222 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 224..245 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 255..284 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 303..324 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 325..327 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 329..341 FT /evidence="ECO:0007829|PDB:8XOG" SQ SEQUENCE 375 AA; 42248 MW; 0A54EED8A698F075 CRC64; MDVTSQARGV GLEMYPGTAQ PAAPNTTSPE LNLSHPLLGT ALANGTGELS EHQQYVIGLF LSCLYTIFLF PIGFVGNILI LVVNISFREK MTIPDLYFIN LAVADLILVA DSLIEVFNLH ERYYDIAVLC TFMSLFLQVN MYSSVFFLTW MSFDRYIALA RAMRCSLFRT KHHARLSCGL IWMASVSATL VPFTAVHLQH TDEACFCFAD VREVQWLEVT LGFIVPFAII GLCYSLIVRV LVRAHRHRGL RPRRQKALRM ILAVVLVFFV CWLPENVFIS VHLLQRTQPG AAPCKQSFRH AHPLTGHIVN LAAFSNSCLN PLIYSFLGET FRDKLRLYIE QKTNLPALNR FCHAALKAVI PDSTEQSDVR FSSAV // ID INSR_HUMAN Reviewed; 1382 AA. AC P06213; Q17RW0; Q59H98; Q9UCB7; Q9UCB8; Q9UCB9; DT 01-JAN-1988, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 4. DT 28-JAN-2026, entry version 294. DE RecName: Full=Insulin receptor; DE Short=IR; DE EC=2.7.10.1; DE AltName: CD_antigen=CD220; DE Contains: DE RecName: Full=Insulin receptor subunit alpha; DE Contains: DE RecName: Full=Insulin receptor subunit beta; DE Flags: Precursor; GN Name=INSR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANTS GLY-2; HIS-171; RP THR-448 AND LYS-492. RX PubMed=2859121; DOI=10.1016/0092-8674(85)90334-4; RA Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E., Ou J.-H., RA Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J.; RT "The human insulin receptor cDNA: the structural basis for hormone- RT activated transmembrane signalling."; RL Cell 40:747-758(1985). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PROTEIN SEQUENCE OF 28-49 AND RP 763-782, GLYCOSYLATION AT ASN-43 AND ASN-769, AND VARIANT GLY-2. RX PubMed=2983222; DOI=10.1038/313756a0; RA Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M., Dull T.J., RA Gray A., Coussens L., Liao Y.-C., Tsubokawa M., Mason A., Seeburg P.H., RA Grunfeld C., Rosen O.M., Ramachandran J.; RT "Human insulin receptor and its relationship to the tyrosine kinase family RT of oncogenes."; RL Nature 313:756-761(1985). RN [3] RP SEQUENCE REVISION TO 899-900. RA Chen E.Y.; RL Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-2. RC TISSUE=Fetal liver; RX PubMed=2210055; DOI=10.2337/diacare.39.1.123; RA Seino S., Seino M., Bell G.I.; RT "Human insulin-receptor gene. Partial sequence and amplification of exons RT by polymerase chain reaction."; RL Diabetes 39:123-128(1990). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT GLY-2. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=3680248; DOI=10.1016/s0021-9258(18)47714-9; RA Araki E., Shimada F., Uzawa H., Mori M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene. Evidence for promoter activity."; RL J. Biol. Chem. 262:16186-16191(1987). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2806055; DOI=10.1016/0168-8227(89)90085-5; RA Araki E., Shimada F., Fukushima H., Mori M., Shichiri M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene."; RL Diabetes Res. Clin. Pract. 7:S31-S33(1989). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2777789; DOI=10.1016/s0021-9258(18)71612-8; RA Tewari D.S., Cook D.M., Taub R.; RT "Characterization of the promoter region and 3' end of the human insulin RT receptor gene."; RL J. Biol. Chem. 264:16238-16245(1989). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RC TISSUE=Skin fibroblast; RX PubMed=2280779; DOI=10.1210/mend-4-4-647; RA McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D., RA Taylor S.I.; RT "Structural and functional analysis of the insulin receptor promoter."; RL Mol. Endocrinol. 4:647-656(1990). RN [11] RP PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780, ACTIVITY RP REGULATION, AND SUBUNIT. RC TISSUE=Placenta; RX PubMed=2211730; DOI=10.1016/s0021-9258(17)44805-8; RA Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.; RT "Substructural analysis of the insulin receptor by microsequence analyses RT of limited tryptic fragments isolated by sodium dodecyl sulfate- RT polyacrylamide gel electrophoresis in the absence or presence of RT dithiothreitol."; RL J. Biol. Chem. 265:18673-18681(1990). RN [12] RP PROTEIN SEQUENCE OF 28-45 AND 763-782, FUNCTION, AND FORMATION OF A HYBRID RP RECEPTOR WITH IGF1R. RC TISSUE=Placenta; RX PubMed=8257688; DOI=10.1021/bi00212a019; RA Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A., RA Fujita-Yamaguchi Y.; RT "Characterization of human placental insulin-like growth factor-I/insulin RT hybrid receptors by protein microsequencing and purification."; RL Biochemistry 32:13531-13536(1993). RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG), AND ALTERNATIVE RP SPLICING. RX PubMed=2538124; DOI=10.1016/0006-291x(89)92439-x; RA Seino S., Bell G.I.; RT "Alternative splicing of human insulin receptor messenger RNA."; RL Biochem. Biophys. Res. Commun. 159:312-316(1989). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG), TISSUE SPECIFICITY, RP LIGAND-BINDING, AND AUTOPHOSPHORYLATION. RX PubMed=2369896; DOI=10.1002/j.1460-2075.1990.tb07416.x; RA Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A., McClain D.A.; RT "Functionally distinct insulin receptors generated by tissue-specific RT alternative splicing."; RL EMBO J. 9:2409-2413(1990). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085. RX PubMed=2566545; DOI=10.2337/diab.38.6.737; RA Elbein S.C.; RT "Molecular and clinical characterization of an insertional polymorphism of RT the insulin-receptor gene."; RL Diabetes 38:737-743(1989). RN [17] RP PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369, AND RP PHOSPHORYLATION AT TYR-999; TYR-1355 AND TYR-1361. RC TISSUE=Placenta; RX PubMed=3166375; DOI=10.1042/bj2520607; RA Tavare J.M., Denton R.M.; RT "Studies on the autophosphorylation of the insulin receptor from human RT placenta. Analysis of the sites phosphorylated by two-dimensional peptide RT mapping."; RL Biochem. J. 252:607-615(1988). RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123. RX PubMed=2544997; DOI=10.1126/science.2544997; RA Taira M., Taira M., Hashimoto N., Shimada F., Suzuki Y., Kanatsuka A., RA Nakamura F., Ebina Y., Tatibana M., Makino H.; RT "Human diabetes associated with a deletion of the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:63-66(1989). RN [19] RP PARTIAL PROTEIN SEQUENCE. RX PubMed=3447155; RA Fujita-Yamaguchi Y., Hawke D., Shively J.E., Choi S.; RT "Partial amino acid sequence analyses of human placental insulin RT receptor."; RL Protein Seq. Data Anal. 1:3-6(1987). RN [20] RP MUTAGENESIS OF LYS-1057. RX PubMed=3101064; DOI=10.1073/pnas.84.3.704; RA Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S., Siddle K., RA Pierce S.B., Roth R.A., Rutter W.J.; RT "Replacement of lysine residue 1030 in the putative ATP-binding region of RT the insulin receptor abolishes insulin- and antibody-stimulated glucose RT uptake and receptor kinase activity."; RL Proc. Natl. Acad. Sci. U.S.A. 84:704-708(1987). RN [21] RP MUTAGENESIS OF TYR-999. RX PubMed=2842060; DOI=10.1016/s0092-8674(88)80008-4; RA White M.F., Livingston J.N., Backer J.M., Lauris V., Dull T.J., Ullrich A., RA Kahn C.R.; RT "Mutation of the insulin receptor at tyrosine 960 inhibits signal RT transmission but does not affect its tyrosine kinase activity."; RL Cell 54:641-649(1988). RN [22] RP AUTOPHOSPHORYLATION. RX PubMed=1321605; DOI=10.1016/s0006-291x(05)80799-5; RA Dickens M., Tavare J.M.; RT "Analysis of the order of autophosphorylation of human insulin receptor RT tyrosines 1158, 1162 and 1163."; RL Biochem. Biophys. Res. Commun. 186:244-250(1992). RN [23] RP DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-541. RX PubMed=1472036; DOI=10.1016/0006-291x(92)92250-2; RA Schaeffer L., Ljungqvist L.; RT "Identification of a disulfide bridge connecting the alpha-subunits of the RT extracellular domain of the insulin receptor."; RL Biochem. Biophys. Res. Commun. 189:650-653(1992). RN [24] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=8452530; DOI=10.1042/bj2900419; RA Soos M.A., Field C.E., Siddle K.; RT "Purified hybrid insulin/insulin-like growth factor-I receptors bind RT insulin-like growth factor-I, but not insulin, with high affinity."; RL Biochem. J. 290:419-426(1993). RN [25] RP FUNCTION, AND INTERACTION WITH PIK3R1. RX PubMed=8276809; DOI=10.1016/s0021-9258(17)42304-0; RA Van Horn D.J., Myers M.G. Jr., Backer J.M.; RT "Direct activation of the phosphatidylinositol 3'-kinase by the insulin RT receptor."; RL J. Biol. Chem. 269:29-32(1994). RN [26] RP INTERACTION WITH IRS1 AND SHC1, AND MUTAGENESIS OF LEU-991; TYR-992; RP ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002. RX PubMed=7559478; DOI=10.1074/jbc.270.40.23258; RA He W., O'Neill T.J., Gustafson T.A.; RT "Distinct modes of interaction of SHC and insulin receptor substrate-1 with RT the insulin receptor NPEY region via non-SH2 domains."; RL J. Biol. Chem. 270:23258-23262(1995). RN [27] RP INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF ASN-996; RP PRO-997; GLU-998; TYR-999 AND LYS-1057. RX PubMed=7537849; DOI=10.1128/mcb.15.5.2500; RA Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.; RT "Phosphotyrosine-dependent interaction of SHC and insulin receptor RT substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 RT domain."; RL Mol. Cell. Biol. 15:2500-2508(1995). RN [28] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9355755; DOI=10.1042/bj3270209; RA Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.; RT "Insulin receptor/IGF-I receptor hybrids are widely distributed in RT mammalian tissues: quantification of individual receptor species by RT selective immunoprecipitation and immunoblotting."; RL Biochem. J. 327:209-215(1997). RN [29] RP FUNCTION IN PHOSPHORYLATION OF STAT5B, MUTAGENESIS OF TYR-999, AND RP INTERACTION WITH STAT5B; IRS1 AND IRS2. RX PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x; RA Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I., RA Van Obberghen E.; RT "Identification of Stat 5B as a substrate of the insulin receptor."; RL Eur. J. Biochem. 250:411-417(1997). RN [30] RP INTERACTION WITH PTPRF. RX PubMed=8995282; DOI=10.1074/jbc.272.11.7519; RA Ahmad F., Goldstein B.J.; RT "Functional association between the insulin receptor and the transmembrane RT protein-tyrosine phosphatase LAR in intact cells."; RL J. Biol. Chem. 272:448-457(1997). RN [31] RP INTERACTION WITH PTPRE, AND DEPHOSPHORYLATION BY PTPRE. RX PubMed=8999839; DOI=10.1074/jbc.272.3.1639; RA Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J., RA Gustafson T.A., Kusari J.; RT "Protein-tyrosine phosphatase 1B complexes with the insulin receptor in RT vivo and is tyrosine-phosphorylated in the presence of insulin."; RL J. Biol. Chem. 272:1639-1645(1997). RN [32] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9202395; DOI=10.1016/s0303-7207(97)04050-1; RA Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D., RA Sesti G.; RT "Distribution of insulin/insulin-like growth factor-I hybrid receptors in RT human tissues."; RL Mol. Cell. Endocrinol. 129:121-126(1997). RN [33] RP TISSUE SPECIFICITY, AND FUNCTION AS RECEPTOR FOR IGFII (ISOFORM SHORT). RX PubMed=10207053; DOI=10.1128/mcb.19.5.3278; RA Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., RA Goldfine I.D., Belfiore A., Vigneri R.; RT "Insulin receptor isoform A, a newly recognized, high-affinity insulin-like RT growth factor II receptor in fetal and cancer cells."; RL Mol. Cell. Biol. 19:3278-3288(1999). RN [34] RP INTERACTION WITH ENPP1, AND ACTIVITY REGULATION. RX PubMed=10615944; DOI=10.2337/diabetes.49.1.13; RA Maddux B.A., Goldfine I.D.; RT "Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs RT via direct interaction with the receptor alpha-subunit."; RL Diabetes 49:13-19(2000). RN [35] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2. RX PubMed=10734133; DOI=10.1074/jbc.275.13.9792; RA Waelchli S., Curchod M.L., Gobert R.P., Arkinstall S., RA Hooft van Huijsduijnen R.; RT "Identification of tyrosine phosphatases that dephosphorylate the insulin RT receptor. A brute force approach based on 'substrate-trapping' mutants."; RL J. Biol. Chem. 275:9792-9796(2000). RN [36] RP INTERACTION WITH GRB7, AND MUTAGENESIS OF LYS-1057; TYR-1189 AND TYR-1190. RX PubMed=10803466; DOI=10.1038/sj.onc.1203469; RA Kasus-Jacobi A., Bereziat V., Perdereau D., Girard J., Burnol A.F.; RT "Evidence for an interaction between the insulin receptor and Grb7. A role RT for two of its binding domains, PIR and SH2."; RL Oncogene 19:2052-2059(2000). RN [37] RP INTERACTION WITH SORBS1. RX PubMed=11374898; DOI=10.1006/geno.2001.6541; RA Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y., RA Chuang L.-M.; RT "Cloning, mapping, and characterization of the human sorbin and SH3 domain RT containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin RT signaling in the hepatoma cell line Hep3B."; RL Genomics 74:12-20(2001). RN [38] RP CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-1159 AND ARG-1163, AND ACTIVITY RP REGULATION. RX PubMed=11598120; DOI=10.1074/jbc.m107236200; RA Ablooglu A.J., Frankel M., Rusinova E., Ross J.B., Kohanski R.A.; RT "Multiple activation loop conformations and their regulatory properties in RT the insulin receptor's kinase domain."; RL J. Biol. Chem. 276:46933-46940(2001). RN [39] RP INTERACTION WITH GRB14, AND ACTIVITY REGULATION. RX PubMed=11726652; DOI=10.1074/jbc.m106574200; RA Bereziat V., Kasus-Jacobi A., Perdereau D., Cariou B., Girard J., RA Burnol A.F.; RT "Inhibition of insulin receptor catalytic activity by the molecular adapter RT Grb14."; RL J. Biol. Chem. 277:4845-4852(2002). RN [40] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=12138094; DOI=10.1074/jbc.m202766200; RA Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.; RT "Insulin/insulin-like growth factor I hybrid receptors have different RT biological characteristics depending on the insulin receptor isoform RT involved."; RL J. Biol. Chem. 277:39684-39695(2002). RN [41] RP INTERACTION WITH GRB10, AND ACTIVITY REGULATION. RX PubMed=12493740; DOI=10.1074/jbc.m208518200; RA Wick K.R., Werner E.D., Langlais P., Ramos F.J., Dong L.Q., Shoelson S.E., RA Liu F.; RT "Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)- RT phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the RT association of IRS-1/IRS-2 with the insulin receptor."; RL J. Biol. Chem. 278:8460-8467(2003). RN [42] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2. RX PubMed=12612081; DOI=10.1128/mcb.23.6.2096-2108.2003; RA Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A., RA Meng T.C., Tonks N.K., Tiganis T.; RT "Regulation of insulin receptor signaling by the protein tyrosine RT phosphatase TCPTP."; RL Mol. Cell. Biol. 23:2096-2108(2003). RN [43] RP INTERACTION WITH SOCS7. RX PubMed=16127460; DOI=10.1172/jci23853; RA Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D., RA Rothman P.B.; RT "Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of RT Langerhans."; RL J. Clin. Invest. 115:2462-2471(2005). RN [44] RP FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=16314505; DOI=10.1128/mcb.25.24.10803-10814.2005; RA Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I., Corbo V., RA Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S., Formisano P., RA Beguinot F.; RT "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the RT insulin receptor is necessary for insulin metabolic signaling."; RL Mol. Cell. Biol. 25:10803-10814(2005). RN [45] RP DEPHOSPHORYLATION BY PTPRE. RX PubMed=15738637; DOI=10.2108/zsj.22.169; RA Nakagawa Y., Aoki N., Aoyama K., Shimizu H., Shimano H., Yamada N., RA Miyazaki H.; RT "Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a RT negative regulator of insulin signaling in primary hepatocytes and liver."; RL Zool. Sci. 22:169-175(2005). RN [46] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=16831875; DOI=10.1074/jbc.m605189200; RA Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C., RA Mathiasen I.S., Brandt J.; RT "Hybrid receptors formed by insulin receptor (IR) and insulin-like growth RT factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity RT irrespective of the IR splice variant."; RL J. Biol. Chem. 281:25869-25874(2006). RN [47] RP REVIEW ON SIGNALING PATHWAYS. RX PubMed=16493415; DOI=10.1038/nrm1837; RA Taniguchi C.M., Emanuelli B., Kahn C.R.; RT "Critical nodes in signalling pathways: insights into insulin action."; RL Nat. Rev. Mol. Cell Biol. 7:85-96(2006). RN [48] RP REVIEW ON REGULATION OF INSR FUNCTION. RX PubMed=17347799; DOI=10.1007/s00018-007-6359-9; RA Youngren J.F.; RT "Regulation of insulin receptor function."; RL Cell. Mol. Life Sci. 64:873-891(2007). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND SER-407, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [50] RP DOMAIN, AND INSULIN-BINDING SITE. RX PubMed=19459609; DOI=10.1021/bi900261q; RA Menting J.G., Ward C.W., Margetts M.B., Lawrence M.C.; RT "A thermodynamic study of ligand binding to the first three domains of the RT human insulin receptor: relationship between the receptor alpha-chain C- RT terminal peptide and the site 1 insulin mimetic peptides."; RL Biochemistry 48:5492-5500(2009). RN [51] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [52] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [53] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [54] RP INTERACTION WITH NCK1, AND PHOSPHORYLATION AT TYR-1189 AND TYR-1190. RX PubMed=21707536; DOI=10.1042/bj20110799; RA Wu C.L., Buszard B., Teng C.H., Chen W.L., Warr C.G., Tiganis T., RA Meng T.C.; RT "Dock/Nck facilitates PTP61F/PTP1B regulation of insulin signalling."; RL Biochem. J. 439:151-159(2011). RN [55] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [56] RP INTERACTION WITH CCDC88A AND GNAI3. RX PubMed=25187647; DOI=10.1091/mbc.e14-05-0978; RA Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M., RA Kufareva I., Abagyan R., Ghosh P.; RT "Structural basis for activation of trimeric Gi proteins by multiple growth RT factor receptors via GIV/Girdin."; RL Mol. Biol. Cell 25:3654-3671(2014). RN [57] RP PHOSPHORYLATION AT TYR-1185 AND TYR-1190. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [58] RP MUTAGENESIS OF LYS-1079, AND UBIQUITINATION AT LYS-1079. RX PubMed=27577745; DOI=10.1038/ncomms12639; RA Nagarajan A., Petersen M.C., Nasiri A.R., Butrico G., Fung A., Ruan H.B., RA Kursawe R., Caprio S., Thibodeau J., Bourgeois-Daigneault M.C., Sun L., RA Gao G., Bhanot S., Jurczak M.J., Green M.R., Shulman G.I., Wajapeyee N.; RT "MARCH1 regulates insulin sensitivity by controlling cell surface insulin RT receptor levels."; RL Nat. Commun. 7:12639-12639(2016). RN [59] RP INTERACTION WITH SORL1. RX PubMed=27322061; DOI=10.1172/jci84708; RA Schmidt V., Schulz N., Yan X., Schuermann A., Kempa S., Kern M., RA Blueher M., Poy M.N., Olivecrona G., Willnow T.E.; RT "SORLA facilitates insulin receptor signaling in adipocytes and exacerbates RT obesity."; RL J. Clin. Invest. 126:2706-2720(2016). RN [60] RP SUBUNIT. RX PubMed=27617429; DOI=10.1038/nsmb.3292; RA Menting J.G., Gajewiak J., MacRaild C.A., Chou D.H., Disotuar M.M., RA Smith N.A., Miller C., Erchegyi J., Rivier J.E., Olivera B.M., Forbes B.E., RA Smith B.J., Norton R.S., Safavi-Hemami H., Lawrence M.C.; RT "A minimized human insulin-receptor-binding motif revealed in a Conus RT geographus venom insulin."; RL Nat. Struct. Mol. Biol. 23:916-920(2016). RN [61] RP S-NITROSYLATION AT CYS-1083, AND MUTAGENESIS OF CYS-462; CYS-825; CYS-834 RP AND CYS-1083. RX PubMed=38056462; DOI=10.1016/j.cell.2023.11.009; RA Zhou H.L., Grimmett Z.W., Venetos N.M., Stomberski C.T., Qian Z., RA McLaughlin P.J., Bansal P.K., Zhang R., Reynolds J.D., Premont R.T., RA Stamler J.S.; RT "An enzyme that selectively S-nitrosylates proteins to regulate insulin RT signaling."; RL Cell 0:0-0(2023). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310. RX PubMed=7997262; DOI=10.1038/372746a0; RA Hubbard S.R., Wei L., Ellis L., Hendrickson W.A.; RT "Crystal structure of the tyrosine kinase domain of the human insulin RT receptor."; RL Nature 372:746-754(1994). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND IRS1 PEPTIDE, CATALYTIC ACTIVITY, ACTIVE SITE, RP AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190. RX PubMed=9312016; DOI=10.1093/emboj/16.18.5572; RA Hubbard S.R.; RT "Crystal structure of the activated insulin receptor tyrosine kinase in RT complex with peptide substrate and ATP analog."; RL EMBO J. 16:5572-5581(1997). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG, AND CATALYTIC ACTIVITY. RX PubMed=11124964; DOI=10.1074/jbc.m010161200; RA Till J.H., Ablooglu A.J., Frankel M., Bishop S.M., Kohanski R.A., RA Hubbard S.R.; RT "Crystallographic and solution studies of an activation loop mutant of the RT insulin receptor tyrosine kinase: insights into kinase mechanism."; RL J. Biol. Chem. 276:10049-10055(2001). RN [65] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1298 OF MUTANT ASN-1159, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF TYR-1011. RX PubMed=12707268; DOI=10.1074/jbc.m302425200; RA Li S., Covino N.D., Stein E.G., Till J.H., Hubbard S.R.; RT "Structural and biochemical evidence for an autoinhibitory role for RT tyrosine 984 in the juxtamembrane region of the insulin receptor."; RL J. Biol. Chem. 278:26007-26014(2003). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND SH2B2, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=14690593; DOI=10.1016/s1097-2765(03)00487-8; RA Hu J., Liu J., Ghirlando R., Saltiel A.R., Hubbard S.R.; RT "Structural basis for recruitment of the adaptor protein APS to the RT activated insulin receptor."; RL Mol. Cell 12:1379-1389(2003). RN [67] RP X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH GRB14, RP INTERACTION WITH GRB14, AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT RP TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16246733; DOI=10.1016/j.molcel.2005.09.001; RA Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J., Hubbard S.R.; RT "Structural basis for inhibition of the insulin receptor by the adaptor RT protein Grb14."; RL Mol. Cell 20:325-333(2005). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH PTPN1, RP AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16271887; DOI=10.1016/j.str.2005.07.019; RA Li S., Depetris R.S., Barford D., Chernoff J., Hubbard S.R.; RT "Crystal structure of a complex between protein tyrosine phosphatase 1B and RT the insulin receptor tyrosine kinase."; RL Structure 13:1643-1651(2005). RN [69] RP X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 28-943 IN COMPLEX WITH INSULIN RP ANALOG, DOMAIN, AND DISULFIDE BONDS. RX PubMed=16957736; DOI=10.1038/nature05106; RA McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E., RA Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A., RA Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E., RA Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J., Sparrow L.G., RA Fernley R.T., Epa V.C., Ward C.W.; RT "Structure of the insulin receptor ectodomain reveals a folded-over RT conformation."; RL Nature 443:218-221(2006). RN [70] RP X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 28-512, GLYCOSYLATION AT ASN-43; RP ASN-52; ASN-138; ASN-242; ASN-282; ASN-364; ASN-424 AND ASN-445, AND RP DISULFIDE BONDS. RX PubMed=16894147; DOI=10.1073/pnas.0605395103; RA Lou M., Garrett T.P., McKern N.M., Hoyne P.A., Epa V.C., Bentley J.D., RA Lovrecz G.O., Cosgrove L.J., Frenkel M.J., Ward C.W.; RT "The first three domains of the insulin receptor differ structurally from RT the insulin-like growth factor 1 receptor in the regions governing ligand RT specificity."; RL Proc. Natl. Acad. Sci. U.S.A. 103:12429-12434(2006). RN [71] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP AND RP IRS2, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190, AND INTERACTION WITH IRS2. RX PubMed=18278056; DOI=10.1038/nsmb.1388; RA Wu J., Tseng Y.D., Xu C.F., Neubert T.A., White M.F., Hubbard S.R.; RT "Structural and biochemical characterization of the KRLB region in insulin RT receptor substrate-2."; RL Nat. Struct. Mol. Biol. 15:251-258(2008). RN [72] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1009-1310 IN COMPLEX WITH RP INHIBITORY PEPTIDE, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=18767165; DOI=10.1002/prot.22207; RA Katayama N., Orita M., Yamaguchi T., Hisamichi H., Kuromitsu S., RA Kurihara H., Sakashita H., Matsumoto Y., Fujita S., Niimi T.; RT "Identification of a key element for hydrogen-bonding patterns between RT protein kinases and their inhibitors."; RL Proteins 73:795-801(2008). RN [73] RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19071018; DOI=10.1016/j.bmcl.2008.11.077; RA Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B., RA Gerding R., Lei H., Yang B., Stevens K.L., Hassell A.M., Shewchuk L.M., RA Leesnitzer M.A., Smith J.L., Sabbatini P., Atkins C., Groy A., Rowand J.L., RA Kumar R., Mook R.A. Jr., Moorthy G., Patnaik S.; RT "Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R RT tyrosine kinase inhibitors towards JNK selectivity."; RL Bioorg. Med. Chem. Lett. 19:360-364(2009). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19056263; DOI=10.1016/j.bmcl.2008.11.046; RA Chamberlain S.D., Wilson J.W., Deanda F., Patnaik S., Redman A.M., Yang B., RA Shewchuk L., Sabbatini P., Leesnitzer M.A., Groy A., Atkins C., Gerding R., RA Hassell A.M., Lei H., Mook R.A. Jr., Moorthy G., Rowand J.L., Stevens K.L., RA Kumar R., Shotwell J.B.; RT "Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent RT inhibitors of the IGF-1R receptor tyrosine kinase."; RL Bioorg. Med. Chem. Lett. 19:469-473(2009). RN [75] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1017-1322 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19394223; DOI=10.1016/j.bmcl.2008.12.110; RA Patnaik S., Stevens K.L., Gerding R., Deanda F., Shotwell J.B., Tang J., RA Hamajima T., Nakamura H., Leesnitzer M.A., Hassell A.M., Shewchuck L.M., RA Kumar R., Lei H., Chamberlain S.D.; RT "Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent RT inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine RT kinase."; RL Bioorg. Med. Chem. Lett. 19:3136-3140(2009). RN [76] RP X-RAY CRYSTALLOGRAPHY (3.80 ANGSTROMS) OF 28-956, INSULIN-BINDING REGION, RP AND DISULFIDE BONDS. RX PubMed=20348418; DOI=10.1073/pnas.1001813107; RA Smith B.J., Huang K., Kong G., Chan S.J., Nakagawa S., Menting J.G., RA Hu S.Q., Whittaker J., Steiner D.F., Katsoyannis P.G., Ward C.W., RA Weiss M.A., Lawrence M.C.; RT "Structural resolution of a tandem hormone-binding element in the insulin RT receptor and its implications for design of peptide agonists."; RL Proc. Natl. Acad. Sci. U.S.A. 107:6771-6776(2010). RN [77] RP X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 28-620 IN COMPLEX WITH INSULIN, RP DOMAIN, GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242 AND ASN-282, AND RP DISULFIDE BONDS. RX PubMed=23302862; DOI=10.1038/nature11781; RA Menting J.G., Whittaker J., Margetts M.B., Whittaker L.J., Kong G.K., RA Smith B.J., Watson C.J., Zakova L., Kletvikova E., Jiracek J., Chan S.J., RA Steiner D.F., Dodson G.G., Brzozowski A.M., Weiss M.A., Ward C.W., RA Lawrence M.C.; RT "How insulin engages its primary binding site on the insulin receptor."; RL Nature 493:241-245(2013). RN [78] RP VARIANT IRAN TYPE A SER-762. RX PubMed=3283938; DOI=10.1126/science.3283938; RA Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H., RA Imura H., Bell G.I., Steiner D.F.; RT "Insulin-resistant diabetes due to a point mutation that prevents insulin RT proreceptor processing."; RL Science 240:784-787(1988). RN [79] RP VARIANT LEPRCH GLU-487. RX PubMed=2834824; DOI=10.1126/science.2834824; RA Kadowaki T., Bevins C., Cama A., Ojamaa K., Marcus-Samuels B., Kadowaki H., RA Beitz L., McKeon C., Taylor S.I.; RT "Two mutant alleles of the insulin receptor gene in a patient with extreme RT insulin resistance."; RL Science 240:787-790(1988). RN [80] RP VARIANT LEPRCH PRO-260. RX PubMed=2479553; DOI=10.1002/j.1460-2075.1989.tb08387.x; RA Klinkhamer M.P., Groen N.A., van der Zon G.C.M., Lindhout D., RA Sandkuyl L.A., Krans H.M.J., Moeller W., Maassen J.A.; RT "A leucine-to-proline mutation in the insulin receptor in a family with RT insulin resistance."; RL EMBO J. 8:2503-2507(1989). RN [81] RP VARIANT IRAN TYPE A VAL-1035. RX PubMed=2544998; DOI=10.1126/science.2544998; RA Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K., Accili D., RA Bevins C., Mikami Y., Matsuura N., Akanuma Y., Takaku F., Taylor S.I., RA Kasuga M.; RT "Human diabetes associated with a mutation in the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:66-68(1989). RN [82] RP VARIANT IRAN TYPE A THR-1161. RX PubMed=2168397; DOI=10.1016/s0021-9258(18)77212-8; RA Moller D.E., Yokota A., White M.F., Pazianos A.G., Flier J.S.; RT "A naturally occurring mutation of insulin receptor alanine 1134 impairs RT tyrosine kinase function and is associated with dominantly inherited RT insulin resistance."; RL J. Biol. Chem. 265:14979-14985(1990). RN [83] RP CHARACTERIZATION OF VARIANT RMS LYS-42. RX PubMed=2121734; DOI=10.1016/s0021-9258(17)30636-1; RA Kadowaki T., Kadowaki H., Accili D., Taylor S.I.; RT "Substitution of lysine for asparagine at position 15 in the alpha-subunit RT of the human insulin receptor. A mutation that impairs transport of RT receptors to the cell surface and decreases the affinity of insulin RT binding."; RL J. Biol. Chem. 265:19143-19150(1990). RN [84] RP VARIANT RMS LYS-42, VARIANT LEPRCH ARG-236, AND VARIANT IRAN TYPE A RP SER-489. RX PubMed=2365819; DOI=10.1172/jci114693; RA Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J., RA Gorden P., Taylor S.I.; RT "Five mutant alleles of the insulin receptor gene in patients with genetic RT forms of insulin resistance."; RL J. Clin. Invest. 86:254-264(1990). RN [85] RP VARIANT IRAN TYPE A SER-1227. RX PubMed=1963473; DOI=10.1210/mend-4-8-1183; RA Moller D.E., Yokota A., Ginsberg-Fellner F., Flier J.S.; RT "Functional properties of a naturally occurring Trp1200-->Ser1200 mutation RT of the insulin receptor."; RL Mol. Endocrinol. 4:1183-1191(1990). RN [86] RP VARIANT GLU-1095. RX PubMed=2040394; DOI=10.2337/diab.40.6.777; RA O'Rahilly S., Choi W.H., Patel P., Turner R.C., Flier J.S., Moller D.E.; RT "Detection of mutations in insulin-receptor gene in NIDDM patients by RT analysis of single-stranded conformation polymorphisms."; RL Diabetes 40:777-782(1991). RN [87] RP VARIANT IRAN TYPE A GLN-1020. RX PubMed=2002058; DOI=10.1016/s0021-9258(19)67781-1; RA Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O., RA Olefsky J.M.; RT "Insulin resistance and diabetes due to different mutations in the tyrosine RT kinase domain of both insulin receptor gene alleles."; RL J. Biol. Chem. 266:5260-5267(1991). RN [88] RP VARIANT INS RESISTANCE ILE-1180. RX PubMed=1890161; DOI=10.1210/jcem-73-4-894; RA Cama A., de la Luz Sierra M., Ottini L., Kadowaki T., Gorden P., RA Imperato-Mcginley J., Taylor S.I.; RT "A mutation in the tyrosine kinase domain of the insulin receptor RT associated with insulin resistance in an obese woman."; RL J. Clin. Endocrinol. Metab. 73:894-901(1991). RN [89] RP VARIANTS LEPRCH ALA-55 AND ARG-393. RX PubMed=1607067; DOI=10.2337/diab.41.4.408; RA Barbetti F., Gejman P.V., Taylor S.I., Raben N., Cama A., Bonora E., RA Pizzo P., Moghetti P., Muggeo M., Roth J.; RT "Detection of mutations in insulin receptor gene by denaturing gradient gel RT electrophoresis."; RL Diabetes 41:408-415(1992). RN [90] RP VARIANT T2D GLN-1191. RX PubMed=1607076; DOI=10.2337/diab.41.4.521; RA Cocozza S., Porcellini A., Riccardi G., Monticelli A., Condorelli G., RA Ferrara A., Pianese L., Miele C., Capaldo B., Beguinot F., Varrone S.; RT "NIDDM associated with mutation in tyrosine kinase domain of insulin RT receptor gene."; RL Diabetes 41:521-526(1992). RN [91] RP VARIANT IRAN TYPE A LEU-1205. RX PubMed=1563582; DOI=10.1007/bf00400927; RA Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y., RA Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., Kasuga M., Taylor S.I., RA Kadowaki T.; RT "Detection of mutations in the insulin receptor gene in patients with RT insulin resistance by analysis of single-stranded conformational RT polymorphisms."; RL Diabetologia 35:261-266(1992). RN [92] RP VARIANT LEPRCH ARG-58. RX PubMed=1730625; DOI=10.1016/s0021-9258(18)48459-1; RA van der Vorm E.R., van der Zon G.C.M., Moeller W., Krans H.M.J., RA Lindhout D., Maassen J.A.; RT "An Arg for Gly substitution at position 31 in the insulin receptor, linked RT to insulin resistance, inhibits receptor processing and transport."; RL J. Biol. Chem. 267:66-71(1992). RN [93] RP VARIANT T2D GLN-1158. RX PubMed=1470163; RA Kasuga M., Kishimoto M., Hashiramoto M., Yonezawa K., Kazumi T., Hagino H., RA Shii K.; RT "Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of RT insulin receptor observed in insulin resistant diabetes."; RL Nihon Geka Gakkai Zasshi 93:968-971(1992). RN [94] RP VARIANT MET-1012. RX PubMed=8432414; DOI=10.2337/diab.42.3.429; RA Elbein S.C., Sorensen L.K., Schumacher M.C.; RT "Methionine for valine substitution in exon 17 of the insulin receptor gene RT in a pedigree with familial NIDDM."; RL Diabetes 42:429-434(1993). RN [95] RP VARIANT IRAN TYPE A ASP-1075. RX PubMed=8243830; DOI=10.2337/diab.42.12.1837; RA Haruta T., Takata Y., Iwanishi M., Maegawa H., Imamura T., Egawa K., RA Itazu T., Kobayashi M.; RT "Ala1048-->Asp mutation in the kinase domain of insulin receptor causes RT defective kinase activity and insulin resistance."; RL Diabetes 42:1837-1844(1993). RN [96] RP VARIANT MET-1012. RX PubMed=8458533; DOI=10.1007/bf00400701; RA van der Vorm E.R., Kuipers A., Bonenkamp J.W., Kleijer W.J., RA van Maldergem L., Herwig J., Maassen J.A.; RT "Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli RT type, express normal insulin receptors."; RL Diabetologia 36:172-174(1993). RN [97] RP VARIANT INS RESISTANCE LEU-1220. RX PubMed=8390949; DOI=10.1007/bf00402277; RA Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K., RA Imamura T., Naitou K., Itazu T., Kobayashi M.; RT "A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the RT insulin receptor associated with type A syndrome of insulin resistance."; RL Diabetologia 36:414-422(1993). RN [98] RP VARIANT INS RESISTANCE LEU-220. RX PubMed=8242067; DOI=10.1093/hmg/2.9.1437; RA Carrera P., Cordera R., Ferrari M., Cremonesi L., Taramelli R., RA Andraghetti G., Carducci C., Dozio N., Pozza G., Taylor S.I., Micossi P., RA Barbetti F.; RT "Substitution of Leu for Pro-193 in the insulin receptor in a patient with RT a genetic form of severe insulin resistance."; RL Hum. Mol. Genet. 2:1437-1441(1993). RN [99] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162. RX PubMed=8096518; DOI=10.1016/s0021-9258(18)53063-5; RA Cama A., de la Luz Sierra M., Quon M.J., Ottini L., Gorden P., Taylor S.I.; RT "Substitution of glutamic acid for alanine 1135 in the putative 'catalytic RT loop' of the tyrosine kinase domain of the human insulin receptor. A RT mutation that impairs proteolytic processing into subunits and inhibits RT receptor tyrosine kinase activity."; RL J. Biol. Chem. 268:8060-8069(1993). RN [100] RP VARIANT IRAN TYPE A VAL-409. RX PubMed=8388389; DOI=10.1016/s0021-9258(18)82120-2; RA Lebrun C., Baron V., Kaliman P., Gautier N., Dolais-Kitabgi J., RA Taylor S.I., Accili D., van Obberghen E.; RT "Antibodies to the extracellular receptor domain restore the hormone- RT insensitive kinase and conformation of the mutant insulin receptor valine RT 382."; RL J. Biol. Chem. 268:11272-11277(1993). RN [101] RP VARIANT LEPRCH MET-146. RX PubMed=8326490; DOI=10.1136/jmg.30.6.470; RA Al-Gazali L.I., Khalil M., Devadas K.; RT "A syndrome of insulin resistance resembling leprechaunism in five sibs of RT consanguineous parents."; RL J. Med. Genet. 30:470-475(1993). RN [102] RP VARIANT LEPRCH PRO-113. RX PubMed=8419945; DOI=10.1073/pnas.90.1.60; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Activation of glucose transport by a natural mutation in the human insulin RT receptor."; RL Proc. Natl. Acad. Sci. U.S.A. 90:60-64(1993). RN [103] RP VARIANT IRAN TYPE A GLN-1201. RX PubMed=8288049; DOI=10.2337/diab.43.2.247; RA Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F., Eberle A., RA Morrow L.A., Moses A.C., Flier J.S.; RT "Prevalence of mutations in the insulin receptor gene in subjects with RT features of the type A syndrome of insulin resistance."; RL Diabetes 43:247-255(1994). RN [104] RP VARIANT RMS SYNDROME LEU-350, VARIANTS IRAN TYPE A LEU-1205 AND GLN-1378, RP AND VARIANT MET-1012. RX PubMed=8314008; DOI=10.2337/diab.43.3.357; RA Krook A., Kumar S., Laing I., Boulton A.J., Wass J.A., O'Rahilly S.; RT "Molecular scanning of the insulin receptor gene in syndromes of insulin RT resistance."; RL Diabetes 43:357-368(1994). RN [105] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201. RX PubMed=8082780; DOI=10.1016/0014-5793(94)00876-0; RA Moritz W., Froesch E.R., Boeni-Schnetzler M.; RT "Functional properties of a heterozygous mutation (Arg1174-->Gln) in the RT tyrosine kinase domain of the insulin receptor from a type A insulin RT resistant patient."; RL FEBS Lett. 351:276-280(1994). RN [106] RP VARIANT LEPRCH SER-439. RX PubMed=8188715; DOI=10.1016/s0021-9258(17)36788-1; RA van der Vorm E.R., Kuipers A., Kielkopf-Renner S., Krans H.M.J., Moller W., RA Maassen J.A.; RT "A mutation in the insulin receptor that impairs proreceptor processing but RT not insulin binding."; RL J. Biol. Chem. 269:14297-14302(1994). RN [107] RP CHARACTERIZATION OF VARIANTS IRAN TYPE A ASP-1206 AND LEU-1220. RX PubMed=7983039; DOI=10.1016/s0021-9258(18)47384-x; RA Imamura T., Takata Y., Sasaoka T., Takada Y., Morioka H., Haruta T., RA Sawa T., Iwanishi M., Hu Y.G., Suzuki Y., Hamada J., Kobayashi M.; RT "Two naturally occurring mutations in the kinase domain of insulin receptor RT accelerate degradation of the insulin receptor and impair the kinase RT activity."; RL J. Biol. Chem. 269:31019-31027(1994). RN [108] RP VARIANT LEPRCH MET-146. RX PubMed=7815442; DOI=10.1136/jmg.31.9.715; RA Hone J., Accili D., al-Gazali L.I., Lestringant G., Orban T., Taylor S.I.; RT "Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor RT gene in five sibs with familial insulin resistance."; RL J. Med. Genet. 31:715-716(1994). RN [109] RP VARIANT T2D ALA-858, AND VARIANT CYS-1361. RX PubMed=7657032; DOI=10.2337/diab.44.9.1081; RA Kan M., Kanai F., Iida M., Jinnouchi H., Todaka M., Imanaka T., Ito K., RA Nishioka Y., Ohnishi T., Kamohara S., Hayashi H., Murakami T., Kagawa S., RA Sano H., Hashimoto N., Yoshida S., Makino H., Ebina Y.; RT "Frequency of mutations of insulin receptor gene in Japanese patients with RT NIDDM."; RL Diabetes 44:1081-1086(1995). RN [110] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=7538143; DOI=10.1210/jcem.80.5.7538143; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Two mutations in the insulin receptor gene of a patient with RT leprechaunism: application to prenatal diagnosis."; RL J. Clin. Endocrinol. Metab. 80:1496-1501(1995). RN [111] RP VARIANT PHE-1023. RX PubMed=8890729; DOI=10.1530/eje.0.1350357; RA Moritz W., Boeni-Schnetzler M., Stevens W., Froesch E.R., Levy J.R.; RT "In-frame exon 2 deletion in insulin receptor RNA in a family with extreme RT insulin resistance in association with defective insulin binding: a case RT report."; RL Eur. J. Endocrinol. 135:357-363(1996). RN [112] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=8636294; DOI=10.1210/jcem.81.2.8636294; RA Desbois-Mouthon C., Sert-Langeron C., Magre J., Oreal E., Blivet M.J., RA Flori E., Besmond C., Capeau J., Caron M.; RT "Deletion of Asn281 in the alpha-subunit of the human insulin receptor RT causes constitutive activation of the receptor and insulin RT desensitization."; RL J. Clin. Endocrinol. Metab. 81:719-727(1996). RN [113] RP VARIANT MET-1012. RX PubMed=9199575; DOI=10.1086/515464; RA Hansen L., Hansen T., Clausen J.O., Echwald S.M., Urhammer S.A., RA Rasmussen S.K., Pedersen O.; RT "The Val985Met insulin-receptor variant in the Danish Caucasian population: RT lack of associations with non-insulin-dependent diabetes mellitus or RT insulin resistance."; RL Am. J. Hum. Genet. 60:1532-1535(1997). RN [114] RP VARIANTS IRAN TYPE A GLY-86 AND PRO-89. RX PubMed=9175790; DOI=10.1006/bbrc.1997.6695; RA Rouard M., Macari F., Bouix O., Lautier C., Brun J.F., Lefebvre P., RA Renard E., Bringer J., Jaffiol C., Grigorescu F.; RT "Identification of two novel insulin receptor mutations, Asp59Gly and RT Leu62Pro, in type A syndrome of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 234:764-768(1997). RN [115] RP CHARACTERIZATION OF VARIANT LEPRCH MET-937. RX PubMed=9299395; DOI=10.1006/bbrc.1997.7181; RA Kadowaki H., Takahashi Y., Ando A., Momomura K., Kaburagi Y., Quin J.D., RA MacCuish A.C., Koda N., Fukushima Y., Taylor S.I., Akanuma Y., Yazaki Y., RA Kadowaki T.; RT "Four mutant alleles of the insulin receptor gene associated with genetic RT syndromes of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 237:516-520(1997). RN [116] RP VARIANTS LEPRCH TRP-1119 AND LYS-1206. RX PubMed=9249867; RX DOI=10.1002/(sici)1097-0223(199707)17:7<657::aid-pd132>3.3.co;2-#; RA Desbois-Mouthon C., Girodon E., Ghanem N., Caron M., Pennerath A., RA Conteville P., Magre J., Besmond C., Goossens M., Capeau J., Amselem S.; RT "Molecular analysis of the insulin receptor gene for prenatal diagnosis of RT leprechaunism in two families."; RL Prenat. Diagn. 17:657-663(1997). RN [117] RP VARIANTS LEPRCH TYR-301 AND TRP-1201. RX PubMed=9703342; DOI=10.2337/diab.47.8.1362; RA Whitehead J.P., Soos M.A., Jackson R., Tasic V., Kocova M., O'Rahilly S.; RT "Multiple molecular mechanisms of insulin receptor dysfunction in a patient RT with Donohue syndrome."; RL Diabetes 47:1362-1364(1998). RN [118] RP VARIANTS RMS THR-1143 AND TRP-1158. RX PubMed=10443650; DOI=10.1210/jcem.84.8.5902; RA Longo N., Wang Y., Pasquali M.; RT "Progressive decline in insulin levels in Rabson-Mendenhall syndrome."; RL J. Clin. Endocrinol. Metab. 84:2623-2629(1999). RN [119] RP VARIANTS IRAN TYPE A LEU-167 AND VAL-1055. RX PubMed=10733238; DOI=10.1034/j.1399-0004.2000.570110.x; RA Rique S., Nogues C., Ibanez L., Marcos M.V., Ferragut J., Carrascosa A., RA Potau N.; RT "Identification of three novel mutations in the insulin receptor gene in RT type A insulin resistant patients."; RL Clin. Genet. 57:67-69(2000). RN [120] RP VARIANT IRAN TYPE A TYR-280. RX PubMed=11260230; DOI=10.1034/j.1399-0004.2001.590309.x; RA Osawa H., Nishimiya T., Ochi M., Niiya T., Onuma H., Kitamuro F., Kaino Y., RA Kida K., Makino H.; RT "Identification of novel C253Y missense and Y864X nonsense mutations in the RT insulin receptor gene in type A insulin-resistant patients."; RL Clin. Genet. 59:194-197(2001). RN [121] RP VARIANT IRAN TYPE A CYS-279. RX PubMed=12107746; DOI=10.1007/s00125-002-0798-5; RA Hamer I., Foti M., Emkey R., Cordier-Bussat M., Philippe J., De Meyts P., RA Maeder C., Kahn C.R., Carpentier J.-L.; RT "An arginine to cysteine(252) mutation in insulin receptors from a patient RT with severe insulin resistance inhibits receptor internalisation but RT preserves signalling events."; RL Diabetologia 45:657-667(2002). RN [122] RP CHARACTERIZATION OF VARIANTS LEPRCH PRO-113; VAL-119; ASN-308 DEL; THR-925 RP AND TRP-926, AND VARIANTS RMS THR-997; THR-1143; TRP-1158 AND TRP-1201. RX PubMed=12023989; DOI=10.1093/hmg/11.12.1465; RA Longo N., Wang Y., Smith S.A., Langley S.D., DiMeglio L.A., RA Giannella-Neto D.; RT "Genotype-phenotype correlation in inherited severe insulin resistance."; RL Hum. Mol. Genet. 11:1465-1475(2002). RN [123] RP VARIANT LEPRCH VAL-362 DEL. RX PubMed=12538626; DOI=10.1210/en.2002-220815; RA George S., Johansen A., Soos M.A., Mortensen H., Gammeltoft S., Saudek V., RA Siddle K., Hansen L., O'Rahilly S.; RT "Deletion of V335 from the L2 domain of the insulin receptor results in a RT conformationally abnormal receptor that is unable to bind insulin and RT causes Donohue's syndrome in a human subject."; RL Endocrinology 144:631-637(2003). RN [124] RP VARIANT IRAN TYPE A HIS-279, VARIANTS LEPRCH GLN-120; LEU-350; ASP-458 AND RP TRP-1119, CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279, AND RP CHARACTERIZATION OF VARIANTS LEPRCH GLN-120 AND ASP-458. RX PubMed=12970295; DOI=10.1210/jc.2003-030034; RA Maassen J.A., Tobias E.S., Kayserilli H., Tukel T., Yuksel-Apak M., RA D'Haens E., Kleijer W.J., Fery F., van der Zon G.C.M.; RT "Identification and functional assessment of novel and known insulin RT receptor mutations in five patients with syndromes of severe insulin RT resistance."; RL J. Clin. Endocrinol. Metab. 88:4251-4257(2003). RN [125] RP VARIANT HHF5 GLN-1201. RX PubMed=15161766; DOI=10.2337/diabetes.53.6.1592; RA Hoejlund K., Hansen T., Lajer M., Henriksen J.E., Levin K., Lindholm J., RA Pedersen O., Bech-Nielsen H.; RT "A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia RT linked to a mutation in the human insulin receptor gene."; RL Diabetes 53:1592-1598(2004). RN [126] RP VARIANTS RMS ARG-236 AND SER-386, AND CHARACTERIZATION OF VARIANTS RMS RP ARG-236 AND SER-386. RX PubMed=17201797; DOI=10.1111/j.1365-2265.2006.02678.x; RA Tuthill A., Semple R.K., Day R., Soos M.A., Sweeney E., Seymour P.J., RA Didi M., O'Rahilly S.; RT "Functional characterization of a novel insulin receptor mutation RT contributing to Rabson-Mendenhall syndrome."; RL Clin. Endocrinol. (Oxf.) 66:21-26(2007). RN [127] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012; RP VAL-1065 AND ALA-1282. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [128] RP VARIANTS LEPRCH CYS-818 AND 890-ARG--SER-1382 DEL. RX PubMed=22768670; DOI=10.1515/jpem-2011-0448; RA Nobile S., Semple R.K., Carnielli V.P.; RT "A novel mutation of the insulin receptor gene in a preterm infant with RT Donohue syndrome and heart failure."; RL J. Pediatr. Endocrinol. Metab. 25:363-366(2012). RN [129] RP VARIANTS LEPRCH THR-56 AND TYR-286, AND CHARACTERIZATION OF VARIANTS LEPRCH RP THR-56 AND TYR-286. RX PubMed=24498630; DOI=10.1002/mgg3.43; RA Falik Zaccai T.C., Kalfon L., Klar A., Elisha M.B., Hurvitz H., RA Weingarten G., Chechik E., Fleisher Sheffer V., Haj Yahya R., Meidan G., RA Gross-Kieselstein E., Bauman D., Hershkovitz S., Yaron Y., Orr-Urtreger A., RA Wertheimer E.; RT "Two novel mutations identified in familial cases with Donohue syndrome."; RL Mol. Genet. Genomic Med. 2:64-72(2014). RN [130] RP VARIANTS RMS CYS-256; LEU-635; ILE-835; VAL-842; LEU-874; SER-878 AND RP 999-TYR--SER-1382 DEL, VARIANTS IRAN TYPE A ASP-489 AND MET-1054, VARIANTS RP LEPRCH PHE-657; ARG-659 AND CYS-818, CHARACTERIZATION OF VARIANTS LEPRCH RP PHE-657; ARG-659; CYS-818; THR-925; TRP-926 AND MET-937, AND RP CHARACTERIZATION OF VARIANTS RMS LEU-635; ILE-835; VAL-842; LEU-874 AND RP SER-878. RX PubMed=28765322; DOI=10.2337/db17-0301; RA Hosoe J., Kadowaki H., Miya F., Aizu K., Kawamura T., Miyata I., RA Satomura K., Ito T., Hara K., Tanaka M., Ishiura H., Tsuji S., Suzuki K., RA Takakura M., Boroevich K.A., Tsunoda T., Yamauchi T., Shojima N., RA Kadowaki T.; RT "Structural Basis and Genotype-Phenotype Correlations of INSR Mutations RT Causing Severe Insulin Resistance."; RL Diabetes 66:2713-2723(2017). CC -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic CC actions of insulin. Binding of insulin leads to phosphorylation of CC several intracellular substrates, including, insulin receptor CC substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling CC intermediates. Each of these phosphorylated proteins serve as docking CC proteins for other signaling proteins that contain Src-homology-2 CC domains (SH2 domain) that specifically recognize different CC phosphotyrosine residues, including the p85 regulatory subunit of PI3K CC and SHP2. Phosphorylation of IRSs proteins lead to the activation of CC two main signaling pathways: the PI3K-AKT/PKB pathway, which is CC responsible for most of the metabolic actions of insulin, and the Ras- CC MAPK pathway, which regulates expression of some genes and cooperates CC with the PI3K pathway to control cell growth and differentiation. CC Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to CC the activation of PI3K and the generation of phosphatidylinositol-(3, CC 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates CC several PIP3-dependent serine/threonine kinases, such as PDPK1 and CC subsequently AKT/PKB. The net effect of this pathway is to produce a CC translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic CC vesicles to the cell membrane to facilitate glucose transport. CC Moreover, upon insulin stimulation, activated AKT/PKB is responsible CC for: anti-apoptotic effect of insulin by inducing phosphorylation of CC BAD; regulates the expression of gluconeogenic and lipogenic enzymes by CC controlling the activity of the winged helix or forkhead (FOX) class of CC transcription factors. Another pathway regulated by PI3K-AKT/PKB CC activation is mTORC1 signaling pathway which regulates cell growth and CC metabolism and integrates signals from insulin. AKT mediates insulin- CC stimulated protein synthesis by phosphorylating TSC2 thereby activating CC mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in CC mediating cell growth, survival and cellular differentiation of CC insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers CC the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to CC binding insulin, the insulin receptor can bind insulin-like growth CC factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII CC binding. When present in a hybrid receptor with IGF1R, binds IGF1. CC PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR CC isoform Long are activated with a high affinity by IGF1, with low CC affinity by IGF2 and not significantly activated by insulin, and that CC hybrid receptors composed of IGF1R and INSR isoform Short are activated CC by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that CC hybrid receptors composed of IGF1R and INSR isoform Long and hybrid CC receptors composed of IGF1R and INSR isoform Short have similar binding CC characteristics, both bind IGF1 and have a low affinity for insulin. In CC adipocytes, inhibits lipolysis (By similarity). CC {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875, CC ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11598120, CC ECO:0000269|PubMed:12707268, ECO:0000269|PubMed:18278056, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:9312016}; CC -!- ACTIVITY REGULATION: Activated in response to insulin. CC Autophosphorylation activates the kinase activity. PTPN1, PTPRE and CC PTPRF dephosphorylate important tyrosine residues, thereby reducing CC INSR activity. Inhibited by ENPP1. GRB10 and GRB14 inhibit the CC catalytic activity of the INSR, they block access of substrates to the CC activated receptor. SOCS1 and SOCS3 act as negative regulators of INSR CC activity, they bind to the activated INRS and interfere with the CC phosphorylation of INSR substrates. {ECO:0000269|PubMed:10615944, CC ECO:0000269|PubMed:11598120, ECO:0000269|PubMed:11726652, CC ECO:0000269|PubMed:12493740, ECO:0000269|PubMed:2211730}. CC -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide CC bonds. The alpha chains carry the insulin-binding regions, while the CC beta chains carry the kinase domain. Forms a hybrid receptor with CC IGF1R, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta CC chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. Interacts CC with SORBS1 but dissociates from it following insulin stimulation. CC Binds SH2B2. Activated form of INSR interacts (via Tyr-999) with the CC PTB/PID domains of IRS1 and SHC1. The sequences surrounding the CC phosphorylated NPXY motif contribute differentially to either IRS1 or CC SHC1 recognition. Interacts (via tyrosines in the C-terminus) with IRS2 CC (via PTB domain and 591-786 AA); the 591-786 would be the primary CC anchor of IRS2 to INSR while the PTB domain would have a stabilizing CC action on the interaction with INSR. Interacts with the SH2 domains of CC the 85 kDa regulatory subunit of PI3K (PIK3R1) in vitro, when CC autophosphorylated on tyrosine residues. Interacts with SOCS7. CC Interacts (via the phosphorylated Tyr-999), with SOCS3. Interacts (via CC the phosphorylated Tyr-1185, Tyr-1189, Tyr-1190) with SOCS1. Interacts CC with CAV2 (tyrosine-phosphorylated form); the interaction is increased CC with 'Tyr-27'phosphorylation of CAV2 (By similarity). Interacts with CC ARRB2 (By similarity). Interacts with GRB10; this interaction blocks CC the association between IRS1/IRS2 and INSR, significantly reduces CC insulin-stimulated tyrosine phosphorylation of IRS1 and IRS2 and thus CC decreases insulin signaling. Interacts with GRB7. Interacts with PDPK1. CC Interacts (via Tyr-1190) with GRB14 (via BPS domain); this interaction CC protects the tyrosines in the activation loop from dephosphorylation, CC but promotes dephosphorylation of Tyr-999, this results in decreased CC interaction with, and phosphorylation of, IRS1. Interacts (via subunit CC alpha) with ENPP1 (via 485-599 AA); this interaction blocks CC autophosphorylation. Interacts with PTPRE; this interaction is CC dependent of Tyr-1185, Tyr-1189 and Tyr-1190 of the INSR. Interacts CC with STAT5B (via SH2 domain). Interacts with PTPRF. Interacts with CC ATIC; ATIC together with PRKAA2/AMPK2 and HACD3/PTPLAD1 is proposed to CC be part of a signaling netwok regulating INSR autophosphorylation and CC endocytosis (By similarity). Interacts with the cone snail venom CC insulin Con-Ins G1 (PubMed:27617429). Interacts with the insulin CC receptor SORL1; this interaction strongly increases its surface CC exposure, hence strengthens insulin signal reception (PubMed:27322061). CC Interacts (tyrosine phosphorylated) with CCDC88A/GIV (via SH2-like CC region); binding requires autophosphorylation of the INSR C-terminal CC region (PubMed:25187647). Interacts with GNAI3; the interaction is CC probably mediated by CCDC88A/GIV (PubMed:25187647). Interacts with CC LMBRD1 (By similarity). Interacts (in response to insulin stimulation) CC with NCK1; this interaction may recruit PTPN1 to mediate INSR CC dephosphorylation (PubMed:21707536). Interacts with CD248; this CC interaction diminishes INSR autophosphorylation (By similarity). CC {ECO:0000250|UniProtKB:P15127, ECO:0000250|UniProtKB:P15208, CC ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:10803466, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11374898, CC ECO:0000269|PubMed:11726652, ECO:0000269|PubMed:12493740, CC ECO:0000269|PubMed:14690593, ECO:0000269|PubMed:16127460, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16957736, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:21707536, CC ECO:0000269|PubMed:2211730, ECO:0000269|PubMed:23302862, CC ECO:0000269|PubMed:25187647, ECO:0000269|PubMed:27322061, CC ECO:0000269|PubMed:27617429, ECO:0000269|PubMed:7537849, CC ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8995282, ECO:0000269|PubMed:8999839, CC ECO:0000269|PubMed:9312016, ECO:0000269|PubMed:9428692}. CC -!- INTERACTION: CC P06213; Q99490: AGAP2; NbExp=2; IntAct=EBI-475899, EBI-2361824; CC P06213; Q8NEJ0: DUSP18; NbExp=2; IntAct=EBI-475899, EBI-10698945; CC P06213; Q13322: GRB10; NbExp=4; IntAct=EBI-475899, EBI-80275; CC P06213; P05019: IGF1; NbExp=4; IntAct=EBI-475899, EBI-7902275; CC P06213; P08069: IGF1R; NbExp=5; IntAct=EBI-475899, EBI-475981; CC P06213; P14616: INSRR; NbExp=6; IntAct=EBI-475899, EBI-6424336; CC P06213; P35568: IRS1; NbExp=5; IntAct=EBI-475899, EBI-517592; CC P06213; Q9Y4H2: IRS2; NbExp=4; IntAct=EBI-475899, EBI-1049582; CC P06213; Q15323: KRT31; NbExp=3; IntAct=EBI-475899, EBI-948001; CC P06213; Q13257: MAD2L1; NbExp=4; IntAct=EBI-475899, EBI-78203; CC P06213; P27986: PIK3R1; NbExp=9; IntAct=EBI-475899, EBI-79464; CC P06213; P19174: PLCG1; NbExp=9; IntAct=EBI-475899, EBI-79387; CC P06213; P18031: PTPN1; NbExp=33; IntAct=EBI-475899, EBI-968788; CC P06213; Q06124: PTPN11; NbExp=3; IntAct=EBI-475899, EBI-297779; CC P06213; Q15262: PTPRK; NbExp=2; IntAct=EBI-475899, EBI-474052; CC P06213; Q15256: PTPRR; NbExp=2; IntAct=EBI-475899, EBI-2265659; CC P06213; Q9NRF2: SH2B1; NbExp=6; IntAct=EBI-475899, EBI-310491; CC P06213; P29353: SHC1; NbExp=2; IntAct=EBI-475899, EBI-78835; CC P06213; P01317: INS; Xeno; NbExp=5; IntAct=EBI-475899, EBI-3989070; CC P06213; P35570: Irs1; Xeno; NbExp=5; IntAct=EBI-475899, EBI-520230; CC P06213-1; P32121: ARRB2; NbExp=2; IntAct=EBI-15558981, EBI-714559; CC P06213-1; P06213-1: INSR; NbExp=4; IntAct=EBI-15558981, EBI-15558981; CC P06213-1; P18031: PTPN1; NbExp=2; IntAct=EBI-15558981, EBI-968788; CC P06213-1; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-15558981, EBI-21501656; CC P06213-1; P81122: Irs2; Xeno; NbExp=8; IntAct=EBI-15558981, EBI-1369862; CC P06213-1; Q1XH17: Trim72; Xeno; NbExp=2; IntAct=EBI-15558981, EBI-16034016; CC P06213-2; P01308: INS; NbExp=6; IntAct=EBI-9984921, EBI-7090529; CC P06213-2; Q13257: MAD2L1; NbExp=3; IntAct=EBI-9984921, EBI-78203; CC P06213-2; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-9984921, EBI-21501656; CC P06213-2; P01317: INS; Xeno; NbExp=2; IntAct=EBI-9984921, EBI-3989070; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P15208}; CC Single-pass type I membrane protein {ECO:0000305}. Late endosome CC {ECO:0000250|UniProtKB:P15208}. Lysosome CC {ECO:0000250|UniProtKB:P15208}. Note=Binding of insulin to INSR induces CC internalization and lysosomal degradation of the receptor, a means for CC down-regulating this signaling pathway after stimulation. In the CC presence of SORL1, internalized INSR molecules are redirected back to CC the cell surface, thereby preventing their lysosomal catabolism and CC strengthening insulin signal reception. {ECO:0000250|UniProtKB:P15208}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; Synonyms=HIR-B; CC IsoId=P06213-1; Sequence=Displayed; CC Name=Short; Synonyms=HIR-A; CC IsoId=P06213-2; Sequence=VSP_002898; CC -!- TISSUE SPECIFICITY: Isoform Long and isoform Short are predominantly CC expressed in tissue targets of insulin metabolic effects: liver, CC adipose tissue and skeletal muscle but are also expressed in the CC peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta CC vascular endothelium, fibroblasts, monocytes, granulocytes, CC erythrocytes and skin. Isoform Short is preferentially expressed in CC fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found CC as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose CC tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at CC protein level). Overexpressed in several tumors, including breast, CC colon, lung, ovary, and thyroid carcinomas. CC {ECO:0000269|PubMed:10207053, ECO:0000269|PubMed:2369896, CC ECO:0000269|PubMed:9202395, ECO:0000269|PubMed:9355755}. CC -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-identical CC regions from two alpha chains, primarily via the C-terminal region of CC the first INSR alpha chain. Residues from the leucine-rich N-terminus CC of the other INSR alpha chain also contribute to this insulin binding CC site. A secondary insulin-binding site is formed by residues at the CC junction of fibronectin type-III domain 1 and 2. CC {ECO:0000269|PubMed:16957736, ECO:0000269|PubMed:19459609, CC ECO:0000269|PubMed:23302862}. CC -!- PTM: After being transported from the endoplasmic reticulum to the CC Golgi apparatus, the single glycosylated precursor is further CC glycosylated and then cleaved, followed by its transport to the plasma CC membrane. {ECO:0000269|PubMed:1472036, ECO:0000269|PubMed:16894147, CC ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973, CC ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to insulin CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Phosphorylation of CC Tyr-999 is required for binding to IRS1, SHC1 and STAT5B CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Dephosphorylated by CC PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190 (PubMed:14690593, CC PubMed:16246733, PubMed:16271887, PubMed:18278056, PubMed:18767165, CC PubMed:3166375, PubMed:9312016). May also be phosphorylated at Tyr-1185 CC and Tyr-1190 by mTORC2 (PubMed:26584640). Dephosphorylated by PTPRF and CC PTPN1 (PubMed:8995282). Dephosphorylated by PTPN2; down-regulates CC insulin-induced signaling (PubMed:10734133, PubMed:12612081). CC Dephosphorylation at Tyr-1189 and Tyr-1190 requires the SH2/SH3 adapter CC protein NCK1, probably to recruit its interaction partner PTPN1 CC (PubMed:21707536). {ECO:0000269|PubMed:10734133, CC ECO:0000269|PubMed:12612081, ECO:0000269|PubMed:14690593, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:21707536, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:8995282, CC ECO:0000269|PubMed:9312016}. CC -!- PTM: S-nitrosylation at Cys-1083 by BLVRB inhibits the receptor CC tyrosine kinase, thereby inhibiting insulin signaling. CC {ECO:0000269|PubMed:38056462}. CC -!- PTM: Ubiquitinated by MARCHF1; leading to degradation thereby reducing CC surface INSR expression. {ECO:0000269|PubMed:27577745}. CC -!- DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe insulin CC resistance syndrome characterized by insulin-resistant diabetes CC mellitus with pineal hyperplasia and somatic abnormalities. Typical CC features include coarse, senile-appearing facies, dental and skin CC abnormalities, abdominal distension, and phallic enlargement. CC Inheritance is autosomal recessive. {ECO:0000269|PubMed:10443650, CC ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:17201797, CC ECO:0000269|PubMed:2121734, ECO:0000269|PubMed:2365819, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:8314008}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most CC severe form of insulin resistance syndrome, characterized by CC intrauterine and postnatal growth retardation and death in early CC infancy. Inheritance is autosomal recessive. CC {ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:12538626, CC ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1607067, CC ECO:0000269|PubMed:1730625, ECO:0000269|PubMed:22768670, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:24498630, CC ECO:0000269|PubMed:2479553, ECO:0000269|PubMed:2834824, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:7538143, CC ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715, CC ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945, CC ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867, CC ECO:0000269|PubMed:9299395, ECO:0000269|PubMed:9703342}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Type 2 diabetes mellitus (T2D) [MIM:125853]: A multifactorial CC disorder of glucose homeostasis caused by a lack of sensitivity to CC insulin. Affected individuals usually have an obese body habitus and CC manifestations of a metabolic syndrome characterized by diabetes, CC insulin resistance, hypertension and hypertriglyceridemia. The disease CC results in long-term complications that affect the eyes, kidneys, CC nerves, and blood vessels. {ECO:0000269|PubMed:1470163, CC ECO:0000269|PubMed:1607076, ECO:0000269|PubMed:7657032}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Hyperinsulinemic hypoglycemia, familial, 5 (HHF5) CC [MIM:609968]: A form of hyperinsulinemic hypoglycemia, a clinically and CC genetically heterogeneous disorder characterized by inappropriate CC insulin secretion from the pancreatic beta-cells in the presence of low CC blood glucose levels. HHF5 clinical features include loss of CC consciousness due to hypoglycemia and hypoglycemic seizures. HHF5 CC inheritance is autosomal dominant. {ECO:0000269|PubMed:15161766}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Insulin-resistant diabetes mellitus with acanthosis nigricans CC type A (IRAN type A) [MIM:610549]: Characterized by the association of CC severe insulin resistance (manifested by marked hyperinsulinemia and a CC failure to respond to exogenous insulin) with the skin lesion CC acanthosis nigricans and ovarian hyperandrogenism in adolescent female CC subjects. Women frequently present with hirsutism, acne, amenorrhea or CC oligomenorrhea, and virilization. This syndrome is different from the CC type B that has been demonstrated to be secondary to the presence of CC circulating autoantibodies against the insulin receptor. CC {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230, CC ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295, CC ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473, CC ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:3283938, CC ECO:0000269|PubMed:8243830, ECO:0000269|PubMed:8288049, CC ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8388389, CC ECO:0000269|PubMed:9175790}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin receptor entry; CC URL="https://en.wikipedia.org/wiki/Insulin_receptor"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M10051; AAA59174.1; -; mRNA. DR EMBL; X02160; CAA26096.1; -; mRNA. DR EMBL; M32972; AAA59452.1; -; Genomic_DNA. DR EMBL; M23100; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32823; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32824; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32825; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32826; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32827; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32828; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32829; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32830; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32831; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32832; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32833; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32834; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32835; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32836; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32837; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32838; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32839; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32840; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32841; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32842; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; AC010311; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010526; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010606; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC125387; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117172; AAI17173.1; -; mRNA. DR EMBL; J03466; AAA59175.1; -; Genomic_DNA. DR EMBL; J05043; AAA59190.1; -; Genomic_DNA. DR EMBL; M76592; AAC37604.1; -; Genomic_DNA. DR EMBL; AB208861; BAD92098.1; -; mRNA. DR EMBL; M24555; AAA59178.1; -; mRNA. DR EMBL; M29929; AAA59176.1; -; Genomic_DNA. DR EMBL; M29930; AAA59177.1; -; Genomic_DNA. DR EMBL; M27197; AAA86791.1; -; Genomic_DNA. DR EMBL; M27195; AAA86791.1; JOINED; Genomic_DNA. DR CCDS; CCDS12176.1; -. [P06213-1] DR CCDS; CCDS42487.1; -. [P06213-2] DR PIR; A37348; INHUR. DR RefSeq; NP_000199.2; NM_000208.4. [P06213-1] DR RefSeq; NP_001073285.1; NM_001079817.3. [P06213-2] DR PDB; 1GAG; X-ray; 2.70 A; A=1005-1310. DR PDB; 1I44; X-ray; 2.40 A; A=1005-1310. DR PDB; 1IR3; X-ray; 1.90 A; A=1005-1310. DR PDB; 1IRK; X-ray; 2.10 A; A=1005-1310. DR PDB; 1P14; X-ray; 1.90 A; A=1005-1310. DR PDB; 1RQQ; X-ray; 2.60 A; A/B=1005-1310. DR PDB; 2AUH; X-ray; 3.20 A; A=1005-1310. DR PDB; 2B4S; X-ray; 2.30 A; B/D=1005-1310. DR PDB; 2HR7; X-ray; 2.32 A; A/B=28-512. DR PDB; 2MFR; NMR; -; A=940-988. DR PDB; 2Z8C; X-ray; 3.25 A; A=1008-1310. DR PDB; 3BU3; X-ray; 1.65 A; A=1005-1310. DR PDB; 3BU5; X-ray; 2.10 A; A=1005-1310. DR PDB; 3BU6; X-ray; 1.95 A; A=1005-1310. DR PDB; 3EKK; X-ray; 2.10 A; A=1005-1310. DR PDB; 3EKN; X-ray; 2.20 A; A=1005-1310. DR PDB; 3ETA; X-ray; 2.60 A; A/B=1017-1322. DR PDB; 3W11; X-ray; 3.90 A; E=28-337, F=731-744. DR PDB; 3W12; X-ray; 4.30 A; E=28-337, F=731-744. DR PDB; 3W13; X-ray; 4.30 A; E=28-337, F=724-744. DR PDB; 4IBM; X-ray; 1.80 A; A/B=1005-1310. DR PDB; 4OGA; X-ray; 3.50 A; E=28-337, F=731-744. DR PDB; 4XLV; X-ray; 2.30 A; A=983-1310. DR PDB; 4XSS; X-ray; 3.00 A; E=28-337. DR PDB; 4XST; X-ray; 3.00 A; E=28-337. DR PDB; 4ZXB; X-ray; 3.30 A; E=28-956. DR PDB; 5E1S; X-ray; 2.26 A; A=1005-1310. DR PDB; 5HHW; X-ray; 1.79 A; A=1005-1310. DR PDB; 5J3H; X-ray; 3.27 A; E=28-337. DR PDB; 5KQV; X-ray; 4.40 A; E/F=28-746. DR PDB; 5U1M; X-ray; 1.80 A; B=991-999. DR PDB; 6HN4; EM; 4.20 A; E/F=28-955. DR PDB; 6HN5; EM; 3.20 A; E/F=28-955. DR PDB; 6PXV; EM; 3.20 A; A/C=28-1382. DR PDB; 6PXW; EM; 3.10 A; A/B=28-1382. DR PDB; 6SOF; EM; 4.30 A; A/C=28-746, B/D=795-956. DR PDB; 6VEP; X-ray; 2.90 A; E/K/Q/W=28-337, F/L/R/X=731-746. DR PDB; 6VEQ; X-ray; 3.25 A; E/K=28-337, F/L=731-746. DR PDB; 7BW7; EM; 4.10 A; A/C=28-1382. DR PDB; 7BW8; EM; 3.80 A; A/C=28-1382. DR PDB; 7BWA; EM; 4.90 A; A/C=28-1382. DR PDB; 7KD6; X-ray; 2.60 A; E/K/Q/W=28-337. DR PDB; 7MQO; EM; 3.40 A; E/F=28-956. DR PDB; 7MQR; EM; 4.10 A; E/F=28-955. DR PDB; 7MQS; EM; 4.40 A; E/F=28-955. DR PDB; 7PG0; EM; 7.60 A; A/B=1-1382. DR PDB; 7PG2; EM; 6.70 A; A/B=1-1382. DR PDB; 7PG3; EM; 7.30 A; A/B=1-1382. DR PDB; 7PG4; EM; 9.10 A; A/B=1-1382. DR PDB; 7PHT; NMR; -; A=953-982. DR PDB; 7QID; EM; 5.00 A; A/C=28-746, B/D=763-956. DR PDB; 7S0Q; EM; 3.70 A; B=28-955. DR PDB; 7S8V; EM; 3.73 A; B=28-955. DR PDB; 7U6D; EM; 5.03 A; B/C=28-955. DR PDB; 7U6E; EM; 3.00 A; E/F=28-955. DR PDB; 7YQ3; EM; 3.60 A; E/F=28-946. DR PDB; 7YQ4; EM; 3.95 A; E/F=28-946. DR PDB; 7YQ5; EM; 4.27 A; E/F=28-946. DR PDB; 7YQ6; EM; 4.18 A; E/F=28-946. DR PDB; 8DWN; X-ray; 2.15 A; A=1005-1310. DR PDB; 8GUY; EM; 4.18 A; E/F=28-946. DR PDB; 8U4B; EM; 3.90 A; A/B=1-1382. DR PDB; 8U4C; EM; 3.60 A; A/B=1-1382. DR PDB; 8U4E; EM; 4.20 A; A/B=1-1382. DR PDB; 8VJB; EM; 3.60 A; A/B=1-1382. DR PDB; 8VJC; EM; 3.80 A; A/B=1-1382. DR PDB; 8X06; EM; 3.24 A; A/B=1-1382. DR PDB; 8X2M; EM; 3.31 A; A/B=1-1382. DR PDB; 8XJS; EM; 3.24 A; A/B=1-1382. DR PDB; 8XK1; EM; 3.31 A; A/B=1-1382. DR PDB; 8XKM; EM; 5.00 A; A/B=1-1382. DR PDB; 8XKR; EM; 3.53 A; A/B=1-1382. DR PDB; 8YSZ; EM; 3.38 A; A/B=1-1382. DR PDB; 8YYL; EM; 4.01 A; A/B=1-1382. DR PDB; 8YYS; EM; 4.14 A; A/B=1-1382. DR PDB; 8YYT; EM; 3.60 A; A/B=1-1382. DR PDBsum; 1GAG; -. DR PDBsum; 1I44; -. DR PDBsum; 1IR3; -. DR PDBsum; 1IRK; -. DR PDBsum; 1P14; -. DR PDBsum; 1RQQ; -. DR PDBsum; 2AUH; -. DR PDBsum; 2B4S; -. DR PDBsum; 2HR7; -. DR PDBsum; 2MFR; -. DR PDBsum; 2Z8C; -. DR PDBsum; 3BU3; -. DR PDBsum; 3BU5; -. DR PDBsum; 3BU6; -. DR PDBsum; 3EKK; -. DR PDBsum; 3EKN; -. DR PDBsum; 3ETA; -. DR PDBsum; 3W11; -. DR PDBsum; 3W12; -. DR PDBsum; 3W13; -. DR PDBsum; 4IBM; -. DR PDBsum; 4OGA; -. DR PDBsum; 4XLV; -. DR PDBsum; 4XSS; -. DR PDBsum; 4XST; -. DR PDBsum; 4ZXB; -. DR PDBsum; 5E1S; -. DR PDBsum; 5HHW; -. DR PDBsum; 5J3H; -. DR PDBsum; 5KQV; -. DR PDBsum; 5U1M; -. DR PDBsum; 6HN4; -. DR PDBsum; 6HN5; -. DR PDBsum; 6PXV; -. DR PDBsum; 6PXW; -. DR PDBsum; 6SOF; -. DR PDBsum; 6VEP; -. DR PDBsum; 6VEQ; -. DR PDBsum; 7BW7; -. DR PDBsum; 7BW8; -. DR PDBsum; 7BWA; -. DR PDBsum; 7KD6; -. DR PDBsum; 7MQO; -. DR PDBsum; 7MQR; -. DR PDBsum; 7MQS; -. DR PDBsum; 7PG0; -. DR PDBsum; 7PG2; -. DR PDBsum; 7PG3; -. DR PDBsum; 7PG4; -. DR PDBsum; 7PHT; -. DR PDBsum; 7QID; -. DR PDBsum; 7S0Q; -. DR PDBsum; 7S8V; -. DR PDBsum; 7U6D; -. DR PDBsum; 7U6E; -. DR PDBsum; 7YQ3; -. DR PDBsum; 7YQ4; -. DR PDBsum; 7YQ5; -. DR PDBsum; 7YQ6; -. DR PDBsum; 8DWN; -. DR PDBsum; 8GUY; -. DR PDBsum; 8U4B; -. DR PDBsum; 8U4C; -. DR PDBsum; 8U4E; -. DR PDBsum; 8VJB; -. DR PDBsum; 8VJC; -. DR PDBsum; 8X06; -. DR PDBsum; 8X2M; -. DR PDBsum; 8XJS; -. DR PDBsum; 8XK1; -. DR PDBsum; 8XKM; -. DR PDBsum; 8XKR; -. DR PDBsum; 8YSZ; -. DR PDBsum; 8YYL; -. DR PDBsum; 8YYS; -. DR PDBsum; 8YYT; -. DR AlphaFoldDB; P06213; -. DR BMRB; P06213; -. DR EMDB; EMD-10273; -. DR EMDB; EMD-10311; -. DR EMDB; EMD-13385; -. DR EMDB; EMD-13386; -. DR EMDB; EMD-13387; -. DR EMDB; EMD-13388; -. DR EMDB; EMD-20522; -. DR EMDB; EMD-20523; -. DR EMDB; EMD-23766; -. DR EMDB; EMD-23767; -. DR EMDB; EMD-23949; -. DR EMDB; EMD-23950; -. DR EMDB; EMD-24791; -. DR EMDB; EMD-24927; -. DR EMDB; EMD-26363; -. DR EMDB; EMD-30225; -. DR EMDB; EMD-30227; -. DR EMDB; EMD-30229; -. DR EMDB; EMD-30230; -. DR EMDB; EMD-30231; -. DR EMDB; EMD-34018; -. DR EMDB; EMD-34019; -. DR EMDB; EMD-34021; -. DR EMDB; EMD-34281; -. DR EMDB; EMD-37970; -. DR EMDB; EMD-38017; -. DR EMDB; EMD-38404; -. DR EMDB; EMD-38413; -. DR EMDB; EMD-38420; -. DR EMDB; EMD-38423; -. DR EMDB; EMD-39566; -. DR EMDB; EMD-39675; -. DR EMDB; EMD-39677; -. DR EMDB; EMD-39678; -. DR EMDB; EMD-41877; -. DR EMDB; EMD-41878; -. DR EMDB; EMD-41880; -. DR EMDB; EMD-43279; -. DR EMDB; EMD-43280; -. DR EMDB; EMD-61431; -. DR EMDB; EMD-61432; -. DR EMDB; EMD-61490; -. DR EMDB; EMD-7461; -. DR EMDB; EMD-7462; -. DR EMDB; EMD-7463; -. DR SASBDB; P06213; -. DR SMR; P06213; -. DR BioGRID; 109854; 380. DR DIP; DIP-480N; -. DR ELM; P06213; -. DR FunCoup; P06213; 1946. DR IntAct; P06213; 709. DR MINT; P06213; -. DR STRING; 9606.ENSP00000303830; -. DR BindingDB; P06213; -. DR ChEMBL; CHEMBL1981; -. DR DrugBank; DB08513; [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID. DR DrugBank; DB03909; Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate. DR DrugBank; DB05120; AT1391. DR DrugBank; DB16028; Azemiglitazone. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB09129; Chromic chloride. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11564; Insulin argine. DR DrugBank; DB01306; Insulin aspart. DR DrugBank; DB09456; Insulin beef. DR DrugBank; DB09564; Insulin degludec. DR DrugBank; DB01307; Insulin detemir. DR DrugBank; DB00047; Insulin glargine. DR DrugBank; DB01309; Insulin glulisine. DR DrugBank; DB00030; Insulin human. DR DrugBank; DB16693; Insulin icodec. DR DrugBank; DB00046; Insulin lispro. DR DrugBank; DB11567; Insulin peglispro. DR DrugBank; DB00071; Insulin pork. DR DrugBank; DB11568; Insulin tregopil. DR DrugBank; DB16637; KW-2450 free base. DR DrugBank; DB06075; Linsitinib. DR DrugBank; DB01277; Mecasermin. DR DrugBank; DB14751; Mecasermin rinfabate. DR DrugBank; DB11721; Mitoglitazone. DR DrugBank; DB05115; NN344. DR DrugBank; DB12518; Raclopride. DR DrugBank; DB06156; Tesofensine. DR DrugCentral; P06213; -. DR GuidetoPHARMACOLOGY; 1800; -. DR GlyConnect; 1402; 8 N-Linked glycans (6 sites). DR GlyCosmos; P06213; 21 sites, 11 glycans. DR GlyGen; P06213; 25 sites, 79 N-linked glycans (13 sites), 4 O-linked glycans (6 sites). DR iPTMnet; P06213; -. DR PhosphoSitePlus; P06213; -. DR SwissPalm; P06213; -. DR BioMuta; INSR; -. DR DMDM; 308153655; -. DR CPTAC; CPTAC-1771; -. DR CPTAC; CPTAC-1772; -. DR CPTAC; CPTAC-2814; -. DR CPTAC; CPTAC-3053; -. DR jPOST; P06213; -. DR MassIVE; P06213; -. DR PaxDb; 9606-ENSP00000303830; -. DR PeptideAtlas; P06213; -. DR ProteomicsDB; 51872; -. [P06213-1] DR ProteomicsDB; 51873; -. [P06213-2] DR Pumba; P06213; -. DR ABCD; P06213; 3 sequenced antibodies. DR Antibodypedia; 3403; 2189 antibodies from 53 providers. DR DNASU; 3643; -. DR Ensembl; ENST00000302850.10; ENSP00000303830.4; ENSG00000171105.15. [P06213-1] DR Ensembl; ENST00000341500.9; ENSP00000342838.4; ENSG00000171105.15. [P06213-2] DR GeneID; 3643; -. DR KEGG; hsa:3643; -. DR MANE-Select; ENST00000302850.10; ENSP00000303830.4; NM_000208.4; NP_000199.2. DR UCSC; uc002mgd.2; human. [P06213-1] DR AGR; HGNC:6091; -. DR ClinPGx; PA202; -. DR CTD; 3643; -. DR DisGeNET; 3643; -. DR GeneCards; INSR; -. DR GeneReviews; INSR; -. DR HGNC; HGNC:6091; INSR. DR HPA; ENSG00000171105; Low tissue specificity. DR MalaCards; INSR; -. DR MIM; 125853; phenotype. DR MIM; 147670; gene. DR MIM; 246200; phenotype. DR MIM; 262190; phenotype. DR MIM; 609968; phenotype. DR MIM; 610549; phenotype. DR OpenTargets; ENSG00000171105; -. DR Orphanet; 508; Donohue syndrome. DR Orphanet; 263458; Hyperinsulinism due to INSR deficiency. DR Orphanet; 2297; Insulin-resistance syndrome type A. DR Orphanet; 769; Rabson-Mendenhall syndrome. DR VEuPathDB; HostDB:ENSG00000171105; -. DR eggNOG; KOG4258; Eukaryota. DR GeneTree; ENSGT00940000155404; -. DR HOGENOM; CLU_000288_166_0_1; -. DR InParanoid; P06213; -. DR OMA; AVESNTW; -. DR OrthoDB; 5809444at2759; -. DR PAN-GO; P06213; 12 GO annotations based on evolutionary models. DR PhylomeDB; P06213; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P06213; -. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-74713; IRS activation. DR Reactome; R-HSA-74749; Signal attenuation. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-74752; Signaling by Insulin receptor. DR Reactome; R-HSA-77387; Insulin receptor recycling. DR SABIO-RK; P06213; -. DR SignaLink; P06213; -. DR SIGNOR; P06213; -. DR Agora; ENSG00000171105; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 3643; 15 hits in 1203 CRISPR screens. DR ChiTaRS; INSR; human. DR EvolutionaryTrace; P06213; -. DR GeneWiki; Insulin_receptor; -. DR GenomeRNAi; 3643; -. DR Pharos; P06213; Tclin. DR PRO; PR:P06213; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P06213; protein. DR Bgee; ENSG00000171105; Expressed in buccal mucosa cell and 209 other cell types or tissues. DR ExpressionAtlas; P06213; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005901; C:caveola; IDA:BHF-UCL. DR GO; GO:0032590; C:dendrite membrane; ISS:ARUK-UCL. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; ISS:ARUK-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005899; C:insulin receptor complex; IDA:UniProtKB. DR GO; GO:0005770; C:late endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0032809; C:neuronal cell body membrane; ISS:ARUK-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IDA:BHF-UCL. DR GO; GO:0038024; F:cargo receptor activity; ISS:ARUK-UCL. DR GO; GO:0005525; F:GTP binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0043559; F:insulin binding; IDA:UniProtKB. DR GO; GO:0005009; F:insulin receptor activity; IDA:UniProtKB. DR GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB. DR GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL. DR GO; GO:0031995; F:insulin-like growth factor II binding; IPI:BHF-UCL. DR GO; GO:0005159; F:insulin-like growth factor receptor binding; IDA:BHF-UCL. DR GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB. DR GO; GO:0019904; F:protein domain specific binding; IPI:CAFA. DR GO; GO:0030295; F:protein kinase activator activity; IMP:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL. DR GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0097242; P:amyloid-beta clearance; ISS:ARUK-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL. DR GO; GO:0097062; P:dendritic spine maintenance; ISS:ARUK-UCL. DR GO; GO:0008544; P:epidermis development; IEA:Ensembl. DR GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL. DR GO; GO:0003007; P:heart morphogenesis; IMP:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007612; P:learning; TAS:ARUK-UCL. DR GO; GO:0008584; P:male gonad development; IEA:Ensembl. DR GO; GO:0030238; P:male sex determination; IEA:Ensembl. DR GO; GO:0007613; P:memory; TAS:ARUK-UCL. DR GO; GO:1990535; P:neuron projection maintenance; ISS:ARUK-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IGI:BHF-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0046326; P:positive regulation of D-glucose import; IDA:BHF-UCL. DR GO; GO:0048639; P:positive regulation of developmental growth; IMP:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; IMP:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0051446; P:positive regulation of meiotic cell cycle; IEA:Ensembl. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:BHF-UCL. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0043243; P:positive regulation of protein-containing complex disassembly; ISS:ARUK-UCL. DR GO; GO:0002092; P:positive regulation of receptor internalization; IDA:CACAO. DR GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0031623; P:receptor internalization; IEA:Ensembl. DR GO; GO:0006898; P:receptor-mediated endocytosis; ISS:ARUK-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:BHF-UCL. DR GO; GO:0045995; P:regulation of embryonic development; IMP:BHF-UCL. DR GO; GO:2000194; P:regulation of female gonad development; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:BHF-UCL. DR GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL. DR CDD; cd00063; FN3; 2. DR CDD; cd00064; FU; 1. DR CDD; cd05061; PTKc_InsR; 1. DR FunFam; 1.10.510.10:FF:000050; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.10.220.10:FF:000005; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000087; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000108; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001010; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000026; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000001; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000002; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR040969; Insulin_TMD. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF535; INSULIN RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF17870; Insulin_TMD; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR PIRSF; PIRSF000620; Insulin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 3. DR SMART; SM00261; FU; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 3. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Carbohydrate metabolism; KW Cell membrane; Cleavage on pair of basic residues; Diabetes mellitus; KW Direct protein sequencing; Disease variant; Disulfide bond; Endosome; KW Glycoprotein; Isopeptide bond; Kinase; Lysosome; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; S-nitrosylation; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..27 FT /evidence="ECO:0000269|PubMed:2211730, FT ECO:0000269|PubMed:2983222, ECO:0000269|PubMed:8257688" FT CHAIN 28..758 FT /note="Insulin receptor subunit alpha" FT /id="PRO_0000016687" FT CHAIN 763..1382 FT /note="Insulin receptor subunit beta" FT /id="PRO_0000016689" FT TOPO_DOM 28..758 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TOPO_DOM 763..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..979 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 980..1382 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 624..726 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 757..842 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 853..947 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1023..1298 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 686..708 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 733..741 FT /note="Insulin-binding" FT REGION 746..766 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 999 FT /note="Important for interaction with IRS1, SHC1 and FT STAT5B" FT /evidence="ECO:0000269|PubMed:9428692" FT REGION 1360..1382 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1361..1364 FT /note="PIK3R1-binding" FT ACT_SITE 1159 FT /note="Proton donor/acceptor" FT /evidence="ECO:0000269|PubMed:9312016" FT BINDING 1033 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1057 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1104..1110 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1163..1164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1177 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT SITE 66 FT /note="Insulin-binding" FT /evidence="ECO:0000305" FT MOD_RES 400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 401 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 407 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 992 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 999 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1011 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 1083 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:38056462" FT MOD_RES 1185 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1189 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016" FT MOD_RES 1190 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1355 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1361 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222" FT CARBOHYD 52 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 105 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 242 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23302862" FT CARBOHYD 282 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 322 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 364 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 424 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 445 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19349973" FT CARBOHYD 541 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:1472036, FT ECO:0000269|PubMed:19159218" FT CARBOHYD 633 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 651 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 698 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 769 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:2983222" FT CARBOHYD 782 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 920 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 933 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 35..53 FT DISULFID 153..182 FT DISULFID 186..209 FT DISULFID 196..215 FT DISULFID 219..228 FT DISULFID 223..234 FT DISULFID 235..243 FT DISULFID 239..252 FT DISULFID 255..264 FT DISULFID 268..280 FT DISULFID 286..311 FT DISULFID 293..301 FT DISULFID 315..328 FT DISULFID 331..335 FT DISULFID 339..360 FT DISULFID 462..495 FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 551 FT /note="Interchain" FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 674..899 FT DISULFID 825..834 FT CROSSLNK 1079 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:27577745" FT VAR_SEQ 745..756 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:2983222, ECO:0000303|Ref.13" FT /id="VSP_002898" FT VARIANT 2 FT /note="A -> G (in dbSNP:rs7508518)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:2210055, ECO:0000269|PubMed:2280779, FT ECO:0000269|PubMed:2777789, ECO:0000269|PubMed:2806055, FT ECO:0000269|PubMed:2859121, ECO:0000269|PubMed:2983222, FT ECO:0000269|PubMed:3680248" FT /id="VAR_058395" FT VARIANT 42 FT /note="N -> K (in RMS; impairs transport to the plasma FT membrane and reduces the affinity to bind insulin; FT dbSNP:rs121913143)" FT /evidence="ECO:0000269|PubMed:2121734, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004079" FT VARIANT 55 FT /note="V -> A (in LEPRCH; Verona-1; dbSNP:rs121913152)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004080" FT VARIANT 56 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; dbSNP:rs1555689937)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079535" FT VARIANT 58 FT /note="G -> R (in LEPRCH; Helmond; inhibits processing and FT transport; dbSNP:rs52836744)" FT /evidence="ECO:0000269|PubMed:1730625" FT /id="VAR_004081" FT VARIANT 86 FT /note="D -> G (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015907" FT VARIANT 89 FT /note="L -> P (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015908" FT VARIANT 113 FT /note="R -> P (in LEPRCH; Atlanta-1; abolishes insulin FT binding; dbSNP:rs121913153)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:8419945" FT /id="VAR_004082" FT VARIANT 119 FT /note="A -> V (in LEPRCH; markedly impairs insulin binding; FT dbSNP:rs1347473020)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015909" FT VARIANT 120 FT /note="L -> Q (in LEPRCH; inhibits receptor processing)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031518" FT VARIANT 146 FT /note="I -> M (in LEPRCH; mild; dbSNP:rs121913159)" FT /evidence="ECO:0000269|PubMed:7815442, FT ECO:0000269|PubMed:8326490" FT /id="VAR_015539" FT VARIANT 167 FT /note="V -> L (in IRAN type A; dbSNP:rs938519025)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015910" FT VARIANT 171 FT /note="Y -> H (in dbSNP:rs1051692)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_058396" FT VARIANT 220 FT /note="P -> L (in Ins resistance; severe; FT dbSNP:rs749094324)" FT /evidence="ECO:0000269|PubMed:8242067" FT /id="VAR_004083" FT VARIANT 228 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041429" FT VARIANT 236 FT /note="H -> R (in RMS and LEPRCH; Winnipeg; may impair FT receptor processing; dbSNP:rs121913145)" FT /evidence="ECO:0000269|PubMed:17201797, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004084" FT VARIANT 256 FT /note="R -> C (in RMS; dbSNP:rs781007453)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079536" FT VARIANT 260 FT /note="L -> P (in LEPRCH; Geldeimalsen; dbSNP:rs121913141)" FT /evidence="ECO:0000269|PubMed:2479553" FT /id="VAR_004085" FT VARIANT 279 FT /note="R -> C (in IRAN type A; inhibits receptor FT internalization; dbSNP:rs1568470274)" FT /evidence="ECO:0000269|PubMed:12107746" FT /id="VAR_015540" FT VARIANT 279 FT /note="R -> H (in IRAN type A; interferes with receptor FT processing; dbSNP:rs1329693158)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031519" FT VARIANT 280 FT /note="C -> Y (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:11260230" FT /id="VAR_015911" FT VARIANT 286 FT /note="C -> Y (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079537" FT VARIANT 301 FT /note="C -> Y (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9703342" FT /id="VAR_015912" FT VARIANT 308 FT /note="Missing (in LEPRCH; abolishes insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:7538143, ECO:0000269|PubMed:8636294" FT /id="VAR_015913" FT VARIANT 350 FT /note="S -> L (in RMS and LEPRCH; dbSNP:rs1974095413)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:8314008" FT /id="VAR_015914" FT VARIANT 362 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:12538626" FT /id="VAR_015541" FT VARIANT 386 FT /note="G -> S (in RMS; may impair receptor processing; FT dbSNP:rs764221583)" FT /evidence="ECO:0000269|PubMed:17201797" FT /id="VAR_031520" FT VARIANT 393 FT /note="G -> R (in LEPRCH; Verona-1; dbSNP:rs267607184)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004086" FT VARIANT 409 FT /note="F -> V (in IRAN type A; dbSNP:rs121913142)" FT /evidence="ECO:0000269|PubMed:8388389" FT /id="VAR_004087" FT VARIANT 439 FT /note="W -> S (in LEPRCH; impairs transport of the receptor FT to the cell surface; dbSNP:rs121913158)" FT /evidence="ECO:0000269|PubMed:8188715" FT /id="VAR_015542" FT VARIANT 448 FT /note="I -> T (in dbSNP:rs1051691)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015915" FT VARIANT 458 FT /note="N -> D (in LEPRCH; partially inhibits receptor FT processing and autophosphorylation; strongly impairs ERK FT phosphorylation; induces wild-type levels of IRS-1 FT phosphorylation; dbSNP:rs121913160)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031521" FT VARIANT 487 FT /note="K -> E (in LEPRCH; ARK-1; dbSNP:rs121913136)" FT /evidence="ECO:0000269|PubMed:2834824" FT /id="VAR_004088" FT VARIANT 489 FT /note="N -> D (in IRAN type A; uncertain significance; FT dbSNP:rs1135401742)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079538" FT VARIANT 489 FT /note="N -> S (in IRAN type A; dbSNP:rs121913147)" FT /evidence="ECO:0000269|PubMed:2365819" FT /id="VAR_004089" FT VARIANT 492 FT /note="Q -> K" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015916" FT VARIANT 635 FT /note="S -> L (in RMS; decreases post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079539" FT VARIANT 657 FT /note="V -> F (in LEPRCH; impairs post-translational FT processing; dbSNP:rs1135401737)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079540" FT VARIANT 659 FT /note="W -> R (in LEPRCH; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079541" FT VARIANT 695 FT /note="Q -> R (in dbSNP:rs55906835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041430" FT VARIANT 762 FT /note="R -> S (in IRAN type A; dbSNP:rs121913138)" FT /evidence="ECO:0000269|PubMed:3283938" FT /id="VAR_004090" FT VARIANT 811 FT /note="G -> S (in dbSNP:rs35045353)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041431" FT VARIANT 818 FT /note="Y -> C (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:22768670, FT ECO:0000269|PubMed:28765322" FT /id="VAR_079542" FT VARIANT 830 FT /note="P -> L (in dbSNP:rs2162771)" FT /id="VAR_055986" FT VARIANT 835 FT /note="S -> I (in RMS; impairs post-translational FT processing; dbSNP:rs1135401739)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079543" FT VARIANT 842 FT /note="A -> V (in RMS; decreases post-translational FT processing; dbSNP:rs1135401738)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079544" FT VARIANT 858 FT /note="T -> A (in T2D; dbSNP:rs182552223)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015917" FT VARIANT 874 FT /note="P -> L (in RMS; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079545" FT VARIANT 878 FT /note="N -> S (in RMS; impairs post-translational FT processing; dbSNP:rs887190835)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079546" FT VARIANT 890..1382 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:22768670" FT /id="VAR_079547" FT VARIANT 925 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; abolishes insulin binding; dbSNP:rs1599881881)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015918" FT VARIANT 926 FT /note="R -> W (in LEPRCH; markedly impairs insulin FT binding;impairs post-translational processing; FT dbSNP:rs911929963)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015919" FT VARIANT 937 FT /note="T -> M (in LEPRCH; impaired receptor processing; FT impairs post-translational processing; dbSNP:rs1972802448)" FT /evidence="ECO:0000269|PubMed:28765322, FT ECO:0000269|PubMed:9299395" FT /id="VAR_015920" FT VARIANT 997 FT /note="P -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015921" FT VARIANT 999..1382 FT /note="Missing (in RMS)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079548" FT VARIANT 1012 FT /note="V -> M (in dbSNP:rs1799816)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8432414, FT ECO:0000269|PubMed:8458533, ECO:0000269|PubMed:9199575" FT /id="VAR_004091" FT VARIANT 1020 FT /note="R -> Q (in IRAN type A; dbSNP:rs121913148)" FT /evidence="ECO:0000269|PubMed:2002058" FT /id="VAR_004092" FT VARIANT 1023 FT /note="I -> F" FT /evidence="ECO:0000269|PubMed:8890729" FT /id="VAR_015922" FT VARIANT 1035 FT /note="G -> V (in IRAN type A; dbSNP:rs121913135)" FT /evidence="ECO:0000269|PubMed:2544998" FT /id="VAR_004093" FT VARIANT 1054 FT /note="V -> M (in IRAN type A; uncertain significance; FT dbSNP:rs1135401741)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079549" FT VARIANT 1055 FT /note="A -> V (in IRAN type A; dbSNP:rs1599874183)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015923" FT VARIANT 1065 FT /note="L -> V (in dbSNP:rs56395521)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041432" FT VARIANT 1075 FT /note="A -> D (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:8243830" FT /id="VAR_004094" FT VARIANT 1095 FT /note="K -> E (in a subject with non-insulin dependent FT diabetes mellitus; dbSNP:rs909008899)" FT /evidence="ECO:0000269|PubMed:2040394" FT /id="VAR_015924" FT VARIANT 1119 FT /note="R -> W (in LEPRCH; dbSNP:rs1229730671)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:9249867" FT /id="VAR_015925" FT VARIANT 1143 FT /note="I -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015926" FT VARIANT 1158 FT /note="R -> Q (in T2D)" FT /evidence="ECO:0000269|PubMed:1470163" FT /id="VAR_015927" FT VARIANT 1158 FT /note="R -> W (in RMS; abolishes insulin binding; FT dbSNP:rs111993466)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015928" FT VARIANT 1161 FT /note="A -> T (in IRAN type A; dbSNP:rs121913139)" FT /evidence="ECO:0000269|PubMed:2168397" FT /id="VAR_004095" FT VARIANT 1162 FT /note="A -> E (in IRAN type A; impairs proteolytic FT processing; dbSNP:rs121913154)" FT /evidence="ECO:0000269|PubMed:8096518" FT /id="VAR_004096" FT VARIANT 1180 FT /note="M -> I (in a patient with insulin resistance; FT dbSNP:rs121913157)" FT /evidence="ECO:0000269|PubMed:1890161" FT /id="VAR_004097" FT VARIANT 1191 FT /note="R -> Q (in T2D; dbSNP:rs121913150)" FT /evidence="ECO:0000269|PubMed:1607076" FT /id="VAR_004098" FT VARIANT 1201 FT /note="R -> Q (in HHF5 and IRAN type A; interferes with FT kinase activation by insulin; dbSNP:rs121913156)" FT /evidence="ECO:0000269|PubMed:15161766, FT ECO:0000269|PubMed:8082780, ECO:0000269|PubMed:8288049" FT /id="VAR_015929" FT VARIANT 1201 FT /note="R -> W (in LEPRCH and RMS; reduces insulin binding FT possibly due to reduced receptor levels on the cell FT surface; dbSNP:rs1568426700)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:9703342" FT /id="VAR_015930" FT VARIANT 1205 FT /note="P -> L (in IRAN type A; moderate; FT dbSNP:rs1295645322)" FT /evidence="ECO:0000269|PubMed:1563582, FT ECO:0000269|PubMed:8314008" FT /id="VAR_004099" FT VARIANT 1206 FT /note="E -> D (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity)" FT /evidence="ECO:0000269|PubMed:7983039" FT /id="VAR_015931" FT VARIANT 1206 FT /note="E -> K (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9249867" FT /id="VAR_015932" FT VARIANT 1220 FT /note="W -> L (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity; dbSNP:rs52800171)" FT /evidence="ECO:0000269|PubMed:7983039, FT ECO:0000269|PubMed:8390949" FT /id="VAR_004100" FT VARIANT 1227 FT /note="W -> S (in IRAN type A; dbSNP:rs121913140)" FT /evidence="ECO:0000269|PubMed:1963473" FT /id="VAR_004101" FT VARIANT 1282 FT /note="T -> A (in dbSNP:rs55875349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041433" FT VARIANT 1361 FT /note="Y -> C (in dbSNP:rs13306449)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015933" FT VARIANT 1378 FT /note="R -> Q (in IRAN type A; dbSNP:rs52826008)" FT /evidence="ECO:0000269|PubMed:8314008" FT /id="VAR_015934" FT MUTAGEN 462 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 825 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 834 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 991 FT /note="L->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 992 FT /note="Y->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996..997 FT /note="NP->AA: Abolishes interaction with IRS1. Severely FT disrupts, but does not abolish interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996 FT /note="N->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 997 FT /note="P->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 998 FT /note="E->A: Does not affect interaction with IRS1, SHC1 or FT PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849" FT MUTAGEN 999 FT /note="Y->E: Abolishes interaction with IRS1 and SHC1." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 999 FT /note="Y->F: Has no effect on insulin-stimulated FT autophosphorylation, but inhibits the biological activity FT of the receptor. Abolishes interaction with IRS1 and almost FT completely prevents interaction with SHC1. Has no effect on FT interaction with PIK3R1. Abolishes interaction with FT STAT5B." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 1000 FT /note="L->A,R: Severely reduces interaction with SHC1. Has FT no effect on interaction with IRS1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1002 FT /note="A->D: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1011 FT /note="Y->A: Increases kinase activity." FT /evidence="ECO:0000269|PubMed:12707268" FT MUTAGEN 1057 FT /note="K->A: Abolishes the kinase activity and abolishes FT interaction with IRS1, SHC1, GRB7 and PIK3R1." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1057 FT /note="K->M,R: Abolishes the kinase activity." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1079 FT /note="K->R: Increased cell surface stability." FT /evidence="ECO:0000269|PubMed:27577745" FT MUTAGEN 1083 FT /note="C->A: Reduced S-nitrosylation by BLVRB, leading to FT increased receptor tyrosine kinase activity." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 1159 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1163 FT /note="R->Q: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1189 FT /note="Y->F: Reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT MUTAGEN 1190 FT /note="Y->F: Strongly reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT CONFLICT 601 FT /note="D -> N (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 830 FT /note="P -> E (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1278 FT /note="K -> N (in Ref. 2; CAA26096)" FT /evidence="ECO:0000305" FT STRAND 33..42 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 45..50 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 53..65 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 73..75 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 88..93 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 100..102 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 103..105 FT /evidence="ECO:0007829|PDB:8X2M" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 118..124 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 141..149 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 160..162 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 171..175 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 187..192 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 224..226 FT /evidence="ECO:0007829|PDB:8X06" FT STRAND 230..232 FT /evidence="ECO:0007829|PDB:7MQO" FT STRAND 243..247 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 273..275 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 279..281 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 283..295 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 305..307 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 310..314 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 323..325 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 327..330 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 338..348 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 351..355 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 356..359 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 361..369 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 377..385 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 390..393 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 395..399 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 404..406 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8X06" FT TURN 422..424 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 425..430 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 437..439 FT /evidence="ECO:0007829|PDB:7U6E" FT TURN 441..443 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 447..450 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 452..458 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 463..472 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 476..478 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 481..483 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 486..490 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 498..500 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 512..515 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 524..526 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 527..536 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 538..540 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 552..554 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 557..561 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 570..573 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 577..580 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 588..597 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 601..603 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 608..610 FT /evidence="ECO:0007829|PDB:4ZXB" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 626..631 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 633..636 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 638..643 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 654..658 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 666..669 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 732..740 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 798..803 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 805..809 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 817..827 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 838..843 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 867..870 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 881..890 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 896..901 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 902..908 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 910..913 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 918..931 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 940..944 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 953..979 FT /evidence="ECO:0007829|PDB:2MFR" FT STRAND 992..995 FT /evidence="ECO:0007829|PDB:5U1M" FT TURN 1003..1005 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1009..1011 FT /evidence="ECO:0007829|PDB:1IR3" FT HELIX 1014..1016 FT /evidence="ECO:0007829|PDB:1IRK" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1023..1031 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1033..1043 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1046..1048 FT /evidence="ECO:0007829|PDB:2Z8C" FT STRAND 1050..1057 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1065..1078 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1089..1093 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1095..1098 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1100..1104 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1111..1117 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1119..1121 FT /evidence="ECO:0007829|PDB:3ETA" FT HELIX 1133..1152 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1154..1156 FT /evidence="ECO:0007829|PDB:2AUH" FT HELIX 1162..1164 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1165..1167 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1173..1175 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1181..1183 FT /evidence="ECO:0007829|PDB:1IRK" FT TURN 1185..1187 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1190..1192 FT /evidence="ECO:0007829|PDB:5HHW" FT STRAND 1194..1198 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1200..1202 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1205..1210 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1215..1230 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1236..1239 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1242..1250 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1263..1272 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1277..1279 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1283..1290 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1291..1293 FT /evidence="ECO:0007829|PDB:5HHW" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1303..1305 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1307..1309 FT /evidence="ECO:0007829|PDB:8DWN" SQ SEQUENCE 1382 AA; 156333 MW; 709A955660739066 CRC64; MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN PS // ID KCC4_HUMAN Reviewed; 473 AA. AC Q16566; D3DSZ7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 215. DE RecName: Full=Calcium/calmodulin-dependent protein kinase type IV; DE Short=CaMK IV; DE EC=2.7.11.17; DE AltName: Full=CaM kinase-GR; GN Name=CAMK4; Synonyms=CAMK, CAMK-GR, CAMKIV; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8089075; DOI=10.1093/oxfordjournals.jbchem.a124387; RA Kitani T., Okuno S., Fujisawa H.; RT "cDNA cloning and expression of human calmodulin-dependent protein kinase RT IV."; RL J. Biochem. 115:637-640(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Cerebellum, and Thymus; RX PubMed=8194751; DOI=10.1016/0378-1119(94)90260-7; RA Bland M.M., Monroe R.S., Ohmstede C.A.; RT "The cDNA sequence and characterization of the Ca2+/calmodulin-dependent RT protein kinase-Gr from human brain and thymus."; RL Gene 142:191-197(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Blood; RX PubMed=8107230; DOI=10.1128/jvi.68.3.1697-1705.1994; RA Mosialos G., Hanissian S.H., Jawahar S., Vara L., Kieff E., Chatila T.A.; RT "A Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, expressed after RT transformation of primary human B lymphocytes by Epstein-Barr virus (EBV) RT is induced by the EBV oncogene LMP1."; RL J. Virol. 68:1697-1705(1994). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain, and Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP TISSUE SPECIFICITY. RX PubMed=8397199; DOI=10.1016/s0021-9258(20)80693-0; RA Hanissian S.H., Frangakis M., Bland M.M., Jawahar S., Chatila T.A.; RT "Expression of a Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, RT in human T lymphocytes. Regulation of kinase activity by T cell receptor RT signaling."; RL J. Biol. Chem. 268:20055-20063(1993). RN [7] RP FUNCTION, TISSUE SPECIFICITY, DOMAIN AUTOINHIBITORY, AND MUTAGENESIS OF RP 309-HIS--THR-312 AND 320-PHE-ASN-321. RX PubMed=7961813; DOI=10.1016/s0021-9258(19)61953-8; RA Tokumitsu H., Brickey D.A., Glod J., Hidaka H., Sikela J., Soderling T.R.; RT "Activation mechanisms for Ca2+/calmodulin-dependent protein kinase IV. RT Identification of a brain CaM-kinase IV kinase."; RL J. Biol. Chem. 269:28640-28647(1994). RN [8] RP FUNCTION IN PHOSPHORYLATION OF CREB1, AND SUBCELLULAR LOCATION. RX PubMed=8065343; DOI=10.1128/mcb.14.9.6107-6116.1994; RA Matthews R.P., Guthrie C.R., Wailes L.M., Zhao X., Means A.R., RA McKnight G.S.; RT "Calcium/calmodulin-dependent protein kinase types II and IV differentially RT regulate CREB-dependent gene expression."; RL Mol. Cell. Biol. 14:6107-6116(1994). RN [9] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=8980227; DOI=10.1016/s0092-8674(00)81816-4; RA Bito H., Deisseroth K., Tsien R.W.; RT "CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus RT duration-dependent switch for hippocampal gene expression."; RL Cell 87:1203-1214(1996). RN [10] RP ACTIVITY REGULATION, PHOSPHORYLATION AT SER-12; SER-13 AND THR-200, AND RP MUTAGENESIS OF SER-12 AND SER-13. RX PubMed=8702940; DOI=10.1074/jbc.271.35.21542; RA Chatila T., Anderson K.A., Ho N., Means A.R.; RT "A unique phosphorylation-dependent mechanism for the activation of RT Ca2+/calmodulin-dependent protein kinase type IV/GR."; RL J. Biol. Chem. 271:21542-21548(1996). RN [11] RP FUNCTION IN PHOSPHORYLATION OF ELK1; JUN AND ATF2, AND MUTAGENESIS OF RP THR-200. RX PubMed=8855261; DOI=10.1073/pnas.93.20.10803; RA Enslen H., Tokumitsu H., Stork P.J., Davis R.J., Soderling T.R.; RT "Regulation of mitogen-activated protein kinases by a calcium/calmodulin- RT dependent protein kinase cascade."; RL Proc. Natl. Acad. Sci. U.S.A. 93:10803-10808(1996). RN [12] RP FUNCTION IN PHOSPHORYLATION OF STMN1. RX PubMed=9154845; DOI=10.1128/mcb.17.6.3459; RA Melander Gradin H., Marklund U., Larsson N., Chatila T.A., Gullberg M.; RT "Regulation of microtubule dynamics by Ca2+/calmodulin-dependent kinase RT IV/Gr-dependent phosphorylation of oncoprotein 18."; RL Mol. Cell. Biol. 17:3459-3467(1997). RN [13] RP FUNCTION IN PHOSPHORYLATION OF MEF2D, AND MUTAGENESIS OF LYS-75. RX PubMed=10617605; DOI=10.1074/jbc.275.1.197; RA Blaeser F., Ho N., Prywes R., Chatila T.A.; RT "Ca(2+)-dependent gene expression mediated by MEF2 transcription factors."; RL J. Biol. Chem. 275:197-209(2000). RN [14] RP TISSUE SPECIFICITY. RX PubMed=12065094; DOI=10.1016/s0304-3835(02)00107-6; RA Takai N., Miyazaki T., Nishida M., Nasu K., Miyakawa I.; RT "Ca(2+)/calmodulin-dependent protein kinase IV expression in epithelial RT ovarian cancer."; RL Cancer Lett. 183:185-193(2002). RN [15] RP ACTIVITY REGULATION, INTERACTION WITH PROTEIN PHOSPHATASE 2A, RP PHOSPHORYLATION AT THR-200, AND MUTAGENESIS OF 320-PHE-ASN-321. RX PubMed=15143065; DOI=10.1074/jbc.m404523200; RA Anderson K.A., Noeldner P.K., Reece K., Wadzinski B.E., Means A.R.; RT "Regulation and function of the calcium/calmodulin-dependent protein kinase RT IV/protein serine/threonine phosphatase 2A signaling complex."; RL J. Biol. Chem. 279:31708-31716(2004). RN [16] RP ACTIVITY REGULATION, AND PROTEIN PHOSPHATASE 2A BINDING DOMAIN. RX PubMed=15769749; DOI=10.1074/jbc.m500067200; RA Chow F.A., Anderson K.A., Noeldner P.K., Means A.R.; RT "The autonomous activity of calcium/calmodulin-dependent protein kinase IV RT is required for its role in transcription."; RL J. Biol. Chem. 280:20530-20538(2005). RN [17] RP FUNCTION IN DENDRITIC CELLS LIFESPAN REGULATION, AND DEVELOPMENTAL STAGE. RX PubMed=17909078; DOI=10.1182/blood-2007-05-091173; RA Illario M., Giardino-Torchia M.L., Sankar U., Ribar T.J., Galgani M., RA Vitiello L., Masci A.M., Bertani F.R., Ciaglia E., Astone D., Maulucci G., RA Cavallo A., Vitale M., Cimini V., Pastore L., Means A.R., Rossi G., RA Racioppi L.; RT "Calmodulin-dependent kinase IV links Toll-like receptor 4 signaling with RT survival pathway of activated dendritic cells."; RL Blood 111:723-731(2008). RN [18] RP FUNCTION. RX PubMed=18829949; DOI=10.1523/jneurosci.2625-08.2008; RA Fukushima H., Maeda R., Suzuki R., Suzuki A., Nomoto M., Toyoda H., RA Wu L.J., Xu H., Zhao M.G., Ueda K., Kitamoto A., Mamiya N., Yoshida T., RA Homma S., Masushige S., Zhuo M., Kida S.; RT "Upregulation of calcium/calmodulin-dependent protein kinase IV improves RT memory formation and rescues memory loss with aging."; RL J. Neurosci. 28:9910-9919(2008). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [20] RP GLYCOSYLATION AT THR-57 SER-58; SER-137; SER-189; SER-344; SER-345 AND RP SER-356, PHOSPHORYLATION AT THR-200, IDENTIFICATION BY MASS SPECTROMETRY, RP AND MUTAGENESIS OF 57-THR-SER-58 AND SER-189. RX PubMed=19506079; DOI=10.1074/jbc.m109.007310; RA Dias W.B., Cheung W.D., Wang Z., Hart G.W.; RT "Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc RT modification."; RL J. Biol. Chem. 284:21327-21337(2009). RN [21] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=9920409; DOI=10.1016/s0167-4889(98)00142-6; RA Krebs J.; RT "Calmodulin-dependent protein kinase IV: regulation of function and RT expression."; RL Biochim. Biophys. Acta 1448:183-189(1998). RN [22] RP REVIEW ON FUNCTION IN NEURONAL PLASTICITY. RX PubMed=18817731; DOI=10.1016/j.neuron.2008.08.021; RA Wayman G.A., Lee Y.S., Tokumitsu H., Silva A.J., Silva A., Soderling T.R.; RT "Calmodulin-kinases: modulators of neuronal development and plasticity."; RL Neuron 59:914-931(2008). RN [23] RP REVIEW ON INVOLVEMENT IN IMMUNE AND INFLAMMATORY RESPONSE. RX PubMed=18930438; DOI=10.1016/j.it.2008.08.005; RA Racioppi L., Means A.R.; RT "Calcium/calmodulin-dependent kinase IV in immune and inflammatory RT responses: novel routes for an ancient traveller."; RL Trends Immunol. 29:600-607(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-360, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 15-340 IN COMPLEX WITH INHIBITOR. RA Muniz J.R.C., Rellos P., Gileadi O., Fedorov O., Filippakopoulos P., RA Salah E., Pike A., Phillips C., Niesen F., Shrestha L., Burgess-Brown N., RA Bullock A., Berridge G., Vondelft F., Edwards A.M., Bountra C., RA Arrowsmith C.H., Weigelt J., Knapp S.; RT "Crystal structure of human CAMK4 in complex with 4-amino(sulfamoyl- RT phenylamino)-triazole-carbothioic acid (2,6-difluoro-phenyl)-amide)."; RL Submitted (NOV-2008) to the PDB data bank. RN [28] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-150; ASN-178; ARG-465 AND MET-469. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium/calmodulin-dependent protein kinase that operates in CC the calcium-triggered CaMKK-CaMK4 signaling cascade and regulates, CC mainly by phosphorylation, the activity of several transcription CC activators, such as CREB1, MEF2D, JUN and RORA, which play pivotal CC roles in immune response, inflammation, and memory consolidation. In CC the thymus, regulates the CD4(+)/CD8(+) double positive thymocytes CC selection threshold during T-cell ontogeny. In CD4 memory T-cells, is CC required to link T-cell antigen receptor (TCR) signaling to the CC production of IL2, IFNG and IL4 (through the regulation of CREB and CC MEF2). Regulates the differentiation and survival phases of osteoclasts CC and dendritic cells (DCs). Mediates DCs survival by linking TLR4 and CC the regulation of temporal expression of BCL2. Phosphorylates the CC transcription activator CREB1 on 'Ser-133' in hippocampal neuron nuclei CC and contribute to memory consolidation and long term potentiation (LTP) CC in the hippocampus. Can activate the MAP kinases MAPK1/ERK2, MAPK8/JNK1 CC and MAPK14/p38 and stimulate transcription through the phosphorylation CC of ELK1 and ATF2. Can also phosphorylate in vitro CREBBP, PRM2, MEF2A CC and STMN1/OP18. {ECO:0000269|PubMed:10617605, CC ECO:0000269|PubMed:17909078, ECO:0000269|PubMed:18829949, CC ECO:0000269|PubMed:7961813, ECO:0000269|PubMed:8065343, CC ECO:0000269|PubMed:8855261, ECO:0000269|PubMed:8980227, CC ECO:0000269|PubMed:9154845}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of CC calmodulin results in conformational change that relieves intrasteric CC autoinhibition and allows phosphorylation of Thr-200 within the CC activation loop by CaMKK1 or CaMKK2. Phosphorylation of Thr-200 results CC in a 10-20-fold increase in total activity to generate CC Ca(2+)/calmodulin-independent activity. Autophosphorylation of the N- CC terminus Ser-12 and Ser-13 is required for full activation. Inactivated CC by protein phosphatase 2A (PPP2CA/PPP2CB) which dephosphorylates Thr- CC 200, thereby terminating autonomous activity and helping to maintain CC the enzyme in its autoinhibited state. {ECO:0000269|PubMed:15143065, CC ECO:0000269|PubMed:15769749, ECO:0000269|PubMed:8702940}. CC -!- SUBUNIT: Monomer (By similarity). Interacts with protein phosphatase 2A CC (PPP2CA/PPP2CB); the interaction is mutually exclusive with binding to CC Ca(2+)/calmodulin. {ECO:0000250, ECO:0000269|PubMed:15143065, CC ECO:0000269|Ref.27}. CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Localized in hippocampal CC neuron nuclei. In spermatids, associated with chromatin and nuclear CC matrix (By similarity). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in brain, thymus, CD4 T-cells, testis and CC epithelial ovarian cancer tissue. {ECO:0000269|PubMed:12065094, CC ECO:0000269|PubMed:7961813, ECO:0000269|PubMed:8397199}. CC -!- DEVELOPMENTAL STAGE: Expressed during differentiation of monocyte- CC derived dendritic cells (at protein level). CC {ECO:0000269|PubMed:17909078}. CC -!- DOMAIN: The autoinhibitory domain overlaps with the calmodulin binding CC region and interacts in the inactive folded state with the catalytic CC domain as a pseudosubstrate. {ECO:0000269|PubMed:7961813}. CC -!- PTM: Phosphorylated by CaMKK1 and CaMKK2 on Thr-200. Dephosphorylated CC by protein phosphatase 2A. Autophosphorylated on Ser-12 and Ser-13. CC {ECO:0000269|PubMed:15143065, ECO:0000269|PubMed:19506079, CC ECO:0000269|PubMed:8702940}. CC -!- PTM: Glycosylation at Ser-189 modulates the phosphorylation of CaMK4 at CC Thr-200 and negatively regulates its activity toward CREB1 in basal CC conditions and during early inomycin stimulation. CC {ECO:0000269|PubMed:15143065, ECO:0000269|PubMed:19506079, CC ECO:0000269|PubMed:8702940}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH16695.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D30742; BAA06403.1; -; mRNA. DR EMBL; L17000; AAA35639.1; -; mRNA. DR EMBL; L24959; AAA18251.1; -; mRNA. DR EMBL; CH471086; EAW49033.1; -; Genomic_DNA. DR EMBL; CH471086; EAW49034.1; -; Genomic_DNA. DR EMBL; BC016695; AAH16695.2; ALT_INIT; mRNA. DR EMBL; BC025687; AAH25687.1; -; mRNA. DR CCDS; CCDS4103.1; -. DR PIR; A53036; A53036. DR RefSeq; NP_001310303.1; NM_001323374.2. DR RefSeq; NP_001310304.1; NM_001323375.2. DR RefSeq; NP_001735.1; NM_001744.6. DR PDB; 2W4O; X-ray; 2.17 A; A=15-340. DR PDBsum; 2W4O; -. DR AlphaFoldDB; Q16566; -. DR SMR; Q16566; -. DR BioGRID; 107264; 53. DR CORUM; Q16566; -. DR DIP; DIP-41997N; -. DR FunCoup; Q16566; 1741. DR IntAct; Q16566; 42. DR STRING; 9606.ENSP00000282356; -. DR BindingDB; Q16566; -. DR ChEMBL; CHEMBL2494; -. DR DrugBank; DB07676; 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one. DR DrugBank; DB07664; K-00546. DR DrugCentral; Q16566; -. DR GlyCosmos; Q16566; 7 sites, 1 glycan. DR GlyGen; Q16566; 7 sites, 1 O-linked glycan (7 sites). DR iPTMnet; Q16566; -. DR MetOSite; Q16566; -. DR PhosphoSitePlus; Q16566; -. DR BioMuta; CAMK4; -. DR DMDM; 2499586; -. DR jPOST; Q16566; -. DR MassIVE; Q16566; -. DR PaxDb; 9606-ENSP00000282356; -. DR PeptideAtlas; Q16566; -. DR ProteomicsDB; 60921; -. DR Pumba; Q16566; -. DR Antibodypedia; 2084; 637 antibodies from 43 providers. DR DNASU; 814; -. DR Ensembl; ENST00000282356.9; ENSP00000282356.4; ENSG00000152495.12. DR Ensembl; ENST00000512453.5; ENSP00000422634.1; ENSG00000152495.12. DR GeneID; 814; -. DR KEGG; hsa:814; -. DR MANE-Select; ENST00000282356.9; ENSP00000282356.4; NM_001744.6; NP_001735.1. DR UCSC; uc003kpf.4; human. DR AGR; HGNC:1464; -. DR ClinPGx; PA26050; -. DR CTD; 814; -. DR DisGeNET; 814; -. DR GeneCards; CAMK4; -. DR HGNC; HGNC:1464; CAMK4. DR HPA; ENSG00000152495; Group enriched (brain, lymphoid tissue). DR MalaCards; CAMK4; -. DR MIM; 114080; gene. DR OpenTargets; ENSG00000152495; -. DR VEuPathDB; HostDB:ENSG00000152495; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000160006; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; Q16566; -. DR OMA; VVPDYWI; -. DR OrthoDB; 40902at2759; -. DR PAN-GO; Q16566; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q16566; -. DR BRENDA; 2.7.11.17; 2681. DR PathwayCommons; Q16566; -. DR Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB. DR Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis. DR Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde. DR Reactome; R-HSA-9022535; Loss of phosphorylation of MECP2 at T308. DR Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity. DR Reactome; R-HSA-9617324; Negative regulation of NMDA receptor-mediated neuronal transmission. DR SignaLink; Q16566; -. DR SIGNOR; Q16566; -. DR Agora; ENSG00000152495; -. DR BioGRID-ORCS; 814; 8 hits in 1186 CRISPR screens. DR ChiTaRS; CAMK4; human. DR EvolutionaryTrace; Q16566; -. DR GeneWiki; CAMK4; -. DR GenomeRNAi; 814; -. DR Pharos; Q16566; Tbio. DR PRO; PR:Q16566; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q16566; protein. DR Bgee; ENSG00000152495; Expressed in cerebellar vermis and 140 other cell types or tissues. DR ExpressionAtlas; Q16566; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0009931; F:calcium-dependent protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IDA:CACAO. DR GO; GO:0005516; F:calmodulin binding; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007616; P:long-term memory; IGI:UniProtKB. DR GO; GO:0043011; P:myeloid dendritic cell differentiation; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0045670; P:regulation of osteoclast differentiation; TAS:UniProtKB. DR GO; GO:0033081; P:regulation of T cell differentiation in thymus; TAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd14085; STKc_CaMKIV; 1. DR FunFam; 1.10.510.10:FF:000255; Calcium/calmodulin-dependent protein kinase type IV; 1. DR FunFam; 3.30.200.20:FF:000279; Calcium/calmodulin-dependent protein kinase type IV; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; ATP-binding; Calcium; Calmodulin-binding; KW Cytoplasm; Glycoprotein; Immunity; Inflammatory response; Kinase; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..473 FT /note="Calcium/calmodulin-dependent protein kinase type IV" FT /id="PRO_0000086106" FT DOMAIN 46..300 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 305..321 FT /note="Autoinhibitory domain" FT REGION 306..323 FT /note="PP2A-binding" FT REGION 322..341 FT /note="Calmodulin-binding" FT /evidence="ECO:0000255" FT REGION 341..368 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 445..473 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 341..350 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 164 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 52..60 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 75 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 12 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8702940" FT MOD_RES 13 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8702940" FT MOD_RES 200 FT /note="Phosphothreonine; by CaMKK1 and CaMKK2" FT /evidence="ECO:0000269|PubMed:15143065, FT ECO:0000269|PubMed:19506079, ECO:0000269|PubMed:8702940" FT MOD_RES 336 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P13234" FT MOD_RES 341 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P13234" FT MOD_RES 360 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT CARBOHYD 57 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 58 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 137 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 189 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 344 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 345 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 356 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT VARIANT 150 FT /note="E -> G (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040604" FT VARIANT 178 FT /note="D -> N (in dbSNP:rs35548075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040605" FT VARIANT 465 FT /note="Q -> R (in dbSNP:rs56360861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040606" FT VARIANT 469 FT /note="I -> M (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1239950009)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040607" FT MUTAGEN 12 FT /note="S->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:8702940" FT MUTAGEN 13 FT /note="S->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:8702940" FT MUTAGEN 57..58 FT /note="TS->AA: Loss of phosphorylation of CREB1." FT /evidence="ECO:0000269|PubMed:19506079" FT MUTAGEN 75 FT /note="K->E: Loss of activity; dominant negative form." FT /evidence="ECO:0000269|PubMed:10617605" FT MUTAGEN 189 FT /note="S->A: Increases phosphorylation of CREB1 2-fold. FT Decreases total O-linked glycosylation 2-fold. Increases FT ATP-binding affinity." FT /evidence="ECO:0000269|PubMed:19506079" FT MUTAGEN 200 FT /note="T->A: Loss of activation by CaMKK1 or CaMKK2." FT /evidence="ECO:0000269|PubMed:8855261" FT MUTAGEN 309..312 FT /note="HMDT->DEDD: Fully active Ca2+/CaM-independent FT kinase; when associated with 320-A-A-321." FT /evidence="ECO:0000269|PubMed:7961813" FT MUTAGEN 320..321 FT /note="FN->DD: Fully active Ca2+/CaM-independent kinase; FT when associated with 309-A--A-312. Loss of interaction with FT PPP2CA/PPP2CB." FT /evidence="ECO:0000269|PubMed:15143065, FT ECO:0000269|PubMed:7961813" FT STRAND 36..38 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 42..44 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 46..54 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 56..65 FT /evidence="ECO:0007829|PDB:2W4O" FT TURN 66..68 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 71..78 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 91..95 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 104..109 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 111..118 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 126..130 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 138..157 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 170..176 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 205..207 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 210..213 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 221..236 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 247..255 FT /evidence="ECO:0007829|PDB:2W4O" FT TURN 263..268 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 271..278 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 285..287 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 291..296 FT /evidence="ECO:0007829|PDB:2W4O" FT TURN 298..301 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 311..335 FT /evidence="ECO:0007829|PDB:2W4O" SQ SEQUENCE 473 AA; 51926 MW; EFEE51E5612326DC CRC64; MLKVTVPSCS ASSCSSVTAS AAPGTASLVP DYWIDGSNRD ALSDFFEVES ELGRGATSIV YRCKQKGTQK PYALKVLKKT VDKKIVRTEI GVLLRLSHPN IIKLKEIFET PTEISLVLEL VTGGELFDRI VEKGYYSERD AADAVKQILE AVAYLHENGI VHRDLKPENL LYATPAPDAP LKIADFGLSK IVEHQVLMKT VCGTPGYCAP EILRGCAYGP EVDMWSVGII TYILLCGFEP FYDERGDQFM FRRILNCEYY FISPWWDEVS LNAKDLVRKL IVLDPKKRLT TFQALQHPWV TGKAANFVHM DTAQKKLQEF NARRKLKAAV KAVVASSRLG SASSSHGSIQ ESHKASRDPS PIQDGNEDMK AIPEGEKIQG DGAQAAVKGA QAELMKVQAL EKVKGADINA EEAPKMVPKA VEDGIKVADL ELEEGLAEEK LKTVEEAAAP REGQGSSAVG FEVPQQDVIL PEY // ID KS6A2_HUMAN Reviewed; 733 AA. AC Q15349; B3KTK9; Q15419; Q59GJ3; Q5TI68; Q96J38; Q9UJN5; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2006, sequence version 2. DT 28-JAN-2026, entry version 230. DE RecName: Full=Ribosomal protein S6 kinase alpha-2; DE Short=S6K-alpha-2; DE EC=2.7.11.1; DE AltName: Full=90 kDa ribosomal protein S6 kinase 2; DE Short=p90-RSK 2; DE Short=p90RSK2; DE AltName: Full=MAP kinase-activated protein kinase 1c; DE Short=MAPK-activated protein kinase 1c; DE Short=MAPKAP kinase 1c; DE Short=MAPKAPK-1c; DE AltName: Full=Ribosomal S6 kinase 3; DE Short=RSK-3; DE AltName: Full=pp90RSK3; GN Name=RPS6KA2; Synonyms=MAPKAPK1C, RSK3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND RP SUBCELLULAR LOCATION. RX PubMed=7623830; DOI=10.1128/mcb.15.8.4353; RA Zhao Y., Bjoerbaek C., Weremowicz S., Morton C.C., Moller D.E.; RT "RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: RT growth factor-stimulated kinase function and nuclear translocation."; RL Mol. Cell. Biol. 15:4353-4363(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-540 (ISOFORM 1). RX PubMed=8141249; DOI=10.1152/ajpcell.1994.266.2.c351; RA Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.; RT "Human rsk isoforms: cloning and characterization of tissue-specific RT expression."; RL Am. J. Physiol. 266:C351-C359(1994). RN [7] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-218. RX PubMed=10480933; DOI=10.1074/jbc.274.38.27168; RA Jensen C.J., Buch M.-B., Krag T.O., Hemmings B.A., Gammeltoft S., RA Froedin M.; RT "90-kDa ribosomal S6 kinase is phosphorylated and activated by 3- RT phosphoinositide-dependent protein kinase-1."; RL J. Biol. Chem. 274:27168-27176(1999). RN [8] RP FUNCTION IN TUMORIGENESIS, AND TISSUE SPECIFICITY. RX PubMed=16878154; DOI=10.1038/sj.onc.1209827; RA Bignone P.A., Lee K.Y., Liu Y., Emilion G., Finch J., Soosay A.E., RA Charnock F.M., Beck S., Dunham I., Mungall A.J., Ganesan T.S.; RT "RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial RT ovarian cancer."; RL Oncogene 26:683-700(2007). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [10] RP REVIEW ON FUNCTION. RX PubMed=18813292; DOI=10.1038/nrm2509; RA Anjum R., Blenis J.; RT "The RSK family of kinases: emerging roles in cellular signalling."; RL Nat. Rev. Mol. Cell Biol. 9:747-758(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-311 AND GLN-732. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of ERK CC (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and CC stress-induced activation of transcription factors, regulates CC translation, and mediates cellular proliferation, survival, and CC differentiation. May function as tumor suppressor in epithelial ovarian CC cancer cells. {ECO:0000269|PubMed:16878154, CC ECO:0000269|PubMed:7623830}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Upon extracellular signal or mitogen stimulation, CC phosphorylated at Thr-570 in the C-terminal kinase domain (CTKD) by CC MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates CC Ser-377, allowing binding of PDPK1, which in turn phosphorylates Ser- CC 218 in the N-terminal kinase domain (NTDK) leading to the full CC activation of the protein and subsequent phosphorylation of the CC substrates by the NTKD. {ECO:0000269|PubMed:10480933}. CC -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in CC quiescent cells. Transiently dissociates following mitogenic CC stimulation (By similarity). Interacts with FBXO5; cooperate to induce CC the metaphase arrest of early blastomeres; increases and stabilizes CC interaction of FBXO5 with CDC20 (By similarity). {ECO:0000250, CC ECO:0000250|UniProtKB:Q9WUT3}. CC -!- INTERACTION: CC Q15349; P05067: APP; NbExp=3; IntAct=EBI-1384149, EBI-77613; CC Q15349; P15056: BRAF; NbExp=2; IntAct=EBI-1384149, EBI-365980; CC Q15349; P67870: CSNK2B; NbExp=4; IntAct=EBI-1384149, EBI-348169; CC Q15349; O14901: KLF11; NbExp=3; IntAct=EBI-1384149, EBI-948266; CC Q15349; P28482: MAPK1; NbExp=12; IntAct=EBI-1384149, EBI-959949; CC Q15349; Q02156: PRKCE; NbExp=2; IntAct=EBI-1384149, EBI-706254; CC Q15349; Q14160: SCRIB; NbExp=9; IntAct=EBI-1384149, EBI-357345; CC Q15349; Q9Y566: SHANK1; NbExp=2; IntAct=EBI-1384149, EBI-3442234; CC Q15349; P62258: YWHAE; NbExp=2; IntAct=EBI-1384149, EBI-356498; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:7623830}. Cytoplasm CC {ECO:0000269|PubMed:7623830}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q15349-1; Sequence=Displayed; CC Name=2; CC IsoId=Q15349-2; Sequence=VSP_017732; CC Name=3; CC IsoId=Q15349-3; Sequence=VSP_041836; CC -!- TISSUE SPECIFICITY: Widely expressed with higher expression in lung, CC skeletal muscle, brain, uterus, ovary, thyroid and prostate. CC {ECO:0000269|PubMed:16878154, ECO:0000269|PubMed:7623830}. CC -!- PTM: Activated by phosphorylation at Ser-218 by PDPK1. CC Autophosphorylated on Ser-377, as part of the activation process. May CC be phosphorylated at Thr-356 and Ser-360 by MAPK1/ERK2 and MAPK3/ERK1 CC (By similarity). {ECO:0000250}. CC -!- PTM: N-terminal myristoylation results in an activated kinase in the CC absence of added growth factors. {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. S6 kinase subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC82496.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAD92353.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAG53121.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X85106; CAA59427.1; -; mRNA. DR EMBL; AB209116; BAD92353.1; ALT_INIT; mRNA. DR EMBL; AK095751; BAG53121.1; ALT_FRAME; mRNA. DR EMBL; AL022069; CAI19651.1; -; Genomic_DNA. DR EMBL; Z98049; CAI19651.1; JOINED; Genomic_DNA. DR EMBL; AL023775; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL159163; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z98049; CAI20579.1; -; Genomic_DNA. DR EMBL; AL022069; CAI20579.1; JOINED; Genomic_DNA. DR EMBL; BC002363; AAH02363.1; -; mRNA. DR EMBL; L07598; AAC82496.1; ALT_INIT; mRNA. DR CCDS; CCDS34570.1; -. [Q15349-3] DR CCDS; CCDS5294.1; -. [Q15349-1] DR CCDS; CCDS83148.1; -. [Q15349-2] DR PIR; A57459; A57459. DR RefSeq; NP_001006933.3; NM_001006932.3. [Q15349-3] DR RefSeq; NP_001305865.2; NM_001318936.2. DR RefSeq; NP_001305866.1; NM_001318937.1. DR RefSeq; NP_001305867.1; NM_001318938.1. DR RefSeq; NP_066958.2; NM_021135.5. [Q15349-1] DR AlphaFoldDB; Q15349; -. DR SMR; Q15349; -. DR BioGRID; 112110; 201. DR DIP; DIP-295N; -. DR FunCoup; Q15349; 3133. DR IntAct; Q15349; 62. DR MINT; Q15349; -. DR STRING; 9606.ENSP00000422435; -. DR BindingDB; Q15349; -. DR ChEMBL; CHEMBL3906; -. DR DrugCentral; Q15349; -. DR GuidetoPHARMACOLOGY; 1529; -. DR iPTMnet; Q15349; -. DR PhosphoSitePlus; Q15349; -. DR BioMuta; RPS6KA2; -. DR DMDM; 90110031; -. DR REPRODUCTION-2DPAGE; Q15349; -. DR CPTAC; CPTAC-2945; -. DR jPOST; Q15349; -. DR MassIVE; Q15349; -. DR PaxDb; 9606-ENSP00000427015; -. DR PeptideAtlas; Q15349; -. DR ProteomicsDB; 60536; -. [Q15349-1] DR ProteomicsDB; 60537; -. [Q15349-2] DR ProteomicsDB; 60538; -. [Q15349-3] DR Antibodypedia; 33522; 564 antibodies from 43 providers. DR DNASU; 6196; -. DR Ensembl; ENST00000265678.9; ENSP00000265678.4; ENSG00000071242.14. [Q15349-1] DR Ensembl; ENST00000503859.5; ENSP00000427015.1; ENSG00000071242.14. [Q15349-3] DR GeneID; 6196; -. DR KEGG; hsa:6196; -. DR MANE-Select; ENST00000265678.9; ENSP00000265678.4; NM_021135.6; NP_066958.2. DR UCSC; uc003qvb.2; human. [Q15349-1] DR AGR; HGNC:10431; -. DR ClinPGx; PA34846; -. DR CTD; 6196; -. DR DisGeNET; 6196; -. DR GeneCards; RPS6KA2; -. DR HGNC; HGNC:10431; RPS6KA2. DR HPA; ENSG00000071242; Low tissue specificity. DR MIM; 601685; gene. DR OpenTargets; ENSG00000071242; -. DR VEuPathDB; HostDB:ENSG00000071242; -. DR eggNOG; KOG0603; Eukaryota. DR GeneTree; ENSGT00940000159956; -. DR InParanoid; Q15349; -. DR OMA; GAMKATY; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q15349; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q15349; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q15349; -. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-199920; CREB phosphorylation. DR Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-HSA-437239; Recycling pathway of L1. DR Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling. DR Reactome; R-HSA-444257; RSK activation. DR Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK. DR SignaLink; Q15349; -. DR SIGNOR; Q15349; -. DR Agora; ENSG00000071242; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 6196; 19 hits in 1179 CRISPR screens. DR ChiTaRS; RPS6KA2; human. DR GeneWiki; RPS6KA2; -. DR GenomeRNAi; 6196; -. DR Pharos; Q15349; Tchem. DR PRO; PR:Q15349; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q15349; protein. DR Bgee; ENSG00000071242; Expressed in inferior olivary complex and 215 other cell types or tissues. DR ExpressionAtlas; Q15349; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0045202; C:synapse; IEA:GOC. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0000287; F:magnesium ion binding; IEA:InterPro. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI. DR GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central. DR GO; GO:0002035; P:brain renin-angiotensin system; IEA:Ensembl. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0071322; P:cellular response to carbohydrate stimulus; IEA:Ensembl. DR GO; GO:0007268; P:chemical synaptic transmission; TAS:Reactome. DR GO; GO:0060047; P:heart contraction; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc. DR GO; GO:0045786; P:negative regulation of cell cycle; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0045835; P:negative regulation of meiotic nuclear division; IEA:Ensembl. DR GO; GO:0001556; P:oocyte maturation; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0070613; P:regulation of protein processing; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; NAS:ProtInc. DR GO; GO:0038202; P:TORC1 signaling; IBA:GO_Central. DR CDD; cd14178; STKc_RSK3_C; 1. DR CDD; cd05582; STKc_RSK_N; 1. DR FunFam; 1.10.510.10:FF:000010; Ribosomal protein S6 kinase; 1. DR FunFam; 1.10.510.10:FF:000041; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000013; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000121; Ribosomal protein S6 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016239; Ribosomal_S6_kinase_II. DR InterPro; IPR042766; RSK3_STKc. DR InterPro; IPR041906; RSK_N. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 2. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Kinase; Magnesium; KW Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT CHAIN 1..733 FT /note="Ribosomal protein S6 kinase alpha-2" FT /id="PRO_0000086201" FT DOMAIN 59..318 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 319..388 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 415..672 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 184 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 532 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 65..73 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 91 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 421..429 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 444 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 218 FT /note="Phosphoserine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10480933" FT MOD_RES 377 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT VAR_SEQ 1..32 FT /note="MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRL -> MPIAQLLELWKKIEVE FT PMEIETTEEDLNLDVGPATEDTAEEGKSDSAACKTKVAGSV (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017732" FT VAR_SEQ 1..32 FT /note="MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRL -> MPIAQLLELWKKIEVE FT PMEIETTEEDLNLDVEPTTEDTAE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041836" FT VARIANT 311 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267600891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040627" FT VARIANT 732 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs376029388)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040628" FT CONFLICT 256 FT /note="S -> A (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 269 FT /note="A -> S (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 339 FT /note="V -> L (in Ref. 1; CAA59427 and 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 447 FT /note="D -> G (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT Q15349-3:32 FT /note="E -> G (in Ref. 3; BAG53121)" FT /evidence="ECO:0000305" FT CONFLICT Q15349-3:34 FT /note="T -> A (in Ref. 3; BAG53121)" FT /evidence="ECO:0000305" SQ SEQUENCE 733 AA; 83239 MW; 087CFB819A313760 CRC64; MDLSMKKFAV RRFFSVYLRR KSRSKSSSLS RLEEEGVVKE IDISHHVKEG FEKADPSQFE LLKVLGQGSY GKVFLVRKVK GSDAGQLYAM KVLKKATLKV RDRVRSKMER DILAEVNHPF IVKLHYAFQT EGKLYLILDF LRGGDLFTRL SKEVMFTEED VKFYLAELAL ALDHLHSLGI IYRDLKPENI LLDEEGHIKI TDFGLSKEAI DHDKRAYSFC GTIEYMAPEV VNRRGHTQSA DWWSFGVLMF EMLTGSLPFQ GKDRKETMAL ILKAKLGMPQ FLSGEAQSLL RALFKRNPCN RLGAGIDGVE EIKRHPFFVT IDWNTLYRKE IKPPFKPAVG RPEDTFHFDP EFTARTPTDS PGVPPSANAH HLFRGFSFVA SSLIQEPSQQ DLHKVPVHPI VQQLHGNNIH FTDGYEIKED IGVGSYSVCK RCVHKATDTE YAVKIIDKSK RDPSEEIEIL LRYGQHPNII TLKDVYDDGK FVYLVMELMR GGELLDRILR QRYFSEREAS DVLCTITKTM DYLHSQGVVH RDLKPSNILY RDESGSPESI RVCDFGFAKQ LRAGNGLLMT PCYTANFVAP EVLKRQGYDA ACDIWSLGIL LYTMLAGFTP FANGPDDTPE EILARIGSGK YALSGGNWDS ISDAAKDVVS KMLHVDPHQR LTAMQVLKHP WVVNREYLSP NQLSRQDVHL VKGAMAATYF ALNRTPQAPR LEPVLSSNLA QRRGMKRLTS TRL // ID KS6C1_HUMAN Reviewed; 1066 AA. AC Q96S38; B1APS8; B3KVM4; D3DTA4; Q8TDD3; Q9NSF4; Q9UL66; DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 02-MAY-2006, sequence version 2. DT 28-JAN-2026, entry version 189. DE RecName: Full=Ribosomal protein S6 kinase delta-1; DE Short=S6K-delta-1; DE EC=2.7.11.1; DE AltName: Full=52 kDa ribosomal protein S6 kinase; DE AltName: Full=Ribosomal S6 kinase-like protein with two PSK domains 118 kDa protein; DE AltName: Full=SPHK1-binding protein; GN Name=RPS6KC1; Synonyms=RPK118; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, INTERACTION RP WITH SPHK1 AND PHOSPHATIDYLINOSITOL 3-PHOSPHATE, SUBCELLULAR LOCATION, AND RP FUNCTION. RX PubMed=12077123; DOI=10.1074/jbc.m201442200; RA Hayashi S., Okada T., Igarashi N., Fujita T., Jahangeer S., Nakamura S.; RT "Identification and characterization of RPK118, a novel sphingosine kinase- RT 1-binding protein."; RL J. Biol. Chem. 277:33319-33324(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Guo J.H., Yu L.; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC TISSUE=Brain; RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 598-1066 (ISOFORM 1). RX PubMed=10552933; DOI=10.1006/geno.1999.5963; RA Zhang H., Yu L., Mao N., Fu Q., Tu Q., Gao J., Zhao S.; RT "Cloning, characterization, and chromosome mapping of RPS6KC1, a novel RT putative member of the ribosome protein S6 kinase family, to chromosome RT 12q12-q13.1."; RL Genomics 61:314-318(1999). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 683-1066 (ISOFORM 1). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PRDX3. RX PubMed=15750338; DOI=10.1016/s1016-8478(23)13134-7; RA Liu L., Yang C., Yuan J., Chen X., Xu J., Wei Y., Yang J., Lin G., Yu L.; RT "RPK118, a PX domain-containing protein, interacts with peroxiredoxin-3 RT through pseudo-kinase domains."; RL Mol. Cells 19:39-45(2005). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-423 AND SER-427, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-282; SER-423; SER-427; RP SER-455; SER-528; SER-583; SER-605; SER-661; SER-664; SER-667 AND SER-872, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [16] RP VARIANTS [LARGE SCALE ANALYSIS] THR-42; LYS-96; LEU-319; LEU-424; PRO-546; RP ILE-554; SER-575; ALA-663; PHE-853; TYR-1003 AND LYS-1022. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: May be involved in transmitting sphingosine-1 phosphate CC (SPP)-mediated signaling into the cell (PubMed:12077123). Plays a role CC in the recruitment of PRDX3 to early endosomes (PubMed:15750338). CC {ECO:0000269|PubMed:12077123, ECO:0000269|PubMed:15750338}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with SPHK1 and phosphatidylinositol 3-phosphate CC (PubMed:12077123). Interacts (via PX domain) with PRDX3 CC (PubMed:15750338). {ECO:0000269|PubMed:12077123, CC ECO:0000269|PubMed:15750338}. CC -!- INTERACTION: CC Q96S38; Q8IWF6: DENND6A; NbExp=2; IntAct=EBI-347731, EBI-2834112; CC Q96S38; P11473-2: VDR; NbExp=3; IntAct=EBI-347731, EBI-12874016; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12077123, CC ECO:0000269|PubMed:15750338}. Membrane {ECO:0000269|PubMed:12077123}. CC Early endosome {ECO:0000269|PubMed:15750338}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q96S38-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96S38-2; Sequence=VSP_046333; CC -!- TISSUE SPECIFICITY: Highly expressed in testis, skeletal muscle, brain, CC heart, placenta, kidney and liver and weakly expressed in thymus, small CC intestine, lung and colon. {ECO:0000269|PubMed:12077123}. CC -!- DOMAIN: The PX domain is essential for its localization to the early CC endosomes. {ECO:0000269|PubMed:15750338}. CC -!- DOMAIN: The first protein kinase domain appears to be a pseudokinase CC domain as it does not contain the classical characteristics, such as CC the ATP-binding motif, ATP-binding site and active site. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. S6 kinase subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Instead of Lys-820, Arg-820 is found at the binding site. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=CAB92850.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB070706; BAB63956.1; -; mRNA. DR EMBL; AF477978; AAL84818.1; -; mRNA. DR EMBL; AK122921; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK122989; BAG53836.1; -; mRNA. DR EMBL; AL645860; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL512449; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL583826; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471100; EAW93362.1; -; Genomic_DNA. DR EMBL; CH471100; EAW93363.1; -; Genomic_DNA. DR EMBL; BC104769; AAI04770.1; -; mRNA. DR EMBL; AF037447; AAF13027.1; -; mRNA. DR EMBL; AL356893; CAB92850.1; ALT_INIT; mRNA. DR CCDS; CCDS1513.1; -. [Q96S38-1] DR CCDS; CCDS44317.1; -. [Q96S38-2] DR RefSeq; NP_001129610.1; NM_001136138.4. [Q96S38-2] DR RefSeq; NP_036556.2; NM_012424.4. [Q96S38-1] DR AlphaFoldDB; Q96S38; -. DR SMR; Q96S38; -. DR BioGRID; 117810; 30. DR FunCoup; Q96S38; 1956. DR IntAct; Q96S38; 15. DR STRING; 9606.ENSP00000355927; -. DR ChEMBL; CHEMBL1795193; -. DR iPTMnet; Q96S38; -. DR PhosphoSitePlus; Q96S38; -. DR BioMuta; RPS6KC1; -. DR DMDM; 94717650; -. DR CPTAC; non-CPTAC-5679; -. DR jPOST; Q96S38; -. DR MassIVE; Q96S38; -. DR PaxDb; 9606-ENSP00000355927; -. DR PeptideAtlas; Q96S38; -. DR ProteomicsDB; 3310; -. DR ProteomicsDB; 78062; -. [Q96S38-1] DR Pumba; Q96S38; -. DR TopDownProteomics; Q96S38-1; -. [Q96S38-1] DR Antibodypedia; 34615; 162 antibodies from 27 providers. DR DNASU; 26750; -. DR Ensembl; ENST00000366959.4; ENSP00000355926.3; ENSG00000136643.13. [Q96S38-2] DR Ensembl; ENST00000366960.8; ENSP00000355927.3; ENSG00000136643.13. [Q96S38-1] DR GeneID; 26750; -. DR KEGG; hsa:26750; -. DR MANE-Select; ENST00000366960.8; ENSP00000355927.3; NM_012424.6; NP_036556.2. DR UCSC; uc001hkd.5; human. [Q96S38-1] DR AGR; HGNC:10439; -. DR ClinPGx; PA34854; -. DR CTD; 26750; -. DR DisGeNET; 26750; -. DR GeneCards; RPS6KC1; -. DR HGNC; HGNC:10439; RPS6KC1. DR HPA; ENSG00000136643; Low tissue specificity. DR MalaCards; RPS6KC1; -. DR MIM; 617517; gene. DR OpenTargets; ENSG00000136643; -. DR VEuPathDB; HostDB:ENSG00000136643; -. DR eggNOG; KOG0603; Eukaryota. DR eggNOG; KOG2101; Eukaryota. DR GeneTree; ENSGT00940000155656; -. DR HOGENOM; CLU_014272_0_0_1; -. DR InParanoid; Q96S38; -. DR OMA; GHSSELW; -. DR OrthoDB; 1278353at2759; -. DR PAN-GO; Q96S38; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q96S38; -. DR PathwayCommons; Q96S38; -. DR SignaLink; Q96S38; -. DR SIGNOR; Q96S38; -. DR Agora; ENSG00000136643; -. DR BioGRID-ORCS; 26750; 8 hits in 1164 CRISPR screens. DR ChiTaRS; RPS6KC1; human. DR GeneWiki; RPS6KC1; -. DR GenomeRNAi; 26750; -. DR Pharos; Q96S38; Tdark. DR PRO; PR:Q96S38; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q96S38; protein. DR Bgee; ENSG00000136643; Expressed in sperm and 193 other cell types or tissues. DR ExpressionAtlas; Q96S38; baseline and differential. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0005768; C:endosome; IDA:HPA. DR GO; GO:0005764; C:lysosome; IDA:HPA. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0035091; F:phosphatidylinositol binding; IEA:InterPro. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd02677; MIT_SNX15; 1. DR CDD; cd07287; PX_RPK118_like; 1. DR CDD; cd05576; STKc_RPK118_like; 1. DR FunFam; 1.10.510.10:FF:000221; ribosomal protein S6 kinase delta-1 isoform X1; 1. DR FunFam; 1.20.58.80:FF:000005; ribosomal protein S6 kinase delta-1 isoform X1; 1. DR FunFam; 3.30.1520.10:FF:000017; ribosomal protein S6 kinase delta-1 isoform X1; 1. DR Gene3D; 1.20.58.80; Phosphotransferase system, lactose/cellobiose-type IIA subunit; 1. DR Gene3D; 3.30.1520.10; Phox-like domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR051866; Intracell_Sig-Traffick_Protein. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR007330; MIT_dom. DR InterPro; IPR036181; MIT_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001683; PX_dom. DR InterPro; IPR036871; PX_dom_sf. DR InterPro; IPR042132; PX_S6K-delta-1. DR InterPro; IPR035053; STK_RPK118-like. DR PANTHER; PTHR15508; RIBOSOMAL PROTEIN S6 KINASE; 1. DR PANTHER; PTHR15508:SF2; RIBOSOMAL PROTEIN S6 KINASE DELTA-1; 1. DR Pfam; PF04212; MIT; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00787; PX; 1. DR SMART; SM00745; MIT; 1. DR SMART; SM00312; PX; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF116846; MIT domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF64268; PX domain; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS50195; PX; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Endosome; Kinase; KW Lipid-binding; Membrane; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1066 FT /note="Ribosomal protein S6 kinase delta-1" FT /id="PRO_0000233127" FT DOMAIN 8..132 FT /note="PX" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00147" FT DOMAIN 277..305 FT /note="MIT" FT DOMAIN 344..445 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 794..1056 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 207..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 441..509 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 553..596 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 212..223 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 448..458 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 474..483 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 492..503 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 582..593 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 929 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 801..809 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 820 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 282 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 427 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 449 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 455 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 494 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 528 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 583 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 605 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 640 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 661 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 664 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 667 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 794 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 872 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 36..47 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046333" FT VARIANT 42 FT /note="P -> T (in dbSNP:rs56087470)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040647" FT VARIANT 96 FT /note="E -> K (in dbSNP:rs56032860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040648" FT VARIANT 319 FT /note="P -> L (in dbSNP:rs56369827)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040649" FT VARIANT 424 FT /note="P -> L (in dbSNP:rs56183862)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040650" FT VARIANT 546 FT /note="A -> P (in dbSNP:rs35281247)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040651" FT VARIANT 554 FT /note="L -> I (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040652" FT VARIANT 561 FT /note="P -> R (in dbSNP:rs17020314)" FT /id="VAR_051635" FT VARIANT 575 FT /note="N -> S (in dbSNP:rs56060894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040653" FT VARIANT 663 FT /note="G -> A (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040654" FT VARIANT 853 FT /note="L -> F (in dbSNP:rs34080597)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040655" FT VARIANT 1003 FT /note="C -> Y (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040656" FT VARIANT 1022 FT /note="E -> K (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040657" FT CONFLICT 35 FT /note="R -> G (in Ref. 1; BAB63956)" FT /evidence="ECO:0000305" FT CONFLICT 250 FT /note="A -> V (in Ref. 1; BAB63956)" FT /evidence="ECO:0000305" FT CONFLICT 1065 FT /note="Missing (in Ref. 7)" FT /evidence="ECO:0000305" SQ SEQUENCE 1066 AA; 118682 MW; 670EE5965F3B8274 CRC64; MTSYRERSAD LARFYTVTEP QRHPRGYTVY KVTARVVSRR NPEDVQEIIV WKRYSDFKKL HKELWQIHKN LFRHSELFPP FAKGIVFGRF DETVIEERRQ CAEDLLQFSA NIPALYNSKQ LEDFFKGGII NDSSELIGPA EAHSDSLIDT FPECSTEGFS SDSDLVSLTV DVDSLAELDD GMASNQNSPI RTFGLNLSSD SSALGAVASD SEQSKTEEER ESRSLFPGSL KPKLGKRDYL EKAGELIKLA LKKEEEDDYE AASDFYRKGV DLLLEGVQGE SSPTRREAVK RRTAEYLMRA ESISSLYGKP QLDDVSQPPG SLSSRPLWNL RSPAEELKAF RVLGVIDKVL LVMDTRTEQT FILKGLRKSS EYSRNRKTII PRCVPNMVCL HKYIISEESV FLVLQHAEGG KLWSYISKFL NRSPEESFDI KEVKKPTLAK VHLQQPTSSP QDSSSFESRG SDGGSMLKAL PLKSSLTPSS QDDSNQEDDG QDSSPKWPDS GSSSEEECTT SYLTLCNEYG QEKIEPGSLN EEPFMKTEGN GVDTKAIKSF PAHLAADSDS PSTQLRAHEL KFFPNDDPEA VSSPRTSDSL SRSKNSPMEF FRIDSKDSAS ELLGLDFGEK LYSLKSEPLK PFFTLPDGDS ASRSFNTSES KVEFKAQDTI SRGSDDSVPV ISFKDAAFDD VSGTDEGRPD LLVNLPGELE STREAAAMGP TKFTQTNIGI IENKLLEAPD VLCLRLSTEQ CQAHEEKGIE ELSDPSGPKS YSITEKHYAQ EDPRMLFVAA VDHSSSGDMS LLPSSDPKFQ GLGVVESAVT ANNTEESLFR ICSPLSGANE YIASTDTLKT EEVLLFTDQT DDLAKEEPTS LFQRDSETKG ESGLVLEGDK EIHQIFEDLD KKLALASRFY IPEGCIQRWA AEMVVALDAL HREGIVCRDL NPNNILLNDR GHIQLTYFSR WSEVEDSCDS DAIERMYCAP EVGAITEETE ACDWWSLGAV LFELLTGKTL VECHPAGINT HTTLNMPECV SEEARSLIQQ LLQFNPLERL GAGVAGVEDI KSHPFFTPVD WAELMR // ID LMTK1_HUMAN Reviewed; 1374 AA. AC Q6ZMQ8; O75136; Q6ZN31; Q86X28; DT 05-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 05-SEP-2006, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Serine/threonine-protein kinase LMTK1; DE EC=2.7.11.1; DE AltName: Full=Apoptosis-associated tyrosine kinase; DE Short=AATYK; DE AltName: Full=Brain apoptosis-associated tyrosine kinase; DE AltName: Full=CDK5-binding protein; DE AltName: Full=Lemur tyrosine kinase 1; DE AltName: Full=p35-binding protein; DE Short=p35BP; GN Name=AATK; Synonyms=AATYK, KIAA0641, LMR1, LMTK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT RP CYS-703. RC TISSUE=Cerebellum, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 49-1374 (ISOFORM 1), AND VARIANT RP CYS-703. RC TISSUE=Brain; RX PubMed=9734811; DOI=10.1093/dnares/5.3.169; RA Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H., RA Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. X. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 5:169-176(1998). RN [3] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 786-1374 (ISOFORM 1), AND VARIANT RP SER-1266. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP ALTERNATIVE SPLICING (ISOFORM 2), INTERACTION WITH CDK5, AND RP PHOSPHORYLATION. RX PubMed=14521924; DOI=10.1016/j.bbrc.2003.08.143; RA Honma N., Asada A., Takeshita S., Enomoto M., Yamakawa E., Tsutsumi K., RA Saito T., Satoh T., Itoh H., Kaziro Y., Kishimoto T., Hisanaga S.; RT "Apoptosis-associated tyrosine kinase is a Cdk5 activator p35 binding RT protein."; RL Biochem. Biophys. Res. Commun. 310:398-404(2003). RN [6] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=10837911; DOI=10.1016/s0169-328x(00)00048-6; RA Raghunath M., Patti R., Bannerman P., Lee C.M., Baker S., Sutton L.N., RA Phillips P.C., Damodar Reddy C.; RT "A novel kinase, AATYK induces and promotes neuronal differentiation in a RT human neuroblastoma (SH-SY5Y) cell line."; RL Brain Res. Mol. Brain Res. 77:151-162(2000). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495 AND SER-1262, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [8] RP VARIANTS PHE-81; VAL-97; VAL-104; CYS-703; ARG-815; LEU-923; LYS-1160; RP SER-1192; SER-1266 AND THR-1332. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: May be involved in neuronal differentiation. CC {ECO:0000269|PubMed:10837911}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with CDK5. {ECO:0000269|PubMed:14521924}. CC -!- INTERACTION: CC Q6ZMQ8; P62136: PPP1CA; NbExp=3; IntAct=EBI-2008380, EBI-357253; CC Q6ZMQ8; P36873: PPP1CC; NbExp=3; IntAct=EBI-2008380, EBI-356283; CC Q6ZMQ8; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-2008380, EBI-11139477; CC Q6ZMQ8-1; Q15078: CDK5R1; NbExp=2; IntAct=EBI-2008436, EBI-746189; CC Q6ZMQ8-2; Q15078: CDK5R1; NbExp=6; IntAct=EBI-2008441, EBI-746189; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I CC membrane protein {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:10837911}. Cytoplasm, perinuclear region CC {ECO:0000269|PubMed:10837911}. Note=Predominantly perinuclear. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q6ZMQ8-1; Sequence=Displayed; CC Name=2; Synonyms=hAATYKs-p35BP; CC IsoId=Q6ZMQ8-2; Sequence=VSP_020225, VSP_020226, VSP_020227, CC VSP_020228; CC Name=3; CC IsoId=Q6ZMQ8-3; Sequence=VSP_020226, VSP_020227, VSP_020228; CC -!- TISSUE SPECIFICITY: Expressed in brain. {ECO:0000269|PubMed:10837911}. CC -!- INDUCTION: Up-regulated during apoptosis. CC -!- PTM: Autophosphorylated. Phosphorylated by CDK5. CC {ECO:0000269|PubMed:14521924}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK131395; BAD18544.1; -; mRNA. DR EMBL; AK131529; BAD18667.1; -; mRNA. DR EMBL; AB014541; BAA31616.2; -; mRNA. DR EMBL; BC047378; AAH47378.1; -; mRNA. DR CCDS; CCDS45807.1; -. [Q6ZMQ8-1] DR RefSeq; NP_001073864.2; NM_001080395.3. [Q6ZMQ8-1] DR RefSeq; NP_004911.2; NM_004920.2. DR AlphaFoldDB; Q6ZMQ8; -. DR SMR; Q6ZMQ8; -. DR BioGRID; 114984; 194. DR FunCoup; Q6ZMQ8; 75. DR IntAct; Q6ZMQ8; 190. DR MINT; Q6ZMQ8; -. DR STRING; 9606.ENSP00000324196; -. DR TCDB; 8.A.23.1.35; the basigin (basigin) family. DR GlyGen; Q6ZMQ8; 4 sites. DR iPTMnet; Q6ZMQ8; -. DR PhosphoSitePlus; Q6ZMQ8; -. DR SwissPalm; Q6ZMQ8; -. DR BioMuta; AATK; -. DR DMDM; 114149222; -. DR jPOST; Q6ZMQ8; -. DR MassIVE; Q6ZMQ8; -. DR PaxDb; 9606-ENSP00000324196; -. DR PeptideAtlas; Q6ZMQ8; -. DR ProteomicsDB; 67901; -. [Q6ZMQ8-1] DR ProteomicsDB; 67902; -. [Q6ZMQ8-2] DR ProteomicsDB; 67903; -. [Q6ZMQ8-3] DR Antibodypedia; 2104; 203 antibodies from 28 providers. DR DNASU; 9625; -. DR Ensembl; ENST00000326724.9; ENSP00000324196.4; ENSG00000181409.15. [Q6ZMQ8-1] DR Ensembl; ENST00000374792.6; ENSP00000363924.2; ENSG00000181409.15. [Q6ZMQ8-3] DR GeneID; 9625; -. DR KEGG; hsa:9625; -. DR MANE-Select; ENST00000326724.9; ENSP00000324196.4; NM_001080395.3; NP_001073864.2. DR UCSC; uc010dia.4; human. [Q6ZMQ8-1] DR AGR; HGNC:21; -. DR ClinPGx; PA24370; -. DR CTD; 9625; -. DR DisGeNET; 9625; -. DR GeneCards; AATK; -. DR HGNC; HGNC:21; AATK. DR HPA; ENSG00000181409; Tissue enhanced (brain, intestine). DR MIM; 605276; gene. DR OpenTargets; ENSG00000181409; -. DR VEuPathDB; HostDB:ENSG00000181409; -. DR eggNOG; ENOG502RCHK; Eukaryota. DR GeneTree; ENSGT00940000154244; -. DR HOGENOM; CLU_004618_1_0_1; -. DR InParanoid; Q6ZMQ8; -. DR OMA; WEPPDYY; -. DR PAN-GO; Q6ZMQ8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZMQ8; -. DR PathwayCommons; Q6ZMQ8; -. DR SignaLink; Q6ZMQ8; -. DR SIGNOR; Q6ZMQ8; -. DR Agora; ENSG00000181409; -. DR BioGRID-ORCS; 9625; 23 hits in 1182 CRISPR screens. DR GeneWiki; AATK; -. DR GenomeRNAi; 9625; -. DR Pharos; Q6ZMQ8; Tbio. DR PRO; PR:Q6ZMQ8; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q6ZMQ8; protein. DR Bgee; ENSG00000181409; Expressed in sural nerve and 183 other cell types or tissues. DR ExpressionAtlas; Q6ZMQ8; baseline and differential. DR GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-ARBA. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0007420; P:brain development; IBA:GO_Central. DR GO; GO:0051402; P:neuron apoptotic process; IBA:GO_Central. DR CDD; cd05087; PTKc_Aatyk1; 1. DR FunFam; 1.10.510.10:FF:000347; Apoptosis associated tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000275; Apoptosis associated tyrosine kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR042817; LMTK1_c. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR24417; SERINE/THREONINE-PROTEIN KINASE LMTK1; 1. DR PANTHER; PTHR24417:SF0; SERINE_THREONINE-PROTEIN KINASE LMTK1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Transmembrane; Transmembrane helix. FT CHAIN 1..1374 FT /note="Serine/threonine-protein kinase LMTK1" FT /id="PRO_0000248300" FT TRANSMEM 32..52 FT /note="Helical" FT /evidence="ECO:0000255" FT DOMAIN 125..395 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 542..622 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 667..731 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 765..1195 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1245..1302 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1320..1374 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 606..620 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 680..690 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 719..731 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 801..831 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 847..856 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 865..878 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 900..914 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 978..987 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1063..1073 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1138..1155 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1158..1173 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1272..1291 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1321..1332 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1337..1352 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1353..1363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1365..1374 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 253 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 131..139 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 156 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 495 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1029 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1168 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1171 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1184 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1187 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1262 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..433 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020225" FT VAR_SEQ 468..503 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020226" FT VAR_SEQ 897..915 FT /note="VGTPDSLDSLDIPSSASDG -> WPQREESLPRLCLLLRPRG (in FT isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020227" FT VAR_SEQ 916..1374 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020228" FT VARIANT 81 FT /note="S -> F (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs2060924369)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032679" FT VARIANT 97 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032680" FT VARIANT 104 FT /note="M -> V (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs1337040042)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032681" FT VARIANT 118 FT /note="T -> M (in dbSNP:rs8082016)" FT /id="VAR_027267" FT VARIANT 703 FT /note="G -> C (in dbSNP:rs7503604)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9734811" FT /id="VAR_032682" FT VARIANT 815 FT /note="S -> R (in dbSNP:rs56032966)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032683" FT VARIANT 923 FT /note="S -> L (in dbSNP:rs56313973)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032684" FT VARIANT 1160 FT /note="E -> K (in dbSNP:rs55793641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032685" FT VARIANT 1192 FT /note="P -> S (in dbSNP:rs55856613)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032686" FT VARIANT 1266 FT /note="F -> S (in dbSNP:rs36000545)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_032687" FT VARIANT 1332 FT /note="A -> T (in dbSNP:rs55713566)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032688" FT CONFLICT 49..63 FT /note="MLACLCCKKGGIGFK -> HQVKVQGCWGRWRWQ (in Ref. 2)" FT /evidence="ECO:0000305" FT CONFLICT 511 FT /note="A -> T (in Ref. 1; BAD18667)" FT /evidence="ECO:0000305" FT CONFLICT 541 FT /note="A -> T (in Ref. 1; BAD18544)" FT /evidence="ECO:0000305" FT CONFLICT 557 FT /note="T -> I (in Ref. 1; BAD18544)" FT /evidence="ECO:0000305" FT CONFLICT 786 FT /note="A -> V (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 790 FT /note="T -> A (in Ref. 1; BAD18667)" FT /evidence="ECO:0000305" FT CONFLICT 1028 FT /note="P -> R (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 1271 FT /note="P -> H (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 1324 FT /note="P -> R (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 1360 FT /note="K -> E (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" SQ SEQUENCE 1374 AA; 144569 MW; AD46BD688AF7103E CRC64; MSSSFFNPSF AFSSHFDPDG APLSELSWPS SLAVVAVSFS GLFAVIVLML ACLCCKKGGI GFKEFENAEG DEYAADLAQG SPATAAQNGP DVYVLPLTEV SLPMAKQPGR SVQLLKSTDV GRHSLLYLKE IGRGWFGKVF LGEVNSGISS AQVVVKELQA SASVQEQMQF LEEVQPYRAL KHSNLLQCLA QCAEVTPYLL VMEFCPLGDL KGYLRSCRVA ESMAPDPRTL QRMACEVACG VLHLHRNNFV HSDLALRNCL LTADLTVKIG DYGLAHCKYR EDYFVTADQL WVPLRWIAPE LVDEVHSNLL VVDQTKSGNV WSLGVTIWEL FELGTQPYPQ HSDQQVLAYT VREQQLKLPK PQLQLTLSDR WYEVMQFCWL QPEQRPTAEE VHLLLSYLCA KGATEAEEEF ERRWRSLRPG GGGVGPGPGA AGPMLGGVVE LAAASSFPLL EQFAGDGFHA DGDDVLTVTE TSRGLNFEYK WEAGRGAEAF PATLSPGRTA RLQELCAPDG APPGVVPVLS AHSPSLGSEY FIRLEEAAPA AGHDPDCAGC APSPPATADQ DDDSDGSTAA SLAMEPLLGH GPPVDVPWGR GDHYPRRSLA RDPLCPSRSP SPSAGPLSLA EGGAEDADWG VAAFCPAFFE DPLGTSPLGS SGAPPLPLTG EDELEEVGAR RAAQRGHWRS NVSANNNSGS RCPESWDPVS AGGHAEGCPS PKQTPRASPE PGYPGEPLLG LQAASAQEPG CCPGLPHLCS AQGLAPAPCL VTPSWTETAS SGGDHPQAEP KLATEAEGTT GPRLPLPSVP SPSQEGAPLP SEEASAPDAP DALPDSPTPA TGGEVSAIKL ASALNGSSSS PEVEAPSSED EDTAEATSGI FTDTSSDGLQ ARRPDVVPAF RSLQKQVGTP DSLDSLDIPS SASDGGYEVF SPSATGPSGG QPRALDSGYD TENYESPEFV LKEAQEGCEP QAFAELASEG EGPGPETRLS TSLSGLNEKN PYRDSAYFSD LEAEAEATSG PEKKCGGDRA PGPELGLPST GQPSEQVCLR PGVSGEAQGS GPGEVLPPLL QLEGSSPEPS TCPSGLVPEP PEPQGPAKVR PGPSPSCSQF FLLTPVPLRS EGNSSEFQGP PGLLSGPAPQ KRMGGPGTPR APLRLALPGL PAALEGRPEE EEEDSEDSDE SDEELRCYSV QEPSEDSEEE APAVPVVVAE SQSARNLRSL LKMPSLLSET FCEDLERKKK AVSFFDDVTV YLFDQESPTR ELGEPFPGAK ESPPTFLRGS PGSPSAPNRP QQADGSPNGS TAEEGGGFAW DDDFPLMTAK AAFAMALDPA APAPAAPTPT PAPFSRFTVS PAPTSRFSIT HVSDSDAESK RGPEAGAGGE SKEA // ID LN28B_HUMAN Reviewed; 250 AA. AC Q6ZN17; A1L165; B2RPN6; Q5TCM4; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 181. DE RecName: Full=Protein lin-28 homolog B; DE Short=Lin-28B; GN Name=LIN28B; Synonyms=CSDD2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Moss E.G., Kemper K.; RT "Expression of Lin28A and Lin28B in post-implantation mouse embryos."; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, TISSUE RP SPECIFICITY, AND INDUCTION. RX PubMed=16971064; DOI=10.1016/j.gene.2006.07.011; RA Guo Y., Chen Y., Ito H., Watanabe A., Ge X., Kodama T., Aburatani H.; RT "Identification and characterization of lin-28 homolog B (LIN28B) in human RT hepatocellular carcinoma."; RL Gene 384:51-61(2006). RN [7] RP FUNCTION, SUBCELLULAR LOCATION, AND RNA-BINDING. RX PubMed=18951094; DOI=10.1016/j.molcel.2008.09.014; RA Heo I., Joo C., Cho J., Ha M., Han J., Kim V.N.; RT "Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA."; RL Mol. Cell 32:276-284(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [9] RP FUNCTION, AND RNA-BINDING. RX PubMed=19703396; DOI=10.1016/j.cell.2009.08.002; RA Heo I., Joo C., Kim Y.-K., Ha M., Yoon M.-J., Cho J., Yeom K.-H., Han J., RA Kim V.N.; RT "TUT4 in concert with Lin28 suppresses MicroRNA biogenesis through pre- RT microRNA uridylation."; RL Cell 138:696-708(2009). RN [10] RP POSSIBLE INVOLVEMENT IN CANCERS. RX PubMed=19483683; DOI=10.1038/ng.392; RA Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., RA Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., Shah S.P., RA Tanwar P.S., Mermel C.H., Beroukhim R., Azam M., Teixeira J., Meyerson M., RA Hughes T.P., Llovet J.M., Radich J., Mullighan C.G., Golub T.R., RA Sorensen P.H., Daley G.Q.; RT "Lin28 promotes transformation and is associated with advanced human RT malignancies."; RL Nat. Genet. 41:843-848(2009). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [12] RP FUNCTION IN PRE-LET-7 REPRESSION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=22118463; DOI=10.1016/j.cell.2011.10.039; RA Piskounova E., Polytarchou C., Thornton J.E., LaPierre R.J., RA Pothoulakis C., Hagan J.P., Iliopoulos D., Gregory R.I.; RT "Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct RT mechanisms."; RL Cell 147:1066-1079(2011). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54; SER-96; SER-105; SER-110 RP AND SER-203, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 24-111, AND ZINC KNUCKLE DOMAIN. RX PubMed=22570413; DOI=10.1093/nar/gks355; RA Mayr F., Schutz A., Doge N., Heinemann U.; RT "The Lin28 cold-shock domain remodels pre-let-7 microRNA."; RL Nucleic Acids Res. 40:7492-7506(2012). CC -!- FUNCTION: Suppressor of microRNA (miRNA) biogenesis, including that of CC let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 CC transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and CC sequester them in the nucleolus, away from the microprocessor complex, CC hence preventing their processing into mature miRNA (PubMed:22118463). CC Does not act on pri-miR21 (PubMed:22118463). The repression of let-7 CC expression is required for normal development and contributes to CC maintain the pluripotent state of embryonic stem cells by preventing CC let-7-mediated differentiation. When overexpressed, recruits CC ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to CC their terminal uridylation and degradation (PubMed:19703396). This CC activity might not be relevant in vivo, as LIN28B-mediated inhibition CC of let-7 miRNA maturation appears to be ZCCHC11-independent CC (PubMed:22118463). Interaction with target pre-miRNAs occurs via an 5'- CC GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let- CC 7 repression (By similarity). When overexpressed, isoform 1 stimulates CC growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no CC effect on cell growth. {ECO:0000250|UniProtKB:Q45KJ6, CC ECO:0000269|PubMed:16971064, ECO:0000269|PubMed:18951094, CC ECO:0000269|PubMed:19703396, ECO:0000269|PubMed:22118463}. CC -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, nucleolus CC {ECO:0000269|PubMed:22118463}. Cytoplasm {ECO:0000269|PubMed:16971064}. CC Note=Predominantly nucleolar (PubMed:22118463). In Huh7 cells, CC predominantly cytoplasmic, with only a subset of cells exhibiting CC strong nuclear staining; however, the specificity of the polyclonal CC antibody used in these experiments has not been not documented CC (PubMed:16971064). {ECO:0000269|PubMed:16971064, CC ECO:0000269|PubMed:22118463}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q6ZN17-1; Sequence=Displayed; CC Name=2; Synonyms=LIN28BS; CC IsoId=Q6ZN17-2; Sequence=VSP_027207; CC -!- TISSUE SPECIFICITY: Expressed at high levels in the placenta and, at CC mucher lower, in testis and fetal liver (PubMed:16971064). Isoform 1 is CC only detected in placenta and in moderately and poorly differentiated CC hepatocellular carcinoma cells (at protein level). Isoform 2 is CC detected in fetal liver, non-tumor liver tissues, as well as well- CC differentiated tumor tissues (at protein level). Tends to be up- CC regulated in triple-negative (ER-,PR-,HER2-) breast tumors, as well as CC in liver, ovarian, and thyroid carcinomas (PubMed:22118463). CC {ECO:0000269|PubMed:16971064, ECO:0000269|PubMed:22118463}. CC -!- INDUCTION: Might be negatively regulated by the microRNA let-7b. CC {ECO:0000269|PubMed:16971064}. CC -!- DOMAIN: The tandem zinc fingers, also referred as zinc knuckle domain CC (ZKD), mediate specific binding to the GGAG/GGUG motif while the CSD CC shows only limited pyrimidine-rich sequence specificity. Both domains CC bind single-stranded nucleic acids. CC -!- SIMILARITY: Belongs to the lin-28 family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/45723/LIN28B"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; DQ127228; AAZ38897.1; -; mRNA. DR EMBL; AK131411; BAD18558.1; -; mRNA. DR EMBL; AL135911; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z95329; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48434.1; -; Genomic_DNA. DR EMBL; BC127712; AAI27713.1; -; mRNA. DR EMBL; BC127713; AAI27714.1; -; mRNA. DR EMBL; BC137526; AAI37527.1; -; mRNA. DR EMBL; BC137527; AAI37528.1; -; mRNA. DR EMBL; BC141960; AAI41961.1; -; mRNA. DR CCDS; CCDS34504.1; -. [Q6ZN17-1] DR RefSeq; NP_001004317.1; NM_001004317.4. [Q6ZN17-1] DR PDB; 4A4I; X-ray; 1.95 A; A/B=24-111. DR PDBsum; 4A4I; -. DR AlphaFoldDB; Q6ZN17; -. DR SMR; Q6ZN17; -. DR BioGRID; 133142; 363. DR FunCoup; Q6ZN17; 1779. DR IntAct; Q6ZN17; 813. DR MINT; Q6ZN17; -. DR STRING; 9606.ENSP00000344401; -. DR ChEMBL; CHEMBL4295873; -. DR GlyGen; Q6ZN17; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q6ZN17; -. DR PhosphoSitePlus; Q6ZN17; -. DR BioMuta; LIN28B; -. DR DMDM; 74758701; -. DR jPOST; Q6ZN17; -. DR MassIVE; Q6ZN17; -. DR PaxDb; 9606-ENSP00000344401; -. DR PeptideAtlas; Q6ZN17; -. DR ProteomicsDB; 67959; -. [Q6ZN17-1] DR ProteomicsDB; 67960; -. [Q6ZN17-2] DR Pumba; Q6ZN17; -. DR Antibodypedia; 32105; 310 antibodies from 36 providers. DR DNASU; 389421; -. DR Ensembl; ENST00000345080.5; ENSP00000344401.4; ENSG00000187772.8. [Q6ZN17-1] DR GeneID; 389421; -. DR KEGG; hsa:389421; -. DR MANE-Select; ENST00000345080.5; ENSP00000344401.4; NM_001004317.4; NP_001004317.1. DR UCSC; uc003pqv.2; human. [Q6ZN17-1] DR AGR; HGNC:32207; -. DR ClinPGx; PA142671543; -. DR CTD; 389421; -. DR DisGeNET; 389421; -. DR GeneCards; LIN28B; -. DR HGNC; HGNC:32207; LIN28B. DR HPA; ENSG00000187772; Tissue enriched (placenta). DR MalaCards; LIN28B; -. DR MIM; 611044; gene. DR OpenTargets; ENSG00000187772; -. DR Orphanet; 635; Neuroblastoma. DR VEuPathDB; HostDB:ENSG00000187772; -. DR eggNOG; KOG3070; Eukaryota. DR GeneTree; ENSGT00940000153295; -. DR HOGENOM; CLU_089169_1_1_1; -. DR InParanoid; Q6ZN17; -. DR OMA; WGNMAEG; -. DR OrthoDB; 422005at2759; -. DR PAN-GO; Q6ZN17; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZN17; -. DR PathwayCommons; Q6ZN17; -. DR SignaLink; Q6ZN17; -. DR SIGNOR; Q6ZN17; -. DR Agora; ENSG00000187772; -. DR BioGRID-ORCS; 389421; 55 hits in 1180 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; LIN28B; human. DR EvolutionaryTrace; Q6ZN17; -. DR GenomeRNAi; 389421; -. DR Pharos; Q6ZN17; Tbio. DR PRO; PR:Q6ZN17; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q6ZN17; protein. DR Bgee; ENSG00000187772; Expressed in placenta and 37 other cell types or tissues. DR ExpressionAtlas; Q6ZN17; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0003729; F:mRNA binding; IBA:GO_Central. DR GO; GO:0003723; F:RNA binding; IDA:UniProtKB. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0010587; P:miRNA catabolic process; IMP:UniProtKB. DR GO; GO:2000632; P:negative regulation of pre-miRNA processing; IDA:CACAO. DR GO; GO:2000635; P:negative regulation of primary miRNA processing; IDA:CACAO. DR GO; GO:2000627; P:positive regulation of miRNA catabolic process; IMP:CACAO. DR GO; GO:0031054; P:pre-miRNA processing; IMP:UniProtKB. DR GO; GO:0031123; P:RNA 3'-end processing; IMP:UniProtKB. DR GO; GO:0050779; P:RNA destabilization; IDA:CACAO. DR CDD; cd04458; CSP_CDS; 1. DR FunFam; 4.10.60.10:FF:000007; Protein lin-28 homolog A; 1. DR FunFam; 2.40.50.140:FF:000087; Protein lin-28 homolog B; 1. DR Gene3D; 2.40.50.140; Nucleic acid-binding proteins; 1. DR Gene3D; 4.10.60.10; Zinc finger, CCHC-type; 1. DR InterPro; IPR011129; CSD. DR InterPro; IPR002059; CSP_DNA-bd. DR InterPro; IPR051373; Lin-28_RNA-binding. DR InterPro; IPR054081; Lin-28A-like_Znf-CCHC_2. DR InterPro; IPR012340; NA-bd_OB-fold. DR InterPro; IPR001878; Znf_CCHC. DR InterPro; IPR036875; Znf_CCHC_sf. DR PANTHER; PTHR46109; PROTEIN LIN-28; 1. DR PANTHER; PTHR46109:SF3; PROTEIN LIN-28 HOMOLOG B; 1. DR Pfam; PF00313; CSD; 1. DR Pfam; PF21890; Lin-28A-like_zf-CCHC_2; 1. DR Pfam; PF00098; zf-CCHC; 1. DR PRINTS; PR00050; COLDSHOCK. DR SMART; SM00357; CSP; 1. DR SMART; SM00343; ZnF_C2HC; 2. DR SUPFAM; SSF50249; Nucleic acid-binding proteins; 1. DR SUPFAM; SSF57756; Retrovirus zinc finger-like domains; 1. DR PROSITE; PS51857; CSD_2; 1. DR PROSITE; PS50158; ZF_CCHC; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; RNA-mediated gene silencing; Zinc; Zinc-finger. FT CHAIN 1..250 FT /note="Protein lin-28 homolog B" FT /id="PRO_0000253793" FT DOMAIN 29..102 FT /note="CSD" FT ZN_FING 127..144 FT /note="CCHC-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00047" FT ZN_FING 149..166 FT /note="CCHC-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00047" FT REGION 1..26 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 98..126 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 169..250 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 112..125 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22118463" FT MOTIF 239..250 FT /note="Nucleolar localization signal" FT /evidence="ECO:0000269|PubMed:22118463" FT COMPBIAS 114..125 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 173..191 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 210..219 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 220..231 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 129 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 137 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 142 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 151 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 154 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 159 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 164 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT MOD_RES 54 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 96 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 105 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 110 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 203 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..70 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_027207" FT STRAND 28..38 FT /evidence="ECO:0007829|PDB:4A4I" FT TURN 39..42 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 43..51 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 54..65 FT /evidence="ECO:0007829|PDB:4A4I" FT HELIX 66..68 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 71..74 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 82..88 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 95..101 FT /evidence="ECO:0007829|PDB:4A4I" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:4A4I" SQ SEQUENCE 250 AA; 27084 MW; DEF2920C5F1D0BBD CRC64; MAEGGASKGG GEEPGKLPEP AEEESQVLRG TGHCKWFNVR MGFGFISMIN REGSPLDIPV DVFVHQSKLF MEGFRSLKEG EPVEFTFKKS SKGLESIRVT GPGGSPCLGS ERRPKGKTLQ KRKPKGDRCY NCGGLDHHAK ECSLPPQPKK CHYCQSIMHM VANCPHKNVA QPPASSQGRQ EAESQPCTST LPREVGGGHG CTSPPFPQEA RAEISERSGR SPQEASSTKS SIAPEEQSKK GPSVQKRKKT // ID MARK1_HUMAN Reviewed; 795 AA. AC Q9P0L2; D3DTB0; D3DTB1; Q2HIY1; Q5VTF9; Q5VTG0; Q96SW9; Q9P251; DT 12-APR-2005, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 2. DT 28-JAN-2026, entry version 205. DE RecName: Full=Serine/threonine-protein kinase MARK1; DE EC=2.7.11.1; DE EC=2.7.11.26; DE AltName: Full=MAP/microtubule affinity-regulating kinase 1; DE AltName: Full=PAR1 homolog c; DE Short=Par-1c; DE Short=Par1c; GN Name=MARK1 {ECO:0000312|HGNC:HGNC:6896}; GN Synonyms=KIAA1477 {ECO:0000312|EMBL:BAA96001.1}, GN MARK {ECO:0000312|EMBL:AAF72103.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-215, AND MUTAGENESIS OF THR-215. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [2] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Zhou H.J., Huang X.W., Zhou Y., Hu S.L., Yuan J.G., Qiang B.Q.; RT "Cloning and isolating human MARK."; RL Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases. RN [3] {ECO:0000305, ECO:0000312|EMBL:BAA96001.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain {ECO:0000269|PubMed:10819331}; RX PubMed=10819331; DOI=10.1093/dnares/7.2.143; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:143-150(2000). RN [4] {ECO:0000305, ECO:0000312|EMBL:BAB55152.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [6] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] {ECO:0000305} RP TISSUE SPECIFICITY. RX PubMed=9108484; DOI=10.1016/s0092-8674(00)80208-1; RA Drewes G., Ebneth A., Preuss U., Mandelkow E.-M., Mandelkow E.; RT "MARK - a novel family of protein kinases that phosphorylate microtubule- RT associated proteins and trigger microtubule disruption."; RL Cell 89:297-308(1997). RN [9] RP NEUROFIBRILLARY TANGLES IN ALZHEIMER BRAIN. RX PubMed=11089574; DOI=10.1093/jnen/59.11.966; RA Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M., RA Hyman B.T.; RT "Microtubule-affinity regulating kinase (MARK) is tightly associated with RT neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy RT transfer study."; RL J. Neuropathol. Exp. Neurol. 59:966-971(2000). RN [10] RP FUNCTION. RX PubMed=11433294; DOI=10.1038/35083016; RA Sun T.-Q., Lu B., Feng J.-J., Reinhard C., Jan Y.N., Fantl W.J., RA Williams L.T.; RT "PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt RT signalling."; RL Nat. Cell Biol. 3:628-636(2001). RN [11] RP PHOSPHORYLATION AT THR-208, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=17573348; DOI=10.1074/jbc.m700590200; RA Kojima Y., Miyoshi H., Clevers H.C., Oshima M., Aoki M., Taketo M.M.; RT "Suppression of tubulin polymerization by the LKB1-microtubule-associated RT protein/microtubule affinity-regulating kinase signaling."; RL J. Biol. Chem. 282:23532-23540(2007). RN [12] RP POSSIBLE INVOLVEMENT IN AUTISM. RX PubMed=18492799; DOI=10.1093/hmg/ddn154; RA Maussion G., Carayol J., Lepagnol-Bestel A.M., Tores F., Loe-Mie Y., RA Milbreta U., Rousseau F., Fontaine K., Renaud J., Moalic J.M., Philippi A., RA Chedotal A., Gorwood P., Ramoz N., Hager J., Simonneau M.; RT "Convergent evidence identifying MAP/microtubule affinity-regulating kinase RT 1 (MARK1) as a susceptibility gene for autism."; RL Hum. Mol. Genet. 17:2541-2551(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-5 AND SER-403, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-588, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [17] RP REVIEW. RX PubMed=19559622; DOI=10.1016/j.tibs.2009.03.008; RA Matenia D., Mandelkow E.M.; RT "The tau of MARK: a polarized view of the cytoskeleton."; RL Trends Biochem. Sci. 34:332-342(2009). RN [18] RP REVIEW. RX PubMed=20071654; DOI=10.1096/fj.09-148064; RA Marx A., Nugoor C., Panneerselvam S., Mandelkow E.; RT "Structure and function of polarity-inducing kinase family MARK/Par-1 RT within the branch of AMPK/Snf1-related kinases."; RL FASEB J. 24:1637-1648(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [22] RP FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION. RX PubMed=23666762; DOI=10.1007/s12017-013-8232-3; RA Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G., RA Landegren U., Sunnemark D., Kamali-Moghaddam M.; RT "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in RT Alzheimer's disease."; RL NeuroMolecular Med. 15:458-469(2013). RN [23] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 45-371. RX PubMed=16803889; DOI=10.1074/jbc.m604865200; RA Marx A., Nugoor C., Muller J., Panneerselvam S., Timm T., Bilang M., RA Mylonas E., Svergun D.I., Mandelkow E.M., Mandelkow E.; RT "Structural variations in the catalytic and ubiquitin-associated domains of RT microtubule-associated protein/microtubule affinity regulating kinase RT (MARK) 1 and MARK2."; RL J. Biol. Chem. 281:27586-27599(2006). RN [24] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 683-795, DOMAIN KA1, SUBCELLULAR RP LOCATION, AND MUTAGENESIS OF ARG-698; ARG-701; 771-ARG--LYS-773 AND RP 773-LYS-ARG-774. RX PubMed=21145462; DOI=10.1016/j.cell.2010.11.028; RA Moravcevic K., Mendrola J.M., Schmitz K.R., Wang Y.H., Slochower D., RA Janmey P.A., Lemmon M.A.; RT "Kinase associated-1 domains drive MARK/PAR1 kinases to membrane targets by RT binding acidic phospholipids."; RL Cell 143:966-977(2010). RN [25] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-233; THR-355; MET-530; LEU-578 AND RP GLY-691. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved CC in cell polarity and microtubule dynamics regulation. Phosphorylates CC DCX, MAP2 and MAP4. Phosphorylates the microtubule-associated protein CC MAPT/TAU (PubMed:23666762). Involved in cell polarity by CC phosphorylating the microtubule-associated proteins MAP2, MAP4 and CC MAPT/TAU at KXGS motifs, causing detachment from microtubules, and CC their disassembly. Involved in the regulation of neuronal migration CC through its dual activities in regulating cellular polarity and CC microtubule dynamics, possibly by phosphorylating and regulating DCX. CC Also acts as a positive regulator of the Wnt signaling pathway, CC probably by mediating phosphorylation of dishevelled proteins (DVL1, CC DVL2 and/or DVL3). {ECO:0000269|PubMed:11433294, CC ECO:0000269|PubMed:17573348, ECO:0000269|PubMed:23666762}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[tau protein] + ATP = O-phospho-L-seryl-[tau protein] CC + ADP + H(+); Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA- CC COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[tau protein] + ATP = O-phospho-L-threonyl-[tau CC protein] + ADP + H(+); Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703, CC Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.26; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Inhibited by phosphorylation at Ser-219 (By CC similarity). Activated by phosphorylation on Thr-215. {ECO:0000250, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:17573348}. CC -!- SUBUNIT: Interacts with MAPT/TAU. {ECO:0000269|PubMed:23666762}. CC -!- INTERACTION: CC Q9P0L2; P05067: APP; NbExp=3; IntAct=EBI-968587, EBI-77613; CC Q9P0L2; P63172: DYNLT1; NbExp=3; IntAct=EBI-968587, EBI-1176455; CC Q9P0L2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-968587, EBI-6509505; CC Q9P0L2; O95988: TCL1B; NbExp=5; IntAct=EBI-968587, EBI-727338; CC Q9P0L2; Q8IY57-5: YAF2; NbExp=3; IntAct=EBI-968587, EBI-12111538; CC Q9P0L2; P61981: YWHAG; NbExp=4; IntAct=EBI-968587, EBI-359832; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21145462}; CC Peripheral membrane protein {ECO:0000269|PubMed:21145462}. Cytoplasm, CC cytoskeleton {ECO:0000250}. Cytoplasm {ECO:0000269|PubMed:23666762}. CC Cell projection, dendrite {ECO:0000269|PubMed:23666762}. Note=Appears CC to localize to an intracellular network. {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9P0L2-1; Sequence=Displayed; CC Name=2 {ECO:0000305}; CC IsoId=Q9P0L2-2; Sequence=VSP_051702, VSP_051704; CC Name=3 {ECO:0000305}; CC IsoId=Q9P0L2-3; Sequence=VSP_051703, VSP_051704; CC -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle, brain, CC fetal brain and fetal kidney. {ECO:0000269|PubMed:9108484}. CC -!- DOMAIN: The UBA domain does not seem to bind ubiquitin and ubiquitin- CC like and might play a role in regulating the enzyme conformation and CC localization. Activation of the kinase activity following CC phosphorylation at Thr-208 is accompanied by a conformational change CC that alters the orientation of the UBA domain with respect to the CC catalytic domain (By similarity). {ECO:0000250}. CC -!- DOMAIN: The KA1 domain mediates binding to phospholipids and targeting CC to membranes. Binds phosphatidic acid (PA), phosphatidylserine (PtdSer) CC and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). CC {ECO:0000269|PubMed:21145462}. CC -!- PTM: Phosphorylation at Thr-613 by PRKCZ/aPKC in polarized epithelial CC cells inhibits the kinase activity (By similarity). Phosphorylated at CC Thr-215 by STK11/LKB1 in complex with STE20-related adapter-alpha CC (STRADA) pseudo kinase and CAB39. Phosphorylation at Thr-215 by TAOK1 CC activates the kinase activity, leading to phosphorylation and CC detachment of MAPT/TAU from microtubules. Phosphorylation at Ser-219 by CC GSK3-beta (GSK3B) inhibits the kinase activity. {ECO:0000250, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:17573348}. CC -!- DISEASE: Note=Genetic variations in MARK1 may be associated with CC susceptibility to autism. MARK1 is overexpressed in the prefrontal CC cortex of patients with autism and causes changes in the function of CC cortical dendrites. CC -!- MISCELLANEOUS: Phosphorylation of MAPT/tau by MARK1 could play a role CC in early steps of Alzheimer disease. Pathological aggregation of CC MAPT/tau to neurofibrillary tangles, filamentous structures consisting CC of paired helical filaments (PHFs), is one of the hallmarks of CC Alzheimer disease. Hyperphosphorylation by MARK1 could be the initial CC step for this abnormal aggregation of tau in Alzheimer disease and CC animal models of tauopathy (PubMed:11089574). CC {ECO:0000305|PubMed:11089574}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA96001.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAB55152.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF154845; AAF72103.1; -; mRNA. DR EMBL; AB040910; BAA96001.1; ALT_INIT; mRNA. DR EMBL; AK027493; BAB55152.1; ALT_FRAME; mRNA. DR EMBL; AC096640; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL592406; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471100; EAW93299.1; -; Genomic_DNA. DR EMBL; CH471100; EAW93300.1; -; Genomic_DNA. DR EMBL; CH471100; EAW93302.1; -; Genomic_DNA. DR EMBL; BC113869; AAI13870.1; -; mRNA. DR EMBL; BC114478; AAI14479.1; -; mRNA. DR CCDS; CCDS31029.2; -. [Q9P0L2-1] DR CCDS; CCDS65789.1; -. [Q9P0L2-3] DR RefSeq; NP_001273057.1; NM_001286128.2. [Q9P0L2-3] DR RefSeq; NP_061120.3; NM_018650.4. [Q9P0L2-1] DR PDB; 2HAK; X-ray; 2.60 A; A/B/C/D/E/F/G/H=45-371. DR PDB; 3OSE; X-ray; 1.70 A; A=683-795. DR PDB; 6C9D; X-ray; 2.50 A; A/B=45-795. DR PDBsum; 2HAK; -. DR PDBsum; 3OSE; -. DR PDBsum; 6C9D; -. DR AlphaFoldDB; Q9P0L2; -. DR SASBDB; Q9P0L2; -. DR SMR; Q9P0L2; -. DR BioGRID; 110309; 84. DR DIP; DIP-39777N; -. DR FunCoup; Q9P0L2; 1289. DR IntAct; Q9P0L2; 53. DR MINT; Q9P0L2; -. DR STRING; 9606.ENSP00000483424; -. DR BindingDB; Q9P0L2; -. DR ChEMBL; CHEMBL5940; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9P0L2; -. DR GuidetoPHARMACOLOGY; 2097; -. DR CarbonylDB; Q9P0L2; -. DR iPTMnet; Q9P0L2; -. DR PhosphoSitePlus; Q9P0L2; -. DR BioMuta; MARK1; -. DR DMDM; 124056494; -. DR jPOST; Q9P0L2; -. DR MassIVE; Q9P0L2; -. DR PaxDb; 9606-ENSP00000483424; -. DR PeptideAtlas; Q9P0L2; -. DR ProteomicsDB; 83571; -. [Q9P0L2-1] DR ProteomicsDB; 83572; -. [Q9P0L2-2] DR ProteomicsDB; 83573; -. [Q9P0L2-3] DR Pumba; Q9P0L2; -. DR Antibodypedia; 2072; 432 antibodies from 33 providers. DR DNASU; 4139; -. DR Ensembl; ENST00000366917.6; ENSP00000355884.5; ENSG00000116141.18. [Q9P0L2-1] DR Ensembl; ENST00000366918.8; ENSP00000355885.4; ENSG00000116141.18. [Q9P0L2-3] DR GeneID; 4139; -. DR KEGG; hsa:4139; -. DR MANE-Select; ENST00000366917.6; ENSP00000355884.5; NM_018650.5; NP_061120.3. DR UCSC; uc001hmm.6; human. [Q9P0L2-1] DR AGR; HGNC:6896; -. DR ClinPGx; PA30639; -. DR CTD; 4139; -. DR DisGeNET; 4139; -. DR GeneCards; MARK1; -. DR HGNC; HGNC:6896; MARK1. DR HPA; ENSG00000116141; Low tissue specificity. DR MIM; 606511; gene. DR OpenTargets; ENSG00000116141; -. DR VEuPathDB; HostDB:ENSG00000116141; -. DR eggNOG; KOG0586; Eukaryota. DR GeneTree; ENSGT00940000157560; -. DR InParanoid; Q9P0L2; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q9P0L2; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9P0L2; -. DR PathwayCommons; Q9P0L2; -. DR SignaLink; Q9P0L2; -. DR SIGNOR; Q9P0L2; -. DR Agora; ENSG00000116141; -. DR BioGRID-ORCS; 4139; 14 hits in 1190 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; MARK1; human. DR EvolutionaryTrace; Q9P0L2; -. DR GeneWiki; MARK1; -. DR GenomeRNAi; 4139; -. DR Pharos; Q9P0L2; Tchem. DR PRO; PR:Q9P0L2; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9P0L2; protein. DR Bgee; ENSG00000116141; Expressed in cortical plate and 178 other cell types or tissues. DR ExpressionAtlas; Q9P0L2; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB. DR GO; GO:0030425; C:dendrite; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0015630; C:microtubule cytoskeleton; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0070300; F:phosphatidic acid binding; IDA:UniProtKB. DR GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IMP:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; ISS:UniProtKB. DR GO; GO:0051654; P:establishment of mitochondrion localization; ISS:ARUK-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; ISS:ARUK-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IDA:ARUK-UCL. DR GO; GO:0010629; P:negative regulation of gene expression; IDA:ARUK-UCL. DR GO; GO:0001764; P:neuron migration; ISS:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:ARUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050773; P:regulation of dendrite development; ISS:ARUK-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0150052; P:regulation of postsynapse assembly; IEA:Ensembl. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd12196; MARK1-3_C; 1. DR CDD; cd14072; STKc_MARK; 1. DR CDD; cd14405; UBA_MARK1; 1. DR FunFam; 1.10.510.10:FF:001032; KP78b, isoform A; 1. DR FunFam; 1.10.8.10:FF:000011; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.310.80:FF:000001; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.310.80; Kinase associated domain 1, KA1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR028375; KA1/Ssp2_C. DR InterPro; IPR001772; KA1_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049508; MARK1-4_cat. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF21; SERINE_THREONINE-PROTEIN KINASE MARK1; 1. DR Pfam; PF02149; KA1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00627; UBA; 1. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00165; UBA; 1. DR SUPFAM; SSF103243; KA1-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50032; KA1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Autism; KW Autism spectrum disorder; Cell membrane; Cell projection; Cytoplasm; KW Cytoskeleton; Kinase; Lipid-binding; Magnesium; Membrane; Metal-binding; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Wnt signaling pathway. FT CHAIN 1..795 FT /note="Serine/threonine-protein kinase MARK1" FT /id="PRO_0000086298" FT DOMAIN 60..311 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 325..370 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 746..795 FT /note="KA1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00565" FT REGION 1..40 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 377..495 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 539..700 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31..40 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 380..403 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 447..459 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 462..473 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 486..495 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 590..599 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 647..657 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 661..676 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 683..697 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 182 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:Q9H0K1, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 66..74 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:Q9H0K1, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 89 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:O08678, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 5 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 208 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17573348" FT MOD_RES 215 FT /note="Phosphothreonine; by LKB1 and TAOK1" FT /evidence="ECO:0000269|PubMed:14976552" FT MOD_RES 219 FT /note="Phosphoserine; by GSK3-beta" FT /evidence="ECO:0000250|UniProtKB:O08678" FT MOD_RES 382 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 390 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 393 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 403 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 444 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08678" FT MOD_RES 475 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 588 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 613 FT /note="Phosphothreonine; by PKC/PRKCZ" FT /evidence="ECO:0000250" FT MOD_RES 666 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT VAR_SEQ 1..135 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_051702" FT VAR_SEQ 120..141 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10819331" FT /id="VSP_051703" FT VAR_SEQ 663..677 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10819331, FT ECO:0000303|PubMed:14702039" FT /id="VSP_051704" FT VARIANT 233 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040760" FT VARIANT 355 FT /note="N -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040761" FT VARIANT 530 FT /note="V -> M (in dbSNP:rs56212551)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040762" FT VARIANT 578 FT /note="P -> L (in dbSNP:rs55691439)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040763" FT VARIANT 645 FT /note="R -> G (in dbSNP:rs12123778)" FT /id="VAR_030018" FT VARIANT 691 FT /note="E -> G (in dbSNP:rs55688276)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040764" FT MUTAGEN 215 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 215 FT /note="T->E: Constitutively active." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 698 FT /note="R->S: Impairs phospholipid-binding, targeting to FT membrane and vesicle-binding; when associated with S-701." FT /evidence="ECO:0000269|PubMed:21145462" FT MUTAGEN 701 FT /note="R->S: Impairs phospholipid-binding, targeting to FT membrane and vesicle-binding; when associated with S-698." FT /evidence="ECO:0000269|PubMed:21145462" FT MUTAGEN 771..773 FT /note="RFK->AFA: Impairs phospholipid-binding." FT /evidence="ECO:0000269|PubMed:21145462" FT CONFLICT 16 FT /note="E -> V (in Ref. 2; AAF72103)" FT /evidence="ECO:0000305" FT CONFLICT 20 FT /note="S -> T (in Ref. 2; AAF72103)" FT /evidence="ECO:0000305" FT CONFLICT 522 FT /note="D -> N (in Ref. 4; BAB55152)" FT /evidence="ECO:0000305" FT CONFLICT 544 FT /note="V -> A (in Ref. 4; BAB55152)" FT /evidence="ECO:0000305" FT CONFLICT 763 FT /note="P -> A (in Ref. 4; BAB55152)" FT /evidence="ECO:0000305" FT CONFLICT 794 FT /note="K -> M (in Ref. 3; BAA96001)" FT /evidence="ECO:0000305" FT STRAND 55..57 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 60..68 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 70..79 FT /evidence="ECO:0007829|PDB:6C9D" FT TURN 80..82 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 85..92 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 98..111 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 122..127 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 129..136 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 146..151 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 156..175 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 185..187 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 188..190 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 196..198 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 201..203 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 220..222 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 225..228 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 236..252 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 262..271 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 282..291 FT /evidence="ECO:0007829|PDB:6C9D" FT TURN 296..298 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 302..305 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 309..312 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 316..318 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 333..341 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 346..355 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 360..368 FT /evidence="ECO:0007829|PDB:6C9D" FT TURN 706..708 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 714..727 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 731..736 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 739..745 FT /evidence="ECO:0007829|PDB:3OSE" FT TURN 747..750 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 753..762 FT /evidence="ECO:0007829|PDB:3OSE" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 767..777 FT /evidence="ECO:0007829|PDB:3OSE" FT HELIX 779..792 FT /evidence="ECO:0007829|PDB:3OSE" SQ SEQUENCE 795 AA; 89003 MW; 71BF6EB76912631B CRC64; MSARTPLPTV NERDTENHTS VDGYTEPHIQ PTKSSSRQNI PRCRNSITSA TDEQPHIGNY RLQKTIGKGN FAKVKLARHV LTGREVAVKI IDKTQLNPTS LQKLFREVRI MKILNHPNIV KLFEVIETEK TLYLVMEYAS GGEVFDYLVA HGRMKEKEAR AKFRQIVSAV QYCHQKYIVH RDLKAENLLL DGDMNIKIAD FGFSNEFTVG NKLDTFCGSP PYAAPELFQG KKYDGPEVDV WSLGVILYTL VSGSLPFDGQ NLKELRERVL RGKYRIPFYM STDCENLLKK LLVLNPIKRG SLEQIMKDRW MNVGHEEEEL KPYTEPDPDF NDTKRIDIMV TMGFARDEIN DALINQKYDE VMATYILLGR KPPEFEGGES LSSGNLCQRS RPSSDLNNST LQSPAHLKVQ RSISANQKQR RFSDHAGPSI PPAVSYTKRP QANSVESEQK EEWDKDVARK LGSTTVGSKS EMTASPLVGP ERKKSSTIPS NNVYSGGSMA RRNTYVCERT TDRYVALQNG KDSSLTEMSV SSISSAGSSV ASAVPSARPR HQKSMSTSGH PIKVTLPTIK DGSEAYRPGT TQRVPAASPS AHSISTATPD RTRFPRGSSS RSTFHGEQLR ERRSVAYNGP PASPSHETGA FAHARRGTST GIISKITSKF VRRDPSEGEA SGRTDTSRST SGEPKERDKE EGKDSKPRSL RFTWSMKTTS SMDPNDMMRE IRKVLDANNC DYEQKERFLL FCVHGDARQD SLVQWEMEVC KLPRLSLNGV RFKRISGTSI AFKNIASKIA NELKL // ID MATK_HUMAN Reviewed; 507 AA. AC P42679; B3KNZ9; Q9NST8; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 230. DE RecName: Full=Megakaryocyte-associated tyrosine-protein kinase; DE EC=2.7.10.2; DE AltName: Full=CSK homologous kinase; DE Short=CHK; DE AltName: Full=Hematopoietic consensus tyrosine-lacking kinase; DE AltName: Full=Protein kinase HYL; DE AltName: Full=Tyrosine-protein kinase CTK; GN Name=MATK; Synonyms=CTK, HYL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8134117; RA Sakano S., Iwama A., Inazawa J., Ariyama T., Ohno M., Suda T.; RT "Molecular cloning of a novel non-receptor tyrosine kinase, HYL RT (hematopoietic consensus tyrosine-lacking kinase)."; RL Oncogene 9:1155-1161(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Megakaryocyte; RX PubMed=8288563; DOI=10.1016/s0021-9258(17)42222-8; RA Bennett B.D., Cowley S., Jiang S., London R., Deng B., Grabarek J., RA Groopman J.E., Goeddel D.V., Avraham H.; RT "Identification and characterization of a novel tyrosine kinase from RT megakaryocytes."; RL J. Biol. Chem. 269:1068-1074(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7530249; DOI=10.1074/jbc.270.4.1833; RA Avraham S., Jiang S., Ota S., Fu Y., Deng B., Dowler L.L., White R.A., RA Avraham H.; RT "Structural and functional studies of the intracellular tyrosine kinase RT MATK gene and its translated product."; RL J. Biol. Chem. 270:1833-1842(1995). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP CHARACTERIZATION. RX PubMed=7936664; RA Hamaguchi I., Iwama A., Yamaguchi N., Sakano S., Matsuda Y., Suda T.; RT "Characterization of mouse non-receptor tyrosine kinase gene, HYL."; RL Oncogene 9:3371-3374(1994). RN [10] RP FUNCTION, AND SUBCELLULAR LOCATION. RC TISSUE=Platelet; RX PubMed=9171348; DOI=10.1093/emboj/16.9.2342; RA Hirao A., Hamaguchi I., Suda T., Yamaguchi N.; RT "Translocation of the Csk homologous kinase (Chk/Hyl) controls activity of RT CD36-anchored Lyn tyrosine kinase in thrombin-stimulated platelets."; RL EMBO J. 16:2342-2351(1997). RN [11] RP INTERACTION WITH KIT. RX PubMed=9038210; DOI=10.1074/jbc.272.9.5915; RA Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.; RT "Direct association of Csk homologous kinase (CHK) with the RT diphosphorylated site Tyr568/570 of the activated c-KIT in RT megakaryocytes."; RL J. Biol. Chem. 272:5915-5920(1997). RN [12] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055; RA Roskoski R. Jr.; RT "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor."; RL Biochem. Biophys. Res. Commun. 337:1-13(2005). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [19] RP STRUCTURE BY NMR OF 39-108. RG RIKEN structural genomics initiative (RSGI); RT "Solution structures of the SH3 domain of human megakaryocyte-associated RT tyrosine-protein kinase."; RL Submitted (NOV-2005) to the PDB data bank. RN [20] RP VARIANTS [LARGE SCALE ANALYSIS] THR-354; THR-496 AND GLN-503. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Could play a significant role in the signal transduction of CC hematopoietic cells. May regulate tyrosine kinase activity of SRC- CC family members in brain by specifically phosphorylating their C- CC terminal regulatory tyrosine residue which acts as a negative CC regulatory site. It may play an inhibitory role in the control of T- CC cell proliferation. {ECO:0000269|PubMed:9171348}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Interacts with KIT. {ECO:0000269|PubMed:9038210}. CC -!- INTERACTION: CC P42679; P10275: AR; NbExp=4; IntAct=EBI-751664, EBI-608057; CC P42679; Q9Y5Z0: BACE2; NbExp=3; IntAct=EBI-751664, EBI-11282723; CC P42679; P04626: ERBB2; NbExp=2; IntAct=EBI-751664, EBI-641062; CC P42679; P08238: HSP90AB1; NbExp=2; IntAct=EBI-751664, EBI-352572; CC P42679; Q92876: KLK6; NbExp=3; IntAct=EBI-751664, EBI-2432309; CC P42679; Q5S007: LRRK2; NbExp=2; IntAct=EBI-751664, EBI-5323863; CC P42679; P62258: YWHAE; NbExp=2; IntAct=EBI-751664, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9171348}. Membrane CC {ECO:0000269|PubMed:9171348}. Note=In platelets, 90% of MATK localizes CC to the membrane fraction, and translocates to the cytoskeleton upon CC thrombin stimulation. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P42679-1; Sequence=Displayed; CC Name=2; CC IsoId=P42679-2; Sequence=VSP_043123; CC Name=3; CC IsoId=P42679-3; Sequence=VSP_044277; CC -!- TISSUE SPECIFICITY: Expressed in various myeloid cell lines, detected CC in brain and lung. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L18974; AAA16703.1; -; mRNA. DR EMBL; X77278; CAA54493.1; -; mRNA. DR EMBL; S75164; AAC60645.1; -; Genomic_DNA. DR EMBL; S75145; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75147; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75166; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75168; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75151; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75153; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75155; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75156; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75158; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75159; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75162; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; AK055395; BAG51511.1; -; mRNA. DR EMBL; AL137754; CAB70906.2; -; mRNA. DR EMBL; AC005777; AAC62843.1; -; Genomic_DNA. DR EMBL; CH471139; EAW69285.1; -; Genomic_DNA. DR EMBL; BC000114; AAH00114.1; -; mRNA. DR EMBL; BC003109; AAH03109.1; -; mRNA. DR CCDS; CCDS12113.1; -. [P42679-2] DR CCDS; CCDS12114.1; -. [P42679-1] DR CCDS; CCDS42468.1; -. [P42679-3] DR PIR; A49865; A49865. DR PIR; A55625; A55625. DR RefSeq; NP_001427506.1; NM_001440577.1. [P42679-1] DR RefSeq; NP_002369.2; NM_002378.3. [P42679-2] DR RefSeq; NP_647611.1; NM_139354.3. [P42679-3] DR RefSeq; NP_647612.1; NM_139355.3. [P42679-1] DR PDB; 1JWO; X-ray; 2.50 A; A=117-213. DR PDB; 1X6G; NMR; -; A=41-108. DR PDB; 3US4; X-ray; 1.50 A; A=117-213. DR PDBsum; 1JWO; -. DR PDBsum; 1X6G; -. DR PDBsum; 3US4; -. DR AlphaFoldDB; P42679; -. DR SMR; P42679; -. DR BioGRID; 110315; 33. DR FunCoup; P42679; 601. DR IntAct; P42679; 20. DR MINT; P42679; -. DR STRING; 9606.ENSP00000378485; -. DR BindingDB; P42679; -. DR ChEMBL; CHEMBL4175; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P42679; -. DR iPTMnet; P42679; -. DR PhosphoSitePlus; P42679; -. DR BioMuta; MATK; -. DR DMDM; 1169123; -. DR CPTAC; CPTAC-1790; -. DR jPOST; P42679; -. DR MassIVE; P42679; -. DR PaxDb; 9606-ENSP00000378485; -. DR PeptideAtlas; P42679; -. DR ProteomicsDB; 55524; -. [P42679-1] DR ProteomicsDB; 55525; -. [P42679-2] DR ProteomicsDB; 82579; -. DR Pumba; P42679; -. DR Antibodypedia; 1174; 359 antibodies from 32 providers. DR DNASU; 4145; -. DR Ensembl; ENST00000310132.11; ENSP00000308734.5; ENSG00000007264.16. [P42679-1] DR Ensembl; ENST00000395040.6; ENSP00000378481.1; ENSG00000007264.16. [P42679-3] DR Ensembl; ENST00000395045.6; ENSP00000378485.1; ENSG00000007264.16. [P42679-2] DR Ensembl; ENST00000619596.4; ENSP00000483213.1; ENSG00000007264.16. [P42679-2] DR GeneID; 4145; -. DR KEGG; hsa:4145; -. DR MANE-Select; ENST00000310132.11; ENSP00000308734.5; NM_139355.3; NP_647612.1. DR UCSC; uc002lyt.4; human. [P42679-1] DR AGR; HGNC:6906; -. DR ClinPGx; PA30649; -. DR CTD; 4145; -. DR DisGeNET; 4145; -. DR GeneCards; MATK; -. DR HGNC; HGNC:6906; MATK. DR HPA; ENSG00000007264; Tissue enhanced (bone marrow, brain). DR MIM; 600038; gene. DR OpenTargets; ENSG00000007264; -. DR VEuPathDB; HostDB:ENSG00000007264; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000160775; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; P42679; -. DR OMA; HDSGQEG; -. DR OrthoDB; 346907at2759; -. DR PAN-GO; P42679; 1 GO annotation based on evolutionary models. DR PhylomeDB; P42679; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P42679; -. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR SignaLink; P42679; -. DR SIGNOR; P42679; -. DR Agora; ENSG00000007264; -. DR BioGRID-ORCS; 4145; 33 hits in 1190 CRISPR screens. DR EvolutionaryTrace; P42679; -. DR GeneWiki; Megakaryocyte-associated_tyrosine_kinase; -. DR GenomeRNAi; 4145; -. DR Pharos; P42679; Tbio. DR PRO; PR:P42679; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P42679; protein. DR Bgee; ENSG00000007264; Expressed in granulocyte and 173 other cell types or tissues. DR ExpressionAtlas; P42679; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR CDD; cd05083; PTKc_Chk; 1. DR CDD; cd09937; SH2_csk_like; 1. DR CDD; cd11811; SH3_CHK; 1. DR FunFam; 1.10.510.10:FF:000376; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000145; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000023; Tyrosine-protein kinase; 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR035027; Csk-like_SH2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase; KW Membrane; Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; SH2 domain; SH3 domain; Transferase; KW Tyrosine-protein kinase. FT CHAIN 1..507 FT /note="Megakaryocyte-associated tyrosine-protein kinase" FT /id="PRO_0000088073" FT DOMAIN 48..110 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 122..211 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 235..482 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 482..507 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 491..507 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 352 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 241..249 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 262 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 501 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..41 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_044277" FT VAR_SEQ 1..24 FT /note="MAGRGSLVSWRAFHGCDSAEELPR -> MQGHFPAERREGRPRRGTRGQQQL FT L (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043123" FT VARIANT 354 FT /note="A -> T (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041679" FT VARIANT 496 FT /note="A -> T (in dbSNP:rs35351680)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041680" FT VARIANT 503 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs778726488)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041681" FT CONFLICT 107..108 FT /note="ER -> DG (in Ref. 1; AAA16703)" FT /evidence="ECO:0000305" FT CONFLICT 400 FT /note="Missing (in Ref. 1; AAA16703)" FT /evidence="ECO:0000305" FT CONFLICT 466..507 FT /note="ARRPPFRKLAEKLARELRSAGAPASVSGQDADGSTSPRSQEP -> PAGHPS FT ANWPRSWPGSYAVQVPQPPSQGRTPTVHLAPKPGALTPPGGPWPQRTERVESAAWGH FT (in Ref. 1; AAA16703)" FT /evidence="ECO:0000305" FT STRAND 52..57 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 59..61 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 74..79 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 83..91 FT /evidence="ECO:0007829|PDB:1X6G" FT TURN 92..94 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 97..101 FT /evidence="ECO:0007829|PDB:1X6G" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 123..126 FT /evidence="ECO:0007829|PDB:1JWO" FT HELIX 129..135 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 144..148 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 150..152 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 156..162 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 165..174 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 177..188 FT /evidence="ECO:0007829|PDB:3US4" FT HELIX 189..198 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:3US4" SQ SEQUENCE 507 AA; 56469 MW; 85721C6E024575EF CRC64; MAGRGSLVSW RAFHGCDSAE ELPRVSPRFL RAWHPPPVSA RMPTRRWAPG TQCITKCEHT RPKPGELAFR KGDVVTILEA CENKSWYRVK HHTSGQEGLL AAGALREREA LSADPKLSLM PWFHGKISGQ EAVQQLQPPE DGLFLVRESA RHPGDYVLCV SFGRDVIHYR VLHRDGHLTI DEAVFFCNLM DMVEHYSKDK GAICTKLVRP KRKHGTKSAE EELARAGWLL NLQHLTLGAQ IGEGEFGAVL QGEYLGQKVA VKNIKCDVTA QAFLDETAVM TKMQHENLVR LLGVILHQGL YIVMEHVSKG NLVNFLRTRG RALVNTAQLL QFSLHVAEGM EYLESKKLVH RDLAARNILV SEDLVAKVSD FGLAKAERKG LDSSRLPVKW TAPEALKHGK FTSKSDVWSF GVLLWEVFSY GRAPYPKMSL KEVSEAVEKG YRMEPPEGCP GPVHVLMSSC WEAEPARRPP FRKLAEKLAR ELRSAGAPAS VSGQDADGST SPRSQEP // ID MP2K4_HUMAN Reviewed; 399 AA. AC P45985; B2R7N7; B3KYB2; D3DTS5; Q5U0B8; Q6FHX4; Q6P9H2; Q6PIE6; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 229. DE RecName: Full=Dual specificity mitogen-activated protein kinase kinase 4; DE Short=MAP kinase kinase 4; DE Short=MAPKK 4; DE EC=2.7.12.2; DE AltName: Full=JNK-activating kinase 1; DE AltName: Full=MAPK/ERK kinase 4; DE Short=MEK 4; DE AltName: Full=SAPK/ERK kinase 1; DE Short=SEK1; DE AltName: Full=Stress-activated protein kinase kinase 1; DE Short=SAPK kinase 1; DE Short=SAPKK-1; DE Short=SAPKK1; DE AltName: Full=c-Jun N-terminal kinase kinase 1; DE Short=JNKK; GN Name=MAP2K4; Synonyms=JNKK1, MEK4, MKK4, PRKMK4, SEK1, SERK1, SKK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=7839144; DOI=10.1126/science.7839144; RA Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J., Ulevitch R.J., RA Davis R.J.; RT "Independent human MAP-kinase signal transduction pathways defined by MEK RT and MKK isoforms."; RL Science 267:682-685(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION. RX PubMed=7716521; DOI=10.1126/science.7716521; RA Lin A., Minden A., Martinetto H., Claret F.-X., Lange-Carter C., RA Mercurio F., Johnson G.L., Karin M.; RT "Identification of a dual specificity kinase that activates the Jun kinases RT and p38-Mpk2."; RL Science 268:286-290(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9622070; RA Su G.H., Hilgers W., Shekher M.C., Tang D.J., Yeo C.J., Hruban R.H., RA Kern S.E.; RT "Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as RT a genetically targeted tumor suppressor gene."; RL Cancer Res. 58:2339-2342(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-16. RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP PHOSPHORYLATION AT THR-261, ACTIVITY REGULATION, AND INTERACTION WITH RP MAP3K11/MLK3. RX PubMed=9003778; DOI=10.1002/j.1460-2075.1996.tb01094.x; RA Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R., RA Lassam N.J.; RT "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6."; RL EMBO J. 15:7026-7035(1996). RN [12] RP CLEAVAGE BY ANTHRAX LETHAL FACTOR. RX PubMed=11104681; DOI=10.1042/bj3520739; RA Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.; RT "Susceptibility of mitogen-activated protein kinase kinase family members RT to proteolysis by anthrax lethal factor."; RL Biochem. J. 352:739-745(2000). RN [13] RP INTERACTION WITH ARRB2. RX PubMed=11090355; DOI=10.1126/science.290.5496.1574; RA McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E., Lin F.-T., RA Davis R.J., Lefkowitz R.J.; RT "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of RT JNK3."; RL Science 290:1574-1577(2000). RN [14] RP INTERACTION WITH MAPK8IP3/JIP3. RX PubMed=12189133; DOI=10.1074/jbc.m202004200; RA Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M., RA Yoshioka K., Ichijo H.; RT "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK RT signaling pathway. A new mode of regulation of the MAP kinase cascade."; RL J. Biol. Chem. 277:40703-40709(2002). RN [15] RP DOMAIN, AND INTERACTION WITH MAPK8/JNK1; MAPK9/JNK2; MAPK10/JNK3; MAPK11 RP AND MAPK14. RX PubMed=12788955; DOI=10.1074/jbc.m304229200; RA Ho D.T., Bardwell A.J., Abdollahi M., Bardwell L.; RT "A docking site in MKK4 mediates high affinity binding to JNK MAPKs and RT competes with similar docking sites in JNK substrates."; RL J. Biol. Chem. 278:32662-32672(2003). RN [16] RP DOMAIN. RX PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001; RA Takekawa M., Tatebayashi K., Saito H.; RT "Conserved docking site is essential for activation of mammalian MAP kinase RT kinases by specific MAP kinase kinase kinases."; RL Mol. Cell 18:295-306(2005). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [18] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [19] RP INTERACTION WITH ARRB1 AND ARRB2. RX PubMed=19782076; DOI=10.1016/j.febslet.2009.09.035; RA Li X., MacLeod R., Dunlop A.J., Edwards H.V., Advant N., Gibson L.C., RA Devine N.M., Brown K.M., Adams D.R., Houslay M.D., Baillie G.S.; RT "A scanning peptide array approach uncovers association sites within the RT JNK/beta arrestin signalling complex."; RL FEBS Lett. 583:3310-3316(2009). RN [20] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17496909; DOI=10.1038/sj.onc.1210392; RA Raman M., Chen W., Cobb M.H.; RT "Differential regulation and properties of MAPKs."; RL Oncogene 26:3100-3112(2007). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP REVIEW ON FUNCTION. RX PubMed=20801953; DOI=10.1093/jb/mvq098; RA Asaoka Y., Nishina H.; RT "Diverse physiological functions of MKK4 and MKK7 during early RT embryogenesis."; RL J. Biochem. 148:393-401(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP REVIEW ON REGULATION, AND REVIEW ON FUNCTION. RX PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008; RA Haeusgen W., Herdegen T., Waetzig V.; RT "The bottleneck of JNK signaling: molecular and functional characteristics RT of MKK4 and MKK7."; RL Eur. J. Cell Biol. 90:536-544(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-58, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [28] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 80-399. RX PubMed=20732303; DOI=10.1016/j.bbrc.2010.08.071; RA Matsumoto T., Kinoshita T., Kirii Y., Yokota K., Hamada K., Tada T.; RT "Crystal structures of MKK4 kinase domain reveal that substrate peptide RT binds to an allosteric site and induces an auto-inhibition state."; RL Biochem. Biophys. Res. Commun. 400:369-373(2010). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-142; TRP-154; ILE-234; ASN-251 AND RP THR-279. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Dual specificity protein kinase which acts as an essential CC component of the MAP kinase signal transduction pathway. Essential CC component of the stress-activated protein kinase/c-Jun N-terminal CC kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the CC only known kinase to directly activate the stress-activated protein CC kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. CC MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, CC but they differ in their preference for the phosphorylation site in the CC Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the CC Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of CC the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK CC activation at least in response to pro-inflammatory cytokines, while CC other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which CC synergistically phosphorylate JNKs. MAP2K4 is required for maintaining CC peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also CC involved in mitochondrial death signaling pathway, including the CC release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 CC exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 CC MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. {ECO:0000269|PubMed:7716521}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- ACTIVITY REGULATION: Activated in response to a variety of cellular CC stresses, including UV and gamma-irradiation, heat shock, CC hyperosmolarity, T-cell receptor stimulation, peroxide and inflammatory CC cytokines. Also activated by developmental cues. MAP2K4/MKK4 is CC activated by the majority of MKKKs, such as MAP3K5/ASK1, MAP3K1/MEKK1, CC MAP3K7/TAK1, MAP3K10/MLK2, MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK. CC {ECO:0000269|PubMed:9003778}. CC -!- SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via its D CC domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3, MAPK11 CC and MAPK14. Interacts (via its DVD domain) with MAP3Ks activators like CC MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts with ARRB1, ARRB2 and CC MAPK8IP3/JIP3. {ECO:0000250, ECO:0000269|PubMed:11090355, CC ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:12788955, CC ECO:0000269|PubMed:19782076, ECO:0000269|PubMed:9003778}. CC -!- INTERACTION: CC P45985; Q13233: MAP3K1; NbExp=3; IntAct=EBI-447868, EBI-49776; CC P45985; P45983: MAPK8; NbExp=4; IntAct=EBI-447868, EBI-286483; CC P45985; P45984: MAPK9; NbExp=3; IntAct=EBI-447868, EBI-713568; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P45985-1; Sequence=Displayed; CC Name=2; CC IsoId=P45985-2; Sequence=VSP_038838; CC -!- TISSUE SPECIFICITY: Abundant expression is seen in the skeletal muscle. CC It is also widely expressed in other tissues. CC -!- DOMAIN: The DVD domain (residues 364-387) contains a conserved docking CC site and is found in the mammalian MAP kinase kinases (MAP2Ks). The DVD CC sites bind to their specific upstream MAP kinase kinase kinases CC (MAP3Ks) and are essential for activation. CC -!- DOMAIN: The D domain (residues 34-52) contains a conserved docking site CC and is required for the binding to MAPK substrates. CC -!- PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAP kinase CC kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/244/MAP2K4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L36870; AAC41719.1; -; mRNA. DR EMBL; U17743; AAC50127.1; -; mRNA. DR EMBL; AF070090; AAC24130.1; -; Genomic_DNA. DR EMBL; AF070080; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070081; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070082; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070083; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070084; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070085; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070086; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070087; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070088; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070089; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; CR536564; CAG38801.1; -; mRNA. DR EMBL; BT019676; AAV38482.1; -; mRNA. DR EMBL; AK131544; BAG54774.1; -; mRNA. DR EMBL; AK313053; BAG35884.1; -; mRNA. DR EMBL; DQ015703; AAY22176.1; -; Genomic_DNA. DR EMBL; AC005244; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005410; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW89975.1; -; Genomic_DNA. DR EMBL; CH471108; EAW89974.1; -; Genomic_DNA. DR EMBL; CH471108; EAW89976.1; -; Genomic_DNA. DR EMBL; BC036032; AAH36032.1; -; mRNA. DR EMBL; BC060764; AAH60764.1; -; mRNA. DR CCDS; CCDS11162.1; -. [P45985-1] DR CCDS; CCDS62095.1; -. [P45985-2] DR PIR; I38901; I38901. DR RefSeq; NP_001268364.1; NM_001281435.2. [P45985-2] DR RefSeq; NP_003001.1; NM_003010.4. [P45985-1] DR PDB; 3ALN; X-ray; 2.30 A; A/B/C=80-399. DR PDB; 3ALO; X-ray; 2.60 A; A=80-399. DR PDB; 3VUT; X-ray; 3.50 A; A/B=80-399. DR PDB; 8YP5; X-ray; 2.50 A; A=80-399. DR PDBsum; 3ALN; -. DR PDBsum; 3ALO; -. DR PDBsum; 3VUT; -. DR PDBsum; 8YP5; -. DR AlphaFoldDB; P45985; -. DR SMR; P45985; -. DR BioGRID; 112315; 69. DR CORUM; P45985; -. DR FunCoup; P45985; 2185. DR IntAct; P45985; 26. DR MINT; P45985; -. DR STRING; 9606.ENSP00000410402; -. DR BindingDB; P45985; -. DR ChEMBL; CHEMBL2897; -. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB14904; Pimasertib. DR DrugCentral; P45985; -. DR GuidetoPHARMACOLOGY; 2065; -. DR GlyCosmos; P45985; 2 sites, 1 glycan. DR GlyGen; P45985; 4 sites, 1 O-linked glycan (2 sites). DR iPTMnet; P45985; -. DR PhosphoSitePlus; P45985; -. DR BioMuta; MAP2K4; -. DR DMDM; 1170596; -. DR CPTAC; CPTAC-816; -. DR CPTAC; CPTAC-817; -. DR jPOST; P45985; -. DR MassIVE; P45985; -. DR PaxDb; 9606-ENSP00000410402; -. DR PeptideAtlas; P45985; -. DR ProteomicsDB; 55703; -. [P45985-1] DR ProteomicsDB; 55704; -. [P45985-2] DR Pumba; P45985; -. DR Antibodypedia; 3571; 1422 antibodies from 43 providers. DR CPTC; P45985; 1 antibody. DR DNASU; 6416; -. DR Ensembl; ENST00000353533.10; ENSP00000262445.5; ENSG00000065559.16. [P45985-1] DR Ensembl; ENST00000415385.7; ENSP00000410402.3; ENSG00000065559.16. [P45985-2] DR GeneID; 6416; -. DR KEGG; hsa:6416; -. DR MANE-Select; ENST00000353533.10; ENSP00000262445.5; NM_003010.4; NP_003001.1. DR UCSC; uc002gnj.5; human. [P45985-1] DR AGR; HGNC:6844; -. DR CIViC; 6416; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA30589; -. DR CTD; 6416; -. DR DisGeNET; 6416; -. DR GeneCards; MAP2K4; -. DR HGNC; HGNC:6844; MAP2K4. DR HPA; ENSG00000065559; Low tissue specificity. DR MalaCards; MAP2K4; -. DR MIM; 601335; gene. DR OpenTargets; ENSG00000065559; -. DR VEuPathDB; HostDB:ENSG00000065559; -. DR eggNOG; KOG1006; Eukaryota. DR GeneTree; ENSGT00940000154744; -. DR HOGENOM; CLU_000288_63_23_1; -. DR InParanoid; P45985; -. DR OMA; HILLEFC; -. DR OrthoDB; 10252354at2759; -. DR PAN-GO; P45985; 2 GO annotations based on evolutionary models. DR PhylomeDB; P45985; -. DR BRENDA; 2.7.12.2; 2681. DR PathwayCommons; P45985; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-5210891; Uptake and function of anthrax toxins. DR Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation. DR SABIO-RK; P45985; -. DR SignaLink; P45985; -. DR SIGNOR; P45985; -. DR Agora; ENSG00000065559; -. DR BioGRID-ORCS; 6416; 53 hits in 1202 CRISPR screens. DR ChiTaRS; MAP2K4; human. DR EvolutionaryTrace; P45985; -. DR GeneWiki; MAP2K4; -. DR GenomeRNAi; 6416; -. DR Pharos; P45985; Tchem. DR PRO; PR:P45985; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P45985; protein. DR Bgee; ENSG00000065559; Expressed in lateral nuclear group of thalamus and 204 other cell types or tissues. DR ExpressionAtlas; P45985; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008545; F:JUN kinase kinase activity; TAS:Reactome. DR GO; GO:0004708; F:MAP kinase kinase activity; IBA:GO_Central. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0036481; P:intrinsic apoptotic signaling pathway in response to hydrogen peroxide; IEA:Ensembl. DR GO; GO:0007254; P:JNK cascade; TAS:Reactome. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0009611; P:response to wounding; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0034390; P:smooth muscle cell apoptotic process; IEA:Ensembl. DR CDD; cd06616; PKc_MKK4; 1. DR DisProt; DP01400; -. DR FunFam; 1.10.510.10:FF:000090; Dual specificity mitogen-activated protein kinase kinase 4; 1. DR FunFam; 3.30.200.20:FF:000126; Dual specificity mitogen-activated protein kinase kinase 4; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR48013:SF15; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4; 1. DR PANTHER; PTHR48013; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 5-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Cytoplasm; Kinase; Methylation; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Stress response; Transferase; KW Tyrosine-protein kinase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..399 FT /note="Dual specificity mitogen-activated protein kinase FT kinase 4" FT /id="PRO_0000086381" FT DOMAIN 102..367 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..40 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 37..52 FT /note="D domain" FT REGION 364..387 FT /note="DVD domain" FT COMPBIAS 7..22 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 229 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 108..116 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 131 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 45..46 FT /note="Cleavage; by anthrax lethal factor" FT SITE 58..59 FT /note="Cleavage; by anthrax lethal factor" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 58 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 58 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 90 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 257 FT /note="Phosphoserine; by MAP3K" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:24275569" FT MOD_RES 261 FT /note="Phosphothreonine; by MAP3K" FT /evidence="ECO:0000269|PubMed:9003778" FT VAR_SEQ 39 FT /note="G -> GFQINFCEKAQS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038838" FT VARIANT 16 FT /note="S -> R (in dbSNP:rs17855590)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_062963" FT VARIANT 142 FT /note="Q -> L (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040818" FT VARIANT 154 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1567657403)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040819" FT VARIANT 234 FT /note="N -> I (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040820" FT VARIANT 251 FT /note="S -> N (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040821" FT VARIANT 279 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs753665559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040822" FT CONFLICT 118 FT /note="K -> R (in Ref. 4; CAG38801)" FT /evidence="ECO:0000305" FT CONFLICT 179 FT /note="E -> G (in Ref. 6; BAG35884)" FT /evidence="ECO:0000305" FT CONFLICT 356 FT /note="P -> L (in Ref. 10; AAH60764)" FT /evidence="ECO:0000305" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:3VUT" FT STRAND 85..88 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 93..95 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 101..103 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 112..121 FT /evidence="ECO:0007829|PDB:3ALN" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 127..134 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 139..153 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 164..169 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 171..178 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 185..194 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 202..223 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 235..237 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 243..245 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 255..259 FT /evidence="ECO:0007829|PDB:3VUT" FT STRAND 267..270 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 272..274 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 287..302 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 312..314 FT /evidence="ECO:0007829|PDB:3ALO" FT STRAND 316..321 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 338..347 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 358..361 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 365..372 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 377..387 FT /evidence="ECO:0007829|PDB:3ALN" SQ SEQUENCE 399 AA; 44288 MW; A472537F2F26770B CRC64; MAAPSPSGGG GSGGGSGSGT PGPVGSPAPG HPAVSSMQGK RKALKLNFAN PPFKSTARFT LNPNPTGVQN PHIERLRTHS IESSGKLKIS PEQHWDFTAE DLKDLGEIGR GAYGSVNKMV HKPSGQIMAV KRIRSTVDEK EQKQLLMDLD VVMRSSDCPY IVQFYGALFR EGDCWICMEL MSTSFDKFYK YVYSVLDDVI PEEILGKITL ATVKALNHLK ENLKIIHRDI KPSNILLDRS GNIKLCDFGI SGQLVDSIAK TRDAGCRPYM APERIDPSAS RQGYDVRSDV WSLGITLYEL ATGRFPYPKW NSVFDQLTQV VKGDPPQLSN SEEREFSPSF INFVNLCLTK DESKRPKYKE LLKHPFILMY EERAVEVACY VCKILDQMPA TPSSPMYVD // ID MTOR_HUMAN Reviewed; 2549 AA. AC P42345; Q4LE76; Q5TER1; Q6LE87; Q96QG3; Q9Y4I3; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 243. DE RecName: Full=Serine/threonine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423}; DE AltName: Full=FK506-binding protein 12-rapamycin complex-associated protein 1; DE AltName: Full=FKBP12-rapamycin complex-associated protein; DE AltName: Full=Mammalian target of rapamycin; DE Short=mTOR; DE AltName: Full=Mechanistic target of rapamycin; DE AltName: Full=Rapamycin and FKBP12 target 1; DE AltName: Full=Rapamycin target protein 1; DE AltName: Full=Tyrosine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.10.2 {ECO:0000305|PubMed:26584640}; GN Name=MTOR {ECO:0000312|HGNC:HGNC:3942}; GN Synonyms=FRAP, FRAP1, FRAP2, RAFT1, RAPT1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RX PubMed=8008069; DOI=10.1038/369756a0; RA Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., RA Schreiber S.L.; RT "A mammalian protein targeted by G1-arresting rapamycin-receptor complex."; RL Nature 369:756-758(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9653645; DOI=10.1006/geno.1997.5186; RA Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.; RT "Molecular cloning and expression analysis of five novel genes in RT chromosome 1p36."; RL Genomics 50:187-198(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R., RA Okazaki N., Koga H., Nagase T., Ohara O.; RT "Preparation of a set of expression-ready clones of mammalian long cDNAs RT encoding large proteins by the ORF trap cloning method."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Cerebellum; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1362-2549. RX PubMed=11426320; DOI=10.1038/sj.gene.6363745; RA Stover C., Endo Y., Takahashi M., Lynch N., Constantinescu C., RA Vorup-Jensen T., Thiel S., Friedl H., Hankeln T., Hall R., Gregory S., RA Fujita T., Schwaeble W.; RT "The human gene for mannan-binding lectin-associated serine protease-2 RT (MASP-2), the effector component of the lectin route of complement RT activation, is part of a tightly linked gene cluster on chromosome 1p36.2- RT 3."; RL Genes Immun. 2:119-127(2001). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1987-2146, AND TISSUE SPECIFICITY. RC TISSUE=B-cell; RX PubMed=7809080; DOI=10.1073/pnas.91.26.12574; RA Chiu M.I., Katz H., Berlin V.; RT "RAPT1, a mammalian homolog of yeast Tor, interacts with the RT FKBP12/rapamycin complex."; RL Proc. Natl. Acad. Sci. U.S.A. 91:12574-12578(1994). RN [8] RP SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION. RX PubMed=9434772; DOI=10.1006/bbrc.1997.7878; RA Withers D.J., Ouwens D.M., Nave B.T., van der Zon G.C.M., Alarcon C.M., RA Cardenas M.E., Heitman J., Maassen J.A., Shepherd P.R.; RT "Expression, enzyme activity, and subcellular localization of mammalian RT target of rapamycin in insulin-responsive cells."; RL Biochem. Biophys. Res. Commun. 241:704-709(1997). RN [9] RP INTERACTION WITH UBQLN1. RX PubMed=11853878; DOI=10.1016/s0167-4889(01)00164-1; RA Wu S., Mikhailov A., Kallo-Hosein H., Hara K., Yonezawa K., Avruch J.; RT "Characterization of ubiquilin 1, an mTOR-interacting protein."; RL Biochim. Biophys. Acta 1542:41-56(2002). RN [10] RP FUNCTION IN NUTRIENT-DEPENDENT CELL GROWTH, CATALYTIC ACTIVITY, FUNCTION IN RP PHOSPHORYLATION OF RPS6KB1, AND INTERACTION WITH RPTOR. RX PubMed=12150925; DOI=10.1016/s0092-8674(02)00808-5; RA Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "mTOR interacts with raptor to form a nutrient-sensitive complex that RT signals to the growth machinery."; RL Cell 110:163-175(2002). RN [11] RP FUNCTION, AND INTERACTION WITH RPTOR. RX PubMed=12150926; DOI=10.1016/s0092-8674(02)00833-4; RA Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., RA Tokunaga C., Avruch J., Yonezawa K.; RT "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR RT action."; RL Cell 110:177-189(2002). RN [12] RP INTERACTION WITH CLIP1, FUNCTION IN PHOSPHORYLATION OF CLIP1, AND CATALYTIC RP ACTIVITY. RX PubMed=12231510; DOI=10.1093/embo-reports/kvf197; RA Choi J.H., Bertram P.G., Drenan R., Carvalho J., Zhou H.H., Zheng X.F.; RT "The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase."; RL EMBO Rep. 3:988-994(2002). RN [13] RP FUNCTION IN PHOSPHORYLATION OF RPS6KB2, AND CATALYTIC ACTIVITY. RX PubMed=12087098; DOI=10.1074/jbc.m204080200; RA Park I.H., Bachmann R., Shirazi H., Chen J.; RT "Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin."; RL J. Biol. Chem. 277:31423-31429(2002). RN [14] RP INTERACTION WITH MLST8 AND RPTOR, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP TISSUE SPECIFICITY. RX PubMed=12408816; DOI=10.1016/s1097-2765(02)00636-6; RA Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., RA Bonenfant D., Oppliger W., Jenoe P., Hall M.N.; RT "Two TOR complexes, only one of which is rapamycin sensitive, have distinct RT roles in cell growth control."; RL Mol. Cell 10:457-468(2002). RN [15] RP SUBCELLULAR LOCATION. RX PubMed=11930000; DOI=10.1073/pnas.261702698; RA Desai B.N., Myers B.R., Schreiber S.L.; RT "FKBP12-rapamycin-associated protein associates with mitochondria and RT senses osmotic stress via mitochondrial dysfunction."; RL Proc. Natl. Acad. Sci. U.S.A. 99:4319-4324(2002). RN [16] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO LOW CELLULAR ENERGY. RX PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2; RA Inoki K., Zhu T., Guan K.L.; RT "TSC2 mediates cellular energy response to control cell growth and RT survival."; RL Cell 115:577-590(2003). RN [17] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH MLST8. RX PubMed=12718876; DOI=10.1016/s1097-2765(03)00114-x; RA Kim D.-H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V.P., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "GbetaL, a positive regulator of the rapamycin-sensitive pathway required RT for the nutrient-sensitive interaction between raptor and mTOR."; RL Mol. Cell 11:895-904(2003). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PRKCA, CATALYTIC ACTIVITY, FUNCTION IN RP REGULATION OF THE ACTIN CYTOSKELETON, IDENTIFICATION IN THE MTORC2 COMPLEX, RP AND INTERACTION WITH RICTOR. RX PubMed=15268862; DOI=10.1016/j.cub.2004.06.054; RA Sarbassov D.D., Ali S.M., Kim D.-H., Guertin D.A., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive RT and raptor-independent pathway that regulates the cytoskeleton."; RL Curr. Biol. 14:1296-1302(2004). RN [19] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO HYPOXIA. RX PubMed=15545625; DOI=10.1101/gad.1256804; RA Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., RA Witters L.A., Ellisen L.W., Kaelin W.G. Jr.; RT "Regulation of mTOR function in response to hypoxia by REDD1 and the RT TSC1/TSC2 tumor suppressor complex."; RL Genes Dev. 18:2893-2904(2004). RN [20] RP SUBCELLULAR LOCATION. RX PubMed=14578359; DOI=10.1074/jbc.m305912200; RA Drenan R.M., Liu X., Bertram P.G., Zheng X.F.S.; RT "FKBP12-rapamycin-associated protein or mammalian target of rapamycin RT (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi RT apparatus."; RL J. Biol. Chem. 279:772-778(2004). RN [21] RP FUNCTION IN REGULATION OF THE ACTIN CYTOSKELETON, CATALYTIC ACTIVITY, RP FUNCTION IN PHOSPHORYLATION OF PXN, IDENTIFICATION IN THE MTORC2 COMPLEX, RP INTERACTION WITH RICTOR, AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=15467718; DOI=10.1038/ncb1183; RA Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., Hall M.N.; RT "Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin RT insensitive."; RL Nat. Cell Biol. 6:1122-1128(2004). RN [22] RP PHOSPHORYLATION AT SER-2448. RX PubMed=15899889; DOI=10.1074/jbc.m501707200; RA Chiang G.G., Abraham R.T.; RT "Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is RT mediated by p70S6 kinase."; RL J. Biol. Chem. 280:25485-25490(2005). RN [23] RP PHOSPHORYLATION AT THR-2446 AND SER-2448. RX PubMed=15905173; DOI=10.1074/jbc.m504045200; RA Holz M.K., Blenis J.; RT "Identification of S6 kinase 1 as a novel mammalian target of rapamycin RT (mTOR)-phosphorylating kinase."; RL J. Biol. Chem. 280:26089-26093(2005). RN [24] RP FUNCTION IN PHOSPHORYLATION OF AKT1, AND CATALYTIC ACTIVITY. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=17517883; DOI=10.1074/jbc.m702636200; RA Oshiro N., Takahashi R., Yoshino K., Tanimura K., Nakashima A., Eguchi S., RA Miyamoto T., Hara K., Takehana K., Avruch J., Kikkawa U., Yonezawa K.; RT "The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological RT substrate of mammalian target of rapamycin complex 1."; RL J. Biol. Chem. 282:20329-20339(2007). RN [26] RP IDENTIFICATION IN THE MTORC2 COMPLEX, AND INTERACTION WITH PRR5. RX PubMed=17599906; DOI=10.1074/jbc.m704343200; RA Woo S.-Y., Kim D.-H., Jun C.-B., Kim Y.-M., Haar E.V., Lee S.-I., RA Hegg J.W., Bandhakavi S., Griffin T.J., Kim D.-H.; RT "PRR5, a novel component of mTOR complex 2, regulates platelet-derived RT growth factor receptor beta expression and signaling."; RL J. Biol. Chem. 282:25604-25612(2007). RN [27] RP INTERACTION WITH AKT1S1, AND ACTIVITY REGULATION. RX PubMed=17386266; DOI=10.1016/j.molcel.2007.03.003; RA Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., RA Spooner E., Carr S.A., Sabatini D.M.; RT "PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase."; RL Mol. Cell 25:903-915(2007). RN [28] RP IDENTIFICATION IN THE MTORC1 AND MTORC2 COMPLEXES, CATALYTIC ACTIVITY, AND RP FUNCTION IN PHOSPHORYLATION OF RPS6KB1 AND SGK1. RX PubMed=18925875; DOI=10.1042/bj20081668; RA Garcia-Martinez J.M., Alessi D.R.; RT "mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and RT activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)."; RL Biochem. J. 416:375-385(2008). RN [29] RP FUNCTION IN LIPID SYNTHESIS AND CELL GROWTH. RX PubMed=18762023; DOI=10.1016/j.cmet.2008.07.007; RA Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., RA Griffiths J.R., Chung Y.L., Schulze A.; RT "SREBP activity is regulated by mTORC1 and contributes to Akt-dependent RT cell growth."; RL Cell Metab. 8:224-236(2008). RN [30] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18372248; DOI=10.1074/jbc.m800723200; RA Wang L., Harris T.E., Lawrence J.C. Jr.; RT "Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by RT mammalian target of rapamycin complex 1 (mTORC1)-mediated RT phosphorylation."; RL J. Biol. Chem. 283:15619-15627(2008). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2478 AND SER-2481, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [33] RP FUNCTION, ACTIVITY REGULATION, AND SUBCELLULAR LOCATION. RX PubMed=18497260; DOI=10.1126/science.1157535; RA Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., RA Bar-Peled L., Sabatini D.M.; RT "The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1."; RL Science 320:1496-1501(2008). RN [34] RP INTERACTION WITH DEPTOR, AND ACTIVITY REGULATION. RX PubMed=19446321; DOI=10.1016/j.cell.2009.03.046; RA Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., RA Gray N.S., Sabatini D.M.; RT "DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma RT cells and required for their survival."; RL Cell 137:873-886(2009). RN [35] RP PHOSPHORYLATION AT SER-1261, AND ACTIVITY REGULATION. RX PubMed=19487463; DOI=10.1128/mcb.01665-08; RA Acosta-Jaquez H.A., Keller J.A., Foster K.G., Ekim B., Soliman G.A., RA Feener E.P., Ballif B.A., Fingar D.C.; RT "Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and RT cell growth."; RL Mol. Cell. Biol. 29:4308-4324(2009). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [37] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1218, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [38] RP PHOSPHORYLATION AT SER-2448. RX PubMed=19145465; DOI=10.1007/s00726-008-0230-7; RA Rosner M., Siegel N., Valli A., Fuchs C., Hengstschlager M.; RT "mTOR phosphorylated at S2448 binds to raptor and rictor."; RL Amino Acids 38:223-228(2010). RN [39] RP SUBCELLULAR LOCATION, AND ACTIVITY REGULATION. RX PubMed=20381137; DOI=10.1016/j.cell.2010.02.024; RA Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M.; RT "Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is RT necessary for its activation by amino acids."; RL Cell 141:290-303(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF DAP, FUNCTION IN AUTOPHAGY, AND CATALYTIC RP ACTIVITY. RX PubMed=20537536; DOI=10.1016/j.cub.2010.04.041; RA Koren I., Reem E., Kimchi A.; RT "DAP1, a novel substrate of mTOR, negatively regulates autophagy."; RL Curr. Biol. 20:1093-1098(2010). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT SER-2481. RX PubMed=20022946; DOI=10.1074/jbc.m109.096222; RA Soliman G.A., Acosta-Jaquez H.A., Dunlop E.A., Ekim B., Maj N.E., Tee A.R., RA Fingar D.C.; RT "mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic RT activity and clarifies rapamycin mechanism of action."; RL J. Biol. Chem. 285:7866-7879(2010). RN [42] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=21376236; DOI=10.1016/j.cell.2011.02.014; RA Zinzalla V., Stracka D., Oppliger W., Hall M.N.; RT "Activation of mTORC2 by association with the ribosome."; RL Cell 144:757-768(2011). RN [43] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [44] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [45] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [46] RP FUNCTION IN REGULATION OF RNA POLYMERASE III TRANSCRIPTION, FUNCTION IN RP PHOSPHORYLATION OF MAF1, AND CATALYTIC ACTIVITY. RX PubMed=20516213; DOI=10.1128/mcb.00319-10; RA Michels A.A., Robitaille A.M., Buczynski-Ruchonnet D., Hodroj W., RA Reina J.H., Hall M.N., Hernandez N.; RT "mTORC1 directly phosphorylates and regulates human MAF1."; RL Mol. Cell. Biol. 30:3749-3757(2010). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567 AND THR-1162, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [48] RP SUBCELLULAR LOCATION. RX PubMed=21867682; DOI=10.1016/j.bbrc.2011.08.034; RA Boulbes D.R., Shaiken T., Sarbassov D.D.; RT "Endoplasmic reticulum is a main localization site of mTORC2."; RL Biochem. Biophys. Res. Commun. 413:46-52(2011). RN [49] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [50] RP PHOSPHORYLATION AT SER-2159; THR-2164 AND SER-2481, AND MUTAGENESIS OF RP SER-2159 AND THR-2164. RX PubMed=21576368; DOI=10.1128/mcb.05437-11; RA Ekim B., Magnuson B., Acosta-Jaquez H.A., Keller J.A., Feener E.P., RA Fingar D.C.; RT "mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, RT and cell cycle progression."; RL Mol. Cell. Biol. 31:2787-2801(2011). RN [51] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [52] RP FUNCTION IN PHOSPHORYLATION OF GRB10, CATALYTIC ACTIVITY, AND FUNCTION IN RP INSR-DEPENDENT SIGNALING. RX PubMed=21659604; DOI=10.1126/science.1199498; RA Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., RA Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M.; RT "The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated RT inhibition of growth factor signaling."; RL Science 332:1317-1322(2011). RN [53] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22576015; DOI=10.4161/auto.19653; RA Martina J.A., Chen Y., Gucek M., Puertollano R.; RT "MTORC1 functions as a transcriptional regulator of autophagy by preventing RT nuclear transport of TFEB."; RL Autophagy 8:903-914(2012). RN [54] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22343943; DOI=10.1038/emboj.2012.32; RA Settembre C., Zoncu R., Medina D.L., Vetrini F., Erdin S., Erdin S., RA Huynh T., Ferron M., Karsenty G., Vellard M.C., Facchinetti V., RA Sabatini D.M., Ballabio A.; RT "A lysosome-to-nucleus signalling mechanism senses and regulates the RT lysosome via mTOR and TFEB."; RL EMBO J. 31:1095-1108(2012). RN [55] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22692423; DOI=10.1126/scisignal.2002790; RA Roczniak-Ferguson A., Petit C.S., Froehlich F., Qian S., Ky J., RA Angarola B., Walther T.C., Ferguson S.M.; RT "The transcription factor TFEB links mTORC1 signaling to transcriptional RT control of lysosome homeostasis."; RL Sci. Signal. 5:RA42-RA42(2012). RN [56] RP INTERACTION WITH HTR6. RX PubMed=23027611; DOI=10.1002/emmm.201201410; RA Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F., Watson D.J., RA Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P., Herve D., RA Fone K.C., Bockaert J., Millan M.J., Marin P.; RT "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed RT cognition in schizophrenia."; RL EMBO Mol. Med. 4:1043-1056(2012). RN [57] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [58] RP FUNCTION, AND INTERACTION WITH TPCN1 AND TPCN2. RX PubMed=23394946; DOI=10.1016/j.cell.2013.01.023; RA Cang C., Zhou Y., Navarro B., Seo Y.J., Aranda K., Shi L., RA Battaglia-Hsu S., Nissim I., Clapham D.E., Ren D.; RT "mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to RT metabolic state."; RL Cell 152:778-790(2013). RN [59] RP FUNCTION. RX PubMed=23426360; DOI=10.1074/jbc.m112.441493; RA Eaton J.M., Mullins G.R., Brindley D.N., Harris T.E.; RT "Phosphorylation of lipin 1 and charge on the phosphatidic acid head group RT control its phosphatidic acid phosphatase activity and membrane RT association."; RL J. Biol. Chem. 288:9933-9945(2013). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=25657994; RA So E.Y., Ouchi T.; RT "The potential role of BRCA1-associated ATM activator-1 (BRAT1) in RT regulation of mTOR."; RL J. Cancer Biol. Res. 1:0-0(2013). RN [61] RP PHOSPHORYLATION AT THR-2173, AND MUTAGENESIS OF THR-2173. RX PubMed=24247430; DOI=10.1083/jcb.201305103; RA Halova L., Du W., Kirkham S., Smith D.L., Petersen J.; RT "Phosphorylation of the TOR ATP binding domain by AGC kinase constitutes a RT novel mode of TOR inhibition."; RL J. Cell Biol. 203:595-604(2013). RN [62] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [63] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=23524951; DOI=10.1038/ncb2708; RA Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V., RA Bordi M., Gretzmeier C., Dengjel J., Piacentini M., Fimia G.M., Cecconi F.; RT "mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self- RT association and function through AMBRA1 and TRAF6."; RL Nat. Cell Biol. 15:406-416(2013). RN [64] RP INTERACTION WITH NBN. RX PubMed=23762398; DOI=10.1371/journal.pone.0065586; RA Wang J.Q., Chen J.H., Chen Y.C., Chen M.Y., Hsieh C.Y., Teng S.C., Wu K.J.; RT "Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific RT domains."; RL PLoS ONE 8:E65586-E65586(2013). RN [65] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429704; DOI=10.1126/science.1228771; RA Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L., RA Moes S., Prescianotto-Baschong C., Sauer U., Jenoe P., Hall M.N.; RT "Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine RT synthesis."; RL Science 339:1320-1323(2013). RN [66] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429703; DOI=10.1126/science.1228792; RA Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D.; RT "Stimulation of de novo pyrimidine synthesis by growth signaling through RT mTOR and S6K1."; RL Science 339:1323-1328(2013). RN [67] RP FUNCTION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=24403073; DOI=10.1074/jbc.m113.482067; RA Coffman K., Yang B., Lu J., Tetlow A.L., Pelliccio E., Lu S., Guo D.C., RA Tang C., Dong M.Q., Tamanoi F.; RT "Characterization of the Raptor/4E-BP1 interaction by chemical cross- RT linking coupled with mass spectrometry analysis."; RL J. Biol. Chem. 289:4723-4734(2014). RN [68] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2448, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [69] RP FUNCTION. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [70] RP FUNCTION. RX PubMed=24448649; DOI=10.1126/scisignal.2004754; RA Martina J.A., Diab H.I., Lishu L., Jeong-A L., Patange S., Raben N., RA Puertollano R.; RT "The nutrient-responsive transcription factor TFE3 promotes autophagy, RT lysosomal biogenesis, and clearance of cellular debris."; RL Sci. Signal. 7:ra9-ra9(2014). RN [71] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=25851998; DOI=10.1002/ajmg.a.37070; RA Baynam G., Overkov A., Davis M., Mina K., Schofield L., Allcock R., RA Laing N., Cook M., Dawkins H., Goldblatt J.; RT "A germline MTOR mutation in Aboriginal Australian siblings with RT intellectual disability, dysmorphism, macrocephaly, and small thoraces."; RL Am. J. Med. Genet. A 167:1659-1667(2015). RN [72] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 ASP-1459; PRO-1460; RP PHE-2215 AND TYR-2215, AND CHARACTERIZATION OF VARIANTS FCORD2 ASP-1459; RP PRO-1460; PHE-2215 AND TYR-2215. RX PubMed=26018084; DOI=10.1002/ana.24444; RA Nakashima M., Saitsu H., Takei N., Tohyama J., Kato M., Kitaura H., RA Shiina M., Shirozu H., Masuda H., Watanabe K., Ohba C., Tsurusaki Y., RA Miyake N., Zheng Y., Sato T., Takebayashi H., Ogata K., Kameyama S., RA Kakita A., Matsumoto N.; RT "Somatic mutations in the MTOR gene cause focal cortical dysplasia type RT IIb."; RL Ann. Neurol. 78:375-386(2015). RN [73] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=26542245; DOI=10.1186/s12881-015-0240-8; RA Mroske C., Rasmussen K., Shinde D.N., Huether R., Powis Z., Lu H.M., RA Baxter R.M., McPherson E., Tang S.; RT "Germline activating MTOR mutation arising through gonadal mosaicism in two RT brothers with megalencephaly and neurodevelopmental abnormalities."; RL BMC Med. Genet. 16:102-102(2015). RN [74] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=25438055; DOI=10.1038/ncb3072; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RT "AMBRA1 links autophagy to cell proliferation and tumorigenesis by RT promoting c-Myc dephosphorylation and degradation."; RL Nat. Cell Biol. 17:20-30(2015). RN [75] RP ERRATUM OF PUBMED:25438055. RX PubMed=25925585; DOI=10.1038/ncb3171; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RL Nat. Cell Biol. 17:706-706(2015). RN [76] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 HIS-624; ASP-1450; RP ARG-1483; HIS-1709; LYS-1977; CYS-2193; PHE-2215; GLN-2427 AND PRO-2427, RP AND CHARACTERIZATION OF VARIANTS FCORD2 ARG-1483; GLN-2427 AND PRO-2427. RX PubMed=25799227; DOI=10.1038/nm.3824; RA Lim J.S., Kim W.I., Kang H.C., Kim S.H., Park A.H., Park E.K., Cho Y.W., RA Kim S., Kim H.M., Kim J.A., Kim J., Rhee H., Kang S.G., Kim H.D., Kim D., RA Kim D.S., Lee J.H.; RT "Brain somatic mutations in MTOR cause focal cortical dysplasia type II RT leading to intractable epilepsy."; RL Nat. Med. 21:395-400(2015). RN [77] RP ACTIVITY REGULATION. RX PubMed=25561175; DOI=10.1038/nature14107; RA Rebsamen M., Pochini L., Stasyk T., de Araujo M.E., Galluccio M., RA Kandasamy R.K., Snijder B., Fauster A., Rudashevskaya E.L., Bruckner M., RA Scorzoni S., Filipek P.A., Huber K.V., Bigenzahn J.W., Heinz L.X., RA Kraft C., Bennett K.L., Indiveri C., Huber L.A., Superti-Furga G.; RT "SLC38A9 is a component of the lysosomal amino acid sensing machinery that RT controls mTORC1."; RL Nature 519:477-481(2015). RN [78] RP INVOLVEMENT IN FCORD2, AND VARIANT FCORD2 GLY-1456. RX PubMed=25878179; DOI=10.1212/wnl.0000000000001594; RA Leventer R.J., Scerri T., Marsh A.P., Pope K., Gillies G., Maixner W., RA MacGregor D., Harvey A.S., Delatycki M.B., Amor D.J., Crino P., Bahlo M., RA Lockhart P.J.; RT "Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in RT MTOR."; RL Neurology 84:2029-2032(2015). RN [79] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [80] RP ACTIVITY REGULATION. RX PubMed=25567906; DOI=10.1126/science.1257132; RA Wang S., Tsun Z.Y., Wolfson R.L., Shen K., Wyant G.A., Plovanich M.E., RA Yuan E.D., Jones T.D., Chantranupong L., Comb W., Wang T., Bar-Peled L., RA Zoncu R., Straub C., Kim C., Park J., Sabatini B.L., Sabatini D.M.; RT "Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine RT sufficiency to mTORC1."; RL Science 347:188-194(2015). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [82] RP INTERACTION WITH WAC. RX PubMed=26812014; DOI=10.1016/j.devcel.2015.12.019; RA David-Morrison G., Xu Z., Rui Y.N., Charng W.L., Jaiswal M., Yamamoto S., RA Xiong B., Zhang K., Sandoval H., Duraine L., Zuo Z., Zhang S., Bellen H.J.; RT "WAC regulates mTOR activity by acting as an adaptor for the TTT and RT Pontin/Reptin complexes."; RL Dev. Cell 36:139-151(2016). RN [83] RP SUBCELLULAR LOCATION. RX PubMed=27623384; DOI=10.1016/j.devcel.2016.08.001; RA Krishna S., Palm W., Lee Y., Yang W., Bandyopadhyay U., Xu H., Florey O., RA Thompson C.B., Overholtzer M.; RT "PIKfyve Regulates Vacuole Maturation and Nutrient Recovery following RT Engulfment."; RL Dev. Cell 38:536-547(2016). RN [84] RP INVOLVEMENT IN FCORD2, VARIANTS GLU-1376 AND VAL-2501, VARIANTS FCORD2 RP SER-1459; PRO-1460; PHE-2215 AND TYR-2215, AND VARIANTS SKS ARG-1490; RP ILE-1595; THR-1832; CYS-1888 AND ILE-2327. RX PubMed=27830187; DOI=10.1212/nxg.0000000000000118; RA Moeller R.S., Weckhuysen S., Chipaux M., Marsan E., Taly V., Bebin E.M., RA Hiatt S.M., Prokop J.W., Bowling K.M., Mei D., Conti V., de la Grange P., RA Ferrand-Sorbets S., Dorfmueller G., Lambrecq V., Larsen L.H., Leguern E., RA Guerrini R., Rubboli G., Cooper G.M., Baulac S.; RT "Germline and somatic mutations in the MTOR gene in focal cortical RT dysplasia and epilepsy."; RL Neurol. Genet. 2:E118-E118(2016). RN [85] RP FUNCTION. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [86] RP SUBCELLULAR LOCATION, AND INTERACTION WITH MEAK7. RX PubMed=29750193; DOI=10.1126/sciadv.aao5838; RA Nguyen J.T., Ray C., Fox A.L., Mendonca D.B., Kim J.K., Krebsbach P.H.; RT "Mammalian EAK-7 activates alternative mTOR signaling to regulate cell RT proliferation and migration."; RL Sci. Adv. 4:EAAO5838-EAAO5838(2018). RN [87] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-2159, AND MUTAGENESIS RP OF SER-2159. RX PubMed=29150432; DOI=10.15252/embj.201696164; RA Bodur C., Kazyken D., Huang K., Ekim Ustunel B., Siroky K.A., Tooley A.S., RA Gonzalez I.E., Foley D.H., Acosta-Jaquez H.A., Barnes T.M., Steinl G.K., RA Cho K.W., Lumeng C.N., Riddle S.M., Myers M.G. Jr., Fingar D.C.; RT "The IKK-related kinase TBK1 activates mTORC1 directly in response to RT growth factors and innate immune agonists."; RL EMBO J. 37:19-38(2018). RN [88] RP INTERACTION WITH TM4SF5, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-2357 RP AND VAL-2364. RX PubMed=30956113; DOI=10.1016/j.cmet.2019.03.005; RA Jung J.W., Macalino S.J.Y., Cui M., Kim J.E., Kim H.J., Song D.G., RA Nam S.H., Kim S., Choi S., Lee J.W.; RT "Transmembrane 4 L six family member 5 senses arginine for mTORC1 RT signaling."; RL Cell Metab. 29:1306-1319(2019). RN [89] RP FUNCTION. RX PubMed=30704899; DOI=10.1016/j.molcel.2018.12.017; RA Cheng X., Ma X., Zhu Q., Song D., Ding X., Li L., Jiang X., Wang X., RA Tian R., Su H., Shen Z., Chen S., Liu T., Gong W., Liu W., Sun Q.; RT "Pacer is a mediator of mTORC1 and GSK3-TIP60 signaling in regulation of RT autophagosome maturation and lipid metabolism."; RL Mol. Cell 73:1-15(2019). RN [90] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=31112131; DOI=10.7554/elife.43038; RA Jewell J.L., Fu V., Hong A.W., Yu F.X., Meng D., Melick C.H., Wang H., RA Lam W.M., Yuan H.X., Taylor S.S., Guan K.L.; RT "GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor."; RL Elife 8:0-0(2019). RN [91] RP FUNCTION. RX PubMed=31695197; DOI=10.1038/s41586-019-1738-6; RA MacVicar T., Ohba Y., Nolte H., Mayer F.C., Tatsuta T., Sprenger H.G., RA Lindner B., Zhao Y., Li J., Bruns C., Krueger M., Habich M., Riemer J., RA Schwarzer R., Pasparakis M., Henschke S., Bruening J.C., Zamboni N., RA Langer T.; RT "Lipid signalling drives proteolytic rewiring of mitochondria by YME1L."; RL Nature 575:361-365(2019). RN [92] RP INTERACTION WITH GPR137B. RX PubMed=31036939; DOI=10.1038/s41556-019-0321-6; RA Gan L., Seki A., Shen K., Iyer H., Han K., Hayer A., Wollman R., Ge X., RA Lin J.R., Dey G., Talbot W.S., Meyer T.; RT "The lysosomal GPCR-like protein GPR137B regulates Rag and mTORC1 RT localization and activity."; RL Nat. Cell Biol. 21:614-626(2019). RN [93] RP FUNCTION. RX PubMed=31601708; DOI=10.1126/science.aay0166; RA Rogala K.B., Gu X., Kedir J.F., Abu-Remaileh M., Bianchi L.F., RA Bottino A.M.S., Dueholm R., Niehaus A., Overwijn D., Fils A.P., Zhou S.X., RA Leary D., Laqtom N.N., Brignole E.J., Sabatini D.M.; RT "Structural basis for the docking of mTORC1 on the lysosomal surface."; RL Science 366:468-475(2019). RN [94] RP INTERACTION WITH RICTOR. RX PubMed=33378666; DOI=10.1016/j.celrep.2020.108564; RA Wrobel L., Siddiqi F.H., Hill S.M., Son S.M., Karabiyik C., Kim H., RA Rubinsztein D.C.; RT "mTORC2 Assembly Is Regulated by USP9X-Mediated Deubiquitination of RT RICTOR."; RL Cell Rep. 33:108564-108564(2020). RN [95] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=32612235; DOI=10.1038/s41586-020-2444-0; RA Napolitano G., Di Malta C., Esposito A., de Araujo M.E.G., Pece S., RA Bertalot G., Matarese M., Benedetti V., Zampelli A., Stasyk T., RA Siciliano D., Venuta A., Cesana M., Vilardo C., Nusco E., Monfregola J., RA Calcagni A., Di Fiore P.P., Huber L.A., Ballabio A.; RT "A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dube syndrome."; RL Nature 585:597-602(2020). RN [96] RP FUNCTION. RX PubMed=32561715; DOI=10.1038/s41467-020-16886-2; RA Son S.M., Park S.J., Stamatakou E., Vicinanza M., Menzies F.M., RA Rubinsztein D.C.; RT "Leucine regulates autophagy via acetylation of the mTORC1 component RT raptor."; RL Nat. Commun. 11:3148-3148(2020). RN [97] RP INTERACTION WITH NCKAP1L. RX PubMed=32647003; DOI=10.1126/science.aay5663; RA Cook S.A., Comrie W.A., Poli M.C., Similuk M., Oler A.J., Faruqi A.J., RA Kuhns D.B., Yang S., Vargas-Hernandez A., Carisey A.F., Fournier B., RA Anderson D.E., Price S., Smelkinson M., Abou Chahla W., Forbes L.R., RA Mace E.M., Cao T.N., Coban-Akdemir Z.H., Jhangiani S.N., Muzny D.M., RA Gibbs R.A., Lupski J.R., Orange J.S., Cuvelier G.D.E., Al Hassani M., RA Al Kaabi N., Al Yafei Z., Jyonouchi S., Raje N., Caldwell J.W., Huang Y., RA Burkhardt J.K., Latour S., Chen B., ElGhazali G., Rao V.K., Chinn I.K., RA Lenardo M.J.; RT "HEM1 deficiency disrupts mTORC2 and F-actin control in inherited RT immunodysregulatory disease."; RL Science 369:202-207(2020). RN [98] RP FUNCTION. RX PubMed=34289345; DOI=10.1016/j.cell.2021.06.028; RA Evavold C.L., Hafner-Bratkovic I., Devant P., D'Andrea J.M., Ngwa E.M., RA Borsic E., Doench J.G., LaFleur M.W., Sharpe A.H., Thiagarajah J.R., RA Kagan J.C.; RT "Control of gasdermin D oligomerization and pyroptosis by the Ragulator- RT Rag-mTORC1 pathway."; RL Cell 184:4495-4511(2021). RN [99] RP INTERACTION WITH SLC38A7. RX PubMed=35561222; DOI=10.1073/pnas.2123261119; RA Meng D., Yang Q., Jeong M.H., Curukovic A., Tiwary S., Melick C.H., RA Lama-Sherpa T.D., Wang H., Huerta-Rosario M., Urquhart G., Zacharias L.G., RA Lewis C., DeBerardinis R.J., Jewell J.L.; RT "SNAT7 regulates mTORC1 via macropinocytosis."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2123261119-e2123261119(2022). RN [100] RP INTERACTION WITH TSPAN8. RX PubMed=35904232; DOI=10.1002/cbin.11870; RA Zhuang L., Jin G., Hu X., Yang Q., Pei X., Zhao W.; RT "TSPAN8 alleviates high glucose-induced apoptosis and autophagy via RT targeting mTORC2."; RL Cell Biol. Int. 46:1693-1703(2022). RN [101] RP FUNCTION. RX PubMed=36691768; DOI=10.15252/embj.2022112344; RA Shetty S., Hofstetter J., Battaglioni S., Ritz D., Hall M.N.; RT "TORC1 phosphorylates and inhibits the ribosome preservation factor Stm1 to RT activate dormant ribosomes."; RL EMBO J. 42:e112344-e112344(2023). RN [102] RP SUBCELLULAR LOCATION. RX PubMed=37057673; DOI=10.1016/j.gim.2023.100838; RA Reijnders M.R.F., Seibt A., Brugger M., Lamers I.J.C., Ott T., Klaas O., RA Horvath J., Rose A.M.S., Craghill I.M., Brunet T., Graf E., Mayerhanser K., RA Hellebrekers D., Pauck D., Neuen-Jacob E., Rodenburg R.J.T., Wieczorek D., RA Klee D., Mayatepek E., Driessen G., Bindermann R., Averdunk L., RA Lohmeier K., Sinnema M., Stegmann A.P.A., Roepman R., Poulter J.A., RA Distelmaier F.; RT "De novo missense variants in RRAGC lead to a fatal mTORopathy of early RT childhood."; RL Genet. Med. 25:100838-100838(2023). RN [103] RP FUNCTION. RX PubMed=36608670; DOI=10.1016/j.molcel.2022.12.013; RA Nardone C., Palanski B.A., Scott D.C., Timms R.T., Barber K.W., Gu X., RA Mao A., Leng Y., Watson E.V., Schulman B.A., Cole P.A., Elledge S.J.; RT "A central role for regulated protein stability in the control of TFE3 and RT MITF by nutrients."; RL Mol. Cell 83:57-73(2023). RN [104] RP FUNCTION, UBIQUITINATION AT LYS-2066, AND MUTAGENESIS OF LYS-2066. RX PubMed=37979583; DOI=10.1016/j.cmet.2023.10.016; RA Ge M.K., Zhang C., Zhang N., He P., Cai H.Y., Li S., Wu S., Chu X.L., RA Zhang Y.X., Ma H.M., Xia L., Yang S., Yu J.X., Yao S.Y., Zhou X.L., Su B., RA Chen G.Q., Shen S.M.; RT "The tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino acid RT insufficiency."; RL Cell Metab. 35:2216-2230.e8(2023). RN [105] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37751742; DOI=10.1016/j.molcel.2023.08.032; RA He L., Chen J., Deng P., Huang S., Liu P., Wang C., Huang X., Li Y., RA Chen B., Shi D., Xiao Y., Chen X., Ouyang Y., Song L., Lin C.; RT "Lysosomal cyst(e)ine storage potentiates tolerance to oxidative stress in RT cancer cells."; RL Mol. Cell 83:3502-3519(2023). RN [106] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=8662507; DOI=10.1126/science.273.5272.239; RA Choi J., Chen J., Schreiber S.L., Clardy J.; RT "Structure of the FKBP12-rapamycin complex interacting with the binding RT domain of human FRAP."; RL Science 273:239-242(1996). RN [107] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=10089303; DOI=10.1107/s0907444998014747; RA Liang J., Choi J., Clardy J.; RT "Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A RT resolution."; RL Acta Crystallogr. D 55:736-744(1999). RN [108] RP 3D-STRUCTURE MODELING, HEAT-REPEATS, AND TPR-REPEATS. RX PubMed=20060908; DOI=10.1016/j.jsb.2010.01.002; RA Knutson B.A.; RT "Insights into the domain and repeat architecture of target of rapamycin."; RL J. Struct. Biol. 170:354-363(2010). RN [109] RP STRUCTURE BY ELECTRON MICROSCOPY (26 ANGSTROMS) OF MTORC1 COMPLEX, AND RP SUBUNIT. RX PubMed=20542007; DOI=10.1016/j.molcel.2010.05.017; RA Yip C.K., Murata K., Walz T., Sabatini D.M., Kang S.A.; RT "Structure of the human mTOR complex I and its implications for rapamycin RT inhibition."; RL Mol. Cell 38:768-774(2010). RN [110] RP X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 1376-2549 IN COMPLEX WITH MLST8, RP SUBUNIT, TPR-REPEATS, DOMAINS, AND MUTAGENESIS OF HIS-2340. RX PubMed=23636326; DOI=10.1038/nature12122; RA Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P.; RT "mTOR kinase structure, mechanism and regulation."; RL Nature 497:217-223(2013). RN [111] {ECO:0007744|PDB:5H64} RP STRUCTURE BY ELECTRON MICROSCOPY (4.40 ANGSTROMS) IN COMPLEX WITH RPTOR AND RP MLST8, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=27909983; DOI=10.1007/s13238-016-0346-6; RA Yang H., Wang J., Liu M., Chen X., Huang M., Tan D., Dong M.Q., Wong C.C., RA Wang J., Xu Y., Wang H.W.; RT "4.4 Aa Resolution Cryo-EM structure of human mTOR Complex 1."; RL Protein Cell 7:878-887(2016). RN [112] {ECO:0007744|PDB:5FLC} RP STRUCTURE BY ELECTRON MICROSCOPY (5.90 ANGSTROMS) IN COMPLEX WITH MLST8. RX PubMed=26678875; DOI=10.1126/science.aaa3870; RA Aylett C.H., Sauer E., Imseng S., Boehringer D., Hall M.N., Ban N., RA Maier T.; RT "Architecture of human mTOR complex 1."; RL Science 351:48-52(2016). RN [113] {ECO:0007744|PDB:5WBH, ECO:0007744|PDB:5WBU, ECO:0007744|PDB:5WBY, ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX} RP STRUCTURE BY ELECTRON MICROSCOPY (3.43 ANGSTROMS) IN COMPLEX WITH ATP; RP MAGNESIUM; MLST8; RPTOR; RHEB; AKT1S1; RPS6KB1 AND EIF4EBP1, FUNCTION, RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 RP COMPLEX. RX PubMed=29236692; DOI=10.1038/nature25023; RA Yang H., Jiang X., Li B., Yang H.J., Miller M., Yang A., Dhar A., RA Pavletich N.P.; RT "Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40."; RL Nature 552:368-373(2017). RN [114] {ECO:0007744|PDB:5ZCS} RP STRUCTURE BY ELECTRON MICROSCOPY (4.90 ANGSTROMS) OF THE MTORC2 COMPLEX, RP AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=29567957; DOI=10.1038/s41422-018-0029-3; RA Chen X., Liu M., Tian Y., Li J., Qi Y., Zhao D., Wu Z., Huang M., RA Wong C.C.L., Wang H.W., Wang J., Yang H., Xu Y.; RT "Cryo-EM structure of human mTOR complex 2."; RL Cell Res. 28:518-528(2018). RN [115] RP STRUCTURE BY ELECTRON MICROSCOPY OF THE MTORC2 COMPLEX, AND IDENTIFICATION RP IN THE MTORC2 COMPLEX. RX PubMed=29424687; DOI=10.7554/elife.33101; RA Stuttfeld E., Aylett C.H., Imseng S., Boehringer D., Scaiola A., Sauer E., RA Hall M.N., Maier T., Ban N.; RT "Architecture of the human mTORC2 core complex."; RL Elife 7:0-0(2018). RN [116] {ECO:0007744|PDB:6SB0, ECO:0007744|PDB:6SB2} RP STRUCTURE BY ELECTRON MICROSCOPY (5.50 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; RPTOR; MLST8 AND AKT1S1, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP SUBCELLULAR LOCATION. RX PubMed=31601764; DOI=10.1126/science.aax3939; RA Anandapadamanaban M., Masson G.R., Perisic O., Berndt A., Kaufman J., RA Johnson C.M., Santhanam B., Rogala K.B., Sabatini D.M., Williams R.L.; RT "Architecture of human Rag GTPase heterodimers and their complex with RT mTORC1."; RL Science 366:203-210(2019). RN [117] {ECO:0007744|PDB:6ZWM, ECO:0007744|PDB:6ZWO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) OF THE MTORC2 COMPLEX IN RP COMPLEX WITH 1D-MYO-INOSITOL HEXAKISPHOSPHATE, AND IDENTIFICATION IN THE RP MTORC2 COMPLEX. RX PubMed=33158864; DOI=10.1126/sciadv.abc1251; RA Scaiola A., Mangia F., Imseng S., Boehringer D., Berneiser K., RA Shimobayashi M., Stuttfeld E., Hall M.N., Ban N., Maier T.; RT "The 3.2-Aa resolution structure of human mTORC2."; RL Sci. Adv. 6:0-0(2020). RN [118] {ECO:0007744|PDB:7PE7, ECO:0007744|PDB:7PE8, ECO:0007744|PDB:7PE9, ECO:0007744|PDB:7PEA, ECO:0007744|PDB:7PEB, ECO:0007744|PDB:7PEC} RP X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 1-230 IN COMPLEX WITH DEPTOR; RP MLST8; MAPKAP1; RICTOR AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN RP THE MTORC1 COMPLEX, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=34519268; DOI=10.7554/elife.70871; RA Waelchli M., Berneiser K., Mangia F., Imseng S., Craigie L.M., RA Stuttfeld E., Hall M.N., Maier T.; RT "Regulation of human mTOR complexes by DEPTOR."; RL Elife 10:0-0(2021). RN [119] {ECO:0007744|PDB:7OWG} RP STRUCTURE BY ELECTRON MICROSCOPY (4.70 ANGSTROMS) IN COMPLEX WITH DEPTOR; RP MLST8 AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN THE MTORC1 COMPLEX, RP AND FUNCTION. RX PubMed=34519269; DOI=10.7554/elife.68799; RA Heimhalt M., Berndt A., Wagstaff J., Anandapadamanaban M., Perisic O., RA Maslen S., McLaughlin S., Yu C.W., Masson G.R., Boland A., Ni X., RA Yamashita K., Murshudov G.N., Skehel M., Freund S.M., Williams R.L.; RT "Bipartite binding and partial inhibition links DEPTOR and mTOR in a RT mutually antagonistic embrace."; RL Elife 10:0-0(2021). RN [120] {ECO:0007744|PDB:7TZO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.28 ANGSTROMS) OF THE MTORC2 COMPLEX, RP FUNCTION, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=35926713; DOI=10.1016/j.jbc.2022.102288; RA Yu Z., Chen J., Takagi E., Wang F., Saha B., Liu X., Joubert L.M., RA Gleason C.E., Jin M., Li C., Nowotny C., Agard D., Cheng Y., Pearce D.; RT "Interactions between mTORC2 core subunits Rictor and mSin1 dictate RT selective and context-dependent phosphorylation of substrate kinases SGK1 RT and Akt."; RL J. Biol. Chem. 298:102288-102288(2022). RN [121] {ECO:0007744|PDB:7UXC, ECO:0007744|PDB:7UXH} RP STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; LAMTOR1; LAMTOR2; LAMTOR3; LAMTOR4; LAMTOR5; RPTOR; MLST8 AND TFEB, RP FUNCTION, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=36697823; DOI=10.1038/s41586-022-05652-7; RA Cui Z., Napolitano G., de Araujo M.E.G., Esposito A., Monfregola J., RA Huber L.A., Ballabio A., Hurley J.H.; RT "Structure of the lysosomal mTORC1-TFEB-Rag-Ragulator megacomplex."; RL Nature 614:572-579(2023). RN [122] RP VARIANTS [LARGE SCALE ANALYSIS] SER-8; THR-135; VAL-1083; VAL-1134; RP PHE-1178; VAL-2011; TYR-2215 AND LEU-2476. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [123] RP VARIANTS PHE-2220 AND ALA-2406. RX PubMed=21248752; DOI=10.1038/nature09639; RA Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., RA Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., RA Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., RA Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., RA Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J., RA Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., RA Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K., RA Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.; RT "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene RT PBRM1 in renal carcinoma."; RL Nature 469:539-542(2011). CC -!- FUNCTION: Serine/threonine protein kinase which is a central regulator CC of cellular metabolism, growth and survival in response to hormones, CC growth factors, nutrients, energy and stress signals (PubMed:12087098, CC PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, CC PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, CC PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, CC PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, CC PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, CC PubMed:29236692, PubMed:31112131, PubMed:31601708, PubMed:32561715, CC PubMed:34519269, PubMed:37751742). MTOR directly or indirectly CC regulates the phosphorylation of at least 800 proteins CC (PubMed:15268862, PubMed:15467718, PubMed:17517883, PubMed:18372248, CC PubMed:18497260, PubMed:18925875, PubMed:20516213, PubMed:21576368, CC PubMed:21659604, PubMed:23429704, PubMed:30171069, PubMed:29236692, CC PubMed:37751742). Functions as part of 2 structurally and functionally CC distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) CC (PubMed:15268862, PubMed:15467718, PubMed:18497260, PubMed:18925875, CC PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704, CC PubMed:29424687, PubMed:29567957, PubMed:35926713). In response to CC nutrients, growth factors or amino acids, mTORC1 is recruited to the CC lysosome membrane and promotes protein, lipid and nucleotide synthesis CC by phosphorylating key regulators of mRNA translation and ribosome CC synthesis (PubMed:12087098, PubMed:12150925, PubMed:12150926, CC PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, CC PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, CC PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, CC PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, CC PubMed:26018084, PubMed:29150432, PubMed:29236692, PubMed:31112131, CC PubMed:34519269). This includes phosphorylation of EIF4EBP1 and release CC of its inhibition toward the elongation initiation factor 4E (eiF4E) CC (PubMed:24403073, PubMed:29236692). Moreover, phosphorylates and CC activates RPS6KB1 and RPS6KB2 that promote protein synthesis by CC modulating the activity of their downstream targets including ribosomal CC protein S6, eukaryotic translation initiation factor EIF4B, and the CC inhibitor of translation initiation PDCD4 (PubMed:12087098, CC PubMed:12150925, PubMed:18925875, PubMed:29150432, PubMed:29236692). CC Stimulates the pyrimidine biosynthesis pathway, both by acute CC regulation through RPS6KB1-mediated phosphorylation of the biosynthetic CC enzyme CAD, and delayed regulation, through transcriptional enhancement CC of the pentose phosphate pathway which produces 5-phosphoribosyl-1- CC pyrophosphate (PRPP), an allosteric activator of CAD at a later step in CC synthesis, this function is dependent on the mTORC1 complex CC (PubMed:23429703, PubMed:23429704). Regulates ribosome synthesis by CC activating RNA polymerase III-dependent transcription through CC phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor CC (PubMed:20516213). Activates dormant ribosomes by mediating CC phosphorylation of SERBP1, leading to SERBP1 inactivation and CC reactivation of translation (PubMed:36691768). In parallel to protein CC synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and CC LPIN1 (PubMed:23426360). To maintain energy homeostasis mTORC1 may also CC regulate mitochondrial biogenesis through regulation of PPARGC1A (By CC similarity). In the same time, mTORC1 inhibits catabolic pathways: CC negatively regulates autophagy through phosphorylation of ULK1 CC (PubMed:32561715). Under nutrient sufficiency, phosphorylates ULK1 at CC 'Ser-758', disrupting the interaction with AMPK and preventing CC activation of ULK1 (PubMed:32561715). Also prevents autophagy through CC phosphorylation of the autophagy inhibitor DAP (PubMed:20537536). Also CC prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich CC conditions (PubMed:30704899). Prevents autophagy by mediating CC phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate CC ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA CC (PubMed:23524951, PubMed:25438055). mTORC1 exerts a feedback control on CC upstream growth factor signaling that includes phosphorylation and CC activation of GRB10 a INSR-dependent signaling suppressor CC (PubMed:21659604). Among other potential targets mTORC1 may CC phosphorylate CLIP1 and regulate microtubules (PubMed:12231510). The CC mTORC1 complex is inhibited in response to starvation and amino acid CC depletion (PubMed:12150925, PubMed:12150926, PubMed:24403073, CC PubMed:31695197). The non-canonical mTORC1 complex, which acts CC independently of RHEB, specifically mediates phosphorylation of MiT/TFE CC factors MITF, TFEB and TFE3 in the presence of nutrients, promoting CC their cytosolic retention and inactivation (PubMed:22343943, CC PubMed:22576015, PubMed:22692423, PubMed:24448649, PubMed:32612235, CC PubMed:36608670, PubMed:36697823). Upon starvation or lysosomal stress, CC inhibition of mTORC1 induces dephosphorylation and nuclear CC translocation of TFEB and TFE3, promoting their transcription factor CC activity (PubMed:22343943, PubMed:22576015, PubMed:22692423, CC PubMed:24448649, PubMed:32612235, PubMed:36608670). The mTORC1 complex CC regulates pyroptosis in macrophages by promoting GSDMD oligomerization CC (PubMed:34289345). MTOR phosphorylates RPTOR which in turn inhibits CC mTORC1 (By similarity). As part of the mTORC2 complex, MTOR transduces CC signals from growth factors to pathways involved in proliferation, CC cytoskeletal organization, lipogenesis and anabolic output CC (PubMed:15268862, PubMed:15467718, PubMed:24670654, PubMed:29424687, CC PubMed:29567957, PubMed:35926713). In response to growth factors, CC mTORC2 phosphorylates and activates AGC protein kinase family members, CC including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and CC SGK1 (PubMed:15268862, PubMed:15467718, PubMed:21376236, CC PubMed:24670654, PubMed:29424687, PubMed:29567957, PubMed:35926713). In CC contrast to mTORC1, mTORC2 is nutrient-insensitive (PubMed:15467718). CC mTORC2 plays a critical role in AKT1 activation by mediating CC phosphorylation of different sites depending on the context, such as CC 'Thr-450', 'Ser-473', 'Ser-477' or 'Thr-479', facilitating the CC phosphorylation of the activation loop of AKT1 on 'Thr-308' by CC PDPK1/PDK1 which is a prerequisite for full activation CC (PubMed:15718470, PubMed:21376236, PubMed:24670654, PubMed:29424687, CC PubMed:29567957). mTORC2 also regulates the phosphorylation of SGK1 at CC 'Ser-422' (PubMed:18925875). mTORC2 may regulate the actin CC cytoskeleton, through phosphorylation of PRKCA, PXN and activation of CC the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or CC RAC1B (PubMed:15268862). The mTORC2 complex also phosphorylates various CC proteins involved in insulin signaling, such as FBXW8 and IGF2BP1 (By CC similarity). May also regulate insulin signaling by acting as a CC tyrosine protein kinase that catalyzes phosphorylation of IGF1R and CC INSR; additional evidence are however required to confirm this result CC in vivo (PubMed:26584640). Regulates osteoclastogenesis by adjusting CC the expression of CEBPB isoforms (By similarity). Plays an important CC regulatory role in the circadian clock function; regulates period CC length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and CC liver clocks (By similarity). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12150926, ECO:0000269|PubMed:12231510, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15545625, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:18762023, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, CC ECO:0000269|PubMed:22692423, ECO:0000269|PubMed:23426360, CC ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:23429704, CC ECO:0000269|PubMed:23524951, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:24448649, ECO:0000269|PubMed:24670654, CC ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25799227, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:29424687, ECO:0000269|PubMed:29567957, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30704899, CC ECO:0000269|PubMed:31112131, ECO:0000269|PubMed:31601708, CC ECO:0000269|PubMed:31695197, ECO:0000269|PubMed:32561715, CC ECO:0000269|PubMed:32612235, ECO:0000269|PubMed:34289345, CC ECO:0000269|PubMed:34519269, ECO:0000269|PubMed:35926713, CC ECO:0000269|PubMed:36608670, ECO:0000269|PubMed:36691768, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:37751742}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:20516213, ECO:0000269|PubMed:20537536, CC ECO:0000269|PubMed:21659604, ECO:0000269|PubMed:22343943, CC ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423, CC ECO:0000269|PubMed:29150432}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:37751742}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000305|PubMed:26584640}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10597; CC Evidence={ECO:0000305|PubMed:26584640}; CC -!- ACTIVITY REGULATION: The mTORC1 complex is activated in response to CC nutrients, growth factors or amino acids: activation requires CC relocalization of the mTORC1 complex to lysosomes that is mediated by CC the Ragulator complex, SLC38A9, and the Rag GTPases RagA/RRAGA, CC RagB/RRAGB, RagC/RRAGC and RagD/RRAGD (PubMed:18497260, CC PubMed:20381137, PubMed:25561175, PubMed:25567906). Activation of CC mTORC1 by growth factors such as insulin involves AKT1-mediated CC phosphorylation of TSC1-TSC2, which leads to the activation of the RHEB CC GTPase a potent activator of the protein kinase activity of mTORC1 CC (PubMed:14651849, PubMed:15545625, PubMed:29236692). Insulin-stimulated CC and amino acid-dependent phosphorylation at Ser-1261 promotes CC autophosphorylation and the activation of mTORC1 (PubMed:19487463). On CC the other hand, low cellular energy levels can inhibit mTORC1 through CC activation of PRKAA1 while hypoxia inhibits mTORC1 through a REDD1- CC dependent mechanism which may also require PRKAA1 (PubMed:14651849, CC PubMed:15545625). The kinase activity of MTOR within the mTORC1 complex CC is positively regulated by MLST8 (PubMed:12718876). The kinase activity CC of MTOR is inhibited by DEPTOR and AKT1S1 (PubMed:17386266, CC PubMed:19446321, PubMed:29236692, PubMed:34519268, PubMed:34519269). CC The non-canonical mTORC1 complex is independent of the RHEB GTPase and CC specifically mediates phosphorylation of MiT/TFE factors TFEB and TFE3 CC but not other mTORC1 substrates: it is activated by FLCN, which CC activates Rag GTPases RagC/RRAGC and RagD/RRAGD (PubMed:32612235, CC PubMed:36697823). MTOR is the target of the immunosuppressive and anti- CC cancer drug rapamycin which acts in complex with FKBP1A/FKBP12, and CC specifically inhibits its kinase activity (PubMed:10089303, CC PubMed:8662507). mTORC2 is also activated by growth factors, but seems CC to be nutrient-insensitive (PubMed:15467718). mTORC2 associates and is CC directly activated by ribosomes (PubMed:21376236). mTORC2 may also be CC regulated by RHEB but in an indirect manner through the PI3K signaling CC pathway (PubMed:15467718). {ECO:0000269|PubMed:10089303, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15545625, CC ECO:0000269|PubMed:17386266, ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:19487463, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:25561175, ECO:0000269|PubMed:25567906, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:32612235, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:8662507}. CC -!- SUBUNIT: Part of the mechanistic target of rapamycin complex 1 (mTORC1) CC which contains MTOR, MLST8 and RPTOR (PubMed:12150925, PubMed:12150926, CC PubMed:12408816, PubMed:12718876, PubMed:18925875, PubMed:20542007, CC PubMed:23636326, PubMed:24403073, PubMed:26678875, PubMed:27909983, CC PubMed:29236692, PubMed:31601764, PubMed:34519268, PubMed:34519269, CC PubMed:36697823). The mTORC1 complex is a 1 Md obligate dimer of two CC stoichiometric heterotetramers with overall dimensions of 290 A x 210 A CC x 135 A (PubMed:20542007, PubMed:23636326). It has a rhomboid shape and CC a central cavity, the dimeric interfaces are formed by interlocking CC interactions between the two MTOR and the two RPTOR subunits CC (PubMed:20542007, PubMed:23636326, PubMed:27909983). The MLST8 subunit CC forms distal foot-like protuberances, and contacts only one MTOR within CC the complex, while the small AKT1S1/PRAS40 localizes to the midsection CC of the central core, in close proximity to RPTOR (PubMed:20542007, CC PubMed:23636326, PubMed:27909983, PubMed:29236692). mTORC1 associates CC with AKT1S1/PRAS40, which inhibits its activity by blocking MTOR CC substrate-recruitment site (PubMed:17386266, PubMed:29236692). CC Component of the mechanistic target of rapamycin complex 2 (mTORC2), CC consisting in two heterotretramers composed of MTOR, MLST8, RICTOR and CC MAPKAP1/SIN1 (PubMed:15268862, PubMed:15467718, PubMed:17599906, CC PubMed:18925875, PubMed:29424687, PubMed:29567957, PubMed:33158864, CC PubMed:35926713). Interacts with PLPP7 and PML (By similarity). CC Interacts with PRR5 and RICTOR; the interaction is direct within the CC mTORC2 complex and interaction with RICTOR is enhanced by CC deubiquitination of RICTOR by USP9X (PubMed:17599906, PubMed:33378666, CC PubMed:29424687, PubMed:34519268). mTORC1 and mTORC2 associate with CC DEPTOR, which regulates their activity (PubMed:19446321, CC PubMed:34519268, PubMed:34519269). Interacts with WAC; WAC positively CC regulates MTOR activity by promoting the assembly of the TTT complex CC composed of TELO2, TTI1 and TTI2 and the RUVBL complex composed of CC RUVBL1 and RUVBL2 into the TTT-RUVBL complex which leads to the CC dimerization of the mTORC1 complex and its subsequent activation CC (PubMed:26812014). Interacts with UBQLN1 (PubMed:11853878). Interacts CC with TTI1 and TELO2 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with CLIP1; phosphorylates and regulates CC CLIP1 (PubMed:12231510). Interacts with NBN (PubMed:23762398). CC Interacts with HTR6 (PubMed:23027611). Interacts with BRAT1 CC (PubMed:25657994). Interacts with MEAK7 (via C-terminal domain); the CC interaction increases upon nutrient stimulation (PubMed:29750193). CC Interacts with TM4SF5; the interaction is positively regulated by CC arginine and is negatively regulated by leucine (PubMed:30956113). CC Interacts with GPR137B (PubMed:31036939). Interacts with NCKAP1L CC (PubMed:32647003). Interacts with TPCN1 and TPCN2; the interaction is CC required for TPCN1 and TPCN2 sensitivity to ATP (PubMed:23394946). CC Interacts with ATP6V1A and with CRYAB, forming a ternary complex (By CC similarity). Interacts with SLC38A7; this interaction mediates the CC recruitment of mTORC1 to the lysosome and its subsequent activation CC (PubMed:35561222). Interacts with TSPAN8 (PubMed:35904232). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:11853878, CC ECO:0000269|PubMed:12150925, ECO:0000269|PubMed:12150926, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:12408816, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:17386266, CC ECO:0000269|PubMed:17599906, ECO:0000269|PubMed:18925875, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:20542007, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:23027611, CC ECO:0000269|PubMed:23394946, ECO:0000269|PubMed:23636326, CC ECO:0000269|PubMed:23762398, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:25657994, ECO:0000269|PubMed:26678875, CC ECO:0000269|PubMed:26812014, ECO:0000269|PubMed:27909983, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:29424687, CC ECO:0000269|PubMed:29567957, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31036939, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:32647003, CC ECO:0000269|PubMed:33158864, ECO:0000269|PubMed:33378666, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:35561222, ECO:0000269|PubMed:35904232, CC ECO:0000269|PubMed:35926713, ECO:0000269|PubMed:36697823}. CC -!- INTERACTION: CC P42345; P31749: AKT1; NbExp=6; IntAct=EBI-359260, EBI-296087; CC P42345; Q07817-1: BCL2L1; NbExp=4; IntAct=EBI-359260, EBI-287195; CC P42345; Q6UXB4: CLEC4G; NbExp=4; IntAct=EBI-359260, EBI-2114729; CC P42345; Q8TB45: DEPTOR; NbExp=5; IntAct=EBI-359260, EBI-2359040; CC P42345; Q13541: EIF4EBP1; NbExp=2; IntAct=EBI-359260, EBI-74090; CC P42345; Q969H0: FBXW7; NbExp=5; IntAct=EBI-359260, EBI-359574; CC P42345; P62942: FKBP1A; NbExp=5; IntAct=EBI-359260, EBI-1027571; CC P42345; P24522: GADD45A; NbExp=4; IntAct=EBI-359260, EBI-448167; CC P42345; Q8WUA4: GTF3C2; NbExp=3; IntAct=EBI-359260, EBI-1237062; CC P42345; Q9BVC4: MLST8; NbExp=7; IntAct=EBI-359260, EBI-1387471; CC P42345; Q9BVC4-1: MLST8; NbExp=7; IntAct=EBI-359260, EBI-16056342; CC P42345; Q13615: MTMR3; NbExp=3; IntAct=EBI-359260, EBI-371938; CC P42345; P42345: MTOR; NbExp=2; IntAct=EBI-359260, EBI-359260; CC P42345; Q9Y4G2: PLEKHM1; NbExp=6; IntAct=EBI-359260, EBI-473814; CC P42345; Q8TCU6: PREX1; NbExp=11; IntAct=EBI-359260, EBI-1046542; CC P42345; P62820: RAB1A; NbExp=4; IntAct=EBI-359260, EBI-716845; CC P42345; Q15382: RHEB; NbExp=4; IntAct=EBI-359260, EBI-1055287; CC P42345; Q6R327: RICTOR; NbExp=37; IntAct=EBI-359260, EBI-1387196; CC P42345; Q8N122: RPTOR; NbExp=48; IntAct=EBI-359260, EBI-1567928; CC P42345; Q96EB6: SIRT1; NbExp=2; IntAct=EBI-359260, EBI-1802965; CC P42345; O14894: TM4SF5; NbExp=7; IntAct=EBI-359260, EBI-19125949; CC P42345; Q92544: TM9SF4; NbExp=4; IntAct=EBI-359260, EBI-6138615; CC P42345; Q8NHX9: TPCN2; NbExp=2; IntAct=EBI-359260, EBI-5239949; CC P42345; O75385: ULK1; NbExp=7; IntAct=EBI-359260, EBI-908831; CC P42345; P63104: YWHAZ; NbExp=3; IntAct=EBI-359260, EBI-347088; CC -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:37057673}; Peripheral CC membrane protein {ECO:0000269|PubMed:30956113, CC ECO:0000269|PubMed:31112131}; Cytoplasmic side CC {ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:14578359}; Peripheral membrane CC protein {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Golgi apparatus membrane CC {ECO:0000269|PubMed:14578359}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Cell membrane CC {ECO:0000269|PubMed:21867682}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}. Mitochondrion outer membrane CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}; Peripheral CC membrane protein {ECO:0000269|PubMed:11930000, CC ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}. Cytoplasm CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:18497260}. Nucleus CC {ECO:0000250|UniProtKB:Q9JLN9}. Nucleus, PML body CC {ECO:0000250|UniProtKB:Q9JLN9}. Microsome membrane CC {ECO:0000269|PubMed:9434772}. Cytoplasmic vesicle, phagosome CC {ECO:0000269|PubMed:27623384}. Note=Shuttles between cytoplasm and CC nucleus. Accumulates in the nucleus in response to hypoxia (By CC similarity). Targeting to lysosomes depends on amino acid availability CC and RRAGA and RRAGB (PubMed:18497260, PubMed:20381137). Lysosome CC targeting also depends on interaction with MEAK7. Translocates to the CC lysosome membrane in the presence of TM4SF5 (PubMed:30956113). The CC mTORC2 complex localizes to membranes: mTORC2 is active at the plasma CC membrane, endoplasmic reticulum membrane and lysosomes CC (PubMed:21867682). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:20381137, CC ECO:0000269|PubMed:21867682, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113}. CC -!- TISSUE SPECIFICITY: Expressed in numerous tissues, with highest levels CC in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}. CC -!- DOMAIN: The kinase domain (PI3K/PI4K) is intrinsically active but has a CC highly restricted catalytic center. {ECO:0000269|PubMed:23636326}. CC -!- DOMAIN: The FAT domain forms three discontinuous subdomains of alpha- CC helical TPR repeats plus a single subdomain of HEAT repeats. The four CC domains pack sequentially to form a C-shaped a-solenoid that clamps CC onto the kinase domain (PubMed:23636326). CC {ECO:0000269|PubMed:23636326}. CC -!- PTM: Autophosphorylates when part of mTORC1 or mTORC2 (PubMed:15467718, CC PubMed:20022946, PubMed:9434772). Phosphorylation at Ser-1261, Ser-2159 CC and Thr-2164 promotes autophosphorylation (PubMed:19487463). CC Phosphorylated at Ser-2448 by RPS6KB1 (PubMed:15899889, CC PubMed:15905173, PubMed:19145465). Phosphorylation in the kinase domain CC modulates the interactions of MTOR with RPTOR and AKT1S1/PRAS40 and CC leads to increased intrinsic mTORC1 kinase activity (PubMed:15905173, CC PubMed:19145465, PubMed:21576368). Phosphorylation at Ser-2159 by TBK1 CC in response to growth factors and pathogen recognition receptors CC promotes mTORC1 activity (PubMed:29150432). Phosphorylation at Ser-2159 CC by TBK1 in response to EGF growth factor promotes mTORC2 activity, CC leading to AKT1 phosphorylation and activation (By similarity). CC Phosphorylation at Thr-2173 in the ATP-binding region by AKT1 strongly CC reduces kinase activity (PubMed:24247430). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, CC ECO:0000269|PubMed:19487463, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:24247430, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:9434772}. CC -!- PTM: Ubiquitinated at Lys-2066 by the SCF(FBXO22) complex via 'Lys-27'- CC linked ubiquitination prevents mTORC1 substrate recruitment. CC {ECO:0000269|PubMed:37979583}. CC -!- DISEASE: Smith-Kingsmore syndrome (SKS) [MIM:616638]: An autosomal CC dominant syndrome characterized by intellectual disability, CC macrocephaly, seizures, umbilical hernia, and facial dysmorphic CC features. {ECO:0000269|PubMed:25851998, ECO:0000269|PubMed:26542245, CC ECO:0000269|PubMed:27830187}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Focal cortical dysplasia 2 (FCORD2) [MIM:607341]: A form of CC focal cortical dysplasia, a malformation of cortical development that CC results in medically refractory epilepsy in the pediatric population CC and in adults. FCORD2 is a severe form, with onset usually in CC childhood, characterized by disrupted cortical lamination and specific CC cytological abnormalities. It is classified in 2 subtypes: type IIA CC characterized by dysmorphic neurons and lack of balloon cells; type IIB CC with dysmorphic neurons and balloon cells. CC {ECO:0000269|PubMed:25799227, ECO:0000269|PubMed:25878179, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC39933.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=BAE06077.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40639/FRAP1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Mammalian target of rapamycin entry; CC URL="https://en.wikipedia.org/wiki/Mammalian_target_of_rapamycin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L34075; AAA58486.1; -; mRNA. DR EMBL; U88966; AAC39933.1; ALT_FRAME; mRNA. DR EMBL; AB209995; BAE06077.1; ALT_INIT; mRNA. DR EMBL; AL109811; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391561; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL049653; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117166; AAI17167.1; -; mRNA. DR EMBL; AJ300188; CAC15570.1; -; Genomic_DNA. DR EMBL; L35478; AAC41713.1; -; mRNA. DR CCDS; CCDS127.1; -. DR PIR; S45340; S45340. DR RefSeq; NP_001373429.1; NM_001386500.1. DR RefSeq; NP_004949.1; NM_004958.4. DR PDB; 1AUE; X-ray; 2.33 A; A/B=2015-2114. DR PDB; 1FAP; X-ray; 2.70 A; B=2018-2112. DR PDB; 1NSG; X-ray; 2.20 A; B=2019-2112. DR PDB; 2FAP; X-ray; 2.20 A; B=2019-2112. DR PDB; 2GAQ; NMR; -; A=2015-2114. DR PDB; 2NPU; NMR; -; A=2015-2114. DR PDB; 2RSE; NMR; -; B=2019-2112. DR PDB; 3FAP; X-ray; 1.85 A; B=2019-2112. DR PDB; 3JBZ; EM; 28.00 A; A=1385-2549. DR PDB; 4DRH; X-ray; 2.30 A; B/E=2025-2114. DR PDB; 4DRI; X-ray; 1.45 A; B=2025-2114. DR PDB; 4DRJ; X-ray; 1.80 A; B=2025-2114. DR PDB; 4FAP; X-ray; 2.80 A; B=2019-2112. DR PDB; 4JSN; X-ray; 3.20 A; A/B=1376-2549. DR PDB; 4JSP; X-ray; 3.30 A; A/B=1376-2549. DR PDB; 4JSV; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JSX; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JT5; X-ray; 3.45 A; A/B=1376-2549. DR PDB; 4JT6; X-ray; 3.60 A; A/B=1376-2549. DR PDB; 5FLC; EM; 5.90 A; B/F=1382-2549. DR PDB; 5GPG; X-ray; 1.67 A; B=2021-2112. DR PDB; 5H64; EM; 4.40 A; A/a=1-2549. DR PDB; 5WBH; X-ray; 1.75 A; A/B/C/D/E=2018-2114. DR PDB; 5WBU; X-ray; 3.42 A; A/B=1376-2549. DR PDB; 5WBY; X-ray; 3.10 A; A/B=1376-2549. DR PDB; 5ZCS; EM; 4.90 A; A/B=1-2549. DR PDB; 6BCU; EM; 3.43 A; A/B=1-2549. DR PDB; 6BCX; EM; 3.00 A; A/B=1-2549. DR PDB; 6M4U; X-ray; 2.20 A; B/F=2021-2113. DR PDB; 6M4W; X-ray; 3.11 A; G/H/I=2021-2113. DR PDB; 6SB0; EM; 5.50 A; A/B=60-2549. DR PDB; 6SB2; EM; 6.20 A; A/B=54-2549. DR PDB; 6ZWM; EM; 3.20 A; A/B=1-2549. DR PDB; 6ZWO; EM; 3.00 A; B=1-2549. DR PDB; 7EPD; EM; 3.90 A; B=2019-2114. DR PDB; 7OWG; EM; 4.70 A; B=1-2549. DR PDB; 7PE7; EM; 3.41 A; A/B=1-2549. DR PDB; 7PE8; EM; 3.20 A; A=1-2549. DR PDB; 7PE9; EM; 3.70 A; A=1-2549. DR PDB; 7PEA; EM; 4.07 A; A/B=1-2549. DR PDB; 7PEB; EM; 3.67 A; A=1-2549. DR PDB; 7PEC; EM; 4.24 A; A=1-2549. DR PDB; 7TZO; EM; 3.28 A; A/B=1-2549. DR PDB; 7UXC; EM; 3.20 A; A=1-2549. DR PDB; 7UXH; EM; 3.20 A; A/C=1-2549. DR PDB; 8ER6; X-ray; 2.81 A; B/D/F=2019-2112. DR PDB; 8ER7; X-ray; 3.07 A; B/D/F=2019-2112. DR PDB; 8ERA; EM; 2.86 A; A=1-2549. DR PDB; 8PPZ; X-ray; 1.85 A; B=2025-2114. DR PDB; 8RCH; EM; 4.00 A; A/B=1-2549. DR PDB; 8RCK; EM; 3.40 A; B=1-2549. DR PDB; 8RCN; EM; 3.10 A; B=1-2549. DR PDB; 9F44; EM; 3.68 A; A/B=1-2549. DR PDB; 9F45; EM; 3.74 A; A/B=1-2549. DR PDBsum; 1AUE; -. DR PDBsum; 1FAP; -. DR PDBsum; 1NSG; -. DR PDBsum; 2FAP; -. DR PDBsum; 2GAQ; -. DR PDBsum; 2NPU; -. DR PDBsum; 2RSE; -. DR PDBsum; 3FAP; -. DR PDBsum; 3JBZ; -. DR PDBsum; 4DRH; -. DR PDBsum; 4DRI; -. DR PDBsum; 4DRJ; -. DR PDBsum; 4FAP; -. DR PDBsum; 4JSN; -. DR PDBsum; 4JSP; -. DR PDBsum; 4JSV; -. DR PDBsum; 4JSX; -. DR PDBsum; 4JT5; -. DR PDBsum; 4JT6; -. DR PDBsum; 5FLC; -. DR PDBsum; 5GPG; -. DR PDBsum; 5H64; -. DR PDBsum; 5WBH; -. DR PDBsum; 5WBU; -. DR PDBsum; 5WBY; -. DR PDBsum; 5ZCS; -. DR PDBsum; 6BCU; -. DR PDBsum; 6BCX; -. DR PDBsum; 6M4U; -. DR PDBsum; 6M4W; -. DR PDBsum; 6SB0; -. DR PDBsum; 6SB2; -. DR PDBsum; 6ZWM; -. DR PDBsum; 6ZWO; -. DR PDBsum; 7EPD; -. DR PDBsum; 7OWG; -. DR PDBsum; 7PE7; -. DR PDBsum; 7PE8; -. DR PDBsum; 7PE9; -. DR PDBsum; 7PEA; -. DR PDBsum; 7PEB; -. DR PDBsum; 7PEC; -. DR PDBsum; 7TZO; -. DR PDBsum; 7UXC; -. DR PDBsum; 7UXH; -. DR PDBsum; 8ER6; -. DR PDBsum; 8ER7; -. DR PDBsum; 8ERA; -. DR PDBsum; 8PPZ; -. DR PDBsum; 8RCH; -. DR PDBsum; 8RCK; -. DR PDBsum; 8RCN; -. DR PDBsum; 9F44; -. DR PDBsum; 9F45; -. DR AlphaFoldDB; P42345; -. DR BMRB; P42345; -. DR EMDB; EMD-10132; -. DR EMDB; EMD-10133; -. DR EMDB; EMD-11488; -. DR EMDB; EMD-11489; -. DR EMDB; EMD-11490; -. DR EMDB; EMD-11491; -. DR EMDB; EMD-11492; -. DR EMDB; EMD-13097; -. DR EMDB; EMD-13347; -. DR EMDB; EMD-13348; -. DR EMDB; EMD-13349; -. DR EMDB; EMD-13350; -. DR EMDB; EMD-13351; -. DR EMDB; EMD-13352; -. DR EMDB; EMD-19052; -. DR EMDB; EMD-19053; -. DR EMDB; EMD-19056; -. DR EMDB; EMD-26213; -. DR EMDB; EMD-26857; -. DR EMDB; EMD-26861; -. DR EMDB; EMD-28551; -. DR EMDB; EMD-3212; -. DR EMDB; EMD-3213; -. DR EMDB; EMD-50183; -. DR EMDB; EMD-50184; -. DR EMDB; EMD-6668; -. DR EMDB; EMD-6913; -. DR EMDB; EMD-7086; -. DR EMDB; EMD-7087; -. DR SMR; P42345; -. DR BioGRID; 108757; 392. DR ComplexPortal; CPX-4402; mTORC2 complex. DR ComplexPortal; CPX-503; mTORC1 complex. DR CORUM; P42345; -. DR DIP; DIP-790N; -. DR FunCoup; P42345; 4303. DR IntAct; P42345; 203. DR MINT; P42345; -. DR STRING; 9606.ENSP00000354558; -. DR BindingDB; P42345; -. DR ChEMBL; CHEMBL2842; -. DR DrugBank; DB12180; Apitolisib. DR DrugBank; DB12774; AZD-8055. DR DrugBank; DB14846; Bimiralisib. DR DrugBank; DB11651; Dactolisib. DR DrugBank; DB01590; Everolimus. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB13072; GDC-0349. DR DrugBank; DB11896; Gedatolisib. DR DrugBank; DB11978; Glasdegib. DR DrugBank; DB11962; GSK-1059615. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB13062; ME-344. DR DrugBank; DB19085; Novolimus. DR DrugBank; DB12843; Oleandrin. DR DrugBank; DB12570; Onatasertib. DR DrugBank; DB12387; OSI-027. DR DrugBank; DB11974; PF-04691502. DR DrugBank; DB00337; Pimecrolimus. DR DrugBank; DB08052; PP-121. DR DrugBank; DB06233; Ridaforolimus. DR DrugBank; DB04974; Rimiducid. DR DrugBank; DB12681; Salirasib. DR DrugBank; DB11836; Sapanisertib. DR DrugBank; DB05210; SF1126. DR DrugBank; DB00877; Sirolimus. DR DrugBank; DB06287; Temsirolimus. DR DrugBank; DB11925; Vistusertib. DR DrugBank; DB12400; Voxtalisib. DR DrugBank; DB12986; VS-5584. DR DrugBank; DB05241; XL765. DR DrugBank; DB18761; Zotarolimus. DR DrugCentral; P42345; -. DR GuidetoPHARMACOLOGY; 2109; -. DR GlyGen; P42345; 5 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P42345; -. DR MetOSite; P42345; -. DR PhosphoSitePlus; P42345; -. DR SwissPalm; P42345; -. DR BioMuta; MTOR; -. DR DMDM; 1169735; -. DR CPTAC; CPTAC-1360; -. DR CPTAC; CPTAC-1361; -. DR CPTAC; CPTAC-3133; -. DR CPTAC; CPTAC-3134; -. DR CPTAC; CPTAC-5752; -. DR CPTAC; CPTAC-5753; -. DR CPTAC; CPTAC-5754; -. DR CPTAC; CPTAC-5755; -. DR CPTAC; CPTAC-5756; -. DR CPTAC; CPTAC-5793; -. DR CPTAC; CPTAC-5794; -. DR CPTAC; CPTAC-5795; -. DR CPTAC; CPTAC-5796; -. DR CPTAC; CPTAC-5797; -. DR CPTAC; CPTAC-5798; -. DR CPTAC; CPTAC-5799; -. DR CPTAC; CPTAC-5800; -. DR CPTAC; non-CPTAC-5421; -. DR CPTAC; non-CPTAC-5422; -. DR CPTAC; non-CPTAC-5423; -. DR CPTAC; non-CPTAC-5424; -. DR CPTAC; non-CPTAC-5425; -. DR CPTAC; non-CPTAC-5560; -. DR CPTAC; non-CPTAC-5561; -. DR CPTAC; non-CPTAC-5562; -. DR CPTAC; non-CPTAC-5563; -. DR CPTAC; non-CPTAC-5709; -. DR CPTAC; non-CPTAC-5710; -. DR CPTAC; non-CPTAC-5711; -. DR CPTAC; non-CPTAC-5712; -. DR jPOST; P42345; -. DR MassIVE; P42345; -. DR PaxDb; 9606-ENSP00000354558; -. DR PeptideAtlas; P42345; -. DR ProteomicsDB; 55511; -. DR Pumba; P42345; -. DR Antibodypedia; 3566; 1829 antibodies from 54 providers. DR CPTC; P42345; 10 antibodies. DR DNASU; 2475; -. DR Ensembl; ENST00000361445.9; ENSP00000354558.4; ENSG00000198793.15. DR Ensembl; ENST00000703143.2; ENSP00000515200.2; ENSG00000198793.15. DR GeneID; 2475; -. DR KEGG; hsa:2475; -. DR MANE-Select; ENST00000361445.9; ENSP00000354558.4; NM_004958.4; NP_004949.1. DR UCSC; uc001asd.4; human. DR AGR; HGNC:3942; -. DR CIViC; 2475; 31 evidence items across 26 molecular profiles. DR ClinPGx; PA28360; -. DR CTD; 2475; -. DR DisGeNET; 2475; -. DR GeneCards; MTOR; -. DR HGNC; HGNC:3942; MTOR. DR HPA; ENSG00000198793; Low tissue specificity. DR MalaCards; MTOR; -. DR MIM; 601231; gene. DR MIM; 607341; phenotype. DR MIM; 616638; phenotype. DR OpenTargets; ENSG00000198793; -. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 269001; Isolated focal cortical dysplasia type IIa. DR Orphanet; 269008; Isolated focal cortical dysplasia type IIb. DR Orphanet; 457485; Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome. DR VEuPathDB; HostDB:ENSG00000198793; -. DR eggNOG; KOG0891; Eukaryota. DR GeneTree; ENSGT00930000151037; -. DR HOGENOM; CLU_000178_7_1_1; -. DR InParanoid; P42345; -. DR OMA; MRQHSAK; -. DR OrthoDB; 2250022at2759; -. DR PAN-GO; P42345; 7 GO annotations based on evolutionary models. DR PhylomeDB; P42345; -. DR PathwayCommons; P42345; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-166208; mTORC1-mediated signalling. DR Reactome; R-HSA-3371571; HSF1-dependent transactivation. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9639288; Amino acids regulate mTORC1. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR SABIO-RK; P42345; -. DR SignaLink; P42345; -. DR SIGNOR; P42345; -. DR Agora; ENSG00000198793; -. DR BioGRID-ORCS; 2475; 805 hits in 1184 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; MTOR; human. DR EvolutionaryTrace; P42345; -. DR GeneWiki; Mammalian_target_of_rapamycin; -. DR GenomeRNAi; 2475; -. DR Pharos; P42345; Tclin. DR PRO; PR:P42345; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P42345; protein. DR Bgee; ENSG00000198793; Expressed in primordial germ cell in gonad and 132 other cell types or tissues. DR ExpressionAtlas; P42345; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:0012505; C:endomembrane system; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB. DR GO; GO:0005764; C:lysosome; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005635; C:nuclear envelope; IDA:CACAO. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0045335; C:phagocytic vesicle; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0031931; C:TORC1 complex; IDA:UniProtKB. DR GO; GO:0031932; C:TORC2 complex; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000822; F:inositol hexakisphosphate binding; IDA:UniProtKB. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:WormBase. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0043022; F:ribosome binding; IDA:UniProtKB. DR GO; GO:0001002; F:RNA polymerase III type 1 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001003; F:RNA polymerase III type 2 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001006; F:RNA polymerase III type 3 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001156; F:TFIIIC-class transcription factor complex binding; IDA:UniProtKB. DR GO; GO:0044325; F:transmembrane transporter binding; IEA:Ensembl. DR GO; GO:0006207; P:'de novo' pyrimidine nucleobase biosynthetic process; IEA:Ensembl. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0033173; P:calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0055013; P:cardiac muscle cell development; IEA:Ensembl. DR GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl. DR GO; GO:0030030; P:cell projection organization; IEA:Ensembl. DR GO; GO:0034198; P:cellular response to amino acid starvation; IDA:UniProtKB. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:CAFA. DR GO; GO:0071456; P:cellular response to hypoxia; ISS:UniProtKB. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0071233; P:cellular response to L-leucine; IDA:CAFA. DR GO; GO:1990253; P:cellular response to leucine starvation; IDA:CAFA. DR GO; GO:0061431; P:cellular response to methionine; IDA:UniProt. DR GO; GO:0031670; P:cellular response to nutrient; IDA:UniProt. DR GO; GO:0031669; P:cellular response to nutrient levels; IDA:UniProt. DR GO; GO:0071470; P:cellular response to osmotic stress; NAS:ComplexPortal. DR GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; NAS:ComplexPortal. DR GO; GO:0006974; P:DNA damage response; NAS:ComplexPortal. DR GO; GO:0006112; P:energy reserve metabolic process; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl. DR GO; GO:0003179; P:heart valve morphogenesis; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0016236; P:macroautophagy; IEA:Ensembl. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0010507; P:negative regulation of autophagy; IDA:UniProtKB. DR GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0045792; P:negative regulation of cell size; IEA:Ensembl. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProt. DR GO; GO:1905672; P:negative regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016242; P:negative regulation of macroautophagy; IDA:MGI. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; IDA:UniProtKB. DR GO; GO:0019228; P:neuronal action potential; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl. DR GO; GO:0030307; P:positive regulation of cell growth; NAS:ComplexPortal. DR GO; GO:1904690; P:positive regulation of cytoplasmic translational initiation; TAS:ARUK-UCL. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; NAS:ComplexPortal. DR GO; GO:0051549; P:positive regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; IEA:Ensembl. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IMP:UniProtKB. DR GO; GO:0010831; P:positive regulation of myotube differentiation; IEA:Ensembl. DR GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:1905857; P:positive regulation of pentose-phosphate shunt; NAS:ComplexPortal. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; TAS:Reactome. DR GO; GO:1900029; P:positive regulation of ruffle assembly; IEA:Ensembl. DR GO; GO:0062027; P:positive regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process; IDA:UniProt. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; IMP:UniProtKB. DR GO; GO:1901838; P:positive regulation of transcription of nucleolar large rRNA by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB. DR GO; GO:0045948; P:positive regulation of translational initiation; IDA:UniProt. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:1903691; P:positive regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0031648; P:protein destabilization; IDA:UniProt. DR GO; GO:0050821; P:protein stabilization; ISS:UniProt. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:2000785; P:regulation of autophagosome assembly; IDA:UniProt. DR GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB. DR GO; GO:0008361; P:regulation of cell size; IMP:CAFA. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:1904059; P:regulation of locomotor rhythm; ISS:UniProtKB. DR GO; GO:1905671; P:regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; TAS:Reactome. DR GO; GO:0090559; P:regulation of membrane permeability; IEA:Ensembl. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0045670; P:regulation of osteoclast differentiation; ISS:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0043200; P:response to amino acid; IDA:UniProtKB. DR GO; GO:0009408; P:response to heat; IEA:Ensembl. DR GO; GO:0031667; P:response to nutrient levels; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0002296; P:T-helper 1 cell lineage commitment; IEA:Ensembl. DR GO; GO:0031929; P:TOR signaling; IMP:UniProtKB. DR GO; GO:0038202; P:TORC1 signaling; IDA:UniProtKB. DR GO; GO:0038203; P:TORC2 signaling; IDA:UniProtKB. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR GO; GO:0050882; P:voluntary musculoskeletal movement; IEA:Ensembl. DR CDD; cd05169; PIKKc_TOR; 1. DR DisProt; DP03874; -. DR FunFam; 1.10.1070.11:FF:000074; DJ576K7.1 (FK506 binding protein 12-rapamycin associated protein 1); 1. DR FunFam; 1.10.1070.11:FF:000058; MTOR isoform 6; 1. DR FunFam; 1.25.10.10:FF:000060; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000094; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000532; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.20.120.150:FF:000001; Serine/threonine-protein kinase TOR; 1. DR FunFam; 1.25.10.10:FF:000083; Serine/threonine-protein kinase TOR; 1. DR FunFam; 3.30.1010.10:FF:000004; Serine/threonine-protein kinase TOR; 1. DR Gene3D; 1.20.120.150; FKBP12-rapamycin binding domain; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 4. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR IDEAL; IID00598; -. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR009076; FRB_dom. DR InterPro; IPR036738; FRB_sf. DR InterPro; IPR057564; HEAT_ATR. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024585; mTOR_dom. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR026683; TOR_cat. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF9; SERINE_THREONINE-PROTEIN KINASE MTOR; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF08771; FRB_dom; 1. DR Pfam; PF23593; HEAT_ATR; 1. DR Pfam; PF11865; mTOR_dom; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR SMART; SM01346; DUF3385; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01345; Rapamycin_bind; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF47212; FKBP12-rapamycin-binding domain of FKBP-rapamycin-associated protein (FRAP); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell membrane; Cytoplasm; KW Cytoplasmic vesicle; Disease variant; Endoplasmic reticulum; Epilepsy; KW Golgi apparatus; Intellectual disability; Isopeptide bond; Kinase; KW Lysosome; Membrane; Microsome; Mitochondrion; Mitochondrion outer membrane; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; TPR repeat; KW Transferase; Ubl conjugation. FT CHAIN 1..2549 FT /note="Serine/threonine-protein kinase mTOR" FT /id="PRO_0000088808" FT REPEAT 16..53 FT /note="HEAT 1" FT REPEAT 55..99 FT /note="HEAT 2" FT REPEAT 100..137 FT /note="HEAT 3" FT REPEAT 138..179 FT /note="HEAT 4" FT REPEAT 180..220 FT /note="HEAT 5" FT REPEAT 222..276 FT /note="HEAT 6" FT REPEAT 277..313 FT /note="HEAT 7" FT REPEAT 314..364 FT /note="HEAT 8" FT REPEAT 365..409 FT /note="HEAT 9" FT REPEAT 410..445 FT /note="HEAT 10" FT REPEAT 446..494 FT /note="HEAT 11" FT REPEAT 495..529 FT /note="HEAT 12" FT REPEAT 530..563 FT /note="HEAT 13" FT REPEAT 564..596 FT /note="HEAT 14" FT REPEAT 597..636 FT /note="HEAT 15" FT REPEAT 637..683 FT /note="HEAT 16" FT REPEAT 686..724 FT /note="HEAT 17" FT REPEAT 727..766 FT /note="HEAT 18" FT REPEAT 769..811 FT /note="HEAT 19" FT REPEAT 814..853 FT /note="HEAT 20" FT REPEAT 857..893 FT /note="HEAT 21" FT REPEAT 894..942 FT /note="HEAT 22" FT REPEAT 943..988 FT /note="HEAT 23" FT REPEAT 989..1027 FT /note="HEAT 24" FT REPEAT 1029..1068 FT /note="HEAT 25" FT REPEAT 1069..1105 FT /note="HEAT 26" FT REPEAT 1106..1144 FT /note="HEAT 27" FT REPEAT 1145..1188 FT /note="HEAT 28" FT REPEAT 1189..1225 FT /note="HEAT 29" FT REPEAT 1226..1273 FT /note="HEAT 30" FT REPEAT 1274..1311 FT /note="HEAT 31" FT REPEAT 1312..1345 FT /note="HEAT 32" FT REPEAT 1346..1382 FT /note="TPR 1" FT DOMAIN 1382..1982 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT REPEAT 1383..1408 FT /note="TPR 2" FT REPEAT 1409..1442 FT /note="TPR 3" FT REPEAT 1443..1473 FT /note="TPR 4" FT REPEAT 1474..1507 FT /note="TPR 5" FT REPEAT 1508..1541 FT /note="TPR 6" FT REPEAT 1542..1574 FT /note="TPR 7" FT REPEAT 1575..1614 FT /note="TPR 8" FT REPEAT 1615..1649 FT /note="TPR 9" FT REPEAT 1650..1693 FT /note="TPR 10" FT REPEAT 1694..1731 FT /note="TPR 11" FT REPEAT 1732..1786 FT /note="TPR 12" FT REPEAT 1787..1846 FT /note="TPR 13" FT REPEAT 1898..1930 FT /note="TPR 14" FT REPEAT 1931..1970 FT /note="TPR 15" FT REPEAT 1971..2005 FT /note="TPR 16" FT DOMAIN 2156..2469 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 2517..2549 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1..651 FT /note="Interaction with NBN" FT /evidence="ECO:0000269|PubMed:23762398" FT REGION 1812..1867 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2012..2144 FT /note="Sufficient for interaction with the FKBP1A/rapamycin FT complex" FT /evidence="ECO:0000250|UniProtKB:Q9JLN9" FT REGION 2162..2168 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2258..2296 FT /note="Interaction with MLST8" FT REGION 2335..2343 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2355..2380 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT COMPBIAS 1820..1860 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 1662 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1702 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1749 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 2165 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2167 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2185 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2187 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2190 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2225 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2238 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2239 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2240 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2245 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2343 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2345 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2356 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2357 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 567 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231" FT MOD_RES 1162 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1218 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19487463, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2159 FT /note="Phosphoserine; by TBK1" FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MOD_RES 2164 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:21576368" FT MOD_RES 2173 FT /note="Phosphothreonine; by PKB/AKT1" FT /evidence="ECO:0000269|PubMed:24247430" FT MOD_RES 2446 FT /note="Phosphothreonine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15905173" FT MOD_RES 2448 FT /note="Phosphoserine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15899889, FT ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, FT ECO:0007744|PubMed:24275569" FT MOD_RES 2478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2481 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:20022946, FT ECO:0000269|PubMed:21576368, ECO:0007744|PubMed:18669648" FT CROSSLNK 2066 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:37979583" FT VARIANT 8 FT /note="A -> S (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs748801456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041537" FT VARIANT 135 FT /note="M -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041538" FT VARIANT 624 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs913197212)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078824" FT VARIANT 1083 FT /note="M -> V (in dbSNP:rs56164650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041539" FT VARIANT 1134 FT /note="A -> V (in dbSNP:rs28730685)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041540" FT VARIANT 1178 FT /note="S -> F (in dbSNP:rs55975118)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041541" FT VARIANT 1376 FT /note="D -> E (found in a patient with focal epilepsy; FT uncertain significance; dbSNP:rs975577894)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078825" FT VARIANT 1450 FT /note="Y -> D (in FCORD2; somatic mutation)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078826" FT VARIANT 1456 FT /note="W -> G (in FCORD2; somatic mutation; FT dbSNP:rs1085307114)" FT /evidence="ECO:0000269|PubMed:25878179" FT /id="VAR_078827" FT VARIANT 1459 FT /note="A -> D (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1644347782)" FT /evidence="ECO:0000269|PubMed:26018084" FT /id="VAR_078828" FT VARIANT 1459 FT /note="A -> S (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs1644347846)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078829" FT VARIANT 1460 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1057519779)" FT /evidence="ECO:0000269|PubMed:26018084, FT ECO:0000269|PubMed:27830187" FT /id="VAR_078830" FT VARIANT 1483 FT /note="C -> R (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1057519914)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078831" FT VARIANT 1490 FT /note="W -> R (in SKS; dbSNP:rs2100566800)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078832" FT VARIANT 1595 FT /note="M -> I (in SKS; dbSNP:rs869312671)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078833" FT VARIANT 1709 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs587777895)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078834" FT VARIANT 1799 FT /note="E -> K (in SKS; results in increased mTOR signaling; FT dbSNP:rs863225264)" FT /evidence="ECO:0000269|PubMed:25851998, FT ECO:0000269|PubMed:26542245" FT /id="VAR_075072" FT VARIANT 1832 FT /note="A -> T (in SKS; dbSNP:rs369088781)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078835" FT VARIANT 1888 FT /note="F -> C (in SKS; dbSNP:rs869312666)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078836" FT VARIANT 1977 FT /note="T -> K (in FCORD2; somatic mutation; FT dbSNP:rs587777893)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078837" FT VARIANT 2011 FT /note="M -> V (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs2100412651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041542" FT VARIANT 2193 FT /note="R -> C (in FCORD2; somatic mutation; FT dbSNP:rs1642723200)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078838" FT VARIANT 2215 FT /note="S -> F (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:25799227, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_078839" FT VARIANT 2215 FT /note="S -> Y (in FCORD2; also found in a colorectal FT adenocarcinoma sample; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_041543" FT VARIANT 2220 FT /note="L -> F (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100381099)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064733" FT VARIANT 2327 FT /note="M -> I (in SKS; dbSNP:rs878855328)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078840" FT VARIANT 2406 FT /note="V -> A (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100316251)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064734" FT VARIANT 2427 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078841" FT VARIANT 2427 FT /note="L -> Q (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078842" FT VARIANT 2476 FT /note="P -> L (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041544" FT VARIANT 2501 FT /note="I -> V (found in a patient with non-lesional FT nocturnal frontal epilepsy; uncertain significance; FT dbSNP:rs968817513)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078843" FT MUTAGEN 2066 FT /note="K->R: Complete loss ubiquitination by the FT SCF(FBXO22) complex." FT /evidence="ECO:0000269|PubMed:37979583" FT MUTAGEN 2159 FT /note="S->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2164. Reduced FT activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2159 FT /note="S->D: Mimics phosphorylation; leading to stronger FT phosphorylation of RPS6KB1; when associated with E-2164. FT Increased activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2164 FT /note="T->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2164 FT /note="T->E: Stronger phosphorylation of RPS6KB1; when FT associated with D-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2173 FT /note="T->A: Increased mTOR kinase activity." FT /evidence="ECO:0000269|PubMed:24247430" FT MUTAGEN 2340 FT /note="H->A: Barely detectable kinase activity." FT /evidence="ECO:0000269|PubMed:23636326" FT MUTAGEN 2357 FT /note="D->E: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with I-2364." FT /evidence="ECO:0000269|PubMed:30956113" FT MUTAGEN 2364 FT /note="V->I: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with E-2357." FT /evidence="ECO:0000269|PubMed:30956113" FT CONFLICT 353 FT /note="K -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 359 FT /note="S -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 364 FT /note="D -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 390 FT /note="M -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="R -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 455..457 FT /note="VLD -> GVE (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 461 FT /note="A -> G (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 482..484 FT /note="VFT -> FFN (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 489 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 513 FT /note="L -> I (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 539 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 553 FT /note="R -> C (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 857 FT /note="P -> L (in Ref. 3; BAE06077)" FT /evidence="ECO:0000305" FT CONFLICT 1075 FT /note="I -> S (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 38..52 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 61..73 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 83..93 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 94..96 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 102..114 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 123..134 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 141..155 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 165..178 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 180..183 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 184..186 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 188..197 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 204..222 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 234..245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 259..275 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 277..288 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 357..360 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 362..375 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 380..382 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 387..402 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 404..409 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 413..424 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 427..443 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 449..451 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 452..462 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 463..465 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 479..490 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 495..497 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 499..510 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 517..527 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 530..532 FT /evidence="ECO:0007829|PDB:6ZWM" FT HELIX 533..548 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 601..611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 616..629 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 646..648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 649..665 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 670..677 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 681..683 FT /evidence="ECO:0007829|PDB:6ZWM" FT TURN 685..688 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 690..699 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 703..705 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 706..717 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 723..742 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 749..762 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 765..767 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 772..783 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 792..808 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 811..813 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 814..816 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 817..828 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 831..833 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 838..851 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 856..860 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 864..870 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 871..873 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 878..891 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 896..902 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 934..937 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 943..958 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 964..982 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 986..989 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 990..1002 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1006..1008 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1009..1023 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1024..1030 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1031..1040 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1046..1062 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1065..1069 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1071..1083 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1088..1090 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 1091..1103 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1104..1107 FT /evidence="ECO:0007829|PDB:7UXC" FT TURN 1108..1110 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1111..1123 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1125..1127 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1129..1142 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1143..1145 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1150..1152 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1153..1163 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1167..1169 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1170..1182 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1185..1191 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1192..1202 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1207..1218 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1222..1226 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1229..1237 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1263..1269 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1277..1293 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1304..1309 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1311..1315 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1318..1328 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1331..1347 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1351..1366 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1367..1369 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1375..1379 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1380..1390 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1393..1406 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1410..1422 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1426..1439 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1441..1444 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1447..1452 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1456..1469 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1474..1487 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1490..1499 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1501..1504 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1506..1523 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1526..1533 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1538..1540 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1541..1553 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1557..1579 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1584..1586 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1587..1602 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1603..1605 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1606..1608 FT /evidence="ECO:0007829|PDB:4JSP" FT HELIX 1609..1611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1612..1623 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1630..1640 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1641..1643 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1646..1648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1650..1662 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1666..1677 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1681..1683 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1685..1687 FT /evidence="ECO:0007829|PDB:6ZWO" FT STRAND 1691..1693 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 1694..1706 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1710..1730 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1737..1758 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1759..1762 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1766..1768 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1769..1782 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1783..1785 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1787..1809 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1810..1813 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1868..1877 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1878..1880 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1881..1893 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1896..1898 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1900..1913 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1917..1929 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1933..1935 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:7PE7" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1944..1947 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1951..1966 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1970..1972 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1973..1980 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1985..1999 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2005..2019 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2020..2022 FT /evidence="ECO:0007829|PDB:2NPU" FT HELIX 2025..2039 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2044..2058 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2065..2091 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2094..2111 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2115..2117 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2120..2122 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2123..2126 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2128..2132 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2137..2139 FT /evidence="ECO:0007829|PDB:6ZWO" FT TURN 2141..2143 FT /evidence="ECO:0007829|PDB:5WBY" FT STRAND 2146..2148 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2152..2156 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2158..2162 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2164..2167 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2170..2179 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2181..2187 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2194..2210 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2213..2216 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2217..2219 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2227..2229 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2231..2233 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2235..2238 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2241..2245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2246..2256 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2263..2271 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2273..2277 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2280..2292 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2298..2305 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2308..2310 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2311..2334 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2341..2343 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2344..2350 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2353..2355 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2362..2364 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2365..2367 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2369..2371 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2381..2385 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2392..2394 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2395..2409 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2411..2422 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2425..2428 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2429..2432 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2433..2435 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 2493..2509 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2512..2516 FT /evidence="ECO:0007829|PDB:4JT5" FT HELIX 2521..2532 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2535..2539 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2543..2545 FT /evidence="ECO:0007829|PDB:8ERA" SQ SEQUENCE 2549 AA; 288892 MW; 7D9AD6E784882AB4 CRC64; MLGTGPAAAT TAATTSSNVS VLQQFASGLK SRNEETRAKA AKELQHYVTM ELREMSQEES TRFYDQLNHH IFELVSSSDA NERKGGILAI ASLIGVEGGN ATRIGRFANY LRNLLPSNDP VVMEMASKAI GRLAMAGDTF TAEYVEFEVK RALEWLGADR NEGRRHAAVL VLRELAISVP TFFFQQVQPF FDNIFVAVWD PKQAIREGAV AALRACLILT TQREPKEMQK PQWYRHTFEE AEKGFDETLA KEKGMNRDDR IHGALLILNE LVRISSMEGE RLREEMEEIT QQQLVHDKYC KDLMGFGTKP RHITPFTSFQ AVQPQQSNAL VGLLGYSSHQ GLMGFGTSPS PAKSTLVESR CCRDLMEEKF DQVCQWVLKC RNSKNSLIQM TILNLLPRLA AFRPSAFTDT QYLQDTMNHV LSCVKKEKER TAAFQALGLL SVAVRSEFKV YLPRVLDIIR AALPPKDFAH KRQKAMQVDA TVFTCISMLA RAMGPGIQQD IKELLEPMLA VGLSPALTAV LYDLSRQIPQ LKKDIQDGLL KMLSLVLMHK PLRHPGMPKG LAHQLASPGL TTLPEASDVG SITLALRTLG SFEFEGHSLT QFVRHCADHF LNSEHKEIRM EAARTCSRLL TPSIHLISGH AHVVSQTAVQ VVADVLSKLL VVGITDPDPD IRYCVLASLD ERFDAHLAQA ENLQALFVAL NDQVFEIREL AICTVGRLSS MNPAFVMPFL RKMLIQILTE LEHSGIGRIK EQSARMLGHL VSNAPRLIRP YMEPILKALI LKLKDPDPDP NPGVINNVLA TIGELAQVSG LEMRKWVDEL FIIIMDMLQD SSLLAKRQVA LWTLGQLVAS TGYVVEPYRK YPTLLEVLLN FLKTEQNQGT RREAIRVLGL LGALDPYKHK VNIGMIDQSR DASAVSLSES KSSQDSSDYS TSEMLVNMGN LPLDEFYPAV SMVALMRIFR DQSLSHHHTM VVQAITFIFK SLGLKCVQFL PQVMPTFLNV IRVCDGAIRE FLFQQLGMLV SFVKSHIRPY MDEIVTLMRE FWVMNTSIQS TIILLIEQIV VALGGEFKLY LPQLIPHMLR VFMHDNSPGR IVSIKLLAAI QLFGANLDDY LHLLLPPIVK LFDAPEAPLP SRKAALETVD RLTESLDFTD YASRIIHPIV RTLDQSPELR STAMDTLSSL VFQLGKKYQI FIPMVNKVLV RHRINHQRYD VLICRIVKGY TLADEEEDPL IYQHRMLRSG QGDALASGPV ETGPMKKLHV STINLQKAWG AARRVSKDDW LEWLRRLSLE LLKDSSSPSL RSCWALAQAY NPMARDLFNA AFVSCWSELN EDQQDELIRS IELALTSQDI AEVTQTLLNL AEFMEHSDKG PLPLRDDNGI VLLGERAAKC RAYAKALHYK ELEFQKGPTP AILESLISIN NKLQQPEAAA GVLEYAMKHF GELEIQATWY EKLHEWEDAL VAYDKKMDTN KDDPELMLGR MRCLEALGEW GQLHQQCCEK WTLVNDETQA KMARMAAAAA WGLGQWDSME EYTCMIPRDT HDGAFYRAVL ALHQDLFSLA QQCIDKARDL LDAELTAMAG ESYSRAYGAM VSCHMLSELE EVIQYKLVPE RREIIRQIWW ERLQGCQRIV EDWQKILMVR SLVVSPHEDM RTWLKYASLC GKSGRLALAH KTLVLLLGVD PSRQLDHPLP TVHPQVTYAY MKNMWKSARK IDAFQHMQHF VQTMQQQAQH AIATEDQQHK QELHKLMARC FLKLGEWQLN LQGINESTIP KVLQYYSAAT EHDRSWYKAW HAWAVMNFEA VLHYKHQNQA RDEKKKLRHA SGANITNATT AATTAATATT TASTEGSNSE SEAESTENSP TPSPLQKKVT EDLSKTLLMY TVPAVQGFFR SISLSRGNNL QDTLRVLTLW FDYGHWPDVN EALVEGVKAI QIDTWLQVIP QLIARIDTPR PLVGRLIHQL LTDIGRYHPQ ALIYPLTVAS KSTTTARHNA ANKILKNMCE HSNTLVQQAM MVSEELIRVA ILWHEMWHEG LEEASRLYFG ERNVKGMFEV LEPLHAMMER GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA WDLYYHVFRR ISKQLPQLTS LELQYVSPKL LMCRDLELAV PGTYDPNQPI IRIQSIAPSL QVITSKQRPR KLTLMGSNGH EFVFLLKGHE DLRQDERVMQ LFGLVNTLLA NDPTSLRKNL SIQRYAVIPL STNSGLIGWV PHCDTLHALI RDYREKKKIL LNIEHRIMLR MAPDYDHLTL MQKVEVFEHA VNNTAGDDLA KLLWLKSPSS EVWFDRRTNY TRSLAVMSMV GYILGLGDRH PSNLMLDRLS GKILHIDFGD CFEVAMTREK FPEKIPFRLT RMLTNAMEVT GLDGNYRITC HTVMEVLREH KDSVMAVLEA FVYDPLLNWR LMDTNTKGNK RSRTRTDSYS AGQSVEILDG VELGEPAHKK TGTTVPESIH SFIGDGLVKP EALNKKAIQI INRVRDKLTG RDFSHDDTLD VPTQVELLIK QATSHENLCQ CYIGWCPFW // ID MUC1_HUMAN Reviewed; 1255 AA. AC P15941; A5YRV1; A6ZID9; A6ZIE0; B1AVQ8; B1AVR0; B6ECA1; E7ESE5; E7EUG9; AC P13931; P15942; P17626; Q0VAP5; Q0VAP6; Q14128; Q14876; Q16437; Q16442; AC Q16615; Q6S4Y3; Q7Z547; Q7Z548; Q7Z550; Q7Z552; Q9BXA4; Q9UE75; Q9UE76; AC Q9UQL1; Q9Y4J2; DT 01-APR-1990, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 3. DT 28-JAN-2026, entry version 249. DE RecName: Full=Mucin-1; DE Short=MUC-1; DE AltName: Full=Breast carcinoma-associated antigen DF3; DE AltName: Full=Cancer antigen 15-3; DE Short=CA 15-3; DE AltName: Full=Carcinoma-associated mucin; DE AltName: Full=Episialin; DE AltName: Full=H23AG; DE AltName: Full=Krebs von den Lungen-6; DE Short=KL-6; DE AltName: Full=PEMT; DE AltName: Full=Peanut-reactive urinary mucin; DE Short=PUM; DE AltName: Full=Polymorphic epithelial mucin; DE Short=PEM; DE AltName: Full=Tumor-associated epithelial membrane antigen; DE Short=EMA; DE AltName: Full=Tumor-associated mucin; DE AltName: CD_antigen=CD227; DE Contains: DE RecName: Full=Mucin-1 subunit alpha; DE Short=MUC1-NT; DE Short=MUC1-alpha; DE Contains: DE RecName: Full=Mucin-1 subunit beta; DE Short=MUC1-beta; DE AltName: Full=MUC1-CT; DE Flags: Precursor; GN Name=MUC1; Synonyms=PUM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Pancreatic carcinoma; RX PubMed=2394722; DOI=10.1016/s0021-9258(18)77255-4; RA Lan M.S., Batra S.K., Qi W.-N., Metzgar R.S., Hollingsworth M.A.; RT "Cloning and sequencing of a human pancreatic tumor mucin cDNA."; RL J. Biol. Chem. 265:15294-15299(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RX PubMed=2318825; DOI=10.1016/s0021-9258(19)39399-8; RA Ligtenberg M.J.L., Vos H.L., Gennissen A.M.C., Hilkens J.; RT "Episialin, a carcinoma-associated mucin, is generated by a polymorphic RT gene encoding splice variants with alternative amino termini."; RL J. Biol. Chem. 265:5573-5578(1990). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary carcinoma; RX PubMed=1697589; DOI=10.1016/s0021-9258(18)77254-2; RA Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T., Peat N., RA Burchell J., Pemberton L., Lalani E.-N., Wilson D.; RT "Molecular cloning and expression of human tumor-associated polymorphic RT epithelial mucin."; RL J. Biol. Chem. 265:15286-15293(1990). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=2268309; DOI=10.1016/s0006-291x(05)80888-5; RA Lancaster C.A., Peat N., Duhig T., Wilson D., Taylor-Papadimitriou J., RA Gendler S.J.; RT "Structure and expression of the human polymorphic epithelial mucin gene: RT an expressed VNTR unit."; RL Biochem. Biophys. Res. Commun. 173:1019-1029(1990). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). RC TISSUE=Mammary carcinoma; RX PubMed=2351132; DOI=10.1111/j.1432-1033.1990.tb15511.x; RA Wreschner D.H., Hareuveni M., Tsarfaty I., Smorodinsky N., Horev J., RA Zaretsky J., Kotkes P., Weiss M., Lathe R., Dion A., Keydar I.; RT "Human epithelial tumor antigen cDNA sequences. Differential splicing may RT generate multiple protein forms."; RL Eur. J. Biochem. 189:463-473(1990). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Mammary carcinoma; RX PubMed=2112460; DOI=10.1111/j.1432-1033.1990.tb15512.x; RA Hareuveni M., Tsarfaty I., Zaretsky J., Kotkes P., Horev J., Zrihan S., RA Weiss M., Green S., Lathe R., Keydar I., Wreschner D.H.; RT "A transcribed gene, containing a variable number of tandem repeats, codes RT for a human epithelial tumor antigen. cDNA cloning, expression of the RT transfected gene and over-expression in breast cancer tissue."; RL Eur. J. Biochem. 189:475-486(1990). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=1688329; DOI=10.1016/0378-1119(90)90242-j; RA Tsarfaty I., Hareuveni M., Horev J., Zaretsky J., Weiss M., Jeltsch J.-M., RA Garnier J.-M., Lathe R., Keydar I., Wreschner D.H.; RT "Isolation and characterization of an expressed hypervariable gene coding RT for a breast-cancer-associated antigen."; RL Gene 93:313-318(1990). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM Y). RX PubMed=7925397; DOI=10.1111/j.1432-1033.1994.00787.x; RA Zrihan-Licht S., Vos H.L., Baruch A., Elroy-Stein O., Sagiv D., Keydar I., RA Hilkens J., Wreschner D.H.; RT "Characterization and molecular cloning of a novel MUC1 protein, devoid of RT tandem repeats, expressed in human breast cancer tissue."; RL Eur. J. Biochem. 224:787-795(1994). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; Y AND 8), AND TISSUE SPECIFICITY. RX PubMed=9212228; RX DOI=10.1002/(sici)1097-0215(19970703)72:1<87::aid-ijc13>3.0.co;2-7; RA Oosterkamp H.M., Scheiner L., Stefanova M.C., Lloyd K.O., Finstad C.L.; RT "Comparison of MUC-1 mucin expression in epithelial and non-epithelial RT cancer cell lines and demonstration of a new short variant form (MUC- RT 1/Z)."; RL Int. J. Cancer 72:87-94(1997). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZD). RX PubMed=15623537; DOI=10.1074/jbc.m406943200; RA Levitin F., Baruch A., Weiss M., Stiegman K., Hartmann M.L., RA Yoeli-Lerner M., Ziv R., Zrihan-Licht S., Shina S., Gat A., Lifschitz B., RA Simha M., Stadler Y., Cholostoy A., Gil B., Greaves D., Keydar I., RA Zaretsky J., Smorodinsky N., Wreschner D.H.; RT "A novel protein derived from the MUC1 gene by alternative splicing and RT frameshifting."; RL J. Biol. Chem. 280:10655-10663(2005). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; E2; J13; M6; S2; T10; Y-LSP AND RP ZD), ALTERNATIVE SPLICING, AND VARIANT MET-1117. RX PubMed=22941036; DOI=10.1007/s00262-012-1325-2; RA Zhang L., Vlad A., Milcarek C., Finn O.J.; RT "Human mucin MUC1 RNA undergoes different types of alternative splicing RT resulting in multiple isoforms."; RL Cancer Immunol. Immunother. 62:423-435(2013). RN [12] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 9). RC TISSUE=Carcinoma; RA Zhang L.X., Li C.H., Sun L.Y., Yue W.; RT "Cloning of a new potential secreted short variant form of MUC1 mucin in RT epithelial cancer cell line."; RL Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM Y), AND VARIANT MET-1117. RC TISSUE=Cervix carcinoma; RX PubMed=15969018; RA Zhang L.X., Li C.H., Sun L.Y., Wang M., Lu H.J.; RT "Soluble expression of peptide containing MUC1/Y-specific epitope in RT Escherichia coli and preparation of the antibody."; RL Sheng Wu Gong Cheng Xue Bao 19:337-342(2003). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM F). RA Zhang L.X., Lu H.J.; RT "Cloning of a new MUC1 short variant mRNA F from HeLa cells."; RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM S2). RA Zhang L.X., Lu H.J.; RT "Cloning of a new MUC1 short variant mRNA S2 from HeLa cells."; RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases. RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM M6). RA Zhang L., Finn O.J.; RT "Isolation of MUC1 isoforms from MCF7 cells."; RL Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases. RN [17] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-1117 AND ASN-1142. RG NIEHS SNPs program; RL Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [19] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [20] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS Y AND Y-LSP). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [21] RP PARTIAL NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=3417635; DOI=10.1016/s0021-9258(18)37632-4; RA Gendler S.J., Taylor-Papadimitriou J., Duhig T., Rothbard J., Burchell J.; RT "A highly immunogenic region of a human polymorphic epithelial mucin RT expressed by carcinomas is made up of tandem repeats."; RL J. Biol. Chem. 263:12820-12823(1988). RN [22] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-160 (ISOFORM 2). RX PubMed=2597151; DOI=10.1016/s0006-291x(89)80014-2; RA Abe M., Siddiqui J., Kufe D.; RT "Sequence analysis of the 5' region of the human DF3 breast carcinoma- RT associated antigen gene."; RL Biochem. Biophys. Res. Commun. 165:644-649(1989). RN [23] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-109 (ISOFORM 2). RC TISSUE=Thyroid; RX PubMed=8608966; RX DOI=10.1002/(sici)1097-0215(19960328)66:1<55::aid-ijc10>3.0.co;2-a; RA Weiss M., Baruch A., Keydar I., Wreschner D.H.; RT "Preoperative diagnosis of thyroid papillary carcinoma by reverse RT transcriptase polymerase chain reaction of the MUC1 gene."; RL Int. J. Cancer 66:55-59(1996). RN [24] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-89. RC TISSUE=Lung; RX PubMed=8604237; DOI=10.1159/000227547; RA Yu C.J., Yang P.C., Shew J.Y., Hong T.M., Yang S.C., Lee Y.C., Lee L.N., RA Luh K.T., Wu C.W.; RT "Mucin mRNA expression in lung adenocarcinoma cell lines and tissues."; RL Oncology 53:118-126(1996). RN [25] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-46 (ISOFORMS 3 AND 4). RC TISSUE=Mammary carcinoma; RA Buluwela L., Liu Q., Luqmani Y.A., Gomm J.J., Coombes R.C.; RL Submitted (OCT-1992) to the EMBL/GenBank/DDBJ databases. RN [26] RP PROTEIN SEQUENCE OF 24-33; 28-37 AND 1098-1107, AND PROTEOLYTIC PROCESSING. RX PubMed=11341784; DOI=10.1006/bbrc.2001.4775; RA Parry S., Silverman H.S., McDermott K., Willis A., Hollingsworth M.A., RA Harris A.; RT "Identification of MUC1 proteolytic cleavage sites in vivo."; RL Biochem. Biophys. Res. Commun. 283:715-720(2001). RN [27] RP PROTEIN SEQUENCE OF 1098-1111, PROTEOLYTIC CLEAVAGE, AND MUTAGENESIS OF RP SER-1098. RX PubMed=15987679; DOI=10.1074/jbc.m506047200; RA Levitin F., Stern O., Weiss M., Gil-Henn C., Ziv R., Prokocimer Z., RA Smorodinsky N.I., Rubinstein D.B., Wreschner D.H.; RT "The MUC1 SEA module is a self-cleaving domain."; RL J. Biol. Chem. 280:33374-33386(2005). RN [28] RP PROTEIN SEQUENCE OF TANDEM REPEAT, IDENTIFICATION BY MASS SPECTROMETRY, AND RP GLYCOSYLATION. RX PubMed=10373415; DOI=10.1074/jbc.274.26.18165; RA Mueller S., Alving K., Peter-Katalinic J., Zachara N., Gooley A.A., RA Hanisch F.-G.; RT "High density O-glycosylation on tandem repeat peptide from secretory MUC1 RT of T47D breast cancer cells."; RL J. Biol. Chem. 274:18165-18172(1999). RN [29] RP PHOSPHORYLATION. RX PubMed=7988707; DOI=10.1016/0014-5793(94)01251-2; RA Zrihan-Licht S., Baruch A., Elroy-Stein O., Keydar I., Wreschner D.H.; RT "Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. RT Cytokine receptor-like molecules."; RL FEBS Lett. 356:130-136(1994). RN [30] RP IDENTIFICATION IN A COMPLEX WITH SOS1 AND GRB2, INTERACTION WITH GRB2 AND RP SOS1, AND PHOSPHORYLATION. RX PubMed=7664271; RA Pandey P., Kharbanda S., Kufe D.; RT "Association of the DF3/MUC1 breast cancer antigen with Grb2 and the RT Sos/Ras exchange protein."; RL Cancer Res. 55:4000-4003(1995). RN [31] RP GLYCOSYLATION AT THR-131 AND THR-139, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=7744025; DOI=10.1111/j.1432-1033.1995.tb20448.x; RA Stadie T.R., Chai W., Lawson A.M., Byfield P.G., Hanisch F.G.; RT "Studies on the order and site specificity of GalNAc transfer to MUC1 RT tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase RT from milk or mammary carcinoma cells."; RL Eur. J. Biochem. 229:140-147(1995). RN [32] RP INTERACTION WITH CTNNB1 AND JUP, AND FUNCTION. RX PubMed=9139698; DOI=10.1074/jbc.272.19.12492; RA Yamamoto M., Bharti A., Li Y., Kufe D.; RT "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta- RT catenin in cell adhesion."; RL J. Biol. Chem. 272:12492-12494(1997). RN [33] RP GLYCOSYLATION. RX PubMed=9312074; DOI=10.1074/jbc.272.40.24780; RA Mueller S., Goletz S., Packer N.H., Gooley A.A., Lawson A.M., RA Hanisch F.-G.; RT "Localization of O-glycosylation sites on glycopeptide fragments from RT lactation-associated MUC1. All putative sites within the tandem repeat are RT glycosylation targets in vivo."; RL J. Biol. Chem. 272:24780-24793(1997). RN [34] RP DEVELOPMENTAL STAGE. RX PubMed=9536947; DOI=10.1136/gut.42.2.220; RA Reid C.J., Harris A.; RT "Developmental expression of mucin genes in the human gastrointestinal RT system."; RL Gut 42:220-226(1998). RN [35] RP GLYCOSYLATION AT THR-131 AND THR-139, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=9597769; RX DOI=10.1002/(sici)1096-9888(199804)33:4<358::aid-jms642>3.0.co;2-3; RA Hanisch F.G., Green B.N., Bateman R., Peter-Katalinic J.; RT "Localization of O-glycosylation sites of MUC1 tandem repeats by QTOF ESI RT mass spectrometry."; RL J. Mass Spectrom. 33:358-362(1998). RN [36] RP INTERACTION WITH GSK3B AND CTNNB1, PHOSPHORYLATION AT SER-1227, AND RP MUTAGENESIS OF SER-1223 AND SER-1227. RX PubMed=9819408; DOI=10.1128/mcb.18.12.7216; RA Li Y., Bharti A., Chen D., Gong J., Kufe D.; RT "Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma- RT associated antigen and beta-catenin."; RL Mol. Cell. Biol. 18:7216-7224(1998). RN [37] RP CHARACTERIZATION (ISOFORM Y), AND MUTAGENESIS OF ASP-1116. RX PubMed=10197628; RA Baruch A., Hartmann M.-L., Yoeli M., Adereth Y., Greenstein S., Stadler Y., RA Skornik Y., Zaretsky J., Smorodinsky N.I., Keydar I., Wreschner D.H.; RT "The breast cancer-associated MUC1 gene generates both a receptor and its RT cognate binding protein."; RL Cancer Res. 59:1552-1561(1999). RN [38] RP INTERACTION WITH ICAM1. RX PubMed=11173916; DOI=10.1159/000051917; RA Hayashi T., Takahashi T., Motoya S., Ishida T., Itoh F., Adachi M., RA Hinoda Y., Imai K.; RT "MUC1 mucin core protein binds to the domain 1 of ICAM-1."; RL Digestion 63 Suppl. 1:87-92(2001). RN [39] RP SUBCELLULAR LOCATION. RX PubMed=11118479; DOI=10.1177/002215540104900107; RA Bennett R. Jr., Jaervelae T., Engelhardt P., Kostamovaara L., Sparks P., RA Carpen O., Turunen O., Vaheri A.; RT "Mucin MUC1 is seen in cell surface protrusions together with ezrin in RT immunoelectron tomography and is concentrated at tips of filopodial RT protrusions in MCF-7 breast carcinoma cells."; RL J. Histochem. Cytochem. 49:67-77(2001). RN [40] RP INTERACTION WITH SRC; GSK3B AND CTNNB1, PHOSPHORYLATION AT TYR-1229, AND RP MUTAGENESIS OF TYR-1229. RX PubMed=11152665; DOI=10.1074/jbc.c000754200; RA Li Y., Kuwahara H., Ren J., Wen G., Kufe D.; RT "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 RT carcinoma-associated antigen with GSK3 beta and beta-catenin."; RL J. Biol. Chem. 276:6061-6064(2001). RN [41] RP POLYMORPHISM WITHIN THE REPEAT. RX PubMed=11350974; DOI=10.1074/jbc.m103187200; RA Engelmann K., Baldus S.E., Hanisch F.-G.; RT "Identification and topology of variant sequences within individual repeat RT domains of the human epithelial tumor mucin MUC1."; RL J. Biol. Chem. 276:27764-27769(2001). RN [42] RP INTERACTION WITH EGFR, PHOSPHORYLATION AT TYR-1229 BY EGFR, AND MUTAGENESIS RP OF TYR-1191; TYR-1203; TYR-1209; TYR-1218 AND TYR-1229. RX PubMed=11483589; DOI=10.1074/jbc.c100359200; RA Li Y., Ren J., Yu W., Li Q., Kuwahara H., Yin L., Carraway K.L. III, RA Kufe D.; RT "The epidermal growth factor receptor regulates interaction of the human RT DF3/MUC1 carcinoma antigen with c-Src and beta-catenin."; RL J. Biol. Chem. 276:35239-35242(2001). RN [43] RP PHOSPHORYLATION AT THR-1224, INTERACTION WITH PRKCD, FUNCTION, AND RP MUTAGENESIS OF SER-1223; THR-1224 AND SER-1227. RX PubMed=11877440; DOI=10.1074/jbc.m200436200; RA Ren J., Li Y., Kufe D.; RT "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma RT antigen in beta-catenin signaling."; RL J. Biol. Chem. 277:17616-17622(2002). RN [44] RP PHOSPHORYLATION AT TYR-1203; TYR-1212; TYR-1229 AND TYR-1243. RX PubMed=14521915; DOI=10.1016/j.bbrc.2003.09.030; RA Wang H., Lillehoj E.P., Kim K.C.; RT "Identification of four sites of stimulated tyrosine phosphorylation in the RT MUC1 cytoplasmic tail."; RL Biochem. Biophys. Res. Commun. 310:341-346(2003). RN [45] RP INTERACTION WITH LYN, AND PHOSPHORYLATION. RX PubMed=12750561; DOI=10.4161/cbt.2.2.282; RA Li Y., Chen W., Ren J., Yu W.H., Li Q., Yoshida K., Kufe D.; RT "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin- RT 7."; RL Cancer Biol. Ther. 2:187-193(2003). RN [46] RP INTERACTION WITH CTNNB1, FUNCTION, AND MUTAGENESIS OF TYR-1229. RX PubMed=14688481; RA Huang L., Ren J., Chen D., Li Y., Kharbanda S., Kufe D.; RT "MUC1 cytoplasmic domain coactivates Wnt target gene transcription and RT confers transformation."; RL Cancer Biol. Ther. 2:702-706(2003). RN [47] RP INTERACTION WITH ADAM17, AND CLEAVAGE. RX PubMed=12441351; DOI=10.1074/jbc.m208326200; RA Thathiah A., Blobel C.P., Carson D.D.; RT "Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 RT shedding."; RL J. Biol. Chem. 278:3386-3394(2003). RN [48] RP INTERACTION WITH CTNNB1, AND SUBCELLULAR LOCATION. RX PubMed=12832415; DOI=10.1074/jbc.m304333200; RA Wen Y., Caffrey T.C., Wheelock M.J., Johnson K.R., Hollingsworth M.A.; RT "Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin."; RL J. Biol. Chem. 278:38029-38039(2003). RN [49] RP INTERACTION WITH ERBB2; ERBB3 AND ERBB4, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF 1187-ARG--LYS-1189. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [50] RP INTERACTION WITH AP1S2 AND GRB2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP TYR-1191; TYR-1203; TYR-1229 AND TYR-1243. RX PubMed=15471854; DOI=10.1074/jbc.m409360200; RA Kinlough C.L., Poland P.A., Bruns J.B., Harkleroad K.L., Hughey R.P.; RT "MUC1 membrane trafficking is modulated by multiple interactions."; RL J. Biol. Chem. 279:53071-53077(2004). RN [51] RP INTERACTION WITH TP53, AND FUNCTION. RX PubMed=15710329; DOI=10.1016/j.ccr.2005.01.008; RA Wei X., Xu H., Kufe D.; RT "Human MUC1 oncoprotein regulates p53-responsive gene transcription in the RT genotoxic stress response."; RL Cancer Cell 7:167-178(2005). RN [52] RP INTERACTION WITH GSK3B, PHOSPHORYLATION, AND FUNCTION. RX PubMed=16288032; DOI=10.1158/0008-5472.can-05-2474; RA Huang L., Chen D., Liu D., Yin L., Kharbanda S., Kufe D.; RT "MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated RT phosphorylation and degradation of beta-catenin."; RL Cancer Res. 65:10413-10422(2005). RN [53] RP ERRATUM OF PUBMED:16288032. RA Kinlough C.L., Poland P.A., Bruns J.B., Harkleroad K.L., Hughey R.P.; RL J. Biol. Chem. 280:28827-28827(2005). RN [54] RP STRUCTURE OF CARBOHYDRATES, IDENTIFICATION BY MASS SPECTROMETRY, AND RP SUBCELLULAR LOCATION. RX PubMed=15972891; DOI=10.1093/glycob/cwi099; RA Engelmann K., Kinlough C.L., Muller S., Razawi H., Baldus S.E., RA Hughey R.P., Hanisch F.-G.; RT "Transmembrane and secreted MUC1 probes show trafficking-dependent changes RT in O-glycan core profiles."; RL Glycobiology 15:1111-1124(2005). RN [55] RP INTERACTION WITH LCK, PHOSPHORYLATION, FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=15513966; DOI=10.1189/jlb.0604333; RA Mukherjee P., Tinder T.L., Basu G.D., Gendler S.J.; RT "MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells RT and normal T cells."; RL J. Leukoc. Biol. 77:90-99(2005). RN [56] RP PALMITOYLATION AT CYS-1184 AND CYS-1186, SUBCELLULAR LOCATION, INTERACTION RP WITH AP1S1 AND AP1S2, AND MUTAGENESIS OF CYS-1184; CYS-1186; TYR-1203 AND RP 1187-ARG--LYS-1189. RX PubMed=16507569; DOI=10.1074/jbc.m512996200; RA Kinlough C.L., McMahan R.J., Poland P.A., Bruns J.B., Harkleroad K.L., RA Stremple R.J., Kashlan O.B., Weixel K.M., Weisz O.A., Hughey R.P.; RT "Recycling of MUC1 is dependent on its palmitoylation."; RL J. Biol. Chem. 281:12112-12122(2006). RN [57] RP INTERACTION WITH ESR1. RX PubMed=16427018; DOI=10.1016/j.molcel.2005.11.030; RA Wei X., Xu H., Kufe D.; RT "MUC1 oncoprotein stabilizes and activates estrogen receptor alpha."; RL Mol. Cell 21:295-305(2006). RN [58] RP INTERACTION WITH CTNNB1, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17524503; DOI=10.1016/j.bbamcr.2007.04.009; RA Lillehoj E.P., Lu W., Kiser T., Goldblum S.E., Kim K.C.; RT "MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism."; RL Biochim. Biophys. Acta 1773:1028-1038(2007). RN [59] RP INTERACTION WITH KLF4, AND FUNCTION. RX PubMed=17308127; DOI=10.1158/0008-5472.can-06-3063; RA Wei X., Xu H., Kufe D.; RT "Human mucin 1 oncoprotein represses transcription of the p53 tumor RT suppressor gene."; RL Cancer Res. 67:1853-1858(2007). RN [60] RP PHOSPHORYLATION AT TYR-1203; TYR-1218 AND TYR-1229, MUTAGENESIS OF TYR-1203 RP AND TYR-1218, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=17545600; DOI=10.1158/0008-5472.can-06-4647; RA Singh P.K., Wen Y., Swanson B.J., Shanmugam K., Kazlauskas A., Cerny R.L., RA Gendler S.J., Hollingsworth M.A.; RT "Platelet-derived growth factor receptor beta-mediated phosphorylation of RT MUC1 enhances invasiveness in pancreatic adenocarcinoma cells."; RL Cancer Res. 67:5201-5210(2007). RN [61] RP INTERACTION WITH EGFR, AND FUNCTION. RX PubMed=16983337; DOI=10.1038/sj.onc.1209976; RA Pochampalli M.R., el Bejjani R.M., Schroeder J.A.; RT "MUC1 is a novel regulator of ErbB1 receptor trafficking."; RL Oncogene 26:1693-1701(2007). RN [62] RP MARKER IN BREAST CANCER. RX PubMed=20816948; DOI=10.1016/j.cca.2010.08.039; RA Duffy M.J., Evoy D., McDermott E.W.; RT "CA 15-3: uses and limitation as a biomarker for breast cancer."; RL Clin. Chim. Acta 411:1869-1874(2010). RN [63] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1227, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [64] RP INVOLVEMENT IN ADTKD2. RX PubMed=23396133; DOI=10.1038/ng.2543; RA Kirby A., Gnirke A., Jaffe D.B., Baresova V., Pochet N., Blumenstiel B., RA Ye C., Aird D., Stevens C., Robinson J.T., Cabili M.N., Gat-Viks I., RA Kelliher E., Daza R., DeFelice M., Hulkova H., Sovova J., Vylet'al P., RA Antignac C., Guttman M., Handsaker R.E., Perrin D., Steelman S., RA Sigurdsson S., Scheinman S.J., Sougnez C., Cibulskis K., Parkin M., RA Green T., Rossin E., Zody M.C., Xavier R.J., Pollak M.R., Alper S.L., RA Lindblad-Toh K., Gabriel S., Hart P.S., Regev A., Nusbaum C., Kmoch S., RA Bleyer A.J., Lander E.S., Daly M.J.; RT "Mutations causing medullary cystic kidney disease type 1 lie in a large RT VNTR in MUC1 missed by massively parallel sequencing."; RL Nat. Genet. 45:299-303(2013). RN [65] RP STRUCTURE BY NMR OF 1041-1097 AND 1098-1152 OF WILD TYPE AND MUTANT RP ALA-1098, IDENTIFICATION BY MASS SPECTROMETRY, STRUCTURE OF CARBOHYDRATES, RP AND AUTOCATALYTIC CLEAVAGE. RX PubMed=16585136; DOI=10.1093/glycob/cwj110; RA Parry S., Hanisch F.G., Leir S.H., Sutton-Smith M., Morris H.R., Dell A., RA Harris A.; RT "N-glycosylation of the MUC1 mucin in epithelial cells and secretions."; RL Glycobiology 16:623-634(2006). RN [66] {ECO:0007744|PDB:7Q4I} RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 921-926 IN COMPLEX WITH RP DROSOPHILA C1GALTA; MN(2+) AND UDP. RX PubMed=35504880; DOI=10.1038/s41467-022-29833-0; RA Gonzalez-Ramirez A.M., Grosso A.S., Yang Z., Companon I., Coelho H., RA Narimatsu Y., Clausen H., Marcelo F., Corzana F., Hurtado-Guerrero R.; RT "Structural basis for the synthesis of the core 1 structure by C1GalT1."; RL Nat. Commun. 13:2398-2398(2022). CC -!- FUNCTION: The alpha subunit has cell adhesive properties. Can act both CC as an adhesion and an anti-adhesion protein. May provide a protective CC layer on epithelial cells against bacterial and enzyme attack. CC -!- FUNCTION: The beta subunit contains a C-terminal domain which is CC involved in cell signaling, through phosphorylations and protein- CC protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B CC pathways. In activated T-cells, influences directly or indirectly the CC Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated CC transcription and determines cell fate in the genotoxic stress CC response. Binds, together with KLF4, the PE21 promoter element of TP53 CC and represses TP53 activity. CC -!- SUBUNIT: The alpha subunit forms a tight, non-covalent heterodimeric CC complex with the proteolytically-released beta-subunit. Interaction, CC via the tandem repeat region, with domain 1 of ICAM1 is implicated in CC cell migration and metastases. Isoform 1 binds directly the SH2 domain CC of GRB2, and forms a MUC1/GRB2/SOS1 complex involved in RAS signaling. CC The cytoplasmic tail (MUC1CT) interacts with several proteins such as CC SRC, CTNNB1 and ERBs. Interaction with the SH2 domain of CSK decreases CC interaction with GSK3B. Interacts with CTNNB1/beta-catenin and CC JUP/gamma-catenin and promotes cell adhesion. Interaction with CC JUP/gamma-catenin is induced by heregulin. Binds PRKCD, ERBB2, ERBB3 CC and ERBB4. Heregulin (HRG) stimulates the interaction with ERBB2 and, CC to a much lesser extent, the interaction with ERBB3 and ERBB4. CC Interacts with P53 in response to DNA damage. Interacts with KLF4. CC Interacts with estrogen receptor alpha/ESR1, through its DNA-binding CC domain, and stimulates its transcription activity. Binds ADAM17. CC Isoform ZD forms disulfide-linked oligomers. CC {ECO:0000269|PubMed:11152665, ECO:0000269|PubMed:11173916, CC ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11877440, CC ECO:0000269|PubMed:12441351, ECO:0000269|PubMed:12750561, CC ECO:0000269|PubMed:12832415, ECO:0000269|PubMed:12939402, CC ECO:0000269|PubMed:14688481, ECO:0000269|PubMed:15471854, CC ECO:0000269|PubMed:15513966, ECO:0000269|PubMed:15710329, CC ECO:0000269|PubMed:16288032, ECO:0000269|PubMed:16427018, CC ECO:0000269|PubMed:16507569, ECO:0000269|PubMed:16983337, CC ECO:0000269|PubMed:17308127, ECO:0000269|PubMed:17524503, CC ECO:0000269|PubMed:7664271, ECO:0000269|PubMed:9139698, CC ECO:0000269|PubMed:9819408}. CC -!- INTERACTION: CC P15941; P00519: ABL1; NbExp=4; IntAct=EBI-2804728, EBI-375543; CC P15941; P00533: EGFR; NbExp=6; IntAct=EBI-2804728, EBI-297353; CC P15941; P08581: MET; NbExp=2; IntAct=EBI-2804728, EBI-1039152; CC P15941; P15941-7: MUC1; NbExp=2; IntAct=EBI-2804728, EBI-4396776; CC P15941; P12931: SRC; NbExp=5; IntAct=EBI-2804728, EBI-621482; CC P15941-11; Q08AM2: ADAM33; NbExp=3; IntAct=EBI-17263240, EBI-10225815; CC P15941-11; O60242: ADGRB3; NbExp=3; IntAct=EBI-17263240, EBI-2682765; CC P15941-11; Q15848: ADIPOQ; NbExp=3; IntAct=EBI-17263240, EBI-10827839; CC P15941-11; Q86W74-2: ANKRD46; NbExp=3; IntAct=EBI-17263240, EBI-12109402; CC P15941-11; P02652: APOA2; NbExp=3; IntAct=EBI-17263240, EBI-1171525; CC P15941-11; P05067-2: APP; NbExp=3; IntAct=EBI-17263240, EBI-17264467; CC P15941-11; P29972: AQP1; NbExp=3; IntAct=EBI-17263240, EBI-745213; CC P15941-11; P41181: AQP2; NbExp=3; IntAct=EBI-17263240, EBI-12701138; CC P15941-11; Q92482: AQP3; NbExp=3; IntAct=EBI-17263240, EBI-2808854; CC P15941-11; Q9H2C2: ARV1; NbExp=3; IntAct=EBI-17263240, EBI-11724186; CC P15941-11; Q92843: BCL2L2; NbExp=3; IntAct=EBI-17263240, EBI-707714; CC P15941-11; Q6PL45-2: BRICD5; NbExp=3; IntAct=EBI-17263240, EBI-12244618; CC P15941-11; Q8WVV5: BTN2A2; NbExp=3; IntAct=EBI-17263240, EBI-8648738; CC P15941-11; P06681: C2; NbExp=3; IntAct=EBI-17263240, EBI-2835920; CC P15941-11; O14523: C2CD2L; NbExp=3; IntAct=EBI-17263240, EBI-12822627; CC P15941-11; Q06432: CACNG1; NbExp=3; IntAct=EBI-17263240, EBI-9686780; CC P15941-11; Q9P0B6: CCDC167; NbExp=3; IntAct=EBI-17263240, EBI-9083477; CC P15941-11; Q08722-3: CD47; NbExp=3; IntAct=EBI-17263240, EBI-17263290; CC P15941-11; P19397: CD53; NbExp=3; IntAct=EBI-17263240, EBI-6657396; CC P15941-11; P34810: CD68; NbExp=3; IntAct=EBI-17263240, EBI-2826276; CC P15941-11; Q8N6F1-2: CLDN19; NbExp=3; IntAct=EBI-17263240, EBI-12256978; CC P15941-11; P56747: CLDN6; NbExp=3; IntAct=EBI-17263240, EBI-12955011; CC P15941-11; Q8NHS1: CLDND2; NbExp=3; IntAct=EBI-17263240, EBI-11959453; CC P15941-11; Q96FZ5: CMTM7; NbExp=3; IntAct=EBI-17263240, EBI-2807956; CC P15941-11; Q4VAQ0: COL8A2; NbExp=3; IntAct=EBI-17263240, EBI-10241815; CC P15941-11; Q8N6G5: CSGALNACT2; NbExp=3; IntAct=EBI-17263240, EBI-10267100; CC P15941-11; Q07325: CXCL9; NbExp=3; IntAct=EBI-17263240, EBI-3911467; CC P15941-11; O43169: CYB5B; NbExp=3; IntAct=EBI-17263240, EBI-1058710; CC P15941-11; P78329: CYP4F2; NbExp=3; IntAct=EBI-17263240, EBI-1752413; CC P15941-11; P56851: EDDM3B; NbExp=3; IntAct=EBI-17263240, EBI-10215665; CC P15941-11; Q9BV81: EMC6; NbExp=3; IntAct=EBI-17263240, EBI-2820492; CC P15941-11; P54852: EMP3; NbExp=3; IntAct=EBI-17263240, EBI-3907816; CC P15941-11; O75355-2: ENTPD3; NbExp=3; IntAct=EBI-17263240, EBI-12279764; CC P15941-11; Q9UKR5: ERG28; NbExp=3; IntAct=EBI-17263240, EBI-711490; CC P15941-11; P01350: GAST; NbExp=3; IntAct=EBI-17263240, EBI-3436637; CC P15941-11; P39905-3: GDNF; NbExp=3; IntAct=EBI-17263240, EBI-12702062; CC P15941-11; Q9Y3E0: GOLT1B; NbExp=3; IntAct=EBI-17263240, EBI-4402607; CC P15941-11; Q9NPR9: GPR108; NbExp=3; IntAct=EBI-17263240, EBI-11343451; CC P15941-11; Q9HCP6: HHATL; NbExp=3; IntAct=EBI-17263240, EBI-5916693; CC P15941-11; O60725: ICMT; NbExp=3; IntAct=EBI-17263240, EBI-11721771; CC P15941-11; Q9Y5U4: INSIG2; NbExp=3; IntAct=EBI-17263240, EBI-8503746; CC P15941-11; P11215: ITGAM; NbExp=3; IntAct=EBI-17263240, EBI-2568251; CC P15941-11; Q969L2: MAL2; NbExp=3; IntAct=EBI-17263240, EBI-944295; CC P15941-11; Q13021: MALL; NbExp=3; IntAct=EBI-17263240, EBI-750078; CC P15941-11; Q9P0N8: MARCHF2; NbExp=3; IntAct=EBI-17263240, EBI-10317612; CC P15941-11; Q6N075: MFSD5; NbExp=3; IntAct=EBI-17263240, EBI-3920969; CC P15941-11; P30301: MIP; NbExp=3; IntAct=EBI-17263240, EBI-8449636; CC P15941-11; Q96S97: MYADM; NbExp=3; IntAct=EBI-17263240, EBI-13301517; CC P15941-11; O95167: NDUFA3; NbExp=3; IntAct=EBI-17263240, EBI-1246131; CC P15941-11; Q99519: NEU1; NbExp=3; IntAct=EBI-17263240, EBI-721517; CC P15941-11; Q92982: NINJ1; NbExp=3; IntAct=EBI-17263240, EBI-2802124; CC P15941-11; Q9NZG7: NINJ2; NbExp=3; IntAct=EBI-17263240, EBI-10317425; CC P15941-11; Q16617: NKG7; NbExp=3; IntAct=EBI-17263240, EBI-3919611; CC P15941-11; Q8N912: NRAC; NbExp=3; IntAct=EBI-17263240, EBI-12051377; CC P15941-11; Q8NH19: OR10AG1; NbExp=3; IntAct=EBI-17263240, EBI-13339917; CC P15941-11; Q6TCH4: PAQR6; NbExp=3; IntAct=EBI-17263240, EBI-17265310; CC P15941-11; P26678: PLN; NbExp=3; IntAct=EBI-17263240, EBI-692836; CC P15941-11; P60201-2: PLP1; NbExp=3; IntAct=EBI-17263240, EBI-12188331; CC P15941-11; Q8IY26: PLPP6; NbExp=3; IntAct=EBI-17263240, EBI-11721828; CC P15941-11; P54315: PNLIPRP1; NbExp=3; IntAct=EBI-17263240, EBI-8652812; CC P15941-11; Q59EV6: PPGB; NbExp=3; IntAct=EBI-17263240, EBI-14210385; CC P15941-11; P30405: PPIF; NbExp=3; IntAct=EBI-17263240, EBI-5544229; CC P15941-11; Q96AA3: RFT1; NbExp=3; IntAct=EBI-17263240, EBI-6269616; CC P15941-11; Q02161-2: RHD; NbExp=3; IntAct=EBI-17263240, EBI-17249212; CC P15941-11; Q8TAC9: SCAMP5; NbExp=3; IntAct=EBI-17263240, EBI-2695784; CC P15941-11; Q9Y6D0: SELENOK; NbExp=3; IntAct=EBI-17263240, EBI-9679163; CC P15941-11; Q8N6R1: SERP2; NbExp=3; IntAct=EBI-17263240, EBI-749270; CC P15941-11; P11686: SFTPC; NbExp=3; IntAct=EBI-17263240, EBI-10197617; CC P15941-11; Q8IWU4: SLC30A8; NbExp=3; IntAct=EBI-17263240, EBI-10262251; CC P15941-11; Q969S0: SLC35B4; NbExp=3; IntAct=EBI-17263240, EBI-10281213; CC P15941-11; Q6ICL7: SLC35E4; NbExp=3; IntAct=EBI-17263240, EBI-12867720; CC P15941-11; Q9NVC3: SLC38A7; NbExp=3; IntAct=EBI-17263240, EBI-10314552; CC P15941-11; Q9NRQ5: SMCO4; NbExp=3; IntAct=EBI-17263240, EBI-8640191; CC P15941-11; B2RUZ4: SMIM1; NbExp=3; IntAct=EBI-17263240, EBI-12188413; CC P15941-11; Q9NZ01: TECR; NbExp=3; IntAct=EBI-17263240, EBI-2877718; CC P15941-11; P07204: THBD; NbExp=3; IntAct=EBI-17263240, EBI-941422; CC P15941-11; Q9BZW4: TM6SF2; NbExp=3; IntAct=EBI-17263240, EBI-13082040; CC P15941-11; P17152: TMEM11; NbExp=3; IntAct=EBI-17263240, EBI-723946; CC P15941-11; A0PK00: TMEM120B; NbExp=3; IntAct=EBI-17263240, EBI-10171534; CC P15941-11; Q9BTD3: TMEM121; NbExp=3; IntAct=EBI-17263240, EBI-12155101; CC P15941-11; Q5BJH2-2: TMEM128; NbExp=3; IntAct=EBI-17263240, EBI-10694905; CC P15941-11; Q9BVK8: TMEM147; NbExp=3; IntAct=EBI-17263240, EBI-348587; CC P15941-11; Q9Y6G1: TMEM14A; NbExp=3; IntAct=EBI-17263240, EBI-2800360; CC P15941-11; Q9P0S9: TMEM14C; NbExp=3; IntAct=EBI-17263240, EBI-2339195; CC P15941-11; Q14656: TMEM187; NbExp=3; IntAct=EBI-17263240, EBI-13046724; CC P15941-11; Q8NBD8: TMEM229B; NbExp=3; IntAct=EBI-17263240, EBI-12195227; CC P15941-11; Q9BU79: TMEM243; NbExp=3; IntAct=EBI-17263240, EBI-12887458; CC P15941-11; Q8N2M4: TMEM86A; NbExp=3; IntAct=EBI-17263240, EBI-12015604; CC P15941-11; Q8N661: TMEM86B; NbExp=3; IntAct=EBI-17263240, EBI-2548832; CC P15941-11; Q5BJF2: TMEM97; NbExp=3; IntAct=EBI-17263240, EBI-12111910; CC P15941-11; Q9Y2Y6: TMEM98; NbExp=3; IntAct=EBI-17263240, EBI-7333781; CC P15941-11; O14763: TNFRSF10B; NbExp=3; IntAct=EBI-17263240, EBI-518882; CC P15941-11; Q8N609: TRAM1L1; NbExp=3; IntAct=EBI-17263240, EBI-11996766; CC P15941-11; Q5BVD1: TTMP; NbExp=3; IntAct=EBI-17263240, EBI-10243654; CC P15941-11; Q53HI1: UNC50; NbExp=3; IntAct=EBI-17263240, EBI-7601760; CC P15941-11; O95183: VAMP5; NbExp=3; IntAct=EBI-17263240, EBI-10191195; CC P15941-11; Q9BQB6: VKORC1; NbExp=3; IntAct=EBI-17263240, EBI-6256462; CC P15941-11; Q8IVQ6: ZDHHC21; NbExp=3; IntAct=EBI-17263240, EBI-2849773; CC P15941-12; P00519: ABL1; NbExp=4; IntAct=EBI-34603716, EBI-375543; CC PRO_0000317447; P17676: CEBPB; NbExp=8; IntAct=EBI-10053698, EBI-969696; CC -!- SUBCELLULAR LOCATION: Apical cell membrane CC {ECO:0000269|PubMed:11118479, ECO:0000269|PubMed:12832415, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15471854, CC ECO:0000269|PubMed:15972891, ECO:0000269|PubMed:16507569, CC ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:17545600}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:11118479, CC ECO:0000269|PubMed:12832415, ECO:0000269|PubMed:12939402, CC ECO:0000269|PubMed:15471854, ECO:0000269|PubMed:15972891, CC ECO:0000269|PubMed:16507569, ECO:0000269|PubMed:17524503, CC ECO:0000269|PubMed:17545600}. Note=Exclusively located in the apical CC domain of the plasma membrane of highly polarized epithelial cells. CC After endocytosis, internalized and recycled to the cell membrane. CC Located to microvilli and to the tips of long filopodial protusions. CC -!- SUBCELLULAR LOCATION: [Isoform 5]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform Y]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Secreted. CC -!- SUBCELLULAR LOCATION: [Mucin-1 subunit beta]: Cell membrane. Cytoplasm. CC Nucleus. Note=On EGF and PDGFRB stimulation, transported to the nucleus CC through interaction with CTNNB1, a process which is stimulated by CC phosphorylation. On HRG stimulation, colocalizes with JUP/gamma-catenin CC at the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=17; CC Comment=Additional isoforms seem to exist.; CC Name=1; Synonyms=A; CC IsoId=P15941-1; Sequence=Displayed; CC Name=2; Synonyms=B; CC IsoId=P15941-2; Sequence=VSP_003280; CC Name=3; Synonyms=C; CC IsoId=P15941-3; Sequence=VSP_003281; CC Name=4; Synonyms=D; CC IsoId=P15941-4; Sequence=VSP_003282; CC Name=5; Synonyms=SEC; CC IsoId=P15941-5; Sequence=VSP_003288, VSP_003289; CC Name=6; Synonyms=X; CC IsoId=P15941-6; Sequence=VSP_003283, VSP_003284; CC Name=Y; Synonyms=MUC1/Y; CC IsoId=P15941-7; Sequence=VSP_003285; CC Name=8; Synonyms=Z; CC IsoId=P15941-8; Sequence=VSP_003286; CC Name=9; Synonyms=S; CC IsoId=P15941-9; Sequence=VSP_003286, VSP_003287; CC Name=F; CC IsoId=P15941-10; Sequence=VSP_035046, VSP_035047; CC Name=Y-LSP; CC IsoId=P15941-11; Sequence=VSP_003280, VSP_003285; CC Name=S2; CC IsoId=P15941-12; Sequence=VSP_003280, VSP_003285, VSP_003287; CC Name=M6; CC IsoId=P15941-13; Sequence=VSP_003286, VSP_046962, VSP_046963; CC Name=ZD; Synonyms=J19; CC IsoId=P15941-14; Sequence=VSP_047575, VSP_047576; CC Name=T10; CC IsoId=P15941-15; Sequence=VSP_003280, VSP_047873; CC Name=E2; CC IsoId=P15941-16; Sequence=VSP_003280, VSP_047872; CC Name=J13; CC IsoId=P15941-17; Sequence=VSP_003280, VSP_003285, VSP_047874; CC -!- TISSUE SPECIFICITY: Expressed on the apical surface of epithelial CC cells, especially of airway passages, breast and uterus. Also expressed CC in activated and unactivated T-cells. Overexpressed in epithelial CC tumors, such as breast or ovarian cancer and also in non-epithelial CC tumor cells. Isoform Y is expressed in tumor cells only. CC {ECO:0000269|PubMed:15513966, ECO:0000269|PubMed:9212228}. CC -!- DEVELOPMENTAL STAGE: During fetal development, expressed at low levels CC in the colonic epithelium from 13 weeks of gestation. CC {ECO:0000269|PubMed:9536947}. CC -!- PTM: Highly glycosylated (N- and O-linked carbohydrates and sialic CC acid). O-glycosylated to a varying degree on serine and threonine CC residues within each tandem repeat, ranging from mono- to penta- CC glycosylation. The average density ranges from about 50% in human milk CC to over 90% in T47D breast cancer cells. Further sialylation occurs CC during recycling. Membrane-shed glycoproteins from kidney and breast CC cancer cells have preferentially sialyated core 1 structures, while CC secreted forms from the same tissues display mainly core 2 structures. CC The O-glycosylated content is overlapping in both these tissues with CC terminal fucose and galactose, 2- and 3-linked galactose, 3- and 3,6- CC linked GalNAc-ol and 4-linked GlcNAc predominating. Differentially O- CC glycosylated in breast carcinomas with 3,4-linked GlcNAc. N- CC glycosylation consists of high-mannose, acidic complex-type and hybrid CC glycans in the secreted form MUC1/SEC, and neutral complex-type in the CC transmembrane form, MUC1/TM. {ECO:0000269|PubMed:10373415, CC ECO:0000269|PubMed:7744025, ECO:0000269|PubMed:9312074, CC ECO:0000269|PubMed:9597769}. CC -!- PTM: Proteolytic cleavage in the SEA domain occurs in the endoplasmic CC reticulum by an autoproteolytic mechanism and requires the full-length CC SEA domain as well as requiring a Ser, Thr or Cys residue at the P + 1 CC site. Cleavage at this site also occurs on isoform MUC1/X but not on CC isoform MUC1/Y. Ectodomain shedding is mediated by ADAM17. CC {ECO:0000269|PubMed:11341784, ECO:0000269|PubMed:12441351, CC ECO:0000269|PubMed:15987679}. CC -!- PTM: Dual palmitoylation on cysteine residues in the CQC motif is CC required for recycling from endosomes back to the plasma membrane. CC {ECO:0000269|PubMed:16507569}. CC -!- PTM: Phosphorylated on tyrosines and serine residues in the C-terminal. CC Phosphorylation on tyrosines in the C-terminal increases the nuclear CC location of MUC1 and beta-catenin. Phosphorylation by PKC delta induces CC binding of MUC1 to beta-catenin/CTNNB1 and thus decreases the formation CC of the beta-catenin/E-cadherin complex. Src-mediated phosphorylation CC inhibits interaction with GSK3B. Src- and EGFR-mediated phosphorylation CC on Tyr-1229 increases binding to beta-catenin/CTNNB1. GSK3B-mediated CC phosphorylation on Ser-1227 decreases this interaction but restores the CC formation of the beta-cadherin/E-cadherin complex. On T-cell receptor CC activation, phosphorylated by LCK. PDGFR-mediated phosphorylation CC increases nuclear colocalization of MUC1CT and CTNNB1. CC {ECO:0000269|PubMed:11152665, ECO:0000269|PubMed:11483589, CC ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12750561, CC ECO:0000269|PubMed:14521915, ECO:0000269|PubMed:15513966, CC ECO:0000269|PubMed:16288032, ECO:0000269|PubMed:17545600, CC ECO:0000269|PubMed:7664271, ECO:0000269|PubMed:7988707, CC ECO:0000269|PubMed:9819408}. CC -!- PTM: The N-terminal sequence has been shown to begin at position 24 or CC 28. {ECO:0000269|PubMed:11341784}. CC -!- POLYMORPHISM: The number of repeats is highly polymorphic. It varies CC from 21 to 125 in the northern European population. The most frequent CC alleles contains 41 and 85 repeats. The tandemly repeated icosapeptide CC underlies polymorphism at three positions: CC PAPGSTAP[PAQT]AHGVTSAP[DT/ES]R, DT -> ES and the single replacements P CC -> A, P -> Q and P-> T. The most frequent replacement DT -> ES occurs CC in up to 50% of the repeats. CC -!- DISEASE: Note=MUC1/CA 15-3 is used as a serological clinical marker of CC breast cancer to monitor response to breast cancer treatment and CC disease recurrence (PubMed:20816948). Decreased levels over time may be CC indicative of a positive response to treatment. Conversely, increased CC levels may indicate disease progression. At an early stage disease, CC only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA CC 15-3 is not a useful screening test. Most antibodies target the highly CC immunodominant core peptide domain of 20 amino acid CC (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize CC glycosylated epitopes. {ECO:0000269|PubMed:20816948}. CC -!- DISEASE: Tubulointerstitial kidney disease, autosomal dominant 2 CC (ADTKD2) [MIM:174000]: A form of autosomal dominant tubulointerstitial CC kidney disease, a genetically heterogeneous disorder characterized by CC slowly progressive loss of kidney function, bland urinary sediment, CC hyperuricemia, absent or mildly increased albuminuria, lack of severe CC hypertension during the early stages, and normal or small kidneys on CC ultrasound. Renal histology shows variable abnormalities including CC interstitial fibrosis with tubular atrophy, microcystic dilatation of CC the tubules, thickening of tubular basement membranes, medullary cysts, CC and secondary glomerulosclerotic or glomerulocystic changes with CC abnormal glomerular tufting. There is significant variability, as well CC as incomplete penetrance. {ECO:0000269|PubMed:23396133}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: The name KL-6 was originally that of a murine monoclonal CC antibody reacting with pulmonary adenocarcinoma cell lines and CC pulmonary epithelial cells. This antibody recognizes a sialylated CC carbohydrate chain on MUC1. CC -!- MISCELLANEOUS: [Isoform Y-LSP]: Lacks the mucin repeats. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform ZD]: Lacks the mucin repeats. Exists as a CC disulfide-linked oligomer. {ECO:0000305}. CC -!- CAUTION: O-glycosylation sites are annotated in first sequence repeat CC only. Residues at similar position are probably glycosylated in all CC repeats. Experimental sites were determined in a synthetic peptide CC glycosylated in vitro (PubMed:7744025, PubMed:9597769). CC {ECO:0000305|PubMed:7744025, ECO:0000305|PubMed:9597769}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD14369.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAD14376.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Mucin database; CC URL="http://www.medkem.gu.se/mucinbiology/databases/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J05582; AAA60019.1; -; mRNA. DR EMBL; M32738; AAA35804.1; -; mRNA. DR EMBL; M32739; AAA35806.1; -; mRNA. DR EMBL; M34089; AAA35807.1; -; mRNA. DR EMBL; M34088; AAA35805.1; -; mRNA. DR EMBL; J05581; AAA59876.1; -; mRNA. DR EMBL; M61170; AAB53150.1; -; Genomic_DNA. DR EMBL; X52229; CAA36478.1; ALT_SEQ; mRNA. DR EMBL; X52228; CAA36477.1; ALT_SEQ; mRNA. DR EMBL; M35093; AAB59612.1; ALT_SEQ; Genomic_DNA. DR EMBL; X80761; CAA56734.1; -; mRNA. DR EMBL; U60259; AAD10856.1; -; mRNA. DR EMBL; U60260; AAD10857.1; -; mRNA. DR EMBL; U60261; AAD10858.1; -; mRNA. DR EMBL; AF125525; AAD27842.1; -; mRNA. DR EMBL; AY466157; AAR28764.1; -; mRNA. DR EMBL; AY327582; AAP97013.1; -; mRNA. DR EMBL; AY327584; AAP97015.1; -; mRNA. DR EMBL; AY327586; AAP97017.1; -; mRNA. DR EMBL; AY327587; AAP97018.1; -; mRNA. DR EMBL; EF583653; ABQ59628.1; -; mRNA. DR EMBL; EF670711; ABS01298.1; -; mRNA. DR EMBL; EF670712; ABS01299.1; -; mRNA. DR EMBL; FJ226040; ACI25172.1; -; mRNA. DR EMBL; FJ226047; ACI25179.1; -; mRNA. DR EMBL; AF348143; AAK30142.1; -; mRNA. DR EMBL; AY463543; AAR18816.1; -; Genomic_DNA. DR EMBL; AL713999; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471121; EAW53116.1; -; Genomic_DNA. DR EMBL; CH471121; EAW53117.1; -; Genomic_DNA. DR EMBL; CH471121; EAW53118.1; -; Genomic_DNA. DR EMBL; CH471121; EAW53119.1; -; Genomic_DNA. DR EMBL; BC120974; AAI20975.1; -; mRNA. DR EMBL; BC120975; AAI20976.1; -; mRNA. DR EMBL; Z17324; CAA78972.1; -; mRNA. DR EMBL; Z17325; CAA78973.1; -; mRNA. DR EMBL; M31823; AAA35757.1; -; mRNA. DR EMBL; S81781; AAD14376.1; ALT_INIT; mRNA. DR EMBL; S81736; AAD14369.1; ALT_INIT; mRNA. DR EMBL; M21868; AAA59874.1; ALT_SEQ; mRNA. DR CCDS; CCDS1098.1; -. [P15941-8] DR CCDS; CCDS30882.1; -. [P15941-11] DR CCDS; CCDS30883.1; -. [P15941-7] DR CCDS; CCDS41408.1; -. [P15941-12] DR CCDS; CCDS41409.1; -. [P15941-10] DR CCDS; CCDS55641.1; -. [P15941-6] DR CCDS; CCDS55642.1; -. [P15941-13] DR PIR; A35175; A35175. DR RefSeq; NP_001018016.1; NM_001018016.3. [P15941-11] DR RefSeq; NP_001018017.1; NM_001018017.3. [P15941-7] DR RefSeq; NP_001037855.1; NM_001044390.3. [P15941-10] DR RefSeq; NP_001037856.1; NM_001044391.2. DR RefSeq; NP_001037857.1; NM_001044392.3. [P15941-12] DR RefSeq; NP_001037858.1; NM_001044393.2. DR RefSeq; NP_001191214.1; NM_001204285.1. DR RefSeq; NP_001191215.1; NM_001204286.1. DR RefSeq; NP_001191216.1; NM_001204287.1. DR RefSeq; NP_001191217.1; NM_001204288.1. DR RefSeq; NP_001191218.1; NM_001204289.1. DR RefSeq; NP_001191219.1; NM_001204290.1. DR RefSeq; NP_001191220.1; NM_001204291.1. DR RefSeq; NP_001191221.1; NM_001204292.1. DR RefSeq; NP_001191222.1; NM_001204293.2. [P15941-13] DR RefSeq; NP_001191223.1; NM_001204294.2. [P15941-6] DR RefSeq; NP_001191224.1; NM_001204295.1. DR RefSeq; NP_001191225.1; NM_001204296.1. DR RefSeq; NP_001191226.1; NM_001204297.1. DR RefSeq; NP_002447.4; NM_002456.5. [P15941-8] DR PDB; 1SM3; X-ray; 1.95 A; P=919-931. DR PDB; 2ACM; NMR; -; A=1042-1097, B=1098-1152. DR PDB; 2FO4; X-ray; 2.70 A; P=140-146. DR PDB; 5T6P; X-ray; 1.97 A; E/F=921-928. DR PDB; 5T78; X-ray; 2.20 A; E/F=921-928. DR PDB; 6BSB; X-ray; 1.60 A; A=1041-1097, B=1098-1152. DR PDB; 6BSC; X-ray; 1.30 A; A=1041-1097, B=1098-1152. DR PDB; 6FZQ; X-ray; 1.70 A; P=921-926. DR PDB; 6FZR; X-ray; 1.80 A; P=921-926. DR PDB; 6KX1; X-ray; 1.77 A; C=918-932. DR PDB; 6TGG; X-ray; 2.00 A; P=921-926. DR PDB; 7Q4I; X-ray; 2.40 A; F/G=921-926. DR PDB; 7V4W; X-ray; 2.10 A; C=925-937. DR PDB; 7V64; X-ray; 1.56 A; C=925-937. DR PDB; 7V7K; X-ray; 2.20 A; C=925-937. DR PDB; 7V8Q; X-ray; 3.20 A; G/H/I=925-937. DR PDB; 7VAC; X-ray; 3.50 A; G/H/I=925-937. DR PDB; 7VAZ; X-ray; 2.73 A; E/G/I=925-937. DR PDB; 8AXH; X-ray; 1.85 A; A=921-926. DR PDB; 8P6I; X-ray; 2.50 A; A/a=921-929. DR PDB; 8S6K; X-ray; 1.75 A; M/N=927-933. DR PDB; 8S6T; X-ray; 1.85 A; C=926-938. DR PDB; 8S6V; X-ray; 1.95 A; M/N=927-935. DR PDBsum; 1SM3; -. DR PDBsum; 2ACM; -. DR PDBsum; 2FO4; -. DR PDBsum; 5T6P; -. DR PDBsum; 5T78; -. DR PDBsum; 6BSB; -. DR PDBsum; 6BSC; -. DR PDBsum; 6FZQ; -. DR PDBsum; 6FZR; -. DR PDBsum; 6KX1; -. DR PDBsum; 6TGG; -. DR PDBsum; 7Q4I; -. DR PDBsum; 7V4W; -. DR PDBsum; 7V64; -. DR PDBsum; 7V7K; -. DR PDBsum; 7V8Q; -. DR PDBsum; 7VAC; -. DR PDBsum; 7VAZ; -. DR PDBsum; 8AXH; -. DR PDBsum; 8P6I; -. DR PDBsum; 8S6K; -. DR PDBsum; 8S6T; -. DR PDBsum; 8S6V; -. DR AlphaFoldDB; P15941; -. DR SMR; P15941; -. DR BioGRID; 110669; 170. DR CORUM; P15941; -. DR DIP; DIP-41890N; -. DR FunCoup; P15941; 33. DR IntAct; P15941; 121. DR MINT; P15941; -. DR STRING; 9606.ENSP00000484824; -. DR ChEMBL; CHEMBL3580494; -. DR DrugBank; DB06373; ASI402. DR DrugBank; DB11090; Potassium nitrate. DR DrugBank; DB06584; TG4010. DR MEROPS; S71.001; -. DR GlyConnect; 372; 9 O-Linked glycans. DR GlyConnect; 373; 8 O-Linked glycans. DR GlyConnect; 374; 7 N-Linked glycans (3 sites), 8 O-Linked glycans. DR GlyConnect; 375; 10 O-Linked glycans. DR GlyConnect; 376; 10 O-Linked glycans. DR GlyConnect; 377; 7 O-Linked glycans. DR GlyConnect; 413; 5 N-Linked glycans (1 site), 14 O-Linked glycans. DR GlyCosmos; P15941; 17 sites, 54 glycans. DR GlyGen; P15941; 33 sites, 5 N-linked glycans (1 site), 37 O-linked glycans (21 sites). DR iPTMnet; P15941; -. DR PhosphoSitePlus; P15941; -. DR SwissPalm; P15941; -. DR BioMuta; MUC1; -. DR DMDM; 296439295; -. DR CPTAC; CPTAC-146; -. DR CPTAC; CPTAC-147; -. DR CPTAC; CPTAC-719; -. DR CPTAC; CPTAC-730; -. DR jPOST; P15941; -. DR MassIVE; P15941; -. DR PaxDb; 9606-ENSP00000484824; -. DR PeptideAtlas; P15941; -. DR ProteomicsDB; 1779; -. DR ProteomicsDB; 53249; -. [P15941-1] DR ProteomicsDB; 53250; -. [P15941-10] DR ProteomicsDB; 53251; -. [P15941-2] DR ProteomicsDB; 53252; -. [P15941-3] DR ProteomicsDB; 53253; -. [P15941-4] DR ProteomicsDB; 53254; -. [P15941-5] DR ProteomicsDB; 53255; -. [P15941-6] DR ProteomicsDB; 53256; -. [P15941-7] DR ProteomicsDB; 53257; -. [P15941-8] DR ProteomicsDB; 53258; -. [P15941-9] DR ProteomicsDB; 58806; -. DR ProteomicsDB; 6245; -. DR ProteomicsDB; 69255; -. DR ProteomicsDB; 69256; -. DR ProteomicsDB; 767; -. DR Pumba; P15941; -. DR ABCD; P15941; 33 sequenced antibodies. DR Antibodypedia; 1298; 4901 antibodies from 58 providers. DR CPTC; P15941; 2 antibodies. DR DNASU; 4582; -. DR Ensembl; ENST00000337604.6; ENSP00000338983.5; ENSG00000185499.17. [P15941-8] DR Ensembl; ENST00000342482.8; ENSP00000342814.4; ENSG00000185499.17. [P15941-16] DR Ensembl; ENST00000343256.9; ENSP00000339690.5; ENSG00000185499.17. [P15941-10] DR Ensembl; ENST00000368389.6; ENSP00000357374.2; ENSG00000185499.17. [P15941-9] DR Ensembl; ENST00000368390.7; ENSP00000357375.3; ENSG00000185499.17. [P15941-7] DR Ensembl; ENST00000368392.7; ENSP00000357377.3; ENSG00000185499.17. [P15941-11] DR Ensembl; ENST00000368393.7; ENSP00000357378.3; ENSG00000185499.17. [P15941-13] DR Ensembl; ENST00000368396.8; ENSP00000357381.4; ENSG00000185499.17. [P15941-12] DR Ensembl; ENST00000368398.7; ENSP00000357383.3; ENSG00000185499.17. [P15941-6] DR GeneID; 4582; -. DR KEGG; hsa:4582; -. DR UCSC; uc001fia.4; human. [P15941-1] DR AGR; HGNC:7508; -. DR ClinPGx; PA31309; -. DR CTD; 4582; -. DR DisGeNET; 4582; -. DR GeneCards; MUC1; -. DR GeneReviews; MUC1; -. DR HGNC; HGNC:7508; MUC1. DR HPA; ENSG00000185499; Tissue enhanced (kidney, stomach). DR MalaCards; MUC1; -. DR MIM; 113720; gene. DR MIM; 158340; gene. DR MIM; 174000; phenotype. DR OpenTargets; ENSG00000185499; -. DR Orphanet; 88949; MUC1-related autosomal dominant tubulointerstitial kidney disease. DR VEuPathDB; HostDB:ENSG00000185499; -. DR eggNOG; ENOG502QWCT; Eukaryota. DR GeneTree; ENSGT00710000106874; -. DR HOGENOM; CLU_1386987_0_0_1; -. DR InParanoid; P15941; -. DR OrthoDB; 9909831at2759; -. DR PAN-GO; P15941; 1 GO annotation based on evolutionary models. DR PhylomeDB; P15941; -. DR PathwayCommons; P15941; -. DR Reactome; R-HSA-5083625; Defective GALNT3 causes HFTC. DR Reactome; R-HSA-5083632; Defective C1GALT1C1 causes TNPS. DR Reactome; R-HSA-5083636; Defective GALNT12 causes CRCS1. DR Reactome; R-HSA-5621480; Dectin-2 family. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-913709; O-linked glycosylation of mucins. DR Reactome; R-HSA-977068; Termination of O-glycan biosynthesis. DR SignaLink; P15941; -. DR SIGNOR; P15941; -. DR Agora; ENSG00000185499; -. DR BioGRID-ORCS; 4582; 31 hits in 1174 CRISPR screens. DR ChiTaRS; MUC1; human. DR EvolutionaryTrace; P15941; -. DR GeneWiki; MUC1; -. DR GenomeRNAi; 4582; -. DR Pharos; P15941; Tchem. DR PRO; PR:P15941; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P15941; protein. DR Bgee; ENSG00000185499; Expressed in pylorus and 172 other cell types or tissues. DR ExpressionAtlas; P15941; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IBA:GO_Central. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:0005796; C:Golgi lumen; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031982; C:vesicle; HDA:UniProtKB. DR GO; GO:0002039; F:p53 binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0003712; F:transcription coregulator activity; IDA:BHF-UCL. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IDA:BHF-UCL. DR GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IDA:CACAO. DR GO; GO:1902166; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0010944; P:negative regulation of transcription by competitive promoter binding; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR DisProt; DP01790; -. DR Gene3D; 6.10.140.600; -; 1. DR IDEAL; IID00195; -. DR InterPro; IPR000082; SEA_dom. DR InterPro; IPR036364; SEA_dom_sf. DR PANTHER; PTHR10006:SF19; MUCIN-1; 1. DR PANTHER; PTHR10006; MUCIN-1-RELATED; 1. DR Pfam; PF01390; SEA; 1. DR SMART; SM00200; SEA; 1. DR SUPFAM; SSF82671; SEA domain; 1. DR PROSITE; PS50024; SEA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Autocatalytic cleavage; Cell membrane; KW Cytoplasm; Direct protein sequencing; Disulfide bond; Glycoprotein; KW Lipoprotein; Membrane; Nucleus; Palmitate; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Secreted; Signal; KW Transmembrane; Transmembrane helix; Tumor suppressor. FT SIGNAL 1..23 FT /evidence="ECO:0000269|PubMed:10373415, FT ECO:0000269|PubMed:11341784" FT CHAIN 24..1255 FT /note="Mucin-1" FT /id="PRO_0000019277" FT CHAIN 24..1097 FT /note="Mucin-1 subunit alpha" FT /id="PRO_0000317446" FT CHAIN 1098..1255 FT /note="Mucin-1 subunit beta" FT /id="PRO_0000317447" FT TOPO_DOM 24..1158 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 1159..1181 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1182..1255 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 61..80 FT /note="1; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 81..100 FT /note="2; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 101..120 FT /note="3" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 121..140 FT /note="4" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 141..160 FT /note="5" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 161..180 FT /note="6" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 181..200 FT /note="7" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 201..220 FT /note="8" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 221..240 FT /note="9" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 241..260 FT /note="10" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 261..280 FT /note="11" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 281..300 FT /note="12" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 301..320 FT /note="13" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 321..340 FT /note="14" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 341..360 FT /note="15" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 361..380 FT /note="16" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 381..400 FT /note="17" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 401..420 FT /note="18" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 421..440 FT /note="19" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 441..460 FT /note="20" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 461..480 FT /note="21" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 481..500 FT /note="22" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 501..520 FT /note="23" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 521..540 FT /note="24" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 541..560 FT /note="25" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 561..580 FT /note="26" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 581..600 FT /note="27" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 601..620 FT /note="28" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 621..640 FT /note="29" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 641..660 FT /note="30" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 661..680 FT /note="31" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 681..700 FT /note="32" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 701..720 FT /note="33" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 721..740 FT /note="34" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 741..760 FT /note="35" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 761..780 FT /note="36" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 781..800 FT /note="37" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 801..820 FT /note="38" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 821..840 FT /note="39" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 841..860 FT /note="40" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 861..880 FT /note="41" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 881..900 FT /note="42" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 901..920 FT /note="43" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 921..940 FT /note="44" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 941..960 FT /note="45" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 961..980 FT /note="46; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 981..1000 FT /note="47; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT REPEAT 1001..1020 FT /note="48; approximate" FT /evidence="ECO:0000269|PubMed:11350974" FT DOMAIN 1039..1148 FT /note="SEA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00188" FT REGION 23..1033 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 126..965 FT /note="42 X 20 AA approximate tandem repeats of P-A-P-G-S- FT T-A-P-P-A-H-G-V-T-S-A-P-D-T-R" FT REGION 1192..1228 FT /note="Interaction with P53" FT REGION 1214..1237 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1223..1230 FT /note="Required for interaction with GSK3B" FT REGION 1233..1241 FT /note="Required for interaction with beta- and gamma- FT catenins" FT MOTIF 1203..1206 FT /note="Interaction with GRB2" FT MOTIF 1229..1232 FT /note="Interaction with SRC and ESR1" FT MOTIF 1243..1246 FT /note="Required for interaction with AP1S2" FT COMPBIAS 38..54 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 55..75 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 90..102 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 960..970 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 971..993 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1001..1033 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT SITE 1097..1098 FT /note="Cleavage; by autolysis" FT MOD_RES 1203 FT /note="Phosphotyrosine; by PDGFR" FT /evidence="ECO:0000269|PubMed:14521915, FT ECO:0000269|PubMed:17545600" FT MOD_RES 1212 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:14521915" FT MOD_RES 1218 FT /note="Phosphotyrosine; by PDGFR" FT /evidence="ECO:0000269|PubMed:17545600" FT MOD_RES 1224 FT /note="Phosphothreonine; by PKC/PRKCD" FT /evidence="ECO:0000269|PubMed:11877440" FT MOD_RES 1227 FT /note="Phosphoserine; by GSK3-beta" FT /evidence="ECO:0000269|PubMed:9819408, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1229 FT /note="Phosphotyrosine; by CSK, EGFR and SRC" FT /evidence="ECO:0000269|PubMed:11152665, FT ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:14521915, FT ECO:0000269|PubMed:17545600" FT MOD_RES 1243 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:14521915" FT LIPID 1184 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:16507569" FT LIPID 1186 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:16507569" FT CARBOHYD 131 FT /note="O-linked (GalNAc...) threonine" FT /evidence="ECO:0000305|PubMed:7744025, FT ECO:0000305|PubMed:9597769" FT CARBOHYD 139 FT /note="O-linked (GalNAc...) threonine" FT /evidence="ECO:0000305|PubMed:7744025, FT ECO:0000305|PubMed:9597769" FT CARBOHYD 140 FT /note="O-linked (GalNAc...) serine" FT /evidence="ECO:0000255" FT CARBOHYD 144 FT /note="O-linked (GalNAc...) threonine" FT /evidence="ECO:0000255" FT CARBOHYD 957 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 975 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1029 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1055 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1133 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 19..21 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.25" FT /id="VSP_003281" FT VAR_SEQ 19 FT /note="T -> TATTAPKPAT (in isoform 2, isoform Y-LSP, FT isoform E2, isoform J13, isoform S2 and isoform T10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:22941036, ECO:0000303|PubMed:2318825, FT ECO:0000303|PubMed:2597151, ECO:0000303|PubMed:8608966, FT ECO:0000303|Ref.15" FT /id="VSP_003280" FT VAR_SEQ 20..31 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|Ref.25" FT /id="VSP_003282" FT VAR_SEQ 54..1151 FT /note="Missing (in isoform E2)" FT /evidence="ECO:0000303|PubMed:22941036" FT /id="VSP_047872" FT VAR_SEQ 54..1093 FT /note="Missing (in isoform T10)" FT /evidence="ECO:0000303|PubMed:22941036" FT /id="VSP_047873" FT VAR_SEQ 54..1053 FT /note="Missing (in isoform J13, isoform Y, isoform Y-LSP FT and isoform S2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:15969018, ECO:0000303|PubMed:22941036, FT ECO:0000303|PubMed:7925397, ECO:0000303|PubMed:9212228, FT ECO:0000303|Ref.15" FT /id="VSP_003285" FT VAR_SEQ 54..1035 FT /note="Missing (in isoform 8, isoform 9 and isoform M6)" FT /evidence="ECO:0000303|PubMed:22941036, FT ECO:0000303|PubMed:9212228, ECO:0000303|Ref.12, FT ECO:0000303|Ref.16" FT /id="VSP_003286" FT VAR_SEQ 54..96 FT /note="VSMTSSVLSSHSPGSGSSTTQGQDVTLAPATEPASGSAATWGQ -> IPAPT FT TTKSCRETFLKCFCRFINKGVFWASPILSSGQDLWWYN (in isoform ZD)" FT /evidence="ECO:0000303|PubMed:15623537, FT ECO:0000303|PubMed:22941036" FT /id="VSP_047575" FT VAR_SEQ 54..87 FT /note="VSMTSSVLSSHSPGSGSSTTQGQDVTLAPATEPA -> IPAPTTTKSCRETF FT LKCFCRFINKGVFWASPILS (in isoform F)" FT /evidence="ECO:0000303|Ref.14" FT /id="VSP_035046" FT VAR_SEQ 54..70 FT /note="VSMTSSVLSSHSPGSGS -> IPAPTTTKSCRETFLKW (in isoform FT 6)" FT /evidence="ECO:0000303|PubMed:22941036, FT ECO:0000303|PubMed:9212228" FT /id="VSP_003283" FT VAR_SEQ 71..1095 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:22941036, FT ECO:0000303|PubMed:9212228" FT /id="VSP_003284" FT VAR_SEQ 88..1139 FT /note="Missing (in isoform F)" FT /evidence="ECO:0000303|Ref.14" FT /id="VSP_035047" FT VAR_SEQ 97..1255 FT /note="Missing (in isoform ZD)" FT /evidence="ECO:0000303|PubMed:15623537, FT ECO:0000303|PubMed:22941036" FT /id="VSP_047576" FT VAR_SEQ 1077..1181 FT /note="Missing (in isoform 9 and isoform S2)" FT /evidence="ECO:0000303|PubMed:22941036, ECO:0000303|Ref.12, FT ECO:0000303|Ref.15" FT /id="VSP_003287" FT VAR_SEQ 1077..1087 FT /note="FLQIYKQGGFL -> VSIGLSFPMLP (in isoform 5)" FT /evidence="ECO:0000303|PubMed:2351132" FT /id="VSP_003288" FT VAR_SEQ 1088..1255 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:2351132" FT /id="VSP_003289" FT VAR_SEQ 1141..1180 FT /note="VSDVPFPFSAQSGAGVPGWGIALLVLVCVLVALAIVYLIA -> GCLSVPPK FT ELRAAGHLSSPGYLPSYERVPHLPHPWALCAP (in isoform M6)" FT /evidence="ECO:0000303|PubMed:22941036, ECO:0000303|Ref.16" FT /id="VSP_046962" FT VAR_SEQ 1181..1255 FT /note="Missing (in isoform M6)" FT /evidence="ECO:0000303|PubMed:22941036, ECO:0000303|Ref.16" FT /id="VSP_046963" FT VAR_SEQ 1232..1255 FT /note="VSAGNGGSSLSYTNPAVAATSANL -> RQNGWSTMPRGALPEESQG (in FT isoform J13)" FT /evidence="ECO:0000303|PubMed:22941036" FT /id="VSP_047874" FT VARIANT 1117 FT /note="V -> M (in dbSNP:rs1611770)" FT /evidence="ECO:0000269|PubMed:15969018, FT ECO:0000269|PubMed:22941036, ECO:0000269|Ref.17" FT /id="VAR_019390" FT VARIANT 1142 FT /note="S -> N (in dbSNP:rs11465207)" FT /evidence="ECO:0000269|Ref.17" FT /id="VAR_019391" FT MUTAGEN 1098 FT /note="S->A,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y: Completely FT abrogates cleavage." FT /evidence="ECO:0000269|PubMed:15987679" FT MUTAGEN 1098 FT /note="S->C,T: Almost complete cleavage." FT /evidence="ECO:0000269|PubMed:15987679" FT MUTAGEN 1116 FT /note="D->A: Greatly reduced formation of isoform 5/isoform FT Y complex." FT /evidence="ECO:0000269|PubMed:10197628" FT MUTAGEN 1116 FT /note="D->E: No effect on formation of isoform 5/isoform Y FT complex." FT /evidence="ECO:0000269|PubMed:10197628" FT MUTAGEN 1184 FT /note="C->A: S-palmitoylation reduced by 50%. Complete loss FT of palmitoylation, no effect on endocytosis, recycling FT inhibited and AP1S1 binding reduced by 30%; when associated FT with C-1186. Accumulates in intracellular compartments; FT when associated with C-1186 and N-1203." FT /evidence="ECO:0000269|PubMed:16507569" FT MUTAGEN 1186 FT /note="C->A: S-palmitoylation reduced by 50%. Complete loss FT of palmitoylation, no effect on endocytosis, recycling FT inhibited, and AP1S1 binding reduced by 30%; when FT associated with C-1184. Accumulates in intracellular FT compartments; when associated with C-1184 and N-1203." FT /evidence="ECO:0000269|PubMed:16507569" FT MUTAGEN 1187..1189 FT /note="RRK->AAA: No nuclear targeting of HRG-stimulated FT MUC1 C-terminal nor JUP/gamma-catenin. No effect on FT interaction with JUP/gamma-catenin." FT /evidence="ECO:0000269|PubMed:12939402, FT ECO:0000269|PubMed:16507569" FT MUTAGEN 1187..1189 FT /note="RRK->QQQ: No effect on palmitoylation." FT /evidence="ECO:0000269|PubMed:12939402, FT ECO:0000269|PubMed:16507569" FT MUTAGEN 1191 FT /note="Y->F: No effect on EGFR-mediated phosphorylation." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854" FT MUTAGEN 1191 FT /note="Y->N: No effect on endocytosis." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854" FT MUTAGEN 1203 FT /note="Y->E: No effect on nuclear colocalization of MUC1CT FT and CTNNB1. No effect on in vitro PDFGR-induced cell FT invasiveness." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854, ECO:0000269|PubMed:16507569, FT ECO:0000269|PubMed:17545600" FT MUTAGEN 1203 FT /note="Y->F: No effect on EGFR-mediated phosphorylation. No FT nuclear localization of MUC1CT. Reduced in vitro PDGFR- FT induced cell invasiveness." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854, ECO:0000269|PubMed:16507569, FT ECO:0000269|PubMed:17545600" FT MUTAGEN 1203 FT /note="Y->N: Reduced endocytosis by 30%. Greatly reduced FT binding to AP1S2 and GRB2. Binding AP1S1 reduced by 25%. FT Reduced endocytosis by 77%; when associated with N-1243. FT Accumulates in intracellular compartments; when associated FT with C-1184 and C-1186." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:15471854, ECO:0000269|PubMed:16507569, FT ECO:0000269|PubMed:17545600" FT MUTAGEN 1209 FT /note="Y->F: Some reduction in EGFR-mediated FT phosphorylation." FT /evidence="ECO:0000269|PubMed:11483589" FT MUTAGEN 1218 FT /note="Y->F: No effect on EGFR-mediated phosphorylation. No FT nuclear colocalization of MUC1CT and CTNNB1." FT /evidence="ECO:0000269|PubMed:11483589, FT ECO:0000269|PubMed:17545600" FT MUTAGEN 1223 FT /note="S->A: No change in PRKCD- nor GSK3B-mediated FT phosphorylation." FT /evidence="ECO:0000269|PubMed:11877440, FT ECO:0000269|PubMed:9819408" FT MUTAGEN 1224 FT /note="T->A: Loss of PRKCD-mediated phosphorylation. FT Decreased PRKCD binding. No increased binding to CTNNB1 in FT the presence of autophosphorylated PRKCD. Increases FT formation of E-cadherin/beta-catenin complex." FT /evidence="ECO:0000269|PubMed:11877440" FT MUTAGEN 1227 FT /note="S->A: No change in PRKCD-mediated phosphorylation. FT Loss of GSK3B-mediated phosphorylation. CTNNB1." FT /evidence="ECO:0000269|PubMed:11877440, FT ECO:0000269|PubMed:9819408" FT MUTAGEN 1229 FT /note="Y->F: Greatly reduced EGFR- and Src-mediated FT phosphorylation. No nuclear localization of MUC1CT. Reduced FT in vitro PDGFR-mediated phosphorylation. Decreased Src- FT binding." FT /evidence="ECO:0000269|PubMed:11152665, FT ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:14688481, FT ECO:0000269|PubMed:15471854" FT MUTAGEN 1229 FT /note="Y->N: No effect on endocytosis." FT /evidence="ECO:0000269|PubMed:11152665, FT ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:14688481, FT ECO:0000269|PubMed:15471854" FT MUTAGEN 1243 FT /note="Y->N: Reduces binding to AP1S2 by 33%. Greatly FT reduced binding to GRB2. Reduced endocytosis by 50%. FT Reduced endocytosis by 77%; when associated with N-1203." FT /evidence="ECO:0000269|PubMed:15471854" FT CONFLICT 2 FT /note="T -> A (in Ref. 24; AAD14369)" FT /evidence="ECO:0000305" FT CONFLICT 134 FT /note="P -> Q (in Ref. 22; AAA35757)" FT /evidence="ECO:0000305" FT CONFLICT 154 FT /note="P -> Q (in Ref. 22; AAA35757)" FT /evidence="ECO:0000305" FT CONFLICT 1021 FT /note="S -> T (in Ref. 2; AAA35805/AAA35807 and 3; FT AAA59876)" FT /evidence="ECO:0000305" FT CONFLICT 1143 FT /note="D -> G (in Ref. 11; AAP97018)" FT /evidence="ECO:0000305" FT CONFLICT 1193 FT /note="Q -> L (in Ref. 13; AAK30142)" FT /evidence="ECO:0000305" FT CONFLICT 1231 FT /note="K -> T (in Ref. 9; AAD10858)" FT /evidence="ECO:0000305" FT CONFLICT 1251 FT /note="T -> A (in Ref. 1; AAA60019)" FT /evidence="ECO:0000305" FT STRAND 1042..1052 FT /evidence="ECO:0007829|PDB:2ACM" FT HELIX 1056..1059 FT /evidence="ECO:0007829|PDB:2ACM" FT HELIX 1064..1080 FT /evidence="ECO:0007829|PDB:2ACM" FT TURN 1082..1085 FT /evidence="ECO:0007829|PDB:2ACM" FT STRAND 1086..1096 FT /evidence="ECO:0007829|PDB:2ACM" FT STRAND 1099..1107 FT /evidence="ECO:0007829|PDB:2ACM" FT TURN 1109..1111 FT /evidence="ECO:0007829|PDB:2ACM" FT HELIX 1114..1132 FT /evidence="ECO:0007829|PDB:2ACM" FT STRAND 1136..1142 FT /evidence="ECO:0007829|PDB:2ACM" SQ SEQUENCE 1255 AA; 122102 MW; 5E28DFC4C20D9A82 CRC64; MTPGTQSPFF LLLLLTVLTV VTGSGHASST PGGEKETSAT QRSSVPSSTE KNAVSMTSSV LSSHSPGSGS STTQGQDVTL APATEPASGS AATWGQDVTS VPVTRPALGS TTPPAHDVTS APDNKPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDNRPALGS TAPPVHNVTS ASGSASGSAS TLVHNGTSAR ATTTPASKST PFSIPSHHSD TPTTLASHST KTDASSTHHS SVPPLTSSNH STSPQLSTGV SFFFLSFHIS NLQFNSSLED PSTDYYQELQ RDISEMFLQI YKQGGFLGLS NIKFRPGSVV VQLTLAFREG TINVHDVETQ FNQYKTEAAS RYNLTISDVS VSDVPFPFSA QSGAGVPGWG IALLVLVCVL VALAIVYLIA LAVCQCRRKN YGQLDIFPAR DTYHPMSEYP TYHTHGRYVP PSSTDRSPYE KVSAGNGGSS LSYTNPAVAA TSANL // ID PAUF_HUMAN Reviewed; 172 AA. AC Q96DA0; A6NIY1; B2R4F6; C3PTT6; Q6UW28; DT 05-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 24-JAN-2024, sequence version 4. DT 28-JAN-2026, entry version 154. DE RecName: Full=Pancreatic adenocarcinoma up-regulated factor {ECO:0000303|PubMed:19302292}; DE AltName: Full=Zymogen granule protein 16 homolog B; DE Flags: Precursor; GN Name=ZG16B; Synonyms=PAUF {ECO:0000303|PubMed:19302292}; GN ORFNames=UNQ773/PRO1567; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 17-22, FUNCTION, RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND GLYCOSYLATION. RC TISSUE=Placenta; RX PubMed=19302292; DOI=10.1111/j.1349-7006.2009.01106.x; RA Kim S.A., Lee Y., Jung D.E., Park K.H., Park J.Y., Gang J., Jeon S.B., RA Park E.C., Kim Y.G., Lee B., Liu Q., Zeng W., Yeramilli S., Lee S., RA Koh S.S., Song S.Y.; RT "Pancreatic adenocarcinoma up-regulated factor (PAUF), a novel up-regulated RT secretory protein in pancreatic ductal adenocarcinoma."; RL Cancer Sci. 100:828-836(2009). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung carcinoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11678034; RX DOI=10.1002/1615-9861(200104)1:5<641::aid-prot641>3.0.co;2-r; RA Kuster B., Mortensen P., Andersen J.S., Mann M.; RT "Mass spectrometry allows direct identification of proteins in large RT genomes."; RL Proteomics 1:641-650(2001). RN [8] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=33207190; DOI=10.1016/j.celrep.2020.108402; RA Saitou M., Gaylord E.A., Xu E., May A.J., Neznanova L., Nathan S., RA Grawe A., Chang J., Ryan W., Ruhl S., Knox S.M., Gokcumen O.; RT "Functional Specialization of Human Salivary Glands and Origins of Proteins RT Intrinsic to Human Saliva."; RL Cell Rep. 33:108402-108402(2020). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TLR4. RX PubMed=36232715; DOI=10.3390/ijms231911414; RA Youn S.E., Jiang F., Won H.Y., Hong D.E., Kang T.H., Park Y.Y., Koh S.S.; RT "PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via RT the TLR4/MyD88/NF-kappaB Signaling Pathway."; RL Int. J. Mol. Sci. 23:0-0(2022). RN [10] RP FUNCTION, AND SUBUNIT. RX PubMed=37216558; DOI=10.1073/pnas.2216304120; RA Ghosh S., Ahearn C.P., Isabella C.R., Marando V.M., Dodge G.J., RA Bartlett H., McPherson R.L., Dugan A.E., Jain S., Neznanova L., RA Tettelin H., Putnik R., Grimes C.L., Ruhl S., Kiessling L.L., Imperiali B.; RT "Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode RT host-microbe interactions with oral commensals."; RL Proc. Natl. Acad. Sci. U.S.A. 120:e2216304120-e2216304120(2023). RN [11] RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 17-172. RX PubMed=21110947; DOI=10.1016/j.bbrc.2010.11.093; RA Kanagawa M., Satoh T., Ikeda A., Nakano Y., Yagi H., Kato K., RA Kojima-Aikawa K., Yamaguchi Y.; RT "Crystal structures of human secretory proteins ZG16p and ZG16b reveal a RT Jacalin-related beta-prism fold."; RL Biochem. Biophys. Res. Commun. 404:201-205(2011). CC -!- FUNCTION: Functions as a lectin that binds to selective commensal CC dental plaque bacteria, such as Streptococcus vestibularis. Contributes CC to maintain homeostasis in the oral microbiome by capturing commensal CC microbes and regulating their growth using a mucin-assisted clearance CC mechanism (PubMed:37216558). Plays an important role in pancreatic CC tumor progression and metastasis (PubMed:19302292, PubMed:36232715). CC Promotes pancreatic cancer cells migration and invasion through the CC TLR4/MyD88/NF-kappaB signaling pathway, without the involvement of the CC TLR4/TRIF pathway (PubMed:36232715). {ECO:0000269|PubMed:19302292, CC ECO:0000269|PubMed:36232715, ECO:0000269|PubMed:37216558}. CC -!- SUBUNIT: Interacts with MUC7; this interaction enhances the capture of CC commensal bacteria and promotes their removal via the mucin-assisted CC clearance pathway (PubMed:37216558). Found in a complex with the CC salivary mucin MUC7 and with Streptococcus vestibularis CC (PubMed:37216558). {ECO:0000269|PubMed:37216558}. CC -!- INTERACTION: CC Q96DA0; Q9BT25: HAUS8; NbExp=3; IntAct=EBI-953824, EBI-2558143; CC Q96DA0; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-953824, EBI-302345; CC Q96DA0; Q9UJW9: SERTAD3; NbExp=5; IntAct=EBI-953824, EBI-748621; CC Q96DA0; O43765: SGTA; NbExp=6; IntAct=EBI-953824, EBI-347996; CC Q96DA0; Q96EQ0: SGTB; NbExp=5; IntAct=EBI-953824, EBI-744081; CC Q96DA0; O60603: TLR2; NbExp=3; IntAct=EBI-953824, EBI-973722; CC Q96DA0; Q9BSL1: UBAC1; NbExp=3; IntAct=EBI-953824, EBI-749370; CC Q96DA0; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-953824, EBI-741480; CC Q96DA0; Q9UMX0-2: UBQLN1; NbExp=3; IntAct=EBI-953824, EBI-10173939; CC Q96DA0; Q9UHD9: UBQLN2; NbExp=6; IntAct=EBI-953824, EBI-947187; CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19302292, CC ECO:0000269|PubMed:33207190}. Cytoplasm {ECO:0000269|PubMed:19302292}. CC Cell membrane {ECO:0000269|PubMed:36232715}. Apicolateral cell membrane CC {ECO:0000269|PubMed:19302292}. Note=Co-localizes with TLR4 at the cell CC membrane of pancreatic cancer cells. {ECO:0000269|PubMed:36232715}. CC -!- TISSUE SPECIFICITY: Highly expressed in pancreatic cancer tissues (at CC protein levels). Also expressed in the placenta and colon and ovarian CC cancer tumors (PubMed:19302292). Highly expressed in salivary glands, CC in submandibular and sublingual glands (PubMed:33207190). CC {ECO:0000269|PubMed:19302292, ECO:0000269|PubMed:33207190}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:19302292}. CC -!- SIMILARITY: Belongs to the jacalin lectin family. {ECO:0000255|PROSITE- CC ProRule:PRU01088, ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH09722.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAQ89380.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=ABM92915.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=EAW85462.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; EF067313; ABM92915.1; ALT_INIT; mRNA. DR EMBL; AY359021; AAQ89380.1; ALT_INIT; mRNA. DR EMBL; AC005361; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471112; EAW85462.1; ALT_SEQ; Genomic_DNA. DR EMBL; BC009722; AAH09722.2; ALT_INIT; mRNA. DR EMBL; AK311810; BAG34753.1; -; mRNA. DR CCDS; CCDS10479.3; -. DR RefSeq; NP_660295.3; NM_145252.3. DR PDB; 3AQG; X-ray; 2.75 A; A/B=17-172. DR PDBsum; 3AQG; -. DR AlphaFoldDB; Q96DA0; -. DR SMR; Q96DA0; -. DR BioGRID; 125855; 202. DR CORUM; Q96DA0; -. DR FunCoup; Q96DA0; 36. DR IntAct; Q96DA0; 143. DR MINT; Q96DA0; -. DR STRING; 9606.ENSP00000371715; -. DR UniLectin; Q96DA0; -. DR GlyConnect; 1909; 6 N-Linked glycans (1 site). DR GlyCosmos; Q96DA0; 1 site, 6 glycans. DR GlyGen; Q96DA0; 2 sites. DR PhosphoSitePlus; Q96DA0; -. DR BioMuta; ZG16B; -. DR DMDM; 152031723; -. DR jPOST; Q96DA0; -. DR MassIVE; Q96DA0; -. DR PaxDb; 9606-ENSP00000371715; -. DR PeptideAtlas; Q96DA0; -. DR PRIDE; Q96DA0; -. DR ProteomicsDB; 76263; -. DR Pumba; Q96DA0; -. DR Antibodypedia; 23906; 125 antibodies from 16 providers. DR DNASU; 124220; -. DR Ensembl; ENST00000382280.8; ENSP00000371715.4; ENSG00000162078.13. DR Ensembl; ENST00000572863.2; ENSP00000461740.2; ENSG00000162078.13. DR Ensembl; ENST00000634500.2; ENSP00000489035.2; ENSG00000283056.2. DR Ensembl; ENST00000634906.2; ENSP00000489251.2; ENSG00000283056.2. DR GeneID; 124220; -. DR KEGG; hsa:124220; -. DR MANE-Select; ENST00000382280.8; ENSP00000371715.4; NM_145252.3; NP_660295.3. DR UCSC; uc002cru.4; human. DR AGR; HGNC:30456; -. DR ClinPGx; PA164727732; -. DR CTD; 124220; -. DR DisGeNET; 124220; -. DR GeneCards; ZG16B; -. DR HGNC; HGNC:30456; ZG16B. DR HPA; ENSG00000162078; Tissue enriched (salivary). DR MIM; 620477; gene. DR OpenTargets; ENSG00000162078; -. DR VEuPathDB; HostDB:ENSG00000162078; -. DR eggNOG; ENOG502SWMW; Eukaryota. DR GeneTree; ENSGT00940000163143; -. DR InParanoid; Q96DA0; -. DR OrthoDB; 9606821at2759; -. DR PAN-GO; Q96DA0; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q96DA0; -. DR PathwayCommons; Q96DA0; -. DR SignaLink; Q96DA0; -. DR BioGRID-ORCS; 124220; 10 hits in 1157 CRISPR screens. DR ChiTaRS; ZG16B; human. DR EvolutionaryTrace; Q96DA0; -. DR GeneWiki; LOC124220; -. DR GenomeRNAi; 124220; -. DR Pharos; Q96DA0; Tbio. DR PRO; PR:Q96DA0; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; Q96DA0; protein. DR Bgee; ENSG00000162078; Expressed in olfactory segment of nasal mucosa and 87 other cell types or tissues. DR ExpressionAtlas; Q96DA0; baseline and differential. DR GO; GO:0016327; C:apicolateral plasma membrane; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; IDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB. DR GO; GO:0043117; P:positive regulation of vascular permeability; IDA:UniProtKB. DR CDD; cd09611; Jacalin_ZG16_like; 1. DR FunFam; 2.100.10.30:FF:000004; Zymogen granule protein 16B; 1. DR Gene3D; 2.100.10.30; Jacalin-like lectin domain; 1. DR InterPro; IPR001229; Jacalin-like_lectin_dom. DR InterPro; IPR036404; Jacalin-like_lectin_dom_sf. DR InterPro; IPR052321; PolyBind_ProtTraffic. DR PANTHER; PTHR33589; OS11G0524900 PROTEIN; 1. DR PANTHER; PTHR33589:SF1; ZYMOGEN GRANULE PROTEIN 16 HOMOLOG B; 1. DR Pfam; PF01419; Jacalin; 1. DR SMART; SM00915; Jacalin; 1. DR SUPFAM; SSF51101; Mannose-binding lectins; 1. DR PROSITE; PS51752; JACALIN_LECTIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Cell membrane; Cytoplasm; Direct protein sequencing; KW Glycoprotein; Lectin; Membrane; Proteomics identification; KW Reference proteome; Secreted; Signal. FT SIGNAL 1..16 FT /evidence="ECO:0000255" FT CHAIN 17..172 FT /note="Pancreatic adenocarcinoma up-regulated factor" FT /id="PRO_0000248073" FT DOMAIN 17..149 FT /note="Jacalin-type lectin" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01088" FT CARBOHYD 161 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VARIANT 97 FT /note="M -> V (in dbSNP:rs35533993)" FT /id="VAR_060067" FT STRAND 20..22 FT /evidence="ECO:0007829|PDB:3AQG" FT STRAND 25..29 FT /evidence="ECO:0007829|PDB:3AQG" FT STRAND 38..45 FT /evidence="ECO:0007829|PDB:3AQG" FT STRAND 47..61 FT /evidence="ECO:0007829|PDB:3AQG" FT STRAND 70..76 FT /evidence="ECO:0007829|PDB:3AQG" FT STRAND 83..101 FT /evidence="ECO:0007829|PDB:3AQG" FT STRAND 106..110 FT /evidence="ECO:0007829|PDB:3AQG" FT STRAND 114..119 FT /evidence="ECO:0007829|PDB:3AQG" FT STRAND 127..136 FT /evidence="ECO:0007829|PDB:3AQG" FT STRAND 139..148 FT /evidence="ECO:0007829|PDB:3AQG" SQ SEQUENCE 172 AA; 18879 MW; BC34ADFB33A99AEF CRC64; MLLLLTLALL GGPTWAGKMY GPGGGKYFST TEDYDHEITG LRVSVGLLLV KSVQVKLGDS WDVKLGALGG NTQEVTLQPG EYITKVFVAF QAFLRGMVMY TSKDRYFYFG KLDGQISSAY PSQEGQVLVG IYGQYQLLGI KSIGFEWNYP LEEPTTEPPV NLTYSANSPV GR // ID PK3CA_HUMAN Reviewed; 1068 AA. AC P42336; Q14CW1; Q99762; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 20-FEB-2007, sequence version 2. DT 28-JAN-2026, entry version 242. DE RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; DE Short=PI3-kinase subunit alpha; DE Short=PI3K-alpha; DE Short=PI3Kalpha {ECO:0000303|PubMed:28676499}; DE Short=PtdIns-3-kinase subunit alpha; DE EC=2.7.1.137 {ECO:0000269|PubMed:23936502}; DE EC=2.7.1.153 {ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; DE AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; DE Short=PtdIns-3-kinase subunit p110-alpha; DE Short=p110alpha {ECO:0000303|PubMed:15135396}; DE AltName: Full=Phosphoinositide 3-kinase alpha {ECO:0000303|PubMed:28676499}; DE AltName: Full=Phosphoinositide-3-kinase catalytic alpha polypeptide; DE AltName: Full=Serine/threonine protein kinase PIK3CA; DE EC=2.7.11.1 {ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; GN Name=PIK3CA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-43 AND ARG-332. RX PubMed=7713498; DOI=10.1006/geno.1994.1655; RA Volinia S., Hiles I., Ormondroyd E., Nizetic D., Antonacci R., Rocchi M., RA Waterfield M.; RT "Molecular cloning, cDNA sequence, and chromosomal localization of the RT human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene."; RL Genomics 24:472-477(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9043658; DOI=10.1016/s0968-0896(96)00196-4; RA Stirdivant S.M., Ahern J., Conroy R.R., Barnett S.F., Ledder L.M., RA Oliff A., Heimbrook D.C.; RT "Cloning and mutagenesis of the p110 alpha subunit of human RT phosphoinositide 3'-hydroxykinase."; RL Bioorg. Med. Chem. 5:65-74(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP INTERACTION WITH APPL1. RX PubMed=10490823; DOI=10.1038/sj.onc.1203080; RA Mitsuuchi Y., Johnson S.W., Sonoda G., Tanno S., Golemis E.A., Testa J.R.; RT "Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor RT molecule that interacts with the oncoprotein-serine/threonine kinase RT AKT2."; RL Oncogene 18:4891-4898(1999). RN [5] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15135396; DOI=10.1016/j.pep.2003.12.010; RA Meier T.I., Cook J.A., Thomas J.E., Radding J.A., Horn C., Lingaraj T., RA Smith M.C.; RT "Cloning, expression, purification, and characterization of the human Class RT Ia phosphoinositide 3-kinase isoforms."; RL Protein Expr. Purif. 35:218-224(2004). RN [6] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=23936502; DOI=10.1371/journal.pone.0071337; RA Buchanan C.M., Dickson J.M., Lee W.J., Guthridge M.A., Kendall J.D., RA Shepherd P.R.; RT "Oncogenic mutations of p110alpha isoform of PI 3-kinase upregulate its RT protein kinase activity."; RL PLoS ONE 8:e71337-e71337(2013). RN [7] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=28676499; DOI=10.1074/jbc.m116.772426; RA Maheshwari S., Miller M.S., O'Meally R., Cole R.N., Amzel L.M., RA Gabelli S.B.; RT "Kinetic and structural analyses reveal residues in phosphoinositide 3- RT kinase alpha that are critical for catalysis and substrate recognition."; RL J. Biol. Chem. 292:13541-13550(2017). RN [8] RP FUNCTION IN INVADOPODIA FORMATION, AND CHARACTERIZATION OF VARIANTS LYS-545 RP AND ARG-1047. RX PubMed=21708979; DOI=10.1083/jcb.201009126; RA Yamaguchi H., Yoshida S., Muroi E., Yoshida N., Kawamura M., Kouchi Z., RA Nakamura Y., Sakai R., Fukami K.; RT "Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha} RT regulates invadopodia formation."; RL J. Cell Biol. 193:1275-1288(2011). RN [9] RP INVOLVEMENT IN MADAC, AND VARIANTS MADAC PRO-115; LYS-542; ARG-1047 AND RP LEU-1047. RX PubMed=23100325; DOI=10.1093/hmg/dds440; RA Rios J.J., Paria N., Burns D.K., Israel B.A., Cornelia R., Wise C.A., RA Ezaki M.; RT "Somatic gain-of-function mutations in PIK3CA in patients with RT macrodactyly."; RL Hum. Mol. Genet. 22:444-451(2013). RN [10] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [11] RP REVIEW ON CANCER. RX PubMed=18418043; DOI=10.4161/cc.7.9.5817; RA Huang C.-H., Mandelker D., Gabelli S.B., Amzel L.M.; RT "Insights into the oncogenic effects of PIK3CA mutations from the structure RT of p110alpha/p85alpha."; RL Cell Cycle 7:1151-1156(2008). RN [12] RP REVIEW ON FUNCTION, AND REVIEW ON CANCER. RX PubMed=18794883; DOI=10.1038/onc.2008.244; RA Zhao L., Vogt P.K.; RT "Class I PI3K in oncogenic cellular transformation."; RL Oncogene 27:5486-5496(2008). RN [13] RP REVIEW ON FUNCTION. RX PubMed=19200708; DOI=10.1016/j.ceb.2008.12.007; RA Jia S., Roberts T.M., Zhao J.J.; RT "Should individual PI3 kinase isoforms be targeted in cancer?"; RL Curr. Opin. Cell Biol. 21:199-208(2009). RN [14] RP INVOLVEMENT IN CLAPO, AND VARIANTS CLAPO SER-83; PRO-115; ARG-420; LYS-542 RP AND LEU-1047. RX PubMed=29446767; DOI=10.1038/gim.2017.200; RA Rodriguez-Laguna L., Ibanez K., Gordo G., Garcia-Minaur S., RA Santos-Simarro F., Agra N., Vallespin E., Fernandez-Montano V.E., RA Martin-Arenas R., Del Pozo A., Gonzalez-Pecellin H., Mena R., RA Rueda-Arenas I., Gomez M.V., Villaverde C., Bustamante A., Ayuso C., RA Ruiz-Perez V.L., Nevado J., Lapunzina P., Lopez-Gutierrez J.C., RA Martinez-Glez V.; RT "CLAPO syndrome: identification of somatic activating PIK3CA mutations and RT delineation of the natural history and phenotype."; RL Genet. Med. 20:882-889(2018). RN [15] RP INVOLVEMENT IN CCM4, AND VARIANTS CCM4 LYS-542; ARG-1047 AND LEU-1047. RX PubMed=34496175; DOI=10.1056/nejmoa2100440; RA Peyre M., Miyagishima D., Bielle F., Chapon F., Sierant M., Venot Q., RA Lerond J., Marijon P., Abi-Jaoude S., Le Van T., Labreche K., Houlston R., RA Faisant M., Clemenceau S., Boch A.L., Nouet A., Carpentier A., Boetto J., RA Louvi A., Kalamarides M.; RT "Somatic PIK3CA mutations in sporadic cerebral cavernous malformations."; RL N. Engl. J. Med. 385:996-996(2021). RN [16] RP INVOLVEMENT IN HFMH, VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047, AND RP CHARACTERIZATION OF VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047. RX PubMed=37712948; DOI=10.1084/jem.20230926; RA Bayard C., Segna E., Taverne M., Fraissenon A., Hennocq Q., Periou B., RA Zerbib L., Ladraa S., Chapelle C., Hoguin C., Kaltenbach S., Villarese P., RA Asnafi V., Broissand C., Nemazanyy I., Autret G., Goudin N., Legendre C., RA Authier F.J., Viel T., Tavitian B., Gitiaux C., Fraitag S., Duong J.P., RA Delcros C., Sergent B., Picard A., Dussiot M., Guibaud L., Khonsari R., RA Canaud G.; RT "Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of- RT function mutations and responds to pharmacological inhibition."; RL J. Exp. Med. 220:0-0(2023). RN [17] RP X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) IN A COMPLEX WITH PIK3R1, AND DOMAINS. RX PubMed=18079394; DOI=10.1126/science.1150799; RA Huang C.-H., Mandelker D., Schmidt-Kittler O., Samuels Y., Velculescu V.E., RA Kinzler K.W., Vogelstein B., Gabelli S.B., Amzel L.M.; RT "The structure of a human p110alpha/p85alpha complex elucidates the effects RT of oncogenic PI3Kalpha mutations."; RL Science 318:1744-1748(2007). RN [18] RP STRUCTURE BY NMR OF 331-481. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C2 domain from human PI3-kinase p110 subunit RT alpha."; RL Submitted (APR-2008) to the PDB data bank. RN [19] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT HIS-1047 IN COMPLEX WITH RP WORTMANNIN AND PIK3R1, INTERACTION WITH PIK3R1, CHARACTERIZATION OF VARIANT RP ARG-1047, AND DOMAINS. RX PubMed=19805105; DOI=10.1073/pnas.0908444106; RA Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I., RA Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M.; RT "A frequent kinase domain mutation that changes the interaction between RT PI3Kalpha and the membrane."; RL Proc. Natl. Acad. Sci. U.S.A. 106:16996-17001(2009). RN [20] RP VARIANTS CANCER LYS-542; LYS-545; PRO-546; ASN-1021; ARG-1047; LEU-1047 AND RP TYR-1065. RX PubMed=15289301; DOI=10.1158/0008-5472.can-04-1170; RA Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M., RA McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., Yan H.; RT "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade RT astrocytomas, and medulloblastomas."; RL Cancer Res. 64:5048-5050(2004). RN [21] RP INVOLVEMENT IN OC, AND VARIANTS CANCER GLY-545; LYS-545; LYS-546; GLU-546; RP ARG-1047 AND LEU-1047. RX PubMed=15520168; DOI=10.1158/0008-5472.can-04-2933; RA Campbell I.G., Russell S.E., Choong D.Y.H., Montgomery K.G., RA Ciavarella M.L., Hooi C.S.F., Cristiano B.E., Pearson R.B., Phillips W.A.; RT "Mutation of the PIK3CA gene in ovarian and breast cancer."; RL Cancer Res. 64:7678-7681(2004). RN [22] RP VARIANT CANCER ARG-1047. RX PubMed=15016963; DOI=10.1126/science.1096502; RA Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., RA Gazdar A., Powell S.M., Riggins G.J., Willson J.K.V., Markowitz S., RA Kinzler K.W., Vogelstein B., Velculescu V.E.; RT "High frequency of mutations of the PIK3CA gene in human cancers."; RL Science 304:554-554(2004). RN [23] RP VARIANTS CANCER GLN-88; LYS-542; ALA-545 AND ASN-1025. RX PubMed=15924253; DOI=10.1007/s00401-005-1000-1; RA Hartmann C., Bartels G., Gehlhaar C., Holtkamp N., von Deimling A.; RT "PIK3CA mutations in glioblastoma multiforme."; RL Acta Neuropathol. 109:639-642(2005). RN [24] RP VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=15784156; DOI=10.1186/1471-2407-5-29; RA Li V.S.W., Wong C.W., Chan T.L., Chan A.S.W., Zhao W., Chu K.-M., So S., RA Chen X., Yuen S.T., Leung S.Y.; RT "Mutations of PIK3CA in gastric adenocarcinoma."; RL BMC Cancer 5:29-29(2005). RN [25] RP INVOLVEMENT IN CRC, AND CHARACTERIZATION OF VARIANTS CRC HIS-38; VAL-106; RP ARG-420; GLN-453; LYS-542; LYS-545; ILE-1043 AND ARG-1047. RX PubMed=15930273; DOI=10.1158/0008-5472.can-04-4114; RA Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J., Ohta M., RA Jazag A., Guleng B., Tateishi K., Asaoka Y., Matsumura M., Kawabe T., RA Omata M.; RT "Functional analysis of PIK3CA gene mutations in human colorectal cancer."; RL Cancer Res. 65:4562-4567(2005). RN [26] RP VARIANTS CANCER GLN-542; LYS-542; GLY-545; LYS-545; ARG-1007; HIS-1021; RP CYS-1021; VAL-1035; ILE-1043; TYR-1047; ARG-1047; ASP-1050; LYS-1052 AND RP LEU-1065. RX PubMed=16322209; DOI=10.1158/0008-5472.can-05-2620; RA Oda K., Stokoe D., Taketani Y., McCormick F.; RT "High frequency of coexistent mutations of PIK3CA and PTEN genes in RT endometrial carcinoma."; RL Cancer Res. 65:10669-10673(2005). RN [27] RP INVOLVEMENT IN CRC, AND VARIANTS CANCER LYS-542; GLY-545; LYS-545; RP GLN-1023; ARG-1047 AND LEU-1047. RX PubMed=15994075; DOI=10.1016/j.ejca.2005.04.022; RA Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G., RA Schwartz S. Jr., Duval A., Carneiro F., Machado J.C., Hamelin R., RA Seruca R.; RT "The prevalence of PIK3CA mutations in gastric and colon cancer."; RL Eur. J. Cancer 41:1649-1654(2005). RN [28] RP VARIANTS CANCER LYS-545 AND ARG-1047. RX PubMed=15712344; DOI=10.1002/humu.9316; RA Wang Y., Helland A., Holm R., Kristensen G.B., Boerresen-Dale A.-L.; RT "PIK3CA mutations in advanced ovarian carcinomas."; RL Hum. Mutat. 25:322-322(2005). RN [29] RP VARIANT HCC ALA-545. RX PubMed=15608678; DOI=10.1038/sj.onc.1208304; RA Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., RA Lee J.Y., Yoo N.J., Lee S.H.; RT "PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular RT carcinomas."; RL Oncogene 24:1477-1480(2005). RN [30] RP VARIANTS CANCER CYS-343; LYS-542; LYS-545 AND ARG-1047, AND VARIANT RP MET-391. RX PubMed=16533766; DOI=10.1158/1078-0432.ccr-05-2173; RA Qiu W., Schoenleben F., Li X., Ho D.J., Close L.G., Manolidis S., RA Bennett B.P., Su G.H.; RT "PIK3CA mutations in head and neck squamous cell carcinoma."; RL Clin. Cancer Res. 12:1441-1446(2006). RN [31] RP VARIANT CANCER ARG-1047. RX PubMed=16114017; DOI=10.1002/ijc.21444; RA Or Y.Y.-Y., Hui A.B.-Y., To K.-F., Lam C.N.-Y., Lo K.-W.; RT "PIK3CA mutations in nasopharyngeal carcinoma."; RL Int. J. Cancer 118:1065-1067(2006). RN [32] RP VARIANTS BC LYS-542; VAL-542; LYS-545; ARG-546; ARG-1047 AND LEU-1047. RX PubMed=16353168; DOI=10.1002/path.1908; RA Buttitta F., Felicioni L., Barassi F., Martella C., Paolizzi D., Fresu G., RA Salvatore S., Cuccurullo F., Mezzetti A., Campani D., Marchetti A.; RT "PIK3CA mutation and histological type in breast carcinoma: high frequency RT of mutations in lobular carcinoma."; RL J. Pathol. 208:350-355(2006). RN [33] RP CHARACTERIZATION OF VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=16432179; DOI=10.1073/pnas.0510857103; RA Bader A.G., Kang S., Vogt P.K.; RT "Cancer-specific mutations in PIK3CA are oncogenic in vivo."; RL Proc. Natl. Acad. Sci. U.S.A. 103:1475-1479(2006). RN [34] RP VARIANTS KERSEB LYS-542; LYS-545; GLY-545 AND ARG-1047. RX PubMed=17673550; DOI=10.1073/pnas.0705218104; RA Hafner C., Lopez-Knowles E., Luis N.M., Toll A., Baselga E., RA Fernandez-Casado A., Hernandez S., Ribe A., Mentzel T., Stoehr R., RA Hofstaedter F., Landthaler M., Vogt T., Pujol R.M., Hartmann A., Real F.X.; RT "Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic RT keratoses with a characteristic mutation pattern."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13450-13454(2007). RN [35] RP VARIANTS CLOVE ARG-420; LYS-542 AND ARG-1047. RX PubMed=22658544; DOI=10.1016/j.ajhg.2012.05.006; RA Kurek K.C., Luks V.L., Ayturk U.M., Alomari A.I., Fishman S.J., RA Spencer S.A., Mulliken J.B., Bowen M.E., Yamamoto G.L., Kozakewich H.P., RA Warman M.L.; RT "Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome."; RL Am. J. Hum. Genet. 90:1108-1115(2012). RN [36] RP VARIANTS MCAP LYS-81; GLN-88; ARG-364; LYS-365; TYR-378; GLU-453 DEL; RP LYS-545; LYS-726; ARG-914; CYS-1021; ALA-1025; VAL-1035; ILE-1043; TYR-1047 RP AND SER-1049. RX PubMed=22729224; DOI=10.1038/ng.2331; RA Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D., RA Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W., Nikkel S.M., RA Worthylake T., Sullivan C.T., Ward T.R., Butler H.E., Kramer N.A., RA Albrecht B., Armour C.M., Armstrong L., Caluseriu O., Cytrynbaum C., RA Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E., Mancini G.M., RA Meschino W.S., Reggin J.D., Saggar A.K., Lerman-Sagie T., Uyanik G., RA Weksberg R., Zirn B., Beaulieu C.L., Majewski J., Bulman D.E., RA O'Driscoll M., Shendure J., Graham J.M. Jr., Boycott K.M., Dobyns W.B.; RT "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA RT cause a spectrum of related megalencephaly syndromes."; RL Nat. Genet. 44:934-940(2012). RN [37] RP VARIANTS CWS5 ASP-118; LYS-135; LYS-218; ILE-356; LYS-382 AND ALA-545. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). RN [38] RP VARIANT MCAP ASN-112, CHARACTERIZATION OF VARIANT MCAP ASN-112, FUNCTION, RP AND SUBUNIT. RX PubMed=26593112; DOI=10.1002/humu.22933; RA Donato N.D., Rump A., Mirzaa G.M., Alcantara D., Oliver A., Schrock E., RA Dobyns W.B., O'Driscoll M.; RT "Identification and characterisation of a novel constitutional PIK3CA RT mutation in a child lacking the typical segmental overgrowth of 'PIK3CA- RT related overgrowth spectrum' (PROS)."; RL Hum. Mutat. 37:242-245(2016). CC -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) phosphorylates CC phosphatidylinositol (PI) and its phosphorylated derivatives at CC position 3 of the inositol ring to produce 3-phosphoinositides CC (PubMed:15135396, PubMed:23936502, PubMed:28676499). Uses ATP and CC PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate CC phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396, CC PubMed:28676499). PIP3 plays a key role by recruiting PH domain- CC containing proteins to the membrane, including AKT1 and PDPK1, CC activating signaling cascades involved in cell growth, survival, CC proliferation, motility and morphology. Participates in cellular CC signaling in response to various growth factors. Involved in the CC activation of AKT1 upon stimulation by receptor tyrosine kinases CC ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in CC signaling via insulin-receptor substrate (IRS) proteins. Essential in CC endothelial cell migration during vascular development through VEGFA CC signaling, possibly by regulating RhoA activity. Required for lymphatic CC vasculature development, possibly by binding to RAS and by activation CC by EGF and FGF2, but not by PDGF. Regulates invadopodia formation CC through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in CC embryonic stem cells through a AKT1 pathway. Participates in CC vasculogenesis in embryonic stem cells through PDK1 and protein kinase CC C pathway. In addition to its lipid kinase activity, it displays a CC serine-protein kinase activity that results in the autophosphorylation CC of the p85alpha regulatory subunit as well as phosphorylation of other CC proteins such as 4EBP1, H-Ras, the IL-3 beta c receptor and possibly CC others (PubMed:23936502, PubMed:28676499). Plays a role in the positive CC regulation of phagocytosis and pinocytosis (By similarity). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:15135396, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:23936502, CC ECO:0000269|PubMed:26593112, ECO:0000269|PubMed:28676499}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:21292, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456, ChEBI:CHEBI:456216; EC=2.7.1.153; CC Evidence={ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21293; CC Evidence={ECO:0000305|PubMed:15135396, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a CC 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + ADP + CC H(+); Xref=Rhea:RHEA:12709, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:57880, ChEBI:CHEBI:58088, ChEBI:CHEBI:456216; CC EC=2.7.1.137; Evidence={ECO:0000269|PubMed:23936502}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12710; CC Evidence={ECO:0000305|PubMed:23936502}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000305|PubMed:23936502, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:55632, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419, ChEBI:CHEBI:456216; CC Evidence={ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55633; CC Evidence={ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero- CC 3-phospho-1D-myo-inositol 4,5-bisphosphate + ATP = 1-octadecanoyl-2- CC (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-(1D-myo- CC inositol 3,4,5-triphosphate) + ADP + H(+); Xref=Rhea:RHEA:43396, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:77137, CC ChEBI:CHEBI:83243, ChEBI:CHEBI:456216; CC Evidence={ECO:0000305|PubMed:15135396}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43397; CC Evidence={ECO:0000305|PubMed:15135396}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=1.77 uM for PIP2 (1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate)) {ECO:0000269|PubMed:28676499}; CC KM=2.00 uM for ATP {ECO:0000269|PubMed:28676499}; CC Vmax=1.70 pmol/min/ng enzyme for the phosphorylation of PIP2 (1,2- CC dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)) CC {ECO:0000269|PubMed:28676499}; CC -!- PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate CC biosynthesis. {ECO:0000305|PubMed:15135396, CC ECO:0000305|PubMed:28676499}. CC -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory CC subunit (PIK3R1, PIK3R2 or PIK3R3) (PubMed:26593112). Interacts with CC IRS1 in nuclear extracts (By similarity). Interacts with RUFY3 (By CC similarity). Interacts with RASD2 (By similarity). Interacts with CC APPL1. Interacts with HRAS and KRAS (By similarity). Interaction with CC HRAS/KRAS is required for PI3K pathway signaling and cell proliferation CC stimulated by EGF and FGF2 (By similarity). Interacts with FAM83B; CC activates the PI3K/AKT signaling cascade (PubMed:23676467). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:23676467, CC ECO:0000269|PubMed:26593112}. CC -!- INTERACTION: CC P42336; P54253: ATXN1; NbExp=3; IntAct=EBI-2116585, EBI-930964; CC P42336; P54252: ATXN3; NbExp=3; IntAct=EBI-2116585, EBI-946046; CC P42336; P21860: ERBB3; NbExp=18; IntAct=EBI-2116585, EBI-720706; CC P42336; P01100: FOS; NbExp=3; IntAct=EBI-2116585, EBI-852851; CC P42336; P62993: GRB2; NbExp=6; IntAct=EBI-2116585, EBI-401755; CC P42336; P42858: HTT; NbExp=3; IntAct=EBI-2116585, EBI-466029; CC P42336; P35568: IRS1; NbExp=42; IntAct=EBI-2116585, EBI-517592; CC P42336; P27986: PIK3R1; NbExp=63; IntAct=EBI-2116585, EBI-79464; CC P42336; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-2116585, EBI-9090282; CC P42336; O00459: PIK3R2; NbExp=49; IntAct=EBI-2116585, EBI-346930; CC P42336; Q92569: PIK3R3; NbExp=48; IntAct=EBI-2116585, EBI-79893; CC P42336; O43791: SPOP; NbExp=4; IntAct=EBI-2116585, EBI-743549; CC -!- DOMAIN: The PI3K-ABD domain and the PI3K-RBD domain interact with the CC PI3K/PI4K kinase domain. The C2 PI3K-type domain may facilitate the CC recruitment to the plasma membrane. The inhibitory interactions with CC PIK3R1 are mediated by the PI3K-ABD domain and the C2 PI3K-type domain CC with the iSH2 (inter-SH2) region of PIK3R1, and the C2 PI3K-type CC domain, the PI3K helical domain, and the PI3K/PI4K kinase domain with CC the nSH2 (N-terminal SH2) region of PIK3R1. CC {ECO:0000269|PubMed:18079394, ECO:0000269|PubMed:19805105}. CC -!- DISEASE: Note=PIK3CA mutations are involved in various type of cancer. CC Most of the cancer-associated mutations are missense mutations and map CC to one of the three hotspots: Glu-542; Glu-545 and His-1047. Mutated CC isoforms participate in cellular transformation and tumorigenesis CC induced by oncogenic receptor tyrosine kinases (RTKs) and HRAS/KRAS. CC Interaction with HRAS/KRAS is required for Ras-driven tumor formation. CC Mutations increasing the lipid kinase activity are required for CC oncogenic signaling. The protein kinase activity may not be required CC for tumorigenesis. {ECO:0000269|PubMed:15016963, CC ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, CC ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, CC ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16114017, CC ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, CC ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, CC ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:19805105, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22658544, CC ECO:0000269|PubMed:22729224}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:16353168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15520168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC {ECO:0000269|PubMed:15608678}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common benign CC skin tumor. Seborrheic keratoses usually begin with the appearance of CC one or more sharply defined, light brown, flat macules. The lesions may CC be sparse or numerous. As they initially grow, they develop a velvety CC to finely verrucous surface, followed by an uneven warty surface with CC multiple plugged follicles and a dull or lackluster appearance. CC {ECO:0000269|PubMed:17673550}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Megalencephaly-capillary malformation-polymicrogyria syndrome CC (MCAP) [MIM:602501]: A syndrome characterized by a spectrum of CC anomalies including primary megalencephaly, prenatal overgrowth, brain CC and body asymmetry, cutaneous vascular malformations, digital anomalies CC consisting of syndactyly with or without postaxial polydactyly, CC connective tissue dysplasia involving the skin, subcutaneous tissue, CC and joints, and cortical brain malformations, most distinctively CC polymicrogyria. {ECO:0000269|PubMed:22729224, CC ECO:0000269|PubMed:26593112}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital lipomatous overgrowth, vascular malformations, and CC epidermal nevi (CLOVE) [MIM:612918]: A sporadically occurring, non- CC hereditary disorder characterized by asymmetric somatic hypertrophy and CC anomalies in multiple organs. It is defined by four main clinical CC findings: congenital lipomatous overgrowth, vascular malformations, CC epidermal nevi, and skeletal/spinal abnormalities. The presence of CC truncal overgrowth and characteristic patterned macrodactyly at birth CC differentiates CLOVE from other syndromic forms of overgrowth. CC {ECO:0000269|PubMed:22658544}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 5 (CWS5) [MIM:615108]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:23246288}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: CLAPO syndrome (CLAPO) [MIM:613089]: A syndrome characterized CC by capillary malformation of the lower lip, lymphatic malformation of CC the face and neck, asymmetry of face and limbs and partial or CC generalised overgrowth. {ECO:0000269|PubMed:29446767}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC The tissue distribution of the clinical manifestations in CLAPO seems CC to follow a pattern of somatic mosaicism. CC {ECO:0000269|PubMed:29446767}. CC -!- DISEASE: Macrodactyly (MADAC) [MIM:155500]: A congenital anomaly CC characterized by fibrofatty tissue enlargement and bony overgrowth CC affecting the digits or the entire hand or foot. CC {ECO:0000269|PubMed:23100325}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. The tissue CC distribution of the clinical manifestations in MADAC seems to follow a CC pattern of somatic mosaicism. {ECO:0000269|PubMed:23100325}. CC -!- DISEASE: Cerebral cavernous malformations 4 (CCM4) [MIM:619538]: A form CC of cerebral cavernous malformations, a congenital vascular anomaly of CC the central nervous system that can result in hemorrhagic stroke, CC seizures, recurrent headaches, and focal neurologic deficits. The CC lesions are characterized by grossly enlarged blood vessels consisting CC of a single layer of endothelium and without any intervening neural CC tissue, ranging in diameter from a few millimeters to several CC centimeters. CCM4 cases occur sporadically. CC {ECO:0000269|PubMed:34496175}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Hemifacial myohyperplasia (HFMH) [MIM:606773]: A rare disease CC characterized by facial asymmetry due to unilateral muscular CC hypertrophy mimicking spasm and orofacial dystonia. CC {ECO:0000269|PubMed:37712948}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: The avian sarcoma virus 16 genome encodes an oncogene CC derived from PIK3CA. {ECO:0000305|PubMed:18418043}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000255|PROSITE- CC ProRule:PRU00877, ECO:0000255|PROSITE-ProRule:PRU00879, CC ECO:0000255|PROSITE-ProRule:PRU00880}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/415/PIK3CA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z29090; CAA82333.1; -; mRNA. DR EMBL; U79143; AAB39753.1; -; mRNA. DR EMBL; BC113601; AAI13602.1; -; mRNA. DR EMBL; BC113603; AAI13604.1; -; mRNA. DR CCDS; CCDS43171.1; -. DR PIR; I38110; I38110. DR RefSeq; NP_006209.2; NM_006218.4. DR RefSeq; XP_006713721.1; XM_006713658.5. DR RefSeq; XP_054202817.1; XM_054346842.1. DR RefSeq; XP_054202818.1; XM_054346843.1. DR RefSeq; XP_054202819.1; XM_054346844.1. DR RefSeq; XP_054202820.1; XM_054346845.1. DR RefSeq; XP_054202821.1; XM_054346846.1. DR RefSeq; XP_054202822.1; XM_054346847.1. DR RefSeq; XP_054202823.1; XM_054346848.1. DR PDB; 2ENQ; NMR; -; A=331-481. DR PDB; 2RD0; X-ray; 3.05 A; A=1-1068. DR PDB; 3HHM; X-ray; 2.80 A; A=1-1068. DR PDB; 3HIZ; X-ray; 3.30 A; A=1-1068. DR PDB; 3ZIM; X-ray; 2.85 A; A=107-1046. DR PDB; 4JPS; X-ray; 2.20 A; A=1-1068. DR PDB; 4L1B; X-ray; 2.59 A; A=1-1068. DR PDB; 4L23; X-ray; 2.50 A; A=1-1068. DR PDB; 4L2Y; X-ray; 2.80 A; A=1-1068. DR PDB; 4OVU; X-ray; 2.96 A; A=1-1068. DR PDB; 4OVV; X-ray; 3.50 A; A=1-1068. DR PDB; 4TUU; X-ray; 2.64 A; A=105-1048. DR PDB; 4TV3; X-ray; 2.85 A; A=105-1048. DR PDB; 4WAF; X-ray; 2.39 A; A=2-1068. DR PDB; 4YKN; X-ray; 2.90 A; A=2-1068. DR PDB; 4ZOP; X-ray; 2.62 A; A=1-1068. DR PDB; 5DXH; X-ray; 3.00 A; A/D=2-1068. DR PDB; 5DXT; X-ray; 2.25 A; A=107-1068. DR PDB; 5FI4; X-ray; 2.50 A; A=1-1068. DR PDB; 5ITD; X-ray; 3.02 A; A=1-1068. DR PDB; 5SW8; X-ray; 3.30 A; A=1-1068. DR PDB; 5SWG; X-ray; 3.11 A; A=1-1068. DR PDB; 5SWO; X-ray; 3.50 A; A=1-1068. DR PDB; 5SWP; X-ray; 3.41 A; A=1-1068. DR PDB; 5SWR; X-ray; 3.31 A; A=1-1068. DR PDB; 5SWT; X-ray; 3.49 A; A=1-1068. DR PDB; 5SX8; X-ray; 3.47 A; A=1-1068. DR PDB; 5SX9; X-ray; 3.52 A; A=1-1068. DR PDB; 5SXA; X-ray; 3.35 A; A=1-1068. DR PDB; 5SXB; X-ray; 3.30 A; A=1-1068. DR PDB; 5SXC; X-ray; 3.55 A; A=1-1068. DR PDB; 5SXD; X-ray; 3.50 A; A=1-1068. DR PDB; 5SXE; X-ray; 3.51 A; A=1-1068. DR PDB; 5SXF; X-ray; 3.46 A; A=1-1068. DR PDB; 5SXI; X-ray; 3.40 A; A=1-1068. DR PDB; 5SXJ; X-ray; 3.42 A; A=1-1068. DR PDB; 5SXK; X-ray; 3.55 A; A=1-1068. DR PDB; 5UBR; X-ray; 2.40 A; A=107-1050. DR PDB; 5UK8; X-ray; 2.50 A; A=1-1068. DR PDB; 5UKJ; X-ray; 2.80 A; A=1-1068. DR PDB; 5UL1; X-ray; 3.00 A; A=1-1068. DR PDB; 5XGH; X-ray; 2.97 A; A=8-1055. DR PDB; 5XGI; X-ray; 2.56 A; A=8-1059. DR PDB; 5XGJ; X-ray; 2.97 A; A=8-1055. DR PDB; 6GVF; X-ray; 2.50 A; A=107-1051. DR PDB; 6GVG; X-ray; 3.00 A; A=107-1068. DR PDB; 6GVH; X-ray; 2.74 A; A=107-1068. DR PDB; 6GVI; X-ray; 2.90 A; A=107-1068. DR PDB; 6NCT; X-ray; 3.35 A; A=1-1068. DR PDB; 6OAC; X-ray; 3.15 A; A=105-1048. DR PDB; 6PYS; X-ray; 2.19 A; A=107-1051. DR PDB; 6VO7; X-ray; 2.31 A; A=157-300. DR PDB; 7JIU; X-ray; 2.12 A; A=107-1052. DR PDB; 7K6M; X-ray; 2.41 A; A=105-1048. DR PDB; 7K6N; X-ray; 2.77 A; A=105-1048. DR PDB; 7K6O; X-ray; 2.74 A; A=105-1048. DR PDB; 7K71; X-ray; 2.90 A; A=105-1048. DR PDB; 7L1B; X-ray; 2.04 A; C=1046-1054. DR PDB; 7L1C; X-ray; 1.96 A; C=1046-1054. DR PDB; 7L1D; X-ray; 3.11 A; C=1046-1054. DR PDB; 7MLK; X-ray; 2.91 A; A=105-1048. DR PDB; 7MYN; EM; 2.79 A; A=1-1068. DR PDB; 7MYO; EM; 2.92 A; A=1-1068. DR PDB; 7PG5; X-ray; 2.20 A; A=1-1068. DR PDB; 7PG6; X-ray; 2.50 A; A=1-1068. DR PDB; 7R9V; X-ray; 2.69 A; A=105-1048. DR PDB; 7R9Y; X-ray; 2.85 A; A=105-1048. DR PDB; 7RRG; X-ray; 2.12 A; C=1046-1054. DR PDB; 7TZ7; X-ray; 2.41 A; A=1-1068. DR PDB; 8AM0; X-ray; 2.82 A; A=1-1068. DR PDB; 8BFU; X-ray; 2.41 A; A=105-1048. DR PDB; 8DCP; EM; 2.41 A; A=1-1068. DR PDB; 8DCX; EM; 2.80 A; A=1-1068. DR PDB; 8DD4; EM; 3.10 A; A=1-1068. DR PDB; 8DD8; EM; 3.40 A; A=1-1068. DR PDB; 8EXL; X-ray; 1.99 A; A=7-1052. DR PDB; 8EXO; X-ray; 2.46 A; A=7-1052. DR PDB; 8EXU; X-ray; 2.68 A; A=7-1052. DR PDB; 8EXV; X-ray; 2.48 A; A=7-1052. DR PDB; 8GUA; EM; 2.77 A; A=1-1068. DR PDB; 8GUB; EM; 2.73 A; A=1-1068. DR PDB; 8GUD; EM; 2.62 A; A=1-1068. DR PDB; 8ILR; EM; 3.05 A; A=1-1068. DR PDB; 8ILS; EM; 3.10 A; A=1-1068. DR PDB; 8ILV; EM; 3.19 A; A=1-1068. DR PDB; 8OW2; X-ray; 2.57 A; A=105-1048. DR PDB; 8SBC; X-ray; 2.30 A; A=1-1068. DR PDB; 8SBJ; X-ray; 3.10 A; A=1-1068. DR PDB; 8TDU; X-ray; 3.11 A; A/C=1-1068. DR PDB; 8TGD; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8TS7; X-ray; 2.71 A; A=2-1053. DR PDB; 8TS8; X-ray; 2.72 A; A=2-1053. DR PDB; 8TS9; X-ray; 2.83 A; A=2-1050. DR PDB; 8TSA; X-ray; 2.51 A; A=2-1050. DR PDB; 8TSB; X-ray; 3.53 A; A=2-1053. DR PDB; 8TSC; X-ray; 3.62 A; A=2-1050. DR PDB; 8TSD; X-ray; 2.70 A; A=2-1053. DR PDB; 8TU6; EM; 3.12 A; A=2-1068. DR PDB; 8TWY; X-ray; 2.67 A; A=105-1048. DR PDB; 8V8H; X-ray; 3.58 A; A/C=1-1068. DR PDB; 8V8I; X-ray; 3.20 A; A/C=1-1068. DR PDB; 8V8J; X-ray; 3.35 A; A/C=1-1068. DR PDB; 8V8U; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8V8V; X-ray; 2.61 A; A/C=1-1068. DR PDB; 8VCL; X-ray; 2.40 A; C=1046-1054. DR PDB; 8W9A; EM; 2.70 A; A=1-1068. DR PDB; 8W9B; EM; 3.00 A; A=1-1068. DR PDB; 9ASF; X-ray; 1.77 A; C=1046-1054. DR PDB; 9ASG; X-ray; 2.03 A; C=1046-1054. DR PDB; 9B4S; X-ray; 3.10 A; A=105-1068. DR PDB; 9B4T; X-ray; 2.75 A; A=105-1068. DR PDB; 9B4U; X-ray; 2.21 A; A/B=157-300. DR PDB; 9C15; X-ray; 2.81 A; A=105-1068. DR PDB; 9CMK; X-ray; 1.75 A; A/B=160-300. DR PDB; 9CML; X-ray; 2.01 A; A/B=160-300. DR PDB; 9CMV; X-ray; 3.01 A; A=105-1068. DR PDB; 9E8M; X-ray; 2.83 A; A/B=157-300. DR PDBsum; 2ENQ; -. DR PDBsum; 2RD0; -. DR PDBsum; 3HHM; -. DR PDBsum; 3HIZ; -. DR PDBsum; 3ZIM; -. DR PDBsum; 4JPS; -. DR PDBsum; 4L1B; -. DR PDBsum; 4L23; -. DR PDBsum; 4L2Y; -. DR PDBsum; 4OVU; -. DR PDBsum; 4OVV; -. DR PDBsum; 4TUU; -. DR PDBsum; 4TV3; -. DR PDBsum; 4WAF; -. DR PDBsum; 4YKN; -. DR PDBsum; 4ZOP; -. DR PDBsum; 5DXH; -. DR PDBsum; 5DXT; -. DR PDBsum; 5FI4; -. DR PDBsum; 5ITD; -. DR PDBsum; 5SW8; -. DR PDBsum; 5SWG; -. DR PDBsum; 5SWO; -. DR PDBsum; 5SWP; -. DR PDBsum; 5SWR; -. DR PDBsum; 5SWT; -. DR PDBsum; 5SX8; -. DR PDBsum; 5SX9; -. DR PDBsum; 5SXA; -. DR PDBsum; 5SXB; -. DR PDBsum; 5SXC; -. DR PDBsum; 5SXD; -. DR PDBsum; 5SXE; -. DR PDBsum; 5SXF; -. DR PDBsum; 5SXI; -. DR PDBsum; 5SXJ; -. DR PDBsum; 5SXK; -. DR PDBsum; 5UBR; -. DR PDBsum; 5UK8; -. DR PDBsum; 5UKJ; -. DR PDBsum; 5UL1; -. DR PDBsum; 5XGH; -. DR PDBsum; 5XGI; -. DR PDBsum; 5XGJ; -. DR PDBsum; 6GVF; -. DR PDBsum; 6GVG; -. DR PDBsum; 6GVH; -. DR PDBsum; 6GVI; -. DR PDBsum; 6NCT; -. DR PDBsum; 6OAC; -. DR PDBsum; 6PYS; -. DR PDBsum; 6VO7; -. DR PDBsum; 7JIU; -. DR PDBsum; 7K6M; -. DR PDBsum; 7K6N; -. DR PDBsum; 7K6O; -. DR PDBsum; 7K71; -. DR PDBsum; 7L1B; -. DR PDBsum; 7L1C; -. DR PDBsum; 7L1D; -. DR PDBsum; 7MLK; -. DR PDBsum; 7MYN; -. DR PDBsum; 7MYO; -. DR PDBsum; 7PG5; -. DR PDBsum; 7PG6; -. DR PDBsum; 7R9V; -. DR PDBsum; 7R9Y; -. DR PDBsum; 7RRG; -. DR PDBsum; 7TZ7; -. DR PDBsum; 8AM0; -. DR PDBsum; 8BFU; -. DR PDBsum; 8DCP; -. DR PDBsum; 8DCX; -. DR PDBsum; 8DD4; -. DR PDBsum; 8DD8; -. DR PDBsum; 8EXL; -. DR PDBsum; 8EXO; -. DR PDBsum; 8EXU; -. DR PDBsum; 8EXV; -. DR PDBsum; 8GUA; -. DR PDBsum; 8GUB; -. DR PDBsum; 8GUD; -. DR PDBsum; 8ILR; -. DR PDBsum; 8ILS; -. DR PDBsum; 8ILV; -. DR PDBsum; 8OW2; -. DR PDBsum; 8SBC; -. DR PDBsum; 8SBJ; -. DR PDBsum; 8TDU; -. DR PDBsum; 8TGD; -. DR PDBsum; 8TS7; -. DR PDBsum; 8TS8; -. DR PDBsum; 8TS9; -. DR PDBsum; 8TSA; -. DR PDBsum; 8TSB; -. DR PDBsum; 8TSC; -. DR PDBsum; 8TSD; -. DR PDBsum; 8TU6; -. DR PDBsum; 8TWY; -. DR PDBsum; 8V8H; -. DR PDBsum; 8V8I; -. DR PDBsum; 8V8J; -. DR PDBsum; 8V8U; -. DR PDBsum; 8V8V; -. DR PDBsum; 8VCL; -. DR PDBsum; 8W9A; -. DR PDBsum; 8W9B; -. DR PDBsum; 9ASF; -. DR PDBsum; 9ASG; -. DR PDBsum; 9B4S; -. DR PDBsum; 9B4T; -. DR PDBsum; 9B4U; -. DR PDBsum; 9C15; -. DR PDBsum; 9CMK; -. DR PDBsum; 9CML; -. DR PDBsum; 9CMV; -. DR PDBsum; 9E8M; -. DR AlphaFoldDB; P42336; -. DR EMDB; EMD-24081; -. DR EMDB; EMD-24082; -. DR EMDB; EMD-27327; -. DR EMDB; EMD-27330; -. DR EMDB; EMD-27334; -. DR EMDB; EMD-27336; -. DR EMDB; EMD-34271; -. DR EMDB; EMD-34272; -. DR EMDB; EMD-34273; -. DR EMDB; EMD-35543; -. DR EMDB; EMD-35545; -. DR EMDB; EMD-35547; -. DR EMDB; EMD-37362; -. DR EMDB; EMD-37363; -. DR EMDB; EMD-41617; -. DR SMR; P42336; -. DR BioGRID; 111308; 178. DR ComplexPortal; CPX-1917; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85beta. DR ComplexPortal; CPX-1918; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55gamma. DR ComplexPortal; CPX-2384; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85alpha. DR ComplexPortal; CPX-5970; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55alpha. DR ComplexPortal; CPX-5971; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p50alpha. DR CORUM; P42336; -. DR DIP; DIP-42728N; -. DR FunCoup; P42336; 3134. DR IntAct; P42336; 216. DR MINT; P42336; -. DR STRING; 9606.ENSP00000263967; -. DR BindingDB; P42336; -. DR ChEMBL; CHEMBL4005; -. DR DrugBank; DB12015; Alpelisib. DR DrugBank; DB00171; ATP. DR DrugBank; DB11666; Buparlisib. DR DrugBank; DB00201; Caffeine. DR DrugBank; DB13051; CH-5132799. DR DrugBank; DB12483; Copanlisib. DR DrugBank; DB15275; Inavolisib. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB11772; Pilaralisib. DR DrugBank; DB14935; Serabelisib. DR DrugBank; DB12108; Taselisib. DR DrugBank; DB08059; Wortmannin. DR DrugBank; DB05241; XL765. DR DrugCentral; P42336; -. DR GuidetoPHARMACOLOGY; 2153; -. DR iPTMnet; P42336; -. DR MetOSite; P42336; -. DR PhosphoSitePlus; P42336; -. DR BioMuta; PIK3CA; -. DR DMDM; 126302584; -. DR CPTAC; CPTAC-1631; -. DR CPTAC; CPTAC-3127; -. DR CPTAC; CPTAC-3128; -. DR CPTAC; CPTAC-3129; -. DR jPOST; P42336; -. DR MassIVE; P42336; -. DR PaxDb; 9606-ENSP00000263967; -. DR PeptideAtlas; P42336; -. DR ProteomicsDB; 55509; -. DR Pumba; P42336; -. DR Antibodypedia; 1374; 746 antibodies from 44 providers. DR CPTC; P42336; 1 antibody. DR DNASU; 5290; -. DR Ensembl; ENST00000263967.4; ENSP00000263967.3; ENSG00000121879.7. DR GeneID; 5290; -. DR KEGG; hsa:5290; -. DR MANE-Select; ENST00000263967.4; ENSP00000263967.3; NM_006218.4; NP_006209.2. DR UCSC; uc003fjk.4; human. DR AGR; HGNC:8975; -. DR CIViC; 5290; 319 evidence items across 211 molecular profiles. DR ClinPGx; PA33308; -. DR CTD; 5290; -. DR DisGeNET; 5290; -. DR GeneCards; PIK3CA; -. DR GeneReviews; PIK3CA; -. DR HGNC; HGNC:8975; PIK3CA. DR HPA; ENSG00000121879; Low tissue specificity. DR MalaCards; PIK3CA; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 114550; phenotype. DR MIM; 155500; phenotype. DR MIM; 167000; phenotype. DR MIM; 171834; gene. DR MIM; 182000; phenotype. DR MIM; 602501; phenotype. DR MIM; 606773; phenotype. DR MIM; 612918; phenotype. DR MIM; 613089; phenotype. DR MIM; 615108; phenotype. DR MIM; 619538; phenotype. DR OpenTargets; ENSG00000121879; -. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 90308; Capillary-lymphatic-venous malformation with segmental distribution. DR Orphanet; 168984; CLAPO syndrome. DR Orphanet; 140944; CLOVES syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 221061; Familial cerebral cavernous malformation. DR Orphanet; 276280; Hemihyperplasia-multiple lipomatosis syndrome. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 295239; Macrodactyly of fingers, unilateral. DR Orphanet; 295243; Macrodactyly of toes, unilateral. DR Orphanet; 60040; Megalencephaly-capillary malformation-polymicrogyria syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 314662; Segmental progressive overgrowth syndrome with fibroadipose hyperplasia. DR VEuPathDB; HostDB:ENSG00000121879; -. DR eggNOG; KOG0904; Eukaryota. DR GeneTree; ENSGT00940000155531; -. DR HOGENOM; CLU_002191_1_1_1; -. DR InParanoid; P42336; -. DR OMA; RWSEWLN; -. DR OrthoDB; 67688at2759; -. DR PAN-GO; P42336; 9 GO annotations based on evolutionary models. DR PhylomeDB; P42336; -. DR BioCyc; MetaCyc:HS04527-MONOMER; -. DR BRENDA; 2.7.1.137; 2681. DR BRENDA; 2.7.1.153; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P42336; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-112399; IRS-mediated signalling. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-180292; GAB1 signalosome. DR Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-198203; PI3K/AKT activation. DR Reactome; R-HSA-201556; Signaling by ALK. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization. DR Reactome; R-HSA-373753; Nephrin family interactions. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-416476; G alpha (q) signalling events. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654689; PI-3K cascade:FGFR1. DR Reactome; R-HSA-5654695; PI-3K cascade:FGFR2. DR Reactome; R-HSA-5654710; PI-3K cascade:FGFR3. DR Reactome; R-HSA-5654720; PI-3K cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8851907; MET activates PI3K/AKT signaling. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K). DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-912526; Interleukin receptor SHC signaling. DR Reactome; R-HSA-912631; Regulation of signaling by CBL. DR Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9842640; Signaling by LTK in cancer. DR Reactome; R-HSA-9842663; Signaling by LTK. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9927354; Co-stimulation by ICOS. DR SABIO-RK; P42336; -. DR SignaLink; P42336; -. DR SIGNOR; P42336; -. DR UniPathway; UPA00220; -. DR Agora; ENSG00000121879; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5290; 275 hits in 1174 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PIK3CA; human. DR EvolutionaryTrace; P42336; -. DR GeneWiki; P110%CE%B1; -. DR GenomeRNAi; 5290; -. DR Pharos; P42336; Tclin. DR PRO; PR:P42336; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P42336; protein. DR Bgee; ENSG00000121879; Expressed in calcaneal tendon and 201 other cell types or tissues. DR ExpressionAtlas; P42336; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0014704; C:intercalated disc; ISS:BHF-UCL. DR GO; GO:0030027; C:lamellipodium; IEA:Ensembl. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:BHF-UCL. DR GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; ISS:BHF-UCL. DR GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; IDA:UniProtKB. DR GO; GO:0005944; C:phosphatidylinositol 3-kinase complex, class IB; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IDA:UniProtKB. DR GO; GO:0046934; F:1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity; IDA:UniProt. DR GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl. DR GO; GO:0030295; F:protein kinase activator activity; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0060612; P:adipose tissue development; IEA:Ensembl. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0141068; P:autosome genomic imprinting; IEA:Ensembl. DR GO; GO:0086003; P:cardiac muscle cell contraction; ISS:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; TAS:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0071464; P:cellular response to hydrostatic pressure; ISS:BHF-UCL. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0043542; P:endothelial cell migration; TAS:UniProtKB. DR GO; GO:0097009; P:energy homeostasis; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0030835; P:negative regulation of actin filament depolymerization; ISS:BHF-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB. DR GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IEA:UniProtKB-KW. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:0046854; P:phosphatidylinositol phosphate biosynthetic process; ISS:BHF-UCL. DR GO; GO:0036092; P:phosphatidylinositol-3-phosphate biosynthetic process; IBA:GO_Central. DR GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central. DR GO; GO:0030168; P:platelet activation; TAS:UniProtKB. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; ISS:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:1905477; P:positive regulation of protein localization to membrane; IDA:UniProt. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0032008; P:positive regulation of TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0110053; P:regulation of actin filament organization; ISS:BHF-UCL. DR GO; GO:0043457; P:regulation of cellular respiration; IEA:Ensembl. DR GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl. DR GO; GO:0055119; P:relaxation of cardiac muscle; ISS:BHF-UCL. DR GO; GO:0014823; P:response to activity; IEA:Ensembl. DR GO; GO:1903544; P:response to butyrate; IEA:Ensembl. DR GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl. DR GO; GO:0043201; P:response to L-leucine; IEA:Ensembl. DR GO; GO:0014870; P:response to muscle inactivity; IEA:Ensembl. DR GO; GO:0035994; P:response to muscle stretch; ISS:BHF-UCL. DR GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome. DR GO; GO:0038203; P:TORC2 signaling; IMP:MGI. DR GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IGI:BHF-UCL. DR GO; GO:0001944; P:vasculature development; TAS:UniProtKB. DR CDD; cd08398; C2_PI3K_class_I_alpha; 1. DR CDD; cd00872; PI3Ka_I; 1. DR CDD; cd05175; PI3Kc_IA_alpha; 1. DR FunFam; 1.10.1070.11:FF:000006; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 1.25.40.70:FF:000001; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 2.60.40.150:FF:000041; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000055; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000074; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.30.1010.10:FF:000007; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.70; Phosphatidylinositol 3-kinase, accessory domain (PIK); 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR037704; PI3-kinase_alpha_cat. DR InterPro; IPR015433; PI3/4_kinase. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR002420; PI3K-type_C2_dom. DR InterPro; IPR003113; PI3K_ABD. DR InterPro; IPR001263; PI3K_accessory_dom. DR InterPro; IPR042236; PI3K_accessory_sf. DR InterPro; IPR000341; PI3K_Ras-bd_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR10048:SF107; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM; 1. DR PANTHER; PTHR10048; PHOSPHATIDYLINOSITOL KINASE; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF00792; PI3K_C2; 1. DR Pfam; PF02192; PI3K_p85B; 1. DR Pfam; PF00794; PI3K_rbd; 1. DR Pfam; PF00613; PI3Ka; 1. DR SMART; SM00142; PI3K_C2; 1. DR SMART; SM00143; PI3K_p85B; 1. DR SMART; SM00144; PI3K_rbd; 1. DR SMART; SM00145; PI3Ka; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS51547; C2_PI3K; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. DR PROSITE; PS51544; PI3K_ABD; 1. DR PROSITE; PS51546; PI3K_RBD; 1. DR PROSITE; PS51545; PIK_HELICAL; 1. PE 1: Evidence at protein level; KW 3D-structure; Angiogenesis; ATP-binding; Disease variant; Kinase; KW Lipid metabolism; Nucleotide-binding; Phagocytosis; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1068 FT /note="Phosphatidylinositol 4,5-bisphosphate 3-kinase FT catalytic subunit alpha isoform" FT /id="PRO_0000088785" FT DOMAIN 16..105 FT /note="PI3K-ABD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00877" FT DOMAIN 187..289 FT /note="PI3K-RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00879" FT DOMAIN 330..487 FT /note="C2 PI3K-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00880" FT DOMAIN 517..694 FT /note="PIK helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00878" FT DOMAIN 765..1051 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 771..777 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 912..920 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 931..957 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT SITE 776 FT /note="Implicated in the recognition of ATP as well as FT PIP2. Also crucial for autophosphorylation of the p85alpha FT subunit" FT /evidence="ECO:0000305|PubMed:23936502" FT VARIANT 38 FT /note="R -> H (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction between the PI3K-ABD domain and FT the N-terminal lobe of PI3K/PI4K kinase domain possibly FT affecting the conformation of the kinase domain; FT dbSNP:rs772110575)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026166" FT VARIANT 43 FT /note="I -> V (in dbSNP:rs1051399)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042942" FT VARIANT 81 FT /note="E -> K (in MCAP; dbSNP:rs1057519929)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069251" FT VARIANT 83 FT /note="F -> S (in CLAPO; uncertain significance; somatic FT mutation; dbSNP:rs1560137208)" FT /evidence="ECO:0000269|PubMed:29446767" FT /id="VAR_081475" FT VARIANT 88 FT /note="R -> Q (in MCAP; also found in a glioblastoma FT multiforme sample; dbSNP:rs121913287)" FT /evidence="ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026167" FT VARIANT 106 FT /note="G -> V (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT dbSNP:rs1057519930)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026168" FT VARIANT 112 FT /note="I -> N (in MCAP; increased phosphatidylinositol 3- FT kinase signaling; decreased interaction with p85 regulatory FT subunit; no effect on protein abundance; FT dbSNP:rs863225460)" FT /evidence="ECO:0000269|PubMed:26593112" FT /id="VAR_075634" FT VARIANT 115 FT /note="R -> P (in CLAPO and MADAC; uncertain significance; FT somatic mutation in CLAPO and MADAC patients; FT dbSNP:rs200018596)" FT /evidence="ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767" FT /id="VAR_081476" FT VARIANT 118 FT /note="G -> D (in CWS5; dbSNP:rs587777790)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069786" FT VARIANT 135 FT /note="E -> K (in CWS5; dbSNP:rs587777791)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069787" FT VARIANT 218 FT /note="E -> K (in CWS5; dbSNP:rs587777792)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069788" FT VARIANT 332 FT /note="S -> R (in dbSNP:rs1051407)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042943" FT VARIANT 343 FT /note="Y -> C (found in a cancer sample; uncertain FT significance; dbSNP:rs2108393253)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026169" FT VARIANT 356 FT /note="V -> I (in CWS5; dbSNP:rs587777793)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069789" FT VARIANT 364 FT /note="G -> R (in MCAP; dbSNP:rs1576935161)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069252" FT VARIANT 365 FT /note="E -> K (in MCAP; dbSNP:rs1064793732)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069253" FT VARIANT 378 FT /note="C -> Y (in MCAP; dbSNP:rs397514565)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069254" FT VARIANT 382 FT /note="R -> K (in CWS5; dbSNP:rs587777794)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069790" FT VARIANT 391 FT /note="I -> M (in dbSNP:rs2230461)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026170" FT VARIANT 420 FT /note="C -> R (in CLOVE, CRC and CLAPO; uncertain FT significance; somatic mutation in CLAPO patients; shows an FT increase in lipid kinase activity; may increase the FT affinity for lipid membranes; dbSNP:rs121913272)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:29446767" FT /id="VAR_026171" FT VARIANT 453 FT /note="E -> Q (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction of the C2 PI3K-type domain with FT the iSH2 region of the p85 regulatory subunit; FT dbSNP:rs1057519925)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026172" FT VARIANT 453 FT /note="Missing (in MCAP)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069255" FT VARIANT 542 FT /note="E -> K (in CLOVE, KERSEB, CRC, BC, CLAPO, MADAC, FT CCM4 and HFMH; somatic mutation; also found in glioblastoma FT multiforme and endometrial carcinoma; somatic mutation; FT shows an increase in lipid kinase activity; oncogenic in FT vivo; occurs in the interface between the PI3K helical FT domain and the nSH2 (N-terminal SH2) region of the p85 FT regulatory subunit and may reduce the inhibitory effect of FT p85; requires interaction with RAS to induce cellular FT transformation; increased AKT and RPS6 phosphorylation in FT HFMH patient's cells; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, FT ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, FT ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:22658544, FT ECO:0000269|PubMed:23100325, ECO:0000269|PubMed:29446767, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026173" FT VARIANT 542 FT /note="E -> Q (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026174" FT VARIANT 542 FT /note="E -> V (in BC; uncertain significance; FT dbSNP:rs1057519927)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026175" FT VARIANT 545 FT /note="E -> A (in CWS5 and HCC; also found in a FT glioblastoma multiforme sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15608678, FT ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:23246288" FT /id="VAR_026176" FT VARIANT 545 FT /note="E -> G (in KERSEB; also found in an endometrial FT carcinoma sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:17673550" FT /id="VAR_026177" FT VARIANT 545 FT /note="E -> K (in MCAP, KERSEB, CRC, BC and HFMH; somatic FT mutation; shows an increase in lipid kinase activity; FT oncogenic in vivo; occurs in the interface between the PI3K FT helical domain and the nSH2 (N-terminal SH2) region of the FT p85 regulatory subunit and may reduce the inhibitory effect FT of p85; requires interaction with RAS to induce cellular FT transformation; enhances invadopodia-mediated extracellular FT matrix degradation and invasion in breast cancer cells; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cells; dbSNP:rs104886003)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15712344, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22729224, FT ECO:0000269|PubMed:37712948" FT /id="VAR_026178" FT VARIANT 546 FT /note="Q -> E (in BC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026179" FT VARIANT 546 FT /note="Q -> K (in OC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026180" FT VARIANT 546 FT /note="Q -> P (found in an anaplastic astrocytoma sample; FT uncertain significance; dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026181" FT VARIANT 546 FT /note="Q -> R (in BC; uncertain significance; FT dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026182" FT VARIANT 726 FT /note="E -> K (in MCAP; dbSNP:rs867262025)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069256" FT VARIANT 914 FT /note="G -> R (in MCAP; dbSNP:rs587776932)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069257" FT VARIANT 1007 FT /note="G -> R (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1448660730)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026183" FT VARIANT 1021 FT /note="Y -> C (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913288)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026184" FT VARIANT 1021 FT /note="Y -> H (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026185" FT VARIANT 1021 FT /note="Y -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026186" FT VARIANT 1023 FT /note="R -> Q (in CRC; uncertain significance; FT dbSNP:rs2108429549)" FT /evidence="ECO:0000269|PubMed:15994075" FT /id="VAR_026187" FT VARIANT 1025 FT /note="T -> A (in MCAP; dbSNP:rs397517202)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069258" FT VARIANT 1025 FT /note="T -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs1553826166)" FT /evidence="ECO:0000269|PubMed:15924253" FT /id="VAR_026188" FT VARIANT 1035 FT /note="A -> V (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs1242945375)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026189" FT VARIANT 1043 FT /note="M -> I (in MCAP and CRC; also found in an FT endometrial carcinoma sample; shows an increase in lipid FT kinase activity; dbSNP:rs121913283)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:22729224" FT /id="VAR_026190" FT VARIANT 1047 FT /note="H -> L (in BC, CLAPO, MADAC and CCM4; somatic FT mutation; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767, ECO:0000269|PubMed:34496175" FT /id="VAR_026191" FT VARIANT 1047 FT /note="H -> R (in CLOVE, KERSEB, CRC, BC, OC, MADAC, CCM4 FT and HFMH; also found in an endometrial carcinoma sample; FT somatic mutation; shows an increase in lipid kinase FT activity; oncogenic in vivo; requires binding to p85 FT regulatory subunit to induce cellular transformation but FT not interaction with RAS; may mimic the conformatitonal FT change triggered by the interaction with RAS; enhances FT invadopodia-mediated extracellular matrix degradation and FT invasion in breast cancer cells; may alter the interaction FT of the PI3K/PI4K kinase domain with the cell membrane; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cell; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15016963, FT ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16114017, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:21708979, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026192" FT VARIANT 1047 FT /note="H -> Y (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913281)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026193" FT VARIANT 1049 FT /note="G -> S (in MCAP; dbSNP:rs121913277)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069259" FT VARIANT 1050 FT /note="G -> D (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429937)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026194" FT VARIANT 1052 FT /note="T -> K (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429956)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026195" FT VARIANT 1065 FT /note="H -> L (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1560150596)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026196" FT VARIANT 1065 FT /note="H -> Y (found in brain tumors; uncertain FT significance; dbSNP:rs2108430115)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026197" FT CONFLICT 170 FT /note="N -> H (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 187 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 286..287 FT /note="ML -> KM (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 346 FT /note="V -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 723 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 751 FT /note="F -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 767 FT /note="E -> K (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT STRAND 5..10 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 13..15 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 18..25 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 27..29 FT /evidence="ECO:0007829|PDB:8TSA" FT STRAND 31..37 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 42..52 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 59..61 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 65..67 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 69..74 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:4OVU" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 89..91 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 94..102 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5SXA" FT HELIX 108..121 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 126..129 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 134..142 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 144..154 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 155..159 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 160..166 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 179..182 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 183..185 FT /evidence="ECO:0007829|PDB:3HHM" FT HELIX 186..188 FT /evidence="ECO:0007829|PDB:8BFU" FT STRAND 189..197 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 199..202 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 204..212 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 217..230 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 231..233 FT /evidence="ECO:0007829|PDB:8V8V" FT HELIX 236..246 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 247..249 FT /evidence="ECO:0007829|PDB:7JIU" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 255..257 FT /evidence="ECO:0007829|PDB:8W9A" FT STRAND 259..261 FT /evidence="ECO:0007829|PDB:8W9B" FT STRAND 263..265 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 267..269 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 271..279 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 284..289 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 290..294 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 306..308 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:5SXA" FT STRAND 323..326 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 327..329 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 332..343 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 348..350 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 353..362 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 365..368 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 378..380 FT /evidence="ECO:0007829|PDB:6PYS" FT STRAND 382..392 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 393..395 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 400..408 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 413..415 FT /evidence="ECO:0007829|PDB:8SBC" FT STRAND 420..430 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 434..436 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 439..444 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8GUA" FT STRAND 454..456 FT /evidence="ECO:0007829|PDB:6GVF" FT STRAND 458..460 FT /evidence="ECO:0007829|PDB:8V8V" FT STRAND 468..470 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 472..477 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 481..485 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 489..504 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 508..511 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:4TUU" FT TURN 520..522 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 525..536 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 539..541 FT /evidence="ECO:0007829|PDB:4TUU" FT HELIX 545..553 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 562..564 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 565..569 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 570..572 FT /evidence="ECO:0007829|PDB:8W9A" FT HELIX 577..588 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 595..598 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 599..602 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 603..605 FT /evidence="ECO:0007829|PDB:8GUD" FT HELIX 609..622 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 625..630 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 632..638 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 639..641 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 643..646 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 648..657 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 661..672 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 673..676 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 678..680 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 681..694 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 698..721 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 724..726 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 728..739 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 742..747 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 749..753 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 756..761 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 766..768 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 773..776 FT /evidence="ECO:0007829|PDB:8DCP" FT STRAND 779..784 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 786..789 FT /evidence="ECO:0007829|PDB:7MYN" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 795..805 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 808..826 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 838..842 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 845..849 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 852..856 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 857..860 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 863..865 FT /evidence="ECO:0007829|PDB:7K6N" FT STRAND 866..868 FT /evidence="ECO:0007829|PDB:8TSA" FT HELIX 869..871 FT /evidence="ECO:0007829|PDB:7K6N" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 876..884 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7JIU" FT HELIX 890..911 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 920..924 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 925..927 FT /evidence="ECO:0007829|PDB:8GUD" FT STRAND 929..931 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 935..937 FT /evidence="ECO:0007829|PDB:8W9B" FT TURN 938..941 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 948..950 FT /evidence="ECO:0007829|PDB:7K6M" FT STRAND 951..954 FT /evidence="ECO:0007829|PDB:7K6M" FT HELIX 958..964 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 965..967 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 971..973 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 975..993 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 995..1003 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1004..1007 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1013..1015 FT /evidence="ECO:0007829|PDB:8EXV" FT HELIX 1016..1025 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1026..1029 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 1032..1047 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1048..1050 FT /evidence="ECO:0007829|PDB:5SW8" FT STRAND 1053..1055 FT /evidence="ECO:0007829|PDB:3HHM" FT STRAND 1056..1058 FT /evidence="ECO:0007829|PDB:4JPS" SQ SEQUENCE 1068 AA; 124284 MW; 041487231A9A1207 CRC64; MPPRPSSGEL WGIHLMPPRI LVECLLPNGM IVTLECLREA TLITIKHELF KEARKYPLHQ LLQDESSYIF VSVTQEAERE EFFDETRRLC DLRLFQPFLK VIEPVGNREE KILNREIGFA IGMPVCEFDM VKDPEVQDFR RNILNVCKEA VDLRDLNSPH SRAMYVYPPN VESSPELPKH IYNKLDKGQI IVVIWVIVSP NNDKQKYTLK INHDCVPEQV IAEAIRKKTR SMLLSSEQLK LCVLEYQGKY ILKVCGCDEY FLEKYPLSQY KYIRSCIMLG RMPNLMLMAK ESLYSQLPMD CFTMPSYSRR ISTATPYMNG ETSTKSLWVI NSALRIKILC ATYVNVNIRD IDKIYVRTGI YHGGEPLCDN VNTQRVPCSN PRWNEWLNYD IYIPDLPRAA RLCLSICSVK GRKGAKEEHC PLAWGNINLF DYTDTLVSGK MALNLWPVPH GLEDLLNPIG VTGSNPNKET PCLELEFDWF SSVVKFPDMS VIEEHANWSV SREAGFSYSH AGLSNRLARD NELRENDKEQ LKAISTRDPL SEITEQEKDF LWSHRHYCVT IPEILPKLLL SVKWNSRDEV AQMYCLVKDW PPIKPEQAME LLDCNYPDPM VRGFAVRCLE KYLTDDKLSQ YLIQLVQVLK YEQYLDNLLV RFLLKKALTN QRIGHFFFWH LKSEMHNKTV SQRFGLLLES YCRACGMYLK HLNRQVEAME KLINLTDILK QEKKDETQKV QMKFLVEQMR RPDFMDALQG FLSPLNPAHQ LGNLRLEECR IMSSAKRPLW LNWENPDIMS ELLFQNNEII FKNGDDLRQD MLTLQIIRIM ENIWQNQGLD LRMLPYGCLS IGDCVGLIEV VRNSHTIMQI QCKGGLKGAL QFNSHTLHQW LKDKNKGEIY DAAIDLFTRS CAGYCVATFI LGIGDRHNSN IMVKDDGQLF HIDFGHFLDH KKKKFGYKRE RVPFVLTQDF LIVISKGAQE CTKTREFERF QEMCYKAYLA IRQHANLFIN LFSMMLGSGM PELQSFDDIA YIRKTLALDK TEQEALEYFM KQMNDAHHGG WTTKMDWIFH TIKQHALN // ID PLK2_HUMAN Reviewed; 685 AA. AC Q9NYY3; A0A087WUH9; O60679; Q96CV7; Q9UE61; DT 11-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 02-AUG-2002, sequence version 3. DT 28-JAN-2026, entry version 207. DE RecName: Full=Serine/threonine-protein kinase PLK2; DE EC=2.7.11.21; DE AltName: Full=Polo-like kinase 2; DE Short=PLK-2; DE Short=hPlk2; DE AltName: Full=Serine/threonine-protein kinase SNK; DE Short=hSNK; DE AltName: Full=Serum-inducible kinase; GN Name=PLK2; Synonyms=SNK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RX PubMed=11696980; DOI=10.3109/10425170109041337; RA Liby K., Wu H., Ouyang B., Wu S., Chen J., Dai W.; RT "Identification of the human homologue of the early-growth response gene RT Snk, encoding a serum-inducible kinase."; RL DNA Seq. 11:527-533(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Colon; RA Anderson K.M., Nerurkar S.S., Hansbury M.J., Fornwald J., Scott G., RA Bouzyk M., Mui P., Imbrugia C.S., Carlson K., Marshall L.A., Roshak A.K.; RT "Identification and characterization of human serum-inducible kinase (SNK), RT a novel member of the polo-kinase family of cell cycle regulators: RT potential implication for regulation of vascular smooth muscle RT proliferation."; RL Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 110-408. RA Fidler C., Boultwood J., Wang Jabs E., Wainscoat J.S.; RL Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP INDUCTION. RX PubMed=11716500; DOI=10.1006/bbrc.2001.5993; RA Shimizu-Yoshida Y., Sugiyama K., Rogounovitch T., Ohtsuru A., Namba H., RA Saenko V., Yamashita S.; RT "Radiation-inducible hSNK gene is transcriptionally regulated by p53 RT binding homology element in human thyroid cells."; RL Biochem. Biophys. Res. Commun. 289:491-498(2001). RN [7] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15242618; DOI=10.1016/j.cub.2004.06.059; RA Warnke S., Kemmler S., Hames R.S., Tsai H.L., Hoffmann-Rohrer U., Fry A.M., RA Hoffmann I.; RT "Polo-like kinase-2 is required for centriole duplication in mammalian RT cells."; RL Curr. Biol. 14:1200-1207(2004). RN [8] RP DOWN-REGULATION IN B-CELL LYMPHOMAS. RX PubMed=16160013; DOI=10.1182/blood-2005-03-1194; RA Syed N., Smith P., Sullivan A., Spender L.C., Dyer M., Karran L., RA O'Nions J., Allday M., Hoffmann I., Crawford D., Griffin B., Farrell P.J., RA Crook T.; RT "Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent RT event in B-cell malignancies."; RL Blood 107:250-256(2006). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-210; TRP-503; RP HIS-629 AND LYS-631. RX PubMed=19001868; DOI=10.4161/cc.7.22.7071; RA Cizmecioglu O., Warnke S., Arnold M., Duensing S., Hoffmann I.; RT "Plk2 regulated centriole duplication is dependent on its localization to RT the centrioles and a functional polo-box domain."; RL Cell Cycle 7:3548-3555(2008). RN [10] RP INDUCTION. RX PubMed=18832181; DOI=10.1073/pnas.0808266105; RA Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R.T., Chen P., Wang Y., Yan M., RA Qian Z., Neilly M.B., Jin J., Zhang Y., Bohlander S.K., Zhang D.E., RA Larson R.A., Le Beau M.M., Thirman M.J., Golub T.R., Rowley J.D., Chen J.; RT "Distinct microRNA expression profiles in acute myeloid leukemia with RT common translocations."; RL Proc. Natl. Acad. Sci. U.S.A. 105:15535-15540(2008). RN [11] RP FUNCTION IN PHOSPHORYLATION OF CPAP. RX PubMed=20531387; DOI=10.1038/emboj.2010.118; RA Chang J., Cizmecioglu O., Hoffmann I., Rhee K.; RT "PLK2 phosphorylation is critical for CPAP function in procentriole RT formation during the centrosome cycle."; RL EMBO J. 29:2395-2406(2010). RN [12] RP FUNCTION IN PHOSPHORYLATION OF NPM. RX PubMed=20352051; DOI=10.1371/journal.pone.0009849; RA Krause A., Hoffmann I.; RT "Polo-like kinase 2-dependent phosphorylation of NPM/B23 on serine 4 RT triggers centriole duplication."; RL PLoS ONE 5:E9849-E9849(2010). RN [13] RP DOWN-REGULATION IN ACUTE MYELOID LEUKEMIA. RX PubMed=21340720; DOI=10.1007/s00277-011-1193-4; RA Benetatos L., Dasoula A., Hatzimichael E., Syed N., Voukelatou M., RA Dranitsaris G., Bourantas K.L., Crook T.; RT "Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in RT acute myeloid leukemia and myelodysplastic syndromes: genetic and RT epigenetic interactions."; RL Ann. Hematol. 90:1037-1045(2011). RN [14] RP REVIEW ON FUNCTION. RX PubMed=20671765; DOI=10.1038/nrd3184; RA Strebhardt K.; RT "Multifaceted polo-like kinases: drug targets and antitargets for cancer RT therapy."; RL Nat. Rev. Drug Discov. 9:643-660(2010). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] THR-14; SER-92; LYS-436 AND LEU-487. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase involved in CC synaptic plasticity, centriole duplication and G1/S phase transition. CC Polo-like kinases act by binding and phosphorylating proteins that are CC already phosphorylated on a specific motif recognized by the POLO box CC domains. Phosphorylates CPAP, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and CC SYNGAP1. Plays a key role in synaptic plasticity and memory by CC regulating the Ras and Rap protein signaling: required for CC overactivity-dependent spine remodeling by phosphorylating the Ras CC activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their CC degradation by the proteasome. Conversely, phosphorylates the Rap CC activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their CC activity. Also regulates synaptic plasticity independently of kinase CC activity, via its interaction with NSF that disrupts the interaction CC between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown CC of AMPAR-mediated current that occludes long term depression. Required CC for procentriole formation and centriole duplication by phosphorylating CC CPAP and NPM1, respectively. Its induction by p53/TP53 suggests that it CC may participate in the mitotic checkpoint following stress. CC {ECO:0000269|PubMed:15242618, ECO:0000269|PubMed:19001868, CC ECO:0000269|PubMed:20352051, ECO:0000269|PubMed:20531387}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.21; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.21; CC -!- ACTIVITY REGULATION: Activated by phosphorylation of Thr-239. Once CC activated, activity is stimulated by binding target proteins (By CC similarity). {ECO:0000250}. CC -!- SUBUNIT: Interacts with NSF; causing NSF dissociation from GRIA2. CC Interacts with CIB1 (By similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q9NYY3; Q86Y33: CDC20B; NbExp=3; IntAct=EBI-721354, EBI-10260504; CC Q9NYY3; Q9HC77: CPAP; NbExp=3; IntAct=EBI-721354, EBI-946194; CC Q9NYY3; P62258: YWHAE; NbExp=2; IntAct=EBI-721354, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome, centriole {ECO:0000269|PubMed:15242618, CC ECO:0000269|PubMed:19001868}. Cell projection, dendrite {ECO:0000250}. CC Note=Localizes to centrosomes during early G1 phase where it only CC associates to the mother centriole and then distributes equally to both CC mother and daughter centrioles at the onset of S phase. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9NYY3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9NYY3-2; Sequence=VSP_062732; CC -!- TISSUE SPECIFICITY: Expressed at higher level in the fetal lung, CC kidney, spleen and heart. {ECO:0000269|PubMed:11696980}. CC -!- INDUCTION: Directly regulated by p53/TP53. Negatively regulated by miR- CC 126. {ECO:0000269|PubMed:11716500, ECO:0000269|PubMed:18832181}. CC -!- DOMAIN: The POLO box domains act as phosphopeptide-binding module that CC recognizes and binds serine-[phosphothreonine/phosphoserine]- CC (proline/X) motifs. PLK2 recognizes and binds docking proteins that are CC already phosphorylated on these motifs, and then phosphorylates them CC (By similarity). {ECO:0000250}. CC -!- PTM: Catalytic activity is enhanced by phosphorylation of Thr-239. CC {ECO:0000250}. CC -!- MISCELLANEOUS: There are indications that PLK2 might act as a tumor CC suppressor: PLK2 is significantly down-regulated in a wide range of CC acute myeloid leukemias (AMLs) and B-cell lymphomas due to aberrant CC cytosine methylation in the CpG island located at the 5' of the PLK2 CC gene (PubMed:16160013, PubMed:21340720). Moreover, miR-126, a microRNA CC that negatively regulates PLK2 is up-regulated in AMLs, suggesting that CC PLK2 down-regulation by miR-126 could also contribute to leukemogenesis CC (PubMed:18832181). {ECO:0000305|PubMed:16160013, CC ECO:0000305|PubMed:18832181, ECO:0000305|PubMed:21340720}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF059617; AAC14573.1; -; mRNA. DR EMBL; AF223574; AAF62897.1; -; mRNA. DR EMBL; U85755; AAD00575.1; -; mRNA. DR EMBL; AC008814; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013879; AAH13879.1; -; mRNA. DR CCDS; CCDS3974.1; -. DR RefSeq; NP_001239155.1; NM_001252226.1. DR RefSeq; NP_006613.2; NM_006622.4. DR PDB; 4I5M; X-ray; 1.80 A; A=57-360. DR PDB; 4I5P; X-ray; 1.74 A; A=57-360. DR PDB; 4I6B; X-ray; 1.80 A; A=57-360. DR PDB; 4I6F; X-ray; 2.90 A; A=57-360. DR PDB; 4I6H; X-ray; 1.91 A; A=57-360. DR PDB; 4RS6; X-ray; 2.60 A; A/B=451-685. DR PDB; 4XB0; X-ray; 2.70 A; A/B=468-685. DR PDBsum; 4I5M; -. DR PDBsum; 4I5P; -. DR PDBsum; 4I6B; -. DR PDBsum; 4I6F; -. DR PDBsum; 4I6H; -. DR PDBsum; 4RS6; -. DR PDBsum; 4XB0; -. DR AlphaFoldDB; Q9NYY3; -. DR SMR; Q9NYY3; -. DR BioGRID; 115988; 72. DR DIP; DIP-48943N; -. DR FunCoup; Q9NYY3; 425. DR IntAct; Q9NYY3; 53. DR MINT; Q9NYY3; -. DR STRING; 9606.ENSP00000274289; -. DR BindingDB; Q9NYY3; -. DR ChEMBL; CHEMBL5938; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9NYY3; -. DR GuidetoPHARMACOLOGY; 2169; -. DR iPTMnet; Q9NYY3; -. DR PhosphoSitePlus; Q9NYY3; -. DR SwissPalm; Q9NYY3; -. DR BioMuta; PLK2; -. DR DMDM; 22096374; -. DR jPOST; Q9NYY3; -. DR MassIVE; Q9NYY3; -. DR PaxDb; 9606-ENSP00000274289; -. DR PeptideAtlas; Q9NYY3; -. DR ProteomicsDB; 83299; -. DR Antibodypedia; 4042; 256 antibodies from 32 providers. DR DNASU; 10769; -. DR Ensembl; ENST00000274289.8; ENSP00000274289.3; ENSG00000145632.16. DR GeneID; 10769; -. DR KEGG; hsa:10769; -. DR MANE-Select; ENST00000274289.8; ENSP00000274289.3; NM_006622.4; NP_006613.2. DR UCSC; uc003jrn.4; human. DR AGR; HGNC:19699; -. DR ClinPGx; PA134940798; -. DR CTD; 10769; -. DR DisGeNET; 10769; -. DR GeneCards; PLK2; -. DR HGNC; HGNC:19699; PLK2. DR HPA; ENSG00000145632; Low tissue specificity. DR MalaCards; PLK2; -. DR MIM; 607023; gene. DR OpenTargets; ENSG00000145632; -. DR VEuPathDB; HostDB:ENSG00000145632; -. DR eggNOG; KOG0575; Eukaryota. DR GeneTree; ENSGT00940000158739; -. DR HOGENOM; CLU_000288_46_1_1; -. DR InParanoid; Q9NYY3; -. DR OMA; NMPESDH; -. DR OrthoDB; 408964at2759; -. DR PAN-GO; Q9NYY3; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q9NYY3; -. DR BRENDA; 2.7.11.21; 2681. DR PathwayCommons; Q9NYY3; -. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-9662834; CD163 mediating an anti-inflammatory response. DR Reactome; R-HSA-9768919; NPAS4 regulates expression of target genes. DR SignaLink; Q9NYY3; -. DR SIGNOR; Q9NYY3; -. DR Agora; ENSG00000145632; -. DR BioGRID-ORCS; 10769; 13 hits in 1185 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PLK2; human. DR EvolutionaryTrace; Q9NYY3; -. DR GeneWiki; PLK2; -. DR GenomeRNAi; 10769; -. DR Pharos; Q9NYY3; Tchem. DR PRO; PR:Q9NYY3; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q9NYY3; protein. DR Bgee; ENSG00000145632; Expressed in spleen and 196 other cell types or tissues. DR ExpressionAtlas; Q9NYY3; baseline and differential. DR GO; GO:0005814; C:centriole; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0043008; F:ATP-dependent protein binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0060292; P:long-term synaptic depression; ISS:UniProtKB. DR GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB. DR GO; GO:0007613; P:memory; ISS:UniProtKB. DR GO; GO:0007052; P:mitotic spindle organization; IDA:UniProtKB. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0071866; P:negative regulation of apoptotic process in bone marrow cell; IEA:Ensembl. DR GO; GO:2000773; P:negative regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome. DR GO; GO:0010508; P:positive regulation of autophagy; IDA:ParkinsonsUK-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; HMP:UniProtKB. DR GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IEA:Ensembl. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:ParkinsonsUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032486; P:Rap protein signal transduction; ISS:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; ISS:UniProtKB. DR GO; GO:0046599; P:regulation of centriole replication; IDA:UniProtKB. DR GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB. DR CDD; cd13118; POLO_box_1; 1. DR CDD; cd13117; POLO_box_2; 1. DR CDD; cd14188; STKc_PLK2; 1. DR FunFam; 1.10.510.10:FF:001498; Serine/threonine-protein kinase PLK; 1. DR FunFam; 3.30.1120.30:FF:000001; Serine/threonine-protein kinase PLK; 1. DR FunFam; 3.30.200.20:FF:000091; Serine/threonine-protein kinase PLK; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.30.1120.30; POLO box domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR042825; PLK2_STKc. DR InterPro; IPR033701; POLO_box_1. DR InterPro; IPR033695; POLO_box_2. DR InterPro; IPR000959; POLO_box_dom. DR InterPro; IPR036947; POLO_box_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24345; SERINE/THREONINE-PROTEIN KINASE PLK; 1. DR PANTHER; PTHR24345:SF44; SERINE_THREONINE-PROTEIN KINASE PLK2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00659; POLO_box; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF82615; Polo-box domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50078; POLO_BOX; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; KW Cytoplasm; Cytoskeleton; Kinase; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT CHAIN 1..685 FT /note="Serine/threonine-protein kinase PLK2" FT /id="PRO_0000086561" FT DOMAIN 82..334 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 503..581 FT /note="POLO box 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00154" FT DOMAIN 601..685 FT /note="POLO box 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00154" FT REGION 21..70 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 406..433 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 43..52 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 205 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 88..96 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 111 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 239 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P53351" FT VAR_SEQ 55..68 FT /note="Missing (in isoform 2)" FT /id="VSP_062732" FT VARIANT 14 FT /note="S -> T (in an ovarian endometrioid carcinoma sample; FT somatic mutation; dbSNP:rs1404394734)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041023" FT VARIANT 92 FT /note="G -> S (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041024" FT VARIANT 436 FT /note="E -> K (in dbSNP:rs55768901)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041025" FT VARIANT 487 FT /note="P -> L (in dbSNP:rs55645589)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041026" FT MUTAGEN 210 FT /note="N->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:19001868" FT MUTAGEN 503 FT /note="W->F: Impairs localization to the centrosome and FT centriole duplication; when associated with A-629 and M- FT 631." FT /evidence="ECO:0000269|PubMed:19001868" FT MUTAGEN 629 FT /note="H->A: Impairs localization to the centrosome and FT centriole duplication; when associated with F-503 and M- FT 631." FT /evidence="ECO:0000269|PubMed:19001868" FT MUTAGEN 631 FT /note="K->M: Impairs localization to the centrosome and FT centriole duplication; when associated with F-503 and A- FT 631." FT /evidence="ECO:0000269|PubMed:19001868" FT CONFLICT 28 FT /note="A -> G (in Ref. 1; AAC14573)" FT /evidence="ECO:0000305" FT STRAND 72..74 FT /evidence="ECO:0007829|PDB:4I5P" FT TURN 76..78 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 81..91 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 94..101 FT /evidence="ECO:0007829|PDB:4I5P" FT TURN 102..105 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 106..114 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 121..134 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 145..150 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 152..159 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 167..174 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 179..198 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 208..210 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 211..213 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 219..221 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 224..226 FT /evidence="ECO:0007829|PDB:4I5M" FT TURN 233..235 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 249..252 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 259..275 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 286..288 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 289..293 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 305..314 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 319..321 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 325..329 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 332..335 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 345..348 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 471..485 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 490..492 FT /evidence="ECO:0007829|PDB:4XB0" FT STRAND 504..510 FT /evidence="ECO:0007829|PDB:4RS6" FT TURN 511..514 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 515..520 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 525..529 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 534..537 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 541..547 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 553..558 FT /evidence="ECO:0007829|PDB:4RS6" FT HELIX 563..582 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 602..616 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 621..625 FT /evidence="ECO:0007829|PDB:4RS6" FT TURN 626..628 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 631..646 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 652..656 FT /evidence="ECO:0007829|PDB:4RS6" FT HELIX 657..663 FT /evidence="ECO:0007829|PDB:4RS6" FT HELIX 667..680 FT /evidence="ECO:0007829|PDB:4RS6" SQ SEQUENCE 685 AA; 78237 MW; 6429F6EFD830B333 CRC64; MELLRTITYQ PAASTKMCEQ ALGKGCGADS KKKRPPQPPE ESQPPQSQAQ VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT VPDFHLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH DLKKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYYAEL GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN // ID PTK6_HUMAN Reviewed; 451 AA. AC Q13882; B2RCR3; B4DW46; Q58F01; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 234. DE RecName: Full=Protein-tyrosine kinase 6; DE EC=2.7.10.2 {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680}; DE AltName: Full=Breast tumor kinase; DE AltName: Full=Tyrosine-protein kinase BRK; GN Name=PTK6; Synonyms=BRK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary tumor; RX PubMed=8036022; RA Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N., RA Page M.J., Gusterson B.A., Crompton M.R.; RT "Cloning and characterisation of cDNAs encoding a novel non-receptor RT tyrosine kinase, brk, expressed in human breast tumours."; RL Oncogene 9:2383-2390(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RX PubMed=9333026; DOI=10.1038/sj.onc.1201292; RA Mitchell P.J., Barker K.T., Shipley J., Crompton M.R.; RT "Characterisation and chromosome mapping of the human non receptor tyrosine RT kinase gene, brk."; RL Oncogene 15:1497-1502(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Melanocyte; RX PubMed=9749526; RA Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T.; RT "Exon-intron structure of the human PTK6 gene demonstrates that PTK6 RT constitutes a distinct family of non-receptor tyrosine kinase."; RL Mol. Cells 8:401-407(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Urinary bladder; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP CHARACTERIZATION, INTERACTION WITH EGFR, AND MUTAGENESIS OF LYS-219 AND RP TYR-447. RX PubMed=8940083; DOI=10.1074/jbc.271.48.30956; RA Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E., RA Dean C.J., Page M.J., Gusterson B.A., Crompton M.R.; RT "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, RT sensitizes mammary epithelial cells to epidermal growth factor."; RL J. Biol. Chem. 271:30956-30963(1996). RN [8] RP TISSUE SPECIFICITY. RX PubMed=9185712; RX DOI=10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f; RA Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A., RA Bennett D.C.; RT "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK RT in metastatic melanoma."; RL Int. J. Cancer 71:1061-1065(1997). RN [9] RP FUNCTION, INTERACTION WITH STAP2, AND MUTAGENESIS OF TRP-44; TYR-66; RP ARG-105 AND LYS-219. RX PubMed=10980601; DOI=10.1038/sj.onc.1203775; RA Mitchell P.J., Sara E.A., Crompton M.R.; RT "A novel adaptor-like protein which is a substrate for the non-receptor RT tyrosine kinase, BRK."; RL Oncogene 19:4273-4282(2000). RN [10] RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-447, AND INTERACTION WITH RP KHDRBS1. RX PubMed=10913193; DOI=10.1128/mcb.20.16.6114-6126.2000; RA Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V., RA Cochrane A.W., Chen T., Tyner A.L.; RT "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RT RNA binding ability."; RL Mol. Cell. Biol. 20:6114-6126(2000). RN [11] RP PHOSPHORYLATION AT TYR-13; TYR-61; TYR-66; TYR-114; TYR-342 AND TYR-351, RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF TYR-342 RP AND TYR-447, ACTIVITY REGULATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12121988; DOI=10.1074/jbc.m203877200; RA Qiu H., Miller W.T.; RT "Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation RT and by autoinhibition."; RL J. Biol. Chem. 277:34634-34641(2002). RN [12] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=12833144; DOI=10.1038/sj.onc.1206465; RA Derry J.J., Prins G.S., Ray V., Tyner A.L.; RT "Altered localization and activity of the intracellular tyrosine kinase RT BRK/Sik in prostate tumor cells."; RL Oncogene 22:4212-4220(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447, AND RP PHOSPHORYLATION. RX PubMed=15471878; DOI=10.1074/jbc.m409579200; RA Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L.; RT "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA- RT binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2."; RL J. Biol. Chem. 279:54398-54404(2004). RN [14] RP FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN, SUBCELLULAR RP LOCATION, AND INTERACTION WITH PXN. RX PubMed=15572663; DOI=10.1128/mcb.24.24.10558-10572.2004; RA Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H.; RT "Brk activates rac1 and promotes cell migration and invasion by RT phosphorylating paxillin."; RL Mol. Cell. Biol. 24:10558-10572(2004). RN [15] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15509496; DOI=10.1016/j.oraloncology.2004.05.010; RA Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K.; RT "Differential expression of the non-receptor tyrosine kinase BRK in oral RT squamous cell carcinoma and normal oral epithelium."; RL Oral Oncol. 40:1040-1047(2004). RN [16] RP FUNCTION IN PHOSPHORYLATION OF BTK, AND INTERACTION WITH BTK. RX PubMed=15539407; DOI=10.1074/jbc.m412038200; RA Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D., RA Lange C.A.; RT "Regulated association of protein kinase B/Akt with breast tumor kinase."; RL J. Biol. Chem. 280:1982-1991(2005). RN [17] RP MUTAGENESIS OF TRP-184, AND ACTIVITY REGULATION. RX PubMed=15961400; DOI=10.1074/jbc.m504568200; RA Kim H.I.E., Lee S.T.; RT "An intramolecular interaction between SH2-kinase linker and kinase domain RT is essential for the catalytic activity of protein-tyrosine kinase-6."; RL J. Biol. Chem. 280:28973-28980(2005). RN [18] RP FUNCTION IN PHOSPHORYLATION OF KHDRBS1. RX PubMed=16179349; DOI=10.1074/jbc.m505802200; RA Lukong K.E., Larocque D., Tyner A.L., Richard S.; RT "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates RT intranuclear localization and cell cycle progression."; RL J. Biol. Chem. 280:38639-38647(2005). RN [19] RP INTERACTION WITH IRS4, AND ACTIVITY REGULATION. RX PubMed=15870689; DOI=10.1038/sj.onc.1208721; RA Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.; RT "Interaction between Brk kinase and insulin receptor substrate-4."; RL Oncogene 24:5656-5664(2005). RN [20] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=16651629; DOI=10.2353/ajpath.2006.050521; RA Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M., Zhang Q., RA Marzec M., Gimotty P., Crompton M.R., Wasik M.A.; RT "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in RT lymphocytes."; RL Am. J. Pathol. 168:1631-1641(2006). RN [21] RP FUNCTION IN PHOSPHORYLATION OF STAT3, AND ACTIVITY REGULATION. RX PubMed=16568091; DOI=10.1038/sj.onc.1209501; RA Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.; RT "Identification of STAT3 as a specific substrate of breast tumor kinase."; RL Oncogene 25:4904-4912(2006). RN [22] RP ACTIVITY REGULATION, AND MUTAGENESIS OF TRP-44. RX PubMed=17822667; DOI=10.1016/j.bbrc.2007.08.055; RA Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T.; RT "Molecular dissection of the interaction between the SH3 domain and the RT SH2-Kinase Linker region in PTK6."; RL Biochem. Biophys. Res. Commun. 362:829-834(2007). RN [23] RP FUNCTION IN PHOSPHORYLATION OF STAT5B. RX PubMed=17997837; DOI=10.1186/bcr1794; RA Weaver A.M., Silva C.M.; RT "Signal transducer and activator of transcription 5b: a new target of RT breast tumor kinase/protein tyrosine kinase 6."; RL Breast Cancer Res. 9:R79-R79(2007). RN [24] RP FUNCTION IN PHOSPHORYLATION OF ARHGAP35. RX PubMed=18829532; DOI=10.1158/0008-5472.can-08-0997; RA Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L., RA Settleman J., Chen R.H.; RT "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and RT promote breast carcinoma growth, migration, and invasion."; RL Cancer Res. 68:7779-7787(2008). RN [25] RP INTERACTION WITH ADAM15. RX PubMed=18296648; DOI=10.1158/1541-7786.mcr-07-2028; RA Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M., RA Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C., RA Edwards D.R.; RT "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human RT mammary carcinoma."; RL Mol. Cancer Res. 6:383-394(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [27] RP INTERACTION WITH ERBB2. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [28] RP INTERACTION WITH SFPQ. RX PubMed=19439179; DOI=10.1016/j.cellsig.2009.04.008; RA Lukong K.E., Huot M.E., Richard S.; RT "BRK phosphorylates PSF promoting its cytoplasmic localization and cell RT cycle arrest."; RL Cell. Signal. 21:1415-1422(2009). RN [29] RP REVIEW ON FUNCTION. RX PubMed=20193745; DOI=10.1016/j.bbcan.2010.02.003; RA Brauer P.M., Tyner A.L.; RT "Building a better understanding of the intracellular tyrosine kinase PTK6 RT - BRK by BRK."; RL Biochim. Biophys. Acta 1806:66-73(2010). RN [30] RP FUNCTION, AND MUTAGENESIS OF ARG-105 AND LYS-219. RX PubMed=20554524; DOI=10.1074/jbc.m109.088971; RA Kang S.A., Lee E.S., Yoon H.Y., Randazzo P.A., Lee S.T.; RT "PTK6 inhibits down-regulation of EGF receptor through phosphorylation of RT ARAP1."; RL J. Biol. Chem. 285:26013-26021(2010). RN [31] RP PHOSPHORYLATION OF CTNNB1, AND INTERACTION WITH CTNNB1. RX PubMed=20026641; DOI=10.1242/jcs.053264; RA Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., RA Tyner A.L.; RT "Identification of beta-catenin as a target of the intracellular tyrosine RT kinase PTK6."; RL J. Cell Sci. 123:236-245(2010). RN [32] RP FUNCTION (ISOFORM 2), AND INTERACTION (ISOFORM 2) WITH KHDRBS1 AND CTNNB1. RX PubMed=21479203; DOI=10.1371/journal.pone.0014789; RA Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M., RA Tyner A.L.; RT "The alternative splice variant of protein tyrosine kinase 6 negatively RT regulates growth and enhances PTK6-mediated inhibition of beta-catenin."; RL PLoS ONE 6:E14789-E14789(2011). RN [33] RP STRUCTURE BY NMR OF 75-174. RX PubMed=15056653; DOI=10.1074/jbc.m313185200; RA Hong E., Shin J., Kim H.I., Lee S.T., Lee W.; RT "Solution structure and backbone dynamics of the non-receptor protein- RT tyrosine kinase-6 Src homology 2 domain."; RL J. Biol. Chem. 279:29700-29708(2004). RN [34] RP X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 185-446, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF LYS-219. RX PubMed=27480927; DOI=10.1016/j.bbrc.2016.07.121; RA Thakur M.K., Kumar A., Birudukota S., Swaminathan S., Tyagi R., Gosu R.; RT "Crystal structure of the kinase domain of human protein tyrosine kinase 6 RT (PTK6) at 2.33 A resolution."; RL Biochem. Biophys. Res. Commun. 478:637-642(2016). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 185-446 IN COMPLEXES WITH RP INHIBITORS, AND CATALYTIC ACTIVITY. RX PubMed=27993680; DOI=10.1016/j.bbrc.2016.12.030; RA Thakur M.K., Birudukota S., Swaminathan S., Battula S.K., Vadivelu S., RA Tyagi R., Gosu R.; RT "Co-crystal structures of PTK6: With Dasatinib at 2.24 A, with novel RT imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 A resolution."; RL Biochem. Biophys. Res. Commun. 482:1289-1295(2017). RN [36] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Non-receptor tyrosine-protein kinase implicated in the CC regulation of a variety of signaling pathways that control the CC differentiation and maintenance of normal epithelia, as well as tumor CC growth. Function seems to be context dependent and differ depending on CC cell type, as well as its intracellular localization. A number of CC potential nuclear and cytoplasmic substrates have been identified. CC These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, CC KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B CC and a variety of signaling molecules: ARHGAP35/p190RhoGAP, CC PXN/paxillin, BTK/ATK, STAP2/BKS. Phosphorylates the GTPase-activating CC protein ARAP1 following EGF stimulation which enhances EGFR signaling CC by delaying EGFR down-regulation (PubMed:20554524). Also associates CC with a variety of proteins that are likely upstream of PTK6 in various CC signaling pathways, or for which PTK6 may play an adapter-like role. CC These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal CC or non-tumorigenic tissues, PTK6 promotes cellular differentiation and CC apoptosis. In tumors PTK6 contributes to cancer progression by CC sensitizing cells to mitogenic signals and enhancing proliferation, CC anchorage-independent survival and migration/invasion. Association with CC EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and CC growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 CC kinase. Contributes to migration and proliferation by contributing to CC EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes CC association with RASA1/p120RasGAP, inactivating RhoA while activating CC RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by CC PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration CC and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. CC Nuclear PTK6 may be important for regulating growth in normal CC epithelia, while cytoplasmic PTK6 might activate oncogenic signaling CC pathways. {ECO:0000269|PubMed:20554524}. CC -!- FUNCTION: [Isoform 2]: Inhibits PTK6 phosphorylation and PTK6 CC association with other tyrosine-phosphorylated proteins. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, CC ECO:0000269|PubMed:27993680}; CC -!- ACTIVITY REGULATION: Activated by EGF, NRG1 and IGF1. Inhibited by CC SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by an CC association between the SH3 domain and the SH2-TK linker region. CC Interaction between Trp-184 within SH2-TK linker region and the CC catalytic domain appears essential for positive regulation of kinase CC activity. {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:15961400, ECO:0000269|PubMed:16568091, CC ECO:0000269|PubMed:17822667}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=83 uM for ATP {ECO:0000269|PubMed:12121988}; CC Vmax=37 nmol/min/mg enzyme {ECO:0000269|PubMed:12121988}; CC -!- SUBUNIT: Interacts with GAP-A.p65 (By similarity). Interacts (via SH3 CC and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2 domains) with CC phosphorylated IRS4. Interacts with ADAM15. Interacts (via SH3 domain) CC with SFPQ. Interacts with EGFR and ERBB2. Interacts with STAP2. CC Interacts with PNX. Interacts with SFPQ. Interacts with PTK/ATK. CC Interacts with CTNNB1. {ECO:0000250, ECO:0000269|PubMed:10913193, CC ECO:0000269|PubMed:10980601, ECO:0000269|PubMed:15539407, CC ECO:0000269|PubMed:15572663, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:18296648, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:19439179, ECO:0000269|PubMed:20026641, CC ECO:0000269|PubMed:8940083}. CC -!- INTERACTION: CC Q13882; Q08043: ACTN3; NbExp=3; IntAct=EBI-1383632, EBI-2880652; CC Q13882; Q3KP44: ANKRD55; NbExp=3; IntAct=EBI-1383632, EBI-14493093; CC Q13882; Q13191: CBLB; NbExp=3; IntAct=EBI-1383632, EBI-744027; CC Q13882; Q16543: CDC37; NbExp=4; IntAct=EBI-1383632, EBI-295634; CC Q13882; Q92841: DDX17; NbExp=4; IntAct=EBI-1383632, EBI-746012; CC Q13882; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-1383632, EBI-2340258; CC Q13882; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-1383632, EBI-2349927; CC Q13882; P00533: EGFR; NbExp=2; IntAct=EBI-1383632, EBI-297353; CC Q13882; P04626: ERBB2; NbExp=4; IntAct=EBI-1383632, EBI-641062; CC Q13882; O00471: EXOC5; NbExp=6; IntAct=EBI-1383632, EBI-949824; CC Q13882; O14526: FCHO1; NbExp=4; IntAct=EBI-1383632, EBI-719823; CC Q13882; Q13480: GAB1; NbExp=6; IntAct=EBI-1383632, EBI-517684; CC Q13882; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1383632, EBI-352572; CC Q13882; P42858: HTT; NbExp=4; IntAct=EBI-1383632, EBI-466029; CC Q13882; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383632, EBI-747204; CC Q13882; Q5VWX1: KHDRBS2; NbExp=4; IntAct=EBI-1383632, EBI-742808; CC Q13882; Q5T5P2-6: KIAA1217; NbExp=3; IntAct=EBI-1383632, EBI-10188326; CC Q13882; P10721: KIT; NbExp=4; IntAct=EBI-1383632, EBI-1379503; CC Q13882; O14770-4: MEIS2; NbExp=3; IntAct=EBI-1383632, EBI-8025850; CC Q13882; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383632, EBI-2340269; CC Q13882; Q8TDC0: MYOZ3; NbExp=3; IntAct=EBI-1383632, EBI-5662487; CC Q13882; P78337: PITX1; NbExp=3; IntAct=EBI-1383632, EBI-748265; CC Q13882; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383632, EBI-11320284; CC Q13882; Q13882: PTK6; NbExp=3; IntAct=EBI-1383632, EBI-1383632; CC Q13882; Q04864: REL; NbExp=3; IntAct=EBI-1383632, EBI-307352; CC Q13882; P23246: SFPQ; NbExp=5; IntAct=EBI-1383632, EBI-355453; CC Q13882; Q13239-3: SLA; NbExp=3; IntAct=EBI-1383632, EBI-17630587; CC Q13882; O00401: WASL; NbExp=3; IntAct=EBI-1383632, EBI-957615; CC Q13882; Q9BYN7: ZNF341; NbExp=3; IntAct=EBI-1383632, EBI-9089622; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle. CC Membrane {ECO:0000250}. Note=Colocalizes with KHDRBS1, KHDRBS2 or CC KHDRBS3, within the nucleus. Nuclear localization in epithelial cells CC of normal prostate but cytoplasmic localization in cancer prostate. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13882-1; Sequence=Displayed; CC Name=2; Synonyms=ALT-PTK6, LambdaM5; CC IsoId=Q13882-2; Sequence=VSP_042066, VSP_042067; CC -!- TISSUE SPECIFICITY: Epithelia-specific. Very high level in colon and CC high levels in small intestine and prostate, and low levels in some CC fetal tissues. Not expressed in breast or ovarian tissue but expressed CC in high percentage of breast and ovarian cancers. Also overexpressed in CC some metastatic melanomas, lymphomas, colon cancers, squamous cell CC carcinomas and prostate cancers. Also found in melanocytes. Not CC expressed in heart, brain, placenta, lung, liver, skeletal muscle, CC kidney and pancreas. Isoform 2 is present in prostate epithelial cell CC lines derived from normal prostate and prostate adenocarcinomas, as CC well as in a variety of cell lines. {ECO:0000269|PubMed:12833144, CC ECO:0000269|PubMed:15509496, ECO:0000269|PubMed:16651629, CC ECO:0000269|PubMed:9185712}. CC -!- DOMAIN: The SH3 domain plays a major role in substrate interactions. CC The SH2 domain of PTK6 plays a role in protein-protein interactions, CC but is likely more important for the regulation of catalytic activity. CC -!- PTM: Autophosphorylated. Autophosphorylation of Tyr-342 leads to an CC increase of kinase activity. Tyr-447 binds to the SH2 domain when CC phosphorylated and negatively regulates kinase activity. CC {ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:12121988, CC ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20026641}. CC -!- MISCELLANEOUS: The inhibitors bind to the ATP-binding pocket. CC {ECO:0000269|PubMed:27993680}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. BRK/PTK6/SIK subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG62908.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X78549; CAA55295.1; -; mRNA. DR EMBL; U61412; AAC34935.1; -; Genomic_DNA. DR EMBL; U61406; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61407; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61408; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61409; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61410; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61411; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; AK315232; BAG37660.1; -; mRNA. DR EMBL; AK301364; BAG62908.1; ALT_SEQ; mRNA. DR EMBL; AL121829; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC035843; AAH35843.1; -; mRNA. DR CCDS; CCDS13524.1; -. [Q13882-1] DR CCDS; CCDS74750.1; -. [Q13882-2] DR PIR; S49016; S49016. DR RefSeq; NP_001243287.1; NM_001256358.2. [Q13882-2] DR RefSeq; NP_005966.1; NM_005975.4. [Q13882-1] DR PDB; 1RJA; NMR; -; A=75-174. DR PDB; 2KGT; NMR; -; A=1-72. DR PDB; 5D7V; X-ray; 2.33 A; A/B/C/D=185-446. DR PDB; 5DA3; X-ray; 1.70 A; A=185-446. DR PDB; 5H2U; X-ray; 2.24 A; A/B/C/D=185-446. DR PDB; 6CZ2; X-ray; 2.50 A; A=182-443. DR PDB; 6CZ3; X-ray; 1.80 A; A=182-443. DR PDB; 6CZ4; X-ray; 1.50 A; A=182-443. DR PDB; 8S1C; X-ray; 1.75 A; A/B=11-72. DR PDBsum; 1RJA; -. DR PDBsum; 2KGT; -. DR PDBsum; 5D7V; -. DR PDBsum; 5DA3; -. DR PDBsum; 5H2U; -. DR PDBsum; 6CZ2; -. DR PDBsum; 6CZ3; -. DR PDBsum; 6CZ4; -. DR PDBsum; 8S1C; -. DR AlphaFoldDB; Q13882; -. DR BMRB; Q13882; -. DR SMR; Q13882; -. DR BioGRID; 111720; 103. DR DIP; DIP-39785N; -. DR FunCoup; Q13882; 312. DR IntAct; Q13882; 83. DR MINT; Q13882; -. DR STRING; 9606.ENSP00000442460; -. DR BindingDB; Q13882; -. DR ChEMBL; CHEMBL4601; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q13882; -. DR GuidetoPHARMACOLOGY; 2182; -. DR GlyGen; Q13882; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13882; -. DR PhosphoSitePlus; Q13882; -. DR BioMuta; PTK6; -. DR DMDM; 8928302; -. DR CPTAC; CPTAC-2842; -. DR CPTAC; CPTAC-2880; -. DR jPOST; Q13882; -. DR MassIVE; Q13882; -. DR PaxDb; 9606-ENSP00000442460; -. DR PeptideAtlas; Q13882; -. DR ProteomicsDB; 59709; -. [Q13882-1] DR ProteomicsDB; 59710; -. [Q13882-2] DR Antibodypedia; 29774; 545 antibodies from 39 providers. DR DNASU; 5753; -. DR Ensembl; ENST00000217185.3; ENSP00000217185.3; ENSG00000101213.8. [Q13882-2] DR Ensembl; ENST00000542869.3; ENSP00000442460.2; ENSG00000101213.8. [Q13882-1] DR GeneID; 5753; -. DR KEGG; hsa:5753; -. DR MANE-Select; ENST00000542869.3; ENSP00000442460.2; NM_005975.4; NP_005966.1. DR UCSC; uc002yfg.5; human. [Q13882-1] DR AGR; HGNC:9617; -. DR ClinPGx; PA33960; -. DR CTD; 5753; -. DR DisGeNET; 5753; -. DR GeneCards; PTK6; -. DR HGNC; HGNC:9617; PTK6. DR HPA; ENSG00000101213; Tissue enhanced (esophagus, skin, vagina). DR MIM; 602004; gene. DR OpenTargets; ENSG00000101213; -. DR VEuPathDB; HostDB:ENSG00000101213; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000161218; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; Q13882; -. DR OMA; LWKGQVR; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q13882; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q13882; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q13882; -. DR Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8849468; PTK6 Regulates Proteins Involved in RNA Processing. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8849472; PTK6 Down-Regulation. DR Reactome; R-HSA-8849473; PTK6 Expression. DR Reactome; R-HSA-8849474; PTK6 Activates STAT3. DR Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization. DR Reactome; R-HSA-9707564; Cytoprotection by HMOX1. DR SABIO-RK; Q13882; -. DR SignaLink; Q13882; -. DR SIGNOR; Q13882; -. DR Agora; ENSG00000101213; -. DR BioGRID-ORCS; 5753; 17 hits in 1179 CRISPR screens. DR EvolutionaryTrace; Q13882; -. DR GeneWiki; PTK6; -. DR GenomeRNAi; 5753; -. DR Pharos; Q13882; Tchem. DR PRO; PR:Q13882; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q13882; protein. DR Bgee; ENSG00000101213; Expressed in esophagus squamous epithelium and 125 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0001726; C:ruffle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome. DR GO; GO:0060575; P:intestinal epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl. DR GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome. DR GO; GO:0045740; P:positive regulation of DNA replication; TAS:Reactome. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; TAS:Reactome. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:UniProtKB. DR CDD; cd05148; PTKc_Srm_Brk; 1. DR CDD; cd10358; SH2_PTK6_Brk; 1. DR CDD; cd11847; SH3_Brk; 1. DR FunFam; 1.10.510.10:FF:000399; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000229; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000074; Tyrosine-protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR035846; PTK6_SH2. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; KW Cytoplasm; Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase. FT CHAIN 1..451 FT /note="Protein-tyrosine kinase 6" FT /id="PRO_0000088133" FT DOMAIN 8..72 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 78..170 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 191..445 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 171..190 FT /note="Linker" FT ACT_SITE 312 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 197..205 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 219 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:27480927, ECO:0000305|PubMed:27993680" FT MOD_RES 13 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 61 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 66 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 114 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0007744|PubMed:18691976" FT MOD_RES 342 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 351 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 447 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:10913193" FT VAR_SEQ 78..134 FT /note="WFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKI FT WRRAG -> AGHAGCAALQDLAACRGPAAPERGGVLPQPARACELPQGPEPVPRPAAGR FT ALPEARA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042066" FT VAR_SEQ 135..451 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042067" FT VARIANT 16 FT /note="L -> F (in a renal papillary sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041760" FT VARIANT 436 FT /note="A -> T (in dbSNP:rs56145017)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041761" FT MUTAGEN 44 FT /note="W->A: Strong decrease in STAP2 phosphorylation. FT Markedly decreased interaction between SH3 domain the FT linker region." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:17822667" FT MUTAGEN 66 FT /note="Y->A: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 105 FT /note="R->A: Abolishes interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:20554524" FT MUTAGEN 105 FT /note="R->L: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 184 FT /note="W->A: Abrogates interaction between PTK6-domain FT kinase and PTK6-linker. Abrogates autophosphorylation and FT phosphorylation of KHDRBS1." FT /evidence="ECO:0000269|PubMed:15961400" FT MUTAGEN 219 FT /note="K->M: Abolishes kinase activity and cell FT transformation, and phosphorylation of STAP2. Reduces FT interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20554524, FT ECO:0000269|PubMed:8940083" FT MUTAGEN 219 FT /note="K->R: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:27480927" FT MUTAGEN 342 FT /note="Y->A: 3-fold lower specific kinase activity. FT Decreased, but still significant, autophosphorylation. FT Decreased, but still significant, autophosphorylation; when FT associated with A-447." FT /evidence="ECO:0000269|PubMed:12121988" FT MUTAGEN 447 FT /note="Y->F: Decrease in transforming potential and FT increase in the kinase activity level. Decreased, but still FT significant, autophosphorylation; when associated with A- FT 342." FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 35..40 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 45..50 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 56..62 FT /evidence="ECO:0007829|PDB:2KGT" FT TURN 64..66 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 67..70 FT /evidence="ECO:0007829|PDB:2KGT" FT HELIX 85..92 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 102..106 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 108..112 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 114..118 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 125..131 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 137..140 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 143..147 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 148..157 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 162..164 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 188..190 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 191..200 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 211..213 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 214..221 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 229..240 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 256..264 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 268..271 FT /evidence="ECO:0007829|PDB:6CZ2" FT HELIX 272..278 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 281..283 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 286..305 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 315..317 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:5DA3" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 334..336 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 339..342 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 345..348 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 356..361 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 366..380 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 381..384 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 428..430 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 434..441 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 442..444 FT /evidence="ECO:0007829|PDB:5D7V" SQ SEQUENCE 451 AA; 51834 MW; CDCAC0EE242E1BD7 CRC64; MVSRDQAHLG PKYVGLWDFK SRTDEELSFR AGDVFHVARK EEQWWWATLL DEAGGAVAQG YVPHNYLAER ETVESEPWFF GCISRSEAVR RLQAEGNATG AFLIRVSEKP SADYVLSVRD TQAVRHYKIW RRAGGRLHLN EAVSFLSLPE LVNYHRAQSL SHGLRLAAPC RKHEPEPLPH WDDWERPREE FTLCRKLGSG YFGEVFEGLW KDRVQVAIKV ISRDNLLHQQ MLQSEIQAMK KLRHKHILAL YAVVSVGDPV YIITELMAKG SLLELLRDSD EKVLPVSELL DIAWQVAEGM CYLESQNYIH RDLAARNILV GENTLCKVGD FGLARLIKED VYLSHDHNIP YKWTAPEALS RGHYSTKSDV WSFGILLHEM FSRGQVPYPG MSNHEAFLRV DAGYRMPCPL ECPPSVHKLM LTCWCRDPEQ RPCFKALRER LSSFTSYENP T // ID RAF1_HUMAN Reviewed; 648 AA. AC P04049; B0LPH8; B2R5N3; Q15278; Q9UC20; DT 01-NOV-1986, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1986, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=RAF proto-oncogene serine/threonine-protein kinase {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:17603483}; DE AltName: Full=Proto-oncogene c-RAF; DE Short=cRaf; DE AltName: Full=Raf-1; GN Name=RAF1 {ECO:0000312|HGNC:HGNC:9829}; Synonyms=RAF; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003687; DOI=10.1093/nar/14.2.1009; RA Bonner T.I., Oppermann H., Seeburg P., Kerby S.B., Gunnell M.A., RA Young A.C., Rapp U.R.; RT "The complete coding sequence of the human raf oncogene and the RT corresponding structure of the c-raf-1 gene."; RL Nucleic Acids Res. 14:1009-1015(1986). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-308. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-308. RG NIEHS SNPs program; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 228-648. RX PubMed=2993863; DOI=10.1128/mcb.5.6.1400-1407.1985; RA Bonner T.I., Kerby S.B., Sutrave P., Gunnell M.A., Mark G., Rapp U.R.; RT "Structure and biological activity of human homologs of the raf/mil RT oncogene."; RL Mol. Cell. Biol. 5:1400-1407(1985). RN [7] RP PROTEIN SEQUENCE OF 42-53; 60-65; 310-316 AND 564-572, INTERACTION WITH RP PRMT5, METHYLATION AT ARG-563, PHOSPHORYLATION AT SER-289; SER-296; RP SER-301; SER-338 AND SER-621, AND MUTAGENESIS OF ARG-563. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [8] RP PROTEIN SEQUENCE OF 254-278, AND PHOSPHORYLATION AT THR-269. RX PubMed=7477354; DOI=10.1038/378307a0; RA Yao B., Zhang Y., Delikat S., Mathias S., Basu S., Kolesnick R.; RT "Phosphorylation of Raf by ceramide-activated protein kinase."; RL Nature 378:307-310(1995). RN [9] RP PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Placenta; RX PubMed=1886707; RA Dozier C., Ansieau S., Ferreira E., Coll J., Stehelin D.; RT "An alternatively spliced c-mil/raf mRNA is predominantly expressed in RT chicken muscular tissues and conserved among vertebrate species."; RL Oncogene 6:1307-1311(1991). RN [10] RP PHOSPHORYLATION AT SER-43; SER-259; THR-268; SER-499 AND SER-621. RX PubMed=8349614; DOI=10.1016/s0021-9258(19)85336-x; RA Morrison D.K., Heidecker G., Rapp U.R., Copeland T.D.; RT "Identification of the major phosphorylation sites of the Raf-1 kinase."; RL J. Biol. Chem. 268:17309-17316(1993). RN [11] RP INTERACTION WITH YWHAZ, AND FUNCTION. RX PubMed=9360956; DOI=10.1074/jbc.272.46.28882; RA Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y., Morrice N., RA Moelling K., Aitken A.; RT "14-3-3 is phosphorylated by casein kinase I on residue 233. RT Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction."; RL J. Biol. Chem. 272:28882-28888(1997). RN [12] RP PHOSPHORYLATION. RX PubMed=9823899; DOI=10.1038/24184; RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RT "The protein kinase Pak3 positively regulates Raf-1 activity through RT phosphorylation of serine 338."; RL Nature 396:180-183(1998). RN [13] RP ERRATUM OF PUBMED:9823899. RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RL Nature 406:439-439(2000). RN [14] RP PHOSPHORYLATION AT SER-259 BY PKB/AKT1, ACTIVITY REGULATION, AND RP INTERACTION WITH PKB/AKT1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP PHOSPHORYLATION AT SER-259 AND SER-621, DEPHOSPHORYLATION AT SER-43; RP SER-259 AND SER-621, ACTIVITY REGULATION, AND INTERACTION WITH PPP2CA AND RP PPP2R1B. RX PubMed=10801873; DOI=10.1074/jbc.m003259200; RA Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A., RA Dilworth S.M., Mischak H., Kolch W., Baccarini M.; RT "Raf-1-associated protein phosphatase 2A as a positive regulator of kinase RT activation."; RL J. Biol. Chem. 275:22300-22304(2000). RN [16] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-491 AND SER-494. RX PubMed=11447113; DOI=10.1093/emboj/20.14.3716; RA Chong H., Lee J., Guan K.L.; RT "Positive and negative regulation of Raf kinase activity and function by RT phosphorylation."; RL EMBO J. 20:3716-3727(2001). RN [17] RP FUNCTION, AND INTERACTION WITH MAP3K5/ASK1. RX PubMed=11427728; DOI=10.1073/pnas.141224398; RA Chen J., Fujii K., Zhang L., Roberts T., Fu H.; RT "Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating RT kinase 1 through a MEK-ERK independent mechanism."; RL Proc. Natl. Acad. Sci. U.S.A. 98:7783-7788(2001). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PPP1R12A, AND INTERACTION WITH PPP1R12A. RX PubMed=11719507; DOI=10.1074/jbc.m106343200; RA Broustas C.G., Grammatikakis N., Eto M., Dent P., Brautigan D.L., Kasid U.; RT "Phosphorylation of the myosin-binding subunit of myosin phosphatase by RT Raf-1 and inhibition of phosphatase activity."; RL J. Biol. Chem. 277:3053-3059(2002). RN [19] RP PHOSPHORYLATION AT SER-338 BY PAK1, ACTIVITY REGULATION, AND INTERACTION RP WITH PAK1. RX PubMed=11733498; DOI=10.1074/jbc.m110000200; RA Zang M., Hayne C., Luo Z.; RT "Interaction between active Pak1 and Raf-1 is necessary for phosphorylation RT and activation of Raf-1."; RL J. Biol. Chem. 277:4395-4405(2002). RN [20] RP PHOSPHORYLATION AT SER-259, DEPHOSPHORYLATION AT SER-259, AND SUBCELLULAR RP LOCATION. RX PubMed=11756411; DOI=10.1074/jbc.m108733200; RA Kubicek M., Pacher M., Abraham D., Podar K., Eulitz M., Baccarini M.; RT "Dephosphorylation of Ser-259 regulates Raf-1 membrane association."; RL J. Biol. Chem. 277:7913-7919(2002). RN [21] RP COMPETITION WITH RIN1. RX PubMed=11784866; DOI=10.1128/mcb.22.3.916-926.2001; RA Wang Y., Waldron R.T., Dhaka A., Patel A., Riley M.M., Rozengurt E., RA Colicelli J.; RT "The RAS effector RIN1 directly competes with RAF and is regulated by 14-3- RT 3 proteins."; RL Mol. Cell. Biol. 22:916-926(2002). RN [22] RP ACTIVITY REGULATION, AND INTERACTION WITH SPRY2 AND SPRY4. RX PubMed=12717443; DOI=10.1038/ncb978; RA Sasaki A., Taketomi T., Kato R., Saeki K., Nonami A., Sasaki M., RA Kuriyama M., Saito N., Shibuya M., Yoshimura A.; RT "Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to RT Raf1."; RL Nat. Cell Biol. 5:427-432(2003). RN [23] RP PHOSPHORYLATION AT SER-259. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [24] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [25] RP FUNCTION IN PHOSPHORYLATION OF ADCY2; ADCY5 AND ADCY6, AND INTERACTION WITH RP ADCY2; ADCY5 AND ADCY6. RX PubMed=15385642; DOI=10.1124/mol.66.4.921; RA Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., Feldman R.D.; RT "Raf kinase activation of adenylyl cyclases: isoform-selective RT regulation."; RL Mol. Pharmacol. 66:921-928(2004). RN [26] RP INTERACTION WITH STK3/MST2, AND FUNCTION. RX PubMed=15618521; DOI=10.1126/science.1103233; RA O'Neill E., Rushworth L., Baccarini M., Kolch W.; RT "Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene RT product Raf-1."; RL Science 306:2267-2270(2004). RN [27] RP INTERACTION WITH RCAN1/DSCR1. RX PubMed=15935327; DOI=10.1016/j.abb.2005.05.002; RA Cho Y.J., Abe M., Kim S.Y., Sato Y.; RT "Raf-1 is a binding partner of DSCR1."; RL Arch. Biochem. Biophys. 439:121-128(2005). RN [28] RP REVIEW ON FUNCTION. RX PubMed=15943972; DOI=10.1016/j.febslet.2005.03.024; RA Baccarini M.; RT "Second nature: biological functions of the Raf-1 'kinase'."; RL FEBS Lett. 579:3271-3277(2005). RN [29] RP FUNCTION IN PHOSPHORYLATION OF BAD, PHOSPHORYLATION AT SER-338 AND SER-339 RP BY PAK1, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2. RX PubMed=15849194; DOI=10.1074/jbc.m413374200; RA Jin S., Zhuo Y., Guo W., Field J.; RT "p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates RT its mitochondrial localization, phosphorylation of BAD, and Bcl-2 RT association."; RL J. Biol. Chem. 280:24698-24705(2005). RN [30] RP PHOSPHORYLATION AT SER-471. RX PubMed=16093354; DOI=10.1091/mbc.e05-02-0090; RA Zhu J., Balan V., Bronisz A., Balan K., Sun H., Leicht D.T., Luo Z., RA Qin J., Avruch J., Tzivion G.; RT "Identification of Raf-1 S471 as a novel phosphorylation site critical for RT Raf-1 and B-Raf kinase activities and for MEK binding."; RL Mol. Biol. Cell 16:4733-4744(2005). RN [31] RP IDENTIFICATION IN A COMPLEX WITH PP1CA; PPP1CB; PPP1CC; SHOC2 AND MRAS, RP PHOSPHORYLATION AT SER-259, AND CHARACTERIZATION OF VARIANT ALA-259. RX PubMed=16630891; DOI=10.1016/j.molcel.2006.03.027; RA Rodriguez-Viciana P., Oses-Prieto J., Burlingame A., Fried M., RA McCormick F.; RT "A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit RT of PP1 functions as an M-Ras effector to modulate Raf activity."; RL Mol. Cell 22:217-230(2006). RN [32] RP SUBUNIT. RX PubMed=16508002; DOI=10.1128/mcb.26.6.2262-2272.2006; RA Rushworth L.K., Hindley A.D., O'Neill E., Kolch W.; RT "Regulation and role of Raf-1/B-Raf heterodimerization."; RL Mol. Cell. Biol. 26:2262-2272(2006). RN [33] RP FUNCTION AS KINASE, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-259; RP SER-338; TYR-340; TYR-341 AND SER-621, DEPHOSPHORYLATION AT SER-338 BY RP PPP5C, AND MUTAGENESIS OF 338-SER-SER-339; 340-TYR-TYR-341; THR-491 AND RP SER-494. RX PubMed=16892053; DOI=10.1038/ncb1465; RA von Kriegsheim A., Pitt A., Grindlay G.J., Kolch W., Dhillon A.S.; RT "Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5."; RL Nat. Cell Biol. 8:1011-1016(2006). RN [34] RP REVIEW ON REGULATION. RX PubMed=17218791; DOI=10.4161/cc.6.1.3593; RA Dhillon A.S., von Kriegsheim A., Grindlay J., Kolch W.; RT "Phosphatase and feedback regulation of Raf-1 signaling."; RL Cell Cycle 6:3-7(2007). RN [35] RP FUNCTION. RX PubMed=16924233; DOI=10.1038/sj.onc.1209902; RA Wang Z., Wade P., Mandell K.J., Akyildiz A., Parkos C.A., Mrsny R.J., RA Nusrat A.; RT "Raf 1 represses expression of the tight junction protein occludin via RT activation of the zinc-finger transcription factor slug."; RL Oncogene 26:1222-1230(2007). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [37] RP ACTIVITY REGULATION, AND INTERACTION WITH PEBP1/RKIP. RX PubMed=18294816; DOI=10.1016/j.cellsig.2008.01.012; RA Rath O., Park S., Tang H.H., Banfield M.J., Brady R.L., Lee Y.C., RA Dignam J.D., Sedivy J.M., Kolch W., Yeung K.C.; RT "The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the RT phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated RT phosphorylation of MEK."; RL Cell. Signal. 20:935-941(2008). RN [38] RP PHOSPHORYLATION AT SER-338 BY PAK5. RX PubMed=18465753; DOI=10.1002/jcb.21809; RA Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.; RT "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria."; RL J. Cell. Biochem. 105:167-175(2008). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [40] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP SUBCELLULAR LOCATION. RX PubMed=19298812; DOI=10.1016/j.yexcr.2009.03.004; RA Smith J., Bunaciu R.P., Reiterer G., Coder D., George T., Asaly M., Yen A.; RT "Retinoic acid induces nuclear accumulation of Raf1 during differentiation RT of HL-60 cells."; RL Exp. Cell Res. 315:2241-2248(2009). RN [43] RP ACTIVITY REGULATION, SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH RP DGKH. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289 AND SER-301, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [45] RP REVIEW. RX PubMed=20674547; DOI=10.1016/j.bbrc.2010.07.092; RA Roskoski R. Jr.; RT "RAF protein-serine/threonine kinases: structure and regulation."; RL Biochem. Biophys. Res. Commun. 399:313-317(2010). RN [46] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [47] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [48] RP REVIEW. RX PubMed=21779496; DOI=10.1177/1947601911407323; RA Matallanas D., Birtwistle M., Romano D., Zebisch A., Rauch J., RA von Kriegsheim A., Kolch W.; RT "Raf family kinases: old dogs have learned new tricks."; RL Genes Cancer 2:232-260(2011). RN [49] RP MUTAGENESIS OF LYS-375, AND INTERACTION WITH NEK10 AND MAP2K1. RX PubMed=20956560; DOI=10.1128/mcb.00648-10; RA Moniz L.S., Stambolic V.; RT "Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response RT to UV irradiation."; RL Mol. Cell. Biol. 31:30-42(2011). RN [50] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [51] RP INTERACTION WITH FAM83B. RX PubMed=22886302; DOI=10.1172/jci60517; RA Cipriano R., Graham J., Miskimen K.L., Bryson B.L., Bruntz R.C., RA Scott S.A., Brown H.A., Stark G.R., Jackson M.W.; RT "FAM83B mediates EGFR- and RAS-driven oncogenic transformation."; RL J. Clin. Invest. 122:3197-3210(2012). RN [52] RP INTERACTION WITH GLS. RX PubMed=22538822; DOI=10.1073/pnas.1116573109; RA Thangavelu K., Pan C.Q., Karlberg T., Balaji G., Uttamchandani M., RA Suresh V., Schuler H., Low B.C., Sivaraman J.; RT "Structural basis for the allosteric inhibitory mechanism of human kidney- RT type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in RT cancer cell metabolism."; RL Proc. Natl. Acad. Sci. U.S.A. 109:7705-7710(2012). RN [53] RP INTERACTION WITH MFHAS1. RX PubMed=23327923; DOI=10.1182/blood-2011-10-385252; RA Kumkhaek C., Aerbajinai W., Liu W., Zhu J., Uchida N., Kurlander R., RA Hsieh M.M., Tisdale J.F., Rodgers G.P.; RT "MASL1 induces erythroid differentiation in human erythropoietin-dependent RT CD34+ cells through the Raf/MEK/ERK pathway."; RL Blood 121:3216-3227(2013). RN [54] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296; SER-301 AND SER-642, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [55] RP INTERACTION WITH PDE8A. RX PubMed=23509299; DOI=10.1073/pnas.1303004110; RA Brown K.M., Day J.P., Huston E., Zimmermann B., Hampel K., Christian F., RA Romano D., Terhzaz S., Lee L.C., Willis M.J., Morton D.B., Beavo J.A., RA Shimizu-Albergine M., Davies S.A., Kolch W., Houslay M.D., Baillie G.S.; RT "Phosphodiesterase-8A binds to and regulates Raf-1 kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 110:E1533-E1542(2013). RN [56] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [57] RP IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2; RP AKT; CDK4 AND NR3C1. RX PubMed=29127155; DOI=10.15252/embj.201796700; RA Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L., RA Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H., RA Bourboulia D., Bratslavsky G., Wong M., Mollapour M.; RT "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding RT of kinase and non-kinase clients."; RL EMBO J. 36:3650-3665(2017). RN [58] RP INTERACTION WITH LZTR1. RX PubMed=30368668; DOI=10.1007/s00439-018-1951-7; RA Umeki I., Niihori T., Abe T., Kanno S.I., Okamoto N., Mizuno S., RA Kurosawa K., Nagasaki K., Yoshida M., Ohashi H., Inoue S.I., Matsubara Y., RA Fujiwara I., Kure S., Aoki Y.; RT "Delineation of LZTR1 mutation-positive patients with Noonan syndrome and RT identification of LZTR1 binding to RAF1-PPP1CB complexes."; RL Hum. Genet. 138:21-35(2019). RN [59] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [60] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [61] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [62] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 51-131. RX PubMed=7791872; DOI=10.1038/375554a0; RA Nassar N., Horn G., Herrmann C., Scherer A., McCormick F., Wittinghofer A.; RT "The 2.2 A crystal structure of the Ras-binding domain of the RT serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue."; RL Nature 375:554-560(1995). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 56-131. RX PubMed=8756332; DOI=10.1038/nsb0896-723; RA Nassar N., Horn G., Herrmann C., Block C., Janknecht R., Wittinghofer A.; RT "Ras/Rap effector specificity determined by charge reversal."; RL Nat. Struct. Biol. 3:723-729(1996). RN [65] RP STRUCTURE BY NMR OF 55-132. RX PubMed=7766599; DOI=10.1021/bi00021a001; RA Emerson S.D., Madison V.S., Palermo R.E., Waugh D.S., Scheffler J.E., RA Tsao K.L., Kiefer S.E., Liu S.P., Fry D.C.; RT "Solution structure of the Ras-binding domain of c-Raf-1 and identification RT of its Ras interaction surface."; RL Biochemistry 34:6911-6918(1995). RN [66] RP STRUCTURE BY NMR OF 136-187. RX PubMed=8710867; DOI=10.1073/pnas.93.16.8312; RA Mott H.R., Carpenter J.W., Zhong S., Ghosh S., Bell R.M., Campbell S.L.; RT "The solution structure of the Raf-1 cysteine-rich domain: a novel ras and RT phospholipid binding site."; RL Proc. Natl. Acad. Sci. U.S.A. 93:8312-8317(1996). RN [67] RP VARIANTS NS5 SER-256; LEU-257; PHE-259; ARG-260; LEU-261; SER-261; ASN-486; RP GLY-486; ILE-491; ARG-491 AND THR-612, VARIANT HYPERTROPHIC CARDIOMYOPATHY RP ILE-260, VARIANTS LPRD2 LEU-257 AND VAL-613, CHARACTERIZATION OF VARIANTS RP NS5 SER-261; ASN-486 AND ILE-491, CHARACTERIZATION OF VARIANT LPRD2 RP VAL-613, AND CATALYTIC ACTIVITY. RX PubMed=17603483; DOI=10.1038/ng2073; RA Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., Martinelli S., RA Pogna E.A., Schackwitz W., Ustaszewska A., Landstrom A., Bos J.M., RA Ommen S.R., Esposito G., Lepri F., Faul C., Mundel P., Lopez Siguero J.P., RA Tenconi R., Selicorni A., Rossi C., Mazzanti L., Torrente I., Marino B., RA Digilio M.C., Zampino G., Ackerman M.J., Dallapiccola B., Tartaglia M., RA Gelb B.D.; RT "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with RT hypertrophic cardiomyopathy."; RL Nat. Genet. 39:1007-1012(2007). RN [68] RP VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND VAL-613, AND RP CHARACTERIZATION OF VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND RP VAL-613. RX PubMed=17603482; DOI=10.1038/ng2078; RA Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R., RA Kamisago M., Momma K., Katayama H., Nakagawa M., Fujiwara Y., RA Matsushima M., Mizuno K., Tokuyama M., Hirota H., Muneuchi J., RA Higashinakagawa T., Matsuoka R.; RT "Germline gain-of-function mutations in RAF1 cause Noonan syndrome."; RL Nat. Genet. 39:1013-1017(2007). RN [69] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-259 AND HIS-335. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [70] RP VARIANT NS5 SER-261. RX PubMed=20683980; DOI=10.1002/ajmg.a.33564; RA Longoni M., Moncini S., Cisternino M., Morella I.M., Ferraiuolo S., RA Russo S., Mannarino S., Brazzelli V., Coi P., Zippel R., Venturin M., RA Riva P.; RT "Noonan syndrome associated with both a new Jnk-activating familial SOS1 RT and a de novo RAF1 mutations."; RL Am. J. Med. Genet. A 152:2176-2184(2010). RN [71] RP INVOLVEMENT IN CMD1NN, VARIANTS CMD1NN THR-237; ALA-310; ALA-332; PRO-603; RP ARG-626 AND MET-641, AND CHARACTERIZATION OF VARIANTS CMD1NN THR-237; RP ALA-310; ALA-332; PRO-603; ARG-626 AND MET-641. RX PubMed=24777450; DOI=10.1038/ng.2963; RA Dhandapany P.S., Razzaque M.A., Muthusami U., Kunnoth S., Edwards J.J., RA Mulero-Navarro S., Riess I., Pardo S., Sheng J., Rani D.S., Rani B., RA Govindaraj P., Flex E., Yokota T., Furutani M., Nishizawa T., Nakanishi T., RA Robbins J., Limongelli G., Hajjar R.J., Lebeche D., Bahl A., Khullar M., RA Rathinavel A., Sadler K.C., Tartaglia M., Matsuoka R., Thangaraj K., RA Gelb B.D.; RT "RAF1 mutations in childhood-onset dilated cardiomyopathy."; RL Nat. Genet. 46:635-639(2014). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a regulatory CC link between the membrane-associated Ras GTPases and the MAPK/ERK CC cascade, and this critical regulatory link functions as a switch CC determining cell fate decisions including proliferation, CC differentiation, apoptosis, survival and oncogenic transformation. RAF1 CC activation initiates a mitogen-activated protein kinase (MAPK) cascade CC that comprises a sequential phosphorylation of the dual-specific MAPK CC kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal- CC regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form CC of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates CC BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl CC cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. CC Phosphorylates PPP1R12A resulting in inhibition of the phosphatase CC activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote CC NF-kB activation and inhibit signal transducers involved in motility CC (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and CC angiogenesis (RB1). Can protect cells from apoptosis also by CC translocating to the mitochondria where it binds BCL2 and displaces CC BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and CC migration, and is required for normal wound healing. Plays a role in CC the oncogenic transformation of epithelial cells via repression of the CC TJ protein, occludin (OCLN) by inducing the up-regulation of a CC transcriptional repressor SNAI2/SLUG, which induces down-regulation of CC OCLN. Restricts caspase activation in response to selected stimuli, CC notably Fas stimulation, pathogen-mediated macrophage apoptosis, and CC erythroid differentiation. {ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642, CC ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233, CC ECO:0000269|PubMed:9360956}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Note=Binds 2 Zn(2+) ions per subunit.; CC -!- ACTIVITY REGULATION: Regulation is a highly complex process involving CC membrane recruitment, protein-protein interactions, dimerization, and CC phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the CC membrane, thereby promoting its activation. The inactive conformation CC of RAF1 is maintained by autoinhibitory interactions occurring between CC the N-terminal regulatory and the C-terminal catalytic domains and by CC the binding of a 14-3-3 protein that contacts two phosphorylation CC sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1A CC cooperate to release autoinhibition and the subsequent phosphorylation CC of activating sites: Ser-338, Tyr-341, Thr-491, and Ser-494, yields a CC fully active kinase. Through a negative feedback mechanism involving CC MAPK1/ERK2, RAF1 is phosphorylated on Ser-29, Ser-43, Ser-289, Ser-296, CC Ser-301 and Ser-642 by MAPK1/ERK2, which yields an inactive, CC desensitized kinase. The signaling-competent conformation of RAF1 is CC finally re-established by the coordinated action of PIN1, a prolyl CC isomerase that converts pSer and pThr residues from the cis to the CC trans conformation, which is preferentially recognized and CC dephosphorylated by PPP2R1A. Activated by homodimerization and CC heterodimerization (with BRAF). Also regulated through association with CC other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP, PHB/prohibitin CC and SPRY4. PEBP1/RKIP acts by dissociating RAF1 from its substrates CC MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitin facilitates the CC displacement of 14-3-3 from RAF1 by activated Ras, thereby promoting CC cell membrane localization and phosphorylation of RAF1 at the CC activating Ser-338. SPRY4 inhibits Ras-independent, but not Ras- CC dependent, activation of RAF1. CNKSR1/CNK1 regulates Src-mediated RAF1 CC activation. {ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873, CC ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:16892053, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016}. CC -!- SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and this CC heterodimer possesses a highly increased kinase activity compared to CC the respective homodimers or monomers (PubMed:16508002). CC Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins CC (PubMed:16508002). MAPK1/ERK2 activation can induce a negative feedback CC that promotes the dissociation of the heterodimer (PubMed:16508002). CC Forms a multiprotein complex with Ras (M-Ras/MRAS), SHOC2 and protein CC phosphatase 1 (PPP1CA, PPP1CB and PPP1CC) (PubMed:16630891). Interacts CC with LZTR1 (PubMed:30368668). Interacts with Ras proteins; the CC interaction is antagonized by RIN1 (PubMed:11784866). Weakly interacts CC with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with BRAF, a CC ternary complex inhibited by GNAI1 (By similarity). Probably forms a CC complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, CC PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this CC complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 CC (PubMed:29127155). Interacts with STK3/MST2; the interaction inhibits CC its pro-apoptotic activity (PubMed:15618521). Interacts (when CC phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') CC (PubMed:31024343, PubMed:9360956). Interacts with MAP2K1/MEK1 and CC MAP2K2/MEK2 (By similarity). Interacts with MAP3K5/ASF1 (via N- CC terminus) and this interaction inhibits the proapoptotic function of CC MAP3K5/ASK1 (PubMed:11427728). Interacts with PAK1 (via kinase domain) CC (PubMed:11733498). The phosphorylated form interacts with PIN1 (By CC similarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1) CC interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIP and CC this interaction is enhanced if RAF1 is phosphorylated on residues Ser- CC 338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816). Interacts with CC ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A, PKB/AKT1, PPP2CA, CC PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 and PHB/prohibitin CC (PubMed:10576742, PubMed:10801873, PubMed:11719507, PubMed:12717443, CC PubMed:15385642, PubMed:15935327, PubMed:19710016). Interacts with CC ROCK2 (By similarity). In its active form, interacts with PRMT5 CC (PubMed:21917714). Interacts with FAM83B; displaces 14-3-3 proteins CC from RAF1 and activates RAF1 (PubMed:22886302). Interacts with PDE8A; CC the interaction promotes RAF1 activity (PubMed:23509299). Interacts CC with MFHAS1 (PubMed:23327923). Interacts with GLS (PubMed:22538822). CC Interacts with NEK10 and MAP2K1; the interaction is direct with NEK10 CC and required for ERK1/2-signaling pathway activation in response to UV CC irradiation (PubMed:20956560). {ECO:0000250|UniProtKB:P11345, CC ECO:0000250|UniProtKB:Q99N57, ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:11784866, ECO:0000269|PubMed:12717443, CC ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:15618521, CC ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:15935327, CC ECO:0000269|PubMed:16508002, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:20956560, ECO:0000269|PubMed:21917714, CC ECO:0000269|PubMed:22538822, ECO:0000269|PubMed:22886302, CC ECO:0000269|PubMed:23327923, ECO:0000269|PubMed:23509299, CC ECO:0000269|PubMed:29127155, ECO:0000269|PubMed:30368668, CC ECO:0000269|PubMed:9360956}. CC -!- INTERACTION: CC P04049; P31749: AKT1; NbExp=3; IntAct=EBI-365996, EBI-296087; CC P04049; P05067: APP; NbExp=3; IntAct=EBI-365996, EBI-77613; CC P04049; Q99933: BAG1; NbExp=2; IntAct=EBI-365996, EBI-1030678; CC P04049; O95816: BAG2; NbExp=12; IntAct=EBI-365996, EBI-355275; CC P04049; P15056: BRAF; NbExp=73; IntAct=EBI-365996, EBI-365980; CC P04049; Q14790: CASP8; NbExp=3; IntAct=EBI-365996, EBI-78060; CC P04049; P49368: CCT3; NbExp=8; IntAct=EBI-365996, EBI-356673; CC P04049; P30304: CDC25A; NbExp=4; IntAct=EBI-365996, EBI-747671; CC P04049; Q16543: CDC37; NbExp=20; IntAct=EBI-365996, EBI-295634; CC P04049; P31327: CPS1; NbExp=4; IntAct=EBI-365996, EBI-536811; CC P04049; P00533: EGFR; NbExp=3; IntAct=EBI-365996, EBI-297353; CC P04049; O15371: EIF3D; NbExp=4; IntAct=EBI-365996, EBI-353818; CC P04049; O95714: HERC2; NbExp=6; IntAct=EBI-365996, EBI-1058922; CC P04049; P01112: HRAS; NbExp=30; IntAct=EBI-365996, EBI-350145; CC P04049; P07900: HSP90AA1; NbExp=15; IntAct=EBI-365996, EBI-296047; CC P04049; P08238: HSP90AB1; NbExp=17; IntAct=EBI-365996, EBI-352572; CC P04049; P11021: HSPA5; NbExp=5; IntAct=EBI-365996, EBI-354921; CC P04049; P01116: KRAS; NbExp=6; IntAct=EBI-365996, EBI-367415; CC P04049; P01116-2: KRAS; NbExp=3; IntAct=EBI-365996, EBI-367427; CC P04049; P05783: KRT18; NbExp=5; IntAct=EBI-365996, EBI-297888; CC P04049; P08727: KRT19; NbExp=2; IntAct=EBI-365996, EBI-742756; CC P04049; Q8IVT5: KSR1; NbExp=5; IntAct=EBI-365996, EBI-486984; CC P04049; Q02750: MAP2K1; NbExp=39; IntAct=EBI-365996, EBI-492564; CC P04049; P36507: MAP2K2; NbExp=7; IntAct=EBI-365996, EBI-1056930; CC P04049; Q15773: MLF2; NbExp=4; IntAct=EBI-365996, EBI-1051875; CC P04049; Q12968: NFATC3; NbExp=2; IntAct=EBI-365996, EBI-5278441; CC P04049; P01111: NRAS; NbExp=12; IntAct=EBI-365996, EBI-721993; CC P04049; O43482: OIP5; NbExp=4; IntAct=EBI-365996, EBI-536879; CC P04049; Q13153: PAK1; NbExp=2; IntAct=EBI-365996, EBI-1307; CC P04049; Q13177: PAK2; NbExp=2; IntAct=EBI-365996, EBI-1045887; CC P04049; Q6TCH7: PAQR3; NbExp=3; IntAct=EBI-365996, EBI-15654365; CC P04049; P30086: PEBP1; NbExp=10; IntAct=EBI-365996, EBI-716384; CC P04049; Q96S96: PEBP4; NbExp=4; IntAct=EBI-365996, EBI-8563667; CC P04049; Q13526: PIN1; NbExp=2; IntAct=EBI-365996, EBI-714158; CC P04049; P14618: PKM; NbExp=3; IntAct=EBI-365996, EBI-353408; CC P04049; P62136: PPP1CA; NbExp=2; IntAct=EBI-365996, EBI-357253; CC P04049; P67775: PPP2CA; NbExp=2; IntAct=EBI-365996, EBI-712311; CC P04049; Q13362: PPP2R5C; NbExp=2; IntAct=EBI-365996, EBI-1266156; CC P04049; P04049: RAF1; NbExp=6; IntAct=EBI-365996, EBI-365996; CC P04049; P62834: RAP1A; NbExp=2; IntAct=EBI-365996, EBI-491414; CC P04049; P06400: RB1; NbExp=3; IntAct=EBI-365996, EBI-491274; CC P04049; P53805-2: RCAN1; NbExp=4; IntAct=EBI-365996, EBI-1541912; CC P04049; P31947: SFN; NbExp=9; IntAct=EBI-365996, EBI-476295; CC P04049; Q13485: SMAD4; NbExp=6; IntAct=EBI-365996, EBI-347263; CC P04049; Q13188: STK3; NbExp=6; IntAct=EBI-365996, EBI-992580; CC P04049; Q9UNE7: STUB1; NbExp=8; IntAct=EBI-365996, EBI-357085; CC P04049; Q3ZCQ8: TIMM50; NbExp=7; IntAct=EBI-365996, EBI-355175; CC P04049; P31946: YWHAB; NbExp=39; IntAct=EBI-365996, EBI-359815; CC P04049; P62258: YWHAE; NbExp=24; IntAct=EBI-365996, EBI-356498; CC P04049; P61981: YWHAG; NbExp=25; IntAct=EBI-365996, EBI-359832; CC P04049; Q04917: YWHAH; NbExp=27; IntAct=EBI-365996, EBI-306940; CC P04049; P27348: YWHAQ; NbExp=25; IntAct=EBI-365996, EBI-359854; CC P04049; P63104: YWHAZ; NbExp=35; IntAct=EBI-365996, EBI-347088; CC P04049; P32883: Kras; Xeno; NbExp=2; IntAct=EBI-365996, EBI-644267; CC P04049; P28301: Lox; Xeno; NbExp=2; IntAct=EBI-365996, EBI-642911; CC P04049; Q9ESN9-2: Mapk8ip3; Xeno; NbExp=2; IntAct=EBI-365996, EBI-9549291; CC P04049; P03495: NS; Xeno; NbExp=2; IntAct=EBI-365996, EBI-2548993; CC P04049; O39474: NS5A; Xeno; NbExp=4; IntAct=EBI-365996, EBI-7016711; CC P04049; P01120: RAS2; Xeno; NbExp=2; IntAct=EBI-365996, EBI-14838; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion. Nucleus. CC Note=Colocalizes with RGS14 and BRAF in both the cytoplasm and CC membranes. Phosphorylation at Ser-259 impairs its membrane CC accumulation. Recruited to the cell membrane by the active Ras protein. CC Phosphorylation at Ser-338 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Retinoic acid-induced Ser-621 CC phosphorylated form of RAF1 is predominantly localized at the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=6C; CC IsoId=P04049-1; Sequence=Displayed; CC Name=2; Synonyms=1A; CC IsoId=P04049-2; Sequence=VSP_034649; CC -!- TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundant than CC isoform 2. {ECO:0000269|PubMed:1886707}. CC -!- PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 and Ser-494 CC results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, CC Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results in its inactivation. CC Phosphorylation at Ser-259 induces the interaction with YWHAZ and CC inactivates kinase activity. Dephosphorylation of Ser-259 by the SHOC2- CC MRAS-PP1c (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and CC the catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or CC PPP1CC); this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35831509, PubMed:35830882). Phosphorylation at CC Ser-338 by PAK1 and PAK5 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Phosphorylation at Ser-621 in response to CC growth factor treatment stabilizes the protein, possibly by preventing CC proteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, CC Ser-338 and Ser-621 are somehow linked to the methylation potential of CC cells. Treatment of cells with HGF in the presence of the methylation CC inhibitor 5'-methylthioadenosine (MTA) results in increased CC phosphorylation at Ser-338 and Ser-621 and decreased phosphorylation at CC Ser-296, Ser-301 and Ser-338. Dephosphorylation at Ser-338 by PPP5C CC results in an activity decrease. {ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113, CC ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11756411, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16093354, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18465753, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614, CC ECO:0000269|PubMed:9823899}. CC -!- PTM: Methylated at Arg-563 in response to EGF treatment. This CC modification leads to destabilization of the protein, possibly through CC proteasomal degradation. {ECO:0000269|PubMed:21917714}. CC -!- DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:17603482, CC ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:17603483}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1NN (CMD1NN) [MIM:615916]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42032/RAF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X03484; CAA27204.1; -; mRNA. DR EMBL; AY271661; AAP03432.1; -; Genomic_DNA. DR EMBL; AK312248; BAG35180.1; -; mRNA. DR EMBL; EU332868; ABY87557.1; -; Genomic_DNA. DR EMBL; CH471055; EAW64134.1; -; Genomic_DNA. DR EMBL; BC018119; AAH18119.1; -; mRNA. DR EMBL; L00212; AAA60247.1; -; Genomic_DNA. DR EMBL; L00206; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00207; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00208; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00209; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00210; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00211; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00213; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; M11376; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; X54851; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS2612.1; -. [P04049-1] DR CCDS; CCDS87047.1; -. [P04049-2] DR PIR; A00637; TVHUF6. DR PIR; S60341; S60341. DR RefSeq; NP_001341618.1; NM_001354689.3. [P04049-2] DR RefSeq; NP_001341619.1; NM_001354690.3. [P04049-1] DR RefSeq; NP_002871.1; NM_002880.4. [P04049-1] DR RefSeq; XP_011532276.1; XM_011533974.3. [P04049-1] DR RefSeq; XP_047304605.1; XM_047448649.1. [P04049-1] DR RefSeq; XP_047304606.1; XM_047448650.1. [P04049-1] DR RefSeq; XP_054203389.1; XM_054347414.1. [P04049-1] DR RefSeq; XP_054203390.1; XM_054347415.1. [P04049-1] DR RefSeq; XP_054203391.1; XM_054347416.1. [P04049-1] DR PDB; 1C1Y; X-ray; 1.90 A; B=55-131. DR PDB; 1FAQ; NMR; -; A=136-187. DR PDB; 1FAR; NMR; -; A=136-187. DR PDB; 1GUA; X-ray; 2.00 A; B=51-131. DR PDB; 1RFA; NMR; -; A=55-132. DR PDB; 3CU8; X-ray; 2.40 A; P/Q=256-264. DR PDB; 3IQJ; X-ray; 1.15 A; P=255-264. DR PDB; 3IQU; X-ray; 1.05 A; P=255-260. DR PDB; 3IQV; X-ray; 1.20 A; P=255-260. DR PDB; 3KUC; X-ray; 1.92 A; B=51-131. DR PDB; 3KUD; X-ray; 2.15 A; B=51-131. DR PDB; 3NKX; X-ray; 2.40 A; P/Q=255-264. DR PDB; 3O8I; X-ray; 2.00 A; B=255-264. DR PDB; 3OMV; X-ray; 4.00 A; A/B=323-618. DR PDB; 4FJ3; X-ray; 1.95 A; P=229-264. DR PDB; 4G0N; X-ray; 2.45 A; B=54-131. DR PDB; 4G3X; X-ray; 3.25 A; B=55-131. DR PDB; 4IEA; X-ray; 1.70 A; P=618-625. DR PDB; 4IHL; X-ray; 2.20 A; P=229-264. DR PDB; 6NTC; X-ray; 2.90 A; B=55-131. DR PDB; 6NTD; X-ray; 3.15 A; B=55-131. DR PDB; 6PTS; NMR; -; D=56-187. DR PDB; 6PTW; NMR; -; D=56-187. DR PDB; 6VJJ; X-ray; 1.40 A; B=52-131. DR PDB; 6XGU; X-ray; 2.70 A; B=52-188. DR PDB; 6XGV; X-ray; 2.11 A; B=52-188. DR PDB; 6XHA; X-ray; 2.87 A; B=52-188. DR PDB; 6XHB; X-ray; 2.50 A; B=52-188. DR PDB; 6XI7; X-ray; 1.95 A; B=52-188. DR PDB; 7JHP; X-ray; 2.77 A; C=55-187. DR PDB; 7Z37; EM; 3.67 A; CP1=1-648. DR PDB; 7Z38; EM; 3.16 A; C=1-648. DR PDB; 8A68; X-ray; 1.60 A; B=255-263. DR PDB; 8A6F; X-ray; 1.60 A; P=255-264. DR PDB; 8A6H; X-ray; 1.60 A; P=255-264. DR PDB; 8ATR; X-ray; 1.70 A; P=255-263. DR PDB; 8ATS; X-ray; 1.40 A; P=255-263. DR PDB; 8AV0; X-ray; 1.50 A; P=256-264. DR PDB; 8CHF; EM; 4.25 A; A/B=1-648. DR PDB; 8CPD; EM; 3.46 A; A/B=1-648. DR PDB; 8EPW; X-ray; 2.00 A; B=52-131. DR PDB; 8GAE; EM; 3.30 A; D=404-610. DR PDB; 8GFT; EM; 3.80 A; D=336-618. DR PDB; 8JOF; NMR; -; A=51-131. DR PDB; 8JOG; NMR; -; A=51-131. DR PDB; 8Q5C; X-ray; 2.00 A; P=255-264. DR PDB; 8S42; X-ray; 1.70 A; P=255-263. DR PDB; 8T74; X-ray; 1.65 A; B=52-131. DR PDB; 8T75; X-ray; 2.65 A; B/D/F/H=52-188. DR PDB; 8U1L; EM; 3.70 A; C=2-648. DR PDB; 9AXA; EM; 4.36 A; A/C=306-648. DR PDB; 9AXC; EM; 4.16 A; A/C=306-648. DR PDB; 9AY7; X-ray; 2.41 A; A=337-615. DR PDB; 9AYA; X-ray; 2.59 A; A/C=337-615. DR PDB; 9EW1; X-ray; 1.40 A; P=255-263. DR PDB; 9EW3; X-ray; 1.40 A; P=255-263. DR PDB; 9EW4; X-ray; 1.60 A; P=255-263. DR PDB; 9EW5; X-ray; 1.50 A; C/F=255-265. DR PDB; 9EW7; X-ray; 1.80 A; P=255-264. DR PDBsum; 1C1Y; -. DR PDBsum; 1FAQ; -. DR PDBsum; 1FAR; -. DR PDBsum; 1GUA; -. DR PDBsum; 1RFA; -. DR PDBsum; 3CU8; -. DR PDBsum; 3IQJ; -. DR PDBsum; 3IQU; -. DR PDBsum; 3IQV; -. DR PDBsum; 3KUC; -. DR PDBsum; 3KUD; -. DR PDBsum; 3NKX; -. DR PDBsum; 3O8I; -. DR PDBsum; 3OMV; -. DR PDBsum; 4FJ3; -. DR PDBsum; 4G0N; -. DR PDBsum; 4G3X; -. DR PDBsum; 4IEA; -. DR PDBsum; 4IHL; -. DR PDBsum; 6NTC; -. DR PDBsum; 6NTD; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6XI7; -. DR PDBsum; 7JHP; -. DR PDBsum; 7Z37; -. DR PDBsum; 7Z38; -. DR PDBsum; 8A68; -. DR PDBsum; 8A6F; -. DR PDBsum; 8A6H; -. DR PDBsum; 8ATR; -. DR PDBsum; 8ATS; -. DR PDBsum; 8AV0; -. DR PDBsum; 8CHF; -. DR PDBsum; 8CPD; -. DR PDBsum; 8EPW; -. DR PDBsum; 8GAE; -. DR PDBsum; 8GFT; -. DR PDBsum; 8JOF; -. DR PDBsum; 8JOG; -. DR PDBsum; 8Q5C; -. DR PDBsum; 8S42; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8U1L; -. DR PDBsum; 9AXA; -. DR PDBsum; 9AXC; -. DR PDBsum; 9AY7; -. DR PDBsum; 9AYA; -. DR PDBsum; 9EW1; -. DR PDBsum; 9EW3; -. DR PDBsum; 9EW4; -. DR PDBsum; 9EW5; -. DR PDBsum; 9EW7; -. DR AlphaFoldDB; P04049; -. DR BMRB; P04049; -. DR EMDB; EMD-14472; -. DR EMDB; EMD-14473; -. DR EMDB; EMD-16660; -. DR EMDB; EMD-16779; -. DR EMDB; EMD-29895; -. DR EMDB; EMD-29949; -. DR EMDB; EMD-29957; -. DR EMDB; EMD-29973; -. DR EMDB; EMD-29976; -. DR EMDB; EMD-29984; -. DR EMDB; EMD-41816; -. DR EMDB; EMD-43931; -. DR EMDB; EMD-43932; -. DR SMR; P04049; -. DR BioGRID; 111831; 1867. DR CORUM; P04049; -. DR DIP; DIP-1048N; -. DR FunCoup; P04049; 4763. DR IntAct; P04049; 435. DR MINT; P04049; -. DR STRING; 9606.ENSP00000401888; -. DR BindingDB; P04049; -. DR ChEMBL; CHEMBL1906; -. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB17568; Belvarafenib. DR DrugBank; DB08862; Cholecystokinin. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB05268; iCo-007. DR DrugBank; DB04973; LErafAON. DR DrugBank; DB18865; Naporafenib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB12094; Semapimod. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P04049; -. DR GuidetoPHARMACOLOGY; 2184; -. DR MoonDB; P04049; Predicted. DR GlyCosmos; P04049; 1 site, 1 glycan. DR GlyGen; P04049; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P04049; -. DR PhosphoSitePlus; P04049; -. DR SwissPalm; P04049; -. DR BioMuta; RAF1; -. DR DMDM; 125651; -. DR CPTAC; CPTAC-1335; -. DR CPTAC; CPTAC-1336; -. DR CPTAC; CPTAC-1546; -. DR CPTAC; CPTAC-1762; -. DR CPTAC; CPTAC-5778; -. DR CPTAC; CPTAC-5779; -. DR CPTAC; CPTAC-5780; -. DR CPTAC; CPTAC-5828; -. DR CPTAC; CPTAC-5829; -. DR CPTAC; non-CPTAC-5431; -. DR CPTAC; non-CPTAC-5432; -. DR CPTAC; non-CPTAC-5433; -. DR CPTAC; non-CPTAC-5569; -. DR CPTAC; non-CPTAC-5570; -. DR CPTAC; non-CPTAC-5734; -. DR jPOST; P04049; -. DR MassIVE; P04049; -. DR PaxDb; 9606-ENSP00000251849; -. DR PeptideAtlas; P04049; -. DR ProteomicsDB; 51637; -. [P04049-1] DR ProteomicsDB; 51638; -. [P04049-2] DR Pumba; P04049; -. DR ABCD; P04049; 5 sequenced antibodies. DR Antibodypedia; 1131; 3127 antibodies from 52 providers. DR CPTC; P04049; 8 antibodies. DR DNASU; 5894; -. DR Ensembl; ENST00000251849.9; ENSP00000251849.4; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000442415.7; ENSP00000401888.2; ENSG00000132155.15. [P04049-2] DR Ensembl; ENST00000685653.1; ENSP00000509968.1; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000691899.1; ENSP00000508763.1; ENSG00000132155.15. [P04049-1] DR GeneID; 5894; -. DR KEGG; hsa:5894; -. DR MANE-Select; ENST00000251849.9; ENSP00000251849.4; NM_002880.4; NP_002871.1. DR UCSC; uc003bxf.5; human. [P04049-1] DR AGR; HGNC:9829; -. DR CIViC; 5894; 7 evidence items across 4 molecular profiles. DR ClinPGx; PA34183; -. DR CTD; 5894; -. DR DisGeNET; 5894; -. DR GeneCards; RAF1; -. DR GeneReviews; RAF1; -. DR HGNC; HGNC:9829; RAF1. DR HPA; ENSG00000132155; Low tissue specificity. DR MalaCards; RAF1; -. DR MIM; 164760; gene. DR MIM; 611553; phenotype. DR MIM; 611554; phenotype. DR MIM; 615916; phenotype. DR OpenTargets; ENSG00000132155; -. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000132155; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156084; -. DR InParanoid; P04049; -. DR OMA; SAYKRHA; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P04049; 5 GO annotations based on evolutionary models. DR PhylomeDB; P04049; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P04049; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR Reactome; R-HSA-392517; Rap1 signalling. DR Reactome; R-HSA-430116; GP1b-IX-V activation signalling. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR Reactome; R-HSA-9732724; IFNG signaling activates MAPKs. DR SignaLink; P04049; -. DR SIGNOR; P04049; -. DR Agora; ENSG00000132155; -. DR BioGRID-ORCS; 5894; 99 hits in 1206 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; RAF1; human. DR EvolutionaryTrace; P04049; -. DR GeneWiki; C-Raf; -. DR GenomeRNAi; 5894; -. DR Pharos; P04049; Tclin. DR PRO; PR:P04049; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P04049; protein. DR Bgee; ENSG00000132155; Expressed in gastrocnemius and 214 other cell types or tissues. DR ExpressionAtlas; P04049; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IPI:MGI. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031143; C:pseudopodium; IEA:Ensembl. DR GO; GO:0010856; F:adenylate cyclase activator activity; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; EXP:Reactome. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006915; P:apoptotic process; TAS:GO_Central. DR GO; GO:0071550; P:death-inducing signaling complex assembly; IEA:Ensembl. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl. DR GO; GO:0035773; P:insulin secretion involved in cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0045104; P:intermediate filament cytoskeleton organization; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:GO_Central. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB. DR GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB. DR GO; GO:0035023; P:regulation of Rho protein signal transduction; TAS:UniProtKB. DR GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0044342; P:type B pancreatic cell proliferation; IEA:Ensembl. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; TAS:Reactome. DR GO; GO:0042060; P:wound healing; TAS:UniProtKB. DR CDD; cd20870; C1_A_C-Raf; 1. DR CDD; cd17135; RBD_CRAF; 1. DR CDD; cd14149; STKc_C-Raf; 1. DR DisProt; DP00171; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00292; -. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329:SF22; RAF PROTO-ONCOGENE SERINE_THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Kinase; Membrane; Metal-binding; Methylation; KW Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..648 FT /note="RAF proto-oncogene serine/threonine-protein kinase" FT /id="PRO_0000086596" FT DOMAIN 56..131 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 349..609 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 138..184 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 220..334 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 331..349 FT /note="Interaction with PEBP1/RKIP" FT COMPBIAS 239..271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 275..285 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 286..301 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 468 FT /note="Proton acceptor" FT BINDING 139 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 152 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 155 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 165 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 168 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 173 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 184 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 355..363 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 375 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 29 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000250|UniProtKB:Q99N57" FT MOD_RES 43 FT /note="Phosphoserine; by PKA and MAPK1" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 252 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 259 FT /note="Phosphoserine; by PKA, PKC and PKB/AKT1" FT /evidence="ECO:0000269|PubMed:10576742, FT ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11756411, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:8349614" FT MOD_RES 268 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 269 FT /note="Phosphothreonine; by PKA" FT /evidence="ECO:0000269|PubMed:7477354" FT MOD_RES 289 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332" FT MOD_RES 296 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 301 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 338 FT /note="Phosphoserine; by PAK1, PAK2, PAK3 and PAK5" FT /evidence="ECO:0000269|PubMed:11733498, FT ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16892053, FT ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714" FT MOD_RES 339 FT /note="Phosphoserine; by PAK1, PAK2 and PAK3" FT /evidence="ECO:0000269|PubMed:15849194" FT MOD_RES 340 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 341 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 471 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16093354" FT MOD_RES 491 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 494 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 499 FT /note="Phosphoserine; by PKC" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 563 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 621 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:10801873, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:21917714, FT ECO:0000269|PubMed:8349614" FT MOD_RES 642 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 278 FT /note="E -> ENNNLSASPRAWSRRFCLRGR (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_034649" FT VARIANT 237 FT /note="A -> T (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777588)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071844" FT VARIANT 256 FT /note="R -> S (in NS5; dbSNP:rs397516826)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037807" FT VARIANT 257 FT /note="S -> L (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced ERK activation than wild-type; FT dbSNP:rs80338796)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037808" FT VARIANT 259 FT /note="S -> A (in an ovarian serous carcinoma sample; FT somatic mutation; increased ERK activation; FT dbSNP:rs3730271)" FT /evidence="ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041037" FT VARIANT 259 FT /note="S -> F (in NS5; dbSNP:rs397516827)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037809" FT VARIANT 260 FT /note="T -> I (in hypertrophic cardiomyopathy; uncertain FT significance; dbSNP:rs869025501)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037810" FT VARIANT 260 FT /note="T -> R (in NS5)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037811" FT VARIANT 261 FT /note="P -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037812" FT VARIANT 261 FT /note="P -> L (in NS5; shows greater kinase activity and FT enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516828)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037813" FT VARIANT 261 FT /note="P -> S (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980" FT /id="VAR_037814" FT VARIANT 263 FT /note="V -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516830)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037815" FT VARIANT 308 FT /note="P -> L (in dbSNP:rs5746220)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.3" FT /id="VAR_018840" FT VARIANT 310 FT /note="T -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs778155315)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071845" FT VARIANT 332 FT /note="P -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1057403865)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071846" FT VARIANT 335 FT /note="Q -> H (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041038" FT VARIANT 486 FT /note="D -> G (in NS5; dbSNP:rs397516815)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037816" FT VARIANT 486 FT /note="D -> N (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338798)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037817" FT VARIANT 491 FT /note="T -> I (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037818" FT VARIANT 491 FT /note="T -> R (in NS5; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037819" FT VARIANT 603 FT /note="L -> P (in CMD1NN; shows impaired kinase activity FT and reduced MAPK3 activation with this mutation; FT dbSNP:rs587777586)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071847" FT VARIANT 612 FT /note="S -> T (in NS5; dbSNP:rs1448392469)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037820" FT VARIANT 613 FT /note="L -> V (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced MAPK1 activation than wild- FT type; dbSNP:rs80338797)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037821" FT VARIANT 626 FT /note="H -> R (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1553609795)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071848" FT VARIANT 641 FT /note="T -> M (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777587)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071849" FT MUTAGEN 338..339 FT /note="SS->AA: Reduced kinase activity; when associated FT with 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 338..339 FT /note="SS->DE: Non-inhibited by PPP5C. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 340..341 FT /note="YY->DD: Constitutively active and highly FT phosphorylated on S-338, inhibited by PPP5C. Reduced kinase FT activity; when associated with 338-A-A-339. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 338-D-E-339." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 375 FT /note="K->W: Catalytically inactive." FT /evidence="ECO:0000269|PubMed:20956560" FT MUTAGEN 491 FT /note="T->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-494." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 494 FT /note="S->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-491." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 563 FT /note="R->K: Loss of methylation. Increased stability and FT catalytic activity in response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 240 FT /note="F -> L (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT CONFLICT 542 FT /note="M -> I (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:6VJJ" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:8T74" FT STRAND 67..71 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 78..88 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 96..100 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 103..107 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:8T74" FT HELIX 118..121 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:6PTW" FT STRAND 135..137 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 141..145 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 153..155 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 160..165 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 170..172 FT /evidence="ECO:0007829|PDB:7JHP" FT HELIX 174..179 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 182..185 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 350..353 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 363..376 FT /evidence="ECO:0007829|PDB:8CPD" FT HELIX 384..397 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 408..412 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 418..422 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 434..437 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 442..461 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 471..473 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 478..480 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 481..484 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 510..512 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 514..518 FT /evidence="ECO:0007829|PDB:7Z38" FT STRAND 520..522 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 527..542 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 547..550 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 554..563 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 593..595 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 599..611 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 612..614 FT /evidence="ECO:0007829|PDB:7Z38" SQ SEQUENCE 648 AA; 73052 MW; EF821B5349711BC3 CRC64; MEHIQGAWKT ISNGFGFKDA VFDGSSCISP TIVQQFGYQR RASDDGKLTD PSKTSNTIRV FLPNKQRTVV NVRNGMSLHD CLMKALKVRG LQPECCAVFR LLHEHKGKKA RLDWNTDAAS LIGEELQVDF LDHVPLTTHN FARKTFLKLA FCDICQKFLL NGFRCQTCGY KFHEHCSTKV PTMCVDWSNI RQLLLFPNST IGDSGVPALP SLTMRRMRES VSRMPVSSQH RYSTPHAFTF NTSSPSSEGS LSQRQRSTST PNVHMVSTTL PVDSRMIEDA IRSHSESASP SALSSSPNNL SPTGWSQPKT PVPAQRERAP VSGTQEKNKI RPRGQRDSSY YWEIEASEVM LSTRIGSGSF GTVYKGKWHG DVAVKILKVV DPTPEQFQAF RNEVAVLRKT RHVNILLFMG YMTKDNLAIV TQWCEGSSLY KHLHVQETKF QMFQLIDIAR QTAQGMDYLH AKNIIHRDMK SNNIFLHEGL TVKIGDFGLA TVKSRWSGSQ QVEQPTGSVL WMAPEVIRMQ DNNPFSFQSD VYSYGIVLYE LMTGELPYSH INNRDQIIFM VGRGYASPDL SKLYKNCPKA MKRLVADCVK KVKEERPLFP QILSSIELLQ HSLPKINRSA SEPSLHRAAH TEDINACTLT TSPRLPVF // ID ROR1_HUMAN Reviewed; 937 AA. AC Q01973; Q5VVX6; Q66K77; Q92776; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 28-NOV-2006, sequence version 2. DT 28-JAN-2026, entry version 230. DE RecName: Full=Inactive tyrosine-protein kinase transmembrane receptor ROR1 {ECO:0000305}; DE AltName: Full=Neurotrophic tyrosine kinase, receptor-related 1; DE Flags: Precursor; GN Name=ROR1; Synonyms=NTRKR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT MET-518. RX PubMed=1334494; DOI=10.1016/s0021-9258(18)35733-8; RA Masiakowski P., Carroll R.D.; RT "A novel family of cell surface receptors with tyrosine kinase-like RT domain."; RL J. Biol. Chem. 267:26181-26190(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT). RX PubMed=8875995; RA Reddy U.R., Phatak S., Pleasure D.; RT "Human neural tissues express a truncated Ror1 receptor tyrosine kinase, RT lacking both extracellular and transmembrane domains."; RL Oncogene 13:1555-1559(1996). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP LACK OF CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-482. RX PubMed=25029443; DOI=10.1371/journal.pone.0102695; RA Bainbridge T.W., DeAlmeida V.I., Izrael-Tomasevic A., Chalouni C., Pan B., RA Goldsmith J., Schoen A.P., Quinones G.A., Kelly R., Lill J.R., Sandoval W., RA Costa M., Polakis P., Arnott D., Rubinfeld B., Ernst J.A.; RT "Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and RT ROR2 kinase domains."; RL PLoS ONE 9:E102695-E102695(2014). RN [7] RP FUNCTION, AND INTERACTION WITH IGFBP5 AND ERBB2. RX PubMed=36949068; DOI=10.1038/s41467-023-37306-1; RA Lin W., Niu R., Park S.M., Zou Y., Kim S.S., Xia X., Xing S., Yang Q., RA Sun X., Yuan Z., Zhou S., Zhang D., Kwon H.J., Park S., Il Kim C., Koo H., RA Liu Y., Wu H., Zheng M., Yoo H., Shi B., Park J.B., Yin J.; RT "IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2- RT CREB signaling axis."; RL Nat. Commun. 14:1578-1578(2023). RN [8] RP VARIANT [LARGE SCALE ANALYSIS] ASP-562. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-144; LEU-150; VAL-301; MET-518; RP ILE-567; ARG-624; CYS-646 AND ASN-776. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [10] RP INVOLVEMENT IN DFNB108, VARIANT DFNB108 THR-736, CHARACTERIZATION OF RP VARIANT DFNB108 THR-736, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=27162350; DOI=10.1073/pnas.1522512113; RA Diaz-Horta O., Abad C., Sennaroglu L., Foster J. II, DeSmidt A., RA Bademci G., Tokgoz-Yilmaz S., Duman D., Cengiz F.B., Grati M., Fitoz S., RA Liu X.Z., Farooq A., Imtiaz F., Currall B.B., Morton C.C., Nishita M., RA Minami Y., Lu Z., Walz K., Tekin M.; RT "ROR1 is essential for proper innervation of auditory hair cells and RT hearing in humans and mice."; RL Proc. Natl. Acad. Sci. U.S.A. 113:5993-5998(2016). CC -!- FUNCTION: Has very low kinase activity in vitro and is unlikely to CC function as a tyrosine kinase in vivo (PubMed:25029443). Receptor for CC ligand WNT5A which activate downstream NFkB signaling pathway and may CC result in the inhibition of WNT3A-mediated signaling (PubMed:25029443, CC PubMed:27162350). In inner ear, crucial for spiral ganglion neurons to CC innervate auditory hair cells (PubMed:27162350). Via IGFBP5 ligand, CC forms a complex with ERBB2 to enhance CREB oncogenic signaling CC (PubMed:36949068). {ECO:0000269|PubMed:25029443, CC ECO:0000269|PubMed:27162350, ECO:0000269|PubMed:36949068}. CC -!- SUBUNIT: Interacts with ERBB2 and IGFBP5. CC {ECO:0000269|PubMed:36949068}. CC -!- INTERACTION: CC Q01973; P00533: EGFR; NbExp=8; IntAct=EBI-6082337, EBI-297353; CC Q01973; P12931: SRC; NbExp=9; IntAct=EBI-6082337, EBI-621482; CC Q01973; P05480: Src; Xeno; NbExp=2; IntAct=EBI-6082337, EBI-298680; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:27162350}; Single- CC pass type I membrane protein. Cell projection, axon CC {ECO:0000250|UniProtKB:Q9Z139}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=Long; CC IsoId=Q01973-1; Sequence=Displayed; CC Name=Short; Synonyms=T-ROR1; CC IsoId=Q01973-2; Sequence=VSP_005008; CC Name=3; CC IsoId=Q01973-3; Sequence=VSP_043663, VSP_043664; CC -!- TISSUE SPECIFICITY: Expressed strongly in human heart, lung and kidney, CC but weakly in the CNS. Isoform Short is strongly expressed in fetal and CC adult CNS and in a variety of human cancers, including those CC originating from CNS or PNS neuroectoderm. CC -!- DEVELOPMENTAL STAGE: Expressed at high levels during early embryonic CC development. The expression levels drop strongly around day 16 and CC there are only very low levels in adult tissues. CC -!- DISEASE: Deafness, autosomal recessive, 108 (DFNB108) [MIM:617654]: A CC form of non-syndromic sensorineural hearing loss. Sensorineural CC deafness results from damage to the neural receptors of the inner ear, CC the nerve pathways to the brain, or the area of the brain that receives CC sound information. {ECO:0000269|PubMed:27162350}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. ROR subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: The kinase domain has very low catalytic activity in vitro. CC {ECO:0000269|PubMed:25029443}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M97675; AAA60275.1; -; mRNA. DR EMBL; U38894; AAC50714.1; -; mRNA. DR EMBL; AL137859; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL161742; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445205; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL138793; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL353713; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL808029; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL808030; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX06556.1; -; Genomic_DNA. DR EMBL; BC080541; AAH80541.1; -; mRNA. DR CCDS; CCDS41344.1; -. [Q01973-3] DR CCDS; CCDS626.1; -. [Q01973-1] DR PIR; A45082; A45082. DR RefSeq; NP_001077061.1; NM_001083592.2. [Q01973-3] DR RefSeq; NP_005003.2; NM_005012.4. [Q01973-1] DR PDB; 5Z55; NMR; -; A=312-394. DR PDB; 6BA5; X-ray; 1.62 A; M/N/O/P=311-391. DR PDB; 6BAN; X-ray; 1.95 A; M/N/O/P=311-391. DR PDB; 6TU9; X-ray; 1.94 A; A/B=453-752. DR PDB; 7TNG; X-ray; 1.40 A; A=312-393. DR PDBsum; 5Z55; -. DR PDBsum; 6BA5; -. DR PDBsum; 6BAN; -. DR PDBsum; 6TU9; -. DR PDBsum; 7TNG; -. DR AlphaFoldDB; Q01973; -. DR SMR; Q01973; -. DR BioGRID; 110973; 124. DR DIP; DIP-29734N; -. DR FunCoup; Q01973; 357. DR IntAct; Q01973; 107. DR MINT; Q01973; -. DR STRING; 9606.ENSP00000360120; -. DR BindingDB; Q01973; -. DR ChEMBL; CHEMBL4665585; -. DR TCDB; 8.A.23.1.60; the basigin (basigin) family. DR GlyCosmos; Q01973; 4 sites, No reported glycans. DR GlyGen; Q01973; 5 sites, 5 N-linked glycans (2 sites). DR iPTMnet; Q01973; -. DR PhosphoSitePlus; Q01973; -. DR SwissPalm; Q01973; -. DR BioMuta; ROR1; -. DR DMDM; 118572711; -. DR jPOST; Q01973; -. DR MassIVE; Q01973; -. DR PaxDb; 9606-ENSP00000360120; -. DR PeptideAtlas; Q01973; -. DR ProteomicsDB; 58025; -. [Q01973-1] DR ProteomicsDB; 58026; -. [Q01973-2] DR ProteomicsDB; 58027; -. [Q01973-3] DR Pumba; Q01973; -. DR ABCD; Q01973; 29 sequenced antibodies. DR Antibodypedia; 33360; 927 antibodies from 43 providers. DR DNASU; 4919; -. DR Ensembl; ENST00000371079.6; ENSP00000360120.1; ENSG00000185483.13. [Q01973-1] DR Ensembl; ENST00000371080.5; ENSP00000360121.1; ENSG00000185483.13. [Q01973-3] DR GeneID; 4919; -. DR KEGG; hsa:4919; -. DR MANE-Select; ENST00000371079.6; ENSP00000360120.1; NM_005012.4; NP_005003.2. DR UCSC; uc001dbi.5; human. [Q01973-1] DR AGR; HGNC:10256; -. DR ClinPGx; PA34628; -. DR CTD; 4919; -. DR DisGeNET; 4919; -. DR GeneCards; ROR1; -. DR HGNC; HGNC:10256; ROR1. DR HPA; ENSG00000185483; Tissue enhanced (parathyroid). DR MalaCards; ROR1; -. DR MIM; 602336; gene. DR MIM; 617654; phenotype. DR OpenTargets; ENSG00000185483; -. DR Orphanet; 90636; Rare autosomal recessive non-syndromic sensorineural deafness type DFNB. DR VEuPathDB; HostDB:ENSG00000185483; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000153947; -. DR HOGENOM; CLU_701993_0_0_1; -. DR InParanoid; Q01973; -. DR OMA; IQNDECP; -. DR OrthoDB; 2431000at2759; -. DR PAN-GO; Q01973; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q01973; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q01973; -. DR Reactome; R-HSA-5140745; WNT5A-dependent internalization of FZD2, FZD5 and ROR2. DR SignaLink; Q01973; -. DR SIGNOR; Q01973; -. DR Agora; ENSG00000185483; -. DR BioGRID-ORCS; 4919; 17 hits in 1190 CRISPR screens. DR ChiTaRS; ROR1; human. DR GeneWiki; ROR1; -. DR GenomeRNAi; 4919; -. DR Pharos; Q01973; Tbio. DR PRO; PR:Q01973; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q01973; protein. DR Bgee; ENSG00000185483; Expressed in germinal epithelium of ovary and 154 other cell types or tissues. DR ExpressionAtlas; Q01973; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0043679; C:axon terminus; ISS:UniProtKB. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0001725; C:stress fiber; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015026; F:coreceptor activity; TAS:ParkinsonsUK-UCL. DR GO; GO:0038023; F:signaling receptor activity; IDA:UniProt. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0042813; F:Wnt receptor activity; IMP:UniProtKB. DR GO; GO:0017147; F:Wnt-protein binding; IPI:UniProtKB. DR GO; GO:0014002; P:astrocyte development; IEA:Ensembl. DR GO; GO:0008283; P:cell population proliferation; IDA:UniProt. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; TAS:ProtInc. DR GO; GO:0048839; P:inner ear development; ISS:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB. DR CDD; cd07467; CRD_TK_ROR1; 1. DR CDD; cd00108; KR; 1. DR CDD; cd05090; PTKc_Ror1; 1. DR FunFam; 1.10.2000.10:FF:000002; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 2.40.20.10:FF:000003; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 2.60.40.10:FF:000242; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 1.10.510.10:FF:000116; inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 3.30.200.20:FF:000139; inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR Gene3D; 1.10.2000.10; Frizzled cysteine-rich domain; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.40.20.10; Plasminogen Kringle 4; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR020067; Frizzled_dom. DR InterPro; IPR036790; Frizzled_dom_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000001; Kringle. DR InterPro; IPR013806; Kringle-like. DR InterPro; IPR018056; Kringle_CS. DR InterPro; IPR038178; Kringle_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR016247; Tyr_kinase_rcpt_ROR. DR PANTHER; PTHR24416:SF134; INACTIVE TYROSINE-PROTEIN KINASE TRANSMEMBRANE RECEPTOR ROR1; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF01392; Fz; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF00051; Kringle; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000624; TyrPK_TMrec_ROR; 1. DR PRINTS; PR00018; KRINGLE. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00408; IGc2; 1. DR SMART; SM00130; KR; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF57440; Kringle-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50038; FZ; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00021; KRINGLE_1; 1. DR PROSITE; PS50070; KRINGLE_2; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; Deafness; KW Disease variant; Disulfide bond; Glycoprotein; Immunoglobulin domain; KW Kinase; Kringle; Membrane; Non-syndromic deafness; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Signal; Transferase; Transmembrane; Transmembrane helix; KW Wnt signaling pathway. FT SIGNAL 1..29 FT /evidence="ECO:0000255" FT CHAIN 30..937 FT /note="Inactive tyrosine-protein kinase transmembrane FT receptor ROR1" FT /id="PRO_0000024458" FT TOPO_DOM 30..406 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 407..427 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 428..937 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 42..147 FT /note="Ig-like C2-type" FT DOMAIN 165..299 FT /note="FZ" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00090" FT DOMAIN 312..391 FT /note="Kringle" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00121" FT DOMAIN 473..746 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 753..779 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 833..890 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 753..762 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 763..779 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 854..864 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 865..880 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 479..487 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 506 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 645 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 47 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 66 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 184 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 315 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 79..131 FT /evidence="ECO:0000250" FT DISULFID 170..235 FT /evidence="ECO:0000250" FT DISULFID 178..228 FT /evidence="ECO:0000250" FT DISULFID 219..260 FT /evidence="ECO:0000250" FT DISULFID 248..296 FT /evidence="ECO:0000250" FT DISULFID 252..282 FT /evidence="ECO:0000250" FT DISULFID 313..391 FT /evidence="ECO:0000250" FT DISULFID 334..374 FT /evidence="ECO:0000250" FT DISULFID 362..386 FT /evidence="ECO:0000250" FT VAR_SEQ 1..549 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:8875995" FT /id="VSP_005008" FT VAR_SEQ 392..393 FT /note="DS -> GK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_043663" FT VAR_SEQ 394..937 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_043664" FT VARIANT 144 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041779" FT VARIANT 150 FT /note="F -> L (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041780" FT VARIANT 301 FT /note="I -> V (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041781" FT VARIANT 518 FT /note="T -> M (in dbSNP:rs7527017)" FT /evidence="ECO:0000269|PubMed:1334494, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041782" FT VARIANT 562 FT /note="E -> D (in a breast cancer sample; somatic mutation; FT dbSNP:rs760789417)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035713" FT VARIANT 567 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041783" FT VARIANT 624 FT /note="G -> R (in dbSNP:rs55832740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041784" FT VARIANT 646 FT /note="Y -> C (in dbSNP:rs34109134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041785" FT VARIANT 736 FT /note="R -> T (in DFNB108; impairs plasma membrane FT location; abolishes downstream NFkB activation; FT dbSNP:rs1553163562)" FT /evidence="ECO:0000269|PubMed:27162350" FT /id="VAR_079530" FT VARIANT 776 FT /note="S -> N (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041786" FT MUTAGEN 482 FT /note="C->G: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:25029443" FT STRAND 312..314 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 341..343 FT /evidence="ECO:0007829|PDB:7TNG" FT TURN 349..351 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 353..355 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 365..367 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 373..377 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 383..387 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 470..472 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 473..481 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 486..492 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 501..507 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 514..527 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 538..542 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 544..547 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 549..553 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 560..566 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 589..608 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 621..623 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 625..627 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 636..640 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 642..644 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 656..658 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 661..666 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 671..686 FT /evidence="ECO:0007829|PDB:6TU9" FT TURN 692..695 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 698..706 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 719..728 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 733..735 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 739..748 FT /evidence="ECO:0007829|PDB:6TU9" SQ SEQUENCE 937 AA; 104283 MW; 0EC0E4762A90C6C7 CRC64; MHRPRRRGTR PPLLALLAAL LLAARGAAAQ ETELSVSAEL VPTSSWNISS ELNKDSYLTL DEPMNNITTS LGQTAELHCK VSGNPPPTIR WFKNDAPVVQ EPRRLSFRST IYGSRLRIRN LDTTDTGYFQ CVATNGKEVV SSTGVLFVKF GPPPTASPGY SDEYEEDGFC QPYRGIACAR FIGNRTVYME SLHMQGEIEN QITAAFTMIG TSSHLSDKCS QFAIPSLCHY AFPYCDETSS VPKPRDLCRD ECEILENVLC QTEYIFARSN PMILMRLKLP NCEDLPQPES PEAANCIRIG IPMADPINKN HKCYNSTGVD YRGTVSVTKS GRQCQPWNSQ YPHTHTFTAL RFPELNGGHS YCRNPGNQKE APWCFTLDEN FKSDLCDIPA CDSKDSKEKN KMEILYILVP SVAIPLAIAL LFFFICVCRN NQKSSSAPVQ RQPKHVRGQN VEMSMLNAYK PKSKAKELPL SAVRFMEELG ECAFGKIYKG HLYLPGMDHA QLVAIKTLKD YNNPQQWTEF QQEASLMAEL HHPNIVCLLG AVTQEQPVCM LFEYINQGDL HEFLIMRSPH SDVGCSSDED GTVKSSLDHG DFLHIAIQIA AGMEYLSSHF FVHKDLAARN ILIGEQLHVK ISDLGLSREI YSADYYRVQS KSLLPIRWMP PEAIMYGKFS SDSDIWSFGV VLWEIFSFGL QPYYGFSNQE VIEMVRKRQL LPCSEDCPPR MYSLMTECWN EIPSRRPRFK DIHVRLRSWE GLSSHTSSTT PSGGNATTQT TSLSASPVSN LSNPRYPNYM FPSQGITPQG QIAGFIGPPI PQNQRFIPIN GYPIPPGYAA FPAAHYQPTG PPRVIQHCPP PKSRSPSSAS GSTSTGHVTS LPSSGSNQEA NIPLLPHMSI PNHPGGMGIT VFGNKSQKPY KIDSKQASLL GDANIHGHTE SMISAEL // ID S22AG_HUMAN Reviewed; 577 AA. AC Q86VW1; O14567; Q5JXM1; Q8IUG8; Q8IZD5; Q96M90; Q96RU0; DT 26-FEB-2008, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2003, sequence version 1. DT 28-JAN-2026, entry version 177. DE RecName: Full=Solute carrier family 22 member 16 {ECO:0000303|PubMed:15963465}; DE AltName: Full=Carnitine transporter 2 {ECO:0000303|PubMed:12089149}; DE Short=CT2 {ECO:0000303|PubMed:12372408}; DE AltName: Full=Fly-like putative transporter 2 {ECO:0000303|PubMed:12372408}; DE Short=FLIPT2 {ECO:0000303|PubMed:12372408}; DE Short=Flipt 2 {ECO:0000303|PubMed:12372408}; DE AltName: Full=Organic cation transporter OKB1; DE AltName: Full=Organic cation/carnitine transporter 6; GN Name=SLC22A16 {ECO:0000312|HGNC:HGNC:20302}; Synonyms=OCT6; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT THR-409, AND TISSUE RP SPECIFICITY. RC TISSUE=Kidney; RX PubMed=12372408; DOI=10.1016/s0006-291x(02)02343-4; RA Eraly S.A., Nigam S.K.; RT "Novel human cDNAs homologous to Drosophila Orct and mammalian carnitine RT transporters."; RL Biochem. Biophys. Res. Commun. 297:1159-1166(2002). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT THR-409. RX PubMed=12384147; DOI=10.1016/s0301-472x(02)00901-3; RA Gong S., Lu X., Xu Y., Swiderski C.F., Jordan C.T., Moscow J.A.; RT "Identification of OCT6 as a novel organic cation transporter prefrentially RT expressed in hematopoietic cells and leukemias."; RL Exp. Hematol. 30:1162-1169(2002). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TRANSPORTER ACTIVITY, RP BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=12089149; DOI=10.1074/jbc.m203883200; RA Enomoto A., Wempe M.F., Tsuchida H., Shin H.J., Cha S.H., Anzai N., RA Goto A., Sakamoto A., Niwa T., Kanai Y., Anders M.W., Endou H.; RT "Molecular identification of a novel carnitine transporter specific to RT human testis. Insights into the mechanism of carnitine recognition."; RL J. Biol. Chem. 277:36262-36271(2002). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, VARIANT RP THR-409, AND MISCELLANEOUS. RX PubMed=15963465; DOI=10.1016/j.bbrc.2005.05.174; RA Okabe M., Unno M., Harigae H., Kaku M., Okitsu Y., Sasaki T., Mizoi T., RA Shiiba K., Takanaga H., Terasaki T., Matsuno S., Sasaki I., Ito S., Abe T.; RT "Characterization of the organic cation transporter SLC22A16: a doxorubicin RT importer."; RL Biochem. Biophys. Res. Commun. 333:754-762(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 84-577 (ISOFORM 3), AND VARIANT RP THR-409. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP TISSUE SPECIFICITY. RX PubMed=17197897; DOI=10.1097/01.pgp.0000225845.67245.b3; RA Sato N., Ito K., Onogawa T., Akahira J., Unno M., Abe T., Niikura H., RA Yaegashi N.; RT "Expression of organic cation transporter SLC22A16 in human endometria."; RL Int. J. Gynecol. Pathol. 26:53-60(2007). RN [10] RP TISSUE SPECIFICITY. RX PubMed=17581421; DOI=10.1097/01.pgp.0000236951.33914.1b; RA Ota K., Ito K., Akahira J., Sato N., Onogawa T., Moriya T., Unno M., RA Abe T., Niikura H., Takano T., Yaegashi N.; RT "Expression of organic cation transporter SLC22A16 in human epithelial RT ovarian cancer: a possible role of the adriamycin importer."; RL Int. J. Gynecol. Pathol. 26:334-340(2007). RN [11] RP FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, AND MISCELLANEOUS. RX PubMed=20037140; DOI=10.1074/jbc.m109.046151; RA Aouida M., Poulin R., Ramotar D.; RT "The human carnitine transporter SLC22A16 mediates high affinity uptake of RT the anticancer polyamine analogue bleomycin-A5."; RL J. Biol. Chem. 285:6275-6284(2010). CC -!- FUNCTION: Facilitative organic cation transporter that mediates the CC transport of carnitine as well as the polyamine spermidine CC (PubMed:12089149, PubMed:20037140). Mediates the partially Na(+)- CC dependent bidirectional transport of carnitine (PubMed:12089149). May CC mediate L-carnitine secretion from testis epididymal epithelium into CC the lumen which is involved in the maturation of spermatozoa CC (PubMed:12089149). {ECO:0000269|PubMed:12089149, CC ECO:0000269|PubMed:20037140}. CC -!- CATALYTIC ACTIVITY: CC Reaction=(R)-carnitine(in) = (R)-carnitine(out); Xref=Rhea:RHEA:34959, CC ChEBI:CHEBI:16347; Evidence={ECO:0000269|PubMed:12089149, CC ECO:0000269|PubMed:20037140}; CC -!- CATALYTIC ACTIVITY: CC Reaction=spermidine(in) = spermidine(out); Xref=Rhea:RHEA:35039, CC ChEBI:CHEBI:57834; Evidence={ECO:0000269|PubMed:20037140}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=20.3 uM for L-carnitine {ECO:0000269|PubMed:12089149}; CC KM=8 uM for L-carnitine {ECO:0000269|PubMed:20037140}; CC KM=0.35 uM for spermidine {ECO:0000269|PubMed:20037140}; CC pH dependence: CC Optimum pH is 8.5 for carnitine uptake and transport efficiency CC decreased at more acidic pHs. {ECO:0000269|PubMed:12089149}; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12089149, CC ECO:0000269|PubMed:20037140}; Multi-pass membrane protein CC {ECO:0000305}. Note=Detected in the plasma membrane of Sertoli cells CC and in the luminal membrane of epithelial cells in the epididymis. CC {ECO:0000269|PubMed:12089149}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q86VW1-1; Sequence=Displayed; CC Name=2; CC IsoId=Q86VW1-2; Sequence=VSP_031336, VSP_031337; CC Name=3; CC IsoId=Q86VW1-3; Sequence=VSP_031338; CC -!- TISSUE SPECIFICITY: Expressed in testis and epididymis (at protein CC level) (PubMed:12089149, PubMed:12384147, PubMed:15963465). Expressed CC in endometrium (at protein level); highly expressed during the normal CC secretory phase, but expression is significantly reduced in the CC proliferative phase (PubMed:17197897). Expressed at lower levels in CC adult tissues including bone marrow (at protein level) CC (PubMed:12372408, PubMed:12384147, PubMed:15963465). Expressed in CC hematopoietic cells, including CD34(+) leukocytes (PubMed:12384147). CC Expressed in fetal liver (at protein level), brain, lung, kidney, CC heart, skeletal muscle, spleen and thymus (PubMed:12372408, CC PubMed:12384147, PubMed:15963465). Expressed in leukemia cells CC (PubMed:12384147). Abundantly expressed in ovarian cancer clear-cell CC adenocarcinoma (PubMed:17581421). {ECO:0000269|PubMed:12089149, CC ECO:0000269|PubMed:12372408, ECO:0000269|PubMed:12384147, CC ECO:0000269|PubMed:15963465, ECO:0000269|PubMed:17197897, CC ECO:0000269|PubMed:17581421}. CC -!- MISCELLANEOUS: Involved in the uptake of clinically used drugs such as CC anticancer agents doxorubicin and bleomycin. CC {ECO:0000269|PubMed:15963465, ECO:0000269|PubMed:20037140}. CC -!- SIMILARITY: Belongs to the major facilitator (TC 2.A.1) superfamily. CC Organic cation transporter (TC 2.A.1.19) family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB71419.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY145502; AAN52928.1; -; mRNA. DR EMBL; AB055798; BAC23062.1; -; mRNA. DR EMBL; AF268892; AAK58593.1; -; mRNA. DR EMBL; AC002464; AAB67044.1; -; Genomic_DNA. DR EMBL; AL050350; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48313.1; -; Genomic_DNA. DR EMBL; BC047565; AAH47565.1; -; mRNA. DR EMBL; AK057306; BAB71419.1; ALT_INIT; mRNA. DR CCDS; CCDS5084.1; -. [Q86VW1-1] DR RefSeq; NP_149116.2; NM_033125.3. [Q86VW1-1] DR RefSeq; XP_011534507.1; XM_011536205.3. [Q86VW1-3] DR RefSeq; XP_054212602.1; XM_054356627.1. [Q86VW1-3] DR AlphaFoldDB; Q86VW1; -. DR SMR; Q86VW1; -. DR BioGRID; 124519; 55. DR FunCoup; Q86VW1; 146. DR IntAct; Q86VW1; 48. DR STRING; 9606.ENSP00000357915; -. DR BindingDB; Q86VW1; -. DR ChEMBL; CHEMBL2073722; -. DR DrugBank; DB00997; Doxorubicin. DR DrugBank; DB00583; Levocarnitine. DR TCDB; 2.A.1.19.12; the major facilitator superfamily (mfs). DR GlyCosmos; Q86VW1; 8 sites, No reported glycans. DR GlyGen; Q86VW1; 8 sites. DR iPTMnet; Q86VW1; -. DR PhosphoSitePlus; Q86VW1; -. DR BioMuta; SLC22A16; -. DR DMDM; 74750474; -. DR jPOST; Q86VW1; -. DR MassIVE; Q86VW1; -. DR PaxDb; 9606-ENSP00000357915; -. DR PeptideAtlas; Q86VW1; -. DR ProteomicsDB; 70079; -. [Q86VW1-1] DR ProteomicsDB; 70080; -. [Q86VW1-2] DR Antibodypedia; 32327; 110 antibodies from 22 providers. DR DNASU; 85413; -. DR Ensembl; ENST00000330550.8; ENSP00000328583.4; ENSG00000004809.15. [Q86VW1-2] DR Ensembl; ENST00000368919.8; ENSP00000357915.3; ENSG00000004809.15. [Q86VW1-1] DR GeneID; 85413; -. DR KEGG; hsa:85413; -. DR MANE-Select; ENST00000368919.8; ENSP00000357915.3; NM_033125.4; NP_149116.2. DR UCSC; uc003puf.5; human. [Q86VW1-1] DR AGR; HGNC:20302; -. DR ClinPGx; PA134911502; -. DR CTD; 85413; -. DR DisGeNET; 85413; -. DR GeneCards; SLC22A16; -. DR HGNC; HGNC:20302; SLC22A16. DR HPA; ENSG00000004809; Group enriched (bone marrow, testis). DR MIM; 608276; gene. DR OpenTargets; ENSG00000004809; -. DR VEuPathDB; HostDB:ENSG00000004809; -. DR eggNOG; KOG0255; Eukaryota. DR GeneTree; ENSGT00940000160723; -. DR InParanoid; Q86VW1; -. DR OMA; MEAYMGA; -. DR OrthoDB; 2261376at2759; -. DR PAN-GO; Q86VW1; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q86VW1; -. DR PathwayCommons; Q86VW1; -. DR Reactome; R-HSA-549127; Organic cation transport. DR SignaLink; Q86VW1; -. DR Agora; ENSG00000004809; -. DR BioGRID-ORCS; 85413; 11 hits in 1147 CRISPR screens. DR GenomeRNAi; 85413; -. DR Pharos; Q86VW1; Tbio. DR PRO; PR:Q86VW1; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q86VW1; protein. DR Bgee; ENSG00000004809; Expressed in trabecular bone tissue and 112 other cell types or tissues. DR ExpressionAtlas; Q86VW1; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005275; F:amine transmembrane transporter activity; IDA:MGI. DR GO; GO:0015226; F:carnitine transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0015101; F:organic cation transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0015606; F:spermidine transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046717; P:acid secretion; IDA:UniProtKB. DR GO; GO:1902603; P:carnitine transmembrane transport; IDA:UniProtKB. DR GO; GO:0015879; P:carnitine transport; IDA:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0030317; P:flagellated sperm motility; IMP:UniProtKB. DR GO; GO:0006811; P:monoatomic ion transport; IEA:UniProtKB-KW. DR GO; GO:0015695; P:organic cation transport; IDA:UniProtKB. DR GO; GO:0007338; P:single fertilization; IMP:UniProtKB. DR GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW. DR GO; GO:1903711; P:spermidine transmembrane transport; IDA:UniProtKB. DR CDD; cd17375; MFS_SLC22A16_CT2; 1. DR FunFam; 1.20.1250.20:FF:000154; Solute carrier family 22 member 16; 1. DR Gene3D; 1.20.1250.20; MFS general substrate transporter like domains; 1. DR InterPro; IPR020846; MFS_dom. DR InterPro; IPR005828; MFS_sugar_transport-like. DR InterPro; IPR036259; MFS_trans_sf. DR PANTHER; PTHR24064; SOLUTE CARRIER FAMILY 22 MEMBER; 1. DR Pfam; PF00083; Sugar_tr; 1. DR SUPFAM; SSF103473; MFS general substrate transporter; 1. DR PROSITE; PS50850; MFS; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Developmental protein; KW Differentiation; Glycoprotein; Ion transport; Membrane; KW Proteomics identification; Reference proteome; Spermatogenesis; KW Transmembrane; Transmembrane helix; Transport. FT CHAIN 1..577 FT /note="Solute carrier family 22 member 16" FT /id="PRO_0000318991" FT TRANSMEM 23..43 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 152..172 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 183..203 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 214..234 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 244..264 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 268..288 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 359..379 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 389..409 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 416..436 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 441..461 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 476..496 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 501..521 FT /note="Helical" FT /evidence="ECO:0000255" FT REGION 543..577 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 551..560 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 57 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 65 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 68 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 108 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 352 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 546 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 558 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..17 FT /note="MGSRHFEGIYDHVGHFG -> MRTLHAVSHPYSNSM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12089149" FT /id="VSP_031336" FT VAR_SEQ 58..89 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12089149" FT /id="VSP_031337" FT VAR_SEQ 509..577 FT /note="FVGTMALLSGVLTLKLPETLGKRLATTWEEAAKLESENESKSSKLLLTTNNS FT GLEKTEAITPRDSGLGE -> LGQHLQE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_031338" FT VARIANT 49 FT /note="H -> R (in dbSNP:rs714368)" FT /id="VAR_038930" FT VARIANT 252 FT /note="V -> A (in dbSNP:rs723685)" FT /id="VAR_038931" FT VARIANT 409 FT /note="M -> T (in dbSNP:rs12210538)" FT /evidence="ECO:0000269|PubMed:12372408, FT ECO:0000269|PubMed:12384147, ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15963465" FT /id="VAR_038932" FT VARIANT 431 FT /note="V -> I (in dbSNP:rs35948062)" FT /id="VAR_038933" FT CONFLICT 257 FT /note="V -> G (in Ref. 1; AAN52928)" FT /evidence="ECO:0000305" SQ SEQUENCE 577 AA; 64614 MW; EA4ABBED0AE99632 CRC64; MGSRHFEGIY DHVGHFGRFQ RVLYFICAFQ NISCGIHYLA SVFMGVTPHH VCRPPGNVSQ VVFHNHSNWS LEDTGALLSS GQKDYVTVQL QNGEIWELSR CSRNKRENTS SLGYEYTGSK KEFPCVDGYI YDQNTWKSTA VTQWNLVCDR KWLAMLIQPL FMFGVLLGSV TFGYFSDRLG RRVVLWATSS SMFLFGIAAA FAVDYYTFMA ARFFLAMVAS GYLVVGFVYV MEFIGMKSRT WASVHLHSFF AVGTLLVALT GYLVRTWWLY QMILSTVTVP FILCCWVLPE TPFWLLSEGR YEEAQKIVDI MAKWNRASSC KLSELLSLDL QGPVSNSPTE VQKHNLSYLF YNWSITKRTL TVWLIWFTGS LGFYSFSLNS VNLGGNEYLN LFLLGVVEIP AYTFVCIAMD KVGRRTVLAY SLFCSALACG VVMVIPQKHY ILGVVTAMVG KFAIGAAFGL IYLYTAELYP TIVRSLAVGS GSMVCRLASI LAPFSVDLSS IWIFIPQLFV GTMALLSGVL TLKLPETLGK RLATTWEEAA KLESENESKS SKLLLTTNNS GLEKTEAITP RDSGLGE // ID SBP1_HUMAN Reviewed; 472 AA. AC Q13228; A6NML9; A6PVW9; B2RDR3; B4DKP6; B4E1F3; Q49AQ8; Q96GX7; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 29-MAY-2007, sequence version 2. DT 28-JAN-2026, entry version 195. DE RecName: Full=Methanethiol oxidase {ECO:0000303|PubMed:29255262}; DE Short=MTO {ECO:0000303|PubMed:29255262}; DE EC=1.8.3.4 {ECO:0000269|PubMed:29255262}; DE AltName: Full=56 kDa selenium-binding protein; DE Short=SBP56; DE Short=SP56; DE AltName: Full=Selenium-binding protein 1; GN Name=SELENBP1; Synonyms=SBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Heart; RX PubMed=9027582; RX DOI=10.1002/(sici)1097-4644(199702)64:2<217::aid-jcb5>3.0.co;2-#; RA Chang P.W.G., Tsui S.K.W., Liew C., Lee C., Waye M.M.Y., Fung K.; RT "Isolation, characterization, and chromosomal mapping of a novel cDNA clone RT encoding human selenium binding protein."; RL J. Cell. Biochem. 64:217-224(1997). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4). RC TISSUE=Colon, Lung, and Synovial cell; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Colon, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP PROTEIN SEQUENCE OF 255-276, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Brain, and Cajal-Retzius cell; RA Lubec G., Vishwanath V.; RL Submitted (MAR-2007) to UniProtKB. RN [8] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=9679983; RA Yang M., Sytkowski A.J.; RT "Differential expression and androgen regulation of the human selenium- RT binding protein gene hSP56 in prostate cancer cells."; RL Cancer Res. 58:3150-3153(1998). RN [9] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14991897; DOI=10.1002/path.1524; RA Chen G., Wang H., Miller C.T., Thomas D.G., Gharib T.G., Misek D.E., RA Giordano T.J., Orringer M.B., Hanash S.M., Beer D.G.; RT "Reduced selenium-binding protein 1 expression is associated with poor RT outcome in lung adenocarcinomas."; RL J. Pathol. 202:321-329(2004). RN [10] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=16223876; DOI=10.1073/pnas.0507666102; RA Glatt S.J., Everall I.P., Kremen W.S., Corbeil J., Sasik R., Khanlou N., RA Han M., Liew C.-C., Tsuang M.T.; RT "Comparative gene expression analysis of blood and brain provides RT concurrent validation of SELENBP1 up-regulation in schizophrenia."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15533-15538(2005). RN [11] RP TISSUE SPECIFICITY, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16380993; DOI=10.1002/ijc.21671; RA Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X., Ng W.-C., Bandera C.A., RA Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.; RT "Selenium binding protein 1 in ovarian cancer."; RL Int. J. Cancer 118:2433-2440(2006). RN [12] RP TISSUE SPECIFICITY, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16645984; DOI=10.1002/pmic.200500629; RA Kim H., Kang H.J., You K.T., Kim S.H., Lee K.Y., Kim T.I., Kim C., RA Song S.Y., Kim H.-J., Lee C., Kim H.; RT "Suppression of human selenium-binding protein 1 is a late event in RT colorectal carcinogenesis and is associated with poor survival."; RL Proteomics 6:3466-3476(2006). RN [13] RP INTERACTION WITH USP33. RX PubMed=19118533; DOI=10.1016/j.bbrc.2008.12.110; RA Jeong J.Y., Wang Y., Sytkowski A.J.; RT "Human selenium binding protein-1 (hSP56) interacts with VDU1 in a RT selenium-dependent manner."; RL Biochem. Biophys. Res. Commun. 379:583-588(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-111 AND SER-371, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, TISSUE SPECIFICITY, INVOLVEMENT IN RP EHMTO, VARIANTS EHMTO TRP-225; TYR-329 AND 347-GLY--ILE-472 DEL, RP CHARACTERIZATION OF VARIANTS EHMTO TRP-225; TYR-329 AND 347-GLY--ILE-472 RP DEL, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=29255262; DOI=10.1038/s41588-017-0006-7; RA Pol A., Renkema G.H., Tangerman A., Winkel E.G., Engelke U.F., RA de Brouwer A.P.M., Lloyd K.C., Araiza R.S., van den Heuvel L., Omran H., RA Olbrich H., Oude Elberink M., Gilissen C., Rodenburg R.J., Sass J.O., RA Schwab K.O., Schaefer H., Venselaar H., Sequeira J.S., Op den Camp H.J.M., RA Wevers R.A.; RT "Mutations in SELENBP1, encoding a novel human methanethiol oxidase, cause RT extraoral halitosis."; RL Nat. Genet. 50:120-129(2018). CC -!- FUNCTION: Catalyzes the oxidation of methanethiol, an organosulfur CC compound known to be produced in substantial amounts by gut bacteria CC (PubMed:29255262). Selenium-binding protein which may be involved in CC the sensing of reactive xenobiotics in the cytoplasm. May be involved CC in intra-Golgi protein transport (By similarity). CC {ECO:0000250|UniProtKB:Q8VIF7, ECO:0000269|PubMed:29255262}. CC -!- CATALYTIC ACTIVITY: CC Reaction=methanethiol + O2 + H2O = hydrogen sulfide + formaldehyde + CC H2O2 + H(+); Xref=Rhea:RHEA:11812, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16007, CC ChEBI:CHEBI:16240, ChEBI:CHEBI:16842, ChEBI:CHEBI:29919; EC=1.8.3.4; CC Evidence={ECO:0000269|PubMed:29255262}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=4.8 nM for methanethiol {ECO:0000269|PubMed:29255262}; CC -!- PATHWAY: Organosulfur degradation. {ECO:0000269|PubMed:29255262}. CC -!- SUBUNIT: Interacts with USP33. {ECO:0000269|PubMed:19118533}. CC -!- INTERACTION: CC Q13228; Q9UJ68: MSRA; NbExp=3; IntAct=EBI-711619, EBI-19157918; CC Q13228; O43422: THAP12; NbExp=3; IntAct=EBI-711619, EBI-2828217; CC Q13228; Q15645: TRIP13; NbExp=6; IntAct=EBI-711619, EBI-358993; CC Q13228; Q8TEY7-2: USP33; NbExp=5; IntAct=EBI-711619, EBI-719307; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14991897}. Cytoplasm, CC cytosol {ECO:0000269|PubMed:14991897, ECO:0000269|PubMed:16223876}. CC Membrane {ECO:0000250|UniProtKB:Q8VIF7}; Peripheral membrane protein CC {ECO:0000250|UniProtKB:Q8VIF7}. Note=May associate with Golgi membrane CC (By similarity). May associate with the membrane of autophagosomes (By CC similarity). {ECO:0000250|UniProtKB:Q8VIF7}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q13228-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13228-2; Sequence=VSP_038440; CC Name=3; CC IsoId=Q13228-3; Sequence=VSP_045425; CC Name=4; CC IsoId=Q13228-4; Sequence=VSP_055126; CC -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in liver, lung, CC colon, prostate, kidney and pancreas. In brain, present both in neurons CC and glia (at protein level). Down-regulated in lung adenocarcinoma, CC colorectal carcinoma and ovarian cancer. Two-fold up-regulated in brain CC and blood from schizophrenia patients. {ECO:0000269|PubMed:14991897, CC ECO:0000269|PubMed:16223876, ECO:0000269|PubMed:16380993, CC ECO:0000269|PubMed:16645984, ECO:0000269|PubMed:29255262, CC ECO:0000269|PubMed:9679983}. CC -!- INDUCTION: Down-regulated by androgen in prostate cancer cells. CC {ECO:0000269|PubMed:9679983}. CC -!- PTM: Phosphorylated. {ECO:0000305|PubMed:14991897}. CC -!- PTM: The N-terminus is blocked. {ECO:0000250}. CC -!- DISEASE: Extraoral halitosis due to methanethiol oxidase deficiency CC (EHMTO) [MIM:618148]: An autosomal recessive malodor condition CC characterized by extraoral blood-borne halitosis resulting from the CC accumulation of sulfur-containing metabolites. In extraoral blood-borne CC halitosis, malodorant compounds are carried to the lungs, where they CC enter the breath. Affected individuals have a cabbage-like breath odor, CC high levels of methanethiol and dimethylsulfide in oral and nasal CC breath, and elevated urinary excretion of dimethylsulfoxide in the CC absence of intake of dimethylsulfide-containing food or use of sulfur- CC containing medication, lower-gastrointestinal problems, and known CC metabolic defects, such as methionine adenosyltransferase deficiency CC and tyrosinemia. {ECO:0000269|PubMed:29255262}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the selenium-binding protein family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U29091; AAB02395.1; -; mRNA. DR EMBL; CR456852; CAG33133.1; -; mRNA. DR EMBL; AK296661; BAG59258.1; -; mRNA. DR EMBL; AK303815; BAG64765.1; -; mRNA. DR EMBL; AK315643; BAG38010.1; -; mRNA. DR EMBL; AL391069; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471121; EAW53443.1; -; Genomic_DNA. DR EMBL; CH471121; EAW53445.1; -; Genomic_DNA. DR EMBL; BC009084; AAH09084.1; -; mRNA. DR EMBL; BC032997; AAH32997.1; -; mRNA. DR CCDS; CCDS58027.1; -. [Q13228-3] DR CCDS; CCDS60266.1; -. [Q13228-4] DR CCDS; CCDS995.1; -. [Q13228-1] DR PIR; G01872; G01872. DR RefSeq; NP_001245217.1; NM_001258288.2. [Q13228-3] DR RefSeq; NP_001245218.1; NM_001258289.2. [Q13228-4] DR RefSeq; NP_003935.2; NM_003944.3. [Q13228-1] DR AlphaFoldDB; Q13228; -. DR SMR; Q13228; -. DR BioGRID; 114472; 214. DR CORUM; Q13228; -. DR FunCoup; Q13228; 548. DR IntAct; Q13228; 108. DR MINT; Q13228; -. DR STRING; 9606.ENSP00000397261; -. DR GlyGen; Q13228; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13228; -. DR PhosphoSitePlus; Q13228; -. DR SwissPalm; Q13228; -. DR BioMuta; SELENBP1; -. DR DMDM; 148840437; -. DR REPRODUCTION-2DPAGE; IPI00012303; -. DR REPRODUCTION-2DPAGE; Q13228; -. DR jPOST; Q13228; -. DR MassIVE; Q13228; -. DR PaxDb; 9606-ENSP00000397261; -. DR PeptideAtlas; Q13228; -. DR ProteomicsDB; 1722; -. DR ProteomicsDB; 5753; -. DR ProteomicsDB; 59234; -. [Q13228-1] DR ProteomicsDB; 59235; -. [Q13228-2] DR Pumba; Q13228; -. DR Antibodypedia; 1584; 393 antibodies from 30 providers. DR DNASU; 8991; -. DR Ensembl; ENST00000368868.10; ENSP00000357861.5; ENSG00000143416.22. [Q13228-1] DR Ensembl; ENST00000426705.6; ENSP00000397261.2; ENSG00000143416.22. [Q13228-4] DR Ensembl; ENST00000447402.7; ENSP00000413960.3; ENSG00000143416.22. [Q13228-3] DR GeneID; 8991; -. DR KEGG; hsa:8991; -. DR MANE-Select; ENST00000368868.10; ENSP00000357861.5; NM_003944.4; NP_003935.2. DR UCSC; uc010pcy.4; human. [Q13228-1] DR AGR; HGNC:10719; -. DR ClinPGx; PA35641; -. DR CTD; 8991; -. DR DisGeNET; 8991; -. DR GeneCards; SELENBP1; -. DR HGNC; HGNC:10719; SELENBP1. DR HPA; ENSG00000143416; Tissue enhanced (intestine). DR MalaCards; SELENBP1; -. DR MIM; 604188; gene. DR MIM; 618148; phenotype. DR OpenTargets; ENSG00000143416; -. DR Orphanet; 562538; Autosomal recessive extra-oral halitosis. DR VEuPathDB; HostDB:ENSG00000143416; -. DR eggNOG; KOG0918; Eukaryota. DR GeneTree; ENSGT00390000014244; -. DR HOGENOM; CLU_032512_0_0_1; -. DR InParanoid; Q13228; -. DR OMA; AYDFWWH; -. DR OrthoDB; 10252446at2759; -. DR PAN-GO; Q13228; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q13228; -. DR PathwayCommons; Q13228; -. DR SABIO-RK; Q13228; -. DR SignaLink; Q13228; -. DR Agora; ENSG00000143416; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 8991; 20 hits in 1164 CRISPR screens. DR ChiTaRS; SELENBP1; human. DR GeneWiki; SELENBP1; -. DR GenomeRNAi; 8991; -. DR Pharos; Q13228; Tbio. DR PRO; PR:Q13228; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q13228; protein. DR Bgee; ENSG00000143416; Expressed in mucosa of transverse colon and 202 other cell types or tissues. DR ExpressionAtlas; Q13228; baseline and differential. DR GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0018549; F:methanethiol oxidase activity; IMP:FlyBase. DR GO; GO:0008430; F:selenium binding; TAS:ProtInc. DR GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW. DR InterPro; IPR008826; Se-bd. DR PANTHER; PTHR23300; METHANETHIOL OXIDASE; 1. DR PANTHER; PTHR23300:SF0; METHANETHIOL OXIDASE; 1. DR Pfam; PF05694; SBP56; 1. DR SUPFAM; SSF75011; 3-carboxy-cis,cis-mucoante lactonizing enzyme; 1. PE 1: Evidence at protein level; KW Acetylation; Alternative splicing; Cytoplasm; Direct protein sequencing; KW Disease variant; Membrane; Nucleus; Oxidoreductase; Phosphoprotein; KW Protein transport; Proteomics identification; Reference proteome; Selenium; KW Transport. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..472 FT /note="Methanethiol oxidase" FT /id="PRO_0000174633" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 111 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 467 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P17563" FT VAR_SEQ 1..64 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_038440" FT VAR_SEQ 1 FT /note="M -> MRLEWGPRPAALPWPAGMCAAERAEGAFTLQSVAQPMRPIAST (in FT isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055126" FT VAR_SEQ 59..120 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045425" FT VARIANT 225 FT /note="G -> W (in EHMTO; loss of methanethiol oxidation in FT patient cells; dbSNP:rs758495626)" FT /evidence="ECO:0000269|PubMed:29255262" FT /id="VAR_080207" FT VARIANT 329 FT /note="H -> Y (in EHMTO; loss of methanethiol oxidation in FT patient cells; dbSNP:rs1553204840)" FT /evidence="ECO:0000269|PubMed:29255262" FT /id="VAR_080208" FT VARIANT 347..472 FT /note="Missing (in EHMTO; loss of methanethiol oxidation in FT patient cells)" FT /evidence="ECO:0000269|PubMed:29255262" FT /id="VAR_080209" FT CONFLICT 80 FT /note="C -> Y (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 92 FT /note="T -> N (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 114..116 FT /note="RAP -> GPQ (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 135 FT /note="F -> C (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 260..262 FT /note="DAA -> SAT (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 270..273 FT /note="LSST -> SAPN (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 278 FT /note="Y -> C (in Ref. 3; BAG59258)" FT /evidence="ECO:0000305" FT CONFLICT 280..282 FT /note="NEG -> TRE (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 305..306 FT /note="EM -> GV (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 410 FT /note="D -> E (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 442 FT /note="F -> C (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" SQ SEQUENCE 472 AA; 52391 MW; 6DC68F9B45FEC1BC CRC64; MATKCGNCGP GYSTPLEAMK GPREEIVYLP CIYRNTGTEA PDYLATVDVD PKSPQYCQVI HRLPMPNLKD ELHHSGWNTC SSCFGDSTKS RTKLVLPSLI SSRIYVVDVG SEPRAPKLHK VIEPKDIHAK CELAFLHTSH CLASGEVMIS SLGDVKGNGK GGFVLLDGET FEVKGTWERP GGAAPLGYDF WYQPRHNVMI STEWAAPNVL RDGFNPADVE AGLYGSHLYV WDWQRHEIVQ TLSLKDGLIP LEIRFLHNPD AAQGFVGCAL SSTIQRFYKN EGGTWSVEKV IQVPPKKVKG WLLPEMPGLI TDILLSLDDR FLYFSNWLHG DLRQYDISDP QRPRLTGQLF LGGSIVKGGP VQVLEDEELK SQPEPLVVKG KRVAGGPQMI QLSLDGKRLY ITTSLYSAWD KQFYPDLIRE GSVMLQVDVD TVKGGLKLNP NFLVDFGKEP LGPALAHELR YPGGDCSSDI WI // ID SLK_HUMAN Reviewed; 1235 AA. AC Q9H2G2; D3DRA0; D3DRA1; O00211; Q6P1Z4; Q86WU7; Q86WW1; Q92603; Q9NQL0; AC Q9NQL1; DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2001, sequence version 1. DT 28-JAN-2026, entry version 206. DE RecName: Full=STE20-like serine/threonine-protein kinase; DE Short=STE20-like kinase; DE Short=hSLK; DE EC=2.7.11.1; DE AltName: Full=CTCL tumor antigen se20-9; DE AltName: Full=STE20-related serine/threonine-protein kinase; DE Short=STE20-related kinase; DE AltName: Full=Serine/threonine-protein kinase 2; GN Name=SLK; Synonyms=KIAA0204, STK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, RP PHOSPHORYLATION, AND MUTAGENESIS OF LYS-63. RC TISSUE=Lung carcinoma; RX PubMed=10699464; DOI=10.1016/s0167-4889(99)00164-0; RA Yamada E., Tsujikawa K., Itoh S., Kameda Y., Kohama Y., Yamamoto H.; RT "Molecular cloning and characterization of a novel human STE20-like kinase, RT hSLK."; RL Biochim. Biophys. Acta 1495:250-262(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=11149944; DOI=10.1073/pnas.98.2.629; RA Eichmueller S., Usener D., Dummer R., Stein A., Thiel D., Schadendorf D.; RT "Serological detection of cutaneous T-cell lymphoma-associated antigens."; RL Proc. Natl. Acad. Sci. U.S.A. 98:629-634(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Bone marrow; RX PubMed=9039502; DOI=10.1093/dnares/3.5.321; RA Nagase T., Seki N., Ishikawa K., Ohira M., Kawarabayasi Y., Ohara O., RA Tanaka A., Kotani H., Miyajima N., Nomura N.; RT "Prediction of the coding sequences of unidentified human genes. VI. The RT coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of RT cDNA clones from cell line KG-1 and brain."; RL DNA Res. 3:321-329(1996). RN [4] RP SEQUENCE REVISION. RA Ohara O., Nagase T., Kikuno R., Nomura N.; RL Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Testis, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-330; SER-565 AND RP SER-655, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-347; SER-348; RP SER-571; SER-777; SER-779 AND SER-818, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-344 AND SER-565, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-779, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-571; SER-779 AND RP THR-1097, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-347; SER-348; SER-565 RP AND SER-571, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-189; SER-341; RP SER-518; SER-565; SER-571; SER-779; THR-814 AND SER-818, AND IDENTIFICATION RP BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-372; SER-518; SER-565; RP THR-569 AND SER-571, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-405; TYR-552; GLN-604; GLY-658; RP THR-679; ASN-683 AND ILE-697. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [18] RP VARIANT 472-GLU--SER-1235 DEL. RX PubMed=28940097; DOI=10.1007/s00439-017-1843-2; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Expanding the genetic heterogeneity of intellectual disability."; RL Hum. Genet. 136:1419-1429(2017). RN [19] RP ERRATUM OF PUBMED:28940097. RX PubMed=29288388; DOI=10.1007/s00439-017-1859-7; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Correction to: Expanding the genetic heterogeneity of intellectual RT disability."; RL Hum. Genet. 137:105-109(2018). CC -!- FUNCTION: Mediates apoptosis and actin stress fiber dissolution. CC {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- INTERACTION: CC Q9H2G2; Q9H2G2: SLK; NbExp=3; IntAct=EBI-1022272, EBI-1022272; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9H2G2-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9H2G2-2; Sequence=VSP_018100; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Highest expression is found CC in heart and in skeletal muscle. {ECO:0000269|PubMed:10699464}. CC -!- PTM: Proteolytically cleaved by caspase-3. CC -!- PTM: Autophosphorylated. {ECO:0000269|PubMed:10699464}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH47762.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 611.; Evidence={ECO:0000305}; CC Sequence=AAH47885.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 422.; Evidence={ECO:0000305}; CC Sequence=AAH64804.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 614.; Evidence={ECO:0000305}; CC Sequence=BAA13195.2; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB002804; BAA19655.1; -; mRNA. DR EMBL; AF273048; AAG34908.1; -; mRNA. DR EMBL; D86959; BAA13195.2; ALT_SEQ; mRNA. DR EMBL; AL360170; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL138761; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471066; EAW49615.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49616.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49617.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49618.1; -; Genomic_DNA. DR EMBL; BC047762; AAH47762.1; ALT_SEQ; mRNA. DR EMBL; BC047885; AAH47885.1; ALT_SEQ; mRNA. DR EMBL; BC064804; AAH64804.1; ALT_SEQ; mRNA. DR EMBL; BC111565; AAI11566.1; -; mRNA. DR CCDS; CCDS7553.1; -. [Q9H2G2-1] DR CCDS; CCDS76334.1; -. [Q9H2G2-2] DR RefSeq; NP_001291672.1; NM_001304743.2. [Q9H2G2-2] DR RefSeq; NP_055535.2; NM_014720.3. [Q9H2G2-1] DR PDB; 2J51; X-ray; 2.10 A; A=19-320. DR PDB; 2JFL; X-ray; 2.20 A; A=19-320. DR PDB; 2JFM; X-ray; 2.85 A; A=19-320. DR PDB; 2UV2; X-ray; 2.30 A; A=19-320. DR PDB; 4USF; X-ray; 1.75 A; A/B=19-320. DR PDB; 6HVD; X-ray; 1.63 A; A=19-320. DR PDB; 8BEM; X-ray; 2.60 A; A/B/D/G=19-319. DR PDBsum; 2J51; -. DR PDBsum; 2JFL; -. DR PDBsum; 2JFM; -. DR PDBsum; 2UV2; -. DR PDBsum; 4USF; -. DR PDBsum; 6HVD; -. DR PDBsum; 8BEM; -. DR AlphaFoldDB; Q9H2G2; -. DR PCDDB; Q9H2G2; -. DR SMR; Q9H2G2; -. DR BioGRID; 115096; 194. DR FunCoup; Q9H2G2; 2503. DR IntAct; Q9H2G2; 85. DR MINT; Q9H2G2; -. DR STRING; 9606.ENSP00000358770; -. DR BindingDB; Q9H2G2; -. DR ChEMBL; CHEMBL4202; -. DR DrugBank; DB07853; 2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile. DR DrugBank; DB06616; Bosutinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07664; K-00546. DR DrugCentral; Q9H2G2; -. DR GuidetoPHARMACOLOGY; 2200; -. DR GlyGen; Q9H2G2; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9H2G2; -. DR MetOSite; Q9H2G2; -. DR PhosphoSitePlus; Q9H2G2; -. DR SwissPalm; Q9H2G2; -. DR BioMuta; SLK; -. DR DMDM; 74762732; -. DR CPTAC; CPTAC-2845; -. DR CPTAC; CPTAC-2948; -. DR jPOST; Q9H2G2; -. DR MassIVE; Q9H2G2; -. DR PaxDb; 9606-ENSP00000358770; -. DR PeptideAtlas; Q9H2G2; -. DR ProteomicsDB; 80544; -. [Q9H2G2-1] DR ProteomicsDB; 80545; -. [Q9H2G2-2] DR Pumba; Q9H2G2; -. DR Antibodypedia; 18194; 291 antibodies from 34 providers. DR DNASU; 9748; -. DR Ensembl; ENST00000335753.8; ENSP00000336824.4; ENSG00000065613.16. [Q9H2G2-2] DR Ensembl; ENST00000369755.4; ENSP00000358770.3; ENSG00000065613.16. [Q9H2G2-1] DR GeneID; 9748; -. DR KEGG; hsa:9748; -. DR MANE-Select; ENST00000369755.4; ENSP00000358770.3; NM_014720.4; NP_055535.2. DR UCSC; uc001kxo.2; human. [Q9H2G2-1] DR AGR; HGNC:11088; -. DR ClinPGx; PA35941; -. DR CTD; 9748; -. DR DisGeNET; 9748; -. DR GeneCards; SLK; -. DR HGNC; HGNC:11088; SLK. DR HPA; ENSG00000065613; Low tissue specificity. DR MalaCards; SLK; -. DR MIM; 616563; gene. DR OpenTargets; ENSG00000065613; -. DR VEuPathDB; HostDB:ENSG00000065613; -. DR eggNOG; KOG0579; Eukaryota. DR GeneTree; ENSGT00940000156184; -. DR HOGENOM; CLU_001965_3_0_1; -. DR InParanoid; Q9H2G2; -. DR OMA; DESCADS; -. DR OrthoDB; 10027016at2759; -. DR PAN-GO; Q9H2G2; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9H2G2; -. DR PathwayCommons; Q9H2G2; -. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013106; RHOC GTPase cycle. DR SignaLink; Q9H2G2; -. DR SIGNOR; Q9H2G2; -. DR Agora; ENSG00000065613; -. DR BioGRID-ORCS; 9748; 24 hits in 1189 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; SLK; human. DR EvolutionaryTrace; Q9H2G2; -. DR GeneWiki; SLK_(gene); -. DR GenomeRNAi; 9748; -. DR Pharos; Q9H2G2; Tchem. DR PRO; PR:Q9H2G2; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q9H2G2; protein. DR Bgee; ENSG00000065613; Expressed in esophagus squamous epithelium and 213 other cell types or tissues. DR ExpressionAtlas; Q9H2G2; baseline and differential. DR GO; GO:0031252; C:cell leading edge; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0031122; P:cytoplasmic microtubule organization; IMP:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB. DR CDD; cd06643; STKc_SLK; 1. DR FunFam; 1.10.510.10:FF:000081; STE20-like serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000120; STE20-like serine/threonine-protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR022165; PKK. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051585; STE20_Ser/Thr_Kinases. DR InterPro; IPR001943; UVR_dom. DR PANTHER; PTHR46538:SF1; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR PANTHER; PTHR46538; PROTEIN KINASE DOMAIN-CONTAINING PROTEIN; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF12474; PKK; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50151; UVR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Coiled coil; KW Cytoplasm; Kinase; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1235 FT /note="STE20-like serine/threonine-protein kinase" FT /id="PRO_0000233239" FT DOMAIN 34..292 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 875..910 FT /note="UVR" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00217" FT REGION 309..351 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 363..393 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 421..441 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 519..539 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 613..760 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 826..1069 FT /evidence="ECO:0000255" FT COILED 1109..1183 FT /evidence="ECO:0000255" FT COMPBIAS 312..328 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 421..432 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 522..539 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 638..650 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 679..695 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 749..760 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 155 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 40..48 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 438..439 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000250" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 183 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 189 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 330 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 340 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08815" FT MOD_RES 341 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 344 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 347 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 348 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 354 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 372 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 518 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 565 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 569 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 571 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 647 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 655 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 667 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 777 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 779 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 814 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 818 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1097 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT VAR_SEQ 929..959 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10699464, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9039502" FT /id="VSP_018100" FT VARIANT 405 FT /note="Q -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041080" FT VARIANT 472..1235 FT /note="Missing (found in a patient with global FT developmental delay; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28940097" FT /id="VAR_084656" FT VARIANT 552 FT /note="C -> Y (in dbSNP:rs805657)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041081" FT VARIANT 604 FT /note="E -> Q (in an ovarian serous carcinoma sample; FT somatic mutation; dbSNP:rs190220654)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041082" FT VARIANT 658 FT /note="A -> G (in dbSNP:rs56400929)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041083" FT VARIANT 666 FT /note="G -> E (in dbSNP:rs7071400)" FT /id="VAR_051666" FT VARIANT 679 FT /note="I -> T (in dbSNP:rs34326537)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041084" FT VARIANT 683 FT /note="K -> N (in dbSNP:rs35389916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041085" FT VARIANT 697 FT /note="T -> I (in dbSNP:rs3740469)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041086" FT MUTAGEN 63 FT /note="K->R: Loss of activity." FT /evidence="ECO:0000269|PubMed:10699464" FT CONFLICT 5 FT /note="N -> S (in Ref. 3; BAA13195)" FT /evidence="ECO:0000305" FT STRAND 25..28 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 34..41 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 48..53 FT /evidence="ECO:0007829|PDB:6HVD" FT TURN 54..56 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 59..66 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 70..85 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 94..100 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 103..109 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 116..123 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 129..148 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 158..160 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 169..171 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 181..187 FT /evidence="ECO:0007829|PDB:2J51" FT HELIX 199..202 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 207..209 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 212..214 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 215..230 FT /evidence="ECO:0007829|PDB:6HVD" FT TURN 234..237 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 240..249 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 258..260 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 263..272 FT /evidence="ECO:0007829|PDB:6HVD" FT TURN 277..279 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 283..286 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 290..292 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 298..308 FT /evidence="ECO:0007829|PDB:6HVD" SQ SEQUENCE 1235 AA; 142695 MW; 53A43E7CA29B0ED3 CRC64; MSFFNFRKIF KLGSEKKKKQ YEHVKRDLNP EDFWEIIGEL GDGAFGKVYK AQNKETSVLA AAKVIDTKSE EELEDYMVEI DILASCDHPN IVKLLDAFYY ENNLWILIEF CAGGAVDAVM LELERPLTES QIQVVCKQTL DALNYLHDNK IIHRDLKAGN ILFTLDGDIK LADFGVSAKN TRTIQRRDSF IGTPYWMAPE VVMCETSKDR PYDYKADVWS LGITLIEMAE IEPPHHELNP MRVLLKIAKS EPPTLAQPSR WSSNFKDFLK KCLEKNVDAR WTTSQLLQHP FVTVDSNKPI RELIAEAKAE VTEEVEDGKE EDEEEETENS LPIPASKRAS SDLSIASSEE DKLSQNACIL ESVSEKTERS NSEDKLNSKI LNEKPTTDEP EKAVEDINEH ITDAQLEAMT ELHDRTAVIK ENEREKRPKL ENLPDTEDQE TVDINSVSEG KENNIMITLE TNIEHNLKSE EEKDQEKQQM FENKLIKSEE IKDTILQTVD LVSQETGEKE ANIQAVDSEV GLTKEDTQEK LGEDDKTQKD VISNTSDVIG TCEAADVAQK VDEDSAEDTQ SNDGKEVVEV GQKLINKPMV GPEAGGTKEV PIKEIVEMNE IEEGKNKEQA INSSENIMDI NEEPGTTEGE EITESSSTEE MEVRSVVADT DQKALGSEVQ DASKVTTQID KEKKEIPVSI KKEPEVTVVS QPTEPQPVLI PSININSDSG ENKEEIGSLS KTETILPPES ENPKENDNDS GTGSTADTSS IDLNLSISSF LSKTKDSGSI SLQETRRQKK TLKKTRKFIV DGVEVSVTTS KIVTDSDSKT EELRFLRRQE LRELRFLQKE EQRAQQQLNS KLQQQREQIF RRFEQEMMSK KRQYDQEIEN LEKQQKQTIE RLEQEHTNRL RDEAKRIKGE QEKELSKFQN MLKNRKKEVI NEVEKAPKEL RKELMKRRKE ELAQSQHAQE QEFVQKQQQE LDGSLKKIIQ QQKAELANIE RECLNNKQQL MRAREAAIWE LEERHLQEKH QLLKQQLKDQ YFMQRHQLLK RHEKETEQMQ RYNQRLIEEL KNRQTQERAR LPKIQRSEAK TRMAMFKKSL RINSTATPDQ DRDKIKQFAA QEEKRQKNER MAQHQKHENQ MRDLQLQCEA NVRELHQLQN EKCHLLVEHE TQKLKELDEE HSQELKEWRE KLRPRKKTLE EEFARKLQEQ EVFFKMTGES ECLNPSTQSR ISKFYPIPSL HSTGS // ID SLN11_HUMAN Reviewed; 901 AA. AC Q7Z7L1; E1P643; Q8N3S8; Q8N762; Q8TEE0; DT 03-APR-2007, integrated into UniProtKB/Swiss-Prot. DT 30-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 167. DE RecName: Full=Schlafen family member 11 {ECO:0000305}; DE EC=3.1.-.- {ECO:0000269|PubMed:29395061, ECO:0000269|PubMed:36115853}; GN Name=SLFN11 {ECO:0000312|HGNC:HGNC:26633}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS PHE-121 AND ASP-301. RC TISSUE=Spleen; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-301. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-301. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-301. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP INDUCTION. RX PubMed=20956525; DOI=10.1074/jbc.m110.151076; RA Katsoulidis E., Mavrommatis E., Woodard J., Shields M.A., Sassano A., RA Carayol N., Sawicki K.T., Munshi H.G., Platanias L.C.; RT "Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation RT of anchorage-independent growth and invasion of malignant melanoma cells."; RL J. Biol. Chem. 285:40333-40341(2010). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [8] RP FUNCTION, TRNA-BINDING, AND INDUCTION. RX PubMed=23000900; DOI=10.1038/nature11433; RA Li M., Kao E., Gao X., Sandig H., Limmer K., Pavon-Eternod M., Jones T.E., RA Landry S., Pan T., Weitzman M.D., David M.; RT "Codon-usage-based inhibition of HIV protein synthesis by human schlafen RT 11."; RL Nature 491:125-128(2012). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=22927417; DOI=10.1073/pnas.1205943109; RA Zoppoli G., Regairaz M., Leo E., Reinhold W.C., Varma S., Ballestrero A., RA Doroshow J.H., Pommier Y.; RT "Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to RT DNA-damaging agents."; RL Proc. Natl. Acad. Sci. U.S.A. 109:15030-15035(2012). RN [10] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RPA1, AND MUTAGENESIS OF RP LYS-605 AND ASP-668. RX PubMed=26658330; DOI=10.15252/embr.201540964; RA Mu Y., Lou J., Srivastava M., Zhao B., Feng X.H., Liu T., Chen J., RA Huang J.; RT "SLFN11 inhibits checkpoint maintenance and homologous recombination RT repair."; RL EMBO Rep. 17:94-109(2016). RN [11] RP INDUCTION, AND INTERACTION WITH DHX9. RX PubMed=26625211; DOI=10.18632/oncotarget.6413; RA Nogales V., Reinhold W.C., Varma S., Martinez-Cardus A., Moutinho C., RA Moran S., Heyn H., Sebio A., Barnadas A., Pommier Y., Esteller M.; RT "Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human RT cancer confers resistance to platinum drugs."; RL Oncotarget 7:3084-3097(2016). RN [12] RP INDUCTION. RX PubMed=28196596; DOI=10.1016/j.ccell.2017.01.006; RA Gardner E.E., Lok B.H., Schneeberger V.E., Desmeules P., Miles L.A., RA Arnold P.K., Ni A., Khodos I., de Stanchina E., Nguyen T., Sage J., RA Campbell J.E., Ribich S., Rekhtman N., Dowlati A., Massion P.P., RA Rudin C.M., Poirier J.T.; RT "Chemosensitive relapse in small cell lung cancer proceeds through an EZH2- RT SLFN11 axis."; RL Cancer Cell 31:286-299(2017). RN [13] RP INDUCTION. RX PubMed=27440269; DOI=10.1158/1078-0432.ccr-16-1040; RA Lok B.H., Gardner E.E., Schneeberger V.E., Ni A., Desmeules P., RA Rekhtman N., de Stanchina E., Teicher B.A., Riaz N., Powell S.N., RA Poirier J.T., Rudin C.M.; RT "PARP inhibitor activity correlates with SLFN11 expression and demonstrates RT synergy with temozolomide in small cell lung cancer."; RL Clin. Cancer Res. 23:523-535(2017). RN [14] RP INDUCTION. RX PubMed=28212573; DOI=10.18632/oncotarget.15338; RA Allison Stewart C., Tong P., Cardnell R.J., Sen T., Li L., Gay C.M., RA Masrorpour F., Fan Y., Bara R.O., Feng Y., Ru Y., Fujimoto J., Kundu S.T., RA Post L.E., Yu K., Shen Y., Glisson B.S., Wistuba I., Heymach J.V., RA Gibbons D.L., Wang J., Byers L.A.; RT "Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and RT SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung RT cancer."; RL Oncotarget 8:28575-28587(2017). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RPA1; MCM3 AND DHX9, AND RP MUTAGENESIS OF GLU-669. RX PubMed=29395061; DOI=10.1016/j.molcel.2018.01.012; RA Murai J., Tang S.W., Leo E., Baechler S.A., Redon C.E., Zhang H., RA Al Abo M., Rajapakse V.N., Nakamura E., Jenkins L.M.M., Aladjem M.I., RA Pommier Y.; RT "SLFN11 blocks stressed replication forks independently of ATR."; RL Mol. Cell 69:371-384(2018). RN [16] RP FUNCTION. RX PubMed=30374083; DOI=10.1038/s41594-018-0142-5; RA Li M., Kao E., Malone D., Gao X., Wang J.Y.J., David M.; RT "DNA damage-induced cell death relies on SLFN11-dependent cleavage of RT distinct type II tRNAs."; RL Nat. Struct. Mol. Biol. 25:1047-1058(2018). RN [17] {ECO:0007744|PDB:7ZEL, ECO:0007744|PDB:7ZEP, ECO:0007744|PDB:7ZES} RP STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS) IN COMPLEX WITH DNA AND RP TRNA, FUNCTION, SUBUNIT, DOMAIN, ACTIVE SITE, CATALYTIC ACTIVITY, RP MUTAGENESIS OF E209A, E214A; K216A; Y234A; D252A AND SER-753, DNA-BINDING, RP AND COFACTOR. RX PubMed=36115853; DOI=10.1038/s41467-022-33123-0; RA Metzner F.J., Wenzl S.J., Kugler M., Krebs S., Hopfner K.P., Lammens K.; RT "Mechanistic understanding of human SLFN11."; RL Nat. Commun. 13:5464-5464(2022). RN [18] RP FUNCTION. RX PubMed=35105802; DOI=10.1073/pnas.2108173119; RA Nightingale K., Potts M., Hunter L.M., Fielding C.A., Zerbe C.M., RA Fletcher-Etherington A., Nobre L., Wang E.C.Y., Strang B.L., Houghton J.W., RA Antrobus R., Suarez N.M., Nichols J., Davison A.J., Stanton R.J., RA Weekes M.P.; RT "Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via RT recruitment of the CRL4 E3 ubiquitin ligase complex."; RL Proc. Natl. Acad. Sci. U.S.A. 119:0-0(2022). CC -!- FUNCTION: Inhibitor of DNA replication that promotes cell death in CC response to DNA damage (PubMed:22927417, PubMed:26658330, CC PubMed:29395061). Acts as a guardian of the genome by killing cells CC with defective replication (PubMed:29395061). Persistently blocks CC stressed replication forks by opening chromatin across replication CC initiation sites at stressed replication forks, possibly leading to CC unwind DNA ahead of the MCM helicase and block fork progression, CC ultimately leading to cell death (PubMed:29395061). Upon DNA damage, CC inhibits translation of ATR or ATM based on distinct codon usage CC without disrupting early DNA damage response signaling CC (PubMed:30374083). Antiviral restriction factor with manganese- CC dependent type II tRNA endoribonuclease (PubMed:36115853). A single CC tRNA molecule is bound and cleaved by the SLFN11 dimer CC (PubMed:36115853). Specifically abrogates the production of CC retroviruses such as human immunodeficiency virus 1 (HIV-1) by acting CC as a specific inhibitor of the synthesis of retroviruses encoded CC proteins in a codon-usage-dependent manner (PubMed:23000900). Impairs CC the replication of human cytomegalovirus (HCMV) and some Flaviviruses CC (PubMed:35105802, PubMed:36115853). Exploits the unique viral codon CC bias towards A/T nucleotides (PubMed:23000900). Also acts as an CC interferon (IFN)-induced antiviral protein which acts as an inhibitor CC of retrovirus protein synthesis (PubMed:23000900). CC {ECO:0000269|PubMed:22927417, ECO:0000269|PubMed:23000900, CC ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061, CC ECO:0000269|PubMed:30374083, ECO:0000269|PubMed:35105802, CC ECO:0000269|PubMed:36115853}. CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:36115853}; CC -!- SUBUNIT: Homodimer (PubMed:36115853). Interacts with MCM3 CC (PubMed:29395061). Interacts with DHX9 (PubMed:26625211, CC PubMed:29395061). Interacts with RPA1 (PubMed:26658330, CC PubMed:29395061). {ECO:0000269|PubMed:26625211, CC ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061, CC ECO:0000269|PubMed:36115853}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:22927417, CC ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061}. Chromosome CC {ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061}. CC Note=Recruited to stressed replication forks carrying extended RPA CC filaments (PubMed:29395061). Recruited to DNA damage sites via CC interaction with RPA1 (PubMed:26658330, PubMed:29395061). CC {ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061}. CC -!- TISSUE SPECIFICITY: Exhibits a wider expression range in ovarian and CC colon adenocarcinoma than in their corresponding healthy tissues. CC {ECO:0000269|PubMed:22927417}. CC -!- INDUCTION: Down-regulated in small cell lung cancer (SCLC) cells CC resistant to PARP inhibitor drugs (PubMed:26625211, PubMed:27440269, CC PubMed:28196596, PubMed:28212573). Up-regulated by type I interferons, CC poly-IC and poly-dAdT (PubMed:20956525, PubMed:23000900). CC {ECO:0000269|PubMed:20956525, ECO:0000269|PubMed:23000900, CC ECO:0000269|PubMed:26625211, ECO:0000269|PubMed:27440269, CC ECO:0000269|PubMed:28196596, ECO:0000269|PubMed:28212573}. CC -!- DOMAIN: The N-terminus contains an endonuclease domain. The C-terminus CC displays homology to superfamily I DNA/RNA helicases, although it is in CC an autoinhibited conformation. {ECO:0000269|PubMed:36115853}. CC -!- MISCELLANEOUS: Dominant determinant of sensitivity to DNA-damaging CC anticancer drugs: acts by mediating cell death in response to DNA CC damage induced by anticancer drugs (PubMed:29395061). Down-regulated in CC a number of chemoresistant tumors (PubMed:26625211, PubMed:27440269, CC PubMed:28196596, PubMed:28212573). {ECO:0000269|PubMed:26625211, CC ECO:0000269|PubMed:27440269, ECO:0000269|PubMed:28196596, CC ECO:0000269|PubMed:28212573, ECO:0000269|PubMed:29395061}. CC -!- SIMILARITY: Belongs to the Schlafen family. Subgroup III subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB85010.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK074184; BAB85010.1; ALT_FRAME; mRNA. DR EMBL; AK092241; BAC03835.1; -; mRNA. DR EMBL; AL831964; CAD38606.2; -; mRNA. DR EMBL; AC060766; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471147; EAW80156.1; -; Genomic_DNA. DR EMBL; CH471147; EAW80157.1; -; Genomic_DNA. DR EMBL; CH471147; EAW80158.1; -; Genomic_DNA. DR EMBL; BC052586; AAH52586.1; -; mRNA. DR CCDS; CCDS11294.1; -. DR RefSeq; NP_001098057.1; NM_001104587.2. DR RefSeq; NP_001098058.1; NM_001104588.2. DR RefSeq; NP_001098059.1; NM_001104589.2. DR RefSeq; NP_001098060.1; NM_001104590.2. DR RefSeq; NP_001362936.1; NM_001376007.1. DR RefSeq; NP_001362937.1; NM_001376008.1. DR RefSeq; NP_001362938.1; NM_001376009.1. DR RefSeq; NP_001362939.1; NM_001376010.1. DR RefSeq; NP_001362940.1; NM_001376011.1. DR RefSeq; NP_001374087.1; NM_001387158.1. DR RefSeq; NP_001374088.1; NM_001387159.1. DR RefSeq; NP_001374089.1; NM_001387160.1. DR RefSeq; NP_001374090.1; NM_001387161.1. DR RefSeq; NP_001374091.1; NM_001387162.1. DR RefSeq; NP_001374092.1; NM_001387163.1. DR RefSeq; NP_689483.3; NM_152270.3. DR RefSeq; XP_047292998.1; XM_047437042.1. DR PDB; 7ZEL; EM; 2.80 A; A/B=1-901. DR PDB; 7ZEP; EM; 3.20 A; A/B=1-901. DR PDB; 7ZES; EM; 3.10 A; A/B=1-901. DR PDB; 9ERD; EM; 3.72 A; A=1-901. DR PDB; 9ERE; EM; 2.82 A; A/B=1-901. DR PDB; 9ERF; EM; 2.64 A; A/B=1-901. DR PDB; 9GMW; EM; 3.00 A; A/B=1-901. DR PDB; 9GMX; EM; 2.82 A; A/B=1-901. DR PDBsum; 7ZEL; -. DR PDBsum; 7ZEP; -. DR PDBsum; 7ZES; -. DR PDBsum; 9ERD; -. DR PDBsum; 9ERE; -. DR PDBsum; 9ERF; -. DR PDBsum; 9GMW; -. DR PDBsum; 9GMX; -. DR AlphaFoldDB; Q7Z7L1; -. DR EMDB; EMD-14690; -. DR EMDB; EMD-14691; -. DR EMDB; EMD-14692; -. DR EMDB; EMD-19912; -. DR EMDB; EMD-19913; -. DR EMDB; EMD-19914; -. DR EMDB; EMD-51456; -. DR EMDB; EMD-51457; -. DR SMR; Q7Z7L1; -. DR BioGRID; 124851; 380. DR FunCoup; Q7Z7L1; 1154. DR IntAct; Q7Z7L1; 18. DR MINT; Q7Z7L1; -. DR STRING; 9606.ENSP00000378067; -. DR iPTMnet; Q7Z7L1; -. DR PhosphoSitePlus; Q7Z7L1; -. DR SwissPalm; Q7Z7L1; -. DR BioMuta; SLFN11; -. DR DMDM; 313104011; -. DR jPOST; Q7Z7L1; -. DR MassIVE; Q7Z7L1; -. DR PaxDb; 9606-ENSP00000378067; -. DR PeptideAtlas; Q7Z7L1; -. DR ProteomicsDB; 69561; -. DR Pumba; Q7Z7L1; -. DR Antibodypedia; 15596; 58 antibodies from 17 providers. DR DNASU; 91607; -. DR Ensembl; ENST00000308377.8; ENSP00000312402.4; ENSG00000172716.18. DR Ensembl; ENST00000394566.5; ENSP00000378067.1; ENSG00000172716.18. DR Ensembl; ENST00000685675.1; ENSP00000510787.1; ENSG00000172716.18. DR GeneID; 91607; -. DR KEGG; hsa:91607; -. DR MANE-Select; ENST00000685675.1; ENSP00000510787.1; NM_001376007.1; NP_001362936.1. DR UCSC; uc002hjg.5; human. DR AGR; HGNC:26633; -. DR CIViC; 91607; 3 evidence items across 1 molecular profile. DR ClinPGx; PA144596358; -. DR CTD; 91607; -. DR DisGeNET; 91607; -. DR GeneCards; SLFN11; -. DR HGNC; HGNC:26633; SLFN11. DR HPA; ENSG00000172716; Low tissue specificity. DR MIM; 614953; gene. DR OpenTargets; ENSG00000172716; -. DR VEuPathDB; HostDB:ENSG00000172716; -. DR eggNOG; ENOG502QWKG; Eukaryota. DR GeneTree; ENSGT00410000025651; -. DR HOGENOM; CLU_007071_0_0_1; -. DR InParanoid; Q7Z7L1; -. DR OMA; HKLCVIP; -. DR OrthoDB; 6052143at2759; -. DR PAN-GO; Q7Z7L1; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q7Z7L1; -. DR PathwayCommons; Q7Z7L1; -. DR SignaLink; Q7Z7L1; -. DR Agora; ENSG00000172716; -. DR BioGRID-ORCS; 91607; 17 hits in 1154 CRISPR screens. DR ChiTaRS; SLFN11; human. DR GeneWiki; SLFN11; -. DR GenomeRNAi; 91607; -. DR Pharos; Q7Z7L1; Tbio. DR PRO; PR:Q7Z7L1; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q7Z7L1; protein. DR Bgee; ENSG00000172716; Expressed in monocyte and 140 other cell types or tissues. DR ExpressionAtlas; Q7Z7L1; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0090734; C:site of DNA damage; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW. DR GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW. DR GO; GO:0000049; F:tRNA binding; IDA:UniProtKB. DR GO; GO:0006338; P:chromatin remodeling; IDA:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW. DR GO; GO:0008156; P:negative regulation of DNA replication; IDA:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0043111; P:replication fork arrest; IDA:UniProtKB. DR FunFam; 3.30.950.30:FF:000002; Schlafen family member 11; 1. DR FunFam; 3.40.50.300:FF:001322; Schlafen family member 11; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR Gene3D; 3.30.950.30; Schlafen, AAA domain; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR031450; Poxin-SLFN/SLFN_N. DR InterPro; IPR029684; Schlafen. DR InterPro; IPR007421; Schlafen_AlbA_2_dom. DR InterPro; IPR038461; Schlafen_AlbA_2_dom_sf. DR InterPro; IPR018647; SLFN_3-like_DNA/RNA_helicase. DR InterPro; IPR048729; SLFN_GTPase-like. DR PANTHER; PTHR12155; SCHLAFEN; 1. DR PANTHER; PTHR12155:SF45; SCHLAFEN FAMILY MEMBER 11; 1. DR Pfam; PF17057; B3R; 1. DR Pfam; PF09848; SLFN-g3_helicase; 1. DR Pfam; PF04326; SLFN_AlbA_2; 1. DR Pfam; PF21026; SLFN_GTPase-like; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. PE 1: Evidence at protein level; KW 3D-structure; Antiviral defense; ATP-binding; Chromosome; DNA damage; KW DNA-binding; Endonuclease; Helicase; Hydrolase; Immunity; Nuclease; KW Nucleotide-binding; Nucleus; Proteomics identification; Reference proteome; KW RNA-binding; tRNA-binding. FT CHAIN 1..901 FT /note="Schlafen family member 11" FT /id="PRO_0000283091" FT ACT_SITE 216 FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 209 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 214 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 285 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 287 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 321 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 322 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 599..606 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT VARIANT 121 FT /note="V -> F (in dbSNP:rs12453150)" FT /evidence="ECO:0000269|PubMed:14702039" FT /id="VAR_031492" FT VARIANT 301 FT /note="N -> D (in dbSNP:rs4796077)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005, FT ECO:0000269|Ref.4" FT /id="VAR_031493" FT VARIANT 489 FT /note="R -> L (in dbSNP:rs9898983)" FT /id="VAR_062186" FT VARIANT 822 FT /note="Y -> C (in dbSNP:rs3803860)" FT /id="VAR_031494" FT MUTAGEN 209 FT /note="E->A: Complete loss of endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 214 FT /note="E->A: Complete loss of endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 216 FT /note="K->A: Complete loss of endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 234 FT /note="Y->A: No effect on endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 252 FT /note="D->A: Slight increase in endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 605 FT /note="K->M: Abolishes ATPase activity without affecting FT its role in DNA damage response; when associated with A- FT 668." FT /evidence="ECO:0000269|PubMed:26658330" FT MUTAGEN 668 FT /note="D->A: Abolishes ATPase activity without affecting FT its role in DNA damage response; when associated with M- FT 605." FT /evidence="ECO:0000269|PubMed:26658330" FT MUTAGEN 669 FT /note="E->Q: Abolishes ATPase activity, leading to abolish FT ability to inhibit DNA replication without affecting FT subcellular location." FT /evidence="ECO:0000269|PubMed:29395061" FT MUTAGEN 753 FT /note="S->D: Complete loss of tRNA cleavage and ssDNA FT binding." FT /evidence="ECO:0000269|PubMed:36115853" FT CONFLICT 20 FT /note="N -> S (in Ref. 1; BAC03835)" FT /evidence="ECO:0000305" FT CONFLICT 143 FT /note="M -> T (in Ref. 1; BAC03835)" FT /evidence="ECO:0000305" FT CONFLICT 324 FT /note="V -> M (in Ref. 2; CAD38606)" FT /evidence="ECO:0000305" FT CONFLICT 665 FT /note="I -> V (in Ref. 1; BAC03835 and 2; CAD38606)" FT /evidence="ECO:0000305" FT STRAND 9..11 FT /evidence="ECO:0007829|PDB:7ZEL" FT STRAND 14..16 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 18..23 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 28..32 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 36..55 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 59..64 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 66..69 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 75..85 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 90..92 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 94..99 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 102..107 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 113..115 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 117..120 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 133..136 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 139..142 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 145..156 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 189..195 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 211..216 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 223..240 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 244..250 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 252..254 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 262..264 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 267..280 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 286..288 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 295..304 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 307..317 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 321..324 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:9ERE" FT STRAND 332..335 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 338..341 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 344..352 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 384..397 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 402..409 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 410..419 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 423..430 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 431..433 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 436..443 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 445..448 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 457..465 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 471..478 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 483..500 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 511..517 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 537..539 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 544..559 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 564..585 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 589..591 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 593..599 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 605..620 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 624..626 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 627..632 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 634..641 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 642..644 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 645..650 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 651..656 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 664..667 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 670..672 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 675..677 FT /evidence="ECO:0007829|PDB:9GMW" FT HELIX 680..689 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 692..695 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 698..702 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 704..706 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 718..720 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 723..727 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 735..750 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:7ZEL" FT HELIX 760..762 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 776..779 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 785..802 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 806..808 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 809..814 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 816..818 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 819..830 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 831..833 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 841..843 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 846..853 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 855..857 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 862..868 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 875..877 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 878..886 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 889..896 FT /evidence="ECO:0007829|PDB:9ERF" SQ SEQUENCE 901 AA; 102836 MW; 514FD89CB7C12E8D CRC64; MEANQCPLVV EPSYPDLVIN VGEVTLGEEN RKKLQKIQRD QEKERVMRAA CALLNSGGGV IRMAKKVEHP VEMGLDLEQS LRELIQSSDL QAFFETKQQG RCFYIFVKSW SSGPFPEDRS VKPRLCSLSS SLYRRSETSV RSMDSREAFC FLKTKRKPKI LEEGPFHKIH KGVYQELPNS DPADPNSDPA DLIFQKDYLE YGEILPFPES QLVEFKQFST KHFQEYVKRT IPEYVPAFAN TGGGYLFIGV DDKSREVLGC AKENVDPDSL RRKIEQAIYK LPCVHFCQPQ RPITFTLKIV NVLKRGELYG YACMIRVNPF CCAVFSEAPN SWIVEDKYVC SLTTEKWVGM MTDTDPDLLQ LSEDFECQLS LSSGPPLSRP VYSKKGLEHK KELQQLLFSV PPGYLRYTPE SLWRDLISEH RGLEELINKQ MQPFFRGILI FSRSWAVDLN LQEKPGVICD ALLIAQNSTP ILYTILREQD AEGQDYCTRT AFTLKQKLVN MGGYTGKVCV RAKVLCLSPE SSAEALEAAV SPMDYPASYS LAGTQHMEAL LQSLVIVLLG FRSLLSDQLG CEVLNLLTAQ QYEIFSRSLR KNRELFVHGL PGSGKTIMAM KIMEKIRNVF HCEAHRILYV CENQPLRNFI SDRNICRAET RKTFLRENFE HIQHIVIDEA QNFRTEDGDW YGKAKSITRR AKGGPGILWI FLDYFQTSHL DCSGLPPLSD QYPREELTRI VRNADPIAKY LQKEMQVIRS NPSFNIPTGC LEVFPEAEWS QGVQGTLRIK KYLTVEQIMT CVADTCRRFF DRGYSPKDVA VLVSTAKEVE HYKYELLKAM RKKRVVQLSD ACDMLGDHIV LDSVRRFSGL ERSIVFGIHP RTADPAILPN VLICLASRAK QHLYIFPWGG H // ID SPEG_HUMAN Reviewed; 3267 AA. AC Q15772; A8K0G6; A8MRU0; Q27J74; Q695L1; Q6FGA6; Q6ZQW1; Q6ZTL8; Q9P2P9; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 16-DEC-2008, sequence version 4. DT 28-JAN-2026, entry version 210. DE RecName: Full=Striated muscle preferentially expressed protein kinase; DE EC=2.7.11.1; DE AltName: Full=Aortic preferentially expressed protein 1; DE Short=APEG-1; GN Name=SPEG; Synonyms=APEG1, KIAA1297; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND INDUCTION. RX PubMed=8663449; DOI=10.1074/jbc.271.29.17354; RA Hsieh C.-M., Yoshizumi M., Endege W.O., Kho C.-J., Jain M.K., Kashiki S., RA de Los Santos R., Lee W.-S., Perrella M.A., Lee M.-E.; RT "APEG-1, a novel gene preferentially expressed in aortic smooth muscle RT cells, is down-regulated by vascular injury."; RL J. Biol. Chem. 271:17354-17359(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Cerebellum, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12-129 (ISOFORM 1), AND ALTERNATIVE PROMOTER RP USAGE. RX PubMed=16545539; DOI=10.1016/j.ygeno.2006.01.009; RA Tam J.L.Y., Triantaphyllopoulos K., Todd H., Raguz S., de Wit T., RA Morgan J.E., Partridge T.A., Makrinou E., Grosveld F., Antoniou M.; RT "The human desmin locus: gene organization and LCR-mediated transcriptional RT control."; RL Genomics 87:733-746(2006). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 130-3267 (ISOFORM 1), TISSUE SPECIFICITY, AND RP VARIANT THR-2687. RX PubMed=15185077; DOI=10.1007/s00427-004-0413-5; RA Sutter S.B., Raeker M.O., Borisov A.B., Russell M.W.; RT "Orthologous relationship of obscurin and Unc-89: phylogeny of a novel RT family of tandem myosin light chain kinases."; RL Dev. Genes Evol. 214:352-359(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 982-3267 (ISOFORM 1), AND VARIANT RP THR-2687. RC TISSUE=Brain; RX PubMed=10718198; DOI=10.1093/dnares/7.1.65; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVI. The RT complete sequences of 150 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:65-73(2000). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-488, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP X-RAY CRYSTALLOGRAPHY (0.96 ANGSTROMS) OF 864-962, AND SUBUNIT. RX PubMed=16354304; DOI=10.1186/1472-6807-5-21; RA Manjasetty B.A., Niesen F.H., Scheich C., Roske Y., Goetz F., Behlke J., RA Sievert V., Heinemann U., Bussow K.; RT "X-ray structure of engineered human aortic preferentially expressed RT protein-1 (APEG-1)."; RL BMC Struct. Biol. 5:21-21(2005). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-206; CYS-934; GLN-966; LEU-1103; RP VAL-1135; ASP-1178; TRP-1234; GLN-1340; CYS-1621; TRP-1903; THR-2687; RP MET-2742 AND ARG-3079. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [13] RP INTERACTION WITH MTM1, INVOLVEMENT IN CNM5, AND VARIANT CNM5 VAL-2757. RX PubMed=25087613; DOI=10.1016/j.ajhg.2014.07.004; RA Agrawal P.B., Pierson C.R., Joshi M., Liu X., Ravenscroft G., RA Moghadaszadeh B., Talabere T., Viola M., Swanson L.C., Haliloglu G., RA Talim B., Yau K.S., Allcock R.J., Laing N.G., Perrella M.A., Beggs A.H.; RT "SPEG interacts with myotubularin, and its deficiency causes centronuclear RT myopathy with dilated cardiomyopathy."; RL Am. J. Hum. Genet. 95:218-226(2014). CC -!- FUNCTION: Isoform 3 may have a role in regulating the growth and CC differentiation of arterial smooth muscle cells. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with MTM1. Isoform 3 is found as a monomer or CC homodimer. {ECO:0000269|PubMed:16354304, ECO:0000269|PubMed:25087613}. CC -!- INTERACTION: CC Q15772; Q99873: PRMT1; NbExp=3; IntAct=EBI-1384196, EBI-78738; CC Q15772-4; O75031: HSF2BP; NbExp=3; IntAct=EBI-12175897, EBI-7116203; CC Q15772-4; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-12175897, EBI-16439278; CC Q15772-4; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-12175897, EBI-79165; CC Q15772-4; Q99873-3: PRMT1; NbExp=3; IntAct=EBI-12175897, EBI-17165527; CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=4; CC Name=4; CC IsoId=Q15772-5; Sequence=Displayed; CC Name=2; CC IsoId=Q15772-3; Sequence=VSP_018259, VSP_018261, VSP_018262; CC Name=3; Synonyms=APEG1; CC IsoId=Q15772-4; Sequence=VSP_018258, VSP_018261, VSP_018262; CC Name=1; Synonyms=SPEG; CC IsoId=Q15772-1; Sequence=VSP_036071; CC -!- TISSUE SPECIFICITY: Isoform 1 is preferentially expressed in striated CC muscle. Non-kinase form such as isoform 3 is predominantly expressed in CC the aorta. Isoform 3 appears to be expressed only in highly CC differentiated ASMC in normal vessel walls and down-regulated in CC dedifferentiated ASMC in vivo. In response to vascular injuries ASMC CC dedifferentiate and change from a quiescent and contractile phenotype CC to a proliferative and synthetic phenotype. This proliferation of CC vascular smooth muscle cells is one of the most prominent features of CC atherosclerosis. {ECO:0000269|PubMed:15185077, CC ECO:0000269|PubMed:8663449}. CC -!- INDUCTION: Isoform 3 is quickly down-regulated in response to vascular CC injury, when ASMC cells change from a quiescent to a proliferative CC phenotype. {ECO:0000269|PubMed:8663449}. CC -!- PTM: May be autophosphorylated. CC -!- DISEASE: Myopathy, centronuclear, 5 (CNM5) [MIM:615959]: A form of CC centronuclear myopathy, a congenital muscle disorder characterized by CC progressive muscular weakness and wasting involving mainly limb girdle, CC trunk, and neck muscles. It may also affect distal muscles. Weakness CC may be present during childhood or adolescence or may not become CC evident until the third decade of life. Ptosis is a frequent clinical CC feature. The most prominent histopathologic features include high CC frequency of centrally located nuclei in muscle fibers not secondary to CC regeneration, radial arrangement of sarcoplasmic strands around the CC central nuclei, and predominance and hypotrophy of type 1 fibers. CNM5 CC features include severe neonatal hypotonia with respiratory CC insufficiency, difficulty feeding, and delayed motor development. Some CC patients die in infancy, and some develop dilated cardiomyopathy. CC {ECO:0000269|PubMed:25087613}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: Expression is under the tight control of the locus CC control region (LCRs). CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative splicing. CC {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAY15052.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=ABD61734.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U57099; AAC50599.1; -; mRNA. DR EMBL; AK126500; BAC86568.1; -; mRNA. DR EMBL; AK289531; BAF82220.1; -; mRNA. DR EMBL; CR542201; CAG46998.1; -; mRNA. DR EMBL; AC053503; AAY15052.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH471063; EAW70747.1; -; Genomic_DNA. DR EMBL; BC006346; AAH06346.1; -; mRNA. DR EMBL; DQ395348; ABD61734.1; ALT_FRAME; mRNA. DR EMBL; AY603755; AAT80901.1; -; mRNA. DR EMBL; AB037718; BAA92535.1; -; mRNA. DR CCDS; CCDS42824.1; -. [Q15772-5] DR CCDS; CCDS54432.1; -. [Q15772-4] DR RefSeq; NP_001166947.1; NM_001173476.2. [Q15772-4] DR RefSeq; NP_005867.3; NM_005876.4. [Q15772-5] DR RefSeq; XP_047298873.1; XM_047442917.1. [Q15772-3] DR RefSeq; XP_047298874.1; XM_047442918.1. [Q15772-3] DR RefSeq; XP_047298875.1; XM_047442919.1. [Q15772-3] DR RefSeq; XP_047298876.1; XM_047442920.1. [Q15772-3] DR RefSeq; XP_047298877.1; XM_047442921.1. [Q15772-4] DR RefSeq; XP_047298878.1; XM_047442922.1. [Q15772-4] DR RefSeq; XP_047298879.1; XM_047442923.1. [Q15772-4] DR RefSeq; XP_054196142.1; XM_054340167.1. [Q15772-3] DR RefSeq; XP_054196143.1; XM_054340168.1. [Q15772-3] DR RefSeq; XP_054196144.1; XM_054340169.1. [Q15772-3] DR RefSeq; XP_054196145.1; XM_054340170.1. [Q15772-3] DR RefSeq; XP_054196146.1; XM_054340171.1. [Q15772-4] DR RefSeq; XP_054196147.1; XM_054340172.1. [Q15772-4] DR RefSeq; XP_054196148.1; XM_054340173.1. [Q15772-4] DR PDB; 1U2H; X-ray; 0.96 A; A=864-960. DR PDBsum; 1U2H; -. DR SMR; Q15772; -. DR BioGRID; 115579; 21. DR FunCoup; Q15772; 144. DR IntAct; Q15772; 13. DR STRING; 9606.ENSP00000311684; -. DR GlyCosmos; Q15772; 1 site, 1 glycan. DR GlyGen; Q15772; 8 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q15772; -. DR PhosphoSitePlus; Q15772; -. DR BioMuta; SPEG; -. DR DMDM; 218512143; -. DR jPOST; Q15772; -. DR MassIVE; Q15772; -. DR PaxDb; 9606-ENSP00000311684; -. DR PeptideAtlas; Q15772; -. DR ProteomicsDB; 60751; -. [Q15772-5] DR ProteomicsDB; 60752; -. [Q15772-1] DR ProteomicsDB; 60753; -. [Q15772-3] DR ProteomicsDB; 60754; -. [Q15772-4] DR Pumba; Q15772; -. DR Antibodypedia; 11575; 81 antibodies from 22 providers. DR DNASU; 10290; -. DR Ensembl; ENST00000312358.12; ENSP00000311684.7; ENSG00000072195.15. [Q15772-5] DR Ensembl; ENST00000396686.5; ENSP00000379917.1; ENSG00000072195.15. [Q15772-4] DR Ensembl; ENST00000396688.5; ENSP00000379919.1; ENSG00000072195.15. [Q15772-4] DR Ensembl; ENST00000396689.2; ENSP00000379920.2; ENSG00000072195.15. [Q15772-4] DR GeneID; 10290; -. DR KEGG; hsa:10290; -. DR MANE-Select; ENST00000312358.12; ENSP00000311684.7; NM_005876.5; NP_005867.3. DR UCSC; uc002vlq.4; human. [Q15772-5] DR AGR; HGNC:16901; -. DR ClinPGx; PA142672598; -. DR CTD; 10290; -. DR DisGeNET; 10290; -. DR GeneCards; SPEG; -. DR HGNC; HGNC:16901; SPEG. DR HPA; ENSG00000072195; Tissue enhanced (intestine). DR MalaCards; SPEG; -. DR MIM; 615950; gene. DR MIM; 615959; phenotype. DR OpenTargets; ENSG00000072195; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR VEuPathDB; HostDB:ENSG00000072195; -. DR eggNOG; KOG0032; Eukaryota. DR eggNOG; KOG0613; Eukaryota. DR GeneTree; ENSGT00940000161126; -. DR HOGENOM; CLU_000381_0_0_1; -. DR InParanoid; Q15772; -. DR OrthoDB; 2570713at2759; -. DR PAN-GO; Q15772; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q15772; -. DR PathwayCommons; Q15772; -. DR SignaLink; Q15772; -. DR SIGNOR; Q15772; -. DR Agora; ENSG00000072195; -. DR BioGRID-ORCS; 10290; 9 hits in 1166 CRISPR screens. DR ChiTaRS; SPEG; human. DR EvolutionaryTrace; Q15772; -. DR GeneWiki; SPEG; -. DR GenomeRNAi; 10290; -. DR Pharos; Q15772; Tbio. DR PRO; PR:Q15772; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15772; protein. DR Bgee; ENSG00000072195; Expressed in popliteal artery and 171 other cell types or tissues. DR ExpressionAtlas; Q15772; baseline and differential. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0042692; P:muscle cell differentiation; IBA:GO_Central. DR GO; GO:0007517; P:muscle organ development; TAS:ProtInc. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR CDD; cd00063; FN3; 2. DR CDD; cd20975; IgI_APEG-1_like; 1. DR CDD; cd14108; STKc_SPEG_rpt1; 1. DR CDD; cd14111; STKc_SPEG_rpt2; 1. DR FunFam; 2.60.40.10:FF:000080; Myosin light chain kinase, smooth muscle; 1. DR FunFam; 2.60.40.10:FF:000145; Myosin light chain kinase, smooth muscle; 1. DR FunFam; 1.10.510.10:FF:000363; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000497; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000538; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000784; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:001056; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000428; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000513; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000539; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000541; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000601; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 3.30.200.20:FF:000302; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 3.30.200.20:FF:000312; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 1.10.510.10:FF:000344; striated muscle preferentially expressed protein kinase isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 11. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR47633; IMMUNOGLOBULIN; 1. DR PANTHER; PTHR47633:SF3; STRIATED MUSCLE PREFERENTIALLY EXPRESSED PROTEIN KINASE; 1. DR Pfam; PF07679; I-set; 9. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF16650; SPEG_u2; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00409; IG; 9. DR SMART; SM00408; IGc2; 9. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF48726; Immunoglobulin; 9. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50835; IG_LIKE; 8. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative promoter usage; Alternative splicing; KW ATP-binding; Differentiation; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Methylation; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..3267 FT /note="Striated muscle preferentially expressed protein FT kinase" FT /id="PRO_0000072666" FT DOMAIN 43..124 FT /note="Ig-like 1" FT DOMAIN 722..810 FT /note="Ig-like 2" FT DOMAIN 869..958 FT /note="Ig-like 3" FT DOMAIN 963..1057 FT /note="Ig-like 4" FT DOMAIN 1064..1152 FT /note="Ig-like 5" FT DOMAIN 1188..1278 FT /note="Ig-like 6" FT DOMAIN 1285..1382 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1384..1480 FT /note="Ig-like 7" FT DOMAIN 1485..1573 FT /note="Ig-like 8" FT DOMAIN 1601..1854 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 2583..2673 FT /note="Ig-like 9" FT DOMAIN 2680..2774 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 2966..3218 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..33 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 132..227 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 276..714 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 812..872 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1157..1180 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1906..2060 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2074..2239 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2253..2325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2339..2399 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2411..2452 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2466..2564 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2771..2896 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2909..2966 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 156..195 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 298..314 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 400..418 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 434..443 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 505..517 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 619..633 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 658..675 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 815..825 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 850..864 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2171..2180 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2188..2201 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2214..2224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2343..2354 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2355..2366 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2384..2395 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2466..2484 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2521..2540 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2806..2815 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2910..2924 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2937..2954 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1719 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 3085 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1607..1615 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 1630 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 2972..2980 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 2995 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 139 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 364 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 371 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 375 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 378 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 381 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 419 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 449 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 453 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 488 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 506 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 526 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 549 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 1128 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 1172 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 1988 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2014 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2015 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2037 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2055 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2055 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2109 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2130 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2139 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2177 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2376 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2380 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2410 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2414 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2438 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2439 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2444 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2448 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2521 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2524 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2559 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2771 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2774 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2949 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT DISULFID 989..1041 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2605..2657 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 1..849 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:8663449, ECO:0000303|Ref.3" FT /id="VSP_018258" FT VAR_SEQ 1..792 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_018259" FT VAR_SEQ 961..962 FT /note="AH -> GE (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449, FT ECO:0000303|Ref.3" FT /id="VSP_018261" FT VAR_SEQ 963..3267 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449, FT ECO:0000303|Ref.3" FT /id="VSP_018262" FT VAR_SEQ 3209..3267 FT /note="LQDCLAHPWLQDAYLMKLRRQTLTFTTNRLKEFLGEQRRRRAEAATRHKVLL FT RSYPGGP -> SCLSVCHKEIKMASS (in isoform 1)" FT /evidence="ECO:0000303|PubMed:10718198, FT ECO:0000303|PubMed:15185077, ECO:0000303|PubMed:16545539" FT /id="VSP_036071" FT VARIANT 206 FT /note="R -> H (in dbSNP:rs55821435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041101" FT VARIANT 934 FT /note="R -> C (in dbSNP:rs34398769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041102" FT VARIANT 966 FT /note="R -> Q (in dbSNP:rs34861443)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041103" FT VARIANT 1103 FT /note="P -> L (in dbSNP:rs56334571)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041104" FT VARIANT 1135 FT /note="A -> V (in dbSNP:rs55670811)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041105" FT VARIANT 1178 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs757589345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041106" FT VARIANT 1234 FT /note="R -> W (in dbSNP:rs55916864)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041107" FT VARIANT 1340 FT /note="R -> Q (in dbSNP:rs34994343)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041108" FT VARIANT 1621 FT /note="R -> C (in dbSNP:rs55646900)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041109" FT VARIANT 1903 FT /note="R -> W (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs762000831)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041110" FT VARIANT 2189 FT /note="P -> L (in dbSNP:rs10755037)" FT /id="VAR_059769" FT VARIANT 2687 FT /note="P -> T (in dbSNP:rs13026308)" FT /evidence="ECO:0000269|PubMed:10718198, FT ECO:0000269|PubMed:15185077, ECO:0000269|PubMed:17344846" FT /id="VAR_041111" FT VARIANT 2742 FT /note="V -> M (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs566841339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041112" FT VARIANT 2757 FT /note="G -> V (in CNM5; dbSNP:rs587777676)" FT /evidence="ECO:0000269|PubMed:25087613" FT /id="VAR_071808" FT VARIANT 3079 FT /note="H -> R (in dbSNP:rs12464085)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041113" FT CONFLICT 71 FT /note="Q -> H (in Ref. 7; ABD61734)" FT /evidence="ECO:0000305" FT CONFLICT 73 FT /note="S -> I (in Ref. 7; ABD61734)" FT /evidence="ECO:0000305" FT CONFLICT 2047 FT /note="S -> G (in Ref. 8; AAT80901 and 9; BAA92535)" FT /evidence="ECO:0000305" FT CONFLICT 3005 FT /note="R -> P (in Ref. 8; AAT80901 and 9; BAA92535)" FT /evidence="ECO:0000305" FT STRAND 867..873 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 878..881 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 886..896 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 899..904 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 915..919 FT /evidence="ECO:0007829|PDB:1U2H" FT HELIX 921..923 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 924..931 FT /evidence="ECO:0007829|PDB:1U2H" FT HELIX 934..936 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 938..946 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 949..960 FT /evidence="ECO:0007829|PDB:1U2H" SQ SEQUENCE 3267 AA; 354289 MW; E67BEB5624144233 CRC64; MQKARGTRGE DAGTRAPPSP GVPPKRAKVG AGGGAPVAVA GAPVFLRPLK NAAVCAGSDV RLRVVVSGTP QPSLRWFRDG QLLPAPAPEP SCLWLRRCGA QDAGVYSCMA QNERGRASCE AVLTVLEVGD SETAEDDISD VQGTQRLELR DDGAFSTPTG GSDTLVGTSL DTPPTSVTGT SEEQVSWWGS GQTVLEQEAG SGGGTRRLPG SPRQAQATGA GPRHLGVEPL VRASRANLVG ASWGSEDSLS VASDLYGSAF SLYRGRALSI HVSVPQSGLR REEPDLQPQL ASEAPRRPAQ PPPSKSALLP PPSPRVGKRS PPGPPAQPAA TPTSPHRRTQ EPVLPEDTTT EEKRGKKSKS SGPSLAGTAE SRPQTPLSEA SGRLSALGRS PRLVRAGSRI LDKLQFFEER RRSLERSDSP PAPLRPWVPL RKARSLEQPK SERGAPWGTP GASQEELRAP GSVAERRRLF QQKAASLDER TRQRSPASDL ELRFAQELGR IRRSTSREEL VRSHESLRAT LQRAPSPREP GEPPLFSRPS TPKTSRAVSP AAAQPPSPSS AEKPGDEPGR PRSRGPAGRT EPGEGPQQEV RRRDQFPLTR SRAIQECRSP VPPPAADPPE ARTKAPPGRK REPPAQAVRF LPWATPGLEG AAVPQTLEKN RAGPEAEKRL RRGPEEDGPW GPWDRRGARS QGKGRRARPT SPELESSDDS YVSAGEEPLE APVFEIPLQN VVVAPGADVL LKCIITANPP PQVSWHKDGS ALRSEGRLLL RAEGERHTLL LREARAADAG SYMATATNEL GQATCAASLT VRPGGSTSPF SSPITSDEEY LSPPEEFPEP GETWPRTPTM KPSPSQNRRS SDTGSKAPPT FKVSLMDQSV REGQDVIMSI RVQGEPKPVV SWLRNRQPVR PDQRRFAEEA EGGLCRLRIL AAERGDAGFY TCKAVNEYGA RQCEARLEVR AHPESRSLAV LAPLQDVDVG AGEMALFECL VAGPTDVEVD WLCRGRLLQP ALLKCKMHFD GRKCKLLLTS VHEDDSGVYT CKLSTAKDEL TCSARLTVRP SLAPLFTRLL EDVEVLEGRA ARFDCKISGT PPPVVTWTHF GCPMEESENL RLRQDGGLHS LHIAHVGSED EGLYAVSAVN THGQAHCSAQ LYVEEPRTAA SGPSSKLEKM PSIPEEPEQG ELERLSIPDF LRPLQDLEVG LAKEAMLECQ VTGLPYPTIS WFHNGHRIQS SDDRRMTQYR DVHRLVFPAV GPQHAGVYKS VIANKLGKAA CYAHLYVTDV VPGPPDGAPQ VVAVTGRMVT LTWNPPRSLD MAIDPDSLTY TVQHQVLGSD QWTALVTGLR EPGWAATGLR KGVQHIFRVL STTVKSSSKP SPPSEPVQLL EHGPTLEEAP AMLDKPDIVY VVEGQPASVT VTFNHVEAQV VWRSCRGALL EARAGVYELS QPDDDQYCLR ICRVSRRDMG ALTCTARNRH GTQTCSVTLE LAEAPRFESI MEDVEVGAGE TARFAVVVEG KPLPDIMWYK DEVLLTESSH VSFVYEENEC SLVVLSTGAQ DGGVYTCTAQ NLAGEVSCKA ELAVHSAQTA MEVEGVGEDE DHRGRRLSDF YDIHQEIGRG AFSYLRRIVE RSSGLEFAAK FIPSQAKPKA SARREARLLA RLQHDCVLYF HEAFERRRGL VIVTELCTEE LLERIARKPT VCESEIRAYM RQVLEGIHYL HQSHVLHLDV KPENLLVWDG AAGEQQVRIC DFGNAQELTP GEPQYCQYGT PEFVAPEIVN QSPVSGVTDI WPVGVVAFLC LTGISPFVGE NDRTTLMNIR NYNVAFEETT FLSLSREARG FLIKVLVQDR LRPTAEETLE HPWFKTQAKG AEVSTDHLKL FLSRRRWQRS QISYKCHLVL RPIPELLRAP PERVWVTMPR RPPPSGGLSS SSDSEEEELE ELPSVPRPLQ PEFSGSRVSL TDIPTEDEAL GTPETGAATP MDWQEQGRAP SQDQEAPSPE ALPSPGQEPA AGASPRRGEL RRGSSAESAL PRAGPRELGR GLHKAASVEL PQRRSPSPGA TRLARGGLGE GEYAQRLQAL RQRLLRGGPE DGKVSGLRGP LLESLGGRAR DPRMARAASS EAAPHHQPPL ENRGLQKSSS FSQGEAEPRG RHRRAGAPLE IPVARLGARR LQESPSLSAL SEAQPSSPAR PSAPKPSTPK SAEPSATTPS DAPQPPAPQP AQDKAPEPRP EPVRASKPAP PPQALQTLAL PLTPYAQIIQ SLQLSGHAQG PSQGPAAPPS EPKPHAAVFA RVASPPPGAP EKRVPSAGGP PVLAEKARVP TVPPRPGSSL SSSIENLESE AVFEAKFKRS RESPLSLGLR LLSRSRSEER GPFRGAEEED GIYRPSPAGT PLELVRRPER SRSVQDLRAV GEPGLVRRLS LSLSQRLRRT PPAQRHPAWE ARGGDGESSE GGSSARGSPV LAMRRRLSFT LERLSSRLQR SGSSEDSGGA SGRSTPLFGR LRRATSEGES LRRLGLPHNQ LAAQAGATTP SAESLGSEAS ATSGSSAPGE SRSRLRWGFS RPRKDKGLSP PNLSASVQEE LGHQYVRSES DFPPVFHIKL KDQVLLEGEA ATLLCLPAAC PAPHISWMKD KKSLRSEPSV IIVSCKDGRQ LLSIPRAGKR HAGLYECSAT NVLGSITSSC TVAVARVPGK LAPPEVPQTY QDTALVLWKP GDSRAPCTYT LERRVDGESV WHPVSSGIPD CYYNVTHLPV GVTVRFRVAC ANRAGQGPFS NSSEKVFVRG TQDSSAVPSA AHQEAPVTSR PARARPPDSP TSLAPPLAPA APTPPSVTVS PSSPPTPPSQ ALSSLKAVGP PPQTPPRRHR GLQAARPAEP TLPSTHVTPS EPKPFVLDTG TPIPASTPQG VKPVSSSTPV YVVTSFVSAP PAPEPPAPEP PPEPTKVTVQ SLSPAKEVVS SPGSSPRSSP RPEGTTLRQG PPQKPYTFLE EKARGRFGVV RACRENATGR TFVAKIVPYA AEGKRRVLQE YEVLRTLHHE RIMSLHEAYI TPRYLVLIAE SCGNRELLCG LSDRFRYSED DVATYMVQLL QGLDYLHGHH VLHLDIKPDN LLLAPDNALK IVDFGSAQPY NPQALRPLGH RTGTLEFMAP EMVKGEPIGS ATDIWGAGVL TYIMLSGRSP FYEPDPQETE ARIVGGRFDA FQLYPNTSQS ATLFLRKVLS VHPWSRPSLQ DCLAHPWLQD AYLMKLRRQT LTFTTNRLKE FLGEQRRRRA EAATRHKVLL RSYPGGP // ID STK11_HUMAN Reviewed; 433 AA. AC Q15831; B2RBX7; E7EW76; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 245. DE RecName: Full=Serine/threonine-protein kinase STK11 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:14976552}; DE AltName: Full=Liver kinase B1; DE Short=LKB1; DE Short=hLKB1; DE AltName: Full=Renal carcinoma antigen NY-REN-19; DE Flags: Precursor; GN Name=STK11 {ECO:0000312|HGNC:HGNC:11389}; Synonyms=LKB1, PJS; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND INVOLVEMENT IN PJS. RC TISSUE=Liver; RX PubMed=9425897; DOI=10.1038/ng0198-38; RA Jenne D.E., Reimann H., Nezu J., Friedl W., Loff S., Jeschke R., RA Mueller O., Back W., Zimmer M.; RT "Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine RT kinase."; RL Nat. Genet. 18:38-43(1998). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9537235; RA Bignell G.R., Barfoot R., Seal S., Collins N., Warren W., Stratton M.R.; RT "Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene RT in sporadic breast cancer."; RL Cancer Res. 58:1384-1386(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP IDENTIFICATION AS A RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [8] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=11212897; DOI=10.1023/a:1006442024874; RA Sobottka S.B., Haase M., Fitze G., Hahn M., Schackert H.K., Schackert G.; RT "Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 RT mutations in human carcinoma metastases to the brain."; RL J. Neurooncol. 49:187-195(2000). RN [9] RP IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF SMAD4 AND STK11IP, AND RP INTERACTION WITH SMAD4 AND STK11IP. RX PubMed=11741830; DOI=10.1093/hmg/10.25.2869; RA Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M., RA Ashworth A.; RT "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers RT syndrome kinase LKB1."; RL Hum. Mol. Genet. 10:2869-2877(2001). RN [10] RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, FUNCTION, MUTAGENESIS OF LYS-78 RP AND THR-189, AND PHOSPHORYLATION AT THR-189. RX PubMed=11430832; DOI=10.1016/s1097-2765(01)00258-1; RA Karuman P., Gozani O., Odze R.D., Zhou X.C., Zhu H., Shaw R., Brien T.P., RA Bozzuto C.D., Ooi D., Cantley L.C., Yuan J.; RT "The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell RT death."; RL Mol. Cell 7:1307-1319(2001). RN [11] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=12097271; RA Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., RA Engles J.M., Westra W.H., Herman J.G., Sidransky D.; RT "Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the RT lung."; RL Cancer Res. 62:3659-3662(2002). RN [12] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STRADA, PHOSPHORYLATION AT RP THR-336 AND THR-363, AND CHARACTERIZATION OF VARIANT SPORADIC CANCER RP TYR-176. RX PubMed=12805220; DOI=10.1093/emboj/cdg292; RA Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A., RA Alessi D.R., Clevers H.C.; RT "Activation of the tumour suppressor kinase LKB1 by the STE20-like RT pseudokinase STRAD."; RL EMBO J. 22:3062-3072(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF ASP-194, IDENTIFICATION IN A RP COMPLEX WITH STRADA AND CAB39, AND INTERACTION WITH STRADA; STRADB; CAB39 RP AND CAB39L. RX PubMed=14517248; DOI=10.1093/emboj/cdg490; RA Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A., Schutkowski M., RA Prescott A.R., Clevers H.C., Alessi D.R.; RT "MO25alpha/beta interact with STRADalpha/beta enhancing their ability to RT bind, activate and localize LKB1 in the cytoplasm."; RL EMBO J. 22:5102-5114(2003). RN [14] RP FUNCTION IN CELL POLARITY. RX PubMed=15016379; DOI=10.1016/s0092-8674(04)00114-x; RA Baas A.F., Kuipers J., van der Wel N.N., Batlle E., Koerten H.K., RA Peters P.J., Clevers H.C.; RT "Complete polarization of single intestinal epithelial cells upon RT activation of LKB1 by STRAD."; RL Cell 116:457-466(2004). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-194. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [16] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=15021901; DOI=10.1038/sj.onc.1207502; RA Carretero J., Medina P.P., Pio R., Montuenga L.M., Sanchez-Cespedes M.; RT "Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor RT suppressor gene."; RL Oncogene 23:4037-4040(2004). RN [17] RP FUNCTION. RX PubMed=15733851; DOI=10.1016/j.febslet.2005.01.042; RA Jaleel M., McBride A., Lizcano J.M., Deak M., Toth R., Morrice N.A., RA Alessi D.R.; RT "Identification of the sucrose non-fermenting related kinase SNRK, as a RT novel LKB1 substrate."; RL FEBS Lett. 579:1417-1423(2005). RN [18] RP FUNCTION, INTERACTION WITH PTEN, SUBCELLULAR LOCATION, AND CHARACTERIZATION RP OF VARIANT PJS ASN-176. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [19] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TP53. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [20] RP INTERACTION WITH WDR6. RX PubMed=17216128; DOI=10.1007/s11010-006-9402-5; RA Xie X., Wang Z., Chen Y.; RT "Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell RT growth arrest and p27(Kip1) induction."; RL Mol. Cell. Biochem. 301:115-122(2007). RN [21] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17711506; DOI=10.1111/j.1349-7006.2007.00585.x; RA Onozato R., Kosaka T., Achiwa H., Kuwano H., Takahashi T., Yatabe Y., RA Mitsudomi T.; RT "LKB1 gene mutations in Japanese lung cancer patients."; RL Cancer Sci. 98:1747-1751(2007). RN [22] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17676035; DOI=10.1038/nature06030; RA Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P., RA Torrice C., Wu M.C., Shimamura T., Perera S.A., Liang M.C., Cai D., RA Naumov G.N., Bao L., Contreras C.M., Li D., Chen L., Krishnamurthy J., RA Koivunen J., Chirieac L.R., Padera R.F., Bronson R.T., Lindeman N.I., RA Christiani D.C., Lin X., Shapiro G.I., Janne P.A., Johnson B.E., RA Meyerson M., Kwiatkowski D.J., Castrillon D.H., Bardeesy N., RA Sharpless N.E., Wong K.K.; RT "LKB1 modulates lung cancer differentiation and metastasis."; RL Nature 448:807-810(2007). RN [23] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17384680; DOI=10.1038/sj.onc.1210418; RA Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y., Matsuno Y., RA Suzuki K., Nakamoto M., Shimizu E., Minna J.D., Yokota J.; RT "Prevalence and specificity of LKB1 genetic alterations in lung cancers."; RL Oncogene 26:5911-5918(2007). RN [24] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=18594528; DOI=10.1038/sj.bjc.6604469; RA Koivunen J.P., Kim J., Lee J., Rogers A.M., Park J.O., Zhao X., Naoki K., RA Okamoto I., Nakagawa K., Yeap B.Y., Meyerson M., Wong K.K., Richards W.G., RA Sugarbaker D.J., Johnson B.E., Janne P.A.; RT "Mutations in the LKB1 tumour suppressor are frequently detected in tumours RT from Caucasian but not Asian lung cancer patients."; RL Br. J. Cancer 99:245-252(2008). RN [25] RP RETRACTED PAPER. RX PubMed=18321849; DOI=10.1074/jbc.m708208200; RA Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.; RT "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases RT LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 283:12446-12455(2008). RN [26] RP RETRACTION NOTICE OF PUBMED:18321849. RX PubMed=31519760; DOI=10.1074/jbc.w119.010661; RA Song P., Xie Z., Wu Y., Dong Y., Zou M.H.; RT "Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation RT increases LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 294:13831-13831(2019). RN [27] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-44; LYS-48; LYS-96; LYS-97; RP LYS-296; LYS-311; LYS-416; LYS-423 AND LYS-431, AND MUTAGENESIS OF LYS-44; RP LYS-48; LYS-96 AND LYS-97. RX PubMed=18687677; DOI=10.1074/jbc.m805711200; RA Lan F., Cacicedo J.M., Ruderman N., Ido Y.; RT "SIRT1 modulation of the acetylation status, cytosolic localization, and RT activity of LKB1. Possible role in AMP-activated protein kinase RT activation."; RL J. Biol. Chem. 283:27628-27635(2008). RN [28] RP ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, RP PHOSPHORYLATION AT SER-428, AND MUTAGENESIS OF SER-428. RX PubMed=18854309; DOI=10.1074/jbc.m806153200; RA Denison F.C., Hiscock N.J., Carling D., Woods A.; RT "Characterization of an alternative splice variant of LKB1."; RL J. Biol. Chem. 284:67-76(2009). RN [29] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [30] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=20559149; DOI=10.1097/jto.0b013e3181e05016; RA Gao B., Sun Y., Zhang J., Ren Y., Fang R., Han X., Shen L., Liu X.Y., RA Pao W., Chen H., Ji H.; RT "Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung RT adenocarcinomas."; RL J. Thorac. Oncol. 5:1130-1135(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [32] RP FUNCTION. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [33] RP REVIEW ON FUNCTION. RX PubMed=21396365; DOI=10.1016/j.febslet.2011.03.010; RA Alexander A., Walker C.L.; RT "The role of LKB1 and AMPK in cellular responses to stress and damage."; RL FEBS Lett. 585:952-957(2011). RN [34] RP REVIEW ON INVOLVEMENT IN LUNG CANCER. RX PubMed=21380642; DOI=10.1007/s13238-011-1021-6; RA Gao Y., Ge G., Ji H.; RT "LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor RT suppressor."; RL Protein Cell 2:99-107(2011). RN [35] RP ACTIVITY REGULATION, INTERACTION WITH NR4A1, AND SUBCELLULAR LOCATION. RX PubMed=22983157; DOI=10.1038/nchembio.1069; RA Zhan Y.Y., Chen Y., Zhang Q., Zhuang J.J., Tian M., Chen H.Z., Zhang L.R., RA Zhang H.K., He J.P., Wang W.J., Wu R., Wang Y., Shi C., Yang K., Li A.Z., RA Xin Y.Z., Li T.Y., Yang J.Y., Zheng Z.H., Yu C.D., Lin S.C., Chang C., RA Huang P.Q., Lin T., Wu Q.; RT "The orphan nuclear receptor Nur77 regulates LKB1 localization and RT activates AMPK."; RL Nat. Chem. Biol. 8:897-904(2012). RN [36] RP INTERACTION WITH NISCH, AND SUBCELLULAR LOCATION. RX PubMed=23572524; DOI=10.1074/jbc.m112.418103; RA Jain P., Baranwal S., Dong S., Struckhoff A.P., Worthylake R.A., RA Alahari S.K.; RT "Integrin-binding protein nischarin interacts with tumor suppressor liver RT kinase B1 (LKB1) to regulate cell migration of breast epithelial cells."; RL J. Biol. Chem. 288:15495-15509(2013). RN [37] RP SUBCELLULAR LOCATION (ISOFORM 2), AND PHOSPHORYLATION AT SER-399 (ISOFORM RP 2). RX PubMed=23612973; DOI=10.1074/jbc.m112.443580; RA Zhu H., Moriasi C.M., Zhang M., Zhao Y., Zou M.H.; RT "Phosphorylation of serine 399 in LKB1 protein short form by protein kinase RT Czeta is required for its nucleocytoplasmic transport and consequent AMP- RT activated protein kinase (AMPK) activation."; RL J. Biol. Chem. 288:16495-16505(2013). RN [38] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31 AND SER-401, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [40] RP FUNCTION, AND INTERACTION WITH CDKN1A. RX PubMed=25329316; DOI=10.1371/journal.pgen.1004721; RA Esteve-Puig R., Gil R., Gonzalez-Sanchez E., Bech-Serra J.J., Grueso J., RA Hernandez-Losa J., Moline T., Canals F., Ferrer B., Cortes J., Bastian B., RA Cajal S.R.Y., Martin-Caballero J., Flores J.M., Vivancos A., RA Garcia-Patos V., Recio J.A.; RT "A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating RT CDKN1A (p21WAF1/CIP1) degradation."; RL PLoS Genet. 10:E1004721-E1004721(2014). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 43-347 IN COMPLEX WITH STRADA AND RP CAB39, ACTIVITY REGULATION, CHARACTERIZATION OF VARIANTS SPORADIC CANCER RP MET-66; GLY-86; ARG-123; SER-157; ASP-163; PRO-170; SER-171; ARG-174; RP TYR-176; ASN-177; GLU-181; GLN-199; THR-205; PHE-216; VAL-223; PRO-230; RP PRO-232; ARG-245; PRO-250; HIS-272; TYR-277; GLN-285 AND SER-315, AND RP MUTAGENESIS OF ARG-74; ASP-194 AND PHE-204. RX PubMed=19892943; DOI=10.1126/science.1178377; RA Zeqiraj E., Filippi B.M., Deak M., Alessi D.R., van Aalten D.M.; RT "Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism RT of kinase activation."; RL Science 326:1707-1711(2009). RN [42] RP VARIANTS PJS 50-LEU--ASP-53 DEL; ASN-176 AND CYS-308, CHARACTERIZATION OF RP VARIANTS PJS PRO-67; ASN-176 AND CYS-308, AND MUTAGENESIS OF LYS-78. RX PubMed=9837816; DOI=10.1086/302159; RA Mehenni H., Gehrig C., Nezu J., Oku A., Shimane M., Rossier C., Guex N., RA Blouin J.L., Scott H.S., Antonarakis S.E.; RT "Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for RT allelic and locus heterogeneity."; RL Am. J. Hum. Genet. 63:1641-1650(1998). RN [43] RP VARIANT TGCT ASP-163. RX PubMed=9605748; RA Avizienyte E., Roth S., Loukola A., Hemminki A., Lothe R.A., Stenwig A.E., RA Fossaa S.D., Salovaara R., Aaltonen L.A.; RT "Somatic mutations in LKB1 are rare in sporadic colorectal and testicular RT tumors."; RL Cancer Res. 58:2087-2090(1998). RN [44] RP VARIANTS COLORECTAL CANCER SER-171; LYS-199; ASN-208; ASP-215; LEU-354 AND RP MET-367. RX PubMed=9731485; RA Dong S.M., Kim K.M., Kim S.Y., Shin M.S., Na E.Y., Lee S.H., Park W.S., RA Yoo N.J., Jang J.J., Yoon C.Y., Kim J.W., Kim S.Y., Yang Y.M., Kim S.H., RA Kim C.S., Lee J.Y.; RT "Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers RT syndrome gene in left-sided colon cancer."; RL Cancer Res. 58:3787-3790(1998). RN [45] RP VARIANT COLORECTAL CANCER HIS-314. RX PubMed=9809980; RA Resta N., Simone C., Mareni C., Montera M., Gentile M., Susca F., RA Gristina R., Pozzi S., Bertario L., Bufo P., Carlomagno N., Ingrosso M., RA Rossini F.P., Tenconi R., Guanti G.; RT "STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer."; RL Cancer Res. 58:4799-4801(1998). RN [46] RP VARIANT PJS ASN-247 DEL. RX PubMed=9760200; DOI=10.1007/s004390050801; RA Nakagawa H., Koyama K., Miyoshi Y., Ando H., Baba S., Watatani M., RA Yasutomi M., Matsuura N., Monden M., Nakamura Y.; RT "Nine novel germline mutations of STK11 in ten families with Peutz-Jeghers RT syndrome."; RL Hum. Genet. 103:168-172(1998). RN [47] RP VARIANT GASTRIC CARCINOMA LEU-324. RX PubMed=9683800; RA Park W.S., Moon Y.W., Yang Y.M., Kim Y.S., Kim Y.D., Fuller B.G., RA Vortmeyer A.O., Fogt F., Lubensky I.A., Zhuang Z.; RT "Mutations of the STK11 gene in sporadic gastric carcinoma."; RL Int. J. Oncol. 13:601-604(1998). RN [48] RP VARIANTS PJS PRO-67 AND 303-ILE--GLN-306 DELINS ASN. RX PubMed=9428765; DOI=10.1038/34432; RA Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., RA Bignell G., Warren W., Aminoff M., Hoeglund P., Jaervinen H., Kristo P., RA Pelin K., Ridanpaeae M., Salovaara R., Toro T., Bodmer W., Olschwang S., RA Olsen A.S., Stratton M.R., de la Chapelle A., Aaltonen L.A.; RT "A serine/threonine kinase gene defective in Peutz-Jeghers syndrome."; RL Nature 391:184-187(1998). RN [49] RP VARIANT LUNG CANCER VAL-194. RX PubMed=10079245; DOI=10.1016/s0002-9440(10)65314-x; RA Avizienyte E., Loukola A., Roth S., Hemminki A., Tarkkanen M., RA Salovaara R., Arola J., Butzow R., Husgafvel-Pursiainen K., Kokkola A., RA Jarvinen H., Aaltonen L.A.; RT "LKB1 somatic mutations in sporadic cancers."; RL Am. J. Pathol. 154:677-681(1999). RN [50] RP VARIANTS PJS 162-ASP--LEU-164 DELINS ASN-ASP-MET; ASN-194 AND LYS-297. RX PubMed=10408777; RX DOI=10.1002/(sici)1098-1004(1999)13:6<476::aid-humu7>3.0.co;2-2; RA Westerman A.M., Entius M.M., Boor P.P.C., Koole R., de Baar E., RA Offerhaus G.J.A., Lubinski J., Lindhout D., Halley D.J.J., de Rooij F.W.M., RA Wilson J.H.P.; RT "Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families."; RL Hum. Mutat. 13:476-481(1999). RN [51] RP CHARACTERIZATION OF VARIANT TGCT ASP-163. RX PubMed=9887330; DOI=10.1093/hmg/8.1.45; RA Ylikorkala A., Avizienyte E., Tomlinson I.P., Tiainen M., Roth S., RA Loukola A., Hemminki A., Johansson M., Sistonen P., Markie D., Neale K., RA Phillips R., Zauber P., Twama T., Sampson J., Jaervinen H., Maekelae T.P., RA Aaltonen L.A.; RT "Mutations and impaired function of LKB1 in familial and non-familial RT Peutz-Jeghers syndrome and a sporadic testicular cancer."; RL Hum. Mol. Genet. 8:45-51(1999). RN [52] RP VARIANT OVARIAN CARCINOMA LEU-281. RX PubMed=10429654; DOI=10.1111/j.1349-7006.1999.tb00793.x; RA Nishioka Y., Kobayashi K., Sagae S., Sugimura M., Ishioka S., Nagata M., RA Terasawa K., Tokino T., Kudo R.; RT "Mutational analysis of STK11 gene in ovarian carcinomas."; RL Jpn. J. Cancer Res. 90:629-632(1999). RN [53] RP VARIANTS MELANOMA ASP-49 AND ARG-135. RX PubMed=10201537; DOI=10.1046/j.1523-1747.1999.00551.x; RA Rowan A., Bataille V., MacKie R., Healy E., Bicknell D., Bodmer W., RA Tomlinson I.; RT "Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic RT malignant melanomas."; RL J. Invest. Dermatol. 112:509-511(1999). RN [54] RP VARIANT MELANOMA TYR-194. RX PubMed=10208439; DOI=10.1038/sj.onc.1202486; RA Guldberg P., thor Straten P., Ahrenkiel V., Seremet T., Kirkin A.F., RA Zeuthen J.; RT "Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in RT malignant melanoma."; RL Oncogene 18:1777-1780(1999). RN [55] RP VARIANTS PJS CYS-239 AND SER-315. RX PubMed=12372054; DOI=10.1034/j.1399-0004.2002.620405.x; RA Scott R.J., Crooks R., Meldrum C.J., Thomas L., Smith C.J.A., Mowat D., RA McPhillips M., Spigelman A.D.; RT "Mutation analysis of the STK11/LKB1 gene and clinical characteristics of RT an Australian series of Peutz-Jeghers syndrome patients."; RL Clin. Genet. 62:282-287(2002). RN [56] RP VARIANTS CERVICAL CANCER LYS-14; PRO-160 AND LEU-231, AND VARIANT CERVICAL RP CARCINOMA MET-66. RX PubMed=12533684; DOI=10.1097/01.lab.0000049821.16698.d0; RA Kuragaki C., Enomoto T., Ueno Y., Sun H., Fujita M., Nakashima R., Ueda Y., RA Wada H., Murata Y., Toki T., Konishi I., Fujii S.; RT "Mutations in the STK11 gene characterize minimal deviation adenocarcinoma RT of the uterine cervix."; RL Lab. Invest. 83:35-45(2003). RN [57] RP VARIANT [LARGE SCALE ANALYSIS] LYS-87. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [58] RP VARIANT PJS GLY-16. RX PubMed=21411391; DOI=10.1016/j.clinre.2010.11.008; RA Liu L., Du X., Nie J.; RT "A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers syndrome RT patient significantly diminished p53 activity."; RL Clin. Res. Hepatol. Gastroenterol. 35:221-226(2011). CC -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase that CC controls the activity of AMP-activated protein kinase (AMPK) family CC members, thereby playing a role in various processes such as cell CC metabolism, cell polarity, apoptosis and DNA damage response. Acts by CC phosphorylating the T-loop of AMPK family proteins, thus promoting CC their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, CC MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not CC MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN CC and possibly p53/TP53. Acts as a key upstream regulator of AMPK by CC mediating phosphorylation and activation of AMPK catalytic subunits CC PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition CC of signaling pathways that promote cell growth and proliferation when CC energy levels are low, glucose homeostasis in liver, activation of CC autophagy when cells undergo nutrient deprivation, and B-cell CC differentiation in the germinal center in response to DNA damage. Also CC acts as a regulator of cellular polarity by remodeling the actin CC cytoskeleton. Required for cortical neuron polarization by mediating CC phosphorylation and activation of BRSK1 and BRSK2, leading to axon CC initiation and specification. Involved in DNA damage response: CC interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to CC participate in transcription activation. Able to phosphorylate CC p53/TP53; the relevance of such result in vivo is however unclear and CC phosphorylation may be indirect and mediated by downstream STK11/LKB1 CC kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis CC via interaction with p53/TP53: translocates to the mitochondrion during CC apoptosis and regulates p53/TP53-dependent apoptosis pathways. CC Regulates UV radiation-induced DNA damage response mediated by CDKN1A. CC In association with NUAK1, phosphorylates CDKN1A in response to UV CC radiation and contributes to its degradation which is necessary for CC optimal DNA repair (PubMed:25329316). {ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:14517248, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15016379, CC ECO:0000269|PubMed:15733851, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:25329316}. CC -!- FUNCTION: [Isoform 2]: Has a role in spermiogenesis. {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC -!- ACTIVITY REGULATION: Activated by forming a complex with STRAD (STRADA CC or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta): STRADA CC (or STRADB)-binding promotes a conformational change of STK11/LKB1 in CC an active conformation, which is stabilized by CAB39/MO25alpha (or CC CAB39L/MO25beta) interacting with the STK11/LKB1 activation loop. CC Sequestration in the nucleus by NR4A1 prevents it from phosphorylating CC and activating cytoplasmic AMPK. {ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157}. CC -!- SUBUNIT: Catalytic component of a trimeric complex composed of CC STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CC CAB39L/MO25beta): the complex tethers STK11/LKB1 in the cytoplasm and CC stimulates its catalytic activity. Found in a ternary complex composed CC of SMAD4, STK11/LKB1 and STK11IP. Interacts with p53/TP53, SMAD4, CC STK11IP and WDR6. Interacts with NR4A1. Interacts with NISCH; this CC interaction may increase STK11 activity. Interacts with PTEN; leading CC to PTEN phosphorylation. Interacts with SIRT1; the interaction CC deacetylates STK11. Interacts with CDKN1A. CC {ECO:0000269|PubMed:11741830, ECO:0000269|PubMed:12805220, CC ECO:0000269|PubMed:14517248, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17216128, CC ECO:0000269|PubMed:18687677, ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157, ECO:0000269|PubMed:23572524, CC ECO:0000269|PubMed:25329316}. CC -!- INTERACTION: CC Q15831; Q9Y376: CAB39; NbExp=23; IntAct=EBI-306838, EBI-306905; CC Q15831; Q16543: CDC37; NbExp=6; IntAct=EBI-306838, EBI-295634; CC Q15831; Q9BT78: COPS4; NbExp=5; IntAct=EBI-306838, EBI-742413; CC Q15831; Q13451: FKBP5; NbExp=11; IntAct=EBI-306838, EBI-306914; CC Q15831; P07900: HSP90AA1; NbExp=6; IntAct=EBI-306838, EBI-296047; CC Q15831; P08238: HSP90AB1; NbExp=8; IntAct=EBI-306838, EBI-352572; CC Q15831; O95835: LATS1; NbExp=2; IntAct=EBI-306838, EBI-444209; CC Q15831; Q96L34: MARK4; NbExp=2; IntAct=EBI-306838, EBI-302319; CC Q15831; P26927: MST1; NbExp=2; IntAct=EBI-306838, EBI-6929133; CC Q15831; P54646: PRKAA2; NbExp=3; IntAct=EBI-306838, EBI-1383852; CC Q15831; Q7RTN6: STRADA; NbExp=23; IntAct=EBI-306838, EBI-1109114; CC Q15831; Q7RTN6-1: STRADA; NbExp=3; IntAct=EBI-306838, EBI-15787241; CC Q15831; Q9C0K7: STRADB; NbExp=14; IntAct=EBI-306838, EBI-306893; CC Q15831; Q8NFZ5: TNIP2; NbExp=5; IntAct=EBI-306838, EBI-359372; CC Q15831; Q9NNW5: WDR6; NbExp=3; IntAct=EBI-306838, EBI-1568315; CC Q15831; P63104: YWHAZ; NbExp=6; IntAct=EBI-306838, EBI-347088; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Membrane {ECO:0000250}. CC Mitochondrion. Note=A small fraction localizes at membranes (By CC similarity). Relocates to the cytoplasm when bound to STRAD (STRADA or CC STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta). CC Translocates to the mitochondrion during apoptosis. PTEN promotes CC cytoplasmic localization. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus CC {ECO:0000269|PubMed:23612973}. Cytoplasm {ECO:0000269|PubMed:23612973}. CC Note=Predominantly nuclear, but translocates to the cytoplasm in CC response to metformin or peroxynitrite treatment. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LKB1(L); CC IsoId=Q15831-1; Sequence=Displayed; CC Name=2; Synonyms=LKB1(S); CC IsoId=Q15831-2; Sequence=VSP_041746; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Strongest expression in CC testis and fetal liver. CC -!- PTM: Phosphorylated by ATM at Thr-363 following ionizing radiation CC (IR). Phosphorylation at Ser-428 by RPS6KA1 and/or some PKA is required CC to inhibit cell growth. Phosphorylation at Ser-428 is also required CC during neuronal polarization to mediate phosphorylation of BRSK1 and CC BRSK2 (By similarity). Phosphorylation by PKC/PRKCZ at Ser-399 in CC isoform 2 promotes metformin (or peroxynitrite)-induced nuclear export CC of STK11 and activation of AMPK. UV radiation-induced phosphorylation CC at Thr-363 mediates CDKN1A degradation (By similarity). CC {ECO:0000250|UniProtKB:Q9WTK7, ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:18854309}. CC -!- PTM: Acetylated. Deacetylation at Lys-48 enhances cytoplasmic CC localization and kinase activity in vitro. CC {ECO:0000269|PubMed:18687677}. CC -!- DISEASE: Peutz-Jeghers syndrome (PJS) [MIM:175200]: An autosomal CC dominant disorder characterized by melanocytic macules of the lips, CC multiple gastrointestinal hamartomatous polyps and an increased risk CC for various neoplasms, including gastrointestinal cancer. CC {ECO:0000269|PubMed:10408777, ECO:0000269|PubMed:12372054, CC ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:21411391, CC ECO:0000269|PubMed:9425897, ECO:0000269|PubMed:9428765, CC ECO:0000269|PubMed:9760200, ECO:0000269|PubMed:9837816}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common CC malignancy in males representing 95% of all testicular neoplasms. TGCTs CC have various pathologic subtypes including: unclassified intratubular CC germ cell neoplasia, seminoma (including cases with CC syncytiotrophoblastic cells), spermatocytic seminoma, embryonal CC carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. CC {ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Note=Defects in STK11 are associated with some sporadic CC cancers, especially lung cancers. Frequently mutated and inactivated in CC non-small cell lung cancer (NSCLC). Defects promote lung cancerigenesis CC process, especially lung cancer progression and metastasis. Confers CC lung adenocarcinoma the ability to trans-differentiate into squamous CC cell carcinoma. Also able to promote lung cancer metastasis, via both CC cancer-cell autonomous and non-cancer-cell autonomous mechanisms. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. LKB1 subfamily. {ECO:0000305}. CC -!- CAUTION: Its phosphorylation by PKC/PRKCZ at Ser-428 is reported to CC promote peroxynitrite-induced nuclear export of STK11, leading to PTEN CC activation and subsequent inhibition of PI3K/AKT signaling and CC induction of apoptosis in vein endothelial cells (PubMed:18321849). CC However this paper was withdrawn by the authors due to concerns of CC image duplication in the figures. Its phosphorylation by PKC/PRKCZ has CC been confirmed in other studies (PubMed:18854309, PubMed:23612973). CC {ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:18854309, CC ECO:0000269|PubMed:23612973, ECO:0000305|PubMed:31519760}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/292/STK11"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=PJS entry; CC URL="https://en.wikipedia.org/wiki/PJS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U63333; AAB05809.1; -; mRNA. DR EMBL; AF035625; AAC39527.1; -; mRNA. DR EMBL; AF032984; AAB97833.1; -; Genomic_DNA. DR EMBL; AF055327; AAC15742.1; -; Genomic_DNA. DR EMBL; AF055320; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055321; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055322; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055323; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055324; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055325; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055326; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AK314858; BAG37374.1; -; mRNA. DR EMBL; AC011544; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004221; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471139; EAW69540.1; -; Genomic_DNA. DR EMBL; BC007981; AAH07981.1; -; mRNA. DR EMBL; BC019334; AAH19334.1; -; mRNA. DR CCDS; CCDS45896.1; -. [Q15831-1] DR RefSeq; NP_000446.1; NM_000455.5. [Q15831-1] DR RefSeq; NP_001394184.1; NM_001407255.1. [Q15831-2] DR PDB; 2WTK; X-ray; 2.65 A; C/F=43-347. DR PDB; 4ZDR; X-ray; 2.90 A; A/B=333-340. DR PDB; 5WXN; X-ray; 2.93 A; C/D=331-343. DR PDB; 8VSU; EM; 2.86 A; C=1-433. DR PDBsum; 2WTK; -. DR PDBsum; 4ZDR; -. DR PDBsum; 5WXN; -. DR PDBsum; 8VSU; -. DR AlphaFoldDB; Q15831; -. DR EMDB; EMD-43506; -. DR SMR; Q15831; -. DR BioGRID; 112670; 322. DR ComplexPortal; CPX-2431; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADA variant. DR ComplexPortal; CPX-2845; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADA variant. DR ComplexPortal; CPX-2868; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADB variant. DR ComplexPortal; CPX-2869; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADB variant. DR CORUM; Q15831; -. DR DIP; DIP-31317N; -. DR FunCoup; Q15831; 3083. DR IntAct; Q15831; 222. DR MINT; Q15831; -. DR STRING; 9606.ENSP00000324856; -. DR BindingDB; Q15831; -. DR ChEMBL; CHEMBL5606; -. DR DrugCentral; Q15831; -. DR GlyGen; Q15831; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q15831; -. DR PhosphoSitePlus; Q15831; -. DR BioMuta; STK11; -. DR DMDM; 3024670; -. DR CPTAC; CPTAC-2999; -. DR CPTAC; CPTAC-3000; -. DR jPOST; Q15831; -. DR MassIVE; Q15831; -. DR PaxDb; 9606-ENSP00000324856; -. DR PeptideAtlas; Q15831; -. DR ProteomicsDB; 60780; -. [Q15831-1] DR ProteomicsDB; 60781; -. [Q15831-2] DR Pumba; Q15831; -. DR Antibodypedia; 2048; 1357 antibodies from 44 providers. DR CPTC; Q15831; 1 antibody. DR DNASU; 6794; -. DR Ensembl; ENST00000326873.12; ENSP00000324856.6; ENSG00000118046.19. [Q15831-1] DR Ensembl; ENST00000585465.3; ENSP00000490268.2; ENSG00000118046.19. [Q15831-2] DR Ensembl; ENST00000652231.1; ENSP00000498804.1; ENSG00000118046.19. [Q15831-2] DR GeneID; 6794; -. DR KEGG; hsa:6794; -. DR MANE-Select; ENST00000326873.12; ENSP00000324856.6; NM_000455.5; NP_000446.1. DR UCSC; uc002lrl.2; human. [Q15831-1] DR AGR; HGNC:11389; -. DR CIViC; 6794; 20 evidence items across 8 molecular profiles. DR ClinPGx; PA36198; -. DR CTD; 6794; -. DR DisGeNET; 6794; -. DR GeneCards; STK11; -. DR GeneReviews; STK11; -. DR HGNC; HGNC:11389; STK11. DR HPA; ENSG00000118046; Low tissue specificity. DR MalaCards; STK11; -. DR MIM; 175200; phenotype. DR MIM; 273300; phenotype. DR MIM; 602216; gene. DR OpenTargets; ENSG00000118046; -. DR Orphanet; 2869; Peutz-Jeghers syndrome. DR VEuPathDB; HostDB:ENSG00000118046; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00940000158050; -. DR HOGENOM; CLU_000288_1_2_1; -. DR InParanoid; Q15831; -. DR OMA; AYHYGSE; -. DR OrthoDB; 68483at2759; -. DR PAN-GO; Q15831; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q15831; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q15831; -. DR Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes. DR SignaLink; Q15831; -. DR SIGNOR; Q15831; -. DR Agora; ENSG00000118046; -. DR BioGRID-ORCS; 6794; 153 hits in 1229 CRISPR screens. DR ChiTaRS; STK11; human. DR EvolutionaryTrace; Q15831; -. DR GeneWiki; STK11; -. DR GenomeRNAi; 6794; -. DR Pharos; Q15831; Tchem. DR PRO; PR:Q15831; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q15831; protein. DR Bgee; ENSG00000118046; Expressed in left testis and 156 other cell types or tissues. DR ExpressionAtlas; Q15831; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0140535; C:intracellular protein-containing complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:1902554; C:serine/threonine protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0002039; F:p53 binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0032147; P:activation of protein kinase activity; IDA:MGI. DR GO; GO:0043276; P:anoikis; IMP:BHF-UCL. DR GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW. DR GO; GO:0007409; P:axonogenesis; IEA:Ensembl. DR GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB. DR GO; GO:0097484; P:dendrite extension; IEA:Ensembl. DR GO; GO:0006974; P:DNA damage response; IMP:UniProtKB. DR GO; GO:0060767; P:epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0030010; P:establishment of cell polarity; IMP:UniProtKB. DR GO; GO:0070314; P:G1 to G0 transition; IDA:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0051645; P:Golgi localization; IEA:Ensembl. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IDA:UniProtKB. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0060770; P:negative regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0010508; P:positive regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:1901610; P:positive regulation of vesicle transport along microtubule; IMP:UniProtKB. DR GO; GO:0045059; P:positive thymic T cell selection; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006470; P:protein dephosphorylation; IMP:UniProtKB. DR GO; GO:0034504; P:protein localization to nucleus; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome. DR GO; GO:0001558; P:regulation of cell growth; ISS:UniProtKB. DR GO; GO:0048814; P:regulation of dendrite morphogenesis; IEA:Ensembl. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0030111; P:regulation of Wnt signaling pathway; IBA:GO_Central. DR GO; GO:0010212; P:response to ionizing radiation; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0001944; P:vasculature development; ISS:UniProtKB. DR CDD; cd14119; STKc_LKB1; 1. DR FunFam; 1.10.510.10:FF:000245; serine/threonine-protein kinase STK11; 1. DR FunFam; 3.30.200.20:FF:000235; serine/threonine-protein kinase STK11; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00613; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR039154; LKB1_c. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF94; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Autophagy; Cell cycle; Cytoplasm; Differentiation; Disease variant; KW DNA damage; Kinase; Lipoprotein; Magnesium; Manganese; Membrane; KW Metal-binding; Methylation; Mitochondrion; Nucleotide-binding; Nucleus; KW Palmitate; Phosphoprotein; Prenylation; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Spermatogenesis; KW Transferase; Tumor suppressor. FT CHAIN 1..430 FT /note="Serine/threonine-protein kinase STK11" FT /id="PRO_0000086699" FT PROPEP 431..433 FT /note="Removed in mature form" FT /evidence="ECO:0000250" FT /id="PRO_0000422300" FT DOMAIN 49..309 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 45..90 FT /note="Sufficient for interaction with SIRT1" FT /evidence="ECO:0000269|PubMed:18687677" FT REGION 312..331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 397..433 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 316..326 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..433 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 176 FT /note="Proton acceptor" FT BINDING 55..63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 78 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 31 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 44 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 48 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 96 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 97 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 189 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11430832" FT MOD_RES 296 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 311 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 325 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9WTK7" FT MOD_RES 336 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 363 FT /note="Phosphothreonine; by ATM and autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 401 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 416 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 423 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 428 FT /note="Phosphoserine; by autocatalysis, PKA, PKC/PRKCZ and FT RPS6KA1" FT /evidence="ECO:0000269|PubMed:18854309" FT MOD_RES 430 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000250" FT MOD_RES 431 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT LIPID 418 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000250" FT LIPID 430 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000250" FT VAR_SEQ 371..433 FT /note="QVPEEEASHNGQRRGLPKAVCMNGTEAAQLSTKSRAEGRAPNPARKACSASS FT KIRRLSACKQQ -> GEEASEAGLRAERGLQKSEGSDLSGEEASRPAPQ (in FT isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_041746" FT VARIANT 14 FT /note="E -> K (in cervical cancer; somatic mutation; FT dbSNP:rs2145404557)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065627" FT VARIANT 16 FT /note="E -> G (in PJS; dbSNP:rs2145404592)" FT /evidence="ECO:0000269|PubMed:21411391" FT /id="VAR_065628" FT VARIANT 49 FT /note="Y -> D (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853080)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033138" FT VARIANT 50..53 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071057" FT VARIANT 66 FT /note="V -> M (in cervical carcinoma; somatic mutation; FT dbSNP:rs1599915144)" FT /evidence="ECO:0000269|PubMed:12533684, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065629" FT VARIANT 67 FT /note="L -> P (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs137853077)" FT /evidence="ECO:0000269|PubMed:9428765, FT ECO:0000269|PubMed:9837816" FT /id="VAR_006202" FT VARIANT 86 FT /note="R -> G (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1057520039)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065630" FT VARIANT 87 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1568690463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041139" FT VARIANT 123 FT /note="Q -> R (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs764449808)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065631" FT VARIANT 135 FT /note="G -> R (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853081)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033139" FT VARIANT 157 FT /note="F -> S (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145424124)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065632" FT VARIANT 160 FT /note="L -> P (in cervical cancer; somatic mutation; FT dbSNP:rs2145424155)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065633" FT VARIANT 162..164 FT /note="DGL -> NDM (in PJS)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007920" FT VARIANT 163 FT /note="G -> D (in TGCT; a tumor with seminoma and teratoma FT components; somatic mutation; severely impaired but FT detectable kinase activity; impairs heterotrimeric complex FT assembly with STRADA and CAB39; predominantly nuclear FT localization; dbSNP:rs137853078)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330" FT /id="VAR_033140" FT VARIANT 170 FT /note="Q -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs876659972)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065634" FT VARIANT 171 FT /note="G -> S (in colorectal cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1599926499)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9731485" FT /id="VAR_065635" FT VARIANT 174 FT /note="H -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065636" FT VARIANT 176 FT /note="D -> N (in PJS; loss of kinase activity, leading to FT greatly reduced autophosphorylation; fails to phosphorylate FT PTEN in vitro; no significant effect on nucleocytoplasmic FT localization; dbSNP:rs730881979)" FT /evidence="ECO:0000269|PubMed:15987703, FT ECO:0000269|PubMed:9837816" FT /id="VAR_071058" FT VARIANT 176 FT /note="D -> Y (in sporadic cancer; somatic mutation; Loss FT of kinase activity)" FT /evidence="ECO:0000269|PubMed:12805220, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065637" FT VARIANT 177 FT /note="I -> N (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520041)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065638" FT VARIANT 181 FT /note="N -> E (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; requires 2 nucleotide substitutions; FT dbSNP:rs1568707668)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065639" FT VARIANT 194 FT /note="D -> N (in PJS; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007921" FT VARIANT 194 FT /note="D -> V (in lung cancer; somatic mutation; FT dbSNP:rs121913316)" FT /evidence="ECO:0000269|PubMed:10079245" FT /id="VAR_065640" FT VARIANT 194 FT /note="D -> Y (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10208439" FT /id="VAR_033141" FT VARIANT 199 FT /note="E -> K (in colorectal cancer; somatic mutation; FT impaired kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065641" FT VARIANT 199 FT /note="E -> Q (in sporadic cancer; somatic mutation; does FT not affect kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065642" FT VARIANT 205 FT /note="A -> T (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs730881981)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065643" FT VARIANT 208 FT /note="D -> N (in colorectal cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738372)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065644" FT VARIANT 215 FT /note="G -> D (in colorectal cancer; somatic mutation; FT dbSNP:rs1057520038)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065645" FT VARIANT 216 FT /note="S -> F (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520017)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065646" FT VARIANT 223 FT /note="E -> V (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2080776621)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065647" FT VARIANT 230 FT /note="T -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425367)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065648" FT VARIANT 231 FT /note="F -> L (in cervical cancer; somatic mutation; FT dbSNP:rs929783669)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065649" FT VARIANT 232 FT /note="S -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425398)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065650" FT VARIANT 239 FT /note="W -> C (in PJS; late onset suggests reduced FT penetrance; dbSNP:rs137853082)" FT /evidence="ECO:0000269|PubMed:12372054" FT /id="VAR_033142" FT VARIANT 245 FT /note="L -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065651" FT VARIANT 247 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9760200" FT /id="VAR_006203" FT VARIANT 250 FT /note="T -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1568709142)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065652" FT VARIANT 272 FT /note="Y -> H (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs2145427076)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065653" FT VARIANT 277 FT /note="D -> Y (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1555738692)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065654" FT VARIANT 281 FT /note="P -> L (in ovarian carcinoma; somatic mutation; FT dbSNP:rs121913322)" FT /evidence="ECO:0000269|PubMed:10429654" FT /id="VAR_065655" FT VARIANT 285 FT /note="L -> Q (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738724)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065656" FT VARIANT 297 FT /note="R -> K (in PJS; dbSNP:rs1568710381)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007922" FT VARIANT 303..306 FT /note="IRQH -> N (in PJS)" FT /id="VAR_033143" FT VARIANT 308 FT /note="W -> C (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs1057520042)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071059" FT VARIANT 314 FT /note="P -> H (in colorectal cancer; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs1064795752)" FT /evidence="ECO:0000269|PubMed:9809980" FT /id="VAR_065657" FT VARIANT 315 FT /note="P -> S (in PJS; uncertain significance; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs786202431)" FT /evidence="ECO:0000269|PubMed:12372054, FT ECO:0000269|PubMed:19892943" FT /id="VAR_033144" FT VARIANT 324 FT /note="P -> L (in gastric carcinoma; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs367807476)" FT /evidence="ECO:0000269|PubMed:9683800" FT /id="VAR_065658" FT VARIANT 354 FT /note="F -> L (in colorectal cancer; somatic mutation; FT dbSNP:rs59912467)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065659" FT VARIANT 367 FT /note="T -> M (in colorectal cancer; somatic mutation; FT dbSNP:rs587782835)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065660" FT MUTAGEN 44 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->Q: No effect on basal nucleocytoplasmic FT localization, but fails to translocate to the cytoplasm FT when coexpressed with SIRT1." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->R: Enhanced phosphorylation at Thr-336 and Ser- FT 428, enhanced cytoplasmic localization and increased kinase FT activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 74 FT /note="R->A: Impaired formation of a heterotrimeric complex FT with STRADA and CAB39; when associated with A-204." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 78 FT /note="K->I: Loss of kinase activity, leading to greatly FT reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 78 FT /note="K->M: Loss of kinase activity, leading to reduced FT autophosphorylation and acting as a dominant-negative FT mutant." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 96 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 97 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 189 FT /note="T->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:11430832" FT MUTAGEN 194 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14517248, FT ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:19892943" FT MUTAGEN 204 FT /note="F->A: No effect. Impaired formation of a FT heterotrimeric complex with STRADA and CAB39; when FT associated with A-74." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 428 FT /note="S->A,E: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18854309" FT STRAND 54..57 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 62..68 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 69..71 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 74..80 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 82..87 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 91..102 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 113..118 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 120..123 FT /evidence="ECO:0007829|PDB:8VSU" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 136..142 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 150..169 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 190..192 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 217..219 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 231..233 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 234..250 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 260..269 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 280..289 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 294..296 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 300..305 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 307..310 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 326..328 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:4ZDR" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:2WTK" FT MOD_RES Q15831-2:399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:23612973" SQ SEQUENCE 433 AA; 48636 MW; 6DF4C37AB7A89569 CRC64; MEVVDPQQLG MFTEGELMSV GMDTFIHRID STEVIYQPRR KRAKLIGKYL MGDLLGEGSY GKVKEVLDSE TLCRRAVKIL KKKKLRRIPN GEANVKKEIQ LLRRLRHKNV IQLVDVLYNE EKQKMYMVME YCVCGMQEML DSVPEKRFPV CQAHGYFCQL IDGLEYLHSQ GIVHKDIKPG NLLLTTGGTL KISDLGVAEA LHPFAADDTC RTSQGSPAFQ PPEIANGLDT FSGFKVDIWS AGVTLYNITT GLYPFEGDNI YKLFENIGKG SYAIPGDCGP PLSDLLKGML EYEPAKRFSI RQIRQHSWFR KKHPPAEAPV PIPPSPDTKD RWRSMTVVPY LEDLHGADED EDLFDIEDDI IYTQDFTVPG QVPEEEASHN GQRRGLPKAV CMNGTEAAQL STKSRAEGRA PNPARKACSA SSKIRRLSAC KQQ // ID STK36_HUMAN Reviewed; 1315 AA. AC Q9NRP7; B7WPM3; Q8TC32; Q9H9N9; Q9UF35; Q9ULE2; DT 21-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2006, sequence version 2. DT 28-JAN-2026, entry version 203. DE RecName: Full=Serine/threonine-protein kinase 36; DE EC=2.7.11.1; DE AltName: Full=Fused homolog; GN Name=STK36 {ECO:0000312|EMBL:AAH26158.1}; GN Synonyms=KIAA1278 {ECO:0000312|EMBL:BAA86592.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAF97028.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH GLI1; RP GLI2; GLI3 AND SUFU, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF LYS-33. RX PubMed=10806483; DOI=10.1038/35010610; RA Murone M., Luoh S.-L., Stone D., Li W., Gurney A., Armanini M., Grey C., RA Rosenthal A., de Sauvage F.J.; RT "Gli regulation by the opposing activities of fused and suppressor of RT fused."; RL Nat. Cell Biol. 2:310-312(2000). RN [2] {ECO:0000305, ECO:0000312|EMBL:BAA86592.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain {ECO:0000312|EMBL:BAA86592.1}; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] {ECO:0000305, ECO:0000312|EMBL:AAH26158.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS ASN-463 RP AND THR-767. RC TISSUE=Testis {ECO:0000312|EMBL:AAH26158.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 823-1315 (ISOFORM 1). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [6] {ECO:0000305, ECO:0000312|EMBL:BAB14184.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 839-1315 (ISOFORM 1), AND VARIANT RP ASP-1003. RC TISSUE=Teratocarcinoma {ECO:0000312|EMBL:BAB14184.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP VARIANTS [LARGE SCALE ANALYSIS] MET-90; TRP-240; ARG-295; ASN-329; VAL-462; RP SER-476; TRP-477; GLN-583; CYS-660; PRO-672; TYR-767; ALA-816; GLN-839; RP VAL-840; ASP-1003; CYS-1111; GLN-1112; LYS-1138; SER-1185 AND PRO-1313. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [8] RP INVOLVEMENT IN CILD46, FUNCTION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=28543983; DOI=10.1002/humu.23261; RA Edelbusch C., Cindric S., Dougherty G.W., Loges N.T., Olbrich H., RA Rivlin J., Wallmeier J., Pennekamp P., Amirav I., Omran H.; RT "Mutation of serine/threonine protein kinase 36 (STK36) causes primary RT ciliary dyskinesia with a central pair defect."; RL Hum. Mutat. 38:964-969(2017). CC -!- FUNCTION: Serine/threonine protein kinase which plays an important role CC in the sonic hedgehog (Shh) pathway by regulating the activity of GLI CC transcription factors (PubMed:10806483). Controls the activity of the CC transcriptional regulators GLI1, GLI2 and GLI3 by opposing the effect CC of SUFU and promoting their nuclear localization (PubMed:10806483). CC GLI2 requires an additional function of STK36 to become CC transcriptionally active, but the enzyme does not need to possess an CC active kinase catalytic site for this to occur (PubMed:10806483). CC Required for postnatal development, possibly by regulating the CC homeostasis of cerebral spinal fluid or ciliary function. Essential for CC construction of the central pair apparatus of motile cilia. CC {ECO:0000269|PubMed:10806483, ECO:0000269|PubMed:28543983}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:P23647}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:P23647}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305}; CC -!- SUBUNIT: Interacts with GLI1, GLI2 and GLI3 (PubMed:10806483). CC Interacts with SPAG16 and KIF27. {ECO:0000250|UniProtKB:Q69ZM6, CC ECO:0000269|PubMed:10806483}. CC -!- INTERACTION: CC Q9NRP7; P54252: ATXN3; NbExp=3; IntAct=EBI-863797, EBI-946046; CC Q9NRP7; G5E9A7: DMWD; NbExp=3; IntAct=EBI-863797, EBI-10976677; CC Q9NRP7; P14136: GFAP; NbExp=3; IntAct=EBI-863797, EBI-744302; CC Q9NRP7; O14901: KLF11; NbExp=3; IntAct=EBI-863797, EBI-948266; CC Q9NRP7; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-863797, EBI-5235340; CC Q9NRP7; Q9UMX1: SUFU; NbExp=3; IntAct=EBI-863797, EBI-740595; CC Q9NRP7; Q96C45: ULK4; NbExp=4; IntAct=EBI-863797, EBI-3922541; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10806483}. Nucleus CC {ECO:0000269|PubMed:10806483}. Cytoplasm, cytoskeleton, cilium axoneme CC {ECO:0000269|PubMed:28543983}. Note=Low levels also present in the CC nucleus. {ECO:0000269|PubMed:10806483}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000269|PubMed:10806483, ECO:0000269|PubMed:14702039, CC ECO:0000269|PubMed:15489334}; CC IsoId=Q9NRP7-1; Sequence=Displayed; CC Name=2 {ECO:0000269|PubMed:10574462}; CC IsoId=Q9NRP7-2; Sequence=VSP_051983; CC -!- TISSUE SPECIFICITY: Expressed at low levels in most fetal tissues, CC adult ovaries and at high levels in adult testis, where it is localized CC in germ cells (PubMed:10806483). Expressed in respiratory epithelial CC cells of the lung (PubMed:28543983). {ECO:0000269|PubMed:10806483, CC ECO:0000269|PubMed:28543983}. CC -!- DISEASE: Ciliary dyskinesia, primary, 46 (CILD46) [MIM:619436]: A form CC of primary ciliary dyskinesia, a disorder characterized by CC abnormalities of motile cilia. Respiratory infections leading to CC chronic inflammation and bronchiectasis are recurrent, due to defects CC in the respiratory cilia. CILD46 is an autosomal recessive form. No CC situs abnormalities have been observed. {ECO:0000269|PubMed:28543983}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA86592.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB14184.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF200815; AAF97028.1; -; mRNA. DR EMBL; AB033104; BAA86592.1; ALT_INIT; mRNA. DR EMBL; AC009974; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC026158; AAH26158.1; -; mRNA. DR EMBL; AL133630; CAB63754.1; -; mRNA. DR EMBL; AK022692; BAB14184.1; ALT_FRAME; mRNA. DR CCDS; CCDS2421.1; -. [Q9NRP7-1] DR CCDS; CCDS58750.1; -. [Q9NRP7-2] DR PIR; T43465; T43465. DR RefSeq; NP_001230242.1; NM_001243313.2. [Q9NRP7-2] DR RefSeq; NP_001356352.1; NM_001369423.1. [Q9NRP7-1] DR RefSeq; NP_056505.2; NM_015690.5. [Q9NRP7-1] DR AlphaFoldDB; Q9NRP7; -. DR SMR; Q9NRP7; -. DR BioGRID; 118032; 44. DR FunCoup; Q9NRP7; 1539. DR IntAct; Q9NRP7; 40. DR STRING; 9606.ENSP00000295709; -. DR BindingDB; Q9NRP7; -. DR ChEMBL; CHEMBL4312; -. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9NRP7; -. DR iPTMnet; Q9NRP7; -. DR PhosphoSitePlus; Q9NRP7; -. DR BioMuta; STK36; -. DR DMDM; 90101761; -. DR jPOST; Q9NRP7; -. DR MassIVE; Q9NRP7; -. DR PaxDb; 9606-ENSP00000295709; -. DR PeptideAtlas; Q9NRP7; -. DR ProteomicsDB; 82401; -. [Q9NRP7-1] DR ProteomicsDB; 82402; -. [Q9NRP7-2] DR Antibodypedia; 34284; 179 antibodies from 29 providers. DR DNASU; 27148; -. DR Ensembl; ENST00000295709.8; ENSP00000295709.3; ENSG00000163482.13. [Q9NRP7-1] DR Ensembl; ENST00000392105.7; ENSP00000375954.3; ENSG00000163482.13. [Q9NRP7-2] DR Ensembl; ENST00000440309.5; ENSP00000394095.1; ENSG00000163482.13. [Q9NRP7-1] DR GeneID; 27148; -. DR KEGG; hsa:27148; -. DR MANE-Select; ENST00000295709.8; ENSP00000295709.3; NM_015690.5; NP_056505.2. DR UCSC; uc002viu.4; human. [Q9NRP7-1] DR AGR; HGNC:17209; -. DR ClinPGx; PA38212; -. DR CTD; 27148; -. DR DisGeNET; 27148; -. DR GeneCards; STK36; -. DR HGNC; HGNC:17209; STK36. DR HPA; ENSG00000163482; Low tissue specificity. DR MalaCards; STK36; -. DR MIM; 607652; gene. DR MIM; 619436; phenotype. DR OpenTargets; ENSG00000163482; -. DR Orphanet; 244; Primary ciliary dyskinesia. DR VEuPathDB; HostDB:ENSG00000163482; -. DR eggNOG; KOG0597; Eukaryota. DR GeneTree; ENSGT00940000158375; -. DR HOGENOM; CLU_002453_2_0_1; -. DR InParanoid; Q9NRP7; -. DR OMA; LCPSFLH; -. DR OrthoDB; 266718at2759; -. DR PAN-GO; Q9NRP7; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9NRP7; -. DR PathwayCommons; Q9NRP7; -. DR SignaLink; Q9NRP7; -. DR SIGNOR; Q9NRP7; -. DR Agora; ENSG00000163482; -. DR BioGRID-ORCS; 27148; 6 hits in 1185 CRISPR screens. DR ChiTaRS; STK36; human. DR GeneWiki; STK36; -. DR GenomeRNAi; 27148; -. DR Pharos; Q9NRP7; Tbio. DR PRO; PR:Q9NRP7; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q9NRP7; protein. DR Bgee; ENSG00000163482; Expressed in right uterine tube and 146 other cell types or tissues. DR ExpressionAtlas; Q9NRP7; baseline and differential. DR GO; GO:0005930; C:axoneme; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005576; C:extracellular region; IEA:GOC. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; TAS:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:FlyBase. DR GO; GO:0001222; F:transcription corepressor binding; IDA:UniProtKB. DR GO; GO:0035082; P:axoneme assembly; IMP:UniProtKB. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0060271; P:cilium assembly; IMP:UniProtKB. DR GO; GO:0003351; P:epithelial cilium movement involved in extracellular fluid movement; IEA:Ensembl. DR GO; GO:0045880; P:positive regulation of smoothened signaling pathway; ISS:UniProtKB. DR GO; GO:0009791; P:post-embryonic development; ISS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:UniProtKB. DR GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0007224; P:smoothened signaling pathway; IMP:FlyBase. DR CDD; cd14002; STKc_STK36; 1. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR FunFam; 1.10.510.10:FF:000292; Serine/threonine-protein kinase 36; 1. DR FunFam; 1.25.10.10:FF:000325; Serine/threonine-protein kinase 36; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR22983; PROTEIN KINASE RELATED; 1. DR PANTHER; PTHR22983:SF6; SERINE_THREONINE-PROTEIN KINASE 36; 1. DR Pfam; PF13646; HEAT_2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell projection; Ciliopathy; KW Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; KW Developmental protein; Kinase; Magnesium; Metal-binding; KW Nucleotide-binding; Nucleus; Primary ciliary dyskinesia; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1315 FT /note="Serine/threonine-protein kinase 36" FT /id="PRO_0000229020" FT DOMAIN 4..254 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 312..346 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 365..387 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 125 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P23647, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P23647, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT VAR_SEQ 838..858 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10574462" FT /id="VSP_051983" FT VARIANT 90 FT /note="I -> M (in dbSNP:rs55706732)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041177" FT VARIANT 240 FT /note="R -> W (in dbSNP:rs35038757)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041178" FT VARIANT 295 FT /note="K -> R (in dbSNP:rs1863703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041179" FT VARIANT 329 FT /note="D -> N (in dbSNP:rs34027859)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041180" FT VARIANT 462 FT /note="L -> V (in dbSNP:rs45586733)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041181" FT VARIANT 463 FT /note="K -> N (in dbSNP:rs17856747)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_025727" FT VARIANT 476 FT /note="F -> S (in dbSNP:rs34128793)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041182" FT VARIANT 477 FT /note="R -> W (in dbSNP:rs16859180)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041183" FT VARIANT 583 FT /note="R -> Q (in dbSNP:rs1344642)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041184" FT VARIANT 638 FT /note="Q -> P (in dbSNP:rs6709303)" FT /id="VAR_057112" FT VARIANT 660 FT /note="S -> C (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation; dbSNP:rs1244829273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041185" FT VARIANT 672 FT /note="L -> P (in dbSNP:rs35448374)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041186" FT VARIANT 767 FT /note="S -> T (in dbSNP:rs17856748)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_025728" FT VARIANT 767 FT /note="S -> Y (in an ovarian papillary serous FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041187" FT VARIANT 816 FT /note="T -> A (in dbSNP:rs34271431)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041188" FT VARIANT 839 FT /note="R -> Q (in dbSNP:rs13023540)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041189" FT VARIANT 840 FT /note="L -> V (in dbSNP:rs36099639)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041190" FT VARIANT 1003 FT /note="G -> D (in dbSNP:rs1863704)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_025729" FT VARIANT 1004 FT /note="V -> I (in dbSNP:rs55633575)" FT /id="VAR_061747" FT VARIANT 1111 FT /note="Y -> C (in dbSNP:rs56278660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041191" FT VARIANT 1112 FT /note="R -> Q (in dbSNP:rs12993599)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041192" FT VARIANT 1138 FT /note="Q -> K (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041193" FT VARIANT 1185 FT /note="P -> S (in an ovarian endometrioid sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041194" FT VARIANT 1313 FT /note="H -> P" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041195" FT MUTAGEN 33 FT /note="K->R: No effect on nuclear localization of GLI1 or FT GLI2 or on GLI-mediated transcription." FT /evidence="ECO:0000269|PubMed:10806483" FT CONFLICT 229 FT /note="N -> D (in Ref. 4; AAH26158)" FT /evidence="ECO:0000305" FT CONFLICT 971..986 FT /note="Missing (in Ref. 6)" FT /evidence="ECO:0000305" FT CONFLICT 1003 FT /note="G -> V (in Ref. 1; AAF97028)" FT /evidence="ECO:0000305" SQ SEQUENCE 1315 AA; 143995 MW; 793F4638F1871C01 CRC64; MEKYHVLEMI GEGSFGRVYK GRRKYSAQVV ALKFIPKLGR SEKELRNLQR EIEIMRGLRH PNIVHMLDSF ETDKEVVVVT DYAEGELFQI LEDDGKLPED QVQAIAAQLV SALYYLHSHR ILHRDMKPQN ILLAKGGGIK LCDFGFARAM STNTMVLTSI KGTPLYMSPE LVEERPYDHT ADLWSVGCIL YELAVGTPPF YATSIFQLVS LILKDPVRWP STISPCFKNF LQGLLTKDPR QRLSWPDLLY HPFIAGHVTI ITEPAGPDLG TPFTSRLPPE LQVLKDEQAH RLAPKGNQSR ILTQAYKRMA EEAMQKKHQN TGPALEQEDK TSKVAPGTAP LPRLGATPQE SSLLAGILAS ELKSSWAKSG TGEVPSAPRE NRTTPDCERA FPEERPEVLG QRSTDVVDLE NEEPDSDNEW QHLLETTEPV PIQLKAPLTL LCNPDFCQRI QSQLHEAGGQ ILKGILEGAS HILPAFRVLS SLLSSCSDSV ALYSFCREAG LPGLLLSLLR HSQESNSLQQ QSWYGTFLQD LMAVIQAYFA CTFNLERSQT SDSLQVFQEA ANLFLDLLGK LLAQPDDSEQ TLRRDSLMCF TVLCEAMDGN SRAISKAFYS SLLTTQQVVL DGLLHGLTVP QLPVHTPQGA PQVSQPLREQ SEDIPGAISS ALAAICTAPV GLPDCWDAKE QVCWHLANQL TEDSSQLRPS LISGLQHPIL CLHLLKVLYS CCLVSEGLCR LLGQEPLALE SLFMLIQGKV KVVDWEESTE VTLYFLSLLV FRLQNLPCGM EKLGSDVATL FTHSHVVSLV SAAACLLGQL GQQGVTFDLQ PMEWMAAATH ALSAPAEVRL TPPGSCGFYD GLLILLLQLL TEQGKASLIR DMSSSEMWTV LWHRFSMVLR LPEEASAQEG ELSLSSPPSP EPDWTLISPQ GMAALLSLAM ATFTQEPQLC LSCLSQHGSI LMSILKHLLC PSFLNQLRQA PHGSEFLPVV VLSVCQLLCF PFALDMDADL LIGVLADLRD SEVAAHLLQV CCYHLPLMQV ELPISLLTRL ALMDPTSLNQ FVNTVSASPR TIVSFLSVAL LSDQPLLTSD LLSLLAHTAR VLSPSHLSFI QELLAGSDES YRPLRSLLGH PENSVRAHTY RLLGHLLQHS MALRGALQSQ SGLLSLLLLG LGDKDPVVRC SASFAVGNAA YQAGPLGPAL AAAVPSMTQL LGDPQAGIRR NVASALGNLG PEGLGEELLQ CEVPQRLLEM ACGDPQPNVK EAALIALRSL QQEPGIHQVL VSLGASEKLS LLSLGNQSLP HSSPRPASAK HCRKLIHLLR PAHSM // ID THMS2_HUMAN Reviewed; 643 AA. AC Q5TEJ8; A2RTZ3; B4DZT9; B4DZY3; O60560; Q5TEJ1; Q5TEJ9; Q5TEK1; Q68DP4; AC Q9BYB6; Q9NS90; DT 30-AUG-2005, integrated into UniProtKB/Swiss-Prot. DT 21-DEC-2004, sequence version 1. DT 28-JAN-2026, entry version 146. DE RecName: Full=Protein THEMIS2 {ECO:0000305}; DE AltName: Full=Induced by contact to basement membrane 1 protein {ECO:0000303|PubMed:20644716}; DE Short=Protein ICB-1; DE AltName: Full=Thymocyte-expressed molecule involved in selection protein 2; GN Name=THEMIS2 {ECO:0000312|HGNC:HGNC:16839}; GN Synonyms=C1orf38, ICB1 {ECO:0000303|PubMed:20644716}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6), NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 4-643 (ISOFORM 5), AND VARIANT GLU-511. RC TISSUE=Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 112-643 (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Endometrial adenocarcinoma; RX PubMed=9563507; DOI=10.1016/s0014-5793(98)00278-6; RA Treeck O., Strunck E., Vollmer G.; RT "A novel basement membrane-induced gene identified in the human endometrial RT adenocarcinoma cell line HEC1B."; RL FEBS Lett. 425:426-430(1998). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 112-643 (ISOFORM 3), NUCLEOTIDE RP SEQUENCE [LARGE SCALE MRNA] OF 143-643 (ISOFORM 2), AND VARIANT GLU-511. RC TISSUE=Leukocyte; RA Tanaka K., Imai H., Odani T., Tachibana M., Fujita S.; RL Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases. RN [7] RP FUNCTION. RX PubMed=20644716; DOI=10.1371/journal.pone.0011465; RA Peirce M.J., Brook M., Morrice N., Snelgrove R., Begum S., Lanfrancotti A., RA Notley C., Hussell T., Cope A.P., Wait R.; RT "Themis2/ICB1 is a signaling scaffold that selectively regulates macrophage RT Toll-like receptor signaling and cytokine production."; RL PLoS ONE 5:E11465-E11465(2010). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-593, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). CC -!- FUNCTION: May constitute a control point in macrophage inflammatory CC response, promoting LPS-induced TLR4-mediated TNF production CC (PubMed:20644716). Determines the threshold for activation of B cells CC by low-affinity and low-avidity ligands via PLCG2 activation and its CC downstream pathways (By similarity). {ECO:0000250|UniProtKB:Q91YX0, CC ECO:0000269|PubMed:20644716}. CC -!- SUBUNIT: Interacts with VAV1. Interacts with LAT. Interacts CC constitutively with GRB2, LYN and PLCG2; these interactions increase CC the activation of PLCG2 and its downstream pathways following B cell CC receptor stimulation. {ECO:0000250|UniProtKB:Q91YX0}. CC -!- INTERACTION: CC Q5TEJ8; Q7Z3S9: NOTCH2NLA; NbExp=4; IntAct=EBI-2806032, EBI-945833; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q91YX0}. Cytoplasm CC {ECO:0000250|UniProtKB:Q91YX0}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q5TEJ8-1; Sequence=Displayed; CC Name=2; Synonyms=ICB1-beta; CC IsoId=Q5TEJ8-2; Sequence=VSP_015326, VSP_015327; CC Name=3; Synonyms=ICB1-gamma; CC IsoId=Q5TEJ8-3; Sequence=VSP_015330; CC Name=4; CC IsoId=Q5TEJ8-4; Sequence=VSP_015328, VSP_015329; CC Name=5; CC IsoId=Q5TEJ8-5; Sequence=VSP_037967; CC Name=6; CC IsoId=Q5TEJ8-6; Sequence=VSP_037966; CC -!- TISSUE SPECIFICITY: Expressed in different endometrial adenocarcinoma CC cell lines and various other cell lines apart from the prostate cell CC line LNCaP and the ovarian cancer cell line BG1. CC {ECO:0000269|PubMed:9563507}. CC -!- INDUCTION: By contact to a reconstituted basement membrane. CC -!- PTM: Phosphorylation at Tyr-632 is induced by LPS. Phosphorylated by CC Src kinases (Lck or Fyn) following BCR engagement. CC {ECO:0000250|UniProtKB:Q91YX0}. CC -!- SIMILARITY: Belongs to the themis family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC16284.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=BAA96464.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB33313.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAG64201.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAI21769.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAI21771.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAI21773.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; CR749321; CAH18176.1; -; mRNA. DR EMBL; AK303090; BAG64201.1; ALT_INIT; mRNA. DR EMBL; AK303141; BAG64245.1; -; mRNA. DR EMBL; AL109927; CAI21769.1; ALT_SEQ; Genomic_DNA. DR EMBL; AL109927; CAI21770.1; -; Genomic_DNA. DR EMBL; AL109927; CAI21771.1; ALT_SEQ; Genomic_DNA. DR EMBL; AL109927; CAI21772.1; -; Genomic_DNA. DR EMBL; AL109927; CAI21773.1; ALT_SEQ; Genomic_DNA. DR EMBL; BC031655; AAH31655.2; -; mRNA. DR EMBL; BC132692; AAI32693.1; -; mRNA. DR EMBL; BC133049; AAI33050.1; -; mRNA. DR EMBL; AF044895; AAC16284.1; ALT_FRAME; mRNA. DR EMBL; AB050854; BAB33313.1; ALT_INIT; mRNA. DR EMBL; AB035482; BAA96464.1; ALT_INIT; mRNA. DR CCDS; CCDS30653.1; -. [Q5TEJ8-2] DR CCDS; CCDS30654.1; -. [Q5TEJ8-4] DR CCDS; CCDS41290.1; -. [Q5TEJ8-1] DR CCDS; CCDS65461.1; -. [Q5TEJ8-5] DR RefSeq; NP_001034566.1; NM_001039477.3. [Q5TEJ8-4] DR RefSeq; NP_001099026.1; NM_001105556.3. [Q5TEJ8-1] DR RefSeq; NP_001273042.1; NM_001286113.2. [Q5TEJ8-5] DR RefSeq; NP_001273044.1; NM_001286115.2. [Q5TEJ8-6] DR RefSeq; NP_004839.2; NM_004848.4. [Q5TEJ8-2] DR RefSeq; XP_006711113.1; XM_006711050.2. [Q5TEJ8-3] DR AlphaFoldDB; Q5TEJ8; -. DR BioGRID; 114858; 4. DR FunCoup; Q5TEJ8; 67. DR IntAct; Q5TEJ8; 9. DR STRING; 9606.ENSP00000363031; -. DR iPTMnet; Q5TEJ8; -. DR PhosphoSitePlus; Q5TEJ8; -. DR BioMuta; THEMIS2; -. DR DMDM; 73920021; -. DR jPOST; Q5TEJ8; -. DR MassIVE; Q5TEJ8; -. DR PaxDb; 9606-ENSP00000363031; -. DR PeptideAtlas; Q5TEJ8; -. DR ProteomicsDB; 65054; -. [Q5TEJ8-1] DR ProteomicsDB; 65055; -. [Q5TEJ8-2] DR ProteomicsDB; 65056; -. [Q5TEJ8-3] DR ProteomicsDB; 65057; -. [Q5TEJ8-4] DR ProteomicsDB; 65058; -. [Q5TEJ8-5] DR ProteomicsDB; 65059; -. [Q5TEJ8-6] DR Pumba; Q5TEJ8; -. DR Antibodypedia; 30867; 106 antibodies from 21 providers. DR DNASU; 9473; -. DR Ensembl; ENST00000328928.11; ENSP00000329862.7; ENSG00000130775.17. [Q5TEJ8-5] DR Ensembl; ENST00000373921.8; ENSP00000363031.3; ENSG00000130775.17. [Q5TEJ8-1] DR Ensembl; ENST00000373925.5; ENSP00000363035.1; ENSG00000130775.17. [Q5TEJ8-2] DR Ensembl; ENST00000373927.7; ENSP00000363037.3; ENSG00000130775.17. [Q5TEJ8-4] DR GeneID; 9473; -. DR KEGG; hsa:9473; -. DR MANE-Select; ENST00000373921.8; ENSP00000363031.3; NM_001105556.3; NP_001099026.1. DR UCSC; uc001boz.5; human. [Q5TEJ8-1] DR AGR; HGNC:16839; -. DR ClinPGx; PA128394550; -. DR CTD; 9473; -. DR DisGeNET; 9473; -. DR GeneCards; THEMIS2; -. DR HGNC; HGNC:16839; THEMIS2. DR HPA; ENSG00000130775; Tissue enhanced (bone marrow, lymphoid tissue). DR MIM; 617856; gene. DR OpenTargets; ENSG00000130775; -. DR VEuPathDB; HostDB:ENSG00000130775; -. DR eggNOG; ENOG502QSJR; Eukaryota. DR GeneTree; ENSGT00530000063770; -. DR HOGENOM; CLU_1069427_0_0_1; -. DR InParanoid; Q5TEJ8; -. DR OMA; RPEYEVQ; -. DR OrthoDB; 9030353at2759; -. DR PAN-GO; Q5TEJ8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q5TEJ8; -. DR PathwayCommons; Q5TEJ8; -. DR SignaLink; Q5TEJ8; -. DR Agora; ENSG00000130775; -. DR BioGRID-ORCS; 9473; 18 hits in 1161 CRISPR screens. DR ChiTaRS; THEMIS2; human. DR GenomeRNAi; 9473; -. DR Pharos; Q5TEJ8; Tbio. DR PRO; PR:Q5TEJ8; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q5TEJ8; protein. DR Bgee; ENSG00000130775; Expressed in monocyte and 160 other cell types or tissues. DR ExpressionAtlas; Q5TEJ8; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0007155; P:cell adhesion; TAS:ProtInc. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0050864; P:regulation of B cell activation; ISS:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; IBA:GO_Central. DR InterPro; IPR025946; CABIT_dom. DR InterPro; IPR039671; THEMIS. DR PANTHER; PTHR15215; CABIT DOMAIN-CONTAINING PROTEIN; 1. DR PANTHER; PTHR15215:SF2; PROTEIN THEMIS2; 1. DR Pfam; PF12736; CABIT; 2. PE 1: Evidence at protein level; KW Alternative splicing; Cytoplasm; Immunity; Inflammatory response; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..643 FT /note="Protein THEMIS2" FT /id="PRO_0000084143" FT REGION 1..238 FT /note="CABIT 1" FT REGION 239..514 FT /note="CABIT 2" FT REGION 546..631 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 609..619 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 593 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 632 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q91YX0" FT VAR_SEQ 79..123 FT /note="GYFTPLNTPQSYETLEELVSATTQSSKQLPTCFMSTHRIVTEGRV -> VFS FT SLRIAATRSAAQTQGEDLARVHQGWLQYVQQDSCPQEGPQAR (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_015328" FT VAR_SEQ 124..643 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_015329" FT VAR_SEQ 186..381 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037966" FT VAR_SEQ 216..260 FT /note="MRRTIVKIPSTLEVDVEDVTASSRHVHFIKPLLLSEVLAWEGPFP -> IFS FT SLRIAATRSAAQTQGEDLARVHQGWLQYVQQDSCPQEGPQAR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.6" FT /id="VSP_015326" FT VAR_SEQ 252..396 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.6" FT /id="VSP_015330" FT VAR_SEQ 261..643 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.6" FT /id="VSP_015327" FT VAR_SEQ 268..396 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037967" FT VARIANT 431 FT /note="V -> L (in dbSNP:rs35995543)" FT /id="VAR_051060" FT VARIANT 511 FT /note="K -> E (in dbSNP:rs3766400)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.6" FT /id="VAR_051061" FT CONFLICT 451 FT /note="L -> M (in Ref. 6; AAC16284)" FT /evidence="ECO:0000305" FT CONFLICT 466 FT /note="T -> N (in Ref. 6; AAC16284)" FT /evidence="ECO:0000305" FT CONFLICT 504 FT /note="W -> R (in Ref. 6; AAC16284)" FT /evidence="ECO:0000305" FT CONFLICT 538 FT /note="R -> C (in Ref. 6; AAC16284)" FT /evidence="ECO:0000305" FT CONFLICT 584 FT /note="A -> V (in Ref. 6; AAC16284)" FT /evidence="ECO:0000305" SQ SEQUENCE 643 AA; 72049 MW; 1D5FA24F88D2F8EA CRC64; MEPVPLQDFV RALDPASLPR VLRVCSGVYF EGSIYEISGN ECCLSTGDLI KVTQVRLQKV VCENPKTSQT MELAPNFQGY FTPLNTPQSY ETLEELVSAT TQSSKQLPTC FMSTHRIVTE GRVVTEDQLL MLEAVVMHLG IRSARCVLGM EGQQVILHLP LSQKGPFWTW EPSAPRTLLQ VLQDPALKDL VLTCPTLPWH SLILRPQYEI QAIMHMRRTI VKIPSTLEVD VEDVTASSRH VHFIKPLLLS EVLAWEGPFP LSMEILEVPE GRPIFLSPWV GSLQKGQRLC VYGLASPPWR VLASSKGRKV PRHFLVSGGY QGKLRRRPRE FPTAYDLLGA FQPGRPLRVV ATKDCEGERE ENPEFTSLAV GDRLEVLGPG QAHGAQGSDV DVLVCQRLSD QAGEDEEEEC KEEAESPERV LLPFHFPGSF VEEMSDSRRY SLADLTAQFS LPCEVKVVAK DTSHPTDPLT SFLGLRLEEK ITEPFLVVSL DSEPGMCFEI PPRWLDLTVV KAKGQPDLPE GSLPIATVEE LTDTFYYRLR KLPACEIQAP PPRPPKNQGL SKQRRHSSEG GVKSSQVLGL QQHARLPKPK AKTLPEFIKD GSSTYSKIPA HRKGHRPAKP QRQDLDDDEH DYEEILEQFQ KTI // ID TITIN_HUMAN Reviewed; 34350 AA. AC Q8WZ42; A0A0A0MTS7; A6NKB1; C9JQJ2; E7EQE6; E7ET18; K7ENY1; Q10465; Q10466; AC Q15598; Q2XUS3; Q32Q60; Q4U1Z6; Q4ZG20; Q6NSG0; Q6PDB1; Q6PJP0; Q7KYM2; AC Q7KYN4; Q7KYN5; Q7LDM3; Q7Z2X3; Q8TCG8; Q8WZ51; Q8WZ52; Q8WZ53; Q8WZB3; AC Q92761; Q92762; Q9UD97; Q9UP84; Q9Y6L9; DT 13-JUN-2006, integrated into UniProtKB/Swiss-Prot. DT 18-APR-2012, sequence version 4. DT 28-JAN-2026, entry version 220. DE RecName: Full=Titin; DE EC=2.7.11.1; DE AltName: Full=Connectin; DE AltName: Full=Rhabdomyosarcoma antigen MU-RMS-40.14; GN Name=TTN; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF RP 3336-12202 (ISOFORM 4), AND VARIANTS ILE-498; GLU-1201; MET-3261; ASN-3419; RP SER-3491; GLU-12679; ILE-19762; ILE-20718; ASN-23807; MET-24980 AND RP THR-27755. RC TISSUE=Skeletal muscle; RX PubMed=7569978; DOI=10.1126/science.270.5234.293; RA Labeit S., Kolmerer B.; RT "Titins, giant proteins in charge of muscle ultrastructure and RT elasticity."; RL Science 270:293-296(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS RP LEU-1295; GLN-1572; ILE-2610; ASN-2831; SER-3491; PRO-4215; PHE-4283 AND RP ARG-12383. RX PubMed=10850961; DOI=10.1161/01.res.86.11.1114; RA Freiburg A., Trombitas K., Hell W., Cazorla O., Fougerousse F., Centner T., RA Kolmerer B., Witt C., Beckmann J.S., Gregorio C.C., Granzier H., Labeit S.; RT "Series of exon-skipping events in the elastic spring region of titin as RT the structural basis for myofibrillar elastic diversity."; RL Circ. Res. 86:1114-1121(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, TISSUE RP SPECIFICITY, INTERACTION WITH OBSCN, AND VARIANTS LEU-1295; GLN-1572; RP ILE-2610; ASN-2831; SER-3491; PRO-4215 AND PHE-4283. RX PubMed=11717165; DOI=10.1161/hh2301.100981; RA Bang M.-L., Centner T., Fornoff F., Geach A.J., Gotthardt M., McNabb M., RA Witt C.C., Labeit D., Gregorio C.C., Granzier H., Labeit S.; RT "The complete gene sequence of titin, expression of an unusual ~700 kDa RT titin isoform and its interaction with obscurin identify a novel Z-line to RT I-band linking system."; RL Circ. Res. 89:1065-1072(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-626 AND 34071-34350 (ISOFORM RP 3). RC TISSUE=Muscle, and Skeletal muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 405-709 (ISOFORMS 1 AND 2). RC TISSUE=Heart muscle; RX PubMed=8937992; DOI=10.1242/jcs.109.11.2747; RA Gautel M., Goulding D., Bullard B., Weber K., Furst D.O.; RT "The central Z-disk region of titin is assembled from a novel repeat in RT variable copy numbers."; RL J. Cell Sci. 109:2747-2754(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2023-2060, AND TISSUE SPECIFICITY. RC TISSUE=Heart muscle; RX PubMed=7819249; DOI=10.1021/bi00002a021; RA Musco G., Tziatzos C., Schuck P., Pastore A.; RT "Dissecting titin into its structural motifs: identification of an alpha RT helix near the N-terminus."; RL Biochemistry 34:553-561(1995). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3455-4473, AND VARIANTS PRO-4215 AND RP PHE-4283. RX PubMed=10051295; DOI=10.1161/01.cir.99.8.1022; RA Siu B.L., Niimura H., Osborne J.A., Fatkin D., MacRae C., Solomon S., RA Benson D.W., Seidman J.G., Seidman C.E.; RT "Familial dilated cardiomyopathy locus maps to chromosome 2q31."; RL Circulation 99:1022-1026(1999). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 9806-12017 (ISOFORM 5). RC TISSUE=Heart ventricle; RX PubMed=12785098; DOI=10.1023/a:1023410523184; RA Greaser M.L., Berri M., Warren C.M., Mozdziak P.E.; RT "Species variations in cDNA sequence and exon splicing patterns in the RT extensible I-band region of cardiac titin: relation to passive tension."; RL J. Muscle Res. Cell Motil. 23:473-482(2002). RN [10] RP PROTEIN SEQUENCE OF 11773-11783; 17908-17931; 18656-18669; 26545-26553; RP 28758-28774 AND 32920-32928, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12947-13797. RC TISSUE=Embryonic rhabdomyosarcoma; RA Behrends U., Gotz C., Mautner J.; RT "Serological identification of rhabdomyosarcoma antigens."; RL Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE OF 14257-14543. RX PubMed=8351016; DOI=10.1212/wnl.43.8.1581; RA Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K., RA Labeit S., Mygland A., Gilhus N.E., Aarli J.A.; RT "Titin antibodies in myasthenia gravis: identification of a major RT immunogenic region of titin."; RL Neurology 43:1581-1585(1993). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 21021-22120, AND NUCLEOTIDE SEQUENCE [GENOMIC RP DNA] OF 23754-24284. RX PubMed=1582406; DOI=10.1002/j.1460-2075.1992.tb05222.x; RA Labeit S., Gautel M., Lakey A., Trinick J.; RT "Towards a molecular understanding of titin."; RL EMBO J. 11:1711-1716(1992). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 29701-34350, AND PHOSPHORYLATION. RX PubMed=8404852; DOI=10.1002/j.1460-2075.1993.tb06061.x; RA Gautel M., Leonard K., Labeit S.; RT "Phosphorylation of KSF motifs in the C-terminal region of titin in RT differentiating myoblasts."; RL EMBO J. 12:3827-3834(1993). RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 33119-34350. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [16] RP INTERACTION WITH TCAP. RX PubMed=9645487; DOI=10.1016/s0014-5793(98)00501-8; RA Mues A., van der Ven P.F.M., Young P., Furst D.O., Gautel M.; RT "Two immunoglobulin-like domains of the Z-disc portion of titin interact in RT a conformation-dependent way with telethonin."; RL FEBS Lett. 428:111-114(1998). RN [17] RP INTERACTION WITH NEB. RX PubMed=12482578; DOI=10.1016/s0014-5793(02)03655-4; RA Ma K., Wang K.; RT "Interaction of nebulin SH3 domain with titin PEVK and myopalladin: RT implications for the signaling and assembly role of titin and nebulin."; RL FEBS Lett. 532:273-278(2002). RN [18] RP INTERACTION WITH FHL2. RX PubMed=12432079; DOI=10.1242/jcs.00181; RA Lange S., Auerbach D., McLoughlin P., Perriard E., Schafer B.W., RA Perriard J.-C., Ehler E.; RT "Subcellular targeting of metabolic enzymes to titin in heart muscle may be RT mediated by DRAL/FHL-2."; RL J. Cell Sci. 115:4925-4936(2002). RN [19] RP INTERACTION WITH ANK1. RX PubMed=12444090; DOI=10.1074/jbc.m209012200; RA Kontrogianni-Konstantopoulos A., Bloch R.J.; RT "The hydrophilic domain of small ankyrin-1 interacts with the two N- RT terminal immunoglobulin domains of titin."; RL J. Biol. Chem. 278:3985-3991(2003). RN [20] RP INTERACTION WITH ANKRD1; ANKRD2; ANKRD23 AND CAPN3. RX PubMed=14583192; DOI=10.1016/j.jmb.2003.09.012; RA Miller M.K., Bang M.-L., Witt C.C., Labeit D., Trombitas C., Watanabe K., RA Granzier H., McElhinny A.S., Gregorio C.C., Labeit S.; RT "The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family RT of titin filament-based stress response molecules."; RL J. Mol. Biol. 333:951-964(2003). RN [21] RP INTERACTION WITH CRYAB. RX PubMed=14676215; DOI=10.1074/jbc.m307473200; RA Bullard B., Ferguson C., Minajeva A., Leake M.C., Gautel M., Labeit D., RA Ding L., Labeit S., Horwitz J., Leonard K.R., Linke W.A.; RT "Association of the chaperone alphaB-crystallin with titin in heart RT muscle."; RL J. Biol. Chem. 279:7917-7924(2004). RN [22] RP INTERACTION WITH TRIM63 AND TRIM55. RX PubMed=15967462; DOI=10.1016/j.jmb.2005.05.021; RA Witt S.H., Granzier H., Witt C.C., Labeit S.; RT "MURF-1 and MURF-2 target a specific subset of myofibrillar proteins RT redundantly: towards understanding MURF-dependent muscle ubiquitination."; RL J. Mol. Biol. 350:713-722(2005). RN [23] RP INTERACTION WITH LAMIN, AND SUBCELLULAR LOCATION. RX PubMed=16410549; DOI=10.1242/jcs.02728; RA Zastrow M.S., Flaherty D.B., Benian G.M., Wilson K.L.; RT "Nuclear titin interacts with A- and B-type lamins in vitro and in vivo."; RL J. Cell Sci. 119:239-249(2006). RN [24] RP REVIEW. RX PubMed=16537787; DOI=10.1152/ajpheart.00816.2005; RA Hoshijima M.; RT "Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, RT titin, and associated structures."; RL Am. J. Physiol. 290:H1313-H1325(2006). RN [25] RP INTERACTION WITH CMYA5. RX PubMed=20634290; DOI=10.1074/jbc.m110.108720; RA Sarparanta J., Blandin G., Charton K., Vihola A., Marchand S., Milic A., RA Hackman P., Ehler E., Richard I., Udd B.; RT "Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to RT tibial and limb-girdle muscular dystrophies."; RL J. Biol. Chem. 285:30304-30315(2010). RN [26] RP STRUCTURE BY NMR OF 33483-33579. RX PubMed=7613868; DOI=10.1016/s0969-2126(01)00170-8; RA Pfuhl M., Pastore A.; RT "Tertiary structure of an immunoglobulin-like domain from the giant muscle RT protein titin: a new member of the I set."; RL Structure 3:391-401(1995). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 32172-32489, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH CALM, PHOSPHORYLATION AT TYR-32341, AND RP MUTAGENESIS OF LYS-32207 AND TYR-32341. RX PubMed=9804419; DOI=10.1038/27603; RA Mayans O., van der Ven P.F.M., Wilm M., Mues A., Young P., Furst D.O., RA Wilmanns M., Gautel M.; RT "Structural basis for activation of the titin kinase domain during RT myofibrillogenesis."; RL Nature 395:863-869(1998). RN [28] RP STRUCTURE BY NMR OF 22283-22385. RX PubMed=9782056; DOI=10.1016/s0969-2126(98)00129-4; RA Goll C.M., Pastore A., Nilges M.; RT "The three-dimensional structure of a type I module from titin: a prototype RT of intracellular fibronectin type III domains."; RL Structure 6:1291-1302(1998). RN [29] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2073-2171, AND DISULFIDE BOND. RX PubMed=11525170; DOI=10.1016/s0969-2126(01)00591-3; RA Mayans O., Wuerges J., Canela S., Gautel M., Wilmanns M.; RT "Structural evidence for a possible role of reversible disulphide bridge RT formation in the elasticity of the muscle protein titin."; RL Structure 9:331-340(2001). RN [30] RP X-RAY CRYSTALLOGRAPHY (2.44 ANGSTROMS) OF 1-196 IN COMPLEX WITH TCAP. RX PubMed=16407954; DOI=10.1038/nature04343; RA Zou P., Pinotsis N., Lange S., Song Y.-H., Popov A., Mavridis I., RA Mayans O.M., Gautel M., Wilmanns M.; RT "Palindromic assembly of the giant muscle protein titin in the sarcomeric RT Z-disk."; RL Nature 439:229-233(2006). RN [31] RP VARIANT CMH9 LEU-740. RX PubMed=10462489; DOI=10.1006/bbrc.1999.1221; RA Satoh M., Takahashi M., Sakamoto T., Hiroe M., Marumo F., Kimura A.; RT "Structural analysis of the titin gene in hypertrophic cardiomyopathy: RT identification of a novel disease gene."; RL Biochem. Biophys. Res. Commun. 262:411-417(1999). RN [32] RP INVOLVEMENT IN LGMDR10, AND VARIANT TMD PRO-34315. RX PubMed=12145747; DOI=10.1086/342380; RA Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J., RA De Seze J., Labeit S., Witt C., Peltonen L., Richard I., Udd B.; RT "Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the RT gene encoding the giant skeletal-muscle protein titin."; RL Am. J. Hum. Genet. 71:492-500(2002). RN [33] RP VARIANTS CMD1G MET-54; VAL-743; TYR-3799 AND ASN-4465, VARIANTS CYS-328; RP GLN-4084 AND PRO-4215, CHARACTERIZATION OF VARIANTS CMD1G MET-54 AND RP VAL-743, AND FUNCTION. RX PubMed=11846417; DOI=10.1006/bbrc.2002.6448; RA Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., Arimura T., Koyanagi T., RA Takahashi M., Hohda S., Ueda K., Nouchi T., Hiroe M., Marumo F., RA Imaizumi T., Yasunami M., Kimura A.; RT "Titin mutations as the molecular basis for dilated cardiomyopathy."; RL Biochem. Biophys. Res. Commun. 291:385-393(2002). RN [34] RP VARIANT CMD1G ARG-976. RX PubMed=11788824; DOI=10.1038/ng815; RA Gerull B., Gramlich M., Atherton J., McNabb M., Trombitas K., RA Sasse-Klaassen S., Seidman J.G., Seidman C., Granzier H., Labeit S., RA Frenneaux M., Thierfelder L.; RT "Mutations of TTN, encoding the giant muscle filament titin, cause familial RT dilated cardiomyopathy."; RL Nat. Genet. 30:201-204(2002). RN [35] RP VARIANT TMD ASN-34306. RX PubMed=12891679; DOI=10.1002/ana.10647; RA Van den Bergh P.Y.K., Bouquiaux O., Verellen C., Marchand S., Richard I., RA Hackman P., Udd B.; RT "Tibial muscular dystrophy in a Belgian family."; RL Ann. Neurol. 54:248-251(2003). RN [36] RP VARIANT CMD1G GLN-32996. RX PubMed=16465475; DOI=10.1007/s10974-005-9018-5; RA Matsumoto Y., Hayashi T., Inagaki N., Takahashi M., Hiroi S., Nakamura T., RA Arimura T., Nakamura K., Ashizawa N., Yasunami M., Ohe T., Yano K., RA Kimura A.; RT "Functional analysis of titin/connectin N2-B mutations found in RT cardiomyopathy."; RL J. Muscle Res. Cell Motil. 26:367-374(2005). RN [37] RP VARIANT MFM9 TRP-279, CHARACTERIZATION OF VARIANT MFM9 TRP-279, AND RP INTERACTION WITH NBR1. RX PubMed=15802564; DOI=10.1126/science.1110463; RA Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E., RA Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G., RA Hughes S.M., Marchand S., Sejersen T., Richard I., Edstroem L., Ehler E., RA Udd B., Gautel M.; RT "The kinase domain of titin controls muscle gene expression and protein RT turnover."; RL Science 308:1599-1603(2005). RN [38] RP INVOLVEMENT IN CMYO5. RX PubMed=17444505; DOI=10.1002/ana.21089; RA Carmignac V., Salih M.A.M., Quijano-Roy S., Marchand S., Al Rayess M.M., RA Mukhtar M.M., Urtizberea J.A., Labeit S., Guicheney P., Leturcq F., RA Gautel M., Fardeau M., Campbell K.P., Richard I., Estournet B., RA Ferreiro A.; RT "C-terminal titin deletions cause a novel early-onset myopathy with fatal RT cardiomyopathy."; RL Ann. Neurol. 61:340-351(2007). RN [39] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-60; MET-115; CYS-328; THR-360; ILE-498; RP MET-799; ILE-811; HIS-922; ASP-937; THR-1081; ARG-1137; GLU-1201; ALA-1202; RP LEU-1295; ASP-1345; THR-1347; HIS-1350; LEU-1353; VAL-1393; CYS-1416; RP PRO-1441; VAL-1544; GLN-1572; GLY-1658; GLN-1664; ASP-1692; LEU-1744; RP GLY-1772; ILE-1907; HIS-1998; LEU-2107; THR-2118; THR-2164; TYR-2240; RP SER-2392; PHE-2432; ILE-2610; MET-2771; PHE-2823; ASN-2831; ILE-2930; RP ARG-3154; GLU-3191; LEU-3238; GLY-3250; MET-3261; GLN-3367; LYS-3482; RP LYS-3570; VAL-3590; VAL-3762; PHE-3877; LEU-3965; PRO-4215; TRP-4238; RP PHE-4283; THR-4291; ASP-4303; GLU-4427; GLU-12310; ALA-12469; CYS-12642; RP LYS-12657; GLU-12679; PHE-12720; CYS-12798; GLY-13049; LYS-13083; RP LEU-13096; ARG-13099; ALA-13297; MET-13399; THR-13418; VAL-13428; RP THR-13430; LYS-13434; ASN-13469; ASN-13495; SER-13785; HIS-13870; RP ILE-14109; GLN-14131; THR-14208; VAL-14728; THR-14999; THR-15021; RP VAL-15520; ILE-15555; GLN-15620; ILE-15629; CYS-15635; GLN-15700; RP PRO-15705; MET-15837; HIS-16058; ILE-16067; THR-16090; HIS-16195; RP CYS-16409; PRO-16424; MET-16629; ARG-16877; ASP-17060; VAL-17637; RP HIS-17838; ASN-17866; GLU-17906; ALA-18094; SER-18109; THR-18164; RP LEU-18221; THR-18222; GLN-18726; ALA-18835; LYS-18881; SER-18939; RP GLN-19000; GLN-19060; LYS-19091; SER-19224; ILE-19367; LYS-19392; RP SER-19480; GLY-19495; HIS-19665; ILE-19762; ARG-19947; MET-19956; RP GLN-19992; CYS-20057; LEU-20075; LYS-20179; THR-20198; VAL-20198; RP HIS-20331; THR-20408; LYS-20564; ILE-20718; PRO-20726; ASN-20892; RP ARG-20894; GLU-21125; SER-21403; CYS-21730; GLN-21747; ARG-21851; RP ARG-21851; ARG-21925; HIS-21995; VAL-22045; HIS-22149; ILE-22160; RP THR-22261; ASN-22306; HIS-22357; PRO-22408; HIS-22537; LEU-22584; RP PRO-22646; ALA-22670; ASP-22770; THR-22801; TRP-22823; GLN-22968; RP LEU-23074; PHE-23079; ASN-23282; TYR-23303; CYS-23306; SER-23515; RP GLN-23551; ASN-23807; ASN-23872; ALA-23891; HIS-23933; MET-23939; RP LEU-23952; GLY-24098; SER-24119; ILE-24133; ALA-24159; ALA-24239; RP LYS-24265; THR-24584; THR-24781; HIS-24799; HIS-24954; MET-24980; RP HIS-25659; THR-25679; ALA-25720; LYS-25821; LYS-25859; LYS-25879; RP VAL-25923; ILE-26045; GLU-26059; VAL-26134; CYS-26477; TYR-26843; RP ARG-27346; CYS-27652; VAL-27728; LEU-27754; THR-27755; VAL-27929; RP LEU-28132; GLN-28168; HIS-28538; THR-28572; THR-28948; VAL-28986; RP GLU-28993; VAL-28998; MET-29070; VAL-29090; CYS-29419; PRO-29479; RP LEU-29880; GLU-29976; GLY-30042; CYS-30107; PHE-30125; PRO-30211; RP THR-30412; SER-30617; ILE-30674; ILE-30809; ILE-30818; LYS-30825; RP THR-30856; ASP-30887; SER-30887; HIS-30897; HIS-30907; HIS-30946; RP PHE-31081; CYS-31107; GLY-31124; SER-31156; THR-31246; HIS-31330; RP ARG-31690; GLN-31724; ILE-31725; SER-31732; ILE-31886; CYS-32097; RP ASN-32171; ILE-32248; HIS-32281; HIS-32323; TRP-32411; VAL-32558; RP VAL-32610; VAL-32637; ALA-32922; ARG-32943; HIS-32953; LEU-33213; RP CYS-33242; MET-33387; ASP-33419; MET-33536; GLN-33568; LYS-33616; RP LEU-33620; VAL-33886; THR-33899; PRO-33904; ILE-33955 AND ALA-34115. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [40] RP VARIANTS VAL-16046 AND GLN-32742. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [41] RP VARIANTS PRO-2963 AND GLN-14750. RX PubMed=25173926; DOI=10.1161/circgenetics.113.000486; RA Girolami F., Iascone M., Tomberli B., Bardi S., Benelli M., Marseglia G., RA Pescucci C., Pezzoli L., Sana M.E., Basso C., Marziliano N., Merlini P.A., RA Fornaro A., Cecchi F., Torricelli F., Olivotto I.; RT "Novel alpha-actinin 2 variant associated with familial hypertrophic RT cardiomyopathy and juvenile atrial arrhythmias: a massively parallel RT sequencing study."; RL Circ. Cardiovasc. Genet. 7:741-750(2014). CC -!- FUNCTION: Key component in the assembly and functioning of vertebrate CC striated muscles. By providing connections at the level of individual CC microfilaments, it contributes to the fine balance of forces between CC the two halves of the sarcomere. The size and extensibility of the CC cross-links are the main determinants of sarcomere extensibility CC properties of muscle. In non-muscle cells, seems to play a role in CC chromosome condensation and chromosome segregation during mitosis. CC Might link the lamina network to chromatin or nuclear actin, or both CC during interphase. {ECO:0000269|PubMed:11846417, CC ECO:0000269|PubMed:9804419}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Full activation of the protein kinase domain CC requires both phosphorylation of Tyr-32341, preventing it from blocking CC the catalytic aspartate residue, and binding of Ca/CALM to the C- CC terminal regulatory tail of the molecule which results in ATP binding CC to the kinase. {ECO:0000269|PubMed:9804419}. CC -!- SUBUNIT: Interacts with MYOM1, MYOM2, tropomyosin and myosin. Interacts CC with actin, primarily via the PEVK domains and with MYPN (By CC similarity). Interacts with FHL2, NEB, CRYAB, LMNA/lamin-A and CC LMNB/lamin-B. Interacts with TCAP/telethonin and/or ANK1 isoform CC Mu17/ank1.5, via the first two N-terminal immunoglobulin domains. CC Interacts with TRIM63 and TRIM55, through several domains including CC immunoglobulin domains 141 and 142. Interacts with ANKRD1, ANKRD2 and CC ANKRD23, via the region between immunoglobulin domains 77 and 78 and CC interacts with CAPN3, via immunoglobulin domain 79. Interacts with NBR1 CC through the protein kinase domain. Interacts with CALM/calmodulin. CC Isoform 6 interacts with OBSCN isoform 3. Interacts with CMYA5. CC {ECO:0000250, ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:12432079, CC ECO:0000269|PubMed:12444090, ECO:0000269|PubMed:12482578, CC ECO:0000269|PubMed:14583192, ECO:0000269|PubMed:14676215, CC ECO:0000269|PubMed:15802564, ECO:0000269|PubMed:15967462, CC ECO:0000269|PubMed:16407954, ECO:0000269|PubMed:16410549, CC ECO:0000269|PubMed:20634290, ECO:0000269|PubMed:9645487, CC ECO:0000269|PubMed:9804419}. CC -!- INTERACTION: CC Q8WZ42; P12814: ACTN1; NbExp=2; IntAct=EBI-681210, EBI-351710; CC Q8WZ42; P35609: ACTN2; NbExp=16; IntAct=EBI-681210, EBI-77797; CC Q8WZ42; P62158: CALM3; NbExp=2; IntAct=EBI-681210, EBI-397435; CC Q8WZ42; P20807: CAPN3; NbExp=4; IntAct=EBI-681210, EBI-5655000; CC Q8WZ42; O75953: DNAJB5; NbExp=4; IntAct=EBI-681210, EBI-5655937; CC Q8WZ42; O75923: DYSF; NbExp=17; IntAct=EBI-681210, EBI-2799016; CC Q8WZ42; P06733: ENO1; NbExp=3; IntAct=EBI-681210, EBI-353877; CC Q8WZ42; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-681210, EBI-373144; CC Q8WZ42; Q14324: MYBPC2; NbExp=14; IntAct=EBI-681210, EBI-5653200; CC Q8WZ42; Q13203: MYBPH; NbExp=3; IntAct=EBI-681210, EBI-5655165; CC Q8WZ42; P20929: NEB; NbExp=6; IntAct=EBI-681210, EBI-1049657; CC Q8WZ42; Q5VST9: OBSCN; NbExp=15; IntAct=EBI-681210, EBI-941850; CC Q8WZ42; O75147: OBSL1; NbExp=13; IntAct=EBI-681210, EBI-1223896; CC Q8WZ42; O15061: SYNM; NbExp=3; IntAct=EBI-681210, EBI-7843148; CC Q8WZ42; O15273: TCAP; NbExp=9; IntAct=EBI-681210, EBI-954089; CC Q8WZ42; Q969Q1: TRIM63; NbExp=3; IntAct=EBI-681210, EBI-5661333; CC Q8WZ42; Q8WZ42: TTN; NbExp=16; IntAct=EBI-681210, EBI-681210; CC Q8WZ42-3; O15273: TCAP; NbExp=2; IntAct=EBI-15564183, EBI-954089; CC Q8WZ42-3; Q8WZ42-3: TTN; NbExp=9; IntAct=EBI-15564183, EBI-15564183; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:16410549}. Nucleus CC {ECO:0000269|PubMed:16410549}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=13; CC Comment=A number of isoforms may be produced, ranging from 27000 to CC 33000 residues in different striated muscle tissues, the size of the CC full-length protein may be up to 38138 residues.; CC Name=1; CC IsoId=Q8WZ42-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WZ42-2; Sequence=VSP_019138; CC Name=3; Synonyms=Small cardiac N2-B; CC IsoId=Q8WZ42-3; Sequence=VSP_019139, VSP_019145; CC Name=4; Synonyms=Soleus; CC IsoId=Q8WZ42-4; Sequence=VSP_019142, VSP_019151; CC Name=5; CC IsoId=Q8WZ42-5; Sequence=VSP_019147, VSP_019148, VSP_019149, CC VSP_019150, VSP_019152; CC Name=6; Synonyms=Small cardiac novex-3; CC IsoId=Q8WZ42-6; Sequence=VSP_019143, VSP_019146; CC Name=7; Synonyms=Cardiac novex-2; CC IsoId=Q8WZ42-7; Sequence=VSP_019141, VSP_019144; CC Name=8; Synonyms=Cardiac novex-1; CC IsoId=Q8WZ42-8; Sequence=VSP_019140; CC Name=9; CC IsoId=Q8WZ42-9; Sequence=VSP_019139, VSP_042903, VSP_019145; CC Name=10; CC IsoId=Q8WZ42-10; Sequence=VSP_019139, VSP_019140, VSP_019145; CC Name=11; CC IsoId=Q8WZ42-11; Sequence=VSP_019142; CC Name=12; CC IsoId=Q8WZ42-12; Sequence=VSP_045935, VSP_045929, VSP_045930, CC VSP_045931, VSP_045932, VSP_045933, CC VSP_045934; CC Name=13; CC IsoId=Q8WZ42-13; Sequence=VSP_047142; CC -!- TISSUE SPECIFICITY: Isoforms 3, 7 and 8 are expressed in cardiac CC muscle. Isoform 4 is expressed in vertebrate skeletal muscle. Isoform 6 CC is expressed in skeletal muscle (at protein level). CC {ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7819249}. CC -!- DOMAIN: ZIS1 and ZIS5 regions contain multiple SPXR consensus sites for CC ERK- and CDK-like protein kinases as well as multiple SP motifs. ZIS1 CC could adopt a closed conformation which would block the TCAP-binding CC site. CC -!- DOMAIN: The PEVK region may serve as an entropic spring of a chain of CC structural folds and may also be an interaction site to other CC myofilament proteins to form interfilament connectivity in the CC sarcomere. CC -!- PTM: Autophosphorylated. {ECO:0000250}. CC -!- DISEASE: Myopathy, myofibrillar, 9, with early respiratory failure CC (MFM9) [MIM:603689]: An autosomal dominant myopathy characterized by CC adulthood onset of weakness in proximal, distal, axial and respiratory CC muscles. Pelvic girdle weakness, foot drop and neck weakness are the CC main symptoms at onset, but ultimately the weakness usually involves CC the proximal compartment of both upper and lower limbs. Additional CC features include variable degrees of Achilles tendon contractures, CC spinal rigidity and muscle hypertrophy. Respiratory involvement often CC leads to requirement for non-invasive ventilation support. CC {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, familial hypertrophic, 9 (CMH9) [MIM:613765]: CC A hereditary heart disorder characterized by ventricular hypertrophy, CC which is usually asymmetric and often involves the interventricular CC septum. The symptoms include dyspnea, syncope, collapse, palpitations, CC and chest pain. They can be readily provoked by exercise. The disorder CC has inter- and intrafamilial variability ranging from benign to CC malignant forms with high risk of cardiac failure and sudden cardiac CC death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1G (CMD1G) [MIM:604145]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:11788824, CC ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Tardive tibial muscular dystrophy (TMD) [MIM:600334]: CC Autosomal dominant, late-onset distal myopathy. Muscle weakness and CC atrophy are usually confined to the anterior compartment of the lower CC leg, in particular the tibialis anterior muscle. Clinical symptoms CC usually occur at age 35-45 years or much later. CC {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal recessive 10 CC (LGMDR10) [MIM:608807]: An autosomal recessive degenerative myopathy CC characterized by progressive weakness of the pelvic and shoulder girdle CC muscles. Severe disability is observed within 20 years of onset. CC {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital myopathy 5 with cardiomyopathy (CMYO5) CC [MIM:611705]: An autosomal recessive, early-onset muscular disorder CC characterized by dilated cardiomyopathy, delayed motor development with CC generalized muscle weakness predominantly affecting proximal and distal CC lower limbs. Skeletal muscle biopsies show minicore-like lesions with CC mitochondrial depletion and sarcomere disorganization, centralized CC nuclei, and type 1 fiber predominance. Dystrophic changes become CC apparent in the second decade. Cardiac muscle biopsies show disruption CC of myocardial architecture, nuclear hypertrophy, and endomysial CC fibrosis. Sudden death may occurr due to cardiomyopathy. CC {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In some isoforms, after the PEVK repeat region there is CC a long PEVK duplicated region. On account of this region, it has been CC very difficult to sequence the whole protein. The length of this region CC (ranging from 183 to 2174 residues), may be a key elastic element of CC titin. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH58824.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 553.; Evidence={ECO:0000305}; CC Sequence=AAH70170.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 627.; Evidence={ECO:0000305}; CC Sequence=CAA62188.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=CAD12455.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Titin entry; CC URL="https://en.wikipedia.org/wiki/Titin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X90568; CAA62188.1; ALT_FRAME; mRNA. DR EMBL; X90569; CAA62189.1; -; mRNA. DR EMBL; AJ277892; CAD12455.1; ALT_FRAME; Genomic_DNA. DR EMBL; AJ277892; CAD12456.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12457.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12458.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12459.1; -; Genomic_DNA. DR EMBL; AC009948; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010680; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC023270; AAX88844.1; -; Genomic_DNA. DR EMBL; FJ695199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF459616; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013396; AAH13396.1; -; mRNA. DR EMBL; BC058824; AAH58824.1; ALT_SEQ; mRNA. DR EMBL; BC070170; AAH70170.1; ALT_SEQ; mRNA. DR EMBL; BC107797; AAI07798.1; -; mRNA. DR EMBL; X98114; CAA66795.1; -; mRNA. DR EMBL; X98115; CAA66796.1; -; mRNA. DR EMBL; X83270; CAA58243.1; -; mRNA. DR EMBL; AF058332; AAD22603.1; -; Genomic_DNA. DR EMBL; AF058332; AAD22604.1; -; Genomic_DNA. DR EMBL; AF525413; AAP80791.1; -; mRNA. DR EMBL; DQ248309; ABB55264.1; -; mRNA. DR EMBL; X64698; CAA45939.1; -; mRNA. DR EMBL; X64699; CAA45940.1; -; Genomic_DNA. DR EMBL; X64697; CAA45938.1; -; mRNA. DR EMBL; X69490; CAA49245.1; -; mRNA. DR EMBL; AL713647; CAD28458.1; -; mRNA. DR CCDS; CCDS33337.1; -. [Q8WZ42-6] DR CCDS; CCDS54421.1; -. [Q8WZ42-3] DR CCDS; CCDS54422.1; -. [Q8WZ42-9] DR CCDS; CCDS54423.1; -. [Q8WZ42-10] DR CCDS; CCDS54424.1; -. [Q8WZ42-11] DR CCDS; CCDS59435.1; -. [Q8WZ42-12] DR PIR; I38344; I38344. DR PIR; I38346; I38346. DR RefSeq; NP_001243779.1; NM_001256850.1. [Q8WZ42-1] DR RefSeq; NP_001254479.2; NM_001267550.2. [Q8WZ42-12] DR RefSeq; NP_003310.4; NM_003319.4. [Q8WZ42-3] DR RefSeq; NP_596869.4; NM_133378.4. [Q8WZ42-11] DR RefSeq; NP_596870.2; NM_133379.5. [Q8WZ42-6] DR RefSeq; NP_597676.3; NM_133432.3. [Q8WZ42-10] DR PDB; 1BPV; NMR; -; A=22283-22385. DR PDB; 1G1C; X-ray; 2.10 A; A/B=2073-2171. DR PDB; 1NCT; NMR; -; A=33483-33579. DR PDB; 1NCU; NMR; -; A=33483-33579. DR PDB; 1TIT; NMR; -; A=12680-12765. DR PDB; 1TIU; NMR; -; A=12680-12765. DR PDB; 1TKI; X-ray; 2.00 A; A/B=32172-32492. DR PDB; 1TNM; NMR; -; A=33489-33579. DR PDB; 1TNN; NMR; -; A=33489-33579. DR PDB; 1WAA; X-ray; 1.80 A; A/B/C/D/E/F=12677-12765. DR PDB; 1YA5; X-ray; 2.44 A; A/B=1-196. DR PDB; 2A38; X-ray; 2.00 A; A/B/C=1-194. DR PDB; 2BK8; X-ray; 1.69 A; A=32497-32590. DR PDB; 2F8V; X-ray; 2.75 A; A/B/C/D=1-196. DR PDB; 2ILL; X-ray; 2.20 A; A=31854-32047. DR PDB; 2J8H; X-ray; 1.99 A; A=31854-32047. DR PDB; 2J8O; X-ray; 2.49 A; A/B=31854-32047. DR PDB; 2NZI; X-ray; 2.90 A; A/B=31854-32155. DR PDB; 2RQ8; NMR; -; A=12677-12765. DR PDB; 2WP3; X-ray; 1.48 A; T=34252-34350. DR PDB; 2WWK; X-ray; 1.70 A; T=34252-34350. DR PDB; 2WWM; X-ray; 2.30 A; D/T=34252-34350. DR PDB; 2Y9R; X-ray; 1.90 A; T=34252-34350. DR PDB; 3B43; X-ray; 3.30 A; A=7945-8511. DR PDB; 3KNB; X-ray; 1.40 A; A=34253-34350. DR PDB; 3LCY; X-ray; 2.50 A; A/B/C/D=31456-31649. DR PDB; 3LPW; X-ray; 1.65 A; A/B=22877-23070. DR PDB; 3PUC; X-ray; 0.96 A; A=33774-33871. DR PDB; 3Q5O; X-ray; 2.05 A; A/B=34253-34350. DR PDB; 3QP3; X-ray; 2.00 A; A/B/C=33294-33395. DR PDB; 4C4K; X-ray; 1.95 A; T=34252-34350. DR PDB; 4JNW; X-ray; 2.06 A; A/B=32172-32492. DR PDB; 4O00; X-ray; 1.85 A; A/B=14217-14319. DR PDB; 4QEG; X-ray; 2.00 A; A=2880-2967. DR PDB; 4UOW; X-ray; 3.30 A; 1/3/5/7/9/B/D/F/H/J/L/N/P/R/T/V/X/Z=7-99. DR PDB; 5BS0; X-ray; 2.40 A; C=24337-24345. DR PDB; 5JDD; X-ray; 1.53 A; A=2795-3053. DR PDB; 5JDE; X-ray; 1.90 A; A/B=2795-3053. DR PDB; 5JDJ; X-ray; 1.74 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=2880-2967. DR PDB; 5JOE; X-ray; 2.00 A; A=9582-9671. DR PDB; 6DL4; NMR; -; A=1821-1931. DR PDB; 6FWX; X-ray; 3.00 A; A/B=1-243. DR PDB; 6H4L; X-ray; 1.60 A; A=33294-33395. DR PDB; 6HCI; X-ray; 2.12 A; A/B/C/D=32712-32816. DR PDB; 6I0Y; EM; 3.20 A; z=12677-12765. DR PDB; 6SDB; X-ray; 2.80 A; A/B/C/D/E=3-196. DR PDB; 6YGN; X-ray; 2.40 A; A/B=32046-32594. DR PDB; 7AHS; X-ray; 2.05 A; A/B/C/D=9582-9851. DR PDB; 7NIP; NMR; -; A=9504-9544. DR PDB; 8BNQ; X-ray; 2.30 A; A/B=23562-23862. DR PDB; 8BVO; X-ray; 2.55 A; A=14415-14609. DR PDB; 8BW6; X-ray; 1.95 A; A=14415-14509. DR PDB; 8BXR; X-ray; 2.70 A; A=14319-14615. DR PDB; 8G4L; EM; 6.40 A; am/an/bm/bn/m/n=22784-23867. DR PDB; 8OIY; X-ray; 2.10 A; A/B/C/D/E/F=14217-14319. DR PDB; 8OMW; X-ray; 1.05 A; A=16525-16630. DR PDB; 8OQ9; X-ray; 1.65 A; A/B/C=21497-21598. DR PDB; 8ORL; X-ray; 1.43 A; A/B/C=21497-21598. DR PDB; 8OS3; X-ray; 1.68 A; A=15210-15313. DR PDB; 8OSD; X-ray; 1.70 A; A/B=20511-20616. DR PDB; 8OT5; X-ray; 1.56 A; A/B/C/D/E/F=25430-25531. DR PDB; 8OTY; X-ray; 1.90 A; A/B/C/D=26124-26224. DR PDB; 8OVU; X-ray; 1.95 A; A/B=3500-3598. DR PDB; 8P35; X-ray; 2.20 A; A/B/C/D/E/F=3500-3598. DR PDBsum; 1BPV; -. DR PDBsum; 1G1C; -. DR PDBsum; 1NCT; -. DR PDBsum; 1NCU; -. DR PDBsum; 1TIT; -. DR PDBsum; 1TIU; -. DR PDBsum; 1TKI; -. DR PDBsum; 1TNM; -. DR PDBsum; 1TNN; -. DR PDBsum; 1WAA; -. DR PDBsum; 1YA5; -. DR PDBsum; 2A38; -. DR PDBsum; 2BK8; -. DR PDBsum; 2F8V; -. DR PDBsum; 2ILL; -. DR PDBsum; 2J8H; -. DR PDBsum; 2J8O; -. DR PDBsum; 2NZI; -. DR PDBsum; 2RQ8; -. DR PDBsum; 2WP3; -. DR PDBsum; 2WWK; -. DR PDBsum; 2WWM; -. DR PDBsum; 2Y9R; -. DR PDBsum; 3B43; -. DR PDBsum; 3KNB; -. DR PDBsum; 3LCY; -. DR PDBsum; 3LPW; -. DR PDBsum; 3PUC; -. DR PDBsum; 3Q5O; -. DR PDBsum; 3QP3; -. DR PDBsum; 4C4K; -. DR PDBsum; 4JNW; -. DR PDBsum; 4O00; -. DR PDBsum; 4QEG; -. DR PDBsum; 4UOW; -. DR PDBsum; 5BS0; -. DR PDBsum; 5JDD; -. DR PDBsum; 5JDE; -. DR PDBsum; 5JDJ; -. DR PDBsum; 5JOE; -. DR PDBsum; 6DL4; -. DR PDBsum; 6FWX; -. DR PDBsum; 6H4L; -. DR PDBsum; 6HCI; -. DR PDBsum; 6I0Y; -. DR PDBsum; 6SDB; -. DR PDBsum; 6YGN; -. DR PDBsum; 7AHS; -. DR PDBsum; 7NIP; -. DR PDBsum; 8BNQ; -. DR PDBsum; 8BVO; -. DR PDBsum; 8BW6; -. DR PDBsum; 8BXR; -. DR PDBsum; 8G4L; -. DR PDBsum; 8OIY; -. DR PDBsum; 8OMW; -. DR PDBsum; 8OQ9; -. DR PDBsum; 8ORL; -. DR PDBsum; 8OS3; -. DR PDBsum; 8OSD; -. DR PDBsum; 8OT5; -. DR PDBsum; 8OTY; -. DR PDBsum; 8OVU; -. DR PDBsum; 8P35; -. DR EMDB; EMD-0322; -. DR EMDB; EMD-29722; -. DR SASBDB; Q8WZ42; -. DR SMR; Q8WZ42; -. DR BioGRID; 113124; 328. DR ComplexPortal; CPX-101; Titin-Telethonin complex. DR CORUM; Q8WZ42; -. DR DIP; DIP-33449N; -. DR FunCoup; Q8WZ42; 665. DR IntAct; Q8WZ42; 167. DR MINT; Q8WZ42; -. DR STRING; 9606.ENSP00000467141; -. DR MoonDB; Q8WZ42; Predicted. DR CarbonylDB; Q8WZ42; -. DR GlyCosmos; Q8WZ42; 11 sites, 2 glycans. DR GlyGen; Q8WZ42; 39 sites, 3 O-linked glycans (22 sites). DR iPTMnet; Q8WZ42; -. DR MetOSite; Q8WZ42; -. DR PhosphoSitePlus; Q8WZ42; -. DR SwissPalm; Q8WZ42; -. DR BioMuta; TTN; -. DR jPOST; Q8WZ42; -. DR MassIVE; Q8WZ42; -. DR PaxDb; 9606-ENSP00000467141; -. DR PeptideAtlas; Q8WZ42; -. DR ProteomicsDB; 75209; -. [Q8WZ42-1] DR ProteomicsDB; 75210; -. [Q8WZ42-10] DR ProteomicsDB; 75211; -. [Q8WZ42-11] DR ProteomicsDB; 75212; -. [Q8WZ42-2] DR ProteomicsDB; 75213; -. [Q8WZ42-3] DR ProteomicsDB; 75214; -. [Q8WZ42-4] DR ProteomicsDB; 75215; -. [Q8WZ42-5] DR ProteomicsDB; 75216; -. [Q8WZ42-6] DR ProteomicsDB; 75217; -. [Q8WZ42-7] DR ProteomicsDB; 75218; -. [Q8WZ42-8] DR ProteomicsDB; 75219; -. [Q8WZ42-9] DR Pumba; Q8WZ42; -. DR ABCD; Q8WZ42; 2 sequenced antibodies. DR Antibodypedia; 2056; 211 antibodies from 28 providers. DR DNASU; 7273; -. DR Ensembl; ENST00000342992.11; ENSP00000343764.6; ENSG00000155657.29. [Q8WZ42-11] DR Ensembl; ENST00000359218.11; ENSP00000352154.5; ENSG00000155657.29. [Q8WZ42-10] DR Ensembl; ENST00000360870.10; ENSP00000354117.4; ENSG00000155657.29. [Q8WZ42-6] DR Ensembl; ENST00000412264.2; ENSP00000394672.2; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000460472.6; ENSP00000434586.1; ENSG00000155657.29. [Q8WZ42-3] DR Ensembl; ENST00000589042.5; ENSP00000467141.1; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000591111.5; ENSP00000465570.1; ENSG00000155657.29. [Q8WZ42-1] DR GeneID; 7273; -. DR KEGG; hsa:7273; -. DR MANE-Select; ENST00000589042.5; ENSP00000467141.1; NM_001267550.2; NP_001254479.2. [Q8WZ42-12] DR UCSC; uc002unb.4; human. [Q8WZ42-1] DR UCSC; uc031rqc.3; human. DR AGR; HGNC:12403; -. DR ClinPGx; PA37067; -. DR CTD; 7273; -. DR DisGeNET; 7273; -. DR GeneCards; TTN; -. DR GeneReviews; TTN; -. DR HGNC; HGNC:12403; TTN. DR HPA; ENSG00000155657; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; TTN; -. DR MIM; 188840; gene. DR MIM; 600334; phenotype. DR MIM; 603689; phenotype. DR MIM; 604145; phenotype. DR MIM; 608807; phenotype. DR MIM; 611705; phenotype. DR MIM; 613765; phenotype. DR OpenTargets; ENSG00000155657; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR Orphanet; 466921; Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome. DR Orphanet; 324604; Classic multiminicore myopathy. DR Orphanet; 707983; Early-onset autosomal recessive TTN-related distal myopathy. DR Orphanet; 289377; Early-onset myopathy with fatal cardiomyopathy. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 334; Hereditary atrial fibrillation. DR Orphanet; 178464; Hereditary myopathy with early respiratory failure. DR Orphanet; 293888; Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant. DR Orphanet; 293910; Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant. DR Orphanet; 293899; Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant. DR Orphanet; 609; Tibial muscular dystrophy. DR Orphanet; 140922; Titin-related limb-girdle muscular dystrophy R10. DR VEuPathDB; HostDB:ENSG00000155657; -. DR eggNOG; KOG0613; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT01150000286978; -. DR HOGENOM; CLU_000001_1_0_1; -. DR InParanoid; Q8WZ42; -. DR OMA; TSSWPEY; -. DR OrthoDB; 5969272at2759; -. DR PAN-GO; Q8WZ42; 0 GO annotations based on evolutionary models. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q8WZ42; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-390522; Striated Muscle Contraction. DR SignaLink; Q8WZ42; -. DR SIGNOR; Q8WZ42; -. DR Agora; ENSG00000155657; -. DR BioGRID-ORCS; 7273; 10 hits in 1181 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR ChiTaRS; TTN; human. DR EvolutionaryTrace; Q8WZ42; -. DR GeneWiki; Titin; -. DR GenomeRNAi; 7273; -. DR Pharos; Q8WZ42; Tbio. DR PRO; PR:Q8WZ42; -. DR Proteomes; UP000005640; Chromosome 2. DR Bgee; ENSG00000155657; Expressed in gluteal muscle and 163 other cell types or tissues. DR ExpressionAtlas; Q8WZ42; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IEA:UniProtKB-ARBA. DR GO; GO:0000794; C:condensed nuclear chromosome; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0031674; C:I band; IDA:BHF-UCL. DR GO; GO:0031430; C:M band; IDA:BHF-UCL. DR GO; GO:0005865; C:striated muscle thin filament; IDA:BHF-UCL. DR GO; GO:1990733; C:titin-telethonin complex; IPI:ComplexPortal. DR GO; GO:0030018; C:Z disc; IDA:BHF-UCL. DR GO; GO:0051015; F:actin filament binding; IDA:BHF-UCL. DR GO; GO:0042805; F:actinin binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0005516; F:calmodulin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0051371; F:muscle alpha-actinin binding; IPI:BHF-UCL. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL. DR GO; GO:0019887; F:protein kinase regulator activity; IMP:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI. DR GO; GO:0008307; F:structural constituent of muscle; IMP:BHF-UCL. DR GO; GO:0097493; F:structural molecule activity conferring elasticity; IDA:BHF-UCL. DR GO; GO:0031433; F:telethonin binding; IPI:BHF-UCL. DR GO; GO:0055013; P:cardiac muscle cell development; IMP:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL. DR GO; GO:0003300; P:cardiac muscle hypertrophy; IMP:BHF-UCL. DR GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; IMP:BHF-UCL. DR GO; GO:0035995; P:detection of muscle stretch; IDA:MGI. DR GO; GO:0007076; P:mitotic chromosome condensation; IEP:BHF-UCL. DR GO; GO:0006936; P:muscle contraction; TAS:UniProtKB. DR GO; GO:0030049; P:muscle filament sliding; NAS:ComplexPortal. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA. DR GO; GO:0050714; P:positive regulation of protein secretion; IMP:CAFA. DR GO; GO:0010737; P:protein kinase A signaling; IMP:CAFA. DR GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL. DR GO; GO:0045214; P:sarcomere organization; IMP:BHF-UCL. DR GO; GO:0048769; P:sarcomerogenesis; IMP:BHF-UCL. DR GO; GO:0003009; P:skeletal muscle contraction; NAS:ComplexPortal. DR GO; GO:0030241; P:skeletal muscle myosin thick filament assembly; IMP:BHF-UCL. DR GO; GO:0030240; P:skeletal muscle thin filament assembly; IMP:BHF-UCL. DR GO; GO:0006941; P:striated muscle contraction; TAS:UniProtKB. DR CDD; cd00063; FN3; 132. DR CDD; cd00096; Ig; 31. DR CDD; cd05748; Ig_Titin_like; 28. DR CDD; cd20974; IgI_1_Titin_Z1z2-like; 2. DR CDD; cd20972; IgI_2_Titin_Z1z2-like; 1. DR CDD; cd20951; IgI_titin_I1-like; 1. DR CDD; cd05747; IgI_Titin_like; 1. DR CDD; cd20927; IgI_Titin_M1-like; 1. DR CDD; cd14104; STKc_Titin; 1. DR DisProt; DP00072; -. DR FunFam; 2.60.40.10:FF:000022; Cardiac titin; 44. DR FunFam; 2.60.40.10:FF:000800; Cardiac titin; 1. DR FunFam; 2.60.40.10:FF:000345; Muscle M-line assembly protein unc-89; 1. DR FunFam; 2.60.40.10:FF:001284; Myomesin 2; 1. DR FunFam; 2.60.40.10:FF:000147; Myosin light chain kinase; 2. DR FunFam; 2.60.40.10:FF:000107; Myosin, light chain kinase a; 2. DR FunFam; 2.60.40.10:FF:000031; Myosin-binding protein C, slow type; 7. DR FunFam; 2.60.40.10:FF:001867; Titin; 1. DR FunFam; 2.60.40.10:FF:001911; Titin; 1. DR FunFam; 1.10.510.10:FF:000329; Titin a; 1. DR FunFam; 2.60.40.10:FF:000002; Titin a; 32. DR FunFam; 2.60.40.10:FF:000112; Titin a; 8. DR FunFam; 2.60.40.10:FF:000135; Titin a; 7. DR FunFam; 2.60.40.10:FF:000160; Titin a; 1. DR FunFam; 2.60.40.10:FF:000547; Titin a; 2. DR FunFam; 2.60.40.10:FF:000672; Titin a; 1. DR FunFam; 2.60.40.10:FF:000673; Titin a; 1. DR FunFam; 2.60.40.10:FF:000811; Titin a; 1. DR FunFam; 2.60.40.10:FF:000867; Titin a; 1. DR FunFam; 2.60.40.10:FF:000891; Titin a; 1. DR FunFam; 2.60.40.10:FF:000900; Titin a; 1. DR FunFam; 2.60.40.10:FF:000981; Titin a; 1. DR FunFam; 2.60.40.10:FF:001200; Titin a; 1. DR FunFam; 2.60.40.10:FF:001399; Titin a; 1. DR FunFam; 2.60.40.10:FF:001400; Titin a; 1. DR FunFam; 2.60.40.10:FF:001459; Titin a; 1. DR FunFam; 2.60.40.10:FF:001500; Titin a; 1. DR FunFam; 2.60.40.10:FF:001579; Titin a; 1. DR FunFam; 2.60.40.10:FF:001697; Titin a; 1. DR FunFam; 3.30.200.20:FF:000286; Titin a; 1. DR FunFam; 2.60.40.10:FF:000011; Titin b; 11. DR FunFam; 2.60.40.10:FF:000629; Titin b; 1. DR FunFam; 2.60.40.10:FF:000635; Titin b; 1. DR FunFam; 2.60.40.10:FF:000779; Titin b; 1. DR FunFam; 2.60.40.10:FF:000833; Titin b; 1. DR FunFam; 2.60.40.10:FF:000859; Titin b; 1. DR FunFam; 2.60.40.10:FF:000864; Titin b; 1. DR FunFam; 2.60.40.10:FF:000901; Titin b; 1. DR FunFam; 2.60.40.10:FF:000980; Titin b; 1. DR FunFam; 2.60.40.10:FF:000986; Titin b; 1. DR FunFam; 2.60.40.10:FF:001115; Titin b; 1. DR FunFam; 2.60.40.10:FF:001190; Titin b; 1. DR FunFam; 2.60.40.10:FF:001477; Titin b; 1. DR FunFam; 2.60.40.10:FF:000034; Titin isoform A; 26. DR FunFam; 2.60.40.10:FF:000050; Titin isoform B; 8. DR FunFam; 2.60.40.10:FF:000003; Titin isoform E; 22. DR FunFam; 2.60.40.10:FF:000012; titin isoform X1; 26. DR FunFam; 2.60.40.10:FF:000073; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000127; titin isoform X1; 4. DR FunFam; 2.60.40.10:FF:000148; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000214; titin isoform X1; 7. DR FunFam; 2.60.40.10:FF:000218; titin isoform X1; 6. DR FunFam; 2.60.40.10:FF:000659; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000697; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000770; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000792; titin isoform X1; 2. DR FunFam; 2.60.40.10:FF:000983; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001003; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001213; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001229; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001272; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001327; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001328; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001342; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001343; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001344; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001345; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001350; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001365; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001367; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001382; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001385; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001408; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001430; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001434; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001454; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001476; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001544; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001581; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001610; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001612; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001663; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000714; Titin novex-3; 3. DR FunFam; 2.60.40.10:FF:001082; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001089; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001098; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001116; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001804; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:001844; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002231; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002123; Titin, tandem duplicate 1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 299. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013106; Ig_V-set. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR040849; MyBP-C_THB. DR InterPro; IPR004168; PPAK_motif. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR015129; Titin_Z_rpt. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR14340; MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 3; 1. DR PANTHER; PTHR14340:SF13; TITIN; 1. DR Pfam; PF00041; fn3; 132. DR Pfam; PF07679; I-set; 162. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF02818; PPAK; 9. DR Pfam; PF18362; THB; 1. DR Pfam; PF09042; Titin_Z; 2. DR SMART; SM00060; FN3; 132. DR SMART; SM00409; IG; 167. DR SMART; SM00408; IGc2; 148. DR SMART; SM00406; IGv; 23. DR SUPFAM; SSF49265; Fibronectin type III; 74. DR SUPFAM; SSF48726; Immunoglobulin; 167. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 132. DR PROSITE; PS50835; IG_LIKE; 143. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Calcium; KW Calmodulin-binding; Cardiomyopathy; Coiled coil; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Limb-girdle muscular dystrophy; Magnesium; KW Metal-binding; Myofibrillar myopathy; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..34350 FT /note="Titin" FT /id="PRO_0000239311" FT DOMAIN 6..96 FT /note="Ig-like 1" FT DOMAIN 104..192 FT /note="Ig-like 2" FT REPEAT 417..462 FT /note="Z-repeat 1" FT REPEAT 466..511 FT /note="Z-repeat 2" FT REPEAT 512..554 FT /note="Z-repeat 3" FT REPEAT 555..600 FT /note="Z-repeat 4" FT REPEAT 601..646 FT /note="Z-repeat 5" FT REPEAT 647..691 FT /note="Z-repeat 6" FT REPEAT 692..740 FT /note="Z-repeat 7" FT DOMAIN 943..1031 FT /note="Ig-like 3" FT DOMAIN 1082..1172 FT /note="Ig-like 4" FT DOMAIN 1291..1382 FT /note="Ig-like 5" FT DOMAIN 1457..1546 FT /note="Ig-like 6" FT DOMAIN 1556..1646 FT /note="Ig-like 7" FT DOMAIN 1703..1793 FT /note="Ig-like 8" FT DOMAIN 1841..1928 FT /note="Ig-like 9" FT DOMAIN 2078..2167 FT /note="Ig-like 10" FT DOMAIN 2171..2262 FT /note="Ig-like 11" FT DOMAIN 2264..2354 FT /note="Ig-like 12" FT DOMAIN 2353..2443 FT /note="Ig-like 13" FT DOMAIN 2430..2529 FT /note="Ig-like 14" FT DOMAIN 2620..2703 FT /note="Ig-like 15" FT DOMAIN 2880..2965 FT /note="Ig-like 16" FT DOMAIN 2968..3050 FT /note="Ig-like 17" FT DOMAIN 3058..3141 FT /note="Ig-like 18" FT DOMAIN 3239..3327 FT /note="Ig-like 19" FT DOMAIN 3344..3432 FT /note="Ig-like 20" FT DOMAIN 3503..3586 FT /note="Ig-like 21" FT DOMAIN 3621..3712 FT /note="Ig-like 22" FT DOMAIN 4289..4376 FT /note="Ig-like 23" FT DOMAIN 4383..4471 FT /note="Ig-like 24" FT DOMAIN 4478..4566 FT /note="Ig-like 25" FT DOMAIN 4571..4659 FT /note="Ig-like 26" FT DOMAIN 4664..4753 FT /note="Ig-like 27" FT DOMAIN 4758..4846 FT /note="Ig-like 28" FT DOMAIN 4851..4936 FT /note="Ig-like 29" FT DOMAIN 4943..5032 FT /note="Ig-like 30" FT DOMAIN 5040..5128 FT /note="Ig-like 31" FT DOMAIN 5133..5221 FT /note="Ig-like 32" FT DOMAIN 5225..5314 FT /note="Ig-like 33" FT DOMAIN 5320..5408 FT /note="Ig-like 34" FT DOMAIN 5413..5501 FT /note="Ig-like 35" FT DOMAIN 5505..5594 FT /note="Ig-like 36" FT DOMAIN 5602..5690 FT /note="Ig-like 37" FT DOMAIN 5695..5783 FT /note="Ig-like 38" FT DOMAIN 5788..5877 FT /note="Ig-like 39" FT DOMAIN 5882..5970 FT /note="Ig-like 40" FT DOMAIN 5975..6063 FT /note="Ig-like 41" FT DOMAIN 6067..6156 FT /note="Ig-like 42" FT DOMAIN 6164..6252 FT /note="Ig-like 43" FT DOMAIN 6257..6347 FT /note="Ig-like 44" FT DOMAIN 6350..6440 FT /note="Ig-like 45" FT DOMAIN 6444..6534 FT /note="Ig-like 46" FT DOMAIN 6537..6626 FT /note="Ig-like 47" FT DOMAIN 6630..6721 FT /note="Ig-like 48" FT DOMAIN 6727..6815 FT /note="Ig-like 49" FT DOMAIN 6820..6908 FT /note="Ig-like 50" FT DOMAIN 6912..7001 FT /note="Ig-like 51" FT DOMAIN 7005..7093 FT /note="Ig-like 52" FT DOMAIN 7102..7190 FT /note="Ig-like 53" FT DOMAIN 7198..7286 FT /note="Ig-like 54" FT DOMAIN 7291..7380 FT /note="Ig-like 55" FT DOMAIN 7385..7473 FT /note="Ig-like 56" FT DOMAIN 7478..7567 FT /note="Ig-like 57" FT DOMAIN 7571..7662 FT /note="Ig-like 58" FT DOMAIN 7668..7756 FT /note="Ig-like 59" FT DOMAIN 7761..7849 FT /note="Ig-like 60" FT DOMAIN 7853..7942 FT /note="Ig-like 61" FT DOMAIN 7946..8035 FT /note="Ig-like 62" FT DOMAIN 8042..8133 FT /note="Ig-like 63" FT DOMAIN 8138..8229 FT /note="Ig-like 64" FT DOMAIN 8232..8321 FT /note="Ig-like 65" FT DOMAIN 8326..8414 FT /note="Ig-like 66" FT DOMAIN 8419..8508 FT /note="Ig-like 67" FT DOMAIN 8512..8603 FT /note="Ig-like 68" FT DOMAIN 8609..8697 FT /note="Ig-like 69" FT DOMAIN 8702..8790 FT /note="Ig-like 70" FT DOMAIN 8794..8883 FT /note="Ig-like 71" FT DOMAIN 8888..8976 FT /note="Ig-like 72" FT DOMAIN 8984..9074 FT /note="Ig-like 73" FT DOMAIN 9079..9168 FT /note="Ig-like 74" FT DOMAIN 9176..9265 FT /note="Ig-like 75" FT DOMAIN 9272..9361 FT /note="Ig-like 76" FT DOMAIN 9366..9470 FT /note="Ig-like 77" FT DOMAIN 9660..9755 FT /note="Ig-like 78" FT DOMAIN 9760..9851 FT /note="Ig-like 79" FT REPEAT 10216..10242 FT /note="PEVK 1" FT REPEAT 10244..10270 FT /note="PEVK 2" FT REPEAT 10272..10298 FT /note="PEVK 3" FT REPEAT 10300..10326 FT /note="PEVK 4" FT REPEAT 10327..10353 FT /note="PEVK 5" FT REPEAT 10355..10381 FT /note="PEVK 6" FT REPEAT 10508..10534 FT /note="PEVK 7" FT REPEAT 10536..10562 FT /note="PEVK 8" FT REPEAT 10592..10618 FT /note="PEVK 9" FT REPEAT 10878..10904 FT /note="PEVK 10" FT REPEAT 10906..10930 FT /note="PEVK 11" FT REPEAT 10932..10958 FT /note="PEVK 12" FT REPEAT 10960..10986 FT /note="PEVK 13" FT REPEAT 10987..11014 FT /note="PEVK 14" FT REPEAT 11363..11396 FT /note="PEVK 15" FT REPEAT 11397..11421 FT /note="PEVK 16" FT REPEAT 11453..11479 FT /note="PEVK 17" FT REPEAT 11481..11507 FT /note="PEVK 18" FT REPEAT 11509..11535 FT /note="PEVK 19" FT REPEAT 11537..11563 FT /note="PEVK 20" FT REPEAT 11565..11591 FT /note="PEVK 21" FT REPEAT 11657..11683 FT /note="PEVK 22" FT REPEAT 11703..11729 FT /note="PEVK 23" FT REPEAT 11745..11771 FT /note="PEVK 24" FT REPEAT 11775..11801 FT /note="PEVK 25" FT REPEAT 11836..11862 FT /note="PEVK 26" FT REPEAT 11864..11890 FT /note="PEVK 27" FT REPEAT 11893..11919 FT /note="PEVK 28" FT REPEAT 11929..11955 FT /note="PEVK 29" FT REPEAT 11966..11992 FT /note="PEVK 30" FT REPEAT 11996..12022 FT /note="PEVK 31" FT DOMAIN 12041..12133 FT /note="Ig-like 80" FT DOMAIN 12138..12222 FT /note="Ig-like 81" FT DOMAIN 12233..12318 FT /note="Ig-like 82" FT DOMAIN 12499..12584 FT /note="Ig-like 83" FT DOMAIN 12590..12672 FT /note="Ig-like 84" FT DOMAIN 12766..12850 FT /note="Ig-like 85" FT DOMAIN 12945..13032 FT /note="Ig-like 86" FT DOMAIN 13120..13206 FT /note="Ig-like 87" FT DOMAIN 13210..13295 FT /note="Ig-like 88" FT DOMAIN 13299..13384 FT /note="Ig-like 89" FT DOMAIN 13388..13478 FT /note="Ig-like 90" FT DOMAIN 13479..13562 FT /note="Ig-like 91" FT DOMAIN 13565..13655 FT /note="Ig-like 92" FT DOMAIN 13659..13748 FT /note="Ig-like 93" FT DOMAIN 13749..13833 FT /note="Ig-like 94" FT DOMAIN 13927..14012 FT /note="Ig-like 95" FT DOMAIN 14019..14114 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14120..14215 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14221..14316 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14417..14513 FT /note="Fibronectin type-III 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14517..14614 FT /note="Fibronectin type-III 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14615..14708 FT /note="Ig-like 96" FT DOMAIN 14713..14806 FT /note="Fibronectin type-III 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14812..14907 FT /note="Fibronectin type-III 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14913..15007 FT /note="Fibronectin type-III 8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15010..15107 FT /note="Fibronectin type-III 9" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15113..15207 FT /note="Fibronectin type-III 10" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15214..15310 FT /note="Fibronectin type-III 11" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15314..15402 FT /note="Ig-like 97" FT DOMAIN 15409..15503 FT /note="Fibronectin type-III 12" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15509..15604 FT /note="Fibronectin type-III 13" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15608..15724 FT /note="Ig-like 98" FT DOMAIN 15731..15826 FT /note="Fibronectin type-III 14" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15832..15926 FT /note="Fibronectin type-III 15" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15929..16025 FT /note="Fibronectin type-III 16" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16029..16119 FT /note="Ig-like 99" FT DOMAIN 16126..16218 FT /note="Fibronectin type-III 17" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16224..16318 FT /note="Fibronectin type-III 18" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16322..16420 FT /note="Ig-like 100" FT DOMAIN 16427..16522 FT /note="Fibronectin type-III 19" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16528..16628 FT /note="Fibronectin type-III 20" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16634..16734 FT /note="Fibronectin type-III 21" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16727..16834 FT /note="Ig-like 101" FT DOMAIN 16841..16934 FT /note="Fibronectin type-III 22" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16941..17041 FT /note="Fibronectin type-III 23" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17044..17139 FT /note="Ig-like 102" FT DOMAIN 17147..17240 FT /note="Fibronectin type-III 24" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17246..17345 FT /note="Fibronectin type-III 25" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17348..17445 FT /note="Fibronectin type-III 26" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17449..17536 FT /note="Ig-like 103" FT DOMAIN 17545..17640 FT /note="Fibronectin type-III 27" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17646..17741 FT /note="Fibronectin type-III 28" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17745..17834 FT /note="Ig-like 104" FT DOMAIN 17842..17935 FT /note="Fibronectin type-III 29" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17941..18036 FT /note="Fibronectin type-III 30" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18042..18139 FT /note="Fibronectin type-III 31" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18143..18228 FT /note="Ig-like 105" FT DOMAIN 18239..18333 FT /note="Fibronectin type-III 32" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18339..18431 FT /note="Fibronectin type-III 33" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18435..18526 FT /note="Ig-like 106" FT DOMAIN 18533..18632 FT /note="Fibronectin type-III 34" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18633..18727 FT /note="Fibronectin type-III 35" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18733..18829 FT /note="Fibronectin type-III 36" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18833..18924 FT /note="Ig-like 107" FT DOMAIN 18931..19025 FT /note="Fibronectin type-III 37" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19030..19124 FT /note="Fibronectin type-III 38" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19128..19219 FT /note="Ig-like 108" FT DOMAIN 19226..19321 FT /note="Fibronectin type-III 39" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19325..19420 FT /note="Fibronectin type-III 40" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19426..19527 FT /note="Fibronectin type-III 41" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19531..19617 FT /note="Ig-like 109" FT DOMAIN 19628..19722 FT /note="Fibronectin type-III 42" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19728..19823 FT /note="Fibronectin type-III 43" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19826..19914 FT /note="Ig-like 110" FT DOMAIN 19921..20017 FT /note="Fibronectin type-III 44" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20018..20116 FT /note="Fibronectin type-III 45" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20119..20217 FT /note="Fibronectin type-III 46" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20220..20311 FT /note="Ig-like 111" FT DOMAIN 20318..20411 FT /note="Fibronectin type-III 47" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20417..20512 FT /note="Fibronectin type-III 48" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20518..20613 FT /note="Fibronectin type-III 49" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20716..20813 FT /note="Fibronectin type-III 50" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20814..20908 FT /note="Fibronectin type-III 51" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20893..20996 FT /note="Ig-like 112" FT DOMAIN 21006..21101 FT /note="Fibronectin type-III 52" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21105..21200 FT /note="Fibronectin type-III 53" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21203..21299 FT /note="Fibronectin type-III 54" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21303..21395 FT /note="Ig-like 113" FT DOMAIN 21402..21495 FT /note="Fibronectin type-III 55" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21501..21596 FT /note="Fibronectin type-III 56" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21602..21697 FT /note="Fibronectin type-III 57" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21701..21793 FT /note="Ig-like 114" FT DOMAIN 21797..21891 FT /note="Fibronectin type-III 58" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21894..21986 FT /note="Fibronectin type-III 59" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21990..22083 FT /note="Ig-like 115" FT DOMAIN 22088..22182 FT /note="Fibronectin type-III 60" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22188..22283 FT /note="Fibronectin type-III 61" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22286..22382 FT /note="Fibronectin type-III 62" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22386..22477 FT /note="Ig-like 116" FT DOMAIN 22484..22578 FT /note="Fibronectin type-III 63" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22584..22679 FT /note="Fibronectin type-III 64" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22685..22781 FT /note="Fibronectin type-III 65" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22785..22874 FT /note="Ig-like 117" FT DOMAIN 22881..22976 FT /note="Fibronectin type-III 66" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22978..23071 FT /note="Fibronectin type-III 67" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23075..23163 FT /note="Ig-like 118" FT DOMAIN 23170..23264 FT /note="Fibronectin type-III 68" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23270..23364 FT /note="Fibronectin type-III 69" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23368..23463 FT /note="Fibronectin type-III 70" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23468..23555 FT /note="Ig-like 119" FT DOMAIN 23566..23660 FT /note="Fibronectin type-III 71" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23666..23761 FT /note="Fibronectin type-III 72" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23767..23863 FT /note="Fibronectin type-III 73" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23867..23954 FT /note="Ig-like 120" FT DOMAIN 23963..24057 FT /note="Fibronectin type-III 74" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24060..24153 FT /note="Fibronectin type-III 75" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24157..24241 FT /note="Ig-like 121" FT DOMAIN 24252..24346 FT /note="Fibronectin type-III 76" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24352..24446 FT /note="Fibronectin type-III 77" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24450..24546 FT /note="Fibronectin type-III 78" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24550..24641 FT /note="Ig-like 122" FT DOMAIN 24648..24742 FT /note="Fibronectin type-III 79" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24748..24843 FT /note="Fibronectin type-III 80" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24849..24945 FT /note="Fibronectin type-III 81" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24949..25038 FT /note="Ig-like 123" FT DOMAIN 25045..25139 FT /note="Fibronectin type-III 82" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25142..25235 FT /note="Fibronectin type-III 83" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25239..25325 FT /note="Ig-like 124" FT DOMAIN 25335..25428 FT /note="Fibronectin type-III 84" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25434..25529 FT /note="Fibronectin type-III 85" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25532..25627 FT /note="Fibronectin type-III 86" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25632..25722 FT /note="Ig-like 125" FT DOMAIN 25731..25825 FT /note="Fibronectin type-III 87" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25831..25926 FT /note="Fibronectin type-III 88" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25932..26028 FT /note="Fibronectin type-III 89" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26032..26121 FT /note="Ig-like 126" FT DOMAIN 26128..26222 FT /note="Fibronectin type-III 90" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26225..26318 FT /note="Fibronectin type-III 91" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26322..26410 FT /note="Ig-like 127" FT DOMAIN 26417..26510 FT /note="Fibronectin type-III 92" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26516..26611 FT /note="Fibronectin type-III 93" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26614..26710 FT /note="Fibronectin type-III 94" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26714..26801 FT /note="Ig-like 128" FT DOMAIN 26812..26906 FT /note="Fibronectin type-III 95" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26912..27007 FT /note="Fibronectin type-III 96" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27013..27107 FT /note="Fibronectin type-III 97" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27101..27196 FT /note="Ig-like 129" FT DOMAIN 27205..27296 FT /note="Fibronectin type-III 98" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27302..27392 FT /note="Fibronectin type-III 99" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27499..27593 FT /note="Fibronectin type-III 100" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27599..27694 FT /note="Fibronectin type-III 101" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27697..27793 FT /note="Fibronectin type-III 102" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27797..27888 FT /note="Ig-like 130" FT DOMAIN 27895..27989 FT /note="Fibronectin type-III 103" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27995..28090 FT /note="Fibronectin type-III 104" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28096..28192 FT /note="Fibronectin type-III 105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28196..28286 FT /note="Ig-like 131" FT DOMAIN 28295..28389 FT /note="Fibronectin type-III 106" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28392..28484 FT /note="Fibronectin type-III 107" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28488..28577 FT /note="Ig-like 132" FT DOMAIN 28583..28680 FT /note="Fibronectin type-III 108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28686..28781 FT /note="Fibronectin type-III 109" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28784..28879 FT /note="Fibronectin type-III 110" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28882..28974 FT /note="Ig-like 133" FT DOMAIN 28979..29071 FT /note="Fibronectin type-III 111" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29081..29177 FT /note="Fibronectin type-III 112" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29180..29278 FT /note="Fibronectin type-III 113" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29282..29367 FT /note="Ig-like 134" FT DOMAIN 29378..29473 FT /note="Fibronectin type-III 114" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29475..29568 FT /note="Fibronectin type-III 115" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29568..29663 FT /note="Ig-like 135" FT DOMAIN 29670..29764 FT /note="Fibronectin type-III 116" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29770..29865 FT /note="Fibronectin type-III 117" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29868..29967 FT /note="Fibronectin type-III 118" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29971..30059 FT /note="Ig-like 136" FT DOMAIN 30070..30163 FT /note="Fibronectin type-III 119" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30169..30265 FT /note="Fibronectin type-III 120" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30271..30367 FT /note="Fibronectin type-III 121" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30371..30460 FT /note="Ig-like 137" FT DOMAIN 30467..30561 FT /note="Fibronectin type-III 122" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30564..30658 FT /note="Fibronectin type-III 123" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30663..30754 FT /note="Ig-like 138" FT DOMAIN 30761..30855 FT /note="Fibronectin type-III 124" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30861..30956 FT /note="Fibronectin type-III 125" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30962..31058 FT /note="Fibronectin type-III 126" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31061..31150 FT /note="Ig-like 139" FT DOMAIN 31158..31254 FT /note="Fibronectin type-III 127" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31258..31354 FT /note="Fibronectin type-III 128" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31360..31455 FT /note="Fibronectin type-III 129" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31460..31548 FT /note="Ig-like 140" FT DOMAIN 31653..31748 FT /note="Fibronectin type-III 130" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31754..31849 FT /note="Fibronectin type-III 131" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31855..31945 FT /note="Ig-like 141" FT DOMAIN 31955..32046 FT /note="Ig-like 142" FT DOMAIN 32051..32144 FT /note="Fibronectin type-III 132" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 32178..32432 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 32496..32584 FT /note="Ig-like 143" FT DOMAIN 32617..32710 FT /note="Ig-like 144" FT DOMAIN 32722..32811 FT /note="Ig-like 145" FT DOMAIN 33301..33391 FT /note="Ig-like 146" FT DOMAIN 33488..33576 FT /note="Ig-like 147" FT DOMAIN 33645..33732 FT /note="Ig-like 148" FT DOMAIN 33779..33867 FT /note="Ig-like 149" FT DOMAIN 33963..34052 FT /note="Ig-like 150" FT DOMAIN 34061..34149 FT /note="Ig-like 151" FT DOMAIN 34256..34344 FT /note="Ig-like 152" FT REGION 244..313 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 253..341 FT /note="ZIS1" FT REGION 333..356 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 859..886 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1408..1443 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1410..1440 FT /note="ZIS5" FT REGION 4241..4272 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 9920..9945 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10039..10070 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10087..10109 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10207..10280 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10314..10361 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10412..10457 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10499..10566 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10583..10617 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10661..10743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10882..11102 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11158..11193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11362..11636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11666..12032 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14216..14236 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14891..14921 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 15911..15939 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 16614..16654 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18614..18637 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18716..18743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 19304..19331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 27090..27110 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 31238..31267 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33213..33256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33432..33463 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33584..33638 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33749..33777 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 529..561 FT /evidence="ECO:0000255" FT COILED 2025..2052 FT /evidence="ECO:0000255" FT COILED 3462..3487 FT /evidence="ECO:0000255" FT COILED 9534..9577 FT /evidence="ECO:0000255" FT COMPBIAS 1408..1419 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 4245..4257 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9920..9938 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10041..10052 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10058..10070 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10087..10101 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10207..10224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10245..10265 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10329..10347 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10349..10360 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10418..10430 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10440..10457 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10684..10701 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10702..10720 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10721..10737 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10882..10944 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10961..10972 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10989..11009 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11030..11101 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11164..11190 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11388..11416 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11438..11453 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11454..11465 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11466..11479 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11496..11509 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11510..11521 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11538..11549 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11550..11563 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11580..11591 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11592..11613 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11614..11626 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11678..11696 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11704..11715 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11730..11745 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11768..11803 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11816..11825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11834..11846 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11854..11875 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11882..11900 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11927..11936 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11948..11958 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11960..11971 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11972..11981 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11982..11995 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11996..12008 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 14223..14236 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19318..19331 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31252..31262 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33231..33242 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33439..33450 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33594..33604 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33625..33634 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33749..33771 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 32298 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32184..32192 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32207 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 263 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 265 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 267 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 6920 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 9122 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 11503 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12007 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 12009 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12022 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 30443 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 32341 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:9804419" FT MOD_RES 33245 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33247 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33602 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33614 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT DISULFID 964..1015 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1724..1777 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2109..2134 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:11525170" FT DISULFID 2196..2246 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 3259..3311 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4404..4455 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4499..4550 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4592..4643 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4686..4737 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4779..4830 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5061..5112 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5248..5299 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5623..5674 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5810..5861 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5903..5954 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6185..6236 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6372..6423 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6465..6516 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6748..6799 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7027..7078 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7123..7174 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7219..7270 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7313..7364 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7406..7457 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7689..7740 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7968..8019 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8064..8115 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8160..8211 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8254..8305 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8347..8398 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8630..8681 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8909..8960 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9005..9056 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9101..9152 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9294..9345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9693..9743 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12067..12117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12611..12660 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12966..13016 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13233..13283 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13322..13372 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13411..13461 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13771..13821 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 31481..31532 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 32516..32568 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 33664..33718 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 555..646 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:8937992" FT /id="VSP_019138" FT VAR_SEQ 556..601 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019139" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPKVQALDRQSSGKDVRESTKSQAVADSSFTKEESKISQKEI FT KSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTG FT EAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQF FT LTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045935" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPK (in isoform 8 and isoform 10)" FT /evidence="ECO:0000305" FT /id="VSP_019140" FT VAR_SEQ 3434 FT /note="E -> EVQALDRQSSGKDVRESAKSQAVADSSFTKEESKISQKEIKSFQGSS FT YEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTGEAPKIFL FT HLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQFLTICNVQ FT LVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 9)" FT /evidence="ECO:0000305" FT /id="VSP_042903" FT VAR_SEQ 3435..3645 FT /note="APESILHERIEQEIEMEMKEFSSSFLSAEEEGLHSAELQLSKINETLELLSE FT SPVYPTKFDSEKEGTGPIFIKEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTP FT SADYKFVFDGDDHSLIILFTKLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTET FT ESAVAKSLEKLGGPCPPHFLKELKPIRCAQGLPAIFEYTVV -> VQALDRQSSGKDVR FT ESTKSQAVADSSFTKEESKISQKEIKSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQL FT CHTASLSQIAESTELSKECAKESTGEAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDV FT TWTHEGAKIEESERLKQSQNGNIQFLTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVE FT GAPESILHERIEQEIEMEMK (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019141" FT VAR_SEQ 3454..4380 FT /note="Missing (in isoform 4 and isoform 11)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019142" FT VAR_SEQ 3455..5604 FT /note="FSSSFLSAEEEGLHSAELQLSKINETLELLSESPVYPTKFDSEKEGTGPIFI FT KEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTPSADYKFVFDGDDHSLIILFT FT KLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTETESAVAKSLEKLGGPCPPHFL FT KELKPIRCAQGLPAIFEYTVVGEPAPTVTWFKENKQLCTSVYYTIIHNPNGSGTFIVND FT PQREDSGLYICKAENMLGESTCAAELLVLLEDTDMTDTPCKAKSTPEAPEDFPQTPLKG FT PAVEALDSEQEIATFVKDTILKAALITEENQQLSYEHIAKANELSSQLPLGAQELQSIL FT EQDKLTPESTREFLCINGSIHFQPLKEPSPNLQLQIVQSQKTFSKEGILMPEEPETQAV FT LSDTEKIFPSAMSIEQINSLTVEPLKTLLAEPEGNYPQSSIEPPMHSYLTSVAEEVLSP FT KEKTVSDTNREQRVTLQKQEAQSALILSQSLAEGHVESLQSPDVMISQVNYEPLVPSEH FT SCTEGGKILIESANPLENAGQDSAVRIEEGKSLRFPLALEEKQVLLKEEHSDNVVMPPD FT QIIESKREPVAIKKVQEVQGRDLLSKESLLSGIPEEQRLNLKIQICRALQAAVASEQPG FT LFSEWLRNIEKVEVEAVNITQEPRHIMCMYLVTSAKSVTEEVTIIIEDVDPQMANLKME FT LRDALCAIIYEEIDILTAEGPRIQQGAKTSLQEEMDSFSGSQKVEPITEPEVESKYLIS FT TEEVSYFNVQSRVKYLDATPVTKGVASAVVSDEKQDESLKPSEEKEESSSESGTEEVAT FT VKIQEAEGGLIKEDGPMIHTPLVDTVSEEGDIVHLTTSITNAKEVNWYFENKLVPSDEK FT FKCLQDQNTYTLVIDKVNTEDHQGEYVCEALNDSGKTATSAKLTVVKRAAPVIKRKIEP FT LEVALGHLAKFTCEIQSAPNVRFQWFKAGREIYESDKCSIRSSKYISSLEILRTQVVDC FT GEYTCKASNEYGSVSCTATLTVTEAYPPTFLSRPKSLTTFVGKAAKFICTVTGTPVIET FT IWQKDGAALSPSPNWRISDAENKHILELSNLTIQDRGVYSCKASNKFGADICQAELIII FT DKPHFIKELEPVQSAINKKVHLECQVDEDRKVTVTWSKDGQKLPPGKDYKICFEDKIAT FT LEIPLAKLKDSGTYVCTASNEAGSSSCSATVTVREPPSFVKKVDPSYLMLPGESARLHC FT KLKGSPVIQVTWFKNNKELSESNTVRMYFVNSEAILDITDVKVEDSGSYSCEAVNDVGS FT DSCSTEIVIKEPPSFIKTLEPADIVRGTNALLQCEVSGTGPFEISWFKDKKQIRSSKKY FT RLFSQKSLVCLEIFSFNSADVGEYECVVANEVGKCGCMATHLLKEPPTFVKKVDDLIAL FT GGQTVTLQAAVRGSEPISVTWMKGQEVIREDGKIKMSFSNGVAVLIIPDVQISFGGKYT FT CLAENEAGSQTSVGELIVKEPAKIIERAELIQVTAGDPATLEYTVAGTPELKPKWYKDG FT RPLVASKKYRISFKNNVAQLKFYSAELHDSGQYTFEISNEVGSSSCETTFTVLDRDIAP FT FFTKPLRNVDSVVNGTCRLDCKIAGSLPMRVSWFKDGKEIAASDRYRIAFVEGTASLEI FT IRVDMNDAGNFTCRATNSVGSKDSSGALIVQEPPSFVTKPGSKDVLPGSAVCLKSTFQG FT STPLTIRWFKGNKELVSGGSCYITKEALESSLELYLVKTSDSGTYTCKVSNVAGGVECS FT ANLFVKEPATFVEKLEPSQLLKKGDATQLACKVTGTPPIKITWFANDREIKESSKHRMS FT FVESTAVLRLTDVGIEDSGEYMCEAQNEAGSDHCSSIVIVKESPYFTKEFKPIEVLKEY FT DVMLLAEVAGTPPFEITWFKDNTILRSGRKYKTFIQDHLVSLQILKFVAADAGEYQCRV FT TNEVGSSICSARVTLREPPSFIKKIESTSSLRGGTAAFQATLKGSLPITVTWLKDSDEI FT TEDDNIRMTFENNVASLYLSGIEVKHDGKYVCQAKNDAGIQRCSALLSVKEPATITEEA FT VSIDVTQGDPATLQVKFSGTKEITAKWFKDGQELTLGSKYKISVTDTVSILKIISTEKK FT DSGEYTFEVQNDVGRSSCKARINVLDLIIPPSF -> LFSEGESEHSERDTRDAFSDSE FT DIDHKSMAAKRYASRISSTSSWPEYFKPSFTQKLTFKYVLEGEPVVFTCRLIACPTPEM FT TWFHNNRPIPTGLRRIIKAESDLHHHSSSLEIKRVQDRDSGSYRLLAINSEGSAESTAS FT LLVIQKGQDEKYLEFLKRAERTHENVEALVERGEDRIKVDLRFTGSPFNKKQDVEQKGM FT MRTIHFKTMSSAKKTDYMYDEEYLESKSDIRGWLNVGESFLDKETKVKLQRLREARKTL FT MEKKKLSLLDTSSEISSRTLRSEASDKDILFSREDMKIRSMSDLAESYKVDHSAESIVQ FT NPHALSNQMDQNIESEELPTSFQTIVDEEIFQTEIRMSQEALVKESLPKDHLYGEILVN FT ENTQARGQLEEIMANTTIGESSTYITNVCEKEEVYETPENVSQAITPHASESFGTLVNV FT EESEEIASERIKKDDLRELQLSASTRIDEFKTEQKEENMRFFENSFRKRPQRCPPSFLQ FT EIESQEVYEGDSCNFVCHFQGYPQPIVTWYNNDMPIPRNQNFIIHSLENYSILTLSSVH FT HQNEGSITCVLFNQYGTVKTTSMLKVKAKQKHDVKAHKVPVFHDYLDEEEELALVFDQA FT KGAHPSMSQEGQTNLHLLKTNPPVPPSGDTELLSFPVEIQVTAATPIPEQDKESKEVFQ FT TEELEPKAMPQDQVTQSPKHRFVFLSDITNEPPKMLQEMPKHARCREGDSIILECLISG FT EPQPVVTWFQNGVLLKQNQKFQFEEVNCSHQLYIKDVNSQDSGKYKCVAENNSGAVESV FT SDLTVEPVTYRENSQFENIGEIYGKYSRDQQLQDQGESVRAHFYDYPAGPFTPWTNVKE FT YSVRDYFQSLETIEQIDQKEQVRCIPSREKIPRFVHGASRTIKISKPIRAEFIQCQAEG FT KERHVSEKSKLHQAEGTVYPFVDDFSDVTIKKEIRNNFGKLGRSEKENVQECAQSDYLP FT NIHSERISDSYNTKDSSAIVYEESLGEEIHYPGKKVKHRIIEFEKLHVEKGVLEKRPTR FT TSIVNPPQKKIDDKAFSLKQRESRSSNLNANMYQAEKMSPNTESDSSNIAINLKLLSSQ FT THKEFDAQEREQQEKISLIDKPAISKRAEHESPITFDLKQFHTQIKHTDVKFQELDSGQ FT PEEAYFKIQHPADTENIVFDLKQMYSHIGDPALEFQGQETREQQEIHYKEKIPSPETLQ FT PDTHNISKSVQNNVFASQEISSSQELSNRTMVEKSSIDENSISLEKEVRHVQEQNLDIL FT KTDLSLKSFSEEIYSESCALLPTSSADIEETDLSEKSCPLENGGRSSISHLKKAASEEK FT PLGVGEMEEECTLEPELAAFPKQDGGTQEYTDATLEDHRGDVQEADTLHRQLSLSQCFP FT LLMTEEQQNPGEQISTNIHASGEEKCYEEVQVQNEASFSTLEGEMIETSFSQNIPKLDE FT AHTTEAAESETSLTQYLLAAGKREVPETKDTRDQAKLVQSESITSMEVEEVTFNTVYEY FT YNQKQESLGRPLSPESDISIGVGSTTSEEISELDQFYTPPSSVEYFESPKSPDLYFNPS FT DITKQSSIHSGGETVERYSTPLGEVAERYSTPSEGEVGERYSTPPGETLERYSTPPGET FT LERYSTPPGETLERYSTPPGETLERYSTPPGETLERYSTPPGEALERYSIPTGGPNPTG FT TFKTYPSKIEREDGTPNEHFYTPTEERGSAYEIWRSDSFGTPNEAIEPKDNEMPPSFIE FT PLTKRKVYENTTLGFIVEVEGLPVPGVKWYRNKSLLEPDERIKMERVGNVCSLEISNIQ FT KGEGGEYMCHAVNIIGEAKSFANVDIMPQEERVVALPPPVTHQHVMEFDLEHTTSSRTP FT SPQEIVLEVELSEKDVKEFEKQVKIVTVPEFTPDHKSMIVSLDVLPFNFVDPNMDSREG FT EDKELKIDLEVFEMPPRFIMPICDFKIPENSDAVFKCSVIGIPTPEVKWYKEYMCIEPD FT NIKYVISEEKGSHTLKIRNVCLSDSATYRCRAVNCVGEAICRGFLTMGDSEIFAVIAKK FT SKVTLSSLMEELVLKSNYTDSFFEFQVVEGPPRFIKGISDCYAPIGTAAYFQCLVRGSP FT RPTVYWYKDGKLVQGRRFTVEESGTGFHNLFITSLVKSDEGEYRCVATNKSGMAESFAA FT LTLT (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019143" FT VAR_SEQ 3646..4380 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019144" FT VAR_SEQ 4474..11851 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019145" FT VAR_SEQ 5605..34350 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019146" FT VAR_SEQ 10382..10645 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019147" FT VAR_SEQ 10742..10931 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019148" FT VAR_SEQ 11015..11163 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019149" FT VAR_SEQ 11117 FT /note="I -> VPKKPVPEKKVPVPAPKKVEPPPPPKVPEI (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045929" FT VAR_SEQ 11133 FT /note="E -> EAPPAKVSVVPKKPEPEKKVPPPGLKKAV (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045930" FT VAR_SEQ 11223..11852 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019150" FT VAR_SEQ 11421 FT /note="K -> KAPEVPKKIVPEEKVREAVLKKPEVPPAKVPGMPKKSVQEEKSPIVI FT SEDTEMYIYEASEEAVLEEKVLVTQPQKTKPKLAKVPEPPKKVVPEDKIYVTIPKKRET FT PATKEPDTTRGIFPEVEPPEAIPEIPEHPPTEEFEVFKEVIPEGETPIVKRRKTPSPTV FT PESPREIVPVKETPMAAPLEIEIPPTKAPEAMKEVVPEMKIFEDVPEEPETPRMKTPEA FT PQEIIPAKTVPSKKREPPSVKVPEALQEIVPEKKTLVVPLRKPEVLPDEVPEALREVVP FT EKKVHPPQRAEVVPVKVHEAPKEIIPEKKVSVVPPKKPEVPPVKVPEASKEVIREEKVP FT LAPPKEPEVPPVKVPEPPKEVVPEKKAPVAPPKEPEVPPVKVPEAPKEVVPEKKVPVPP FT PKKPEVPPTKVPEVPKAAVPEKKLPEAIPPKPESPPPE (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045931" FT VAR_SEQ 11450 FT /note="P -> PKVPEAPKEVVLEKKASVAVPKKPEAPRAKVPEAAQEVVPEKKIPKA FT PIKKPEAPAVTVPEVPQEATEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKP FT EAPPATVPEVPQEIVPEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPSAPPKKPEVPP FT V (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045932" FT VAR_SEQ 11507 FT /note="E -> EVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKVPEAPKEVVLEKKASV FT AVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEVPQEAAEKEIPVAPPK FT KPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIVPEKKTLVLPKKPEVP FT PVTVPEAPKEVVLEKKVPSTPPKKPEVPPVKVPEAPKEVVPEKKVPVPPPKKPEVPPTK FT VPEVPKAAVPEKKVPEAIPPKPESPPPEVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKV FT PEAPKEVVLEKKVSVAVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEV FT PQEAAEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIV FT PEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPLAPPKKPEVPPVKVPEAPKEVVPEKK FT VPVTPPKKPEVPPVKVPEAPIEVVPEKKMPLAPPKKPEVPPVKVPEAPKEVVPEKKVPS FT APPKKPEVPPVK (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045933" FT VAR_SEQ 11507 FT /note="E -> EVFEEPEESPSAPPKKPEVPPVR (in isoform 4)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019151" FT VAR_SEQ 11790 FT /note="P -> PKEPEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVT FT KKPEVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKE FT TPPVEEREIEKYIKPEEPEPEPQPEEIPV (in isoform 13)" FT /evidence="ECO:0000305" FT /id="VSP_047142" FT VAR_SEQ 11793 FT /note="P -> PEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVTKKP FT EVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKETPP FT VEEREIEKYIKPEEPEPEPQPEEIPVKEP (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045934" FT VAR_SEQ 11985..12201 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019152" FT VARIANT 54 FT /note="V -> M (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs139517732)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026685" FT VARIANT 60 FT /note="D -> Y (in dbSNP:rs35683768)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040078" FT VARIANT 115 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs564777385)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040079" FT VARIANT 279 FT /note="R -> W (in MFM9; disrupts NBR1-binding; FT dbSNP:rs138060032)" FT /evidence="ECO:0000269|PubMed:15802564" FT /id="VAR_026634" FT VARIANT 328 FT /note="R -> C (in dbSNP:rs16866538)" FT /evidence="ECO:0000269|PubMed:11846417, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026686" FT VARIANT 360 FT /note="R -> T (in dbSNP:rs56128843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040080" FT VARIANT 498 FT /note="V -> I (in dbSNP:rs72647851)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040081" FT VARIANT 740 FT /note="R -> L (in CMH9; dbSNP:rs28933405)" FT /evidence="ECO:0000269|PubMed:10462489" FT /id="VAR_026687" FT VARIANT 743 FT /note="A -> V (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs267607157)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026688" FT VARIANT 799 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149061352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040082" FT VARIANT 811 FT /note="T -> I (in dbSNP:rs35813871)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040083" FT VARIANT 922 FT /note="R -> H (in dbSNP:rs56046320)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040084" FT VARIANT 937 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040085" FT VARIANT 976 FT /note="W -> R (in CMD1G; dbSNP:rs267607155)" FT /evidence="ECO:0000269|PubMed:11788824" FT /id="VAR_026689" FT VARIANT 1081 FT /note="A -> T (in dbSNP:rs55914517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040086" FT VARIANT 1137 FT /note="G -> R (in dbSNP:rs72647870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040087" FT VARIANT 1201 FT /note="K -> E (in dbSNP:rs10497520)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040088" FT VARIANT 1202 FT /note="V -> A (in dbSNP:rs150667217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040089" FT VARIANT 1249 FT /note="S -> L (in dbSNP:rs1552280)" FT /id="VAR_056081" FT VARIANT 1295 FT /note="S -> L (in dbSNP:rs1552280)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040090" FT VARIANT 1345 FT /note="G -> D (in dbSNP:rs36021856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040091" FT VARIANT 1347 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267599092)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040092" FT VARIANT 1350 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs539470256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040093" FT VARIANT 1353 FT /note="V -> L (in dbSNP:rs36062108)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040094" FT VARIANT 1393 FT /note="I -> V (in dbSNP:rs16866531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040095" FT VARIANT 1416 FT /note="R -> C (in dbSNP:rs72647875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040096" FT VARIANT 1441 FT /note="R -> P (in dbSNP:rs72647876)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040097" FT VARIANT 1544 FT /note="I -> V (in dbSNP:rs72647877)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040098" FT VARIANT 1572 FT /note="R -> Q (in dbSNP:rs12476289)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040099" FT VARIANT 1658 FT /note="R -> G (in dbSNP:rs56270960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040100" FT VARIANT 1664 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs375029799)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040101" FT VARIANT 1692 FT /note="G -> D (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs370004591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040102" FT VARIANT 1744 FT /note="P -> L (in dbSNP:rs75686037)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040103" FT VARIANT 1772 FT /note="S -> G (in dbSNP:rs150725992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040104" FT VARIANT 1907 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040105" FT VARIANT 1998 FT /note="R -> H (in dbSNP:rs144135510)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040106" FT VARIANT 2107 FT /note="P -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040107" FT VARIANT 2118 FT /note="I -> T (in dbSNP:rs56404770)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040108" FT VARIANT 2164 FT /note="A -> T (in dbSNP:rs56285559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040109" FT VARIANT 2240 FT /note="D -> Y" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040110" FT VARIANT 2392 FT /note="G -> S (in dbSNP:rs4894048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040111" FT VARIANT 2432 FT /note="L -> F (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs571572592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040112" FT VARIANT 2610 FT /note="M -> I (in dbSNP:rs56142888)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040113" FT VARIANT 2771 FT /note="I -> M (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs576644663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040114" FT VARIANT 2823 FT /note="V -> F (in dbSNP:rs33917087)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040115" FT VARIANT 2831 FT /note="S -> N (in dbSNP:rs2306636)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040116" FT VARIANT 2930 FT /note="V -> I (in dbSNP:rs56373393)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040117" FT VARIANT 2963 FT /note="T -> P (in dbSNP:rs200875815)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074293" FT VARIANT 3026 FT /note="N -> I (in dbSNP:rs11900987)" FT /id="VAR_056082" FT VARIANT 3154 FT /note="K -> R (in dbSNP:rs4893853)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040118" FT VARIANT 3191 FT /note="Q -> E (in dbSNP:rs33997263)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040119" FT VARIANT 3238 FT /note="P -> L (in a bladder carcinoma sample; somatic FT mutation; dbSNP:rs397517792)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040120" FT VARIANT 3250 FT /note="V -> G (in dbSNP:rs55634230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040121" FT VARIANT 3261 FT /note="V -> M (in dbSNP:rs2291311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040122" FT VARIANT 3367 FT /note="R -> Q (in dbSNP:rs34819099)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040123" FT VARIANT 3419 FT /note="S -> N (in dbSNP:rs2291310)" FT /evidence="ECO:0000269|PubMed:7569978" FT /id="VAR_056083" FT VARIANT 3482 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040124" FT VARIANT 3491 FT /note="P -> S (in dbSNP:rs2627037)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7569978" FT /id="VAR_040125" FT VARIANT 3570 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040126" FT VARIANT 3590 FT /note="L -> V (in dbSNP:rs55853696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040127" FT VARIANT 3637 FT /note="P -> S (in dbSNP:rs757223770)" FT /id="VAR_056084" FT VARIANT 3762 FT /note="I -> V (in dbSNP:rs34070843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040128" FT VARIANT 3799 FT /note="S -> Y (in CMD1G)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026690" FT VARIANT 3877 FT /note="I -> F (in dbSNP:rs34618570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040129" FT VARIANT 3965 FT /note="I -> L (in dbSNP:rs56244420)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040130" FT VARIANT 4084 FT /note="R -> Q (in dbSNP:rs200431386)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026691" FT VARIANT 4215 FT /note="T -> P (in dbSNP:rs2562829)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:17344846" FT /id="VAR_026635" FT VARIANT 4238 FT /note="G -> W (in dbSNP:rs56030296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040131" FT VARIANT 4283 FT /note="L -> F (in dbSNP:rs1883085)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026636" FT VARIANT 4291 FT /note="I -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040132" FT VARIANT 4303 FT /note="G -> D (in dbSNP:rs55857742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040133" FT VARIANT 4427 FT /note="D -> E (in dbSNP:rs55906845)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040134" FT VARIANT 4465 FT /note="S -> N (in CMD1G; dbSNP:rs281864908)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026692" FT VARIANT 8288 FT /note="A -> V (in dbSNP:rs16866412)" FT /id="VAR_056085" FT VARIANT 8474 FT /note="I -> T (in dbSNP:rs4893852)" FT /id="VAR_056086" FT VARIANT 12310 FT /note="G -> E (in dbSNP:rs55723264)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040135" FT VARIANT 12383 FT /note="H -> R (in dbSNP:rs2288563)" FT /evidence="ECO:0000269|PubMed:10850961" FT /id="VAR_040136" FT VARIANT 12469 FT /note="V -> A (in dbSNP:rs34706299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040137" FT VARIANT 12642 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs199684560)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040138" FT VARIANT 12657 FT /note="E -> K (in a Wilms tumor; somatic mutation; FT dbSNP:rs778634417)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040139" FT VARIANT 12679 FT /note="K -> E (in dbSNP:rs6723526)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040140" FT VARIANT 12720 FT /note="S -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040141" FT VARIANT 12798 FT /note="R -> C (in dbSNP:rs200914097)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040142" FT VARIANT 13049 FT /note="E -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040143" FT VARIANT 13083 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1458591077)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040144" FT VARIANT 13096 FT /note="R -> L (in dbSNP:rs373298007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040145" FT VARIANT 13099 FT /note="Q -> R (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040146" FT VARIANT 13297 FT /note="V -> A (in dbSNP:rs571522834)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040147" FT VARIANT 13399 FT /note="I -> M (in dbSNP:rs74580375)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040148" FT VARIANT 13418 FT /note="A -> T (in dbSNP:rs144668626)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040149" FT VARIANT 13428 FT /note="E -> V (in dbSNP:rs114331773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040150" FT VARIANT 13430 FT /note="I -> T (in dbSNP:rs184078045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040151" FT VARIANT 13434 FT /note="R -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040152" FT VARIANT 13469 FT /note="D -> N (in dbSNP:rs17354992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040153" FT VARIANT 13495 FT /note="K -> N (in dbSNP:rs72677225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040154" FT VARIANT 13785 FT /note="N -> S (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040155" FT VARIANT 13870 FT /note="Q -> H (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040156" FT VARIANT 14109 FT /note="V -> I (in dbSNP:rs72677232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040157" FT VARIANT 14131 FT /note="R -> Q (in dbSNP:rs72677233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040158" FT VARIANT 14208 FT /note="P -> T (in dbSNP:rs146181477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040159" FT VARIANT 14728 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040160" FT VARIANT 14750 FT /note="R -> Q (in dbSNP:rs200944827)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074294" FT VARIANT 14999 FT /note="S -> T (in dbSNP:rs55663050)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040161" FT VARIANT 15021 FT /note="N -> T (in dbSNP:rs36043230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040162" FT VARIANT 15520 FT /note="A -> V (in dbSNP:rs16866412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040163" FT VARIANT 15555 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs751398376)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040164" FT VARIANT 15620 FT /note="R -> Q (in dbSNP:rs201825412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040165" FT VARIANT 15629 FT /note="S -> I (in dbSNP:rs200650668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040166" FT VARIANT 15635 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040167" FT VARIANT 15700 FT /note="R -> Q (in dbSNP:rs370390570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040168" FT VARIANT 15705 FT /note="L -> P (in dbSNP:rs755155531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040169" FT VARIANT 15837 FT /note="I -> M (in dbSNP:rs554368924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040170" FT VARIANT 16046 FT /note="G -> V (in dbSNP:rs780672348)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069432" FT VARIANT 16058 FT /note="R -> H (in dbSNP:rs72646808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040171" FT VARIANT 16067 FT /note="K -> I (in dbSNP:rs2303832)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040172" FT VARIANT 16090 FT /note="I -> T (in dbSNP:rs72646809)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040173" FT VARIANT 16195 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs373526624)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040174" FT VARIANT 16409 FT /note="R -> C (in dbSNP:rs55734111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040175" FT VARIANT 16424 FT /note="R -> P (in dbSNP:rs375895183)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040176" FT VARIANT 16575 FT /note="V -> M (in dbSNP:rs3813243)" FT /id="VAR_056087" FT VARIANT 16629 FT /note="I -> M (in dbSNP:rs55809450)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040177" FT VARIANT 16877 FT /note="K -> R (in dbSNP:rs72646823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040178" FT VARIANT 17060 FT /note="N -> D (in dbSNP:rs1001238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040179" FT VARIANT 17637 FT /note="I -> V (in dbSNP:rs56025724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040180" FT VARIANT 17838 FT /note="R -> H (in dbSNP:rs2288569)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040181" FT VARIANT 17866 FT /note="D -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040182" FT VARIANT 17906 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs374713701)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040183" FT VARIANT 18094 FT /note="E -> A (in dbSNP:rs769852851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040184" FT VARIANT 18109 FT /note="G -> S (in dbSNP:rs200732032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040185" FT VARIANT 18164 FT /note="R -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040186" FT VARIANT 18221 FT /note="P -> L (in dbSNP:rs16866406)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040187" FT VARIANT 18222 FT /note="A -> T" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040188" FT VARIANT 18726 FT /note="R -> Q (in dbSNP:rs141973925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040189" FT VARIANT 18835 FT /note="V -> A (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1336054298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040190" FT VARIANT 18881 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1204056923)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040191" FT VARIANT 18939 FT /note="N -> S (in dbSNP:rs1470758075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040192" FT VARIANT 19000 FT /note="R -> Q (in dbSNP:rs199895260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040193" FT VARIANT 19060 FT /note="L -> Q (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1383995916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040194" FT VARIANT 19091 FT /note="R -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040195" FT VARIANT 19224 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040196" FT VARIANT 19367 FT /note="T -> I (in dbSNP:rs72646850)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040197" FT VARIANT 19392 FT /note="E -> K (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040198" FT VARIANT 19480 FT /note="A -> S (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040199" FT VARIANT 19495 FT /note="D -> G (in dbSNP:rs773075736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040200" FT VARIANT 19665 FT /note="R -> H (in dbSNP:rs202240487)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040201" FT VARIANT 19762 FT /note="T -> I (in dbSNP:rs2042996)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040202" FT VARIANT 19947 FT /note="G -> R (in dbSNP:rs181717727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040203" FT VARIANT 19956 FT /note="V -> M (in dbSNP:rs150661999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040204" FT VARIANT 19992 FT /note="R -> Q (in dbSNP:rs141965360)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040205" FT VARIANT 20057 FT /note="R -> C (in dbSNP:rs72646861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040206" FT VARIANT 20075 FT /note="S -> L (in dbSNP:rs13021201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040207" FT VARIANT 20179 FT /note="T -> K" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040208" FT VARIANT 20198 FT /note="A -> T (in dbSNP:rs56378177)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040209" FT VARIANT 20198 FT /note="A -> V (in dbSNP:rs55948748)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040210" FT VARIANT 20331 FT /note="R -> H (in dbSNP:rs200217934)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040211" FT VARIANT 20359 FT /note="R -> K (in dbSNP:rs9808036)" FT /id="VAR_056088" FT VARIANT 20408 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040212" FT VARIANT 20564 FT /note="R -> K (in dbSNP:rs72646869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040213" FT VARIANT 20718 FT /note="V -> I (in dbSNP:rs2303838)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040214" FT VARIANT 20726 FT /note="S -> P (in dbSNP:rs72646873)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040215" FT VARIANT 20892 FT /note="T -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040216" FT VARIANT 20894 FT /note="S -> R (in dbSNP:rs750847940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040217" FT VARIANT 21125 FT /note="D -> E (in dbSNP:rs534340303)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040218" FT VARIANT 21403 FT /note="P -> S (in dbSNP:rs55980498)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040219" FT VARIANT 21730 FT /note="R -> C (in dbSNP:rs56141309)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040220" FT VARIANT 21747 FT /note="R -> Q (in dbSNP:rs55853138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040221" FT VARIANT 21851 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs55713867)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040222" FT VARIANT 21925 FT /note="G -> R (in dbSNP:rs55801134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040223" FT VARIANT 21995 FT /note="R -> H (in dbSNP:rs56071233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040224" FT VARIANT 22045 FT /note="A -> V (in dbSNP:rs55903402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040225" FT VARIANT 22149 FT /note="R -> H (in dbSNP:rs55677134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040226" FT VARIANT 22160 FT /note="V -> I (in dbSNP:rs55885640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040227" FT VARIANT 22261 FT /note="I -> T (in dbSNP:rs55837610)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040228" FT VARIANT 22306 FT /note="K -> N (in dbSNP:rs56019808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040229" FT VARIANT 22357 FT /note="R -> H (in dbSNP:rs10164753)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040230" FT VARIANT 22408 FT /note="L -> P (in dbSNP:rs56399205)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040231" FT VARIANT 22537 FT /note="Q -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040232" FT VARIANT 22584 FT /note="P -> L (in dbSNP:rs55992239)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040233" FT VARIANT 22646 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040234" FT VARIANT 22670 FT /note="T -> A (in dbSNP:rs56201325)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040235" FT VARIANT 22770 FT /note="A -> D (in dbSNP:rs55991022)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040236" FT VARIANT 22801 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs764005465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040237" FT VARIANT 22823 FT /note="R -> W (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs369098292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040238" FT VARIANT 22968 FT /note="E -> Q (in dbSNP:rs55762754)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040239" FT VARIANT 23074 FT /note="P -> L (in dbSNP:rs55713856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040240" FT VARIANT 23079 FT /note="L -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040241" FT VARIANT 23282 FT /note="D -> N (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040242" FT VARIANT 23303 FT /note="H -> Y (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040243" FT VARIANT 23306 FT /note="R -> C (in dbSNP:rs744426)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040244" FT VARIANT 23515 FT /note="A -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040245" FT VARIANT 23551 FT /note="E -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040246" FT VARIANT 23807 FT /note="S -> N (in dbSNP:rs3813243)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040247" FT VARIANT 23872 FT /note="D -> N (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040248" FT VARIANT 23891 FT /note="V -> A (in dbSNP:rs55984930)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040249" FT VARIANT 23933 FT /note="Y -> H (in dbSNP:rs3813245)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040250" FT VARIANT 23939 FT /note="T -> M (in dbSNP:rs56372592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040251" FT VARIANT 23952 FT /note="F -> L (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040252" FT VARIANT 24098 FT /note="A -> G (in dbSNP:rs56391938)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040253" FT VARIANT 24098 FT /note="A -> T (in dbSNP:rs4894028)" FT /id="VAR_056089" FT VARIANT 24119 FT /note="N -> S (in dbSNP:rs3813246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040254" FT VARIANT 24133 FT /note="V -> I (in dbSNP:rs56340968)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040255" FT VARIANT 24159 FT /note="V -> A (in a head and neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040256" FT VARIANT 24239 FT /note="T -> A (in dbSNP:rs56018860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040257" FT VARIANT 24265 FT /note="E -> K (in dbSNP:rs56341835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040258" FT VARIANT 24584 FT /note="I -> T (in dbSNP:rs12463674)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040259" FT VARIANT 24781 FT /note="I -> T (in dbSNP:rs3731745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040260" FT VARIANT 24799 FT /note="R -> H (in dbSNP:rs56044609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040261" FT VARIANT 24954 FT /note="D -> H (in dbSNP:rs56307213)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040262" FT VARIANT 24980 FT /note="T -> M (in dbSNP:rs3731746)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040263" FT VARIANT 25659 FT /note="R -> H (in dbSNP:rs55850344)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040264" FT VARIANT 25679 FT /note="A -> T (in dbSNP:rs56365600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040265" FT VARIANT 25720 FT /note="P -> A (in dbSNP:rs56137800)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040266" FT VARIANT 25821 FT /note="T -> K (in dbSNP:rs55933739)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040267" FT VARIANT 25859 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs375422359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040268" FT VARIANT 25879 FT /note="N -> K (in dbSNP:rs56264840)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040269" FT VARIANT 25923 FT /note="A -> V (in dbSNP:rs55634791)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040270" FT VARIANT 26045 FT /note="V -> I (in dbSNP:rs56309296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040271" FT VARIANT 26059 FT /note="K -> E (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040272" FT VARIANT 26134 FT /note="I -> V (in dbSNP:rs3829746)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040273" FT VARIANT 26477 FT /note="R -> C (in dbSNP:rs56057221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040274" FT VARIANT 26843 FT /note="D -> Y (in dbSNP:rs56330345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040275" FT VARIANT 27346 FT /note="K -> R (in dbSNP:rs1186947794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040276" FT VARIANT 27652 FT /note="R -> C (in dbSNP:rs191482653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040277" FT VARIANT 27728 FT /note="G -> V (in dbSNP:rs55898359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040278" FT VARIANT 27754 FT /note="F -> L (in dbSNP:rs55940667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040279" FT VARIANT 27755 FT /note="I -> T (in dbSNP:rs9808377)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040280" FT VARIANT 27929 FT /note="I -> V (in dbSNP:rs139506970)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040281" FT VARIANT 28132 FT /note="I -> L (in dbSNP:rs77853750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040282" FT VARIANT 28168 FT /note="R -> Q (in dbSNP:rs72648238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040283" FT VARIANT 28538 FT /note="R -> H (in dbSNP:rs149567378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040284" FT VARIANT 28572 FT /note="I -> T (in dbSNP:rs114026724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040285" FT VARIANT 28948 FT /note="A -> T (in dbSNP:rs148617456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040286" FT VARIANT 28986 FT /note="I -> V (in dbSNP:rs535151633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040287" FT VARIANT 28993 FT /note="G -> E (in dbSNP:rs376628842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040288" FT VARIANT 28998 FT /note="L -> V (in dbSNP:rs373049260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040289" FT VARIANT 29070 FT /note="V -> M (in dbSNP:rs747122)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040290" FT VARIANT 29090 FT /note="I -> V (in dbSNP:rs16866391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040291" FT VARIANT 29419 FT /note="R -> C (in dbSNP:rs750303653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040292" FT VARIANT 29479 FT /note="L -> P (in dbSNP:rs1310673663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040293" FT VARIANT 29880 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040294" FT VARIANT 29976 FT /note="D -> E (in dbSNP:rs72648256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040295" FT VARIANT 30042 FT /note="S -> G (in dbSNP:rs72648257)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040296" FT VARIANT 30107 FT /note="R -> C (in dbSNP:rs142525903)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040297" FT VARIANT 30125 FT /note="S -> F (in dbSNP:rs191484894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040298" FT VARIANT 30211 FT /note="L -> P (in dbSNP:rs62621206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040299" FT VARIANT 30412 FT /note="I -> T (in dbSNP:rs62621236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040300" FT VARIANT 30617 FT /note="T -> S (in a renal chromophobe cancer sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040301" FT VARIANT 30674 FT /note="T -> I (in dbSNP:rs56027402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040302" FT VARIANT 30809 FT /note="V -> I (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs397517769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040303" FT VARIANT 30818 FT /note="F -> I (in dbSNP:rs56009327)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040304" FT VARIANT 30825 FT /note="E -> K (in dbSNP:rs55915651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040305" FT VARIANT 30856 FT /note="I -> T (in dbSNP:rs55660660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040306" FT VARIANT 30887 FT /note="G -> D (in dbSNP:rs56066673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040307" FT VARIANT 30887 FT /note="G -> S (in dbSNP:rs56233675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040308" FT VARIANT 30897 FT /note="R -> H (in dbSNP:rs3731749)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040309" FT VARIANT 30907 FT /note="R -> H (in dbSNP:rs55676195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040310" FT VARIANT 30946 FT /note="R -> H (in dbSNP:rs55704830)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040311" FT VARIANT 31081 FT /note="I -> F (in dbSNP:rs72648270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040312" FT VARIANT 31107 FT /note="R -> C (in dbSNP:rs72648272)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040313" FT VARIANT 31124 FT /note="A -> G (in dbSNP:rs72648273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040314" FT VARIANT 31156 FT /note="N -> S (in dbSNP:rs149001703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040315" FT VARIANT 31246 FT /note="P -> T (in dbSNP:rs55653324)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040316" FT VARIANT 31330 FT /note="R -> H (in dbSNP:rs4894028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040317" FT VARIANT 31690 FT /note="C -> R (in dbSNP:rs56061641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040318" FT VARIANT 31724 FT /note="R -> Q (in dbSNP:rs55742743)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040319" FT VARIANT 31725 FT /note="V -> I (in dbSNP:rs55675869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040320" FT VARIANT 31732 FT /note="G -> S (in dbSNP:rs55880786)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040321" FT VARIANT 31886 FT /note="V -> I (in dbSNP:rs2278196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040322" FT VARIANT 32097 FT /note="R -> C (in dbSNP:rs56273463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040323" FT VARIANT 32171 FT /note="T -> N (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040324" FT VARIANT 32248 FT /note="V -> I (in dbSNP:rs34924609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040325" FT VARIANT 32281 FT /note="Q -> H (in dbSNP:rs55886356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040326" FT VARIANT 32323 FT /note="R -> H (in dbSNP:rs55669553)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040327" FT VARIANT 32411 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs756924372)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040328" FT VARIANT 32558 FT /note="I -> V (in dbSNP:rs56347248)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040329" FT VARIANT 32610 FT /note="M -> V (in dbSNP:rs56173891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040330" FT VARIANT 32637 FT /note="G -> V (in dbSNP:rs3731752)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040331" FT VARIANT 32742 FT /note="E -> Q (in dbSNP:rs148525155)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069433" FT VARIANT 32922 FT /note="V -> A (in dbSNP:rs55945684)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040332" FT VARIANT 32943 FT /note="L -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040333" FT VARIANT 32953 FT /note="R -> H (in dbSNP:rs3829747)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040334" FT VARIANT 32996 FT /note="R -> Q (in CMD1G; dbSNP:rs199642423)" FT /evidence="ECO:0000269|PubMed:16465475" FT /id="VAR_026693" FT VARIANT 33213 FT /note="V -> L (in dbSNP:rs55866005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040335" FT VARIANT 33242 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1003158162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040336" FT VARIANT 33387 FT /note="T -> M (in dbSNP:rs56001826)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040337" FT VARIANT 33419 FT /note="E -> D (in dbSNP:rs56308529)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040338" FT VARIANT 33536 FT /note="V -> M (in dbSNP:rs55865284)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040339" FT VARIANT 33568 FT /note="K -> Q (in dbSNP:rs56365812)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040340" FT VARIANT 33616 FT /note="E -> K (in dbSNP:rs56324595)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040341" FT VARIANT 33620 FT /note="P -> L (in dbSNP:rs16866380)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040342" FT VARIANT 33886 FT /note="E -> V (in dbSNP:rs55725279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040343" FT VARIANT 33899 FT /note="I -> T (in dbSNP:rs55880440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040344" FT VARIANT 33904 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040345" FT VARIANT 33955 FT /note="T -> I (in dbSNP:rs55842557)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040346" FT VARIANT 34115 FT /note="V -> A (in dbSNP:rs16866378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040347" FT VARIANT 34306 FT /note="I -> N (in TMD; dbSNP:rs281864928)" FT /evidence="ECO:0000269|PubMed:12891679" FT /id="VAR_026694" FT VARIANT 34315 FT /note="L -> P (in TMD; dbSNP:rs267607156)" FT /evidence="ECO:0000269|PubMed:12145747" FT /id="VAR_026695" FT MUTAGEN 32207 FT /note="K->A: Disrupts catalytic activity." FT /evidence="ECO:0000269|PubMed:9804419" FT MUTAGEN 32341 FT /note="Y->E: No phosphorylation on tyrosine." FT /evidence="ECO:0000269|PubMed:9804419" FT CONFLICT 132 FT /note="T -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 255 FT /note="P -> H (in Ref. 3; CAD12455/CAD12456/CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT 1472..1474 FT /note="QTA -> ANC (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 1730 FT /note="G -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 3919 FT /note="P -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 4525 FT /note="R -> K (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 6619 FT /note="R -> E (in Ref. 1; CAA62189 and 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 7145 FT /note="D -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 7441 FT /note="S -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 8038 FT /note="A -> E (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8225 FT /note="Q -> H (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8850 FT /note="A -> P (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9693 FT /note="C -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9892 FT /note="I -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10205 FT /note="I -> V (in Ref. 3; CAD12456 and 9; AAP80791)" FT /evidence="ECO:0000305" FT CONFLICT 10305 FT /note="G -> R (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 10566 FT /note="R -> K (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10779 FT /note="R -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11424 FT /note="E -> D (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 11511 FT /note="A -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11626 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11838 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 12994 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 13795..13797 FT /note="YKF -> IQI (in Ref. 11)" FT /evidence="ECO:0000305" FT CONFLICT 14590 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 14792 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 15974 FT /note="E -> K (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 16234..16235 FT /note="TK -> QR (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17238 FT /note="R -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17423 FT /note="R -> S (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 19734 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20517 FT /note="G -> A (in Ref. 1; CAA62188 and 3; CAD12455)" FT /evidence="ECO:0000305" FT CONFLICT 20622 FT /note="L -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20775 FT /note="A -> P (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 21625 FT /note="Y -> I (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 21795..21800 FT /note="PGPVLN -> ARPSPQ (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 22176 FT /note="C -> W (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22816 FT /note="A -> D (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22837 FT /note="T -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 24176 FT /note="I -> M (in Ref. 1; CAA62188 and 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 24181 FT /note="S -> F (in Ref. 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 25731 FT /note="P -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26573 FT /note="M -> V (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26846..26848 FT /note="IVE -> HRK (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 27879 FT /note="G -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 28936 FT /note="D -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29222 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29518 FT /note="F -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29701 FT /note="T -> P (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29873 FT /note="E -> G (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29878 FT /note="T -> Q (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30209 FT /note="K -> E (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30256 FT /note="A -> R (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30496 FT /note="V -> I (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30534 FT /note="Y -> H (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30748 FT /note="S -> L (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 31303 FT /note="W -> V (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 32060 FT /note="V -> A (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33084 FT /note="D -> N (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33120 FT /note="R -> W (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33382 FT /note="A -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33424 FT /note="S -> P (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33526 FT /note="Q -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33633 FT /note="T -> I (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33716 FT /note="Y -> V (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33995 FT /note="V -> A (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 34071 FT /note="N -> G (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT CONFLICT 34082 FT /note="C -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 34253 FT /note="G -> R (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT STRAND 4..10 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 15..18 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 23..33 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 36..45 FT /evidence="ECO:0007829|PDB:2A38" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 55..59 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 62..69 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 87..98 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 102..108 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 113..116 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 119..131 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:1YA5" FT STRAND 147..155 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 158..166 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 168..170 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 172..180 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 183..194 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 199..205 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 225..233 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 236..241 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 1850..1852 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1858..1863 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1866..1869 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1871..1876 FT /evidence="ECO:0007829|PDB:6DL4" FT TURN 1891..1893 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1894..1899 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1908..1916 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1919..1929 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 2076..2082 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2087..2090 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2095..2105 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2108..2113 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2122..2130 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2133..2138 FT /evidence="ECO:0007829|PDB:1G1C" FT HELIX 2143..2145 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2147..2155 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2158..2169 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2797..2799 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2804..2807 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2812..2820 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2826..2829 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2838..2845 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2848..2853 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2858..2860 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2862..2868 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2871..2880 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2884..2886 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2891..2894 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2899..2907 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2914..2916 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2924..2932 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2935..2940 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2945..2947 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2949..2955 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2958..2967 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2971..2973 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2978..2981 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2986..2994 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3000..3003 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3012..3019 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3022..3027 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 3032..3034 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3036..3042 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3045..3053 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3504..3507 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3512..3515 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3520..3527 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3533..3538 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3547..3554 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3557..3562 FT /evidence="ECO:0007829|PDB:8OVU" FT HELIX 3567..3569 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3571..3579 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3582..3593 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 7948..7951 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7956..7958 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7964..7975 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7977..7981 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7983..7986 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7991..7996 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8001..8008 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8011..8013 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8015..8023 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8026..8036 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8044..8047 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8052..8055 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8060..8071 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8073..8078 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8087..8094 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8097..8104 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8107..8109 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8111..8119 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8122..8133 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8140..8143 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8151..8154 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8156..8166 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8169..8174 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8183..8190 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8193..8201 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8203..8205 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8207..8215 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8218..8226 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8233..8236 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8244..8247 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8249..8261 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8263..8268 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8276..8284 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8287..8294 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8297..8299 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8301..8309 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8315..8320 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8335..8337 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8343..8354 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8358..8361 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8368..8377 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8380..8385 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8390..8392 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8394..8401 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8406..8415 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8420..8423 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8436..8444 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8451..8454 FT /evidence="ECO:0007829|PDB:3B43" FT TURN 8463..8465 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8466..8468 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8472..8481 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8488..8495 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8500..8507 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 9506..9510 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9518..9525 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9530..9543 FT /evidence="ECO:0007829|PDB:7NIP" FT STRAND 9582..9587 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9592..9595 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9600..9608 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9616..9619 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9628..9635 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9638..9643 FT /evidence="ECO:0007829|PDB:5JOE" FT HELIX 9648..9650 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9652..9658 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9661..9670 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9674..9676 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9681..9684 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9689..9697 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9703..9706 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9717..9722 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9725..9732 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9735..9737 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9739..9745 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9748..9757 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9763..9765 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9770..9772 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9778..9786 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9790..9795 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9803..9811 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9814..9819 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9824..9826 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9828..9835 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9841..9850 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 12680..12682 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12687..12690 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12691..12693 FT /evidence="ECO:0007829|PDB:6I0Y" FT STRAND 12695..12705 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12709..12712 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12719..12722 FT /evidence="ECO:0007829|PDB:1TIU" FT STRAND 12723..12728 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12731..12736 FT /evidence="ECO:0007829|PDB:1WAA" FT HELIX 12741..12743 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12745..12751 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12754..12763 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 14223..14228 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14232..14240 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14252..14259 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14275..14281 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14288..14296 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14308..14314 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14319..14322 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14325..14327 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14331..14334 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14339..14349 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14352..14357 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14368..14372 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14374..14381 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14386..14388 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14390..14397 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14402..14412 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14419..14424 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14431..14436 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14446..14455 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14462..14468 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14470..14475 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14484..14492 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14506..14509 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14522..14524 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14528..14534 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14549..14555 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14568..14576 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14584..14592 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 15216..15224 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15227..15233 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15245..15252 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15268..15273 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15282..15290 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15305..15307 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 16533..16538 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16541..16546 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16559..16566 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16585..16592 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16600..16609 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16623..16626 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 20520..20528 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20531..20537 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20549..20556 FT /evidence="ECO:0007829|PDB:8OSD" FT HELIX 20568..20570 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20573..20580 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20587..20594 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 21506..21509 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21515..21518 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21532..21539 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21546..21551 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21553..21560 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21568..21577 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 22291..22296 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22299..22303 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22319..22324 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22340..22345 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22354..22361 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22367..22377 FT /evidence="ECO:0007829|PDB:1BPV" FT HELIX 22381..22384 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22883..22890 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22895..22900 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22912..22919 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22926..22932 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22934..22939 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22947..22956 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22970..22972 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22982..22987 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22992..22996 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23009..23016 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23023..23035 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23043..23052 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23568..23575 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23581..23586 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23596..23605 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23612..23618 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23620..23625 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23633..23642 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23671..23676 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23679..23683 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23697..23704 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23711..23716 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23720..23725 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23733..23742 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23769..23776 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23781..23786 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23798..23805 FT /evidence="ECO:0007829|PDB:8BNQ" FT TURN 23806..23808 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23811..23815 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23820..23827 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23835..23843 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 25439..25443 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25448..25451 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25465..25472 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25479..25481 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25486..25493 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25501..25509 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25514..25517 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 26130..26137 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26142..26147 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26157..26166 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26173..26179 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26181..26186 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26194..26203 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26206..26212 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 31458..31464 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31469..31472 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31475..31487 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31490..31495 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31498..31500 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31504..31520 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31524..31526 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31528..31535 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31540..31555 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31563..31568 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31573..31583 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31586..31591 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31600..31606 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31608..31617 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31620..31623 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31625..31632 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31637..31647 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31856..31859 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31864..31867 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31872..31879 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31885..31890 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31893..31895 FT /evidence="ECO:0007829|PDB:2J8O" FT STRAND 31899..31907 FT /evidence="ECO:0007829|PDB:2J8H" FT TURN 31908..31910 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31911..31916 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31921..31923 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31925..31933 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31936..31952 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31956..31959 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 31961..31967 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31973..31982 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31985..31992 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31997..32000 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32002..32005 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32007..32013 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 32020..32022 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32024..32032 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32035..32046 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32053..32061 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32063..32070 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32076..32078 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 32082..32089 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32095..32111 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32117..32125 FT /evidence="ECO:0007829|PDB:6YGN" FT HELIX 32142..32154 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32167..32170 FT /evidence="ECO:0007829|PDB:6YGN" FT TURN 32175..32177 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32178..32186 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32188..32197 FT /evidence="ECO:0007829|PDB:1TKI" FT TURN 32198..32201 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32202..32209 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32214..32228 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32237..32243 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32246..32251 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32259..32263 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32265..32267 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32272..32291 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32301..32303 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32304..32310 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32314..32316 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32330..32336 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32338..32340 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32343..32346 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32353..32369 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32379..32388 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32395..32398 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32403..32410 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32417..32419 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32423..32428 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32430..32433 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32436..32438 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32447..32457 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32466..32472 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32474..32476 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32483..32489 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32504..32506 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32512..32520 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32526..32531 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32538..32547 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32550..32555 FT /evidence="ECO:0007829|PDB:2BK8" FT HELIX 32560..32562 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32564..32571 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32576..32585 FT /evidence="ECO:0007829|PDB:2BK8" FT TURN 32586..32588 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32720..32726 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32731..32734 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32739..32749 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32752..32757 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32765..32767 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32768..32773 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32774..32776 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32777..32784 FT /evidence="ECO:0007829|PDB:6HCI" FT HELIX 32787..32789 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32791..32799 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32802..32813 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 33294..33297 FT /evidence="ECO:0007829|PDB:3QP3" FT STRAND 33299..33305 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33310..33313 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33318..33328 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33331..33336 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33345..33352 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33355..33360 FT /evidence="ECO:0007829|PDB:6H4L" FT HELIX 33365..33367 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33369..33377 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33380..33391 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33489..33492 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33497..33503 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33509..33512 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33514..33516 FT /evidence="ECO:0007829|PDB:1TNM" FT STRAND 33523..33526 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33532..33538 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33540..33547 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33556..33560 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33571..33577 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33777..33783 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33788..33794 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33796..33806 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33809..33814 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33821..33830 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33833..33838 FT /evidence="ECO:0007829|PDB:3PUC" FT HELIX 33843..33845 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33847..33855 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33858..33869 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 34060..34071 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34078..34088 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34091..34096 FT /evidence="ECO:0007829|PDB:4UOW" FT TURN 34104..34106 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34107..34112 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34115..34122 FT /evidence="ECO:0007829|PDB:4UOW" FT HELIX 34125..34127 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34129..34136 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34138..34148 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34254..34258 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34263..34268 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34271..34283 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34286..34291 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34300..34302 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34304..34308 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34310..34319 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34322..34324 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34326..34334 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34337..34348 FT /evidence="ECO:0007829|PDB:3KNB" FT CONFLICT Q8WZ42-6:3732 FT /note="L -> F (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT Q8WZ42-6:5139 FT /note="R -> M (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" SQ SEQUENCE 34350 AA; 3816030 MW; DEB216410AD560D9 CRC64; MTTQAPTFTQ PLQSVVVLEG STATFEAHIS GFPVPEVSWF RDGQVISTST LPGVQISFSD GRAKLTIPAV TKANSGRYSL KATNGSGQAT STAELLVKAE TAPPNFVQRL QSMTVRQGSQ VRLQVRVTGI PTPVVKFYRD GAEIQSSLDF QISQEGDLYS LLIAEAYPED SGTYSVNATN SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR IEKKIEAHFD ARSIATVEMV IDGAAGQQLP HKTPPRIPPK PKSRSPTPPS IAAKAQLARQ QSPSPIRHSP SPVRHVRAPT PSPVRSVSPA ARISTSPIRS VRSPLLMRKT QASTVATGPE VPPPWKQEGY VASSSEAEMR ETTLTTSTQI RTEERWEGRY GVQEQVTISG AAGAAASVSA SASYAAEAVA TGAKEVKQDA DKSAAVATVV AAVDMARVRE PVISAVEQTA QRTTTTAVHI QPAQEQVRKE AEKTAVTKVV VAADKAKEQE LKSRTKEVIT TKQEQMHVTH EQIRKETEKT FVPKVVISAA KAKEQETRIS EEITKKQKQV TQEAIRQETE ITAASMVVVA TAKSTKLETV PGAQEETTTQ QDQMHLSYEK IMKETRKTVV PKVIVATPKV KEQDLVSRGR EGITTKREQV QITQEKMRKE AEKTALSTIA VATAKAKEQE TILRTRETMA TRQEQIQVTH GKVDVGKKAE AVATVVAAVD QARVREPREP GHLEESYAQQ TTLEYGYKER ISAAKVAEPP QRPASEPHVV PKAVKPRVIQ APSETHIKTT DQKGMHISSQ IKKTTDLTTE RLVHVDKRPR TASPHFTVSK ISVPKTEHGY EASIAGSAIA TLQKELSATS SAQKITKSVK APTVKPSETR VRAEPTPLPQ FPFADTPDTY KSEAGVEVKK EVGVSITGTT VREERFEVLH GREAKVTETA RVPAPVEIPV TPPTLVSGLK NVTVIEGESV TLECHISGYP SPTVTWYRED YQIESSIDFQ ITFQSGIARL MIREAFAEDS GRFTCSAVNE AGTVSTSCYL AVQVSEEFEK ETTAVTEKFT TEEKRFVESR DVVMTDTSLT EEQAGPGEPA APYFITKPVV QKLVEGGSVV FGCQVGGNPK PHVYWKKSGV PLTTGYRYKV SYNKQTGECK LVISMTFADD AGEYTIVVRN KHGETSASAS LLEEADYELL MKSQQEMLYQ TQVTAFVQEP KVGETAPGFV YSEYEKEYEK EQALIRKKMA KDTVVVRTYV EDQEFHISSF EERLIKEIEY RIIKTTLEEL LEEDGEEKMA VDISESEAVE SGFDSRIKNY RILEGMGVTF HCKMSGYPLP KIAWYKDGKR IKHGERYQMD FLQDGRASLR IPVVLPEDEG IYTAFASNIK GNAICSGKLY VEPAAPLGAP TYIPTLEPVS RIRSLSPRSV SRSPIRMSPA RMSPARMSPA RMSPARMSPG RRLEETDESQ LERLYKPVFV LKPVSFKCLE GQTARFDLKV VGRPMPETFW FHDGQQIVND YTHKVVIKED GTQSLIIVPA TPSDSGEWTV VAQNRAGRSS ISVILTVEAV EHQVKPMFVE KLKNVNIKEG SRLEMKVRAT GNPNPDIVWL KNSDIIVPHK YPKIRIEGTK GEAALKIDST VSQDSAWYTA TAINKAGRDT TRCKVNVEVE FAEPEPERKL IIPRGTYRAK EIAAPELEPL HLRYGQEQWE EGDLYDKEKQ QKPFFKKKLT SLRLKRFGPA HFECRLTPIG DPTMVVEWLH DGKPLEAANR LRMINEFGYC SLDYGVAYSR DSGIITCRAT NKYGTDHTSA TLIVKDEKSL VEESQLPEGR KGLQRIEELE RMAHEGALTG VTTDQKEKQK PDIVLYPEPV RVLEGETARF RCRVTGYPQP KVNWYLNGQL IRKSKRFRVR YDGIHYLDIV DCKSYDTGEV KVTAENPEGV IEHKVKLEIQ QREDFRSVLR RAPEPRPEFH VHEPGKLQFE VQKVDRPVDT TETKEVVKLK RAERITHEKV PEESEELRSK FKRRTEEGYY EAITAVELKS RKKDESYEEL LRKTKDELLH WTKELTEEEK KALAEEGKIT IPTFKPDKIE LSPSMEAPKI FERIQSQTVG QGSDAHFRVR VVGKPDPECE WYKNGVKIER SDRIYWYWPE DNVCELVIRD VTAEDSASIM VKAINIAGET SSHAFLLVQA KQLITFTQEL QDVVAKEKDT MATFECETSE PFVKVKWYKD GMEVHEGDKY RMHSDRKVHF LSILTIDTSD AEDYSCVLVE DENVKTTAKL IVEGAVVEFV KELQDIEVPE SYSGELECIV SPENIEGKWY HNDVELKSNG KYTITSRRGR QNLTVKDVTK EDQGEYSFVI DGKKTTCKLK MKPRPIAILQ GLSDQKVCEG DIVQLEVKVS LESVEGVWMK DGQEVQPSDR VHIVIDKQSH MLLIEDMTKE DAGNYSFTIP ALGLSTSGRV SVYSVDVITP LKDVNVIEGT KAVLECKVSV PDVTSVKWYL NDEQIKPDDR VQAIVKGTKQ RLVINRTHAS DEGPYKLIVG RVETNCNLSV EKIKIIRGLR DLTCTETQNV VFEVELSHSG IDVLWNFKDK EIKPSSKYKI EAHGKIYKLT VLNMMKDDEG KYTFYAGENM TSGKLTVAGG AISKPLTDQT VAESQEAVFE CEVANPDSKG EWLRDGKHLP LTNNIRSESD GHKRRLIIAA TKLDDIGEYT YKVATSKTSA KLKVEAVKIK KTLKNLTVTE TQDAVFTVEL THPNVKGVQW IKNGVVLESN EKYAISVKGT IYSLRIKNCA IVDESVYGFR LGRLGASARL HVETVKIIKK PKDVTALENA TVAFEVSVSH DTVPVKWFHK SVEIKPSDKH RLVSERKVHK LMLQNISPSD AGEYTAVVGQ LECKAKLFVE TLHITKTMKN IEVPETKTAS FECEVSHFNV PSMWLKNGVE IEMSEKFKIV VQGKLHQLII MNTSTEDSAE YTFVCGNDQV SATLTVTPIM ITSMLKDINA EEKDTITFEV TVNYEGISYK WLKNGVEIKS TDKCQMRTKK LTHSLNIRNV HFGDAADYTF VAGKATSTAT LYVEARHIEF RKHIKDIKVL EKKRAMFECE VSEPDITVQW MKDDQELQIT DRIKIQKEKY VHRLLIPSTR MSDAGKYTVV AGGNVSTAKL FVEGRDVRIR SIKKEVQVIE KQRAVVEFEV NEDDVDAHWY KDGIEINFQV QERHKYVVER RIHRMFISET RQSDAGEYTF VAGRNRSSVT LYVNAPEPPQ VLQELQPVTV QSGKPARFCA VISGRPQPKI SWYKEEQLLS TGFKCKFLHD GQEYTLLLIE AFPEDAAVYT CEAKNDYGVA TTSASLSVEV PEVVSPDQEM PVYPPAIITP LQDTVTSEGQ PARFQCRVSG TDLKVSWYSK DKKIKPSRFF RMTQFEDTYQ LEIAEAYPED EGTYTFVASN AVGQVSSTAN LSLEAPESIL HERIEQEIEM EMKEFSSSFL SAEEEGLHSA ELQLSKINET LELLSESPVY PTKFDSEKEG TGPIFIKEVS NADISMGDVA TLSVTVIGIP KPKIQWFFNG VLLTPSADYK FVFDGDDHSL IILFTKLEDE GEYTCMASND YGKTICSAYL KINSKGEGHK DTETESAVAK SLEKLGGPCP PHFLKELKPI RCAQGLPAIF EYTVVGEPAP TVTWFKENKQ LCTSVYYTII HNPNGSGTFI VNDPQREDSG LYICKAENML GESTCAAELL VLLEDTDMTD TPCKAKSTPE APEDFPQTPL KGPAVEALDS EQEIATFVKD TILKAALITE ENQQLSYEHI AKANELSSQL PLGAQELQSI LEQDKLTPES TREFLCINGS IHFQPLKEPS PNLQLQIVQS QKTFSKEGIL MPEEPETQAV LSDTEKIFPS AMSIEQINSL TVEPLKTLLA EPEGNYPQSS IEPPMHSYLT SVAEEVLSPK EKTVSDTNRE QRVTLQKQEA QSALILSQSL AEGHVESLQS PDVMISQVNY EPLVPSEHSC TEGGKILIES ANPLENAGQD SAVRIEEGKS LRFPLALEEK QVLLKEEHSD NVVMPPDQII ESKREPVAIK KVQEVQGRDL LSKESLLSGI PEEQRLNLKI QICRALQAAV ASEQPGLFSE WLRNIEKVEV EAVNITQEPR HIMCMYLVTS AKSVTEEVTI IIEDVDPQMA NLKMELRDAL CAIIYEEIDI LTAEGPRIQQ GAKTSLQEEM DSFSGSQKVE PITEPEVESK YLISTEEVSY FNVQSRVKYL DATPVTKGVA SAVVSDEKQD ESLKPSEEKE ESSSESGTEE VATVKIQEAE GGLIKEDGPM IHTPLVDTVS EEGDIVHLTT SITNAKEVNW YFENKLVPSD EKFKCLQDQN TYTLVIDKVN TEDHQGEYVC EALNDSGKTA TSAKLTVVKR AAPVIKRKIE PLEVALGHLA KFTCEIQSAP NVRFQWFKAG REIYESDKCS IRSSKYISSL EILRTQVVDC GEYTCKASNE YGSVSCTATL TVTEAYPPTF LSRPKSLTTF VGKAAKFICT VTGTPVIETI WQKDGAALSP SPNWRISDAE NKHILELSNL TIQDRGVYSC KASNKFGADI CQAELIIIDK PHFIKELEPV QSAINKKVHL ECQVDEDRKV TVTWSKDGQK LPPGKDYKIC FEDKIATLEI PLAKLKDSGT YVCTASNEAG SSSCSATVTV REPPSFVKKV DPSYLMLPGE SARLHCKLKG SPVIQVTWFK NNKELSESNT VRMYFVNSEA ILDITDVKVE DSGSYSCEAV NDVGSDSCST EIVIKEPPSF IKTLEPADIV RGTNALLQCE VSGTGPFEIS WFKDKKQIRS SKKYRLFSQK SLVCLEIFSF NSADVGEYEC VVANEVGKCG CMATHLLKEP PTFVKKVDDL IALGGQTVTL QAAVRGSEPI SVTWMKGQEV IREDGKIKMS FSNGVAVLII PDVQISFGGK YTCLAENEAG SQTSVGELIV KEPAKIIERA ELIQVTAGDP ATLEYTVAGT PELKPKWYKD GRPLVASKKY RISFKNNVAQ LKFYSAELHD SGQYTFEISN EVGSSSCETT FTVLDRDIAP FFTKPLRNVD SVVNGTCRLD CKIAGSLPMR VSWFKDGKEI AASDRYRIAF VEGTASLEII RVDMNDAGNF TCRATNSVGS KDSSGALIVQ EPPSFVTKPG SKDVLPGSAV CLKSTFQGST PLTIRWFKGN KELVSGGSCY ITKEALESSL ELYLVKTSDS GTYTCKVSNV AGGVECSANL FVKEPATFVE KLEPSQLLKK GDATQLACKV TGTPPIKITW FANDREIKES SKHRMSFVES TAVLRLTDVG IEDSGEYMCE AQNEAGSDHC SSIVIVKESP YFTKEFKPIE VLKEYDVMLL AEVAGTPPFE ITWFKDNTIL RSGRKYKTFI QDHLVSLQIL KFVAADAGEY QCRVTNEVGS SICSARVTLR EPPSFIKKIE STSSLRGGTA AFQATLKGSL PITVTWLKDS DEITEDDNIR MTFENNVASL YLSGIEVKHD GKYVCQAKND AGIQRCSALL SVKEPATITE EAVSIDVTQG DPATLQVKFS GTKEITAKWF KDGQELTLGS KYKISVTDTV SILKIISTEK KDSGEYTFEV QNDVGRSSCK ARINVLDLII PPSFTKKLKK MDSIKGSFID LECIVAGSHP ISIQWFKDDQ EISASEKYKF SFHDNTAFLE ISQLEGTDSG TYTCSATNKA GHNQCSGHLT VKEPPYFVEK PQSQDVNPNT RVQLKALVGG TAPMTIKWFK DNKELHSGAA RSVWKDDTST SLELFAAKAT DSGTYICQLS NDVGTATSKA TLFVKEPPQF IKKPSPVLVL RNGQSTTFEC QITGTPKIRV SWYLDGNEIT AIQKHGISFI DGLATFQISG ARVENSGTYV CEARNDAGTA SCSIELKVKE PPTFIRELKP VEVVKYSDVE LECEVTGTPP FEVTWLKNNR EIRSSKKYTL TDRVSVFNLH ITKCDPSDTG EYQCIVSNEG GSCSCSTRVA LKEPPSFIKK IENTTTVLKS SATFQSTVAG SPPISITWLK DDQILDEDDN VYISFVDSVA TLQIRSVDNG HSGRYTCQAK NESGVERCYA FLLVQEPAQI VEKAKSVDVT EKDPMTLECV VAGTPELKVK WLKDGKQIVP SRYFSMSFEN NVASFRIQSV MKQDSGQYTF KVENDFGSSS CDAYLRVLDQ NIPPSFTKKL TKMDKVLGSS IHMECKVSGS LPISAQWFKD GKEISTSAKY RLVCHERSVS LEVNNLELED TANYTCKVSN VAGDDACSGI LTVKEPPSFL VKPGRQQAIP DSTVEFKAIL KGTPPFKIKW FKDDVELVSG PKCFIGLEGS TSFLNLYSVD ASKTGQYTCH VTNDVGSDSC TTMLLVTEPP KFVKKLEASK IVKAGDSSRL ECKIAGSPEI RVVWFRNEHE LPASDKYRMT FIDSVAVIQM NNLSTEDSGD FICEAQNPAG STSCSTKVIV KEPPVFSSFP PIVETLKNAE VSLECELSGT PPFEVVWYKD KRQLRSSKKY KIASKNFHTS IHILNVDTSD IGEYHCKAQN EVGSDTCVCT VKLKEPPRFV SKLNSLTVVA GEPAELQASI EGAQPIFVQW LKEKEEVIRE SENIRITFVE NVATLQFAKA EPANAGKYIC QIKNDGGMRE NMATLMVLEP AVIVEKAGPM TVTVGETCTL ECKVAGTPEL SVEWYKDGKL LTSSQKHKFS FYNKISSLRI LSVERQDAGT YTFQVQNNVG KSSCTAVVDV SDRAVPPSFT RRLKNTGGVL GASCILECKV AGSSPISVAW FHEKTKIVSG AKYQTTFSDN VCTLQLNSLD SSDMGNYTCV AANVAGSDEC RAVLTVQEPP SFVKEPEPLE VLPGKNVTFT SVIRGTPPFK VNWFRGAREL VKGDRCNIYF EDTVAELELF NIDISQSGEY TCVVSNNAGQ ASCTTRLFVK EPAAFLKRLS DHSVEPGKSI ILESTYTGTL PISVTWKKDG FNITTSEKCN IVTTEKTCIL EILNSTKRDA GQYSCEIENE AGRDVCGALV STLEPPYFVT ELEPLEAAVG DSVSLQCQVA GTPEITVSWY KGDTKLRPTP EYRTYFTNNV ATLVFNKVNI NDSGEYTCKA ENSIGTASSK TVFRIQERQL PPSFARQLKD IEQTVGLPVT LTCRLNGSAP IQVCWYRDGV LLRDDENLQT SFVDNVATLK ILQTDLSHSG QYSCSASNPL GTASSSARLT AREPKKSPFF DIKPVSIDVI AGESADFECH VTGAQPMRIT WSKDNKEIRP GGNYTITCVG NTPHLRILKV GKGDSGQYTC QATNDVGKDM CSAQLSVKEP PKFVKKLEAS KVAKQGESIQ LECKISGSPE IKVSWFRNDS ELHESWKYNM SFINSVALLT INEASAEDSG DYICEAHNGV GDASCSTALT VKAPPVFTQK PSPVGALKGS DVILQCEISG TPPFEVVWVK DRKQVRNSKK FKITSKHFDT SLHILNLEAS DVGEYHCKAT NEVGSDTCSC SVKFKEPPRF VKKLSDTSTL IGDAVELRAI VEGFQPISVV WLKDRGEVIR ESENTRISFI DNIATLQLGS PEASNSGKYI CQIKNDAGMR ECSAVLTVLE PARIIEKPEP MTVTTGNPFA LECVVTGTPE LSAKWFKDGR ELSADSKHHI TFINKVASLK IPCAEMSDKG LYSFEVKNSV GKSNCTVSVH VSDRIVPPSF IRKLKDVNAI LGASVVLECR VSGSAPISVG WFQDGNEIVS GPKCQSSFSE NVCTLNLSLL EPSDTGIYTC VAANVAGSDE CSAVLTVQEP PSFEQTPDSV EVLPGMSLTF TSVIRGTPPF KVKWFKGSRE LVPGESCNIS LEDFVTELEL FEVQPLESGD YSCLVTNDAG SASCTTHLFV KEPATFVKRL ADFSVETGSP IVLEATYTGT PPISVSWIKD EYLISQSERC SITMTEKSTI LEILESTIED YAQYSCLIEN EAGQDICEAL VSVLEPPYFI EPLEHVEAVI GEPATLQCKV DGTPEIRISW YKEHTKLRSA PAYKMQFKNN VASLVINKVD HSDVGEYSCK ADNSVGAVAS SAVLVIKARK LPPFFARKLK DVHETLGFPV AFECRINGSE PLQVSWYKDG VLLKDDANLQ TSFVHNVATL QILQTDQSHI GQYNCSASNP LGTASSSAKL ILSEHEVPPF FDLKPVSVDL ALGESGTFKC HVTGTAPIKI TWAKDNREIR PGGNYKMTLV ENTATLTVLK VGKGDAGQYT CYASNIAGKD SCSAQLGVQE PPRFIKKLEP SRIVKQDEFT RYECKIGGSP EIKVLWYKDE TEIQESSKFR MSFVDSVAVL EMHNLSVEDS GDYTCEAHNA AGSASSSTSL KVKEPPIFRK KPHPIETLKG ADVHLECELQ GTPPFHVSWY KDKRELRSGK KYKIMSENFL TSIHILNVDA ADIGEYQCKA TNDVGSDTCV GSIALKAPPR FVKKLSDIST VVGKEVQLQT TIEGAEPISV VWFKDKGEIV RESDNIWISY SENIATLQFS RVEPANAGKY TCQIKNDAGM QECFATLSVL EPATIVEKPE SIKVTTGDTC TLECTVAGTP ELSTKWFKDG KELTSDNKYK ISFFNKVSGL KIINVAPSDS GVYSFEVQNP VGKDSCTASL QVSDRTVPPS FTRKLKETNG LSGSSVVMEC KVYGSPPISV SWFHEGNEIS SGRKYQTTLT DNTCALTVNM LEESDSGDYT CIATNMAGSD ECSAPLTVRE PPSFVQKPDP MDVLTGTNVT FTSIVKGTPP FSVSWFKGSS ELVPGDRCNV SLEDSVAELE LFDVDTSQSG EYTCIVSNEA GKASCTTHLY IKAPAKFVKR LNDYSIEKGK PLILEGTFTG TPPISVTWKK NGINVTPSQR CNITTTEKSA ILEIPSSTVE DAGQYNCYIE NASGKDSCSA QILILEPPYF VKQLEPVKVS VGDSASLQCQ LAGTPEIGVS WYKGDTKLRP TTTYKMHFRN NVATLVFNQV DINDSGEYIC KAENSVGEVS ASTFLTVQEQ KLPPSFSRQL RDVQETVGLP VVFDCAISGS EPISVSWYKD GKPLKDSPNV QTSFLDNTAT LNIFKTDRSL AGQYSCTATN PIGSASSSAR LILTEGKNPP FFDIRLAPVD AVVGESADFE CHVTGTQPIK VSWAKDSREI RSGGKYQISY LENSAHLTVL KVDKGDSGQY TCYAVNEVGK DSCTAQLNIK ERLIPPSFTK RLSETVEETE GNSFKLEGRV AGSQPITVAW YKNNIEIQPT SNCEITFKNN TLVLQVRKAG MNDAGLYTCK VSNDAGSALC TSSIVIKEPK KPPVFDQHLT PVTVSEGEYV QLSCHVQGSE PIRIQWLKAG REIKPSDRCS FSFASGTAVL ELRDVAKADS GDYVCKASNV AGSDTTKSKV TIKDKPAVAP ATKKAAVDGR LFFVSEPQSI RVVEKTTATF IAKVGGDPIP NVKWTKGKWR QLNQGGRVFI HQKGDEAKLE IRDTTKTDSG LYRCVAFNEH GEIESNVNLQ VDERKKQEKI EGDLRAMLKK TPILKKGAGE EEEIDIMELL KNVDPKEYEK YARMYGITDF RGLLQAFELL KQSQEEETHR LEIEEIERSE RDEKEFEELV SFIQQRLSQT EPVTLIKDIE NQTVLKDNDA VFEIDIKINY PEIKLSWYKG TEKLEPSDKF EISIDGDRHT LRVKNCQLKD QGNYRLVCGP HIASAKLTVI EPAWERHLQD VTLKEGQTCT MTCQFSVPNV KSEWFRNGRI LKPQGRHKTE VEHKVHKLTI ADVRAEDQGQ YTCKYEDLET SAELRIEAEP IQFTKRIQNI VVSEHQSATF ECEVSFDDAI VTWYKGPTEL TESQKYNFRN DGRCHYMTIH NVTPDDEGVY SVIARLEPRG EARSTAELYL TTKEIKLELK PPDIPDSRVP IPTMPIRAVP PEEIPPVVAP PIPLLLPTPE EKKPPPKRIE VTKKAVKKDA KKVVAKPKEM TPREEIVKKP PPPTTLIPAK APEIIDVSSK AEEVKIMTIT RKKEVQKEKE AVYEKKQAVH KEKRVFIESF EEPYDELEVE PYTEPFEQPY YEEPDEDYEE IKVEAKKEVH EEWEEDFEEG QEYYEREEGY DEGEEEWEEA YQEREVIQVQ KEVYEESHER KVPAKVPEKK APPPPKVIKK PVIEKIEKTS RRMEEEKVQV TKVPEVSKKI VPQKPSRTPV QEEVIEVKVP AVHTKKMVIS EEKMFFASHT EEEVSVTVPE VQKEIVTEEK IHVAISKRVE PPPKVPELPE KPAPEEVAPV PIPKKVEPPA PKVPEVPKKP VPEEKKPVPV PKKEPAAPPK VPEVPKKPVP EEKIPVPVAK KKEAPPAKVP EVQKGVVTEE KITIVTQREE SPPPAVPEIP KKKVPEERKP VPRKEEEVPP PPKVPALPKK PVPEEKVAVP VPVAKKAPPP RAEVSKKTVV EEKRFVAEEK LSFAVPQRVE VTRHEVSAEE EWSYSEEEEG VSISVYREEE REEEEEAEVT EYEVMEEPEE YVVEEKLHII SKRVEAEPAE VTERQEKKIV LKPKIPAKIE EPPPAKVPEA PKKIVPEKKV PAPVPKKEKV PPPKVPEEPK KPVPEKKVPP KVIKMEEPLP AKVTERHMQI TQEEKVLVAV TKKEAPPKAR VPEEPKRAVP EEKVLKLKPK REEEPPAKVT EFRKRVVKEE KVSIEAPKRE PQPIKEVTIM EEKERAYTLE EEAVSVQREE EYEEYEEYDY KEFEEYEPTE EYDQYEEYEE REYERYEEHE EYITEPEKPI PVKPVPEEPV PTKPKAPPAK VLKKAVPEEK VPVPIPKKLK PPPPKVPEEP KKVFEEKIRI SITKREKEQV TEPAAKVPMK PKRVVAEEKV PVPRKEVAPP VRVPEVPKEL EPEEVAFEEE VVTHVEEYLV EEEEEYIHEE EEFITEEEVV PVIPVKVPEV PRKPVPEEKK PVPVPKKKEA PPAKVPEVPK KPEEKVPVLI PKKEKPPPAK VPEVPKKPVP EEKVPVPVPK KVEAPPAKVP EVPKKPVPEK KVPVPAPKKV EAPPAKVPEV PKKLIPEEKK PTPVPKKVEA PPPKVPKKRE PVPVPVALPQ EEEVLFEEEI VPEEEVLPEE EEVLPEEEEV LPEEEEVLPE EEEIPPEEEE VPPEEEYVPE EEEFVPEEEV LPEVKPKVPV PAPVPEIKKK VTEKKVVIPK KEEAPPAKVP EVPKKVEEKR IILPKEEEVL PVEVTEEPEE EPISEEEIPE EPPSIEEVEE VAPPRVPEVI KKAVPEAPTP VPKKVEAPPA KVSKKIPEEK VPVPVQKKEA PPAKVPEVPK KVPEKKVLVP KKEAVPPAKG RTVLEEKVSV AFRQEVVVKE RLELEVVEAE VEEIPEEEEF HEVEEYFEEG EFHEVEEFIK LEQHRVEEEH RVEKVHRVIE VFEAEEVEVF EKPKAPPKGP EISEKIIPPK KPPTKVVPRK EPPAKVPEVP KKIVVEEKVR VPEEPRVPPT KVPEVLPPKE VVPEKKVPVP PAKKPEAPPP KVPEAPKEVV PEKKVPVPPP KKPEVPPTKV PEVPKAAVPE KKVPEAIPPK PESPPPEVPE APKEVVPEKK VPAAPPKKPE VTPVKVPEAP KEVVPEKKVP VPPPKKPEVP PTKVPEVPKV AVPEKKVPEA IPPKPESPPP EVFEEPEEVA LEEPPAEVVE EPEPAAPPQV TVPPKKPVPE KKAPAVVAKK PELPPVKVPE VPKEVVPEKK VPLVVPKKPE APPAKVPEVP KEVVPEKKVA VPKKPEVPPA KVPEVPKKPV LEEKPAVPVP ERAESPPPEV YEEPEEIAPE EEIAPEEEKP VPVAEEEEPE VPPPAVPEEP KKIIPEKKVP VIKKPEAPPP KEPEPEKVIE KPKLKPRPPP PPPAPPKEDV KEKIFQLKAI PKKKVPEKPQ VPEKVELTPL KVPGGEKKVR KLLPERKPEP KEEVVLKSVL RKRPEEEEPK VEPKKLEKVK KPAVPEPPPP KPVEEVEVPT VTKRERKIPE PTKVPEIKPA IPLPAPEPKP KPEAEVKTIK PPPVEPEPTP IAAPVTVPVV GKKAEAKAPK EEAAKPKGPI KGVPKKTPSP IEAERRKLRP GSGGEKPPDE APFTYQLKAV PLKFVKEIKD IILTESEFVG SSAIFECLVS PSTAITTWMK DGSNIRESPK HRFIADGKDR KLHIIDVQLS DAGEYTCVLR LGNKEKTSTA KLVVEELPVR FVKTLEEEVT VVKGQPLYLS CELNKERDVV WRKDGKIVVE KPGRIVPGVI GLMRALTIND ADDTDAGTYT VTVENANNLE CSSCVKVVEV IRDWLVKPIR DQHVKPKGTA IFACDIAKDT PNIKWFKGYD EIPAEPNDKT EILRDGNHLY LKIKNAMPED IAEYAVEIEG KRYPAKLTLG EREVELLKPI EDVTIYEKES ASFDAEISEA DIPGQWKLKG ELLRPSPTCE IKAEGGKRFL TLHKVKLDQA GEVLYQALNA ITTAILTVKE IELDFAVPLK DVTVPERRQA RFECVLTREA NVIWSKGPDI IKSSDKFDII ADGKKHILVI NDSQFDDEGV YTAEVEGKKT SARLFVTGIR LKFMSPLEDQ TVKEGETATF VCELSHEKMH VVWFKNDAKL HTSRTVLISS EGKTHKLEMK EVTLDDISQI KAQVKELSST AQLKVLEADP YFTVKLHDKT AVEKDEITLK CEVSKDVPVK WFKDGEEIVP SPKYSIKADG LRRILKIKKA DLKDKGEYVC DCGTDKTKAN VTVEARLIKV EKPLYGVEVF VGETAHFEIE LSEPDVHGQW KLKGQPLTAS PDCEIIEDGK KHILILHNCQ LGMTGEVSFQ AANAKSAANL KVKELPLIFI TPLSDVKVFE KDEAKFECEV SREPKTFRWL KGTQEITGDD RFELIKDGTK HSMVIKSAAF EDEAKYMFEA EDKHTSGKLI IEGIRLKFLT PLKDVTAKEK ESAVFTVELS HDNIRVKWFK NDQRLHTTRS VSMQDEGKTH SITFKDLSID DTSQIRVEAM GMSSEAKLTV LEGDPYFTGK LQDYTGVEKD EVILQCEISK ADAPVKWFKD GKEIKPSKNA VIKADGKKRM LILKKALKSD IGQYTCDCGT DKTSGKLDIE DREIKLVRPL HSVEVMETET ARFETEISED DIHANWKLKG EALLQTPDCE IKEEGKIHSL VLHNCRLDQT GGVDFQAANV KSSAHLRVKP RVIGLLRPLK DVTVTAGETA TFDCELSYED IPVEWYLKGK KLEPSDKVVP RSEGKVHTLT LRDVKLEDAG EVQLTAKDFK THANLFVKEP PVEFTKPLED QTVEEGATAV LECEVSRENA KVKWFKNGTE ILKSKKYEIV ADGRVRKLVI HDCTPEDIKT YTCDAKDFKT SCNLNVVPPH VEFLRPLTDL QVREKEMARF ECELSRENAK VKWFKDGAEI KKGKKYDIIS KGAVRILVIN KCLLDDEAEY SCEVRTARTS GMLTVLEEEA VFTKNLANIE VSETDTIKLV CEVSKPGAEV IWYKGDEEII ETGRYEILTE GRKRILVIQN AHLEDAGNYN CRLPSSRTDG KVKVHELAAE FISKPQNLEI LEGEKAEFVC SISKESFPVQ WKRDDKTLES GDKYDVIADG KKRVLVVKDA TLQDMGTYVV MVGAARAAAH LTVIEKLRIV VPLKDTRVKE QQEVVFNCEV NTEGAKAKWF RNEEAIFDSS KYIILQKDLV YTLRIRDAHL DDQANYNVSL TNHRGENVKS AANLIVEEED LRIVEPLKDI ETMEKKSVTF WCKVNRLNVT LKWTKNGEEV PFDNRVSYRV DKYKHMLTIK DCGFPDEGEY IVTAGQDKSV AELLIIEAPT EFVEHLEDQT VTEFDDAVFS CQLSREKANV KWYRNGREIK EGKKYKFEKD GSIHRLIIKD CRLDDECEYA CGVEDRKSRA RLFVEEIPVE IIRPPQDILE APGADVVFLA ELNKDKVEVQ WLRNNMVVVQ GDKHQMMSEG KIHRLQICDI KPRDQGEYRF IAKDKEARAK LELAAAPKIK TADQDLVVDV GKPLTMVVPY DAYPKAEAEW FKENEPLSTK TIDTTAEQTS FRILEAKKGD KGRYKIVLQN KHGKAEGFIN LKVIDVPGPV RNLEVTETFD GEVSLAWEEP LTDGGSKIIG YVVERRDIKR KTWVLATDRA ESCEFTVTGL QKGGVEYLFR VSARNRVGTG EPVETDNPVE ARSKYDVPGP PLNVTITDVN RFGVSLTWEP PEYDGGAEIT NYVIELRDKT SIRWDTAMTV RAEDLSATVT DVVEGQEYSF RVRAQNRIGV GKPSAATPFV KVADPIERPS PPVNLTSSDQ TQSSVQLKWE PPLKDGGSPI LGYIIERCEE GKDNWIRCNM KLVPELTYKV TGLEKGNKYL YRVSAENKAG VSDPSEILGP LTADDAFVEP TMDLSAFKDG LEVIVPNPIT ILVPSTGYPR PTATWCFGDK VLETGDRVKM KTLSAYAELV ISPSERSDKG IYTLKLENRV KTISGEIDVN VIARPSAPKE LKFGDITKDS VHLTWEPPDD DGGSPLTGYV VEKREVSRKT WTKVMDFVTD LEFTVPDLVQ GKEYLFKVCA RNKCGPGEPA YVDEPVNMST PATVPDPPEN VKWRDRTANS IFLTWDPPKN DGGSRIKGYI VERCPRGSDK WVACGEPVAE TKMEVTGLEE GKWYAYRVKA LNRQGASKPS RPTEEIQAVD TQEAPEIFLD VKLLAGLTVK AGTKIELPAT VTGKPEPKIT WTKADMILKQ DKRITIENVP KKSTVTIVDS KRSDTGTYII EAVNVCGRAT AVVEVNVLDK PGPPAAFDIT DVTNESCLLT WNPPRDDGGS KITNYVVERR ATDSEVWHKL SSTVKDTNFK ATKLIPNKEY IFRVAAENMY GVGEPVQASP ITAKYQFDPP GPPTRLEPSD ITKDAVTLTW CEPDDDGGSP ITGYWVERLD PDTDKWVRCN KMPVKDTTYR VKGLTNKKKY RFRVLAENLA GPGKPSKSTE PILIKDPIDP PWPPGKPTVK DVGKTSVRLN WTKPEHDGGA KIESYVIEML KTGTDEWVRV AEGVPTTQHL LPGLMEGQEY SFRVRAVNKA GESEPSEPSD PVLCREKLYP PSPPRWLEVI NITKNTADLK WTVPEKDGGS PITNYIVEKR DVRRKGWQTV DTTVKDTKCT VTPLTEGSLY VFRVAAENAI GQSDYTEIED SVLAKDTFTT PGPPYALAVV DVTKRHVDLK WEPPKNDGGR PIQRYVIEKK ERLGTRWVKA GKTAGPDCNF RVTDVIEGTE VQFQVRAENE AGVGHPSEPT EILSIEDPTS PPSPPLDLHV TDAGRKHIAI AWKPPEKNGG SPIIGYHVEM CPVGTEKWMR VNSRPIKDLK FKVEEGVVPD KEYVLRVRAV NAIGVSEPSE ISENVVAKDP DCKPTIDLET HDIIVIEGEK LSIPVPFRAV PVPTVSWHKD GKEVKASDRL TMKNDHISAH LEVPKSVRAD AGIYTITLEN KLGSATASIN VKVIGLPGPC KDIKASDITK SSCKLTWEPP EFDGGTPILH YVLERREAGR RTYIPVMSGE NKLSWTVKDL IPNGEYFFRV KAVNKVGGGE YIELKNPVIA QDPKQPPDPP VDVEVHNPTA EAMTITWKPP LYDGGSKIMG YIIEKIAKGE ERWKRCNEHL VPILTYTAKG LEEGKEYQFR VRAENAAGIS EPSRATPPTK AVDPIDAPKV ILRTSLEVKR GDEIALDASI SGSPYPTITW IKDENVIVPE EIKKRAAPLV RRRKGEVQEE EPFVLPLTQR LSIDNSKKGE SQLRVRDSLR PDHGLYMIKV ENDHGIAKAP CTVSVLDTPG PPINFVFEDI RKTSVLCKWE PPLDDGGSEI INYTLEKKDK TKPDSEWIVV TSTLRHCKYS VTKLIEGKEY LFRVRAENRF GPGPPCVSKP LVAKDPFGPP DAPDKPIVED VTSNSMLVKW NEPKDNGSPI LGYWLEKREV NSTHWSRVNK SLLNALKANV DGLLEGLTYV FRVCAENAAG PGKFSPPSDP KTAHDPISPP GPPIPRVTDT SSTTIELEWE PPAFNGGGEI VGYFVDKQLV GTNEWSRCTE KMIKVRQYTV KEIREGADYK LRVSAVNAAG EGPPGETQPV TVAEPQEPPA VELDVSVKGG IQIMAGKTLR IPAVVTGRPV PTKVWTKEEG ELDKDRVVID NVGTKSELII KDALRKDHGR YVITATNSCG SKFAAARVEV FDVPGPVLDL KPVVTNRKMC LLNWSDPEDD GGSEITGFII ERKDAKMHTW RQPIETERSK CDITGLLEGQ EYKFRVIAKN KFGCGPPVEI GPILAVDPLG PPTSPERLTY TERTKSTITL DWKEPRSNGG SPIQGYIIEK RRHDKPDFER VNKRLCPTTS FLVENLDEHQ MYEFRVKAVN EIGESEPSLP LNVVIQDDEV PPTIKLRLSV RGDTIKVKAG EPVHIPADVT GLPMPKIEWS KNETVIEKPT DALQITKEEV SRSEAKTELS IPKAVREDKG TYTVTASNRL GSVFRNVHVE VYDRPSPPRN LAVTDIKAES CYLTWDAPLD NGGSEITHYV IDKRDASRKK AEWEEVTNTA VEKRYGIWKL IPNGQYEFRV RAVNKYGISD ECKSDKVVIQ DPYRLPGPPG KPKVLARTKG SMLVSWTPPL DNGGSPITGY WLEKREEGSP YWSRVSRAPI TKVGLKGVEF NVPRLLEGVK YQFRAMAINA AGIGPPSEPS DPEVAGDPIF PPGPPSCPEV KDKTKSSISL GWKPPAKDGG SPIKGYIVEM QEEGTTDWKR VNEPDKLITT CECVVPNLKE LRKYRFRVKA VNEAGESEPS DTTGEIPATD IQEEPEVFID IGAQDCLVCK AGSQIRIPAV IKGRPTPKSS WEFDGKAKKA MKDGVHDIPE DAQLETAENS SVIIIPECKR SHTGKYSITA KNKAGQKTAN CRVKVMDVPG PPKDLKVSDI TRGSCRLSWK MPDDDGGDRI KGYVIEKRTI DGKAWTKVNP DCGSTTFVVP DLLSEQQYFF RVRAENRFGI GPPVETIQRT TARDPIYPPD PPIKLKIGLI TKNTVHLSWK PPKNDGGSPV THYIVECLAW DPTGTKKEAW RQCNKRDVEE LQFTVEDLVE GGEYEFRVKA VNAAGVSKPS ATVGPVTVKD QTCPPSIDLK EFMEVEEGTN VNIVAKIKGV PFPTLTWFKA PPKKPDNKEP VLYDTHVNKL VVDDTCTLVI PQSRRSDTGL YTITAVNNLG TASKEMRLNV LGRPGPPVGP IKFESVSADQ MTLSWFPPKD DGGSKITNYV IEKREANRKT WVHVSSEPKE CTYTIPKLLE GHEYVFRIMA QNKYGIGEPL DSEPETARNL FSVPGAPDKP TVSSVTRNSM TVNWEEPEYD GGSPVTGYWL EMKDTTSKRW KRVNRDPIKA MTLGVSYKVT GLIEGSDYQF RVYAINAAGV GPASLPSDPA TARDPIAPPG PPFPKVTDWT KSSADLEWSP PLKDGGSKVT GYIVEYKEEG KEEWEKGKDK EVRGTKLVVT GLKEGAFYKF RVRAVNIAGI GEPGEVTDVI EMKDRLVSPD LQLDASVRDR IVVHAGGVIR IIAYVSGKPP PTVTWNMNER TLPQEATIET TAISSSMVIK NCQRSHQGVY SLLAKNEAGE RKKTIIVDVL DVPGPVGTPF LAHNLTNESC KLTWFSPEDD GGSPITNYVI EKRESDRRAW TPVTYTVTRQ NATVQGLIQG KAYFFRIAAE NSIGMGPFVE TSEALVIREP ITVPERPEDL EVKEVTKNTV TLTWNPPKYD GGSEIINYVL ESRLIGTEKF HKVTNDNLLS RKYTVKGLKE GDTYEYRVSA VNIVGQGKPS FCTKPITCKD ELAPPTLHLD FRDKLTIRVG EAFALTGRYS GKPKPKVSWF KDEADVLEDD RTHIKTTPAT LALEKIKAKR SDSGKYCVVV ENSTGSRKGF CQVNVVDRPG PPVGPVSFDE VTKDYMVISW KPPLDDGGSK ITNYIIEKKE VGKDVWMPVT SASAKTTCKV SKLLEGKDYI FRIHAENLYG ISDPLVSDSM KAKDRFRVPD APDQPIVTEV TKDSALVTWN KPHDGGKPIT NYILEKRETM SKRWARVTKD PIHPYTKFRV PDLLEGCQYE FRVSAENEIG IGDPSPPSKP VFAKDPIAKP SPPVNPEAID TTCNSVDLTW QPPRHDGGSK ILGYIVEYQK VGDEEWRRAN HTPESCPETK YKVTGLRDGQ TYKFRVLAVN AAGESDPAHV PEPVLVKDRL EPPELILDAN MAREQHIKVG DTLRLSAIIK GVPFPKVTWK KEDRDAPTKA RIDVTPVGSK LEIRNAAHED GGIYSLTVEN PAGSKTVSVK VLVLDKPGPP RDLEVSEIRK DSCYLTWKEP LDDGGSVITN YVVERRDVAS AQWSPLSATS KKKSHFAKHL NEGNQYLFRV AAENQYGRGP FVETPKPIKA LDPLHPPGPP KDLHHVDVDK TEVSLVWNKP DRDGGSPITG YLVEYQEEGT QDWIKFKTVT NLECVVTGLQ QGKTYRFRVK AENIVGLGLP DTTIPIECQE KLVPPSVELD VKLIEGLVVK AGTTVRFPAI IRGVPVPTAK WTTDGSEIKT DEHYTVETDN FSSVLTIKNC LRRDTGEYQI TVSNAAGSKT VAVHLTVLDV PGPPTGPINI LDVTPEHMTI SWQPPKDDGG SPVINYIVEK QDTRKDTWGV VSSGSSKTKL KIPHLQKGCE YVFRVRAENK IGVGPPLDST PTVAKHKFSP PSPPGKPVVT DITENAATVS WTLPKSDGGS PITGYYMERR EVTGKWVRVN KTPIADLKFR VTGLYEGNTY EFRVFAENLA GLSKPSPSSD PIKACRPIKP PGPPINPKLK DKSRETADLV WTKPLSDGGS PILGYVVECQ KPGTAQWNRI NKDELIRQCA FRVPGLIEGN EYRFRIKAAN IVGEGEPREL AESVIAKDIL HPPEVELDVT CRDVITVRVG QTIRILARVK GRPEPDITWT KEGKVLVREK RVDLIQDLPR VELQIKEAVR ADHGKYIISA KNSSGHAQGS AIVNVLDRPG PCQNLKVTNV TKENCTISWE NPLDNGGSEI TNFIVEYRKP NQKGWSIVAS DVTKRLIKAN LLANNEYYFR VCAENKVGVG PTIETKTPIL AINPIDRPGE PENLHIADKG KTFVYLKWRR PDYDGGSPNL SYHVERRLKG SDDWERVHKG SIKETHYMVD RCVENQIYEF RVQTKNEGGE SDWVKTEEVV VKEDLQKPVL DLKLSGVLTV KAGDTIRLEA GVRGKPFPEV AWTKDKDATD LTRSPRVKID TRADSSKFSL TKAKRSDGGK YVVTATNTAG SFVAYATVNV LDKPGPVRNL KIVDVSSDRC TVCWDPPEDD GGCEIQNYIL EKCETKRMVW STYSATVLTP GTTVTRLIEG NEYIFRVRAE NKIGTGPPTE SKPVIAKTKY DKPGRPDPPE VTKVSKEEMT VVWNPPEYDG GKSITGYFLE KKEKHSTRWV PVNKSAIPER RMKVQNLLPD HEYQFRVKAE NEIGIGEPSL PSRPVVAKDP IEPPGPPTNF RVVDTTKHSI TLGWGKPVYD GGAPIIGYVV EMRPKIADAS PDEGWKRCNA AAQLVRKEFT VTSLDENQEY EFRVCAQNQV GIGRPAELKE AIKPKEILEP PEIDLDASMR KLVIVRAGCP IRLFAIVRGR PAPKVTWRKV GIDNVVRKGQ VDLVDTMAFL VIPNSTRDDS GKYSLTLVNP AGEKAVFVNV RVLDTPGPVS DLKVSDVTKT SCHVSWAPPE NDGGSQVTHY IVEKREADRK TWSTVTPEVK KTSFHVTNLV PGNEYYFRVT AVNEYGPGVP TDVPKPVLAS DPLSEPDPPR KLEVTEMTKN SATLAWLPPL RDGGAKIDGY ITSYREEEQP ADRWTEYSVV KDLSLVVTGL KEGKKYKFRV AARNAVGVSL PREAEGVYEA KEQLLPPKIL MPEQITIKAG KKLRIEAHVY GKPHPTCKWK KGEDEVVTSS HLAVHKADSS SILIIKDVTR KDSGYYSLTA ENSSGTDTQK IKVVVMDAPG PPQPPFDISD IDADACSLSW HIPLEDGGSN ITNYIVEKCD VSRGDWVTAL ASVTKTSCRV GKLIPGQEYI FRVRAENRFG ISEPLTSPKM VAQFPFGVPS EPKNARVTKV NKDCIFVAWD RPDSDGGSPI IGYLIERKER NSLLWVKAND TLVRSTEYPC AGLVEGLEYS FRIYALNKAG SSPPSKPTEY VTARMPVDPP GKPEVIDVTK STVSLIWARP KHDGGSKIIG YFVEACKLPG DKWVRCNTAP HQIPQEEYTA TGLEEKAQYQ FRAIARTAVN ISPPSEPSDP VTILAENVPP RIDLSVAMKS LLTVKAGTNV CLDATVFGKP MPTVSWKKDG TLLKPAEGIK MAMQRNLCTL ELFSVNRKDS GDYTITAENS SGSKSATIKL KVLDKPGPPA SVKINKMYSD RAMLSWEPPL EDGGSEITNY IVDKRETSRP NWAQVSATVP ITSCSVEKLI EGHEYQFRIC AENKYGVGDP VFTEPAIAKN PYDPPGRCDP PVISNITKDH MTVSWKPPAD DGGSPITGYL LEKRETQAVN WTKVNRKPII ERTLKATGLQ EGTEYEFRVT AINKAGPGKP SDASKAAYAR DPQYPPGPPA FPKVYDTTRS SVSLSWGKPA YDGGSPIIGY LVEVKRADSD NWVRCNLPQN LQKTRFEVTG LMEDTQYQFR VYAVNKIGYS DPSDVPDKHY PKDILIPPEG ELDADLRKTL ILRAGVTMRL YVPVKGRPPP KITWSKPNVN LRDRIGLDIK STDFDTFLRC ENVNKYDAGK YILTLENSCG KKEYTIVVKV LDTPGPPVNV TVKEISKDSA YVTWEPPIID GGSPIINYVV QKRDAERKSW STVTTECSKT SFRVANLEEG KSYFFRVFAE NEYGIGDPGE TRDAVKASQT PGPVVDLKVR SVSKSSCSIG WKKPHSDGGS RIIGYVVDFL TEENKWQRVM KSLSLQYSAK DLTEGKEYTF RVSAENENGE GTPSEITVVA RDDVVAPDLD LKGLPDLCYL AKENSNFRLK IPIKGKPAPS VSWKKGEDPL ATDTRVSVES SAVNTTLIVY DCQKSDAGKY TITLKNVAGT KEGTISIKVV GKPGIPTGPI KFDEVTAEAM TLKWAPPKDD GGSEITNYIL EKRDSVNNKW VTCASAVQKT TFRVTRLHEG MEYTFRVSAE NKYGVGEGLK SEPIVARHPF DVPDAPPPPN IVDVRHDSVS LTWTDPKKTG GSPITGYHLE FKERNSLLWK RANKTPIRMR DFKVTGLTEG LEYEFRVMAI NLAGVGKPSL PSEPVVALDP IDPPGKPEVI NITRNSVTLI WTEPKYDGGH KLTGYIVEKR DLPSKSWMKA NHVNVPECAF TVTDLVEGGK YEFRIRAKNT AGAISAPSES TETIICKDEY EAPTIVLDPT IKDGLTIKAG DTIVLNAISI LGKPLPKSSW SKAGKDIRPS DITQITSTPT SSMLTIKYAT RKDAGEYTIT ATNPFGTKVE HVKVTVLDVP GPPGPVEISN VSAEKATLTW TPPLEDGGSP IKSYILEKRE TSRLLWTVVS EDIQSCRHVA TKLIQGNEYI FRVSAVNHYG KGEPVQSEPV KMVDRFGPPG PPEKPEVSNV TKNTATVSWK RPVDDGGSEI TGYHVERREK KSLRWVRAIK TPVSDLRCKV TGLQEGSTYE FRVSAENRAG IGPPSEASDS VLMKDAAYPP GPPSNPHVTD TTKKSASLAW GKPHYDGGLE ITGYVVEHQK VGDEAWIKDT TGTALRITQF VVPDLQTKEK YNFRISAIND AGVGEPAVIP DVEIVEREMA PDFELDAELR RTLVVRAGLS IRIFVPIKGR PAPEVTWTKD NINLKNRANI ENTESFTLLI IPECNRYDTG KFVMTIENPA GKKSGFVNVR VLDTPGPVLN LRPTDITKDS VTLHWDLPLI DGGSRITNYI VEKREATRKS YSTATTKCHK CTYKVTGLSE GCEYFFRVMA ENEYGIGEPT ETTEPVKASE APSPPDSLNI MDITKSTVSL AWPKPKHDGG SKITGYVIEA QRKGSDQWTH ITTVKGLECV VRNLTEGEEY TFQVMAVNSA GRSAPRESRP VIVKEQTMLP ELDLRGIYQK LVIAKAGDNI KVEIPVLGRP KPTVTWKKGD QILKQTQRVN FETTATSTIL NINECVRSDS GPYPLTARNI VGEVGDVITI QVHDIPGPPT GPIKFDEVSS DFVTFSWDPP ENDGGVPISN YVVEMRQTDS TTWVELATTV IRTTYKATRL TTGLEYQFRV KAQNRYGVGP GITSACIVAN YPFKVPGPPG TPQVTAVTKD SMTISWHEPL SDGGSPILGY HVERKERNGI LWQTVSKALV PGNIFKSSGL TDGIAYEFRV IAENMAGKSK PSKPSEPMLA LDPIDPPGKP VPLNITRHTV TLKWAKPEYT GGFKITSYIV EKRDLPNGRW LKANFSNILE NEFTVSGLTE DAAYEFRVIA KNAAGAISPP SEPSDAITCR DDVEAPKIKV DVKFKDTVIL KAGEAFRLEA DVSGRPPPTM EWSKDGKELE GTAKLEIKIA DFSTNLVNKD STRRDSGAYT LTATNPGGFA KHIFNVKVLD RPGPPEGPLA VTEVTSEKCV LSWFPPLDDG GAKIDHYIVQ KRETSRLAWT NVASEVQVTK LKVTKLLKGN EYIFRVMAVN KYGVGEPLES EPVLAVNPYG PPDPPKNPEV TTITKDSMVV CWGHPDSDGG SEIINYIVER RDKAGQRWIK CNKKTLTDLR YKVSGLTEGH EYEFRIMAEN AAGISAPSPT SPFYKACDTV FKPGPPGNPR VLDTSRSSIS IAWNKPIYDG GSEITGYMVE IALPEEDEWQ IVTPPAGLKA TSYTITGLTE NQEYKIRIYA MNSEGLGEPA LVPGTPKAED RMLPPEIELD ADLRKVVTIR ACCTLRLFVP IKGRPAPEVK WARDHGESLD KASIESTSSY TLLIVGNVNR FDSGKYILTV ENSSGSKSAF VNVRVLDTPG PPQDLKVKEV TKTSVTLTWD PPLLDGGSKI KNYIVEKRES TRKAYSTVAT NCHKTSWKVD QLQEGCSYYF RVLAENEYGI GLPAETAESV KASERPLPPG KITLMDVTRN SVSLSWEKPE HDGGSRILGY IVEMQTKGSD KWATCATVKV TEATITGLIQ GEEYSFRVSA QNEKGISDPR QLSVPVIAKD LVIPPAFKLL FNTFTVLAGE DLKVDVPFIG RPTPAVTWHK DNVPLKQTTR VNAESTENNS LLTIKDACRE DVGHYVVKLT NSAGEAIETL NVIVLDKPGP PTGPVKMDEV TADSITLSWG PPKYDGGSSI NNYIVEKRDT STTTWQIVSA TVARTTIKAC RLKTGCEYQF RIAAENRYGK STYLNSEPTV AQYPFKVPGP PGTPVVTLSS RDSMEVQWNE PISDGGSRVI GYHLERKERN SILWVKLNKT PIPQTKFKTT GLEEGVEYEF RVSAENIVGI GKPSKVSECY VARDPCDPPG RPEAIIVTRN SVTLQWKKPT YDGGSKITGY IVEKKELPEG RWMKASFTNI IDTHFEVTGL VEDHRYEFRV IARNAAGVFS EPSESTGAIT ARDEVDPPRI SMDPKYKDTI VVHAGESFKV DADIYGKPIP TIQWIKGDQE LSNTARLEIK STDFATSLSV KDAVRVDSGN YILKAKNVAG ERSVTVNVKV LDRPGPPEGP VVISGVTAEK CTLAWKPPLQ DGGSDIINYI VERRETSRLV WTVVDANVQT LSCKVTKLLE GNEYTFRIMA VNKYGVGEPL ESEPVVAKNP FVVPDAPKAP EVTTVTKDSM IVVWERPASD GGSEILGYVL EKRDKEGIRW TRCHKRLIGE LRLRVTGLIE NHDYEFRVSA ENAAGLSEPS PPSAYQKACD PIYKPGPPNN PKVIDITRSS VFLSWSKPIY DGGCEIQGYI VEKCDVSVGE WTMCTPPTGI NKTNIEVEKL LEKHEYNFRI CAINKAGVGE HADVPGPIIV EEKLEAPDID LDLELRKIIN IRAGGSLRLF VPIKGRPTPE VKWGKVDGEI RDAAIIDVTS SFTSLVLDNV NRYDSGKYTL TLENSSGTKS AFVTVRVLDT PSPPVNLKVT EITKDSVSIT WEPPLLDGGS KIKNYIVEKR EATRKSYAAV VTNCHKNSWK IDQLQEGCSY YFRVTAENEY GIGLPAQTAD PIKVAEVPQP PGKITVDDVT RNSVSLSWTK PEHDGGSKII QYIVEMQAKH SEKWSECARV KSLQAVITNL TQGEEYLFRV VAVNEKGRSD PRSLAVPIVA KDLVIEPDVK PAFSSYSVQV GQDLKIEVPI SGRPKPTITW TKDGLPLKQT TRINVTDSLD LTTLSIKETH KDDGGQYGIT VANVVGQKTA SIEIVTLDKP DPPKGPVKFD DVSAESITLS WNPPLYTGGC QITNYIVQKR DTTTTVWDVV SATVARTTLK VTKLKTGTEY QFRIFAENRY GQSFALESDP IVAQYPYKEP GPPGTPFATA ISKDSMVIQW HEPVNNGGSP VIGYHLERKE RNSILWTKVN KTIIHDTQFK AQNLEEGIEY EFRVYAENIV GVGKASKNSE CYVARDPCDP PGTPEPIMVK RNEITLQWTK PVYDGGSMIT GYIVEKRDLP DGRWMKASFT NVIETQFTVS GLTEDQRYEF RVIAKNAAGA ISKPSDSTGP ITAKDEVELP RISMDPKFRD TIVVNAGETF RLEADVHGKP LPTIEWLRGD KEIEESARCE IKNTDFKALL IVKDAIRIDG GQYILRASNV AGSKSFPVNV KVLDRPGPPE GPVQVTGVTS EKCSLTWSPP LQDGGSDISH YVVEKRETSR LAWTVVASEV VTNSLKVTKL LEGNEYVFRI MAVNKYGVGE PLESAPVLMK NPFVLPGPPK SLEVTNIAKD SMTVCWNRPD SDGGSEIIGY IVEKRDRSGI RWIKCNKRRI TDLRLRVTGL TEDHEYEFRV SAENAAGVGE PSPATVYYKA CDPVFKPGPP TNAHIVDTTK NSITLAWGKP IYDGGSEILG YVVEICKADE EEWQIVTPQT GLRVTRFEIS KLTEHQEYKI RVCALNKVGL GEATSVPGTV KPEDKLEAPE LDLDSELRKG IVVRAGGSAR IHIPFKGRPT PEITWSREEG EFTDKVQIEK GVNYTQLSID NCDRNDAGKY ILKLENSSGS KSAFVTVKVL DTPGPPQNLA VKEVRKDSAF LVWEPPIIDG GAKVKNYVID KRESTRKAYA NVSSKCSKTS FKVENLTEGA IYYFRVMAEN EFGVGVPVET VDAVKAAEPP SPPGKVTLTD VSQTSASLMW EKPEHDGGSR VLGYVVEMQP KGTEKWSIVA ESKVCNAVVT GLSSGQEYQF RVKAYNEKGK SDPRVLGVPV IAKDLTIQPS LKLPFNTYSI QAGEDLKIEI PVIGRPRPNI SWVKDGEPLK QTTRVNVEET ATSTVLHIKE GNKDDFGKYT VTATNSAGTA TENLSVIVLE KPGPPVGPVR FDEVSADFVV ISWEPPAYTG GCQISNYIVE KRDTTTTTWH MVSATVARTT IKITKLKTGT EYQFRIFAEN RYGKSAPLDS KAVIVQYPFK EPGPPGTPFV TSISKDQMLV QWHEPVNDGG TKIIGYHLEQ KEKNSILWVK LNKTPIQDTK FKTTGLDEGL EYEFKVSAEN IVGIGKPSKV SECFVARDPC DPPGRPEAIV ITRNNVTLKW KKPAYDGGSK ITGYIVEKKD LPDGRWMKAS FTNVLETEFT VSGLVEDQRY EFRVIARNAA GNFSEPSDSS GAITARDEID APNASLDPKY KDVIVVHAGE TFVLEADIRG KPIPDVVWSK DGKELEETAA RMEIKSTIQK TTLVVKDCIR TDGGQYILKL SNVGGTKSIP ITVKVLDRPG PPEGPLKVTG VTAEKCYLAW NPPLQDGGAN ISHYIIEKRE TSRLSWTQVS TEVQALNYKV TKLLPGNEYI FRVMAVNKYG IGEPLESGPV TACNPYKPPG PPSTPEVSAI TKDSMVVTWA RPVDDGGTEI EGYILEKRDK EGVRWTKCNK KTLTDLRLRV TGLTEGHSYE FRVAAENAAG VGEPSEPSVF YRACDALYPP GPPSNPKVTD TSRSSVSLAW SKPIYDGGAP VKGYVVEVKE AAADEWTTCT PPTGLQGKQF TVTKLKENTE YNFRICAINS EGVGEPATLP GSVVAQERIE PPEIELDADL RKVVVLRASA TLRLFVTIKG RPEPEVKWEK AEGILTDRAQ IEVTSSFTML VIDNVTRFDS GRYNLTLENN SGSKTAFVNV RVLDSPSAPV NLTIREVKKD SVTLSWEPPL IDGGAKITNY IVEKRETTRK AYATITNNCT KTTFRIENLQ EGCSYYFRVL ASNEYGIGLP AETTEPVKVS EPPLPPGRVT LVDVTRNTAT IKWEKPESDG GSKITGYVVE MQTKGSEKWS TCTQVKTLEA TISGLTAGEE YVFRVAAVNE KGRSDPRQLG VPVIARDIEI KPSVELPFHT FNVKAREQLK IDVPFKGRPQ ATVNWRKDGQ TLKETTRVNV SSSKTVTSLS IKEASKEDVG TYELCVSNSA GSITVPITII VLDRPGPPGP IRIDEVSCDS ITISWNPPEY DGGCQISNYI VEKKETTSTT WHIVSQAVAR TSIKIVRLTT GSEYQFRVCA ENRYGKSSYS ESSAVVAEYP FSPPGPPGTP KVVHATKSTM LVTWQVPVND GGSRVIGYHL EYKERSSILW SKANKILIAD TQMKVSGLDE GLMYEYRVYA ENIAGIGKCS KSCEPVPARD PCDPPGQPEV TNITRKSVSL KWSKPHYDGG AKITGYIVER RELPDGRWLK CNYTNIQETY FEVTELTEDQ RYEFRVFARN AADSVSEPSE STGPIIVKDD VEPPRVMMDV KFRDVIVVKA GEVLKINADI AGRPLPVISW AKDGIEIEER ARTEIISTDN HTLLTVKDCI RRDTGQYVLT LKNVAGTRSV AVNCKVLDKP GPPAGPLEIN GLTAEKCSLS WGRPQEDGGA DIDYYIVEKR ETSHLAWTIC EGELQMTSCK VTKLLKGNEY IFRVTGVNKY GVGEPLESVA IKALDPFTVP SPPTSLEITS VTKESMTLCW SRPESDGGSE ISGYIIERRE KNSLRWVRVN KKPVYDLRVK STGLREGCEY EYRVYAENAA GLSLPSETSP LIRAEDPVFL PSPPSKPKIV DSGKTTITIA WVKPLFDGGA PITGYTVEYK KSDDTDWKTS IQSLRGTEYT ISGLTTGAEY VFRVKSVNKV GASDPSDSSD PQIAKEREEE PLFDIDSEMR KTLIVKAGAS FTMTVPFRGR PVPNVLWSKP DTDLRTRAYV DTTDSRTSLT IENANRNDSG KYTLTIQNVL SAASLTLVVK VLDTPGPPTN ITVQDVTKES AVLSWDVPEN DGGAPVKNYH IEKREASKKA WVSVTNNCNR LSYKVTNLQE GAIYYFRVSG ENEFGVGIPA ETKEGVKITE KPSPPEKLGV TSISKDSVSL TWLKPEHDGG SRIVHYVVEA LEKGQKNWVK CAVAKSTHHV VSGLRENSEY FFRVFAENQA GLSDPRELLL PVLIKEQLEP PEIDMKNFPS HTVYVRAGSN LKVDIPISGK PLPKVTLSRD GVPLKATMRF NTEITAENLT INLKESVTAD AGRYEITAAN SSGTTKAFIN IVVLDRPGPP TGPVVISDIT EESVTLKWEP PKYDGGSQVT NYILLKRETS TAVWTEVSAT VARTMMKVMK LTTGEEYQFR IKAENRFGIS DHIDSACVTV KLPYTTPGPP STPWVTNVTR ESITVGWHEP VSNGGSAVVG YHLEMKDRNS ILWQKANKLV IRTTHFKVTT ISAGLIYEFR VYAENAAGVG KPSHPSEPVL AIDACEPPRN VRITDISKNS VSLSWQQPAF DGGSKITGYI VERRDLPDGR WTKASFTNVT ETQFIISGLT QNSQYEFRVF ARNAVGSISN PSEVVGPITC IDSYGGPVID LPLEYTEVVK YRAGTSVKLR AGISGKPAPT IEWYKDDKEL QTNALVCVEN TTDLASILIK DADRLNSGCY ELKLRNAMGS ASATIRVQIL DKPGPPGGPI EFKTVTAEKI TLLWRPPADD GGAKITHYIV EKRETSRVVW SMVSEHLEEC IITTTKIIKG NEYIFRVRAV NKYGIGEPLE SDSVVAKNAF VTPGPPGIPE VTKITKNSMT VVWSRPIADG GSDISGYFLE KRDKKSLGWF KVLKETIRDT RQKVTGLTEN SDYQYRVCAV NAAGQGPFSE PSEFYKAADP IDPPGPPAKI RIADSTKSSI TLGWSKPVYD GGSAVTGYVV EIRQGEEEEW TTVSTKGEVR TTEYVVSNLK PGVNYYFRVS AVNCAGQGEP IEMNEPVQAK DILEAPEIDL DVALRTSVIA KAGEDVQVLI PFKGRPPPTV TWRKDEKNLG SDARYSIENT DSSSLLTIPQ VTRNDTGKYI LTIENGVGEP KSSTVSVKVL DTPAACQKLQ VKHVSRGTVT LLWDPPLIDG GSPIINYVIE KRDATKRTWS VVSHKCSSTS FKLIDLSEKT PFFFRVLAEN EIGIGEPCET TEPVKAAEVP APIRDLSMKD STKTSVILSW TKPDFDGGSV ITEYVVERKG KGEQTWSHAG ISKTCEIEVS QLKEQSVLEF RVFAKNEKGL SDPVTIGPIT VKELIITPEV DLSDIPGAQV TVRIGHNVHL ELPYKGKPKP SISWLKDGLP LKESEFVRFS KTENKITLSI KNAKKEHGGK YTVILDNAVC RIAVPITVIT LGPPSKPKGP IRFDEIKADS VILSWDVPED NGGGEITCYS IEKRETSQTN WKMVCSSVAR TTFKVPNLVK DAEYQFRVRA ENRYGVSQPL VSSIIVAKHQ FRIPGPPGKP VIYNVTSDGM SLTWDAPVYD GGSEVTGFHV EKKERNSILW QKVNTSPISG REYRATGLVE GLDYQFRVYA ENSAGLSSPS DPSKFTLAVS PVDPPGTPDY IDVTRETITL KWNPPLRDGG SKIVGYSIEK RQGNERWVRC NFTDVSECQY TVTGLSPGDR YEFRIIARNA VGTISPPSQS SGIIMTRDEN VPPIVEFGPE YFDGLIIKSG ESLRIKALVQ GRPVPRVTWF KDGVEIEKRM NMEITDVLGS TSLFVRDATR DHRGVYTVEA KNASGSAKAE IKVKVQDTPG KVVGPIRFTN ITGEKMTLWW DAPLNDGCAP ITHYIIEKRE TSRLAWALIE DKCEAQSYTA IKLINGNEYQ FRVSAVNKFG VGRPLDSDPV VAQIQYTVPD APGIPEPSNI TGNSITLTWA RPESDGGSEI QQYILERREK KSTRWVKVIS KRPISETRFK VTGLTEGNEY EFHVMAENAA GVGPASGISR LIKCREPVNP PGPPTVVKVT DTSKTTVSLE WSKPVFDGGM EIIGYIIEMC KADLGDWHKV NAEACVKTRY TVTDLQAGEE YKFRVSAING AGKGDSCEVT GTIKAVDRLT APELDIDANF KQTHVVRAGA SIRLFIAYQG RPTPTAVWSK PDSNLSLRAD IHTTDSFSTL TVENCNRNDA GKYTLTVENN SGSKSITFTV KVLDTPGPPG PITFKDVTRG SATLMWDAPL LDGGARIHHY VVEKREASRR SWQVISEKCT RQIFKVNDLA EGVPYYFRVS AVNEYGVGEP YEMPEPIVAT EQPAPPRRLD VVDTSKSSAV LAWLKPDHDG GSRITGYLLE MRQKGSDFWV EAGHTKQLTF TVERLVEKTE YEFRVKAKND AGYSEPREAF SSVIIKEPQI EPTADLTGIT NQLITCKAGS PFTIDVPISG RPAPKVTWKL EEMRLKETDR VSITTTKDRT TLTVKDSMRG DSGRYFLTLE NTAGVKTFSV TVVVIGRPGP VTGPIEVSSV SAESCVLSWG EPKDGGGTEI TNYIVEKRES GTTAWQLVNS SVKRTQIKVT HLTKYMEYSF RVSSENRFGV SKPLESAPII AEHPFVPPSA PTRPEVYHVS ANAMSIRWEE PYHDGGSKII GYWVEKKERN TILWVKENKV PCLECNYKVT GLVEGLEYQF RTYALNAAGV SKASEASRPI MAQNPVDAPG RPEVTDVTRS TVSLIWSAPA YDGGSKVVGY IIERKPVSEV GDGRWLKCNY TIVSDNFFTV TALSEGDTYE FRVLAKNAAG VISKGSESTG PVTCRDEYAP PKAELDARLH GDLVTIRAGS DLVLDAAVGG KPEPKIIWTK GDKELDLCEK VSLQYTGKRA TAVIKFCDRS DSGKYTLTVK NASGTKAVSV MVKVLDSPGP CGKLTVSRVT QEKCTLAWSL PQEDGGAEIT HYIVERRETS RLNWVIVEGE CPTLSYVVTR LIKNNEYIFR VRAVNKYGPG VPVESEPIVA RNSFTIPSPP GIPEEVGTGK EHIIIQWTKP ESDGGNEISN YLVDKREKKS LRWTRVNKDY VVYDTRLKVT SLMEGCDYQF RVTAVNAAGN SEPSEASNFI SCREPSYTPG PPSAPRVVDT TKHSISLAWT KPMYDGGTDI VGYVLEMQEK DTDQWYRVHT NATIRNTEFT VPDLKMGQKY SFRVAAVNVK GMSEYSESIA EIEPVERIEI PDLELADDLK KTVTIRAGAS LRLMVSVSGR PPPVITWSKQ GIDLASRAII DTTESYSLLI VDKVNRYDAG KYTIEAENQS GKKSATVLVK VYDTPGPCPS VKVKEVSRDS VTITWEIPTI DGGAPVNNYI VEKREAAMRA FKTVTTKCSK TLYRISGLVE GTMYYFRVLP ENIYGIGEPC ETSDAVLVSE VPLVPAKLEV VDVTKSTVTL AWEKPLYDGG SRLTGYVLEA CKAGTERWMK VVTLKPTVLE HTVTSLNEGE QYLFRIRAQN EKGVSEPRET VTAVTVQDLR VLPTIDLSTM PQKTIHVPAG RPVELVIPIA GRPPPAASWF FAGSKLRESE RVTVETHTKV AKLTIRETTI RDTGEYTLEL KNVTGTTSET IKVIILDKPG PPTGPIKIDE IDATSITISW EPPELDGGAP LSGYVVEQRD AHRPGWLPVS ESVTRSTFKF TRLTEGNEYV FRVAATNRFG IGSYLQSEVI ECRSSIRIPG PPETLQIFDV SRDGMTLTWY PPEDDGGSQV TGYIVERKEV RADRWVRVNK VPVTMTRYRS TGLTEGLEYE HRVTAINARG SGKPSRPSKP IVAMDPIAPP GKPQNPRVTD TTRTSVSLAW SVPEDEGGSK VTGYLIEMQK VDQHEWTKCN TTPTKIREYT LTHLPQGAEY RFRVLACNAG GPGEPAEVPG TVKVTEMLEY PDYELDERYQ EGIFVRQGGV IRLTIPIKGK PFPICKWTKE GQDISKRAMI ATSETHTELV IKEADRGDSG TYDLVLENKC GKKAVYIKVR VIGSPNSPEG PLEYDDIQVR SVRVSWRPPA DDGGADILGY ILERREVPKA AWYTIDSRVR GTSLVVKGLK ENVEYHFRVS AENQFGISKP LKSEEPVTPK TPLNPPEPPS NPPEVLDVTK SSVSLSWSRP KDDGGSRVTG YYIERKETST DKWVRHNKTQ ITTTMYTVTG LVPDAEYQFR IIAQNDVGLS ETSPASEPVV CKDPFDKPSQ PGELEILSIS KDSVTLQWEK PECDGGKEIL GYWVEYRQSG DSAWKKSNKE RIKDKQFTIG GLLEATEYEF RVFAENETGL SRPRRTAMSI KTKLTSGEAP GIRKEMKDVT TKLGEAAQLS CQIVGRPLPD IKWYRFGKEL IQSRKYKMSS DGRTHTLTVM TEEQEDEGVY TCIATNEVGE VETSSKLLLQ ATPQFHPGYP LKEKYYGAVG STLRLHVMYI GRPVPAMTWF HGQKLLQNSE NITIENTEHY THLVMKNVQR KTHAGKYKVQ LSNVFGTVDA ILDVEIQDKP DKPTGPIVIE ALLKNSAVIS WKPPADDGGS WITNYVVEKC EAKEGAEWQL VSSAISVTTC RIVNLTENAG YYFRVSAQNT FGISDPLEVS SVVIIKSPFE KPGAPGKPTI TAVTKDSCVV AWKPPASDGG AKIRNYYLEK REKKQNKWIS VTTEEIRETV FSVKNLIEGL EYEFRVKCEN LGGESEWSEI SEPITPKSDV PIQAPHFKEE LRNLNVRYQS NATLVCKVTG HPKPIVKWYR QGKEIIADGL KYRIQEFKGG YHQLIIASVT DDDATVYQVR ATNQGGSVSG TASLEVEVPA KIHLPKTLEG MGAVHALRGE VVSIKIPFSG KPDPVITWQK GQDLIDNNGH YQVIVTRSFT SLVFPNGVER KDAGFYVVCA KNRFGIDQKT VELDVADVPD PPRGVKVSDV SRDSVNLTWT EPASDGGSKI TNYIVEKCAT TAERWLRVGQ ARETRYTVIN LFGKTSYQFR VIAENKFGLS KPSEPSEPTI TKEDKTRAMN YDEEVDETRE VSMTKASHSS TKELYEKYMI AEDLGRGEFG IVHRCVETSS KKTYMAKFVK VKGTDQVLVK KEISILNIAR HRNILHLHES FESMEELVMI FEFISGLDIF ERINTSAFEL NEREIVSYVH QVCEALQFLH SHNIGHFDIR PENIIYQTRR SSTIKIIEFG QARQLKPGDN FRLLFTAPEY YAPEVHQHDV VSTATDMWSL GTLVYVLLSG INPFLAETNQ QIIENIMNAE YTFDEEAFKE ISIEAMDFVD RLLVKERKSR MTASEALQHP WLKQKIERVS TKVIRTLKHR RYYHTLIKKD LNMVVSAARI SCGGAIRSQK GVSVAKVKVA SIEIGPVSGQ IMHAVGEEGG HVKYVCKIEN YDQSTQVTWY FGVRQLENSE KYEITYEDGV AILYVKDITK LDDGTYRCKV VNDYGEDSSY AELFVKGVRE VYDYYCRRTM KKIKRRTDTM RLLERPPEFT LPLYNKTAYV GENVRFGVTI TVHPEPHVTW YKSGQKIKPG DNDKKYTFES DKGLYQLTIN SVTTDDDAEY TVVARNKYGE DSCKAKLTVT LHPPPTDSTL RPMFKRLLAN AECQEGQSVC FEIRVSGIPP PTLKWEKDGQ PLSLGPNIEI IHEGLDYYAL HIRDTLPEDT GYYRVTATNT AGSTSCQAHL QVERLRYKKQ EFKSKEEHER HVQKQIDKTL RMAEILSGTE SVPLTQVAKE ALREAAVLYK PAVSTKTVKG EFRLEIEEKK EERKLRMPYD VPEPRKYKQT TIEEDQRIKQ FVPMSDMKWY KKIRDQYEMP GKLDRVVQKR PKRIRLSRWE QFYVMPLPRI TDQYRPKWRI PKLSQDDLEI VRPARRRTPS PDYDFYYRPR RRSLGDISDE ELLLPIDDYL AMKRTEEERL RLEEELELGF SASPPSRSPP HFELSSLRYS SPQAHVKVEE TRKDFRYSTY HIPTKAEAST SYAELRERHA QAAYRQPKQR QRIMAEREDE ELLRPVTTTQ HLSEYKSELD FMSKEEKSRK KSRRQREVTE ITEIEEEYEI SKHAQRESSS SASRLLRRRR SLSPTYIELM RPVSELIRSR PQPAEEYEDD TERRSPTPER TRPRSPSPVS SERSLSRFER SARFDIFSRY ESMKAALKTQ KTSERKYEVL SQQPFTLDHA PRITLRMRSH RVPCGQNTRF ILNVQSKPTA EVKWYHNGVE LQESSKIHYT NTSGVLTLEI LDCHTDDSGT YRAVCTNYKG EASDYATLDV TGGDYTTYAS QRRDEEVPRS VFPELTRTEA YAVSSFKKTS EMEASSSVRE VKSQMTETRE SLSSYEHSAS AEMKSAALEE KSLEEKSTTR KIKTTLAARI LTKPRSMTVY EGESARFSCD TDGEPVPTVT WLRKGQVLST SARHQVTTTK YKSTFEISSV QASDEGNYSV VVENSEGKQE AEFTLTIQKA RVTEKAVTSP PRVKSPEPRV KSPEAVKSPK RVKSPEPSHP KAVSPTETKP TPTEKVQHLP VSAPPKITQF LKAEASKEIA KLTCVVESSV LRAKEVTWYK DGKKLKENGH FQFHYSADGT YELKINNLTE SDQGEYVCEI SGEGGTSKTN LQFMGQAFKS IHEKVSKISE TKKSDQKTTE STVTRKTEPK APEPISSKPV IVTGLQDTTV SSDSVAKFAV KATGEPRPTA IWTKDGKAIT QGGKYKLSED KGGFFLEIHK TDTSDSGLYT CTVKNSAGSV SSSCKLTIKA IKDTEAQKVS TQKTSEITPQ KKAVVQEEIS QKALRSEEIK MSEAKSQEKL ALKEEASKVL ISEEVKKSAA TSLEKSIVHE EITKTSQASE EVRTHAEIKA FSTQMSINEG QRLVLKANIA GATDVKWVLN GVELTNSEEY RYGVSGSDQT LTIKQASHRD EGILTCISKT KEGIVKCQYD LTLSKELSDA PAFISQPRSQ NINEGQNVLF TCEISGEPSP EIEWFKNNLP ISISSNVSIS RSRNVYSLEI RNASVSDSGK YTIKAKNFRG QCSATASLMV LPLVEEPSRE VVLRTSGDTS LQGSFSSQSV QMSASKQEAS FSSFSSSSAS SMTEMKFASM SAQSMSSMQE SFVEMSSSSF MGISNMTQLE SSTSKMLKAG IRGIPPKIEA LPSDISIDEG KVLTVACAFT GEPTPEVTWS CGGRKIHSQE QGRFHIENTD DLTTLIIMDV QKQDGGLYTL SLGNEFGSDS ATVNIHIRSI // ID TRPM7_HUMAN Reviewed; 1865 AA. AC Q96QT4; Q6ZMF5; Q86VJ4; Q8NBW2; Q9BXB2; Q9NXQ2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Transient receptor potential cation channel subfamily M member 7; DE EC=2.7.11.1 {ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; DE AltName: Full=Channel-kinase 1; DE AltName: Full=Long transient receptor potential channel 7 {ECO:0000303|PubMed:11385574}; DE Short=LTrpC-7; DE Short=LTrpC7; DE Contains: DE RecName: Full=TRPM7 kinase, cleaved form {ECO:0000250|UniProtKB:Q923J1}; DE Short=M7CK; DE Contains: DE RecName: Full=TRPM7 channel, cleaved form {ECO:0000250|UniProtKB:Q923J1}; GN Name=TRPM7; Synonyms=CHAK1, LTRPC7 {ECO:0000303|PubMed:11385574}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY RP REGULATION. RX PubMed=11385574; DOI=10.1038/35079092; RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RT "LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell RT viability."; RL Nature 411:590-595(2001). RN [2] RP ERRATUM OF PUBMED:11385574. RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RL Nature 412:660-660(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RX PubMed=14594813; DOI=10.1074/jbc.m308820200; RA Ryazanova L.V., Dorovkov M.V., Ansari A., Ryazanov A.G.; RT "Characterization of the protein kinase activity of TRPM7/ChaK1, a protein RT kinase fused to the transient receptor potential ion channel."; RL J. Biol. Chem. 279:3708-3716(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-575 AND 1096-1865, AND VARIANT RP ILE-1482. RC TISSUE=Colon, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 464-998. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF LYS-1648 AND GLY-1799. RX PubMed=12887921; DOI=10.1016/s0092-8674(03)00556-7; RA Schmitz C., Perraud A.-L., Johnson C.O., Inabe K., Smith M.K., Penner R., RA Kurosaki T., Fleig A., Scharenberg A.M.; RT "Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7."; RL Cell 114:191-200(2003). RN [7] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15485879; DOI=10.1074/jbc.c400441200; RA Dorovkov M.V., Ryazanov A.G.; RT "Phosphorylation of annexin I by TRPM7 channel-kinase."; RL J. Biol. Chem. 279:50643-50646(2004). RN [8] RP INTERACTION WITH TRPM6. RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [9] RP INTERACTION WITH TRPM6. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [10] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18394644; DOI=10.1016/j.jmb.2008.02.057; RA Clark K., Middelbeek J., Lasonder E., Dulyaninova N.G., Morrice N.A., RA Ryazanov A.G., Bresnick A.R., Figdor C.G., van Leeuwen F.N.; RT "TRPM7 regulates myosin IIA filament stability and protein localization by RT heavy chain phosphorylation."; RL J. Mol. Biol. 378:790-803(2008). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP THR-1163; SER-1191; SER-1193; SER-1255; SER-1258; THR-1265; SER-1287; RP SER-1358; SER-1361; SER-1387; SER-1390; SER-1396; SER-1404; THR-1405; RP SER-1407; THR-1435; SER-1446; THR-1455; SER-1456; SER-1463; SER-1468; RP THR-1471; SER-1476; SER-1477; THR-1482; SER-1493; SER-1504; THR-1508; RP SER-1513; SER-1527; SER-1533; THR-1537; THR-1542; SER-1543; THR-1551; RP SER-1567; SER-1569; THR-1583; SER-1598; SER-1615; SER-1660; THR-1685; RP SER-1779; THR-1830 AND SER-1860. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101; SER-1387; SER-1390; RP SER-1395; SER-1404; SER-1477; SER-1527 AND SER-1569, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=24316671; DOI=10.1038/ncb2883; RA Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y., RA Wu L.G., Liu Z.G.; RT "Plasma membrane translocation of trimerized MLKL protein is required for RT TNF-induced necroptosis."; RL Nat. Cell Biol. 16:55-65(2014). RN [17] RP PALMITOYLATION AT CYS-1143; CYS-1144 AND CYS-1146, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=36027648; DOI=10.1016/j.ceca.2022.102639; RA Gao X., Kuo C.W., Main A., Brown E., Rios F.J., Camargo L.L., Mary S., RA Wypijewski K., Goek C., Touyz R.M., Fuller W.; RT "Palmitoylation regulates cellular distribution of and transmembrane Ca RT flux through TrpM7."; RL Cell Calcium 106:102639-102639(2022). RN [18] RP VARIANT ILE-1482, CHARACTERIZATION OF VARIANT ILE-1482, AND ACTIVITY RP REGULATION. RX PubMed=16051700; DOI=10.1073/pnas.0505149102; RA Hermosura M.C., Nayakanti H., Dorovkov M.V., Calderon F.R., Ryazanov A.G., RA Haymer D.S., Garruto R.M.; RT "A TRPM7 variant shows altered sensitivity to magnesium that may contribute RT to the pathogenesis of two Guamanian neurodegenerative disorders."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11510-11515(2005). RN [19] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-68; CYS-406; THR-459; ASN-574; SER-720; RP VAL-830; TYR-949; ARG-1064; THR-1211; VAL-1254; GLU-1306; LYS-1444 AND RP ILE-1482. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, VARIANT ASP-1046, RP CHARACTERIZATION OF VARIANT ASP-1046, AND INVOLVEMENT IN HYPOMAGNESEMIA RP WITH SECONDARY HYPOCALCEMIA. RX PubMed=35561741; DOI=10.1093/ndt/gfac182; RA Vargas-Poussou R., Claverie-Martin F., Prot-Bertoye C., Carotti V., RA van der Wijst J., Perdomo-Ramirez A., Fraga-Rodriguez G.M., Hureaux M., RA Bos C., Latta F., Houillier P., Hoenderop J., de Baaij J.; RT "Possible role for rare TRPM7 variants in patients with hypomagnesemia with RT secondary hypocalcemia."; RL Nephrol. Dial. Transplant. 0:0-0(2022). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain. The channel is highly CC permeable to divalent cations, specifically calcium (Ca2+), magnesium CC (Mg2+) and zinc (Zn2+) and mediates their influx (PubMed:11385574, CC PubMed:12887921, PubMed:15485879, PubMed:24316671, PubMed:35561741, CC PubMed:36027648). Controls a wide range of biological processes such as CC Ca2(+), Mg(2+) and Zn(2+) homeostasis, vesicular Zn(2+) release channel CC and intracellular Ca(2+) signaling, embryonic development, immune CC responses, cell motility, proliferation and differentiation (By CC similarity). The C-terminal alpha-kinase domain autophosphorylates CC cytoplasmic residues of TRPM7 (PubMed:18365021). In vivo, TRPM7 CC phosphorylates SMAD2, suggesting that TRPM7 kinase may play a role in CC activating SMAD signaling pathways. In vitro, TRPM7 kinase CC phosphorylates ANXA1 (annexin A1), myosin II isoforms and a variety of CC proteins with diverse cellular functions (PubMed:15485879, CC PubMed:18394644). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:12887921, CC ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644, ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741, ECO:0000269|PubMed:36027648}. CC -!- FUNCTION: [TRPM7 channel, cleaved form]: The cleaved channel exhibits CC substantially higher current and potentiates Fas receptor signaling. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- FUNCTION: [TRPM7 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. In immune cells, the TRPM7 kinase domain is clipped from the CC channel domain by caspases in response to Fas-receptor stimulation. The CC cleaved kinase fragments can translocate to the nucleus, and bind CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones known to CC be functionally important for cell differentiation and embryonic CC development. {ECO:0000250|UniProtKB:Q923J1}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:12887921, ECO:0000269|PubMed:35561741}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:36027648}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000250|UniProtKB:Q923J1}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000250|UniProtKB:Q923J1}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q923J1}; CC -!- ACTIVITY REGULATION: Channel displays constitutive activity. Channel CC activity is negatively regulated by cytosolic Mg(2+) and Mg-ATP CC (PubMed:11385574, PubMed:16051700). Channel activity is negatively CC regulated by low intracellular pH (By similarity). Resting free CC cytosolic Mg(2+) and Mg-ATP concentrations seem to be sufficient to CC block native TRPM7 channel activity (By similarity). TRPM7 channel CC activity is highly dependent on membrane levels of phosphatidylinositol CC 4,5 bisphosphate (PIP2). PIP2 hydrolysis negatively regulates TRPM7 CC channel activity (By similarity). TRPM7 kinase activity does not affect CC channel activity (By similarity). The kinase activity is controlled CC through the autophosphorylation of a serine/threonine-rich region CC located N-terminal to the catalytic domain (PubMed:18365021). CC {ECO:0000250|UniProtKB:Q923J1, ECO:0000250|UniProtKB:Q925B3, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:16051700, CC ECO:0000269|PubMed:18365021}. CC -!- SUBUNIT: Homotetramer (By similarity). Interacts with PLCB1 (By CC similarity). Forms heteromers with TRPM6; heteromeric channels are CC functionally different from the homomeric channels (PubMed:14976260, CC PubMed:16636202). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000250|UniProtKB:Q925B3, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Cytoplasmic vesicle membrane CC {ECO:0000250|UniProtKB:Q923J1}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Note=Localized largely in intracellular CC Zn(2+)-storage vesicles. {ECO:0000250|UniProtKB:Q923J1}. CC -!- SUBCELLULAR LOCATION: [TRPM7 kinase, cleaved form]: Nucleus CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- PTM: Palmitoylated; palmitoylation at Cys-1143, Cys-1144 and Cys-1146 CC promotes TRPM7 trafficking from the Golgi to the surface membrane. CC {ECO:0000269|PubMed:36027648}. CC -!- PTM: Autophosphorylated; autophosphorylation of C-terminus regulates CC TRPM7 kinase activity towards its substrates. CC {ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminal kinase domain can be cleaved from the channel CC segment in a cell-type-specific fashion. TRPM7 is cleaved by caspase-8, CC dissociating the kinase from the ion-conducting pore. The cleaved CC kinase fragments (M7CKs) can translocate to the cell nucleus and binds CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- DISEASE: Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 CC (ALS-PDC1) [MIM:105500]: A neurodegenerative disorder characterized by CC chronic, progressive and uniformly fatal amyotrophic lateral sclerosis CC and parkinsonism-dementia. Both diseases are known to occur in the same CC kindred, the same sibship and even the same individual. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=TRPM7 variants have been identified as a potential cause CC of disease in patients suffering from seizures and muscle cramps due to CC magnesium deficiency and episodes of hypocalcemia. CC {ECO:0000269|PubMed:35561741}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAC11462.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAD18773.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY032950; AAK44211.1; -; mRNA. DR EMBL; AF346629; AAK19738.2; -; mRNA. DR EMBL; AK000124; BAA90958.1; -; mRNA. DR EMBL; AK172800; BAD18773.1; ALT_INIT; mRNA. DR EMBL; AK075193; BAC11462.1; ALT_INIT; mRNA. DR EMBL; BC051024; AAH51024.1; -; mRNA. DR CCDS; CCDS42035.1; -. DR RefSeq; NP_001288141.1; NM_001301212.1. DR RefSeq; NP_060142.3; NM_017672.5. DR AlphaFoldDB; Q96QT4; -. DR SMR; Q96QT4; -. DR BioGRID; 120177; 153. DR CORUM; Q96QT4; -. DR FunCoup; Q96QT4; 1775. DR IntAct; Q96QT4; 44. DR MINT; Q96QT4; -. DR STRING; 9606.ENSP00000495860; -. DR BindingDB; Q96QT4; -. DR ChEMBL; CHEMBL1250412; -. DR DrugBank; DB04447; 1,4-Dithiothreitol. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR DrugBank; DB06757; Manganese cation. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR GuidetoPHARMACOLOGY; 499; -. DR TCDB; 1.A.4.5.1; the transient receptor potential ca2+/cation channel (trp-cc) family. DR CarbonylDB; Q96QT4; -. DR iPTMnet; Q96QT4; -. DR PhosphoSitePlus; Q96QT4; -. DR SwissPalm; Q96QT4; -. DR BioMuta; TRPM7; -. DR DMDM; 56404941; -. DR jPOST; Q96QT4; -. DR MassIVE; Q96QT4; -. DR PaxDb; 9606-ENSP00000320239; -. DR PeptideAtlas; Q96QT4; -. DR ProteomicsDB; 77898; -. DR Pumba; Q96QT4; -. DR Antibodypedia; 24755; 465 antibodies from 40 providers. DR DNASU; 54822; -. DR Ensembl; ENST00000646667.1; ENSP00000495860.1; ENSG00000092439.16. DR GeneID; 54822; -. DR KEGG; hsa:54822; -. DR MANE-Select; ENST00000646667.1; ENSP00000495860.1; NM_017672.6; NP_060142.3. DR UCSC; uc001zyt.5; human. DR AGR; HGNC:17994; -. DR ClinPGx; PA38273; -. DR CTD; 54822; -. DR DisGeNET; 54822; -. DR GeneCards; TRPM7; -. DR HGNC; HGNC:17994; TRPM7. DR HPA; ENSG00000092439; Tissue enriched (parathyroid). DR MalaCards; TRPM7; -. DR MIM; 105500; phenotype. DR MIM; 605692; gene. DR OpenTargets; ENSG00000092439; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 90020; Parkinson-dementia complex of Guam. DR VEuPathDB; HostDB:ENSG00000092439; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000157091; -. DR InParanoid; Q96QT4; -. DR OMA; SSKDPHX; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q96QT4; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96QT4; -. DR PathwayCommons; Q96QT4; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q96QT4; -. DR SIGNOR; Q96QT4; -. DR Agora; ENSG00000092439; -. DR BioGRID-ORCS; 54822; 406 hits in 1198 CRISPR screens. DR ChiTaRS; TRPM7; human. DR GeneWiki; TRPM7; -. DR GenomeRNAi; 54822; -. DR Pharos; Q96QT4; Tchem. DR PRO; PR:Q96QT4; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q96QT4; protein. DR Bgee; ENSG00000092439; Expressed in left ventricle myocardium and 179 other cell types or tissues. DR ExpressionAtlas; Q96QT4; baseline and differential. DR GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0001726; C:ruffle; IEA:Ensembl. DR GO; GO:0003779; F:actin binding; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0017022; F:myosin binding; IEA:Ensembl. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IEA:Ensembl. DR GO; GO:0031032; P:actomyosin structure organization; IEA:Ensembl. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0010961; P:intracellular magnesium ion homeostasis; ISS:UniProtKB. DR GO; GO:0010960; P:magnesium ion homeostasis; IDA:UniProtKB. DR GO; GO:0015693; P:magnesium ion transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0051289; P:protein homotetramerization; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0006829; P:zinc ion transport; ISS:UniProtKB. DR CDD; cd16971; Alpha_kinase_ChaK1_TRMP7; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029601; TRPM7_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF8; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 7; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 2. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Acetylation; Amyotrophic lateral sclerosis; ATP-binding; Calcium; KW Calcium channel; Calcium transport; Cell membrane; Coiled coil; KW Cytoplasmic vesicle; Disease variant; Ion channel; Ion transport; Kinase; KW Lipoprotein; Membrane; Metal-binding; Necrosis; Neurodegeneration; KW Nucleotide-binding; Nucleus; Palmitate; Parkinsonism; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Transmembrane; KW Transmembrane helix; Transport; Zinc. FT CHAIN 1..1865 FT /note="Transient receptor potential cation channel FT subfamily M member 7" FT /id="PRO_0000215331" FT CHAIN 1..? FT /note="TRPM7 channel, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461294" FT CHAIN ?..1865 FT /note="TRPM7 kinase, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461295" FT TOPO_DOM 1..850 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 851..876 FT /note="Helical; Name=1" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 877..882 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 883..904 FT /note="Helical; Name=2" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 905..923 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 924..943 FT /note="Helical; Name=3" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 944..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..980 FT /note="Helical; Name=4" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 981..999 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1000..1023 FT /note="Helical; Name=5" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1024..1025 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 1026..1066 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1067..1069 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1070..1098 FT /note="Helical; Name=6" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1099..1865 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 1594..1824 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 544..575 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1386..1407 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1492..1511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1524..1543 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1836..1865 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1198..1250 FT /evidence="ECO:0000250" FT COMPBIAS 544..555 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 560..573 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1386..1398 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1511 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1844..1865 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1767 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1621 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1622 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1623 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1624 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1648 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1720 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1721 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1723 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1753 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1810 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1812 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1816 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 101 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1163 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1191 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1193 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1224 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1255 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1258 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1265 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1287 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1301 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1358 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1361 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1386 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1387 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1390 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1396 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1404 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1405 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1407 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1435 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1446 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1455 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1456 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1463 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1467 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1468 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1471 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1476 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1477 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 1482 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1493 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1500 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1504 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1508 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1513 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1527 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1533 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1537 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1542 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1543 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1551 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1567 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1569 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1583 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1598 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1615 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1660 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1685 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1779 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1830 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1851 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1860 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT LIPID 1143 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1144 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT VARIANT 68 FT /note="G -> V (in dbSNP:rs56064201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042395" FT VARIANT 406 FT /note="S -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042396" FT VARIANT 459 FT /note="I -> T (in dbSNP:rs55924090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042397" FT VARIANT 574 FT /note="K -> N (in dbSNP:rs56040619)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042398" FT VARIANT 720 FT /note="T -> S (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1040254222)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042399" FT VARIANT 830 FT /note="M -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042400" FT VARIANT 949 FT /note="F -> Y (in dbSNP:rs55681028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042401" FT VARIANT 1033 FT /note="A -> G (in dbSNP:rs34530969)" FT /id="VAR_052381" FT VARIANT 1046 FT /note="G -> D (found in a patient with hypomagnesemia and FT secondary hypocalcemia; likely pathogenic; de novo variant; FT causes severely reduced Mg(2+) uptake in transfected cells; FT dbSNP:rs2059709974)" FT /evidence="ECO:0000269|PubMed:35561741" FT /id="VAR_086707" FT VARIANT 1064 FT /note="Q -> R (in dbSNP:rs56298128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042402" FT VARIANT 1145 FT /note="I -> V (in dbSNP:rs34711809)" FT /id="VAR_052382" FT VARIANT 1211 FT /note="I -> T (in dbSNP:rs56090496)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042403" FT VARIANT 1254 FT /note="A -> V (in dbSNP:rs56288221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042404" FT VARIANT 1306 FT /note="D -> E (in dbSNP:rs55970334)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042405" FT VARIANT 1444 FT /note="R -> K (in dbSNP:rs55840070)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042406" FT VARIANT 1482 FT /note="T -> I (mutant channels are functional but show FT increased susceptibility to inhibition by intracellular FT Mg(2+) concentrations compared to wild-type channels; FT dbSNP:rs8042919)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16051700, ECO:0000269|PubMed:17344846" FT /id="VAR_019967" FT MUTAGEN 1648 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT MUTAGEN 1799 FT /note="G->D: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT CONFLICT 573..575 FT /note="EKM -> KKK (in Ref. 4; BAD18773)" FT /evidence="ECO:0000305" FT CONFLICT 998 FT /note="A -> S (in Ref. 5)" FT /evidence="ECO:0000305" FT CONFLICT 1496 FT /note="Missing (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" FT CONFLICT 1520 FT /note="D -> V (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" SQ SEQUENCE 1865 AA; 212697 MW; BE732674D52D7485 CRC64; MSQKSWIEST LTKRECVYII PSSKDPHRCL PGCQICQQLV RCFCGRLVKQ HACFTASLAM KYSDVKLGDH FNQAIEEWSV EKHTEQSPTD AYGVINFQGG SHSYRAKYVR LSYDTKPEVI LQLLLKEWQM ELPKLVISVH GGMQKFELHP RIKQLLGKGL IKAAVTTGAW ILTGGVNTGV AKHVGDALKE HASRSSRKIC TIGIAPWGVI ENRNDLVGRD VVAPYQTLLN PLSKLNVLNN LHSHFILVDD GTVGKYGAEV RLRRELEKTI NQQRIHARIG QGVPVVALIF EGGPNVILTV LEYLQESPPV PVVVCEGTGR AADLLAYIHK QTEEGGNLPD AAEPDIISTI KKTFNFGQNE ALHLFQTLME CMKRKELITV FHIGSDEHQD IDVAILTALL KGTNASAFDQ LILTLAWDRV DIAKNHVFVY GQQWLVGSLE QAMLDALVMD RVAFVKLLIE NGVSMHKFLT IPRLEELYNT KQGPTNPMLF HLVRDVKQGN LPPGYKITLI DIGLVIEYLM GGTYRCTYTR KRFRLIYNSL GGNNRRSGRN TSSSTPQLRK SHESFGNRAD KKEKMRHNHF IKTAQPYRPK IDTVMEEGKK KRTKDEIVDI DDPETKRFPY PLNELLIWAC LMKRQVMARF LWQHGEESMA KALVACKIYR SMAYEAKQSD LVDDTSEELK QYSNDFGQLA VELLEQSFRQ DETMAMKLLT YELKNWSNST CLKLAVSSRL RPFVAHTCTQ MLLSDMWMGR LNMRKNSWYK VILSILVPPA ILLLEYKTKA EMSHIPQSQD AHQMTMDDSE NNFQNITEEI PMEVFKEVRI LDSNEGKNEM EIQMKSKKLP ITRKFYAFYH APIVKFWFNT LAYLGFLMLY TFVVLVQMEQ LPSVQEWIVI AYIFTYAIEK VREIFMSEAG KVNQKIKVWF SDYFNISDTI AIISFFIGFG LRFGAKWNFA NAYDNHVFVA GRLIYCLNII FWYVRLLDFL AVNQQAGPYV MMIGKMVANM FYIVVIMALV LLSFGVPRKA ILYPHEAPSW TLAKDIVFHP YWMIFGEVYA YEIDVCANDS VIPQICGPGT WLTPFLQAVY LFVQYIIMVN LLIAFFNNVY LQVKAISNIV WKYQRYHFIM AYHEKPVLPP PLIILSHIVS LFCCICKRRK KDKTSDGPKL FLTEEDQKKL HDFEEQCVEM YFNEKDDKFH SGSEERIRVT FERVEQMCIQ IKEVGDRVNY IKRSLQSLDS QIGHLQDLSA LTVDTLKTLT AQKASEASKV HNEITRELSI SKHLAQNLID DGPVRPSVWK KHGVVNTLSS SLPQGDLESN NPFHCNILMK DDKDPQCNIF GQDLPAVPQR KEFNFPEAGS SSGALFPSAV SPPELRQRLH GVELLKIFNK NQKLGSSSTS IPHLSSPPTK FFVSTPSQPS CKSHLETGTK DQETVCSKAT EGDNTEFGAF VGHRDSMDLQ RFKETSNKIK ILSNNNTSEN TLKRVSSLAG FTDCHRTSIP VHSKQAEKIS RRPSTEDTHE VDSKAALIPD WLQDRPSNRE MPSEEGTLNG LTSPFKPAMD TNYYYSAVER NNLMRLSQSI PFTPVPPRGE PVTVYRLEES SPNILNNSMS SWSQLGLCAK IEFLSKEEMG GGLRRAVKVQ CTWSEHDILK SGHLYIIKSF LPEVVNTWSS IYKEDTVLHL CLREIQQQRA AQKLTFAFNQ MKPKSIPYSP RFLEVFLLYC HSAGQWFAVE ECMTGEFRKY NNNNGDEIIP TNTLEEIMLA FSHWTYEYTR GELLVLDLQG VGENLTDPSV IKAEEKRSCD MVFGPANLGE DAIKNFRAKH HCNSCCRKLK LPDLKRNDYT PDKIIFPQDE PSDLNLQPGN STKESESTNS VRLML // ID TRRAP_HUMAN Reviewed; 3859 AA. AC Q9Y4A5; A4D265; O75218; Q9Y631; Q9Y6H4; DT 28-NOV-2003, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 226. DE RecName: Full=Transformation/transcription domain-associated protein; DE AltName: Full=350/400 kDa PCAF-associated factor; DE Short=PAF350/400; DE AltName: Full=STAF40; DE AltName: Full=Tra1 homolog; GN Name=TRRAP; Synonyms=PAF400; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE, FUNCTION, RP SUBCELLULAR LOCATION, AND INTERACTION WITH MYC AND E2F1. RC TISSUE=Cervix carcinoma; RX PubMed=9708738; DOI=10.1016/s0092-8674(00)81479-8; RA McMahon S.B., Van Buskirk H.A., Dugan K.A., Copeland T.D., Cole M.D.; RT "The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc RT and E2F oncoproteins."; RL Cell 94:363-374(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 41-90; 337-344; RP 369-387; 879-892; 997-1005; 1171-1184; 1237-1247; 1545-1560; 1815-1820; RP 1922-1934; 2211-2218; 2260-2275; 2534-2547; 2583-2594; 2706-2726; RP 2830-2844; 3567-3573; 3583-3598; 3604-3614; 3712-3730 AND 3822-3834, AND RP IDENTIFICATION IN THE PCAF COMPLEX WITH TADA2L; TADA3L; TAF5L; TAF6L; RP TAF10; SUPT3H; TAF12 AND TAF9. RC TISSUE=Fetal heart; RX PubMed=9885574; DOI=10.1016/s1097-2765(00)80301-9; RA Vassilev A., Yamauchi J., Kotani T., Prives C., Avantaggiati M.L., Qin J., RA Nakatani Y.; RT "The 400 kDa subunit of the PCAF histone acetylase complex belongs to the RT ATM superfamily."; RL Mol. Cell 2:869-875(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [6] RP SUBCELLULAR LOCATION, IDENTIFICATION IN THE STAGA COMPLEX WITH SUPT3H; RP GCN5L2; KIAA0764; TAF5L; TAF6L; TADA3L; TAF10; TAF12 AND TAF9, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11564863; DOI=10.1128/mcb.21.20.6782-6795.2001; RA Martinez E., Palhan V.B., Tjernberg A., Lymar E.S., Gamper A.M., RA Kundu T.K., Chait B.T., Roeder R.G.; RT "Human STAGA complex is a chromatin-acetylating transcription coactivator RT that interacts with pre-mRNA splicing and DNA damage-binding factors in RT vivo."; RL Mol. Cell. Biol. 21:6782-6795(2001). RN [7] RP IDENTIFICATION IN THE TFTC-HAT COMPLEX WITH TAF5L; TAF6L; TADA3L; SUPT3H; RP TAF2; TAF4; TAF5; GCN5L2 AND TAF10. RX PubMed=10373431; DOI=10.1074/jbc.274.26.18285; RA Brand M., Yamamoto K., Staub A., Tora L.; RT "Identification of TATA-binding protein-free TAFII-containing complex RT subunits suggests a role in nucleosome acetylation and signal RT transduction."; RL J. Biol. Chem. 274:18285-18289(1999). RN [8] RP IDENTIFICATION IN THE TIP60 HAT COMPLEX WITH KAT5; RUVBL1 AND RUVBL2. RX PubMed=10966108; DOI=10.1016/s0092-8674(00)00051-9; RA Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., RA Scully R., Qin J., Nakatani Y.; RT "Involvement of the TIP60 histone acetylase complex in DNA repair and RT apoptosis."; RL Cell 102:463-473(2000). RN [9] RP INTERACTION WITH GCN5L2. RX PubMed=10611234; DOI=10.1128/mcb.20.2.556-562.2000; RA McMahon S.B., Wood M.A., Cole M.D.; RT "The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 RT to c-Myc."; RL Mol. Cell. Biol. 20:556-562(2000). RN [10] RP INTERACTION WITH E2F1 AND E2F4, AND FUNCTION. RX PubMed=11418595; DOI=10.1074/jbc.m102067200; RA Lang S.E., McMahon S.B., Cole M.D., Hearing P.; RT "E2F transcriptional activation requires TRRAP and GCN5 cofactors."; RL J. Biol. Chem. 276:32627-32634(2001). RN [11] RP DOMAIN. RX PubMed=11445536; DOI=10.1101/gad.900101; RA Park J., Kunjibettu S., McMahon S.B., Cole M.D.; RT "The ATM-related domain of TRRAP is required for histone acetyltransferase RT recruitment and Myc-dependent oncogenesis."; RL Genes Dev. 15:1619-1624(2001). RN [12] RP FUNCTION, AND INTERACTION WITH TP53. RX PubMed=12138177; DOI=10.1128/mcb.22.16.5650-5661.2002; RA Ard P.G., Chatterjee C., Kunjibettu S., Adside L.R., Gralinski L.E., RA McMahon S.B.; RT "Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP RT acetyltransferase complexes."; RL Mol. Cell. Biol. 22:5650-5661(2002). RN [13] RP IDENTIFICATION IN THE BAF53 COMPLEX WITH BAF53A; RUVBL1 AND SMARCA4. RX PubMed=11839798; DOI=10.1128/mcb.22.5.1307-1316.2002; RA Park J., Wood M.A., Cole M.D.; RT "BAF53 forms distinct nuclear complexes and functions as a critical c-Myc- RT interacting nuclear cofactor for oncogenic transformation."; RL Mol. Cell. Biol. 22:1307-1316(2002). RN [14] RP FUNCTION. RX PubMed=12743606; DOI=10.1038/sj.onc.1206376; RA Lang S.E., Hearing P.; RT "The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone RT acetyltransferase complex."; RL Oncogene 22:2836-2841(2003). RN [15] RP FUNCTION. RX PubMed=12660246; DOI=10.1074/jbc.m211795200; RA Liu X., Tesfai J., Evrard Y.A., Dent S.Y.R., Martinez E.; RT "c-Myc transformation domain recruits the human STAGA complex and requires RT TRRAP and GCN5 acetylase activity for transcription activation."; RL J. Biol. Chem. 278:20405-20412(2003). RN [16] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE RP NUA4 COMPLEX. RX PubMed=14966270; DOI=10.1128/mcb.24.5.1884-1896.2004; RA Doyon Y., Selleck W., Lane W.S., Tan S., Cote J.; RT "Structural and functional conservation of the NuA4 histone RT acetyltransferase complex from yeast to humans."; RL Mol. Cell. Biol. 24:1884-1896(2004). RN [17] RP IDENTIFICATION IN STAGA COMPLEX. RX PubMed=18206972; DOI=10.1016/j.molcel.2007.12.011; RA Zhao Y., Lang G., Ito S., Bonnet J., Metzger E., Sawatsubashi S., RA Suzuki E., Le Guezennec X., Stunnenberg H.G., Krasnov A., Georgieva S.G., RA Schuele R., Takeyama K., Kato S., Tora L., Devys D.; RT "A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, RT coactivates nuclear receptors, and counteracts heterochromatin silencing."; RL Mol. Cell 29:92-101(2008). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [19] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH NPAT. RX PubMed=17967892; DOI=10.1128/mcb.00607-07; RA DeRan M., Pulvino M., Greene E., Su C., Zhao J.; RT "Transcriptional activation of histone genes requires NPAT-dependent RT recruitment of TRRAP-Tip60 complex to histone promoters during the G1/S RT phase transition."; RL Mol. Cell. Biol. 28:435-447(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051 AND SER-2077, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3078, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [22] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP PROBABLE INVOLVEMENT IN MELANOMA, VARIANT PHE-722, AND CHARACTERIZATION OF RP VARIANT PHE-722. RX PubMed=21499247; DOI=10.1038/ng.810; RA Wei X., Walia V., Lin J.C., Teer J.K., Prickett T.D., Gartner J., Davis S., RA Stemke-Hale K., Davies M.A., Gershenwald J.E., Robinson W., Robinson S., RA Rosenberg S.A., Samuels Y.; RT "Exome sequencing identifies GRIN2A as frequently mutated in melanoma."; RL Nat. Genet. 43:442-446(2011). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1628; SER-2051 AND SER-2077, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [29] RP FUNCTION, AND IDENTIFICATION IN THE SWR1-LIKE COMPLEX. RX PubMed=24463511; DOI=10.1038/nature12922; RA Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M., RA Stoll I., Roy L., Reilly P.T., Mak T.W., Dimitrov S., Romier C., RA Hamiche A.; RT "ANP32E is a histone chaperone that removes H2A.Z from chromatin."; RL Nature 505:648-653(2014). RN [30] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-2543, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-893; GLY-1070; HIS-1669; HIS-1724; RP VAL-1925; LEU-1932; LEU-1947; GLY-2139; TRP-2302; GLY-2433; LEU-2690; RP ASP-2750; GLU-2801 AND MET-2931. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [32] RP INVOLVEMENT IN DEDDFA, AND VARIANT DEDDFA GLN-2004. RX PubMed=30424743; DOI=10.1186/s12881-018-0711-9; RA Mavros C.F., Brownstein C.A., Thyagrajan R., Genetti C.A., Tembulkar S., RA Graber K., Murphy Q., Cabral K., VanNoy G.E., Bainbridge M., Shi J., RA Agrawal P.B., Beggs A.H., D'Angelo E., Gonzalez-Heydrich J.; RT "De novo variant of TRRAP in a patient with very early onset psychosis in RT the context of non-verbal learning disability and obsessive-compulsive RT disorder: a case report."; RL BMC Med. Genet. 19:197-197(2018). RN [33] RP VARIANTS DEDDFA PHE-805; LEU-860; LEU-893; MET-1031; GLN-1035; ARG-1037; RP THR-1043; GLY-1104; LYS-1106; TRP-1111; ARG-1159; CYS-1859; CYS-1866; RP ARG-1866; ARG-1883; LEU-1932 AND GLN-3757. RX PubMed=30827496; DOI=10.1016/j.ajhg.2019.01.010; RG CAUSES Study; RG Deciphering Developmental Disorders study; RA Cogne B., Ehresmann S., Beauregard-Lacroix E., Rousseau J., Besnard T., RA Garcia T., Petrovski S., Avni S., McWalter K., Blackburn P.R., RA Sanders S.J., Uguen K., Harris J., Cohen J.S., Blyth M., Lehman A., RA Berg J., Li M.H., Kini U., Joss S., von der Lippe C., Gordon C.T., RA Humberson J.B., Robak L., Scott D.A., Sutton V.R., Skraban C.M., RA Johnston J.J., Poduri A., Nordenskjoeld M., Shashi V., Gerkes E.H., RA Bongers E.M.H.F., Gilissen C., Zarate Y.A., Kvarnung M., Lally K.P., RA Kulch P.A., Daniels B., Hernandez-Garcia A., Stong N., McGaughran J., RA Retterer K., Tveten K., Sullivan J., Geisheker M.R., Stray-Pedersen A., RA Tarpinian J.M., Klee E.W., Sapp J.C., Zyskind J., Holla O.L., Bedoukian E., RA Filippini F., Guimier A., Picard A., Busk O.L., Punetha J., Pfundt R., RA Lindstrand A., Nordgren A., Kalb F., Desai M., Ebanks A.H., Jhangiani S.N., RA Dewan T., Coban Akdemir Z.H., Telegrafi A., Zackai E.H., Begtrup A., RA Song X., Toutain A., Wentzensen I.M., Odent S., Bonneau D., Latypova X., RA Deb W., Redon S., Bilan F., Legendre M., Troyer C., Whitlock K., RA Caluseriu O., Murphree M.I., Pichurin P.N., Agre K., Gavrilova R., RA Rinne T., Park M., Shain C., Heinzen E.L., Xiao R., Amiel J., Lyonnet S., RA Isidor B., Biesecker L.G., Lowenstein D., Posey J.E., Denomme-Pichon A.S., RA Ferec C., Yang X.J., Rosenfeld J.A., Gilbert-Dussardier B., RA Audebert-Bellanger S., Redon R., Stessman H.A.F., Nellaker C., Yang Y., RA Lupski J.R., Goldstein D.B., Eichler E.E., Bolduc F., Bezieau S., Kuery S., RA Campeau P.M.; RT "Missense Variants in the Histone Acetyltransferase Complex Component Gene RT TRRAP Cause Autism and Syndromic Intellectual Disability."; RL Am. J. Hum. Genet. 104:530-541(2019). RN [34] RP VARIANTS DFNA75 CYS-171 AND ASN-394, VARIANT ASP-2750, AND INVOLVEMENT IN RP DFNA75. RX PubMed=31231791; DOI=10.1111/cge.13590; RA Xia W., Hu J., Ma J., Huang J., Wang X., Jiang N., Zhang J., Ma Z., Ma D.; RT "Novel TRRAP mutation causes autosomal dominant non-syndromic hearing RT loss."; RL Clin. Genet. 96:300-308(2019). CC -!- FUNCTION: Adapter protein, which is found in various multiprotein CC chromatin complexes with histone acetyltransferase activity (HAT), CC which gives a specific tag for epigenetic transcription activation. CC Component of the NuA4 histone acetyltransferase complex which is CC responsible for acetylation of nucleosomal histones H4 and H2A. Plays a CC central role in MYC transcription activation, and also participates in CC cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4- CC mediated transcription activation. Also involved in transcription CC activation mediated by the adenovirus E1A, a viral oncoprotein that CC deregulates transcription of key genes. Probably acts by linking CC transcription factors such as E1A, MYC or E2F1 to HAT complexes such as CC STAGA thereby allowing transcription activation. Probably not required CC in the steps following histone acetylation in processes of CC transcription activation. May be required for the mitotic checkpoint CC and normal cell cycle progression. Component of a SWR1-like complex CC that specifically mediates the removal of histone H2A.Z/H2AZ1 from the CC nucleosome. May play a role in the formation and maintenance of the CC auditory system (By similarity). {ECO:0000250|UniProtKB:A0A0R4ITC5, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:12660246, ECO:0000269|PubMed:12743606, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738}. CC -!- SUBUNIT: Interacts with MYC, E2F1 and E2F4 transcription factors. CC Interacts directly with p53/TP53. Interacts with GCN5L2. Component of CC various HAT complexes. Component of the PCAF complex, at least composed CC of TADA2L/ADA2, SUPT3H, TADA3L/ADA3, TAF5L/PAF65-beta, TAF6L/PAF65- CC alpha, TAF10/TAFII30, TAF12/TAFII20, TAF9/TAFII31 and TRRAP. Component CC of the TFTC-HAT complex, at least composed of TAF5L, TAF6L, TADA3L, CC SUPT3H/SPT3, TAF2/TAFII150, TAF4/TAFII135, TAF5/TAFII100, GCN5L2/GCN5, CC TAF10 and TRRAP. Component of the NuA4 histone acetyltransferase CC complex which contains the catalytic subunit KAT5/TIP60 and the CC subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1, CC RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15, CC MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. Component of CC the STAGA complex, at least composed of SUPT3H, GCN5L2, SUPT7L, TAF5L, CC TAF6L, TADA3L, TAD1L, TAF10, TAF12, TRRAP and TAF9. The STAGA core CC complex is associated with a subcomplex required for histone CC deubiquitination composed of ATXN7L3, ENY2 and USP22. Component of the CC BAF53 complex, at least composed of BAF53A, RUVBL1, SMARCA4/BRG1, and CC TRRAP, which preferentially acetylates histone H4 (and H2A) within CC nucleosomes. Interacts with NPAT. Interaction with TELO2 and TTI1. CC Component of a SWR1-like complex. {ECO:0000269|PubMed:10373431, CC ECO:0000269|PubMed:10611234, ECO:0000269|PubMed:10966108, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:11839798, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:18206972, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738, CC ECO:0000269|PubMed:9885574}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:9708738}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9Y4A5-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9Y4A5-2; Sequence=VSP_009102, VSP_009103; CC -!- DOMAIN: The PI3K/PI4K domain is required for the recruitment of HAT CC complexes, and the MYC-dependent transactivation. Although it is CC strongly related to the PI3/PI4-kinase family, it lacks the typical CC motifs that constitute the catalytic site of PI3/PI4-kinase proteins, CC and lacks such activity. {ECO:0000269|PubMed:11445536}. CC -!- DISEASE: Note=TRRAP mutation Phe-722 has been frequently found in CC cutaneous malignant melanoma, suggesting that TRRAP may play a role in CC the pathogenesis of melanoma. {ECO:0000269|PubMed:21499247}. CC -!- DISEASE: Developmental delay with or without dysmorphic facies and CC autism (DEDDFA) [MIM:618454]: An autosomal dominant neurodevelopmental CC disorder apparent from infancy or early childhood. Some patients CC present with intellectual disability and renal, cardiac, genitourinary CC systems, as well as structural brain abnormalities. In some cases, the CC phenotype is less severe, has no systemic involvement and is CC characterized by autism spectrum disorder and/or intellectual CC disability, sometimes associated with epilepsy. Affected individuals CC manifest variable dysmorphic features. {ECO:0000269|PubMed:30424743, CC ECO:0000269|PubMed:30827496}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Deafness, autosomal dominant, 75 (DFNA75) [MIM:618778]: A form CC of non-syndromic deafness characterized by late-onset hearing loss that CC involves mid and high frequencies, and progresses to encompass all CC frequencies. {ECO:0000269|PubMed:31231791}. Note=The disease may be CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. TRA1 subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC62433.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF076974; AAD09420.1; -; mRNA. DR EMBL; AF110377; AAD04629.1; -; mRNA. DR EMBL; AC004893; AAC62433.1; ALT_SEQ; Genomic_DNA. DR EMBL; AC004991; AAC27675.2; -; Genomic_DNA. DR EMBL; CH471091; EAW76694.1; -; Genomic_DNA. DR EMBL; CH236956; EAL23887.1; -; Genomic_DNA. DR CCDS; CCDS5659.1; -. [Q9Y4A5-2] DR CCDS; CCDS59066.1; -. [Q9Y4A5-1] DR PIR; T02632; T02632. DR RefSeq; NP_001231509.1; NM_001244580.2. [Q9Y4A5-1] DR RefSeq; NP_003487.1; NM_003496.4. [Q9Y4A5-2] DR PDB; 7KTR; EM; 2.93 A; A=369-3859. DR PDB; 8H7G; EM; 3.70 A; C=1-3859. DR PDB; 8QRI; EM; 3.50 A; C=1-3859. DR PDB; 8XVG; EM; 9.40 A; L=1-3859. DR PDB; 8XVV; EM; 3.20 A; L=1-3859. DR PDB; 9C47; EM; 3.40 A; C=1-3859. DR PDB; 9CAD; EM; 3.05 A; D=1-3859. DR PDB; 9CAF; EM; 2.35 A; D=1-3859. DR PDBsum; 7KTR; -. DR PDBsum; 8H7G; -. DR PDBsum; 8QRI; -. DR PDBsum; 8XVG; -. DR PDBsum; 8XVV; -. DR PDBsum; 9C47; -. DR PDBsum; 9CAD; -. DR PDBsum; 9CAF; -. DR EMDB; EMD-18612; -. DR EMDB; EMD-18613; -. DR EMDB; EMD-18618; -. DR EMDB; EMD-18619; -. DR EMDB; EMD-34520; -. DR EMDB; EMD-38703; -. DR EMDB; EMD-38720; -. DR EMDB; EMD-45176; -. DR EMDB; EMD-45387; -. DR EMDB; EMD-45389; -. DR SMR; Q9Y4A5; -. DR BioGRID; 113900; 797. DR ComplexPortal; CPX-6802; SAGA complex, KAT2B variant. DR ComplexPortal; CPX-900; SAGA complex, KAT2A variant. DR ComplexPortal; CPX-903; TFTC histone acetylation complex. DR ComplexPortal; CPX-978; NuA4 histone acetyltransferase complex. DR ComplexPortal; CPX-989; PCAF histone acetylase complex. DR CORUM; Q9Y4A5; -. DR DIP; DIP-28149N; -. DR FunCoup; Q9Y4A5; 1798. DR MINT; Q9Y4A5; -. DR STRING; 9606.ENSP00000352925; -. DR GlyGen; Q9Y4A5; 9 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (5 sites). DR iPTMnet; Q9Y4A5; -. DR MetOSite; Q9Y4A5; -. DR PhosphoSitePlus; Q9Y4A5; -. DR SwissPalm; Q9Y4A5; -. DR BioMuta; TRRAP; -. DR DMDM; 116242829; -. DR jPOST; Q9Y4A5; -. DR MassIVE; Q9Y4A5; -. DR PaxDb; 9606-ENSP00000352925; -. DR PeptideAtlas; Q9Y4A5; -. DR ProteomicsDB; 86142; -. [Q9Y4A5-1] DR ProteomicsDB; 86143; -. [Q9Y4A5-2] DR Pumba; Q9Y4A5; -. DR Antibodypedia; 16027; 189 antibodies from 23 providers. DR DNASU; 8295; -. DR Ensembl; ENST00000355540.7; ENSP00000347733.3; ENSG00000196367.15. [Q9Y4A5-2] DR Ensembl; ENST00000359863.8; ENSP00000352925.4; ENSG00000196367.15. [Q9Y4A5-1] DR GeneID; 8295; -. DR KEGG; hsa:8295; -. DR UCSC; uc003upp.3; human. [Q9Y4A5-1] DR AGR; HGNC:12347; -. DR ClinPGx; PA37020; -. DR CTD; 8295; -. DR DisGeNET; 8295; -. DR GeneCards; TRRAP; -. DR HGNC; HGNC:12347; TRRAP. DR HPA; ENSG00000196367; Low tissue specificity. DR MalaCards; TRRAP; -. DR MIM; 603015; gene. DR MIM; 618454; phenotype. DR MIM; 618778; phenotype. DR OpenTargets; ENSG00000196367; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000196367; -. DR eggNOG; KOG0889; Eukaryota. DR GeneTree; ENSGT00390000017961; -. DR InParanoid; Q9Y4A5; -. DR OrthoDB; 5570127at2759; -. DR PAN-GO; Q9Y4A5; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y4A5; -. DR PathwayCommons; Q9Y4A5; -. DR Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex. DR Reactome; R-HSA-3214847; HATs acetylate histones. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR SignaLink; Q9Y4A5; -. DR SIGNOR; Q9Y4A5; -. DR Agora; ENSG00000196367; -. DR BioGRID-ORCS; 8295; 773 hits in 1197 CRISPR screens. DR ChiTaRS; TRRAP; human. DR GenomeRNAi; 8295; -. DR Pharos; Q9Y4A5; Tbio. DR PRO; PR:Q9Y4A5; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q9Y4A5; protein. DR Bgee; ENSG00000196367; Expressed in ventricular zone and 156 other cell types or tissues. DR ExpressionAtlas; Q9Y4A5; baseline and differential. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0035267; C:NuA4 histone acetyltransferase complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0000786; C:nucleosome; IDA:ComplexPortal. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000124; C:SAGA complex; IDA:UniProtKB. DR GO; GO:0000812; C:Swr1 complex; IDA:UniProtKB. DR GO; GO:0033276; C:transcription factor TFTC complex; IDA:UniProtKB. DR GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB. DR GO; GO:0140861; P:DNA repair-dependent chromatin remodeling; IBA:GO_Central. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:ComplexPortal. DR GO; GO:1905168; P:positive regulation of double-strand break repair via homologous recombination; IDA:ComplexPortal. DR GO; GO:0042981; P:regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0051726; P:regulation of cell cycle; IMP:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central. DR GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal. DR GO; GO:0043484; P:regulation of RNA splicing; NAS:ComplexPortal. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR CDD; cd05163; PIKK_TRRAP; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR046807; Tra1_central. DR InterPro; IPR046805; Tra1_ring. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF1; TRANSFORMATION_TRANSCRIPTION DOMAIN-ASSOCIATED PROTEIN; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF20175; Tra1_central; 1. DR Pfam; PF20206; Tra1_ring; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; KW Autism spectrum disorder; Chromatin regulator; Deafness; KW Direct protein sequencing; Disease variant; Intellectual disability; KW Isopeptide bond; Non-syndromic deafness; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3859 FT /note="Transformation/transcription domain-associated FT protein" FT /id="PRO_0000088851" FT DOMAIN 2692..3275 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 3500..3823 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3827..3859 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 491..541 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2010..2388 FT /note="Interaction with TP53" FT /evidence="ECO:0000269|PubMed:12138177" FT REGION 2023..2044 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2543..2578 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 3506..3512 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3687..3695 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3707..3732 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 2047..2062 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 491..526 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 529..539 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2033..2044 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2543..2554 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 1628 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2051 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163" FT MOD_RES 2077 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 3078 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT CROSSLNK 2543 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1492..1509 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009102" FT VAR_SEQ 3001..3012 FT /note="GKPTWSGMHSSS -> A (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009103" FT VARIANT 171 FT /note="R -> C (in DFNA75; uncertain significance; FT dbSNP:rs200157211)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083794" FT VARIANT 394 FT /note="D -> N (in DFNA75; uncertain significance; FT dbSNP:rs1554407965)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083795" FT VARIANT 722 FT /note="S -> F (found in a cutaneous malignant melanoma FT sample; somatic mutation; induces cell transformation and FT confers resistance to apoptosis; dbSNP:rs147405090)" FT /evidence="ECO:0000269|PubMed:21499247" FT /id="VAR_067754" FT VARIANT 805 FT /note="L -> F (in DEDDFA; uncertain significance; FT dbSNP:rs1562940289)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082969" FT VARIANT 860 FT /note="F -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082970" FT VARIANT 878 FT /note="R -> L (in dbSNP:rs17161510)" FT /id="VAR_028359" FT VARIANT 893 FT /note="R -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041658" FT VARIANT 893 FT /note="R -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082971" FT VARIANT 1031 FT /note="I -> M (in DEDDFA; dbSNP:rs1187165148)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082972" FT VARIANT 1035 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs2116495143)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082973" FT VARIANT 1037 FT /note="S -> R (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082974" FT VARIANT 1043 FT /note="A -> T (in DEDDFA; dbSNP:rs1562945106)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082975" FT VARIANT 1070 FT /note="S -> G (in dbSNP:rs55920979)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041659" FT VARIANT 1104 FT /note="E -> G (in DEDDFA; dbSNP:rs1790257064)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082976" FT VARIANT 1106 FT /note="E -> K (in DEDDFA; dbSNP:rs1584324956)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082977" FT VARIANT 1111 FT /note="G -> W (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082978" FT VARIANT 1159 FT /note="G -> R (in DEDDFA; dbSNP:rs1790288810)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082979" FT VARIANT 1669 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs373632999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041660" FT VARIANT 1724 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs782203759)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041661" FT VARIANT 1859 FT /note="R -> C (in DEDDFA; dbSNP:rs1791432323)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082980" FT VARIANT 1866 FT /note="W -> C (in DEDDFA; uncertain significance; FT dbSNP:rs1562957576)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082981" FT VARIANT 1866 FT /note="W -> R (in DEDDFA; dbSNP:rs1562957569)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082982" FT VARIANT 1883 FT /note="G -> R (in DEDDFA)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082983" FT VARIANT 1925 FT /note="A -> V (in dbSNP:rs56197298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041662" FT VARIANT 1932 FT /note="P -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:30827496" FT /id="VAR_041663" FT VARIANT 1947 FT /note="R -> L (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041664" FT VARIANT 2004 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs1562959030)" FT /evidence="ECO:0000269|PubMed:30424743" FT /id="VAR_082984" FT VARIANT 2139 FT /note="W -> G (in dbSNP:rs34185633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041665" FT VARIANT 2302 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs528967912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041666" FT VARIANT 2433 FT /note="S -> G (in dbSNP:rs35634065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041667" FT VARIANT 2690 FT /note="P -> L (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs753661271)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041668" FT VARIANT 2750 FT /note="E -> D (in dbSNP:rs55755466)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:31231791" FT /id="VAR_041669" FT VARIANT 2801 FT /note="K -> E (in dbSNP:rs56341061)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041670" FT VARIANT 2931 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1294404368)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041671" FT VARIANT 3757 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs987263983)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082985" FT CONFLICT 660 FT /note="E -> D (in Ref. 2; AAD04629)" FT /evidence="ECO:0000305" FT HELIX 20..26 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 30..33 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 37..50 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 55..57 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 59..74 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 80..84 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 85..99 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 107..118 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 122..124 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 128..139 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 140..142 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 145..147 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 148..171 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 214..227 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 234..243 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 244..254 FT /evidence="ECO:0007829|PDB:9C47" FT TURN 255..259 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 276..293 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 294..298 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 307..319 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 320..322 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 325..338 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 342..345 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 347..351 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 357..359 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 365..367 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 371..385 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 387..389 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 392..406 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 409..411 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 413..434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 436..438 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 442..469 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 535..564 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 583..599 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 600..604 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 605..607 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 613..615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 624..626 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 627..639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 644..654 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 657..664 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 666..668 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 669..677 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 679..681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 682..695 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 698..702 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 704..723 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 725..732 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 733..735 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 736..747 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 754..768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 774..779 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 780..782 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 783..795 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 800..811 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 817..820 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 821..827 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 828..835 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 839..855 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 858..865 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 866..868 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 869..879 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 885..898 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 899..903 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 923..927 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 929..931 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 934..938 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 940..951 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 952..955 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 957..973 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 981..988 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 992..995 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1005..1007 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1013..1029 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1032..1034 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1035..1057 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1058..1061 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1064..1066 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1067..1069 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1074..1076 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1080..1082 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1085..1087 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1091..1101 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1102..1104 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1107..1126 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1129..1132 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1136..1146 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1147..1150 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1151..1153 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1154..1170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1173..1193 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1194..1196 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1199..1201 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1202..1218 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1223..1225 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1228..1248 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1254..1271 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1275..1279 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1280..1285 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1287..1289 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1297..1299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1302..1315 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1317..1320 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1327..1329 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1330..1344 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1347..1351 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1354..1357 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1360..1362 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1363..1375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1376..1378 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1380..1382 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1383..1394 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1399..1413 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1415..1418 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1420..1431 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1432..1434 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1435..1437 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1442..1454 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1456..1458 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1461..1484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1490..1492 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1511..1523 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1524..1526 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1529..1531 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1532..1546 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1549..1551 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1555..1562 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1566..1573 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1576..1579 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1582..1592 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1594..1596 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1598..1605 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1609..1612 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1613..1615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1638..1653 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1657..1659 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1661..1672 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1674..1681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1692..1706 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1707..1709 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1710..1715 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1716..1718 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1719..1721 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1723..1725 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1728..1738 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1740..1743 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1746..1748 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1749..1758 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1760..1766 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1770..1773 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1774..1776 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1777..1786 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1804..1813 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1818..1820 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1828..1841 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1846..1853 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1854..1859 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1861..1870 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1877..1893 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1900..1911 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1913..1915 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1921..1925 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1928..1931 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1950..1964 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1966..1970 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1972..1974 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1976..1985 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1990..2000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2003..2016 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2021..2026 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2031..2042 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2045..2060 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2064..2073 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2077..2088 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2096..2099 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2105..2111 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2114..2118 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2120..2133 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2139..2141 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2146..2154 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2155..2157 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2158..2161 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2165..2182 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2184..2189 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2191..2200 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 2201..2203 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2205..2207 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 2212..2219 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2226..2232 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2233..2235 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2240..2251 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2257..2273 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2278..2286 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2287..2290 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2292..2294 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2295..2299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2301..2312 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2320..2331 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2340..2357 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2361..2375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2382..2384 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2389..2406 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2411..2426 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2429..2434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2435..2439 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2440..2448 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2452..2464 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2470..2478 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2483..2486 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2492..2500 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2506..2508 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2514..2516 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2523..2527 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2530..2538 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2586..2602 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2607..2618 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2622..2639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2642..2656 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2659..2666 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2671..2679 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2682..2684 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2690..2699 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2703..2714 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2718..2720 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2728..2730 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2742..2755 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2758..2768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2772..2781 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2782..2784 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2786..2806 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2811..2813 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2814..2830 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2834..2841 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2844..2847 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2849..2856 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2857..2859 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2862..2872 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2873..2875 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2878..2880 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2881..2894 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2904..2919 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2928..2930 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2931..2952 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2955..2957 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2961..2976 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2985..3000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3012..3020 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3028..3051 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3054..3062 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3063..3066 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3072..3089 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3090..3092 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3095..3106 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3115..3131 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3132..3134 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3135..3148 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3153..3170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3173..3186 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3192..3195 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3196..3205 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3206..3208 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3214..3222 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3224..3226 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 3228..3234 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3235..3242 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3247..3260 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3262..3283 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3284..3286 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3295..3310 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3312..3324 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3325..3328 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3332..3354 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3355..3358 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3365..3376 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3396..3407 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3411..3423 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3429..3432 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3434..3452 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3457..3460 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3461..3463 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3466..3470 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3473..3475 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3481..3484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3489..3491 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3495..3499 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3501..3507 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3509..3520 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3525..3531 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3536..3552 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3553..3557 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3562..3565 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3574..3578 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3581..3585 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3588..3592 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3593..3604 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3610..3625 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3631..3644 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3650..3658 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3662..3685 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3693..3695 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3696..3699 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3700..3702 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3705..3708 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3716..3718 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3719..3721 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3726..3729 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3733..3739 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3741..3745 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3747..3759 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3762..3764 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3766..3789 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3798..3800 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3804..3826 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3829..3831 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3834..3842 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3845..3848 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3853..3855 FT /evidence="ECO:0007829|PDB:7KTR" SQ SEQUENCE 3859 AA; 437600 MW; 391E467C0047B00B CRC64; MAFVATQGAT VVDQTTLMKK YLQFVAALTD VNTPDETKLK MMQEVSENFE NVTSSPQYST FLEHIIPRFL TFLQDGEVQF LQEKPAQQLR KLVLEIIHRI PTNEHLRPHT KNVLSVMFRF LETENEENVL ICLRIIIELH KQFRPPITQE IHHFLDFVKQ IYKELPKVVN RYFENPQVIP ENTVPPPEMV GMITTIAVKV NPEREDSETR THSIIPRGSL SLKVLAELPI IVVLMYQLYK LNIHNVVAEF VPLIMNTIAI QVSAQARQHK LYNKELYADF IAAQIKTLSF LAYIIRIYQE LVTKYSQQMV KGMLQLLSNC PAETAHLRKE LLIAAKHILT TELRNQFIPC MDKLFDESIL IGSGYTARET LRPLAYSTLA DLVHHVRQHL PLSDLSLAVQ LFAKNIDDES LPSSIQTMSC KLLLNLVDCI RSKSEQESGN GRDVLMRMLE VFVLKFHTIA RYQLSAIFKK CKPQSELGAV EAALPGVPTA PAAPGPAPSP APVPAPPPPP PPPPPATPVT PAPVPPFEKQ GEKDKEDKQT FQVTDCRSLV KTLVCGVKTI TWGITSCKAP GEAQFIPNKQ LQPKETQIYI KLVKYAMQAL DIYQVQIAGN GQTYIRVANC QTVRMKEEKE VLEHFAGVFT MMNPLTFKEI FQTTVPYMVE RISKNYALQI VANSFLANPT TSALFATILV EYLLDRLPEM GSNVELSNLY LKLFKLVFGS VSLFAAENEQ MLKPHLHKIV NSSMELAQTA KEPYNYFLLL RALFRSIGGG SHDLLYQEFL PLLPNLLQGL NMLQSGLHKQ HMKDLFVELC LTVPVRLSSL LPYLPMLMDP LVSALNGSQT LVSQGLRTLE LCVDNLQPDF LYDHIQPVRA ELMQALWRTL RNPADSISHV AYRVLGKFGG SNRKMLKESQ KLHYVVTEVQ GPSITVEFSD CKASLQLPME KAIETALDCL KSANTEPYYR RQAWEVIKCF LVAMMSLEDN KHALYQLLAH PNFTEKTIPN VIISHRYKAQ DTPARKTFEQ ALTGAFMSAV IKDLRPSALP FVASLIRHYT MVAVAQQCGP FLLPCYQVGS QPSTAMFHSE ENGSKGMDPL VLIDAIAICM AYEEKELCKI GEVALAVIFD VASIILGSKE RACQLPLFSY IVERLCACCY EQAWYAKLGG VVSIKFLMER LPLTWVLQNQ QTFLKALLFV MMDLTGEVSN GAVAMAKTTL EQLLMRCATP LKDEERAEEI VAAQEKSFHH VTHDLVREVT SPNSTVRKQA MHSLQVLAQV TGKSVTVIME PHKEVLQDMV PPKKHLLRHQ PANAQIGLME GNTFCTTLQP RLFTMDLNVV EHKVFYTELL NLCEAEDSAL TKLPCYKSLP SLVPLRIAAL NALAACNYLP QSREKIIAAL FKALNSTNSE LQEAGEACMR KFLEGATIEV DQIHTHMRPL LMMLGDYRSL TLNVVNRLTS VTRLFPNSFN DKFCDQMMQH LRKWMEVVVI THKGGQRSDG NESISECGRC PLSPFCQFEE MKICSAIINL FHLIPAAPQT LVKPLLEVVM KTERAMLIEA GSPFREPLIK FLTRHPSQTV ELFMMEATLN DPQWSRMFMS FLKHKDARPL RDVLAANPNR FITLLLPGGA QTAVRPGSPS TSTMRLDLQF QAIKIISIIV KNDDSWLASQ HSLVSQLRRV WVSENFQERH RKENMAATNW KEPKLLAYCL LNYCKRNYGD IELLFQLLRA FTGRFLCNMT FLKEYMEEEI PKNYSIAQKR ALFFRFVDFN DPNFGDELKA KVLQHILNPA FLYSFEKGEG EQLLGPPNPE GDNPESITSV FITKVLDPEK QADMLDSLRI YLLQYATLLV EHAPHHIHDN NKNRNSKLRR LMTFAWPCLL SKACVDPACK YSGHLLLAHI IAKFAIHKKI VLQVFHSLLK AHAMEARAIV RQAMAILTPA VPARMEDGHQ MLTHWTRKII VEEGHTVPQL VHILHLIVQH FKVYYPVRHH LVQHMVSAMQ RLGFTPSVTI EQRRLAVDLS EVVIKWELQR IKDQQPDSDM DPNSSGEGVN SVSSSIKRGL SVDSAQEVKR FRTATGAISA VFGRSQSLPG ADSLLAKPID KQHTDTVVNF LIRVACQVND NTNTAGSPGE VLSRRCVNLL KTALRPDMWP KSELKLQWFD KLLMTVEQPN QVNYGNICTG LEVLSFLLTV LQSPAILSSF KPLQRGIAAC MTCGNTKVLR AVHSLLSRLM SIFPTEPSTS SVASKYEELE CLYAAVGKVI YEGLTNYEKA TNANPSQLFG TLMILKSACS NNPSYIDRLI SVFMRSLQKM VREHLNPQAA SGSTEATSGT SELVMLSLEL VKTRLAVMSM EMRKNFIQAI LTSLIEKSPD AKILRAVVKI VEEWVKNNSP MAANQTPTLR EKSILLVKMM TYIEKRFPED LELNAQFLDL VNYVYRDETL SGSELTAKLE PAFLSGLRCA QPLIRAKFFE VFDNSMKRRV YERLLYVTCS QNWEAMGNHF WIKQCIELLL AVCEKSTPIG TSCQGAMLPS ITNVINLADS HDRAAFAMVT HVKQEPRERE NSESKEEDVE IDIELAPGDQ TSTPKTKELS EKDIGNQLHM LTNRHDKFLD TLREVKTGAL LSAFVQLCHI STTLAEKTWV QLFPRLWKIL SDRQQHALAG EISPFLCSGS HQVQRDCQPS ALNCFVEAMS QCVPPIPIRP CVLKYLGKTH NLWFRSTLML EHQAFEKGLS LQIKPKQTTE FYEQESITPP QQEILDSLAE LYSLLQEEDM WAGLWQKRCK YSETATAIAY EQHGFFEQAQ ESYEKAMDKA KKEHERSNAS PAIFPEYQLW EDHWIRCSKE LNQWEALTEY GQSKGHINPY LVLECAWRVS NWTAMKEALV QVEVSCPKEM AWKVNMYRGY LAICHPEEQQ LSFIERLVEM ASSLAIREWR RLPHVVSHVH TPLLQAAQQI IELQEAAQIN AGLQPTNLGR NNSLHDMKTV VKTWRNRLPI VSDDLSHWSS IFMWRQHHYQ GKPTWSGMHS SSIVTAYENS SQHDPSSNNA MLGVHASASA IIQYGKIARK QGLVNVALDI LSRIHTIPTV PIVDCFQKIR QQVKCYLQLA GVMGKNECMQ GLEVIESTNL KYFTKEMTAE FYALKGMFLA QINKSEEANK AFSAAVQMHD VLVKAWAMWG DYLENIFVKE RQLHLGVSAI TCYLHACRHQ NESKSRKYLA KVLWLLSFDD DKNTLADAVD KYCIGVPPIQ WLAWIPQLLT CLVGSEGKLL LNLISQVGRV YPQAVYFPIR TLYLTLKIEQ RERYKSDPGP IRATAPMWRC SRIMHMQREL HPTLLSSLEG IVDQMVWFRE NWHEEVLRQL QQGLAKCYSV AFEKSGAVSD AKITPHTLNF VKKLVSTFGV GLENVSNVST MFSSAASESL ARRAQATAQD PVFQKLKGQF TTDFDFSVPG SMKLHNLISK LKKWIKILEA KTKQLPKFFL IEEKCRFLSN FSAQTAEVEI PGEFLMPKPT HYYIKIARFM PRVEIVQKHN TAARRLYIRG HNGKIYPYLV MNDACLTESR REERVLQLLR LLNPCLEKRK ETTKRHLFFT VPRVVAVSPQ MRLVEDNPSS LSLVEIYKQR CAKKGIEHDN PISRYYDRLA TVQARGTQAS HQVLRDILKE VQSNMVPRSM LKEWALHTFP NATDYWTFRK MFTIQLALIG FAEFVLHLNR LNPEMLQIAQ DTGKLNVAYF RFDINDATGD LDANRPVPFR LTPNISEFLT TIGVSGPLTA SMIAVARCFA QPNFKVDGIL KTVLRDEIIA WHKKTQEDTS SPLSAAGQPE NMDSQQLVSL VQKAVTAIMT RLHNLAQFEG GESKVNTLVA AANSLDNLCR MDPAWHPWL // ID ULK1_HUMAN Reviewed; 1050 AA. AC O75385; Q9UQ28; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=Serine/threonine-protein kinase ULK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:18936157, ECO:0000269|PubMed:25126726, ECO:0000269|PubMed:28821708, ECO:0000269|PubMed:31123703, ECO:0000269|PubMed:37306101}; DE AltName: Full=Autophagy-related protein 1 homolog; DE Short=ATG1; DE Short=hATG1 {ECO:0000303|PubMed:21205641}; DE AltName: Full=Unc-51-like kinase 1 {ECO:0000303|PubMed:9693035}; GN Name=ULK1 {ECO:0000303|PubMed:9693035, ECO:0000312|HGNC:HGNC:12558}; GN Synonyms=KIAA0722 {ECO:0000303|PubMed:9872452}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-816. RX PubMed=9693035; DOI=10.1006/geno.1998.5340; RA Kuroyanagi H., Yan J., Seki N., Yamanouchi Y., Suzuki Y., Takano T., RA Muramatsu M., Shirasawa T.; RT "Human ULK1, a novel serine/threonine kinase related to UNC-51 kinase of RT Caenorhabditis elegans: cDNA cloning, expression, and chromosomal RT assignment."; RL Genomics 51:76-85(1998). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-816. RC TISSUE=Brain; RX PubMed=9872452; DOI=10.1093/dnares/5.5.277; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XI. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:277-286(1998). RN [3] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [5] RP FUNCTION, INTERACTION WITH GABARAP AND GABARAPL2, AND REGION. RX PubMed=11146101; DOI=10.1016/s0169-328x(00)00218-7; RA Okazaki N., Yan J., Yuasa S., Ueno T., Kominami E., Masuho Y., Koga H., RA Muramatsu M.-A.; RT "Interaction of the Unc-51-like kinase and microtubule-associated protein RT light chain 3 related proteins in the brain: possible role of vesicular RT transport in axonal elongation."; RL Brain Res. Mol. Brain Res. 85:1-12(2000). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477 AND SER-479, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-450; THR-456 AND SER-556, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [9] RP SUBUNIT, AND COMPLEX FORMATION WITH ATG13; ATG101 AND RB1CC1. RX PubMed=19287211; DOI=10.4161/auto.5.5.8249; RA Mercer C.A., Kaliappan A., Dennis P.B.; RT "A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is RT essential for macroautophagy."; RL Autophagy 5:649-662(2009). RN [10] RP SUBUNIT. RX PubMed=19597335; DOI=10.4161/auto.5.7.9296; RA Hosokawa N., Sasaki T., Iemura S.I., Natsume T., Hara T., Mizushima N.; RT "Atg101, a novel mammalian autophagy protein interacting with Atg13."; RL Autophagy 5:973-979(2009). RN [11] RP SUBUNIT, AND INTERACTION WITH RPTOR AND TORC1 COMPLEX. RX PubMed=19211835; DOI=10.1091/mbc.e08-12-1248; RA Hosokawa N., Hara T., Kaizuka T., Kishi C., Takamura A., Miura Y., RA Iemura S., Natsume T., Takehana K., Yamada N., Guan J.L., Oshiro N., RA Mizushima N.; RT "Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex RT required for autophagy."; RL Mol. Biol. Cell 20:1981-1991(2009). RN [12] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH ATG13. RX PubMed=18936157; DOI=10.1128/mcb.01082-08; RA Chan E.Y.W., Longatti A., McKnight N.C., Tooze S.A.; RT "Kinase-inactivated ULK proteins inhibit autophagy via their conserved C- RT terminal domains using an Atg13-independent mechanism."; RL Mol. Cell. Biol. 29:157-171(2009). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-450 AND SER-638, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP FUNCTION, AND MUTAGENESIS OF LYS-46. RX PubMed=20921139; DOI=10.1083/jcb.201002100; RA Di Bartolomeo S., Corazzari M., Nazio F., Oliverio S., Lisi G., RA Antonioli M., Pagliarini V., Matteoni S., Fuoco C., Giunta L., D'Amelio M., RA Nardacci R., Romagnoli A., Piacentini M., Cecconi F., Fimia G.M.; RT "The dynamic interaction of AMBRA1 with the dynein motor complex regulates RT mammalian autophagy."; RL J. Cell Biol. 191:155-168(2010). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-450; THR-456 AND SER-638, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [17] RP FUNCTION IN PHOSPHORYLATION OF AMPK. RX PubMed=21460634; DOI=10.4161/auto.7.7.15451; RA Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M., RA Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.; RT "Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory RT feedback loop."; RL Autophagy 7:696-706(2011). RN [18] RP FUNCTION, AND INTERACTION WITH RPTOR. RX PubMed=21795849; DOI=10.4161/auto.7.10.16660; RA Jung C.H., Seo M., Otto N.M., Kim D.H.; RT "ULK1 inhibits the kinase activity of mTORC1 and cell proliferation."; RL Autophagy 7:1212-1221(2011). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-450; SER-469; SER-556 AND RP SER-638, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [20] RP PHOSPHORYLATION BY AMPK. RX PubMed=21205641; DOI=10.1126/science.1196371; RA Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., RA Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M., RA Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.; RT "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects RT energy sensing to mitophagy."; RL Science 331:456-461(2011). RN [21] RP INTERACTION WITH FEZ1. RX PubMed=22354037; DOI=10.1038/emboj.2012.36; RA McKnight N.C., Jefferies H.B., Alemu E.A., Saunders R.E., Howell M., RA Johansen T., Tooze S.A.; RT "Genome-wide siRNA screen reveals amino acid starvation-induced autophagy RT requires SCOC and WAC."; RL EMBO J. 31:1931-1946(2012). RN [22] RP INTERACTION WITH TBC1D14. RX PubMed=22613832; DOI=10.1083/jcb.201111079; RA Longatti A., Lamb C.A., Razi M., Yoshimura S., Barr F.A., Tooze S.A.; RT "TBC1D14 regulates autophagosome formation via Rab11- and ULK1-positive RT recycling endosomes."; RL J. Cell Biol. 197:659-675(2012). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403; SER-450; SER-467; RP SER-469; SER-477; SER-479; SER-556; SER-638; SER-758 AND SER-775, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [24] RP FUNCTION, AND UBIQUITINATION. RX PubMed=23524951; DOI=10.1038/ncb2708; RA Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V., RA Bordi M., Gretzmeier C., Dengjel J., Piacentini M., Fimia G.M., Cecconi F.; RT "mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self- RT association and function through AMBRA1 and TRAF6."; RL Nat. Cell Biol. 15:406-416(2013). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25126726; DOI=10.4161/auto.29640; RA Dunlop E.A., Seifan S., Claessens T., Behrends C., Kamps M.A., Rozycka E., RA Kemp A.J., Nookala R.K., Blenis J., Coull B.J., Murray J.T., RA van Steensel M.A., Wilkinson S., Tee A.R.; RT "FLCN, a novel autophagy component, interacts with GABARAP and is regulated RT by ULK1 phosphorylation."; RL Autophagy 10:1749-1760(2014). RN [26] RP PHOSPHORYLATION AT SER-556. RX PubMed=24767988; DOI=10.1016/j.celrep.2014.03.065; RA Lanning N.J., Looyenga B.D., Kauffman A.L., Niemi N.M., Sudderth J., RA DeBerardinis R.J., MacKeigan J.P.; RT "A mitochondrial RNAi screen defines cellular bioenergetic determinants and RT identifies an adenylate kinase as a key regulator of ATP levels."; RL Cell Rep. 7:907-917(2014). RN [27] RP FUNCTION, INTERACTION WITH SESN2 AND SQSTM1, AND REGION. RX PubMed=25040165; DOI=10.1111/febs.12905; RA Ro S.H., Semple I.A., Park H., Park H., Park H.W., Kim M., Kim J.S., RA Lee J.H.; RT "Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of RT p62/sequestosome-1."; RL FEBS J. 281:3816-3827(2014). RN [28] RP INTERACTION WITH TRIM5. RX PubMed=25127057; DOI=10.1016/j.devcel.2014.06.013; RA Mandell M.A., Jain A., Arko-Mensah J., Chauhan S., Kimura T., Dinkins C., RA Silvestri G., Munch J., Kirchhoff F., Simonsen A., Wei Y., Levine B., RA Johansen T., Deretic V.; RT "TRIM proteins regulate autophagy and can target autophagic substrates by RT direct recognition."; RL Dev. Cell 30:394-409(2014). RN [29] RP INTERACTION WITH BECN1; IRF3; MEFV AND TRIM21. RX PubMed=26347139; DOI=10.1083/jcb.201503023; RA Kimura T., Jain A., Choi S.W., Mandell M.A., Schroder K., Johansen T., RA Deretic V.; RT "TRIM-mediated precision autophagy targets cytoplasmic regulators of innate RT immunity."; RL J. Cell Biol. 210:973-989(2015). RN [30] RP INTERACTION WITH IRGM, AND PHOSPHORYLATION AT SER-317 AND SER-556. RX PubMed=25891078; DOI=10.1016/j.molcel.2015.03.020; RA Chauhan S., Mandell M.A., Deretic V.; RT "IRGM governs the core autophagy machinery to conduct antimicrobial RT defense."; RL Mol. Cell 58:507-521(2015). RN [31] RP INTERACTION WITH AMBRA1. RX PubMed=25438055; DOI=10.1038/ncb3072; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RT "AMBRA1 links autophagy to cell proliferation and tumorigenesis by RT promoting c-Myc dephosphorylation and degradation."; RL Nat. Cell Biol. 17:20-30(2015). RN [32] RP ERRATUM OF PUBMED:25438055. RX PubMed=25925585; DOI=10.1038/ncb3171; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RL Nat. Cell Biol. 17:706-706(2015). RN [33] RP INTERACTION WITH C9ORF72. RX PubMed=27334615; DOI=10.15252/embj.201694401; RA Webster C.P., Smith E.F., Bauer C.S., Moller A., Hautbergue G.M., RA Ferraiuolo L., Myszczynska M.A., Higginbottom A., Walsh M.J., RA Whitworth A.J., Kaspar B.K., Meyer K., Shaw P.J., Grierson A.J., RA De Vos K.J.; RT "The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate RT initiation of autophagy."; RL EMBO J. 35:1656-1676(2016). RN [34] RP INTERACTION WITH ATP2A2 AND WIPI2. RX PubMed=28890335; DOI=10.1016/j.molcel.2017.08.005; RA Zhao Y.G., Chen Y., Miao G., Zhao H., Qu W., Li D., Wang Z., Liu N., Li L., RA Chen S., Liu P., Feng D., Zhang H.; RT "The ER-Localized Transmembrane Protein EPG-3/VMP1 Regulates SERCA Activity RT to Control ER-Isolation Membrane Contacts for Autophagosome Formation."; RL Mol. Cell 67:974.e6-989.e6(2017). RN [35] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-46. RX PubMed=28821708; DOI=10.1038/s41467-017-00303-2; RA Pengo N., Agrotis A., Prak K., Jones J., Ketteler R.; RT "A reversible phospho-switch mediated by ULK1 regulates the activity of RT autophagy protease ATG4B."; RL Nat. Commun. 8:294-294(2017). RN [36] RP INTERACTION WITH WDR45. RX PubMed=28561066; DOI=10.1038/ncomms15637; RA Bakula D., Mueller A.J., Zuleger T., Takacs Z., Franz-Wachtel M., RA Thost A.K., Brigger D., Tschan M.P., Frickey T., Robenek H., Macek B., RA Proikas-Cezanne T.; RT "WIPI3 and WIPI4 beta-propellers are scaffolds for LKB1-AMPK-TSC signalling RT circuits in the control of autophagy."; RL Nat. Commun. 8:15637-15637(2017). RN [37] RP FUNCTION, AND DEUBIQUITINATION BY USP20. RX PubMed=29487085; DOI=10.15252/embr.201744378; RA Kim J.H., Seo D., Kim S.J., Choi D.W., Park J.S., Ha J., Choi J., Lee J.H., RA Jung S.M., Seo K.W., Lee E.W., Lee Y.S., Cheong H., Choi C.Y., Park S.H.; RT "The deubiquitinating enzyme USP20 stabilizes ULK1 and promotes autophagy RT initiation."; RL EMBO Rep. 19:0-0(2018). RN [38] RP INTERACTION WITH ATG13. RX PubMed=31806350; DOI=10.1016/j.molcel.2019.10.035; RA Miao G., Zhang Y., Chen D., Zhang H.; RT "The ER-Localized Transmembrane Protein TMEM39A/SUSR2 Regulates Autophagy RT by Controlling the Trafficking of the PtdIns(4)P Phosphatase SAC1."; RL Mol. Cell 0:0-0(2019). RN [39] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP AMBRA1. RX PubMed=31123703; DOI=10.1126/sciadv.aau8857; RA Di Rienzo M., Antonioli M., Fusco C., Liu Y., Mari M., Orhon I., Refolo G., RA Germani F., Corazzari M., Romagnoli A., Ciccosanti F., Mandriani B., RA Pellico M.T., De La Torre R., Ding H., Dentice M., Neri M., Ferlini A., RA Reggiori F., Kulesz-Martin M., Piacentini M., Merla G., Fimia G.M.; RT "Autophagy induction in atrophic muscle cells requires ULK1 activation by RT TRIM32 through unanchored K63-linked polyubiquitin chains."; RL Sci. Adv. 5:eaau8857-eaau8857(2019). RN [40] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37306101; DOI=10.15252/embj.2022113349; RA Ikeda R., Noshiro D., Morishita H., Takada S., Kageyama S., Fujioka Y., RA Funakoshi T., Komatsu-Hirota S., Arai R., Ryzhii E., Abe M., Koga T., RA Motohashi H., Nakao M., Sakimura K., Horii A., Waguri S., Ichimura Y., RA Noda N.N., Komatsu M.; RT "Phosphorylation of phase-separated p62 bodies by ULK1 activates a redox- RT independent stress response."; RL EMBO J. 42:e113349-e113349(2023). RN [41] RP FUNCTION, AND INTERACTION WITH FBXO16. RX PubMed=39384743; DOI=10.1038/s41419-024-07120-8; RA Zhang Z., Liu X., Chu C., Zhang Y., Li W., Yu X., Han Q., Sun H., Zhang Y., RA Zhu X., Chen L., Wei R., Fan N., Zhou M., Li X.; RT "MIR937 amplification potentiates ovarian cancer progression by attenuating RT FBXO16 inhibition on ULK1-mediated autophagy."; RL Cell Death Dis. 15:735-735(2024). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] MET-290; LEU-298; LEU-478; MET-503; RP LEU-665; LEU-714 AND CYS-784. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase involved in autophagy in CC response to starvation (PubMed:18936157, PubMed:21460634, CC PubMed:21795849, PubMed:23524951, PubMed:25040165, PubMed:29487085, CC PubMed:31123703). Acts upstream of phosphatidylinositol 3-kinase PIK3C3 CC to regulate the formation of autophagophores, the precursors of CC autophagosomes (PubMed:18936157, PubMed:21460634, PubMed:21795849, CC PubMed:25040165, PubMed:39384743). Part of regulatory feedback loops in CC autophagy: acts both as a downstream effector and negative regulator of CC mammalian target of rapamycin complex 1 (mTORC1) via interaction with CC RPTOR (PubMed:21795849). Activated via phosphorylation by AMPK and also CC acts as a regulator of AMPK by mediating phosphorylation of AMPK CC subunits PRKAA1, PRKAB2 and PRKAG1, leading to negatively regulate AMPK CC activity (PubMed:21460634). May phosphorylate ATG13/KIAA0652 and RPTOR; CC however such data need additional evidences (PubMed:18936157). Plays a CC role early in neuronal differentiation and is required for granule cell CC axon formation (PubMed:11146101). Also phosphorylates SESN2 and SQSTM1 CC to regulate autophagy (PubMed:25040165, PubMed:37306101). CC Phosphorylates FLCN, promoting autophagy (PubMed:25126726). CC Phosphorylates AMBRA1 in response to autophagy induction, releasing CC AMBRA1 from the cytoskeletal docking site to induce autophagosome CC nucleation (PubMed:20921139). Phosphorylates ATG4B, leading to inhibit CC autophagy by decreasing both proteolytic activation and delipidation CC activities of ATG4B (PubMed:28821708). {ECO:0000269|PubMed:11146101, CC ECO:0000269|PubMed:18936157, ECO:0000269|PubMed:20921139, CC ECO:0000269|PubMed:21460634, ECO:0000269|PubMed:21795849, CC ECO:0000269|PubMed:23524951, ECO:0000269|PubMed:25040165, CC ECO:0000269|PubMed:25126726, ECO:0000269|PubMed:28821708, CC ECO:0000269|PubMed:29487085, ECO:0000269|PubMed:31123703, CC ECO:0000269|PubMed:37306101, ECO:0000269|PubMed:39384743}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18936157, ECO:0000269|PubMed:25126726, CC ECO:0000269|PubMed:28821708, ECO:0000269|PubMed:31123703, CC ECO:0000269|PubMed:37306101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:18936157, ECO:0000269|PubMed:25126726, CC ECO:0000269|PubMed:31123703, ECO:0000269|PubMed:37306101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18936157}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:18936157}; CC -!- ACTIVITY REGULATION: Acetylation by KAT5/TIP60 stimulates the protein CC kinase activity (By similarity). The protein kinase activity is CC activated by unanchored 'Lys-63'-linked polyubiquitin chains: CC unanchored 'Lys-63'-linked polyubiquitin chains are catalyzed by TRIM32 CC in an AMBRA1-dependent manner (PubMed:31123703). CC {ECO:0000250|UniProtKB:O70405, ECO:0000269|PubMed:31123703}. CC -!- SUBUNIT: Interacts with GABARAP and GABARAPL2 (PubMed:11146101). CC Interacts (via C-terminus) with ATG13 (PubMed:18936157). Part of a CC complex consisting of ATG13, ATG101, ULK1 and RB1CC1 (PubMed:19287211). CC Associates with the mammalian target of rapamycin complex 1 (mTORC1) CC through an interaction with RPTOR; the association depends on nutrient CC conditions and is reduced during starvation (PubMed:19211835, CC PubMed:21795849). Interacts with FEZ1; SCOC interferes with FEZ1- CC binding (PubMed:22354037). Interacts with TBC1D14 (PubMed:22613832). CC Interacts (phosphorylated form) with TRIM5 (PubMed:25127057). When CC phosphorylated at Ser-317, interacts with MEFV and BECN1 simultaneously CC (PubMed:26347139). Interacts with TRIM21 and IRF3, in the presence of CC TRIM21 (PubMed:26347139). Interacts with SESN2 (PubMed:25040165). CC Interacts with SQSTM1 (PubMed:25040165). Interacts with C9orf72 CC (PubMed:27334615). Interacts with WDR45 (PubMed:28561066). Interacts CC with ATG13; this interaction is increased in the absence of TMEM39A CC (PubMed:31806350). Interacts with WIPI2 (PubMed:28890335). Interacts CC with ATP2A2 (PubMed:28890335). Interacts with AMBRA1 (PubMed:25438055, CC PubMed:31123703). Interacts with IRGM; promoting the coassembly of ULK1 CC and BECN1 (PubMed:25891078). Interacts with FBXO16 (PubMed:39384743). CC {ECO:0000269|PubMed:11146101, ECO:0000269|PubMed:18936157, CC ECO:0000269|PubMed:19211835, ECO:0000269|PubMed:19287211, CC ECO:0000269|PubMed:19597335, ECO:0000269|PubMed:21795849, CC ECO:0000269|PubMed:22354037, ECO:0000269|PubMed:22613832, CC ECO:0000269|PubMed:25040165, ECO:0000269|PubMed:25127057, CC ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25891078, CC ECO:0000269|PubMed:26347139, ECO:0000269|PubMed:27334615, CC ECO:0000269|PubMed:28561066, ECO:0000269|PubMed:28890335, CC ECO:0000269|PubMed:31123703, ECO:0000269|PubMed:31806350, CC ECO:0000269|PubMed:39384743}. CC -!- INTERACTION: CC O75385; Q9C0C7: AMBRA1; NbExp=3; IntAct=EBI-908831, EBI-2512975; CC O75385; Q9C0C7-3: AMBRA1; NbExp=4; IntAct=EBI-908831, EBI-16042318; CC O75385; O75143: ATG13; NbExp=15; IntAct=EBI-908831, EBI-2798775; CC O75385; Q96LT7-1: C9orf72; NbExp=5; IntAct=EBI-908831, EBI-16693635; CC O75385; Q96LT7-2: C9orf72; NbExp=4; IntAct=EBI-908831, EBI-16693673; CC O75385; O95166: GABARAP; NbExp=2; IntAct=EBI-908831, EBI-712001; CC O75385; Q9H0R8: GABARAPL1; NbExp=3; IntAct=EBI-908831, EBI-746969; CC O75385; P60520: GABARAPL2; NbExp=4; IntAct=EBI-908831, EBI-720116; CC O75385; P42858: HTT; NbExp=8; IntAct=EBI-908831, EBI-466029; CC O75385; Q9GZQ8: MAP1LC3B; NbExp=3; IntAct=EBI-908831, EBI-373144; CC O75385; Q9BXW4: MAP1LC3C; NbExp=4; IntAct=EBI-908831, EBI-2603996; CC O75385; P42345: MTOR; NbExp=7; IntAct=EBI-908831, EBI-359260; CC O75385; P04629: NTRK1; NbExp=2; IntAct=EBI-908831, EBI-1028226; CC O75385; O15530: PDPK1; NbExp=2; IntAct=EBI-908831, EBI-717097; CC O75385; P54646: PRKAA2; NbExp=2; IntAct=EBI-908831, EBI-1383852; CC O75385; Q9Y478: PRKAB1; NbExp=3; IntAct=EBI-908831, EBI-719769; CC O75385; Q8TDY2: RB1CC1; NbExp=13; IntAct=EBI-908831, EBI-1047793; CC O75385; Q8N122: RPTOR; NbExp=3; IntAct=EBI-908831, EBI-1567928; CC O75385; Q9P2M4: TBC1D14; NbExp=4; IntAct=EBI-908831, EBI-2797718; CC O75385; Q9Y4K3: TRAF6; NbExp=2; IntAct=EBI-908831, EBI-359276; CC O75385; O75385: ULK1; NbExp=3; IntAct=EBI-908831, EBI-908831; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000250}. CC Preautophagosomal structure {ECO:0000250}. Note=Under starvation CC conditions, is localized to puncate structures primarily representing CC the isolation membrane that sequesters a portion of the cytoplasm CC resulting in the formation of an autophagosome. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Detected in the following CC adult tissues: skeletal muscle, heart, pancreas, brain, placenta, CC liver, kidney, and lung. CC -!- PTM: Autophosphorylated. Phosphorylated under nutrient-rich conditions; CC dephosphorylated during starvation or following treatment with CC rapamycin. Under nutrient sufficiency, phosphorylated by MTOR/mTOR, CC disrupting the interaction with AMPK and preventing activation of ULK1 CC (By similarity). In response to nutrient limitation, phosphorylated and CC activated by AMPK, leading to activate autophagy (PubMed:21205641, CC PubMed:25891078). {ECO:0000250|UniProtKB:O70405, CC ECO:0000269|PubMed:21205641, ECO:0000269|PubMed:25891078}. CC -!- PTM: Ubiquitinated via 'Lys-63'-linkage by a complex composed of AMBRA1 CC and TRAF6 following autophagy induction, promoting ULK1 stability and CC kinase activity. Deubiquitinated by USP20; leading to ULK1 stability CC and autophagy initiation (PubMed:29487085). Ubiquitinated by the SCF- CC FBXO16 E3 ubiquitin ligase, leading to proteasomal degradation CC (PubMed:39384743). {ECO:0000269|PubMed:23524951, CC ECO:0000269|PubMed:29487085, ECO:0000269|PubMed:39384743}. CC -!- PTM: Acetylated by KAT5/TIP60 under autophagy induction, promoting CC protein kinase activity. {ECO:0000250|UniProtKB:O70405}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. APG1/unc-51/ULK1 subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA34442.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF045458; AAC32326.1; -; mRNA. DR EMBL; AB018265; BAA34442.2; ALT_INIT; mRNA. DR EMBL; AC131009; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS9274.1; -. DR RefSeq; NP_003556.2; NM_003565.4. DR PDB; 4WNO; X-ray; 1.56 A; A=1-283. DR PDB; 4WNP; X-ray; 1.88 A; A/B/C/D=1-283. DR PDB; 5CI7; X-ray; 1.74 A; A=1-283. DR PDB; 6HYO; X-ray; 1.07 A; A=354-366. DR PDB; 6MNH; X-ray; 1.73 A; A=6-290. DR PDB; 6QAS; X-ray; 1.75 A; A/B=1-283. DR PDB; 8P5G; X-ray; 2.02 A; A/B=1-283. DR PDB; 8P5H; X-ray; 1.94 A; A/B=1-283. DR PDB; 8P5I; X-ray; 1.83 A; A/B/C/D=1-283. DR PDB; 8P5J; X-ray; 2.16 A; A/B=1-283. DR PDB; 8P5K; X-ray; 2.21 A; A/B/C/D=1-283. DR PDB; 8P5L; X-ray; 1.84 A; A/B=1-283. DR PDB; 8SOI; EM; 4.20 A; C=840-1044. DR PDB; 8SQZ; EM; 5.85 A; C/D=836-1050. DR PDB; 8SRM; EM; 4.46 A; C/D=836-1050. DR PDB; 8SV9; X-ray; 2.30 A; A/B=1-283. DR PDB; 9C82; EM; 6.20 A; C=840-1044. DR PDB; 9F32; X-ray; 2.10 A; A=1-283. DR PDBsum; 4WNO; -. DR PDBsum; 4WNP; -. DR PDBsum; 5CI7; -. DR PDBsum; 6HYO; -. DR PDBsum; 6MNH; -. DR PDBsum; 6QAS; -. DR PDBsum; 8P5G; -. DR PDBsum; 8P5H; -. DR PDBsum; 8P5I; -. DR PDBsum; 8P5J; -. DR PDBsum; 8P5K; -. DR PDBsum; 8P5L; -. DR PDBsum; 8SOI; -. DR PDBsum; 8SQZ; -. DR PDBsum; 8SRM; -. DR PDBsum; 8SV9; -. DR PDBsum; 9C82; -. DR PDBsum; 9F32; -. DR AlphaFoldDB; O75385; -. DR EMDB; EMD-40658; -. DR EMDB; EMD-40715; -. DR EMDB; EMD-40735; -. DR EMDB; EMD-40738; -. DR SMR; O75385; -. DR BioGRID; 113996; 182. DR ComplexPortal; CPX-26575; ATG13-ATG14-BECN1-PIK3C3-PIK3R4-RB1CC1, autophagy initiation complex. DR ComplexPortal; CPX-373; ULK1-ATG13-RB1CC1-ATG101 autophagy initiation complex. DR CORUM; O75385; -. DR DIP; DIP-35196N; -. DR FunCoup; O75385; 1578. DR IntAct; O75385; 136. DR MINT; O75385; -. DR STRING; 9606.ENSP00000324560; -. DR BindingDB; O75385; -. DR ChEMBL; CHEMBL6006; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O75385; -. DR GuidetoPHARMACOLOGY; 2271; -. DR GlyCosmos; O75385; 1 site, 1 glycan. DR GlyGen; O75385; 6 sites, 1 O-linked glycan (2 sites). DR iPTMnet; O75385; -. DR PhosphoSitePlus; O75385; -. DR SwissPalm; O75385; -. DR BioMuta; ULK1; -. DR CPTAC; CPTAC-3098; -. DR CPTAC; CPTAC-3099; -. DR jPOST; O75385; -. DR MassIVE; O75385; -. DR PaxDb; 9606-ENSP00000324560; -. DR PeptideAtlas; O75385; -. DR ProteomicsDB; 49958; -. DR Pumba; O75385; -. DR Antibodypedia; 31999; 908 antibodies from 39 providers. DR DNASU; 8408; -. DR Ensembl; ENST00000321867.6; ENSP00000324560.3; ENSG00000177169.11. DR GeneID; 8408; -. DR KEGG; hsa:8408; -. DR MANE-Select; ENST00000321867.6; ENSP00000324560.3; NM_003565.4; NP_003556.2. DR UCSC; uc001uje.4; human. DR AGR; HGNC:12558; -. DR ClinPGx; PA37198; -. DR CTD; 8408; -. DR DisGeNET; 8408; -. DR GeneCards; ULK1; -. DR HGNC; HGNC:12558; ULK1. DR HPA; ENSG00000177169; Low tissue specificity. DR MIM; 603168; gene. DR OpenTargets; ENSG00000177169; -. DR VEuPathDB; HostDB:ENSG00000177169; -. DR eggNOG; KOG0595; Eukaryota. DR GeneTree; ENSGT00940000156664; -. DR HOGENOM; CLU_011264_0_0_1; -. DR InParanoid; O75385; -. DR OMA; PQPHQIT; -. DR OrthoDB; 346907at2759; -. DR PAN-GO; O75385; 13 GO annotations based on evolutionary models. DR PhylomeDB; O75385; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O75385; -. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-5357905; Regulation of TNFR1 signaling. DR Reactome; R-HSA-8854214; TBC/RABGAPs. DR Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs. DR Reactome; R-HSA-8934903; Receptor Mediated Mitophagy. DR SignaLink; O75385; -. DR SIGNOR; O75385; -. DR Agora; ENSG00000177169; -. DR BioGRID-ORCS; 8408; 18 hits in 1202 CRISPR screens. DR ChiTaRS; ULK1; human. DR EvolutionaryTrace; O75385; -. DR GeneWiki; ULK1; -. DR GenomeRNAi; 8408; -. DR Pharos; O75385; Tchem. DR PRO; PR:O75385; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; O75385; protein. DR Bgee; ENSG00000177169; Expressed in body of pancreas and 161 other cell types or tissues. DR GO; GO:1990316; C:Atg1/ULK1 kinase complex; IPI:UniProtKB. DR GO; GO:0005776; C:autophagosome; IDA:UniProtKB. DR GO; GO:0000421; C:autophagosome membrane; IDA:UniProtKB. DR GO; GO:0030424; C:axon; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:1903349; C:omegasome membrane; IDA:UniProtKB. DR GO; GO:0000407; C:phagophore assembly site; IDA:ComplexPortal. DR GO; GO:0034045; C:phagophore assembly site membrane; IDA:UniProtKB. DR GO; GO:0055037; C:recycling endosome; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0051020; F:GTPase binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IPI:BHF-UCL. DR GO; GO:0000045; P:autophagosome assembly; IDA:UniProtKB. DR GO; GO:0006914; P:autophagy; IDA:UniProtKB. DR GO; GO:0048675; P:axon extension; IBA:GO_Central. DR GO; GO:0031669; P:cellular response to nutrient levels; ISS:UniProtKB. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0008104; P:intracellular protein localization; IMP:UniProtKB. DR GO; GO:0016236; P:macroautophagy; IMP:BHF-UCL. DR GO; GO:0000423; P:mitophagy; IBA:GO_Central. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:ComplexPortal. DR GO; GO:0048671; P:negative regulation of collateral sprouting; IBA:GO_Central. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:ParkinsonsUK-UCL. DR GO; GO:0031175; P:neuron projection development; IMP:UniProtKB. DR GO; GO:0031102; P:neuron projection regeneration; IEA:Ensembl. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0034727; P:piecemeal microautophagy of the nucleus; IBA:GO_Central. DR GO; GO:2000786; P:positive regulation of autophagosome assembly; IEA:Ensembl. DR GO; GO:0010508; P:positive regulation of autophagy; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB. DR GO; GO:0010506; P:regulation of autophagy; IBA:GO_Central. DR GO; GO:0016241; P:regulation of macroautophagy; IDA:UniProtKB. DR GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; TAS:Reactome. DR GO; GO:0042594; P:response to starvation; ISS:UniProtKB. DR GO; GO:0061709; P:reticulophagy; IBA:GO_Central. DR GO; GO:0007165; P:signal transduction; IEA:InterPro. DR CDD; cd14202; STKc_ULK1; 1. DR FunFam; 1.10.510.10:FF:000128; serine/threonine-protein kinase ULK2 isoform X2; 1. DR FunFam; 3.30.200.20:FF:000149; serine/threonine-protein kinase unc-51 isoform X1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR045269; Atg1-like. DR InterPro; IPR048941; ATG1-like_MIT2. DR InterPro; IPR022708; Atg1-like_tMIT. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016237; Ser/Thr_kin_STPK_Ulk-1/2. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24348; SERINE/THREONINE-PROTEIN KINASE UNC-51-RELATED; 1. DR PANTHER; PTHR24348:SF19; SERINE_THREONINE-PROTEIN KINASE ULK1; 1. DR Pfam; PF12063; ATG1-like_MIT1; 1. DR Pfam; PF21127; ATG1-like_MIT2; 1. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF000580; Ser/Thr_PK_STPK_ULK-1/2; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Autophagy; Cytoplasm; Kinase; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Ubl conjugation. FT CHAIN 1..1050 FT /note="Serine/threonine-protein kinase ULK1" FT /id="PRO_0000086780" FT DOMAIN 16..278 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 283..358 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 287..416 FT /note="Interaction with GABARAP and GABARAPL2" FT /evidence="ECO:0000269|PubMed:11146101" FT REGION 393..608 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 728..791 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 828..1050 FT /note="C-terminal domain; mediates interaction with SESN2" FT /evidence="ECO:0000269|PubMed:25040165" FT COMPBIAS 295..317 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 410..425 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 436..459 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 775..786 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 138 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 22..30 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 46 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:20921139" FT MOD_RES 162 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 317 FT /note="Phosphoserine; by AMPK" FT /evidence="ECO:0000269|PubMed:25891078" FT MOD_RES 403 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 450 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 456 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231" FT MOD_RES 467 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 469 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT MOD_RES 479 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT MOD_RES 522 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 556 FT /note="Phosphoserine; by AMPK" FT /evidence="ECO:0000269|PubMed:24767988, FT ECO:0000269|PubMed:25891078, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 575 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 607 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 636 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 638 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 639 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 758 FT /note="Phosphoserine; by MTOR" FT /evidence="ECO:0000305|PubMed:21205641, FT ECO:0007744|PubMed:23186163" FT MOD_RES 775 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 290 FT /note="V -> M (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs370624303)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041274" FT VARIANT 298 FT /note="S -> L (in dbSNP:rs56364352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041275" FT VARIANT 478 FT /note="P -> L (in dbSNP:rs12827141)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041276" FT VARIANT 503 FT /note="T -> M (in dbSNP:rs55824543)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041277" FT VARIANT 665 FT /note="S -> L (in dbSNP:rs55815560)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041278" FT VARIANT 714 FT /note="P -> L (in dbSNP:rs11546871)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041279" FT VARIANT 784 FT /note="S -> C (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041280" FT VARIANT 816 FT /note="T -> A (in dbSNP:rs11609348)" FT /evidence="ECO:0000269|PubMed:9693035, FT ECO:0000269|PubMed:9872452" FT /id="VAR_054892" FT MUTAGEN 46 FT /note="K->I: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:20921139, FT ECO:0000269|PubMed:28821708" FT STRAND 9..11 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 14..24 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 29..37 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 42..47 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 53..67 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 78..83 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 88..93 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 100..106 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 112..132 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 141..143 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 144..147 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 151..153 FT /evidence="ECO:0007829|PDB:4WNP" FT HELIX 156..158 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 160..163 FT /evidence="ECO:0007829|PDB:4WNO" FT TURN 185..187 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 190..193 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 201..216 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 226..235 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 249..258 FT /evidence="ECO:0007829|PDB:4WNO" FT TURN 263..265 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 269..273 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 276..278 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 281..284 FT /evidence="ECO:0007829|PDB:6MNH" SQ SEQUENCE 1050 AA; 112631 MW; AED9BD5139F2DB92 CRC64; MEPGRGGTET VGKFEFSRKD LIGHGAFAVV FKGRHREKHD LEVAVKCINK KNLAKSQTLL GKEIKILKEL KHENIVALYD FQEMANSVYL VMEYCNGGDL ADYLHAMRTL SEDTIRLFLQ QIAGAMRLLH SKGIIHRDLK PQNILLSNPA GRRANPNSIR VKIADFGFAR YLQSNMMAAT LCGSPMYMAP EVIMSQHYDG KADLWSIGTI VYQCLTGKAP FQASSPQDLR LFYEKNKTLV PTIPRETSAP LRQLLLALLQ RNHKDRMDFD EFFHHPFLDA SPSVRKSPPV PVPSYPSSGS GSSSSSSSTS HLASPPSLGE MQQLQKTLAS PADTAGFLHS SRDSGGSKDS SCDTDDFVMV PAQFPGDLVA EAPSAKPPPD SLMCSGSSLV ASAGLESHGR TPSPSPPCSS SPSPSGRAGP FSSSRCGASV PIPVPTQVQN YQRIERNLQS PTQFQTPRSS AIRRSGSTSP LGFARASPSP PAHAEHGGVL ARKMSLGGGR PYTPSPQVGT IPERPGWSGT PSPQGAEMRG GRSPRPGSSA PEHSPRTSGL GCRLHSAPNL SDLHVVRPKL PKPPTDPLGA VFSPPQASPP QPSHGLQSCR NLRGSPKLPD FLQRNPLPPI LGSPTKAVPS FDFPKTPSSQ NLLALLARQG VVMTPPRNRT LPDLSEVGPF HGQPLGPGLR PGEDPKGPFG RSFSTSRLTD LLLKAAFGTQ APDPGSTESL QEKPMEIAPS AGFGGSLHPG ARAGGTSSPS PVVFTVGSPP SGSTPPQGPR TRMFSAGPTG SASSSARHLV PGPCSEAPAP ELPAPGHGCS FADPITANLE GAVTFEAPDL PEETLMEQEH TEILRGLRFT LLFVQHVLEI AALKGSASEA AGGPEYQLQE SVVADQISLL SREWGFAEQL VLYLKVAELL SSGLQSAIDQ IRAGKLCLSS TVKQVVRRLN ELYKASVVSC QGLSLRLQRF FLDKQRLLDR IHSITAERLI FSHAVQMVQS AALDEMFQHR EGCVPRYHKA LLLLEGLQHM LSDQADIENV TKCKLCIERR LSALLTGICA // ID WEE2_HUMAN Reviewed; 567 AA. AC P0C1S8; DT 05-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 28-JUL-2009, sequence version 2. DT 28-JAN-2026, entry version 147. DE RecName: Full=Wee1-like protein kinase 2; DE EC=2.7.10.2; DE AltName: Full=Wee1-like protein kinase 1B; DE AltName: Full=Wee1B kinase; GN Name=WEE2; Synonyms=WEE1B; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=11029659; DOI=10.1046/j.1365-2443.2000.00367.x; RA Nakanishi M., Ando H., Watanabe N., Kitamura K., Ito K., Okayama H., RA Miyamoto T., Agui T., Sasaki M.; RT "Identification and characterization of human Wee1B, a new member of the RT Wee1 family of Cdk-inhibitory kinases."; RL Genes Cells 5:839-847(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [4] RP VARIANTS [LARGE SCALE ANALYSIS] THR-8; LYS-332; HIS-398; GLU-470 AND RP ASP-526. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [5] RP INVOLVEMENT IN OZEMA5, VARIANT OZEMA5 HIS-234, CHARACTERIZATION OF VARIANT RP OZEMA5 HIS-234, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND RP PHOSPHORYLATION. RX PubMed=29606300; DOI=10.1016/j.ajhg.2018.02.015; RA Sang Q., Li B., Kuang Y., Wang X., Zhang Z., Chen B., Wu L., Lyu Q., Fu Y., RA Yan Z., Mao X., Xu Y., Mu J., Li Q., Jin L., He L., Wang L.; RT "Homozygous Mutations in WEE2 Cause Fertilization Failure and Female RT Infertility."; RL Am. J. Hum. Genet. 102:649-657(2018). CC -!- FUNCTION: Oocyte-specific protein tyrosine kinase that phosphorylates CC and inhibits CDK1/CDC2 and acts as a key regulator of meiosis during CC both prophase I and metaphase II (PubMed:29606300). Required to CC maintain meiotic arrest in oocytes during the germinal vesicle (GV) CC stage, a long period of quiescence at dictyate prophase I, by CC phosphorylating CDK1 at 'Tyr-15', leading to inhibit CDK1 activity and CC prevent meiotic reentry. Also required for metaphase II exit during egg CC activation by phosphorylating CDK1 at 'Tyr-15', to ensure exit from CC meiosis in oocytes and promote pronuclear formation (By similarity). CC {ECO:0000250|UniProtKB:Q66JT0, ECO:0000269|PubMed:29606300}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10027}; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11029659, CC ECO:0000269|PubMed:29606300}. CC -!- TISSUE SPECIFICITY: Expressed in oocytes (at protein level) CC (PubMed:29606300). May also be expressed in testis (PubMed:11029659). CC {ECO:0000269|PubMed:11029659, ECO:0000269|PubMed:29606300}. CC -!- PTM: Phosphorylated on serine residues (PubMed:29606300). CC Phosphorylation leads to increase its activity (By similarity). CC {ECO:0000250|UniProtKB:Q66JT0, ECO:0000269|PubMed:29606300}. CC -!- DISEASE: Oocyte/zygote/embryo maturation arrest 5 (OZEMA5) CC [MIM:617996]: An autosomal recessive infertility disorder characterized CC by oocyte inability to exit metaphase II, resulting in fertilization CC failure. {ECO:0000269|PubMed:29606300}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. WEE1 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK131218; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AC004918; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS43660.1; -. DR RefSeq; NP_001099028.1; NM_001105558.1. DR PDB; 5VDK; X-ray; 2.70 A; A=202-492. DR PDBsum; 5VDK; -. DR AlphaFoldDB; P0C1S8; -. DR SMR; P0C1S8; -. DR BioGRID; 138978; 2. DR FunCoup; P0C1S8; 956. DR STRING; 9606.ENSP00000380675; -. DR BindingDB; P0C1S8; -. DR ChEMBL; CHEMBL5095; -. DR DrugCentral; P0C1S8; -. DR GlyGen; P0C1S8; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P0C1S8; -. DR PhosphoSitePlus; P0C1S8; -. DR BioMuta; WEE2; -. DR DMDM; 254763343; -. DR jPOST; P0C1S8; -. DR MassIVE; P0C1S8; -. DR PaxDb; 9606-ENSP00000380675; -. DR PeptideAtlas; P0C1S8; -. DR Antibodypedia; 32491; 120 antibodies from 24 providers. DR DNASU; 494551; -. DR Ensembl; ENST00000397541.6; ENSP00000380675.2; ENSG00000214102.8. DR Ensembl; ENST00000574659.5; ENSP00000459392.1; ENSG00000263042.5. DR GeneID; 494551; -. DR KEGG; hsa:494551; -. DR MANE-Select; ENST00000397541.6; ENSP00000380675.2; NM_001105558.1; NP_001099028.1. DR UCSC; uc003vwn.2; human. DR AGR; HGNC:19684; -. DR ClinPGx; PA134909633; -. DR CTD; 494551; -. DR DisGeNET; 494551; -. DR GeneCards; WEE2; -. DR HGNC; HGNC:19684; WEE2. DR HPA; ENSG00000214102; Not detected. DR MalaCards; WEE2; -. DR MIM; 614084; gene. DR MIM; 617996; phenotype. DR OpenTargets; ENSG00000214102; -. DR Orphanet; 488191; Female infertility due to oocyte meiotic arrest. DR VEuPathDB; HostDB:ENSG00000214102; -. DR eggNOG; KOG0601; Eukaryota. DR GeneTree; ENSGT00940000158803; -. DR HOGENOM; CLU_000288_25_1_1; -. DR InParanoid; P0C1S8; -. DR OMA; PLKDEMT; -. DR OrthoDB; 5337378at2759; -. DR PAN-GO; P0C1S8; 3 GO annotations based on evolutionary models. DR PhylomeDB; P0C1S8; -. DR PathwayCommons; P0C1S8; -. DR SignaLink; P0C1S8; -. DR SIGNOR; P0C1S8; -. DR Agora; ENSG00000214102; -. DR BioGRID-ORCS; 494551; 11 hits in 1174 CRISPR screens. DR GenomeRNAi; 494551; -. DR Pharos; P0C1S8; Tchem. DR PRO; PR:P0C1S8; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P0C1S8; protein. DR Bgee; ENSG00000214102; Expressed in primordial germ cell in gonad and 83 other cell types or tissues. DR ExpressionAtlas; P0C1S8; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0000287; F:magnesium ion binding; IEA:InterPro. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0007143; P:female meiotic nuclear division; ISS:UniProtKB. DR GO; GO:0035038; P:female pronucleus assembly; ISS:UniProtKB. DR GO; GO:0000278; P:mitotic cell cycle; IEA:InterPro. DR GO; GO:1900194; P:negative regulation of oocyte maturation; ISS:UniProtKB. DR GO; GO:0042327; P:positive regulation of phosphorylation; IEA:Ensembl. DR GO; GO:0080154; P:regulation of fertilization; IEA:Ensembl. DR GO; GO:0060631; P:regulation of meiosis I; ISS:UniProtKB. DR CDD; cd14139; PTKc_Wee1b; 1. DR FunFam; 3.30.200.20:FF:000115; Wee1-like kinase 2; 1. DR FunFam; 1.10.510.10:FF:000217; Wee1-like protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050339; CC_SR_Kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR017164; Wee1-like_protein_kinase. DR PANTHER; PTHR11042; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE EIF2-ALPHA KINASE -RELATED; 1. DR PANTHER; PTHR11042:SF75; WEE1-LIKE PROTEIN KINASE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF037281; Wee1-like_protein_kinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Coiled coil; Disease variant; Kinase; Magnesium; KW Meiosis; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transferase; KW Tyrosine-protein kinase. FT CHAIN 1..567 FT /note="Wee1-like protein kinase 2" FT /id="PRO_0000248079" FT DOMAIN 212..486 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..117 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 514..567 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 494..519 FT /evidence="ECO:0000255" FT MOTIF 173..175 FT /note="Nuclear localization signal" FT /evidence="ECO:0000250" FT MOTIF 315..329 FT /note="Nuclear export signal" FT /evidence="ECO:0000250" FT COMPBIAS 1..12 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 25..35 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 42..51 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 64..77 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 339 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 218..226 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 241 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 344 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250" FT BINDING 380 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250" FT MOD_RES 76 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:A4PES0" FT VARIANT 8 FT /note="K -> T (in dbSNP:rs35672788)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041304" FT VARIANT 234 FT /note="D -> H (in OZEMA5; decreased WEE2 phosphorylation at FT serine residues; decreased CDK1/CDC2 phosphorylation at 'Y- FT 15'; dbSNP:rs1554415096)" FT /evidence="ECO:0000269|PubMed:29606300" FT /id="VAR_080992" FT VARIANT 332 FT /note="N -> K (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041305" FT VARIANT 398 FT /note="R -> H (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs200610853)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041306" FT VARIANT 470 FT /note="D -> E (in dbSNP:rs55901099)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041307" FT VARIANT 526 FT /note="Y -> D (in dbSNP:rs35683659)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041308" FT CONFLICT 351 FT /note="M -> V (in Ref. 2; AK131218)" FT /evidence="ECO:0000305" FT CONFLICT 529 FT /note="H -> Y (in Ref. 2; AK131218)" FT /evidence="ECO:0000305" FT HELIX 207..211 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 212..221 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 224..231 FT /evidence="ECO:0007829|PDB:5VDK" FT TURN 232..234 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 237..245 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 251..253 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 255..265 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 275..281 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 284..290 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 297..306 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 313..332 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 344..348 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 375..378 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 385..389 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 397..399 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 402..405 FT /evidence="ECO:0007829|PDB:5VDK" FT TURN 410..412 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 413..428 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 437..443 FT /evidence="ECO:0007829|PDB:5VDK" FT TURN 444..446 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 457..467 FT /evidence="ECO:0007829|PDB:5VDK" FT STRAND 469..471 FT /evidence="ECO:0007829|PDB:5VDK" FT HELIX 477..481 FT /evidence="ECO:0007829|PDB:5VDK" SQ SEQUENCE 567 AA; 62925 MW; BC05DDFE96D87E3F CRC64; MDDKDIDKEL RQKLNFSYCE ETEIEGQKKV EESREASSQT PEKGEVQDSE AKGTPPWTPL SNVHELDTSS EKDKESPDQI LRTPVSHPLK CPETPAQPDS RSKLLPSDSP STPKTMLSRL VISPTGKLPS RGPKHLKLTP APLKDEMTSL ALVNINPFTP ESYKKLFLQS GGKRKIRGDL EEAGPEEGKG GLPAKRCVLR ETNMASRYEK EFLEVEKIGV GEFGTVYKCI KRLDGCVYAI KRSMKTFTEL SNENSALHEV YAHAVLGHHP HVVRYYSSWA EDDHMIIQNE YCNGGSLQAA ISENTKSGNH FEEPKLKDIL LQISLGLNYI HNSSMVHLDI KPSNIFICHK MQSESSGVIE EVENEADWFL SANVMYKIGD LGHATSINKP KVEEGDSRFL ANEILQEDYR HLPKADIFAL GLTIAVAAGA ESLPTNGAAW HHIRKGNFPD VPQELSESFS SLLKNMIQPD AEQRPSAAAL ARNTVLRPSL GKTEELQQQL NLEKFKTATL ERELREAQQA QSPQGYTHHG DTGVSGTHTG SRSTKRLVGG KSARSSSFTS GEREPLH // ID WNT4_HUMAN Reviewed; 351 AA. AC P56705; B4DJF9; Q5TZQ0; Q96T81; Q9BXF5; Q9H1J8; Q9UJM2; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 10-MAY-2002, sequence version 4. DT 28-JAN-2026, entry version 207. DE RecName: Full=Protein Wnt-4; DE Flags: Precursor; GN Name=WNT4; ORFNames=UNQ426/PRO864; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Testa T.T., Mossakowska D.E., Carter P.S., Hu E., Zhu Y., Kelsell D.P., RA Murdock P.R., Herrity N.C., Lewis C.J., Cross D.A., Culbert A.A., RA Reith A.D., Barnes M.R.; RT "Molecular cloning and characterization of six novel human WNT genes."; RL Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=11283799; DOI=10.1086/320125; RA Jordan B.K., Mohammed M., Ching S.T., Delot E., Chen X.N., Dewing P., RA Swain A., Rao P.N., Elejalde B.R., Vilain E.; RT "Up-regulation of wnt-4 signaling and dosage-sensitive sex reversal in RT humans."; RL Am. J. Hum. Genet. 68:1102-1109(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Subthalamic nucleus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 210-329 (ISOFORM 1/2). RC TISSUE=Mammary gland; RX PubMed=8168088; RA Huguet E.L., McMahon J.A., McMahon A.P., Bicknell R., Harris A.L.; RT "Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast RT cell lines and normal and disease states of human breast tissue."; RL Cancer Res. 54:2615-2621(1994). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26. RA Peltoketo H., Heikkila M., Vainio S.; RL Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26. RA Sim U.E., Smith A., Szilagi E., Ioannou P., Lindsay M.H., Little M.H.; RT "Expression of Wnt-4 can be regulated by the Wilms' tumor suppressor gene, RT WT1."; RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases. RN [11] RP INTERACTION WITH PKD1. RX PubMed=27214281; DOI=10.1038/ncb3363; RA Kim S., Nie H., Nesin V., Tran U., Outeda P., Bai C.X., Keeling J., RA Maskey D., Watnick T., Wessely O., Tsiokas L.; RT "The polycystin complex mediates Wnt/Ca(2+) signalling."; RL Nat. Cell Biol. 18:752-764(2016). RN [12] RP VARIANT MULLAPL GLY-216, AND CHARACTERIZATION OF VARIANT MULLAPL GLY-216. RX PubMed=15317892; DOI=10.1056/nejmoa040533; RA Biason-Lauber A., Konrad D., Navratil F., Schoenle E.J.; RT "A WNT4 mutation associated with Muellerian-duct regression and RT virilization in a 46,XX woman."; RL N. Engl. J. Med. 351:792-798(2004). RN [13] RP VARIANT MULLAPL CYS-83, AND CHARACTERIZATION OF VARIANT MULLAPL CYS-83. RX PubMed=16959810; DOI=10.1093/humrep/del360; RA Biason-Lauber A., De Filippo G., Konrad D., Scarano G., Nazzaro A., RA Schoenle E.J.; RT "WNT4 deficiency-a clinical phenotype distinct from the classic Mayer- RT Rokitansky-Kuster-Hauser syndrome: a case report."; RL Hum. Reprod. 22:224-229(2007). RN [14] RP VARIANT SERKAL VAL-114, AND CHARACTERIZATION OF VARIANT SERKAL VAL-114. RX PubMed=18179883; DOI=10.1016/j.ajhg.2007.08.005; RA Mandel H., Shemer R., Borochowitz Z.U., Okopnik M., Knopf C., Indelman M., RA Drugan A., Tiosano D., Gershoni-Baruch R., Choder M., Sprecher E.; RT "SERKAL syndrome: an autosomal-recessive disorder caused by a loss-of- RT function mutation in WNT4."; RL Am. J. Hum. Genet. 82:39-47(2008). RN [15] RP VARIANT MULLAPL PRO-12, AND CHARACTERIZATION OF VARIANT MULLAPL PRO-12. RX PubMed=18182450; DOI=10.1210/jc.2007-2023; RA Philibert P., Biason-Lauber A., Rouzier R., Pienkowski C., Paris F., RA Konrad D., Schoenle E., Sultan C.; RT "Identification and functional analysis of a new WNT4 gene mutation among RT 28 adolescent girls with primary amenorrhea and Muellerian duct RT abnormalities: a French collaborative study."; RL J. Clin. Endocrinol. Metab. 93:895-900(2008). CC -!- FUNCTION: Ligand for members of the frizzled family of seven CC transmembrane receptors (Probable). Plays an important role in the CC embryonic development of the urogenital tract and the lung CC (PubMed:15317892, PubMed:16959810, PubMed:18179883, PubMed:18182450). CC Required for normal mesenchyme to epithelium transition during CC embryonic kidney development. Required for the formation of early CC epithelial renal vesicles during kidney development (By similarity). CC Required for normal formation of the Mullerian duct in females, and CC normal levels of oocytes in the ovaries (PubMed:15317892, CC PubMed:16959810, PubMed:18182450). Required for normal down-regulation CC of 3 beta-hydroxysteroid dehydrogenase in the ovary (PubMed:15317892, CC PubMed:16959810, PubMed:18182450). Required for normal lung development CC and for normal patterning of trachael cartilage rings (By similarity). CC {ECO:0000250|UniProtKB:P22724, ECO:0000269|PubMed:15317892, CC ECO:0000269|PubMed:16959810, ECO:0000269|PubMed:18179883, CC ECO:0000269|PubMed:18182450, ECO:0000305}. CC -!- SUBUNIT: Interacts with PORCN (By similarity). Interacts with PKD1 CC (PubMed:27214281). {ECO:0000250|UniProtKB:P22724, CC ECO:0000269|PubMed:27214281}. CC -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular CC matrix. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P56705-1; Sequence=Displayed; CC Name=2; CC IsoId=P56705-2; Sequence=VSP_054017; CC -!- PTM: Palmitoleoylation is required for efficient binding to frizzled CC receptors. Depalmitoleoylation leads to Wnt signaling pathway CC inhibition. {ECO:0000250|UniProtKB:P27467, CC ECO:0000250|UniProtKB:P56704}. CC -!- DISEASE: 46,XX sex reversal with dysgenesis of kidneys, adrenals, and CC lungs (SERKAL) [MIM:611812]: A disease characterized by the association CC of female-to-male sex reversal with dysgenesis of kidneys, adrenals, CC and lungs. {ECO:0000269|PubMed:18179883}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Mullerian aplasia and hyperandrogenism (MULLAPL) [MIM:158330]: CC A disorder of sex development. Affected females manifest dysgenesis of CC Mullerian duct derivatives absent or rudimentary uterus and vagina, CC functional ovaries, primary amenorrhea, hyperandrogenism and hirsutism. CC {ECO:0000269|PubMed:15317892, ECO:0000269|PubMed:16959810, CC ECO:0000269|PubMed:18182450}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the Wnt family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY009398; AAG38658.1; -; mRNA. DR EMBL; AF316543; AAK51699.1; -; mRNA. DR EMBL; AY358947; AAQ89306.1; -; mRNA. DR EMBL; AK296058; BAG58821.1; -; mRNA. DR EMBL; BT020125; AAV38928.1; -; mRNA. DR EMBL; AL031281; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445253; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC057781; AAH57781.1; -; mRNA. DR EMBL; AF335591; AAK25765.1; -; Genomic_DNA. DR EMBL; AH010731; AAK50427.1; -; Genomic_DNA. DR CCDS; CCDS223.1; -. [P56705-1] DR RefSeq; NP_110388.2; NM_030761.4. [P56705-1] DR AlphaFoldDB; P56705; -. DR SMR; P56705; -. DR BioGRID; 119939; 88. DR FunCoup; P56705; 661. DR IntAct; P56705; 25. DR STRING; 9606.ENSP00000290167; -. DR GlyCosmos; P56705; 2 sites, No reported glycans. DR GlyGen; P56705; 3 sites. DR iPTMnet; P56705; -. DR PhosphoSitePlus; P56705; -. DR BioMuta; WNT4; -. DR DMDM; 20532425; -. DR jPOST; P56705; -. DR MassIVE; P56705; -. DR PaxDb; 9606-ENSP00000290167; -. DR PeptideAtlas; P56705; -. DR ProteomicsDB; 4376; -. DR ProteomicsDB; 56938; -. [P56705-1] DR Antibodypedia; 2555; 459 antibodies from 35 providers. DR DNASU; 54361; -. DR Ensembl; ENST00000290167.11; ENSP00000290167.5; ENSG00000162552.16. [P56705-1] DR GeneID; 54361; -. DR KEGG; hsa:54361; -. DR MANE-Select; ENST00000290167.11; ENSP00000290167.5; NM_030761.5; NP_110388.2. DR UCSC; uc001bfs.5; human. [P56705-1] DR AGR; HGNC:12783; -. DR ClinPGx; PA37384; -. DR CTD; 54361; -. DR DisGeNET; 54361; -. DR GeneCards; WNT4; -. DR HGNC; HGNC:12783; WNT4. DR HPA; ENSG00000162552; Tissue enhanced (skin). DR MalaCards; WNT4; -. DR MIM; 158330; phenotype. DR MIM; 603490; gene. DR MIM; 611812; phenotype. DR OpenTargets; ENSG00000162552; -. DR Orphanet; 2578; Mayer-Rokitansky-Kuester-Hauser syndrome type 2. DR Orphanet; 247768; Muellerian aplasia and hyperandrogenism. DR Orphanet; 139466; SERKAL syndrome. DR VEuPathDB; HostDB:ENSG00000162552; -. DR eggNOG; KOG3913; Eukaryota. DR GeneTree; ENSGT00940000159654; -. DR HOGENOM; CLU_033039_1_0_1; -. DR InParanoid; P56705; -. DR OMA; NFEWSGC; -. DR OrthoDB; 5945655at2759; -. DR PAN-GO; P56705; 6 GO annotations based on evolutionary models. DR PhylomeDB; P56705; -. DR PathwayCommons; P56705; -. DR Reactome; R-HSA-201681; TCF dependent signaling in response to WNT. DR Reactome; R-HSA-3238698; WNT ligand biogenesis and trafficking. DR Reactome; R-HSA-373080; Class B/2 (Secretin family receptors). DR Reactome; R-HSA-3772470; Negative regulation of TCF-dependent signaling by WNT ligand antagonists. DR Reactome; R-HSA-4086400; PCP/CE pathway. DR Reactome; R-HSA-9831926; Nephron development. DR SignaLink; P56705; -. DR SIGNOR; P56705; -. DR Agora; ENSG00000162552; -. DR BioGRID-ORCS; 54361; 11 hits in 1147 CRISPR screens. DR ChiTaRS; WNT4; human. DR GeneWiki; WNT4; -. DR GenomeRNAi; 54361; -. DR Pharos; P56705; Tbio. DR PRO; PR:P56705; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P56705; protein. DR Bgee; ENSG00000162552; Expressed in islet of Langerhans and 104 other cell types or tissues. DR ExpressionAtlas; P56705; baseline and differential. DR GO; GO:0009986; C:cell surface; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; TAS:Reactome. DR GO; GO:0031012; C:extracellular matrix; IEA:Ensembl. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0005796; C:Golgi lumen; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0005125; F:cytokine activity; IBA:GO_Central. DR GO; GO:0005109; F:frizzled binding; IBA:GO_Central. DR GO; GO:0048018; F:receptor ligand activity; IDA:BHF-UCL. DR GO; GO:0003714; F:transcription corepressor activity; ISS:UniProtKB. DR GO; GO:0030325; P:adrenal gland development; IEP:UniProtKB. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; IBA:GO_Central. DR GO; GO:0009267; P:cellular response to starvation; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEP:UniProtKB. DR GO; GO:0001838; P:embryonic epithelial tube formation; IEA:Ensembl. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IEP:UniProtKB. DR GO; GO:0008585; P:female gonad development; IEA:Ensembl. DR GO; GO:0030237; P:female sex determination; IMP:UniProtKB. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl. DR GO; GO:0033080; P:immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0001822; P:kidney development; IEP:UniProtKB. DR GO; GO:0001889; P:liver development; IEP:UniProtKB. DR GO; GO:0008584; P:male gonad development; IMP:UniProtKB. DR GO; GO:0061180; P:mammary gland epithelium development; IEP:UniProtKB. DR GO; GO:0140013; P:meiotic nuclear division; IEA:Ensembl. DR GO; GO:0060231; P:mesenchymal to epithelial transition; IEA:Ensembl. DR GO; GO:0072162; P:metanephric mesenchymal cell differentiation; NAS:UniProtKB. DR GO; GO:0072273; P:metanephric nephron morphogenesis; IEA:Ensembl. DR GO; GO:0072174; P:metanephric tubule formation; IEA:Ensembl. DR GO; GO:2000180; P:negative regulation of androgen biosynthetic process; IDA:UniProtKB. DR GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0045596; P:negative regulation of cell differentiation; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0040037; P:negative regulation of fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB. DR GO; GO:2000019; P:negative regulation of male gonad development; IMP:UniProtKB. DR GO; GO:0046580; P:negative regulation of Ras protein signal transduction; IEA:Ensembl. DR GO; GO:0010894; P:negative regulation of steroid biosynthetic process; IDA:UniProtKB. DR GO; GO:0061369; P:negative regulation of testicular blood vessel morphogenesis; IMP:UniProtKB. DR GO; GO:2000225; P:negative regulation of testosterone biosynthetic process; IMP:UniProtKB. DR GO; GO:0061045; P:negative regulation of wound healing; IEA:Ensembl. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0035567; P:non-canonical Wnt signaling pathway; IDA:BHF-UCL. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0061205; P:paramesonephric duct development; IMP:UniProtKB. DR GO; GO:1904238; P:pericyte cell differentiation; IEA:Ensembl. DR GO; GO:0032349; P:positive regulation of aldosterone biosynthetic process; IDA:UniProtKB. DR GO; GO:0030501; P:positive regulation of bone mineralization; IDA:BHF-UCL. DR GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IDA:BHF-UCL. DR GO; GO:2000066; P:positive regulation of cortisol biosynthetic process; IDA:UniProtKB. DR GO; GO:0061184; P:positive regulation of dermatome development; IDA:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0051894; P:positive regulation of focal adhesion assembly; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0045836; P:positive regulation of meiotic nuclear division; IEA:Ensembl. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IDA:BHF-UCL. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:0022407; P:regulation of cell-cell adhesion; IEA:Ensembl. DR GO; GO:0072033; P:renal vesicle formation; IEA:Ensembl. DR GO; GO:0072034; P:renal vesicle induction; IEA:Ensembl. DR GO; GO:0060008; P:Sertoli cell differentiation; IEA:Ensembl. DR GO; GO:0051145; P:smooth muscle cell differentiation; IEA:Ensembl. DR GO; GO:0060126; P:somatotropin secreting cell differentiation; IEA:Ensembl. DR GO; GO:0060748; P:tertiary branching involved in mammary gland duct morphogenesis; IEA:Ensembl. DR GO; GO:0060129; P:thyroid-stimulating hormone-secreting cell differentiation; IEA:Ensembl. DR CDD; cd19336; Wnt_Wnt4; 1. DR FunFam; 3.30.2460.20:FF:000001; Wnt homolog; 1. DR Gene3D; 3.30.2460.20; -; 1. DR InterPro; IPR005817; Wnt. DR InterPro; IPR009142; Wnt4. DR InterPro; IPR043158; Wnt_C. DR InterPro; IPR018161; Wnt_CS. DR PANTHER; PTHR12027:SF101; PROTEIN WNT-4; 1. DR PANTHER; PTHR12027; WNT RELATED; 1. DR Pfam; PF00110; wnt; 1. DR PRINTS; PR01844; WNT4PROTEIN. DR PRINTS; PR01349; WNTPROTEIN. DR SMART; SM00097; WNT1; 1. DR PROSITE; PS00246; WNT1; 1. PE 1: Evidence at protein level; KW Alternative splicing; Developmental protein; Disease variant; KW Disulfide bond; Extracellular matrix; Glycoprotein; Lipoprotein; KW Proteomics identification; Reference proteome; Secreted; Signal; KW Wnt signaling pathway. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..351 FT /note="Protein Wnt-4" FT /id="PRO_0000041421" FT LIPID 212 FT /note="O-palmitoleoyl serine; by PORCN" FT /evidence="ECO:0000250|UniProtKB:P56704" FT CARBOHYD 88 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 297 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 78..89 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 128..136 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 138..155 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 206..220 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 208..215 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 280..311 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 296..306 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 310..350 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 326..341 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 328..338 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 333..334 FT /evidence="ECO:0000250|UniProtKB:P28026" FT VAR_SEQ 1..55 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_054017" FT VARIANT 12 FT /note="L -> P (in MULLAPL; unable to suppress FT steroidogenesis in an ovarian adenocarcinoma cell line FT resulting in increased androgen production; FT dbSNP:rs121908653)" FT /evidence="ECO:0000269|PubMed:18182450" FT /id="VAR_043497" FT VARIANT 83 FT /note="R -> C (in MULLAPL; with androgen excess, normal FT kidney size and location; unable to suppress expression of FT steroidogenic enzymes in ovarian; impairs protein FT secretion)" FT /evidence="ECO:0000269|PubMed:16959810" FT /id="VAR_043498" FT VARIANT 114 FT /note="A -> V (in SERKAL; reduced transcript levels; FT dbSNP:rs121908651)" FT /evidence="ECO:0000269|PubMed:18179883" FT /id="VAR_043499" FT VARIANT 216 FT /note="E -> G (in MULLAPL; unable to suppress expression of FT steroidogenic enzymes in ovarian and adrenal cell lines; FT dbSNP:rs121908650)" FT /evidence="ECO:0000269|PubMed:15317892" FT /id="VAR_034703" FT VARIANT 277 FT /note="P -> L (in dbSNP:rs34228276)" FT /id="VAR_052955" FT CONFLICT 106 FT /note="T -> I (in Ref. 1; AAG38658)" FT /evidence="ECO:0000305" FT CONFLICT 111 FT /note="F -> L (in Ref. 1; AAG38658)" FT /evidence="ECO:0000305" SQ SEQUENCE 351 AA; 39052 MW; 465D08755C992DA8 CRC64; MSPRSCLRSL RLLVFAVFSA AASNWLYLAK LSSVGSISEE ETCEKLKGLI QRQVQMCKRN LEVMDSVRRG AQLAIEECQY QFRNRRWNCS TLDSLPVFGK VVTQGTREAA FVYAISSAGV AFAVTRACSS GELEKCGCDR TVHGVSPQGF QWSGCSDNIA YGVAFSQSFV DVRERSKGAS SSRALMNLHN NEAGRKAILT HMRVECKCHG VSGSCEVKTC WRAVPPFRQV GHALKEKFDG ATEVEPRRVG SSRALVPRNA QFKPHTDEDL VYLEPSPDFC EQDMRSGVLG TRGRTCNKTS KAIDGCELLC CGRGFHTAQV ELAERCSCKF HWCCFVKCRQ CQRLVELHTC R //